<SEC-DOCUMENT>0001558370-25-002631.txt : 20250311
<SEC-HEADER>0001558370-25-002631.hdr.sgml : 20250311
<ACCEPTANCE-DATETIME>20250311061529
ACCESSION NUMBER:		0001558370-25-002631
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		115
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250311
DATE AS OF CHANGE:		20250311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zenas BioPharma, Inc.
		CENTRAL INDEX KEY:			0001953926
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42270
		FILM NUMBER:		25725757

	BUSINESS ADDRESS:	
		STREET 1:		852 WINTER STREET, SUITE 250
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		857-271-2954

	MAIL ADDRESS:	
		STREET 1:		852 WINTER STREET, SUITE 250
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zenas BioPharma (Cayman) Ltd
		DATE OF NAME CHANGE:	20221108
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>zbio-20241231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/10/2025 9:10:58 PM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: c44339bb-a1b2-49e5-aa27-ac9fe091a6b5 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:zbio="http://zenasbio.com/20241231" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>Zenas BioPharma, Inc._December 31, 2024</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityCentralIndexKey" id="Tc_cchFbnGap0WnIciwC6uxpg_2_1">0001953926</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:CurrentFiscalYearEndDate" id="Tc_vfGvexh720S7hVqr07MGtg_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:DocumentFiscalYearFocus" id="Tc_4hrYWDZfAUikKwSQfiiehA_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:DocumentFiscalPeriodFocus" id="Tc_DW30foDI10KMyOOkaBg4Vg_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:AmendmentFlag" id="Tc_hIP6fBUXSUagePgzwDLPgA_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" xs:nil="true" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_RszIZHKCe0GMwqFl0OU5UA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" xs:nil="true" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_u6rv2-q7MkCwQ_XM0Co-uQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_H6svqTBFo02ndFqe1K9qSw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_wjmjNqhE-0KUgjj9Uzc5Cw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_RvIdhgb7eUKUzcaW1bgoAg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_vM7VdH5LuUSIBHOTQRq6nQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" id="Hidden_sW4Bekr-zkyy8cLJvx_IHg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" id="Hidden_ROUB4IaZ3Eu4s5Lk4YZGGQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="0" name="zbio:FairValueLiabilitiesLevel1ToLevel2TransferAmount" id="Hidden_bSbgkoQjBUSLdj7WXI6fFQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="0" name="zbio:FairValueLiabilitiesLevel1ToLevel2TransferAmount" id="Hidden_B8tiQTeac0KDjUIoilEa5w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" id="Hidden_-Wi87NuziUOMzVc46Eo1mw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" id="Hidden_o1GGffggSEu4tW6nelxegg">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_NYcJR8lqrkCLowTMNFUBTg" name="us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_-H1KgnAtXU2ARs6PtzO9-g">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_N0JzawarFE2rMLM5lKwjiw" name="us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_0gQq9Ba02Ey1cgd67d3AOg">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_ywEHHvSO902MFN2_jPD2tQ" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_tse8iP5LeU69vjWcjdtpow">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_F93rW4YniU-isgi4W6XJYA">1785714</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_ywEHHvSO902MFN2_jPD2tQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_rI0dKlRWL0ul7X3z9V1xFQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_M56D618pS0enhKGKHqPd0A">1785714</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_-xEDVh4-qkqlm3ytowN9Zw" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_JnN4uMYIgkCjRU4tOzxuiw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_vdtRe09mgUqM8NRIjiuQ1g">17589380</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_-xEDVh4-qkqlm3ytowN9Zw" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_i15PFzsJrE-iCOvEYrCCgQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_0P5EwUDT8EyCGvpmm1IS7w">17589380</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vZWP1gyCtEu9w9OaIMGbpg" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_f4mwZhVtbEuTypHhSfyNFQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_l5gOCjZrikynZQNbg-mghw">81242587</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vZWP1gyCtEu9w9OaIMGbpg" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_Ra8EPcJLvkyQ0y8ZKYex4A">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_3dAB6-rVS0a4E97pEhf7Sw">81242587</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" id="Hidden_VttpHrPuBUSgpDKjk2Zk4w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" xs:nil="true" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" name="us-gaap:PreferredStockValue" id="Hidden_qnhQqOYVT0yoQAvJgJA5vQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" xs:nil="true" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" name="us-gaap:PreferredStockValue" id="Hidden_KM8jL8QJ50CvOax1NG6sbA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_E6IzMDPGE0WVp6F4hT3pfA">1576854</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_8h-g-kbq5Uie_MXjyiAoRw">41793412</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_QdIMiSdGW0WnhcGmUQtR9A" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_b_kdHKCFF0avLUjrQ41Fwg">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_O9B88gheUkaquoX_9DV5hA">http://zenasbio.com/20241231#FairValueAdjustmentOfConvertibleNotes</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_jVXKwJzbK06otYl6OvTOJw">http://zenasbio.com/20241231#FairValueAdjustmentOfConvertibleNotes</ix:nonNumeric><ix:nonNumeric contextRef="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_QSgjONif-0yTKlXy2bMn7g" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_JhL2WXriOku-gXN73DMQHw">P36M</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="zbio-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_11_1_2022_To_11_30_2022_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_R9s5xpFO902Z05RAdLWrnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jtEg9vA0hUWnfXmt4HMTXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:XencorIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2020Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ybTmDoxkwUu0xUQqRigT7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zbio:XencorAgreement2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_kl-ar1okCk6X0Cdxj6jlyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:XencorIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_3_2024_To_5_3_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_lcOoNTIEC06PQFCU3DRl5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:BmsConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-03</xbrli:startDate><xbrli:endDate>2024-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2024_To_5_31_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_5MuMZ5_MaUWYN1Qu9wlrYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:BmsConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_30_2022_us-gaap_DebtInstrumentAxis_zbio_ConvertiblePromissoryNotes2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_cwy_9SZUtkSEG0gNp7CNjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:ConvertiblePromissoryNotes2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2PJ0fHjSGkqSUHx6Zr4K0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gw2rhLbrokS2ngyRmmip4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_t-hVZE_DQ0aHW393n9Fzew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_T7YsONiFE0CzJJl1iFaCYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_P-kTuepM7kKaqc4rCr2AAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_j5jOOcuea0CX4dm8xBjYxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_np8ZhIOstUKtfTT_-Yj3vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_lwKQYiDgb0GvlfNmmVeNtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_3_2024_To_9_3_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_bmG8cOK5ekOayAksSxcSeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EquityIncentivePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-03</xbrli:startDate><xbrli:endDate>2024-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_3_2024_To_9_3_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_mqyL0U5nuU2EVYmKwAc9sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-03</xbrli:startDate><xbrli:endDate>2024-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember__kat8-A7DkaDtefaqsDstA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:XencorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-yJXARaZ-0OBYdCxepkloA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:XencorIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_DianthusTherapeuticsincMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CAe46DStS0ayGHbh_yaH1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:DianthusTherapeuticsincMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_dei_LegalEntityAxis_zbio_FairmountFundsManagementLlcMember_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QkW1FJbql0yPxwXvk72juA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">zbio:FairmountFundsManagementLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:ViridianTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_I6CRPAIoAkK_QxeW-_WiBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:ViridianTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_zbio_DianthusTherapeuticsincMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ZTb-Cr_H-k6rrUVG_vWbag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:DianthusTherapeuticsincMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_u2OmFVykgEeCNR0zO3JP-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_zbio_FairmountFundsManagementLlcMember_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hnbEkcn98U2igS-6OHbaDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">zbio:FairmountFundsManagementLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:ViridianTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_WGP9j066HEmWArI6WB0Cow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_PgETU9rFK0q2wG2LI9cG2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2023_To_8_31_2023_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_P-ll4OVb3EWjFIKqvZMELA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:BmsConvertiblePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_qV1cIVkt2kOoAoLtymHm9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:ViridianAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_ucAh8N2LEkm-jJRZJUsugg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_4pkbHJxyX0aZXqN77xa8Kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:ViridianAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_3OZtyHKQXEeOnEHLhY6SNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_ZrowpMBVWkeOdGC2HRwpgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2021_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_r2kEzq5fF0emBdihAC_LuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_JXqZc5v7Z0WJSg_JLf5b5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2023_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_DlfSbRkRKkikwGFbk82kmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2021_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_Bm0Xi9UVpUmszqhYv-4qFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2020_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_LluPYzM7VEa_H16QX3m4Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:ViridianAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_4_30_2023_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_TKtQMBOy0kys1OFuL5HUrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember__ZDd67Q9eUCGYKadM0BTGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:BmsConvertiblePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_24_2025_To_1_24_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_zbio_ZaiLicenseAgreementMember_OHpbECa01k2mu2U9YBMjnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:ZaiLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-24</xbrli:startDate><xbrli:endDate>2025-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_us-gaap_TypeOfArrangementAxis_zbio_NovationAgreementMember_lnQAUx2mlkib0BNiLe_Jxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:NovationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_86ES1U6DdEiWj8UWmZ87Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2023_To_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_68E-30ZXOka0SQILO84I2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:LicenseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_dyYvSl_2AEyLjKyAcaDc4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_24_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_zbio_ZaiLicenseAgreementMember_E1agUD26v0u0FuWVhieCXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:ZaiLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_CISJK2ppnkmIAMwch3Q_OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:LicenseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_q9l-Yh0Dr0qScfAPmFwVvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:LicenseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2024_us-gaap_TypeOfArrangementAxis_zbio_NovationAgreementMember_8o3sYZV3iUWz0FuKhL7jow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:NovationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_yjecN0IOyEe3rAsWgnm7iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:LicenseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember__L6rvMfPYE6KDEiKRpOSYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_ywEHHvSO902MFN2_jPD2tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vZWP1gyCtEu9w9OaIMGbpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_-xEDVh4-qkqlm3ytowN9Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ocu-YDmfGkytPLv371WO_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mIxda3QBT0eGgkr2-TLdAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xCsVy9CxU-Q-Ca38CHdgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWOR2Y6eb0qw6h_ECNiCyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zyuRWER_rEGXi84E3qArrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-zW7TSnNlEOWNVAWJEAmqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_twRRvxhUHkGVSVijS4AHpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_skdQla54vkylvNLfiCBCHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_lvF2unTWUEenGdpAx5Ec3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_aeVZjo1Bqk-9JQbx0cC7vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mWc24hPae06GpXVuJlDs0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Zu6GA717E0C8cJ-Hhbeflg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-16</xbrli:startDate><xbrli:endDate>2024-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_NlzJf7p5-kuuwrGA0pNVzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_XJAUtiSe802lS1JD3MLPpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:ViridianTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_zbio_DianthusTherapeuticsincMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lvI7Gb31J0y7HORj3pCOSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:DianthusTherapeuticsincMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_KSqzhLiyzEyDgl5ybmBLIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:ViridianAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_bzLuOSUTJEyZzSgS11je2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_l5vJE3DbIEKeKPth4gy8Kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3nxvET59Gki8LFIKljY7FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_o_4zbocCK0S4kVmIQxpThw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vq8gJuFgxUeW6Sum5gLP_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tGb0cUxC9kK9Z8w9yezpew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PBJ1X1nFxEWp13l1OkKMvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uUos0deBaEyEN6bFnRun4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Uz8_I3wLr0SnQHkp_bKCXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_nl_IrRmKGUmQBClrdDVOTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wA5OCDooWEKaI_O_5zlfDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0joMr_rkEkm7x1ZuVCT9ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MtK5qqSc7EWFj3hxdd6E6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vp9jOynptE6b6qFRS-0X-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_KToxdb6KqkaQTUoti9SqTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EquityIncentivePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cZRERuEIiEGchuqk65A2pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2025_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HT5QNFavaEuMvtiRET_mAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_3_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member__gcr5m9F8EmwZjNOy4gdqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember__QbnTUUJpUmGv43XtvhTNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W4Yt2rBhJE-FLWW_GHB-Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_n3k32el71EGZ_NhKc4uVgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:TwoThousandTwentyPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_QSgjONif-0yTKlXy2bMn7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:TwoThousandTwentyPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_RshCuHFfukSw2KF3sIAoJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:TwoThousandTwentyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_WGWYo6VeoEWAuqXTVFh8WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_UnallocatedMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_ebJVNQcIrE6ToW4JVW_66A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:UnallocatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_PartneredRegionalProgramsZb001Zb005Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_Rh91EjE7O02oJHALLAAHdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:PartneredRegionalProgramsZb001Zb005Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_OtherProgramsZb002Zb004Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_7d3JG86c_Eaat0gaHhQcQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:OtherProgramsZb002Zb004Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_ObexelimabMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_BA-_9VIA-E-YvYOM66DKZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:ObexelimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_UnallocatedMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_FtxZwqa3A020C1JNgu1N7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:UnallocatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_PartneredRegionalProgramsZb001Zb005Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_yj8rbVJ6iEu1uke5hj5FiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:PartneredRegionalProgramsZb001Zb005Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_OtherProgramsZb002Zb004Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_VixgjipTjEKqNxHHsetS4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:OtherProgramsZb002Zb004Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_ObexelimabMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_Ue5uXg-mLkyi2JN6fkIuQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:ObexelimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_ZeD0YqL9rEiNGm87-Fn0jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_QdIMiSdGW0WnhcGmUQtR9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_f7tghFWG2USaAbs-bXl6Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2024_To_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve5fM4bIxUmgiWyD_r9iHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_TYxqnXTkYU-hgPL5w_6nXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VUl7HtcvHkydsDN2_JnMRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_O_WkNZwcXUq8f-ADKZOHMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rPANXOD_Fku39IGeijPdfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-16</xbrli:startDate><xbrli:endDate>2024-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6aV-4PBKtEOUPe_8Z_Aj_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_b_-Mw3ef7kWZpywvWrh-sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_ftIqpFVSOkq5tizkN79ucQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_JZN4FpSog0SrROrSycy9eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_MfqeZTH_FECRP_tS5UQvHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Tjq4ptXuakWz2N7XO70BFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_03uBPrMelEOQgnXfrO0Rdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_LJ7TMbhoFUe0nr0lDe3Lmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I3LY6QQrkkmN4CYZS5IM0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xmuQWu9BX0O2k_q1aI5KuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_98SvbTRA50yOezeZ029LuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_3_2024_To_5_3_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_cwXLzP0nA0KjySFxWk-Usw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:BmsConvertiblePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-03</xbrli:startDate><xbrli:endDate>2024-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SB8hnByb2k6XmWq5YFUxLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:XencorIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_2NdTZEI7VEekOwqqgqrnHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_2-euo0XGO0qIb5EsNIp7SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_ExKbMgkUn0ititCiAzolAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:BmsConvertiblePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_jvKsbpTO10eG_t6mtZmxgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_FVi09Cz6lESIybH__dVf2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9vmGc1uJ-UKFfbOjwwSZLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2024_R3mnM-yuCkeUi3lI4lcTJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2025_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hb-DK0AUdkWTw3-eUcEHIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EquityIncentivePlan2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_xOEKuB9Y7kOpDa77H2eCCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EquityIncentivePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_CULdaUsOIkCpMGAD6CrOEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:TwoThousandTwentyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_N0JzawarFE2rMLM5lKwjiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:LicenseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_NYcJR8lqrkCLowTMNFUBTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:LicenseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_7aoYVm8LsEqvEfiPlkF4lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_EbY1u8wvo0uxDj6anPPPCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_45gRULzuSUK5_ORGEXpLOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_cT92xtQ8cECq2AFu-XJeOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_iSqSAz9x4k2LDrxzSKy2MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_LvhP6kTZU06gMvlc3p7_eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_82fSkNrj5kGcJKb3RNQoNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_wgLHoHG1-0qDKJPNdf5zYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_fNDpCNYLYE233dylDwz8eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_efoaGSp1_UmRJh64ycKRPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_T3DzdxiqpEyWSibLwwGToQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_u4MSiO-PeECFV2npmPDRmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_tAB8gHGpxEa_vZYJC85hXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ujsrnzhxWkaowceDO8G96A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_GlXgsGQE-0GNbt0DsdtK9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_KwwFNWvkbkepTCv4eJzXUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_LWrKtXp_xEeU8LAphW72jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_M12KVoNGq02-s4clKubiaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember__ml10lATXUGvzgwEsGWE_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_8iYMmA8-mkONHhlH8V6H4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_c8gM2cWCLkC5U2Dqd6witg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_Uu3p6qpokUGtpEZwlhfejQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fB6rJscJqE2qELeYONH6iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_AkdY1KqPtUenQWgty7TKCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_pAV7g9BFKE2QQiAhjUp8uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_jq1Qp6HsIE2fmcD8wUHsAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DSs7gyVtbUGlXl8c8Se1DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-I220YjrTES2zT0dh6nXJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Gh9QtBp7z0aJp2U6HTSmvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jWL8Je-UBU2gqCEY8KUEpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QXQPHb61tUenoW1KiYC_bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_yR58FFqVa0-kULPck87ZxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_IxVPwAMKEkiMUjSqIZE_PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UAmlIVGtOke4L0fxZoW0Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4dqDswEkwU-V1_i6DzMeew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2025_53upKo0a90ad249nOUw4cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001953926</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_S86Rw8jTyUm70oUkTaBnEw"><xbrli:measure>zbio:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_HZAN3AhGAkmyDfnWsC8kqg"><xbrli:measure>zbio:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw"><xbrli:measure>zbio:item</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:33pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_4006e466_1c47_490d_b4fb_cc2a00bc4a26"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:DocumentType" id="Narr_Nrd3JLEcFU2G_8VYhavuuA"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 46.8pt;"><b style="font-weight:bold;">(Mark&#160;One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:DocumentAnnualReport" id="Narr_Vjt2vE2jwEyAv69mY9dYIg"><b style="font-family:'Segoe UI Symbol';font-size:8pt;font-style:normal;font-weight:bold;">&#9746;</b></ix:nonNumeric></span><b style="font-size:8pt;font-weight:bold;">ANNUAL&#160;REPORT&#160;PURSUANT&#160;TO&#160;SECTION&#160;13&#160;OR&#160;15(d)&#160;OF&#160;THE&#160;SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">EXCHANGE&#160;ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:6pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:DocumentPeriodEndDate" id="Narr__oBZTN1IR0axWiBc-XgHtQ"><b style="font-size:6pt;font-weight:bold;">December 31, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">or</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:DocumentTransitionReport" id="Narr_QkwRpIgcf0-5LmDwf4uWhQ"><b style="font-family:'Segoe UI Symbol';font-size:8pt;font-style:normal;font-weight:bold;">&#9744;</b></ix:nonNumeric></span><b style="font-size:8pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">EXCHANGE&#160;ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;"> to</b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:6pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityFileNumber" id="Narr_a5HD7RE8OkWiCs0XMaNNdw"><b style="font-size:6pt;font-weight:bold;">001-42270</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><img src="zbio-20241231x10k004.jpg" alt="Graphic" style="display:inline-block;height:32.85pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:97.35pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:20pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityRegistrantName" id="Narr_EKATh28O_0yhrWz1dM8t1g"><b style="font-weight:bold;">Zenas BioPharma, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_791445a6_add2_4d2d_85ad_4f19390e0ac7"></a><a id="Tc_TcLfouaFPEOtoKXdbZIiwQ_2_0"></a><a id="Tc_Z82nxLZv_Ua5cup012sq9g_2_1"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityIncorporationStateCountryCode" id="Tc_TLagL9frb06i7bGNKrYYrQ_1_0"><b style="font-size:6pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityTaxIdentificationNumber" id="Tc_7nJrxHxnEUepBg9JpbiEBA_1_1"><span style="font-size:6pt;">93-2749244</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other&#160;jurisdiction of</b><br/><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b><br/><b style="font-weight:bold;">Identification Number)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityAddressAddressLine1" id="Narr_rF4qa9y8TkSogbAEfAsMKQ"><b style="font-size:6pt;font-weight:bold;">852 Winter Street</b></ix:nonNumeric><b style="font-size:6pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityAddressAddressLine2" id="Narr_krHNQYCVL0SVOzWVJ3w_AA"><b style="font-size:6pt;font-weight:bold;">Suite 250</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityAddressCityOrTown" id="Narr_-q7jOwQKWE-HvQcDdcxRaA"><b style="font-size:6pt;font-weight:bold;">Waltham</b></ix:nonNumeric><b style="font-size:6pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityAddressStateOrProvince" id="Narr_AalBGt5g_U-xcjuwIIEf2Q"><b style="font-size:6pt;font-weight:bold;">MA</b></ix:nonNumeric><b style="font-size:6pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityAddressPostalZipCode" id="Narr_xElLVPNiJkO_H-qtlwsf1Q"><b style="font-size:6pt;font-weight:bold;">02451</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">(Address of Principal Executive Offices)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:6pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:CityAreaCode" id="Narr_k8zCES-5602U00FB-PY19w"><b style="font-size:6pt;font-weight:bold;">857</b></ix:nonNumeric><b style="font-size:6pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:LocalPhoneNumber" id="Narr_uXETooDQpkqYXcCqcqsS_w"><b style="font-size:6pt;font-weight:bold;">271-2954</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 3pt 0pt;"><span style="white-space:pre-wrap;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:6pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9744;</span><span style="font-size:6pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_XpXaZXtx_kCUXxekSH93kw"><span style="font-size:6pt;">No</span></ix:nonNumeric><span style="font-size:6pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 3pt 0pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:6pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9744;</span><span style="font-size:6pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityVoluntaryFilers" id="Narr_eOUddGmnX0ikaBmw1-a4cw"><span style="font-size:6pt;">No</span></ix:nonNumeric><span style="font-size:6pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9746;</span><span style="font-size:6pt;">&#160;&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:6pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9744;</span><span style="font-size:6pt;">&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityCurrentReportingStatus" id="Narr_jzUZGrHlWU28xoSqTirvbg"><span style="font-size:6pt;">No</span></ix:nonNumeric><span style="font-size:6pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9746;</span><span style="font-size:6pt;">&#160;&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:6pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityInteractiveDataCurrent" id="Narr_5BrWiKaguU6ojOBe8HhmWA"><span style="font-size:6pt;">Yes</span></ix:nonNumeric><span style="font-size:6pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9746;</span><span style="font-size:6pt;">&#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><a id="_ac547a95_956b_43a9_977b_10e3160b1a74"></a><a id="Tc_zVWYqPqkV0C6c7xyk2bBww_1_0"></a><a id="Tc_opdA-yC98U2kpBH-CBvGFg_1_1"></a><a id="Tc_eVppWmVwlkSbj8E3acrW2w_1_2"></a><a id="Tc_Q1vOdR-Vd0OoxIMYbXY_bg_1_3"></a><a id="Tc_pewQBoYluE2DH2Vfe76DZA_2_1"></a><a id="Tc_A0mlV3gXtkGpWBmCSFmjtQ_2_2"></a><a id="Tc_SIGEy2CQIEWktvNSrGwsLw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:16.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:23.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:20.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:20.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:3.65pt;"><td style="vertical-align:bottom;width:16.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:23.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:20.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:top;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-family:'Wingdings';">&#168;</span></p></td><td style="vertical-align:top;width:20.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.05pt;"><td style="vertical-align:bottom;width:16.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityFilerCategory" id="Tc_BuPISTz0HU-BJhIPhNGrQg_2_0"><span style="font-size:6pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:23.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span>&#160;&#160;</p></td><td style="vertical-align:bottom;width:20.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:top;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntitySmallBusiness" id="Tc_jXEyElTVt0GB2fHLRd55GA_2_3"><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:20.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Emerging&#160;growth&#160;company</p></td><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityEmergingGrowthCompany" id="Tc_GCRelm4nwkGHDYX3NnCPuQ_2_5"><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:6pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityExTransitionPeriod" id="Narr_KHiDKeVy8kqPMEWub1aoiQ"><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 3pt 0pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:6pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_i2zCtsLUn0Sq5gcLhIhUNw"><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 3pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:6pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:EntityShellCompany" id="Narr_LXKFNkYSg0qMnMN4k6umLg"><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9744;</span></ix:nonNumeric><span style="font-size:6pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:6pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_b3bbfce3_5bc8_4c46_bc69_045f4de696f5"></a><a id="Tc_lmforaXyekGMW__OUfMc-Q_1_0"></a><a id="Tc_R__Ce3iN_k6oowa8y5AF0g_1_1"></a><a id="Tc_kA_mAeZKbUSrla0yIf3bHQ_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of Each Class</b></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading symbol</b></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name of Exchange on which registered</b></p></td></tr><tr style="height:3.25pt;"><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:Security12bTitle" id="Tc_62uYISbbBEGdwndZPNssfg_2_0"><b style="font-size:6pt;font-weight:bold;">Common stock, par value $0.0001 per share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:TradingSymbol" id="Tc_YI8LN3zGO0e3BUK948LQzA_2_1"><b style="font-size:6pt;font-weight:bold;">ZBIO</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:SecurityExchangeName" id="Tc_agk-AzerAEuFTTYxNNbtFA_2_2"><b style="font-size:6pt;font-weight:bold;">Nasdaq Global Select Market</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 3pt 0pt;">The registrant was <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" format="ixt-sec:numwordsen" scale="0" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="0" name="dei:EntityPublicFloat" id="Narr_-1cDrho7wkCfY2U0372N4A">no</ix:nonFraction>t a public company as of the last business day of its most recently completed second fiscal quarter and, therefore, cannot calculate the aggregate market value of its voting equity held by non-affiliates as of such date. The number of shares of Registrant&#8217;s Common Stock outstanding as of February 28, 2025 was <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_2_28_2025_53upKo0a90ad249nOUw4cw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_qxPRazrFt0moOEliKUFaNg">41,799,336</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Documents Incorporated by Reference</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="Tb_i9o69y1ZXUuUPkjApqp4Mw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Portions of the Registrant&#8217;s definitive proxy statement relating to the 2025 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant&#8217;s fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="TOC"></a><a id="_5385ad5f_cf5f_4269_bd93_b7c12a4802bc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="font-size:9.5pt;" href="#PARTI_6261"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item1Business_267971"><span style="font-style:normal;font-weight:normal;">Item 1. Business</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">6</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item1ARiskFactors_747397"><span style="font-style:normal;font-weight:normal;">Item 1A. Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">60</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item1BUnresolvedStaffComments_597814"><span style="font-style:normal;font-weight:normal;">Item 1B. Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">117</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1CCyberSecurity"><span style="font-style:normal;font-weight:normal;">Item 1C. Cyber Security</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">117</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item2Properties_556040"><span style="font-style:normal;font-weight:normal;">Item 2. Properties</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">118</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item3LegalProceedings_489086"><span style="font-style:normal;font-weight:normal;">Item 3. Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">118</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item4MineSafetyDisclosures_472006"><span style="font-style:normal;font-weight:normal;">Item 4. Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">118</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="font-size:9.5pt;" href="#PARTII_711631"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">119</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item6SelectedFinancialData_251755"><span style="font-style:normal;font-weight:normal;">Item 6. Reserved</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">119</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">120</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">133</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item 8. Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">134</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">169</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item9AControlsandProcedures_496308"><span style="font-style:normal;font-weight:normal;">Item 9A. Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">169</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item9BOtherInformation_603035"><span style="font-style:normal;font-weight:normal;">Item 9B. Other Information</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">169</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item9CForeignJurisdication"><span style="font-style:normal;font-weight:normal;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">169</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="font-size:9.5pt;" href="#PARTIII_517092"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item 10. Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">170</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item11ExecutiveCompensation_760525"><span style="font-style:normal;font-weight:normal;">Item 11. Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">170</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">170</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">170</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Item 14. Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">170</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="font-size:9.5pt;" href="#PARTIV_161604"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item15Exhibits_681346"><span style="font-style:normal;font-weight:normal;">Item 15. Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">170</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Item16Form10KSummary_6829"><span style="font-style:normal;font-weight:normal;">Item 16. Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">174</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#SIGNATURES_688965"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:7.55%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">175</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:92.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#INDEXTOCONSOLIDATEDFINANCIALSTATEMENTS_9"><span style="font-style:normal;font-weight:normal;">Index to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">134</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0bf81e3e_03c2_491e_9d35_1f56c1f215c4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">This Annual Report on Form 10-K (&#8220;Annual Report&#8221;) contains forward-looking statements. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the commercial opportunities stemming from the development of obexelimab for multiple immunology and inflammation (&#8220;I&amp;I&#8221;) diseases;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to develop and, if approved, ultimately commercialize obexelimab and, with partners, our other programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to obtain or maintain orphan drug designation for certain of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the initiation, timing, progress, results, and cost of our development programs, and our current and future preclinical and clinical studies, including statements regarding the timing of initiation and completion of our clinical trials, and the period during which the results of the trials will become available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the success, cost and timing of our clinical development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to establish clinical differentiation of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to develop product candidates that have broad therapeutic potential;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to utilize our business development strategy and expertise to build a balanced portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to identify collaborations and strategic partnerships to maximize the value of our portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to build our operational and commercial capabilities for supplying and marketing our products, if approved, in key markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">an inability to obtain additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to initiate, recruit and enroll patients in and conduct our clinical trials at the pace that we project;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations or warnings in the label of any of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our reliance on third parties to manufacture drug substance and drug product for use in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to retain and recruit key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to obtain and maintain adequate intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our expectations regarding government and third-party payor coverage and reimbursement;</span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our estimates of our expenses, ongoing losses, capital requirements and our needs for or ability to obtain additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our existing cash and the sufficiency of our existing cash and proceeds from future capital-raising efforts, if any, to fund our future operating expenses and capital expenditure requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the potential benefits of strategic collaboration agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to enter into strategic collaborations or arrangements, including potential business development opportunities and potential licensing partnerships, and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">sales of our stock by us, our insiders or our stockholders, as well as expected lock-up releases or expiration of market stand-off or lock-up agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our expectations regarding the time during which we will be an emerging growth company and smaller reporting company under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">general economic, industry, geopolitical and market conditions, such as military conflict or war, inflation and financial institution instability, or pandemic or epidemic disease outbreaks, many of which are beyond our control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">additions or departures of senior management, directors or key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our financial performance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">developments and projections relating to our competitors or our industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">other risks and uncertainties, including those included in the section titled &#8220;Risk Factors.&#8221;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The forward-looking statements in this Annual Report may prove incorrect. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and should not be unduly relied upon. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, these forward-looking statements should not be relied upon as guarantees of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Except as required by applicable law, we do not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUMMARY RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Our business is subject to a number of risks of which investors should be aware before making an investment decision. These risks are discussed more fully in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report. These risks include the following: </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We are a clinical stage biopharma company with a limited operating history and no products approved for commercial sale; we have incurred substantial losses since our inception, and we anticipate incurring substantial and increasing losses for the foreseeable future; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We will require substantial additional financing to achieve our goals, and failure to obtain additional capital when needed, or on acceptable terms, would cause us to delay, limit, reduce or terminate our product development efforts; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Raising additional capital may cause dilution to our stockholders, imposing restrictions on our operations or require us to relinquish rights to our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Clinical development is lengthy and expensive, characterized by uncertain outcomes, with results of earlier studies and trials often failing to predict future trial results or results in other indications of a product candidate. We may incur additional costs or experience delays in completing, or fail to complete, the development and commercialization of our current product candidates or any future product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Delays or difficulties in the enrollment and dosing of patients in clinical trials, delay or prevent receipt of necessary regulatory approvals; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Any significant adverse events or undesirable side effects caused by our product candidates may delay or prevent regulatory approval or market acceptance of our product candidates, or result in significant negative consequences following marketing approval, if any; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We face potential competition from different sources that have made substantial investments into the rapid development of novel treatments for immunological indications, including large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies in our current indications; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We may not realize the benefits of our current or future collaborations or licensing arrangements and may be unsuccessful in consummating future partnerships; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize any product candidate in the U.S. or any other jurisdiction, and any such approval may be for a more narrow indication than we seek; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We are dependent on the services of our senior management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We will need to grow our organization, and we may experience difficulties in managing our growth and expanding our operations, which could adversely affect our business; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">The manufacturing of our product candidates is complex, and our third-party manufacturers may encounter difficulties in production. If our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or provide commercial supply of our products, if approved, could be delayed or halted; </span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates or any future product candidates we may develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, and our ability to successfully develop and commercialize our product candidates may be adversely impacted; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We have relied and expect to continue to rely on third parties to conduct our preclinical studies and clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss deadlines or terminate the relationship, our development programs could be delayed, more costly or unsuccessful, and we may never be able to seek or obtain regulatory approval for or commercialize our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Our rights to develop and commercialize our product candidates are subject, in large part, to the terms and conditions of licenses granted to us by others, such as Xencor, Inc. (&#8220;Xencor&#8221;). If we fail to comply with our obligations in the agreements under which we in-license or acquire development or commercialization rights to product candidates, or data from third parties, we could lose such rights that are important to our business; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">The operations of our suppliers, many of which are located outside of the U.S., including our current sole contract manufacturing organization (&#8220;CMO&#8221;) for drug substance and drug product, WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics&#8221;), which is located in China, are subject to additional risks that are beyond our control and that could harm our business, financial condition, results of operations and prospects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">An active and liquid trading market for our common stock may not be sustained; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">The market price of our common stock may be volatile, which could result in substantial losses for investors. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">If we are unable to adequately address these and other risks we face, our business, results of operations, financial condition and prospects may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE REGARDING TRADEMARKS </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Zenas BioPharma word mark, logo mark, and the &#8220;lightning bolt&#8221; design are trademarks of Zenas BioPharma, Inc. or its affiliated companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We have, in certain cases, omitted the &#174; and &#8482; designations for these trademarks used in this Annual Report. Nevertheless, all rights to such trademarks are owned by Zenas BioPharma, Inc. Other trademarks referenced in this Annual Report are the property of their respective owners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_81783c27_7b15_4bc8_b666_ce0f8fc2d5ce"></a><a id="PARTI_6261"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART I</p><a id="Item1Business_267971"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 1. Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. With the evolving understanding of the pathogenesis of autoimmune diseases, along with the expansion of promising immunology-based pharmacologic targets, we are building an immunology and inflammation (&#8220;I&amp;I&#8221;) focused biopharmaceutical company. Our core business strategy combines disciplined product candidate acquisition with strategic deployment of internal expertise and effective use of external resources. We leverage our experienced executive management team and our established networks throughout the biopharmaceutical industry to identify, acquire and develop product candidates that we believe can provide superior clinical benefits to patients living with autoimmune diseases. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our lead I&amp;I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc&#947;RIIb, which are broadly present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. Based on existing clinical data generated to date, we believe that targeting B cell lineage via CD19 and Fc&#947;RIIb can inhibit B cells and has been shown to be well-tolerated. While anti-CD20 or other anti-CD19 targeting agents may effectively deplete B cells in systemic circulation, these agents do not fully impact B cells in relevant tissue, and the intermittent dosing regimens of these agents may not provide optimal benefits for all patients. In addition, anti-CD20 and other anti-CD19 targeting agents may cause prolonged depletion of circulating B cells for six months or longer, placing patients at higher risk of opportunistic infections and potentially reducing their ability to respond to, and receive full benefit from, vaccines. We believe obexelimab&#8217;s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Across five clinical trials, in which 198 subjects were dosed, obexelimab was well-tolerated and demonstrated clinical activity that we believe provides POC for obexelimab as a B cell inhibitor for the treatment of patients living with certain autoimmune diseases and, together with its mechanism of action, positions obexelimab to be a potentially differentiated B cell therapy for the treatment of such patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe obexelimab holds the potential to provide meaningful clinical benefit for patients in multiple I&amp;I indications. &#160;We are developing obexelimab as a potential I&amp;I franchise for patients in several autoimmune diseases, representing substantial commercial opportunities, individually and in the aggregate. The first three indications we are pursuing include immunoglobulin G4-related disease (&#8220;IgG4-RD&#8221;) through an ongoing registration-directed Phase 3 trial which completed enrollment in November 2024 and relapsing multiple sclerosis (&#8220;RMS&#8221;) and systemic lupus erythematosus (&#8220;SLE&#8221;) through ongoing Phase 2, double-blind, randomized, placebo-controlled trials, each of which are currently enrolling. We estimate that each of these potential indications represent a multi-billion-dollar commercial opportunity in the U.S. alone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Beyond our lead product candidate, obexelimab, we have two other programs for the potential treatment of other I&amp;I indications that we may continue to advance and ultimately develop and commercialize with partners. These consist of ZB002 (an anti-TNF&#945; monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion). We retain global rights for both assets. In addition, we hold the development and commercialization rights to one regional program, ZB001 (also known as VRDN-001, an insulin-like growth factor-1 receptor (&#8220;IGF-1R&#8221;) monoclonal antibody and related programs, which were recently exclusively sublicensed to a partner in greater China. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, we have no product candidates approved for commercial sale in any country and have not generated any revenue from product sales.&#8195;</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:213.2pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Obexelimab Overview </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing obexelimab for the treatment of several I&amp;I diseases summarized in the pipeline figure below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="zbio-20241231x10k007.jpg" alt="Graphic" style="display:inline-block;height:213.2pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our lead product candidate, obexelimab, was engineered to mimic the natural antigen-antibody complex for the inhibition of B cells. By targeting CD19, obexelimab is designed to inhibit a broader B cell population, including plasmablasts and the subpopulation of CD19 expressing plasma cells, each of which produces high amounts of auto-antibodies. Co-engagement of CD19 and Fc&#947;RIIb by obexelimab has been shown to inhibit B cell activity, including antibody production, proliferation, cytokine secretion, B cell differentiation, and antigen presentation to T cells. In addition, obexelimab is designed to inhibit rather than destroy or deplete B cell lineage. Other anti-CD19 and CD20 targeting antibodies rely on antibody-dependent cell-mediated cytotoxicity (&#8220;ADCC&#8221;), complement-dependent cytotoxicity (&#8220;CDC&#8221;) and/or apoptosis or programmed cell death as a key component of their mechanism of action. ADCC, CDC and apoptosis activity are generally lower in disease-relevant tissue than the peripheral blood. In addition, in clinical practice other CD19 and CD20 targeted antibodies are typically dosed once every six months which has demonstrated efficacy, but may not provide sustained benefit in all patients due to variability in B cell depletion and recovery. The obexelimab mechanism of action and chronic dosing regimen may more broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease and has the potential to show greater clinical benefits, especially over a longer course of maintenance treatment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The inhibitory mechanism of obexelimab is believed to reduce the number of B cells in systemic circulation through margination of B cells to other tissues such as the lymph nodes and the spleen, rather than through depletion. The concept of margination is supported by preclinical and clinical data, where the substantial return of B cells in circulation of subjects receiving obexelimab was observed to occur as soon as six weeks after discontinuation of obexelimab administration, contrasted with the much longer period of B cell recovery observed with other CD19 and CD20 targeted depleting agents, which can take six months or longer following the last dose. The risks of prolonged B cell depletion include limitations on a patient&#8217;s ability to fight serious and opportunistic infections and on a patient&#8217;s ability to generate an adequate response to vaccines such as influenza, shingles, respiratory syncytial virus, and COVID-19. We believe the rapid return in B cell activity following the cessation or pause in obexelimab dosing could allow the patient&#8217;s immune system to more quickly return to baseline to protect against infections and allow a patient to receive vaccinations within as few as six weeks of his or her last dose, rather than potentially waiting six months or longer following treatment with an anti-CD19 or anti-CD20 targeted depleting therapy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Obexelimab has been evaluated in five completed clinical trials in which a total of 198 subjects have received obexelimab either as IV infusion at doses of up to 10 mg/kg (n=158) or as a SC injection at doses of up to 375 mg (n=40). Obexelimab was well-tolerated across these five trials and demonstrated PK, as well as clinical activity providing POC in multiple I&amp;I </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">indications. Based on this clinical data, we believe obexelimab could have potential advantages over anti-CD19 and -CD20 targeted depleting agents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Programs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Beyond our lead product candidate, obexelimab, we have two other programs for the potential treatment of other I&amp;I indications that we may continue to advance and ultimately develop and commercialize with partners. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:65.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Product Candidate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Territory</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:65.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Plan of Development</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ZB002 (anti-TNF&#945; mAb)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Global</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:65.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase 1b multiple ascending dose ("MAD") study in patients with RA ongoing</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ZB004 (CTLA-4-Ig fusion)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Global</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase 1 single ascending dose ("SAD") study in healthy volunteers completed</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ZB002, an anti-TNF&#945; therapy designed to have an extended half-life as compared to existing anti-TNF&#945; therapies. ZB002 is a recombinant human monoclonal antibody directed at human TNF&#945;. ZB002 has an identical amino acid sequence to Humira (adalimumab) in the TNF&#945;-binding region of the fragment variable domain; however, the Fc domain of ZB002 contains modifications designed to extend its half-life <i style="font-style:italic;">in vivo</i>. If the results of our ongoing Phase 1b MAD study of ZB002 are favorable, we may seek to identify a partner to advance ZB002 in subsequent trials for potential use as a treatment for certain I&amp;I diseases that can benefit from TNF&#945; inhibition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also own the global development and commercialization rights to ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life compared to approved CTLA-4-Ig fusion protein therapies, such as Orencia (abatacept) and Nulojix (belatacept). Similar to approved CTLA-4-Ig fusion protein therapies, the ZB004 mechanism of action is selective inhibition of T cell co-stimulation. The CTLA-4 motif binds to CD80 and CD86 on antigen-presenting cells, blocking the interaction of these receptors with CD28 on T lymphocytes, and thus inhibiting T cell co-stimulation. ZB004 contains two CTLA-4 extracellular domain substitutions designed to potentially produce greater CD80 and CD86 binding. Based on the ongoing analysis of data from the Phase 1 study, along with the known clinical efficacy of approved CTLA-4-Ig fusion protein therapies, we are seeking to advance the clinical development of ZB004 with a potential partner in indications where it could be uniquely positioned given its profile. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Partnered Regional Programs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also have in-licensed the development and commercialization rights to ZB001 (also known as VRDN-001), an IGF-1R monoclonal antibody, and related programs from Viridian Therapeutics, Inc. (&#8220;Viridian&#8221;) in China, Hong Kong, Macau and Taiwan (collectively, &#8220;greater China&#8221;). On January 24, 2025, we entered into a license agreement (the &#8220;Zai License Agreement&#8221;) with Zai Lab (Hong Kong) Limited (&#8220;Zai&#8221;), under which we granted Zai an exclusive sublicense to develop and commercialize ZB001 and related programs in greater China. As partial consideration for the Zai License Agreement, we received an upfront fee of $10.0 million from Zai. In addition, we are eligible to receive up to $96.0 million upon the achievement of certain future development and commercial milestones and royalty percentage rates from the low to mid-single digits, net of pass-through obligations due to Viridian. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, on October 21, 2024, we entered into a novation agreement with Tenacia Biotechnology (Hong Kong) Co., Limited (&#8220;Tenacia&#8221;), under which we transferred to Tenacia our rights and obligations under our agreements with Dianthus Therapeutics Inc. (&#8220;Dianthus&#8221;) for ZB005 (the &#8220;Tenacia Agreement&#8221;). As partial consideration for the Tenacia Agreement, we received an upfront fee of $5.0 million from Tenacia. In addition, we are eligible to receive up to $86.0 million upon the achievement of certain future regulatory and commercial milestones. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Management Team</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our executive management team is comprised of seasoned executives and scientists with extensive experience in the biopharmaceutical industry, leading drug development and commercialization and executing successful business development strategies. Our company is led by Leon (Lonnie) O. Moulder, Jr., our Founder, Chief Executive Officer and Chairman, and the Managing Member of Tellus BioVentures, LLC, an early-stage life sciences investment fund. Prior to founding Zenas, Mr. Moulder co-founded TESARO, an oncology-focused biopharmaceutical company, serving as Chief Executive Officer and Director until its acquisition by GlaxoSmithKline. He previously served as President and Chief </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Executive Officer of Abraxis BioScience and as Vice Chairman of Eisai Corporation of North America following Eisai&#8217;s acquisition of MGI PHARMA, where he served as President and Chief Executive Officer. Mr. Moulder is joined by our team of veteran biopharmaceutical executives, including Joseph Farmer, Jennifer Fox and Orlando Oliveira, who together with the leadership team, bring exceptional track records and experiences across the industry at companies such as TESARO, Inc., GlaxoSmithKline plc., Amgen Inc., Nuvation Bio Inc., Mirati Therapeutics, Inc., Cubist Pharmaceuticals, Inc. and other biopharmaceutical companies. Our leadership team has collectively been responsible for numerous INDs, and NDAs/BLAs and the associated commercial product launches of several successful pharmaceutical products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Strategy </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our vision is to become a global leader in delivering transformative I&amp;I therapeutics to patients in need. We intend to leverage the experience and capabilities of our executive management team and our established networks throughout the biopharmaceutical industry to identify, acquire, develop and, if approved, commercialize product candidates that we believe can offer enhanced efficacy, safety and/or convenience over existing therapies and thereby provide superior benefits to patients. We intend to achieve our goals by implementing the following strategies: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Develop and commercialize our obexelimab franchise across multiple I&amp;I indications</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We are developing obexelimab as a potential I&amp;I franchise for patients in several autoimmune diseases, representing substantial commercial opportunities individually and in the aggregate. The first three indications we are pursuing include IgG4-RD through an ongoing registration-directed Phase 3 trial; and RMS and SLE through ongoing Phase 2, double-blind, randomized, placebo-controlled trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Build our operational capabilities to develop and potentially commercialize our products in key regions.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> With plans to advance our obexelimab franchise in multiple I&amp;I indications, we intend to build the commercial capabilities necessary to achieve our goal of becoming a global development and commercial stage biopharma company. To that end, we have hired a Chief Commercial Officer and others within the commercial organization.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Utilize our business development experience and expertise to continue to build a deep and balanced portfolio of products and product candidates.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We acquired each of our product candidates through in-licensing from third parties. We intend to continue to utilize our business development strategy and expertise to build a balanced portfolio of new product candidates from preclinical through commercial assets. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Leverage success with initial indications to expand into broader I&amp;I opportunities.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our strategy for each product candidate is to initially pursue indications where the clinical translatability of the mechanism of action has been validated, where we believe we can independently and efficiently pursue clinical development and regulatory approval, and where we believe an attractive commercial opportunity exists. We also intend to pursue additional indications with larger patient populations where we believe our product candidates&#8217; mechanisms may be relevant. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Evaluate strategic collaborations as appropriate.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We may in the future seek arrangements with other biopharmaceutical companies with strong and proven commercial capabilities for them to commercialize or co-commercialize our potential therapies in certain territories, if approved. In addition, for certain indications that may require larger clinical development programs, we may selectively seek to collaborate to help fund development.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obexelimab (CD19 x Fc&#947;RIIb bifunctional monoclonal antibody) Program </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that our lead product candidate, obexelimab, has the potential to address key unmet needs in multiple I&amp;I indications due to its mechanism of action and chronic dosing regimen that may broadly and effectively address the pathogenic role of B cell lineage through reversible inhibition of B cell activity without causing B cell depletion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Obexelimab is a bifunctional, non-depleting, humanized monoclonal antibody designed to bind CD19 and Fc&#947;RIIb to inhibit B-lineage cell activity. The antibody variable region of obexelimab has been engineered to bind CD19, whereas the constant region has been engineered to enhance affinity for the inhibitory Fc&#947;RIIb receptor. Fc&#947;RIIb is the only Fc receptor on B cells and serves as an antibody-sensing down-regulator of humoral immunity that is naturally engaged by </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:191.22pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">immune complexes. In addition, Fc&#947;RIIb regulates the activity of other B cell stimulators including interleukin-4, lipopolysaccharide and B cell activating factor (&#8220;BAFF&#8221;) that amplify BCR-driven proliferation and differentiation. By binding CD19 and Fc&#947;RIIb, obexelimab mimics the action of naturally occurring antigen-antibody complexes and inhibits B cell activity without depleting B cells in the lymph nodes or spleen. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The mechanism of action of obexelimab shown below in Figure 1, involves co-engagement of CD19 and Fc&#947;RIIb, leading to inhibition of B cell activity, including antibody production, proliferation, cytokine secretion, B cell differentiation, and antigen presentation to T cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Figure 1: Mechanism of Action of Obexelimab</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="zbio-20241231x10k008.jpg" alt="Graphic" style="display:inline-block;height:191.22pt;width:161.22pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Through <i style="font-style:italic;">in vitro, in vivo</i> and classical animal models of autoimmune disease, obexelimab&#8217;s binding to CD19 and Fc&#947;RIIb has been shown to enable the inhibition of B cell activity without depleting B cells. Preclinical and clinical studies have demonstrated that obexelimab rapidly achieved nearly 100% CD19 receptor occupancy, potently inhibiting B cell activity along with a decrease of approximately 50% in circulating B cell levels observed within one to two days. We believe the decrease in circulating B cell levels results from margination of B cells in lymphatic tissues, such as the lymph nodes and spleen, rather than depletion or elimination of the B cells. In contrast, anti-CD20 and other anti-CD19 B cell-targeting agents deplete B cells through B cell destruction. In clinical studies, we have observed substantial recovery of B cell levels in circulation following cessation of therapy with obexelimab within six weeks, as opposed to six months or longer that has been observed with B cell depleting agents. This rapid return in B cell activity following the cessation or pause in obexelimab dosing could allow the patient&#8217;s immune system to more quickly return to baseline to protect against infections and could allow a patient to receive vaccination within as few as six weeks of his or her last dose, rather than potentially waiting six months or more following treatment with an anti-CD19 or anti-CD20 targeted depleting therapy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Development </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obexelimab has been evaluated in five completed clinical trials in which a total of 198 subjects have received obexelimab either as an IV infusion at doses of up to 10 mg/kg (n=158) or as a SC injection at doses up to 375 mg (n=40). Across these five trials obexelimab was well-tolerated and demonstrated clinical activity that we believe provides POC for obexelimab as a B cell inhibitor for the treatment of patients living with certain autoimmune diseases. Our current ongoing and planned future trials of obexelimab utilize a fixed 250 mg, dosed weekly as a self-administered SC injection. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:6.9pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Summary of Completed Clinical Trials for Obexelimab </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:67.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Study Description*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Phase</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:67.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Key Results</b></p></td></tr><tr><td style="vertical-align:top;width:13.27%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Healthy Volunteers Study</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase 1a</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">48</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:67.83%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Demonstrated tolerability, PK and target engagement</p></td></tr><tr><td style="vertical-align:top;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Rheumatoid Arthritis (&#8220;RA&#8221;) Trial</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase 1b / 2a</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">56</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:67.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Demonstrated POC by showing clinical activity in patients with RA</p></td></tr><tr><td style="vertical-align:top;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">IgG4-RD Trial</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase 2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">20</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:67.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Demonstrated POC in patients with IgG4-RD</p></td></tr><tr><td style="vertical-align:top;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">SLE Trial</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase 2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">104</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:67.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Demonstrated POC in patients with SLE by showing a reduction in disease relapse**</p></td></tr><tr><td style="vertical-align:top;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">SC &amp; IV Formulation Bioavailability Study</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase 1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">50</p></td><td style="vertical-align:top;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:67.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Established bridging of IV to SC formulation</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>These clinical studies were conducted by Xencor. The results of these studies are further described below. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">**</span></span>Primary endpoint did not achieve statistical significance. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Study in Healthy Adult Volunteers:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> XmAb5871-01 was a Phase 1, randomized, blinded, placebo-controlled, SAD IV study of the safety, tolerability and PK of obexelimab in 48 healthy adult volunteers, with 36 receiving study drug, conducted in the United Kingdom. The primary objective of the study was to evaluate the safety and tolerability profile of a single-dose IV administration of obexelimab. The secondary objective was to characterize the single-dose PK and immunogenicity of obexelimab. The study demonstrated that obexelimab was well tolerated at all doses, including the highest dose of 10 mg/kg. Gastrointestinal (&#8220;GI&#8221;)-related TEAE (including nausea, vomiting, abdominal pain, abdominal discomfort, epigastric discomfort and diarrhea) were the most frequently reported (14/36, 38.9%). There were no SAEs reported. The study was not powered for statistical significance. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Trial in Rheumatoid Arthritis:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> XmAb5871-02 was a Phase 1b/2a, randomized, placebo-controlled, double-blind, ascending multiple-IV dose trial of the safety, tolerability, PK, and PD of obexelimab in 56 patients with RA, with 40 receiving study drug. The trial was conducted at nine sites in four countries, including, Hungary, Poland, Czech Republic and Slovakia. The primary objective of the trial was to evaluate the safety and tolerability profile of multiple-dose, every 14-day, IV administration of obexelimab in patients with RA. The secondary objectives were to (i) characterize the PK and immunogenicity of multiple-dose, IV administered obexelimab in patients with RA and (ii) evaluate the effect of obexelimab on RA disease response. Complete CD19 receptor occupancy was seen at doses as low as 1 mg/kg from the first dose through the completion of dosing. The efficacy parameters evaluated in the trial showed an improvement trend in RA patients who received obexelimab when compared to patients who received placebo, although the trial was not powered to show significant changes. Patients who received obexelimab generally had improvement in ACR20, ACR50, ACR70, and DAS28-CRP Disease Activity when compared to patients who received placebo. In general, obexelimab was well tolerated, and the most common TEAEs were vomiting (7/40, 17.5%), headache (7/40, 17.5%), nausea (6/40, 15.0%), pyrexia (4/40, 10.0%), and arthralgia (4/40, 10.0%). Two subjects experienced infusion-related reactions (both at 10.0 mg/kg), one of which was considered an SAE. The other event, associated with the first infusion, was considered of moderate severity. In both cases, the infusion was terminated, and the patients recovered without sequelae. The trial was not powered for statistical significance. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Trial in IgG4-RD:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> XmAb5871-03 was a Phase 2, open-label, single-arm IV, trial in 20 patients with IgG4-RD, including 15 patients dosed with 5 mg/kg of obexelimab, conducted in Boston, Massachusetts. The primary objective of the trial was to evaluate the effect of every-other-week IV administration of obexelimab on the IgG4-RD Responder Index (&#8220;RI&#8221;). The secondary objectives were to (i) evaluate the safety and tolerability of every-other-week IV administration of obexelimab in subjects with active IgG4-RD and (ii) evaluate the PK and immunogenicity of every-other-week IV administration of obexelimab in subjects with active IgG4-RD. In the </span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">primary efficacy analysis, in patients receiving 5 mg/kg, the IgG4-related disease RI score at Day 169 had decreased by two or more points versus baseline in 12 (80%) patients, eight (67%) of whom had a score of zero (complete remission). Fourteen (93%) patients achieved an improvement on the RI of two or more points during at least one trial assessment at a median of 15 days (range 14 to 90) from treatment initiation. We believe these data demonstrated POC for obexelimab in IgG4-RD. In general, obexelimab was observed to be well tolerated in patients with IgG4-RD. The most common TEAEs were abdominal pain and nausea (4/20, 20.0%), vomiting (3/20, 15.0%), and diarrhea, chills, headache, nasal congestion, and upper respiratory tract infection (2/20, 10.0%). There was one case of pneumonia accounting for two SAEs (initial and recurrence due to non-compliance with therapy) in one patient and a second patient experienced one SAE (chronic inflammation demyelinating polyradiculoneuropathy in the setting of small lymphocytic lymphoma (pre-existing)). None of the SAEs were considered to be related to obexelimab. The trial was not powered for statistical significance. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Trial in SLE:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> XmAb5871-04 was a Phase 2, double-blind, randomized, placebo-controlled, potential POC trial in 104 patients with SLE administered IV, with 52 receiving study drug. The trial was conducted at 23 sites in the U.S. The primary objective of the trial was to determine the ability of obexelimab to maintain SLE disease activity improvement achieved by a brief course of disease-suppressing intramuscular (&#8220;IM&#8221;) steroid therapy. The secondary objectives were to (i) evaluate time to loss of SLE disease activity improvement achieved by a brief course of disease-suppressing IM steroid therapy, (ii) evaluate the safety and tolerability of every-other-week IV administration of obexelimab in subjects with SLE and (iii) evaluate the PK and immunogenicity of every-other-week IV administration of obexelimab in subjects with SLE. Although the primary endpoint (the proportion of patients without loss of improvement in SLE disease activity) in the Efficacy Evaluable (&#8220;EE&#8221;) population was not achieved with statistical significance, the absolute treatment difference in the ITT population was 17.3% (40.4% obexelimab versus 23.1% placebo response, p = 0.06). The ITT analysis is relevant because all patients are considered in these analyses, whereas in the EE analysis there was a larger number of patients treated with placebo who discontinued treatment for reasons that removed them from the analysis. The difference in response rates between the obexelimab and placebo arms in this trial was similar to that observed in SLE registration-directed trials with other agents, although with different trial design and endpoints. Accordingly, we believe these data demonstrated POC for obexelimab in SLE. Obexelimab was generally well tolerated in patients with SLE. The most frequently occurring TEAEs were nausea (20/52, 39%), headache (12/52, 23%), vomiting (9/52, 17%), back pain and dizziness (8/52, 15%), flushing (7/52, 14%), and pain in extremity (6/52, 12%). There were eight SAEs in patients administered obexelimab, only one SAE (infusion-related reaction) of which was considered related to study drug. Adverse events led to the withdrawal of seven (13%) obexelimab-treated patients (most of which were infusion-related reactions) and two (4%) patients that were administered placebo. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">PK and Relative Bioavailability Study of SC versus IV Formulation:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> XmAb5871-05 was a Phase 1 PK and relative bioavailability study of obexelimab administered either intravenously or subcutaneously in 50 healthy volunteers, conducted in Glendale, California, USA. The primary objectives of the study were to (i) characterize and compare the PK and bioavailability of obexelimab administered either IV or SC and (ii) evaluate the safety and tolerability of obexelimab administered SC. The secondary objectives of the study were to (i) determine the immunogenicity of obexelimab administered SC and (ii) characterize and compare the PK of healthy subjects with healthy Japanese subjects. In this study, five separate cohorts were treated with five separate obexelimab dosing regimens: 125 mg SC, 250 mg SC, 375 mg SC, or 250 mg IV every two weeks for six weeks, or 125 mg SC every week for three weeks. The absolute bioavailability of obexelimab across all cohorts after the SC administration was observed to be 58.1% and 53.6% after the first and third doses, respectively. All of the SC doses were observed to be well tolerated in all subjects. In the SC cohorts, the only TEAE occurring in more than two subjects was injection site bruising, which occurred in less than 2% of injections, was considered mild and resolved within 24 hours. The incidence of GI TEAE attributed to SC administration of obexelimab was less than 3%. There were no SAEs reported. Accordingly, we believe that the PK, relative bioavailability, and tolerability demonstrated in this study support the continued clinical development of the SC formulation of obexelimab. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Obexelimab has demonstrated clinical activity across multiple I&amp;I indications. We are currently pursuing a registration-directed trial in patients with IgG4-RD and ongoing Phase 2, double-blind, randomized, placebo-controlled clinical trials of obexelimab in patients with RMS and SLE. Despite the promising results from the Phase 1b/2a trial of obexelimab in RA, we do not intend to develop obexelimab further in RA due to the competitive landscape in that disease. While we believe that the preliminary results from the SApHiAre Trial in patients with warm autoimmune hemolytic anemia </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(&#8220;wAIHA&#8221;) patients established proof of mechanism through an increase in Hgb and a positive effect on other clinical markers, we have determined not to progress to a registration-directed trial of obexelimab for the wAIHA indication based on several factors, including the expected length and expense of a potential Phase 3 trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obexelimab for the Treatment of IgG4-RD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe obexelimab&#8217;s differentiated mechanism of action as an inhibitor of B cell lineage supports its potential to play an important role in the treatment of IgG4-RD. The reported evidence for the role of B cells in the pathogenesis of IgG4-RD, the observed effects of B cell targeting agents in previous trials in IgG4-RD and the data from our Phase 2 IgG4-RD trial with obexelimab support the continued development of obexelimab in patients with IgG4-RD. In November 2024, we completed enrollment of in our INDIGO Trial, a global Phase 3 registration-directed, randomized, double-blind placebo-controlled trial of obexelimab delivered 250 mg subcutaneously weekly to evaluate the prevention of flares in patients with IgG4-RD. We expect to report topline data from our INDIGO Trial year end 2025 and, subject to the data, submit a biologics license application (&#8220;BLA&#8221;) in 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">IgG4-RD Histology and Disease Background </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">IgG4-RD is a chronic fibro-inflammatory condition that can affect virtually all organ systems, including the pancreas, biliary tract, salivary and lacrimal glands, lungs, and kidneys. Patients with IgG4-RD may present with a single organ involved but more frequently present with multiple organ involvement. As the disease progresses and patients experience new or worsening symptoms (i.e., flares), lesions develop in additional organs and the cellular inflammation characterizing early disease moves toward a more fibrotic stage, which can lead to major irreversible tissue damage and ultimately organ failure. The most common symptoms in patients with IgG4-RD and their relative frequency of presentation are highlighted below in Figure 2. IgG4-RD is a relatively recently described disease that incorporates groups of manifestations that were diagnosed as separate disease entities prior to 2003. We estimate that the currently diagnosed population of IgG4-RD patients in the U.S. is approximately 20,000, with what we believe to be comparable prevalence rates globally. The pathogenesis of IgG4-RD suggests that B cell-targeted therapies may provide therapeutic benefit. Several B cell subsets have recently been shown to be elevated in the peripheral blood of IgG4-RD patients. Moreover, plasmablasts have been shown to actively contribute to tissue fibrosis through multiple mechanisms, including production of pro-fibrotic molecules and stimulation of collagen production by fibroblasts. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:272.21pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Figure 2: IgG4-RD: A Chronic Fibro-inflammatory Disease Characterized by Flares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="zbio-20241231x10k010.jpg" alt="Graphic" style="display:inline-block;height:272.21pt;width:432.69pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Current Treatment and Unmet Need </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Despite the growing recognition of IgG4-RD and advances in the understanding of its pathophysiology, there are no approved therapies for the treatment of this disease and there remains high unmet medical need. There are few treatment options, which are often limited by co-morbidities common among patients with IgG4-RD, including diabetes, obesity and hypertension. The current standard of care is glucocorticoid treatment (&#8220;GCs&#8221;), however such treatment often results in various complications. Although GCs are initially effective in most patients, up to 60% of patients with IgG4-RD will relapse within 12 months of discontinuing GC treatment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">IgG4-RD is a disease commonly marked by flares, which can lead to the accumulation of fibrosis, resulting in irreversible organ damage, often involving multiple organs, and past flares are often a strong indicator of future flares. Therefore, patients are in need of long-term maintenance treatment. However, maintenance therapy with GCs has not been shown to prevent recurrence of disease and can lead to significant toxicity and complications, including osteoporosis, hypertension, and diabetes, especially in elderly patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to GCs, the pathogenesis of IgG4-RD suggests that B cell-targeted therapies may provide therapeutic benefit. As a result, although not approved by any regulatory bodies to treat IgG4-RD, certain B cell depleting agents (e.g. rituximab) are occasionally used in such patients. However, B cell depleting agents are often associated with infections, including serious opportunistic infections, and can compromise a patient&#8217;s ability to mount a response to vaccinations. This was shown in a small pilot study of rituximab, a B cell-targeted therapy, in patients with IgG4-RD. We believe this is due to the fact that rituximab and other B cell depleting agents can cause prolonged depletion of B cells for six months or longer, which places patients at risk of opportunistic infections and potentially reduces response to vaccines. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Summary of the Completed Phase 2 Trial of Obexelimab in IgG4-RD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2023, the results of the Phase 2, open-label, single-arm, trial of obexelimab for the treatment of patients with IgG4-RD were published in The Lancet Rheumatology. Twenty patients with active IgG4-RD, defined as an IgG4-RD RI score of three or more, were enrolled. Fifteen patients received obexelimab 5 mg/kg IV every two weeks for 24 weeks. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:216.02pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The protocol was later amended to also provide for the enrollment of an additional five patients who would receive a fixed dose of obexelimab of 90 mg IV or 180 mg IV every two weeks for 24 weeks. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The pre-specified primary analysis of this study focused on the 15 patients enrolled at obexelimab 5 mg/kg. At baseline, the median IgG4-RD RI score was 12 (IQR 7-13). In the primary efficacy analysis, as shown in Figure 3 below, the median decrease in the IgG4-RD RI score was 11.5 points (IQR 7.5-14.5). The IgG4-RD RI score at day 169 had decreased by two or more points from baseline in 12 (80%) patients, eight (67%) of whom had a score of zero (complete remission). These patients included four (80%) of five patients who had achieved remission on previous therapies. Fourteen (93%) patients achieved an improvement on the RI of two or more points during at least one trial assessment at a median of 15 days (range 14 to 90) from treatment initiation. One (7%) patient did not achieve an improvement on the RI score of two or more points, and further evaluation found that this patient who failed to achieve at least a two point improvement on the RI scale had atypical disease activity in only the larynx. Twelve (80%) patients achieved a combined (secondary) endpoint of a decrease on the RI of two or more points at day 169, with no steroid use after day 57, and no disease flares. All primary responders had sustained responses through the end of the trial. The one (7%) patient who did not meet clinical response criteria had a RI score of two at baseline and a score of one before withdrawing from the trial after the Day 71 dose due to lack of efficacy (an IgG4-RD RI score reduction of less than two). Two responders also did not complete the trial: one discontinued after experiencing a disease relapse and one discontinued after an infusion-related hypersensitivity reaction during the fifth infusion. Thirteen (87%) patients experienced adverse events with the most common adverse event of GI infusion-related, including nausea, abdominal pain, and diarrhea. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Figure 3: Rapid and Sustained IgG4-RD RI Responses from Phase 2 Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="zbio-20241231x10k011.jpg" alt="Graphic" style="display:inline-block;height:215.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:449.19pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, as shown in Figure 4 below, circulating B cell counts decreased by approximately 60% throughout the treatment period. However, among seven patients with post-treatment follow-up data, four (57%) demonstrated recovery of circulating B cells to at least 75% of baseline within 42 days of the final obexelimab dose. Circulating plasmablasts also decreased quickly, by approximately 70 to 80%, and began returning following cessation of obexelimab. Obexelimab inhibited B cell receptor-linked signaling pathways but did not induce B cell depletion. Both reductions in circulating B cells without evidence of depletion during obexelimab treatment and their rapid rebound after treatment discontinuation suggest that obexelimab might lead to B cell sequestration (margination) in lymphoid organs or the bone marrow. After the first dose of obexelimab, CD19 receptor occupancy was nearly 100% for most patients and remained at or near complete occupancy until after the last dose of obexelimab at day 155. We believe these results are promising and support the continued development of obexelimab for the treatment of IgG4-RD and potentially other B cell-mediated I&amp;I conditions. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:216.72pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Figure 4: Rapid Recovery of Systemic B Cells Upon Discontinuation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="zbio-20241231x10k012.jpg" alt="Graphic" style="display:inline-block;height:216.72pt;width:429.69pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following enrollment of the first 15 patients treated at 5 mg/kg every other week, an additional five patients were enrolled in a separate cohort to explore a fixed dose regimen of obexelimab 90 mg IV every other week. All five patients achieved a decrease of two points or greater in the IgG4-RD RI at some time during the trial; however, three patients required an increased dose of obexelimab 180 mg IV every other week for disease flare, and two patients also received corticosteroids after Day 57. Peak serum concentration for patients who received 90 mg of obexelimab was approximately 25% and at 180 mg were approximately 50% of those patients who received 5 mg/kg. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Safety Summary </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One patient experienced pneumonia accounting for two SAEs (initial and recurrence due to non-compliance with antibiotic therapy), and a second patient experienced one SAE (chronic inflammatory demyelinating polyradiculoneuropathy in the setting of small lymphocytic lymphoma (preexisting)). None of these events were considered by the investigator to be related to obexelimab. Certain patients also experienced mild to moderate IV infusion-related GI symptoms. The most common TEAEs were abdominal pain and nausea (4/20, 20.0%), vomiting (3/20, 15.0%), and diarrhea, chills, headache, nasal congestion and upper respiratory tract infection (2/20, 10.0%). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">INDIGO Trial&#8212;Our Ongoing Global Phase 3 Trial in IgG4-RD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2024, we completed enrollment of patients in our INDIGO Trial, a global Phase 3 registration-directed, double-blind, placebo-controlled trial to evaluate the safety and efficacy of SC obexelimab in patients with active IgG4-RD in a randomized controlled period followed by an optional open-label extension period. Approximately 190 patients were enrolled in the RCP and all patients from the RCP will be eligible for the OLE period. The trial is being conducted at approximately 100 sites in 20 countries. The RCP consists of a screening period (Day -28 to Day -1) and a 52-week treatment period, during which 250 mg of obexelimab or placebo will be administered as an SC injection every seven days. Following the 52-week RCP, eligible patients will have the opportunity to continue in an OLE period where all patients will receive obexelimab. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:96.35pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Figure 5: INDIGO Trial Schema</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;"><img src="zbio-20241231x10k013.jpg" alt="Graphic" style="display:inline-block;height:96.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To be considered eligible for the screening period, patients must have had a clinical diagnosis of IgG4-RD, met the 2019 ACR/EULAR classification criteria for IgG4-RD, as determined by an Adjudication Committee (&#8220;AC&#8221;), and had active IgG4-RD signs/symptoms (i.e., flare) that require, as assessed by the investigator, the initiation of GC therapy or an increase in background long-term GC therapy. All patients were required to receive three to six weeks of GC treatment at a dose of 20 to 60 mg/day prednisone equivalent prior to randomization. The required GC therapy could either have been newly initiated or an increase in long-term GC therapy (i.e., patient was previously on a dose of &#8804; 10 mg/day prednisone equivalent). The exact dose and taper schedule during the screening period and prior to randomization are at the discretion of the investigator. However, on the day of randomization, patients must have had no disease activity and been at a dose of 20 mg/day prednisone equivalent. Patients were randomized 1:1 to receive obexelimab or placebo. The primary efficacy assessment was time to first IgG4-RD flare, as determined by the investigator and the AC. If the investigator suspected an IgG4-RD flare, based on reappearance of previous signs/symptoms or appearance of new signs/symptoms of IgG4-RD, organ-specific diagnostic assessments were conducted, including a physical examination, imaging and/or testing of biochemical parameters specific to the involved organ(s), to correlate symptoms and to document disease activity. The investigator then determined if an IgG4-RD flare occurred and whether the initiation of rescue therapy was required. The AC independently reviewed these diagnostic assessments to determine if, in their judgement, the signs/symptoms represent a flare. Patients who met the protocol-defined criteria for IgG4-RD flare, by both the investigator and the AC, were counted as treatment failures for the primary endpoint of time to first flare and the key secondary endpoint of proportion of patients who remain free of IgG4-RD flare (i.e., complete remission). Rescue therapy outside of permitted GC therapy would result in discontinuation from obexelimab or placebo treatment, as the case may be. The trial was designed with approximately 90% power to detect a hazard ratio of 0.376 using a one-sided log-rank test at a significance level equal to 0.025. Secondary endpoints include: 52-week flare rate, the proportion of patients achieving complete remission, use and quantity of rescue medication and the change in GC-associated toxicity as measured by the Glucocorticoid Toxicity Index (&#8220;GTI&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patients who complete the RCP Week 52 visit and meet all OLE eligibility criteria will have the option to participate in the trial for up to an additional 116 weeks (104-week treatment period followed by a 12-week follow-up) in the OLE period. During the OLE, all patients will receive obexelimab once every seven days beginning on Day 1 of the OLE period, regardless of their treatment assignment during the RCP. The primary objectives for the OLE are to evaluate the safety and efficacy of obexelimab in patients with IgG4-RD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obexelimab for the Treatment of MS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe obexelimab&#8217;s differentiated mechanism of action as an inhibitor of B cell lineage supports its potential for the treatment of MS. The role of B cells in the pathogenesis of MS has been demonstrated through the successful clinical development, approval and clinical use of anti-CD20 B cell targeting therapies of other companies, including OCREVUS (ocrelizumab) and KESIMPTA (ofatumumab), which selectively deplete peripheral CD20-expressing B cells. B cells are thought to play a central role in MS pathology and its concomitant neurodegeneration via multiple mechanisms. In addition to antibody secretion by plasmablasts and plasma cells, B cell functions implicated in MS pathogenesis include antigen presentation to T cells and production of pro-inflammation cytokines. We believe this activity observed from B cells may contribute to both MS relapses as well as the underlying disease progression. In the third quarter of 2024, we initiated the MoonStone Trial, a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial, to evaluate the efficacy and safety of obexelimab in patients with RMS. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">MS Histology and Disease Background </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">MS is the most common immune-mediated, chronic inflammatory demyelinating disease of the central nervous system (&#8220;CNS&#8221;), affecting over two million people worldwide including as many as 1,000,000 in the U.S., according to the National MS Society and the MS Foundation. We estimate a diagnosed prevalence of approximately 650,000 patients in the U.S. with MS. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">MS is characterized by numerous demyelinating lesions of the brain and spinal cord. The magnetic resonance imaging (&#8220;MRI&#8221;) hallmark of the disease are multiple areas of demyelination in the CNS. The clinical features of an MS attack depend on the areas of the brain or spinal cord involved, thus symptoms may include sensory and visual disturbances, motor, coordination impairment and spasticity, fatigue, pain, and cognitive deficits. Its peak onset is typically in adults between 20&#8201;&#8211;&#8201;40 years old. The most common course of MS is relapsing-remitting (&#8220;RRMS&#8221;), which affects as many as 85% of MS patients. Patients with RRMS experience episodes of neurological dysfunction followed by complete or incomplete recovery. Over time, the majority of RRMS patients develop disease progression, with or without relapses, referred to as secondary progressive MS (&#8220;SPMS&#8221;). Patients with RRMS and SPMS with relapses are typically referred to as having RMS. Lastly, 10 to 15% of patients present with a gradually progressive disease course from onset known as primary progressive MS (&#8220;PPMS&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Most patients initially diagnosed with RRMS experience two distinct clinical phases, the relapsing-remitting and progressive phases, each of which is reflected by a distinct pathological process. During the relapsing-remitting phase, inflammation drives disease activity while neurodegeneration, which is characterized by accumulating disability, is predominant in the progressive phase. However, underlying progression occurs in all forms of MS, and obexelimab&#8217;s unique mechanism of action has the potential to impact both the inflammation and neurodegeneration aspects of MS pathogenesis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Currently, the cause of MS remains unknown; however, both B and T cells play an important role in the pathogenesis of the disease, including inflammation and demyelination process. In addition to producing autoantibodies and inflammatory cytokines, B cells have an important function as antigen-presenting cells (&#8220;APCs&#8221;) involved in T cell activation. The APC function of B cells is thought to be an important reason for the beneficial effects of B cell therapies in MS. Chronic CNS inflammation in the MS lesion is maintained, in part, with activated pro-inflammatory macrophages, microglia and astrocytes at the rim of chronic active or slowly expanding MS lesions, which are the site of ongoing demyelination and neuronal damage. The continued expansion of chronic active lesions is believed to play a role in the pathogenesis of disease progression in MS. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:227.22pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Figure 6: Role of B and T Cells in Multiple Sclerosis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="zbio-20241231x10k014.jpg" alt="Graphic" style="display:inline-block;height:227.22pt;width:447.69pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The potential efficacy of obexelimab in the treatment of MS has been demonstrated preclinically in a prophylactic disease animal model. An obexelimab surrogate antibody (XENP8206) was evaluated versus a rituximab surrogate antibody and vehicle control in a preclinical experimental autoimmune encephalomyelitis (&#8220;EAE&#8221;) model. As shown in Figure 7 below, XENP8206 prevented disease incidence to a greater extent than the rituximab surrogate antibody and the activity of XENP8206 was not associated with B cell depletion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Figure 7: Suppression of Disease Activity in EAE Model Without B Cell Depletion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="zbio-20241231x10k015.jpg" alt="Graphic" style="display:inline-block;height:149.23pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:455.94pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Current Treatment, Limitations and Remaining Unmet Need </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Despite various treatments available for MS patients, unmet clinical needs remain, including a lack of an effect on progression independent of relapse activity (&#8220;PIRA&#8221; or also known as &#8220;silent progression&#8221;), which has been observed even in patients with early RMS on highly effective therapies. Gadolinium enhancement is a sensitive technique for detecting active MS lesions and confirms the inflammatory activity of the disease. Monitoring the change in these MRI contrast enhancing lesions is routine and decreased MRI activity represents the earliest treatment effects in clinical trials. In many MS Phase 3 trials, including those of B cell therapies, reductions in inflammatory lesions, initially demonstrated in Phase </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2 POC trials utilizing MRI endpoints, were often accompanied by clinical improvements. The paramagnetic rim lesion may serve as another important emerging MRI marker of chronic neuroinflammation, with any modification observed in a clinical trial potentially indicating a change in disease progression. In the third quarter of 2024, we initiated a Phase 2 potential POC trial of obexelimab in RMS patients, utilizing various MRI detection techniques and biomarkers to assess its impact in both the acute and chronic aspects of the disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, there are a number of therapies that have been approved for the treatment of MS, including injectable, oral and infused medications. Although MS is historically considered a T cell disease, blockade of B cell autoreactivity inhibits neuroinflammation through several pathways, including (i) preventing B cells from acting as antigen-presenting cells that activate autoreactive T cells, (ii) preventing B cells from releasing proinflammatory cytokines, (iii) preventing B cells from transforming into plasma cells that may produce myelin-directed autoantibodies, and (iv) preventing B cells from forming meningeal lymphoid follicles. Despite effective treatment for relapses, there remains a considerable proportion of patients who experience ongoing disease activity and/or accumulating progression of disability. Within 20 years of diagnosis, 30&#8201;&#8211;&#8201;60% of patients with RRMS convert to SPMS with relapse-independent disability progression resulting in severe limitations on quality of life. Despite currently approved therapies, there is an enduring need for additional safe and effective treatments that address the underlying progression seen in MS to potentially alter the course of disability. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Our Global Phase 2 Trial in RMS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Given the clinical activity observed with B cell depleting agents, we are currently enrolling patients in the MoonStone Trial, a global Phase 2 potential POC trial of obexelimab in RMS patients. We expect to enroll approximately 93 patients and to conduct the trial at multiple sites worldwide. The Phase 2 trial in RMS is a randomized, placebo-controlled trial in patients with relapsing active forms of MS in order to assess the safety and efficacy of a 250 mg weekly SC dose of obexelimab, utilizing various MRI detection techniques and biomarkers to assess its impact in both the active and chronic aspects of the disease. The primary objective of this trial is to assess the change from baseline in the cumulative number of new Gd-enhancing lesions identified on T1-weighted MRI over the course of three months. Upon completion of the three-month period, patients on placebo will receive obexelimab treatment for at least three months and patients initially randomized to obexelimab will continue on treatment. Important secondary endpoints include changes in various other MRI assessments (i.e., changes in T2-weighted lesions, changes in the number of new phase RIM lesions, number of T1 lesion conversions to phase RIM lesions, etc.). We expect to report data from the MoonStone Trial on the primary endpoint at 12 weeks in the third quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obexelimab for the Treatment of SLE </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The crucial role of B cells in SLE pathogenesis is well recognized, from producing autoantibodies to abnormal regulation of immune responses. Moreover, SLE is an autoimmune disease characterized by B cell dysfunction, the production of autoantibodies toward cellular and nuclear components, and multiorgan damage caused by immune complex deposition and inflammation within affected tissues. Obexelimab has demonstrated clinical activity as a B cell-directed agent due to its inhibitory effect on B cell lineage via its binding to CD19 and Fc&#947;RIIb, and a prior Phase 2 double-blind, randomized trial we believe demonstrated POC in SLE. In the third quarter of 2024, we initiated the SunStone Trial, a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial, to evaluate the efficacy and safety of obexelimab to reduce disease activity in patients with SLE. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">SLE Histology and Disease Background </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">SLE, the most common form of lupus, is a complex, chronic autoimmune disease characterized most notably by unpredictable flares in joints, skin, kidneys and other vital organs that cause progressive organ damage. The prognosis of SLE varies from patient to patient, with alternating periods of active symptoms and remission throughout their lifetime. SLE ranges from a relatively benign disease to rapidly progressive and even fatal. Comorbidities, such as infections, malignancies, hypertension, lipid disorders and diabetes, increase the risk of disability and death in patients. SLE commonly affects the central nervous system, kidneys, gastrointestinal system, mucous membranes, heart, skin, hematologic system, musculoskeletal system and lungs. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:380.2pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Figure 8: SLE Disease Characteristics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="zbio-20241231x10k016.jpg" alt="Graphic" style="display:inline-block;height:380.2pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:404.94pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Increased B cell activity and survival mediated through BCR abnormalities is a classic feature of SLE. BCR signals are impacted by several regulatory surface proteins, including CD19 and Fc&#947;RIIb. Activation of Fc&#947;RIIb is known to effectively dampen BCR signaling and decrease B cell responses to activating signals, which may play a pivotal role in suppressing a patient&#8217;s own immune system from attacking cells. In addition, data in both murine lupus models and human lupus studies provide a rationale for targeting CD19 and Fc&#947;RIIb as a treatment for SLE. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Current Treatment, Limitations and Remaining Unmet Need </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">According to the Lupus Foundation of America, at least 1.5 million Americans are afflicted by lupus and more than 16,000 new cases are reported annually. It is estimated that five million people throughout the world suffer from some form of lupus, of which approximately 70% suffer from the most common form, SLE. Lupus affects primarily women of childbearing age (15 to 44 years). However, men, children and teenagers can also develop lupus. We estimate a diagnosed prevalence of approximately 245,000 patients in the U.S. having lupus, with approximately 150,000 having SLE. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The current treatment strategy for SLE is based on treating the affected organ(s) and focuses on achieving a defined state of remission or low disease activity. Targeting B and plasma cells may have positive results in the overall treatment of SLE because of the role autoantibodies play in the pathogenesis of the disease. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Current treatments include non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, hydroxychloroquine, Benlysta (belimumab) (FDA approved for SLE in 2011), and Saphnelo (anifrolumab) (FDA approved for SLE in 2021). These limited FDA approved options are modestly effective with improvement in combination with standard therapy versus standard therapy alone in Phase 3 trials of nine to seventeen percentage points. We believe there is an opportunity to identify a clinically-validated biomarker to guide the selection or optimal administration of treatments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Summary of Obexelimab&#8212;Phase 2 Trial in Patients with SLE </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Study XmAb5871-04 was a Phase 2, double-blind, randomized, placebo-controlled trial to evaluate the ability of obexelimab to maintain SLE disease activity improvement in patients after brief treatment of active disease with corticosteroids. Patients were randomized 1:1 to receive intravenous obexelimab (5 mg/kg) or matching placebo every two weeks for 16 doses or until loss of improvement (&#8220;LOI&#8221;). LOI was defined by either a 4-point increase in the hybrid Systemic Lupus Erythematosus Disease Activity Index (&#8220;hSLEDAI&#8221;) score or at least one British Isles Lupus Assessment Group (&#8220;BILAG&#8221;) A or B score rated &#8220;new&#8221; or &#8220;worse&#8221;. One hundred and four patients were randomized, with 52 assigned to obexelimab treatment and 52 to placebo. Patients completing the trial included 28 (53.8%) receiving obexelimab and 17 (32.7%) receiving placebo. Median months of treatment was 6.9 (range 0&#8201;&#8211;&#8201;7.4) with obexelimab and 3.6 (range 0&#8201;&#8211;&#8201;7) with placebo. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The primary endpoint was assessed as the proportion of patients reaching week 32 without LOI, using an EE population, defined as patients who completed the trial or withdrew for flare or treatment-related toxicity. Twenty-one out of 50 (42.0%) obexelimab-treated patients versus 12 out of 42 (28.6%) placebo-treated patients achieved the primary endpoint. Although the primary endpoint was not achieved with statistical significance (p = 0.183), the ITT population revealed a larger absolute treatment difference of 17.3% (40.4% versus 23.1%, p=0.06) in the obexelimab-treated group versus the placebo-treated group. The ITT analysis is relevant since all patients are considered in this analysis, whereas in the EE analysis a larger number of placebo-treated patients than obexelimab-treated patients discontinued treatment for reasons that removed them from the analysis (10 patients versus 2 patients). Furthermore, the placebo response rate (28.6% in the EE analysis and 23.1% in the ITT analysis) was higher than the 10% rate which was assumed in the statistical assumptions for the trial. Nevertheless, the difference in response rates between the obexelimab and placebo arms in this trial was similar to that observed in SLE registration-directed trials with other agents, although with different trial design and endpoints. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, there was an association between obexelimab concentration and time to LOI. PK analysis revealed that quartiles of patients with progressively higher drug concentration had progressively longer time to LOI. In the EE analysis, patients in Ctrough quartiles three and four exhibited a larger absolute LOI treatment difference of 35% in the obexelimab-treated group versus the placebo-treated group. Accordingly, we believe these data demonstrated POC for obexelimab in SLE. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fourteen (26.9%) patients that received obexelimab and 25 (48.1%) patients that received placebo withdrew for LOI. Adverse events led to the withdrawal of seven (13%) obexelimab-treated patients (most of which were infusion-related reactions) and two (4%) patients that were administered placebo. Withdrawal for other reasons occurred in three patients that were administered obexelimab and eight that were administered placebo. There was no increase in the proportion of patients with infection in obexelimab as compared to placebo treated groups. The most frequently occurring TEAEs in patients who received obexelimab administered IV were nausea (20/52, 39%), headache (12/52, 23%), vomiting (9/52, 17%), back pain and dizziness (8/52, 15%), flushing (7/52, 14%) and pain in extremity (6/52, 12%). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Biomarker analysis identified baseline gene expression profiles associated with increased response to obexelimab. Patients with adequate baseline RNA samples (71 in total) were assigned into one of seven clusters (immunophenotypes) as defined by Guthridge et al. 2020 using the Oklahoma Lupus Cohort. Patients in gene expression clusters three and six exhibited greater prolongation of time-to-flare with obexelimab, whereas in the other clusters obexelimab was not associated with a prolongation in time-to-flare. Patients in gene expression clusters three and six exhibited a larger absolute treatment difference in LOI of 52% in the obexelimab-treated group versus the placebo-treated group. There was a relatively small difference in time-to-flare between patients treated with placebo in clusters three and six compared with patients treated with placebo in the other clusters, suggesting that clusters three and six had higher predictive than prognostic value. Clusters three and six represent 38% of the population tested, which is similar to the 31% of cluster three and six patients in the original Oklahoma cohort. These clusters include patients of African and European descent and share increased expression of B cell pathways and low expression of inflammation pathways. These responsive immunophenotype </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">subgroups are thus consistent with the drug&#8217;s mechanism of action, inhibition of B cell, plasmablasts, and plasma cell activity, an impact that was observed in patients treated with obexelimab. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe the obexelimab efficacy data in the overall trial population and the increased response in biomarker-defined subpopulations, coupled with the safety data obtained to date, provide support for further clinical trials and the use of a SC obexelimab formulation in patients with SLE. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Our Global Phase 2 Trial in Patients with SLE </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are currently enrolling patients in the SunStone Trial, a global Phase 2, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of obexelimab when used to reduce disease activity in patients with SLE. We expect to enroll approximately 190 patients and to conduct the trial at multiple sites worldwide. We expect to complete enrollment of the SunStone Trial in 2025 and report data on the primary endpoint at 24 weeks in the first half of 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To be eligible for the trial, patients enrolled must have active SLE at screening, as defined by BILAG 2004 and hSLEDAI. Patients will be randomized 1:1 to obexelimab 250 mg or placebo SC injection every seven days over 24 weeks. The primary endpoint is the percentage of responders, defined by BILAG-based Composite Lupus Assessment, with a reduction of SLE disease activity at week 24. Biomarker analysis is planned to be conducted in all patients. This includes baseline RNA expression profiles to immunophenotype patients and evaluation of their differential responses to treatment. Additional biomarker assessments include serum cytokines and chemokines, SLE disease markers (complement C3/ C4, anti-dsDNA), and immune cell subsets (B cells, plasma cells, etc.). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Obexelimab for the Treatment of wAIHA &#8211; SApHiAre Trial </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2024, we announced preliminary results from patients in the open-label SRP of the Phase 2 portion of our SApHiAre Trial, a global study of obexelimab in patients with wAIHA.&#160; The primary objectives of the SRP are to provide preliminary safety, tolerability, PK/PD and efficacy data of obexelimab in patients with wAIHA. Patients were given 250 mg obexelimab weekly through subcutaneous administration for 24 weeks. The primary efficacy endpoint in the SRP is proportion of patients with a hemoglobin (&#8220;Hgb&#8221;) &#8805; 10 g/dL and &#8805; 2 g/dL increase from baseline on or after Week 8, with no use of blood transfusion or GC rescue therapy prior to attaining response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of the cut-off date, nine patients had been enrolled in the SRP over an approximately one-year period, including eight patients with primary wAIHA and one patient with secondary wAIHA due to autoimmune disease. One patient had not reached week four by the cut-off date and was not included in the analysis. Five of eight patients achieved an increase of &gt;1 g/dL of Hgb from baseline during weeks 8-24 without influence of concomitant medications. Additionally, a Hgb increase of &#8805; 2 g/dL measured from Hgb nadir to peak was observed in five of eight patients.&#160;LDH and total bilirubin levels decreased overall during weeks 8-24. No patients received transfusions. Obexelimab was well tolerated in patients with wAIHA with a safety profile similar to that observed in earlier studies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">While we believe that the preliminary results from the SApHiAre Trial established proof of mechanism through an increase in Hgb and a positive effect on other clinical markers, we have determined not to progress to a registration-directed trial of obexelimab for the wAIHA indication based on several factors, including the expected length and expense of potential Phase 3 trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Safety Profile of Obexelimab </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the completed studies, 198 subjects have received obexelimab, 158 subjects as an IV infusion at doses of up to 10 mg/kg and 40 subjects as a SC injection of up to 375 mg. The majority of TEAEs in the studies using obexelimab were mild or moderate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The clinically important identified risk of obexelimab, defined by serious and related events observed in obexelimab treated subjects, included unanticipated infusion related reactions which have not been observed for the subcutaneous injection of obexelimab. The clinically non-important identified risks of obexelimab, defined as non-serious and related events, included intravenous infusion related GI events and injection site reactions via the SC administration. The injection </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">site reactions were of minimal clinical impact, non-serious, did not lead to study drug discontinuation, and are anticipated to occur in less than 2% of injections. The IV infusion related GI events were non-serious and were not observed with SC injection. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Serious Adverse Events </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The only SAEs considered by the investigator to be related to obexelimab or placebo across the five clinical studies completed to date were: two IV infusion related reactions, one in each of two obexelimab treated patients, one venous thrombosis in an obexelimab treated patient, one herpes zoster in a placebo treated patient and a post herpetic neuralgia in a placebo treated patient. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Anti-Drug Antibodies </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The development of anti-drug antibodies (&#8220;ADA&#8221;) has been observed in all studies; however, the ADA response did not have an apparent effect on PK or safety parameters (i.e., accelerated clearance), with the possible exception of one subject (in the first in human (&#8220;FIH&#8221;) study) and the three subjects with hypersensitivity reactions mentioned above. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Safety Summary of Previously Completed Clinical Studies </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Study XmAb5871-01 </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overall, doses of up to and including 10 mg/kg obexelimab were well tolerated by healthy male subjects. GI-related TEAEs (including nausea, vomiting, abdominal pain, abdominal discomfort, epigastric discomfort and diarrhea) were the most frequently reported (14/36, 38.9%). Eight subjects (8/36, 22.2%) who had received 0.2 to 10 mg/kg obexelimab had their IV infusion temporarily interrupted as a result of the GI-related symptoms. In all cases, symptoms leading to infusion interruption were transient and subjects were able to continue the infusion after a short break without recurrence of symptoms. Symptom resolution did not require the use of concomitant medications. No infusion-related reactions or hypersensitivity reactions were observed. There were no SAEs reported. No subject was withdrawn and none self-withdrew. There was no consistent dose-response relationship with the incidence of TEAEs and no dose-limiting toxicities were observed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Study XmAb5871-02 </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Among the 40 patients who received obexelimab, the most common TEAEs were vomiting (7/40, 17.5%), headache (7/40, 17.5%), nausea (6/40, 15.0%), pyrexia (4/40, 10.0%), and arthralgia (4/40, 10.0%). As in the FIH study in healthy male volunteers (Study XmAb5871-01), gastrointestinal-related TEAEs (nausea, vomiting, diarrhea) were mostly mild to moderate, resolved with interruption of infusion and did not reoccur with reinitiation of infusion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In general, multiple doses of up to 10 mg/kg obexelimab were well tolerated in patients with RA. Two subjects experienced infusion-related reactions (both at 10.0 mg/kg), one of which was considered an SAE. The other event, associated with the first infusion, was considered of moderate severity. In both cases, the infusion was terminated, and the patients recovered without sequelae. The nature and severity of these infusion reactions were consistent with those reported for other monoclonal antibody therapies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Study XmAb5871-03 </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In general, obexelimab was well tolerated in patients with IgG4-RD. The most common TEAEs were abdominal pain and nausea (4/20, 20%), vomiting (3/20, 15%), and diarrhea, chills, headache, nasal congestion, and upper respiratory tract infection (2/20, 10%). Four patients (4/20, 20%) had first dose GI symptoms of nausea, vomiting, and/or diarrhea as described previously with IV infusions. The symptoms were relieved by interrupting the infusion for a short period of time. There was one infusion-related hypersensitivity reaction that was associated with the presence of ADA, that was treated with symptomatic medications and that resolved after obexelimab was stopped. This patient recovered fully and discontinued the trial. There was one case of pneumonia accounting for two SAEs (initial and recurrence due to non-compliance with therapy) in one patient and a second patient experienced one SAE (chronic inflammation demyelinating </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">polyradiculoneuropathy in the setting of small lymphocytic lymphoma (pre-existing)). None of the SAEs were considered to be related to obexelimab. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Study XmAb5871-04 </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obexelimab was generally well tolerated in patients with SLE. The most frequently occurring TEAEs were nausea (20/52, 39%), headache (12/52, 23%), vomiting (9/52, 17%), back pain and dizziness (8/52, 15%), flushing (7/52, 14%), and pain in extremity (6/52, 12%). The majority of these events were mild and resolved. There were 8 SAEs in patients administered obexelimab, only one (infusion-related reaction) of which was considered related to study drug. Fourteen (14/52, 26.9%) patients that received obexelimab and 25 (48.1%) patients that received placebo withdrew for LOI. Adverse events led to the withdrawal of seven (7/52, 13%) obexelimab-treated patients (most of which were infusion-related reactions) and two (4%) patients that were administered placebo. Withdrawal for other reasons occurred in three patients that were administered obexelimab and eight that were administered placebo. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Study XmAb5871-05 </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overall, the SC administration of obexelimab was well tolerated. The most common TEAEs across all SC dose regimens were headache and injection site reaction (3/40, 8%). The incidence of injections with injection site erythema, induration and/or pain as a total out of all injections was 4/207 (total), or 1.9% of injections. The symptoms involved only one of the possible two or three sites injected on that day, were mild, and resolved within 24 hours. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dosage and Administration for Obexelimab </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obexelimab has been evaluated in five completed clinical trials in which a total of 198 subjects have received obexelimab either as an IV infusion at doses of up to 10 mg/kg (n=158) or as a SC injection at does up to 375 mg (n=40). We believe these trials have demonstrated obexelimab&#8217;s PK/PD and tolerability profile. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our current ongoing and planned trials of obexelimab utilize or will utilize a fixed 250 mg self-administered SC injection dosed weekly. This dosing regimen is supported by the totality of existing clinical efficacy and safety data, PK/PD modeling, and nonclinical data. The 250 mg weekly SC dose is designed to maximize the potential for efficacy by providing maximum PD target engagement, comparable exposure and, importantly, a higher Ctrough when compared with the 5 mg/kg IV every two weeks dosing regimen, which demonstrated clinical activity in the IgG4-RD and SLE Phase 2 trials of obexelimab. In addition, the 250 mg weekly SC dose was designed to maintain a lower Cmax than the 5 mg/kg IV every two weeks dosing regimen to provide sufficient safety margins and an acceptable tolerability profile based on both clinical and nonclinical study data of obexelimab. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical Characterization </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">In vitro</i> studies demonstrated that obexelimab has a high affinity for human CD19 and human Fc&#947;RIIb. The half-maximal effective concentration (&#8220;EC50&#8221;) of binding of obexelimab to a human CD19 expressing cell line is 0.3 nM, and the EC50 of binding of obexelimab to human primary B cells is 1.4 nM. The binding affinity of obexelimab for human Fc&#947;RIIb (8 nM) has been increased approximately 230-fold relative to human native IgG1 as a result of Fc engineering. <i style="font-style:italic;">In vitro</i>, co-engagement of CD19 and Fc&#947;RIIb by obexelimab results in the inhibition of calcium mobilization upon stimulation of B cells from normal volunteers as well as in RA and SLE patients. <i style="font-style:italic;">In vivo</i>, obexelimab demonstrated inhibition of an induced human B cell response to immunization with tetanus toxoid in severe combined immunodeficient mice engrafted with human peripheral blood mononuclear cells. In addition, obexelimab demonstrated disease improvement in several animal models of disease, including collagen-induced arthritis, AIHA and MS. Obexelimab has shown no antibody-dependent cellular cytotoxicity mediated B cell depletion <i style="font-style:italic;">in vitro,</i> nor has there been any significant obexelimab-mediated IL-6 or TNF-&#945; cytokine release. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Programs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Beyond our lead product candidate, obexelimab, we have two other programs for the potential treatment of other I&amp;I indications that we may continue to advance and ultimately commercialize with partners. These consist of ZB002 (an anti-TNF&#945; monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion). We retain global rights for both assets. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ZB002 Program (anti-tumor necrosis alpha monoclonal antibody) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ZB002 is a monoclonal antibody inhibitor of TNF&#945; designed to have an extended half-life as compared to existing anti-TNF&#945; therapies. ZB002 is identical to adalimumab in the TNF&#945;-binding region of the fragment variable domain, but the Fc domain contains modifications to extend ZB002&#8217;s half-life <i style="font-style:italic;">in vivo</i> (Xencor&#8217;s Xtend technology). Our Phase 1 SAD study demonstrated a half-life of approximately 55 days for ZB002, which we believe may allow for dosing once every four to eight weeks. In the second quarter of 2024, we initiated a Phase 1b MAD study of ZB002 in patients with rheumatoid arthritis. A head-to-head preclinical study in mice demonstrated ZB002&#8217;s extended (&#8805; 2-fold longer) half-life over adalimumab. If the results of our ongoing Phase 1b MAD study of ZB002 are favorable, we may seek to identify a partner to advance ZB002 in subsequent trials for potential use as a treatment for certain I&amp;I diseases that can benefit from TNF&#945; inhibition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Anti-TNF&#945; Background and Mechanism of Action </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">TNF&#945; is a potent inflammatory cytokine, produced primarily by activated monocytes, macrophages and T cells, as a cell surface protein. After being activated, TNF&#945; is released and binds to receptors on TNF&#945;-responsive cells to enhance the inflammation and immune response to environmental stimuli such as foreign antigens. Elevated expression of TNF&#945; has been linked to a number of I&amp;I diseases, and inhibition of TNF&#945; signaling has been validated as a therapeutic approach to treat several diseases. The FDA and other comparable foreign regulatory agencies have approved five anti-TNF&#945; therapies to treat diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn&#8217;s disease, psoriasis, ulcerative colitis, hidradenitis suppurativa, and uveitis. Among those approved therapies are Remicade (infliximab), Simponi (golimumab) and Humira (adalimumab), monoclonal antibodies that target TNF&#945; for inhibition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Summary of Clinical Trials </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We conducted a Phase 1 SAD study designed to evaluate the safety, tolerability, PK and PD profiles of ZB002 in healthy volunteers. We enrolled 48 healthy volunteers across six cohorts of varying dose levels, ranging from 20 mg to 240 mg, for the study. Eight healthy volunteers were randomized 3:1 to ZB002 or placebo, per cohort. There was one SAE of peri-anal abscess. Our Phase 1 SAD study demonstrated a half-life of approximately 55 days for ZB002, which we believe may allow for dosing once every four to eight weeks. In the second quarter of 2024, we initiated a Phase 1b MAD study of ZB002 in patients with rheumatoid arthritis. If the results of our ongoing Phase 1b MAD study of ZB002 are favorable, we may seek to identify a partner to advance ZB002 in subsequent trials and ultimately, if approved, commercialize ZB002 for potential use as a treatment for certain I&amp;I diseases that can benefit from TNF&#945; inhibition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Preclinical Characterization </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ZB002 has similar pharmacological characteristics to adalimumab, including TNF&#945; binding and inhibition. The EC50 for <i style="font-style:italic;">in vitro</i> inhibition of TNF&#945; signaling is roughly equivalent (18.17 ng/mL for ZB002 and 14.25 ng/mL for adalimumab), and ZB002 and adalimumab inhibited TNF&#945;-induced lethality in <i style="font-style:italic;">in vivo</i> mouse models at similar rates. However, ZB002 has a higher fragment crystallizable receptor (&#8220;FcRn&#8221;) binding affinity (KD = 6.54 &#215;10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#8722;8</sup> M) compared to adalimumab (KD = 1.88 &#215;10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#8722;6</sup> M), which is designed to extend ZB002&#8217;s <i style="font-style:italic;">in vivo</i> half-life. In the human neonatal FcRn expressed transgenic mice, the PK profile of ZB002 was found to be similar to that of adalimumab with the exception of an extended (&#8805; 2-fold longer) half-life (t1/2 = 9.9 hours and 4.1 hours for ZB002 and adalimumab, respectively). The subcutaneous bioavailability of ZB002 was 62.4% to 106.0% in cynomolgus monkeys, depending on the dose. Weekly subcutaneous administration of ZB002 for 13 weeks in cynomolgus monkeys demonstrated no adverse safety findings at any dose tested up to 200 mg/kg, providing an adequate therapeutic window for assessment in humans. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ZB004 Program (CTLA-4-IG fusion) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ZB004 is a CTLA-4-Ig fusion protein designed to have an extended half-life versus existing CTLA-4-Ig fusion protein therapies. Based on the results from our ongoing Phase 1 study, we plan to evaluate the path forward for the development of ZB004 in the treatment of I&amp;I indications. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">CTLA-4-Ig Background and Mechanism of Action </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ZB004 is comprised of two CTLA-4 extracellular domain substitutions and an IgG Fc region containing substitutions (Xencor&#8217;s Xtend technology). This design allows for increased binding affinity to human CD80 and CD86 and FcRn. Its mechanism of action is selective inhibition of T cell co-stimulation by binding to CD80 and CD86 receptors, which blocks their interaction with CD28 on T cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In rheumatoid arthritis, T cells contribute to lymphoid organogenesis in the inflamed joint and neoangiogenesis, stimulate synoviocyte proliferation, and support the development of osteoclasts. CTLA-4, a protein expressed on the surface of CD4+ and CD8+ T cells, is an inhibitory receptor with high homology to the costimulatory receptor CD28. It acts as a negative regulator of CD28-mediated activation of CD4+ and CD8+ T cells. CTLA-4-Ig fusion proteins disrupt binding of CD28 with ligand B7 molecules, CD80 and CD86, expressed on antigen-presenting cells. Inhibition of this signaling pathway results in a suppression of T cell effector function and is clinically validated by the regulatory approval of two CTLA-4-Ig therapeutics in several I&amp;I diseases: Orencia (abatacept) and Nulojix (belatacept). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Clinical Development </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We conducted a Phase 1 SAD study designed to evaluate the safety, tolerability, PK immunogenicity and PD profiles of ZB004 in healthy volunteers. Our Phase 1 SAD study enrolled 40 healthy volunteers across five cohorts of varying dose levels, ranging from 3 mg to 200 mg, with eight healthy volunteers randomized 3:1 to ZB004 or placebo, per cohort. Our Phase 1 SAD study demonstrated a half-life of approximately 17.4 days at the highest dose level of 200 mg, where CD86 receptor occupancy reached a maximum peak value of 81%, overcoming the effect of target mediated drug disposition. There were no SAEs reported. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Preclinical Characterization </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ZB004 has been engineered to increase its affinity to human CD80 and CD86 by approximately six-fold compared to abatacept. ZB004 also binds with higher affinity to human FcRn which is expected to extend ZB004 half-life <i style="font-style:italic;">in vivo</i>. ZB004 has shown potency by inhibiting T cell activity and cytokine release. In an <i style="font-style:italic;">in vitro</i> functional inhibition assay of T cell activity, the mean half-maximal inhibitory concentration (&#8220;IC50&#8221;) value was 0.334 &#181;g/mL for ZB004 (2 donors) and &gt; 50 &#181;g/mL for abatacept. When the inhibition of inflammation cytokine release was assessed, the IC50 values for interleukin 2 (IL-2) secretion driven by ZB004 or abatacept were &lt; 0.003 &#181;g/mL and 0.152 &#181;g/mL, respectively. The IC50 values for interferon gamma secretion driven by ZB004 and abatacept were 0.0054 &#181;g/mL and &gt; 50 &#181;g/mL, respectively. ZB004 has shown prophylactic efficacy in a collagen-induced arthritis disease model. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ZB004 was well tolerated in toxicology studies up to 13 weeks via subcutaneous administration in cynomolgus monkeys and rats, providing an adequate therapeutic window for assessment in humans. In addition, ZB004 has a PK profile in animals with a dose-disproportional increase in exposure. The terminal half-life parameter of ZB004 was determined at least 1.39-fold longer than that of abatacept in cynomolgus monkeys. The subcutaneous bioavailability of ZB004 was 45.4% to 72.5% for rats and 73.4% to 79.9% for cynomolgus monkeys, depending upon the doses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Partnered Regional Programs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We license ZB001, an anti-IGF-1R monoclonal antibody, and related programs, from Viridian. For these assets we hold the development and commercialization rights in greater China and recently sublicensed these rights to Zai. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ZB001 is a monoclonal antibody that binds to, and is designed to act as a full antagonist of, IGF-1 receptor. This mechanism of action has been clinically and commercially validated by the only FDA product approved for the treatment of thyroid eye disease (&#8220;TED&#8221;), Tepezza (teprotumumab). TED is a debilitating condition that significantly impacts quality of life </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and can cause proptosis, double vision and vision loss. In October 2020, we entered into an exclusive license with Viridian, to develop, manufacture, and commercialize certain IGF-1R directed antibody products, including ZB001, for non-oncology indications in greater China. Pursuant to our agreement with Viridian, we are obligated to reimburse Viridian for certain CMC and development expenses, and pay Viridian upon achievement of development milestones and royalties on net sales. With our sublicense to Zai, Zai will pay for the reimbursement obligations and provide us with specified milestones and royalties. For more information on our agreement with Viridian, see the section titled &#8220;Certain Relationships and Related Party Transactions&#8212;Director Affiliations&#8212;Agreements with Viridian Therapeutics Inc.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April 2023, we completed a Phase 1 SAD study in China in healthy volunteers showing ZB001 was well tolerated when administered in doses up to 20 mg/kg. In April 2024, we completed the last patient visit in the Phase 1 MAD study of ZB001 in Chinese patients with active TED. Preliminary data showed significant and rapid improvement in both signs and symptoms after 4 infusions of ZB001 in both 2 dose cohorts of 3mg/kg and 10mg/kg. All AEs were mild or moderate in severity and no SAEs were reported. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 24, 2025, we entered into the Zai License Agreement with Zai, under which we granted Zai an exclusive sublicense to develop and commercialize ZB001 and related programs in greater China. &#160;As partial consideration for the Zai License Agreement, we received an upfront fee of $10.0 million from Zai. In addition, we are eligible to receive up to $96.0 million upon the achievement of certain future development and commercial milestones and royalty percentage rates from the low to mid-single digits, net of pass-through obligations due to Viridian.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, on October 21, 2024, we entered into the Tenacia Agreement, under which we transferred to Tenacia our rights and obligations under our agreements with Dianthus for ZB005. As partial consideration for the Tenacia Agreement, we received an upfront fee of $5.0 million from Tenacia. In addition, we are eligible to receive up to $86.0 million upon the achievement of certain future regulatory and commercial milestones. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreements with Xencor </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2020 Xencor Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2020, we entered into a license agreement (the &#8220;2020 Xencor Agreement&#8221;) with Xencor, to obtain (i) an exclusive, royalty-bearing, sublicensable worldwide license under certain patent rights controlled by Xencor and (ii) a non-exclusive payment bearing license under certain know-how controlled by Xencor to research, develop, manufacture, market and sell three antibody product candidates (the &#8220;2020 Licensed Assets&#8221;), including ZB002 and ZB004. We subsequently relinquished rights to the third product candidate back to Xencor and that asset is no longer a 2020 Licensed Asset. Xencor obtained the rights to some of the intellectual property licensed to us pursuant to license agreements between Xencor and a third party (each such agreement, an &#8220;Upstream License Agreement&#8221;). As such, the 2020 Xencor Agreement provides that the parties agree that some of the licenses granted by Xencor to us constitute sublicenses under the Upstream License Agreements and are subject, and subordinate, to the terms and conditions of the Upstream License Agreements. As consideration for the 2020 Xencor Agreement, we issued Xencor a 15% equity interest in Zenas. The 2020 Xencor Agreement became effective in November 2020, upon Zenas&#8217; issuance of 5,041,542 shares of its Series A Preferred Stock with a fair value of $16.1 million to Xencor as initial consideration. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under the 2020 Xencor Agreement, we are obligated to use commercially reasonable efforts to conduct all future preclinical, clinical and regulatory activities necessary to develop and obtain the regulatory approval of the 2020 Licensed Assets worldwide. We are further required to use commercially reasonable efforts to commercialize the 2020 Licensed Assets having regulatory approvals in certain specified countries (U.S., UK, France, Germany, Italy, and Spain). We are not required to pay any development, regulatory or sales milestone payments under the 2020 Xencor Agreement. We are required to pay Xencor tiered royalties on annual net sales of successfully commercialized products utilizing the 2020 Licensed Assets. The royalty percentage rates vary by geographic areas and range from the mid-single digits to the mid-teens. On a region-by region basis and product-by-product basis, the term during which the royalties are payable by us to Xencor is until the latest of (a) last-to-expire licensed patent covering the product in the applicable region, (b) the expiration of regulatory exclusivity for the product in the applicable region, or (c) the twelfth anniversary of the first commercial sale of the product in the applicable region. The last-to-expire patent under the 2020 Xencor Agreement will have an expiration </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">date of December 22, 2028 for ZB002 and February 22, 2031 for ZB004, provided the latest application in each of these countries is allowed. The expected termination of the royalty obligations will depend on factors such as the filing of additional patents covering the products during the term of the 2020 Xencor Agreement, the availability and application of patent term extensions and/or expiration of regulatory exclusivity for the products in the applicable region. We are obligated to reimburse Xencor for certain third-party costs as further specified under the 2020 Xencor Agreement. During the years ended December 31, 2024 and 2023, no costs and immaterial third-party costs were reimbursed, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the 2020 Xencor Agreement, (i) Xencor owns all know-how and patent rights invented solely by Xencor, (ii) we own all know-how and patent rights invented solely by us; and (iii) Xencor and we jointly own all joint intellectual property. Subject to the license grants under the 2020 Xencor Agreement, both parties may practice the joint intellectual property for all purposes on a worldwide basis without consent of and without a duty of accounting to the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the 2020 Xencor Agreement, during the term of the agreement and for two years thereafter, we agree we will not develop, manufacture, or commercialize a competing product for any 2020 Licensed Asset (i.e., any product that binds to the same target as such 2020 Licensed Asset). The 2020 Xencor Agreement will remain in effect, on a region-by region basis and product-by-product basis, until the expiration of all royalty payment obligations. The 2020 Xencor Agreement may be terminated by either party for the other party&#8217;s uncured material breach or insolvency. Xencor may terminate the 2020 Xencor Agreement if we challenge a licensed patent. We may terminate for convenience on a country-by-country basis with advance notice to Xencor, with the notice period differing based on whether such termination right is exercised prior to or following the first commercial sale. Upon termination, all licenses granted by Xencor to us automatically terminate. We are obligated to assign to Xencor all regulatory filings or approvals specifically related to the terminated assets or products. At Xencor&#8217;s sole discretion, we are obligated to transfer (a) our rights under agreements between us and third parties that solely relate to the development, manufacture or commercialization of terminated assets or products, (b) all materials developed by us for use for commercialization of terminated assets or products and (c) any product mark for terminated assets or products. Upon termination, if Xencor elects to continue development and commercialization of terminated assets or products, we are obligated to grant to Xencor (a) an exclusive license under certain of our patent rights and (b) a nonexclusive license under certain of our know-how, where such licenses are irrevocable, perpetual, royalty-bearing and sublicensable solely to develop, manufacture, and commercialize the terminated assets or products. In consideration for these licenses, Xencor is obligated to pay us (a) mid-single digits royalty on net sales of the terminated assets or products if Xencor commercializes such terminated assets or products and (b) low double digits percentage of all payments receives from sublicensees if Xencor sublicenses the licenses granted by us. Xencor&#8217;s obligation to make payments for these licenses is, on a product-by-product basis and region-by-region basis, until last-to-expire licensed patent covering the product in the applicable region. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2021 Xencor Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2021, we entered into a license agreement (the &#8220;2021 Xencor Agreement&#8221;) with Xencor to obtain (i) an exclusive, royalty-bearing, sublicensable worldwide license under certain patent rights controlled by Xencor and (ii) a non-exclusive payment bearing license under certain know-how controlled by Xencor to research, develop, manufacture, market and sell obexelimab, an antibody product candidate based on Xencor&#8217;s (and its licensors&#8217;) proprietary technology. In addition, Xencor granted us a non-exclusive, royalty-free, sublicensable worldwide license under the same patent and know-how rights to develop, manufacture and commercialize companion diagnostics for obexelimab. Xencor obtained the rights to some of the intellectual property licensed to us pursuant to the Upstream Agreements. As such, the 2021 Xencor Agreement provides that the parties agree that some of the licenses granted by Xencor to us constitute sublicenses under the Upstream Agreements and are subject and subordinate to the terms and conditions of the Upstream Agreements. The 2021 Xencor Agreement became effective in November 2021, upon the execution of an amendment to the 2021 Xencor Agreement and Zenas&#8217; concurrent issuance to Xencor of a warrant with a fair value of $20.7 million to Xencor as initial consideration providing Xencor the right to acquire additional equity, such that its total equity in Zenas would be 15% of its fully diluted capitalization at the completion of our Series B financing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under the 2021 Xencor Agreement, we are obligated to use commercially reasonable efforts to conduct all future preclinical, clinical, regulatory and other activities necessary to develop and obtain the regulatory approval of obexelimab worldwide. We are further required to use commercially reasonable efforts to commercialize obexelimab following regulatory approvals in certain specified countries (U.S., UK, France, Germany, Italy, and Spain). We were obligated to </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">make development milestone payments of up to $10.0 million, at Xencor&#8217;s option either in cash or fully-paid newly issued shares, which milestone payment was paid in Series B Preferred Shares in June 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are obligated to make regulatory milestone payments up to $75.0 million. We are also obligated to make one-time sales milestone payments up to $385.0 million upon achieving milestone events of net sales in a given calendar year in the territory equal to certain threshold amounts. In addition, we are required to pay Xencor tiered royalties on annual net sales of successfully commercialized products utilizing obexelimab, with the royalty rates varying based on regions and ranging from the mid-single digits to the mid-teens. On a region-by region basis and product-by-product basis, the term during which the royalties are payable by us to Xencor is until the latest of (i) the last-to-expire licensed patent covering the product in the applicable region, (ii) the expiration of regulatory exclusivity for the product in the applicable region, or (c) the twelfth anniversary of the first commercial sale of the product in the applicable region. The last-to-expire patent under the 2021 Xencor Agreement will have an expiration date of October 6, 2041, provided the latest application in each of these countries is allowed. The expected termination of the royalty obligations will depend on factors such as the filing of additional patents covering product during the term of the 2021 Xencor Agreement, the availability and application of patent term extensions and/or expiration of regulatory exclusivity for the product in the applicable region. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the 2021 Xencor Agreement, we agree we will not research or develop obexelimab in a way that would produce a molecule that would be classified as obexelimab or an obexelimab product. In addition, during the term and for two years thereafter, we agree not to develop, manufacture, or commercialize a competing product to obexelimab (i.e., any product that binds to CD19 and incorporates Fc&#947;RIIb Technology). During the term, Xencor is obligated to refrain from developing, manufacturing, or commercializing a competing product to obexelimab as well. The non-competes do not apply to any pre-existing activity for a competing product of an acquirer, subject to customary restrictions on such activity following such acquisition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The 2021 Xencor Agreement will remain in effect, on a region-by region basis and product-by-product basis, until the expiration of all royalty payment obligations. The 2021 Xencor Agreement may be terminated by either party for the other party&#8217;s uncured material breach or insolvency. We may terminate for convenience on a country-by-country basis with advance notice to Xencor, with the notice period differing based on whether such termination right is exercised prior to or following the first commercial sale. Upon termination, all licenses granted by Xencor to us automatically terminate. We are obligated to assign to Xencor all regulatory filings or approvals specifically related to the terminated assets or products. At Xencor&#8217;s sole discretion, we are obligated to transfer (a) our rights under agreements between us and third parties that solely relate to the development, manufacture or commercialization of terminated assets or products, (b) all materials developed by us for use for commercialization of terminated assets or products; and (c) any product mark in relation to the Compound or the Products. Upon termination, if Xencor elects to continue development and commercialization of terminated assets or products, we are obligated to grant to Xencor (a) an exclusive license under certain of our patent rights, and (ii) a nonexclusive license under certain of our know-how, where such licenses are irrevocable, perpetual, royalty-bearing and sublicensable solely to develop, manufacture, and commercialize the terminated assets or products. In consideration for these licenses, Xencor is obligated to pay us (a) mid-single digits royalty on net sales of the terminated assets or products if Xencor commercializes such terminated assets or products and (b) low double digits percentage of all payments receives from sublicensees if Xencor sublicenses the licenses granted by us. Xencor&#8217;s obligation to make payments for these licenses is, on a product-by-product basis and region-by-region basis, until the last-to-expire licensed patent covering the product in the applicable region. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreement with Bristol-Myers Squibb </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 30, 2023 (the &#8220;BMS Effective Date&#8221;), we entered into a strategic license and collaboration agreement with BMS (the &#8220;BMS Agreement&#8221;) under which we provided (a) an exclusive (even as to us) license under certain of our patents and joint patents to be developed under the BMS Agreement, and (b) a non-exclusive license under certain of our know-how. The license grants are for BMS to (a) develop, manufacture (subject to our rights to be the exclusive manufacturer for BMS for a certain period of time), commercialize or otherwise exploit our proprietary CD19 x Fc&#947;RIIb antibody, obexelimab (the &#8220;Compound&#8221;) and any biological product (irrespective of presentations, formulations or dosages) containing the Compound but not any of our other proprietary active ingredient (the &#8220;Product&#8221;) for treatment of any disease in human or animal in the BMS Territory and (b) conduct development and manufacture of the Compound and Products outside the BMS Territory provided that the Compound and Product are solely used in the BMS Territory. We also provided BMS a non-exclusive and royalty-free license under the same patent and know-how rights for BMS to develop, </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">manufacture, commercialize, or otherwise exploit companion diagnostics for the Compound and Products in the BMS Territory. We retain all rights to commercialize obexelimab outside of the BMS Territory. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the BMS Agreement, during the term of the BMS Agreement and for a certain period thereafter, BMS has agreed not to develop, manufacture, or commercialize in the BMS Territory a competing product to obexelimab. We have similarly agreed, during the term of the BMS Agreement and for a certain period thereafter, not to develop, manufacture of commercialize in the BMS Territory a product that competes with obexelimab. The non-competes do not apply to any pre-existing activity for a competing product of an acquirer, subject to customary restrictions on such activity following such acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the BMS Agreement, we own all intellectual property in (a) improvements and modification to our pre-existing intellectual property, irrespective of which party develops such improvements and modification, (b) any item relating solely to the Compound and Products derived from use of our pre-existing intellectual property and confidential information, irrespective of which party develops such item and (c) any item generated solely by us in relation to the BMS Agreement. With the exclusion of intellectual property allocated as our intellectual property pursuant to (a) or (b) in the foregoing, (a) BMS shall own intellectual property generated solely by BMS under this Agreement and (b) parties will jointly own all other jointly developed intellectual property. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the BMS Agreement, BMS is solely responsible for conducting all development activities required to obtain regulatory approval for the Compound or Products in the BMS Territory and BMS is obligated to use commercially reasonable efforts to develop at least one Product and seek and maintain regulatory approvals for such Product in Japan and certain other jurisdictions in the BMS Territory. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The parties agreed that we will manufacture and supply and BMS will exclusively purchase all of BMS&#8217;s requirements of (a) Products (and placebo) for development in the BMS Territory, subject to the terms of a separate clinical supply agreement and clinical supply quality agreement, to be executed after the BMS Effective Date and (b) finished Products for commercialization in the BMS Territory, subject to the terms of a separate commercial supply agreement and commercial supply quality agreement, to be executed within a certain number of months prior to the first regulatory approval in the BMS Territory. However, BMS may elect to manufacture the Product itself or via a third party (a) at any time after a certain period following the BMS Effective Date or (b) during such period following the BMS Effective Date if we fail to supply above a certain threshold quantity of the Product ordered in any given calendar quarter. BMS has exclusive rights to commercialize the Product in the BMS Territory and is obligated to use commercially reasonable efforts to commercialize Products in Japan and certain other jurisdictions in the BMS Territory after obtaining the applicable regulatory approvals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the terms of the BMS Agreement, we have received a one-time upfront payment of $50.0 million. We are entitled to receive further separate development and regulatory milestone payments up to $79.5 million and sales milestone payments up to $70.0 million upon BMS achieving certain net sales milestones in a given calendar year in the BMS Territory. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, if BMS successfully develops and commercializes the Product in the BMS Territory, BMS will pay us tiered royalties ranging from (a) the mid-teens to very-low twenties for net sales of Product in Japan and (b) high single digit to low-teens for net sales of Product in all other countries in the BMS Territory, subject to specified reductions. On a country-by-country basis, the term during which the royalties are payable to us is until the latest of (a) the last-to-expire licensed patent covering the Product, (b) the expiration of regulatory exclusivity for the Product or (c) the twelfth anniversary of the first commercial sale of the Product. As of the date of this prospectus, the last-to-expire patent under the BMS Agreement will have an expiration date of October 2, 2044, provided the latest application in each of these countries is allowed. The expected termination of the royalty obligations will depend on factors such as the filing of additional patents covering the Product during the term of the BMS Agreement, the availability and application of patent term extensions and/or expiration of regulatory exclusivity for the Product in the BMS Territory. Finally, BMS will be required to pay a portion of the costs associated with our ongoing INDIGO Trial, in which BMS is participating, as well as any other global study in which BMS elects to participate. During the years ended December 31, 2024 and 2023, we recorded $6.0 million and $4.1 million, respectively, as a reduction to research and development expense for costs associated with our INDIGO Trial that will be reimbursed by BMS. We recognized no revenue during the fiscal year ended December 31, 2024 pursuant to the BMS Agreement. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The BMS Agreement will remain in effect, on a country-by-country basis, until the expiration of all royalty payment obligations, and may be earlier terminated by either party for the other party&#8217;s uncured material breach or insolvency. BMS may terminate for convenience on a country-by-country basis with advance notice to us, with the notice period differing based on whether such termination right is exercised prior to or following the first commercial sale. In addition to customary events of termination, we also have a right to terminate the agreement (a) automatically upon written notice if the upstream Xencor License Agreement terminates and (b) with written notice if BMS challenges the licensed patents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon termination of the BMS Agreement, all licenses granted by us to BMS will automatically terminate and BMS is obligated to cease developing, manufacturing (subject to any transition assistance) and commercializing the Compound and Products in the BMS Territory. Additionally, BMS is obligated to transfer to us all regulatory filings and regulatory approvals related to the Compound or the Products in the Field in the BMS Territory. BMS is further obligated, at our sole discretion, to assign to us (to the extent permissible) (a) BMS&#8217;s rights under agreements between BMS and third parties that solely relate to the development, commercialization or manufacture of the Compound or the Products, (b) documentation relating to the commercialization of the Compound or the Products in the BMS Territory; and (c) any BMS owned marks for the Compound or the Products. BMS is obligated to provide reasonable transition supply assistance with respect to any agreement for manufacturing Compound or Products transferred to us, including manufacturing the Compound or Products for up to 18 months following termination. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We own or license patents in the U.S. and foreign countries that protect our products, their methods of use and manufacture, as well as other innovations important to our business, and in order to help bring new therapies to patients. We consider the overall protection of our patents, trademarks, licenses and other intellectual property rights to be of material value. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Our success will, in part, depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on regulatory protection, particularly biological data exclusivity, know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain the proprietary position of our products and development programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the biopharmaceutical industry, a substantial portion of an innovative product&#8217;s commercial value is usually realized during the period in which the product has exclusivity. A product&#8217;s exclusivity is generally determined by two forms of intellectual property: patent rights held by the innovator company and any regulatory forms of exclusivity to which the innovative drug is entitled. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patents are a key determinant of exclusivity for most pharmaceuticals. Patents provide the innovator with the right to exclude others from practicing an invention related to the medicine. Patents may cover, among other things, the active ingredient(s), various uses of a drug product, discovery tools, pharmaceutical formulations, biomarkers, drug delivery mechanisms and processes for (or intermediates useful in) the manufacture of products. The protection afforded by a patent extends for a 20-year term from its filing date, without taking into account any potential patent term adjustment or extension. The protection provided by a patent depends on the scope of its coverage and the availability of meaningful legal remedies to enforce patent claims in the country or countries where it has issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Market exclusivity can also be influenced by regulatory data protection (&#8220;RDP&#8221;). Many developed countries provide certain non-patent incentives for the development of medicines. For example, in the U.S., EU member states, UK, Japan, and certain other countries, RDP intellectual property rights are offered to: (i) provide a time period of data protection during which a generic company is not allowed to rely on the innovator&#8217;s data in seeking approval; (ii) restore patent term lost during drug development and approval; and (iii) provide incentives for research on medicines for rare diseases, or orphan drugs, and on medicines useful in treating pediatric patients. These incentives may extend a product&#8217;s market exclusivity period beyond the patent term. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Portfolio </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 11, 2025, we own or exclusively in-license 14 patent families that specifically cover our product candidates obexelimab (our CD19 x Fc&#947;RIIb antibody), ZB002 (our anti-TNF&#945; antibody), and ZB004 (our CTLA-4-Ig fusion protein). These families include 14 issued U.S. patents, nine pending U.S. applications, 123 issued foreign patents, four pending PCT applications and 41 pending foreign patent applications in Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, Japan, Malaysia, Mexico, New Zealand, Saudi Arabia, Singapore, South Africa, South Korea, Taiwan and the United Arab Emirates. In addition, we own or exclusively in-license eight U.S. provisional patent applications, which belong to four different patent families, within the priority year. Any U.S. or foreign patents issued from national stage filings of our owned, or exclusively in-licensed PCT patent applications, any U.S. patents issued from our exclusively in-licensed non-provisional applications, and any U.S. patents or foreign patents issued from non-provisional applications we may file in connection with our provisional patent applications would be scheduled to expire on various dates from 2027 through 2045. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All expected expiration dates provided herein are based on a 20-year term, without taking into account any possible PTA or PTE and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obexelimab </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obexelimab is a bifunctional, non-cytolytic, humanized monoclonal antibody that binds CD19 and Fc&#947;RIIb to inhibit B-lineage cell activity. As of March 11, 2025, we own or exclusively in-license from Xencor ten patent families that specifically cover the composition of matter, mechanism of action, manufacturing, biomarkers and the clinical uses of obexelimab for treating IgG4-RD, SLE, MS and wAIHA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A first patent family specifically covers the composition of matter of obexelimab and includes six issued patents and two pending applications in the U.S., and 21 issued foreign patents in Australia, Hong Kong, India, Israel and various European countries including Belgium, Denmark, France, Germany, Ireland, Italy, Latvia, Lithuania, Luxembourg, Monaco, Netherlands, Spain, Sweden, Switzerland, and UK. The 20-year statutory term for the patents issued in this family expires in May 2028, excluding any extension of patent term that may be available. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A second patent family is directed to obexelimab&#8217;s mechanism of action and includes one issued patent and one pending application in the U.S., five pending applications in Canada, Europe, Hong Kong and Japan, and 20 issued patents in Japan and European countries including Austria, Belgium, Denmark, France, Finland, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Spain, Switzerland, Sweden, Turkey and UK. The 20-year statutory term for any patents issued in this family expires in June 2037, excluding any extension of patent term that may be available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>A third patent family is directed to the use of biomarkers for treating autoimmune diseases (e.g., SLE) and includes one pending U.S. application, and 13 pending applications in Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, Japan, South Korea, Mexico, South Africa and Taiwan. The 20-year statutory term for any patents issued in this family would expire in October 2041, excluding any extension of patent term that may be available. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A fourth patent family is directed to the clinical use of obexelimab for treating IgG4-RD, currently including one pending U.S. Application, and 17 pending applications in Australia, Brazil, Canada, China, Eurasia, Europe, Isreal, Japan, Malaysia, Mexico, New Zealand, Saudi Arabia, Singapore, South Africa, South Korea, Taiwan and the United Arab Emirates. The 20-year statutory term for any patents issued in this family would expire in June 2043, excluding any extension of patent term that may be available. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A fifth patent family is directed to the clinical use of obexelimab for treating AIHA, including wAIHA, currently including a pending PCT application and a Taiwanese application. The 20-year statutory term for any patents issued in this family would expire in April 2044, excluding any extension of patent term that may be available. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A sixth patent family is directed to the clinical use and dosing regimen of obexelimab for treating forms of MS, including RMS, and currently including a pending PCT application and a pending U.S. application, and a pending Taiwanese application. The 20-year statutory term for any patents issued in this family would expire in October 2044, excluding any extension of patent term that may be available. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A seventh patent family is directed to the clinical use and dosing regimen of obexelimab for treating forms of MS, including RMS, and currently including a pending PCT application, a pending U.S. application, and a pending Taiwanese application. The 20-year statutory term for any patents issued in this family would expire in January 2045, excluding any extension of patent term that may be available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An eighth patent family is directed to the SC administration of obexelimab for treating SLE currently including a pending PCT application, a pending U.S. application, and a pending Taiwanese application. The 20-year statutory term for any patents issued in this family would expire in January 2045, excluding any extension of patent term that may be available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>A ninth patent family is directed to the manufacturing processes for obexelimab currently including one provisional application. Assuming the provisional application is converted to a non-provisional application at the 12-month from priority deadline, the 20-year statutory term for any patents issued in this family would expire in June 2045, excluding any extension of patent term that may be available. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A tenth patent family is related to the clinical use of obexelimab for treating wAIHA currently including two provisional applications within the priority year. Assuming the provisional applications are converted to a non-provisional application at the 12-month from priority deadline, the 20-year statutory term for any patents issued in this family would expire in October 2045, excluding any extension of patent term that may be available. A PTE of up to five years may be available and can be applied in one of these families as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ZB002 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ZB002 is an anti-TNF&#945; monoclonal antibody with the Xtend technology modified to have an extended half-life as compared to existing anti- TNF&#945; therapies. As of March 11, 2025, we exclusively own or in-licensed two patent families covering ZB002. A first patent family specifically covers the full-length amino acid sequences of ZB002, including four issued patents in the U.S., Brazil, Japan and Russia, and two pending applications in Europe and Hong Kong. The 20-year statutory term for U.S. patents in this family expires in October 2027 and any foreign patents that are in this family are expected to expire in December 2028, excluding any extension of patent term that may be available. A second patent family is directed to the formulation and dosing of ZB002 in treating autoimmune diseases including one pending U.S. application, one pending PCT application and one pending application in Taiwan. The 20-year statutory term for any patents issued in this family would expire in March 2045. A PTE of up to five years may be available and can be applied in one of these families as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ZB004 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ZB004 is a CTLA-4-Ig fusion protein with the Xtend technology modified to have an extended half-life versus existing CTLA-4-Ig fusion protein therapies. As of March 11, 2025, we own or exclusively in-licensed two patent families relating to the composition of matter of ZB004 and related methods of use. A first patent family specifically covers the composition of matter and related methods of use ZB004 including six issued patents and one pending application in the U.S., &#160;and 79 issued foreign patents in Australia, Canada, China, Hong Kong, India, Japan, South Korea and European countries including Albania, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lichtenstein, Lithuania, Luxembourg, Macedonia, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, and UK. The 20-year statutory term for the patents issued in this family expires in February 2031, excluding any extension of patent term that may be available. A second patent family is related to the formulation and dosing regimen of ZB004 in treating autoimmune diseases currently including two provisional applications within the priority year. Assuming the provisional applications are converted to a non-provisional application at the 12-month from priority deadline, the 20-year statutory term for any patents issued in this family would expire in September 2045. A PTE of up to five years may be available and can be applied in one of these families as appropriate. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trademark Portfolio </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company owns trademark applications and registrations for &#8220;Zenas BioPharma&#8221; and the Zenas BioPharma logo, and the &#8220;lightning bold&#8221; design in the U.S. and other foreign jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We have engaged, and currently rely on, a single third-party CMO, WuXi Biologics, for the supply of our product candidates for use in our preclinical studies and clinical trials. In addition, we have selected new CMOs in the U.S., which are not affiliated with Wuxi Biologics, to establish additional sources of supply for drug substance and drug product for both commercial and clinical use. However, should our CMO, Wuxi Biologics, become unavailable to us for any reason, we believe that we would incur delay and cost in order to complete the manufacturing validation and qualification process for such replacements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We maintain a master services agreement with Wuxi Biologics pursuant to which it provides biologics development and manufacturing services on a per-project basis. We may terminate the master services agreement at any time for convenience in accordance with the terms of the agreement. We may also terminate the master services agreement in the event that Wuxi Biologics does not obtain or maintain any material governmental license or approval in accordance with the terms of the agreement. The agreement includes confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates. While any reduction or halt in supply from the CMO could limit our ability to develop our product candidates until a replacement CMO is found and qualified, we believe that we have sufficient supply to support our current clinical trial programs. See &#8220;Risk Factors&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have a long-term&#160;commercial&#160;supply&#160;agreement with WuXi Biologics&#160;to&#160;fulfill&#160;and&#160;secure&#160;obexelimab drug substance and drug product for an anticipated commercial launch, if approved.&#160;In&#160;addition,&#160;we&#160;have selected new&#160;CMOs in the U.S., which are not affiliated with WuXi Biologics, to establish additional sources of supply for drug substance and drug product for both commercial and clinical use. For the medical device component of our product (i.e., prefilled syringe or autoinjector), we plan to utilize device assembly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufacturer to manufacture and supply the drug substances, drug products, raw materials, samples, components and other materials for our product candidates. In the event it is necessary or advisable to acquire supplies from alternative sources, we might not be able to obtain them at reasonable prices, or at all. It could also require significant time and expense to transfer our manufacturing processes to another company. If we need to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with applicable quality standards, regulations and guidelines, and we may be required to conduct additional studies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, to adequately meet our projected manufacturing needs for commercializing obexelimab and our other product candidates, our CMOs will need to scale-up production or we will need to secure additional suppliers. Processes for producing obexelimab drug substance and drug product for commercial supply have been developed and defined. We believe the drug substance and drug product processes for obexelimab and our other product candidates are amenable to scale-up. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales, Marketing and Commercialization </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None of our product candidates have been approved for sale in any country. We hold global development and commercialization rights to obexelimab, excluding Japan, Taiwan, South Korea, Singapore, Hong Kong and Australia, which we have licensed to BMS. We also hold the global development and commercialization rights to ZB002 and ZB004. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our product candidates receive FDA or EMA approval, we intend to build our own commercialization infrastructure in the U.S. and Europe, to market and sell our products. For Asia and other geographies, we plan to conduct the initial clinical development work and then seek to enter into an agreement with a third party to complete the clinical development work, obtain regulatory approval, and ultimately commercialize in these territories. However, we intend to continually evaluate the economics of potentially commercializing our product candidates ourselves, if approved, versus other strategic commercialization arrangements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We currently have no sales, marketing or commercialization capabilities and have no experience as a company performing such activities. However, we intend to build the necessary capabilities and infrastructure over time as our product candidates continue to advance through clinical development. We believe that clinical data, the size of the market </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">opportunity and the size of the required commercial infrastructure will influence our commercialization plans and decision making. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies, as well as public and private research institutions. Any product candidates that we successfully develop and commercialize, if approved, will compete with existing therapies and new therapies that may become available in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their safety, efficacy, convenience, price, the level of generic competition, the existence of therapeutic alternatives and the availability of coverage and reimbursement from government and other third-party payors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many of the companies against which we are competing, or against which we may compete in the future, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are currently developing obexelimab for IgG4-RD, MS, and SLE. There are currently no approved products for IgG4-RD. A number of products are approved for MS and two products are approved for SLE. However, there are a number of product candidates in clinical development by other companies for IgG4-RD, MS, and SLE which may become available in the future. Potentially competitive therapies by indication fall primarily into the following groups of treatment: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">IgG4-RD: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">UPLIZNA (inebilizumab-cdon), an anti-CD19 antibody being developed by Amgen Inc., for which Amgen filed a BLA and was granted Priority Review based on the results of its Phase 3 trial; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a small molecule Bruton&#8217;s tyrosine kinase (&#8220;BTK&#8221;) inhibitor in a Phase 2 trial, being developed by Sanofi S.A.; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other clinical or preclinical small molecules, biologics (including cell-based therapies), or other therapeutic modalities that may be or are being developed for IgG4-RD; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other therapies such as corticosteroids and immunosuppressants like cyclophosphamide and rituximab have been used off-label. While these other therapies have not been shown to be effective, and carry significant side effects, their off-label use could reduce or delay treatment in the addressable patient population for obexelimab. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">MS: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approved monoclonal antibody biologic therapies including anti-CD20 antibodies such as Ocrevus marketed by F. Hoffmann-La Roche Ltd., Kesimpta marketed by Novartis AG, Briumvi marketed by TG Therapeutics Inc., an anti-CD52 antibody Lemtrada marketed by Sanofi S.A., and an &#945;4-integrin antibody Tysabri marketed by Biogen; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approved non-antibody-based injectable therapies including interferon beta-1a therapies such as Avonex marketed by Biogen, Plegridy marketed by Biogen, Betaseron marketed by Bayer AG, Extavia marketed by </span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Novartis AG, Rebif marketed by Merck KGaA, and myelin basic protein-based therapies such as Copaxone marketed by Teva Neuroscience Inc.; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approved small molecule oral therapies including Aubagio marketed by Genzyme Corporation, Bafiertam marketed by Banner Life Sciences, Gilenya marketed by Novartis AG, Mavenclad marketed by Merck KGaA, Mayzent marketed by Novartis AG, Ponvory marketed by Janssen Pharmaceuticals, Inc., Tascenso ODT marketed by Cycle Pharmaceuticals Ltd., Tecfidera marketed by Biogen, Vumerity marketed by Biogen, and Zeposia marketed by Bristol Myers Squibb Company; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three small molecule BTK inhibitor programs in Phase 3 development by Sanofi S.A., Novartis AG, and Hoffmann-La Roche Ltd.; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a vidofludimus calcium program in Phase 3 development by Immunic Therapeutics Inc.; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a small molecule selective tyrosine kinase inhibitor program in Phase 3 development by AB Science; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an anti-CD40/CD40L antibody in a Phase 3 trial being developed by Sanofi S.A; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">several Phase 2 trial programs evaluating multiple targets / mechanisms of action including but not limited to CD19, BTK, M1R (muscarinic type 1 receptor), BLyS/APRIL, MOG (myelin oligodendrocyte glycoprotein), VLA-4 (very late antigen 4), Treg cells, undisclosed targets / mechanisms and allogenic, autologous, mesenchymal, and CAR-T cell therapies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other clinical or preclinical disease modifying small molecules, biologics, or other therapeutic modalities that may be or are being developed for MS; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and, approved generic and biosimilar therapies. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">SLE: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approved therapies including an anti-BLyS antibody Benlysta marketed by GSK plc., an anti-IFNAR (type I interferon receptor) antibody Saphnelo marketed by AstraZeneca plc., and a dual antagonist of BlyS and APRIL Tai&#8217;ai approved and marketed only in China, by RemeGen Co., Ltd.; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an anti-CD40L (CD40 ligand) pegylated Fab (antigen binding fragment) program in a Phase 3 clinical trial, being developed by UCB Biopharma SRL; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an anti-BDCA2 (blood dendritic cell antigen 2) antibody program in Phase 3 trials, being conducted by Biogen Inc.; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a dual antagonist of BLyS and APRIL program in a Phase 3 (ex-China) trial, being developed by RemeGen Co., Ltd.; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two anti-CD20 antibody programs in Phase 3 trials, being developed by F. Hoffmann-La Roche Ltd. and Beijing Mabworks Biotech Co., Ltd., the latter in China only; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a small molecule tyrosine kinase 2 (&#8220;TYK2&#8221;) inhibitor in Phase 3 trials, being developed by Bristol Myers Squibb Company; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a sphingosine-1-phosphate 1 receptor modulator in Phase 3 trials, being developed by Idorsia Pharmaceuticals Ltd.; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a small molecule Janus kinase inhibitor in Phase 3 trials, being developed by AbbVie Inc.; </span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an anti-BAFF-R antibody program in Phase 3 trials, being developed by Novartis AG; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">several Phase 2 trial programs evaluating multiple targets / mechanisms of action including but not limited to TLR7/8, CD28/ICOS, CD40/CD40L, BAFF/APRIL, IL2, IL21, CRL4-CRBN, IFNB1, BTLA, FcRn, TYK2, BTK, CD22, CD32B/CD79B, CD19, a CD19 CAR-&#947;&#948;T program, CD19/CD20/BCMA-CAR T programs and undisclosed targets / mechanisms; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other clinical or preclinical small molecules, biologics, or other therapeutic modalities that may be or are being developed for SLE; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other therapies such as antimalarials (e.g., hydroxychloroquine), corticosteroid, and immunosuppressants (e.g., cyclophosphamide or rituximab) have been used off-label. While these other therapies have not been shown to be effective, and carry significant side effects, their off-label use could reduce or delay treatment in the addressable patient population for obexelimab. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also developing ZB002, an anti-TNF&#945; therapy with an extended half-life. The TNF&#945;-binding region within the fragment variable (Fv) domain has an identical amino acid sequence to Humira (adalimumab). The fragment crystallizable (Fc) domain consists of a hybrid immunoglobulin (IgG1/2) constant region containing amino acid substitutions for extended half-life. There are 5 FDA-approved innovator anti-TNF programs for various indications including Humira marketed by AbbVie Biotechnology Ltd., Enbrel marketed by Amgen Inc., Remicade, marketed by Janssen Biotech, Inc., Simponi, marketed by Janssen Biotech, Inc., and Cimzia, marketed by UCB, Inc. In addition to these five innovator anti-TNF programs, a number of biosimilar anti-TNF programs are FDA-approved including Humira biosimilars (such as Amjevita marketed by Amgen Inc., Abrilada marketed by Pfizer Inc., Cyltezo marketed by Boehringer Ingelheim Pharmaceuticals, Inc., Hadlima Organon group of companies, Hulio marketed by Veritas Inc., Hyrimoz marketed by Sandoz Inc., Idacio marketed by Fresenius Kabi USA, LLC, Yuflyma marketed by Celltrion Healthcare Co., Ltd., and Yusimry marketed by Coherus BioSciences, Inc.). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ZB004 is a CTLA-4-Ig fusion protein with an extended half-life and potential improved potency versus existing CTLA-4-Ig fusion protein therapies. There are two marketed CTLA-4-Ig fusion protein therapies. Orencia, marketed by BMS, is FDA-approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and prophylaxis of acute graft versus host disease. Nulojix, marketed by BMS, is FDA-approved for prophylaxis of organ rejection in adult patients receiving a kidney transplant. One Orencia biosimilar program recently entered Phase 1 clinical development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Government authorities at the federal, state and local level in the U.S. and in other countries and jurisdictions, including the EU, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting and import and export of biological products such as those we are developing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We, along with our CMOs, CROs and third-party vendors, will be required to satisfy these requirements in each of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The processes for obtaining marketing approvals in the U.S. and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes, regulations, and other regulatory requirements, require the expenditure of substantial time and financial resources. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Licensure and Regulation of Biologics in the U.S. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are currently developing product candidates that are biological products, or biologics. In the U.S., where we are initially focusing our product development, the FDA regulates biologics under the FDCA and the Public Health Service Act (&#8220;PHSA&#8221;), and their implementing regulations. Biologics are also subject to other federal, state and local statutes and regulations. Our product candidates are early-stage and have not been approved for marketing in the U.S. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An applicant seeking approval to market and distribute a new biologic in the U.S. must satisfactorily complete each of the following steps: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preclinical laboratory tests, animal studies and formulation studies performed in accordance with the FDA&#8217;s GLPs; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture of the drug substance and drug product in accordance with the FDA&#8217;s cGMPs, along with required analytical and stability testing; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an Investigational New Drug Application (&#8220;IND&#8221;) for human clinical testing, which must become effective before human clinical trials may begin; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent IRB, representing each clinical trial site before each clinical trial may be initiated; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials, in accordance with current Good Clinical Practice requirements (&#8220;cGCPs&#8221;), necessary to establish the safety, potency and purity of the product candidate for each proposed indication; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation and submission to the FDA of a BLA, requesting marketing approval for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product and proposed labeling; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMPs and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of any FDA audits of the preclinical studies and clinical trial sites to assure compliance with GLPs and cGCPs, as applicable, and the integrity of clinical data in support of the BLA; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of user fees under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), unless exempted; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s review and approval of the BLA, including consideration of the views of any FDA advisory committee, if applicable; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if approved, compliance with any post-approval requirements, including the potential requirement to implement a REMS and any post-approval studies or other post-marketing commitments required by the FDA. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure to comply with the applicable requirements at any time during the product development process, including preclinical testing, clinical testing, the approval process, or post-approval process, may subject an applicant to delays in the conduct of the study or regulatory review and approval, as well as administrative or judicial sanctions or other consequences. These sanctions or consequences may include, but are not limited to, the FDA&#8217;s refusal to allow an applicant to proceed with clinical testing, issuance of clinical holds for planned or ongoing studies, refusal to approve pending applications, suspension or revocation of existing product licenses or approvals, issuance of warning or untitled letters, adverse publicity, product recalls, marketing restrictions, product seizures, import detentions and refusals, total or partial suspension of manufacturing or distribution, injunctions, fines and civil or criminal investigations and penalties brought by the FDA or the Department of Justice (&#8220;DOJ&#8221;), and other governmental entities, including state agencies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical Studies and Investigational New Drug Application </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Once a therapeutic product candidate is identified for development, it must undergo preclinical studies (also known as preclinical testing) before any testing may be conducted in humans. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animals. The conduct of preclinical tests and formulation of the compounds for testing must comply with federal regulations and </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">requirements, including GLPs. The results of the preclinical tests, together with manufacturing information, analytical data, and plans for the proposed clinical studies, are submitted to the FDA as part of an IND. Some preclinical testing may continue after an IND is submitted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An IND is a request for FDA authorization to administer an investigational new drug product to humans. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or the conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trials can begin. As a result, submission of an IND may or may not result in FDA authorization to begin a clinical trial, or to begin a clinical trial on the terms originally specified by the sponsor in the IND. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At any time during the initial 30-day IND review period or while clinical trials are ongoing under the IND, the FDA may impose a partial or complete clinical hold. Clinical holds may be imposed by the FDA when there is concern for patient safety, and may be a result of new data, findings, or developments in clinical, preclinical, and/or chemistry, CMC or where there is non-compliance with regulatory requirements. This order would delay either a proposed clinical trial or cause suspension of an ongoing trial, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigations may proceed. A separate submission to an existing IND must also be made for each successive clinical trial conducted, and the FDA must grant permission, either explicitly or implicitly, by not objecting before each clinical trial can begin. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Clinical Trials </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of an investigational drug product to healthy volunteers or patients with the disease or condition to be treated under the supervision of qualified investigators. Clinical trials must be conducted in accordance with GCPs, which establish ethical and data integrity standards for clinical testing, as well as the requirements for informed consent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For clinical trials conducted in the U.S., an IND is required, and each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA, IRB or the trial sponsor may suspend a clinical trial at any time on various grounds, including a finding that the trial is not being conducted in accordance with GCPs or IRB requirements or that research subjects or patients are being exposed to an unacceptable health risk. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or data monitoring committee. Depending on its charter, this group may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on certain available data from the trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A sponsor who wishes to conduct a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, FDA may accept the results of the study in support of a BLA if the study was well-designed and conducted in accordance with GCPs, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1 trials are initially conducted in a limited population of healthy subjects to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and PD. In the </span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">case of some products designed to address severe or life-threatening diseases, initial human testing is often conducted in patients with the disease, especially when the product may be too inherently toxic to ethically administer to healthy volunteers. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2 trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the preliminary efficacy of the product candidate for specific targeted indications and determine dose tolerance and recommended dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3 trials are generally undertaken to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a biologic; such Phase 3 studies are generally referred to as &#8220;pivotal,&#8221; however, for some investigational products, Phase 2 may be considered pivotal trials if such trials are expected to provide the clinical evidence needed to support a marketing application. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In some cases, the FDA may approve a BLA for a product but require the sponsor to conduct additional clinical trials to further assess the product&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as confirmatory studies, or Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and verify clinical benefit for products approved under accelerated approval regulations. Failure to exercise due diligence with regard to conducting required confirmatory studies could result in withdrawal of approval for products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the IND is active and before approval, progress reports detailing the results of the clinical trials and preclinical studies performed since the last progress report must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies or animal or <i style="font-style:italic;">in vitro</i> testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products are required to register and disclose information about ongoing clinical trials, including information related to the drug, patient population, phase of investigation, trial sites and investigators. Sponsors are also obligated to disclose the results of completed clinical trials, other than Phase 1 clinical trials, within specific timeframes. Information about applicable clinical trials is published on www.ClinicalTrials.gov, a clinical trials database maintained by the National Institutes of Health. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the development of a new biologic, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before a BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Compliance with cGMPs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Concurrent with clinical trials, companies must finalize a process for manufacturing the product in commercial quantities in accordance with cGMPs. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the products do not undergo unacceptable deterioration over their shelf life. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMPs and </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">adequate to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing controls for products like biologics whose attributes cannot be precisely defined. Material changes in manufacturing equipment, location, or process post-approval, may result in additional regulatory review and approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Review and Approval of a BLA </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The results of clinical trials and preclinical studies, together with detailed information regarding the manufacturing processes, chemistry and composition of the product, the proposed labeling and other relevant information, are submitted to the FDA as part of a BLA requesting approval to market the product for one or more specified indications. Clinical and preclinical data may come from company-sponsored trials or from a number of alternative sources, including studies initiated by investigators, and the BLA must include any negative and ambiguous results, as well as positive findings. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety, purity, and potency of the investigational product to the satisfaction of the FDA. For most BLAs, the sponsor is required to pay a substantial application user fee at the time of submission and the sponsor of an approved BLA is subject to an annual program fee. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA has 60 days after submission of the application to conduct an initial review to determine whether to accept it for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. If the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from the acceptance date in which to complete its initial review of a standard application and respond to the applicant, and six months for a priority review of the application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and the review process may be significantly extended by FDA requests for additional information or clarification. For example, the review process and the PDUFA goal date may be extended by three months if the FDA requests or if the applicant otherwise provides additional data, analysis or information that FDA deems a major amendment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During its review of a BLA, the FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of preclinical and clinical trial sites to assure compliance with GLPs or GCPs, the FDA may approve the BLA or issue a complete response letter. Under the PHSA, the FDA may approve a BLA if it determines the product is safe, pure, and potent, and that the facility in which the product will be manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. If FDA determines the product meets these standards, it may issue an approval letter authorizing the commercial marketing of the product with specific prescribing information for specific indications. If the application is not approved, the FDA will issue a complete response letter, which will contain the conditions that must be met in order to secure final approval of the application, and when possible, will outline recommended actions the sponsor might take to obtain approval of the application. A complete response letter may require additional clinical data and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Sponsors that receive a complete response letter have one year to submit information that represents a complete response to the deficiencies identified by the FDA. The FDA will then re-review the application, taking into consideration the response, and determine whether the application meets the criteria for approval. Failure to respond to a complete response letter will serve as a withdrawal of an application. The FDA will not approve an application until issues identified in any complete response letters have been addressed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If the FDA approves a new product, it may limit the approved indication(s) for use of the product. It may also require that contraindications, warnings, or precautions be included in the product labeling. In addition, the FDA may require post-approval studies, including Phase 4 clinical trials, to further assess the product&#8217;s efficacy and/or safety after approval. The </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals and elements to assure safe use (also known as ETASU). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After approval, if there are any modifications to the approved product, including changes in the indications, dosage forms, labeling, or manufacturing processes or facilities, the sponsor may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require the generation of additional data or the conduct of additional preclinical studies and clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-Approval Regulation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon FDA approval of a BLA, the sponsor will be required to comply with all post-approval regulatory requirements for biologics, as well as any specific post-approval requirements that the FDA has imposed as part of the product or indication&#8217;s approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information, obtain FDA approval for certain manufacturing and labeling changes, and comply with requirements concerning advertising and promotional labeling, record-keeping, and drug supply chain security. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections for compliance with ongoing regulatory requirements, including cGMPs. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control, as well as pharmacovigilance activities, to maintain compliance with cGMPs and other regulatory requirements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A biological product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may perform certain confirmatory tests on lots of some products before releasing the lots for distribution. In addition, the FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products, including biological products. These regulations include, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the BLA is approved. Once a BLA is approved, the sponsor can make only those claims relating to safety, efficacy, purity and potency that are in accordance with the provisions of the approved label. In the U.S., healthcare professionals are generally permitted to prescribe legally available drugs for uses that are not described in the product&#8217;s labeling and that differ from those approved by the FDA. Such off-label uses are common across medical specialties. The FDA does not regulate the practice of medicine or healthcare providers&#8217; choice of treatments. However, FDA regulations do impose rigorous restrictions on manufacturers&#8217; communications of off-label uses. Additionally, promotional materials for prescription drug products must be submitted to the FDA in conjunction with their first use. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a company, including any agent of the company or anyone speaking on behalf of the company, is found to have promoted off-label uses, the company may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the DOJ, or the Office of the Inspector General of the Department of Health and Human Services (&#8220;HHS&#8221;), as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw product approval if compliance with regulatory requirements and standards is not maintained or if issues occur after the product reaches the market. Later discovery of previously unknown issues with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, including total or partial suspension of production, or complete withdrawal of the product from the market; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or untitled letters; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recall, seizure or detention, or refusal to permit the import or export of products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of clinical holds on ongoing clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandated modification of promotional materials and labeling and the issuance of corrective information; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, injunctions or the imposition of civil or criminal penalties. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">FDA Regulation of Combination Products </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain therapeutic products are comprised of multiple FDA-regulated components, such as drugs and medical devices, that are physically combined and produced as a single entity, packaged together in a single package, or packaged separately but intended to be labeled for use together. These products are known as combination products. We expect that obexelimab and our other product candidates packaged in a prefilled syringe or autoinjector would be subject to regulation as a combination product if consisting of a therapeutic biologic and a delivery device. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The constituent elements of such combination products would normally be subject to different FDA regulatory frameworks and regulated by different Centers at the FDA. Depending on the type of combination product, its approval, clearance or licensure may usually be obtained through the submission of a single marketing application; however, FDA could require separate marketing applications for individual constituent parts of the combination product which may require additional time, effort and information. Even when a single marketing application is required for a combination product, such as a BLA for a combination biologic and device product, both FDA&#8217;s Center for Biologics Evaluation and Research and FDA&#8217;s Center for Devices and Radiological Health may participate in the review. If a product candidate is considered a biologic-device combination product, the sponsor will also need to comply with post-marketing regulatory requirements, including adverse event reporting and applicable portions of the FDA&#8217;s Quality System regulation, applicable to combination products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fast Track, Breakthrough Therapy and Priority Review Designations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The FDA has several programs intended to facilitate and expedite development and review of new products that are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as fast track designation, breakthrough therapy designation and priority review designation. These designations are not mutually exclusive, and a product candidate may qualify for one or more of these programs. While </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">these programs are intended to expedite product development and approval, they do not alter the standards for FDA approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may designate a product for fast track designation if it is intended for the treatment of a serious or life-threatening disease or condition, and preclinical or clinical data demonstrate the potential to address unmet medical needs for such a disease or condition. For products with fast track designation, sponsors may have more frequent interactions with the FDA, the product is potentially eligible for accelerated approval and priority review, if relevant criteria are met, and the BLA may be eligible for &#8220;rolling review,&#8221; under which the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a product with fast track designation may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining sections of the BLA, and the sponsor must pay any required user fees upon submission of the first section of the BLA. The FDA&#8217;s time goal for reviewing a fast track application does not begin until the last section of the application is submitted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A product may be designated as a breakthrough therapy if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The designation includes all of the fast track program features, including eligibility for rolling review. Additionally, the FDA may take certain actions to expedite the development and review of breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff managers in the review process; assigning a cross-disciplinary lead for the review team; and taking other steps to design the clinical trials in an efficient manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared with other available therapies. A priority review designation is intended to direct the FDA&#8217;s attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on an original BLA from ten months to six months from the acceptance date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fast track designation, breakthrough therapy designation, and priority review do not change the standards for approval but may expedite the development or approval process. Even if a drug qualifies for one or more of these programs, the FDA may later withdraw or rescind the designation if it decides that the drug no longer meets the conditions for qualification or decides that the time period for FDA review or approval will not be shortened. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accelerated Approval Pathway </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides a meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (&#8220;IMM&#8221;), and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The FDA&#8217;s approval of a candidate product under the accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit, and the FDA may require such studies to be underway prior to approval. Failure to conduct required post-approval studies, confirm a clinical benefit during post-marketing studies may result in the FDA&#8217;s withdrawal of the product from the market on an </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">expedited basis. All promotional materials for therapeutic candidates approved under accelerated regulations are subject to prior review by the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Orphan Drug Designation and Exclusivity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Orphan drug designation in the U.S. is designed to encourage sponsors to develop products intended for treatment of rare diseases or conditions. In the U.S., a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the U.S. or that affects 200,000 or more individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available the drug or biologic for the disease or condition will be recovered from sales of the product in the U.S. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product&#8217;s marketing approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. If orphan drug designation is granted by the FDA, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. After FDA grants orphan designation, the product must then go through the review and approval process like any other product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same product for the same indication for seven years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. The FDA cannot, however, approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor, or the sponsor is unable to provide sufficient quantities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA has historically taken the position that the scope of orphan exclusivity aligns with the approved indication or use of a product, rather than the disease or condition for which the product received orphan designation. However, in <i style="font-style:italic;">Catalyst Pharms., Inc. v. Becerra</i>, 14 F.4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> 1299 (11<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Cir. 2021), the court disagreed with this position, holding that orphan-drug exclusivity blocked the FDA&#8217;s approval of the same drug for all uses or indications within the same orphan-designated disease. On January 24, 2023, the FDA published a notice in the Federal Register to clarify that the FDA intends to continue to apply its longstanding interpretation of the regulations to all matters outside of the scope of the <i style="font-style:italic;">Catalyst</i> order and will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions will impact the scope of the orphan drug exclusivity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Development in Pediatric Patients </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under the Pediatric Research Equity Act of 2003, a BLA or BLA supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. A sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">dosage form, new dosing regimen or new route of administration must submit a Pediatric Study Plan (&#8220;PSP&#8221;) that contains an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The sponsor and the FDA must reach agreement on the PSP. The FDA or the applicant may request an amendment to the plan at any time. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pediatric Exclusivity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity is a type of non-patent marketing exclusivity in the U.S. and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Biosimilars and Exclusivity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The ACA, which was signed into law in March 2010, included the BPCIA. The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. A biosimilar is a biological product that is highly similar to an existing FDA-licensed &#8220;reference product.&#8221; Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product in any given patient, and (for products administered multiple times to an individual) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA-approved reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. The law also includes an extensive process for the innovator biologic and biosimilar manufacturer to litigate patent infringement, validity and enforceability prior to the approval of the biosimilar. Since the passage of the BPCIA, many states have passed laws or amendments to laws, including laws governing pharmacy practices, which are state regulated, to regulate the use of biosimilars. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S. Patent Term Restoration and Extension </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the U.S., a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the time between the effective date of the IND and the submission date of the BLA, plus the time between the submission date of the BLA and </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the ultimate approval date, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date in the U.S. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The United States Patent and Trademark Office (&#8220;USPTO&#8221;) reviews and approves the application for any patent term extension in consultation with the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Federal and State Data Privacy and Security Laws </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under HIPAA, HHS has issued regulations to protect the privacy and security of protected health information, used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 or HITECH, and their regulations, including the final omnibus rule published on January 25, 2013, also imposes certain obligations on the business associates of covered entities and their covered subcontractors that obtain protected health information in providing services to or on behalf of covered entities or business associates. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that are applicable to our business. In addition to possible federal, administrative, civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Accordingly, state attorneys general have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. New laws and regulations governing privacy and security may be adopted in the future as well. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, states, such as California, Virginia and Colorado have recently enacted the consumer privacy laws that grant rights to data subjects and place increased privacy and security obligations on entities handling personal data of consumers or households. While we are not currently subject to laws such as the CCPA, some observers note that the CCPA and similar legislation could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions under such laws, it is possible that some of our current or future business activities, including certain clinical research, sales and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that we may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any applicable privacy or data security laws or regulations, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a consent decree or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that we collect or otherwise process personal information, we may be subject to privacy or data protection laws that are in effect in such third countries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulation and Procedures Governing Approval of Medicinal Products in Europe </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to market any medicinal product outside of the U.S., a company must also comply with numerous and varying regulatory requirements to generate relevant data for the purpose of establishing its quality, safety and efficacy. There are specific rules governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Regardless of the product approval status in the U.S., an applicant will need to obtain the necessary approvals granted by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of a medicinal product in those countries or jurisdictions. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The processes governing approval of medicinal products in the EU and UK generally adopt a similar approach to that applied in the U.S. They entail satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. Data should be generated to demonstrate that a drug substance and a drug product can be manufactured and controlled according to the pre-specified quality standards. The data relating to quality, preclinical testing and clinical trials should be submitted to the relevant competent authorities in a marketing authorization application (&#8220;MAA&#8221;) for regulatory review in order to determine whether a marketing authorization can be granted. Even if a marketing authorization has been granted, there is a need to obtain a pricing and reimbursement decision before a new medicinal product can be marketed and sold in the EU and/or the UK (as applicable). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Trial Approval </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the currently applicable Regulation (EU) No 536/2014 (CTR) and Directive 2005/28/EC on GCP, an applicant must obtain approval from the national competent authority of an EU member state in which the clinical trial is to be conducted, or in multiple member states if the clinical trial is to be conducted in a number of member states. Furthermore, the applicant can only start a clinical trial at a specific site after a research ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by the CTR and corresponding national laws of the member states. All suspected unexpected serious adverse reactions to the investigational medicinal product that occur during the clinical trial have to be reported to the national competent authorities and research ethics committees of the member state where they occurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the CTR, a sponsor must submit a single application for a new clinical trial authorization through a centralized EU clinical trials portal called the Clinical Trials Information System (&#8220;CTIS&#8221;). One national competent authority (from the reporting EU member state selected by the applicant) takes the lead in validating and evaluating the application, as well as consulting and coordinating with the other concerned member states in which the clinical trial is to be conducted. If an application is rejected, it may be amended and resubmitted through CTIS. A concerned member state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted in that member state. By January 31, 2025, all ongoing trials approved under the CTD must comply with the CTR and information relating to such clinical trials must be recorded in CTIS. The CTR aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the CTIS. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The UK formally left the EU on January 31, 2020, under the terms of the Agreement on the withdrawal of the UK of Great Britain and Northern Ireland from the EU and the European Atomic Energy Community (the EU-UK Withdrawal Agreement). Despite this, EU law continued to apply in the UK until the expiry of the transition period on 31 December 2020. Following the UK&#8217;s departure from the EU, the UK and the EU entered into a trade and cooperation agreement (&#8220;TCA&#8221;), which includes specific provisions concerning pharmaceuticals (such as the mutual recognition of cGMP inspections of manufacturing facilities for medicinal products and cGMP documents issued), but which does not provide for wholesale mutual recognition of UK and EU pharmaceutical regulations. At the point that the transition period expired, the Northern Ireland Protocol, which is contained in the EU-UK Withdrawal Agreement, took effect. The Northern Ireland Protocol makes certain provisions of EU law, including several concerning medicinal products, applicable in Northern Ireland. This position has recently been revised via the Windsor Framework. Under the Windsor Framework, from January 1, 2025, all new medicinal products for the UK market will be authorized by the UK&#8217;s Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) (see further below). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the UK, clinical trials of medicinal products are primarily governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended (the UK Regulations). The UK Regulations sought to implement the CTD while the UK was a member state of the EU. Since the CTR was not in force in the EU at the time when the UK exited the EU, it was not retained in UK law on exit day under the terms of the European Union (Withdrawal) Act 2018. Following a public consultation which was conducted in early 2022, the UK authorities are in the process of developing legislation which seeks to improve and strengthen the clinical trials regulatory regime in the UK. The extent to which the regulation of clinical trials in the UK will mirror the CTR is unknown at present. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accelerated Assessment Pathways </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The EU&#8217;s Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and facilitates accelerated assessment of medicinal products representing substantial innovation reviewed under the centralized procedure. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EEA or, if there is, the new medicine will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by, for example, introducing new methods of therapy or improving existing ones. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme. Many benefits accrue to sponsors of therapeutic candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the European Medicines Agency (&#8220;EMA&#8221;), frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, an EMA contact and rapporteur from the Committee for Human Medicinal Products (&#8220;CHMP&#8221;), or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased understanding of the product at the EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The UK&#8217;s Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;) aims to accelerate the time to market of innovative medicinal products. It is open to both commercial and non-commercial applicants, who are based in the UK or global, and who are developing medicinal products which include products containing new chemical entities, biological medicinal products, new indications and repurposed medicinal products. It comprises of an Innovation Passport designation and a Target Development Profile, and provides applicants with access to a toolkit to support all stages of the design, development and approvals process. The major benefit of the ILAP scheme is that it provides applicants with opportunities for enhanced regulatory and stakeholder input during the development of their medicinal products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketing Authorization </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To obtain a marketing authorization for a medicinal product under the EU regulatory system, an applicant must submit an MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in EU member states (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the EU. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the EU, an applicant must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan (&#8220;PIP&#8221;), covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver or a deferral for one or more of the measures included in the PIP. The Paediatric Committee of the EMA (&#8220;PDCO&#8221;), may grant deferrals for some medicines, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. An application for marketing authorization or a variation or a variation or a line-extension which is accompanied by the pediatric clinical trials conducted in accordance with the PIP (even where such results are negative) are eligible for a six months extension of their supplementary protection certificate. In the case of orphan medicinal products, a two-year extension of the orphan market exclusivity may be available. This pediatric reward is not automatically available and is subject to the EMA or the relevant national competent authorities confirming compliance with the agreed PIP that may require an opinion to be given by the EMA&#8217;s Pediatric Committee. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all EU member states, as well as the additional member states of the EEA (Norway, Iceland and Liechtenstein). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines developed by means of certain biotechnological processes (including, recombinant DNA technology, controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including transformed mammalian cells, and hybridoma and monoclonal antibody methods), products designated as orphan medicinal products, advanced therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products containing a new active substance indicated for the treatment of certain diseases, including products for the treatment of </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">cancer, HIV / AIDS, neurodegenerative disorders, diabetes, auto-immune diseases and other immune dysfunctions, and viral diseases. The centralized procedure is optional for products containing a new active substance which was not authorized in the EU on May 20, 2004, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. An applicant for the centralized MA must demonstrate the quality, safety and efficacy of their products to the EMA for an opinion to be adopted regarding the approvability of the MAA. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the centralized procedure, the CHMP established within the EMA is responsible for conducting an initial assessment of a medicinal product. The maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued ordinarily within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days (excluding clock stops), but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">National marketing authorizations, which are issued by the national competent authorities of the member states of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the centralized procedure. Where a medicinal product has already been authorized for marketing in a member state of the EEA, this national authorization can be recognized in other member states through the mutual recognition procedure. If the product has not received a national authorization in any member state at the time of application, it can be approved simultaneously in two or more member states through the decentralized procedure. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the time being, under the Northern Ireland Protocol, centralized marketing authorizations continue to provide a valid basis for commercializing medicinal products in Northern Ireland. However, centralized marketing authorizations no longer provide a valid basis for the commercialization of medicinal products in Great Britain. Pursuant to the Windsor Framework, from January 1, 2025, all new medicinal products for the UK market will be authorized by the MHRA. In this regard, the MHRA will grant a single UK-wide marketing authorization for all medicinal products intended for sale in the UK, enabling medicinal products to be sold in a single pack and under a single authorization throughout the UK. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following its departure from the EU, the UK has introduced changes to its national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, ILAP (described above) and new routes of evaluation for novel products and biotechnological products. Notwithstanding that there is no wholesale recognition of EU pharmaceutical legislation under the TCA, and that EU marketing authorizations do not automatically provide a valid basis for the commercialization of medicinal products in Great Britain from January 1, 2024, applicants will be able to request the MHRA to recognize marketing authorizations granted in foreign jurisdictions (including the EU) under a new International Recognition Procedure. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulatory Data Protection in Europe </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the EU and the UK, new chemical entities (including both small molecules and biological medicinal products) and new biological substances approved on the basis of a complete independent data package consisting of quality, preclinical testing results and clinical trial data qualify for eight years of RDP upon grant of a marketing authorization and two years of marketing protection. Data protection prevents generic or biosimilar applicants from referencing the innovator&#8217;s preclinical and clinical trial data contained in the MAA dossier of the reference medicinal product when applying for a generic or biosimilar marketing authorization, for a period of eight years from the date on which the reference product was first authorized in the EU. During the two-year period of marketing protection, a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced. Even if a generic or biosimilar medicinal product is approved, it cannot be marketed until the expiration of the marketing protection. The ten-year protection period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical or a new biological entity so that the innovator gains the prescribed period of data protection, another company may market another version of the medicinal product if such company obtained marketing authorization based on an MAA with a complete and independent data package consisting of pharmaceutical and preclinical testing results and clinical trial data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Term Extensions in the EU and Other Jurisdictions </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The EU also provides for patent term extension through SPCs which aim to offset the loss of patent protection for pharmaceutical products arising from the lengthy testing and clinical trials required to obtain an MA. The rules and requirements for obtaining a SPC are similar to those in the U.S. An SPC may extend the term of a basic patent for up to five years after its originally scheduled expiration date in order to provide up to a maximum of fifteen years of exclusivity from the time the medicinal product in question first obtains an MA for it to be placed on the market. As mentioned above, in certain circumstances, these periods may be extended for six additional months if pediatric exclusivity is obtained; and in the case of orphan medicinal products, a two-year extension of the orphan market exclusivity may be available. Although SPCs are available throughout the EU, holders must apply the patent term extension on a country-by-country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the EU. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Orphan Drug Designation and Exclusivity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 provide that a medicinal product can be designated as an orphan medicinal product by the European Commission, upon satisfactory scientific assessment by the EMA&#8217;s Committee for Orphan Medicinal Products (&#8220;COMP&#8221;), if the sponsor can establish: (1) that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition, where either (i) such condition affects not more than five in ten thousand persons in the EU when the application is made, or (ii) without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment in its development, and (2) that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition. In the UK, the MHRA conducts an equivalent assessment, against criteria which have been tailored for the UK population. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The COMP is required to re-assess the granted orphan designation at the time of marketing authorization grant to ensure that it continues to meet the criteria for the designation to be maintained. Otherwise, the orphan designation can be revoked. In relation to the UK, the MHRA does not grant orphan designations during the development of the medicinal product. Instead, the MHRA will decide whether the criteria are satisfied at the point of marketing authorization grant. An orphan drug designation provides a number of benefits, including fee reductions, fee waivers, protocol assistance (as a type of scientific advice specific for orphan medicinal products) and the possibility to apply for a centralized EU marketing authorization. Marketing authorization for an orphan medicinal product benefits from a ten-year period of market exclusivity. During this period of market exclusivity, the European Commission, national competent authorities of the EU member states may only grant marketing authorization to a &#8220;similar medicinal product&#8221; for the same therapeutic indication if: (i) a second applicant can establish that its medicinal product, although similar to the authorized product, is safer, more effective or otherwise clinically superior; (ii) the marketing authorization holder for the authorized product consents to a second orphan medicinal product application; or (iii) the marketing authorization holder for the authorized product cannot supply enough orphan medicinal product. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The period of marketing protection for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable not to justify market exclusivity. Orphan medicinal product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Following the UK&#8217;s exit from the EU, the MHRA continues to apply the same orphan market exclusivity framework as the EU. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Periods of Authorization and Renewals </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A marketing authorization is valid for five years, in principle, and it may be renewed indefinitely after five years on the basis of a reevaluation of the risk-benefit balance by the EMA, the competent authority of the authorizing member state, or the MHRA. To that end, the marketing authorization holder must provide the EMA, the relevant national competent authority, or the MHRA with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization expiry date. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission, the relevant national competent authority, or the MHRA decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any marketing authorization ceases to be valid if it is not followed by the placement of the medicinal product on the EU market (in the case of the centralized procedure), on the market of the authorizing member state (in the case of a national procedure), or the UK market (as applicable), within three years after grant of such an authorization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulatory Requirements After Marketing Authorization </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product, and must adhere in strict compliance with the applicable EU laws, regulations and guidance. These include compliance with stringent pharmacovigilance rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, manufacture and control must also be conducted in strict compliance with cGMP requirements and comparable requirements of other regulatory bodies in the EU and UK. cGMP requirements apply to the methods, facilities and controls used in manufacturing, processing and packing of drugs against the quality standards appropriate to the intended use of a medicinal product and as required by the marketing authorization, clinical trial authorization or product specification. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Much like the federal healthcare program anti-kickback law in the U.S., the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU and the UK. The provision of benefits or advantages to induce or reward improper performance generally is governed by the national anti-bribery laws of EU member states and the Bribery Act 2010 in the UK. Infringement of these laws could result in substantial fines and imprisonment. Applicable law in Europe further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to national laws, industry codes or professional codes of conduct payments made to physicians in certain EU member states and the UK must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU member states, or the UK (as applicable). Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the EU and the UK. Although general requirements for advertising and promotion of medicinal products are established under Directive 2001/83/EC, which was transposed into national law in the UK via the Human Medicines Regulations 2012, the details are governed by regulations in each European jurisdiction and can differ from one country to another. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Data Protection Regulation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The processing of personal data regarding individuals in the EU, including personal health data, is regulated by Regulation (EU) 2016/679, which took effect on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the U.S., and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require us to change our business practices to ensure full compliance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of January 1, 2021, the UK&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Coverage and Reimbursement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may seek regulatory approval by the FDA or other government authorities. In the U.S. and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health authorities or programs, private health insurers and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular drug product or service does not ensure that other payors will also provide coverage for the drug product, or will provide coverage at an adequate reimbursement rate. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more product candidates for which we receive regulatory approval from one or more third party payors, less favorable coverage policies and reimbursement rates may be implemented in the future. Additionally, if a companion diagnostic test is developed for use with a drug product, any coverage and reimbursement for that test would be separate and apart from the coverage and reimbursement sought for such product. A lack of coverage or adequate reimbursement for such a test could adversely affect access to a drug product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Within the U.S., third-party payors are increasingly seeking to control drug costs by examining the cost-effectiveness of new products and services in addition to their safety and efficacy; managing drug utilization and challenging the price of drugs. To obtain or maintain coverage and reimbursement for any future product, we may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our product. These studies will be in addition to the studies required to obtain regulatory approvals. Third-party payors may limit coverage of product by, for example, only covering specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. Some third-party payors may manage utilization of a particular product by requiring pre-approval (known as &#8220;prior authorization&#8221;) for coverage of particular prescriptions (to allow the payor to assess medical necessity) or otherwise restricting coverage of a product even if used consistent with its approved indication. Manufacturers of marketed drugs may be required to provide discounts or rebates under government healthcare programs or to certain government and private purchasers in order to obtain coverage under federal healthcare programs such as Medicaid. More generally, price concessions may need to be offered to third party payors to obtain favorable coverage or to purchasers to achieve sales. Arrangements with third party payors or purchasers may include value-based arrangements under which the amount paid for products depends on the performance of the product. Net prices for drugs may be further reduced by mandatory discounts or rebates required by government healthcare programs or private payors </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular medicinal product candidate to currently available therapies. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare Reform </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for therapies addressing rare diseases such as those we are developing. In both the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our product candidates profitably if and when approved for marketing. In particular, in 2010, the ACA was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. More generally, the ACA expanded healthcare coverage through Medicaid expansion and the implementation of the &#8220;individual mandate&#8221; for health insurance coverage. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Beyond the ACA, there have been ongoing healthcare reform efforts. Drug pricing and payment reform was a focus of the Trump administration and has been a focus of the Biden administration. For example, federal legislation enacted in 2021 eliminates the statutory cap on Medicaid drug rebate program rebates (currently set at 100% of a drug&#8217;s &#8220;average manufacturer price&#8221;), effective January 1, 2024. As another example, the IRA, includes a number of changes intended to address rising prescription drug prices in Medicare Parts B and D. These changes include caps on Medicare Part D out-of-pocket costs, Medicare Part B and Part D drug price inflation rebates, a new Medicare Part D manufacturer discount drug program (replacing the ACA Medicare Part D coverage gap discount program) and a drug price negotiation program for certain high spend Medicare Part B and D drugs (with the first list of drugs announced in 2023). The IRA changes have varying implementation dates that start in 2022. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. The focus on healthcare reform, including reform of drug pricing and payment, has continued in the wake of the IRA. For example, in 2022, subsequent to the enactment of the IRA, the Biden administration released an executive order directing the HHS to report on how the Center for Medicare and Medicaid Innovation (&#8220;CMMI&#8221;) could be leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. The report was issued in 2023 and proposed various models that CMMI is currently developing which seek to lower the cost of drugs, promote accessibility and improve quality of care. Further, in December 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act (which allow the government, in specified circumstances, to grant or require a patent-holder of technology funded by the federal government to grant a license to certain third parties). The announcement was followed by publication of Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, given these actions, there can be no certainty that such rights will not be exercised in the future. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare reform efforts have been and may continue to be subject to scrutiny and legal challenge. For example, with respect to the ACA, tax reform legislation was enacted that eliminated the tax penalty established for individuals who do not maintain mandated health insurance coverage beginning in 2019 and, in 2021, the U.S. Supreme Court dismissed the latest judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. As another example, revisions to regulations under the federal anti-kickback statute would remove protection for traditional Medicare Part D discounts offered by pharmaceutical manufacturers to pharmacy benefit managers and health plans. Pursuant to court order, the removal was delayed and recent legislation imposed a moratorium on implementation of the rule until January 2032. As another example, the IRA drug price negotiation program has been challenged in litigation filed by various pharmaceutical manufacturers and industry groups. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have also been efforts by federal and state government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the U.S. or Canada. Other states have also submitted Section 804 Importation Program (&#8220;SIP&#8221;) proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. Recently, there has been considerable public and government scrutiny of pharmaceutical pricing and proposals to address the perceived high cost of pharmaceuticals. There have also been recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around drug costs or limiting drug prices. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General legislative cost control measures may also affect reimbursement for our product candidates. The Budget Control Act, as amended, resulted in the imposition of reductions in Medicare (but not Medicaid) payments to providers in 2013 that remain in effect through 2032 unless additional Congressional action is taken. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us could have an adverse impact on our results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Adoption of new legislation at the federal or state level could affect demand for, or pricing of, any future products if approved for sale. We cannot, however, predict the ultimate content, timing or effect of any federal and state reform efforts. There is no assurance that federal or state healthcare reform will not adversely affect our future business and financial results. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Healthcare Laws </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business that may constrain how we conduct our business, including the financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Restrictions under applicable federal and state healthcare laws and regulations, some of which will apply only if and when we receive marketing approval for a product candidate, include the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims, false statements and civil monetary penalties laws which prohibit, among other activities, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid and may be implicated if claims are submitted that result from a violation of the federal anti-kickback statute; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products for off-label use and regulates the distribution of samples; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the so-called &#8220;federal sunshine&#8221; law, which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with physicians, certain non-physician practitioners and teaching hospitals to the federal government for re-disclosure to the public; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state and foreign laws and regulations, such as state anti-bribery, anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Some state laws require pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to healthcare providers or marketing expenditures. Other state laws may require pharmaceutical companies to file reports relating to pricing and marketing information, and state and local laws may require registration of pharmaceutical sales representatives. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices may not comply with healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including significant civil and criminal penalties, damages, fines, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations, and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employees and Human Capital Resources </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of February 28, 2025, we had 130 full-time employees, consisting of clinical, scientific, development, medical affairs, technical operations, regulatory, finance, legal and operational personnel. None of our employees is represented by labor unions or subject to a collective bargaining agreement. Our personnel outside of the U.S. are subject to employment contracts which contain customary notice periods. We consider our relationship with our employees to be good. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Of our 130 full-time employees as of February 28, 2025, 14 were located in China and consisted of clinical, technical operations, regulatory, finance and human resources personnel. Our China-based employees support clinical operations and regulatory matters related to obexelimab in the Asia-Pacific region and technical operations, with all functions in China reporting to management in the U.S. We also have dedicated medical and commercial personnel located in Europe to advance our obexelimab strategy in that region.<span style="color:#ff0000;"> </span>We recognize that our continued ability to attract, retain, and motivate exceptional employees is vital to ensuring our long-term competitive advantage. Our employees are critical to our long-term success and are essential to helping us meet our goals. Among other things, we support and incentivize our employees in the following ways: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Talent development, compensation, and retention</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and future employees. Our compensation program is designed to retain, motivate and attract highly qualified employees. Accordingly, we </span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use a mix of competitive base salary, cash-based annual incentive compensation, performance-based equity compensation awards and other employee benefits. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Health and safety</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: We value the health and safety of our employees and provide comprehensive insurance benefits, an employee assistance program, paid holidays, a personal time-off program, and other benefits which are intended to assist employees to manage their well-being. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Inclusion and diversity</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: We are committed to efforts to increase diversity and foster an inclusive professional environment that supports our workforce.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate and Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We incorporated in November&#160;2019 as Zenas BioPharma (Cayman) Limited, an exempted company incorporated in the Cayman Islands with limited liability, and commenced operations in 2020. On August&#160;2, 2023, the Company (then known as Zenas BioPharma (Cayman) Limited) de-registered from the Cayman Islands and registered by way of continuation in the State of Delaware. Our principal executive offices are located at 852 Winter Street, Suite 250, Waltham MA 02451, and our telephone number at that address is&#160;(857) 271-2954. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;16, 2024, the Company completed its initial public offering (&#8220;IPO&#8221;), in which the Company issued and sold&#160;15,220,588&#160;shares of its common stock, including&#160;1,985,294&#160;shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $17.00&#160;per share, for aggregate gross proceeds of $258.7&#160;million. The Company received approximately $234.3&#160;million in net proceeds after deducting underwriting discounts, commissions and other offering expenses.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Internet address is www.zenasbio.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this Annual Report on Form 10-K. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) are available through the &#8220;Investor &amp; Media Relations&#8221; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. In addition, our filings with the SEC may be accessed through the SEC&#8217;s Electronic Data Gathering, Analysis and Retrieval system at http://www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_44d1a415_28c4_4bcb_9b1e_da1f8194d42d"></a><a id="Item1ARiskFactors_747397"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">Investors should carefully consider the risks described below, together with the other information contained</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">in</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">this</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">Annual Report,</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">including</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">in</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">the</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">section</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">titled</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">&#8220;Management&#8217;s</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">Discussion</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">and</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">Analysis</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="color:#231f20;font-style:italic;">of Financial Condition and Results of Operations&#8221; and in our audited consolidated financial statements and the related notes contained in this Annual Report. The events discussed below may occur and adversely impact our business, financial condition, results of operations and prospects,</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.3pt;"> </i><i style="color:#231f20;font-style:italic;">which</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.3pt;"> </i><i style="color:#231f20;font-style:italic;">may</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.3pt;"> </i><i style="color:#231f20;font-style:italic;">cause</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.3pt;"> </i><i style="color:#231f20;font-style:italic;">the</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.3pt;"> </i><i style="color:#231f20;font-style:italic;">trading</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.3pt;"> </i><i style="color:#231f20;font-style:italic;">price</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.3pt;"> </i><i style="color:#231f20;font-style:italic;">of our</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.3pt;"> </i><i style="color:#231f20;font-style:italic;">common</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.3pt;"> </i><i style="color:#231f20;font-style:italic;">stock</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.3pt;"> </i><i style="color:#231f20;font-style:italic;">to</i><i style="color:#231f20;font-style:italic;letter-spacing:-0.3pt;"> </i><i style="color:#231f20;font-style:italic;">decline. These risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also affect our business. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;">Risks</b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.5pt;"> </b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;">Related</b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;">to</b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;">Our</b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.5pt;"> </b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;">Financial</b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;">Position</b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;">and</b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;">Need</b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.5pt;"> </b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;">for</b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;">Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are a clinical stage biopharma company with a limited operating history and no products approved for commercial sale; we have incurred substantial losses since our inception, and we anticipate incurring substantial and increasing losses for the foreseeable future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical stage biopharma company with a limited operating history on which to base an investment decision. We have no product candidates approved for commercial sale in any country and have not generated any revenue from sales of products. Biopharmaceutical product development is a highly speculative undertaking, involving substantial upfront capital expenditure and significant risk. Any product candidate<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>fail<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>demonstrate<span style="letter-spacing:-0.25pt;"> </span>adequate<span style="letter-spacing:-0.25pt;"> </span>efficacy<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.25pt;"> </span>acceptable<span style="letter-spacing:-0.25pt;"> </span>safety<span style="letter-spacing:-0.25pt;"> </span>profile,<span style="letter-spacing:-0.25pt;"> </span>gain<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>approval or become commercially viable, despite substantial investment on development or commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>incurred,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.3pt;"> </span>continue<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>incur,<span style="letter-spacing:-0.3pt;"> </span>significant<span style="letter-spacing:-0.3pt;"> </span>expenses<span style="letter-spacing:-0.3pt;"> </span>related<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.3pt;"> </span>of our product candidates and ongoing operations. &#160;For the year ended December 31, 2024, we reported a net loss of $157.0 million. As of December 31, 2024, we had accumulated deficit of $387.4 million, which included non-cash charges for stock-based compensation and acquisition and development expenses. We<span style="letter-spacing:-0.5pt;"> </span>expect<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>continue to incur<span style="letter-spacing:-0.5pt;"> </span>significant<span style="letter-spacing:-0.5pt;"> </span>losses<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>foreseeable<span style="letter-spacing:-0.5pt;"> </span>future,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>expect these losses to increase as we advance the development of<span style="letter-spacing:1.65pt;"> </span>our product candidates. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. <span style="letter-spacing:-0.1pt;">The</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">size</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:-0.1pt;">our </span>future<span style="letter-spacing:-0.7pt;"> </span>net<span style="letter-spacing:-0.65pt;"> </span>losses<span style="letter-spacing:-0.65pt;"> </span>will<span style="letter-spacing:-0.65pt;"> </span>depend,<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>part,<span style="letter-spacing:-0.65pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.7pt;"> </span>rate<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>expenses<span style="letter-spacing:-0.65pt;"> </span>increase<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>ability<span style="letter-spacing:-0.7pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>generate<span style="letter-spacing:-0.65pt;"> </span>revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and our working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.45pt;"> </span>anticipate<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>expenses<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.4pt;"> </span>increase<span style="letter-spacing:-0.45pt;"> </span>substantially<span style="letter-spacing:-0.4pt;"> </span>if,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>as,<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.25pt;">we:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obexelimab</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance our obexelimab program and our other product candidates through preclinical development and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rights</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">parties</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">those</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates through</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">licenses</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquisitions</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">activities,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">including</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preclinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">studies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">royalty,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">milestone</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payments</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">license</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">procure</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of preclinical,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supply</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approvals</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercialize</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.95pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">approved;</span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">take steps toward our goal of being an integrated biopharma company capable of supporting commercial activities, including establishing sales, marketing and distribution infrastructure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">qualified</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical, scientific,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">management</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defend</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">property</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">portfolio,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">including</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">against third-party interference, infringement and other intellectual property claims, if</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operational,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">information</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">management</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attempt</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">address</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">therapies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experience</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preclinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">studies,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trials</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any future</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">including</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">respect</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failed</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">studies,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inconclusive</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issues</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or other regulatory challenges;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agreements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">contract</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">organizations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(&#8220;CROs&#8221;)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> contract manufacturing organizations (&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CMOs&#8221;);</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur additional costs associated with being a public company, including audit, legal, regulatory and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">tax-related</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">services</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">associated</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">maintaining</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">compliance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">an</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">exchange</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">listing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Securities </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and Exchange Commission (the &#8220;SEC&#8221;) requirements, director and officer insurance premiums and investor relations costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we succeed in commercializing one or more product candidates, we expect to incur substantial expenditures to develop and market additional product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will require substantial additional financing to achieve our goals, and failure to obtain additional capital when needed, or on acceptable terms, would cause us to delay, limit, reduce or terminate our product development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The<span style="letter-spacing:-0.5pt;"> </span>development<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.5pt;"> </span>product<span style="letter-spacing:-0.5pt;"> </span>candidates,<span style="letter-spacing:-0.5pt;"> </span>including<span style="letter-spacing:-0.5pt;"> </span>conducting<span style="letter-spacing:-0.5pt;"> </span>preclinical<span style="letter-spacing:-0.5pt;"> </span>studies<span style="letter-spacing:-0.5pt;"> </span>and clinical trials, is a time consuming, capital-intensive and uncertain process. Our operations have consumed substantial amounts of cash since inception. We expect our expenses to substantially increase in connection with our ongoing and future activities. If we obtain regulatory approval for obexelimab or other product candidates, we also expect to incur significant commercialization expenses related to manufacturing, marketing, sales and distribution of such products. Because the outcome of any clinical trial or preclinical study<span style="letter-spacing:-0.7pt;"> </span>is<span style="letter-spacing:-0.65pt;"> </span>uncertain,<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>cannot<span style="letter-spacing:-0.65pt;"> </span>reliably<span style="letter-spacing:-0.65pt;"> </span>estimate<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>actual<span style="letter-spacing:-0.7pt;"> </span>amount<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.55pt;"> </span>capital<span style="letter-spacing:-0.65pt;"> </span>necessary<span style="letter-spacing:-0.7pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>successfully<span style="letter-spacing:-0.65pt;"> </span>complete the<span style="letter-spacing:-0.6pt;"> </span>development<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>commercialization<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>obexelimab<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>other<span style="letter-spacing:-0.6pt;"> </span>product<span style="letter-spacing:-0.6pt;"> </span>candidates.<span style="letter-spacing:-0.6pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As<span style="letter-spacing:-0.05pt;"> </span>of December 31, 2024,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>had<span style="letter-spacing:-0.05pt;"> </span>$350.8<span style="letter-spacing:-0.05pt;"> </span>million<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>cash, cash equivalents and short-term investments.<span style="letter-spacing:-0.05pt;"> </span>Based<span style="letter-spacing:-0.05pt;"> </span>upon<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.05pt;"> </span>operating<span style="letter-spacing:-0.05pt;"> </span>plan,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>believe that<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>cash, cash equivalents and investments<span style="letter-spacing:-0.65pt;"> as of &#160;December 31, 2024, </span>will<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>sufficient<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>fund<span style="letter-spacing:-0.65pt;"> </span>our operating<span style="letter-spacing:-0.1pt;"> </span>expenses<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>capital<span style="letter-spacing:-0.1pt;"> </span>expenditure<span style="letter-spacing:-0.1pt;"> </span>requirements<span style="letter-spacing:-0.1pt;"> into the fourth quarter</span> of 2026.<span style="letter-spacing:-0.1pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>based<span style="letter-spacing:-0.1pt;"> </span>this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We expect to attempt to raise additional cash in advance of exhausting our available capital resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will not generate revenue from product sales unless and until we successfully complete clinical development<span style="letter-spacing:-0.7pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>obtain<span style="letter-spacing:-0.65pt;"> </span>regulatory<span style="letter-spacing:-0.65pt;"> </span>approval<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidate,<span style="letter-spacing:-0.7pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>ever<span style="letter-spacing:-0.65pt;"> </span>generate<span style="letter-spacing:-0.65pt;"> </span>significant revenue or profits. In addition, we expect to incur costs associated<span style="letter-spacing:-0.55pt;"> </span>with<span style="letter-spacing:-0.55pt;"> </span>operating<span style="letter-spacing:-0.55pt;"> </span>as<span style="letter-spacing:-0.55pt;"> </span>a<span style="letter-spacing:-0.55pt;"> </span>public<span style="letter-spacing:-0.55pt;"> </span>company,<span style="letter-spacing:-0.55pt;"> </span>including<span style="letter-spacing:-0.55pt;"> </span>significant<span style="letter-spacing:-0.55pt;"> </span>legal,<span style="letter-spacing:-0.55pt;"> </span>accounting,<span style="letter-spacing:-0.55pt;"> </span>investor<span style="letter-spacing:-0.55pt;"> </span>relations,<span style="letter-spacing:-0.55pt;"> </span>and other expenses that we did not incur prior to our IPO. If we obtain regulatory approval for a product candidate and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities. We may also require additional capital to pursue in-licenses or acquisitions of other product candidates. As a result, we expect to incur substantial operating losses and negative operating cash flows for the foreseeable future.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with research, development and commercialization<span style="letter-spacing:-0.2pt;"> </span>of product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>estimate<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>exact<span style="letter-spacing:-0.2pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of our<span style="letter-spacing:-0.2pt;"> </span>working<span style="letter-spacing:-0.2pt;"> </span>capital requirements.<span style="letter-spacing:-0.4pt;"> </span>Our<span style="letter-spacing:-0.4pt;"> </span>future<span style="letter-spacing:-0.4pt;"> </span>funding<span style="letter-spacing:-0.4pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.4pt;"> </span>depend<span style="letter-spacing:-0.4pt;"> </span>on,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.4pt;"> </span>increase<span style="letter-spacing:-0.4pt;"> </span>significantly<span style="letter-spacing:-0.4pt;"> </span>as<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>result<span style="letter-spacing:-0.4pt;"> </span>of, many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, timing and progress of our ongoing obexelimab clinical studies and other research and development activities associated with the development of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">number</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scope</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preclinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">programs</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decide</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">programs</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enrollment</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trials</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tolerability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">profiles</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are satisfactory to the FDA, or any comparable foreign regulatory authority;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terms</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approvals</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">applicable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">licensing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">arrangements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supply</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of products that receive marketing approval, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delivery</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercial-grade</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">drug</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">formulations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">can</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">used</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our planned clinical trials and for commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defending</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enforcing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">claims</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">property</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to hire additional personnel and consultants as our business grows, including additional </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">executive officers and clinical development, regulatory, chemistry, manufacturing and controls, quality </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercializing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approved,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alone</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">securing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">capabilities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achieve</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficient</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">coverage</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adequate</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reimbursement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from third-party payors and adequate market share and revenue for any approved products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">profile</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">following</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.2pt;"> </span>expect<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>commercial<span style="letter-spacing:-0.2pt;"> </span>revenue,<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:1pt;"> </span>any,<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>initially<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>derived<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>sales<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:1pt;"> </span>obexelimab,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>we do<span style="letter-spacing:-0.55pt;"> </span>not<span style="letter-spacing:-0.55pt;"> </span>expect<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>be<span style="letter-spacing:-0.55pt;"> </span>commercially<span style="letter-spacing:-0.55pt;"> </span>available<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>several<span style="letter-spacing:-0.55pt;"> </span>years,<span style="letter-spacing:-0.55pt;"> </span>if ever.<span style="letter-spacing:-0.55pt;"> </span>Accordingly,<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>will<span style="letter-spacing:-0.55pt;"> </span>need<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>continue<span style="letter-spacing:-0.55pt;"> </span>to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.25pt;"> </span>acceptable<span style="letter-spacing:-0.25pt;"> </span>terms,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>at<span style="letter-spacing:-0.25pt;"> </span>all,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>credit<span style="letter-spacing:-0.25pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>deterioration or instability, market-wide liquidity shortages, geopolitical events or otherwise. If we are unable to raise sufficient additional capital, we would be forced to curtail our planned operations and the pursuit of our growth strategy.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Raising additional capital may cause dilution to our stockholders imposing restrictions on our operations or require us to relinquish rights to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Until<span style="letter-spacing:-0.7pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>time,<span style="letter-spacing:-0.65pt;"> </span>if<span style="letter-spacing:-0.65pt;"> </span>ever,<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>generate<span style="letter-spacing:-0.65pt;"> </span>substantial<span style="letter-spacing:-0.7pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>revenue,<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>expect<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>finance<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>cash<span style="letter-spacing:-0.7pt;"> </span>needs through<span style="letter-spacing:-0.3pt;"> </span>equity<span style="letter-spacing:-0.3pt;"> </span>offerings,<span style="letter-spacing:-0.3pt;"> </span>debt<span style="letter-spacing:-0.3pt;"> </span>financings<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.3pt;"> </span>capital<span style="letter-spacing:-0.3pt;"> </span>sources,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>collaborations,<span style="letter-spacing:-0.3pt;"> </span>licenses and<span style="letter-spacing:-0.55pt;"> </span>other<span style="letter-spacing:-0.55pt;"> </span>arrangements.<span style="letter-spacing:-0.55pt;"> </span>To<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>extent<span style="letter-spacing:-0.55pt;"> </span>that<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>raise<span style="letter-spacing:-0.55pt;"> </span>additional<span style="letter-spacing:-0.55pt;"> </span>capital<span style="letter-spacing:-0.55pt;"> </span>through<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>sale<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>equity<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>convertible <span style="letter-spacing:-0.1pt;">debt</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">securities,</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">stockholders&#8217;</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">ownership</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">interest</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">will</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">diluted,</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">terms</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.55pt;"> </span><span style="letter-spacing:-0.1pt;">these</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">securities</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">include</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">liquidation </span>or other preferences that adversely affect their rights as a holder of our common stock. Any future debt or preferred<span style="letter-spacing:-0.5pt;"> </span>equity<span style="letter-spacing:-0.5pt;"> </span>financing,<span style="letter-spacing:-0.5pt;"> </span>if<span style="letter-spacing:0.35pt;"> </span>available,<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>involve<span style="letter-spacing:-0.5pt;"> </span>agreements<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.5pt;"> </span>include<span style="letter-spacing:-0.5pt;"> </span>covenants<span style="letter-spacing:-0.5pt;"> </span>limiting<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through future collaborations, licenses and other arrangements, we likely would<span style="letter-spacing:-0.05pt;"> </span>relinquish<span style="letter-spacing:-0.05pt;"> </span>valuable<span style="letter-spacing:-0.05pt;"> </span>rights<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.05pt;"> </span>revenue<span style="letter-spacing:-0.05pt;"> </span>streams<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.05pt;"> </span>candidates.<span style="letter-spacing:-0.05pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.05pt;"> </span>may grant<span style="letter-spacing:-0.65pt;"> </span>licenses<span style="letter-spacing:-0.65pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>terms<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>favorable<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>us<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>reduce<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>value<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>common<span style="letter-spacing:-0.65pt;"> </span>stock.<span style="letter-spacing:-0.65pt;"> </span>If<span style="letter-spacing:0.35pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>are unable<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>raise<span style="letter-spacing:-0.05pt;"> </span>additional<span style="letter-spacing:-0.05pt;"> </span>funds<span style="letter-spacing:-0.1pt;"> </span>through<span style="letter-spacing:-0.05pt;"> </span>equity<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>debt<span style="letter-spacing:-0.05pt;"> </span>financings<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.05pt;"> </span>arrangements<span style="letter-spacing:-0.05pt;"> </span>when<span style="letter-spacing:-0.05pt;"> </span>needed,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>on acceptable<span style="letter-spacing:-0.8pt;"> </span>terms,<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>would<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>required<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>delay,<span style="letter-spacing:-0.65pt;"> </span>limit,<span style="letter-spacing:-0.7pt;"> </span>reduce<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>terminate<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>development<span style="letter-spacing:-0.65pt;"> </span>efforts<span style="letter-spacing:-0.65pt;"> </span>or grant<span style="letter-spacing:-0.15pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>develop<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>market<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:-0.15pt;"> </span>otherwise<span style="letter-spacing:-0.15pt;"> </span>prefer<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>develop<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>market <span style="letter-spacing:-0.1pt;">ourselves.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, we may not be able to access a portion of our existing cash due to market conditions. If banks and<span style="letter-spacing:-0.4pt;"> </span>financial<span style="letter-spacing:-0.4pt;"> </span>institutions<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.4pt;"> </span>whom<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>hold<span style="letter-spacing:-0.4pt;"> </span>accounts<span style="letter-spacing:-0.4pt;"> </span>enter<span style="letter-spacing:-0.4pt;"> </span>receivership<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>become<span style="letter-spacing:-0.4pt;"> </span>insolvent<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>future<span style="letter-spacing:-0.4pt;"> </span>in response<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>financial<span style="letter-spacing:-0.2pt;"> </span>conditions<span style="letter-spacing:-0.2pt;"> </span>affecting<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>banking<span style="letter-spacing:-0.2pt;"> </span>system<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>financial<span style="letter-spacing:-0.2pt;"> </span>markets,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>our existing cash may be threatened and could have a material adverse effect on our business and financial <span style="letter-spacing:-0.1pt;">condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks<b style="font-weight:bold;letter-spacing:-0.3pt;"> </b>Related<b style="font-weight:bold;letter-spacing:-0.3pt;"> </b>to<b style="font-weight:bold;letter-spacing:-0.3pt;"> </b>Product<b style="font-weight:bold;letter-spacing:-0.3pt;"> </b>Candidate<b style="font-weight:bold;letter-spacing:-0.3pt;"> </b>Development<b style="font-weight:bold;letter-spacing:-0.3pt;"> </b>and<b style="font-weight:bold;letter-spacing:-0.3pt;"> </b>Commercialization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical development is lengthy and expensive, characterized by uncertain outcomes, with results of earlier studies and trials often failing to predict future trial results or results in other indications of a product candidate. We may incur additional costs or experience delays in completing, or fail to complete, the development and commercialization of our current product candidates or any future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face substantial risk of failure with our product candidates and we may fail to receive regulatory approval<span style="letter-spacing:-0.6pt;"> </span>for<span style="letter-spacing:-0.6pt;"> </span>any<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>product<span style="letter-spacing:-0.6pt;"> </span>candidates.<span style="letter-spacing:-0.6pt;"> </span>To<span style="letter-spacing:-0.6pt;"> </span>obtain<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>requisite<span style="letter-spacing:-0.6pt;"> </span>regulatory<span style="letter-spacing:-0.6pt;"> </span>approvals<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>commercialize<span style="letter-spacing:-0.6pt;"> </span>any product candidate, we must demonstrate, through extensive preclinical studies and lengthy, complex and expensive clinical trials, that a product candidate is safe, pure and potent and has a favorable risk-benefit profile. Clinical testing often takes many years to complete, and its outcome is inherently uncertain. The results of<span style="letter-spacing:1.9pt;"> </span>preclinical studies and early clinical trials of<span style="letter-spacing:1.9pt;"> </span>our product candidates may not predict results of later-stage<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.15pt;"> </span>trials,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>indication<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>predict<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>same<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidate <span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">another</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">indication.</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">Differences</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">trial</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">design</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">between</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">early-stage</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">trials</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">later-stage</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">trials </span>raise challenges for extrapolating the results of<span style="letter-spacing:1.25pt;"> </span>earlier clinical trials to later clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A<span style="letter-spacing:-0.7pt;"> </span>number<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>companies<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.65pt;"> </span>industry<span style="letter-spacing:-0.65pt;"> </span>have<span style="letter-spacing:-0.7pt;"> </span>suffered<span style="letter-spacing:-0.65pt;"> </span>significant<span style="letter-spacing:-0.65pt;"> </span>setbacks<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>advanced <span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">trials</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">due</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">lack</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:-0.1pt;">efficacy</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">unfavorable</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">safety</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">profiles,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">notwithstanding</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">promising</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">results</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">earlier </span>trials. Prior<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>acquisition<span style="letter-spacing:-0.05pt;"> </span>of obexelimab,<span style="letter-spacing:-0.05pt;"> </span>Xencor<span style="letter-spacing:-0.05pt;"> </span>conducted<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>Phase<span style="letter-spacing:-0.05pt;"> </span>2<span style="letter-spacing:-0.05pt;"> </span>trial<span style="letter-spacing:-0.05pt;"> </span>of obexelimab<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>patients <span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">SLE,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">where</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">primary</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">endpoint</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">was</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">achieved</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">statistical</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">significance.</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">The</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">results</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">clinical </span>trials<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>obexelimab<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.5pt;"> </span>SLE<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>other<span style="letter-spacing:-0.5pt;"> </span>indications<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>clinical<span style="letter-spacing:-0.5pt;"> </span>trials<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.5pt;"> </span>any<span style="letter-spacing:-0.5pt;"> </span>other<span style="letter-spacing:-0.5pt;"> </span>product<span style="letter-spacing:-0.5pt;"> </span>candidates<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>not achieve<span style="letter-spacing:-0.1pt;"> </span>statistical<span style="letter-spacing:-0.1pt;"> </span>significance<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>demonstrate<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>favorable<span style="letter-spacing:-0.1pt;"> </span>risk-benefit<span style="letter-spacing:-0.1pt;"> </span>profile.<span style="letter-spacing:-0.1pt;"> </span>Further,<span style="letter-spacing:-0.1pt;"> </span>negative<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.1pt;"> </span>trial results<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.1pt;"> </span>candidate<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>respect<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>indication<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>impact<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>potential<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>perceived<span style="letter-spacing:-0.1pt;"> </span>potential of<span style="letter-spacing:0.5pt;"> </span>other<span style="letter-spacing:-0.5pt;"> </span>indications.<span style="letter-spacing:-0.5pt;"> </span>Moreover,<span style="letter-spacing:-0.5pt;"> </span>clinical<span style="letter-spacing:-0.5pt;"> </span>data<span style="letter-spacing:-0.5pt;"> </span>are<span style="letter-spacing:-0.5pt;"> </span>often<span style="letter-spacing:-0.5pt;"> </span>susceptible<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>varying<span style="letter-spacing:-0.5pt;"> </span>interpretations<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>analyses,<span style="letter-spacing:-0.5pt;"> </span>and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of<span style="letter-spacing:2pt;"> </span>such product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="letter-spacing:-0.1pt;">Commencing</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">any</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">future</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">trials</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">is</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">subject</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">finalizing</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">trial</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">design</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">submitting</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">an</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">application, </span>such as an IND or BLA, to the FDA or a comparable foreign regulatory authority. Even after the submission of an IND or BLA, the FDA or comparable foreign regulatory authorities could disagree that their requirements to commence a clinical trial have been satisfied or disagree with the study design, which may require the completion of additional trials or the amendment of the </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">trial&#8217;s protocols or the imposition of stricter conditions<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>commencement<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>trial.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>establish<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>endpoints,<span style="letter-spacing:-0.3pt;"> </span>dose levels and regimens or bioanalytical assay methods that regulatory authorities would consider clinically meaningful.<span style="letter-spacing:-0.65pt;"> </span>A<span style="letter-spacing:-0.65pt;"> </span>high<span style="letter-spacing:-0.65pt;"> </span>failure<span style="letter-spacing:-0.65pt;"> </span>rate<span style="letter-spacing:-0.65pt;"> </span>characterizes<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidates<span style="letter-spacing:-0.65pt;"> </span>proceeding<span style="letter-spacing:-0.65pt;"> </span>through<span style="letter-spacing:-0.65pt;"> </span>clinical<span style="letter-spacing:-0.65pt;"> </span>trials,<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>failure may<span style="letter-spacing:-0.3pt;"> </span>occur<span style="letter-spacing:-0.3pt;"> </span>at<span style="letter-spacing:-0.3pt;"> </span>all<span style="letter-spacing:-0.3pt;"> </span>stages<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>trial<span style="letter-spacing:-0.3pt;"> </span>process.<span style="letter-spacing:-0.3pt;"> </span>Most<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.3pt;"> </span>commence<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>trials<span style="letter-spacing:-0.3pt;"> </span>are never<span style="letter-spacing:-0.6pt;"> </span>approved<span style="letter-spacing:-0.6pt;"> </span>as<span style="letter-spacing:-0.6pt;"> </span>products,<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>current<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>future<span style="letter-spacing:-0.6pt;"> </span>clinical<span style="letter-spacing:-0.6pt;"> </span>trials<span style="letter-spacing:-0.6pt;"> </span>ultimately<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>fail<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>support<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>approval of<span style="letter-spacing:2pt;"> </span>our current or any future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to continue to rely, in part, on collaborators, CROs and clinical trial sites to conduct our clinical<span style="letter-spacing:-0.3pt;"> </span>trials,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>participant<span style="letter-spacing:-0.3pt;"> </span>enrollment,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>limited<span style="letter-spacing:-0.3pt;"> </span>influence<span style="letter-spacing:-0.3pt;"> </span>over<span style="letter-spacing:-0.3pt;"> </span>their<span style="letter-spacing:-0.3pt;"> </span>performance.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.3pt;"> </span>or our collaborators may experience delays in initiating or completing clinical trials and preclinical studies or other<span style="letter-spacing:-0.15pt;"> </span>issues<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>prevent<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>ability<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>receive<span style="letter-spacing:-0.15pt;"> </span>marketing<span style="letter-spacing:-0.15pt;"> </span>approval<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>commercialize<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>current<span style="letter-spacing:-0.15pt;"> </span>and any future product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">comparable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">us</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preclinical studies or impose additional requirements before permitting us to initiate a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">comparable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorities,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Institutional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Review</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Boards</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(&#8220;IRBs&#8221;)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ethics committees</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagree</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">study</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">design,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">modify</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amend</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trial </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protocols, or may not authorize us or our investigators to commence or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experience</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fail</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reach,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agreement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terms</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sites and CROs, the terms of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which can be subject to extensive negotiation and may vary significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical investigators or clinical trial sites may deviate from trial protocols or Good Clinical Practice requirements (&#8220;GCPs&#8221;) or drop out of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a trial, and we may need to add new investigators or sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CROs</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fail</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">comply</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">meet</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">their</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">contractual</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obligations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">us in a timely manner, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">participants required for clinical trials may be larger than expected, enrollment in clinical </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trials</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">slower</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">than</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expected</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">participants</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">drop</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">out</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fail</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">return</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">post-treatment follow-up</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">higher</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rate</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">than</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">observe</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpectedly</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">high</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">placebo</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">response</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials and preclinical studies may be greater than we anticipate, or we may have insufficient</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">funds</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">study</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pay</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">user</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fees</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">required</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA upon the submission of a BLA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of our product candidates or other materials necessary to conduct our clinical trials or preclinical studies may be insufficient or inadequate to initiate or complete a given clinical </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates may have undesirable side effects or other unexpected characteristics that are viewed to outweigh their potential benefits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">reports</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">from</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">testing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">similar</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">therapies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">raise</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">safety,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">tolerability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">efficacy</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">concerns </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">about our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of our product candidates may fail to show appropriate safety, tolerability or efficacy, may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">produce</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negative</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inconclusive</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fail</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improve</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">existing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">standard of care, and we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies or we may decide to abandon product candidate development.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:-0.35pt;"> </span>addition,<span style="letter-spacing:-0.35pt;"> </span>delays<span style="letter-spacing:-0.35pt;"> </span>occur<span style="letter-spacing:-0.35pt;"> </span>when<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.35pt;"> </span>trial<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.35pt;"> </span>suspended,<span style="letter-spacing:-0.35pt;"> </span>put<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.35pt;"> </span>hold<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>terminated<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>trial sponsor,<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>comparable<span style="letter-spacing:-0.1pt;"> </span>foreign<span style="letter-spacing:-0.1pt;"> </span>regulatory<span style="letter-spacing:-0.1pt;"> </span>authorities,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>IRBs<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>institutions<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.1pt;"> </span>such trials are being conducted, or when a clinical trial is recommended for suspension or termination by a data safety monitoring board. Suspensions and terminations are imposed due to a number of factors, including failure to conduct a clinical trial in accordance with regulatory requirements or trial protocols, failure to conduct the trial in accordance with GCPs or applicable regulatory guidelines, failed inspections of clinical trial<span style="letter-spacing:-0.7pt;"> </span>operations<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>trial<span style="letter-spacing:-0.65pt;"> </span>sites<span style="letter-spacing:-0.65pt;"> </span>by<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>FDA<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.7pt;"> </span>comparable<span style="letter-spacing:-0.65pt;"> </span>foreign<span style="letter-spacing:-0.65pt;"> </span>regulatory<span style="letter-spacing:-0.65pt;"> </span>authorities,<span style="letter-spacing:-0.65pt;"> </span>unforeseen<span style="letter-spacing:-0.65pt;"> </span>safety<span style="letter-spacing:-0.65pt;"> </span>issues or adverse side effects, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental<span style="letter-spacing:-0.1pt;"> </span>regulations<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>administrative<span style="letter-spacing:-0.1pt;"> </span>actions<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>lack<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.9pt;"> </span>adequate<span style="letter-spacing:-0.05pt;"> </span>funding<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>continue<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.1pt;">trial.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials frequently are delayed or terminated as a result of<span style="letter-spacing:2pt;"> </span>ambiguous or negative interim results or unanticipated<span style="letter-spacing:-0.6pt;"> </span>adverse<span style="letter-spacing:-0.6pt;"> </span>events.<span style="letter-spacing:-0.6pt;"> </span>If trials<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>tests<span style="letter-spacing:-0.6pt;"> </span>are<span style="letter-spacing:-0.6pt;"> </span>not<span style="letter-spacing:-0.6pt;"> </span>positive<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>are<span style="letter-spacing:-0.6pt;"> </span>only<span style="letter-spacing:-0.6pt;"> </span>modestly<span style="letter-spacing:-0.6pt;"> </span>positive<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>if there<span style="letter-spacing:-0.6pt;"> </span>are safety concerns, we may be required to repeat or conduct additional clinical trials or preclinical studies for our product<span style="letter-spacing:-0.55pt;"> </span>candidates<span style="letter-spacing:-0.55pt;"> </span>beyond<span style="letter-spacing:-0.55pt;"> </span>those<span style="letter-spacing:-0.55pt;"> </span>that<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>currently<span style="letter-spacing:-0.55pt;"> </span>contemplate,<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>be<span style="letter-spacing:-0.55pt;"> </span>delayed<span style="letter-spacing:-0.55pt;"> </span>in<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>prevented<span style="letter-spacing:-0.55pt;"> </span>from obtaining marketing approval or may obtain marketing approval in some countries and not in others, we may <span style="letter-spacing:-0.1pt;">obtain</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">approval</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">indications</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">patient</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">populations</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">that</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">are</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">as</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">broad</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">as</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">intended</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">desired</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">obtain </span>approval<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.45pt;"> </span>significant<span style="letter-spacing:-0.45pt;"> </span>use<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>distribution<span style="letter-spacing:-0.45pt;"> </span>restrictions<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>safety<span style="letter-spacing:-0.45pt;"> </span>warnings,<span style="letter-spacing:-0.45pt;"> </span>be<span style="letter-spacing:-0.45pt;"> </span>subject<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>post-marketing testing<span style="letter-spacing:-0.7pt;"> </span>requirements,<span style="letter-spacing:-0.7pt;"> </span>or<span style="letter-spacing:-0.7pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>subject<span style="letter-spacing:-0.7pt;"> </span>to<span style="letter-spacing:-0.7pt;"> </span>increased<span style="letter-spacing:-0.7pt;"> </span>pricing<span style="letter-spacing:-0.65pt;"> </span>pressure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many of<span style="letter-spacing:2pt;"> </span>the factors that cause, or lead to, a delay in the commencement or completion of<span style="letter-spacing:2pt;"> </span>clinical trials<span style="letter-spacing:2pt;"> </span>also<span style="letter-spacing:-0.55pt;"> </span>ultimately<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>lead<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>denial<span style="letter-spacing:-0.55pt;"> </span>of regulatory<span style="letter-spacing:-0.55pt;"> </span>approval<span style="letter-spacing:-0.55pt;"> </span>of a<span style="letter-spacing:-0.55pt;"> </span>product<span style="letter-spacing:-0.55pt;"> </span>candidate.<span style="letter-spacing:-0.55pt;"> </span>Further,<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>FDA<span style="letter-spacing:-0.55pt;"> </span>or comparable foreign regulatory authorities may disagree with our clinical trial design and our interpretation of data<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>change<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>requirements<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>approval<span style="letter-spacing:-0.2pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>after<span style="letter-spacing:-0.2pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>reviewed<span style="letter-spacing:-0.2pt;"> </span>and commented<span style="letter-spacing:-0.45pt;"> </span>on<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>design<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>clinical<span style="letter-spacing:-0.45pt;"> </span>trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">When<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>conduct<span style="letter-spacing:-0.4pt;"> </span>preclinical<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>clinical<span style="letter-spacing:-0.4pt;"> </span>research<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>collaboration<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.4pt;"> </span>other<span style="letter-spacing:-0.4pt;"> </span>academic,<span style="letter-spacing:-0.4pt;"> </span>pharmaceutical and biotechnology entities, we risk additional delays due to the frequent need to align on decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">development</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">costs</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">increased,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">continue</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">increase,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">when</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">experience</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">delays </span>in clinical testing. Our clinical trials may not begin when expected, may require restructuring or may not be completed<span style="letter-spacing:-0.7pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>schedule,<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>at<span style="letter-spacing:-0.65pt;"> </span>all.<span style="letter-spacing:-0.65pt;"> </span>Significant<span style="letter-spacing:-0.65pt;"> </span>clinical<span style="letter-spacing:-0.65pt;"> </span>trial<span style="letter-spacing:-0.7pt;"> </span>delays<span style="letter-spacing:-0.65pt;"> </span>also<span style="letter-spacing:-0.65pt;"> </span>shorten<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>periods<span style="letter-spacing:-0.65pt;"> </span>during<span style="letter-spacing:-0.65pt;"> </span>which<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.7pt;"> </span>may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully manufacture and commercialize our product candidates, if approved. Delays and increased costs in our clinical development programs would harm our business, financial condition, results of<span style="letter-spacing:2pt;"> </span>operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Delays or difficulties in the enrollment and dosing of patients in clinical trials, delay or prevent receipt of necessary regulatory approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The timing of<span style="letter-spacing:1pt;"> </span>our clinical trials depends on our ability to recruit patients to participate in our studies as well as the dosing of such patients and completion of required follow-up periods. Participant enrollment, a significant<span style="letter-spacing:-0.05pt;"> </span>factor<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>timing<span style="letter-spacing:-0.05pt;"> </span>of clinical<span style="letter-spacing:-0.05pt;"> </span>trials,<span style="letter-spacing:-0.05pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>affected<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>many<span style="letter-spacing:-0.05pt;"> </span>factors,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>size<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>nature<span style="letter-spacing:-0.05pt;"> </span>of the<span style="letter-spacing:-0.45pt;"> </span>patient<span style="letter-spacing:-0.45pt;"> </span>population,<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>number<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>location<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>clinical<span style="letter-spacing:-0.45pt;"> </span>sites,<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>proximity<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>participants<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>clinical<span style="letter-spacing:-0.45pt;"> </span>sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, challenges in obtaining and maintaining<span style="letter-spacing:-0.2pt;"> </span>participant<span style="letter-spacing:-0.2pt;"> </span>consents,<span style="letter-spacing:-0.2pt;"> </span>enrolled<span style="letter-spacing:-0.2pt;"> </span>participants<span style="letter-spacing:-0.2pt;"> </span>dropping<span style="letter-spacing:-0.2pt;"> </span>out,<span style="letter-spacing:-0.2pt;"> </span>competing<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>clinicians&#8217; and patients&#8217;<span style="letter-spacing:-0.35pt;"> </span>perceptions as to the potential advantages of<span style="letter-spacing:1.15pt;"> </span>the product candidate being studied in relation to other<span style="letter-spacing:-0.6pt;"> </span>available<span style="letter-spacing:-0.6pt;"> </span>therapies,<span style="letter-spacing:-0.6pt;"> </span>including<span style="letter-spacing:-0.6pt;"> </span>any<span style="letter-spacing:-0.6pt;"> </span>new<span style="letter-spacing:-0.6pt;"> </span>drugs<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>biologics<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>be<span style="letter-spacing:-0.6pt;"> </span>approved<span style="letter-spacing:-0.6pt;"> </span>for<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>indications<span style="letter-spacing:-0.6pt;"> </span>being investigated<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:-0.5pt;"> </span>us.<span style="letter-spacing:-0.5pt;"> </span>Rare<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>orphan<span style="letter-spacing:-0.5pt;"> </span>diseases<span style="letter-spacing:-0.5pt;"> </span>like<span style="letter-spacing:-0.5pt;"> </span>IgG4-RD<span style="letter-spacing:-0.5pt;"> </span>pose<span style="letter-spacing:-0.5pt;"> </span>additional<span style="letter-spacing:-0.5pt;"> </span>risk<span style="letter-spacing:-0.5pt;"> </span>due<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>difficulty<span style="letter-spacing:-0.5pt;"> </span>identifying study subjects and ensuring each participant&#8217;s disease state meets the study parameters. Further, because screening for many of these diseases is not widely adopted, and because it can be difficult to diagnose these diseases in the absence of screening, it can be difficult to find patients who are eligible to participate in our studies or trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:-0.2pt;"> </span>addition,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>currently,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>future,<span style="letter-spacing:-0.2pt;"> </span>compete<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>for product candidates that address the same disease as our product candidates, and this competition reduces the number and types of<span style="letter-spacing:2pt;"> </span>participants available to us, because some participants who might have opted to enroll in<span style="letter-spacing:2pt;"> </span>our trials instead opt to enroll in a trial conducted by a competitor or elect to use a marketed therapy. We also could<span style="letter-spacing:1.8pt;"> </span>encounter<span style="letter-spacing:1.8pt;"> </span>delays<span style="letter-spacing:1.8pt;"> </span>if<span style="letter-spacing:2pt;"> </span>doctors<span style="letter-spacing:1.8pt;"> </span>face<span style="letter-spacing:1.8pt;"> </span>ethical<span style="letter-spacing:1.8pt;"> </span>challenges<span style="letter-spacing:1.8pt;"> </span>associated<span style="letter-spacing:1.8pt;"> </span>with<span style="letter-spacing:1.8pt;"> </span>enrolling<span style="letter-spacing:1.8pt;"> </span>participants<span style="letter-spacing:1.8pt;"> </span>in<span style="letter-spacing:1.8pt;"> </span>a<span style="letter-spacing:1.8pt;"> </span>clinical <span style="letter-spacing:-0.1pt;">trial</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">rather</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">than</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">prescribing</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">an</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">existing</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">treatment</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">an</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">established</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">safety</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">efficacy</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">profile.</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If<span style="letter-spacing:0.45pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>collaborators<span style="letter-spacing:-0.6pt;"> </span>are<span style="letter-spacing:-0.6pt;"> </span>unable<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>enroll<span style="letter-spacing:-0.6pt;"> </span>a<span style="letter-spacing:-0.6pt;"> </span>sufficient<span style="letter-spacing:-0.6pt;"> </span>number<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>eligible<span style="letter-spacing:-0.6pt;"> </span>patients<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>participate<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>our clinical trials, we may not be able to initiate, continue or complete clinical trials for our product candidates. Even<span style="letter-spacing:-0.6pt;"> </span>if<span style="letter-spacing:0.25pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>are<span style="letter-spacing:-0.6pt;"> </span>able<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>enroll<span style="letter-spacing:-0.6pt;"> </span>a<span style="letter-spacing:-0.6pt;"> </span>sufficient<span style="letter-spacing:-0.6pt;"> </span>number<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>participants<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>clinical<span style="letter-spacing:-0.6pt;"> </span>trials,<span style="letter-spacing:-0.6pt;"> </span>delays<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>enrollment<span style="letter-spacing:-0.6pt;"> </span>may result in increased costs, delay completion or adversely impact the outcome of<span style="letter-spacing:1.65pt;"> </span>the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Additionally,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">ability</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">successfully</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">initiate,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">enroll,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">complete</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">trial</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">any</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">foreign</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">country </span>is subject to numerous risks unique to conducting business in foreign countries, including: difficulty in establishing or managing relationships with CROs and physicians; different standards for the conduct of clinical<span style="letter-spacing:-0.05pt;"> </span>trials;<span style="letter-spacing:-0.1pt;"> </span>different<span style="letter-spacing:-0.05pt;"> </span>standard-of-care<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>patients<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>particular<span style="letter-spacing:-0.05pt;"> </span>disease;<span style="letter-spacing:-0.1pt;"> </span>difficulty<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>locating<span style="letter-spacing:-0.05pt;"> </span>qualified local<span style="letter-spacing:-0.2pt;"> </span>consultants,<span style="letter-spacing:-0.2pt;"> </span>physicians<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>partners;<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>potential<span style="letter-spacing:-0.2pt;"> </span>burden<span style="letter-spacing:-0.2pt;"> </span>of complying<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>variety<span style="letter-spacing:-0.2pt;"> </span>of foreign<span style="letter-spacing:-0.2pt;"> </span>laws, medical<span style="letter-spacing:-0.7pt;"> </span>standards<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>regulatory<span style="letter-spacing:-0.65pt;"> </span>requirements,<span style="letter-spacing:-0.65pt;"> </span>including<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>regulation<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.7pt;"> </span>pharmaceutical<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>biotechnology products and treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have experienced participant withdrawals or discontinuations from our trials. Participants, including in any<span style="letter-spacing:-0.65pt;"> </span>control<span style="letter-spacing:-0.65pt;"> </span>groups,<span style="letter-spacing:-0.65pt;"> </span>frequently<span style="letter-spacing:-0.65pt;"> </span>withdraw<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>clinical<span style="letter-spacing:-0.65pt;"> </span>trial<span style="letter-spacing:-0.65pt;"> </span>if<span style="letter-spacing:0.25pt;"> </span>they<span style="letter-spacing:-0.65pt;"> </span>are<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>experiencing<span style="letter-spacing:-0.65pt;"> </span>improvement<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>their underlying disease or condition or if they experience adverse side effects or other issues. Withdrawal of participants from our clinical trials may compromise the quality of<span style="letter-spacing:2pt;"> </span>our data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Difficulties<span style="letter-spacing:-0.65pt;"> </span>enrolling<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>sufficient<span style="letter-spacing:-0.65pt;"> </span>number<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>patients<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>conduct<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>clinical<span style="letter-spacing:-0.65pt;"> </span>trials<span style="letter-spacing:-0.65pt;"> </span>as<span style="letter-spacing:-0.65pt;"> </span>planned<span style="letter-spacing:-0.65pt;"> could </span>require<span style="letter-spacing:-0.65pt;"> </span>us<span style="letter-spacing:-0.65pt;"> </span>to delay,<span style="letter-spacing:-0.45pt;"> </span>limit<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>terminate<span style="letter-spacing:-0.45pt;"> </span>clinical<span style="letter-spacing:-0.45pt;"> </span>trials<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>product<span style="letter-spacing:-0.45pt;"> </span>candidates,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>expand<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>additional<span style="letter-spacing:-0.45pt;"> </span>jurisdictions,<span style="letter-spacing:-0.45pt;"> </span>which could impose additional challenges on our company. Failure to successfully conduct our clinical trials as planned, would have an adverse effect on our business, financial condition, results of operations and <span style="letter-spacing:-0.1pt;">prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any<span style="letter-spacing:-0.65pt;"> </span>significant<span style="letter-spacing:-0.6pt;"> </span>adverse<span style="letter-spacing:-0.65pt;"> </span>events<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>undesirable<span style="letter-spacing:-0.6pt;"> </span>side<span style="letter-spacing:-0.65pt;"> </span>effects<span style="letter-spacing:-0.6pt;"> </span>caused<span style="letter-spacing:-0.65pt;"> </span>by<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.6pt;"> </span>candidates<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>delay<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>prevent <span style="letter-spacing:-0.2pt;">regulatory approval or market acceptance of</span><span style="letter-spacing:1.05pt;"> </span><span style="letter-spacing:-0.2pt;">our product candidates, or result in significant negative consequences </span>following marketing approval, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unacceptable, undesirable or clinically unmanageable side effects, caused by any of our product candidates could cause us or regulatory authorities to interrupt, delay or halt our clinical trials and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable <span style="letter-spacing:-0.1pt;">foreign</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">regulatory</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">authorities.</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">observed</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">certain</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">adverse</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">events</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">(&#8220;AEs&#8221;)</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">SAEs</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">trials </span>of obexelimab administered through IV infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>trials<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>obexelimab<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.3pt;"> </span>administered<span style="letter-spacing:-0.3pt;"> </span>through<span style="letter-spacing:-0.3pt;"> </span>SC<span style="letter-spacing:-0.3pt;"> </span>injection.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>Phase<span style="letter-spacing:-0.3pt;"> </span>1<span style="letter-spacing:-0.3pt;"> </span>pharmacokinetic (&#8220;PK&#8221;)<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>relative<span style="letter-spacing:-0.5pt;"> </span>bioavailability<span style="letter-spacing:-0.5pt;"> </span>study<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>obexelimab<span style="letter-spacing:-0.5pt;"> </span>administered<span style="letter-spacing:-0.5pt;"> </span>either<span style="letter-spacing:-0.5pt;"> </span>intravenously<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>subcutaneously, the most common related treatment emergent adverse events (&#8220;TEAEs&#8221;) across all SC dose regimens were headache<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>injection<span style="letter-spacing:-0.2pt;"> </span>site<span style="letter-spacing:-0.2pt;"> </span>reactions.<span style="letter-spacing:-0.2pt;"> </span>GI-related<span style="letter-spacing:-0.2pt;"> </span>events<span style="letter-spacing:-0.2pt;"> </span>seen<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>IV<span style="letter-spacing:-0.2pt;"> </span>infusions<span style="letter-spacing:-0.2pt;"> </span>were<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.2pt;"> </span>observed<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>subjects who received SC formulation, but future studies may reveal similar issues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">AEs, SAEs or other side effects in clinical trials often make it difficult to recruit participants to clinical trials<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>participants<span style="letter-spacing:-0.25pt;"> </span>dropping<span style="letter-spacing:-0.25pt;"> </span>out<span style="letter-spacing:-0.25pt;"> </span>of trials.<span style="letter-spacing:-0.25pt;"> </span>While<span style="letter-spacing:-0.25pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>side<span style="letter-spacing:-0.25pt;"> </span>effects<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.25pt;"> </span>reversible<span style="letter-spacing:-0.25pt;"> </span>following discontinuation<span style="letter-spacing:-0.7pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidate<span style="letter-spacing:-0.65pt;"> </span>with<span style="letter-spacing:-0.7pt;"> </span>sufficient<span style="letter-spacing:-0.65pt;"> </span>recovery<span style="letter-spacing:-0.65pt;"> </span>periods,<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>will<span style="letter-spacing:-0.65pt;"> </span>need<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>monitor<span style="letter-spacing:-0.7pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>severity and<span style="letter-spacing:-0.65pt;"> </span>duration<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.15pt;"> </span>side<span style="letter-spacing:-0.65pt;"> </span>effects<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>clinical<span style="letter-spacing:-0.65pt;"> </span>trials.<span style="letter-spacing:-0.65pt;"> </span>If<span style="letter-spacing:0.15pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>effects<span style="letter-spacing:-0.65pt;"> </span>are<span style="letter-spacing:-0.65pt;"> </span>more<span style="letter-spacing:-0.65pt;"> </span>severe,<span style="letter-spacing:-0.65pt;"> </span>less<span style="letter-spacing:-0.65pt;"> </span>reversible<span style="letter-spacing:-0.65pt;"> </span>than<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>expect or<span style="letter-spacing:-0.35pt;"> </span>not<span style="letter-spacing:-0.35pt;"> </span>reversible<span style="letter-spacing:-0.35pt;"> </span>at<span style="letter-spacing:-0.35pt;"> </span>all,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>decide,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.35pt;"> </span>required,<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>perform<span style="letter-spacing:-0.35pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>studies<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>halt<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>delay<span style="letter-spacing:-0.35pt;"> </span>further clinical development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>believe<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.45pt;"> </span>obexelimab<span style="letter-spacing:-0.45pt;"> </span>has<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>potential<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>offer<span style="letter-spacing:-0.45pt;"> </span>benefits,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>regard<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>its<span style="letter-spacing:-0.45pt;"> </span>side-effect <span style="letter-spacing:-0.1pt;">profile,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">over</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">B</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">cell</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">depleting</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">agents,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">if</span><span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:-0.1pt;">obexelimab</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">is</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">shown</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">adverse</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">events,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">side</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">effects</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">safety </span>or<span style="letter-spacing:-0.15pt;"> </span>tolerability<span style="letter-spacing:-0.15pt;"> </span>concerns,<span style="letter-spacing:-0.15pt;"> </span>then<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>opportunity<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>disrupt<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>current<span style="letter-spacing:-0.15pt;"> </span>standard<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:1pt;"> </span>care<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>limited.<span style="letter-spacing:-0.15pt;"> </span>AEs<span style="letter-spacing:-0.15pt;"> </span>and SAEs may be deemed to be related to our product candidates. Such a determination may require longer and more extensive clinical development, or regulatory authorities may increase the amount of data and information required to approve, market or maintain approval of<span style="letter-spacing:2pt;"> </span>our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="letter-spacing:-0.1pt;">We,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">FDA</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">applicable</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">regulatory</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">authorities,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">an</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">IRB,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">suspend</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">trials</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">product </span>candidate<span style="letter-spacing:-0.2pt;"> </span>at<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>time<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>various<span style="letter-spacing:-0.2pt;"> </span>reasons,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>belief<span style="letter-spacing:0.8pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>participants<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>being<span style="letter-spacing:-0.2pt;"> </span>exposed to unacceptable health risks or adverse side effects. Many potential product candidates developed in the biotechnology<span style="letter-spacing:-0.1pt;"> </span>industry<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>initially<span style="letter-spacing:-0.1pt;"> </span>showed<span style="letter-spacing:-0.1pt;"> </span>promise<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>early-stage<span style="letter-spacing:-0.1pt;"> </span>trials<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>later<span style="letter-spacing:-0.1pt;"> </span>been<span style="letter-spacing:-0.1pt;"> </span>found<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>cause<span style="letter-spacing:-0.1pt;"> </span>side effects<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>prevented<span style="letter-spacing:-0.6pt;"> </span>their<span style="letter-spacing:-0.6pt;"> </span>further<span style="letter-spacing:-0.6pt;"> </span>development<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">approval.<span style="letter-spacing:-0.6pt;"> </span>Even<span style="letter-spacing:-0.6pt;"> </span>if<span style="letter-spacing:0.35pt;"> </span>side<span style="letter-spacing:-0.6pt;"> </span>effects<span style="letter-spacing:-0.6pt;"> </span>do<span style="letter-spacing:-0.6pt;"> </span>not<span style="letter-spacing:-0.6pt;"> </span>preclude<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market <span style="letter-spacing:-0.1pt;">acceptance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:0.65pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>successfully<span style="letter-spacing:-0.25pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidate<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>it<span style="letter-spacing:-0.25pt;"> </span>receives<span style="letter-spacing:-0.25pt;"> </span>marketing<span style="letter-spacing:-0.25pt;"> </span>approval,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>FDA<span style="letter-spacing:-0.25pt;"> </span>could require us to adopt a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure that the benefits of treatment<span style="letter-spacing:-0.3pt;"> </span>outweigh<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>risks<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>each<span style="letter-spacing:-0.3pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>patient,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>include,<span style="letter-spacing:-0.3pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.3pt;"> </span>things,<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>medication guide outlining the risks of the product for distribution to patients, a communication plan to healthcare practitioners, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. Furthermore, if we or others later identify undesirable side effects caused by any product candidate that we obtain marketing approval for, several potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may limit, suspend or withdraw approvals of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such product, or may refuse to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approve supplemental applications for such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warnings</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">label,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Boxed</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warning,&#8221; contraindications or precautions, or otherwise limit the approved use of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may impose additional restrictions on the marketing of, or the manufacturing processes for, the particular product, including requiring a REMS;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">required</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">change</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">way</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">administered</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">required</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decide</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">remove</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">could</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sued</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">held</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">harm</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">caused</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">reputation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>these<span style="letter-spacing:-0.55pt;"> </span>events<span style="letter-spacing:-0.55pt;"> </span>could<span style="letter-spacing:-0.55pt;"> </span>prevent<span style="letter-spacing:-0.55pt;"> </span>us<span style="letter-spacing:-0.55pt;"> </span>from<span style="letter-spacing:-0.55pt;"> </span>obtaining<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>maintaining<span style="letter-spacing:-0.55pt;"> </span>regulatory<span style="letter-spacing:-0.55pt;"> </span>approvals<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>achieving<span style="letter-spacing:-0.55pt;"> </span>or maintaining market acceptance of<span style="letter-spacing:1.4pt;"> </span>our current and future product candidates or could substantially increase the<span style="letter-spacing:-0.3pt;"> </span>costs<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>expenses<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>commercializing<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>affected<span style="letter-spacing:-0.3pt;"> </span>product,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>turn<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.3pt;"> </span>significantly<span style="letter-spacing:-0.3pt;"> </span>impact<span style="letter-spacing:-0.3pt;"> </span>our ability to successfully commercialize our product candidates and generate revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks associated with the in-licensing or acquisition of product candidates could cause substantial delays in the preclinical and clinical development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>relied<span style="letter-spacing:-0.3pt;"> </span>on,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>continue<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>rely<span style="letter-spacing:-0.3pt;"> </span>on,<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>licensing<span style="letter-spacing:-0.3pt;"> </span>partners,<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:-0.3pt;"> </span>Xencor,<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>(i)<span style="letter-spacing:-0.3pt;"> </span>conducted research and development in accordance with the applicable protocol, legal, regulatory and scientific standards, (ii) accurately reported the results of all clinical trials conducted prior to our acquisition of the relevant product candidates and (iii) correctly collected and interpreted the data from these trials. If the research and development processes or the results of the development programs prior to our acquisition of <span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">product</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">candidates</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">prove</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">unreliable,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">this</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">result</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">increased</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">costs</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">delays</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">development </span>of our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.05pt;"> </span>candidates,<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.05pt;"> </span>affect<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.05pt;"> </span>revenue<span style="letter-spacing:-0.05pt;"> </span>from<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.05pt;"> </span>candidates,<span style="letter-spacing:-0.05pt;"> </span>if <span style="letter-spacing:-0.1pt;">approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.7pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>also<span style="letter-spacing:-0.65pt;"> </span>acquire<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>in-license<span style="letter-spacing:-0.65pt;"> </span>additional<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidates<span style="letter-spacing:-0.7pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>preclinical<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>clinical<span style="letter-spacing:-0.65pt;"> </span>development<span style="letter-spacing:-0.65pt;"> </span>in the future as we continue to build our pipeline. The risks associated with acquiring or in-licensing product candidates could result in delays in the commencement or completion of our preclinical studies and clinical trials, if ever, and our ability to generate revenues from our product candidates may be delayed. Please see &#8220;&#8212;Risks Related to Our Intellectual Property&#8212;We may not obtain or maintain necessary rights to our product candidates through acquisitions and in-licenses&#8221; for additional information regarding such risks.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face potential competition from different sources that have made substantial investments into the rapid development<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">novel</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">treatments</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">immunological</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">indications,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">including</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">large</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">specialty</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">pharmaceutical</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">and </span>biotechnology<span style="letter-spacing:-0.2pt;"> </span>companies,<span style="letter-spacing:-0.2pt;"> </span>many<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>already<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>approved<span style="letter-spacing:-0.2pt;"> </span>therapies<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic<span style="letter-spacing:-0.35pt;"> </span>research<span style="letter-spacing:-0.35pt;"> </span>institutions<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>governmental<span style="letter-spacing:-0.35pt;"> </span>agencies,<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.35pt;"> </span>well<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.35pt;"> </span>public<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>private<span style="letter-spacing:-0.35pt;"> </span>research<span style="letter-spacing:-0.35pt;"> </span>institutions. Any product candidates that we successfully develop and commercialize, if approved, will compete with existing therapies and new therapies that may become available in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The<span style="letter-spacing:-0.55pt;"> </span>key<span style="letter-spacing:-0.55pt;"> </span>competitive<span style="letter-spacing:-0.55pt;"> </span>factors<span style="letter-spacing:-0.55pt;"> </span>affecting<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>success<span style="letter-spacing:-0.55pt;"> </span>of all<span style="letter-spacing:-0.55pt;"> </span>of our<span style="letter-spacing:-0.55pt;"> </span>product<span style="letter-spacing:-0.55pt;"> </span>candidates,<span style="letter-spacing:-0.55pt;"> </span>if approved,<span style="letter-spacing:-0.55pt;"> </span>are<span style="letter-spacing:-0.55pt;"> </span>likely to<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>their<span style="letter-spacing:-0.05pt;"> </span>safety,<span style="letter-spacing:-0.05pt;"> </span>efficacy,<span style="letter-spacing:-0.05pt;"> </span>convenience,<span style="letter-spacing:-0.05pt;"> </span>price,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>level<span style="letter-spacing:-0.05pt;"> </span>of generic<span style="letter-spacing:-0.05pt;"> </span>competition,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>existence<span style="letter-spacing:-0.05pt;"> </span>of therapeutic <span style="letter-spacing:-0.1pt;">alternatives</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">availability</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:-0.1pt;">coverage</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">reimbursement</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">government</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">third-party</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">payors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>companies<span style="letter-spacing:-0.6pt;"> </span>against<span style="letter-spacing:-0.6pt;"> </span>which<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>are<span style="letter-spacing:-0.6pt;"> </span>competing,<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>against<span style="letter-spacing:-0.6pt;"> </span>which<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>compete<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>future, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>do.<span style="letter-spacing:-0.05pt;"> </span>Mergers<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>acquisitions<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>pharmaceutical<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>biotechnology<span style="letter-spacing:-0.05pt;"> </span>industries<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>result<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>also<span style="letter-spacing:-0.65pt;"> </span>prove<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>significant<span style="letter-spacing:-0.65pt;"> </span>competitors,<span style="letter-spacing:-0.65pt;"> </span>particularly<span style="letter-spacing:-0.65pt;"> </span>through<span style="letter-spacing:-0.65pt;"> </span>collaborative<span style="letter-spacing:-0.65pt;"> </span>arrangements<span style="letter-spacing:-0.65pt;"> </span>with large<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>established<span style="letter-spacing:-0.6pt;"> </span>companies.<span style="letter-spacing:-0.6pt;"> </span>These<span style="letter-spacing:-0.6pt;"> </span>competitors<span style="letter-spacing:-0.6pt;"> </span>also<span style="letter-spacing:-0.6pt;"> </span>compete<span style="letter-spacing:-0.6pt;"> </span>with<span style="letter-spacing:-0.6pt;"> </span>us<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>recruiting<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>retaining<span style="letter-spacing:-0.6pt;"> </span>qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our current product candidates, initially under development for treatment of various I&amp;I indications would,<span style="letter-spacing:-0.6pt;"> </span>if approved,<span style="letter-spacing:-0.6pt;"> </span>face<span style="letter-spacing:-0.6pt;"> </span>competition<span style="letter-spacing:-0.6pt;"> </span>from<span style="letter-spacing:-0.6pt;"> </span>existing<span style="letter-spacing:-0.6pt;"> </span>approved<span style="letter-spacing:-0.6pt;"> </span>immunological<span style="letter-spacing:-0.6pt;"> </span>treatments,<span style="letter-spacing:-0.6pt;"> </span>many<span style="letter-spacing:-0.6pt;"> </span>of which<span style="letter-spacing:-0.6pt;"> </span>have achieved commercial success. For example, we are currently developing obexelimab for the treatment of IgG4-RD,<span style="letter-spacing:0.6pt;"> </span>MS,<span style="letter-spacing:0.65pt;"> and </span>SLE.<span style="letter-spacing:0.6pt;"> </span>There<span style="letter-spacing:0.65pt;"> </span>are<span style="letter-spacing:0.65pt;"> </span>currently<span style="letter-spacing:0.6pt;"> </span>no<span style="letter-spacing:0.65pt;"> </span>approved<span style="letter-spacing:0.6pt;"> </span>therapies<span style="letter-spacing:0.65pt;"> </span>for<span style="letter-spacing:0.65pt;"> </span>IgG4-RD,<span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:-0.25pt;">but</span> there<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>two<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:-0.1pt;"> </span>approved<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>SLE,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>number<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>products<span style="letter-spacing:-0.1pt;"> </span>approved<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>MS.<span style="letter-spacing:-0.1pt;"> </span>Moreover,<span style="letter-spacing:-0.1pt;"> </span>there<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>a number of product candidates in clinical development by other companies for IgG4-RD, MS, and SLE that<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>become<span style="letter-spacing:-0.2pt;"> </span>available<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>future,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.2pt;"> </span>UPLIZNA<span style="letter-spacing:-0.2pt;"> </span>(inebilizumab-cdon),<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>anti-CD19 antibody being developed by Amgen Inc., for which Amgen filed a BLA based on the results of its Phase 3 trial in patients with IgG4-RD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To compete successfully, we need to disrupt currently marketed drugs, meaning we must demonstrate that the relative cost, method of administration, safety, tolerability and efficacy of our product candidates provides a better alternative to existing and new therapies. Our commercial opportunity and likelihood of success will be reduced or eliminated if our product candidates are not ultimately demonstrated to be safer, more<span style="letter-spacing:-0.1pt;"> </span>effective,<span style="letter-spacing:-0.1pt;"> </span>more<span style="letter-spacing:-0.1pt;"> </span>conveniently<span style="letter-spacing:-0.1pt;"> </span>administered<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>less<span style="letter-spacing:-0.1pt;"> </span>expensive<span style="letter-spacing:-0.1pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>current<span style="letter-spacing:-0.1pt;"> </span>standard<span style="letter-spacing:-0.1pt;"> </span>of care<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>future competing products. Furthermore, even if our product candidates are able to achieve these attributes, acceptance<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>products<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>be<span style="letter-spacing:-0.5pt;"> </span>inhibited<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>reluctance<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>physicians<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>switch<span style="letter-spacing:-0.5pt;"> </span>from<span style="letter-spacing:-0.5pt;"> </span>existing<span style="letter-spacing:-0.5pt;"> </span>therapies to our products, or if<span style="letter-spacing:1.6pt;"> </span>physicians choose to reserve our products for use in limited circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competitive<span style="letter-spacing:-0.5pt;"> </span>products<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>make<span style="letter-spacing:-0.5pt;"> </span>any<span style="letter-spacing:-0.5pt;"> </span>products<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>develop<span style="letter-spacing:-0.5pt;"> </span>obsolete<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>noncompetitive<span style="letter-spacing:-0.5pt;"> </span>before<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>recover <span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">expense</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:-0.1pt;">development</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">commercialization.</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">Such</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">competitors</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">also</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">recruit</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">employees,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">which </span>could<span style="letter-spacing:-0.7pt;"> </span>negatively<span style="letter-spacing:-0.65pt;"> </span>impact<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>level<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>expertise<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.7pt;"> </span>ability<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>execute<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>business<span style="letter-spacing:-0.65pt;"> </span>plan.<span style="letter-spacing:-0.65pt;"> </span>If<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.7pt;"> </span>are<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>able<span style="letter-spacing:-0.65pt;"> </span>to effectively compete for any of<span style="letter-spacing:1.2pt;"> </span>the foregoing reasons, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interim<span style="letter-spacing:-0.1pt;">,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">initial,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">&#8220;top-line&#8221;</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">preliminary</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">data</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">trials</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">announce</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">publish</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">time</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">to </span>time are subject to audit and verification procedures and may differ materially from final data as more patient data become available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Preliminary or top-line data from our preclinical studies and clinical trials that we publish from time to time<span style="letter-spacing:-0.7pt;"> </span>are<span style="letter-spacing:-0.65pt;"> </span>based<span style="letter-spacing:-0.65pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>preliminary<span style="letter-spacing:-0.65pt;"> </span>analyses<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>then-available<span style="letter-spacing:-0.65pt;"> </span>data,<span style="letter-spacing:-0.7pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>results,<span style="letter-spacing:-0.65pt;"> </span>related<span style="letter-spacing:-0.65pt;"> </span>findings<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>conclusions are<span style="letter-spacing:-0.2pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>change<span style="letter-spacing:-0.2pt;"> </span>following<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>comprehensive<span style="letter-spacing:-0.2pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>of the<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>particular<span style="letter-spacing:-0.2pt;"> </span>preclinical study or clinical trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>data,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>not<span style="letter-spacing:-0.45pt;"> </span>have<span style="letter-spacing:-0.45pt;"> </span>received<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>had<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>opportunity<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>fully<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>carefully<span style="letter-spacing:-0.45pt;"> </span>evaluate<span style="letter-spacing:-0.45pt;"> </span>all<span style="letter-spacing:-0.45pt;"> </span>data. As a result, the top-line or preliminary results may differ from </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">future results of<span style="letter-spacing:1.05pt;"> </span>the same studies or trials, or different<span style="letter-spacing:-0.25pt;"> </span>conclusions<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>considerations<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>qualify<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:-0.25pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>once<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.25pt;"> </span>data<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.25pt;"> </span>been<span style="letter-spacing:-0.25pt;"> </span>received<span style="letter-spacing:-0.25pt;"> </span>and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final<span style="letter-spacing:-0.7pt;"> </span>data<span style="letter-spacing:-0.65pt;"> </span>being<span style="letter-spacing:-0.65pt;"> </span>materially<span style="letter-spacing:-0.65pt;"> </span>different<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>preliminary<span style="letter-spacing:-0.65pt;"> </span>data.<span style="letter-spacing:-0.7pt;"> </span>As<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>result,<span style="letter-spacing:-0.65pt;"> </span>top-line<span style="letter-spacing:-0.65pt;"> </span>data<span style="letter-spacing:-0.65pt;"> </span>should<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>viewed<span style="letter-spacing:-0.7pt;"> </span>with caution until the final data are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From<span style="letter-spacing:-0.4pt;"> </span>time<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>time,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>also<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.4pt;"> </span>disclose<span style="letter-spacing:-0.4pt;"> </span>interim<span style="letter-spacing:-0.4pt;"> </span>data<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>preclinical<span style="letter-spacing:-0.4pt;"> </span>studies<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>clinical<span style="letter-spacing:-0.4pt;"> </span>trials. Interim data from clinical trials are subject to the risk that one or more of<span style="letter-spacing:1.95pt;"> </span>the clinical outcomes may materially change<span style="letter-spacing:-0.55pt;"> </span>as<span style="letter-spacing:-0.55pt;"> </span>participant<span style="letter-spacing:-0.55pt;"> </span>enrollment<span style="letter-spacing:-0.55pt;"> </span>continues<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>more<span style="letter-spacing:-0.55pt;"> </span>participant<span style="letter-spacing:-0.55pt;"> </span>data<span style="letter-spacing:-0.55pt;"> </span>become<span style="letter-spacing:-0.55pt;"> </span>available<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>as<span style="letter-spacing:-0.55pt;"> </span>participants from<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>clinical<span style="letter-spacing:-0.65pt;"> </span>trials<span style="letter-spacing:-0.65pt;"> </span>continue<span style="letter-spacing:-0.65pt;"> </span>other<span style="letter-spacing:-0.65pt;"> </span>treatments<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>their<span style="letter-spacing:-0.65pt;"> </span>disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, third parties, including regulatory authorities, may not accept or agree with our assumptions,<span style="letter-spacing:-0.7pt;"> </span>estimates,<span style="letter-spacing:-0.65pt;"> </span>calculations,<span style="letter-spacing:-0.65pt;"> </span>conclusions<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>analyses<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>interpret<span style="letter-spacing:-0.7pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>weigh<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>importance<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>data differently, which could delay or prevent regulatory approval of, or limit commercial prospects for, the particular<span style="letter-spacing:-0.7pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidate.<span style="letter-spacing:-0.65pt;"> </span>In<span style="letter-spacing:-0.65pt;"> </span>addition,<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>information<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>choose<span style="letter-spacing:-0.7pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>publicly<span style="letter-spacing:-0.65pt;"> </span>disclose<span style="letter-spacing:-0.65pt;"> </span>regarding<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>particular study<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>clinical<span style="letter-spacing:-0.65pt;"> </span>trial<span style="letter-spacing:-0.65pt;"> </span>is<span style="letter-spacing:-0.65pt;"> </span>based<span style="letter-spacing:-0.65pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>what<span style="letter-spacing:-0.65pt;"> </span>is<span style="letter-spacing:-0.65pt;"> </span>typically<span style="letter-spacing:-0.65pt;"> </span>extensive<span style="letter-spacing:-0.65pt;"> </span>information,<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>investors<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>others<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>agree<span style="letter-spacing:-0.65pt;"> </span>with what we determine to disclose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>interim,<span style="letter-spacing:-0.2pt;"> </span>top-line<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>preliminary<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>report<span style="letter-spacing:-0.2pt;"> </span>differ<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>final<span style="letter-spacing:-0.2pt;"> </span>results,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:0.8pt;"> </span>others,<span style="letter-spacing:-0.2pt;"> </span>including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, financial condition, results of<span style="letter-spacing:1.45pt;"> </span>operations and prospects. Further, disclosure of<span style="letter-spacing:1.45pt;"> </span>interim, top-line or preliminary data by us or by our competitors could result in volatility in the price of our common stock<span style="letter-spacing:-0.1pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ongoing Phase 3 trial of obexelimab for IgG4-RD and other clinical trials of obexelimab, even if successfully completed, may not be sufficient for approval of<span style="letter-spacing:1.3pt;"> </span>obexelimab for the applicable indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">FDA</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">approval</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">new</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">biologic</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">generally</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">requires</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">data</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">two</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">well-controlled</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">Phase</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">3</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">trials</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of the</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">relevant</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">biologic</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">relevant</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">patient</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">population;</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">however,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">some</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">cases</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">FDA</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">accept</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">data</span><span style="letter-spacing:-0.2pt;"> from</span> a<span style="letter-spacing:-0.4pt;"> </span>single<span style="letter-spacing:-0.4pt;"> </span>Phase<span style="letter-spacing:-0.4pt;"> </span>3<span style="letter-spacing:-0.4pt;"> </span>trial<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>support<span style="letter-spacing:-0.4pt;"> </span>marketing<span style="letter-spacing:-0.4pt;"> </span>approval.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.4pt;"> </span>conducting<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>Phase<span style="letter-spacing:-0.4pt;"> </span>3<span style="letter-spacing:-0.4pt;"> </span>trial<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>obexelimab for<span style="letter-spacing:-0.55pt;"> </span>IgG4-RD,<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>believe<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>results<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>this<span style="letter-spacing:-0.55pt;"> </span>trial<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>be<span style="letter-spacing:-0.55pt;"> </span>sufficient<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>support<span style="letter-spacing:-0.55pt;"> </span>submission<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>a<span style="letter-spacing:-0.55pt;"> </span>BLA<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>this indication.<span style="letter-spacing:-0.65pt;"> </span>Although<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>have<span style="letter-spacing:-0.65pt;"> </span>discussed<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>plans<span style="letter-spacing:-0.65pt;"> </span>with<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>FDA,<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>do<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>have<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>agreement<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>FDA that<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.3pt;"> </span>plans<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.3pt;"> </span>provide<span style="letter-spacing:-0.3pt;"> </span>adequate<span style="letter-spacing:-0.3pt;"> </span>safety<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>efficacy<span style="letter-spacing:-0.3pt;"> </span>data<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>proposed<span style="letter-spacing:-0.3pt;"> </span>dosing regimen<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>otherwise<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>sufficient<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>submission<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>BLA.<span style="letter-spacing:-0.65pt;"> </span>The<span style="letter-spacing:-0.65pt;"> </span>FDA<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>require<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>conduct<span style="letter-spacing:-0.65pt;"> </span>additional clinical<span style="letter-spacing:-0.4pt;"> </span>trials,<span style="letter-spacing:-0.4pt;"> </span>including<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>comparative<span style="letter-spacing:-0.4pt;"> </span>trial<span style="letter-spacing:-0.4pt;"> </span>against<span style="letter-spacing:-0.4pt;"> </span>an<span style="letter-spacing:-0.4pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>therapy,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.4pt;"> </span>would<span style="letter-spacing:-0.4pt;"> </span>significantly<span style="letter-spacing:-0.4pt;"> </span>delay<span style="letter-spacing:-0.4pt;"> </span>our development timelines and require substantially more resources. If we are required to conduct two Phase 3 clinical<span style="letter-spacing:-0.7pt;"> </span>trials<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>IgG4-RD,<span style="letter-spacing:-0.65pt;"> </span>then<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>development<span style="letter-spacing:-0.65pt;"> </span>timeline<span style="letter-spacing:-0.65pt;"> </span>would<span style="letter-spacing:-0.7pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>extended,<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>related<span style="letter-spacing:-0.65pt;"> </span>expenses<span style="letter-spacing:-0.65pt;"> </span>would be significantly increased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although obexelimab has been granted orphan drug designation by the FDA for IgG4-RD, such designation does not guarantee that any regulatory authority will accept fewer trials, accelerate regulatory review of, or ultimately approve obexelimab for IgG4-RD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the FDA does not agree with our planned strategy, the FDA may ultimately require us to conduct additional Phase 3 clinical trials prior to approval of an indication. In addition, the standard of care may change<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>approval<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>new<span style="letter-spacing:-0.4pt;"> </span>products<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>same<span style="letter-spacing:-0.4pt;"> </span>indications<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.4pt;"> </span>studying.<span style="letter-spacing:-0.4pt;"> </span>This<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.4pt;"> </span>result<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>the FDA or other regulatory authorities requesting additional studies to show that our product candidate is superior to the new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not realize the benefits of our current or future collaborations or licensing arrangements and may be unsuccessful in consummating future partnerships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our current or future collaborations or licensing arrangements may not be successful. Additionally, we have partnered, and intend to further partner, with third parties with respect to the clinical development and commercialization, if approved,<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>certain<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>programs<span style="letter-spacing:-0.55pt;"> </span>in<span style="letter-spacing:-0.55pt;"> </span>certain<span style="letter-spacing:-0.55pt;"> </span>regions<span style="letter-spacing:-0.55pt;"> </span>outside<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>U.S.<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>Europe,<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>not be successful in identifying, negotiating and executing partnerships. The success of our collaboration arrangements<span style="letter-spacing:-0.5pt;"> </span>will<span style="letter-spacing:-0.5pt;"> </span>depend<span style="letter-spacing:-0.5pt;"> </span>heavily<span style="letter-spacing:-0.5pt;"> </span>on<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>efforts<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>activities<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>collaborators.<span style="letter-spacing:-0.5pt;"> </span>Collaborations<span style="letter-spacing:-0.5pt;"> </span>are<span style="letter-spacing:-0.5pt;"> </span>subject to numerous risks, which may include that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discretion</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determining</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">resources</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">they</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">will</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">apply</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of our product candidates or may elect</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">renew</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercialization</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">programs</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">based</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">test</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results, changes</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">their</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">focus</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">due</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquisition</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of competitive</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">products,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agreements with collaborators may not provide exclusive rights to use their intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">indirectly</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborator</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rights</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">more</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">products</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not commit</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficient</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">resources</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perform</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactorily</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">carrying</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">out</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">these</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the grant of exclusive rights to our collaborators would prevent us from collaborating with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">properly</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defend</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">property</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rights</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between us and a collaborator that cause the delay or termination of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the research, development or commercialization of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our future product candidates or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the applicable future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may own or co-own intellectual property covering our product candidates that results from</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborating</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">them,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cases,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">would</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exclusive</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">right</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop or commercialize such intellectual property; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:0.6pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>complete<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>necessary<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.35pt;"> </span>trials,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>cannot<span style="letter-spacing:-0.35pt;"> </span>predict<span style="letter-spacing:-0.35pt;"> </span>when,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>if,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.35pt;"> </span>obtain<span style="letter-spacing:-0.35pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval to<span style="letter-spacing:-0.35pt;"> </span>commercialize<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>U.S.<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>other<span style="letter-spacing:-0.35pt;"> </span>jurisdiction,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>may be for a more narrow indication than we seek.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We cannot commercialize a product candidate unless and until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely<span style="letter-spacing:-0.2pt;"> </span>manner,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">regulatory<span style="letter-spacing:-0.2pt;"> </span>approval.<span style="letter-spacing:-0.2pt;"> </span>Additional<span style="letter-spacing:-0.2pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:0.75pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials, and the review process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Regulatory authorities may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a REMS. These regulatory authorities may require labeling that includes precautions or contraindications with respect to conditions of use, or they may grant approval subject to the performance of costly post marketing clinical trials.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:-0.4pt;"> </span>addition,<span style="letter-spacing:-0.4pt;"> </span>regulatory<span style="letter-spacing:-0.4pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.4pt;"> </span>not<span style="letter-spacing:-0.4pt;"> </span>approve<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>labeling<span style="letter-spacing:-0.4pt;"> </span>claims<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>believe<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.4pt;"> </span>necessary<span style="letter-spacing:-0.4pt;"> </span>or <span style="letter-spacing:-0.1pt;">desirable</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">successful</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">commercialization</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">any</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">product</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">candidates</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">develop.</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">Any</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">foregoing </span>scenarios<span style="letter-spacing:-0.6pt;"> </span>could<span style="letter-spacing:-0.6pt;"> </span>materially<span style="letter-spacing:-0.6pt;"> </span>harm<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>commercial<span style="letter-spacing:-0.6pt;"> </span>prospects<span style="letter-spacing:-0.6pt;"> </span>for<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>product<span style="letter-spacing:-0.6pt;"> </span>candidates<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>adversely<span style="letter-spacing:-0.6pt;"> </span>affect<span style="letter-spacing:-0.6pt;"> </span>our business, financial condition, results of<span style="letter-spacing:2pt;"> </span>operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our clinical trial results may not support approval and our product candidates could fail to receive regulatory approval for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">comparable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagree</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">design</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">their proposed indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations, or apparent improvement in trial participants receiving placebo;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">comparable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagree</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interpretation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">data from</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preclinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">studies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">data</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collected</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trials</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficient</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfaction of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">comparable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">support</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BLA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other comparable submission in foreign jurisdictions or to obtain regulatory approval in the U.S. or </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may not approve our CMOs&#8217; manufacturing process or facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accept</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">data</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trials</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conducted</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">individual</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investigators</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">countries where the standard of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">care is potentially different from the U.S.; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">policies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">comparable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Regulatory approval for our product candidates may not be obtained without lengthy delays, if at all. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us from commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>expend<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>limited<span style="letter-spacing:-0.45pt;"> </span>resources<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>pursue<span style="letter-spacing:-0.5pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>particular<span style="letter-spacing:-0.5pt;"> </span>product<span style="letter-spacing:-0.45pt;"> </span>candidate<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>specific<span style="letter-spacing:-0.5pt;"> </span>indications<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>fail<span style="letter-spacing:-0.45pt;"> </span>to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="letter-spacing:-0.1pt;">Because</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">limited</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">financial</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">managerial</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">resources,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">focus</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">development</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">efforts</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">certain </span>selected<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.05pt;"> </span>candidates<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.05pt;"> </span>selected<span style="letter-spacing:-0.05pt;"> </span>indications.<span style="letter-spacing:-0.05pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>initially<span style="letter-spacing:-0.05pt;"> </span>focused<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>lead product candidate, obexelimab, </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for the treatment of IgG4-RD, MS, and SLE. As a result, we may forgo or delay pursuit of opportunities with other product candidates or other indications for our existing product<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>later<span style="letter-spacing:-0.1pt;"> </span>prove<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>greater<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:-0.1pt;"> </span>potential.<span style="letter-spacing:-0.1pt;"> </span>Additionally,<span style="letter-spacing:-0.1pt;"> </span>negative<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.1pt;"> </span>trial results with respect to one indication of<span style="letter-spacing:1.05pt;"> </span>a product candidate may impact the potential or perception of<span style="letter-spacing:1.05pt;"> </span>other indications<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.1pt;"> </span>candidate.<span style="letter-spacing:-0.1pt;"> </span>Our<span style="letter-spacing:-0.1pt;"> </span>resource<span style="letter-spacing:-0.1pt;"> </span>allocation<span style="letter-spacing:-0.1pt;"> </span>decisions<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>failure<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development<span style="letter-spacing:-0.65pt;"> </span>programs<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidates<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>specific<span style="letter-spacing:-0.65pt;"> </span>indications<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>yield<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>commercially<span style="letter-spacing:-0.65pt;"> </span>viable product<span style="letter-spacing:-0.55pt;"> </span>candidates.<span style="letter-spacing:-0.55pt;"> </span>If<span style="letter-spacing:0.5pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>do<span style="letter-spacing:-0.55pt;"> </span>not<span style="letter-spacing:-0.55pt;"> </span>accurately<span style="letter-spacing:-0.55pt;"> </span>evaluate<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>commercial<span style="letter-spacing:-0.55pt;"> </span>potential<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>target<span style="letter-spacing:-0.55pt;"> </span>market<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>a<span style="letter-spacing:-0.55pt;"> </span>particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are currently conducting, and may in the future conduct, clinical trials for current or future product candidates outside<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>U.S.,<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>FDA<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>comparable<span style="letter-spacing:-0.55pt;"> </span>foreign<span style="letter-spacing:-0.55pt;"> </span>regulatory<span style="letter-spacing:-0.55pt;"> </span>authorities<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>not<span style="letter-spacing:-0.55pt;"> </span>accept<span style="letter-spacing:-0.55pt;"> </span>data<span style="letter-spacing:-0.55pt;"> </span>from such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are currently conducting clinical trials outside the U.S., including in Europe and Asia, and we<span style="letter-spacing:-0.6pt;"> </span>expect<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>continue<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>conduct<span style="letter-spacing:-0.6pt;"> </span>trials<span style="letter-spacing:-0.6pt;"> </span>internationally<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>future.<span style="letter-spacing:-0.6pt;"> </span>The<span style="letter-spacing:-0.6pt;"> </span>acceptance<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>data<span style="letter-spacing:-0.6pt;"> </span>from<span style="letter-spacing:-0.6pt;"> </span>clinical<span style="letter-spacing:-0.6pt;"> </span>trials conducted<span style="letter-spacing:-0.25pt;"> </span>outside<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>U.S.<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>FDA<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>comparable<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>authorities<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.25pt;"> </span>subject to<span style="letter-spacing:-0.55pt;"> </span>certain<span style="letter-spacing:-0.55pt;"> </span>conditions<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>not<span style="letter-spacing:-0.55pt;"> </span>be<span style="letter-spacing:-0.55pt;"> </span>accepted<span style="letter-spacing:-0.55pt;"> </span>at<span style="letter-spacing:-0.55pt;"> </span>all.<span style="letter-spacing:-0.55pt;"> </span>In<span style="letter-spacing:-0.55pt;"> </span>cases<span style="letter-spacing:-0.55pt;"> </span>where<span style="letter-spacing:-0.55pt;"> </span>data<span style="letter-spacing:-0.55pt;"> </span>from<span style="letter-spacing:-0.55pt;"> </span>foreign<span style="letter-spacing:-0.55pt;"> </span>clinical<span style="letter-spacing:-0.55pt;"> </span>trials<span style="letter-spacing:-0.55pt;"> </span>are<span style="letter-spacing:-0.55pt;"> </span>intended to serve as the basis for marketing approval in the U.S., the FDA will generally not approve the application<span style="letter-spacing:-0.2pt;"> </span>unless<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>applicable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>U.S.<span style="letter-spacing:-0.2pt;"> </span>population<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>U.S.<span style="letter-spacing:-0.2pt;"> </span>medical<span style="letter-spacing:-0.2pt;"> </span>practice, the<span style="letter-spacing:-0.65pt;"> </span>trials<span style="letter-spacing:-0.65pt;"> </span>were<span style="letter-spacing:-0.65pt;"> </span>performed<span style="letter-spacing:-0.65pt;"> </span>by<span style="letter-spacing:-0.65pt;"> </span>clinical<span style="letter-spacing:-0.65pt;"> </span>investigators<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>recognized<span style="letter-spacing:-0.65pt;"> </span>competence<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>pursuant<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>GCP<span style="letter-spacing:-0.65pt;"> </span>regulations and the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many comparable foreign regulatory authorities have similar approval requirements.<span style="letter-spacing:-0.7pt;"> </span>In<span style="letter-spacing:-0.65pt;"> </span>addition,<span style="letter-spacing:-0.65pt;"> </span>foreign<span style="letter-spacing:-0.65pt;"> </span>trials<span style="letter-spacing:-0.65pt;"> </span>are<span style="letter-spacing:-0.65pt;"> </span>subject<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>local<span style="letter-spacing:-0.7pt;"> </span>laws<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>foreign<span style="letter-spacing:-0.65pt;"> </span>jurisdictions<span style="letter-spacing:-0.65pt;"> </span>where<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>trials<span style="letter-spacing:-0.7pt;"> </span>are conducted. The FDA or any comparable foreign regulatory authority may not accept data from trials conducted outside of the U.S. or the applicable jurisdiction, which would result in the need for additional trials that could be costly and time consuming and could result in the product candidate not receiving approval for commercialization in the applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even<span style="letter-spacing:-0.55pt;"> </span>if<span style="letter-spacing:0.25pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>receive<span style="letter-spacing:-0.55pt;"> </span>marketing<span style="letter-spacing:-0.55pt;"> </span>approval<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>current<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>future<span style="letter-spacing:-0.55pt;"> </span>product<span style="letter-spacing:-0.55pt;"> </span>candidates<span style="letter-spacing:-0.55pt;"> </span>in<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>U.S.,<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>may never receive regulatory approval to market outside of<span style="letter-spacing:1.85pt;"> </span>the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to seek regulatory approval of our current or future product candidates outside of the U.S. In order to market any product outside of the U.S. we must establish and comply with the numerous and varying safety, efficacy and other regulatory requirements of other applicable jurisdictions. Marketing approval processes vary among countries but generally implicate all of the risks detailed above regarding FDA approval in the U.S. as well as other risks. The time required to obtain approvals in other countries might differ substantially from that required to obtain FDA approval and can require additional<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.1pt;"> </span>candidate<span style="letter-spacing:-0.1pt;"> </span>testing<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.1pt;"> </span>administrative<span style="letter-spacing:-0.1pt;"> </span>review<span style="letter-spacing:-0.1pt;"> </span>periods.<span style="letter-spacing:-0.1pt;"> </span>In<span style="letter-spacing:-0.1pt;"> </span>many<span style="letter-spacing:-0.1pt;"> </span>countries<span style="letter-spacing:-0.1pt;"> </span>outside of the U.S., products must receive pricing and reimbursement approval before the product can be commercialized.<span style="letter-spacing:0.65pt;"> </span>Obtaining<span style="letter-spacing:0.65pt;"> </span>this<span style="letter-spacing:0.65pt;"> </span>approval<span style="letter-spacing:0.65pt;"> </span>can<span style="letter-spacing:0.7pt;"> </span>result<span style="letter-spacing:0.65pt;"> </span>in<span style="letter-spacing:0.65pt;"> </span>substantial<span style="letter-spacing:0.65pt;"> </span>delays<span style="letter-spacing:0.7pt;"> </span>in<span style="letter-spacing:0.65pt;"> </span>bringing<span style="letter-spacing:0.65pt;"> </span>products<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.7pt;"> </span>market<span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:-0.25pt;">in</span> such countries. Marketing approval in one country does not ensure marketing approval in another, but a failure<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>delay<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>obtaining<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.1pt;"> </span>approval<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>one<span style="letter-spacing:-0.1pt;"> </span>country<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>negative<span style="letter-spacing:-0.1pt;"> </span>effect<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>regulatory process in others and would impair our ability to market our current or future product candidates in such foreign<span style="letter-spacing:-0.3pt;"> </span>markets.<span style="letter-spacing:-0.3pt;"> </span>Any<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.3pt;"> </span>impairment<span style="letter-spacing:-0.3pt;"> </span>would<span style="letter-spacing:-0.3pt;"> </span>limit<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>commercial<span style="letter-spacing:-0.3pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidate,<span style="letter-spacing:-0.3pt;"> </span>which could adversely affect our business, financial condition, results of<span style="letter-spacing:1.75pt;"> </span>operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which<span style="letter-spacing:-0.6pt;"> </span>governmental<span style="letter-spacing:-0.6pt;"> </span>authorities<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>other<span style="letter-spacing:-0.6pt;"> </span>third<span style="letter-spacing:-0.6pt;"> </span>party<span style="letter-spacing:-0.6pt;"> </span>payors<span style="letter-spacing:-0.6pt;"> </span>establish<span style="letter-spacing:-0.6pt;"> </span>broad<span style="letter-spacing:-0.6pt;"> </span>coverage,<span style="letter-spacing:-0.6pt;"> </span>adequate<span style="letter-spacing:-0.6pt;"> </span>reimbursement <span style="letter-spacing:-0.1pt;">levels</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">favorable</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">pricing</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">products.</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">Failure</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">obtain</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">maintain</span><span style="letter-spacing:-0.5pt;"> such </span><span style="letter-spacing:-0.1pt;">coverage</span><span style="letter-spacing:-0.55pt;">, </span><span style="letter-spacing:-0.1pt;">reimbursement and pricing </span>for any approved products could limit our ability to market those products and would decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The<span style="letter-spacing:-0.45pt;"> </span>availability<span style="letter-spacing:-0.45pt;"> </span>of coverage<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>adequacy<span style="letter-spacing:-0.45pt;"> </span>of reimbursement<span style="letter-spacing:-0.45pt;"> </span>by<span style="letter-spacing:-0.45pt;"> </span>governmental<span style="letter-spacing:-0.45pt;"> </span>healthcare<span style="letter-spacing:-0.45pt;"> </span>authorities or<span style="letter-spacing:-0.45pt;"> </span>programs<span style="letter-spacing:-0.45pt;"> </span>such<span style="letter-spacing:-0.45pt;"> </span>as<span style="letter-spacing:-0.45pt;"> </span>Medicare<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>Medicaid,<span style="letter-spacing:-0.45pt;"> </span>private<span style="letter-spacing:-0.45pt;"> </span>health<span style="letter-spacing:-0.45pt;"> </span>insurers<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>other<span style="letter-spacing:-0.45pt;"> </span>third-party<span style="letter-spacing:-0.45pt;"> </span>payors<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.45pt;"> </span>essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our<span style="letter-spacing:1.85pt;"> </span>ability<span style="letter-spacing:1.85pt;"> </span>to<span style="letter-spacing:1.85pt;"> </span>achieve<span style="letter-spacing:1.85pt;"> </span>coverage<span style="letter-spacing:1.85pt;"> </span>and<span style="letter-spacing:1.85pt;"> </span>acceptable<span style="letter-spacing:1.85pt;"> </span>levels<span style="letter-spacing:1.85pt;"> </span>of<span style="letter-spacing:2pt;"> </span>reimbursement<span style="letter-spacing:1.85pt;"> </span>for<span style="letter-spacing:1.85pt;"> </span>our<span style="letter-spacing:1.85pt;"> </span>approved<span style="letter-spacing:1.85pt;"> </span>products<span style="letter-spacing:1.85pt;"> </span>by third-party<span style="letter-spacing:-0.35pt;"> </span>payors<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.35pt;"> </span>affect<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>ability<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>successfully<span style="letter-spacing:-0.35pt;"> </span>commercialize<span style="letter-spacing:-0.35pt;"> </span>those<span style="letter-spacing:-0.35pt;"> </span>products.<span style="letter-spacing:-0.35pt;"> </span>No<span style="letter-spacing:-0.35pt;"> </span>uniform<span style="letter-spacing:-0.35pt;"> </span>policy<span style="letter-spacing:-0.35pt;"> </span>for coverage and reimbursement for products exists among third-party payors in the U.S. Coverage and reimbursement for products can therefore differ significantly from payor to payor. Even </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">if we obtain coverage<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>given<span style="letter-spacing:-0.45pt;"> </span>product<span style="letter-spacing:-0.45pt;"> </span>by<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>third-party<span style="letter-spacing:-0.45pt;"> </span>payor,<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>reimbursement<span style="letter-spacing:-0.45pt;"> </span>payment<span style="letter-spacing:-0.45pt;"> </span>rates<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>not<span style="letter-spacing:-0.45pt;"> </span>be<span style="letter-spacing:-0.45pt;"> </span>adequate<span style="letter-spacing:-0.45pt;"> </span>or may<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.1pt;"> </span>co-payments<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>patients<span style="letter-spacing:-0.1pt;"> </span>find<span style="letter-spacing:-0.1pt;"> </span>unacceptably<span style="letter-spacing:-0.1pt;"> </span>high.<span style="letter-spacing:-0.1pt;"> </span>Coverage<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>adequate<span style="letter-spacing:-0.1pt;"> </span>reimbursement<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the U.S. or elsewhere may not be available for any product that we may develop, and any coverage or reimbursement that may be obtained could be reduced or eliminated in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved<span style="letter-spacing:-0.15pt;"> </span>products.<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>coverage<span style="letter-spacing:-0.15pt;"> </span>determination<span style="letter-spacing:-0.15pt;"> </span>process<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.15pt;"> </span>often<span style="letter-spacing:-0.15pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>consuming<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>costly<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance<span style="letter-spacing:-0.8pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>coverage<span style="letter-spacing:-0.65pt;"> </span>will<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>obtained.<span style="letter-spacing:-0.65pt;"> </span>Third<span style="letter-spacing:-0.65pt;"> </span>party<span style="letter-spacing:-0.65pt;"> </span>payors<span style="letter-spacing:-0.7pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>provide<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>limit<span style="letter-spacing:-0.65pt;"> </span>coverage,<span style="letter-spacing:-0.65pt;"> </span>including to a subset of the patient population for which the treatment is approved by the FDA, or may control utilization including by requiring that patients try other therapies first or that prescribers obtain specific approval of coverage on a patient by patient basis. Many third-party payors refuse to provide coverage and reimbursement<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>particular<span style="letter-spacing:-0.55pt;"> </span>drugs<span style="letter-spacing:-0.55pt;"> </span>when<span style="letter-spacing:-0.55pt;"> </span>equivalent<span style="letter-spacing:-0.55pt;"> </span>generic<span style="letter-spacing:-0.55pt;"> </span>drugs,<span style="letter-spacing:-0.55pt;"> </span>biosimilars<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>less<span style="letter-spacing:-0.55pt;"> </span>expensive<span style="letter-spacing:-0.55pt;"> </span>therapies<span style="letter-spacing:-0.55pt;"> </span>are available.<span style="letter-spacing:-0.45pt;"> </span>A<span style="letter-spacing:-0.45pt;"> </span>third-party<span style="letter-spacing:-0.45pt;"> </span>payor<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>consider<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>product<span style="letter-spacing:-0.45pt;"> </span>candidates,<span style="letter-spacing:-0.45pt;"> </span>if<span style="letter-spacing:0.5pt;"> </span>approved,<span style="letter-spacing:-0.45pt;"> </span>as<span style="letter-spacing:-0.45pt;"> </span>substitutes<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.45pt;"> </span>alternative products on the market now or in the future and only be willing to cover the cost of<span style="letter-spacing:1.2pt;"> </span>the alternative product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services.<span style="letter-spacing:-0.7pt;"> </span>Even<span style="letter-spacing:-0.65pt;"> </span>if<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>show<span style="letter-spacing:-0.65pt;"> </span>improved<span style="letter-spacing:-0.65pt;"> </span>efficacy,<span style="letter-spacing:-0.65pt;"> </span>safety<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>convenience<span style="letter-spacing:-0.65pt;"> </span>of administration<span style="letter-spacing:-0.7pt;"> </span>with<span style="letter-spacing:-0.65pt;"> </span>obexelimab<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>any of our other product candidates, pricing of competitive products may limit the amount we will be able to charge for any of our product candidates, if approved. Third-party payors may deny or revoke the reimbursement status of<span style="letter-spacing:1.1pt;"> </span>a product or establish payment for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. When new<span style="letter-spacing:-0.25pt;"> </span>competitor<span style="letter-spacing:-0.25pt;"> </span>generic<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>biosimilar<span style="letter-spacing:-0.25pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>enter<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>market,<span style="letter-spacing:-0.25pt;"> </span>pricing<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>reimbursement<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>innovator compound may be reduced. More generally, the existence of generic and biosimilar products or other therapeutic alternatives within a &#8220;therapeutic category&#8221; may result in reduced reimbursement from payors. <span style="letter-spacing:-0.1pt;">Additionally,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">new</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">competitor</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">brand</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">drugs</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">can</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">trigger</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">therapeutic</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">category</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">reviews</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">interest</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:1pt;"> </span><span style="letter-spacing:-0.1pt;">modifying </span>coverage<span style="letter-spacing:-0.6pt;"> </span>and/or<span style="letter-spacing:-0.6pt;"> </span>reimbursement<span style="letter-spacing:-0.6pt;"> </span>levels.<span style="letter-spacing:-0.6pt;"> </span>We<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>be<span style="letter-spacing:-0.6pt;"> </span>required<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>provide<span style="letter-spacing:-0.6pt;"> </span>discounts<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>rebates<span style="letter-spacing:-0.6pt;"> </span>under<span style="letter-spacing:-0.6pt;"> </span>government healthcare<span style="letter-spacing:-0.65pt;"> </span>programs<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>certain<span style="letter-spacing:-0.65pt;"> </span>government<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>private<span style="letter-spacing:-0.65pt;"> </span>purchasers<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>order<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>obtain<span style="letter-spacing:-0.65pt;"> </span>coverage<span style="letter-spacing:-0.65pt;"> </span>under<span style="letter-spacing:-0.65pt;"> </span>federal healthcare<span style="letter-spacing:-0.35pt;"> </span>programs<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.35pt;"> </span>Medicaid.<span style="letter-spacing:-0.35pt;"> </span>More<span style="letter-spacing:-0.35pt;"> </span>generally,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>need<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>offer<span style="letter-spacing:-0.35pt;"> </span>price<span style="letter-spacing:-0.35pt;"> </span>concessions<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>third<span style="letter-spacing:-0.35pt;"> </span>party payors to obtain favorable coverage or to purchasers to achieve sales. Such actions could have a negative impact<span style="letter-spacing:-0.5pt;"> </span>on<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>ability<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>successfully<span style="letter-spacing:-0.5pt;"> </span>commercialize<span style="letter-spacing:-0.5pt;"> </span>any<span style="letter-spacing:-0.5pt;"> </span>of our<span style="letter-spacing:-0.5pt;"> </span>product<span style="letter-spacing:-0.5pt;"> </span>candidates,<span style="letter-spacing:-0.5pt;"> </span>if approved.<span style="letter-spacing:-0.5pt;"> </span>Additionally, if<span style="letter-spacing:0.6pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>companion<span style="letter-spacing:-0.3pt;"> </span>diagnostic<span style="letter-spacing:-0.3pt;"> </span>test<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.3pt;"> </span>developed<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>use<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>drug<span style="letter-spacing:-0.3pt;"> </span>product,<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.3pt;"> </span>coverage<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>reimbursement<span style="letter-spacing:-0.3pt;"> </span>for that<span style="letter-spacing:-0.45pt;"> </span>test<span style="letter-spacing:-0.45pt;"> </span>would<span style="letter-spacing:-0.45pt;"> </span>be<span style="letter-spacing:-0.45pt;"> </span>separate<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>apart<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>coverage<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>reimbursement<span style="letter-spacing:-0.45pt;"> </span>sought<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.45pt;"> </span>such drug<span style="letter-spacing:-0.45pt;"> </span>product.<span style="letter-spacing:-0.45pt;"> </span>A<span style="letter-spacing:-0.45pt;"> </span>lack<span style="letter-spacing:-0.45pt;"> </span>of coverage or adequate reimbursement for such a test could adversely affect access to a drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Outside<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>U.S.,<span style="letter-spacing:-0.45pt;"> </span>international<span style="letter-spacing:-0.45pt;"> </span>operations<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.45pt;"> </span>generally<span style="letter-spacing:-0.45pt;"> </span>subject<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>extensive<span style="letter-spacing:-0.45pt;"> </span>governmental<span style="letter-spacing:-0.45pt;"> </span>price controls<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>other<span style="letter-spacing:-0.55pt;"> </span>market<span style="letter-spacing:-0.55pt;"> </span>regulations,<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>believe<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>increasing<span style="letter-spacing:-0.55pt;"> </span>emphasis<span style="letter-spacing:-0.55pt;"> </span>on<span style="letter-spacing:-0.55pt;"> </span>cost-containment<span style="letter-spacing:-0.55pt;"> </span>initiatives in<span style="letter-spacing:-0.15pt;"> </span>Europe<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>countries<span style="letter-spacing:-0.1pt;"> </span>has<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>continue<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>put<span style="letter-spacing:-0.1pt;"> </span>pressure<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>pricing<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>usage<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.9pt;"> </span>products<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.2pt;">like</span> our<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:-0.35pt;"> </span>many<span style="letter-spacing:-0.35pt;"> </span>countries,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>prices<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>medical<span style="letter-spacing:-0.35pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>subject<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>varying<span style="letter-spacing:-0.35pt;"> </span>price<span style="letter-spacing:-0.35pt;"> </span>control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical<span style="letter-spacing:-0.55pt;"> </span>products<span style="letter-spacing:-0.55pt;"> </span>but<span style="letter-spacing:-0.55pt;"> </span>monitor<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>control<span style="letter-spacing:-0.55pt;"> </span>company<span style="letter-spacing:-0.55pt;"> </span>profits.<span style="letter-spacing:-0.55pt;"> </span>Additional<span style="letter-spacing:-0.55pt;"> </span>foreign<span style="letter-spacing:-0.55pt;"> </span>price<span style="letter-spacing:-0.55pt;"> </span>controls<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>other<span style="letter-spacing:-0.55pt;"> </span>changes in pricing regulation could restrict the amount that we are able to charge for our product candidates, if approved. Accordingly, in markets outside the U.S., the reimbursement for our product candidates may be lower than in the U.S. and may be insufficient to generate meaningful revenue and profits. Factors outside the U.S. that may be relevant in pricing and reimbursement determinations by health authorities, including in European countries, may include, without limitation, perceived cost-effectiveness perceived benefit to patient quality of life, and designation as an orphan drug indication, among others. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover,<span style="letter-spacing:-0.1pt;"> </span>increasing<span style="letter-spacing:-0.1pt;"> </span>efforts<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>governmental<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>third-party<span style="letter-spacing:-0.1pt;"> </span>payors<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>U.S.<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>abroad<span style="letter-spacing:-0.1pt;"> </span>to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement<span style="letter-spacing:-0.6pt;"> </span>for<span style="letter-spacing:-0.6pt;"> </span>newly<span style="letter-spacing:-0.6pt;"> </span>approved<span style="letter-spacing:-0.6pt;"> </span>products<span style="letter-spacing:-0.6pt;"> </span>and,<span style="letter-spacing:-0.6pt;"> </span>as<span style="letter-spacing:-0.6pt;"> </span>a<span style="letter-spacing:-0.6pt;"> </span>result,<span style="letter-spacing:-0.6pt;"> </span>they<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>not<span style="letter-spacing:-0.6pt;"> </span>cover<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>provide<span style="letter-spacing:-0.6pt;"> </span>adequate<span style="letter-spacing:-0.6pt;"> </span>payment for our products, if approved. We expect to experience pricing pressures for any of our product candidates that may be approved due to the continuing trend toward managed healthcare and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">able</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">obtain</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">maintain</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">orphan</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">drug</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">designations</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">certain</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">product</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">candidates,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">we </span>may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in some jurisdictions, including the U.S. and Europe, may designate drugs<span style="letter-spacing:-0.6pt;"> </span>for<span style="letter-spacing:-0.6pt;"> </span>relatively<span style="letter-spacing:-0.6pt;"> </span>small<span style="letter-spacing:-0.6pt;"> </span>patient<span style="letter-spacing:-0.6pt;"> </span>populations<span style="letter-spacing:-0.6pt;"> </span>as<span style="letter-spacing:-0.6pt;"> </span>orphan<span style="letter-spacing:-0.6pt;"> </span>drugs.<span style="letter-spacing:-0.6pt;"> </span>For<span style="letter-spacing:-0.6pt;"> </span>example,<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>FDA<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>designate<span style="letter-spacing:-0.6pt;"> </span>a<span style="letter-spacing:-0.6pt;"> </span>product as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the U.S., or a patient population of greater than<span style="letter-spacing:-0.3pt;"> </span>200,000<span style="letter-spacing:-0.3pt;"> </span>individuals<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>U.S.<span style="letter-spacing:-0.3pt;"> </span>but<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.3pt;"> </span>there<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.3pt;"> </span>no<span style="letter-spacing:-0.3pt;"> </span>reasonable<span style="letter-spacing:-0.3pt;"> </span>expectation<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>cost<span style="letter-spacing:-0.3pt;"> </span>of developing the drug will be recovered from sales in the U.S. The FDA and the EMA have each granted orphan drug designation to obexelimab for IgG4-RD.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>not<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.25pt;"> </span>able<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> maintain orphan drug designation for obexelimab for IgG4-RD. Additionally, we may not be able to </span>obtain<span style="letter-spacing:-0.25pt;"> </span>orphan<span style="letter-spacing:-0.25pt;"> </span>drug<span style="letter-spacing:-0.25pt;"> </span>designation<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>additional indications for our product candidates, and we may not be able to maintain such designations if<span style="letter-spacing:1.85pt;"> </span>granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>indication<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.1pt;"> </span>it<span style="letter-spacing:-0.1pt;"> </span>has<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>designation,<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>entitled<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>period<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>marketing exclusivity,<span style="letter-spacing:-0.65pt;"> </span>which<span style="letter-spacing:-0.65pt;"> </span>precludes<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>FDA<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.65pt;"> </span>approving<span style="letter-spacing:-0.65pt;"> </span>another<span style="letter-spacing:-0.65pt;"> </span>marketing<span style="letter-spacing:-0.65pt;"> </span>application<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>same<span style="letter-spacing:-0.65pt;"> </span>biologic<span style="letter-spacing:-0.65pt;"> </span>for the<span style="letter-spacing:-0.55pt;"> </span>same<span style="letter-spacing:-0.55pt;"> </span>indications<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>seven<span style="letter-spacing:-0.55pt;"> </span>years.<span style="letter-spacing:-0.55pt;"> </span>Even<span style="letter-spacing:-0.55pt;"> </span>if<span style="letter-spacing:0.4pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>are<span style="letter-spacing:-0.55pt;"> </span>able<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>maintain<span style="letter-spacing:-0.55pt;"> </span>orphan<span style="letter-spacing:-0.55pt;"> </span>drug<span style="letter-spacing:-0.55pt;"> </span>designation<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>IgG4-RD<span style="letter-spacing:-0.55pt;"> </span>or obtain orphan drug exclusivity for any other indication or product candidate, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same<span style="letter-spacing:-0.4pt;"> </span>condition.<span style="letter-spacing:-0.4pt;"> </span>Even<span style="letter-spacing:-0.4pt;"> </span>after<span style="letter-spacing:-0.4pt;"> </span>an<span style="letter-spacing:-0.4pt;"> </span>orphan<span style="letter-spacing:-0.4pt;"> </span>drug<span style="letter-spacing:-0.4pt;"> </span>is<span style="letter-spacing:-0.4pt;"> </span>approved,<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>FDA<span style="letter-spacing:-0.4pt;"> </span>can<span style="letter-spacing:-0.4pt;"> </span>subsequently<span style="letter-spacing:-0.4pt;"> </span>approve<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>same<span style="letter-spacing:-0.4pt;"> </span>drug<span style="letter-spacing:-0.4pt;"> </span>for the<span style="letter-spacing:-0.2pt;"> </span>same<span style="letter-spacing:-0.2pt;"> </span>condition<span style="letter-spacing:-0.2pt;"> </span>if,<span style="letter-spacing:-0.2pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>things,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:-0.2pt;"> </span>concludes<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>later<span style="letter-spacing:-0.2pt;"> </span>drug<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>clinically<span style="letter-spacing:-0.2pt;"> </span>superior,<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:0.7pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>is shown<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>be<span style="letter-spacing:-0.6pt;"> </span>safer,<span style="letter-spacing:-0.6pt;"> </span>more<span style="letter-spacing:-0.6pt;"> </span>effective<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>makes<span style="letter-spacing:-0.6pt;"> </span>a<span style="letter-spacing:-0.6pt;"> </span>major<span style="letter-spacing:-0.6pt;"> </span>contribution<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>patient<span style="letter-spacing:-0.6pt;"> </span>care.<span style="letter-spacing:-0.6pt;"> </span>The EMA is required to re-assess granted orphan designation at the time of marketing authorization to ensure that it continues to meet the criteria for the designation to be maintained. Otherwise, the orphan designation can be revoked.<span style="letter-spacing:-0.6pt;"> </span>Orphan<span style="letter-spacing:-0.6pt;"> </span>drug<span style="letter-spacing:-0.6pt;"> </span>designation<span style="letter-spacing:-0.6pt;"> </span>does not<span style="letter-spacing:-0.7pt;"> </span>convey<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>advantage<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>shorten<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>duration<span style="letter-spacing:-0.7pt;"> </span>of<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.7pt;"> </span>regulatory<span style="letter-spacing:-0.65pt;"> </span>review<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>approval<span style="letter-spacing:-0.65pt;"> </span>process.<span style="letter-spacing:-0.65pt;"> </span>Even<span style="letter-spacing:-0.65pt;"> </span>if<span style="letter-spacing:0.2pt;"> </span>we receive orphan drug designation or orphan drug exclusivity for any of our product candidates, there is no guarantee that we will enjoy the benefits of<span style="letter-spacing:1.45pt;"> </span>such designations or exclusivity periods, and granted designations, if not maintained, will not provide the benefits of such designation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The<span style="letter-spacing:0.85pt;"> </span>decision<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:1.7pt;"> </span>the<span style="letter-spacing:0.85pt;"> </span>U.S.<span style="letter-spacing:0.85pt;"> </span>Court<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:1.7pt;"> </span>Appeals<span style="letter-spacing:0.85pt;"> </span>for<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:0.85pt;"> </span>11th<span style="letter-spacing:0.85pt;"> </span>Circuit<span style="letter-spacing:0.85pt;"> </span>in<span style="letter-spacing:0.85pt;"> </span><i style="font-style:italic;">Catalyst</i><i style="font-style:italic;letter-spacing:0.85pt;"> </i><i style="font-style:italic;">Pharms.,</i><i style="font-style:italic;letter-spacing:0.85pt;"> </i><i style="font-style:italic;">Inc.</i><i style="font-style:italic;letter-spacing:0.85pt;"> </i><i style="font-style:italic;">v.</i><i style="font-style:italic;letter-spacing:0.85pt;"> </i><i style="font-style:italic;">Becerra</i>, <span style="letter-spacing:-0.1pt;">14</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">F.4</span><sup style="font-size:7.5pt;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">1299</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">(11</span><sup style="font-size:7.5pt;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">Cir.</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">2021)</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">has</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">created</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">uncertainty</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">regarding</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">scope</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:-0.1pt;">orphan</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">drug</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">exclusivity.</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">Although </span>the FDA subsequently announced that it intends to continue to apply its longstanding interpretation of the regulations<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>matters<span style="letter-spacing:-0.3pt;"> </span>outside<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>scope<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span><i style="font-style:italic;">Catalyst</i><i style="font-style:italic;letter-spacing:-0.3pt;"> </i>order<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>continue<span style="letter-spacing:-0.3pt;"> </span>tying<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>scope<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>orphan-drug <span style="letter-spacing:-0.1pt;">exclusivity</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">uses</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">indications</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">which</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">drug</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">is</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">approved,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">it</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">is</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">unclear</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">how</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">future</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">litigation,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">legislation, </span>agency decisions, and administrative actions will impact the scope of<span style="letter-spacing:1.45pt;"> </span>the orphan drug exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>seek<span style="letter-spacing:-0.15pt;"> </span>fast<span style="letter-spacing:-0.15pt;"> </span>track<span style="letter-spacing:-0.15pt;"> </span>designation,<span style="letter-spacing:-0.15pt;"> </span>breakthrough<span style="letter-spacing:-0.15pt;"> </span>therapy<span style="letter-spacing:-0.15pt;"> </span>designation<span style="letter-spacing:-0.15pt;"> </span>and/or<span style="letter-spacing:-0.15pt;"> </span>priority<span style="letter-spacing:-0.15pt;"> </span>review<span style="letter-spacing:-0.15pt;"> </span>designation<span style="letter-spacing:-0.15pt;"> </span>from the<span style="letter-spacing:-0.5pt;"> </span>FDA<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>similar<span style="letter-spacing:-0.5pt;"> </span>designations<span style="letter-spacing:-0.5pt;"> </span>from<span style="letter-spacing:-0.5pt;"> </span>comparable<span style="letter-spacing:-0.5pt;"> </span>foreign<span style="letter-spacing:-0.5pt;"> </span>regulatory<span style="letter-spacing:-0.5pt;"> </span>authorities<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.5pt;"> </span>one<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>more<span style="letter-spacing:-0.5pt;"> </span>of our<span style="letter-spacing:-0.5pt;"> </span>product <span style="letter-spacing:-0.1pt;">candidates.</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">Even</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">if</span><span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:-0.1pt;">one</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">more</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">product</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">receive</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">these</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">designations,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">unable</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">obtain </span>or maintain the benefits associated with such designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA has established various designations to facilitate more rapid and efficient development and approval of certain types of drugs intended to treat serious conditions that fill an unmet medical need. Such designations<span style="letter-spacing:4pt;"> </span>include<span style="letter-spacing:4pt;"> </span>fast<span style="letter-spacing:4pt;"> </span>track<span style="letter-spacing:4pt;"> </span>designation,<span style="letter-spacing:4pt;"> </span>breakthrough<span style="letter-spacing:4pt;"> </span>therapy<span style="letter-spacing:4pt;"> </span>designation,<span style="letter-spacing:4pt;"> </span>and<span style="letter-spacing:4pt;"> </span>priority<span style="letter-spacing:4pt;"> </span>review designation.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.3pt;"> </span>intend<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>seek<span style="letter-spacing:-0.3pt;"> </span>priority<span style="letter-spacing:-0.3pt;"> </span>review<span style="letter-spacing:-0.3pt;"> </span>designation<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>obexelimab<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>IgG4-RD.<span style="letter-spacing:-0.3pt;"> </span>The<span style="letter-spacing:-0.3pt;"> </span>FDA<span style="letter-spacing:-0.3pt;"> </span>has<span style="letter-spacing:-0.3pt;"> </span>broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, the FDA could decide not to grant it. If any of our programs or product candidates receive any of these designations by the FDA or similar designations by comparable foreign regulatory authorities, there is no assurance that we will receive any benefits from such programs or that we will continue to meet the criteria to maintain such designation. Even if we obtain such designations, we may not experience a faster development process, review or approval compared to conventional<span style="letter-spacing:-0.1pt;"> </span>procedures.<span style="letter-spacing:-0.1pt;"> </span>A<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>these<span style="letter-spacing:-0.1pt;"> </span>designations<span style="letter-spacing:-0.1pt;"> </span>does<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>ensure<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.1pt;"> </span>candidate<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>receive marketing approval or that approval will be granted within any particular timeframe. In addition, the FDA may<span style="letter-spacing:-0.45pt;"> </span>withdraw<span style="letter-spacing:-0.45pt;"> </span>any<span style="letter-spacing:-0.45pt;"> </span>such<span style="letter-spacing:-0.45pt;"> </span>designation<span style="letter-spacing:-0.45pt;"> </span>if<span style="letter-spacing:0.5pt;"> </span>it<span style="letter-spacing:-0.45pt;"> </span>believes<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>designation<span style="letter-spacing:-0.45pt;"> </span>is<span style="letter-spacing:-0.45pt;"> </span>no<span style="letter-spacing:-0.45pt;"> </span>longer<span style="letter-spacing:-0.45pt;"> </span>supported<span style="letter-spacing:-0.45pt;"> </span>by<span style="letter-spacing:-0.45pt;"> </span>data<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span>our clinical development program.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may seek accelerated approval for some of our product candidates but may not be able to obtain it as the sufficiency of<span style="letter-spacing:1pt;"> </span>our clinical trial results for accelerated approval are subject to the FDA&#8217;s discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>explore<span style="letter-spacing:-0.6pt;"> </span>strategies<span style="letter-spacing:-0.6pt;"> </span>for<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>product<span style="letter-spacing:-0.6pt;"> </span>candidates<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>involve<span style="letter-spacing:-0.6pt;"> </span>use<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>FDA&#8217;s<span style="letter-spacing:-0.6pt;"> </span>accelerated<span style="letter-spacing:-0.6pt;"> </span>approval <span style="letter-spacing:-0.1pt;">pathway.</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">Obtaining</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">accelerated</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">approval</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">requires</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">demonstration</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:-0.1pt;">meaningful</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">benefit</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">over</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">available</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">therapies </span>for<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>serious<span style="letter-spacing:-0.2pt;"> </span>condition.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>determination<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>what<span style="letter-spacing:-0.2pt;"> </span>constitutes<span style="letter-spacing:-0.2pt;"> </span>available<span style="letter-spacing:-0.2pt;"> </span>therapy<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>wholly<span style="letter-spacing:-0.2pt;"> </span>up<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:-0.2pt;"> </span>and is<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>change.<span style="letter-spacing:-0.05pt;"> </span>No<span style="letter-spacing:-0.05pt;"> </span>assurance<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>given<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.05pt;"> </span>therapeutics<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>receive<span style="letter-spacing:-0.05pt;"> </span>full<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.05pt;"> </span>prior<span style="letter-spacing:-0.05pt;"> </span>to our<span style="letter-spacing:-0.7pt;"> </span>potential<span style="letter-spacing:-0.65pt;"> </span>receipt<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>accelerated<span style="letter-spacing:-0.65pt;"> </span>approval.<span style="letter-spacing:-0.65pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>were<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.7pt;"> </span>occur,<span style="letter-spacing:-0.65pt;"> </span>no<span style="letter-spacing:-0.65pt;"> </span>assurance<span style="letter-spacing:-0.65pt;"> </span>can<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>given<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.7pt;"> </span>would<span style="letter-spacing:-0.65pt;"> </span>be successful in proving meaningful benefit over those later approved products. If we were unable to prove <span style="letter-spacing:-0.1pt;">meaningful</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">benefit</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">over</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">any</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">such</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">agents,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">would</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">effectively</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">blocked</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">receiving</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">accelerated</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">approval. </span>If<span style="letter-spacing:0.45pt;"> </span>any<span style="letter-spacing:-0.4pt;"> </span>of our<span style="letter-spacing:-0.4pt;"> </span>drugs<span style="letter-spacing:-0.4pt;"> </span>were<span style="letter-spacing:-0.4pt;"> </span>ever<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>receive<span style="letter-spacing:-0.4pt;"> </span>accelerated<span style="letter-spacing:-0.4pt;"> </span>approval,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>would<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.4pt;"> </span>required<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>conduct<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>post-market confirmatory<span style="letter-spacing:-0.2pt;"> </span>study,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.2pt;"> </span>complete,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>if completed,<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>prove<span style="letter-spacing:-0.2pt;"> </span>unsuccessful.<span style="letter-spacing:-0.2pt;"> </span>In<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:-0.2pt;"> </span>instance, the FDA can remove the product from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks<b style="font-weight:bold;letter-spacing:-0.1pt;"> </b>Related<b style="font-weight:bold;letter-spacing:-0.05pt;"> </b>to<b style="font-weight:bold;letter-spacing:-0.1pt;"> </b>Our<b style="font-weight:bold;letter-spacing:-0.05pt;"> </b>Business<b style="font-weight:bold;letter-spacing:-0.1pt;"> </b>and<b style="font-weight:bold;letter-spacing:-0.05pt;"> </b>Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.6pt;"> </span>business<span style="letter-spacing:-0.6pt;"> </span>depends<span style="letter-spacing:-0.6pt;"> </span>entirely<span style="letter-spacing:-0.6pt;"> </span>on<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>success<span style="letter-spacing:-0.6pt;"> </span>of our<span style="letter-spacing:-0.6pt;"> </span>product<span style="letter-spacing:-0.6pt;"> </span>candidates,<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>fail<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>successfully<span style="letter-spacing:-0.6pt;"> </span>develop, receive regulatory approval for, or successfully commercialize any or all of<span style="letter-spacing:1.05pt;"> </span>our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not have any products approved for commercial sale. We have invested substantially all of our efforts<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>resources<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.3pt;"> </span>of our<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.3pt;"> </span>each<span style="letter-spacing:-0.3pt;"> </span>of which<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.3pt;"> </span>still<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>clinical development,<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>expect<span style="letter-spacing:-0.55pt;"> </span>that<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>will<span style="letter-spacing:-0.55pt;"> </span>continue<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>invest<span style="letter-spacing:-0.55pt;"> </span>heavily<span style="letter-spacing:-0.55pt;"> </span>in<span style="letter-spacing:-0.55pt;"> </span>these<span style="letter-spacing:-0.55pt;"> </span>product<span style="letter-spacing:-0.55pt;"> </span>candidates<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>any<span style="letter-spacing:-0.6pt;"> </span>future product<span style="letter-spacing:-0.65pt;"> </span>candidates<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>develop.<span style="letter-spacing:-0.65pt;"> </span>Our<span style="letter-spacing:-0.65pt;"> </span>business<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>ability<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>generate<span style="letter-spacing:-0.65pt;"> </span>revenue,<span style="letter-spacing:-0.65pt;"> </span>which<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>do<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>expect will occur for many years, if ever, are substantially dependent on our ability to acquire, develop, obtain regulatory approval for and successfully commercialize our product candidates, which may never occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our product candidates will require substantial additional clinical development time, regulatory approval, </span>commercial<span style="letter-spacing:-0.45pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>arrangements,<span style="letter-spacing:-0.45pt;"> </span>establishment<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>commercial<span style="letter-spacing:-0.45pt;"> </span>organization,<span style="letter-spacing:-0.45pt;"> </span>significant<span style="letter-spacing:-0.45pt;"> </span>marketing efforts<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>further<span style="letter-spacing:-0.15pt;"> </span>investment<span style="letter-spacing:-0.15pt;"> </span>before<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>generate<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>revenue<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>sales.<span style="letter-spacing:-0.15pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>meet<span style="letter-spacing:-0.15pt;"> </span>our timelines for our current or future clinical trials, which may be delayed or not completed for a number of reasons (see &#8220;&#8212;Risks Related to Product Candidate Development and Commercialization&#8212;Clinical development<span style="letter-spacing:-0.7pt;"> </span>is<span style="letter-spacing:-0.65pt;"> </span>lengthy<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>expensive,<span style="letter-spacing:-0.65pt;"> </span>characterized<span style="letter-spacing:-0.65pt;"> </span>by<span style="letter-spacing:-0.65pt;"> </span>uncertain<span style="letter-spacing:-0.65pt;"> </span>outcomes,<span style="letter-spacing:-0.7pt;"> </span>with<span style="letter-spacing:-0.65pt;"> </span>results<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>earlier<span style="letter-spacing:-0.65pt;"> </span>studies<span style="letter-spacing:-0.65pt;"> </span>and trials often failing to predict future trial results. We may incur additional costs or experience delays in completing,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>fail<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>complete,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>commercialization<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>current<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.3pt;"> </span>or any<span style="letter-spacing:-0.4pt;"> </span>future<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.4pt;"> </span>candidates.&#8221;).<span style="letter-spacing:-0.4pt;"> </span>Our<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.4pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.4pt;"> </span>susceptible<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>risks<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>failure<span style="letter-spacing:-0.4pt;"> </span>inherent<span style="letter-spacing:-0.4pt;"> </span>at<span style="letter-spacing:-0.4pt;"> </span>any stage of product development, including the appearance of unexpected AEs or failure to achieve primary endpoints in clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even<span style="letter-spacing:-0.55pt;"> </span>if<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>product<span style="letter-spacing:-0.55pt;"> </span>candidates<span style="letter-spacing:-0.55pt;"> </span>are<span style="letter-spacing:-0.55pt;"> </span>successful<span style="letter-spacing:-0.55pt;"> </span>in<span style="letter-spacing:-0.55pt;"> </span>clinical<span style="letter-spacing:-0.55pt;"> </span>trials,<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>are<span style="letter-spacing:-0.55pt;"> </span>not<span style="letter-spacing:-0.55pt;"> </span>permitted<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>market<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>promote any<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.4pt;"> </span>candidate<span style="letter-spacing:-0.4pt;"> </span>before<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>receive<span style="letter-spacing:-0.4pt;"> </span>regulatory<span style="letter-spacing:-0.4pt;"> </span>approval<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>FDA<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>comparable<span style="letter-spacing:-0.4pt;"> </span>foreign<span style="letter-spacing:-0.4pt;"> </span>regulatory authorities.<span style="letter-spacing:-0.7pt;"> </span>If<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>do<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>receive<span style="letter-spacing:-0.65pt;"> </span>FDA<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>comparable<span style="letter-spacing:-0.7pt;"> </span>foreign<span style="letter-spacing:-0.65pt;"> </span>regulatory<span style="letter-spacing:-0.65pt;"> </span>approval<span style="letter-spacing:-0.65pt;"> </span>with<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>necessary<span style="letter-spacing:-0.65pt;"> </span>conditions to allow commercialization, we will not be able to generate revenue from those product candidates in the U.S. or elsewhere in the foreseeable future, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never submitted a BLA for our product candidates to the FDA, or a similar marketing application to a comparable foreign regulatory authority, and our current or any future product candidates may not be successful in clinical trials or receive regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If approved for marketing by applicable regulatory authorities, our ability to generate revenue from our product<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>depend<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>ability<span style="letter-spacing:-0.1pt;"> </span>to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receive regulatory approval for the targeted patient populations and claims that are necessary or </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">desirable for successful marketing and maintain an acceptable safety profile for the products following </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">price our products competitively such that third-party and government reimbursement permits broad product adoption;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">coverage</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adequate</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">reimbursement;</span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achieve</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">products</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">medical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">community</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrate the superiority of our products compared to the standard of care, as well as other therapies in development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">create market demand for our product candidates through our own marketing and sales activities or any co-promotion or other arrangements that we may otherwise establish;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture product candidates through CMOs in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch and thereafter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish sales and marketing capabilities, whether alone or through a collaboration, to support commercialization</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish and maintain agreements with wholesalers, distributors, pharmacies and group purchasing organizations on commercially reasonable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain, maintain, protect and enforce patent and other intellectual property protection and regulatory </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exclusivity for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain compliance with applicable laws, regulations and guidance including interactions with healthcare professionals, patient advocacy groups and communication of healthcare economic information to payors and formularies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">logistics</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">network</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">capable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">storage</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">within</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">specifications</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and regulatory guidelines, and capable of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely product delivery; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assure that our product will be used as directed and that additional unexpected safety risks will not </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">arise.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any significant delays in obtaining approval for or inability to successfully commercialize our product candidates would adversely affect our business, financial condition, results of<span style="letter-spacing:1.65pt;"> </span>operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">are</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">dependent</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">services</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">senior</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">management</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">scientific</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">personnel,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">if</span><span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:-0.1pt;">we </span>are<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.6pt;"> </span>able<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>retain<span style="letter-spacing:-0.65pt;"> </span>these<span style="letter-spacing:-0.6pt;"> </span>individuals<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>recruit<span style="letter-spacing:-0.65pt;"> </span>additional<span style="letter-spacing:-0.6pt;"> </span>management<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>clinical<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>scientific<span style="letter-spacing:-0.65pt;"> </span>personnel,<span style="letter-spacing:-0.6pt;"> </span>our business will suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our Founder and Chief Executive<span style="letter-spacing:-0.65pt;"> </span>Officer,<span style="letter-spacing:-0.65pt;"> </span>Leon<span style="letter-spacing:-0.65pt;"> </span>O.<span style="letter-spacing:-0.65pt;"> </span>Moulder,<span style="letter-spacing:-0.65pt;"> </span>Jr.<span style="letter-spacing:-0.65pt;"> </span>We<span style="letter-spacing:-0.65pt;"> </span>are<span style="letter-spacing:-0.65pt;"> </span>also<span style="letter-spacing:-0.65pt;"> </span>dependent<span style="letter-spacing:-0.65pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>President<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>Chief<span style="letter-spacing:0.25pt;"> </span>Operating<span style="letter-spacing:-0.65pt;"> </span>Officer, Joseph Farmer, Chief Business Officer and Chief Financial Officer, Jennifer Fox, and Chief Commercial Officer,<span style="letter-spacing:-0.55pt;"> </span>Orlando<span style="letter-spacing:-0.55pt;"> </span>Oliveira<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>other<span style="letter-spacing:-0.55pt;"> </span>members<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>senior<span style="letter-spacing:-0.55pt;"> </span>management<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>clinical<span style="letter-spacing:-0.55pt;"> </span>development<span style="letter-spacing:-0.55pt;"> </span>teams.<span style="letter-spacing:-0.55pt;"> </span>The loss<span style="letter-spacing:-0.35pt;"> </span>of services<span style="letter-spacing:-0.35pt;"> </span>of any<span style="letter-spacing:-0.35pt;"> </span>of these<span style="letter-spacing:-0.35pt;"> </span>individuals<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.35pt;"> </span>delay<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>prevent<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>successful<span style="letter-spacing:-0.35pt;"> </span>development<span style="letter-spacing:-0.35pt;"> </span>of our<span style="letter-spacing:-0.35pt;"> </span>product pipeline,<span style="letter-spacing:-0.3pt;"> </span>initiation<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>completion<span style="letter-spacing:-0.3pt;"> </span>of our<span style="letter-spacing:-0.3pt;"> </span>preclinical<span style="letter-spacing:-0.3pt;"> </span>studies<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>trials<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>commercialization<span style="letter-spacing:-0.3pt;"> </span>of our product candidates, if approved. Although we have executed employment agreements or offer letters with each<span style="letter-spacing:-0.3pt;"> </span>member<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>senior<span style="letter-spacing:-0.3pt;"> </span>management<span style="letter-spacing:-0.3pt;"> </span>team,<span style="letter-spacing:-0.3pt;"> </span>these<span style="letter-spacing:-0.3pt;"> </span>agreements<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.3pt;"> </span>terminable<span style="letter-spacing:-0.3pt;"> </span>at<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>without<span style="letter-spacing:-0.3pt;"> </span>notice and, therefore, we may not be able to retain their services. We do not currently maintain &#8220;key person&#8221;<span style="letter-spacing:-0.05pt;"> </span>life insurance<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>lives<span style="letter-spacing:-0.15pt;"> </span>of our<span style="letter-spacing:-0.15pt;"> </span>executives<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>of our<span style="letter-spacing:-0.15pt;"> </span>employees.<span style="letter-spacing:-0.15pt;"> </span>This<span style="letter-spacing:-0.15pt;"> </span>lack<span style="letter-spacing:-0.15pt;"> </span>of insurance<span style="letter-spacing:-0.15pt;"> </span>means<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>may not have adequate compensation for the loss of the services of these individuals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">will</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">need</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">expand</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">effectively</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">manage</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">managerial,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">operational,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">financial</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">resources </span>in<span style="letter-spacing:1.35pt;"> </span>order<span style="letter-spacing:1.35pt;"> </span>to<span style="letter-spacing:1.35pt;"> </span>successfully<span style="letter-spacing:1.35pt;"> </span>pursue<span style="letter-spacing:1.4pt;"> </span>our<span style="letter-spacing:1.35pt;"> </span>clinical<span style="letter-spacing:1.35pt;"> </span>development<span style="letter-spacing:1.35pt;"> </span>and<span style="letter-spacing:1.35pt;"> </span>commercialization<span style="letter-spacing:1.4pt;"> </span>efforts.<span style="letter-spacing:1.35pt;"> </span>We<span style="letter-spacing:1.35pt;"> </span>may<span style="letter-spacing:1.35pt;"> </span>not<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:-0.25pt;">be</span> successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among biopharmaceutical, biotechnology and other businesses, particularly in the greater Boston area. If we are not able to attract, integrate, retain and motivate personnel </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">necessary to accomplish our business objectives, we may experience constraints that significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business <span style="letter-spacing:-0.1pt;">strategy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.55pt;"> </span>will<span style="letter-spacing:-0.5pt;"> </span>need<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>grow<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>organization,<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>experience<span style="letter-spacing:-0.55pt;"> </span>difficulties<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.55pt;"> </span>managing<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>growth<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>expanding our operations, which could adversely affect our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>commercialization<span style="letter-spacing:-0.45pt;"> </span>plans and strategies develop, and as we transition into operating as a public company, we expect to expand our employee base for managerial, operational, financial and other resources. As our product candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development and regulatory<span style="letter-spacing:-0.05pt;"> </span>capabilities<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>contract<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.05pt;"> </span>parties<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>provide<span style="letter-spacing:-0.05pt;"> </span>manufacturing<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.05pt;"> </span>capabilities<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and<span style="letter-spacing:-0.45pt;"> </span>other<span style="letter-spacing:-0.45pt;"> </span>organizations.<span style="letter-spacing:-0.45pt;"> </span>Our<span style="letter-spacing:-0.45pt;"> </span>ability<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>manage<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>operations<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>future<span style="letter-spacing:-0.45pt;"> </span>growth<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.45pt;"> </span>require<span style="letter-spacing:-0.45pt;"> </span>us<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>continue<span style="letter-spacing:-0.45pt;"> </span>to improve<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>operational,<span style="letter-spacing:-0.25pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>management<span style="letter-spacing:-0.25pt;"> </span>controls,<span style="letter-spacing:-0.25pt;"> </span>reporting<span style="letter-spacing:-0.25pt;"> </span>systems<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>procedures,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>may not be able to implement improvements in an efficient or timely manner or may discover deficiencies in existing systems and controls. Our inability to successfully manage our growth and expand our operations could adversely affect our business, financial condition, results of<span style="letter-spacing:1.8pt;"> </span>operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The manufacturing of our product candidates is complex, and our third-party manufacturers may encounter difficulties in production. If our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or provide commercial supply of<span style="letter-spacing:1.3pt;"> </span>our products, if<span style="letter-spacing:1.3pt;"> </span>approved, could be delayed or halted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>biopharmaceuticals<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>process<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>manufacturing<span style="letter-spacing:-0.2pt;"> </span>biopharmaceuticals<span style="letter-spacing:-0.2pt;"> </span>is complex,<span style="letter-spacing:-0.4pt;"> </span>time consuming,<span style="letter-spacing:-0.4pt;"> </span>highly<span style="letter-spacing:-0.4pt;"> </span>regulated<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>subject<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>multiple<span style="letter-spacing:-0.4pt;"> </span>risks.<span style="letter-spacing:-0.4pt;"> </span>Our<span style="letter-spacing:-0.4pt;"> </span>CMOs<span style="letter-spacing:-0.4pt;"> </span>must<span style="letter-spacing:-0.4pt;"> </span>comply<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.4pt;"> </span>legal requirements, current Good Manufacturing Practices requirements (&#8220;cGMPs&#8221;) and guidelines for the manufacturing<span style="letter-spacing:-0.15pt;"> </span>of biopharmaceuticals<span style="letter-spacing:-0.15pt;"> </span>used<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.15pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>and,<span style="letter-spacing:-0.15pt;"> </span>if approved,<span style="letter-spacing:-0.15pt;"> </span>marketed<span style="letter-spacing:-0.15pt;"> </span>products.<span style="letter-spacing:-0.15pt;"> </span>Our<span style="letter-spacing:-0.15pt;"> </span>CMOs may have limited experience in the manufacturing of cGMP batches of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Manufacturing biopharmaceuticals is highly susceptible to drug product loss due to contamination, equipment failure, improper installation or operation of<span style="letter-spacing:1.4pt;"> </span>equipment, vendor or operator error, inconsistency in<span style="letter-spacing:-0.7pt;"> </span>yields,<span style="letter-spacing:-0.65pt;"> </span>variability<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>characteristics<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>difficulties<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.7pt;"> </span>scaling<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>production<span style="letter-spacing:-0.65pt;"> </span>process.<span style="letter-spacing:-0.65pt;"> </span>The<span style="letter-spacing:-0.65pt;"> </span>impact<span style="letter-spacing:-0.65pt;"> </span>of drug product loss is compounded by the long lead times needed to procure additional drug product due to plant capacity limitations or other restrictions at our CMOs. Even minor deviations from normal manufacturing processes could result in reduced production yields, lot failures, product defects, product liability<span style="letter-spacing:-0.1pt;"> </span>claims,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>supply<span style="letter-spacing:-0.1pt;"> </span>disruptions.<span style="letter-spacing:-0.1pt;"> </span>If<span style="letter-spacing:0.9pt;"> </span>microbial,<span style="letter-spacing:-0.1pt;"> </span>viral<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>contaminations<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>discovered<span style="letter-spacing:-0.1pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>our third-party manufacturers&#8217;<span style="letter-spacing:-0.3pt;"> </span>facilities, such facilities may need to be closed for an extended period of time to investigate<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>remedy<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>contamination,<span style="letter-spacing:-0.45pt;"> </span>which<span style="letter-spacing:-0.45pt;"> </span>could<span style="letter-spacing:-0.45pt;"> </span>delay<span style="letter-spacing:-0.45pt;"> </span>clinical<span style="letter-spacing:-0.45pt;"> </span>trials<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>adversely<span style="letter-spacing:-0.45pt;"> </span>affect<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>business. <span style="letter-spacing:-0.1pt;">Problems</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">third-party</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">manufacturing</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">process</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">facilities</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">restrict</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">ability</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">ensure</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">sufficient</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">clinical </span>material for our clinical trials or delay or prevent us from obtaining marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Scaling up a biopharmaceutical manufacturing process is a difficult and uncertain task and involves <span style="letter-spacing:-0.1pt;">additional</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">risks,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">including</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">cost</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">overruns,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">process</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">scale-up,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">process</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">reproducibility,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">stability</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">issues,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">compliance </span>with<span style="letter-spacing:-0.55pt;"> </span>cGMPs,<span style="letter-spacing:-0.55pt;"> </span>lot<span style="letter-spacing:-0.55pt;"> </span>consistency<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>timely<span style="letter-spacing:-0.55pt;"> </span>availability<span style="letter-spacing:-0.55pt;"> </span>of sufficient<span style="letter-spacing:-0.55pt;"> </span>quantity<span style="letter-spacing:-0.55pt;"> </span>of raw<span style="letter-spacing:-0.55pt;"> </span>materials.<span style="letter-spacing:-0.55pt;"> </span>Even<span style="letter-spacing:-0.55pt;"> </span>if we<span style="letter-spacing:-0.55pt;"> </span>obtain regulatory approval for any of our product candidates, manufacturers may not be able to manufacture the approved<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>specifications<span style="letter-spacing:-0.35pt;"> </span>acceptable<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>FDA<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>other<span style="letter-spacing:-0.35pt;"> </span>comparable<span style="letter-spacing:-0.35pt;"> </span>foreign<span style="letter-spacing:-0.35pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of<span style="letter-spacing:1.7pt;"> </span>the product or to meet potential future demand. If our third-party manufacturers are unable, or decide not, to adequately validate<span style="letter-spacing:-0.7pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>scale-up<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>manufacturing<span style="letter-spacing:-0.65pt;"> </span>process<span style="letter-spacing:-0.65pt;"> </span>at<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>current<span style="letter-spacing:-0.7pt;"> </span>manufacturers&#8217;<span style="letter-spacing:-0.65pt;"> </span>facilities,<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>will<span style="letter-spacing:-0.65pt;"> </span>need<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If our manufacturers are unable to produce sufficient quantities of drug substance and/or drug product for clinical trials<span style="letter-spacing:0.85pt;"> </span>or<span style="letter-spacing:0.9pt;"> </span>for<span style="letter-spacing:0.85pt;"> </span>commercialization<span style="letter-spacing:0.9pt;"> </span>we<span style="letter-spacing:0.85pt;"> </span>will<span style="letter-spacing:0.9pt;"> </span>need<span style="letter-spacing:0.85pt;"> </span>to<span style="letter-spacing:0.9pt;"> </span>identify<span style="letter-spacing:0.85pt;"> </span>and<span style="letter-spacing:0.9pt;"> </span>negotiate<span style="letter-spacing:0.85pt;"> </span>with<span style="letter-spacing:0.9pt;"> </span>other<span style="letter-spacing:0.85pt;"> </span>CMOs<span style="letter-spacing:0.9pt;"> </span>an<span style="letter-spacing:0.85pt;"> </span>agreement<span style="letter-spacing:0.9pt;"> </span><span style="letter-spacing:-0.25pt;">for</span> clinical<span style="letter-spacing:-0.65pt;"> </span>and/or<span style="letter-spacing:-0.65pt;"> </span>commercial<span style="letter-spacing:-0.65pt;"> </span>supply<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>it<span style="letter-spacing:-0.65pt;"> </span>is<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>certain<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>will<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>able<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>come<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>agreement<span style="letter-spacing:-0.65pt;"> </span>timely<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>terms acceptable<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>us,<span style="letter-spacing:-0.65pt;"> </span>which<span style="letter-spacing:-0.65pt;"> </span>would<span style="letter-spacing:-0.65pt;"> </span>likely<span style="letter-spacing:-0.65pt;"> </span>jeopardize<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>ability<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>provide<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidates<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>study<span style="letter-spacing:-0.65pt;"> </span>subjects in clinical trials and products to patients, if<span style="letter-spacing:2pt;"> </span>approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any delay or interruption in clinical trial supplies will likely delay the completion of planned clinical trials,<span style="letter-spacing:-0.1pt;"> </span>increases<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>costs<span style="letter-spacing:-0.1pt;"> </span>associated<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>maintaining<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.1pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>programs<span style="letter-spacing:-0.1pt;"> </span>and,<span style="letter-spacing:-0.1pt;"> </span>depending<span style="letter-spacing:-0.1pt;"> </span>upon<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>period of delay, could require new </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">clinical trials at additional expense or terminate clinical trials completely. Any adverse<span style="letter-spacing:-0.15pt;"> </span>developments<span style="letter-spacing:-0.15pt;"> </span>affecting<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>commercial<span style="letter-spacing:-0.15pt;"> </span>manufacturing<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of<span style="letter-spacing:2pt;"> </span>our product candidates or products. We may also have to take inventory<span style="letter-spacing:2pt;"> </span>write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly,<span style="letter-spacing:-0.45pt;"> </span>failures<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>difficulties<span style="letter-spacing:-0.45pt;"> </span>faced<span style="letter-spacing:-0.45pt;"> </span>at<span style="letter-spacing:-0.45pt;"> </span>any<span style="letter-spacing:-0.45pt;"> </span>level<span style="letter-spacing:-0.45pt;"> </span>of our<span style="letter-spacing:-0.45pt;"> </span>supply<span style="letter-spacing:-0.45pt;"> </span>chain<span style="letter-spacing:-0.45pt;"> </span>could<span style="letter-spacing:-0.45pt;"> </span>adversely<span style="letter-spacing:-0.45pt;"> </span>affect<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>business and<span style="letter-spacing:-0.4pt;"> </span>delay<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>impede<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>commercialization<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>any<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.4pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>products,<span style="letter-spacing:-0.4pt;"> </span>if approved, and could have an adverse effect on our business, financial condition, results of operations and <span style="letter-spacing:-0.1pt;">prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As<span style="letter-spacing:-0.65pt;"> </span>part<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>process<span style="letter-spacing:-0.65pt;"> </span>development<span style="letter-spacing:-0.65pt;"> </span>efforts,<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>also<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>make<span style="letter-spacing:-0.65pt;"> </span>changes<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>manufacturing<span style="letter-spacing:-0.65pt;"> </span>processes<span style="letter-spacing:-0.65pt;"> </span>at various<span style="letter-spacing:-0.5pt;"> </span>points<span style="letter-spacing:-0.5pt;"> </span>during<span style="letter-spacing:-0.5pt;"> </span>development,<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.5pt;"> </span>various<span style="letter-spacing:-0.5pt;"> </span>reasons,<span style="letter-spacing:-0.5pt;"> </span>such<span style="letter-spacing:-0.5pt;"> </span>as<span style="letter-spacing:-0.5pt;"> </span>controlling<span style="letter-spacing:-0.5pt;"> </span>costs,<span style="letter-spacing:-0.5pt;"> </span>achieving<span style="letter-spacing:-0.5pt;"> </span>scale,<span style="letter-spacing:-0.5pt;"> </span>decreasing processing time, increasing manufacturing success rate, proximity to global regions we intend to target or other<span style="letter-spacing:-0.35pt;"> </span>reasons.<span style="letter-spacing:-0.35pt;"> </span>Such<span style="letter-spacing:-0.35pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>not<span style="letter-spacing:-0.35pt;"> </span>achieve<span style="letter-spacing:-0.35pt;"> </span>their<span style="letter-spacing:-0.35pt;"> </span>intended<span style="letter-spacing:-0.35pt;"> </span>objectives,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>these<span style="letter-spacing:-0.35pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.35pt;"> </span>cause our<span style="letter-spacing:-0.5pt;"> </span>current<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>future<span style="letter-spacing:-0.5pt;"> </span>product<span style="letter-spacing:-0.5pt;"> </span>candidates<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>perform<span style="letter-spacing:-0.5pt;"> </span>differently<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>affect<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>results<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>future<span style="letter-spacing:-0.5pt;"> </span>clinical<span style="letter-spacing:-0.5pt;"> </span>trials. In some circumstances, changes in the manufacturing process require us to perform ex vivo comparability studies<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>collect<span style="letter-spacing:-0.35pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>data<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.35pt;"> </span>participants<span style="letter-spacing:-0.35pt;"> </span>prior<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>undertaking<span style="letter-spacing:-0.35pt;"> </span>more<span style="letter-spacing:-0.35pt;"> </span>advanced<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.35pt;"> </span>trials.<span style="letter-spacing:-0.35pt;"> </span>For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a clinical trial to the product used in later clinical phases or later portions of the clinical trial. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.35pt;"> </span>trial<span style="letter-spacing:-0.35pt;"> </span>costs,<span style="letter-spacing:-0.35pt;"> </span>delay<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>jeopardize<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>ability<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>commence sales and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Revenue<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.3pt;"> </span>if approved,<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>limited<span style="letter-spacing:-0.3pt;"> </span>if the<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>does<span style="letter-spacing:-0.3pt;"> </span>not<span style="letter-spacing:-0.3pt;"> </span>achieve<span style="letter-spacing:-0.3pt;"> </span>broad<span style="letter-spacing:-0.3pt;"> </span>market <span style="letter-spacing:-0.1pt;">acceptance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>company,<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>never<span style="letter-spacing:-0.2pt;"> </span>commercialized<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>indication.<span style="letter-spacing:-0.2pt;"> </span>Even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:0.7pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>product candidate is approved by the appropriate regulatory authorities for marketing and sale, it may not gain <span style="letter-spacing:-0.1pt;">acceptance</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">among</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">physicians,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">patients,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">third-party</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">payors</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">others</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">medical</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">community.</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">If</span><span style="letter-spacing:0.9pt;"> </span><span style="letter-spacing:-0.1pt;">any</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">product </span>candidate<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>does<span style="letter-spacing:-0.25pt;"> </span>not<span style="letter-spacing:-0.25pt;"> </span>gain<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.25pt;"> </span>adequate<span style="letter-spacing:-0.25pt;"> </span>level<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>acceptance,<span style="letter-spacing:-0.25pt;"> </span>we may not generate sufficient product revenue or become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The<span style="letter-spacing:-0.05pt;"> </span>degree<span style="letter-spacing:-0.05pt;"> </span>of market<span style="letter-spacing:-0.05pt;"> </span>acceptance<span style="letter-spacing:-0.05pt;"> </span>of any<span style="letter-spacing:-0.05pt;"> </span>of our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.05pt;"> </span>candidates<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.05pt;"> </span>depend<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>number<span style="letter-spacing:-0.05pt;"> </span>of factors, some of<span style="letter-spacing:2pt;"> </span>which are beyond our control, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tolerability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ease</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">administration</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of side effects and AEs associated with our product candidates, and how the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tolerability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">profile</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compares</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">those</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">existing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">emerging </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">indications</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">products</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approved</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approved</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">claims</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make for the products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings contained in the product&#8217;s FDA-approved labeling, including potential limitations or warnings that may be more restrictive than competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution and use restrictions imposed by the FDA with respect to such product candidates or to which we agree as part of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a mandatory REMS or voluntary risk management plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">standard</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">care</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">targeted</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">indications</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.95pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">treatment as</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compared to the clinical benefit in relation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to alternative treatments or </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adequate</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">coverage</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reimbursement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">parties,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">insurance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">companies and other healthcare payors, and by government healthcare programs, including Medicare and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Medicaid;</span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strength</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advantages</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alternative</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">treatments</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">already used or that may later be approved for any of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intended indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">well</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reluctance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">physicians</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">switch</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">their</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">standard</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">care;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reluctance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of patients</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">switch</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">their</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">existing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">therapy</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regardless</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of newer products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">offer</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sale</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strength</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:3.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturer</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supplier</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">about</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">favorable publicity</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">about</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive products;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our efforts to educate the medical community and third-party payors as to the benefits of our product candidates may require significant resources and may never be successful. Even if the medical community accepts that our product candidates are safe and effective for their approved indications, physicians and patients may not be receptive to such product candidates and may be slow to adopt them as an accepted treatment. If<span style="letter-spacing:1.3pt;"> </span>our current or future product candidates are approved, but do not achieve an adequate level of acceptance<span style="letter-spacing:-0.55pt;"> </span>among<span style="letter-spacing:-0.55pt;"> </span>physicians,<span style="letter-spacing:-0.55pt;"> </span>patients<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>third-party<span style="letter-spacing:-0.55pt;"> </span>payors,<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>not<span style="letter-spacing:-0.55pt;"> </span>generate<span style="letter-spacing:-0.55pt;"> </span>meaningful<span style="letter-spacing:-0.55pt;"> </span>revenue<span style="letter-spacing:-0.55pt;"> </span>from our product candidates and may never become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Misconduct or other improper actions, including noncompliance with regulatory standards and requirements, by </span>our<span style="letter-spacing:-0.1pt;"> </span>employees,<span style="letter-spacing:-0.1pt;"> </span>independent<span style="letter-spacing:-0.1pt;"> </span>contractors,<span style="letter-spacing:-0.1pt;"> </span>consultants,<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:-0.1pt;"> </span>partners<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>vendors<span style="letter-spacing:-0.1pt;"> </span>exposes<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>potential noncompliance with regulatory standards and requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial<span style="letter-spacing:-0.4pt;"> </span>partners,<span style="letter-spacing:-0.4pt;"> </span>CROs,<span style="letter-spacing:-0.4pt;"> </span>CMOs<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>vendors<span style="letter-spacing:-0.4pt;"> </span>exposes<span style="letter-spacing:-0.4pt;"> </span>us<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>liability.<span style="letter-spacing:-0.4pt;"> </span>Misconduct<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:-0.4pt;"> </span>these<span style="letter-spacing:-0.4pt;"> </span>parties<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.4pt;"> </span>be intentional, reckless and/or negligent conduct, including failure to comply with FDA or other regulations, provide true, complete and accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we may establish, comply with healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the U.S.,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>potential<span style="letter-spacing:-0.35pt;"> </span>exposure<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.35pt;"> </span>these<span style="letter-spacing:-0.35pt;"> </span>laws<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.35pt;"> </span>increase<span style="letter-spacing:-0.35pt;"> </span>significantly,<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>costs<span style="letter-spacing:-0.35pt;"> </span>associated with compliance. In particular, sales, marketing and business arrangements in the healthcare industry are subject<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>extensive<span style="letter-spacing:-0.4pt;"> </span>laws<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>regulations<span style="letter-spacing:-0.4pt;"> </span>intended<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>prevent<span style="letter-spacing:-0.4pt;"> </span>fraud,<span style="letter-spacing:-0.4pt;"> </span>kickbacks,<span style="letter-spacing:-0.4pt;"> </span>self-dealing<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>other<span style="letter-spacing:-0.4pt;"> </span>abusive practices.<span style="letter-spacing:-0.4pt;"> </span>These<span style="letter-spacing:-0.4pt;"> </span>laws<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>regulations<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.4pt;"> </span>restrict<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>prohibit<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>wide<span style="letter-spacing:-0.4pt;"> </span>range<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>pricing,<span style="letter-spacing:-0.4pt;"> </span>discounting,<span style="letter-spacing:-0.4pt;"> </span>marketing and<span style="letter-spacing:-0.7pt;"> </span>promotion,<span style="letter-spacing:-0.65pt;"> </span>sales<span style="letter-spacing:-0.65pt;"> </span>commission,<span style="letter-spacing:-0.65pt;"> </span>customer<span style="letter-spacing:-0.65pt;"> </span>incentive<span style="letter-spacing:-0.65pt;"> </span>programs<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>other<span style="letter-spacing:-0.7pt;"> </span>business<span style="letter-spacing:-0.65pt;"> </span>arrangements.<span style="letter-spacing:-0.65pt;"> </span>Misconduct could also involve the improper use of information obtained in the course of clinical trials or creation of fraudulent data in preclinical studies or clinical trials, which could result in regulatory sanctions and serious harm<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>reputation.<span style="letter-spacing:-0.15pt;"> </span>Additionally,<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>person<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>allege<span style="letter-spacing:-0.15pt;"> </span>fraud<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>misconduct<span style="letter-spacing:-0.15pt;"> </span>even<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:0.85pt;"> </span>none<span style="letter-spacing:-0.15pt;"> </span>occurred. It<span style="letter-spacing:-0.45pt;"> </span>is<span style="letter-spacing:-0.45pt;"> </span>not<span style="letter-spacing:-0.45pt;"> </span>always<span style="letter-spacing:-0.45pt;"> </span>possible<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>identify<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>deter<span style="letter-spacing:-0.45pt;"> </span>employee<span style="letter-spacing:-0.45pt;"> </span>misconduct,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>precautions<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>take<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>detect<span style="letter-spacing:-0.45pt;"> </span>and prevent<span style="letter-spacing:-0.2pt;"> </span>this<span style="letter-spacing:-0.2pt;"> </span>activity<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>effective<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>controlling<span style="letter-spacing:-0.2pt;"> </span>known<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>unknown<span style="letter-spacing:-0.2pt;"> </span>risks<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>losses<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>protecting<span style="letter-spacing:-0.2pt;"> </span>us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Any such actions instituted against us could have a material and adverse effect on our business,<span style="letter-spacing:-0.7pt;"> </span>financial<span style="letter-spacing:-0.65pt;"> </span>condition,<span style="letter-spacing:-0.65pt;"> </span>results<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>prospects,<span style="letter-spacing:-0.7pt;"> </span>including<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>imposition<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>significant<span style="letter-spacing:-0.7pt;"> </span>civil, criminal or administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>government<span style="letter-spacing:-0.3pt;"> </span>contracting,<span style="letter-spacing:-0.3pt;"> </span>healthcare<span style="letter-spacing:-0.3pt;"> </span>reimbursement<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.3pt;"> </span>government<span style="letter-spacing:-0.3pt;"> </span>programs,<span style="letter-spacing:-0.3pt;"> </span>including Medicare and Medicaid, integrity oversight and reporting obligations, or reputational harm.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our estimates of commercial opportunities for product candidates and forecasts of market growth may<span style="letter-spacing:-0.65pt;"> </span>prove<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.6pt;"> </span>smaller<span style="letter-spacing:-0.65pt;"> </span>than<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>believe,<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>even<span style="letter-spacing:-0.6pt;"> </span>if<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>markets<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>which<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>compete<span style="letter-spacing:-0.65pt;"> </span>achieve<span style="letter-spacing:-0.6pt;"> </span>the forecasted growth, our business may not grow at similar rates, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.7pt;"> </span>intend<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>initially<span style="letter-spacing:-0.65pt;"> </span>focus<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidate<span style="letter-spacing:-0.65pt;"> </span>development<span style="letter-spacing:-0.7pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>treatments<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>various<span style="letter-spacing:-0.65pt;"> </span>I&amp;I<span style="letter-spacing:-0.65pt;"> </span>indications. Our projections of<span style="letter-spacing:1.15pt;"> </span>addressable patient populations within any particular disease state that may benefit from treatment with our product candidates are based on our estimates. Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates.<span style="letter-spacing:-0.4pt;"> </span>Our<span style="letter-spacing:-0.4pt;"> </span>estimates,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.4pt;"> </span>have<span style="letter-spacing:-0.4pt;"> </span>been<span style="letter-spacing:-0.4pt;"> </span>derived<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>variety<span style="letter-spacing:-0.4pt;"> </span>of sources,<span style="letter-spacing:-0.4pt;"> </span>including<span style="letter-spacing:-0.4pt;"> </span>scientific<span style="letter-spacing:-0.4pt;"> </span>literature, surveys<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>clinics,<span style="letter-spacing:-0.45pt;"> </span>patient<span style="letter-spacing:-0.45pt;"> </span>foundations<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>market<span style="letter-spacing:-0.45pt;"> </span>research,<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>prove<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>be<span style="letter-spacing:-0.45pt;"> </span>incorrect<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>general<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>as<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>their applicability<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>company.<span style="letter-spacing:-0.5pt;"> </span>Further,<span style="letter-spacing:-0.5pt;"> </span>new<span style="letter-spacing:-0.5pt;"> </span>studies<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>trials<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>change<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>estimated<span style="letter-spacing:-0.5pt;"> </span>incidence<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>prevalence of<span style="letter-spacing:0.35pt;"> </span>these<span style="letter-spacing:-0.5pt;"> </span>diseases.<span style="letter-spacing:-0.5pt;"> </span>For<span style="letter-spacing:-0.5pt;"> </span>example,<span style="letter-spacing:-0.5pt;"> </span>IgG4-RD<span style="letter-spacing:-0.5pt;"> </span>is<span style="letter-spacing:-0.5pt;"> </span>a<span style="letter-spacing:-0.5pt;"> </span>relatively<span style="letter-spacing:-0.5pt;"> </span>recently<span style="letter-spacing:-0.5pt;"> </span>described<span style="letter-spacing:-0.5pt;"> </span>disease<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.5pt;"> </span>incorporates<span style="letter-spacing:-0.5pt;"> </span>groups<span style="letter-spacing:-0.5pt;"> </span>of manifestations that were diagnosed as separate disease entities prior to 2003. We estimate that the currently diagnosed population of IgG4-RD patients in the U.S. is approximately 20,000, with what we believe to be comparable prevalence rates globally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our commercial opportunity may also be limited<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:-0.5pt;"> </span>future<span style="letter-spacing:-0.5pt;"> </span>competitor<span style="letter-spacing:-0.5pt;"> </span>treatments<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.5pt;"> </span>enter<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>market<span style="letter-spacing:-0.5pt;"> </span>with<span style="letter-spacing:-0.5pt;"> </span>such<span style="letter-spacing:-0.5pt;"> </span>patients.<span style="letter-spacing:-0.5pt;"> </span>If<span style="letter-spacing:0.55pt;"> </span>any<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>estimates<span style="letter-spacing:-0.5pt;"> </span>prove to be inaccurate, the commercial opportunity for any product candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business. Even if we obtain significant market share for our product candidates, because some of<span style="letter-spacing:1.15pt;"> </span>our potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.3pt;"> </span>future<span style="letter-spacing:-0.3pt;"> </span>growth<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>depend,<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>part,<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>ability<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>operate<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>markets,<span style="letter-spacing:-0.3pt;"> </span>where<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.3pt;"> </span>would<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to additional regulatory burdens and other risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets, including in the European Union (&#8220;EU&#8221;), United Kingdom (&#8220;UK&#8221;), Japan<span style="letter-spacing:2pt;"> </span>and China for which we may rely on collaboration with third parties. We are not permitted to market or promote<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.2pt;"> </span>before<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.2pt;"> </span>approval<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>applicable<span style="letter-spacing:-0.2pt;"> </span>regulatory authority in that foreign market, and we may not obtain foreign regulatory approvals on a timely basis, if<span style="letter-spacing:1.1pt;"> </span>at all. To obtain separate regulatory approval in other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates. If we fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our<span style="letter-spacing:-0.4pt;"> </span>ability<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>realize<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>full<span style="letter-spacing:-0.4pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>potential<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.4pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.4pt;"> </span>harmed.<span style="letter-spacing:-0.4pt;"> </span>Failure<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>commercial<span style="letter-spacing:-0.2pt;"> </span>prospects<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>business,<span style="letter-spacing:-0.2pt;"> </span>financial<span style="letter-spacing:-0.2pt;"> </span>condition,<span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of operations and prospects could be adversely affected. Moreover, even if we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to the<span style="letter-spacing:-0.65pt;"> </span>risks<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>uncertainties,<span style="letter-spacing:-0.65pt;"> </span>including<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>burden<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>complying<span style="letter-spacing:-0.65pt;"> </span>with<span style="letter-spacing:-0.65pt;"> </span>complex<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>changing<span style="letter-spacing:-0.65pt;"> </span>foreign<span style="letter-spacing:-0.65pt;"> </span>regulatory, tax,<span style="letter-spacing:-0.25pt;"> </span>accounting<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>legal<span style="letter-spacing:-0.25pt;"> </span>requirements<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>reduced<span style="letter-spacing:-0.25pt;"> </span>protection<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>intellectual<span style="letter-spacing:-0.25pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>foreign <span style="letter-spacing:-0.1pt;">countries.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Strategic<span style="letter-spacing:-0.4pt;"> </span>transactions<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.4pt;"> </span>impact<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>liquidity,<span style="letter-spacing:-0.4pt;"> </span>increase<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>expenses<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>present<span style="letter-spacing:-0.4pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>distractions<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a core part of our strategy, we intend to enter into strategic transactions, which could include acquisitions of companies, asset purchases and in-licensing and out-licensing of intellectual property. For example, we in-licensed the exclusive global rights to develop and commercialize obexelimab, ZB002 and ZB004 from Xencor, and, in August 2023, we entered into a strategic license and collaboration with BMS, pursuant<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>granted<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>exclusive<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>and,<span style="letter-spacing:-0.25pt;"> </span>if approved,<span style="letter-spacing:-0.25pt;"> </span>commercialize<span style="letter-spacing:-0.25pt;"> </span>obexelimab<span style="letter-spacing:-0.25pt;"> </span>in Japan, South Korea, Taiwan, Hong Kong, Singapore and Australia. The expected synergies in development programs,<span style="letter-spacing:-0.7pt;"> </span>pipelines<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>other<span style="letter-spacing:-0.65pt;"> </span>areas<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.35pt;"> </span>focus<span style="letter-spacing:-0.7pt;"> </span>between<span style="letter-spacing:-0.65pt;"> </span>Zenas,<span style="letter-spacing:-0.65pt;"> </span>Xencor<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>BMS<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.7pt;"> </span>realized<span style="letter-spacing:-0.65pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>timely basis or at all, and there may be risks associated with the acquisition that we did not previously anticipate, such as unanticipated liabilities.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.5pt;"> </span>also<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>enter<span style="letter-spacing:-0.5pt;"> </span>into<span style="letter-spacing:-0.5pt;"> </span>a<span style="letter-spacing:-0.5pt;"> </span>variety<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>other<span style="letter-spacing:-0.5pt;"> </span>business<span style="letter-spacing:-0.5pt;"> </span>arrangements,<span style="letter-spacing:-0.5pt;"> </span>including<span style="letter-spacing:-0.5pt;"> </span>strategic<span style="letter-spacing:-0.5pt;"> </span>collaborations,<span style="letter-spacing:-0.5pt;"> </span>joint ventures, restructurings, divestitures, business combinations and investments. Any future transactions could increase<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>near<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>long-term<span style="letter-spacing:-0.25pt;"> </span>expenditures,<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>potentially<span style="letter-spacing:-0.25pt;"> </span>dilutive<span style="letter-spacing:-0.25pt;"> </span>issuances<span style="letter-spacing:-0.25pt;"> </span>of our<span style="letter-spacing:-0.25pt;"> </span>equity<span style="letter-spacing:-0.25pt;"> </span>securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired in-process research and development expenses, any of which could affect our business, financial condition, liquidity and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future acquisitions may require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of our management. In addition, the integration of any business or assets may be disruptive, complex, risky and costly and we may never realize the full benefits of<span style="letter-spacing:1.35pt;"> </span>the acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>future<span style="letter-spacing:-0.5pt;"> </span>changes<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>tax<span style="letter-spacing:-0.5pt;"> </span>laws<span style="letter-spacing:-0.45pt;"> </span>could<span style="letter-spacing:-0.45pt;"> </span>adversely<span style="letter-spacing:-0.5pt;"> </span>affect<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">tax</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">regimes</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">are</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">subject</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">operate</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">under,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">including</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">respect</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">income</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">non-income </span>taxes, are unsettled and may be subject to significant change. Changes in tax laws, regulations, or rulings, or changes in interpretations of<span style="letter-spacing:2pt;"> </span>existing laws and regulations, could adversely affect our company. For example,<span style="letter-spacing:2pt;"> </span>the Tax Cuts and Jobs Act, the Coronavirus Aid, Relief, and Economic Security Act, and the Inflation Reduction<span style="letter-spacing:1.4pt;"> </span>Act<span style="letter-spacing:1.4pt;"> </span>of<span style="letter-spacing:2pt;"> </span>2022<span style="letter-spacing:1.4pt;"> </span>(the<span style="letter-spacing:1.4pt;"> </span>&#8220;IRA&#8221;)<span style="letter-spacing:1.4pt;"> </span>enacted<span style="letter-spacing:1.4pt;"> </span>many<span style="letter-spacing:1.4pt;"> </span>significant<span style="letter-spacing:1.4pt;"> </span>changes<span style="letter-spacing:1.4pt;"> </span>to<span style="letter-spacing:1.4pt;"> </span>the<span style="letter-spacing:1.4pt;"> </span>U.S.<span style="letter-spacing:1.4pt;"> </span>tax<span style="letter-spacing:1.4pt;"> </span>laws.<span style="letter-spacing:1.4pt;"> </span>Future<span style="letter-spacing:1.4pt;"> </span>guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain<span style="letter-spacing:-0.7pt;"> </span>aspects<span style="letter-spacing:-0.7pt;"> </span>thereof<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.7pt;"> </span>be<span style="letter-spacing:-0.7pt;"> </span>repealed<span style="letter-spacing:-0.7pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>modified<span style="letter-spacing:-0.7pt;"> </span>in<span style="letter-spacing:-0.7pt;"> </span>future<span style="letter-spacing:-0.7pt;"> </span>legislation.<span style="letter-spacing:-0.65pt;"> </span>For<span style="letter-spacing:-0.7pt;"> </span>example,<span style="letter-spacing:-0.7pt;"> </span>the<span style="letter-spacing:-0.7pt;"> </span>IRA<span style="letter-spacing:-0.65pt;"> </span>includes provisions that will impact the U.S. federal income taxation of<span style="letter-spacing:2pt;"> </span>certain corporations, including imposing a 15% minimum tax on the book income of<span style="letter-spacing:2pt;"> </span>certain large corporations and a 1% excise tax on certain corporate stock repurchases<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.5pt;"> </span>would<span style="letter-spacing:-0.5pt;"> </span>be<span style="letter-spacing:-0.5pt;"> </span>imposed<span style="letter-spacing:-0.5pt;"> </span>on<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>corporation<span style="letter-spacing:-0.5pt;"> </span>repurchasing<span style="letter-spacing:-0.5pt;"> </span>such<span style="letter-spacing:-0.5pt;"> </span>stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our internal information technology systems, or those used by our CROs, CMOs, clinical sites or other contractors or consultants, are or were compromised, become unavailable or suffer security incidents, loss or leakage of data or other disruptions, we could suffer material adverse consequences, including operational or service interruption, harm to our reputation, litigation, fines, penalties, compromise of sensitive information related our business and other adverse consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">ordinary</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">course</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">business,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">we,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">third</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">parties</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">upon</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">which</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">rely,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">process</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">sensitive</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">data </span>and as a result, we and the third parties upon which we rely face a variety of evolving threats which could cause security incidents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our internal information technology systems and those of our CROs, CMOs, clinical sites and other contractors<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>consultants<span style="letter-spacing:-0.55pt;"> </span>are<span style="letter-spacing:-0.55pt;"> </span>vulnerable<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>cyberattacks,<span style="letter-spacing:-0.55pt;"> </span>computer<span style="letter-spacing:-0.55pt;"> </span>viruses,<span style="letter-spacing:-0.55pt;"> </span>bugs,<span style="letter-spacing:-0.55pt;"> </span>worms,<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>other<span style="letter-spacing:-0.55pt;"> </span>malicious codes,<span style="letter-spacing:-0.25pt;"> </span>malware<span style="letter-spacing:-0.25pt;"> </span>(including<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>advanced<span style="letter-spacing:-0.25pt;"> </span>persistent<span style="letter-spacing:-0.25pt;"> </span>threat<span style="letter-spacing:-0.25pt;"> </span>intrusions)<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>attacks<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.25pt;"> </span>computer <span style="letter-spacing:-0.1pt;">hackers, cracking, application security attacks, social engineering (including through phishing attacks), supply </span>chain<span style="letter-spacing:-0.05pt;"> </span>attacks<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>vulnerabilities<span style="letter-spacing:-0.05pt;"> </span>through<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>third-party<span style="letter-spacing:-0.05pt;"> </span>service<span style="letter-spacing:-0.05pt;"> </span>providers,<span style="letter-spacing:-0.05pt;"> </span>denial-of-service<span style="letter-spacing:-0.05pt;"> </span>attacks<span style="letter-spacing:-0.05pt;"> </span>(such<span style="letter-spacing:-0.05pt;"> </span>as <span style="letter-spacing:-0.1pt;">credential stuffing), credential harvesting, personnel misconduct or error, supply-chain attacks, software bugs, server</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">malfunctions,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">software</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">hardware</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">failures,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">loss</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:-0.1pt;">data</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">information</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">technology</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">assets,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">adware, </span>telecommunications failures, earthquakes, fires, floods and other similar threats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Such</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">threats</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">are</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">prevalent</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">continue</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">rise,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">are</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">increasingly</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">difficult</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">detect</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">come</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">variety </span>of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states and nation-state-supported actors.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:-0.35pt;"> </span>particular,<span style="letter-spacing:-0.35pt;"> </span>ransomware<span style="letter-spacing:-0.35pt;"> </span>attacks,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>those<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.35pt;"> </span>organized<span style="letter-spacing:-0.35pt;"> </span>criminal<span style="letter-spacing:-0.35pt;"> </span>threat<span style="letter-spacing:-0.35pt;"> </span>actors,<span style="letter-spacing:-0.35pt;"> </span>nation-states and<span style="letter-spacing:-0.25pt;"> </span>nation-state<span style="letter-spacing:-0.25pt;"> </span>supported<span style="letter-spacing:-0.25pt;"> </span>actors,<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>becoming<span style="letter-spacing:-0.25pt;"> </span>increasingly<span style="letter-spacing:-0.25pt;"> </span>prevalent<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>severe<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.25pt;"> </span>lead<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>significant interruptions, delays, or outages in our operations, loss of data (including sensitive customer information), loss of income, significant extra expenses to restore data or systems, reputational loss and the diversion of funds. To alleviate the negative impact of a ransomware attack, it may be preferable to make extortion <span style="letter-spacing:-0.1pt;">payments,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">but</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">unwilling</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">unable</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">do</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">so</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">(including,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">example,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">if</span><span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:-0.1pt;">applicable</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">laws</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">regulations </span>prohibit such payments, or our insurance carrier objects to payment).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Some actors, including nation-state actors, also engage in cyber-attacks for geopolitical reasons and in conjunction<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>military<span style="letter-spacing:-0.15pt;"> </span>conflicts<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>defense<span style="letter-spacing:-0.15pt;"> </span>activities.<span style="letter-spacing:-0.15pt;"> </span>During<span style="letter-spacing:-0.15pt;"> </span>times<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>war<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>major<span style="letter-spacing:-0.15pt;"> </span>conflicts,<span style="letter-spacing:-0.15pt;"> </span>we and<span style="letter-spacing:1.35pt;"> </span>the<span style="letter-spacing:1.35pt;"> </span>third<span style="letter-spacing:1.35pt;"> </span>parties<span style="letter-spacing:1.35pt;"> </span>upon<span style="letter-spacing:1.35pt;"> </span>which<span style="letter-spacing:1.35pt;"> </span>we<span style="letter-spacing:1.35pt;"> </span>rely<span style="letter-spacing:1.35pt;"> </span>are<span style="letter-spacing:1.35pt;"> </span>vulnerable<span style="letter-spacing:1.35pt;"> </span>to<span style="letter-spacing:1.35pt;"> </span>a<span style="letter-spacing:1.35pt;"> </span>heightened<span style="letter-spacing:1.35pt;"> </span>risk<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:2pt;"> </span>these<span style="letter-spacing:1.35pt;"> </span>attacks,<span style="letter-spacing:1.35pt;"> </span>including retaliatory<span style="letter-spacing:-0.45pt;"> </span>cyber-attacks,<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.45pt;"> </span>could<span style="letter-spacing:-0.45pt;"> </span>materially<span style="letter-spacing:-0.45pt;"> </span>disrupt<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>systems<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>operations,<span style="letter-spacing:-0.45pt;"> </span>supply<span style="letter-spacing:-0.45pt;"> </span>chain<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>ability<span style="letter-spacing:-0.45pt;"> </span>to conduct our development activities, including clinical trials. In addition to experiencing a security incident, third parties may gather, collect or infer sensitive information </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">about us from public sources, data brokers or other<span style="letter-spacing:-0.2pt;"> </span>means<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>reveals<span style="letter-spacing:-0.15pt;"> </span>competitively<span style="letter-spacing:-0.2pt;"> </span>sensitive<span style="letter-spacing:-0.15pt;"> </span>details<span style="letter-spacing:-0.2pt;"> </span>about<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>organization<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>used<span style="letter-spacing:-0.15pt;"> </span>against<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.25pt;">us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, remote work increases risks to our information technology systems and data, as more of <span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">employees</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">utilize</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">network</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">connections,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">computers</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">devices</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">outside</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">premises</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">network,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">including </span>working at home, while in transit and in public locations. We may be vulnerable to attacks as a result of vulnerabilities<span style="letter-spacing:-0.4pt;"> </span>introduced<span style="letter-spacing:-0.4pt;"> </span>through<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>supply<span style="letter-spacing:-0.4pt;"> </span>chain,<span style="letter-spacing:-0.4pt;"> </span>including<span style="letter-spacing:-0.4pt;"> </span>vendors<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>engage<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>provide<span style="letter-spacing:-0.4pt;"> </span>us<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.4pt;"> </span>security and other technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities present in acquired or integrated entities&#8217; systems and technologies, including security issues that are not identified during due diligence. Additionally, it may be difficult to integrate companies into our information technology environment and security program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to detect and remediate all vulnerabilities and the threats and techniques used to exploit<span style="letter-spacing:-0.45pt;"> </span>such<span style="letter-spacing:-0.45pt;"> </span>vulnerabilities<span style="letter-spacing:-0.45pt;"> </span>change<span style="letter-spacing:-0.45pt;"> </span>frequently<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.45pt;"> </span>often<span style="letter-spacing:-0.45pt;"> </span>sophisticated<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>nature.<span style="letter-spacing:-0.45pt;"> </span>Therefore,<span style="letter-spacing:-0.45pt;"> </span>vulnerabilities could be exploited but may not be detected until after a security incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified <span style="letter-spacing:-0.1pt;">vulnerabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including cloud-based infrastructure, encryption and authentication<span style="letter-spacing:1.3pt;"> </span>technology,<span style="letter-spacing:1.3pt;"> </span>employee<span style="letter-spacing:1.3pt;"> </span>email<span style="letter-spacing:1.3pt;"> </span>and<span style="letter-spacing:1.3pt;"> </span>other<span style="letter-spacing:1.3pt;"> </span>functions.<span style="letter-spacing:1.3pt;"> </span>We<span style="letter-spacing:1.3pt;"> </span>also<span style="letter-spacing:1.3pt;"> </span>rely<span style="letter-spacing:1.3pt;"> </span>on<span style="letter-spacing:1.3pt;"> </span>third-party<span style="letter-spacing:1.3pt;"> </span>service<span style="letter-spacing:1.3pt;"> </span>providers to assist with our clinical trials, provide other products or services or otherwise to operate our business. Our <span style="letter-spacing:-0.1pt;">ability</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">perform</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">diligence</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">monitor</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">third</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">parties&#8217;</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">information</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">security</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">practices</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">is</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">limited,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">third parties</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">adequate</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">information</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">security</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">measures</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">place.</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">If</span><span style="letter-spacing:0.55pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">third-party</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">service</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">providers </span>experience a security incident or other interruption, we could experience adverse consequences. While we may<span style="letter-spacing:2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>entitled<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>damages<span style="letter-spacing:-0.2pt;"> </span>if our<span style="letter-spacing:-0.2pt;"> </span>third-party<span style="letter-spacing:-0.2pt;"> </span>service<span style="letter-spacing:-0.2pt;"> </span>providers<span style="letter-spacing:-0.2pt;"> </span>fail<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>satisfy<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:-0.2pt;"> </span>privacy<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such <span style="letter-spacing:-0.1pt;">award.</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">If</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">information</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">technology</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">systems</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">CROs,</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">CMOs,</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">sites</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">contractors</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">and consultants</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">become</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">subject</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">disruptions</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">security</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">incidents,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">insufficient</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">recourse</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">against </span>such<span style="letter-spacing:1.3pt;"> </span>third<span style="letter-spacing:1.3pt;"> </span>parties<span style="letter-spacing:1.3pt;"> </span>and<span style="letter-spacing:1.3pt;"> </span>we<span style="letter-spacing:1.3pt;"> </span>may<span style="letter-spacing:1.3pt;"> </span>have<span style="letter-spacing:1.3pt;"> </span>to<span style="letter-spacing:1.3pt;"> </span>expend<span style="letter-spacing:1.3pt;"> </span>significant<span style="letter-spacing:1.3pt;"> </span>resources<span style="letter-spacing:1.3pt;"> </span>to<span style="letter-spacing:1.3pt;"> </span>mitigate<span style="letter-spacing:1.3pt;"> </span>the<span style="letter-spacing:1.3pt;"> </span>impact<span style="letter-spacing:1.3pt;"> </span>of<span style="letter-spacing:2pt;"> </span>such<span style="letter-spacing:1.3pt;"> </span>an<span style="letter-spacing:1.3pt;"> </span>event, and to develop and implement protections to prevent future events of<span style="letter-spacing:2pt;"> </span>this nature from occurring. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure<span style="letter-spacing:1.8pt;"> </span>in<span style="letter-spacing:1.8pt;"> </span>our<span style="letter-spacing:1.8pt;"> </span>supply<span style="letter-spacing:1.8pt;"> </span>chain<span style="letter-spacing:1.8pt;"> </span>or<span style="letter-spacing:1.8pt;"> </span>our<span style="letter-spacing:1.8pt;"> </span>third-party<span style="letter-spacing:1.8pt;"> </span>partners&#8217;<span style="letter-spacing:1.1pt;"> </span>supply<span style="letter-spacing:1.8pt;"> </span>chains<span style="letter-spacing:1.8pt;"> </span>have<span style="letter-spacing:1.8pt;"> </span>not<span style="letter-spacing:1.8pt;"> </span>been<span style="letter-spacing:1.8pt;"> </span>compromised<span style="letter-spacing:1.8pt;"> </span>or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information<span style="letter-spacing:2pt;"> </span>technology<span style="letter-spacing:2pt;"> </span>systems<span style="letter-spacing:2pt;"> </span>(including<span style="letter-spacing:2pt;"> </span>our<span style="letter-spacing:2pt;"> </span>services)<span style="letter-spacing:2pt;"> </span>or<span style="letter-spacing:2pt;"> </span>the<span style="letter-spacing:2pt;"> </span>third-party<span style="letter-spacing:2pt;"> </span>information<span style="letter-spacing:2pt;"> </span>technology<span style="letter-spacing:2pt;"> </span>systems that support us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A<span style="letter-spacing:-0.4pt;"> </span>security<span style="letter-spacing:-0.4pt;"> </span>incident<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>other<span style="letter-spacing:-0.4pt;"> </span>interruption<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.4pt;"> </span>result<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>unauthorized,<span style="letter-spacing:-0.4pt;"> </span>unlawful<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>accidental<span style="letter-spacing:-0.4pt;"> </span>acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information<span style="letter-spacing:-0.35pt;"> </span>technology<span style="letter-spacing:-0.35pt;"> </span>systems,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>those<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>third<span style="letter-spacing:-0.35pt;"> </span>parties<span style="letter-spacing:-0.35pt;"> </span>upon<span style="letter-spacing:-0.35pt;"> </span>whom<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>rely,<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>which<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.35pt;"> </span>disrupt our ability (and that of third parties upon whom we rely) to advance clinical development or commercial activities<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>any<span style="letter-spacing:-0.5pt;"> </span>products,<span style="letter-spacing:-0.55pt;"> </span>if<span style="letter-spacing:0.4pt;"> </span>approved.<span style="letter-spacing:-0.5pt;"> </span>For<span style="letter-spacing:-0.55pt;"> </span>example,<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>loss<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>clinical<span style="letter-spacing:-0.5pt;"> </span>trial<span style="letter-spacing:-0.55pt;"> </span>data<span style="letter-spacing:-0.5pt;"> </span>from<span style="letter-spacing:-0.55pt;"> </span>completed<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>ongoing <span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">trials</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">result</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">delays</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">regulatory</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">approval</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">efforts,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">significantly</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">increase</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">costs</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">recover </span>or reproduce the data or limit our ability to effectively execute a product recall, if required. In addition, we could incur liability if any disruption or security incident results in the loss of or damage to our data or applications,<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>inappropriate<span style="letter-spacing:-0.5pt;"> </span>disclosure<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>personal,<span style="letter-spacing:-0.5pt;"> </span>confidential<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>proprietary<span style="letter-spacing:-0.5pt;"> </span>information.<span style="letter-spacing:-0.5pt;"> </span>Applicable<span style="letter-spacing:-0.5pt;"> </span>data privacy<span style="letter-spacing:-0.7pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>security<span style="letter-spacing:-0.65pt;"> </span>obligations<span style="letter-spacing:-0.65pt;"> </span>also<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>require<span style="letter-spacing:-0.65pt;"> </span>us<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.7pt;"> </span>notify<span style="letter-spacing:-0.65pt;"> </span>relevant<span style="letter-spacing:-0.65pt;"> </span>stakeholders<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.35pt;"> </span>security<span style="letter-spacing:-0.65pt;"> </span>incidents.<span style="letter-spacing:-0.7pt;"> </span>Such disclosures<span style="letter-spacing:-0.7pt;"> </span>are<span style="letter-spacing:-0.65pt;"> </span>costly,<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>disclosure<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>failure<span style="letter-spacing:-0.7pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>comply<span style="letter-spacing:-0.65pt;"> </span>with<span style="letter-spacing:-0.65pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>requirements<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>lead<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.7pt;"> </span>adverse consequences.<span style="letter-spacing:-0.1pt;"> </span>Any<span style="letter-spacing:-0.1pt;"> </span>disruption<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>security<span style="letter-spacing:-0.1pt;"> </span>incident<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>legal<span style="letter-spacing:-0.1pt;"> </span>claims<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>proceedings,<span style="letter-spacing:-0.1pt;"> </span>liability<span style="letter-spacing:-0.1pt;"> </span>under laws that protect the privacy of personal information and significant regulatory penalties, damage to our reputation<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>a<span style="letter-spacing:-0.5pt;"> </span>loss<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>confidence<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.5pt;"> </span>us<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>ability<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>conduct<span style="letter-spacing:-0.5pt;"> </span>clinical<span style="letter-spacing:-0.5pt;"> </span>trials,<span style="letter-spacing:-0.5pt;"> </span>which<span style="letter-spacing:-0.5pt;"> </span>could<span style="letter-spacing:-0.5pt;"> </span>delay<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>clinical development<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates.<span style="letter-spacing:-0.15pt;"> </span>Although<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>obtained<span style="letter-spacing:-0.15pt;"> </span>cyber<span style="letter-spacing:-0.15pt;"> </span>insurance,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>cannot<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>sure<span style="letter-spacing:-0.2pt;"> that</span> our<span style="letter-spacing:-0.4pt;"> </span>insurance<span style="letter-spacing:-0.4pt;"> </span>coverage<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.4pt;"> </span>adequate<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>sufficient<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>protect<span style="letter-spacing:-0.4pt;"> </span>us<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>mitigate<span style="letter-spacing:-0.4pt;"> </span>liabilities<span style="letter-spacing:-0.4pt;"> </span>arising<span style="letter-spacing:-0.4pt;"> </span>out<span style="letter-spacing:-0.4pt;"> </span>of a<span style="letter-spacing:-0.55pt;"> </span>cybersecurity<span style="letter-spacing:-0.55pt;"> </span>incident<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>that<span style="letter-spacing:-0.55pt;"> </span>such<span style="letter-spacing:-0.55pt;"> </span>coverage<span style="letter-spacing:-0.55pt;"> </span>will<span style="letter-spacing:-0.55pt;"> </span>continue<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>be<span style="letter-spacing:-0.55pt;"> </span>available<span style="letter-spacing:-0.55pt;"> </span>on<span style="letter-spacing:-0.55pt;"> </span>commercially<span style="letter-spacing:-0.55pt;"> </span>reasonable<span style="letter-spacing:-0.55pt;"> </span>terms in the future.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.55pt;"> </span>business<span style="letter-spacing:-0.55pt;"> </span>entails<span style="letter-spacing:-0.55pt;"> </span>a<span style="letter-spacing:-0.55pt;"> </span>significant<span style="letter-spacing:-0.55pt;"> </span>risk<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>product<span style="letter-spacing:-0.55pt;"> </span>liability<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>ability<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>obtain<span style="letter-spacing:-0.55pt;"> </span>sufficient<span style="letter-spacing:-0.55pt;"> </span>insurance<span style="letter-spacing:-0.55pt;"> </span>coverage could adversely affect our business, financial condition, results of<span style="letter-spacing:1.05pt;"> </span>operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As we conduct clinical trials of our current or future product candidates, we are exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of new therapies. Product liability claims could delay or prevent completion of our development programs. If we succeed in obtaining approval to market any product candidate, product liability claims could result in FDA or other investigation of the safety and effectiveness of our future product candidates, our manufacturing processes and<span style="letter-spacing:-0.35pt;"> </span>facilities<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>programs<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>potentially<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>recall<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>more<span style="letter-spacing:-0.35pt;"> </span>serious<span style="letter-spacing:-0.35pt;"> </span>enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals.<span style="letter-spacing:-0.6pt;"> </span>Regardless<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>merits<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>eventual<span style="letter-spacing:-0.6pt;"> </span>outcome,<span style="letter-spacing:-0.6pt;"> </span>liability<span style="letter-spacing:-0.6pt;"> </span>claims<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>also<span style="letter-spacing:-0.6pt;"> </span>result<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>decreased<span style="letter-spacing:-0.6pt;"> </span>demand for our product candidates, termination of clinical trial sites or entire trial programs, withdrawal of clinical trial participants or inability to enroll participants, injury to our reputation and significant negative media attention,<span style="letter-spacing:-0.7pt;"> </span>significant<span style="letter-spacing:-0.65pt;"> </span>costs<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>defend<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>related<span style="letter-spacing:-0.65pt;"> </span>litigation,<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.7pt;"> </span>diversion<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>management&#8217;s<span style="letter-spacing:-0.65pt;"> </span>time<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>resources from our business operations, substantial monetary awards to trial participants or patients, loss of revenue, the inability to commercialize and products that we may develop, and a decline in our stock price. We may require<span style="letter-spacing:-0.7pt;"> </span>higher<span style="letter-spacing:-0.65pt;"> </span>levels<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>liability<span style="letter-spacing:-0.65pt;"> </span>insurance<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>later<span style="letter-spacing:-0.7pt;"> </span>stages<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>clinical<span style="letter-spacing:-0.7pt;"> </span>development<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>marketing<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>of our product candidates, and our insurance may not provide sufficient coverage against potential liabilities. Furthermore,<span style="letter-spacing:-0.4pt;"> </span>clinical<span style="letter-spacing:-0.4pt;"> </span>trial<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.4pt;"> </span>liability<span style="letter-spacing:-0.4pt;"> </span>insurance<span style="letter-spacing:-0.4pt;"> </span>is<span style="letter-spacing:-0.4pt;"> </span>becoming<span style="letter-spacing:-0.4pt;"> </span>increasingly<span style="letter-spacing:-0.4pt;"> </span>expensive.<span style="letter-spacing:-0.4pt;"> </span>As<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>result,<span style="letter-spacing:-0.4pt;"> </span>we may<span style="letter-spacing:-0.6pt;"> </span>be<span style="letter-spacing:-0.6pt;"> </span>unable<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>obtain<span style="letter-spacing:-0.6pt;"> </span>sufficient<span style="letter-spacing:-0.6pt;"> </span>insurance<span style="letter-spacing:-0.6pt;"> </span>at<span style="letter-spacing:-0.6pt;"> </span>a<span style="letter-spacing:-0.6pt;"> </span>reasonable<span style="letter-spacing:-0.6pt;"> </span>cost<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>protect<span style="letter-spacing:-0.6pt;"> </span>us<span style="letter-spacing:-0.6pt;"> </span>against<span style="letter-spacing:-0.6pt;"> </span>losses<span style="letter-spacing:-0.6pt;"> </span>caused<span style="letter-spacing:-0.6pt;"> </span>by<span style="letter-spacing:-0.6pt;"> </span>product <span style="letter-spacing:-0.1pt;">liability</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">claims</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">that</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">adversely</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">affect</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">business,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">financial</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">condition,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">results</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:-0.1pt;">operations</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Public opinion and scrutiny of I&amp;I treatments may impact public perception of our company and product candidates, or may adversely affect our ability to conduct our business and our business plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Public perception may be influenced by claims, such as claims that our product candidates are unsafe, unethical or immoral and, consequently, our approach may not gain the acceptance of the public or the medical<span style="letter-spacing:-0.4pt;"> </span>community.<span style="letter-spacing:-0.4pt;"> </span>Negative<span style="letter-spacing:-0.4pt;"> </span>public<span style="letter-spacing:-0.4pt;"> </span>reaction<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>I&amp;I<span style="letter-spacing:-0.4pt;"> </span>treatments<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>general<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.4pt;"> </span>result<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>greater<span style="letter-spacing:-0.4pt;"> </span>government regulation and stricter labeling requirements of products to treat immunological diseases, including any of our<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.4pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>if<span style="letter-spacing:0.65pt;"> </span>approved,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.4pt;"> </span>cause<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>decrease<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>demand<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.4pt;"> </span>any<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.4pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>we <span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">develop.</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">Moreover,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">success</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">will</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">depend</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">upon</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">physicians</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">specializing</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">treatment</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">those</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">diseases </span>that our product candidates target prescribing, and their patients being willing to receive, treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. AEs in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in withdrawal of clinical trial participants or impact our ability to enroll participants or lead to increased governmental regulation,<span style="letter-spacing:-0.65pt;"> </span>unfavorable<span style="letter-spacing:-0.65pt;"> </span>public<span style="letter-spacing:-0.65pt;"> </span>perception,<span style="letter-spacing:-0.65pt;"> </span>potential<span style="letter-spacing:-0.65pt;"> </span>regulatory<span style="letter-spacing:-0.65pt;"> </span>delays<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>testing<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>approval<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates.<span style="letter-spacing:-0.3pt;"> </span>More<span style="letter-spacing:-0.3pt;"> </span>restrictive<span style="letter-spacing:-0.3pt;"> </span>government<span style="letter-spacing:-0.3pt;"> </span>regulations<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>negative<span style="letter-spacing:-0.3pt;"> </span>public<span style="letter-spacing:-0.3pt;"> </span>opinion could<span style="letter-spacing:-0.7pt;"> </span>have<span style="letter-spacing:-0.65pt;"> </span>an<span style="letter-spacing:-0.65pt;"> </span>adverse<span style="letter-spacing:-0.65pt;"> </span>effect<span style="letter-spacing:-0.65pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>business,<span style="letter-spacing:-0.65pt;"> </span>financial<span style="letter-spacing:-0.7pt;"> </span>condition,<span style="letter-spacing:-0.65pt;"> </span>results<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>operations<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>prospects,<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>may delay or impair the development and, if approved, commercialization of our product candidates or demand for any products we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Risks<i style="letter-spacing:-0.5pt;"> </i>Related<i style="letter-spacing:-0.45pt;"> </i>to<i style="letter-spacing:-0.45pt;"> </i>Our<i style="letter-spacing:-0.45pt;"> </i>Intellectual<i style="letter-spacing:-0.45pt;"> </i>Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.45pt;"> </span>unable<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>obtain<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>maintain<span style="letter-spacing:-0.45pt;"> </span>sufficient<span style="letter-spacing:-0.45pt;"> </span>intellectual<span style="letter-spacing:-0.45pt;"> </span>property<span style="letter-spacing:-0.45pt;"> </span>protection<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>product<span style="letter-spacing:-0.45pt;"> </span>candidates<span style="letter-spacing:-0.45pt;"> </span>or any<span style="letter-spacing:-0.35pt;"> </span>future<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>develop,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>if the<span style="letter-spacing:-0.35pt;"> </span>scope<span style="letter-spacing:-0.35pt;"> </span>of the<span style="letter-spacing:-0.35pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>obtained<span style="letter-spacing:-0.35pt;"> </span>is <span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">sufficiently</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">broad,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">competitors</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">third</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">parties</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">develop</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">commercialize</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">products</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">similar</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or </span>identical to ours, and our ability to successfully develop and commercialize our product candidates may be adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely upon a combination of patents, know-how and confidentiality agreements to protect the intellectual property related to our product candidates and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries for our product candidates and their uses, as well as our ability to operate without infringing, misappropriating or otherwise violating the proprietary rights of others. We seek to protect our proprietary<span style="letter-spacing:-0.1pt;"> </span>position<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>filing<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>licensing<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.1pt;"> </span>applications<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>U.S.<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>abroad<span style="letter-spacing:-0.1pt;"> </span>related<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our novel<span style="letter-spacing:-0.25pt;"> </span>discoveries<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>technologies<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>important<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>business.<span style="letter-spacing:-0.25pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>in-license<span style="letter-spacing:-0.25pt;"> </span>issued<span style="letter-spacing:-0.25pt;"> </span>patents, we do not own any issued patents and our pending and future patent applications may not result in patents being issued. Issued patents may not afford sufficient protection of<span style="letter-spacing:1.1pt;"> </span>our product candidates or their intended uses against competitors, and the patents issued may be infringed, designed around, invalidated by third parties, or may not effectively prevent others from commercializing competitive technologies, products or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining and enforcing patents is expensive and time consuming, and we may not be able to file, <span style="letter-spacing:-0.1pt;">prosecute,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">maintain,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">enforce</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">license</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">all</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">necessary</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">desirable</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">patent</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">applications</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">maintain</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and/or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">enforce </span>patents that may issue based on our patent applications, at a reasonable cost or in a timely manner. We may not be able to obtain or maintain patent applications and patents due to the subject matter claimed in such patent<span style="letter-spacing:-0.45pt;"> </span>applications<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>patents<span style="letter-spacing:-0.45pt;"> </span>being<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>disclosures<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>public<span style="letter-spacing:-0.45pt;"> </span>domain.<span style="letter-spacing:-0.45pt;"> </span>It<span style="letter-spacing:-0.45pt;"> </span>is<span style="letter-spacing:-0.45pt;"> </span>also<span style="letter-spacing:-0.45pt;"> </span>possible<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.45pt;"> </span>fail<span style="letter-spacing:-0.45pt;"> </span>to identify patentable aspects of our research and development results before it is too late to obtain patent <span style="letter-spacing:-0.1pt;">protection.</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">Although</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">enter</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">into</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">non-disclosure</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">confidentiality</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">agreements</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">parties</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">who</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">access </span>to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties,<span style="letter-spacing:-0.55pt;"> </span>any<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>these<span style="letter-spacing:-0.55pt;"> </span>parties<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>breach<span style="letter-spacing:-0.55pt;"> </span>these<span style="letter-spacing:-0.55pt;"> </span>agreements<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>disclose<span style="letter-spacing:-0.55pt;"> </span>such<span style="letter-spacing:-0.55pt;"> </span>results<span style="letter-spacing:-0.55pt;"> </span>before<span style="letter-spacing:-0.55pt;"> </span>a<span style="letter-spacing:-0.55pt;"> </span>patent<span style="letter-spacing:-0.55pt;"> </span>application <span style="letter-spacing:-0.1pt;">is</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">filed,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">thereby</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">jeopardizing</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">ability</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">seek</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">patent</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">protection.</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">Consequently,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">able</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">prevent </span>third parties from using our technology that is in the public domain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Composition of matter patents for biological and pharmaceutical product candidates often provide a strong<span style="letter-spacing:-0.35pt;"> </span>form<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.35pt;"> </span>those<span style="letter-spacing:-0.35pt;"> </span>types<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>products,<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:-0.35pt;"> </span>patents<span style="letter-spacing:-0.35pt;"> </span>provide<span style="letter-spacing:-0.35pt;"> </span>protection without regard to any method of<span style="letter-spacing:1pt;"> </span>use. However, the claims in our or our collaborators&#8217;<span style="letter-spacing:-0.4pt;"> </span>or licensors&#8217;<span style="letter-spacing:-0.4pt;"> </span>pending patent applications directed to composition of matter of our product candidates may not be considered patentable by the USPTO or by patent offices in foreign countries, or the claims in any of our or our licensors&#8217; issued patents may not be considered valid and enforceable by courts in the U.S. or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product candidates for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications,<span style="letter-spacing:-0.7pt;"> </span>clinicians<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>prescribe<span style="letter-spacing:-0.65pt;"> </span>these<span style="letter-spacing:-0.65pt;"> </span>products<span style="letter-spacing:-0.65pt;"> </span>&#8220;off-label.&#8221;<span style="letter-spacing:-0.65pt;"> </span>Although<span style="letter-spacing:-0.65pt;"> </span>off-label<span style="letter-spacing:-0.7pt;"> </span>prescriptions<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>infringe or<span style="letter-spacing:-0.05pt;"> </span>contribute<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>infringement<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.95pt;"> </span>method<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.95pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>patents,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>practice<span style="letter-spacing:-0.05pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>infringement<span style="letter-spacing:-0.1pt;"> </span>is difficult to prevent or prosecute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.25pt;"> </span>Supreme<span style="letter-spacing:-0.25pt;"> </span>Court<span style="letter-spacing:-0.25pt;"> </span>decisions,<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.25pt;"> </span>increased<span style="letter-spacing:-0.25pt;"> </span>uncertainties<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>enforce <span style="letter-spacing:-0.1pt;">patent</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">rights</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">future.</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">As</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">result,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">issuance,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">scope,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">validity,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">enforceability</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">commercial</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">value</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:-0.1pt;">any </span>patent<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>highly<span style="letter-spacing:-0.35pt;"> </span>uncertain.<span style="letter-spacing:-0.35pt;"> </span>Our<span style="letter-spacing:-0.35pt;"> </span>pending<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>future<span style="letter-spacing:-0.35pt;"> </span>owned<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>in-licensed<span style="letter-spacing:-0.35pt;"> </span>patent<span style="letter-spacing:-0.35pt;"> </span>applications<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>not result in patents being issued which protect our product candidates, effectively prevent others from commercializing our product candidates or otherwise provide any competitive advantage. In fact, patent applications may not issue as patents at all. The coverage claimed in a patent application can also be significantly<span style="letter-spacing:-0.4pt;"> </span>reduced<span style="letter-spacing:-0.4pt;"> </span>before<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>patent<span style="letter-spacing:-0.4pt;"> </span>is<span style="letter-spacing:-0.4pt;"> </span>issued,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>its<span style="letter-spacing:-0.4pt;"> </span>scope<span style="letter-spacing:-0.4pt;"> </span>can<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.4pt;"> </span>reinterpreted<span style="letter-spacing:-0.4pt;"> </span>after<span style="letter-spacing:-0.4pt;"> </span>issuance.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:-0.4pt;"> </span>addition, the<span style="letter-spacing:-0.4pt;"> </span>laws<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>foreign<span style="letter-spacing:-0.4pt;"> </span>countries<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.4pt;"> </span>not<span style="letter-spacing:-0.4pt;"> </span>protect<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>rights<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>same<span style="letter-spacing:-0.4pt;"> </span>extent<span style="letter-spacing:-0.4pt;"> </span>as<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>laws<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>U.S.,<span style="letter-spacing:-0.4pt;"> </span>or vice versa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent application process is subject to numerous risks and uncertainties, and we may not be successful<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>protecting<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>product<span style="letter-spacing:-0.45pt;"> </span>candidates<span style="letter-spacing:-0.45pt;"> </span>by<span style="letter-spacing:-0.45pt;"> </span>obtaining<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>defending<span style="letter-spacing:-0.45pt;"> </span>patents.<span style="letter-spacing:-0.45pt;"> </span>For<span style="letter-spacing:-0.45pt;"> </span>example,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended<span style="letter-spacing:-0.35pt;"> </span>uses,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>result<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>impact<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>such<span style="letter-spacing:-0.35pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.35pt;"> </span>upon<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>patentability of our own or our licensors&#8217; patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Publications of discoveries in the scientific<span style="letter-spacing:0.25pt;"> </span>literature<span style="letter-spacing:0.25pt;"> </span>often<span style="letter-spacing:0.25pt;"> </span>lag<span style="letter-spacing:0.25pt;"> </span>behind<span style="letter-spacing:0.3pt;"> </span>the<span style="letter-spacing:0.25pt;"> </span>actual<span style="letter-spacing:0.25pt;"> </span>discoveries,<span style="letter-spacing:0.25pt;"> </span>and<span style="letter-spacing:0.25pt;"> </span>patent<span style="letter-spacing:0.3pt;"> </span>applications<span style="letter-spacing:0.25pt;"> </span>in<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.25pt;"> </span>U.S.<span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:-0.25pt;">and</span> <span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">jurisdictions</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">are</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">typically</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">published</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">until</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">18</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">months</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">after</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">filing</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">or,</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">some</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">cases,</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">at</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">all.</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">Therefore, </span>we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending<span style="letter-spacing:-0.35pt;"> </span>patent<span style="letter-spacing:-0.35pt;"> </span>applications,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>were<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>first<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>file<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.35pt;"> </span>patent<span style="letter-spacing:-0.35pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>such<span style="letter-spacing:-0.35pt;"> </span>inventions.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:0.6pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>third party can establish that we or our licensors were not the first to make or the first to file for patent protection of<span style="letter-spacing:0.25pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>inventions,<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>owned<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>licensed<span style="letter-spacing:-0.65pt;"> </span>patent<span style="letter-spacing:-0.65pt;"> </span>applications<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>issue<span style="letter-spacing:-0.65pt;"> </span>as<span style="letter-spacing:-0.65pt;"> </span>patents<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>even<span style="letter-spacing:-0.65pt;"> </span>if<span style="letter-spacing:0.25pt;"> </span>issued,<span style="letter-spacing:-0.65pt;"> </span>may <span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">challenged</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">invalidated</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">rendered</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">unenforceable.</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">As</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">result,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">issuance,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">inventorship,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">scope,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">validity, </span>enforceability and commercial value of<span style="letter-spacing:1.7pt;"> </span>our or our licensors&#8217;<span style="letter-spacing:-0.05pt;"> </span>patent rights are highly uncertain.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The<span style="letter-spacing:-0.3pt;"> </span>issuance<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>patent<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.3pt;"> </span>not<span style="letter-spacing:-0.3pt;"> </span>conclusive<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>its<span style="letter-spacing:-0.3pt;"> </span>inventorship,<span style="letter-spacing:-0.3pt;"> </span>scope,<span style="letter-spacing:-0.3pt;"> </span>validity<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>enforceability<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>our or our licensors&#8217; pending patent applications may be challenged in patent offices in the U.S. and abroad. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. For example, our or our licensors&#8217;<span style="letter-spacing:-0.35pt;"> </span>pending patent applications may be subject to third-party pre-issuance submissions of<span style="letter-spacing:1.15pt;"> </span>prior art to the USPTO or our issued patents may be subject to post-grant review proceedings, oppositions, derivations, <span style="letter-spacing:-0.1pt;">reexaminations,</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">interferences,</span><span style="letter-spacing:-0.55pt;"> </span><i style="font-style:italic;letter-spacing:-0.1pt;">inter</i><i style="font-style:italic;letter-spacing:-0.55pt;"> </i><i style="font-style:italic;letter-spacing:-0.1pt;">partes</i><i style="font-style:italic;letter-spacing:-0.55pt;"> </i><span style="letter-spacing:-0.1pt;">review</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">proceedings</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">similar</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">proceedings,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">U.S. </span>or elsewhere, challenging our or our licensors&#8217;<span style="letter-spacing:-0.35pt;"> </span>patent rights or the patent rights of<span style="letter-spacing:1pt;"> </span>others. Such submissions may<span style="letter-spacing:-0.55pt;"> </span>also<span style="letter-spacing:-0.55pt;"> </span>be<span style="letter-spacing:-0.55pt;"> </span>made<span style="letter-spacing:-0.55pt;"> </span>prior<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>a<span style="letter-spacing:-0.55pt;"> </span>patent&#8217;s<span style="letter-spacing:-0.55pt;"> </span>issuance,<span style="letter-spacing:-0.55pt;"> </span>precluding<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>granting<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>a<span style="letter-spacing:-0.55pt;"> </span>patent<span style="letter-spacing:-0.55pt;"> </span>based<span style="letter-spacing:-0.55pt;"> </span>on<span style="letter-spacing:-0.55pt;"> </span>one<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>more<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>our owned<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>licensed<span style="letter-spacing:-0.65pt;"> </span>pending<span style="letter-spacing:-0.65pt;"> </span>patent<span style="letter-spacing:-0.65pt;"> </span>applications.<span style="letter-spacing:-0.65pt;"> </span>An<span style="letter-spacing:-0.65pt;"> </span>adverse<span style="letter-spacing:-0.65pt;"> </span>determination<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>challenges<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>result<span style="letter-spacing:-0.65pt;"> </span>in loss<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>exclusivity<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>patent<span style="letter-spacing:-0.4pt;"> </span>claims<span style="letter-spacing:-0.4pt;"> </span>being<span style="letter-spacing:-0.4pt;"> </span>narrowed,<span style="letter-spacing:-0.4pt;"> </span>invalidated,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>held<span style="letter-spacing:-0.4pt;"> </span>unenforceable,<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>whole<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>part, which<span style="letter-spacing:-0.5pt;"> </span>could<span style="letter-spacing:-0.5pt;"> </span>limit<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>ability<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>stop<span style="letter-spacing:-0.5pt;"> </span>others<span style="letter-spacing:-0.5pt;"> </span>from<span style="letter-spacing:-0.5pt;"> </span>using<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>commercializing<span style="letter-spacing:-0.5pt;"> </span>similar<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>identical<span style="letter-spacing:-0.5pt;"> </span>technology<span style="letter-spacing:-0.5pt;"> </span>and product candidates, or limit the duration of the patent protection of our technology and product candidates. Such challenges also may result in substantial cost and require significant time from our scientists and management,<span style="letter-spacing:-0.55pt;"> </span>even<span style="letter-spacing:-0.55pt;"> </span>if the<span style="letter-spacing:-0.55pt;"> </span>eventual<span style="letter-spacing:-0.55pt;"> </span>outcome<span style="letter-spacing:-0.55pt;"> </span>is<span style="letter-spacing:-0.55pt;"> </span>favorable<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>us.<span style="letter-spacing:-0.55pt;"> </span>Any<span style="letter-spacing:-0.55pt;"> </span>of the<span style="letter-spacing:-0.55pt;"> </span>foregoing<span style="letter-spacing:-0.55pt;"> </span>could<span style="letter-spacing:-0.55pt;"> </span>adversely<span style="letter-spacing:-0.55pt;"> </span>affect<span style="letter-spacing:-0.55pt;"> </span>our business, financial condition, results of<span style="letter-spacing:2pt;"> </span>operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A third party may also claim that our owned or licensed patent rights are invalid or unenforceable in a litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse result in any legal proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly and could allow third parties to commercialize our products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize our technology, products or product candidates without infringing third-party patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:-0.6pt;"> </span>addition,<span style="letter-spacing:-0.6pt;"> </span>given<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>amount<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>time<span style="letter-spacing:-0.6pt;"> </span>required<span style="letter-spacing:-0.6pt;"> </span>for<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>development,<span style="letter-spacing:-0.6pt;"> </span>testing<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>regulatory<span style="letter-spacing:-0.6pt;"> </span>review<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Any failure to obtain or maintain patent protection with respect to our product candidates or their uses could adversely affect our business, financial condition, results of operations and <span style="letter-spacing:-0.1pt;">prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>in-licensed<span style="letter-spacing:-0.3pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>portfolios,<span style="letter-spacing:-0.3pt;"> </span>but<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>no<span style="letter-spacing:-0.25pt;"> </span>solely<span style="letter-spacing:-0.3pt;"> </span>owned<span style="letter-spacing:-0.3pt;"> </span>issued<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>relating<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we exclusively in-license patent portfolios from Xencor related to obexelimab, ZB002 and <span style="letter-spacing:-0.1pt;">ZB004,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">no</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">solely</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">owned</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">issued</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">patents.</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">Although</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">exclusively</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">in-licensed</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">patent</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">portfolios</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">contain </span>pending patent applications, we may not obtain any issued patents from the pending applications directed to our product candidates. Claims in our U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign jurisdictions, or those of our licensors, may not be considered<span style="letter-spacing:-0.45pt;"> </span>patentable<span style="letter-spacing:-0.45pt;"> </span>by<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>USPTO,<span style="letter-spacing:-0.45pt;"> </span>courts<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>U.S.<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>by<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>patent<span style="letter-spacing:-0.45pt;"> </span>offices<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>courts<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>foreign countries, and any issued claims may be found invalid or unenforceable if challenged. Additionally, our provisional<span style="letter-spacing:-0.7pt;"> </span>applications<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>never<span style="letter-spacing:-0.65pt;"> </span>result<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>issued<span style="letter-spacing:-0.65pt;"> </span>patents.<span style="letter-spacing:-0.65pt;"> </span>Accordingly,<span style="letter-spacing:-0.7pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>licensors<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>never<span style="letter-spacing:-0.65pt;"> </span>obtain issued<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.05pt;"> </span>issued<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.05pt;"> </span>obtain<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>provide<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.05pt;"> </span>competitive advantage. Failure to obtain adequate patent protection for our product candidates and technology could adversely affect our business, financial condition, results of<span style="letter-spacing:1.8pt;"> </span>operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>not<span style="letter-spacing:-0.55pt;"> </span>obtain<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>maintain<span style="letter-spacing:-0.55pt;"> </span>necessary<span style="letter-spacing:-0.6pt;"> </span>rights<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>product<span style="letter-spacing:-0.55pt;"> </span>candidates<span style="letter-spacing:-0.55pt;"> </span>through<span style="letter-spacing:-0.55pt;"> </span>acquisitions<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>in-<span style="letter-spacing:-0.1pt;">licenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The growth of our business depends in part on our ability to acquire, in-license, or use third-party proprietary<span style="letter-spacing:-0.3pt;"> </span>rights,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>not<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.25pt;"> </span>able<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>do<span style="letter-spacing:-0.25pt;"> </span>so<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.25pt;"> </span>commercially<span style="letter-spacing:-0.3pt;"> </span>reasonable<span style="letter-spacing:-0.25pt;"> </span>terms<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>at<span style="letter-spacing:-0.25pt;"> </span>all.<span style="letter-spacing:-0.3pt;"> </span>Licenses<span style="letter-spacing:-0.25pt;"> may</span> <span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">nonexclusive</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">terms,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">thereby</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">giving</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">competitors</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">third</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">parties</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">access</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">same</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">intellectual </span>property<span style="letter-spacing:-0.35pt;"> </span>licensed<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>us,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.35pt;"> </span>require<span style="letter-spacing:-0.35pt;"> </span>us<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>make<span style="letter-spacing:-0.35pt;"> </span>substantial<span style="letter-spacing:-0.35pt;"> </span>licensing<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>royalty<span style="letter-spacing:-0.35pt;"> </span>payments.<span style="letter-spacing:-0.35pt;"> </span>The<span style="letter-spacing:-0.35pt;"> </span>licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established<span style="letter-spacing:-0.15pt;"> </span>companies<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>pursue<span style="letter-spacing:-0.15pt;"> </span>strategies<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>license<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>acquire<span style="letter-spacing:-0.15pt;"> </span>third-party<span style="letter-spacing:-0.15pt;"> </span>intellectual<span style="letter-spacing:-0.15pt;"> </span>property<span style="letter-spacing:-0.15pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>that we<span style="letter-spacing:-0.7pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>consider<span style="letter-spacing:-0.65pt;"> </span>attractive<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>necessary.<span style="letter-spacing:-0.65pt;"> </span>These<span style="letter-spacing:-0.65pt;"> </span>established<span style="letter-spacing:-0.65pt;"> </span>companies<span style="letter-spacing:-0.7pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>have<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>competitive<span style="letter-spacing:-0.65pt;"> </span>advantage<span style="letter-spacing:-0.65pt;"> </span>over us due to their size, capital resources or greater clinical development and commercialization capabilities. In addition,<span style="letter-spacing:-0.35pt;"> </span>companies<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>perceive<span style="letter-spacing:-0.35pt;"> </span>us<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>competitor<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.35pt;"> </span>unwilling<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>assign<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>license<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>us.<span style="letter-spacing:-0.35pt;"> </span>We also<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>unable<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>license<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>acquire<span style="letter-spacing:-0.65pt;"> </span>third-party<span style="letter-spacing:-0.65pt;"> </span>intellectual<span style="letter-spacing:-0.65pt;"> </span>property<span style="letter-spacing:-0.65pt;"> </span>rights<span style="letter-spacing:-0.65pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>terms<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>would<span style="letter-spacing:-0.65pt;"> </span>allow<span style="letter-spacing:-0.65pt;"> </span>us<span style="letter-spacing:-0.65pt;"> </span>to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have obtained, we may have to abandon </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">development of the relevant program or product candidate, which could adversely affect our business, financial condition, results of<span style="letter-spacing:1.75pt;"> </span>operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>normally<span style="letter-spacing:-0.05pt;"> </span>seek<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>obtain<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>right<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>control<span style="letter-spacing:-0.05pt;"> </span>prosecution,<span style="letter-spacing:-0.05pt;"> </span>maintenance<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>enforcement<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.95pt;"> </span>the patents relating to our product candidates, there may be times when the filing and prosecution activities for patents and patent applications relating to our product candidates are controlled by our licensors or collaboration<span style="letter-spacing:-0.1pt;"> </span>partners.<span style="letter-spacing:-0.1pt;"> </span>For<span style="letter-spacing:-0.1pt;"> </span>example,<span style="letter-spacing:-0.1pt;"> </span>under<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>license<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>collaboration<span style="letter-spacing:-0.1pt;"> </span>agreements<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>Xencor,<span style="letter-spacing:-0.1pt;"> </span>Xencor<span style="letter-spacing:-0.1pt;"> </span>is responsible for patent prosecution of certain licensed intellectual property. If any of our current or future licensors or collaboration partners fails to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all <span style="letter-spacing:-0.1pt;">applicable</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">fees</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">patents</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">covering</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">candidates,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">lose</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">rights</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">intellectual</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">property </span>or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.35pt;"> </span>adversely<span style="letter-spacing:-0.35pt;"> </span>affected<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>not<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.35pt;"> </span>able<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>prevent<span style="letter-spacing:-0.35pt;"> </span>competitors<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.35pt;"> </span>making,<span style="letter-spacing:-0.35pt;"> </span>using<span style="letter-spacing:-0.35pt;"> </span>and selling<span style="letter-spacing:-0.5pt;"> </span>competing<span style="letter-spacing:-0.5pt;"> </span>products.<span style="letter-spacing:-0.5pt;"> </span>In<span style="letter-spacing:-0.5pt;"> </span>addition,<span style="letter-spacing:-0.5pt;"> </span>even<span style="letter-spacing:-0.5pt;"> </span>where<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>have<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>right<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>control<span style="letter-spacing:-0.5pt;"> </span>patent<span style="letter-spacing:-0.5pt;"> </span>prosecution<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:-0.4pt;"> </span>actions<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>inactions<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>licensees,<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>future<span style="letter-spacing:-0.4pt;"> </span>licensors<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>their<span style="letter-spacing:-0.4pt;"> </span>counsel<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.4pt;"> </span>took<span style="letter-spacing:-0.4pt;"> </span>place<span style="letter-spacing:-0.4pt;"> </span>prior to the date upon which we assumed control over patent prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent<span style="letter-spacing:-0.55pt;"> </span>rights<span style="letter-spacing:-0.5pt;"> </span>relating<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>inventions<span style="letter-spacing:-0.55pt;"> </span>described<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>claimed<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.55pt;"> </span>pending<span style="letter-spacing:-0.5pt;"> </span>patent<span style="letter-spacing:-0.55pt;"> </span>applications<span style="letter-spacing:-0.5pt;"> </span>may not<span style="letter-spacing:-0.25pt;"> </span>issue<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>based<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>applications<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.25pt;"> </span>challenged<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>rendered<span style="letter-spacing:-0.25pt;"> </span>invalid and/or unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent application process is subject to numerous risks and uncertainties, and we, our licensors, or any of our potential future collaborators may not be successful in protecting our product candidates by obtaining and defending patents. We and our licensors have several pending U.S. and foreign patent applications in our portfolio. We cannot predict:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.95pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">when</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patents</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may issue</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">based</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">licensors&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protection</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issuing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">based</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">licensors&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">claims</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issuing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">based</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">licensors&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">applications</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">will</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide protection against competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether or not third parties will find ways to invalidate or circumvent our and our licensors&#8217; patent </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">will</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patents</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">claiming</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">aspects</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">similar</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">those</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">covered</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our licensors&#8217; patents and patent applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our and our licensors&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent rights which will be costly whether we win or lose;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether the patent applications that we own will result in issued patents with claims that cover our product candidates or uses thereof</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the U.S. or in other foreign countries; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experience</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">office</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">secure</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">coverage</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">due</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">global</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pandemics</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">epidemics.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The claims in our or our licensors&#8217;<span style="letter-spacing:-0.25pt;"> </span>pending patent applications directed to our product candidates may not<span style="letter-spacing:0.6pt;"> </span>be<span style="letter-spacing:0.6pt;"> </span>considered<span style="letter-spacing:0.6pt;"> </span>patentable<span style="letter-spacing:0.6pt;"> </span>by<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:0.6pt;"> </span>USPTO<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.6pt;"> </span>by<span style="letter-spacing:0.6pt;"> </span>patent<span style="letter-spacing:0.6pt;"> </span>offices<span style="letter-spacing:0.6pt;"> </span>in<span style="letter-spacing:0.6pt;"> </span>foreign<span style="letter-spacing:0.6pt;"> </span>countries,<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>any<span style="letter-spacing:0.6pt;"> </span>such<span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:-0.1pt;">patent</span> applications<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>not<span style="letter-spacing:-0.45pt;"> </span>issue<span style="letter-spacing:-0.45pt;"> </span>as<span style="letter-spacing:-0.45pt;"> </span>granted<span style="letter-spacing:-0.45pt;"> </span>patents.<span style="letter-spacing:-0.45pt;"> </span>One<span style="letter-spacing:-0.45pt;"> </span>aspect<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>determination<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>patentability<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>our licensors&#8217;<span style="letter-spacing:-0.45pt;"> </span>inventions depends on the scope and content of<span style="letter-spacing:1.05pt;"> </span>the &#8220;prior art,&#8221;<span style="letter-spacing:-0.6pt;"> </span>information that was or is deemed available<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>person<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>skill<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>relevant<span style="letter-spacing:-0.15pt;"> </span>art<span style="letter-spacing:-0.15pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>priority<span style="letter-spacing:-0.15pt;"> </span>date<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>claimed<span style="letter-spacing:-0.15pt;"> </span>invention.<span style="letter-spacing:-0.15pt;"> </span>There<span style="letter-spacing:-0.15pt;"> </span>may be<span style="letter-spacing:-0.15pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>art<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>aware<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>patentability<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.6pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>claims or,<span style="letter-spacing:-0.55pt;"> </span>if<span style="letter-spacing:0.4pt;"> </span>issued,<span style="letter-spacing:-0.55pt;"> </span>affect<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>validity<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>enforceability<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>a<span style="letter-spacing:-0.55pt;"> </span>patent<span style="letter-spacing:-0.55pt;"> </span>claim.<span style="letter-spacing:-0.55pt;"> </span>Even<span style="letter-spacing:-0.55pt;"> </span>if<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>patents<span style="letter-spacing:-0.55pt;"> </span>do<span style="letter-spacing:-0.55pt;"> </span>issue<span style="letter-spacing:-0.55pt;"> </span>based<span style="letter-spacing:-0.55pt;"> </span>on<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>or our licensors&#8217; patent applications, third parties may challenge the validity, enforceability or scope thereof, which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:-0.25pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>being<span style="letter-spacing:-0.25pt;"> </span>narrowed,<span style="letter-spacing:-0.25pt;"> </span>invalidated<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>held<span style="letter-spacing:-0.25pt;"> </span>unenforceable.<span style="letter-spacing:-0.25pt;"> </span>For<span style="letter-spacing:-0.25pt;"> </span>example,<span style="letter-spacing:-0.25pt;"> </span>there<span style="letter-spacing:-0.25pt;"> </span>may be prior art not considered by the patent office that is raised by a third party to challenge the validity of any patents that issue </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">from our or our licensors' patent applications. Furthermore, even if<span style="letter-spacing:1pt;"> </span>they are unchallenged, patents in our and our licensors&#8217;<span style="letter-spacing:-0.35pt;"> </span>portfolio may not adequately exclude third parties from practicing relevant technology<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>prevent<span style="letter-spacing:-0.1pt;"> </span>others<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.1pt;"> </span>designing<span style="letter-spacing:-0.1pt;"> </span>around<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>claims.<span style="letter-spacing:-0.1pt;"> </span>If<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>breadth<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>strength<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.95pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>intellectual property position with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our product candidates. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the U.S. or foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>not<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>able<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>protect<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>intellectual<span style="letter-spacing:-0.3pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.3pt;"> </span>throughout<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patents<span style="letter-spacing:-0.55pt;"> </span>are<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>national<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>regional<span style="letter-spacing:-0.55pt;"> </span>effect.<span style="letter-spacing:-0.55pt;"> </span>Filing,<span style="letter-spacing:-0.55pt;"> </span>prosecuting<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>defending<span style="letter-spacing:-0.55pt;"> </span>patents<span style="letter-spacing:-0.55pt;"> </span>on<span style="letter-spacing:-0.55pt;"> </span>all<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>research programs<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.4pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>all<span style="letter-spacing:-0.4pt;"> </span>countries<span style="letter-spacing:-0.4pt;"> </span>throughout<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>world<span style="letter-spacing:-0.4pt;"> </span>would<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.4pt;"> </span>prohibitively<span style="letter-spacing:-0.4pt;"> </span>expensive,<span style="letter-spacing:-0.4pt;"> </span>and our and our licensors&#8217; intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">property</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">rights</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">same</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">extent</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">as</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">federal</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">state</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">laws</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">U.S.,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">even</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">jurisdictions </span>where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our or our licensors&#8217; inventions in all countries outside the U.S., even in jurisdictions where<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>licensors<span style="letter-spacing:-0.1pt;"> </span>do<span style="letter-spacing:-0.1pt;"> </span>pursue<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.1pt;"> </span>protection,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.1pt;"> </span>selling<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>importing<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:-0.1pt;"> </span>made<span style="letter-spacing:-0.1pt;"> </span>using<span style="letter-spacing:-0.1pt;"> </span>our or our licensors&#8217;<span style="letter-spacing:-0.25pt;"> </span>inventions in and into the U.S. or other jurisdictions. Competitors may use our or our<span style="letter-spacing:-0.7pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.65pt;"> </span>technologies<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.5pt;"> </span>jurisdictions<span style="letter-spacing:-0.55pt;"> </span>where<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>have<span style="letter-spacing:-0.55pt;"> </span>not<span style="letter-spacing:-0.55pt;"> </span>obtained<span style="letter-spacing:-0.55pt;"> </span>patent<span style="letter-spacing:-0.55pt;"> </span>protection<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>develop<span style="letter-spacing:-0.55pt;"> </span>their<span style="letter-spacing:-0.55pt;"> </span>own products<span style="letter-spacing:-0.55pt;"> </span>and,<span style="letter-spacing:-0.55pt;"> </span>further,<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>export<span style="letter-spacing:-0.55pt;"> </span>otherwise<span style="letter-spacing:-0.55pt;"> </span>infringing<span style="letter-spacing:-0.55pt;"> </span>products<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>territories<span style="letter-spacing:-0.55pt;"> </span>where<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>licensors<span style="letter-spacing:-0.55pt;"> </span>have patent protection, but enforcement is not as strong as that in the U.S. These competitor products may compete with our product candidates, and our and our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Various companies have encountered significant problems in protecting and defending intellectual property<span style="letter-spacing:-0.2pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>jurisdictions.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>legal<span style="letter-spacing:-0.2pt;"> </span>systems<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>many<span style="letter-spacing:-0.2pt;"> </span>countries<span style="letter-spacing:-0.2pt;"> </span>do<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.2pt;"> </span>favor<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>enforcement<span style="letter-spacing:-0.2pt;"> </span>of patents<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>intellectual<span style="letter-spacing:-0.25pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>protection,<span style="letter-spacing:-0.25pt;"> </span>particularly<span style="letter-spacing:-0.25pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>relating<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>pharmaceuticals,<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>could make it difficult for us to stop the infringement of<span style="letter-spacing:1.05pt;"> </span>our and our licensors&#8217;<span style="letter-spacing:-0.4pt;"> </span>patents or marketing of<span style="letter-spacing:1.05pt;"> </span>competing products in violation of our proprietary rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Various<span style="letter-spacing:-0.35pt;"> </span>countries<span style="letter-spacing:-0.35pt;"> </span>outside<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>U.S.<span style="letter-spacing:-0.35pt;"> </span>have<span style="letter-spacing:-0.35pt;"> </span>compulsory<span style="letter-spacing:-0.35pt;"> </span>licensing<span style="letter-spacing:-0.35pt;"> </span>laws<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>patent<span style="letter-spacing:-0.35pt;"> </span>owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents<span style="letter-spacing:-0.45pt;"> </span>against<span style="letter-spacing:-0.45pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>agencies<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>contractors.<span style="letter-spacing:-0.45pt;"> </span>As<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>result,<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>patent<span style="letter-spacing:-0.45pt;"> </span>owner<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>have<span style="letter-spacing:-0.45pt;"> </span>limited remedies in certain circumstances, which could materially diminish the value of such patent. If we or our licensors<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>forced<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>license<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>respect<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>patents<span style="letter-spacing:-0.15pt;"> </span>relevant<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>business,<span style="letter-spacing:-0.15pt;"> </span>our competitive position may be impaired, and our business, financial condition, results of operations and <span style="letter-spacing:-0.1pt;">prospects</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">adversely</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">affected.</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">Accordingly,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">efforts</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">enforce</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">intellectual</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">property</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">rights</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">around </span>the<span style="letter-spacing:-0.25pt;"> </span>world<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.25pt;"> </span>inadequate<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>significant<span style="letter-spacing:-0.25pt;"> </span>commercial<span style="letter-spacing:-0.25pt;"> </span>advantage<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>intellectual<span style="letter-spacing:-0.25pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always<span style="letter-spacing:-0.6pt;"> </span>applied<span style="letter-spacing:-0.6pt;"> </span>uniformly<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>predictably.<span style="letter-spacing:-0.6pt;"> </span>As<span style="letter-spacing:-0.6pt;"> </span>such,<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>do<span style="letter-spacing:-0.6pt;"> </span>not<span style="letter-spacing:-0.6pt;"> </span>know<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>degree<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>future<span style="letter-spacing:-0.6pt;"> </span>protection<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>will have on our product candidates. While we will endeavor to try to protect our product candidates with intellectual<span style="letter-spacing:-0.65pt;"> </span>property<span style="letter-spacing:-0.65pt;"> </span>rights<span style="letter-spacing:-0.65pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>as<span style="letter-spacing:-0.65pt;"> </span>patents,<span style="letter-spacing:-0.65pt;"> </span>as<span style="letter-spacing:-0.65pt;"> </span>appropriate,<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>process<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>obtaining<span style="letter-spacing:-0.65pt;"> </span>patents<span style="letter-spacing:-0.65pt;"> </span>is<span style="letter-spacing:-0.65pt;"> </span>time<span style="letter-spacing:-0.65pt;"> </span>consuming, expensive and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual<span style="letter-spacing:-0.3pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.3pt;"> </span>do<span style="letter-spacing:-0.25pt;"> </span>not<span style="letter-spacing:-0.3pt;"> </span>necessarily<span style="letter-spacing:-0.25pt;"> </span>address<span style="letter-spacing:-0.3pt;"> </span>all<span style="letter-spacing:-0.25pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>threats<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>competitive<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">advantage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">able</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">similar</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ours</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">but</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">covered</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the pending patent applications that we own or the patents or patent applications that we license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">licensors</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">might</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">been</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">first</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inventions</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">covered by the pending patent application that we own or have exclusively licensed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">licensors</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">might</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">been</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">first</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">file</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">applications covering</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">their</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inventions;</span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing or otherwise violating our owned or licensed intellectual property </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that noncompliance with the USPTO and foreign governmental patent agencies requirement for a number of procedural, documentary, fee payment and other provisions during the patent process can result in abandonment or lapse of a patent or patent application, and partial or complete loss of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent rights in the relevant jurisdiction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending owned or licensed patent applications or those that we may own or license in the future will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">issued</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">patents</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">either</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">own</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">have</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">exclusively</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">licensed</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">revoked,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">modified,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">held</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">invalid </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or unenforceable, as a result of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">access</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">same</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">property</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rights</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">licensed</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">us</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a non-exclusive basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">might</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">activities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">countries</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">where</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">do</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have patent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rights</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">then</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">information</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">learned</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">activities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proprietary</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">technologies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cannot</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">predict</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scope</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protection</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issuing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">based</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">licensors&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent applications, including whether the patent applications that we own, presently in-license, or, in the future, in-license will result in issued patents with claims that directed to our product candidates or uses thereof</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the U.S. or in other foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">public policy regarding worldwide health concerns;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">countries other than the U.S. may have patent laws less favorable to patentees than those upheld</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">courts,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allowing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">better</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">opportunity</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">create,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market competing product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the claims of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enforced,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">court</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hold</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patents,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">they</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">valid,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enforceable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">infringed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">choose</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">file</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">application</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">order</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trade</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">secrets</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">know-how, and a third party may subsequently file a patent application covering such intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may fail to adequately protect and police our trademarks and trade secrets; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patent applications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Should<span style="letter-spacing:1.75pt;"> </span>any<span style="letter-spacing:1.75pt;"> </span>of<span style="letter-spacing:2pt;"> </span>these<span style="letter-spacing:1.75pt;"> </span>or<span style="letter-spacing:1.75pt;"> </span>similar<span style="letter-spacing:1.75pt;"> </span>events<span style="letter-spacing:1.75pt;"> </span>occur,<span style="letter-spacing:1.75pt;"> </span>they<span style="letter-spacing:1.75pt;"> </span>could<span style="letter-spacing:1.75pt;"> </span>significantly<span style="letter-spacing:1.75pt;"> </span>harm<span style="letter-spacing:1.75pt;"> </span>our<span style="letter-spacing:1.75pt;"> </span>business,<span style="letter-spacing:1.75pt;"> </span>financial condition, results of operations and prospects.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competitors<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>other<span style="letter-spacing:-0.35pt;"> </span>third<span style="letter-spacing:-0.35pt;"> </span>parties<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>infringe<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>patents,<span style="letter-spacing:-0.35pt;"> </span>trademarks<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>other<span style="letter-spacing:-0.35pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property.<span style="letter-spacing:-0.35pt;"> </span>To counter infringement or unauthorized use, we or one of our licensing partners may file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific<span style="letter-spacing:-0.7pt;"> </span>personnel.<span style="letter-spacing:-0.65pt;"> </span>Our<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.7pt;"> </span>pending<span style="letter-spacing:-0.5pt;"> </span>patent<span style="letter-spacing:-0.55pt;"> </span>applications<span style="letter-spacing:-0.55pt;"> </span>cannot<span style="letter-spacing:-0.55pt;"> </span>be<span style="letter-spacing:-0.55pt;"> </span>enforced<span style="letter-spacing:-0.55pt;"> </span>against<span style="letter-spacing:-0.55pt;"> </span>third<span style="letter-spacing:-0.55pt;"> </span>parties practicing<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>technology<span style="letter-spacing:-0.55pt;"> </span>claimed<span style="letter-spacing:-0.55pt;"> </span>in<span style="letter-spacing:-0.55pt;"> </span>such<span style="letter-spacing:-0.55pt;"> </span>applications<span style="letter-spacing:-0.55pt;"> </span>unless<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>until<span style="letter-spacing:-0.55pt;"> </span>a<span style="letter-spacing:-0.55pt;"> </span>patent<span style="letter-spacing:-0.55pt;"> </span>issues<span style="letter-spacing:-0.55pt;"> </span>from<span style="letter-spacing:-0.55pt;"> </span>such<span style="letter-spacing:-0.55pt;"> </span>applications. Claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>infringe<span style="letter-spacing:-0.35pt;"> </span>their<span style="letter-spacing:-0.35pt;"> </span>patents,<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.35pt;"> </span>addition<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>counterclaims<span style="letter-spacing:-0.35pt;"> </span>asserting<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>patents<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>licensors&#8217; patents<span style="letter-spacing:-0.6pt;"> </span>are<span style="letter-spacing:-0.6pt;"> </span>invalid<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>unenforceable,<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>both.<span style="letter-spacing:-0.6pt;"> </span>In<span style="letter-spacing:-0.6pt;"> </span>patent<span style="letter-spacing:-0.6pt;"> </span>litigation<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>U.S.,<span style="letter-spacing:-0.6pt;"> </span>defendant<span style="letter-spacing:-0.6pt;"> </span>counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non- enablement,<span style="letter-spacing:-0.15pt;"> </span>insufficient<span style="letter-spacing:-0.15pt;"> </span>written<span style="letter-spacing:-0.15pt;"> </span>description<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>failure<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>claim<span style="letter-spacing:-0.15pt;"> </span>patent-eligible<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>matter.<span style="letter-spacing:-0.15pt;"> </span>Grounds<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement<span style="letter-spacing:-0.35pt;"> </span>proceeding,<span style="letter-spacing:-0.35pt;"> </span>there<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>risk<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>court<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.35pt;"> </span>decide<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>patent<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>ours<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>licensors<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.35pt;"> </span>invalid or<span style="letter-spacing:-0.1pt;"> </span>unenforceable,<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>whole<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>part,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>do<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>right<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>stop<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>party<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.1pt;"> </span>using<span style="letter-spacing:-0.1pt;"> </span>the invention<span style="letter-spacing:-0.7pt;"> </span>at<span style="letter-spacing:-0.65pt;"> </span>issue.<span style="letter-spacing:-0.65pt;"> </span>There<span style="letter-spacing:-0.65pt;"> </span>is<span style="letter-spacing:-0.65pt;"> </span>also<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>risk<span style="letter-spacing:-0.65pt;"> </span>that,<span style="letter-spacing:-0.7pt;"> </span>even<span style="letter-spacing:-0.65pt;"> </span>if<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>validity<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>patents<span style="letter-spacing:-0.65pt;"> </span>is<span style="letter-spacing:-0.65pt;"> </span>upheld,<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.7pt;"> </span>court<span style="letter-spacing:-0.65pt;"> </span>will<span style="letter-spacing:-0.65pt;"> </span>construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention<span style="letter-spacing:-0.45pt;"> </span>at<span style="letter-spacing:-0.35pt;"> </span>issue<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>grounds<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.7pt;"> </span>patent<span style="letter-spacing:-0.3pt;"> </span>claims<span style="letter-spacing:-0.35pt;"> </span>do<span style="letter-spacing:-0.35pt;"> </span>not<span style="letter-spacing:-0.35pt;"> </span>cover<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>invention,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>decide that the other party&#8217;s use of our or our licensors&#8217; patented technology falls under the safe harbor to patent infringement<span style="letter-spacing:-0.05pt;"> </span>under<span style="letter-spacing:-0.05pt;"> </span>35<span style="letter-spacing:-0.05pt;"> </span>U.S.C.<span style="letter-spacing:-0.05pt;"> </span>&#167;271(e)(1).<span style="letter-spacing:-0.05pt;"> </span>An<span style="letter-spacing:-0.05pt;"> </span>adverse<span style="letter-spacing:-0.05pt;"> </span>outcome<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>litigation<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>proceeding<span style="letter-spacing:-0.05pt;"> </span>involving<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>or our licensors&#8217; patents could limit our ability to assert our or our licensors&#8217; patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive position, business,<span style="letter-spacing:-0.7pt;"> </span>financial<span style="letter-spacing:-0.65pt;"> </span>condition,<span style="letter-spacing:-0.65pt;"> </span>results<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>operations<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>prospects.<span style="letter-spacing:-0.65pt;"> </span>Similarly,<span style="letter-spacing:-0.7pt;"> </span>if<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>assert<span style="letter-spacing:-0.65pt;"> </span>trademark<span style="letter-spacing:-0.65pt;"> </span>infringement claims,<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>court<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>determine<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>marks<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>asserted<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>invalid<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>unenforceable,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of<span style="letter-spacing:1.5pt;"> </span>such trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing<span style="letter-spacing:-0.4pt;"> </span>activity<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>instead<span style="letter-spacing:-0.4pt;"> </span>award<span style="letter-spacing:-0.4pt;"> </span>only<span style="letter-spacing:-0.4pt;"> </span>monetary<span style="letter-spacing:-0.4pt;"> </span>damages,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.4pt;"> </span>not<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.4pt;"> </span>an<span style="letter-spacing:-0.4pt;"> </span>adequate<span style="letter-spacing:-0.4pt;"> </span>remedy. Furthermore,<span style="letter-spacing:-0.7pt;"> </span>because<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.7pt;"> </span>substantial<span style="letter-spacing:-0.65pt;"> </span>amount<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>discovery<span style="letter-spacing:-0.7pt;"> </span>required<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>connection<span style="letter-spacing:-0.65pt;"> </span>with<span style="letter-spacing:-0.65pt;"> </span>intellectual<span style="letter-spacing:-0.65pt;"> </span>property litigation,<span style="letter-spacing:-0.65pt;"> </span>there<span style="letter-spacing:-0.65pt;"> </span>is<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>risk<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>some<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>confidential<span style="letter-spacing:-0.65pt;"> </span>information<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>compromised<span style="letter-spacing:-0.65pt;"> </span>by<span style="letter-spacing:-0.65pt;"> </span>disclosure<span style="letter-spacing:-0.65pt;"> </span>during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>developments.<span style="letter-spacing:-0.3pt;"> </span>If securities<span style="letter-spacing:-0.3pt;"> </span>analysts<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>investors<span style="letter-spacing:-0.3pt;"> </span>perceive<span style="letter-spacing:-0.3pt;"> </span>these<span style="letter-spacing:-0.3pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>negative,<span style="letter-spacing:-0.3pt;"> </span>it<span style="letter-spacing:-0.3pt;"> </span>could adversely<span style="letter-spacing:-0.2pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>price<span style="letter-spacing:-0.2pt;"> </span>of shares<span style="letter-spacing:-0.2pt;"> </span>of our<span style="letter-spacing:-0.2pt;"> </span>common<span style="letter-spacing:-0.2pt;"> </span>stock.<span style="letter-spacing:-0.2pt;"> </span>Moreover,<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>sufficient<span style="letter-spacing:-0.2pt;"> </span>financial<span style="letter-spacing:-0.2pt;"> </span>or other resources to file and pursue such infringement claims, which typically last for years before they are concluded.<span style="letter-spacing:-0.65pt;"> </span>Even<span style="letter-spacing:-0.65pt;"> </span>if<span style="letter-spacing:0.2pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>ultimately<span style="letter-spacing:-0.65pt;"> </span>prevail<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>claims,<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>monetary<span style="letter-spacing:-0.65pt;"> </span>cost<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>litigation<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>diversion of<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>attention<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>management<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>scientific<span style="letter-spacing:-0.5pt;"> </span>personnel<span style="letter-spacing:-0.5pt;"> </span>could<span style="letter-spacing:-0.5pt;"> </span>outweigh<span style="letter-spacing:-0.5pt;"> </span>any<span style="letter-spacing:-0.5pt;"> </span>benefit<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>receive<span style="letter-spacing:-0.5pt;"> </span>as<span style="letter-spacing:-0.5pt;"> </span>a<span style="letter-spacing:-0.5pt;"> </span>result of the proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intellectual property rights of third parties could adversely affect our ability to commercialize obexelimab, or future<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.1pt;"> </span>candidates,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we,<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>licensors<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>collaborators,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.1pt;"> </span>strategic<span style="letter-spacing:-0.1pt;"> </span>partners<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>become <span style="letter-spacing:-0.1pt;">subject</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">third</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">party</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">claims</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">litigation</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">alleging</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">infringement</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:-0.1pt;">patents</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">proprietary</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">rights</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">seeking</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to invalidate</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">patents</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">proprietary</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">rights.</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">might</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">required</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">litigate</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">obtain</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">licenses</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">third</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">parties </span>in<span style="letter-spacing:-0.65pt;"> </span>order<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>develop<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>market<span style="letter-spacing:-0.6pt;"> </span>obexelimab<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>future<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.6pt;"> </span>candidates.<span style="letter-spacing:-0.65pt;"> </span>Such<span style="letter-spacing:-0.6pt;"> </span>litigation<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>licenses<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.6pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>costly or not available on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success depends on our ability to develop, manufacture, market and sell our product candidates without infringing, misappropriating or otherwise violating the valid intellectual property and other proprietary rights of third parties. Identifying third-party patent rights that may be relevant to our operations<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.35pt;"> </span>difficult<span style="letter-spacing:-0.35pt;"> </span>because<span style="letter-spacing:-0.35pt;"> </span>patent<span style="letter-spacing:-0.35pt;"> </span>searching<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.35pt;"> </span>imperfect<span style="letter-spacing:-0.35pt;"> </span>due<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>differences<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.35pt;"> </span>terminology<span style="letter-spacing:-0.35pt;"> </span>among<span style="letter-spacing:-0.35pt;"> </span>patents, incomplete<span style="letter-spacing:-0.1pt;"> </span>databases<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>difficulty<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>assessing<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>meaning<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.9pt;"> </span>patent<span style="letter-spacing:-0.1pt;"> </span>claims.<span style="letter-spacing:-0.1pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>cannot<span style="letter-spacing:-0.1pt;"> </span>guarantee<span style="letter-spacing:-0.1pt;"> </span>that any<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:1.3pt;"> </span>our<span style="letter-spacing:0.4pt;"> </span>patent<span style="letter-spacing:0.45pt;"> </span>searches<span style="letter-spacing:0.4pt;"> </span>or<span style="letter-spacing:0.4pt;"> </span>analyses,<span style="letter-spacing:0.4pt;"> </span>including<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.4pt;"> </span>identification<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:1.3pt;"> </span>relevant<span style="letter-spacing:0.45pt;"> </span>patents,<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:0.4pt;"> </span>scope<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:-0.1pt;">patent</span> claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the U.S. and abroad that is relevant to or necessary for the commercialization of<span style="letter-spacing:1.9pt;"> </span>our product candidates in any jurisdiction.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. Patent applications in the U.S. and elsewhere are typically published approximately 18<span style="letter-spacing:-0.4pt;"> </span>months<span style="letter-spacing:-0.4pt;"> </span>after<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>earliest<span style="letter-spacing:-0.4pt;"> </span>filing<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.4pt;"> </span>priority<span style="letter-spacing:-0.4pt;"> </span>is<span style="letter-spacing:-0.4pt;"> </span>claimed,<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.4pt;"> </span>such<span style="letter-spacing:-0.4pt;"> </span>earliest<span style="letter-spacing:-0.4pt;"> </span>filing<span style="letter-spacing:-0.4pt;"> </span>date<span style="letter-spacing:-0.4pt;"> </span>being<span style="letter-spacing:-0.4pt;"> </span>commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the U.S. can remain<span style="letter-spacing:-0.45pt;"> </span>confidential<span style="letter-spacing:-0.45pt;"> </span>until<span style="letter-spacing:-0.45pt;"> </span>patents<span style="letter-spacing:-0.45pt;"> </span>issue.<span style="letter-spacing:-0.45pt;"> </span>In<span style="letter-spacing:-0.45pt;"> </span>addition,<span style="letter-spacing:-0.45pt;"> </span>patent<span style="letter-spacing:-0.45pt;"> </span>applications<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>U.S.<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>elsewhere<span style="letter-spacing:-0.45pt;"> </span>can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived.<span style="letter-spacing:-0.6pt;"> </span>Furthermore,<span style="letter-spacing:-0.6pt;"> </span>pending<span style="letter-spacing:-0.6pt;"> </span>patent<span style="letter-spacing:-0.6pt;"> </span>applications<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>have<span style="letter-spacing:-0.6pt;"> </span>been<span style="letter-spacing:-0.6pt;"> </span>published<span style="letter-spacing:-0.6pt;"> </span>can,<span style="letter-spacing:-0.6pt;"> </span>subject<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>certain<span style="letter-spacing:-0.6pt;"> </span>limitations, be later amended in a manner that could cover our product candidates or the use of<span style="letter-spacing:1.25pt;"> </span>our product candidates. As<span style="letter-spacing:-0.8pt;"> </span>such,<span style="letter-spacing:-0.75pt;"> </span>there<span style="letter-spacing:-0.8pt;"> </span>may<span style="letter-spacing:-0.75pt;"> </span>be<span style="letter-spacing:-0.8pt;"> </span>applications<span style="letter-spacing:-0.75pt;"> </span>of<span style="letter-spacing:-0.7pt;"> </span>others<span style="letter-spacing:-0.75pt;"> </span>now<span style="letter-spacing:-0.8pt;"> </span>pending<span style="letter-spacing:-0.75pt;"> </span>or<span style="letter-spacing:-0.8pt;"> </span>recently<span style="letter-spacing:-0.75pt;"> </span>revived<span style="letter-spacing:-0.8pt;"> </span>patents<span style="letter-spacing:-0.75pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>which<span style="letter-spacing:-0.8pt;"> </span>we<span style="letter-spacing:-0.75pt;"> </span>are<span style="letter-spacing:-0.8pt;"> </span>unaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending<span style="letter-spacing:-0.65pt;"> </span>application<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>incorrect.<span style="letter-spacing:-0.65pt;"> </span>For<span style="letter-spacing:-0.65pt;"> </span>example,<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>incorrectly<span style="letter-spacing:-0.65pt;"> </span>determine<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidates are<span style="letter-spacing:-0.3pt;"> </span>not<span style="letter-spacing:-0.3pt;"> </span>covered<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>third-party<span style="letter-spacing:-0.3pt;"> </span>patent<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>incorrectly<span style="letter-spacing:-0.3pt;"> </span>predict<span style="letter-spacing:-0.3pt;"> </span>whether<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>third-party&#8217;s<span style="letter-spacing:-0.3pt;"> </span>pending<span style="letter-spacing:-0.3pt;"> </span>application will<span style="letter-spacing:-0.3pt;"> </span>issue<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.3pt;"> </span>claims<span style="letter-spacing:-0.3pt;"> </span>of relevant<span style="letter-spacing:-0.3pt;"> </span>scope.<span style="letter-spacing:-0.3pt;"> </span>Our<span style="letter-spacing:-0.3pt;"> </span>determination<span style="letter-spacing:-0.3pt;"> </span>of the<span style="letter-spacing:-0.3pt;"> </span>expiration<span style="letter-spacing:-0.3pt;"> </span>date<span style="letter-spacing:-0.3pt;"> </span>of any<span style="letter-spacing:-0.3pt;"> </span>patent<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>U.S. or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is <span style="letter-spacing:-0.1pt;">unpredictable</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">generally</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">expensive</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">time</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">consuming</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">and,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">even</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">if</span><span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:-0.1pt;">resolved</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">favor,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">is</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">likely</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">divert </span>significant resources from our core business, including distracting our technical and management personnel from<span style="letter-spacing:-0.7pt;"> </span>their<span style="letter-spacing:-0.65pt;"> </span>normal<span style="letter-spacing:-0.65pt;"> </span>responsibilities.<span style="letter-spacing:-0.65pt;"> </span>In<span style="letter-spacing:-0.65pt;"> </span>addition,<span style="letter-spacing:-0.65pt;"> </span>there<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.7pt;"> </span>public<span style="letter-spacing:-0.65pt;"> </span>announcements<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>results<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>hearings, motions or other interim proceedings or developments which could adversely effect the market price of our common stock and harm our reputation. Such litigation or proceedings could substantially increase our <span style="letter-spacing:-0.1pt;">operating</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">losses</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">reduce</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">resources</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">available</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">development</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">activities</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">any</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">future</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">sales,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">marketing</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">or </span>distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could adversely affect our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>substantial<span style="letter-spacing:-0.3pt;"> </span>amount<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>intellectual<span style="letter-spacing:-0.3pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>biotechnology<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates. We cannot be certain that our product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.3pt;"> </span>not<span style="letter-spacing:-0.3pt;"> </span>infringe<span style="letter-spacing:-0.3pt;"> </span>existing<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>future<span style="letter-spacing:-0.3pt;"> </span>valid<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.3pt;"> </span>owned<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.3pt;"> </span>third<span style="letter-spacing:-0.3pt;"> </span>parties.<span style="letter-spacing:-0.3pt;"> </span>Third<span style="letter-spacing:-0.3pt;"> </span>parties<span style="letter-spacing:-0.3pt;"> </span>may assert infringement claims against us based on existing or future intellectual property rights, regardless of their merit. We may decide in the future to seek a license to such third-party patents or other intellectual property rights, but we might not be able to do so on reasonable terms. Proving patent invalidity may be difficult. For example, in the U.S., proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. As this burden is a high<span style="letter-spacing:-0.3pt;"> </span>one,<span style="letter-spacing:-0.3pt;"> </span>there<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.3pt;"> </span>no<span style="letter-spacing:-0.3pt;"> </span>assurance<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>court<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>competent<span style="letter-spacing:-0.3pt;"> </span>jurisdiction<span style="letter-spacing:-0.3pt;"> </span>would<span style="letter-spacing:-0.3pt;"> </span>invalidate<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>claims<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>any<span style="letter-spacing:-0.3pt;"> </span>such U.S. patent or find that our product candidates do not infringe any such claims. If we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could be forced, including<span style="letter-spacing:-0.65pt;"> </span>by<span style="letter-spacing:-0.65pt;"> </span>court<span style="letter-spacing:-0.65pt;"> </span>order,<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>cease<span style="letter-spacing:-0.65pt;"> </span>developing,<span style="letter-spacing:-0.65pt;"> </span>manufacturing<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>commercializing<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>infringing<span style="letter-spacing:-0.65pt;"> </span>technology<span style="letter-spacing:-0.65pt;"> </span>or product candidate. Further, we may be required to redesign the technology or product candidate in a non- infringing manner, which may not be commercially feasible. Alternatively, we may be required to obtain a <span style="letter-spacing:-0.1pt;">license</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">such</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">third</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">party</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">order</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">use</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">infringing</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">technology</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">continue</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">developing,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">manufacturing </span>or<span style="letter-spacing:-0.55pt;"> </span>marketing<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>infringing<span style="letter-spacing:-0.55pt;"> </span>product<span style="letter-spacing:-0.55pt;"> </span>candidate.<span style="letter-spacing:-0.55pt;"> </span>However,<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>not<span style="letter-spacing:-0.55pt;"> </span>be<span style="letter-spacing:-0.55pt;"> </span>able<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>obtain<span style="letter-spacing:-0.55pt;"> </span>any<span style="letter-spacing:-0.55pt;"> </span>required<span style="letter-spacing:-0.55pt;"> </span>license<span style="letter-spacing:-0.55pt;"> </span>on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby<span style="letter-spacing:-0.4pt;"> </span>giving<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>access<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>same<span style="letter-spacing:-0.4pt;"> </span>technologies<span style="letter-spacing:-0.4pt;"> </span>licensed<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>us,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>it<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.4pt;"> </span>require<span style="letter-spacing:-0.4pt;"> </span>us<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>make substantial licensing and royalty payments. In addition, we could be found liable for monetary damages, including<span style="letter-spacing:-0.55pt;"> </span>treble<span style="letter-spacing:-0.4pt;"> </span>damages<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>attorneys&#8217;<span style="letter-spacing:-0.7pt;"> </span>fees<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:0.45pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.4pt;"> </span>found<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>have<span style="letter-spacing:-0.4pt;"> </span>willfully<span style="letter-spacing:-0.4pt;"> </span>infringed<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>patent.<span style="letter-spacing:-0.4pt;"> </span>A<span style="letter-spacing:-0.4pt;"> </span>finding<span style="letter-spacing:-0.4pt;"> </span>of infringement<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.35pt;"> </span>prevent<span style="letter-spacing:-0.35pt;"> </span>us<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.4pt;"> </span>commercializing<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>force<span style="letter-spacing:-0.35pt;"> </span>us<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>cease<span style="letter-spacing:-0.4pt;"> </span>some<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span><span style="letter-spacing:-0.25pt;">our</span> business operations, which could materially harm our business. Claims that we have misappropriated the<span style="letter-spacing:4pt;"> </span>confidential<span style="letter-spacing:-0.5pt;"> </span>information<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>trade<span style="letter-spacing:-0.45pt;"> </span>secrets<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>third<span style="letter-spacing:-0.45pt;"> </span>parties<span style="letter-spacing:-0.5pt;"> </span>could<span style="letter-spacing:-0.45pt;"> </span>have<span style="letter-spacing:-0.5pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>similar<span style="letter-spacing:-0.5pt;"> </span>negative<span style="letter-spacing:-0.45pt;"> </span>impact<span style="letter-spacing:-0.5pt;"> </span>on<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We may choose to challenge the enforceability or validity of claims in a third party&#8217;s U.S. patent by requesting<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>USPTO<span style="letter-spacing:-0.6pt;"> </span>review<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>patent<span style="letter-spacing:-0.6pt;"> </span>claims<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>an<span style="letter-spacing:-0.6pt;"> </span><i style="font-style:italic;">ex-parte</i><i style="font-style:italic;letter-spacing:-0.6pt;"> </i>reexamination,<span style="letter-spacing:-0.6pt;"> </span><i style="font-style:italic;">inter</i><i style="font-style:italic;letter-spacing:-0.6pt;"> </i><i style="font-style:italic;">partes</i><i style="font-style:italic;letter-spacing:-0.6pt;"> </i>review<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>post- grant<span style="letter-spacing:-0.7pt;"> </span>review<span style="letter-spacing:-0.65pt;"> </span>proceedings.<span style="letter-spacing:-0.65pt;"> </span>These<span style="letter-spacing:-0.65pt;"> </span>proceedings<span style="letter-spacing:-0.65pt;"> </span>are<span style="letter-spacing:-0.65pt;"> </span>expensive<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.7pt;"> </span>consume<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>time<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>other<span style="letter-spacing:-0.65pt;"> </span>resources.<span style="letter-spacing:-0.65pt;"> </span>We may<span style="letter-spacing:-0.45pt;"> </span>choose<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>challenge<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>third<span style="letter-spacing:-0.45pt;"> </span>party&#8217;s<span style="letter-spacing:-0.45pt;"> </span>patent<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>patent<span style="letter-spacing:-0.45pt;"> </span>opposition<span style="letter-spacing:-0.45pt;"> </span>proceedings<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>European<span style="letter-spacing:-0.45pt;"> </span>Patent<span style="letter-spacing:-0.45pt;"> </span>Office (&#8220;EPO&#8221;), or other foreign patent office. The costs of these </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">opposition proceedings could be substantial and may<span style="letter-spacing:-0.15pt;"> </span>consume<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>resources.<span style="letter-spacing:-0.15pt;"> </span>If<span style="letter-spacing:0.85pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>fail<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>favorable<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>at<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>USPTO,<span style="letter-spacing:-0.15pt;"> </span>EPO<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>other patent<span style="letter-spacing:-0.5pt;"> </span>office<span style="letter-spacing:-0.5pt;"> </span>then<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>be<span style="letter-spacing:-0.5pt;"> </span>exposed<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>litigation<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:-0.5pt;"> </span>a<span style="letter-spacing:-0.5pt;"> </span>third<span style="letter-spacing:-0.5pt;"> </span>party<span style="letter-spacing:-0.5pt;"> </span>alleging<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>patent<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>be<span style="letter-spacing:-0.5pt;"> </span>infringed<span style="letter-spacing:-0.5pt;"> </span>by our product candidates. Further, third-party patents or other intellectual property rights may be enforced against our current technology, including our research programs, product candidates, and their respective methods<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>use,<span style="letter-spacing:-0.2pt;"> </span>manufacture<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>formulations<span style="letter-spacing:-0.2pt;"> </span>thereof,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>either<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>injunction<span style="letter-spacing:-0.2pt;"> </span>prohibiting our<span style="letter-spacing:-0.15pt;"> </span>manufacture<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>sales,<span style="letter-spacing:-0.15pt;"> </span>or,<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>respect<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>sales,<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>obligation<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>part<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>pay<span style="letter-spacing:-0.15pt;"> </span>royalties and/or other forms of<span style="letter-spacing:2pt;"> </span>compensation to third parties, which could be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>patent<span style="letter-spacing:-0.65pt;"> </span>law<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>U.S.<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>other<span style="letter-spacing:-0.6pt;"> </span>jurisdictions<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.6pt;"> </span>diminish<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>value<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.4pt;"> </span>patents<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>case<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.15pt;"> </span>companies,<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>success<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.15pt;"> </span>heavily<span style="letter-spacing:-0.15pt;"> </span>dependent<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>intellectual property, particularly patents. Obtaining, defending, maintaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>inherently<span style="letter-spacing:-0.1pt;"> </span>uncertain.<span style="letter-spacing:-0.1pt;"> </span>Changes<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>either<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.1pt;"> </span>laws<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>interpretation<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.1pt;"> </span>laws<span style="letter-spacing:-0.1pt;"> </span>in the<span style="letter-spacing:-0.65pt;"> </span>U.S.<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>increase<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>uncertainties<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>costs<span style="letter-spacing:-0.65pt;"> </span>surrounding<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>prosecution<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>patent<span style="letter-spacing:-0.65pt;"> </span>applications and the enforcement or defense of issued patents, and may diminish our ability to protect our inventions, obtain, maintain, enforce and protect our intellectual property rights and, more generally, could affect the value<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>intellectual<span style="letter-spacing:-0.55pt;"> </span>property<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>narrow<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>scope<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>future<span style="letter-spacing:-0.55pt;"> </span>owned<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>licensed<span style="letter-spacing:-0.55pt;"> </span>patents.<span style="letter-spacing:-0.55pt;"> </span>Patent<span style="letter-spacing:-0.55pt;"> </span>reform legislation in the U.S. and other countries, including the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;), signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our future issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.45pt;"> </span>affect<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>way<span style="letter-spacing:-0.45pt;"> </span>patent<span style="letter-spacing:-0.45pt;"> </span>applications<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.45pt;"> </span>prosecuted,<span style="letter-spacing:-0.45pt;"> </span>redefine<span style="letter-spacing:-0.45pt;"> </span>prior<span style="letter-spacing:-0.45pt;"> </span>art<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>provide<span style="letter-spacing:-0.45pt;"> </span>more<span style="letter-spacing:-0.45pt;"> </span>efficient and cost-effective avenues for competitors to challenge the validity of<span style="letter-spacing:2pt;"> </span>patents. These include allowing<span style="letter-spacing:2pt;"> </span>third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <i style="font-style:italic;">inter partes </i>review, and derivation proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, because of a lower evidentiary standard in these USPTO post-grant proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could<span style="letter-spacing:-0.1pt;"> </span>potentially<span style="letter-spacing:-0.1pt;"> </span>provide<span style="letter-spacing:-0.1pt;"> </span>evidence<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>USPTO<span style="letter-spacing:-0.1pt;"> </span>proceeding<span style="letter-spacing:-0.1pt;"> </span>sufficient<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>USPTO<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>hold<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>claim<span style="letter-spacing:-0.1pt;"> </span>invalid even<span style="letter-spacing:-0.7pt;"> </span>though<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>same<span style="letter-spacing:-0.65pt;"> </span>evidence<span style="letter-spacing:-0.65pt;"> </span>would<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>insufficient<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.7pt;"> </span>invalidate<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>claim<span style="letter-spacing:-0.65pt;"> </span>if<span style="letter-spacing:-0.35pt;"> </span>first<span style="letter-spacing:-0.7pt;"> </span>presented<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>district<span style="letter-spacing:-0.65pt;"> </span>court action.<span style="letter-spacing:-0.7pt;"> </span>Accordingly,<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>third<span style="letter-spacing:-0.65pt;"> </span>party<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>attempt<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>use<span style="letter-spacing:-0.7pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>USPTO<span style="letter-spacing:-0.65pt;"> </span>procedures<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>invalidate<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.7pt;"> </span>licensors&#8217; patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs<span style="letter-spacing:-0.45pt;"> </span>surrounding<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>prosecution<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.7pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>applications<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>enforcement<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>defense of our or our licensors&#8217; future issued patents, all of which could adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After March 2013, under the Leahy-Smith Act, the U.S. transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>claimed<span style="letter-spacing:-0.4pt;"> </span>invention.<span style="letter-spacing:-0.4pt;"> </span>A<span style="letter-spacing:-0.4pt;"> </span>third<span style="letter-spacing:-0.4pt;"> </span>party<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.4pt;"> </span>files<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>patent<span style="letter-spacing:-0.4pt;"> </span>application<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>USPTO<span style="letter-spacing:-0.4pt;"> </span>after<span style="letter-spacing:-0.4pt;"> </span>March<span style="letter-spacing:-0.4pt;"> </span>2013,<span style="letter-spacing:-0.4pt;"> </span>but before we file an application covering the same invention, could therefore be awarded a patent covering an invention<span style="letter-spacing:-0.1pt;"> </span>of ours<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>licensors<span style="letter-spacing:-0.1pt;"> </span>even<span style="letter-spacing:-0.1pt;"> </span>if we<span style="letter-spacing:-0.1pt;"> </span>had<span style="letter-spacing:-0.1pt;"> </span>made<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>invention<span style="letter-spacing:-0.1pt;"> </span>before<span style="letter-spacing:-0.1pt;"> </span>it<span style="letter-spacing:-0.1pt;"> </span>was<span style="letter-spacing:-0.1pt;"> </span>made<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>party. This<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.45pt;"> </span>require<span style="letter-spacing:-0.45pt;"> </span>us<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>be<span style="letter-spacing:-0.45pt;"> </span>cognizant<span style="letter-spacing:-0.45pt;"> </span>going<span style="letter-spacing:-0.45pt;"> </span>forward<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>time<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span>invention<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>filing<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>patent<span style="letter-spacing:-0.45pt;"> </span>application. Since patent applications in the U.S. and most other countries are confidential for a period of<span style="letter-spacing:1.25pt;"> </span>time after<span style="letter-spacing:0.05pt;"> </span>filing<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>until<span style="letter-spacing:0.05pt;"> </span>issuance,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>licensors<span style="letter-spacing:0.05pt;"> </span>were<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>first<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>either<span style="letter-spacing:0.05pt;"> </span>(i)<span style="letter-spacing:0.05pt;"> </span>file<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.25pt;">any</span> patent<span style="letter-spacing:1.95pt;"> </span>application<span style="letter-spacing:1.95pt;"> </span>related<span style="letter-spacing:2pt;"> </span>to<span style="letter-spacing:1.95pt;"> </span>our<span style="letter-spacing:1.95pt;"> </span>product<span style="letter-spacing:2pt;"> </span>candidates<span style="letter-spacing:1.95pt;"> </span>and<span style="letter-spacing:1.95pt;"> </span>other<span style="letter-spacing:2pt;"> </span>proprietary<span style="letter-spacing:1.95pt;"> </span>technologies<span style="letter-spacing:2pt;"> </span>we<span style="letter-spacing:1.95pt;"> </span>may<span style="letter-spacing:1.95pt;"> </span>develop<span style="letter-spacing:2pt;"> </span><span style="letter-spacing:-0.25pt;">or</span> (ii)<span style="letter-spacing:-0.7pt;"> </span>invent<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>inventions<span style="letter-spacing:-0.6pt;"> </span>claimed<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.7pt;"> </span>patents<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>patent<span style="letter-spacing:-0.6pt;"> </span>applications.<span style="letter-spacing:-0.6pt;"> </span>Even<span style="letter-spacing:-0.6pt;"> </span>where<span style="letter-spacing:-0.6pt;"> </span>we <span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">valid</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">enforceable</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">patent,</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">able</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">exclude</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">others</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">practicing</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">claimed</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">invention </span>where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement<span style="letter-spacing:-0.7pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>defense<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>future<span style="letter-spacing:-0.65pt;"> </span>issued<span style="letter-spacing:-0.65pt;"> </span>patents,<span style="letter-spacing:-0.65pt;"> </span>all<span style="letter-spacing:-0.7pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>which<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>adversely<span style="letter-spacing:-0.65pt;"> </span>affect<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.7pt;"> </span>business,<span style="letter-spacing:-0.65pt;"> </span>financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Changes in either the patent laws or interpretation of the patent laws in the U.S. or in other </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In the U.S., numerous recent changes to the patent laws and proposed changes to the rules of the USPTO may have a significant impact on our ability to protect our technology, products and enforce our intellectual property rights. Subsequent rulings could adversely impact our patents or patent applications. In addition to increasing uncertainty regarding our ability to obtain patents in the future, this combination<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>events<span style="letter-spacing:-0.65pt;"> </span>has<span style="letter-spacing:-0.65pt;"> </span>created<span style="letter-spacing:-0.65pt;"> </span>uncertainty<span style="letter-spacing:-0.65pt;"> </span>with<span style="letter-spacing:-0.65pt;"> </span>respect<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>value<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>patents,<span style="letter-spacing:-0.65pt;"> </span>once<span style="letter-spacing:-0.65pt;"> </span>granted.<span style="letter-spacing:-0.65pt;"> </span>For<span style="letter-spacing:-0.65pt;"> </span>example, the<span style="letter-spacing:-0.7pt;"> </span>U.S.<span style="letter-spacing:-0.65pt;"> </span>Supreme<span style="letter-spacing:-0.65pt;"> </span>Court,<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>case<span style="letter-spacing:-0.65pt;"> </span><i style="font-style:italic;">Amgen</i><i style="font-style:italic;letter-spacing:-0.65pt;"> </i><i style="font-style:italic;">v.</i><i style="font-style:italic;letter-spacing:-0.7pt;"> </i><i style="font-style:italic;">Sanofi</i>,<span style="letter-spacing:-0.65pt;"> </span>held<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>broad<span style="letter-spacing:-0.65pt;"> </span>functional<span style="letter-spacing:-0.65pt;"> </span>antibody<span style="letter-spacing:-0.65pt;"> </span>claims<span style="letter-spacing:-0.65pt;"> </span>are<span style="letter-spacing:-0.7pt;"> </span>invalid<span style="letter-spacing:-0.65pt;"> </span>for lack of enablement. As such, our ability to obtain patents with functional claims, or to protect our patent rights with functional claims from third party challenges seeking to invalidate these claims for lacking enablement or adequate support in the specification, is uncertain. In addition, in <i style="font-style:italic;">Juno v. Kite</i>, the Federal <span style="letter-spacing:-0.1pt;">Circuit</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">held</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">broad</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">antibody</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">claims</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">supported</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">by</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">few</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">examples</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">invalid</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">lack</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:-0.1pt;">written</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">description.</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">Recently, </span>the<span style="letter-spacing:-0.7pt;"> </span>Federal<span style="letter-spacing:-0.65pt;"> </span>Circuit<span style="letter-spacing:-0.65pt;"> </span>issued<span style="letter-spacing:-0.65pt;"> </span>precedential<span style="letter-spacing:-0.65pt;"> </span>decisions<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span><i style="font-style:italic;">In</i><i style="font-style:italic;letter-spacing:-0.7pt;"> </i><i style="font-style:italic;">re</i><i style="font-style:italic;letter-spacing:-0.65pt;"> </i><i style="font-style:italic;">Cellect</i><i style="font-style:italic;letter-spacing:-0.65pt;"> </i>(No.<span style="letter-spacing:-0.65pt;"> </span>22-1293)<span style="letter-spacing:-0.65pt;"> and </span><i style="font-style:italic;letter-spacing:-0.65pt;">Allergan v. MSN Laboratories</i><span style="letter-spacing:-0.65pt;"> (No. 24-1061) </span>that<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>shorten<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.7pt;"> </span>eliminate an extended patent term awarded under Patent Term Adjustment (&#8220;PTA&#8221;) in certain patent family members if challenged on the basis of Obvious-Type<span style="letter-spacing:-0.3pt;"> </span>Double<span style="letter-spacing:-0.3pt;"> </span>Patenting.<span style="letter-spacing:-0.3pt;"> </span>Furthermore,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>U.S.<span style="letter-spacing:-0.3pt;"> </span>Supreme<span style="letter-spacing:-0.3pt;"> </span>Court<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>Federal<span style="letter-spacing:-0.3pt;"> </span>Circuits<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>repeatedly held that the use of<span style="letter-spacing:1.85pt;"> </span>biomarkers in diagnosis or monitoring therapeutic treatment is not patent eligible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depending<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.3pt;"> </span>decisions<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>U.S.<span style="letter-spacing:-0.3pt;"> </span>Congress,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>federal<span style="letter-spacing:-0.3pt;"> </span>courts<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>USPTO,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>similar<span style="letter-spacing:-0.3pt;"> </span>legislative and regulatory bodies in other countries in which we may pursue patent protection, the laws and regulations governing patents could change in unpredictable ways, particularly with respect to pharmaceutical patent protection, that would weaken our ability to obtain new patents or to enforce our or our licensors&#8217; or collaborators&#8217; existing patents and patents that we might obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.15pt;"> </span>cannot<span style="letter-spacing:-0.15pt;"> </span>predict<span style="letter-spacing:-0.15pt;"> </span>how<span style="letter-spacing:-0.15pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>decisions<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>courts,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>U.S.<span style="letter-spacing:-0.15pt;"> </span>Congress<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>USPTO<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>impact<span style="letter-spacing:-0.15pt;"> </span>the value<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>patents.<span style="letter-spacing:-0.55pt;"> </span>Any<span style="letter-spacing:-0.55pt;"> </span>similar<span style="letter-spacing:-0.55pt;"> </span>adverse<span style="letter-spacing:-0.55pt;"> </span>change<span style="letter-spacing:-0.55pt;"> </span>in<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>patent<span style="letter-spacing:-0.55pt;"> </span>laws<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>other<span style="letter-spacing:-0.55pt;"> </span>jurisdictions<span style="letter-spacing:-0.55pt;"> </span>could<span style="letter-spacing:-0.55pt;"> </span>also<span style="letter-spacing:-0.55pt;"> </span>adversely affect our business, financial condition, results of<span style="letter-spacing:2pt;"> </span>operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:-0.4pt;"> </span>2012,<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>European<span style="letter-spacing:-0.4pt;"> </span>Union<span style="letter-spacing:-0.4pt;"> </span>Patent<span style="letter-spacing:-0.4pt;"> </span>Package<span style="letter-spacing:-0.4pt;"> </span>(EU<span style="letter-spacing:-0.4pt;"> </span>Patent<span style="letter-spacing:-0.4pt;"> </span>Package)<span style="letter-spacing:-0.4pt;"> </span>regulations<span style="letter-spacing:-0.4pt;"> </span>were<span style="letter-spacing:-0.4pt;"> </span>passed<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court (UPC) for litigation<span style="letter-spacing:-0.4pt;"> </span>involving<span style="letter-spacing:-0.4pt;"> </span>European<span style="letter-spacing:-0.4pt;"> </span>patents.<span style="letter-spacing:-0.4pt;"> </span>The<span style="letter-spacing:-0.4pt;"> </span>EU<span style="letter-spacing:-0.4pt;"> </span>Patent<span style="letter-spacing:-0.4pt;"> </span>Package<span style="letter-spacing:-0.4pt;"> </span>was<span style="letter-spacing:-0.4pt;"> </span>implemented<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:-0.4pt;"> </span>June<span style="letter-spacing:-0.4pt;"> </span>1,<span style="letter-spacing:-0.4pt;"> </span>2023.<span style="letter-spacing:-0.4pt;"> </span>As<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>result, all European patents, including those issued prior to ratification of the EU Patent Package, now by default automatically<span style="letter-spacing:-0.2pt;"> </span>fall<span style="letter-spacing:-0.2pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>jurisdiction<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>UPC,<span style="letter-spacing:-0.2pt;"> </span>unless<span style="letter-spacing:-0.2pt;"> </span>otherwise<span style="letter-spacing:-0.2pt;"> </span>opted<span style="letter-spacing:-0.2pt;"> </span>out.<span style="letter-spacing:-0.2pt;"> </span>It<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>uncertain<span style="letter-spacing:-0.2pt;"> </span>how<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>UPC will impact granted European patents in the biotechnology and pharmaceutical industries. Our owned or licensed<span style="letter-spacing:-0.45pt;"> </span>European<span style="letter-spacing:-0.45pt;"> </span>patent<span style="letter-spacing:-0.45pt;"> </span>applications,<span style="letter-spacing:-0.45pt;"> </span>if<span style="letter-spacing:0.45pt;"> </span>issued,<span style="letter-spacing:-0.45pt;"> </span>could<span style="letter-spacing:-0.45pt;"> </span>be<span style="letter-spacing:-0.45pt;"> </span>challenged<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>UPC.<span style="letter-spacing:-0.45pt;"> </span>During<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>first<span style="letter-spacing:-0.45pt;"> </span>seven<span style="letter-spacing:-0.45pt;"> </span>years of the UPC&#8217;s existence, the UPC legislation allows a patent owner to opt its European patents out of the jurisdiction of<span style="letter-spacing:1.25pt;"> </span>the UPC. We may decide to opt out our owned or licensed future European patents from the UPC,<span style="letter-spacing:-0.2pt;"> </span>but<span style="letter-spacing:-0.2pt;"> </span>doing<span style="letter-spacing:-0.2pt;"> </span>so<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>preclude<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>realizing<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>benefits<span style="letter-spacing:-0.2pt;"> </span>of the<span style="letter-spacing:-0.2pt;"> </span>UPC.<span style="letter-spacing:-0.2pt;"> </span>Moreover,<span style="letter-spacing:-0.2pt;"> </span>if the<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>owner<span style="letter-spacing:-0.2pt;"> </span>of our<span style="letter-spacing:-0.45pt;"> </span>owned<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>licensed<span style="letter-spacing:-0.45pt;"> </span>future<span style="letter-spacing:-0.45pt;"> </span>European<span style="letter-spacing:-0.45pt;"> </span>patents<span style="letter-spacing:-0.45pt;"> </span>do<span style="letter-spacing:-0.45pt;"> </span>not<span style="letter-spacing:-0.45pt;"> </span>meet<span style="letter-spacing:-0.45pt;"> </span>all<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>formalities<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.45pt;"> </span>opt-out under the UPC, said future European patents could remain under the jurisdiction of<span style="letter-spacing:1.1pt;"> </span>the UPC. The UPC will provide our competitors with a new forum to centrally revoke our owned or licensed European patents, and allow for the possibility of<span style="letter-spacing:1.15pt;"> </span>a competitor to obtain a pan-European injunction in UPC member states. Such a <span style="letter-spacing:-0.1pt;">loss</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.9pt;"> </span><span style="letter-spacing:-0.1pt;">patent</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">protection</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">material</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">adverse</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">impact</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">business</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">ability</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">commercialize </span>our technology and any future product candidates due to increased competition and, resultantly, on our business,<span style="letter-spacing:-0.25pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>condition,<span style="letter-spacing:-0.25pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>operations<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>prospects<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>Europe.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.25pt;"> </span>UPC<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>Unitary<span style="letter-spacing:-0.25pt;"> </span>Patent<span style="letter-spacing:-0.25pt;"> </span>are significant<span style="letter-spacing:-0.1pt;"> </span>changes<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>European<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.1pt;"> </span>practice.<span style="letter-spacing:-0.1pt;"> </span>As<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>UPC<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>new<span style="letter-spacing:-0.1pt;"> </span>court<span style="letter-spacing:-0.1pt;"> </span>system,<span style="letter-spacing:-0.1pt;"> </span>there<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>no<span style="letter-spacing:-0.1pt;"> </span>precedent<span style="letter-spacing:-0.1pt;"> </span>for the court, increasing the uncertainty of<span style="letter-spacing:2pt;"> </span>any litigation in the UPC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>become<span style="letter-spacing:-0.65pt;"> </span>subject<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>claims<span style="letter-spacing:-0.6pt;"> </span>challenging<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>inventorship<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>ownership<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.6pt;"> </span>patents<span style="letter-spacing:-0.65pt;"> </span>and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>former<span style="letter-spacing:-0.15pt;"> </span>employees,<span style="letter-spacing:-0.15pt;"> </span>collaborators<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>interest in<span style="letter-spacing:-0.7pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.7pt;"> </span>patents<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>other<span style="letter-spacing:-0.55pt;"> </span>intellectual<span style="letter-spacing:-0.55pt;"> </span>property<span style="letter-spacing:-0.55pt;"> </span>as<span style="letter-spacing:-0.55pt;"> </span>an<span style="letter-spacing:-0.55pt;"> </span>inventor<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>co-inventor.<span style="letter-spacing:-0.55pt;"> </span>The<span style="letter-spacing:-0.55pt;"> </span>failure<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named<span style="letter-spacing:-0.65pt;"> </span>as<span style="letter-spacing:-0.65pt;"> </span>inventors,<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>effects<span style="letter-spacing:-0.65pt;"> </span>of foreign<span style="letter-spacing:-0.65pt;"> </span>laws<span style="letter-spacing:-0.65pt;"> </span>where<span style="letter-spacing:-0.65pt;"> </span>foreign<span style="letter-spacing:-0.65pt;"> </span>nationals<span style="letter-spacing:-0.65pt;"> </span>are<span style="letter-spacing:-0.65pt;"> </span>involved<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>development<span style="letter-spacing:-0.65pt;"> </span>of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>result<span style="letter-spacing:-0.3pt;"> </span>of questions<span style="letter-spacing:-0.3pt;"> </span>regarding<span style="letter-spacing:-0.3pt;"> </span>co-ownership<span style="letter-spacing:-0.3pt;"> </span>of potential<span style="letter-spacing:-0.3pt;"> </span>joint<span style="letter-spacing:-0.3pt;"> </span>inventions.<span style="letter-spacing:-0.3pt;"> </span>Litigation<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>be necessary to resolve these and other claims challenging inventorship or ownership. Alternatively, or additionally,<span style="letter-spacing:-0.7pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>enter<span style="letter-spacing:-0.65pt;"> </span>into<span style="letter-spacing:-0.65pt;"> </span>agreements<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>clarify<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.7pt;"> </span>scope<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>rights<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>intellectual<span style="letter-spacing:-0.65pt;"> </span>property.<span style="letter-spacing:-0.7pt;"> </span>If<span style="letter-spacing:-0.65pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">we fail to defend any such claims, in addition to paying monetary damages, we may lose valuable intellectual <span style="letter-spacing:-0.1pt;">property</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">rights,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">such</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">as</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">exclusive</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">ownership</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">right</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">use,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">valuable</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">intellectual</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">property.</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">Such</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">an</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">outcome could</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">adversely</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">affect</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">business.</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">Even</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">if</span><span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">are</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">successful</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">defending</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">against</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">such</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">claims,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">litigation</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">could </span>result in substantial costs and be a distraction to management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">current</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">future</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">licensors</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">relied</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">third-party</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">consultants</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">collaborators</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">funds </span>from<span style="letter-spacing:0.95pt;"> </span>third<span style="letter-spacing:0.95pt;"> </span>parties,<span style="letter-spacing:0.95pt;"> </span>such<span style="letter-spacing:0.95pt;"> </span>as<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.95pt;"> </span>U.S.<span style="letter-spacing:0.95pt;"> </span>government,<span style="letter-spacing:0.95pt;"> </span>such<span style="letter-spacing:0.95pt;"> </span>that<span style="letter-spacing:0.95pt;"> </span>our<span style="letter-spacing:0.95pt;"> </span>licensors<span style="letter-spacing:0.95pt;"> </span>are<span style="letter-spacing:0.95pt;"> </span>not<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.95pt;"> </span>sole<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.95pt;"> </span>exclusive<span style="letter-spacing:0.95pt;"> </span>owners of<span style="letter-spacing:-0.7pt;"> </span>the<span style="letter-spacing:-0.7pt;"> </span>patents<span style="letter-spacing:-0.7pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>in-licensed.<span style="letter-spacing:-0.7pt;"> </span>If<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.65pt;"> </span>third<span style="letter-spacing:-0.7pt;"> </span>parties<span style="letter-spacing:-0.7pt;"> </span>have<span style="letter-spacing:-0.7pt;"> </span>ownership<span style="letter-spacing:-0.65pt;"> </span>rights<span style="letter-spacing:-0.7pt;"> </span>or<span style="letter-spacing:-0.7pt;"> </span>other<span style="letter-spacing:-0.7pt;"> </span>rights<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.7pt;"> </span>our<span style="letter-spacing:-0.7pt;"> </span>in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could adversely affect our competitive position, business, financial condition,<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.1pt;"> </span>of operations,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception<span style="letter-spacing:-0.7pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>development<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>intellectual<span style="letter-spacing:-0.65pt;"> </span>property<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.7pt;"> </span>execute<span style="letter-spacing:-0.65pt;"> </span>agreements<span style="letter-spacing:-0.65pt;"> </span>assigning<span style="letter-spacing:-0.65pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>intellectual<span style="letter-spacing:-0.65pt;"> </span>property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops<span style="letter-spacing:-0.1pt;"> </span>intellectual<span style="letter-spacing:-0.1pt;"> </span>property<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>regard<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>own.<span style="letter-spacing:-0.1pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>assignment<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>intellectual<span style="letter-spacing:-0.1pt;"> </span>property<span style="letter-spacing:-0.1pt;"> </span>rights<span style="letter-spacing:-0.1pt;"> </span>may not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>self-executing,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>assignment<span style="letter-spacing:-0.15pt;"> </span>agreements<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>breached,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>forced<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>bring<span style="letter-spacing:-0.15pt;"> </span>claims against<span style="letter-spacing:-0.25pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>parties,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>defend<span style="letter-spacing:-0.25pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>they<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>bring<span style="letter-spacing:-0.25pt;"> </span>against<span style="letter-spacing:-0.25pt;"> </span>us,<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>determine<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>ownership<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>what<span style="letter-spacing:-0.25pt;"> </span>we <span style="letter-spacing:-0.1pt;">regard</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">as</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">intellectual</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">property.</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">Such</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">claims</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">adversely</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">affect</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">business,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">financial</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">condition,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">results </span>of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patent terms may be inadequate to protect our competitive position on products or product candidates for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional or international patent application filing date. Various extensions may be available, but the life of a patent, and the protection it affords,<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>limited.<span style="letter-spacing:-0.1pt;"> </span>Even<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:0.9pt;"> </span>patents<span style="letter-spacing:-0.1pt;"> </span>covering<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>obtained,<span style="letter-spacing:-0.1pt;"> </span>once<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>patent life<span style="letter-spacing:-0.6pt;"> </span>has<span style="letter-spacing:-0.6pt;"> </span>expired,<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>be<span style="letter-spacing:-0.6pt;"> </span>open<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>competition<span style="letter-spacing:-0.6pt;"> </span>from<span style="letter-spacing:-0.6pt;"> </span>competitive<span style="letter-spacing:-0.6pt;"> </span>products,<span style="letter-spacing:-0.6pt;"> </span>including<span style="letter-spacing:-0.6pt;"> </span>generics<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>biosimilars. Given the amount of time required for the development, testing and regulatory review of products or new product candidates, patents protecting such products or candidates might expire before or shortly after such products or candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient and continuing rights to exclude others from commercializing products similar or identical<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>ours.<span style="letter-spacing:-0.4pt;"> </span>For<span style="letter-spacing:-0.4pt;"> </span>example,<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>patent<span style="letter-spacing:-0.4pt;"> </span>covering<span style="letter-spacing:-0.4pt;"> </span>obexelimab&#8217;s<span style="letter-spacing:-0.4pt;"> </span>composition<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>matter<span style="letter-spacing:-0.4pt;"> </span>expires<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>May<span style="letter-spacing:-0.4pt;"> </span>2028, excluding any extension of<span style="letter-spacing:1.8pt;"> </span>patent term that may be available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>reduced<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>eliminated<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>result<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.95pt;"> </span>noncompliance<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.05pt;"> </span>requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Periodic</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">maintenance</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">fees,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">renewal</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">fees,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">annuity</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">fees</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">various</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">government</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">fees</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">patents</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">and/or </span>applications will be due to be paid to the USPTO and various government patent agencies outside of the U.S. over the lifetime of our owned or licensed patents and patent applications. Recently, the USPTO implemented new fee rules including Continuing Application Fee (CAF) which would increase our cost for obtaining and maintaining patent protection in the US and potentially limit our ability of seeking additional patents in our existing patent families, especially those early filed patent families that has been pending for close to our more than six years. We rely on our outside counsel or our licensing partners to pay these fees due to U.S. and non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary,<span style="letter-spacing:0.65pt;"> </span>fee<span style="letter-spacing:0.65pt;"> </span>payment<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>other<span style="letter-spacing:0.7pt;"> </span>similar<span style="letter-spacing:0.65pt;"> </span>provisions<span style="letter-spacing:0.65pt;"> </span>during<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:0.65pt;"> </span>patent<span style="letter-spacing:0.7pt;"> </span>application<span style="letter-spacing:0.65pt;"> </span>process.<span style="letter-spacing:0.65pt;"> </span>We<span style="letter-spacing:0.7pt;"> </span>are<span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:-0.2pt;">also</span> dependent<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>licensors<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>take<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>necessary<span style="letter-spacing:-0.4pt;"> </span>action<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>comply<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.4pt;"> </span>these<span style="letter-spacing:-0.4pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.4pt;"> </span>respect<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>our licensed<span style="letter-spacing:-0.4pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:-0.4pt;"> </span>many<span style="letter-spacing:-0.4pt;"> </span>cases,<span style="letter-spacing:-0.4pt;"> </span>an<span style="letter-spacing:-0.4pt;"> </span>inadvertent<span style="letter-spacing:-0.4pt;"> </span>lapse<span style="letter-spacing:-0.4pt;"> </span>can<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.4pt;"> </span>cured<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:-0.4pt;"> </span>payment<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>late<span style="letter-spacing:-0.4pt;"> </span>fee<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>by other<span style="letter-spacing:-0.15pt;"> </span>means<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>accordance<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>applicable<span style="letter-spacing:-0.15pt;"> </span>rules.<span style="letter-spacing:-0.15pt;"> </span>There<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>situations,<span style="letter-spacing:-0.15pt;"> </span>however,<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>noncompliance can<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>abandonment<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>lapse<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>application,<span style="letter-spacing:-0.2pt;"> </span>resulting<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>partial<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>complete<span style="letter-spacing:-0.2pt;"> </span>loss<span style="letter-spacing:-0.2pt;"> </span>of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could adversely affect our business, financial condition, results of operations and prospects.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If<span style="letter-spacing:0.45pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>do<span style="letter-spacing:-0.35pt;"> </span>not<span style="letter-spacing:-0.35pt;"> </span>obtain<span style="letter-spacing:-0.35pt;"> </span>patent<span style="letter-spacing:-0.4pt;"> </span>term<span style="letter-spacing:-0.35pt;"> </span>extension<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>business<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.35pt;"> </span>materially<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depending<span style="letter-spacing:-0.7pt;"> </span>upon<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>timing,<span style="letter-spacing:-0.65pt;"> </span>duration<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>specifics<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>FDA<span style="letter-spacing:-0.65pt;"> </span>marketing<span style="letter-spacing:-0.65pt;"> </span>approval<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>any<span style="letter-spacing:-0.7pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>our<span style="letter-spacing:-0.7pt;"> </span>product candidates,<span style="letter-spacing:-0.65pt;"> </span>one<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>more<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.7pt;"> </span>issued<span style="letter-spacing:-0.4pt;"> </span>U.S.<span style="letter-spacing:-0.45pt;"> </span>patents<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>issued<span style="letter-spacing:-0.45pt;"> </span>U.S.<span style="letter-spacing:-0.45pt;"> </span>patents<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>own<span style="letter-spacing:-0.45pt;"> </span>in the future may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984 (the &#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments permit a patent extension term (&#8220;PTE&#8221;) of up to five years as compensation for patent term lost during the FDA<span style="letter-spacing:-0.65pt;"> </span>regulatory<span style="letter-spacing:-0.65pt;"> </span>review<span style="letter-spacing:-0.65pt;"> </span>process.<span style="letter-spacing:-0.65pt;"> </span>A<span style="letter-spacing:-0.65pt;"> </span>patent<span style="letter-spacing:-0.65pt;"> </span>term<span style="letter-spacing:-0.65pt;"> </span>extension<span style="letter-spacing:-0.65pt;"> </span>cannot<span style="letter-spacing:-0.65pt;"> </span>extend<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>remaining<span style="letter-spacing:-0.65pt;"> </span>term<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>patent<span style="letter-spacing:-0.65pt;"> </span>beyond a<span style="letter-spacing:-0.3pt;"> </span>total<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>14<span style="letter-spacing:-0.3pt;"> </span>years<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>date<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>approval,<span style="letter-spacing:-0.3pt;"> </span>only<span style="letter-spacing:-0.3pt;"> </span>one<span style="letter-spacing:-0.3pt;"> </span>patent<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>extended<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>only<span style="letter-spacing:-0.3pt;"> </span>those<span style="letter-spacing:-0.3pt;"> </span>claims covering<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>drug,<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>method<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>using<span style="letter-spacing:-0.3pt;"> </span>it<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>method<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>manufacturing<span style="letter-spacing:-0.3pt;"> </span>it<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>extended.<span style="letter-spacing:-0.3pt;"> </span>Similar patent<span style="letter-spacing:-0.7pt;"> </span>term<span style="letter-spacing:-0.65pt;"> </span>restoration<span style="letter-spacing:-0.65pt;"> </span>provisions<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>compensate<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>commercialization<span style="letter-spacing:-0.65pt;"> </span>delay<span style="letter-spacing:-0.7pt;"> </span>caused<span style="letter-spacing:-0.65pt;"> </span>by<span style="letter-spacing:-0.65pt;"> </span>regulatory<span style="letter-spacing:-0.65pt;"> </span>review<span style="letter-spacing:-0.65pt;"> </span>are also available in certain foreign jurisdictions, such as in Europe under Supplemental Protection Certificate (&#8220;SPC&#8221;).<span style="letter-spacing:-0.65pt;"> </span>However,<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>granted<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>extensions<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>which<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>apply<span style="letter-spacing:-0.65pt;"> </span>because<span style="letter-spacing:-0.65pt;"> </span>of,<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>example,<span style="letter-spacing:-0.65pt;"> </span>failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. In addition, to the extent we wish to pursue patent term extension based on a patent that we in-license<span style="letter-spacing:-0.6pt;"> </span>from<span style="letter-spacing:-0.6pt;"> </span>a<span style="letter-spacing:-0.6pt;"> </span>third<span style="letter-spacing:-0.6pt;"> </span>party,<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>would<span style="letter-spacing:-0.6pt;"> </span>need<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>cooperation<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>third<span style="letter-spacing:-0.6pt;"> </span>party.<span style="letter-spacing:-0.6pt;"> </span>Moreover,<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>applicable<span style="letter-spacing:-0.6pt;"> </span>time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent<span style="letter-spacing:-0.05pt;"> </span>term<span style="letter-spacing:-0.05pt;"> </span>extension,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>term<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:1pt;"> </span>any<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>extension<span style="letter-spacing:-0.05pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>less<span style="letter-spacing:-0.05pt;"> </span>than<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>request,<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>competitors<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>obtain approval<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>competing<span style="letter-spacing:-0.55pt;"> </span>products<span style="letter-spacing:-0.55pt;"> </span>following<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>patent<span style="letter-spacing:-0.55pt;"> </span>expiration,<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>business,<span style="letter-spacing:-0.55pt;"> </span>financial<span style="letter-spacing:-0.55pt;"> </span>condition,<span style="letter-spacing:-0.55pt;"> </span>results of<span style="letter-spacing:2pt;"> </span>operations and prospects could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If<span style="letter-spacing:0.95pt;"> </span>approved,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>regulated<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>biological<span style="letter-spacing:-0.2pt;"> </span>products<span style="letter-spacing:-0.2pt;"> </span>(&#8220;biologics&#8221;),<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>face<span style="letter-spacing:-0.2pt;"> </span>competition from biosimilars approved through an abbreviated regulatory pathway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;) was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act<span style="letter-spacing:-0.55pt;"> </span>of 2010<span style="letter-spacing:-0.55pt;"> </span>(collectively,<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>&#8220;ACA&#8221;),<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>establish<span style="letter-spacing:-0.55pt;"> </span>an<span style="letter-spacing:-0.55pt;"> </span>abbreviated<span style="letter-spacing:-0.55pt;"> </span>pathway<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>approval<span style="letter-spacing:-0.55pt;"> </span>of biosimilar<span style="letter-spacing:-0.55pt;"> </span>and interchangeable with an FDA-licensed reference biologic product. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>&#8220;interchangeable&#8221;<span style="letter-spacing:-0.65pt;"> </span>based<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>its<span style="letter-spacing:-0.05pt;"> </span>similarity<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>approved<span style="letter-spacing:-0.05pt;"> </span>biologic.<span style="letter-spacing:-0.05pt;"> </span>Under<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>BPCIA,<span style="letter-spacing:-0.05pt;"> </span>reference biological product is granted 12 years of non-patent data exclusivity from the time of first licensure of the product,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>accept<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>application<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>biosimilar<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>interchangeable<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>the reference biological product until four years after the date of first licensure of the reference product. In addition,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>approval<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>biosimilar<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>made<span style="letter-spacing:-0.15pt;"> </span>effective<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:-0.15pt;"> </span>until<span style="letter-spacing:-0.15pt;"> </span>12<span style="letter-spacing:-0.15pt;"> </span>years<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the date on which the reference product was first licensed. During this 12-year period of exclusivity, another <span style="letter-spacing:-0.1pt;">company</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">still</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">develop</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">receive</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">approval</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">competing</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">biologic,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">so</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">long</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">as</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">their</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">BLA</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">does</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">rely</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">on </span>the reference product or sponsor&#8217;s data or submit the application as a biosimilar application. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty, and any new policies or processes adopted by the FDA could have a material adverse effect on the future commercial prospects for our biological products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that any of the product candidates we develop that is approved in the U.S. as a biological<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>BLA<span style="letter-spacing:-0.3pt;"> </span>should<span style="letter-spacing:-0.3pt;"> </span>qualify<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>12-year<span style="letter-spacing:-0.3pt;"> </span>period<span style="letter-spacing:-0.3pt;"> </span>of exclusivity.<span style="letter-spacing:-0.3pt;"> </span>However,<span style="letter-spacing:-0.3pt;"> </span>there<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidate<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>reference<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>competing<span style="letter-spacing:-0.15pt;"> </span>products,<span style="letter-spacing:-0.15pt;"> </span>potentially<span style="letter-spacing:-0.15pt;"> </span>creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar,<span style="letter-spacing:-0.35pt;"> </span>once<span style="letter-spacing:-0.35pt;"> </span>approved,<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.35pt;"> </span>substituted<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>one<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>reference<span style="letter-spacing:-0.35pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>way<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.35pt;"> </span>similar<span style="letter-spacing:-0.35pt;"> </span>to traditional<span style="letter-spacing:0.2pt;"> </span>generic<span style="letter-spacing:0.25pt;"> </span>substitution<span style="letter-spacing:0.25pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>non-biological<span style="letter-spacing:0.25pt;"> </span>products<span style="letter-spacing:0.25pt;"> </span>is<span style="letter-spacing:0.25pt;"> </span>not<span style="letter-spacing:0.25pt;"> </span>yet<span style="letter-spacing:0.25pt;"> </span>clear,<span style="letter-spacing:0.25pt;"> </span>and<span style="letter-spacing:0.25pt;"> </span>will<span style="letter-spacing:0.25pt;"> </span>depend<span style="letter-spacing:0.25pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>a<span style="letter-spacing:0.25pt;"> </span>number<span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:-0.25pt;">of</span> marketplace and regulatory factors that are still developing. The approval of a biosimilar of our product candidates could have a material adverse impact on our business due to increased competition and pricing <span style="letter-spacing:-0.1pt;">pressure.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If<span style="letter-spacing:0.8pt;"> </span>competitors<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>able<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>biosimilars<span style="letter-spacing:-0.25pt;"> </span>referencing<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates, our product candidates may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Laws and regulations outside the U.S. differ, including the length and extent of patent and exclusivity protection and pathways for competition to enter the market. Other countries may have significantly<span style="letter-spacing:-0.7pt;"> </span>shorter<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>longer<span style="letter-spacing:-0.65pt;"> </span>periods<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>exclusivity.<span style="letter-spacing:-0.65pt;"> </span>In<span style="letter-spacing:-0.65pt;"> </span>addition,<span style="letter-spacing:-0.7pt;"> </span>other<span style="letter-spacing:-0.65pt;"> </span>countries<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>have<span style="letter-spacing:-0.65pt;"> </span>different<span style="letter-spacing:-0.65pt;"> </span>standards in determining similarity to a reference product. Any </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">market entry of competing products to our product candidates<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>these<span style="letter-spacing:-0.6pt;"> </span>other<span style="letter-spacing:-0.6pt;"> </span>regions<span style="letter-spacing:-0.6pt;"> </span>could<span style="letter-spacing:-0.6pt;"> </span>adversely<span style="letter-spacing:-0.6pt;"> </span>affect<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>business<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>those<span style="letter-spacing:-0.6pt;"> </span>regions.<span style="letter-spacing:-0.6pt;"> </span>To<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>extent<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>do not receive any anticipated periods of regulatory exclusivity for our product candidates it could adversely affect our business, financial condition, results of<span style="letter-spacing:2pt;"> </span>operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:-0.2pt;"> </span>China,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>Fourth<span style="letter-spacing:-0.2pt;"> </span>Amendments<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>PRC<span style="letter-spacing:-0.2pt;"> </span>Patent<span style="letter-spacing:-0.2pt;"> </span>Law<span style="letter-spacing:-0.2pt;"> </span>became<span style="letter-spacing:-0.2pt;"> </span>effective<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.2pt;"> </span>June<span style="letter-spacing:-0.2pt;"> </span>1,<span style="letter-spacing:-0.2pt;"> </span>2021,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>the first<span style="letter-spacing:-0.55pt;"> </span>time,<span style="letter-spacing:-0.55pt;"> </span>provides<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>PTE,<span style="letter-spacing:-0.55pt;"> </span>PTA<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>a<span style="letter-spacing:-0.55pt;"> </span>patent<span style="letter-spacing:-0.55pt;"> </span>linkage<span style="letter-spacing:-0.55pt;"> </span>system<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>eligible<span style="letter-spacing:-0.55pt;"> </span>Chinese<span style="letter-spacing:-0.55pt;"> </span>patents.<span style="letter-spacing:-0.55pt;"> </span>To<span style="letter-spacing:-0.55pt;"> </span>date,<span style="letter-spacing:-0.55pt;"> </span>no<span style="letter-spacing:-0.55pt;"> </span>PTE<span style="letter-spacing:-0.55pt;"> </span>or PTA<span style="letter-spacing:-0.7pt;"> </span>has<span style="letter-spacing:-0.65pt;"> </span>been<span style="letter-spacing:-0.65pt;"> </span>granted<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>Chinese<span style="letter-spacing:-0.65pt;"> </span>patent,<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.7pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>patent<span style="letter-spacing:-0.65pt;"> </span>linkage<span style="letter-spacing:-0.65pt;"> </span>system<span style="letter-spacing:-0.65pt;"> </span>is<span style="letter-spacing:-0.65pt;"> </span>still<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>its<span style="letter-spacing:-0.7pt;"> </span>early<span style="letter-spacing:-0.65pt;"> </span>stage.<span style="letter-spacing:-0.65pt;"> </span>In<span style="letter-spacing:-0.65pt;"> </span>view<span style="letter-spacing:-0.65pt;"> </span>of the potential changes and development in the implementation rules in PTE, PTA, patent linkage and data exclusivity<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>China,<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>lower-cost<span style="letter-spacing:-0.45pt;"> </span>generic<span style="letter-spacing:-0.45pt;"> </span>drug<span style="letter-spacing:-0.45pt;"> </span>can<span style="letter-spacing:-0.45pt;"> </span>emerge<span style="letter-spacing:-0.45pt;"> </span>onto<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>market<span style="letter-spacing:-0.45pt;"> </span>much<span style="letter-spacing:-0.45pt;"> </span>more<span style="letter-spacing:-0.45pt;"> </span>quickly,<span style="letter-spacing:-0.45pt;"> </span>which<span style="letter-spacing:-0.45pt;"> </span>would result in weaker protection for us against generic competition in China than could be available to us in the U.S., and would materially harm our business, financial condition, results of operations, and <span style="letter-spacing:-0.1pt;">prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If<span style="letter-spacing:0.7pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>unable<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>protect<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>confidentiality<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>trade<span style="letter-spacing:-0.35pt;"> </span>secrets,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>business<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>competitive<span style="letter-spacing:-0.35pt;"> </span>position<span style="letter-spacing:-0.35pt;"> </span>would<span style="letter-spacing:-0.35pt;"> </span>be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>protect<span style="letter-spacing:-0.4pt;"> </span>proprietary<span style="letter-spacing:-0.4pt;"> </span>know-how<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.4pt;"> </span>is<span style="letter-spacing:-0.4pt;"> </span>not<span style="letter-spacing:-0.4pt;"> </span>patentable<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>elect<span style="letter-spacing:-0.4pt;"> </span>not<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>patent,<span style="letter-spacing:-0.4pt;"> </span>processes<span style="letter-spacing:-0.4pt;"> </span>for which<span style="letter-spacing:-0.6pt;"> </span>patents<span style="letter-spacing:-0.6pt;"> </span>are<span style="letter-spacing:-0.6pt;"> </span>difficult<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>enforce<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>any<span style="letter-spacing:-0.6pt;"> </span>other<span style="letter-spacing:-0.6pt;"> </span>elements<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>discovery<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>development<span style="letter-spacing:-0.6pt;"> </span>processes<span style="letter-spacing:-0.6pt;"> </span>that involve<span style="letter-spacing:-0.5pt;"> </span>proprietary<span style="letter-spacing:-0.5pt;"> </span>know-how,<span style="letter-spacing:-0.5pt;"> </span>information<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>technology<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.5pt;"> </span>is<span style="letter-spacing:-0.5pt;"> </span>not<span style="letter-spacing:-0.5pt;"> </span>covered<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:-0.5pt;"> </span>patents.<span style="letter-spacing:-0.5pt;"> </span>We<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>also<span style="letter-spacing:-0.5pt;"> </span>rely<span style="letter-spacing:-0.5pt;"> </span>on trade secret protection as temporary protection for concepts that may be included in a future patent filing. <span style="letter-spacing:-0.1pt;">However,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">trade</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">secret</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">protection</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">will</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">protect</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">us</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">innovations</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">that</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">competitor</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">develops</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">independently </span>of<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>proprietary<span style="letter-spacing:-0.25pt;"> </span>know<span style="letter-spacing:-0.25pt;">-</span>how.<span style="letter-spacing:-0.25pt;"> </span>If<span style="letter-spacing:0.8pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>competitor<span style="letter-spacing:-0.25pt;"> </span>independently<span style="letter-spacing:-0.25pt;"> </span>develops<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>technology<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>protect<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>trade secret<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>files<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.05pt;"> </span>application<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.05pt;"> </span>technology,<span style="letter-spacing:-0.05pt;"> </span>then<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.05pt;"> </span>technology<span style="letter-spacing:-0.05pt;"> </span>in the future, may require a license from the competitor to use our own know-how, and if the license is not <span style="letter-spacing:-0.1pt;">available</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">commercially</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">viable</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">terms,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">then</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">able</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">launch</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">product</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">candidate.</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">Additionally, </span>trade<span style="letter-spacing:-0.5pt;"> </span>secrets<span style="letter-spacing:-0.5pt;"> </span>can<span style="letter-spacing:-0.5pt;"> </span>be<span style="letter-spacing:-0.5pt;"> </span>difficult<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>protect<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>some<span style="letter-spacing:-0.5pt;"> </span>courts<span style="letter-spacing:-0.5pt;"> </span>inside<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>outside<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>U.S.<span style="letter-spacing:-0.5pt;"> </span>are<span style="letter-spacing:-0.5pt;"> </span>less<span style="letter-spacing:-0.5pt;"> </span>willing<span style="letter-spacing:-0.5pt;"> </span>or unwilling to protect trade secrets. Although we require all of our employees to assign their inventions to us, <span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">require</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">all</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">employees,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">consultants,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">advisors</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">any</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">third</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">parties</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">who</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">access</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">proprietary </span>know-how, information or technology to enter into confidentiality agreements, our trade secrets and other confidential proprietary information could be disclosed or competitors could otherwise gain access to our trade secrets. If our trade secrets are not adequately protected, our business, financial condition, results of operations and prospects could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of<span style="letter-spacing:1.25pt;"> </span>interest and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.45pt;"> </span>registered<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>unregistered<span style="letter-spacing:-0.45pt;"> </span>trademarks<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>trade<span style="letter-spacing:-0.45pt;"> </span>names<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>be<span style="letter-spacing:-0.45pt;"> </span>challenged,<span style="letter-spacing:-0.45pt;"> </span>infringed,<span style="letter-spacing:-0.45pt;"> </span>circumvented<span style="letter-spacing:-0.45pt;"> </span>or declared generic or determined to be infringing on other marks. During trademark registration proceedings, we<span style="letter-spacing:-0.7pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>receive<span style="letter-spacing:-0.65pt;"> </span>rejections<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.7pt;"> </span>applications<span style="letter-spacing:-0.65pt;"> </span>by<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>USPTO<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>other<span style="letter-spacing:-0.65pt;"> </span>foreign<span style="letter-spacing:-0.7pt;"> </span>jurisdictions.<span style="letter-spacing:-0.65pt;"> </span>Although<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>are given an opportunity to respond to such rejections, we may be unable to overcome them. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings. Moreover, any name we have proposed to use with our product candidate in the U.S. must be approved<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>FDA,<span style="letter-spacing:0.15pt;"> </span>regardless<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>whether<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.15pt;"> </span>have<span style="letter-spacing:0.15pt;"> </span>registered<span style="letter-spacing:0.2pt;"> </span>it,<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.15pt;"> </span>applied<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.15pt;"> </span>register<span style="letter-spacing:0.2pt;"> </span>it,<span style="letter-spacing:0.15pt;"> </span>as<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.1pt;">trademark.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We may not be able to protect our rights to these trademarks and trade names, which we need to build name<span style="letter-spacing:-0.05pt;"> </span>recognition<span style="letter-spacing:-0.05pt;"> </span>among<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.05pt;"> </span>partners<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>customers<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>markets<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:1pt;"> </span>interest.<span style="letter-spacing:-0.05pt;"> </span>At<span style="letter-spacing:-0.05pt;"> </span>times,<span style="letter-spacing:-0.05pt;"> </span>competitors<span style="letter-spacing:-0.05pt;"> </span>or other<span style="letter-spacing:-0.35pt;"> </span>third<span style="letter-spacing:-0.35pt;"> </span>parties<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>adopt<span style="letter-spacing:-0.35pt;"> </span>trade<span style="letter-spacing:-0.35pt;"> </span>names<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>trademarks<span style="letter-spacing:-0.35pt;"> </span>similar<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>ours,<span style="letter-spacing:-0.35pt;"> </span>thereby<span style="letter-spacing:-0.35pt;"> </span>impeding<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>ability<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other registered trademarks or trademarks that incorporate<span style="letter-spacing:-0.25pt;"> </span>variations<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>registered<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>unregistered<span style="letter-spacing:-0.25pt;"> </span>trademarks<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>names.<span style="letter-spacing:-0.25pt;"> </span>Over<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>long<span style="letter-spacing:-0.25pt;"> </span>term,<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:0.8pt;"> </span>we are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>establish<span style="letter-spacing:-0.05pt;"> </span>name<span style="letter-spacing:-0.05pt;"> </span>recognition<span style="letter-spacing:-0.05pt;"> </span>based<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>trademarks<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>trade<span style="letter-spacing:-0.05pt;"> </span>names,<span style="letter-spacing:-0.05pt;"> </span>then<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain name or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of<span style="letter-spacing:2pt;"> </span>operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>employees,<span style="letter-spacing:-0.2pt;"> </span>consultants<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>advisors<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>past<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>employed<span style="letter-spacing:-0.2pt;"> </span>at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against<span style="letter-spacing:-0.7pt;"> </span>these<span style="letter-spacing:-0.65pt;"> </span>claims.<span style="letter-spacing:-0.65pt;"> </span>If<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>fail<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>defending<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.7pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>claims,<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>addition<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>paying<span style="letter-spacing:-0.65pt;"> </span>monetary<span style="letter-spacing:-0.65pt;"> </span>damages,<span style="letter-spacing:-0.7pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>may <span style="letter-spacing:-0.1pt;">lose valuable intellectual property rights. An inability to incorporate such technologies or features would harm </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>prevent<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>from<span style="letter-spacing:-0.05pt;"> </span>successfully<span style="letter-spacing:-0.05pt;"> </span>commercializing<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.05pt;"> </span>candidates.<span style="letter-spacing:-0.05pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.05pt;"> </span>we may<span style="letter-spacing:-0.6pt;"> </span>lose<span style="letter-spacing:-0.6pt;"> </span>personnel<span style="letter-spacing:-0.6pt;"> </span>as<span style="letter-spacing:-0.6pt;"> </span>a<span style="letter-spacing:-0.6pt;"> </span>result<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>such<span style="letter-spacing:-0.6pt;"> </span>claims<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>any<span style="letter-spacing:-0.6pt;"> </span>such<span style="letter-spacing:-0.6pt;"> </span>litigation<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>threat<span style="letter-spacing:-0.6pt;"> </span>thereof<span style="letter-spacing:0.3pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>adversely<span style="letter-spacing:-0.6pt;"> </span>affect our<span style="letter-spacing:-0.2pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>hire<span style="letter-spacing:-0.2pt;"> </span>employees<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>contract<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>independent<span style="letter-spacing:-0.2pt;"> </span>contractors.<span style="letter-spacing:-0.2pt;"> </span>A<span style="letter-spacing:-0.2pt;"> </span>loss<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>key<span style="letter-spacing:-0.2pt;"> </span>personnel<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:-0.2pt;"> </span>work product<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.3pt;"> </span>hamper<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>prevent<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>ability<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>commercialize<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.3pt;"> </span>adversely affect our business, financial condition, results of operations and prospects. Even if we are successful in defending<span style="letter-spacing:-0.35pt;"> </span>against<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:-0.35pt;"> </span>claims,<span style="letter-spacing:-0.35pt;"> </span>litigation<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.35pt;"> </span>result<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.35pt;"> </span>substantial<span style="letter-spacing:-0.35pt;"> </span>costs<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>distraction<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, former employees, consultants or other third parties may assert an ownership right in our owned or licensed patents or patent applications. An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>held<span style="letter-spacing:-0.2pt;"> </span>unenforceable,<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>whole<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>part,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>limit<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>stop<span style="letter-spacing:-0.2pt;"> </span>others<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>using or<span style="letter-spacing:-0.45pt;"> </span>commercializing<span style="letter-spacing:-0.45pt;"> </span>similar<span style="letter-spacing:-0.45pt;"> </span>technology<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>therapeutics,<span style="letter-spacing:-0.45pt;"> </span>without<span style="letter-spacing:-0.45pt;"> </span>payment<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>us,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>could<span style="letter-spacing:-0.45pt;"> </span>limit<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>duration<span style="letter-spacing:-0.45pt;"> </span>of the patent protection covering our product candidates. Such challenges may also result in our inability to develop, manufacture or commercialize our product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our owned or licensed patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize<span style="letter-spacing:-0.65pt;"> </span>current<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>future<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidates.<span style="letter-spacing:-0.65pt;"> </span>Any<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>foregoing<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>adversely<span style="letter-spacing:-0.65pt;"> </span>affect<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks<b style="font-weight:bold;letter-spacing:-0.35pt;"> </b>Related<b style="font-weight:bold;letter-spacing:-0.3pt;"> </b>to<b style="font-weight:bold;letter-spacing:-0.3pt;"> </b>Government<b style="font-weight:bold;letter-spacing:-0.3pt;"> </b>Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The regulatory approval process is highly uncertain, and we may be unable to obtain, or may be delayed in obtaining,<span style="letter-spacing:-0.45pt;"> </span>U.S.<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>foreign<span style="letter-spacing:-0.45pt;"> </span>regulatory<span style="letter-spacing:-0.45pt;"> </span>approval<span style="letter-spacing:-0.45pt;"> </span>and,<span style="letter-spacing:-0.45pt;"> </span>as<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>result,<span style="letter-spacing:-0.45pt;"> </span>unable<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>commercialize<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>product<span style="letter-spacing:-0.45pt;"> </span>candidates<span style="letter-spacing:-0.45pt;"> </span>or any<span style="letter-spacing:-0.35pt;"> </span>future<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>Even<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:0.5pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>believe<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>current,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>planned<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.35pt;"> </span>trials<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>successful,<span style="letter-spacing:-0.35pt;"> </span>regulatory authorities may not agree that they provide adequate data on safety or efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates and any future product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, post-approval monitoring, marketing and distribution of products. Rigorous preclinical studies and clinical trials and an extensive regulatory approval process are required to be completed successfully in the U.S. and in many foreign jurisdictions before a new product can be marketed. Satisfaction of<span style="letter-spacing:1pt;"> </span>these and other regulatory requirements<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.35pt;"> </span>costly,<span style="letter-spacing:-0.35pt;"> </span>time<span style="letter-spacing:-0.35pt;"> </span>consuming,<span style="letter-spacing:-0.35pt;"> </span>uncertain<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>subject<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>unanticipated<span style="letter-spacing:-0.35pt;"> </span>delays.<span style="letter-spacing:-0.35pt;"> </span>It<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.35pt;"> </span>possible<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>none of<span style="letter-spacing:1.65pt;"> </span>our product candidates will obtain the regulatory approvals necessary for us to begin selling them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our<span style="letter-spacing:-0.2pt;"> </span>company<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:-0.2pt;"> </span>no<span style="letter-spacing:-0.2pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>experience<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>conducting<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>managing<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>necessary<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>obtain regulatory approvals, including approval by the FDA. The time required to obtain FDA and other approvals <span style="letter-spacing:-0.1pt;">is</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">unpredictable</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">but</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">typically</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">takes</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">many</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">years</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">following</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">commencement</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">trials,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">depending</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">upon </span>the type, complexity and novelty of the product candidate. The standards that the FDA and comparable <span style="letter-spacing:-0.1pt;">foreign</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">regulatory</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">authorities</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">use</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">when</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">regulating</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">us</span><span style="letter-spacing:-0.45pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">require</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">judgment</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">can</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">change,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">which</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">makes</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">it</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">difficult to</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">predict</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">certainty</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">their</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">application.</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">Any</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">analysis</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">perform</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:-0.1pt;">data</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">preclinical</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">studies</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">clinical trials</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">is</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">subject</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">confirmation</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">interpretation</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">by</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">regulatory</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">authorities,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">which</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">delay,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">limit</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">prevent </span>regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during<span style="letter-spacing:-0.8pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>period<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>development,<span style="letter-spacing:-0.65pt;"> </span>clinical<span style="letter-spacing:-0.65pt;"> </span>trials<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.7pt;"> </span>FDA<span style="letter-spacing:-0.65pt;"> </span>regulatory<span style="letter-spacing:-0.65pt;"> </span>review.<span style="letter-spacing:-0.65pt;"> </span>It<span style="letter-spacing:-0.65pt;"> </span>is<span style="letter-spacing:-0.65pt;"> </span>impossible<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>predict whether additional legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>changed,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>impact<span style="letter-spacing:-0.15pt;"> </span>of such<span style="letter-spacing:-0.15pt;"> </span>changes,<span style="letter-spacing:-0.15pt;"> </span>if any.<span style="letter-spacing:-0.15pt;"> </span>Any<span style="letter-spacing:-0.15pt;"> </span>elongation<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>de-prioritization<span style="letter-spacing:-0.15pt;"> </span>of preclinical studies or clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of obexelimab or any of our other product candidates or any future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further,<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>FDA<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>its<span style="letter-spacing:-0.65pt;"> </span>foreign<span style="letter-spacing:-0.65pt;"> </span>counterparts<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>respond<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>BLA<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>submit<span style="letter-spacing:-0.65pt;"> </span>by<span style="letter-spacing:-0.65pt;"> </span>requesting additional data or studies that we do not anticipate. Such responses could delay clinical development of our product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.25pt;"> </span>FDA<span style="letter-spacing:-0.25pt;"> </span>also<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>consider<span style="letter-spacing:-0.25pt;"> </span>its<span style="letter-spacing:-0.25pt;"> </span>approvals<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>competing products, which may alter the treatment landscape, and which may lead to changes in the FDA&#8217;s review requirements<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.5pt;"> </span>have<span style="letter-spacing:-0.5pt;"> </span>been<span style="letter-spacing:-0.5pt;"> </span>previously<span style="letter-spacing:-0.5pt;"> </span>communicated<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>us<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>interpretation<span style="letter-spacing:-0.5pt;"> </span>thereof,<span style="letter-spacing:-0.5pt;"> </span>including<span style="letter-spacing:-0.5pt;"> </span>changes to requirements for clinical data or clinical trial design. Such changes could delay approval or necessitate withdrawal of our BLA submissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Any</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">delay</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">failure</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">obtaining</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">required</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">approvals</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">would</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">adversely</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">affect</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">ability</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">generate</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">revenue </span>from the particular product candidate for which we are seeking approval. Furthermore, any regulatory approval<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>market<span style="letter-spacing:-0.5pt;"> </span>a<span style="letter-spacing:-0.5pt;"> </span>product<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>be<span style="letter-spacing:-0.5pt;"> </span>subject<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>limitations<span style="letter-spacing:-0.5pt;"> </span>on<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>approved<span style="letter-spacing:-0.5pt;"> </span>uses<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.5pt;"> </span>which<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>market<span style="letter-spacing:-0.5pt;"> </span>the product or on the labeling or other restrictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.25pt;"> </span>also<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>become<span style="letter-spacing:-0.25pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>numerous<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with the FDA approval process described above, as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. FDA approval does not ensure approval<span style="letter-spacing:-0.6pt;"> </span>by<span style="letter-spacing:-0.6pt;"> </span>regulatory<span style="letter-spacing:-0.6pt;"> </span>authorities<span style="letter-spacing:-0.6pt;"> </span>outside<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>U.S.<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>vice<span style="letter-spacing:-0.6pt;"> </span>versa.<span style="letter-spacing:-0.6pt;"> </span>Any<span style="letter-spacing:-0.6pt;"> </span>delay<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>failure<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>obtain<span style="letter-spacing:-0.6pt;"> </span>U.S. <span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">foreign</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">regulatory</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">approval</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">product</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">candidate</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">material</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">adverse</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">effect</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">business, </span>financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even<span style="letter-spacing:-0.4pt;"> </span>if<span style="letter-spacing:0.5pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>receive<span style="letter-spacing:-0.4pt;"> </span>regulatory<span style="letter-spacing:-0.4pt;"> </span>approval<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.4pt;"> </span>any<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.4pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.4pt;"> </span>subject<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>ongoing<span style="letter-spacing:-0.4pt;"> </span>regulatory obligations<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>continued<span style="letter-spacing:-0.45pt;"> </span>regulatory<span style="letter-spacing:-0.45pt;"> </span>review,<span style="letter-spacing:-0.45pt;"> </span>which<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>result<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>significant<span style="letter-spacing:-0.45pt;"> </span>additional<span style="letter-spacing:-0.45pt;"> </span>expense.<span style="letter-spacing:-0.45pt;"> </span>Additionally,<span style="letter-spacing:-0.45pt;"> </span>our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal. We may also be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any regulatory approvals that we or our existing or future collaborators obtain for our product candidates may<span style="letter-spacing:1pt;"> </span>also<span style="letter-spacing:1pt;"> </span>be<span style="letter-spacing:1pt;"> </span>subject<span style="letter-spacing:1pt;"> </span>to<span style="letter-spacing:1pt;"> </span>limitations<span style="letter-spacing:1pt;"> </span>on<span style="letter-spacing:1pt;"> </span>the<span style="letter-spacing:1pt;"> </span>approved<span style="letter-spacing:1pt;"> </span>indicated<span style="letter-spacing:1pt;"> </span>uses<span style="letter-spacing:1pt;"> </span>for<span style="letter-spacing:1pt;"> </span>which<span style="letter-spacing:1pt;"> </span>a<span style="letter-spacing:1pt;"> </span>product<span style="letter-spacing:1pt;"> </span>may<span style="letter-spacing:1pt;"> </span>be<span style="letter-spacing:1pt;"> </span>marketed<span style="letter-spacing:1pt;"> </span>or<span style="letter-spacing:1pt;"> </span>to the conditions of approval, or contain requirements for potentially costly post-marketing testing and surveillance<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>monitor<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>safety<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>efficacy<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>product<span style="letter-spacing:-0.6pt;"> </span>candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, if the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, post-approval monitoring and adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The FDA has significant post-market authority,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>authority<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>labeling<span style="letter-spacing:-0.2pt;"> </span>changes<span style="letter-spacing:-0.2pt;"> </span>based<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.2pt;"> </span>new<span style="letter-spacing:-0.2pt;"> </span>safety<span style="letter-spacing:-0.2pt;"> </span>information<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. The FDA also has the authority to require a REMS plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. The manufacturing facilities we use to make a future product, if any, will also be subject to periodic review<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>inspection<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.15pt;"> </span>authorities,<span style="letter-spacing:-0.15pt;"> </span>including<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>continued<span style="letter-spacing:-0.15pt;"> </span>compliance<span style="letter-spacing:-0.15pt;"> </span>with cGMPs. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility, <span style="letter-spacing:-0.1pt;">including</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">withdrawal</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">market.</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">will</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">complete</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">control</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">over</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">compliance</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">with </span>applicable rules and regulations by such manufacturers.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory<span style="letter-spacing:-0.25pt;"> </span>review.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.25pt;"> </span>FDA<span style="letter-spacing:-0.25pt;"> </span>imposes<span style="letter-spacing:-0.25pt;"> </span>stringent<span style="letter-spacing:-0.25pt;"> </span>restrictions<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.25pt;"> </span>manufacturers&#8217;<span style="letter-spacing:-0.6pt;"> </span>communications<span style="letter-spacing:-0.25pt;"> </span>regarding<span style="letter-spacing:-0.25pt;"> </span>use of their products. Although clinicians may prescribe products for off-label uses as the FDA and other regulatory authorities do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products. If we promote our products in a manner inconsistent with FDA-approved labeling or otherwise not in compliance with FDA regulations, we may be subject to enforcement<span style="letter-spacing:-0.35pt;"> </span>action.<span style="letter-spacing:-0.35pt;"> </span>The<span style="letter-spacing:-0.35pt;"> </span>failure<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.35pt;"> </span>us<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>collaborators<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>comply<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.35pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>requirements in<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>U.S.<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.25pt;"> </span>jurisdictions<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>seek<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in, among<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>things,<span style="letter-spacing:-0.1pt;"> </span>fines,<span style="letter-spacing:-0.1pt;"> </span>warning<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>untitled<span style="letter-spacing:-0.1pt;"> </span>letters,<span style="letter-spacing:-0.1pt;"> </span>holds<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.1pt;"> </span>trials,<span style="letter-spacing:-0.1pt;"> </span>delay<span style="letter-spacing:-0.1pt;"> </span>of approval<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>refusal<span style="letter-spacing:-0.1pt;"> </span>by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative<span style="letter-spacing:-0.65pt;"> </span>detention<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>products,<span style="letter-spacing:-0.65pt;"> </span>refusal<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>permit<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>import<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>export<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>products,<span style="letter-spacing:-0.65pt;"> </span>operating<span style="letter-spacing:-0.65pt;"> </span>restrictions, injunction, civil penalties and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future<span style="letter-spacing:-0.45pt;"> </span>legislation<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>administrative<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>executive<span style="letter-spacing:-0.45pt;"> </span>action,<span style="letter-spacing:-0.45pt;"> </span>either<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>U.S.<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>abroad.<span style="letter-spacing:-0.45pt;"> </span>Changes<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>FDA <span style="letter-spacing:-0.2pt;">staffing could result in delays in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, </span>issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Disruptions<span style="letter-spacing:-0.55pt;"> </span>at<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>FDA<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>comparable<span style="letter-spacing:-0.5pt;"> </span>foreign<span style="letter-spacing:-0.55pt;"> </span>regulatory<span style="letter-spacing:-0.5pt;"> </span>authorities<span style="letter-spacing:-0.55pt;"> </span>caused<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:-0.55pt;"> </span>funding<span style="letter-spacing:-0.5pt;"> </span>shortages<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>global<span style="letter-spacing:-0.55pt;"> </span>health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent<span style="letter-spacing:-0.3pt;"> </span>new<span style="letter-spacing:-0.3pt;"> </span>products<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.3pt;"> </span>being<span style="letter-spacing:-0.3pt;"> </span>developed,<span style="letter-spacing:-0.3pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>commercialized<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>timely<span style="letter-spacing:-0.3pt;"> </span>manner<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>otherwise<span style="letter-spacing:-0.3pt;"> </span>prevent those<span style="letter-spacing:-0.2pt;"> </span>authorities<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>performing<span style="letter-spacing:-0.2pt;"> </span>normal<span style="letter-spacing:-0.2pt;"> </span>business<span style="letter-spacing:-0.2pt;"> </span>functions<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>operation<span style="letter-spacing:-0.2pt;"> </span>of our<span style="letter-spacing:-0.2pt;"> </span>business<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>rely, which could negatively impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The ability of the FDA and comparable foreign regulatory authorities to review and approve new products is affected by a variety of factors, including government budget and funding levels, statutory, regulatory<span style="letter-spacing:-0.7pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>policy<span style="letter-spacing:-0.65pt;"> </span>changes,<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>ability<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>hire<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.7pt;"> </span>retain<span style="letter-spacing:-0.65pt;"> </span>key<span style="letter-spacing:-0.65pt;"> </span>personnel<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>accept<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>payment<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.15pt;"> </span>user<span style="letter-spacing:-0.65pt;"> </span>fees, and other events that may otherwise affect the regulatory authority&#8217;s ability to perform routine functions. Average<span style="letter-spacing:-0.5pt;"> </span>review<span style="letter-spacing:-0.5pt;"> </span>times<span style="letter-spacing:-0.5pt;"> </span>at<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>FDA<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>other<span style="letter-spacing:-0.5pt;"> </span>regulatory<span style="letter-spacing:-0.5pt;"> </span>authorities<span style="letter-spacing:-0.5pt;"> </span>have<span style="letter-spacing:-0.5pt;"> </span>fluctuated<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.5pt;"> </span>recent<span style="letter-spacing:-0.5pt;"> </span>years.<span style="letter-spacing:-0.5pt;"> </span>In<span style="letter-spacing:-0.5pt;"> </span>addition, government<span style="letter-spacing:-0.55pt;"> </span>funding<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>other<span style="letter-spacing:-0.5pt;"> </span>authorities<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>agencies<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.5pt;"> </span>fund<span style="letter-spacing:-0.5pt;"> </span>research<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>development<span style="letter-spacing:-0.5pt;"> </span>activities<span style="letter-spacing:-0.5pt;"> </span>is<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">subject</span> to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face uncertainty regarding the potential for changes in the regulatory environment following the change in presidential administration in January 2025. While many of the Trump administration&#8217;s proposed policies appear to be focused on deregulation, the new administration and federal government could adopt legislation, regulation, or policy that adversely affects our business or creates a more challenging and costly environment to pursue the development and commercialization of our product candidates. For example, the federal government, including the FDA, may implement legislative, regulatory, or policy changes regarding the standards for approving biologic products that we may be unable to satisfy. It is difficult to predict how executive actions that may be taken under the current Trump administration may affect the FDA&#8217;s ability to exercise its regulatory authority. If such executive actions impose constraints on the FDA&#8217;s ability to engage in routine oversight and product review activities in the normal course, our business may be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>Disruptions at the FDA and other regulatory authorities may also slow the time necessary for new biologics or modifications to approved or licensed<span style="letter-spacing:-0.2pt;"> </span>biologics<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>reviewed<span style="letter-spacing:-0.2pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>approved,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>would<span style="letter-spacing:-0.2pt;"> </span>adversely<span style="letter-spacing:-0.2pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>business.<span style="letter-spacing:-0.2pt;"> </span>For<span style="letter-spacing:-0.2pt;"> </span>example, the current Trump administration appears to be focused on decreasing spending in the federal government, including through significant staff reductions. Any significant staff reductions at FDA could impact the agency&#8217;s ability to engage in routine regulatory and oversight activities and result in delays or limitations on our ability to proceed with clinical development programs and obtain regulatory approvals. Additionally, <span style="letter-spacing:-0.1pt;">over</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">last</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">several</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">years,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">U.S.</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">government</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">has</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">shut</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">down</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">several</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">times</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">certain</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">regulatory</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">authorities, </span>such as the FDA, have had to furlough critical employees and stop critical activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection<span style="letter-spacing:-0.5pt;"> </span>operations<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>domestic<span style="letter-spacing:-0.5pt;"> </span>facilities<span style="letter-spacing:-0.5pt;"> </span>where<span style="letter-spacing:-0.5pt;"> </span>feasible,<span style="letter-spacing:-0.5pt;"> </span>future<span style="letter-spacing:-0.5pt;"> </span>pandemics<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>lead<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>similar<span style="letter-spacing:-0.5pt;"> </span>inspectional delays.<span style="letter-spacing:-0.6pt;"> </span>If<span style="letter-spacing:0.3pt;"> </span>any<span style="letter-spacing:-0.6pt;"> </span>future<span style="letter-spacing:-0.6pt;"> </span>prolonged<span style="letter-spacing:-0.6pt;"> </span>government<span style="letter-spacing:-0.6pt;"> </span>shutdown<span style="letter-spacing:-0.6pt;"> </span>occurs,<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>if<span style="letter-spacing:0.3pt;"> </span>global<span style="letter-spacing:-0.6pt;"> </span>health<span style="letter-spacing:-0.6pt;"> </span>concerns<span style="letter-spacing:-0.6pt;"> </span>prevent<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>FDA<span style="letter-spacing:-0.6pt;"> </span>or other<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>authorities<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.25pt;"> </span>conducting<span style="letter-spacing:-0.25pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">their<span style="letter-spacing:-0.25pt;"> </span>regular<span style="letter-spacing:-0.25pt;"> </span>inspections,<span style="letter-spacing:-0.25pt;"> </span>reviews,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>activities, it<span style="letter-spacing:-0.7pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>significantly<span style="letter-spacing:-0.65pt;"> </span>impact<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>ability<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>FDA<span style="letter-spacing:-0.7pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>other<span style="letter-spacing:-0.65pt;"> </span>regulatory<span style="letter-spacing:-0.65pt;"> </span>authorities<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>timely<span style="letter-spacing:-0.65pt;"> </span>review<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.7pt;"> </span>process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recently enacted legislation, future legislation and other healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>U.S.<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>some<span style="letter-spacing:-0.5pt;"> </span>foreign<span style="letter-spacing:-0.5pt;"> </span>jurisdictions,<span style="letter-spacing:-0.5pt;"> </span>there<span style="letter-spacing:-0.5pt;"> </span>have<span style="letter-spacing:-0.5pt;"> </span>been,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>expect<span style="letter-spacing:-0.5pt;"> </span>there<span style="letter-spacing:-0.5pt;"> </span>will<span style="letter-spacing:-0.5pt;"> </span>continue<span style="letter-spacing:-0.5pt;"> </span>to be, a number of legislative and regulatory changes to the delivery of, and payment for, healthcare services, including cost-containment measures that may limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular,<span style="letter-spacing:-0.05pt;"> </span>there<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.05pt;"> </span>been<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>continue<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>number<span style="letter-spacing:-0.05pt;"> </span>of initiatives<span style="letter-spacing:-0.05pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;"> </span>federal<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>state<span style="letter-spacing:-0.05pt;"> </span>levels<span style="letter-spacing:-0.05pt;"> </span>that seek to reduce healthcare costs and improve the quality of healthcare. See also &#8220;Business&#8212;Government Regulation-Healthcare Reform.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For<span style="letter-spacing:-0.5pt;"> </span>example,<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.5pt;"> </span>March<span style="letter-spacing:-0.5pt;"> </span>2010,<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>ACA<span style="letter-spacing:-0.5pt;"> </span>was<span style="letter-spacing:-0.5pt;"> </span>enacted<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>U.S.,<span style="letter-spacing:-0.5pt;"> </span>which<span style="letter-spacing:-0.5pt;"> </span>substantially<span style="letter-spacing:-0.5pt;"> </span>changed<span style="letter-spacing:-0.5pt;"> </span>the way healthcare is financed by both governmental and private insurers in the U.S. and significantly <span style="letter-spacing:-0.1pt;">affected</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">pharmaceutical</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">industry.</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">Since</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">its</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">enactment,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">there</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">been</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">judicial,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">congressional,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">executive </span>branch<span style="letter-spacing:-0.65pt;"> </span>challenges<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>ACA.<span style="letter-spacing:-0.65pt;"> </span>For<span style="letter-spacing:-0.65pt;"> </span>example,<span style="letter-spacing:-0.65pt;"> </span>tax<span style="letter-spacing:-0.65pt;"> </span>reform<span style="letter-spacing:-0.65pt;"> </span>legislation<span style="letter-spacing:-0.65pt;"> </span>was<span style="letter-spacing:-0.65pt;"> </span>enacted<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>eliminated<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>tax<span style="letter-spacing:-0.65pt;"> </span>penalty established by ACA for individuals who do not maintain mandated health insurance coverage beginning in 2019 and, in 2021, the U.S. Supreme Court dismissed the latest judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of<span style="letter-spacing:1.8pt;"> </span>the ACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Beyond the ACA, there have been ongoing healthcare reform efforts, including under the Biden administration. Notably, the IRA includes a number of healthcare reform provisions, which have varying implementation dates. The IRA extends enhanced subsidies for individuals purchasing health insurance coverage<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>ACA<span style="letter-spacing:-0.4pt;"> </span>marketplaces<span style="letter-spacing:-0.4pt;"> </span>through<span style="letter-spacing:-0.4pt;"> </span>plan<span style="letter-spacing:-0.4pt;"> </span>year<span style="letter-spacing:-0.4pt;"> </span>2025;<span style="letter-spacing:-0.4pt;"> </span>lowers<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>beneficiary<span style="letter-spacing:-0.4pt;"> </span>maximum<span style="letter-spacing:-0.4pt;"> </span>out-of-pocket<span style="letter-spacing:-0.4pt;"> </span>cost; establishes a new manufacturer discount program; imposes new Medicare Part B and Part D drug price inflation rebates, and implements a drug price negotiation program for certain high spend Medicare Part B and D drugs. Such provisions have been and likely will continue to be subject to legal challenge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further,<span style="letter-spacing:-0.4pt;"> </span>there<span style="letter-spacing:-0.4pt;"> </span>has<span style="letter-spacing:-0.4pt;"> </span>been<span style="letter-spacing:-0.4pt;"> </span>heightened<span style="letter-spacing:-0.4pt;"> </span>governmental<span style="letter-spacing:-0.4pt;"> </span>scrutiny<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>U.S.<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>pharmaceutical<span style="letter-spacing:-0.4pt;"> </span>pricing practices<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>light<span style="letter-spacing:-0.05pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>rising<span style="letter-spacing:-0.05pt;"> </span>cost<span style="letter-spacing:-0.05pt;"> </span>of prescription<span style="letter-spacing:-0.05pt;"> </span>drugs.<span style="letter-spacing:-0.05pt;"> </span>Such<span style="letter-spacing:-0.05pt;"> </span>scrutiny<span style="letter-spacing:-0.05pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>resulted<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>several<span style="letter-spacing:-0.05pt;"> </span>congressional inquiries<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>proposed<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>enacted<span style="letter-spacing:-0.1pt;"> </span>federal<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>legislation<span style="letter-spacing:-0.1pt;"> </span>designed<span style="letter-spacing:-0.1pt;"> </span>to,<span style="letter-spacing:-0.1pt;"> </span>among<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>things,<span style="letter-spacing:-0.1pt;"> </span>bring<span style="letter-spacing:-0.1pt;"> </span>more transparency<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>pricing,<span style="letter-spacing:-0.2pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>relationship<span style="letter-spacing:-0.2pt;"> </span>between<span style="letter-spacing:-0.2pt;"> </span>pricing<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>manufacturer<span style="letter-spacing:-0.2pt;"> </span>patient<span style="letter-spacing:-0.2pt;"> </span>programs, and<span style="letter-spacing:-0.2pt;"> </span>reform<span style="letter-spacing:-0.2pt;"> </span>government<span style="letter-spacing:-0.2pt;"> </span>program<span style="letter-spacing:-0.2pt;"> </span>reimbursement<span style="letter-spacing:-0.2pt;"> </span>methodologies<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>products.<span style="letter-spacing:-0.2pt;"> </span>For<span style="letter-spacing:-0.2pt;"> </span>example,<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>addition<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>the IRA drug pricing reforms, federal legislation enacted in 2021 eliminates the statutory cap on Medicaid drug rebate<span style="letter-spacing:-0.4pt;"> </span>program<span style="letter-spacing:-0.4pt;"> </span>rebates<span style="letter-spacing:-0.4pt;"> </span>(currently<span style="letter-spacing:-0.4pt;"> </span>set<span style="letter-spacing:-0.4pt;"> </span>at<span style="letter-spacing:-0.4pt;"> </span>100%<span style="letter-spacing:-0.4pt;"> </span>of a<span style="letter-spacing:-0.4pt;"> </span>drug&#8217;s<span style="letter-spacing:-0.4pt;"> </span>&#8220;average<span style="letter-spacing:-0.4pt;"> </span>manufacturer<span style="letter-spacing:-0.4pt;"> </span>price&#8221;),<span style="letter-spacing:-0.4pt;"> which became </span>effective<span style="letter-spacing:-0.4pt;"> </span>January<span style="letter-spacing:-0.4pt;"> </span>1, <span style="letter-spacing:-0.1pt;">2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At<span style="letter-spacing:-0.7pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>state<span style="letter-spacing:-0.65pt;"> </span>level,<span style="letter-spacing:-0.65pt;"> </span>legislatures<span style="letter-spacing:-0.65pt;"> </span>have<span style="letter-spacing:-0.65pt;"> </span>increasingly<span style="letter-spacing:-0.65pt;"> </span>passed<span style="letter-spacing:-0.65pt;"> </span>legislation<span style="letter-spacing:-0.7pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>implemented<span style="letter-spacing:-0.65pt;"> </span>regulations<span style="letter-spacing:-0.65pt;"> </span>designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,<span style="letter-spacing:-0.45pt;"> </span>and,<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>some<span style="letter-spacing:-0.45pt;"> </span>cases,<span style="letter-spacing:-0.45pt;"> </span>encourage<span style="letter-spacing:-0.45pt;"> </span>importation<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span>other<span style="letter-spacing:-0.45pt;"> </span>countries<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>bulk<span style="letter-spacing:-0.45pt;"> </span>purchasing.<span style="letter-spacing:-0.45pt;"> </span>For<span style="letter-spacing:-0.45pt;"> </span>example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented,<span style="letter-spacing:-0.1pt;"> </span>including<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.05pt;"> </span>drugs<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>chosen,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>whether<span style="letter-spacing:-0.05pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>legal<span style="letter-spacing:-0.05pt;"> </span>challenges<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.25pt;">the</span> U.S.<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>Canada.<span style="letter-spacing:-0.4pt;"> </span>Other<span style="letter-spacing:-0.4pt;"> </span>states<span style="letter-spacing:-0.4pt;"> </span>have<span style="letter-spacing:-0.4pt;"> </span>also<span style="letter-spacing:-0.4pt;"> </span>submitted<span style="letter-spacing:-0.4pt;"> </span>SIP<span style="letter-spacing:-0.4pt;"> </span>proposals<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.4pt;"> </span>pending<span style="letter-spacing:-0.4pt;"> </span>review<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>FDA. <span style="letter-spacing:-0.1pt;">Any</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">such</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">approved</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">importation</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">plans,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">when</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">implemented,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">result</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">lower</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">drug</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">prices</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">products</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">covered </span>by those programs. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, hospitals and health systems are increasingly using bidding procedures to determine what pharmaceutical products<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.1pt;"> </span>suppliers<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>included<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>prescription<span style="letter-spacing:-0.1pt;"> </span>drug<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>healthcare<span style="letter-spacing:-0.1pt;"> </span>programs.<span style="letter-spacing:-0.1pt;"> </span>This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, financial condition, results of<span style="letter-spacing:1.05pt;"> </span>operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General<span style="letter-spacing:-0.5pt;"> </span>legislative<span style="letter-spacing:-0.5pt;"> </span>cost<span style="letter-spacing:-0.5pt;"> </span>control<span style="letter-spacing:-0.5pt;"> </span>measures<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>also<span style="letter-spacing:-0.5pt;"> </span>affect<span style="letter-spacing:-0.5pt;"> </span>reimbursement<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>product<span style="letter-spacing:-0.5pt;"> </span>candidates.<span style="letter-spacing:-0.5pt;"> </span>The Budget Control Act, as amended, resulted in the imposition of reductions in Medicare (but not Medicaid) payments to providers in 2013 that remain in effect through 2032 unless additional Congressional action is taken. Any significant spending reductions </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">affecting Medicare, Medicaid or other publicly funded or subsidized<span style="letter-spacing:-0.65pt;"> </span>health<span style="letter-spacing:-0.65pt;"> </span>programs<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>implemented<span style="letter-spacing:-0.65pt;"> </span>and/or<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>significant<span style="letter-spacing:-0.65pt;"> </span>taxes<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>fees<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>imposed on us could have an adverse impact on our results of<span style="letter-spacing:2pt;"> </span>operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.4pt;"> </span>expect<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.4pt;"> </span>current<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>any<span style="letter-spacing:-0.4pt;"> </span>future<span style="letter-spacing:-0.4pt;"> </span>healthcare<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>budget<span style="letter-spacing:-0.4pt;"> </span>reform<span style="letter-spacing:-0.4pt;"> </span>measures<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.4pt;"> </span>result<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>more<span style="letter-spacing:-0.4pt;"> </span>rigorous coverage criteria, new payment methodologies and additional downward pressure on the payment that we receive or price that we may charge for any approved product. The implementation of such reforms may prevent<span style="letter-spacing:-0.7pt;"> </span>us<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.65pt;"> </span>being<span style="letter-spacing:-0.65pt;"> </span>able<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>generate<span style="letter-spacing:-0.65pt;"> </span>revenue,<span style="letter-spacing:-0.65pt;"> </span>attain<span style="letter-spacing:-0.7pt;"> </span>profitability<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>commercialize<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidates,<span style="letter-spacing:-0.65pt;"> </span>if <span style="letter-spacing:-0.1pt;">approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If<span style="letter-spacing:0.25pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>fail<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>comply<span style="letter-spacing:-0.5pt;"> </span>with<span style="letter-spacing:-0.5pt;"> </span>healthcare<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>other<span style="letter-spacing:-0.5pt;"> </span>regulations,<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>could<span style="letter-spacing:-0.5pt;"> </span>face<span style="letter-spacing:-0.5pt;"> </span>substantial<span style="letter-spacing:-0.5pt;"> </span>penalties<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>business, operations and financial condition could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The marketing of biopharmaceutical products and related arrangements with healthcare providers, third-party payors, patients and other third parties in the healthcare industry are subject to a wide range of federal and state healthcare laws and regulations that may constrain our business and/or financial arrangements.<span style="letter-spacing:-0.4pt;"> </span>Restrictions<span style="letter-spacing:-0.4pt;"> </span>under<span style="letter-spacing:-0.4pt;"> </span>applicable<span style="letter-spacing:-0.4pt;"> </span>federal<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>state<span style="letter-spacing:-0.4pt;"> </span>healthcare<span style="letter-spacing:-0.4pt;"> </span>laws<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>regulations,<span style="letter-spacing:-0.4pt;"> </span>some<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>which will apply only if<span style="letter-spacing:1.15pt;"> </span>and when we receive marketing approval for a product candidate, include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">program</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">anti-kickback</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">law,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibits,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">among</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">things,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual for an item or service or the purchasing or ordering of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a good or service, for which payment </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">made</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">programs</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Medicare</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims, false statements and civil monetary penalties laws which prohibit, among other activities,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">person</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">knowingly</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">presenting,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">causing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">presented,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">false</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">claim</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">government</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">funds</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">knowingly</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">causing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">made,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">false</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">statement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">get</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">false</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">claim paid and may be implicated if claims are submitted that result from a violation of the federal anti- kickback statute;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">federal</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Health</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Insurance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Portability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Accountability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Act</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">1996</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">(&#8220;HIPAA&#8221;),</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">which,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">addition </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), which among other things, strictly regulates drug</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibits</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">products</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">off-label</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulates the distribution of samples;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reimbursement under government healthcare programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">so-called</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;federal</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sunshine&#8221;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">law,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requires</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pharmaceutical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">medical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">device</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">companies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to monitor and report certain financial interactions with physicians, certain non-physician healthcare practitioners and teaching hospitals to the federal government, as well as certain ownership and investment</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interests</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">held</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">these</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">physicians</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">their</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">immediate</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">family</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">members</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">re-disclosure</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Foreign</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Corrupt</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Practices</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Act</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1977,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amended,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibits,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">among</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">things, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employees</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of public</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">international</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">organizations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">government</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">owned</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state and foreign laws and regulations, such as state anti-bribery, anti-kickback and false claims</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">laws,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">apply</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">items</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">services</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reimbursed</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">non-governmental third-party payors, including private insurers.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Some state laws require pharmaceutical companies to comply with specific compliance standards, restrict </span>financial<span style="letter-spacing:-0.35pt;"> </span>interactions<span style="letter-spacing:-0.35pt;"> </span>between<span style="letter-spacing:-0.35pt;"> </span>pharmaceutical<span style="letter-spacing:-0.35pt;"> </span>companies<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>providers<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>require<span style="letter-spacing:-0.35pt;"> </span>pharmaceutical companies<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>report<span style="letter-spacing:-0.6pt;"> </span>information<span style="letter-spacing:-0.6pt;"> </span>related<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>payments<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>healthcare<span style="letter-spacing:-0.6pt;"> </span>providers<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>marketing<span style="letter-spacing:-0.6pt;"> </span>expenditures.<span style="letter-spacing:-0.6pt;"> </span>Other state<span style="letter-spacing:-0.7pt;"> </span>laws<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>require<span style="letter-spacing:-0.65pt;"> </span>pharmaceutical<span style="letter-spacing:-0.65pt;"> </span>companies<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>file<span style="letter-spacing:-0.65pt;"> </span>reports<span style="letter-spacing:-0.7pt;"> </span>relating<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>pricing<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>marketing<span style="letter-spacing:-0.65pt;"> </span>information, and state and local laws may require registration of<span style="letter-spacing:1.65pt;"> </span>pharmaceutical sales representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. Given the breadth of the laws and regulations, limited <span style="letter-spacing:-0.1pt;">guidance</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">certain</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">laws</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">regulations</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">evolving</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">government</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">interpretations</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:1.05pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">laws</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">regulations, </span>governmental<span style="letter-spacing:-0.1pt;"> </span>authorities<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>possibly<span style="letter-spacing:-0.1pt;"> </span>conclude<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>business<span style="letter-spacing:-0.1pt;"> </span>practices<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>comply<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>healthcare laws<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>regulations.<span style="letter-spacing:-0.3pt;"> </span>If our<span style="letter-spacing:-0.3pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.3pt;"> </span>found<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>violation<span style="letter-spacing:-0.3pt;"> </span>of any<span style="letter-spacing:-0.3pt;"> </span>of the<span style="letter-spacing:-0.3pt;"> </span>laws<span style="letter-spacing:-0.3pt;"> </span>described<span style="letter-spacing:-0.3pt;"> </span>above<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>any other<span style="letter-spacing:-0.15pt;"> </span>government<span style="letter-spacing:-0.15pt;"> </span>regulations<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>apply<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>us,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>penalties,<span style="letter-spacing:-0.15pt;"> </span>including<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.15pt;"> </span>civil<span style="letter-spacing:-0.15pt;"> </span>and criminal penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations, and <span style="letter-spacing:-0.1pt;">prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The U.S. Supreme Court&#8217;s June 2024 decision in <i style="font-style:italic;">Loper Bright Enterprises v. Raimondo </i>overturned the longstanding <i style="font-style:italic;">Chevron </i>doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The <i style="font-style:italic;">Loper </i>decision could result in additional legal challenges to regulations and guidance issued by federal agencies, including FDA and the Center for Medicare<span style="letter-spacing:-0.15pt;"> </span>&amp;<span style="letter-spacing:-0.15pt;"> </span>Medicaid<span style="letter-spacing:-0.15pt;"> </span>Services,<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>rely.<span style="letter-spacing:-0.15pt;"> </span>Any<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.15pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>challenges,<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:1.1pt;"> </span>successful,<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>material impact on our business. Additionally, the <i style="font-style:italic;">Loper </i>decision may result in increased regulatory uncertainty, inconsistent<span style="letter-spacing:-0.35pt;"> </span>judicial<span style="letter-spacing:-0.35pt;"> </span>interpretations,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>other<span style="letter-spacing:-0.35pt;"> </span>impacts<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>agency<span style="letter-spacing:-0.35pt;"> </span>rulemaking<span style="letter-spacing:-0.35pt;"> </span>process,<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>which<span style="letter-spacing:-0.35pt;"> </span>could adversely impact our business and operations. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action or as a result of legal challenges, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Governments outside the U.S. tend to impose strict price controls, which may adversely affect our revenue, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In some countries, particularly in the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable<span style="letter-spacing:-0.05pt;"> </span>time<span style="letter-spacing:-0.05pt;"> </span>after<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>receipt<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.95pt;"> </span>marketing<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>drug.<span style="letter-spacing:-0.05pt;"> </span>To<span style="letter-spacing:-0.05pt;"> </span>obtain<span style="letter-spacing:-0.05pt;"> </span>coverage<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>reimbursement or<span style="letter-spacing:1.4pt;"> </span>pricing<span style="letter-spacing:1.4pt;"> </span>approval<span style="letter-spacing:1.4pt;"> </span>in<span style="letter-spacing:1.4pt;"> </span>some<span style="letter-spacing:1.4pt;"> </span>countries,<span style="letter-spacing:1.4pt;"> </span>we<span style="letter-spacing:1.4pt;"> </span>may<span style="letter-spacing:1.4pt;"> </span>be<span style="letter-spacing:1.4pt;"> </span>required<span style="letter-spacing:1.4pt;"> </span>to<span style="letter-spacing:1.4pt;"> </span>conduct<span style="letter-spacing:1.4pt;"> </span>a<span style="letter-spacing:1.4pt;"> </span>clinical<span style="letter-spacing:1.4pt;"> </span>trial<span style="letter-spacing:1.4pt;"> </span>that<span style="letter-spacing:1.4pt;"> </span>compares<span style="letter-spacing:1.4pt;"> </span>the cost-effectiveness of our product candidate to other available therapies. In addition, many countries outside the U.S. have limited government support programs that provide for reimbursement of drugs such as our product<span style="letter-spacing:-0.35pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.35pt;"> </span>an<span style="letter-spacing:-0.35pt;"> </span>emphasis<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:-0.35pt;"> </span>private<span style="letter-spacing:-0.35pt;"> </span>payors<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.35pt;"> </span>access<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>commercial<span style="letter-spacing:-0.35pt;"> </span>products.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:0.6pt;"> </span>reimbursement of<span style="letter-spacing:0.55pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>products,<span style="letter-spacing:-0.45pt;"> </span>if<span style="letter-spacing:0.55pt;"> </span>approved,<span style="letter-spacing:-0.45pt;"> </span>is<span style="letter-spacing:-0.45pt;"> </span>unavailable<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>limited<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>scope<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>amount,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>if<span style="letter-spacing:0.55pt;"> </span>pricing<span style="letter-spacing:-0.45pt;"> </span>is<span style="letter-spacing:-0.45pt;"> </span>set<span style="letter-spacing:-0.45pt;"> </span>at<span style="letter-spacing:-0.45pt;"> </span>unsatisfactory levels, our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>stringent<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>evolving<span style="letter-spacing:-0.15pt;"> </span>U.S.<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>foreign<span style="letter-spacing:-0.15pt;"> </span>laws,<span style="letter-spacing:-0.15pt;"> </span>regulations,<span style="letter-spacing:-0.15pt;"> </span>rules,<span style="letter-spacing:-0.15pt;"> </span>contractual<span style="letter-spacing:-0.15pt;"> </span>obligations,<span style="letter-spacing:-0.15pt;"> </span>and policies<span style="letter-spacing:-0.35pt;"> </span>related<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>data<span style="letter-spacing:-0.35pt;"> </span>privacy<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>security.<span style="letter-spacing:-0.35pt;"> </span>Our<span style="letter-spacing:-0.35pt;"> </span>actual<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>perceived<span style="letter-spacing:-0.35pt;"> </span>failure<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>comply<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:-0.35pt;"> </span>obligations<span style="letter-spacing:-0.35pt;"> </span>could lead<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>regulatory<span style="letter-spacing:-0.4pt;"> </span>investigations<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>actions,<span style="letter-spacing:-0.4pt;"> </span>litigation,<span style="letter-spacing:-0.4pt;"> </span>fines<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>penalties,<span style="letter-spacing:-0.4pt;"> </span>disruptions<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>business<span style="letter-spacing:-0.4pt;"> </span>operations, reputational<span style="letter-spacing:-0.65pt;"> </span>harm,<span style="letter-spacing:-0.65pt;"> </span>loss<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>revenue<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>profits,<span style="letter-spacing:-0.65pt;"> </span>loss<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>customers<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>sales,<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>other<span style="letter-spacing:-0.65pt;"> </span>adverse<span style="letter-spacing:-0.65pt;"> </span>business<span style="letter-spacing:-0.65pt;"> </span>consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make<span style="letter-spacing:-0.55pt;"> </span>accessible,<span style="letter-spacing:-0.55pt;"> </span>protect,<span style="letter-spacing:-0.55pt;"> </span>secure,<span style="letter-spacing:-0.55pt;"> </span>dispose<span style="letter-spacing:-0.55pt;"> </span>of,<span style="letter-spacing:-0.55pt;"> </span>transmit,<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>share<span style="letter-spacing:-0.55pt;"> </span>(collectively,<span style="letter-spacing:-0.55pt;"> </span>process<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>processing)<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">personal</span> data and other sensitive information, including proprietary and confidential business data, trade secrets, employee<span style="letter-spacing:-0.3pt;"> </span>data,<span style="letter-spacing:-0.3pt;"> </span>intellectual<span style="letter-spacing:-0.3pt;"> </span>property,<span style="letter-spacing:-0.3pt;"> </span>data<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.3pt;"> </span>collect<span style="letter-spacing:-0.3pt;"> </span>about<span style="letter-spacing:-0.3pt;"> </span>trial<span style="letter-spacing:-0.3pt;"> </span>participants<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>connection<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>trials, and<span style="letter-spacing:-0.65pt;"> </span>other<span style="letter-spacing:-0.65pt;"> </span>sensitive<span style="letter-spacing:-0.65pt;"> </span>third-party<span style="letter-spacing:-0.65pt;"> </span>data<span style="letter-spacing:-0.65pt;"> </span>(collectively,<span style="letter-spacing:-0.65pt;"> </span>sensitive<span style="letter-spacing:-0.65pt;"> </span>data).<span style="letter-spacing:-0.65pt;"> </span>Our<span style="letter-spacing:-0.65pt;"> </span>data<span style="letter-spacing:-0.65pt;"> </span>processing<span style="letter-spacing:-0.65pt;"> </span>activities<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>subject<span style="letter-spacing:-0.65pt;"> </span>us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards,<span style="letter-spacing:-0.4pt;"> </span>external<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>internal<span style="letter-spacing:-0.4pt;"> </span>privacy<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>security<span style="letter-spacing:-0.4pt;"> </span>policies,<span style="letter-spacing:-0.4pt;"> </span>contractual<span style="letter-spacing:-0.4pt;"> </span>requirements,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>other<span style="letter-spacing:-0.4pt;"> </span>obligations relating to data privacy and security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="letter-spacing:-0.1pt;">Various</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">federal,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">state,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">local</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">foreign</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">legislative</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">regulatory</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">bodies,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">self-regulatory</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">organizations, </span>may expand current laws, rules or regulations, enact new laws, rules or regulations or issue revised rules or guidance<span style="letter-spacing:-0.35pt;"> </span>regarding<span style="letter-spacing:-0.35pt;"> </span>data<span style="letter-spacing:-0.35pt;"> </span>privacy<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>security.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>U.S.,<span style="letter-spacing:-0.35pt;"> </span>federal,<span style="letter-spacing:-0.35pt;"> </span>state,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>local<span style="letter-spacing:-0.35pt;"> </span>governments<span style="letter-spacing:-0.35pt;"> </span>have enacted numerous data privacy and security laws, </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other <span style="letter-spacing:-0.1pt;">similar</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">laws</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">(e.g.,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">wiretapping</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">laws).</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">For</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">example,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">HIPAA,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">as</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">amended</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">by</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">Health</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">Information</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">Technology </span>for Economic and Clinical Health Act (&#8220;HITECH&#8221;), imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. Additionally, the California Consumer<span style="letter-spacing:-0.7pt;"> </span>Privacy<span style="letter-spacing:-0.65pt;"> </span>Act<span style="letter-spacing:-0.65pt;"> </span>(&#8220;CCPA&#8221;)<span style="letter-spacing:-0.65pt;"> </span>applies<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>personal<span style="letter-spacing:-0.65pt;"> </span>information<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>consumers,<span style="letter-spacing:-0.65pt;"> </span>business<span style="letter-spacing:-0.65pt;"> </span>representatives,<span style="letter-spacing:-0.65pt;"> </span>and employees,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.3pt;"> </span>things<span style="letter-spacing:-0.3pt;"> </span>requires<span style="letter-spacing:-0.3pt;"> </span>businesses<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>provide<span style="letter-spacing:-0.3pt;"> </span>specific<span style="letter-spacing:-0.3pt;"> </span>disclosures<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>privacy<span style="letter-spacing:-0.3pt;"> </span>notices<span style="letter-spacing:-0.3pt;"> </span>and honor requests of California residents to exercise certain privacy rights, including the right to opt out of certain<span style="letter-spacing:-0.7pt;"> </span>disclosures<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>their<span style="letter-spacing:-0.65pt;"> </span>information.<span style="letter-spacing:-0.65pt;"> </span>The<span style="letter-spacing:-0.65pt;"> </span>CCPA<span style="letter-spacing:-0.65pt;"> </span>provides<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.7pt;"> </span>civil<span style="letter-spacing:-0.65pt;"> </span>penalties<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>up<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>$7,500<span style="letter-spacing:-0.65pt;"> </span>per<span style="letter-spacing:-0.65pt;"> </span>violation<span style="letter-spacing:-0.7pt;"> </span>as <span style="letter-spacing:-0.1pt;">well</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">as</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">private</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">right</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.95pt;"> </span><span style="letter-spacing:-0.1pt;">action</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">statutory</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">damages</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">certain</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">data</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">breaches,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">thereby</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">potentially</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">increasing </span>risks associated with a data breach. Although the law includes limited exceptions, including for certain information<span style="letter-spacing:-0.25pt;"> </span>collected<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.25pt;"> </span>part<span style="letter-spacing:-0.25pt;"> </span>of clinical<span style="letter-spacing:-0.25pt;"> </span>trials,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>CCPA<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>processing<span style="letter-spacing:-0.25pt;"> </span>of personal<span style="letter-spacing:-0.25pt;"> </span>information and increases our compliance costs. Additionally, the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;) significantly<span style="letter-spacing:-0.4pt;"> </span>expands<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>CCPA,<span style="letter-spacing:-0.4pt;"> </span>such<span style="letter-spacing:-0.4pt;"> </span>as<span style="letter-spacing:-0.4pt;"> </span>granting<span style="letter-spacing:-0.4pt;"> </span>additional<span style="letter-spacing:-0.4pt;"> </span>rights<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>California<span style="letter-spacing:-0.4pt;"> </span>residents,<span style="letter-spacing:-0.4pt;"> </span>including<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>right to<span style="letter-spacing:-0.25pt;"> </span>correct<span style="letter-spacing:-0.25pt;"> </span>personal<span style="letter-spacing:-0.25pt;"> </span>information<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.25pt;"> </span>opt-out<span style="letter-spacing:-0.25pt;"> </span>rights.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.25pt;"> </span>CPRA<span style="letter-spacing:-0.25pt;"> </span>also<span style="letter-spacing:-0.25pt;"> </span>establishes<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>agency dedicated to enforcing the CCPA and the CPRA. At least 11 other states have also passed comprehensive privacy<span style="letter-spacing:-0.1pt;"> </span>laws,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>similar<span style="letter-spacing:-0.1pt;"> </span>laws<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>being<span style="letter-spacing:-0.1pt;"> </span>considered<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>several<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>states,<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.1pt;"> </span>well<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.1pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>federal<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>local levels. While these state privacy laws, like the CCPA, also exempt some data processed in the context of<span style="letter-spacing:1.35pt;"> </span>clinical trials,<span style="letter-spacing:-0.6pt;"> </span>these<span style="letter-spacing:-0.6pt;"> </span>developments<span style="letter-spacing:-0.6pt;"> </span>further<span style="letter-spacing:-0.6pt;"> </span>complicate<span style="letter-spacing:-0.6pt;"> </span>compliance<span style="letter-spacing:-0.6pt;"> </span>efforts,<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>increase<span style="letter-spacing:-0.6pt;"> </span>legal<span style="letter-spacing:-0.6pt;"> </span>risk<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>compliance<span style="letter-spacing:-0.6pt;"> </span>costs for<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.15pt;"> </span>upon<span style="letter-spacing:-0.15pt;"> </span>whom<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>rely.<span style="letter-spacing:-0.15pt;"> </span>In<span style="letter-spacing:-0.15pt;"> </span>addition<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>government<span style="letter-spacing:-0.15pt;"> </span>activity,<span style="letter-spacing:-0.15pt;"> </span>privacy<span style="letter-spacing:-0.15pt;"> </span>advocacy<span style="letter-spacing:-0.15pt;"> </span>groups and technology and other industries are considering various new, additional or different self- regulatory standards that may place additional burdens on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There are also various laws and regulations in other jurisdictions outside the U.S. relating to data privacy and security, with which we may need to comply. For example, the EU GDPR and the UK&#8217;s equivalent<span style="letter-spacing:-0.7pt;"> </span>(&#8220;UK<span style="letter-spacing:-0.65pt;"> </span>GDPR&#8221;<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>collectively,<span style="letter-spacing:-0.65pt;"> </span>&#8220;GDPR&#8221;),<span style="letter-spacing:-0.55pt;"> </span>impose<span style="letter-spacing:-0.55pt;"> </span>strict<span style="letter-spacing:-0.55pt;"> </span>requirements<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>processing<span style="letter-spacing:-0.55pt;"> </span>personal<span style="letter-spacing:-0.55pt;"> </span>data. <span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">also</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">operations</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">Asia,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">subject</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">new</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">emerging</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">data</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">privacy</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">regimes</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">such</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">as</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">Japan&#8217;s </span>Act on the Protection of Personal Information and China&#8217;s Personal Information Protection Law. Notably, the<span style="letter-spacing:-0.05pt;"> </span>EU<span style="letter-spacing:-0.05pt;"> </span>GDPR<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>UK<span style="letter-spacing:-0.05pt;"> </span>GDPR<span style="letter-spacing:-0.05pt;"> </span>impose<span style="letter-spacing:-0.05pt;"> </span>large<span style="letter-spacing:-0.05pt;"> </span>penalties<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>noncompliance,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>fines<span style="letter-spacing:-0.05pt;"> </span>of up to &#8364;20 million under the EU GDPR / &#163;17.5 million under the UK GDPR, or 4% of the annual global revenue of the noncompliant entity, whichever is greater. The EU GDPR and UK GDPR also provide for private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. Additionally, EU member states and other jurisdictions may introduce further conditions, including limitations, and make their own laws and regulations further limiting the processing of special categories of personal data, including personal data related<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>health,<span style="letter-spacing:-0.45pt;"> </span>biometric<span style="letter-spacing:-0.45pt;"> </span>data<span style="letter-spacing:-0.45pt;"> </span>used<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.45pt;"> </span>unique<span style="letter-spacing:-0.45pt;"> </span>identification<span style="letter-spacing:-0.45pt;"> </span>purposes<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>genetic<span style="letter-spacing:-0.45pt;"> </span>information,<span style="letter-spacing:-0.45pt;"> </span>which<span style="letter-spacing:-0.45pt;"> </span>could limit our ability to collect, use and share data from the EU and other jurisdictions, and could cause our compliance costs to increase, ultimately adversely affecting our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:-0.45pt;"> </span>addition,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>be<span style="letter-spacing:-0.45pt;"> </span>unable<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>transfer<span style="letter-spacing:-0.45pt;"> </span>personal<span style="letter-spacing:-0.45pt;"> </span>data<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span>Europe<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>other<span style="letter-spacing:-0.45pt;"> </span>jurisdictions<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>U.S. or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (&#8220;EEA&#8221;) and the UK have significantly<span style="letter-spacing:-0.7pt;"> </span>restricted<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>transfer<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.55pt;"> </span>personal<span style="letter-spacing:-0.65pt;"> </span>data<span style="letter-spacing:-0.7pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>countries<span style="letter-spacing:-0.65pt;"> </span>whose<span style="letter-spacing:-0.65pt;"> </span>privacy<span style="letter-spacing:-0.65pt;"> </span>laws<span style="letter-spacing:-0.65pt;"> </span>it<span style="letter-spacing:-0.65pt;"> </span>believes<span style="letter-spacing:-0.65pt;"> </span>are<span style="letter-spacing:-0.7pt;"> </span>inadequate. Case law from the Court of Justice of the European Union (&#8220;CJEU&#8221;), however, states that reliance on the standard<span style="letter-spacing:1.2pt;"> </span>contractual<span style="letter-spacing:1.2pt;"> </span>clauses&#8212;a<span style="letter-spacing:1.2pt;"> </span>standard<span style="letter-spacing:1.2pt;"> </span>form<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:2.25pt;"> </span>contract<span style="letter-spacing:1.2pt;"> </span>approved<span style="letter-spacing:1.25pt;"> </span>by<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:1.2pt;"> </span>European<span style="letter-spacing:1.2pt;"> </span>Commission<span style="letter-spacing:1.25pt;"> </span>as<span style="letter-spacing:1.2pt;"> </span><span style="letter-spacing:-0.25pt;">an</span> adequate personal information transfer mechanism&#8212;alone may not necessarily be sufficient in all circumstances<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>transfers<span style="letter-spacing:-0.1pt;"> </span>must<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>assessed<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>case-by-case<span style="letter-spacing:-0.1pt;"> </span>basis.<span style="letter-spacing:-0.1pt;"> </span>In<span style="letter-spacing:-0.1pt;"> </span>October<span style="letter-spacing:-0.1pt;"> </span>2022,<span style="letter-spacing:-0.1pt;"> </span>President<span style="letter-spacing:-0.1pt;"> </span>Biden signed<span style="letter-spacing:-0.4pt;"> </span>an<span style="letter-spacing:-0.4pt;"> </span>Executive<span style="letter-spacing:-0.4pt;"> </span>Order<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.4pt;"> </span>introduced<span style="letter-spacing:-0.4pt;"> </span>new<span style="letter-spacing:-0.4pt;"> </span>mechanisms<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>safeguards<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>address<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>concerns<span style="letter-spacing:-0.4pt;"> </span>raised<span style="letter-spacing:-0.4pt;"> </span>by the CJEU in relation to data transfers from the EEA to the U.S. and which formed the basis of<span style="letter-spacing:1.3pt;"> </span>the new EU-US Data Privacy Framework (and corresponding UK data protection framework, collectively the &#8220;DPF&#8221;), as released on December 13, 2022. The European Commission adoption of<span style="letter-spacing:1.15pt;"> </span>its Adequacy Decision means<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>DPF<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>effective<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.25pt;"> </span>EU<span style="letter-spacing:-0.25pt;"> </span>GDPR<span style="letter-spacing:-0.25pt;"> </span>transfer<span style="letter-spacing:-0.25pt;"> </span>mechanism<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>U.S.<span style="letter-spacing:-0.25pt;"> </span>entities<span style="letter-spacing:-0.25pt;"> </span>self-certified<span style="letter-spacing:-0.25pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>DPF. While<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>have<span style="letter-spacing:-0.35pt;"> </span>certified<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>participant<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>DPF,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>cannot<span style="letter-spacing:-0.35pt;"> </span>guarantee<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>validity<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>DPF<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.35pt;"> </span>not <span style="letter-spacing:-0.1pt;">undergo</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">further</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">legal</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">challenge</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">as</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">occurred</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">previous</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">transfer</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">mechanisms</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">like</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">EU/US</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">Privacy</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">Shield.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other<span style="letter-spacing:-0.5pt;"> </span>jurisdictions<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>adopt<span style="letter-spacing:-0.5pt;"> </span>similarly<span style="letter-spacing:-0.5pt;"> </span>stringent<span style="letter-spacing:-0.5pt;"> </span>interpretations<span style="letter-spacing:-0.5pt;"> </span>of their<span style="letter-spacing:-0.5pt;"> </span>data<span style="letter-spacing:-0.5pt;"> </span>localization<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>cross- border<span style="letter-spacing:-0.25pt;"> </span>data<span style="letter-spacing:-0.25pt;"> </span>transfer<span style="letter-spacing:-0.25pt;"> </span>laws.<span style="letter-spacing:-0.25pt;"> </span>Although<span style="letter-spacing:-0.25pt;"> </span>there<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>currently<span style="letter-spacing:-0.25pt;"> </span>various<span style="letter-spacing:-0.25pt;"> </span>mechanisms<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.25pt;"> </span>used<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>transfer personal data from the EEA and UK to the U.S. in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses and the recently approved DPF, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S.<span style="letter-spacing:-0.55pt;"> </span>If there<span style="letter-spacing:-0.55pt;"> </span>is<span style="letter-spacing:-0.55pt;"> </span>no<span style="letter-spacing:-0.55pt;"> </span>lawful<span style="letter-spacing:-0.55pt;"> </span>manner<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>us<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>transfer<span style="letter-spacing:-0.55pt;"> </span>personal<span style="letter-spacing:-0.55pt;"> </span>data<span style="letter-spacing:-0.55pt;"> </span>from<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">EEA,<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>UK<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>other jurisdictions to the U.S., or if<span style="letter-spacing:2pt;"> </span>the requirements for a legally-compliant transfer are too onerous, we<span style="letter-spacing:2pt;"> </span>could face significant adverse consequences, including the interruption or degradation of<span style="letter-spacing:2pt;"> </span>our operations, the<span style="letter-spacing:2pt;"> </span>need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the U.S., are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the EU GDPR&#8217;s cross-border data transfer limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:1.15pt;"> </span>addition<span style="letter-spacing:1.15pt;"> </span>to<span style="letter-spacing:1.15pt;"> </span>data<span style="letter-spacing:1.15pt;"> </span>privacy<span style="letter-spacing:1.15pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>security<span style="letter-spacing:1.15pt;"> </span>laws,<span style="letter-spacing:1.15pt;"> </span>we<span style="letter-spacing:1.15pt;"> </span>are<span style="letter-spacing:1.15pt;"> </span>also<span style="letter-spacing:1.15pt;"> </span>bound<span style="letter-spacing:1.15pt;"> </span>by<span style="letter-spacing:1.15pt;"> </span>other<span style="letter-spacing:1.15pt;"> </span>contractual<span style="letter-spacing:1.15pt;"> </span>obligations<span style="letter-spacing:1.15pt;"> </span>related to<span style="letter-spacing:-0.3pt;"> </span>data<span style="letter-spacing:-0.3pt;"> </span>privacy<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>security,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>efforts<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>comply<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.3pt;"> </span>obligations<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>not<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of these laws, rules, regulations and contractual obligations relating to data privacy and security, and<span style="letter-spacing:-0.6pt;"> </span>any<span style="letter-spacing:-0.6pt;"> </span>other<span style="letter-spacing:-0.6pt;"> </span>such<span style="letter-spacing:-0.6pt;"> </span>changes<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>new<span style="letter-spacing:-0.6pt;"> </span>laws,<span style="letter-spacing:-0.6pt;"> </span>rules,<span style="letter-spacing:-0.6pt;"> </span>regulations<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>contractual<span style="letter-spacing:-0.6pt;"> </span>obligations<span style="letter-spacing:-0.6pt;"> </span>could<span style="letter-spacing:-0.6pt;"> </span>impose<span style="letter-spacing:-0.6pt;"> </span>significant limitations, require changes to our business, or restrict our collection, use, storage or processing of personal information,<span style="letter-spacing:-0.7pt;"> </span>which<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>increase<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>compliance<span style="letter-spacing:-0.65pt;"> </span>expenses<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>make<span style="letter-spacing:-0.7pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>business<span style="letter-spacing:-0.65pt;"> </span>more<span style="letter-spacing:-0.65pt;"> </span>costly<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>less<span style="letter-spacing:-0.65pt;"> </span>efficient to conduct. In addition, any such changes could compromise our ability to develop an adequate marketing strategy and pursue our growth strategy effectively or even prevent us from providing certain products in jurisdictions in which we currently operate and in which we may operate in the future or incur potential liability in an effort to comply with such legislation, which, in turn, could adversely affect our business, financial<span style="letter-spacing:-0.2pt;"> </span>condition,<span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>operations<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>prospects.<span style="letter-spacing:-0.2pt;"> </span>Complying<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>numerous,<span style="letter-spacing:-0.2pt;"> </span>complex<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>often changing<span style="letter-spacing:-0.25pt;"> </span>regulations<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>expensive<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>difficult,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>comply<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>data<span style="letter-spacing:-0.25pt;"> </span>privacy<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>security<span style="letter-spacing:-0.25pt;"> </span>laws, whether<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>us,<span style="letter-spacing:-0.05pt;"> </span>one<span style="letter-spacing:-0.05pt;"> </span>of our<span style="letter-spacing:-0.05pt;"> </span>CROs,<span style="letter-spacing:-0.05pt;"> </span>CMOs<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>associates<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>another<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.05pt;"> </span>party,<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.05pt;"> </span>affect our business, financial condition, results of operations and prospects, including but not limited to: investigation costs; material fines and penalties; compensatory, special, punitive and statutory damages; litigation;<span style="letter-spacing:-0.15pt;"> </span>consent<span style="letter-spacing:-0.15pt;"> </span>orders<span style="letter-spacing:-0.15pt;"> </span>regarding<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>privacy<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>security<span style="letter-spacing:-0.15pt;"> </span>practices;<span style="letter-spacing:-0.15pt;"> </span>requirements<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>provide<span style="letter-spacing:-0.15pt;"> </span>notices, credit<span style="letter-spacing:-0.7pt;"> </span>monitoring<span style="letter-spacing:-0.65pt;"> </span>services<span style="letter-spacing:-0.65pt;"> </span>and/or<span style="letter-spacing:-0.65pt;"> </span>credit<span style="letter-spacing:-0.65pt;"> </span>restoration<span style="letter-spacing:-0.65pt;"> </span>services<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>other<span style="letter-spacing:-0.7pt;"> </span>relevant<span style="letter-spacing:-0.65pt;"> </span>services<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>impacted<span style="letter-spacing:-0.65pt;"> </span>individuals; adverse actions against our licenses to do business; reputational damage; and injunctive relief. The implementation<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>CCPA,<span style="letter-spacing:-0.3pt;"> </span>GDPR<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.3pt;"> </span>similar<span style="letter-spacing:-0.3pt;"> </span>laws<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>increased<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>responsibility<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>liability<span style="letter-spacing:-0.3pt;"> </span>in relation to personal data that we process, including in clinical trials, and we may in the future be required to put<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>place<span style="letter-spacing:-0.15pt;"> </span>additional<span style="letter-spacing:-0.15pt;"> </span>mechanisms<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>ensure<span style="letter-spacing:-0.15pt;"> </span>compliance<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>applicable<span style="letter-spacing:-0.15pt;"> </span>laws<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regulations, which could divert management&#8217;s attention and increase our cost of doing business. In addition, new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the U.S.,<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>EEA<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>other<span style="letter-spacing:-0.5pt;"> </span>jurisdictions,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>cannot<span style="letter-spacing:-0.5pt;"> </span>determine<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>impact<span style="letter-spacing:-0.5pt;"> </span>such<span style="letter-spacing:-0.5pt;"> </span>future<span style="letter-spacing:-0.5pt;"> </span>laws,<span style="letter-spacing:-0.5pt;"> </span>regulations<span style="letter-spacing:-0.5pt;"> </span>and standards may have on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any<span style="letter-spacing:-0.25pt;"> </span>actual<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>perceived<span style="letter-spacing:-0.25pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>third-party<span style="letter-spacing:-0.25pt;"> </span>service<span style="letter-spacing:-0.25pt;"> </span>providers<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>comply<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>federal,<span style="letter-spacing:-0.25pt;"> </span>state or<span style="letter-spacing:-0.6pt;"> </span>foreign<span style="letter-spacing:-0.55pt;"> </span>laws,<span style="letter-spacing:-0.55pt;"> </span>rules,<span style="letter-spacing:-0.55pt;"> </span>regulations,<span style="letter-spacing:-0.55pt;"> </span>industry<span style="letter-spacing:-0.55pt;"> </span>self-regulatory<span style="letter-spacing:-0.55pt;"> </span>principles,<span style="letter-spacing:-0.6pt;"> </span>industry<span style="letter-spacing:-0.55pt;"> </span>standards<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>codes<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>conduct, regulatory guidance, orders to which we may be subject or other legal obligations relating to privacy, data protection, data security or consumer protection could adversely affect our reputation, brand and business. We may also be contractually required to indemnify and hold harmless third parties from the costs or consequences of non-compliance with any laws, rules and regulations or other legal obligations relating to privacy or any inadvertent or unauthorized use or disclosure of data that we store or handle as part of operating our business. Any of these events could adversely affect our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our<span style="letter-spacing:-0.2pt;"> </span>CROs,<span style="letter-spacing:-0.2pt;"> </span>CMOs<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>third-party<span style="letter-spacing:-0.2pt;"> </span>service<span style="letter-spacing:-0.2pt;"> </span>providers<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>or our suppliers&#8217;, manufacturers&#8217;, trial participants&#8217; and employees&#8217; sensitive information for which we are responsible<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>breach<span style="letter-spacing:-0.3pt;"> </span>contractual<span style="letter-spacing:-0.3pt;"> </span>obligations<span style="letter-spacing:-0.3pt;"> </span>imposed<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.3pt;"> </span>us,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>they<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>experience<span style="letter-spacing:-0.3pt;"> </span>data<span style="letter-spacing:-0.3pt;"> </span>security incidents, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, financial condition, results of<span style="letter-spacing:1pt;"> </span>operations and prospects. Our contractual measures and<span style="letter-spacing:1.8pt;"> </span>our<span style="letter-spacing:1.8pt;"> </span>own<span style="letter-spacing:1.8pt;"> </span>privacy<span style="letter-spacing:1.8pt;"> </span>and<span style="letter-spacing:1.8pt;"> </span>security-related<span style="letter-spacing:1.8pt;"> </span>safeguards<span style="letter-spacing:1.8pt;"> </span>may not<span style="letter-spacing:1.8pt;"> </span>protect<span style="letter-spacing:1.8pt;"> </span>us<span style="letter-spacing:1.8pt;"> </span>from<span style="letter-spacing:1.8pt;"> </span>the<span style="letter-spacing:1.8pt;"> </span>risks<span style="letter-spacing:1.8pt;"> </span>associated<span style="letter-spacing:1.8pt;"> </span>with<span style="letter-spacing:1.8pt;"> </span>the third-party<span style="letter-spacing:-0.7pt;"> </span>processing<span style="letter-spacing:-0.65pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of<span style="letter-spacing:-0.65pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>information.<span style="letter-spacing:-0.65pt;"> </span>Any<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>foregoing<span style="letter-spacing:-0.7pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>adversely<span style="letter-spacing:-0.65pt;"> </span>affect<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>business,<span style="letter-spacing:-0.65pt;"> </span>financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also publicly post our privacy policies and practices concerning our collection, use, disclosure and other processing of the personal information provided to us by our website visitors and by our customers. Although<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>endeavor<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>comply<span style="letter-spacing:-0.6pt;"> </span>with<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>public<span style="letter-spacing:-0.6pt;"> </span>statements<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>documentation,<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>at<span style="letter-spacing:-0.6pt;"> </span>times<span style="letter-spacing:-0.6pt;"> </span>fail<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>do<span style="letter-spacing:-0.6pt;"> </span>so or be perceived to have failed to do so. Our publication of our privacy policies and other statements we publish<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>provide<span style="letter-spacing:-0.15pt;"> </span>promises<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>assurances<span style="letter-spacing:-0.15pt;"> </span>about<span style="letter-spacing:-0.15pt;"> </span>privacy<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>security<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>potential<span style="letter-spacing:-0.15pt;"> </span>state<span style="letter-spacing:-0.15pt;"> </span>and federal<span style="letter-spacing:-0.6pt;"> </span>action<span style="letter-spacing:-0.6pt;"> </span>if<span style="letter-spacing:0.35pt;"> </span>they<span style="letter-spacing:-0.6pt;"> </span>are<span style="letter-spacing:-0.6pt;"> </span>found<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>be<span style="letter-spacing:-0.6pt;"> </span>deceptive,<span style="letter-spacing:-0.6pt;"> </span>unfair<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>misrepresentative<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>actual<span style="letter-spacing:-0.6pt;"> </span>practices.<span style="letter-spacing:-0.6pt;"> </span>Any<span style="letter-spacing:-0.6pt;"> </span>actual <span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">perceived</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">failure</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">by</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">us</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">comply</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">federal,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">state</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">foreign</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">laws,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">rules</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">regulations,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">industry</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">standards, </span>contractual<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>other<span style="letter-spacing:-0.55pt;"> </span>legal<span style="letter-spacing:-0.6pt;"> </span>obligations,<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>any<span style="letter-spacing:-0.55pt;"> </span>actual,<span style="letter-spacing:-0.6pt;"> </span>perceived<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>suspected<span style="letter-spacing:-0.55pt;"> </span>cybersecurity<span style="letter-spacing:-0.6pt;"> </span>incident,<span style="letter-spacing:-0.55pt;"> </span>whether<span style="letter-spacing:-0.6pt;"> </span>or not resulting in unauthorized access to, or acquisition, release or transfer of personal information or other data, may result in enforcement actions and prosecutions, private litigation, significant fines, penalties and censure, claims for damages by customers and other affected individuals, regulatory inquiries and investigations or adverse publicity and could cause our customers to lose trust in us, any of which could adversely affect our business, financial condition, results of<span style="letter-spacing:1.8pt;"> </span>operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.4pt;"> </span>contracts<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.4pt;"> </span>not<span style="letter-spacing:-0.4pt;"> </span>contain<span style="letter-spacing:-0.4pt;"> </span>limitations<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>liability,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>even<span style="letter-spacing:-0.4pt;"> </span>where<span style="letter-spacing:-0.4pt;"> </span>they<span style="letter-spacing:-0.4pt;"> </span>do,<span style="letter-spacing:-0.4pt;"> </span>there<span style="letter-spacing:-0.4pt;"> </span>can<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.4pt;"> </span>no<span style="letter-spacing:-0.4pt;"> </span>assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. Further, the successful assertion of one or more large claims<span style="letter-spacing:-0.65pt;"> </span>against<span style="letter-spacing:-0.65pt;"> </span>us<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>exceeds<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>available<span style="letter-spacing:-0.65pt;"> </span>insurance<span style="letter-spacing:-0.65pt;"> </span>coverage,<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>results<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>changes<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>insurance<span style="letter-spacing:-0.65pt;"> </span>policies (including<span style="letter-spacing:-0.65pt;"> </span>premium<span style="letter-spacing:-0.65pt;"> </span>increases<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>imposition<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>large<span style="letter-spacing:-0.65pt;"> </span>deductible<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>co-insurance<span style="letter-spacing:-0.65pt;"> </span>requirements),<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>have an adverse effect on our business. In addition, we cannot be sure that our existing insurance coverage will continue<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>be<span style="letter-spacing:-0.5pt;"> </span>available<span style="letter-spacing:-0.5pt;"> </span>on<span style="letter-spacing:-0.5pt;"> </span>acceptable<span style="letter-spacing:-0.5pt;"> </span>terms<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>insurers<span style="letter-spacing:-0.5pt;"> </span>will<span style="letter-spacing:-0.5pt;"> </span>not<span style="letter-spacing:-0.5pt;"> </span>deny<span style="letter-spacing:-0.5pt;"> </span>coverage<span style="letter-spacing:-0.5pt;"> </span>as<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>any<span style="letter-spacing:-0.5pt;"> </span>future<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">claim.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>anti-money<span style="letter-spacing:-0.5pt;"> </span>laundering<span style="letter-spacing:-0.5pt;"> </span>laws<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>regulations.<span style="letter-spacing:-0.5pt;"> </span>Compliance<span style="letter-spacing:-0.5pt;"> </span>with<span style="letter-spacing:-0.5pt;"> </span>these<span style="letter-spacing:-0.5pt;"> </span>legal<span style="letter-spacing:-0.5pt;"> </span>standards<span style="letter-spacing:-0.5pt;"> </span>could<span style="letter-spacing:-0.5pt;"> </span>impair<span style="letter-spacing:-0.5pt;"> </span>our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>violations,<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.1pt;"> </span>can<span style="letter-spacing:-0.1pt;"> </span>harm<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>U.S.<span style="letter-spacing:-0.5pt;"> </span>Treasury<span style="letter-spacing:-0.5pt;"> </span>Department&#8217;s<span style="letter-spacing:-0.5pt;"> </span>Office<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>Foreign<span style="letter-spacing:-0.5pt;"> </span>Assets<span style="letter-spacing:-0.5pt;"> </span>Controls,<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>U.S.<span style="letter-spacing:-0.5pt;"> </span>Foreign<span style="letter-spacing:-0.5pt;"> </span>Corrupt Practices<span style="letter-spacing:-0.5pt;"> </span>Act<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>1977,<span style="letter-spacing:-0.5pt;"> </span>as<span style="letter-spacing:-0.5pt;"> </span>amended<span style="letter-spacing:-0.5pt;"> </span>(&#8220;FCPA&#8221;),<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>U.S.<span style="letter-spacing:-0.5pt;"> </span>domestic<span style="letter-spacing:-0.5pt;"> </span>bribery<span style="letter-spacing:-0.5pt;"> </span>statute<span style="letter-spacing:-0.5pt;"> </span>contained<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.5pt;"> </span>18<span style="letter-spacing:-0.5pt;"> </span>U.S.C.<span style="letter-spacing:-0.5pt;"> </span>&#167;<span style="letter-spacing:-0.5pt;"> </span>201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>countries<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>conduct<span style="letter-spacing:-0.2pt;"> </span>activities.<span style="letter-spacing:-0.2pt;"> </span>Anti-corruption<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>interpreted<span style="letter-spacing:-0.2pt;"> </span>broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>public<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>private<span style="letter-spacing:-0.2pt;"> </span>sector.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>engage<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>parties<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>sell<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>products<span style="letter-spacing:-0.15pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">U.S.</span>, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government <span style="letter-spacing:-0.1pt;">agencies</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">government-affiliated</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">hospitals,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">universities,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">organizations.</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">can</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">held</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">liable</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">the </span>corrupt<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>other<span style="letter-spacing:-0.5pt;"> </span>illegal<span style="letter-spacing:-0.5pt;"> </span>activities<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>employees,<span style="letter-spacing:-0.5pt;"> </span>agents,<span style="letter-spacing:-0.5pt;"> </span>contractors,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>other<span style="letter-spacing:-0.5pt;"> </span>collaborators,<span style="letter-spacing:-0.5pt;"> </span>even<span style="letter-spacing:-0.5pt;"> </span>if<span style="letter-spacing:0.4pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>do not<span style="letter-spacing:-0.8pt;"> </span>explicitly<span style="letter-spacing:-0.65pt;"> </span>authorize<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>have<span style="letter-spacing:-0.65pt;"> </span>actual<span style="letter-spacing:-0.65pt;"> </span>knowledge<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>such<span style="letter-spacing:-0.7pt;"> </span>activities.<span style="letter-spacing:-0.65pt;"> </span>Any<span style="letter-spacing:-0.65pt;"> </span>violations<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>laws<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export<span style="letter-spacing:-0.7pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>import<span style="letter-spacing:-0.65pt;"> </span>privileges,<span style="letter-spacing:-0.65pt;"> </span>debarment,<span style="letter-spacing:-0.65pt;"> </span>tax<span style="letter-spacing:-0.65pt;"> </span>reassessments,<span style="letter-spacing:-0.65pt;"> </span>breach<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.35pt;"> </span>contract<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.7pt;"> </span>fraud<span style="letter-spacing:-0.65pt;"> </span>litigation,<span style="letter-spacing:-0.65pt;"> </span>reputational harm, and other consequences. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Significant political, trade, regulatory developments, including changes in relations between the U.S. and China, and other circumstances beyond our control, may adversely impact our business, financial condition, and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Various political, trade, or regulatory developments have, and could further, adversely affect our business and the results of our operations and financial condition. For example, recent actions and statements by the governments of the U.S. and China, including those relating to the imposition or threatened imposition of tariffs, or increases to tariffs, affecting certain products manufactured in China, have impacted, and may continue to impact, companies like us who rely on suppliers and other commercial partners with significant operations in China. For example, while we have selected new CMOs in the U.S. to establish additional sources of supply, currently we import from China certain drug substance, drug product and </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other components, and such imports are subject to existing tariffs and may be impacted by additional tariffs. Currently, many of our suppliers primarily operate outside of the U.S., including our current sole CMO, WuXi Biologics, which provides its services to us from facilities located in China, and increases in tariffs could result in increased costs. As a result, we are subject to risks associated with political, trade, regulatory developments with respect to such countries, and between the U.S. and such countries. Any unfavorable legislation, regulations, executive orders, government policies on cross-border relations and/or international trade, including increased scrutiny on certain of our suppliers with significant China-based operations, capital controls, or tariffs, may have an adverse effect on our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks<b style="font-weight:bold;letter-spacing:-0.25pt;"> </b>Related to Our<b style="font-weight:bold;letter-spacing:-0.25pt;"> </b>Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently rely on a single third-party manufacturer, WuXi Biologics, to supply our product candidates, including<span style="letter-spacing:-0.45pt;"> </span>certain<span style="letter-spacing:-0.45pt;"> </span>drug<span style="letter-spacing:-0.45pt;"> </span>substances<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>drug<span style="letter-spacing:-0.45pt;"> </span>products<span style="letter-spacing:-0.45pt;"> </span>used<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>product<span style="letter-spacing:-0.45pt;"> </span>candidates.<span style="letter-spacing:-0.45pt;"> </span>If we<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.45pt;"> </span>unable<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>source these<span style="letter-spacing:-0.1pt;"> </span>supplies<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>timely<span style="letter-spacing:-0.1pt;"> </span>basis,<span style="letter-spacing:-0.1pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>sufficient<span style="letter-spacing:-0.1pt;"> </span>quantities<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>acceptable<span style="letter-spacing:-0.1pt;"> </span>quality<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>prices,<span style="letter-spacing:-0.1pt;"> </span>establish<span style="letter-spacing:-0.1pt;"> </span>longer-term contracts with our CMOs, or our third-party manufacturers fail to comply with applicable regulatory requirements, we will not be able to complete our clinical trials on time and the development of our product candidates may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not own or operate facilities for drug manufacturing, storage, distribution or quality testing. We currently rely on a single third-party manufacturer, WuXi Biologics, located in China, to manufacture and supply the drug substances and drug products for our product candidates, and currently do not have any redundant supply outside of WuXi Biologics, for drug substance and drug product. Reliance on a single third-party manufacturer exposes us to different risks than if we were to manufacture product candidates ourselves. While we believe our current inventory of drug substance and drug product will be sufficient to complete<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>ongoing<span style="letter-spacing:-0.45pt;"> </span>trials<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>obexelimab,<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>preclinical<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>clinical<span style="letter-spacing:-0.45pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>product<span style="letter-spacing:-0.45pt;"> </span>supplies<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>be limited, interrupted, terminated or be of unsatisfactory quality or unavailable at acceptable prices. WuXi Biologics<span style="letter-spacing:-0.65pt;"> </span>does<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>solely<span style="letter-spacing:-0.65pt;"> </span>hold<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>necessary<span style="letter-spacing:-0.65pt;"> </span>intellectual<span style="letter-spacing:-0.65pt;"> </span>property,<span style="letter-spacing:-0.65pt;"> </span>technology<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>know-how<span style="letter-spacing:-0.65pt;"> </span>required<span style="letter-spacing:-0.65pt;"> </span>to manufacture<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidates.<span style="letter-spacing:-0.65pt;"> </span>However,<span style="letter-spacing:-0.65pt;"> </span>while<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>are<span style="letter-spacing:-0.65pt;"> </span>able<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>transfer<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>manufacturing<span style="letter-spacing:-0.65pt;"> </span>process<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>our product candidates to another CMO without the involvement of WuXi Biologics, establishing additional or replacement<span style="letter-spacing:-0.6pt;"> </span>suppliers<span style="letter-spacing:-0.6pt;"> </span>for<span style="letter-spacing:-0.6pt;"> </span>these<span style="letter-spacing:-0.6pt;"> </span>supplies,<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>obtaining<span style="letter-spacing:-0.6pt;"> </span>regulatory<span style="letter-spacing:-0.6pt;"> </span>clearance<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>approvals<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>result<span style="letter-spacing:-0.6pt;"> </span>from adding or replacing suppliers, could take a substantial amount of<span style="letter-spacing:1.4pt;"> </span>time, result in increased costs and impair our<span style="letter-spacing:-0.7pt;"> </span>ability<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>produce<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>products,<span style="letter-spacing:-0.65pt;"> </span>which<span style="letter-spacing:-0.65pt;"> </span>would<span style="letter-spacing:-0.65pt;"> </span>adversely<span style="letter-spacing:-0.7pt;"> </span>impact<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>business,<span style="letter-spacing:-0.65pt;"> </span>financial<span style="letter-spacing:-0.65pt;"> </span>condition,<span style="letter-spacing:-0.65pt;"> </span>results<span style="letter-spacing:-0.65pt;"> </span>of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We order obexelimab drug substance and drug product pursuant to a master services agreement with <span style="letter-spacing:-0.1pt;">WuXi</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">Biologics.</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">If</span><span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:-0.1pt;">any</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">product</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">candidates</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">receives</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">marketing</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">approval,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">intend</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">rely</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">third-party </span>CMOs for commercial manufacturing. We have<span style="letter-spacing:-0.3pt;"> a </span>long-term<span style="letter-spacing:-0.3pt;"> </span>commercial<span style="letter-spacing:-0.3pt;"> </span>supply<span style="letter-spacing:-0.3pt;"> </span>agreement with WuXi Biologics<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>fulfill<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>secure<span style="letter-spacing:-0.3pt;"> </span>obexelimab drug substance and drug product for an anticipated commercial launch, if approved.<span style="letter-spacing:-0.45pt;"> </span>In<span style="letter-spacing:-0.45pt;"> </span>addition,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>have selected new<span style="letter-spacing:-0.45pt;"> </span>CMOs in the U.S., which are not affiliated with WuXi Biologics, to establish additional sources of supply for drug substance and drug product for both commercial and clinical use. For the medical device component<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>product<span style="letter-spacing:-0.45pt;"> </span>(i.e.,<span style="letter-spacing:-0.45pt;"> </span>prefilled<span style="letter-spacing:-0.45pt;"> </span>syringe<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>autoinjector),<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>plan<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>utilize<span style="letter-spacing:-0.45pt;"> </span>device<span style="letter-spacing:-0.45pt;"> </span>assembly<span style="letter-spacing:-0.45pt;"> </span>facilities in the U.S. or EU for the global supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any change in our relationship with our CMOs or changes to contractual terms of our agreements with them could adversely affect our business, financial condition, results of operations and prospects.<span style="letter-spacing:-0.35pt;"> </span>Additionally,<span style="letter-spacing:-0.35pt;"> </span>legislation<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>regulations,<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>proposed<span style="letter-spacing:-0.35pt;"> </span>BIOSECURE<span style="letter-spacing:-0.35pt;"> </span>Act,<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>draft<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>which is<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>legislative<span style="letter-spacing:-0.25pt;"> </span>process<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>U.S.<span style="letter-spacing:-0.25pt;"> </span>Congress,<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.3pt;"> </span>restrict<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>enter<span style="letter-spacing:-0.3pt;"> </span>into new<span style="letter-spacing:-0.25pt;"> </span>long-term<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">commercial</span> agreements with certain CMOs if the proposed legislation and regulations are enacted into law. Please see &#8220;&#8212;Risks Related to Our Reliance on Third Parties&#8212;The operations of our suppliers, many of which are located outside of the U.S., including our current sole CMO for drug substance and drug product, WuXi<span style="letter-spacing:-0.5pt;"> </span>Biologics,<span style="letter-spacing:-0.5pt;"> </span>which<span style="letter-spacing:-0.5pt;"> </span>is<span style="letter-spacing:-0.5pt;"> </span>located<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.5pt;"> </span>China,<span style="letter-spacing:-0.5pt;"> </span>are<span style="letter-spacing:-0.5pt;"> </span>subject<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>additional<span style="letter-spacing:-0.5pt;"> </span>risks<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.5pt;"> </span>are<span style="letter-spacing:-0.5pt;"> </span>beyond<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>control<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>that could harm our business, financial condition, results of<span style="letter-spacing:2pt;"> </span>operations and prospects.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furthermore, any of the sole source and limited source suppliers upon whom we rely could stop producing our supplies, cease operations or be acquired by, or enter into exclusive arrangements with, our competitors. Any interruption or delay in the supply of sole source or limited source components for our product<span style="letter-spacing:-0.55pt;"> </span>candidates,<span style="letter-spacing:-0.55pt;"> </span>including<span style="letter-spacing:-0.55pt;"> </span>as<span style="letter-spacing:-0.55pt;"> </span>a<span style="letter-spacing:-0.55pt;"> </span>result<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>us<span style="letter-spacing:-0.55pt;"> </span>needing<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>seek<span style="letter-spacing:-0.55pt;"> </span>alternative<span style="letter-spacing:-0.55pt;"> </span>sources,<span style="letter-spacing:-0.55pt;"> </span>which<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>not<span style="letter-spacing:-0.55pt;"> </span>be<span style="letter-spacing:-0.55pt;"> </span>available at<span style="letter-spacing:-0.6pt;"> </span>reasonable<span style="letter-spacing:-0.6pt;"> </span>prices<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>at<span style="letter-spacing:-0.6pt;"> </span>all,<span style="letter-spacing:-0.6pt;"> </span>would<span style="letter-spacing:-0.6pt;"> </span>adversely<span style="letter-spacing:-0.6pt;"> </span>affect<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>ability<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>meet<span style="letter-spacing:-0.6pt;"> </span>scheduled<span style="letter-spacing:-0.6pt;"> </span>timelines<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>budget<span style="letter-spacing:-0.6pt;"> </span>for<span style="letter-spacing:-0.6pt;"> </span>the development and commercialization of our product candidates, could result in higher expenses and delayed revenue, if our product candidates are approved, and would harm our business. Although we have not experienced<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>significant<span style="letter-spacing:-0.65pt;"> </span>disruption<span style="letter-spacing:-0.65pt;"> </span>as<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>result<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>reliance<span style="letter-spacing:-0.65pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>limited<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>sole<span style="letter-spacing:-0.65pt;"> </span>source<span style="letter-spacing:-0.65pt;"> </span>suppliers,<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>have<span style="letter-spacing:-0.65pt;"> </span>a limited<span style="letter-spacing:-0.4pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">operating<span style="letter-spacing:-0.4pt;"> </span>history<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.4pt;"> </span>experience<span style="letter-spacing:-0.4pt;"> </span>disruptions<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>supply<span style="letter-spacing:-0.4pt;"> </span>chain<span style="letter-spacing:-0.4pt;"> </span>in the future as a result of<span style="letter-spacing:2pt;"> </span>such reliance or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The manufacturing process for our product candidates is subject to the FDA and comparable foreign regulatory authority review. We and our suppliers and manufacturers, some of which are currently our sole source<span style="letter-spacing:-0.7pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>supply,<span style="letter-spacing:-0.65pt;"> </span>must<span style="letter-spacing:-0.65pt;"> </span>meet<span style="letter-spacing:-0.65pt;"> </span>applicable<span style="letter-spacing:-0.65pt;"> </span>manufacturing<span style="letter-spacing:-0.65pt;"> </span>requirements<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.7pt;"> </span>undergo<span style="letter-spacing:-0.65pt;"> </span>rigorous<span style="letter-spacing:-0.65pt;"> </span>facility<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. If our CMOs cannot successfully manufacture material that conforms to our specifications and regulatory<span style="letter-spacing:-0.3pt;"> </span>requirements<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>FDA<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>comparable<span style="letter-spacing:-0.3pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>authorities,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>not<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>able<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>rely on their facilities for the manufacture of elements of our product candidates. Additionally, our CMOs may face resource constraints due to labor disputes or unstable political environments that impact their ability to supply product candidates on schedule, which would impact the timing of our clinical trials or commercial supply for any products that may be approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.25pt;"> </span>expect<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>continue<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>rely<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.25pt;"> </span>CMOs<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:0.6pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>receive<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidate.<span style="letter-spacing:-0.25pt;"> </span>To the extent<span style="letter-spacing:-0.05pt;"> </span>that we<span style="letter-spacing:-0.05pt;"> </span>have existing,<span style="letter-spacing:-0.05pt;"> </span>or enter<span style="letter-spacing:-0.05pt;"> </span>into future,<span style="letter-spacing:-0.05pt;"> </span>manufacturing arrangements<span style="letter-spacing:-0.05pt;"> </span>with third<span style="letter-spacing:-0.05pt;"> </span>parties, we<span style="letter-spacing:-0.05pt;"> </span>will depend<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.05pt;"> </span>parties<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>perform<span style="letter-spacing:-0.05pt;"> </span>their<span style="letter-spacing:-0.05pt;"> </span>obligations<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>timely<span style="letter-spacing:-0.05pt;"> </span>manner<span style="letter-spacing:-0.05pt;"> </span>consistent<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>contractual<span style="letter-spacing:-0.05pt;"> </span>and <span style="letter-spacing:-0.1pt;">regulatory requirements, including those related to quality control and assurance. Any manufacturing facilities </span>used to produce our product candidates will be subject to periodic review and inspection by the FDA and foreign<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>authorities,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>continued<span style="letter-spacing:-0.25pt;"> </span>compliance<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>cGMP<span style="letter-spacing:-0.25pt;"> </span>requirements,<span style="letter-spacing:-0.25pt;"> </span>quality<span style="letter-spacing:-0.25pt;"> </span>control, quality assurance and corresponding maintenance of records and documents. If we are unable to obtain or maintain<span style="letter-spacing:-0.4pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>manufacturing<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.4pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>do<span style="letter-spacing:-0.4pt;"> </span>so<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:-0.4pt;"> </span>commercially<span style="letter-spacing:-0.4pt;"> </span>reasonable<span style="letter-spacing:-0.4pt;"> </span>terms,<span style="letter-spacing:-0.4pt;"> </span>we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements, comply with cGMPs or maintain a compliance status acceptable to the FDA or comparable foreign regulatory authorities could adversely affect our business in a number of ways, including:</p><div style="margin-top:5.3pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preclinical</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">studies</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trials</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:6.44pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submitting</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">applications,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receiving</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approvals,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:6.44pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.95pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cooperation</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.95pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">existing</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:6.5pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cease</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">batches</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2.85pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:0pt;margin-top:6.44pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></td><td style="width:12.3pt;"/></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>event<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>manufacturers<span style="letter-spacing:-0.35pt;"> </span>fails<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>comply<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.35pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>requirements<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>perform<span style="letter-spacing:-0.35pt;"> </span>its obligations<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>relation<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>quality,<span style="letter-spacing:-0.4pt;"> </span>timing<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>otherwise,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>if<span style="letter-spacing:0.6pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>projected<span style="letter-spacing:-0.4pt;"> </span>manufacturing<span style="letter-spacing:-0.4pt;"> </span>capacity<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>supply<span style="letter-spacing:-0.4pt;"> </span>of materials<span style="letter-spacing:-0.45pt;"> </span>becomes<span style="letter-spacing:-0.45pt;"> </span>limited,<span style="letter-spacing:-0.45pt;"> </span>interrupted<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>more<span style="letter-spacing:-0.45pt;"> </span>costly<span style="letter-spacing:-0.45pt;"> </span>than<span style="letter-spacing:-0.45pt;"> </span>anticipated,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>need<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>secure<span style="letter-spacing:-0.45pt;"> </span>manufacturing from<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>different<span style="letter-spacing:-0.25pt;"> </span>third<span style="letter-spacing:-0.3pt;"> </span>party,<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>not<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>able<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>do<span style="letter-spacing:-0.25pt;"> </span>timely<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.3pt;"> </span>reasonable<span style="letter-spacing:-0.25pt;"> </span>terms,<span style="letter-spacing:-0.3pt;"> </span>if at<span style="letter-spacing:-0.25pt;"> </span>all.<span style="letter-spacing:-0.3pt;"> </span>If we<span style="letter-spacing:-0.25pt;"> </span>are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with applicable quality standards and regulations and guidelines;<span style="letter-spacing:1.4pt;"> </span>and<span style="letter-spacing:1.45pt;"> </span>we<span style="letter-spacing:1.45pt;"> </span>may<span style="letter-spacing:1.4pt;"> </span>be<span style="letter-spacing:1.45pt;"> </span>required<span style="letter-spacing:1.45pt;"> </span>to<span style="letter-spacing:1.45pt;"> </span>repeat<span style="letter-spacing:1.4pt;"> </span>some<span style="letter-spacing:1.45pt;"> </span>of<span style="letter-spacing:2.4pt;"> </span>the<span style="letter-spacing:1.45pt;"> </span>development<span style="letter-spacing:1.45pt;"> </span>program. If we change manufacturers after we receive regulatory approval for a product candidate, we will be required to conduct additional testing, including completion of validation batches, and obtain approval from regulatory authorities for the new manufacturer before we can begin using any drug substance or drug product they manufacture for commercial purposes. The delays and costs associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates or commercialize our products, if approved, in a timely manner or within budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">relied</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">expect</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">continue</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">rely</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">third</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">parties</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">conduct</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">preclinical</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">studies</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">trials. </span>If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss deadlines or terminate the relationship, our development programs could be delayed, more costly or unsuccessful, and we may never be able to seek or obtain regulatory approval<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>commercialize<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>product <span style="letter-spacing:-0.1pt;">candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We rely and intend to continue to rely on third-party clinical investigators, CROs and clinical data management organizations to conduct, supervise and monitor preclinical studies and clinical trials of our current<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates.<span style="letter-spacing:-0.15pt;"> </span>Because<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>this<span style="letter-spacing:-0.15pt;"> </span>reliance,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>less<span style="letter-spacing:-0.15pt;"> </span>control<span style="letter-spacing:-0.15pt;"> </span>over<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>timing,<span style="letter-spacing:-0.15pt;"> </span>quality and<span style="letter-spacing:-0.45pt;"> </span>other<span style="letter-spacing:-0.45pt;"> </span>aspects<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>preclinical<span style="letter-spacing:-0.45pt;"> </span>studies<span style="letter-spacing:-0.45pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and<span style="letter-spacing:-0.45pt;"> </span>clinical<span style="letter-spacing:-0.45pt;"> </span>trials<span style="letter-spacing:-0.45pt;"> </span>than<span style="letter-spacing:-0.45pt;"> </span>if<span style="letter-spacing:0.5pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>conduct<span style="letter-spacing:-0.45pt;"> </span>them<span style="letter-spacing:-0.45pt;"> </span>ourselves.<span style="letter-spacing:-0.45pt;"> </span>Third<span style="letter-spacing:-0.45pt;"> </span>parties<span style="letter-spacing:-0.45pt;"> </span>are not our employees and we have limited control over the amount of time and resources that they dedicate to <span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">programs.</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">Additionally,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">such</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">parties</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">contractual</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">relationships</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">entities,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">some</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:1.05pt;"> </span><span style="letter-spacing:-0.1pt;">which</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">may </span>be our competitors, which may divert time and resources from our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our reliance on third parties reduces our control over our development activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable trial protocol<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>legal,<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>scientific<span style="letter-spacing:-0.15pt;"> </span>standards.<span style="letter-spacing:-0.15pt;"> </span>For<span style="letter-spacing:-0.15pt;"> </span>example,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>remain<span style="letter-spacing:-0.15pt;"> </span>responsible<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>ensuring<span style="letter-spacing:-0.15pt;"> </span>that each of our preclinical studies are conducted in accordance with good laboratory practices (&#8220;GLPs&#8221;) and clinical<span style="letter-spacing:-0.6pt;"> </span>trials<span style="letter-spacing:-0.6pt;"> </span>are<span style="letter-spacing:-0.6pt;"> </span>conducted<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>accordance<span style="letter-spacing:-0.6pt;"> </span>with<span style="letter-spacing:-0.6pt;"> </span>GCPs.<span style="letter-spacing:-0.6pt;"> </span>Moreover,<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>FDA<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>comparable<span style="letter-spacing:-0.6pt;"> </span>foreign<span style="letter-spacing:-0.6pt;"> </span>regulatory authorities<span style="letter-spacing:-0.55pt;"> </span>require<span style="letter-spacing:-0.55pt;"> </span>us<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>comply<span style="letter-spacing:-0.55pt;"> </span>with<span style="letter-spacing:-0.55pt;"> </span>GCP<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>conducting,<span style="letter-spacing:-0.55pt;"> </span>recording<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>reporting<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>results<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>clinical<span style="letter-spacing:-0.55pt;"> </span>trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of<span style="letter-spacing:1.2pt;"> </span>trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections (including pre-approval inspections once a BLA is submitted to the FDA) of trial sponsors,<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>investigators,<span style="letter-spacing:-0.25pt;"> </span>trial<span style="letter-spacing:-0.25pt;"> </span>sites<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.25pt;"> </span>CROs.<span style="letter-spacing:-0.25pt;"> </span>If we,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>CROs,<span style="letter-spacing:-0.25pt;"> </span>clinical trial sites or other third parties fail to comply with applicable GCP or other regulatory requirements, we or they<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>be<span style="letter-spacing:-0.45pt;"> </span>subject<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>enforcement<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>other<span style="letter-spacing:-0.45pt;"> </span>legal<span style="letter-spacing:-0.45pt;"> </span>actions,<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>clinical<span style="letter-spacing:-0.45pt;"> </span>data<span style="letter-spacing:-0.45pt;"> </span>generated<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>clinical<span style="letter-spacing:-0.45pt;"> </span>trials<span style="letter-spacing:-0.45pt;"> </span>may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials. Moreover, our business may be significantly impacted if our CROs, clinical investigators<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>violate<span style="letter-spacing:-0.25pt;"> </span>federal<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>state<span style="letter-spacing:-0.25pt;"> </span>healthcare<span style="letter-spacing:-0.25pt;"> </span>fraud<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>abuse<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>false<span style="letter-spacing:-0.25pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>laws<span style="letter-spacing:-0.25pt;"> </span>and regulations or healthcare privacy and security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our third party contractors do not successfully carry out their contractual duties, meet deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, our clinical trials may need to be repeated, extended, delayed or terminated, we may not be able to obtain, or may be <span style="letter-spacing:-0.1pt;">delayed</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">obtaining,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">marketing</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">approvals</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">product</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">candidates,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">will</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">able</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">to,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">delayed </span>in<span style="letter-spacing:-0.7pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>efforts<span style="letter-spacing:-0.65pt;"> </span>to,<span style="letter-spacing:-0.65pt;"> </span>successfully<span style="letter-spacing:-0.65pt;"> </span>commercialize<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>candidates<span style="letter-spacing:-0.7pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>they<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>subject<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.7pt;"> </span>regulatory enforcement actions. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If<span style="letter-spacing:0.65pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>relationships<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.35pt;"> </span>these<span style="letter-spacing:-0.35pt;"> </span>third<span style="letter-spacing:-0.35pt;"> </span>parties<span style="letter-spacing:-0.35pt;"> </span>terminate,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>not<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.35pt;"> </span>able<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>enter<span style="letter-spacing:-0.35pt;"> </span>into<span style="letter-spacing:-0.35pt;"> </span>alternative arrangements or do so on commercially reasonable terms. Switching or adding contractors involves cost, takes time and diverts management&#8217;s attention. In addition, there is a natural transition period when a new <span style="letter-spacing:-0.1pt;">third</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">party</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">commences</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">work.</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">Delays</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">compromise</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">ability</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">meet</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">desired</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">development</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">timelines. </span>In<span style="letter-spacing:-0.7pt;"> </span>addition,<span style="letter-spacing:-0.65pt;"> </span>if<span style="letter-spacing:-0.65pt;"> </span>an<span style="letter-spacing:-0.65pt;"> </span>agreement<span style="letter-spacing:-0.65pt;"> </span>with<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>collaborators<span style="letter-spacing:-0.65pt;"> </span>terminates,<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>access<span style="letter-spacing:-0.7pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>technology<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator&#8217;s technology or intellectual property or require us to stop development of<span style="letter-spacing:2pt;"> </span>those product candidates completely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:-0.5pt;"> </span>addition,<span style="letter-spacing:-0.5pt;"> </span>principal<span style="letter-spacing:-0.5pt;"> </span>investigators<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>clinical<span style="letter-spacing:-0.5pt;"> </span>trials<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>serve<span style="letter-spacing:-0.5pt;"> </span>as<span style="letter-spacing:-0.5pt;"> </span>scientific<span style="letter-spacing:-0.5pt;"> </span>advisors<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>consultants<span style="letter-spacing:-0.5pt;"> </span>to us<span style="letter-spacing:-0.7pt;"> </span>from<span style="letter-spacing:-0.65pt;"> </span>time<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>time<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>receive<span style="letter-spacing:-0.65pt;"> </span>compensation<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.7pt;"> </span>connection<span style="letter-spacing:-0.65pt;"> </span>with<span style="letter-spacing:-0.65pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>services.<span style="letter-spacing:-0.65pt;"> </span>We<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>required<span style="letter-spacing:-0.7pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>report some of these relationships to the FDA, and the FDA may conclude that a financial relationship between us and/or a principal investigator has created a conflict of interest or otherwise affects interpretation of the study.<span style="letter-spacing:-0.05pt;"> </span>The<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>therefore<span style="letter-spacing:-0.05pt;"> </span>question<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>integrity<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.05pt;"> </span>generated<span style="letter-spacing:-0.05pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>applicable<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.05pt;"> </span>trial<span style="letter-spacing:-0.05pt;"> </span>site <span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">utility</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">clinical</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">trial</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:-0.1pt;">itself</span><span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">jeopardized.</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:-0.1pt;">This</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">result</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">delay</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">approval,</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">rejection,</span> of<span style="letter-spacing:0.45pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>marketing<span style="letter-spacing:-0.6pt;"> </span>applications<span style="letter-spacing:-0.6pt;"> </span>by<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>FDA<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>ultimately<span style="letter-spacing:-0.6pt;"> </span>lead<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>denial<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>regulatory<span style="letter-spacing:-0.6pt;"> </span>approval<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>one or more of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may have conflicts with our current or future licensors or collaborators that could delay or prevent the development or commercialization of<span style="letter-spacing:1.95pt;"> </span>our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>currently<span style="letter-spacing:-0.25pt;"> </span>party<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>collaboration<span style="letter-spacing:-0.25pt;"> </span>agreements<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>Xencor<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>BMS,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>expect<span style="letter-spacing:-0.25pt;"> </span>to enter into similar strategic transactions in the future. Our current or any future collaborators may act in a manner<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>is<span style="letter-spacing:-0.6pt;"> </span>adverse<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>best<span style="letter-spacing:-0.6pt;"> </span>interests<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>interests<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>conflict<span style="letter-spacing:-0.6pt;"> </span>with<span style="letter-spacing:-0.6pt;"> </span>theirs,<span style="letter-spacing:-0.6pt;"> </span>including<span style="letter-spacing:-0.6pt;"> </span>concerning<span style="letter-spacing:-0.6pt;"> </span>the interpretation<span style="letter-spacing:-0.05pt;"> </span>of preclinical<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.05pt;"> </span>data,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>achievement<span style="letter-spacing:-0.05pt;"> </span>of milestones,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>interpretation<span style="letter-spacing:-0.05pt;"> </span>of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during our collaboration. Any disagreement could result in one or more of<span style="letter-spacing:0.95pt;"> </span>the following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn <span style="letter-spacing:-0.1pt;">prevent</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">us</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">generating</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">revenue:</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">disputes</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">regarding</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">milestone</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">payments</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">royalties;</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">uncertainty</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">regarding </span>ownership<span style="letter-spacing:-0.7pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>intellectual<span style="letter-spacing:-0.65pt;"> </span>property<span style="letter-spacing:-0.65pt;"> </span>rights<span style="letter-spacing:-0.65pt;"> </span>arising<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>collaborative<span style="letter-spacing:-0.7pt;"> </span>activities,<span style="letter-spacing:-0.65pt;"> </span>which<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>prevent<span style="letter-spacing:-0.65pt;"> </span>us<span style="letter-spacing:-0.65pt;"> </span>from entering<span style="letter-spacing:-0.15pt;"> </span>into<span style="letter-spacing:-0.15pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">additional<span style="letter-spacing:-0.15pt;"> </span>collaborations;<span style="letter-spacing:-0.15pt;"> </span>unwillingness<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>collaborator<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>cooperate<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.15pt;"> </span>or manufacture<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidate,<span style="letter-spacing:-0.15pt;"> </span>including<span style="letter-spacing:-0.15pt;"> </span>providing<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>materials;<span style="letter-spacing:-0.15pt;"> </span>unwillingness<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>part of a collaborator to keep us informed regarding the progress of its development and commercialization activities<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>permit<span style="letter-spacing:-0.1pt;"> </span>public<span style="letter-spacing:-0.1pt;"> </span>disclosure<span style="letter-spacing:-0.1pt;"> </span>of the<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.1pt;"> </span>of those<span style="letter-spacing:-0.1pt;"> </span>activities;<span style="letter-spacing:-0.1pt;"> </span>initiating<span style="letter-spacing:-0.1pt;"> </span>of litigation<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate the <span style="letter-spacing:-0.1pt;">agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our rights to develop and commercialize our product candidates are subject, in large part, to the terms and conditions of licenses granted to us by others, such as Xencor. If we fail to comply with our obligations in the <span style="letter-spacing:-0.1pt;">agreements</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">under</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">which</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">in-license</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">acquire</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">development</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">commercialization</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">rights</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">candidates, </span>or data from third parties, we could lose such rights that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are heavily reliant upon licenses to certain patent rights and other intellectual property that are important or necessary to the development of our current or future product candidates. For example, we depend on licenses from Xencor for certain intellectual property relating to the development and commercialization of obexelimab, ZB002 and ZB004. However, we have no development and commercialization rights for obexelimab in Japan, South Korea, Taiwan, Hong Kong, Singapore, and Australia, all of<span style="letter-spacing:1.55pt;"> </span>which rights have been sublicensed to BMS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Xencor<span style="letter-spacing:-0.7pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>have<span style="letter-spacing:-0.65pt;"> </span>relied<span style="letter-spacing:-0.65pt;"> </span>upon,<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>future<span style="letter-spacing:-0.65pt;"> </span>licensors<span style="letter-spacing:-0.7pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>rely<span style="letter-spacing:-0.65pt;"> </span>upon,<span style="letter-spacing:-0.65pt;"> </span>third-party<span style="letter-spacing:-0.65pt;"> </span>companies,<span style="letter-spacing:-0.65pt;"> </span>consultants or<span style="letter-spacing:-0.55pt;"> </span>collaborators,<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>on<span style="letter-spacing:-0.55pt;"> </span>funds<span style="letter-spacing:-0.55pt;"> </span>from<span style="letter-spacing:-0.55pt;"> </span>third<span style="letter-spacing:-0.55pt;"> </span>parties<span style="letter-spacing:-0.55pt;"> </span>such<span style="letter-spacing:-0.55pt;"> </span>that<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>licensors<span style="letter-spacing:-0.55pt;"> </span>are<span style="letter-spacing:-0.55pt;"> </span>not<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>sole<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>exclusive<span style="letter-spacing:-0.55pt;"> </span>owners<span style="letter-spacing:-0.55pt;"> </span>of the<span style="letter-spacing:-0.5pt;"> </span>patents<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:-0.5pt;"> </span>in-licensed.<span style="letter-spacing:-0.5pt;"> </span>If<span style="letter-spacing:0.35pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>licensors,<span style="letter-spacing:-0.5pt;"> </span>including<span style="letter-spacing:-0.5pt;"> </span>Xencor,<span style="letter-spacing:-0.5pt;"> </span>fail<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>prosecute,<span style="letter-spacing:-0.5pt;"> </span>maintain,<span style="letter-spacing:-0.5pt;"> </span>enforce,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>defend such<span style="letter-spacing:-0.55pt;"> </span>patents,<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>lose<span style="letter-spacing:-0.55pt;"> </span>rights<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>those<span style="letter-spacing:-0.55pt;"> </span>patents,<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>rights<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>have<span style="letter-spacing:-0.55pt;"> </span>licensed<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>be<span style="letter-spacing:-0.55pt;"> </span>reduced<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>eliminated,<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>our right<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>develop<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commercialize<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>of such<span style="letter-spacing:-0.2pt;"> </span>licensed<span style="letter-spacing:-0.2pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>adversely<span style="letter-spacing:-0.2pt;"> </span>affected.<span style="letter-spacing:-0.2pt;"> </span>Further<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commercialization<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>product candidates<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:1pt;"> </span>any<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.05pt;"> </span>candidates<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>require<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>enter<span style="letter-spacing:-0.05pt;"> </span>into<span style="letter-spacing:-0.05pt;"> </span>additional<span style="letter-spacing:-0.05pt;"> </span>license or<span style="letter-spacing:-0.5pt;"> </span>collaboration<span style="letter-spacing:-0.5pt;"> </span>agreements.<span style="letter-spacing:-0.5pt;"> </span>For<span style="letter-spacing:-0.5pt;"> </span>example,<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>licensors<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>other<span style="letter-spacing:-0.5pt;"> </span>third<span style="letter-spacing:-0.5pt;"> </span>parties<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.5pt;"> </span>obtain<span style="letter-spacing:-0.5pt;"> </span>intellectual<span style="letter-spacing:-0.5pt;"> </span>property covering our current or future product candidates which we have not licensed. Our future licenses may not provide us with exclusive rights to use the licensed patent rights and other intellectual property licensed thereunder,<span style="letter-spacing:-0.7pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>provide<span style="letter-spacing:-0.65pt;"> </span>us<span style="letter-spacing:-0.65pt;"> </span>with<span style="letter-spacing:-0.65pt;"> </span>exclusive<span style="letter-spacing:-0.65pt;"> </span>rights<span style="letter-spacing:-0.7pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>use<span style="letter-spacing:-0.65pt;"> </span>such<span style="letter-spacing:-0.65pt;"> </span>patent<span style="letter-spacing:-0.65pt;"> </span>rights<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>intellectual<span style="letter-spacing:-0.65pt;"> </span>property<span style="letter-spacing:-0.7pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>all relevant<span style="letter-spacing:-0.4pt;"> </span>fields<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>use<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>all<span style="letter-spacing:-0.4pt;"> </span>territories<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>wish<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>develop<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>commercialize<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>current<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In spite of our efforts, Xencor or any future licensors might conclude that we are in material breach of <span style="letter-spacing:-0.1pt;">obligations</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">under</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">license</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">agreements</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">therefore</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">right</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">terminate</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">license</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">agreements, </span>thereby removing our ability to develop and commercialize product candidates and technology covered by such license agreements. If such in-licenses are terminated, or if the underlying patents fail to provide the intended<span style="letter-spacing:-0.15pt;"> </span>exclusivity,<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>competitors<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>freedom<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>seek<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.15pt;"> </span>approval<span style="letter-spacing:-0.15pt;"> </span>of,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>market, products identical to our product candidates and the licensors to such in-licenses could prevent us from developing or commercializing product candidates that rely upon the patents or other intellectual property rights which were the subject matter of such terminated agreements. In addition, we may seek to obtain <span style="letter-spacing:-0.1pt;">additional</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">licenses</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">from</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">licensors</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">and,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">connection</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">obtaining</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">such</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">licenses,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">agree</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">amend</span> our<span style="letter-spacing:-0.15pt;"> </span>existing<span style="letter-spacing:-0.15pt;"> </span>licenses<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>manner<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>favorable<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>licensors,<span style="letter-spacing:-0.15pt;"> </span>including<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.15pt;"> </span>agreeing<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.35pt;"> </span>subject<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>existing<span style="letter-spacing:-0.35pt;"> </span>licenses<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>compete<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>existing<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates. Any of these events could adversely affect our business, financial condition, results of operations, and <span style="letter-spacing:-0.1pt;">prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Disputes<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.3pt;"> </span>arise<span style="letter-spacing:-0.3pt;"> </span>regarding<span style="letter-spacing:-0.3pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>licensing<span style="letter-spacing:-0.3pt;"> </span>agreement,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scope</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rights</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">granted</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">license</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agreement</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interpretation-related</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our financial or other obligations under the license </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extent</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">processes</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">infringe</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">property</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">licensor</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to the licensing agreement;</span></td><td style="width:12.25pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and other rights under our collaborative</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diligence</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obligations</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">license</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agreement</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">what</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">activities</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfy</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">those</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">obligations;</span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inventorship</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ownership</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.85pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inventions</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">know-how</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">resulting</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">joint</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">creation</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of intellectual property by our licensors and us and our partners; and</span></td><td style="width:12.35pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">priority</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">invention</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patented</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, our license agreements are, and future license agreements are likely to be, complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract<span style="letter-spacing:-0.6pt;"> </span>interpretation<span style="letter-spacing:-0.6pt;"> </span>disagreement<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>may<span style="letter-spacing:-0.6pt;"> </span>arise<span style="letter-spacing:-0.6pt;"> </span>could<span style="letter-spacing:-0.6pt;"> </span>narrow<span style="letter-spacing:-0.6pt;"> </span>what<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>believe<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>be<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>scope<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>rights to<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>relevant<span style="letter-spacing:-0.3pt;"> </span>intellectual<span style="letter-spacing:-0.3pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>increase<span style="letter-spacing:-0.3pt;"> </span>what<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.3pt;"> </span>believe<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.3pt;"> </span>obligations<span style="letter-spacing:-0.3pt;"> </span>under the relevant agreement, either of which could adversely affect our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>ability<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>maintain<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>current<span style="letter-spacing:-0.3pt;"> </span>licensing<span style="letter-spacing:-0.3pt;"> </span>arrangements<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.3pt;"> </span>commercially<span style="letter-spacing:-0.3pt;"> </span>acceptable<span style="letter-spacing:-0.3pt;"> </span>terms,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.3pt;"> </span>may be<span style="letter-spacing:-0.3pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>successfully<span style="letter-spacing:-0.3pt;"> </span>develop<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>commercialize<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>affected<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.3pt;"> </span>adversely affect our business, financial condition, results of<span style="letter-spacing:2pt;"> </span>operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The<span style="letter-spacing:-0.15pt;"> </span>operations<span style="letter-spacing:-0.15pt;"> </span>of our<span style="letter-spacing:-0.15pt;"> </span>suppliers,<span style="letter-spacing:-0.15pt;"> </span>many<span style="letter-spacing:-0.15pt;"> </span>of which<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>located<span style="letter-spacing:-0.15pt;"> </span>outside<span style="letter-spacing:-0.15pt;"> </span>of the<span style="letter-spacing:-0.15pt;"> </span>U.S.,<span style="letter-spacing:-0.15pt;"> </span>including<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>current sole CMO for drug substance and drug product, WuXi Biologics, which is located in China, are subject to additional risks that are beyond our control and that could harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Currently, many of our suppliers primarily operate outside of the U.S., including our current sole<span style="letter-spacing:-0.4pt;"> </span>CMO,<span style="letter-spacing:-0.4pt;"> </span>WuXi<span style="letter-spacing:-0.4pt;"> </span>Biologics,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.4pt;"> </span>provides<span style="letter-spacing:-0.4pt;"> </span>its<span style="letter-spacing:-0.4pt;"> </span>services<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>us<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.4pt;"> </span>facilities<span style="letter-spacing:-0.4pt;"> </span>located<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>China.<span style="letter-spacing:-0.4pt;"> </span>As<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>result,<span style="letter-spacing:-0.4pt;"> </span>we are subject to risks associated with doing business abroad, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">geopolitical tensions, political unrest, terrorism, labor disputes and economic instability resulting in the disruption of trade from foreign countries in which our products are manufactured, particularly </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">China;</span></td><td style="width:12.3pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of new laws and regulations, including those relating to labor conditions and safety standards,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">information</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">data</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">transfer,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imports,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">duties,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">taxes,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">charges</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imports,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">well as</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trade</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">currency</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exchange</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">transfer</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">funds,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">particularly</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or increased tariffs imposed on imports, and as a result supply-related costs, from countries where our suppliers operate, including China, pursuant to our master services or commercial supply agreements with WuXi Biologics, as well as tariffs that impact the biopharmaceutical industry generally;</span></td><td style="width:12.3pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">greater challenges and increased costs with enforcing and periodically auditing or reviewing our suppliers&#8217;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers&#8217;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cGMPs</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">status</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptable</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">comparable foreign regulatory authorities;</span></td><td style="width:12.3pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protection</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">property</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rights,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">including</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trade</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">secret</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protection,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">some</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">countries, particularly China;</span></td><td style="width:12.3pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruptions</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operations</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">due</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">global,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regional,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">local</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">epidemics,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pandemics</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">public</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">health crises, or other emergencies or natural disasters;</span></td><td style="width:12.15pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruptions</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shipments;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">local</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conditions</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">countries</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">where</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suppliers</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">located.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If</span><span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:-0.1pt;">enacted,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">BIOSECURE</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">Act,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">which</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">was</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">introduced</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">in 2024,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">Congress,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">would</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">prohibit</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">U.S.</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">federal </span>agencies from entering into or renewing a contract with any company that uses biotechnology equipment or services<span style="letter-spacing:-0.7pt;"> </span>produced<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>provided<span style="letter-spacing:-0.45pt;"> </span>by<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>&#8220;biotechnology<span style="letter-spacing:-0.45pt;"> </span>company<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>concern&#8221;<span style="letter-spacing:-0.7pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>performance<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>that<span style="letter-spacing:-0.45pt;"> </span>contract. This legislation would restrict the ability of biopharmaceutical companies that enter into contracts with or receive funding from U.S. federal agencies from purchasing services or equipment from certain Chinese biotechnology<span style="letter-spacing:-0.55pt;"> </span>companies,<span style="letter-spacing:-0.55pt;"> </span>including<span style="letter-spacing:-0.55pt;"> </span>those<span style="letter-spacing:-0.55pt;"> </span>that<span style="letter-spacing:-0.55pt;"> </span>are<span style="letter-spacing:-0.55pt;"> </span>specifically<span style="letter-spacing:-0.55pt;"> </span>named<span style="letter-spacing:-0.55pt;"> </span>in<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>proposed<span style="letter-spacing:-0.55pt;"> </span>BIOSECURE<span style="letter-spacing:-0.55pt;"> </span>Act.<span style="letter-spacing:-0.55pt;"> </span>The current<span style="letter-spacing:-0.15pt;"> </span>version<span style="letter-spacing:-0.15pt;"> </span>of the<span style="letter-spacing:-0.15pt;"> </span>BIOSECURE<span style="letter-spacing:-0.15pt;"> </span>Act<span style="letter-spacing:-0.15pt;">, which passed </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>House<span style="letter-spacing:-0.15pt;"> </span>of Representatives<span style="letter-spacing:-0.15pt;"> </span>names<span style="letter-spacing:-0.15pt;"> </span>WuXi<span style="letter-spacing:-0.15pt;"> </span>Biologics as a &#8220;biotechnology company of concern.&#8221;</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If<span style="letter-spacing:1.2pt;"> </span>adopted into law, the BIOSECURE Act in its current form would not prevent us from sourcing drug product from WuXi Biologics for clinical use, and we believe our current inventory of drug substance and drug<span style="letter-spacing:-0.65pt;"> </span>product<span style="letter-spacing:-0.65pt;"> </span>will<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>sufficient<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>complete<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>ongoing<span style="letter-spacing:-0.65pt;"> </span>trials<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>obexelimab.<span style="letter-spacing:-0.65pt;"> </span>Depending<span style="letter-spacing:-0.65pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>final<span style="letter-spacing:-0.65pt;"> </span>language of the BIOSECURE Act, and how the law is interpreted by U.S. federal agencies, however, we could be potentially<span style="letter-spacing:-0.1pt;"> </span>restricted<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.1pt;"> </span>pursuing<span style="letter-spacing:-0.1pt;"> </span>U.S.<span style="letter-spacing:-0.1pt;"> </span>federal<span style="letter-spacing:-0.1pt;"> </span>government<span style="letter-spacing:-0.1pt;"> </span>business<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>government<span style="letter-spacing:-0.1pt;"> </span>reimbursement<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>our products manufactured by WuXi Biologics or other suppliers or <span style="letter-spacing:-0.1pt;">partners</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">determined</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">&#8220;biotechnology</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">companies</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.95pt;"> </span><span style="letter-spacing:-0.1pt;">concern.&#8221;</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">Additionally,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">legislation</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">adversely </span>impact<span style="letter-spacing:-0.15pt;"> </span>WuXi<span style="letter-spacing:-0.15pt;"> </span>Biologics&#8217;<span style="letter-spacing:-0.55pt;"> </span>operations<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>financial<span style="letter-spacing:-0.15pt;"> </span>position,<span style="letter-spacing:-0.15pt;"> </span>which,<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>turn,<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>impact<span style="letter-spacing:-0.15pt;"> </span>its<span style="letter-spacing:-0.15pt;"> </span>ability<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>supply<span style="letter-spacing:-0.15pt;"> </span>us with product in the future. We may also face additional manufacturing and supply-chain risks due to the regulatory<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>political<span style="letter-spacing:-0.15pt;"> </span>structure<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:1pt;"> </span>China,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>due<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>deterioration<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>relationship<span style="letter-spacing:-0.15pt;"> </span>between<span style="letter-spacing:-0.15pt;"> </span>China<span style="letter-spacing:-0.15pt;"> </span>and the<span style="letter-spacing:-0.65pt;"> </span>U.S.,<span style="letter-spacing:-0.65pt;"> </span>including<span style="letter-spacing:-0.65pt;"> </span>but<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>limited<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>potential<span style="letter-spacing:-0.65pt;"> </span>sanctions<span style="letter-spacing:-0.65pt;"> </span>imposed<span style="letter-spacing:-0.65pt;"> </span>by<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>U.S.<span style="letter-spacing:-0.65pt;"> </span>government<span style="letter-spacing:-0.65pt;"> </span>on<span style="letter-spacing:-0.65pt;"> </span>WuXi<span style="letter-spacing:-0.65pt;"> </span>Biologics, or any of<span style="letter-spacing:2pt;"> </span>the other countries in which our products are marketed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.6pt;"> </span>also<span style="letter-spacing:-0.6pt;"> selected </span>new CMOs<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>U.S. to<span style="letter-spacing:-0.5pt;"> </span>establish<span style="letter-spacing:-0.5pt;"> </span>additional<span style="letter-spacing:-0.5pt;"> </span>sources<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:-0.5pt;"> </span>supply<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.5pt;"> </span>drug<span style="letter-spacing:-0.5pt;"> </span>substance<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>drug<span style="letter-spacing:-0.5pt;"> </span>product<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.5pt;"> </span>both<span style="letter-spacing:-0.5pt;"> </span>commercial and clinical use with third-party manufacturers that are not affiliated with WuXi Biologics or another &#8220;biotechnology company of concern&#8221;<span style="letter-spacing:-0.5pt;"> </span>identified in the proposed BIOSECURE Act. However, establishing new manufacturers<span style="letter-spacing:-0.7pt;"> </span>requires<span style="letter-spacing:-0.65pt;"> </span>significant<span style="letter-spacing:-0.65pt;"> </span>effort<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>time<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>delay<span style="letter-spacing:-0.65pt;"> </span>in securing, or inability to secure, a commercial supplier of drug substance or drug product for a product candidate, if approved, including as a result of delays in contracting, technology transfer, production of validation batches or obtaining an inspection by the FDA or other applicable foreign regulatory authorities, would delay commercialization timelines or prevent commercial sales if manufacturers cannot be qualified. For additional information on risks related to our current reliance on a sole manufacturer, please see &#8220;&#8212; Risks Related to Our Reliance on Third Parties<span style="letter-spacing:-0.05pt;"> </span>&#8212;<span style="letter-spacing:-0.05pt;"> </span>We currently rely on a single third-party manufacturer, WuXi Biologics, to supply our product candidates, including certain drug substances and drug products used in our product candidates. If<span style="letter-spacing:1.15pt;"> </span>we are unable to source these supplies on a timely<span style="letter-spacing:-0.55pt;"> </span>basis,<span style="letter-spacing:-0.55pt;"> </span>at<span style="letter-spacing:-0.55pt;"> </span>sufficient<span style="letter-spacing:-0.55pt;"> </span>quantities<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>at<span style="letter-spacing:-0.55pt;"> </span>acceptable<span style="letter-spacing:-0.55pt;"> </span>quality<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>prices,<span style="letter-spacing:-0.55pt;"> </span>establish<span style="letter-spacing:-0.55pt;"> </span>longer-term<span style="letter-spacing:-0.55pt;"> </span>contracts<span style="letter-spacing:-0.55pt;"> </span>with<span style="letter-spacing:-0.55pt;"> </span>our CMOs,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.2pt;">-</span>party<span style="letter-spacing:-0.2pt;"> </span>manufacturers<span style="letter-spacing:-0.2pt;"> </span>fails<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>applicable<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.2pt;"> </span>requirements,<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>not be<span style="letter-spacing:-0.75pt;"> </span>able<span style="letter-spacing:-0.75pt;"> </span>to<span style="letter-spacing:-0.75pt;"> </span>complete<span style="letter-spacing:-0.75pt;"> </span>our<span style="letter-spacing:-0.75pt;"> </span>clinical<span style="letter-spacing:-0.75pt;"> </span>trials<span style="letter-spacing:-0.75pt;"> </span>on<span style="letter-spacing:-0.75pt;"> </span>time<span style="letter-spacing:-0.75pt;"> </span>and<span style="letter-spacing:-0.75pt;"> </span>the<span style="letter-spacing:-0.75pt;"> </span>development<span style="letter-spacing:-0.75pt;"> </span>of<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:-0.75pt;"> </span>product<span style="letter-spacing:-0.75pt;"> </span>candidates<span style="letter-spacing:-0.75pt;"> </span>may<span style="letter-spacing:-0.75pt;"> </span>be<span style="letter-spacing:-0.75pt;"> </span>delayed.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.05pt;"> </span>factors<span style="letter-spacing:-0.05pt;"> </span>beyond<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>control<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.05pt;"> </span>interrupt<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>suppliers&#8217;<span style="letter-spacing:-0.35pt;"> </span>production,<span style="letter-spacing:-0.05pt;"> </span>influence<span style="letter-spacing:-0.05pt;"> </span>the ability of<span style="letter-spacing:2pt;"> </span>our suppliers to export our clinical supplies cost-effectively or at all and inhibit our suppliers&#8217; ability<span style="letter-spacing:4pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>procure<span style="letter-spacing:-0.35pt;"> </span>certain<span style="letter-spacing:-0.35pt;"> </span>materials,<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>of which<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.35pt;"> </span>delay<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.35pt;"> </span>trials<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>otherwise<span style="letter-spacing:-0.35pt;"> </span>harm<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>business, financial<span style="letter-spacing:-0.35pt;"> </span>condition,<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.35pt;"> </span>of operations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related<b style="font-weight:bold;letter-spacing:-0.15pt;"> </b>to Ownership<b style="font-weight:bold;letter-spacing:-0.15pt;"> </b>of<b style="font-weight:bold;letter-spacing:0.55pt;"> </b>Our Common<b style="font-weight:bold;letter-spacing:-0.15pt;"> </b>Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">An<span style="letter-spacing:-0.45pt;"> </span>active<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>liquid<span style="letter-spacing:-0.45pt;"> </span>trading<span style="letter-spacing:-0.45pt;"> </span>market<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>common<span style="letter-spacing:-0.45pt;"> </span>stock<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>not<span style="letter-spacing:-0.45pt;"> </span>be sustained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock is<span style="letter-spacing:-0.4pt;"> </span>listed<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:-0.4pt;"> the </span>Nasdaq<span style="letter-spacing:-0.4pt;"> Global Select Market </span>under<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>symbol<span style="letter-spacing:-0.4pt;"> </span>&#8220;ZBIO&#8221;.<span style="letter-spacing:-0.4pt;"> </span>If an<span style="letter-spacing:-0.4pt;"> </span>active or<span style="letter-spacing:-0.65pt;"> </span>liquid<span style="letter-spacing:-0.65pt;"> </span>trading<span style="letter-spacing:-0.65pt;"> </span>market<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>common<span style="letter-spacing:-0.65pt;"> </span>stock<span style="letter-spacing:-0.65pt;"> </span>is<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>sustained, it may be difficult for investors to sell their shares of common stock at an attractive price or at all. It is possible that in one or more future periods our results of operations may be below the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. An inactive market may reduce the fair market value of<span style="letter-spacing:1.1pt;"> </span>our common stock, impair our ability to raise capital<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.2pt;"> </span>selling<span style="letter-spacing:-0.2pt;"> </span>shares<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>common<span style="letter-spacing:-0.2pt;"> </span>stock<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>future,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>impair<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>enter<span style="letter-spacing:-0.2pt;"> </span>into<span style="letter-spacing:-0.2pt;"> </span>strategic collaborations or acquire companies or products by using our shares of<span style="letter-spacing:2pt;"> </span>common stock as consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market price of our common stock may be volatile, which could result in substantial losses for investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since shares of our common stock were sold in our IPO in September 2024 at a price of $17.00 per share and through February 28, 2025, the closing price per share of our common stock on Nasdaq has ranged from $6.43 to $25.68. Some of<span style="letter-spacing:1.7pt;"> </span>the factors that may cause the market price of<span style="letter-spacing:1.7pt;"> </span>our common stock to fluctuate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">volatility in our operating results or the failure of our operating results to meet the expectations of investors or securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">success</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">existing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">timing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">results</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">preclinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">clinical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">studies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">develop;</span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discontinuation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2.85pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercialize our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of the development of companion diagnostics, if required, for use with our product </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commencement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">termination</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or legal</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments in the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and other </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">concerning</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">applications,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patents,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proprietary</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruitment</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">departure</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">key</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to any of our research programs or product candidates that we may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stock</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">us,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">insiders</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expiration</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stand-off</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lock-up</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">changes</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">relationship</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">with</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">manufacturers,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">suppliers,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">collaborators</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">strategic</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supply</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">shortages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">those</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.95pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">companies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be similar</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recommendations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">securities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analysts,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cover</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">press</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reports,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">true,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">about</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">failure</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">meet</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">estimates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">projections</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">investment</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">community</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">we</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">otherwise </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the structure</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">valuation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">companies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investors</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">comparable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conditions</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pharmaceutical</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">biotechnology</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">sectors;</span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general global economic, industry, political and market conditions, such as military conflict or war, inflation and financial institution instability, or pandemic or epidemic disease outbreaks, such as COVID-19, many of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which are beyond our control; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this &#8220;Risk Factors&#8221;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">section and elsewhere in this Annual Report, including those which are outside of our control.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing<span style="letter-spacing:-0.4pt;"> </span>those<span style="letter-spacing:-0.4pt;"> </span>price<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>volume<span style="letter-spacing:-0.4pt;"> </span>fluctuations.<span style="letter-spacing:-0.4pt;"> </span>Broad<span style="letter-spacing:-0.4pt;"> </span>market<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>industry<span style="letter-spacing:-0.4pt;"> </span>factors<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.4pt;"> </span>seriously<span style="letter-spacing:-0.4pt;"> </span>affect<span style="letter-spacing:-0.4pt;"> </span>the market price of our common stock, regardless of our actual operating performance. The<span style="letter-spacing:-0.25pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>price<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>decline,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>investors<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>lose some or all of their investment. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of<span style="letter-spacing:1.45pt;"> </span>our stock price, we may become the target of<span style="letter-spacing:1.45pt;"> </span>securities litigation in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A significant portion of our total outstanding shares are, as of the date of filing this Annual Report, restricted from immediate resale but may be sold into the market upon expiration of the lock-up agreement entered into in connection with our IPO, which could cause the market price of our common stock to decline significantly, even if our business is doing well.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales upon the expiration of the lock-up agreements entered into by holders of substantially all of our common stock outstanding immediately prior to our IPO, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. As of December 31, 2024, we had 41,793,412 shares of common stock outstanding. Of these shares, 15,220,588 shares sold in our IPO may be resold in the public market immediately, unless held by our affiliates. The remaining shares are currently restricted under securities laws or other agreements, subject in some cases to applicable volume limitations under Rule 144 beginning after the close of trading on March 11, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, holders of an aggregate of 26,557,087 shares of our <span style="letter-spacing:-0.1pt;">common</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">stock</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">rights,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">subject</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">conditions,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">require</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">us</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">file</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">registration</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">statements</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">covering</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">their </span>shares<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>include<span style="letter-spacing:-0.55pt;"> </span>their<span style="letter-spacing:-0.55pt;"> </span>shares<span style="letter-spacing:-0.55pt;"> </span>in<span style="letter-spacing:-0.55pt;"> </span>registration<span style="letter-spacing:-0.55pt;"> </span>statements<span style="letter-spacing:-0.55pt;"> </span>that<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.55pt;"> </span>file<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>ourselves<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.55pt;"> </span>other<span style="letter-spacing:-0.55pt;"> </span>stockholders. We<span style="letter-spacing:-0.7pt;"> </span>also<span style="letter-spacing:-0.65pt;"> </span>registered<span style="letter-spacing:-0.7pt;"> </span>all<span style="letter-spacing:-0.65pt;"> </span>shares<span style="letter-spacing:-0.7pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.65pt;"> </span>stock<span style="letter-spacing:-0.7pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.7pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>issue<span style="letter-spacing:-0.7pt;"> </span>under<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.7pt;"> </span>equity<span style="letter-spacing:-0.65pt;"> </span>compensation<span style="letter-spacing:-0.7pt;"> </span>plans<span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:-0.25pt;">or </span>that<span style="letter-spacing:-0.7pt;"> </span>are<span style="letter-spacing:-0.65pt;"> </span>issuable<span style="letter-spacing:-0.65pt;"> </span>upon<span style="letter-spacing:-0.65pt;"> </span>exercise<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>outstanding<span style="letter-spacing:-0.65pt;"> </span>options.<span style="letter-spacing:-0.65pt;"> </span>These shares<span style="letter-spacing:-0.65pt;"> </span>can<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>freely<span style="letter-spacing:-0.7pt;"> </span>sold<span style="letter-spacing:-0.65pt;"> </span>in the<span style="letter-spacing:-0.55pt;"> </span>public<span style="letter-spacing:-0.55pt;"> </span>market<span style="letter-spacing:-0.55pt;"> </span>upon<span style="letter-spacing:-0.55pt;"> </span>issuance<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>once<span style="letter-spacing:-0.55pt;"> </span>vested,<span style="letter-spacing:-0.55pt;"> </span>subject<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>volume<span style="letter-spacing:-0.55pt;"> </span>limitations<span style="letter-spacing:-0.55pt;"> </span>applicable<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>affiliates<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>the lock-up agreements entered into in connection with our IPO. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Insiders</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">substantial</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">influence</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">over</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">us,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">which</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">limit </span>other stockholders&#8217; ability to affect the outcome of<span style="letter-spacing:1.35pt;"> </span>key transactions, including a change of<span style="letter-spacing:1.35pt;"> </span>control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.15pt;"> </span>directors,<span style="letter-spacing:-0.15pt;"> </span>executive<span style="letter-spacing:-0.15pt;"> </span>officers<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>greater<span style="letter-spacing:-0.15pt;"> </span>than<span style="letter-spacing:-0.15pt;"> </span>5%<span style="letter-spacing:-0.15pt;"> </span>stockholders and their affiliates, in the aggregate, beneficially own shares representing approximately 59% of our outstanding<span style="letter-spacing:-0.4pt;"> </span>common<span style="letter-spacing:-0.35pt;"> </span>stock<span style="letter-spacing:-0.35pt;"> as of December 31, 2024</span>. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate <span style="letter-spacing:-0.1pt;">transactions.</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">The</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">interests</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:-0.1pt;">these</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">holders</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">always</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">coincide</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">corporate</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">interests</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">interests </span>of<span style="letter-spacing:0.95pt;"> </span>other<span style="letter-spacing:-0.05pt;"> </span>stockholders,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>they<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>act<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>manner<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.05pt;"> </span>other stockholders<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>agree<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the best<span style="letter-spacing:-0.05pt;"> </span>interests<span style="letter-spacing:-0.05pt;"> </span>of our<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.05pt;"> </span>stockholders.<span style="letter-spacing:-0.05pt;"> </span>This<span style="letter-spacing:-0.05pt;"> </span>concentration<span style="letter-spacing:-0.05pt;"> </span>of ownership<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>effect<span style="letter-spacing:-0.05pt;"> </span>of delaying<span style="letter-spacing:-0.05pt;"> </span>or preventing a change in control of<span style="letter-spacing:1.8pt;"> </span>our company and might affect the market price of<span style="letter-spacing:1.8pt;"> </span>our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.3pt;"> </span>do<span style="letter-spacing:-0.3pt;"> </span>not<span style="letter-spacing:-0.3pt;"> </span>anticipate<span style="letter-spacing:-0.3pt;"> </span>paying<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.3pt;"> </span>cash<span style="letter-spacing:-0.3pt;"> </span>dividends<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>common<span style="letter-spacing:-0.3pt;"> </span>stock<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>foreseeable<span style="letter-spacing:-0.3pt;"> </span>future,<span style="letter-spacing:-0.3pt;"> </span>capital appreciation, if any, will be investors&#8217; sole source of gain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">never</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">declared</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">paid</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">any</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">cash</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">dividends</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">on</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">common</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">stock.</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">currently</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">anticipate</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">that</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">we </span>will<span style="letter-spacing:-0.55pt;"> </span>retain<span style="letter-spacing:-0.55pt;"> </span>future<span style="letter-spacing:-0.55pt;"> </span>earnings<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>development,<span style="letter-spacing:-0.55pt;"> </span>operation<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>expansion<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>our<span style="letter-spacing:-0.55pt;"> </span>business<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.55pt;"> </span>do<span style="letter-spacing:-0.55pt;"> </span>not<span style="letter-spacing:-0.55pt;"> </span>anticipate declaring<span style="letter-spacing:-0.7pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>paying<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>cash<span style="letter-spacing:-0.65pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">dividends<span style="letter-spacing:-0.65pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>foreseeable<span style="letter-spacing:-0.7pt;"> </span>future.<span style="letter-spacing:-0.65pt;"> </span>As<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>result,<span style="letter-spacing:-0.65pt;"> </span>capital<span style="letter-spacing:-0.65pt;"> </span>appreciation,<span style="letter-spacing:-0.65pt;"> </span>if<span style="letter-spacing:-0.65pt;"> </span>any,<span style="letter-spacing:-0.7pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>our common stock will be investors&#8217; sole source of gain on an investment in our common stock in the foreseeable future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>&#8220;emerging<span style="letter-spacing:-0.2pt;"> </span>growth<span style="letter-spacing:-0.2pt;"> </span>company,&#8221;<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>reduced<span style="letter-spacing:-0.2pt;"> </span>disclosure<span style="letter-spacing:-0.2pt;"> </span>requirements<span style="letter-spacing:-0.2pt;"> </span>applicable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>emerging<span style="letter-spacing:-0.2pt;"> </span>growth companies may make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221;<span style="letter-spacing:-0.15pt;"> </span>as defined in the JOBS Act and we may remain an emerging growth company until December 31, 2029. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>auditor<span style="letter-spacing:-0.3pt;"> </span>attestation<span style="letter-spacing:-0.3pt;"> </span>requirements<span style="letter-spacing:-0.3pt;"> </span>of Section<span style="letter-spacing:-0.3pt;"> </span>404<span style="letter-spacing:-0.3pt;"> </span>of the<span style="letter-spacing:-0.3pt;"> </span>Sarbanes-Oxley<span style="letter-spacing:-0.3pt;"> </span>Act<span style="letter-spacing:-0.3pt;"> </span>of 2002,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>SOX Section<span style="letter-spacing:-0.35pt;"> </span>404,<span style="letter-spacing:-0.35pt;"> </span>not<span style="letter-spacing:-0.35pt;"> </span>being<span style="letter-spacing:-0.35pt;"> </span>required<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>comply<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>requirement<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.35pt;"> </span>adopted<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>Public<span style="letter-spacing:-0.35pt;"> </span>Company Accounting<span style="letter-spacing:-0.15pt;"> </span>Oversight<span style="letter-spacing:-0.15pt;"> </span>Board<span style="letter-spacing:-0.15pt;"> </span>regarding<span style="letter-spacing:-0.15pt;"> </span>mandatory<span style="letter-spacing:-0.15pt;"> </span>audit<span style="letter-spacing:-0.15pt;"> </span>firm<span style="letter-spacing:-0.15pt;"> </span>rotation<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>supplement<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>auditor&#8217;s<span style="letter-spacing:-0.15pt;"> </span>report providing<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.2pt;"> </span>information<span style="letter-spacing:-0.2pt;"> </span>about<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>audit<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>financial<span style="letter-spacing:-0.2pt;"> </span>statements,<span style="letter-spacing:-0.2pt;"> </span>reduced<span style="letter-spacing:-0.2pt;"> </span>disclosure<span style="letter-spacing:-0.2pt;"> </span>obligations regarding<span style="letter-spacing:-0.15pt;"> </span>executive<span style="letter-spacing:-0.15pt;"> </span>compensation,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>exemptions<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>requirements<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>holding<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>nonbinding<span style="letter-spacing:-0.15pt;"> </span>advisory vote<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>executive<span style="letter-spacing:-0.1pt;"> </span>compensation<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>stockholder<span style="letter-spacing:-0.1pt;"> </span>approval<span style="letter-spacing:-0.1pt;"> </span>of any<span style="letter-spacing:-0.1pt;"> </span>golden<span style="letter-spacing:-0.1pt;"> </span>parachute<span style="letter-spacing:-0.1pt;"> </span>payments<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>previously approved. As a result, the information we provide stockholders will be different than the information that is available<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.45pt;"> </span>respect<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>other<span style="letter-spacing:-0.45pt;"> </span>public<span style="letter-spacing:-0.45pt;"> </span>companies.<span style="letter-spacing:-0.45pt;"> </span>We<span style="letter-spacing:-0.45pt;"> </span>have<span style="letter-spacing:-0.45pt;"> </span>not<span style="letter-spacing:-0.45pt;"> </span>included<span style="letter-spacing:-0.45pt;"> </span>all<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>executive compensation related information that would be required if we were not an emerging growth company. We cannot<span style="letter-spacing:-0.45pt;"> </span>predict<span style="letter-spacing:-0.45pt;"> </span>whether<span style="letter-spacing:-0.45pt;"> </span>investors<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.45pt;"> </span>find<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>common<span style="letter-spacing:-0.45pt;"> </span>stock<span style="letter-spacing:-0.45pt;"> </span>less<span style="letter-spacing:-0.45pt;"> </span>attractive<span style="letter-spacing:-0.45pt;"> </span>if<span style="letter-spacing:0.4pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>rely<span style="letter-spacing:-0.45pt;"> </span>on<span style="letter-spacing:-0.45pt;"> </span>these<span style="letter-spacing:-0.45pt;"> </span>exemptions.<span style="letter-spacing:-0.45pt;"> </span>If some<span style="letter-spacing:-0.35pt;"> </span>investors<span style="letter-spacing:-0.35pt;"> </span>find<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>common<span style="letter-spacing:-0.35pt;"> </span>stock<span style="letter-spacing:-0.35pt;"> </span>less<span style="letter-spacing:-0.35pt;"> </span>attractive<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>result,<span style="letter-spacing:-0.35pt;"> </span>there<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>less<span style="letter-spacing:-0.35pt;"> </span>active<span style="letter-spacing:-0.35pt;"> </span>trading<span style="letter-spacing:-0.35pt;"> </span>market<span style="letter-spacing:-0.35pt;"> </span>for our common stock, and our stock price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:-0.6pt;"> </span>addition,<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>JOBS<span style="letter-spacing:-0.6pt;"> </span>Act<span style="letter-spacing:-0.6pt;"> </span>provides<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>an<span style="letter-spacing:-0.6pt;"> </span>emerging<span style="letter-spacing:-0.6pt;"> </span>growth<span style="letter-spacing:-0.6pt;"> </span>company<span style="letter-spacing:-0.6pt;"> </span>can<span style="letter-spacing:-0.6pt;"> </span>take<span style="letter-spacing:-0.6pt;"> </span>advantage<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>an<span style="letter-spacing:-0.6pt;"> </span>extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of<span style="letter-spacing:1.2pt;"> </span>certain accounting standards until those standards would otherwise apply to<span style="letter-spacing:-0.15pt;"> </span>private<span style="letter-spacing:-0.15pt;"> </span>companies.<span style="letter-spacing:-0.15pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>elected<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>&#8220;opt<span style="letter-spacing:-0.15pt;"> </span>out&#8221;<span style="letter-spacing:-0.7pt;"> </span>of<span style="letter-spacing:0.95pt;"> </span>such<span style="letter-spacing:-0.15pt;"> </span>extended<span style="letter-spacing:-0.15pt;"> </span>transition<span style="letter-spacing:-0.15pt;"> </span>period,<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>means<span style="letter-spacing:-0.15pt;"> </span>that when<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>standard<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.3pt;"> </span>issued<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>revised<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>it<span style="letter-spacing:-0.3pt;"> </span>has<span style="letter-spacing:-0.3pt;"> </span>different<span style="letter-spacing:-0.3pt;"> </span>application<span style="letter-spacing:-0.3pt;"> </span>dates<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>public<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>private<span style="letter-spacing:-0.3pt;"> </span>companies,<span style="letter-spacing:-0.3pt;"> </span>we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will<span style="letter-spacing:-0.6pt;"> </span>do<span style="letter-spacing:-0.55pt;"> </span>so<span style="letter-spacing:-0.6pt;"> </span>until<span style="letter-spacing:-0.55pt;"> </span>such<span style="letter-spacing:-0.55pt;"> </span>time<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.55pt;"> </span>either<span style="letter-spacing:-0.6pt;"> </span>(i)<span style="letter-spacing:-0.55pt;"> </span>irrevocably<span style="letter-spacing:-0.55pt;"> </span>elect<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>&#8220;opt<span style="letter-spacing:-0.55pt;"> </span>out&#8221;<span style="letter-spacing:-1.2pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>such<span style="letter-spacing:-0.55pt;"> </span>extended<span style="letter-spacing:-0.6pt;"> </span>transition<span style="letter-spacing:-0.55pt;"> </span>period,<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.25pt;">or</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(ii) no<span style="letter-spacing:-0.55pt;"> </span>longer<span style="letter-spacing:-0.55pt;"> </span>qualify<span style="letter-spacing:-0.55pt;"> </span>as<span style="letter-spacing:-0.55pt;"> </span>an<span style="letter-spacing:-0.55pt;"> </span>emerging<span style="letter-spacing:-0.55pt;"> </span>growth<span style="letter-spacing:-0.55pt;"> </span>company.<span style="letter-spacing:-0.55pt;"> </span>Therefore,<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.55pt;"> </span>reported<span style="letter-spacing:-0.55pt;"> </span>results<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>operations<span style="letter-spacing:-0.55pt;"> </span>contained in our financial statements may not be directly comparable to those of<span style="letter-spacing:1.8pt;"> </span>other public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Provisions in our Second Restated Certificate of Incorporation (our &#8220;Restated Charter&#8221;), our Amended and Restated Bylaws (our &#8220;Restated Bylaws&#8221;) and Delaware law may have anti-takeover effects that <span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">discourage</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">an</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">acquisition</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">us</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">by</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">others,</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">even</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">if</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">an</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">acquisition</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">would</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">beneficial</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">stockholders,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">and </span>may prevent attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.05pt;"> </span>Restated<span style="letter-spacing:-0.05pt;"> </span>Charter<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>Restated<span style="letter-spacing:-0.05pt;"> </span>Bylaws<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">Delaware</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">law</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">contain</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">provisions</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">that</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">have</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">effect</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:-0.1pt;">discouraging,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">delaying</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">preventing </span>a<span style="letter-spacing:-0.2pt;"> </span>change<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>control<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>us<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>changes<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>management<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>stockholders<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>consider<span style="letter-spacing:-0.2pt;"> </span>favorable,<span style="letter-spacing:-0.2pt;"> </span>including transactions in which investors might otherwise receive a premium for their shares. Our Restated Charter and <span style="letter-spacing:-0.1pt;">Restated</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">Bylaws</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">include</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">provisions</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">that:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">create</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">classified</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">board</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">directors</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whose</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">members</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">serve</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">staggered</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three-year</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">specify</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">special</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">meetings</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">can</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">called</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">only</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">board</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholder</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">action</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">written</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">establish</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">an</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">advance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">notice</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">procedure</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">stockholder</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">approvals</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">brought</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">before</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">an</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">annual</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">meeting </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">including</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proposed</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nominations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of persons</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">election</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">board</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of directors;</span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">directors</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">removed</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">only</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">cause;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">specify</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholder</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permitted</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cumulate</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">votes</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">election</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.9pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expressly</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">board</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:2.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">directors</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">modify,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alter</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">repeal</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restated</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bylaws;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supermajority</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">votes</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">holders</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of our</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stock</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amend</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">specified</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provisions</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of our Restated Charter and Restated Bylaws.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>management.<span style="letter-spacing:-0.45pt;"> </span>These<span style="letter-spacing:-0.45pt;"> </span>provisions<span style="letter-spacing:-0.45pt;"> </span>could<span style="letter-spacing:-0.45pt;"> </span>also<span style="letter-spacing:-0.45pt;"> </span>limit<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>price<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.45pt;"> </span>investors<span style="letter-spacing:-0.45pt;"> </span>might<span style="letter-spacing:-0.45pt;"> </span>be<span style="letter-spacing:-0.45pt;"> </span>willing<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>pay in the future for shares of<span style="letter-spacing:1.8pt;"> </span>our common stock, thereby depressing the market price of<span style="letter-spacing:1.8pt;"> </span>our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:-0.2pt;"> </span>addition,<span style="letter-spacing:-0.2pt;"> </span>because<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>incorporated<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>State<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>Delaware,<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>governed<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>provisions<span style="letter-spacing:-0.2pt;"> </span>of Section 203 of the General Corporation Law of the State of Delaware (&#8220;DGCL&#8221;), which prohibits a person who<span style="letter-spacing:-0.25pt;"> </span>owns<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>excess<span style="letter-spacing:-0.25pt;"> </span>of 15%<span style="letter-spacing:-0.25pt;"> </span>of our<span style="letter-spacing:-0.25pt;"> </span>outstanding<span style="letter-spacing:-0.25pt;"> </span>voting<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.25pt;"> </span>merging<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>combining<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any<span style="letter-spacing:-0.3pt;"> </span>provision<span style="letter-spacing:-0.3pt;"> </span>of our<span style="letter-spacing:-0.3pt;"> </span>Restated<span style="letter-spacing:-0.3pt;"> </span>Charter,<span style="letter-spacing:-0.3pt;"> </span>Restated<span style="letter-spacing:-0.3pt;"> </span>Bylaws<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>Delaware<span style="letter-spacing:-0.3pt;"> </span>law<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.3pt;"> </span>has<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:-0.3pt;"> </span>of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their<span style="letter-spacing:-0.6pt;"> </span>shares<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>common<span style="letter-spacing:-0.6pt;"> </span>stock,<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>could<span style="letter-spacing:-0.6pt;"> </span>also<span style="letter-spacing:-0.6pt;"> </span>affect<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>price<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>some<span style="letter-spacing:-0.6pt;"> </span>investors<span style="letter-spacing:-0.6pt;"> </span>are<span style="letter-spacing:-0.6pt;"> </span>willing<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>pay<span style="letter-spacing:-0.6pt;"> </span>for<span style="letter-spacing:-0.6pt;"> </span>our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.35pt;"> </span>Restated<span style="letter-spacing:-0.35pt;"> </span>Charter<span style="letter-spacing:-0.35pt;"> </span>designates<span style="letter-spacing:-0.35pt;"> </span>specific<span style="letter-spacing:-0.35pt;"> </span>courts<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>sole<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>exclusive<span style="letter-spacing:-0.35pt;"> </span>forum<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.35pt;"> </span>certain<span style="letter-spacing:-0.35pt;"> </span>claims<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>causes<span style="letter-spacing:-0.35pt;"> </span>of action<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.4pt;"> </span>brought<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>stockholders,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.4pt;"> </span>discourage<span style="letter-spacing:-0.4pt;"> </span>lawsuits<span style="letter-spacing:-0.4pt;"> </span>against<span style="letter-spacing:-0.4pt;"> </span>us<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>directors<span style="letter-spacing:-0.4pt;"> </span>and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.35pt;"> </span>Restated<span style="letter-spacing:-0.35pt;"> </span>Charter<span style="letter-spacing:-0.35pt;"> </span>provides<span style="letter-spacing:-0.35pt;"> </span>that,<span style="letter-spacing:-0.35pt;"> </span>subject<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>limited<span style="letter-spacing:-0.35pt;"> </span>exceptions,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>Court<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>Chancery<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>State of<span style="letter-spacing:-0.65pt;"> </span>Delaware<span style="letter-spacing:-0.65pt;"> </span>(or,<span style="letter-spacing:-0.65pt;"> </span>if,<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.7pt;"> </span>only<span style="letter-spacing:-0.65pt;"> </span>if,<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>Court<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.15pt;"> </span>Chancery<span style="letter-spacing:-0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:-0.7pt;"> </span>State<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.15pt;"> </span>Delaware<span style="letter-spacing:-0.7pt;"> </span>dismisses<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>Covered<span style="letter-spacing:-0.65pt;"> </span>Claim<span style="letter-spacing:-0.65pt;"> </span>(as defined<span style="letter-spacing:-0.5pt;"> </span>below)<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.5pt;"> </span>lack<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>subject<span style="letter-spacing:-0.5pt;"> </span>matter<span style="letter-spacing:-0.5pt;"> </span>jurisdiction,<span style="letter-spacing:-0.5pt;"> </span>any<span style="letter-spacing:-0.5pt;"> </span>other<span style="letter-spacing:-0.5pt;"> </span>state<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.5pt;"> </span>federal<span style="letter-spacing:-0.5pt;"> </span>court<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>State<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>Delaware that<span style="letter-spacing:-0.3pt;"> </span>does<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>matter<span style="letter-spacing:-0.3pt;"> </span>jurisdiction)<span style="letter-spacing:-0.3pt;"> </span>will,<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>fullest<span style="letter-spacing:-0.3pt;"> </span>extent<span style="letter-spacing:-0.3pt;"> </span>permitted<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.3pt;"> </span>applicable<span style="letter-spacing:-0.3pt;"> </span>law,<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>sole<span style="letter-spacing:-0.3pt;"> </span>and exclusive<span style="letter-spacing:-0.5pt;"> </span>forum<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>following<span style="letter-spacing:-0.5pt;"> </span>types<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>claims:<span style="letter-spacing:-0.5pt;"> </span>(i)<span style="letter-spacing:-0.45pt;"> </span>any<span style="letter-spacing:-0.5pt;"> </span>derivative<span style="letter-spacing:-0.45pt;"> </span>claim<span style="letter-spacing:-0.5pt;"> </span>brought<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>right<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>Company, (ii) any claim asserting a breach of a fiduciary duty to the Company or the Company&#8217;s stockholders owed by any current or former director, officer or other employee or stockholder of the Company, (iii) any claim against the Company arising pursuant to any provision of the DGCL, our Restated Charter or Restated Bylaws, (iv) any claim to interpret, apply, enforce or determine the validity of our Restated Charter or Restated Bylaws, (v) any claim against the Company governed by the internal affairs doctrine, and (vi) any other claim, not subject to exclusive federal jurisdiction and not asserting a cause of action arising under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), brought in any action asserting one or more of the claims specified in clauses (a)(i) through (v) herein above (each a &#8220;Covered Claim&#8221;). This provision does not apply to claims brought to enforce a duty or liability created by the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Restated Charter further provides that the federal<span style="letter-spacing:-0.3pt;"> </span>district<span style="letter-spacing:-0.3pt;"> </span>courts<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>United States of<span style="letter-spacing:0.8pt;"> </span>America will<span style="letter-spacing:-0.7pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>exclusive<span style="letter-spacing:-0.65pt;"> </span>forum<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>resolving<span style="letter-spacing:-0.65pt;"> </span>any<span style="letter-spacing:-0.65pt;"> </span>complaint<span style="letter-spacing:-0.7pt;"> </span>asserting<span style="letter-spacing:-0.65pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>cause<span style="letter-spacing:-0.65pt;"> </span>of action<span style="letter-spacing:-0.65pt;"> </span>arising<span style="letter-spacing:-0.65pt;"> </span>under<span style="letter-spacing:-0.7pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>Securities Act.<span style="letter-spacing:-0.6pt;"> </span>In<span style="letter-spacing:-0.6pt;"> </span>addition,<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.6pt;"> </span>Restated<span style="letter-spacing:-0.6pt;"> </span>Charter<span style="letter-spacing:-0.6pt;"> </span>provides<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.6pt;"> </span>any<span style="letter-spacing:-0.6pt;"> </span>person<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>entity<span style="letter-spacing:-0.6pt;"> </span>purchasing<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>otherwise<span style="letter-spacing:-0.6pt;"> </span>acquiring any<span style="letter-spacing:-0.2pt;"> </span>interest<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>shares<span style="letter-spacing:-0.2pt;"> </span>of capital<span style="letter-spacing:-0.2pt;"> </span>stock<span style="letter-spacing:-0.2pt;"> </span>of the<span style="letter-spacing:-0.2pt;"> </span>Company<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>deemed<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>notice<span style="letter-spacing:-0.2pt;"> </span>of and<span style="letter-spacing:-0.2pt;"> </span>consented<span style="letter-spacing:-0.2pt;"> </span>to these choice-of-forum provisions and waived any argument relating to the inconvenience of the forums in connection with any Covered Claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The<span style="letter-spacing:-0.4pt;"> </span>choice<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>forum<span style="letter-spacing:-0.4pt;"> </span>provisions<span style="letter-spacing:-0.4pt;"> </span>contained<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>Restated<span style="letter-spacing:-0.4pt;"> </span>Charter<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.4pt;"> </span>limit<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.4pt;"> </span>stockholder&#8217;s<span style="letter-spacing:-0.4pt;"> </span>ability to<span style="letter-spacing:-0.45pt;"> </span>bring<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>claim<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.45pt;"> </span>judicial<span style="letter-spacing:-0.45pt;"> </span>forum<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.45pt;"> </span>it<span style="letter-spacing:-0.45pt;"> </span>finds<span style="letter-spacing:-0.45pt;"> </span>favorable<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.45pt;"> </span>disputes<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.45pt;"> </span>us<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.45pt;"> </span>any<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>directors,<span style="letter-spacing:-0.45pt;"> </span>officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders<span style="letter-spacing:-0.5pt;"> </span>will<span style="letter-spacing:-0.5pt;"> </span>not<span style="letter-spacing:-0.5pt;"> </span>be<span style="letter-spacing:-0.5pt;"> </span>deemed<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.5pt;"> </span>have<span style="letter-spacing:-0.5pt;"> </span>waived<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.5pt;"> </span>compliance<span style="letter-spacing:-0.5pt;"> </span>with<span style="letter-spacing:-0.5pt;"> </span>federal<span style="letter-spacing:-0.5pt;"> </span>securities<span style="letter-spacing:-0.5pt;"> </span>laws<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.5pt;"> </span>rules<span style="letter-spacing:-0.5pt;"> </span>and regulations<span style="letter-spacing:-0.25pt;"> </span>thereunder.<span style="letter-spacing:-0.25pt;"> </span>While<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>Delaware<span style="letter-spacing:-0.25pt;"> </span>courts<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.25pt;"> </span>determined<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:-0.25pt;"> </span>choice<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>forum<span style="letter-spacing:-0.25pt;"> </span>provisions<span style="letter-spacing:-0.25pt;"> </span>are facially valid, it is possible that a court of law in another jurisdiction could rule that the choice of forum provisions<span style="letter-spacing:-0.35pt;"> </span>contained<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>Restated<span style="letter-spacing:-0.35pt;"> </span>Charter<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>inapplicable<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>unenforceable<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:0.55pt;"> </span>they<span style="letter-spacing:-0.35pt;"> </span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">are<span style="letter-spacing:-0.35pt;"> </span>challenged<span style="letter-spacing:-0.35pt;"> </span>in a<span style="letter-spacing:-0.2pt;"> </span>proceeding<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>otherwise,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>cause<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>incur<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.2pt;"> </span>costs<span style="letter-spacing:-0.2pt;"> </span>associated<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>resolving<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:-0.2pt;"> </span>action in other jurisdictions. The choice of forum provisions may also impose additional litigation costs on stockholders who assert that the provisions are not enforceable or invalid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General<b style="font-weight:bold;letter-spacing:-0.15pt;"> </b>Risk<b style="font-weight:bold;letter-spacing:-0.15pt;"> </b>Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unstable economic and market conditions may have serious adverse consequences on our business, financial condition and stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Global<span style="letter-spacing:-0.45pt;"> </span>economic<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>business<span style="letter-spacing:-0.45pt;"> </span>activities<span style="letter-spacing:-0.45pt;"> </span>continue<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.45pt;"> </span>face<span style="letter-spacing:-0.45pt;"> </span>widespread<span style="letter-spacing:-0.45pt;"> </span>uncertainties,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>global<span style="letter-spacing:-0.45pt;"> </span>credit<span style="letter-spacing:-0.45pt;"> </span>and financial markets have experienced extreme volatility and disruptions in the past several years, including severely<span style="letter-spacing:-0.7pt;"> </span>diminished<span style="letter-spacing:-0.65pt;"> </span>liquidity<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>credit<span style="letter-spacing:-0.65pt;"> </span>availability,<span style="letter-spacing:-0.65pt;"> </span>rising<span style="letter-spacing:-0.65pt;"> </span>inflation<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.7pt;"> </span>monetary<span style="letter-spacing:-0.65pt;"> </span>supply<span style="letter-spacing:-0.65pt;"> </span>shifts,<span style="letter-spacing:-0.65pt;"> </span>rising<span style="letter-spacing:-0.65pt;"> </span>interest rates,<span style="letter-spacing:3.2pt;"> </span>labor<span style="letter-spacing:3.25pt;"> </span>shortages,<span style="letter-spacing:3.2pt;"> </span>declines<span style="letter-spacing:3.25pt;"> </span>in<span style="letter-spacing:3.2pt;"> </span>consumer<span style="letter-spacing:3.25pt;"> </span>confidence,<span style="letter-spacing:3.25pt;"> </span>declines<span style="letter-spacing:3.25pt;"> </span>in<span style="letter-spacing:3.2pt;"> </span>economic<span style="letter-spacing:3.25pt;"> </span>growth,<span style="letter-spacing:3.25pt;"> </span>increases<span style="letter-spacing:3.25pt;"> </span><span style="letter-spacing:-0.25pt;">in </span>unemployment<span style="letter-spacing:-0.4pt;"> </span>rates,<span style="letter-spacing:-0.4pt;"> </span>recession<span style="letter-spacing:-0.4pt;"> </span>risks,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>uncertainty<span style="letter-spacing:-0.4pt;"> </span>about<span style="letter-spacing:-0.4pt;"> </span>economic<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>geopolitical<span style="letter-spacing:-0.4pt;"> </span>stability<span style="letter-spacing:-0.4pt;"> </span>(for<span style="letter-spacing:-0.4pt;"> </span>example, related to the ongoing Russia-Ukraine conflict). The extent of the impact of these conditions on our operational<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>financial<span style="letter-spacing:-0.2pt;"> </span>performance,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>execute<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>business<span style="letter-spacing:-0.2pt;"> </span>strategies<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>initiatives in the expected timeframe, as well as that of third parties upon whom we rely, will depend on future developments which are uncertain and cannot be predicted. There can be no assurance that further deterioration<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.6pt;"> </span>economic<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>market<span style="letter-spacing:-0.6pt;"> </span>conditions<span style="letter-spacing:-0.6pt;"> </span>will<span style="letter-spacing:-0.6pt;"> </span>not<span style="letter-spacing:-0.6pt;"> </span>occur,<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>how<span style="letter-spacing:-0.6pt;"> </span>long<span style="letter-spacing:-0.6pt;"> </span>these<span style="letter-spacing:-0.6pt;"> </span>challenges<span style="letter-spacing:-0.6pt;"> </span>will<span style="letter-spacing:-0.6pt;"> </span>persist.<span style="letter-spacing:-0.6pt;"> </span>If<span style="letter-spacing:0.35pt;"> </span>the current equity and credit markets further deteriorate, or do not improve, it may make any necessary debt or equity<span style="letter-spacing:-0.45pt;"> </span>financing<span style="letter-spacing:-0.45pt;"> </span>more<span style="letter-spacing:-0.45pt;"> </span>difficult,<span style="letter-spacing:-0.45pt;"> </span>more<span style="letter-spacing:-0.45pt;"> </span>costly,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.45pt;"> </span>more<span style="letter-spacing:-0.45pt;"> </span>dilutive.<span style="letter-spacing:-0.45pt;"> </span>Furthermore,<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.45pt;"> </span>stock<span style="letter-spacing:-0.45pt;"> </span>price<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>decline<span style="letter-spacing:-0.45pt;"> </span>due in part to the volatility of<span style="letter-spacing:2pt;"> </span>the stock market and the general economic downturn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If<span style="letter-spacing:0.8pt;"> </span>securities<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>industry<span style="letter-spacing:-0.3pt;"> </span>analysts<span style="letter-spacing:-0.3pt;"> </span>cease publishing<span style="letter-spacing:-0.3pt;"> </span>research<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>reports<span style="letter-spacing:-0.3pt;"> </span>about<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>business,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>if<span style="letter-spacing:0.8pt;"> </span>they<span style="letter-spacing:-0.3pt;"> </span>publish<span style="letter-spacing:-0.3pt;"> </span>inaccurate or<span style="letter-spacing:-0.25pt;"> </span>unfavorable<span style="letter-spacing:-0.25pt;"> </span>research<span style="letter-spacing:-0.25pt;"> </span>about<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>business,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>price<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>trading<span style="letter-spacing:-0.25pt;"> </span>volume<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock will be influenced in part by the research and reports that industry<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>securities<span style="letter-spacing:-0.25pt;"> </span>analysts<span style="letter-spacing:-0.25pt;"> </span>publish<span style="letter-spacing:-0.25pt;"> </span>about<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>business.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.25pt;"> </span>do<span style="letter-spacing:-0.25pt;"> </span>not<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>control<span style="letter-spacing:-0.25pt;"> </span>over<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>industry or securities analysts, or the content and opinions included in their reports and may never obtain research <span style="letter-spacing:-0.1pt;">coverage</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">by</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">securities</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">industry</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">analysts.</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">If</span><span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:-0.1pt;">no</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">few</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">securities</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">industry</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">analysts</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">continue to cover us,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">if</span><span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:-0.1pt;">analysts</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">cease</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">coverage</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:-0.1pt;">us,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">could</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">lose</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">visibility</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">financial</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">markets,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">trading</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">price</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">for </span>our common stock could be impacted negatively. If any of the analysts who cover us publish inaccurate or unfavorable research or opinions regarding us, our business model, our intellectual property or our stock performance,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:0.55pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>preclinical<span style="letter-spacing:-0.35pt;"> </span>studies<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.35pt;"> </span>trials<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>operating<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.35pt;"> </span>fail<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>meet<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>expectations of<span style="letter-spacing:1.7pt;"> </span>analysts, our stock price would likely decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.65pt;"> have incurred, and </span>will<span style="letter-spacing:-0.6pt;"> </span>incur,<span style="letter-spacing:-0.65pt;"> </span>increased<span style="letter-spacing:-0.6pt;"> </span>costs<span style="letter-spacing:-0.65pt;"> </span>as<span style="letter-spacing:-0.6pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>result<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operating<span style="letter-spacing:-0.65pt;"> </span>as<span style="letter-spacing:-0.6pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>public<span style="letter-spacing:-0.6pt;"> </span>company,<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>management<span style="letter-spacing:-0.6pt;"> </span>will<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.6pt;"> </span>required to devote substantial time to new compliance initiatives and corporate governance practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a public company, we have incurred, and particularly after we are no longer an <span style="letter-spacing:-0.1pt;">emerging</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">growth</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">company,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">will</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">incur</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">significant</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">legal,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">accounting</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">other</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">expenses</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">that</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">did</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">incur </span>as<span style="letter-spacing:-0.7pt;"> </span>a<span style="letter-spacing:-0.65pt;"> </span>private<span style="letter-spacing:-0.65pt;"> </span>company.<span style="letter-spacing:-0.65pt;"> </span>The<span style="letter-spacing:-0.65pt;"> </span>Securities<span style="letter-spacing:-0.65pt;"> </span>Act,<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>Exchange<span style="letter-spacing:-0.7pt;"> </span>Act,<span style="letter-spacing:-0.65pt;"> </span>Sarbanes-Oxley<span style="letter-spacing:-0.65pt;"> </span>Act,<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>Dodd-Frank<span style="letter-spacing:-0.65pt;"> </span>Wall<span style="letter-spacing:-0.65pt;"> </span>Street Reform and Consumer Protection Act, the listing requirements of<span style="letter-spacing:2pt;"> </span>the Nasdaq Global Select Market and other<span style="letter-spacing:-0.4pt;"> </span>applicable<span style="letter-spacing:-0.4pt;"> </span>securities<span style="letter-spacing:-0.4pt;"> </span>rules<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>regulations<span style="letter-spacing:-0.4pt;"> </span>impose<span style="letter-spacing:-0.4pt;"> </span>various<span style="letter-spacing:-0.4pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:-0.4pt;"> </span>public<span style="letter-spacing:-0.4pt;"> </span>companies,<span style="letter-spacing:-0.4pt;"> </span>including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance<span style="letter-spacing:-0.65pt;"> </span>initiatives.<span style="letter-spacing:-0.65pt;"> </span>Moreover,<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.65pt;"> </span>expect<span style="letter-spacing:-0.65pt;"> </span>these<span style="letter-spacing:-0.65pt;"> </span>rules<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>regulations<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>substantially<span style="letter-spacing:-0.65pt;"> </span>increase<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>legal<span style="letter-spacing:-0.65pt;"> </span>and financial compliance costs and to make some activities more time consuming and costly. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of<span style="letter-spacing:1.05pt;"> </span>these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. The increased costs may require us to reduce costs in other areas of our business. Moreover, these rules and regulations<span style="letter-spacing:-0.55pt;"> </span>are<span style="letter-spacing:-0.55pt;"> </span>often<span style="letter-spacing:-0.55pt;"> </span>subject<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>varying<span style="letter-spacing:-0.55pt;"> </span>interpretations,<span style="letter-spacing:-0.55pt;"> </span>in<span style="letter-spacing:-0.55pt;"> </span>many<span style="letter-spacing:-0.55pt;"> </span>cases<span style="letter-spacing:-0.55pt;"> </span>due<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.55pt;"> </span>their<span style="letter-spacing:-0.55pt;"> </span>lack<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>specificity,<span style="letter-spacing:-0.55pt;"> </span>and,<span style="letter-spacing:-0.55pt;"> </span>as<span style="letter-spacing:-0.55pt;"> </span>a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing<span style="letter-spacing:-0.15pt;"> </span>bodies.<span style="letter-spacing:-0.15pt;"> </span>This<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>continuing<span style="letter-spacing:-0.15pt;"> </span>uncertainty<span style="letter-spacing:-0.15pt;"> </span>regarding<span style="letter-spacing:-0.15pt;"> </span>compliance<span style="letter-spacing:-0.15pt;"> </span>matters<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>higher<span style="letter-spacing:-0.15pt;"> </span>costs necessitated by ongoing revisions to disclosure and governance practices.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure to establish and maintain effective internal control over financial reporting could adversely affect our business<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>if investors<span style="letter-spacing:-0.3pt;"> </span>lose<span style="letter-spacing:-0.3pt;"> </span>confidence<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>accuracy<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>completeness<span style="letter-spacing:-0.3pt;"> </span>of our<span style="letter-spacing:-0.3pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>reports,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>market price of<span style="letter-spacing:1.9pt;"> </span>our common stock could be negatively affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are required to comply with the SEC&#8217;s rules implementing Section 404 of<span style="letter-spacing:1.7pt;"> </span>the Sarbanes-Oxley Act, which requires management to certify financial and other information in our annual and annual reports and provide an annual management report on the effectiveness of internal control over financial reporting. Although<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.15pt;"> </span>be<span style="letter-spacing:0.2pt;"> </span>required<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.15pt;"> </span>disclose<span style="letter-spacing:0.2pt;"> </span>changes<span style="letter-spacing:0.15pt;"> </span>made<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>our<span style="letter-spacing:0.15pt;"> </span>internal<span style="letter-spacing:0.15pt;"> </span>control<span style="letter-spacing:0.2pt;"> </span>over<span style="letter-spacing:0.15pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>reporting<span style="letter-spacing:0.2pt;"> </span>on<span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:-0.5pt;">an</span> annual basis, we will not be required to make our first annual assessment of our internal control over financial<span style="letter-spacing:-0.3pt;"> </span>reporting<span style="letter-spacing:-0.3pt;"> </span>until<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>annual<span style="letter-spacing:-0.3pt;"> </span>report<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.3pt;"> </span>Form<span style="letter-spacing:-0.3pt;"> </span>10-K, for fiscal year ending December 31, 2025.<span style="letter-spacing:-0.35pt;"> </span>However,<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.3pt;"> </span>emerging<span style="letter-spacing:-0.3pt;"> </span>growth<span style="letter-spacing:-0.3pt;"> </span>company, our<span style="letter-spacing:-0.8pt;"> </span>independent<span style="letter-spacing:-0.65pt;"> </span>registered<span style="letter-spacing:-0.65pt;"> </span>public<span style="letter-spacing:-0.65pt;"> </span>accounting<span style="letter-spacing:-0.65pt;"> </span>firm<span style="letter-spacing:-0.65pt;"> </span>will<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>be<span style="letter-spacing:-0.7pt;"> </span>required<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>formally<span style="letter-spacing:-0.65pt;"> </span>attest<span style="letter-spacing:-0.65pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>effectiveness<span style="letter-spacing:-0.65pt;"> </span>of our<span style="letter-spacing:-0.7pt;"> </span>internal<span style="letter-spacing:-0.65pt;"> </span>control<span style="letter-spacing:-0.65pt;"> </span>over<span style="letter-spacing:-0.65pt;"> </span>financial<span style="letter-spacing:-0.65pt;"> </span>reporting<span style="letter-spacing:-0.65pt;"> </span>until<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>later<span style="letter-spacing:-0.7pt;"> </span>of<span style="letter-spacing:-0.65pt;"> </span>the fiscal<span style="letter-spacing:-0.65pt;"> </span>year ending December 31, 2025 or the date we are no longer an emerging growth company. At such time, our independent registered public accounting firm would need to issue a report that is adverse in the event that there are material weaknesses in our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To comply with the requirements<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>being<span style="letter-spacing:-0.6pt;"> </span>a<span style="letter-spacing:-0.6pt;"> </span>public<span style="letter-spacing:-0.6pt;"> </span>company,<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>have<span style="letter-spacing:-0.6pt;"> </span>undertaken<span style="letter-spacing:-0.6pt;"> </span>various<span style="letter-spacing:-0.6pt;"> </span>actions,<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>will<span style="letter-spacing:-0.6pt;"> </span>need<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.6pt;"> </span>take<span style="letter-spacing:-0.6pt;"> </span>additional actions,<span style="letter-spacing:-0.4pt;"> </span>such<span style="letter-spacing:-0.4pt;"> </span>as<span style="letter-spacing:-0.4pt;"> </span>implementing<span style="letter-spacing:-0.4pt;"> </span>numerous<span style="letter-spacing:-0.4pt;"> </span>internal<span style="letter-spacing:-0.4pt;"> </span>controls<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>procedures<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>hiring<span style="letter-spacing:-0.4pt;"> </span>additional<span style="letter-spacing:-0.4pt;"> </span>accounting<span style="letter-spacing:-0.4pt;"> </span>or internal audit staff or consultants. Testing and maintaining internal controls can divert our management&#8217;s attention from other matters that are important to the operation of<span style="letter-spacing:2pt;"> </span>our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.45pt;"> </span>disclosure<span style="letter-spacing:-0.4pt;"> </span>controls<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>procedures<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>not<span style="letter-spacing:-0.4pt;"> </span>prevent<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>detect<span style="letter-spacing:-0.4pt;"> </span>all<span style="letter-spacing:-0.4pt;"> </span>errors<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>acts<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:-0.1pt;">fraud.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to the periodic reporting requirements of the Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Any disclosure controls and procedures, no matter how well- conceived<span style="letter-spacing:-0.7pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>operated,<span style="letter-spacing:-0.65pt;"> </span>can<span style="letter-spacing:-0.65pt;"> </span>provide<span style="letter-spacing:-0.65pt;"> </span>only<span style="letter-spacing:-0.65pt;"> </span>reasonable,<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>absolute,<span style="letter-spacing:-0.7pt;"> </span>assurance<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>objectives<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.7pt;"> </span>control system are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These<span style="letter-spacing:-0.4pt;"> </span>inherent<span style="letter-spacing:-0.4pt;"> </span>limitations<span style="letter-spacing:-0.4pt;"> </span>include<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>realities<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.4pt;"> </span>judgments<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>decision-making<span style="letter-spacing:-0.4pt;"> </span>can<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.4pt;"> </span>faulty,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>inherent<span style="letter-spacing:-0.05pt;"> </span>limitations<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>control<span style="letter-spacing:-0.05pt;"> </span>system,<span style="letter-spacing:-0.05pt;"> </span>misstatements<span style="letter-spacing:-0.05pt;"> </span>due<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>error<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>fraud<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>occur<span style="letter-spacing:-0.05pt;"> </span>and not<span style="letter-spacing:-0.6pt;"> </span>be<span style="letter-spacing:-0.6pt;"> </span>detected.<span style="letter-spacing:-0.6pt;"> </span>In<span style="letter-spacing:-0.6pt;"> </span>addition,<span style="letter-spacing:-0.6pt;"> </span>we<span style="letter-spacing:-0.6pt;"> </span>do<span style="letter-spacing:-0.6pt;"> </span>not<span style="letter-spacing:-0.6pt;"> </span>have<span style="letter-spacing:-0.6pt;"> </span>a<span style="letter-spacing:-0.6pt;"> </span>formal<span style="letter-spacing:-0.6pt;"> </span>risk<span style="letter-spacing:-0.6pt;"> </span>management<span style="letter-spacing:-0.6pt;"> </span>program<span style="letter-spacing:-0.6pt;"> </span>for<span style="letter-spacing:-0.6pt;"> </span>identifying<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.6pt;"> </span>addressing risks to our business in other areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our<span style="letter-spacing:-0.3pt;"> </span>insurance<span style="letter-spacing:-0.3pt;"> </span>policies<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.3pt;"> </span>expensive<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>only<span style="letter-spacing:-0.3pt;"> </span>protect<span style="letter-spacing:-0.3pt;"> </span>us<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.3pt;"> </span>some<span style="letter-spacing:-0.3pt;"> </span>business<span style="letter-spacing:-0.3pt;"> </span>risks,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.3pt;"> </span>leave<span style="letter-spacing:-0.3pt;"> </span>us<span style="letter-spacing:-0.3pt;"> </span>exposed<span style="letter-spacing:-0.3pt;"> </span>to significant uninsured liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.65pt;"> </span>do<span style="letter-spacing:-0.65pt;"> </span>not<span style="letter-spacing:-0.65pt;"> </span>carry<span style="letter-spacing:-0.65pt;"> </span>insurance<span style="letter-spacing:-0.65pt;"> </span>for<span style="letter-spacing:-0.65pt;"> </span>all<span style="letter-spacing:-0.65pt;"> </span>categories<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>risk<span style="letter-spacing:-0.65pt;"> </span>that<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>business<span style="letter-spacing:-0.65pt;"> </span>may<span style="letter-spacing:-0.65pt;"> </span>encounter.<span style="letter-spacing:-0.65pt;"> </span>Some<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>policies we currently maintain include workers&#8217; compensation, clinical trials, and directors&#8217; and officers&#8217; liability <span style="letter-spacing:-0.1pt;">insurance.</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">do</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">not</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">know,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">however,</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">if</span><span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">will</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">able</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">maintain</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">insurance</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">with</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">adequate</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">levels</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.45pt;"> </span><span style="letter-spacing:-0.1pt;">coverage. </span>Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect <span style="letter-spacing:-0.1pt;">our</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">business,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">financial</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">condition,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">results</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">of</span><span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:-0.1pt;">operations</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">and</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">prospects.</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">We</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">be</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">subject</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">securities</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">litigation, </span>which is expensive and could divert management attention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The<span style="letter-spacing:-0.15pt;"> </span>market<span style="letter-spacing:-0.15pt;"> </span>price<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>common<span style="letter-spacing:-0.15pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.15pt;"> </span>likely<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>volatile.<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>market<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>general,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>Nasdaq and biopharmaceutical companies in particular, have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation (including<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>cost<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>defend<span style="letter-spacing:-0.35pt;"> </span>against,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>potential<span style="letter-spacing:-0.35pt;"> </span>adverse<span style="letter-spacing:-0.35pt;"> </span>outcome<span style="letter-spacing:-0.35pt;"> </span>resulting<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:-0.35pt;"> </span>proceeding) can<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>expensive,<span style="letter-spacing:-0.3pt;"> </span>time consuming,<span style="letter-spacing:-0.3pt;"> </span>damage<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>reputation<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>divert<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>management&#8217;s<span style="letter-spacing:-0.3pt;"> </span>attention<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.3pt;"> </span>other business concerns, which could seriously harm our business.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.45pt;"> </span>could<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.4pt;"> </span>subject<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.4pt;"> </span>securities<span style="letter-spacing:-0.4pt;"> </span>class<span style="letter-spacing:-0.4pt;"> </span>action<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">litigation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:-0.7pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>past,<span style="letter-spacing:-0.65pt;"> </span>securities<span style="letter-spacing:-0.65pt;"> </span>class<span style="letter-spacing:-0.65pt;"> </span>action<span style="letter-spacing:-0.65pt;"> </span>litigation<span style="letter-spacing:-0.65pt;"> </span>has<span style="letter-spacing:-0.65pt;"> </span>often<span style="letter-spacing:-0.7pt;"> </span>been<span style="letter-spacing:-0.65pt;"> </span>instituted<span style="letter-spacing:-0.65pt;"> </span>against<span style="letter-spacing:-0.65pt;"> </span>companies<span style="letter-spacing:-0.65pt;"> </span>following<span style="letter-spacing:-0.65pt;"> </span>periods of volatility<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>trading<span style="letter-spacing:-0.4pt;"> </span>price<span style="letter-spacing:-0.4pt;"> </span>of a<span style="letter-spacing:-0.4pt;"> </span>company&#8217;s<span style="letter-spacing:-0.4pt;"> </span>securities.<span style="letter-spacing:-0.4pt;"> </span>This<span style="letter-spacing:-0.4pt;"> </span>type<span style="letter-spacing:-0.4pt;"> </span>of litigation,<span style="letter-spacing:-0.4pt;"> </span>if instituted,<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.4pt;"> </span>result<span style="letter-spacing:-0.4pt;"> </span>in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating<span style="letter-spacing:1.35pt;"> </span>results<span style="letter-spacing:1.35pt;"> </span>or<span style="letter-spacing:1.35pt;"> </span>financial<span style="letter-spacing:1.35pt;"> </span>condition.<span style="letter-spacing:1.35pt;"> </span>Additionally,<span style="letter-spacing:1.35pt;"> </span>the<span style="letter-spacing:1.35pt;"> </span>dramatic<span style="letter-spacing:1.35pt;"> </span>increase<span style="letter-spacing:1.35pt;"> </span>in<span style="letter-spacing:1.35pt;"> </span>the<span style="letter-spacing:1.35pt;"> </span>cost<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:2pt;"> </span>directors&#8217;<span style="letter-spacing:0.95pt;"> </span>and <span style="letter-spacing:-0.1pt;">officers&#8217;</span><span style="letter-spacing:-1pt;"> </span><span style="letter-spacing:-0.1pt;">liability</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">insurance</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">may</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">cause</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">us</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">opt</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">for</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">lower</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">overall</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">policy</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">limits</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">or</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">to</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">forgo</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">insurance</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">that</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">we</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">may </span>otherwise rely on to cover significant defense costs, settlements and damages awarded to plaintiffs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.6pt;"> </span>be<span style="letter-spacing:-0.65pt;"> </span>subject<span style="letter-spacing:-0.6pt;"> </span>to<span style="letter-spacing:-0.65pt;"> </span>changes<span style="letter-spacing:-0.6pt;"> </span>in<span style="letter-spacing:-0.65pt;"> </span>tax<span style="letter-spacing:-0.6pt;"> </span>rates,<span style="letter-spacing:-0.65pt;"> </span>the<span style="letter-spacing:-0.6pt;"> </span>adoption<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>new<span style="letter-spacing:-0.65pt;"> </span>tax<span style="letter-spacing:-0.6pt;"> </span>legislation<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.6pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>otherwise<span style="letter-spacing:-0.6pt;"> </span>have<span style="letter-spacing:-0.65pt;"> </span>exposure to additional tax liabilities, which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Changes to tax laws or regulations in the jurisdictions in which we operate, or in the interpretation of such<span style="letter-spacing:-0.7pt;"> </span>laws<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.65pt;"> </span>regulations,<span style="letter-spacing:-0.65pt;"> </span>could<span style="letter-spacing:-0.65pt;"> </span>significantly<span style="letter-spacing:-0.65pt;"> </span>increase<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:-0.65pt;"> </span>effective<span style="letter-spacing:-0.7pt;"> </span>tax<span style="letter-spacing:-0.65pt;"> </span>rate,<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.65pt;"> </span>otherwise<span style="letter-spacing:-0.65pt;"> </span>materially<span style="letter-spacing:-0.65pt;"> </span>affect<span style="letter-spacing:-0.65pt;"> </span>our financial condition. In addition, other factors or events, including business combinations and investments, changes in stock-based compensation, changes in the valuation of our deferred tax assets and liabilities, adjustments to taxes upon finalization of various tax returns or as a result of deficiencies asserted by taxing authorities,<span style="letter-spacing:-0.35pt;"> </span>increases<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.35pt;"> </span>expenses<span style="letter-spacing:-0.35pt;"> </span>not<span style="letter-spacing:-0.35pt;"> </span>deductible<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.35pt;"> </span>tax<span style="letter-spacing:-0.35pt;"> </span>purposes,<span style="letter-spacing:-0.35pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.35pt;"> </span>available<span style="letter-spacing:-0.35pt;"> </span>tax<span style="letter-spacing:-0.35pt;"> </span>credits,<span style="letter-spacing:-0.35pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>in transfer<span style="letter-spacing:-0.4pt;"> </span>pricing<span style="letter-spacing:-0.4pt;"> </span>methodologies,<span style="letter-spacing:-0.4pt;"> </span>other<span style="letter-spacing:-0.4pt;"> </span>changes<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.4pt;"> </span>apportionment<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>our<span style="letter-spacing:-0.4pt;"> </span>income<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>other<span style="letter-spacing:-0.4pt;"> </span>activities<span style="letter-spacing:-0.4pt;"> </span>among tax<span style="letter-spacing:-0.35pt;"> </span>jurisdictions<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>changes<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.35pt;"> </span>tax<span style="letter-spacing:-0.4pt;"> </span>rates,<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.4pt;"> </span>also<span style="letter-spacing:-0.35pt;"> </span>increase<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>effective<span style="letter-spacing:-0.4pt;"> </span>tax<span style="letter-spacing:-0.35pt;"> </span>rate.<span style="letter-spacing:-0.4pt;"> </span>Our<span style="letter-spacing:-0.35pt;"> </span>tax<span style="letter-spacing:-0.4pt;"> </span>filings<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.4pt;"> </span>subject to review or audit by the U.S. Internal Revenue Service (the &#8220;IRS&#8221;) and state, local and foreign taxing authorities.<span style="letter-spacing:-0.45pt;"> </span>We<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.45pt;"> </span>also<span style="letter-spacing:-0.45pt;"> </span>be<span style="letter-spacing:-0.45pt;"> </span>liable<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.45pt;"> </span>taxes<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.45pt;"> </span>connection<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.45pt;"> </span>businesses<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.45pt;"> </span>acquire.<span style="letter-spacing:-0.45pt;"> </span>Our<span style="letter-spacing:-0.45pt;"> </span>determinations<span style="letter-spacing:-0.45pt;"> </span>are not<span style="letter-spacing:-0.05pt;"> </span>binding<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>IRS<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.05pt;"> </span>taxing<span style="letter-spacing:-0.05pt;"> </span>authorities,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>accordingly<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>final<span style="letter-spacing:-0.05pt;"> </span>determination<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>audit<span style="letter-spacing:-0.05pt;"> </span>or other proceeding may be materially different than the treatment reflected in our tax provisions, accruals and returns. An assessment of<span style="letter-spacing:1.9pt;"> </span>additional taxes because of<span style="letter-spacing:1.9pt;"> </span>an audit could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_d614b10a_3194_43be_a3b5_09e0f5cf2d9e"></a><a id="Item1BUnresolvedStaffComments_597814"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1B. Unresolved Staff Comments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.2pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_3b4b0769_0442_4134_9d94_a90357f97c2e"></a><a id="Item1CCyberSecurity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 1C. Cyber</b><b style="font-weight:bold;"> Security</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Tb_zTSnOFfj6U62HOkA5X0Yww" continuedAt="Tb_zTSnOFfj6U62HOkA5X0Yww_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Risk Management and Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Tb_OEVzFKLZE0ODyVtMuLboAw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have developed and maintain an information security program <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Narr_cmxbDdG_TkaTWkuwItk_hQ">designed to assess, identify, and manage risks</ix:nonNumeric> from cybersecurity threats. As part of this program, we conduct periodic assessments of our assets to evaluate the effectiveness of applicable security controls. These assessments are informed by industry standard frameworks and include a review of our information security controls to assess cybersecurity maturity compared to our peers and other security awareness trainings. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Narr_ybInzAZTH0GBovZCHNUS6w">engage security technology vendors</ix:nonNumeric> to assist with detecting potential threats to our information assets. In addition, we have implemented a cybersecurity <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Narr__8n9Tsrkik6thFJ11MdlmQ">third party risk management process</ix:nonNumeric> to assess mission and business critical third parties for cyber risks and to assist the business in making risk-informed technology product and services decisions. Our practice is to perform due diligence, including the completion of security questionnaires and risk assessments, as appropriate, on third parties who maintain material data or information to help us evaluate and verify third party information security capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our process designed to detect and respond to cybersecurity incidents that may represent a threat to the confidentiality, integrity or availability of our information assets is based on industry standards and best practices of peer companies. Our technology, procedures and key vendors with security responsibilities are designed to help contain, eradicate and recover from cybersecurity incidents in a timely manner. Senior management is informed about incidents that may have a significant impact on the business. Incidents are reviewed once they are resolved, and policies and controls are updated to help mitigate gaps. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Narr_XTyF7TnL3kmE1d7tW2lUyw">We have not identified risks from known cybersecurity threats or past incidents that have materially affected or are reasonably likely to materially affect us.</ix:nonNumeric> </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_zTSnOFfj6U62HOkA5X0Yww_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. &#8220;Risk Factors&#8221; in this Annual Report.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Group_wdpc2szlsEe1OevoojKA4g" continuedAt="Group_wdpc2szlsEe1OevoojKA4g_2" escape="true">Management is responsible for the day-to-day management of risks we face,</ix:nonNumeric> while <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Tb_DpA8_ywOlkykdYdOiGTucQ" escape="true">our Board of Directors, as a whole and through committees, has responsibility for the oversight of risk management, including risks from cybersecurity threats. Our <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_D0vhjqInyUK6xib90-rC-w" escape="true">Audit Committee</ix:nonNumeric> has specific oversight of risk management, including risks from cybersecurity threats.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:continuation id="Group_wdpc2szlsEe1OevoojKA4g_2">Our <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Narr_9XvnJFjj3EWwgSUwtHk2PA"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Tb_gff0Gm28E0-EC5Bd_w4yRQ" escape="true">Executive Director of IT</ix:nonNumeric> is responsible</ix:nonNumeric> for developing, implementing, and maintaining our cybersecurity risk management policies and procedures. The individual currently serving in the role of <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="Tb_oHgOnUWFb0SnQt6kmRfT3w" escape="true">Executive Director of IT has over thirty years of experience in cybersecurity, information security, data protection, privacy, regulatory compliance and risk management within complex and international business verticals such as pharmaceutical/biotech, technology, semiconductor and telecom.</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_T5hec2wB1kWrWg68gjeQHw" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Tb_XL72sE8BikiGQnUGzFy6Ew" escape="true">The Executive Director of IT reports to our Chief Human Resources Officer and <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Narr_XP5VTjwuk0y-4l87yr1snA">provides periodic cybersecurity updates to the Audit Committee of our Board of Directors on at least an annual basis</ix:nonNumeric>. Our incident response process contemplates that the executive team will notify the Audit Committee of our Board of Directors of any material cybersecurity incident.</ix:nonNumeric></ix:nonNumeric></ix:continuation> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_0075bb71_1f94_4784_bbb9_bfc374ed2d05"></a><a id="Item2Properties_556040"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 2. Properties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Our headquarters are located in Waltham, Massachusetts, and consists of 30,102 square feet of leased office space under a lease that expires on April 30, 2026.  On June 28, 2022, we entered into a lease agreement for 5,127 square feet of office space in Shanghai, PRC. On January 13, 2025, we extended the Shanghai lease, which expires on September 9, 2027.  To meet future needs of our business, we may lease additional or alternate space and we believe suitable additional or alternate space will be available in the future on commercially reasonable terms. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.2pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_47f4f70b_7743_487f_85f2_bea20bf90fca"></a><a id="Item3LegalProceedings_489086"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_86062928_62fb_4c4d_a5d3_5cf4bba787a4"></a><a id="Item4MineSafetyDisclosures_472006"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_dd240a87_16a6_4328_a9f0_8df415b3c4aa"></a><a id="PARTII_711631"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Market and Stockholder Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Our common stock began trading on the Nasdaq Global Select Market on September 13, 2024, under the symbol &#8220;ZBIO&#8221;. Prior to that time, there was no public market for our common stock.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Holders of Record</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of February 28, 2025, we had approximately 53 holders of record of our common stock. Certain shares are held in &#8220;street&#8221; name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Dividend Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have not paid cash dividends on our common stock and do not have a current intention to pay cash dividends, we continually review our capital allocation strategies, including, amount other things, payment of cash dividends, share repurchase and acquisitions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information required by this item will be included in our proxy statement with respect to our 2025 Annual Meeting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">of Stockholders, which we intend to file with the SEC within 120 days after the end of our fiscal 2024 year ended and is</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Use of Proceeds from our Initial Public Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On September 16, 2024, the Company completed its IPO, in which the Company issued and sold 15,220,588 shares of its common stock, including 1,985,294 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares. The offer and sale of common stock in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-281713), which was declared effective by the SEC on September 12, 2024 and a registration statement on Form S-1MEF (File No. 333-282082), which was automatically effective upon filing with the SEC on September 12, 2024. Following the sale of all of the shares offered in connection with the closing of our IPO, the offering terminated. Morgan Stanley &amp; Co. LLC, Jefferies LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC acted as underwriters for the IPO. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We received aggregate gross proceeds from our IPO of $258.7 million, or aggregate net proceeds of $234.3 million after deducting underwriting discounts, commissions and other offering costs. None of the underwriting discounts and commissions or other offering costs were incurred or paid, directly or indirectly, to directors or officers of ours or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There has been no material change in the planned use of proceeds from the IPO from that described in the Prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_91751e9c_30b8_49ea_98b2_97d65c5c68ee"></a><a id="Item6SelectedFinancialData_251755"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 6. </b><b style="font-weight:bold;">Reserved</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4534ad64_b371_4378_a797_f1fa1dc8899c"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investors should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. This discussion and analysis contain forward-looking statements based upon current beliefs, plans, and expectations related to future events and our future performance that involve risks, uncertainties, and assumptions, such as statements regarding our intentions, plans, objectives, and expectations for our business. Our actual results and the timing of events could differ materially from those discussed in these forward-looking statements as a result of several factors, including those set forth in the section titled &#8220;Risk Factors.&#8221; See also the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. With the evolving understanding of the pathogenesis of autoimmune diseases, along with the expansion of promising immunology-based pharmacologic targets, we are building an <span style="letter-spacing:0.2pt;">immunology and inflammation</span> (&#8220;I&amp;I&#8221;) focused biopharmaceutical company. Our core business strategy combines disciplined product candidate acquisition with strategic deployment of internal expertise and effective use of external resources. We leverage our experienced executive management team and our established networks throughout the biopharmaceutical industry to identify, acquire and develop product candidates that we believe can provide superior clinical benefits to patients living with autoimmune diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our lead I&amp;I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc&#947;RIIb, which are broadly present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. Based on existing clinical data generated to date, we believe that targeting B cell lineage via CD19 and Fc&#947;RIIb can inhibit B cells and has been shown to be well-tolerated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing obexelimab as a potential I&amp;I franchise for patients in several autoimmune diseases, representing substantial commercial opportunities individually and in the aggregate. The first three indications we are pursuing include IgG4-RD through an ongoing registration-directed Phase&#160;3 trial, RMS and SLE through ongoing Phase&#160;2, double-blind, randomized, placebo-controlled trials, each of which are currently enrolling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Beyond our lead product candidate, obexelimab, we have two other programs for the potential treatment of other I&amp;I indications that we may continue to advance and ultimately commercialize with partners. These consist of ZB002 and ZB004. We retain global rights for both assets. In addition, we hold the development and commercialization rights to one regional program, ZB001, and related programs, which were recently exclusively sublicensed to a partner in greater China. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 16, 2024, we completed our IPO in which we issued and sold an aggregate of 15,220,588 shares of our common stock, including 1,985,294 shares of common stock sold pursuant to the full exercise of the underwriter&#8217;s option to purchase additional shares, at a public offering price of $17.00 per share, for aggregate gross proceeds of $258.7 million. We received $234.3 million in net proceeds after deducting underwriting discounts, commissions and other offering costs payable by us. In connection with the IPO, all outstanding shares of convertible preferred stock (&#8220;Preferred Stock&#8221;) converted into an aggregate of 24,978,715 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 21, 2024, we entered into the Novation Agreement with Tenacia, under which we transferred our rights and obligations under our agreements with Dianthus to Tenacia for ZB005. As partial consideration for the Tenacia Agreement, we received a non-creditable, non-refundable upfront fee of $5.0 million from Tenacia. In addition, we are eligible to receive up to $86.0 million upon the achievement of certain future regulatory and commercial milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Since inception, our operations have focused on research and development activities with respect to our product candidates as described above, as well as raising capital, business planning, organizing and staffing our company, establishing our intellectual property portfolio, establishing arrangements with third parties for the manufacture of our product candidates </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and related raw materials, and providing general and administrative support for these operations. Through December 31, 2024, we have financed our operations primarily with the proceeds from the issuance of Preferred Stock and convertible notes, payments received from our license and collaboration agreement and from the sale of common stock in our IPO completed in September 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses and negative cash flows since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Our net losses for the years ended December 31, 2024 and 2023 were $157.0 million and $37.1 million, respectively. As of December 31, 2024, we had an accumulated deficit of $387.4&#160;million. We expect to continue to incur significant and increasing losses for the foreseeable future. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue clinical development of obexelimab and our other programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance our obexelimab program and our other product candidates through preclinical development and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify additional product candidates and acquire rights from third parties to those product candidates through licenses or acquisitions and conduct development activities, including preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make royalty, milestone or other payments under current, and any future, license or collaboration agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">procure the manufacturing of preclinical, clinical and commercial supply of our current or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek marketing regulatory approvals for our current or any future product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercialize our current or any future product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">take steps toward our goal of being an integrated biopharma company capable of supporting commercial activities, including establishing sales, marketing and distribution infrastructure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to develop, maintain and defend our intellectual property portfolio, including against third-party interference, infringement and other intellectual property claims, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to attract, hire and retain qualified clinical, scientific, operations and management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add and maintain operational, financial and information management systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attempt to address any competing therapies and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experience delays in our preclinical studies, clinical trials or regulatory approval for our current or any future product candidates, including with respect to failed studies, inconclusive results, safety issues or other regulatory challenges;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish agreements with contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur additional costs associated with being a public company, including audit, legal, regulatory, and tax-related services associated with maintaining compliance with an exchange listing and the SEC requirements, director and officer insurance premiums and investor relations costs.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate, and we cannot assure investors that we will ever generate significant revenue or profits. In addition, if we obtain regulatory approval for a product candidate and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities. We expect to continue to incur significant losses for the foreseeable future as we continue to advance the development of our product candidates and incur additional costs associated with being a public company. Our net losses may fluctuate significantly from period to period, depending on the timing of our planned clinical studies and expenditures related to our research and development activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued research and development and other current liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will need to continue to raise substantial additional capital to support our continuing operations and pursue our growth strategy as a public company. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity financings, debt financings or other capital sources, which could include collaborations with other companies, or other strategic transactions and licensing agreements. We may be unable to obtain financing on acceptable terms, or at all, and we may be unable to enter into collaborations or other arrangements. Our failure to raise capital or enter into such agreements as, and when, needed, could have a material adverse effect on our business, prospects, results of operations, and financial condition, including requiring us to have to delay, reduce or eliminate product development or future commercialization efforts, or grant rights to develop and market potential future product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As there are numerous risks and uncertainties associated with development of I&amp;I therapeutics, we are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. We will need to generate significant revenue to achieve profitability, and we may never do so. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, we had $350.8 million in cash, cash equivalents and short-term investments. We believe that our cash, cash equivalents and short-term investments as of December 31, 2024 will be sufficient to fund our operations and capital expenditure requirements into the fourth quarter of 2026. We have based this estimate on our current assumptions, which may prove to be wrong, and we may exhaust our available capital resources sooner than we expect. See section titled &#8220;Liquidity and Capital Resources.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Significant Risks and Uncertainties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The current inflationary environment may materially affect our business and operating results by increasing the costs of our clinical trial materials and supplies, driving the U.S. Federal Reserve system to increase interest rates, which in turn increase our overhead costs. Rising interest rates could make it more difficult to obtain traditional financing on acceptable terms, if at all. Additionally, the ongoing recession risk together with the foregoing, could result in further economic uncertainty and volatility in the capital markets in the near term and, as a result could negatively affect our operations. Furthermore, such economic conditions have produced downward pressure on share prices. Although we do not believe that inflation has had a material impact on our financial positions or results of operations to date, additional high inflation could increase our operating costs, including our labor costs and research and development costs. These costs may also be negatively impacted due to supply chain constraints, global geopolitical tensions, worsening macroeconomic conditions and employee availability and wage increases, which may result in additional stress on our working capital. We import from China drug product and other components for use in our clinical studies, and such products are subject to tariffs. Increases in tariffs could result in increased costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, we are subject to other challenges and risk specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the clinical stage biopharmaceutical industry. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, we have no product candidates approved for commercial sale in any country, and we have not generated any revenues from the sale of products. Our revenue has been derived from collaboration arrangements and license fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">License and Collaboration Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">License and collaboration revenue is generated from our Bristol-Myers Squibb (&#8220;BMS&#8221;) Agreement and our Tenacia Agreement.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the BMS Agreement, we sublicensed the rights to develop and commercialize obexelimab in Japan, South&#160;Korea, Taiwan, Singapore, Hong Kong and Australia (the &#8220;BMS Territory&#8221;). We retain exclusive rights to commercialize the licensed products containing obexelimab outside of the BMS Territory. The revenue recognized to date pursuant to this arrangement relates to the license of obexelimab and the related technology transfer, which was recognized upon delivery of the license. This arrangement includes the participation by BMS in certain joint global studies of obexelimab in accordance with the terms of the BMS Agreement, in which BMS will reimburse us for its share of the related study costs. Such reimbursements will be classified as a reduction to research and development expense in the period such costs are incurred. We will recognize development and regulatory milestones defined in the BMS Agreement when the achievement of the underlying milestone events is deemed probable, which is expected to be upon achievement. Sales milestones and royalties on future sales will be recognized in the period the related sales occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Tenacia Agreement, we transferred our rights, title, interest, liabilities, duties and obligations under the Option and License Agreements with Dianthus to Tenacia for ZB005. The revenue recognized to date pursuant to this arrangement relates to the novation of the ZB005 license, asset transfer and technology transfer, which was recognized upon delivery of the license, related assets and technology transfer. We will recognize development and regulatory milestones as defined in the Tenacia Agreement when the achievement of the underlying milestone events is deemed probable, which is expected to be upon achievement. Sales milestones and royalties on future sales will be recognized in the period the related sales occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For a more detailed description of this agreement, see <i style="font-style:italic;">Note&#160;7, License and Collaboration Revenue</i>, to our consolidated financial statements included elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our operating expenses consist of (i)&#160;research and development expenses, (ii)&#160;general and administrative expenses and (iii)&#160;acquired in-process research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses account for a significant portion of our operating expenses and consist primarily of external and internal costs incurred in connection with the preclinical and clinical development of obexelimab, ZB002, ZB004, ZB001 and ZB005, and include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Direct Costs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred under agreements with CROs and consultants that conduct our clinical studies and other scientific development services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs incurred under agreements with CMOs for manufacturing material for our preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to obtain and maintain licenses to intellectual property, and related future payments should milestones described in those agreements be achieved; and</span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to compliance with regulatory requirements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Indirect Costs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses including salaries, bonuses, benefits, stock-based compensation and other related costs for those employees involved in research and development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of outside consultants, including their fees, stock-based compensation and related travel expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors or our estimate of the level of service that has been performed at each reporting date. Payments for these external development activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as prepaid expenses or accrued expenses. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized, even when there is no alternative future use for the research and development. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A significant portion of our research and development costs have been external costs, which we track on an individual product candidate basis after a clinical product candidate has been identified. We utilize third party contractors for our research and development activities and CMOs for our manufacturing activities and we do not have our own laboratory or manufacturing facilities. Therefore, we have no material facilities expenses attributed to research and development. Our internal research and development costs are primarily personnel-related costs and other indirect costs. We do not track internal costs on a program specific or stage of program basis because these costs are deployed across multiple programs and, as such, are not separately classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Where we share costs with our collaboration partners, such as in our BMS Agreement, research and development expenses may include cost sharing reimbursements from our partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase for the foreseeable future as we advance clinical trials for our product candidates, pursue additional indications, continue to develop additional product candidates, expand our headcount and maintain, expand and enforce our intellectual property portfolio. We also expect our manufacturing costs to increase with our CMOs as we scale up our processes for commercial manufacturing. Product candidates in later stages of clinical development will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials and additional manufacturing activities. There are numerous factors associated with the successful development and commercialization of any product candidates we may develop, including the safety and efficacy of our product candidates, investment in our clinical programs, manufacturing capability and competition with other products, and future commercial and regulatory factors beyond our control that will impact our clinical development program and plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The successful development of our current product candidates, or any product candidates we may develop in the future is highly uncertain. Therefore, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development and commercialization of our product candidates, if approved, and any other product candidates that we may develop. We are also unable to predict when, if ever, material net cash inflows will commence from the sale of any current or future product candidate, if approved. This is due to the numerous risks and uncertainties associated with product development, including the uncertainty of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, timing and progress of our ongoing obexelimab clinical studies and other research and development activities associated with the development of our other and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and scope of preclinical and clinical programs we decide to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain our current research and development programs and to establish new programs;</span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of and successful patient enrollment in, and the initiation and completion of, clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the U.S. Food and Drug Administration (&#8220;FDA&#8221;), or any comparable foreign regulatory authority;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish new licensing or collaboration arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the performance of our future collaborators, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain arrangements with third-party manufacturers for the commercial supply of products that receive marketing approval, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development and timely delivery of commercial-grade drug formulations that can be used in our planned clinical trials and for commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to hire additional personnel and consultants as our business grows, including additional executive officers and clinical development, regulatory, chemistry, manufacturing and controls (&#8220;CMC&#8221;), quality and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercializing product candidates, if approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of establishing or securing sales and marketing capabilities for our product candidates if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of the product candidates following approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any changes in the outcome of any of these variables with respect to the development of our current product candidates or any future product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently anticipate would be required for the completion of clinical development, or if we experience significant delays in enrollment in any clinical trials following the FDA&#8217;s acceptance and clearance of an Investigational New Drug Application (&#8220;IND&#8221;), we could be required to expend significant additional financial resources and time to complete clinical development than we currently expect. We may never obtain regulatory approval for any product candidates that we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel-related expenses, including salaries, bonuses, benefits, and stock-based compensation expenses for personnel in executive, finance, accounting, human resources and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional fees paid for accounting, auditing, tax and consulting and other professional services, and expenses for rent, insurance and other operating costs not otherwise classified as research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We anticipate that our general and administrative expenses will increase in the next few&#160;years as we increase our headcount to support our continued research and development activities of our product candidates. These increases will likely include </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">increased costs related to the hiring of additional personnel and fees to outside consultants, among other expenses. We also anticipate increased expenses associated with being a public company, including costs for accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with the rules&#160;and regulations of the SEC, listing standards applicable to companies listed on a national securities exchange, director and officer insurance costs, and investor and public relations costs. In addition, if we obtain regulatory approval for our current product candidates or any product candidates we may develop in the future and do not enter into a third-party commercialization collaboration, we expect to incur significant expenses related to building a sales and marketing team to support product sales, marketing and distribution activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Acquired In-Process Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expense acquisition costs for assets purchased for use in research and development activities that have no alternative future use as in-process research and development (&#8220;IPR&amp;D&#8221;) expense as of the acquisition date. When we become obligated to make contingent milestone payments under the terms of the agreements by which we acquired the IPR&amp;D assets, we will recognize additional IPR&amp;D expense. We measure and recognize contingent consideration in the period in which the related milestone is achieved and becomes payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Total Other Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other income, net primarily consists of interest income generated from cash equivalents and investments, and realized and unrealized gains and losses on foreign currency transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Change in Fair Value of Convertible Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">In August&#160;2023, we issued a convertible note to BMS (the &#8220;BMS Note&#8221;) in connection with the BMS Agreement, (see </span>Note&#160;7, License and Collaboration Revenue<span style="font-style:normal;"> to our audited consolidated financial statements). We elected to record the BMS Note&#160;at fair value upon issuance and to subsequently remeasure the note at fair value at the end of each reporting period with the change in fair value being recorded as a component of other expense in our consolidated statement of operations and comprehensive loss. In May&#160;2024, in connection with our Series&#160;C convertible preferred stock (&#8220;Series C Preferred Stock&#8221;) financing, the BMS Note&#160;plus accrued interest was automatically converted into 12,284,686 shares of Series&#160;C Preferred Stock. We reassessed the estimated fair value of the BMS Note&#160;immediately prior to the conversion utilizing the fair value of the shares of Series&#160;C Preferred Stock for which the note subsequently converted into and recorded the change in fair value as a component of other income (expense), net in our consolidated statement of operations and comprehensive loss during the years ended December 31, 2024 and 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since our inception, we have not recorded income tax benefits for any of our deferred tax assets, including the net operating losses (&#8220;NOLs&#8221;) incurred or the research and development tax credits generated in each&#160;year, as we have concluded that it is more likely than not that these deferred tax assets will not be realized. </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the Years Ended December 31, 2024 and 2023 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes our results of operations for each of the periods presented (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:32.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Increase (Decrease)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">License and collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (45,000)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (45,000)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 139,139</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 60,033</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 79,106</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29,749</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,114</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,635</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquired in-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (10,000)</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 168,888</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 87,147</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 81,741</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (163,888)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (37,147)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (126,741)</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income, net:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value adjustments to convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (846)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (300)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (546)</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,175</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 624</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,551</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,329</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 324</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,005</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (156,559)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (36,823)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (119,736)</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (429)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (301)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (128)</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (156,988)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (37,124)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (119,864)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2024, we recognized revenue of $5.0 million, related to the upfront payment under the Tenacia Agreement. For the year ended December 31, 2023, we recognized revenue of $50.0 million, related to the upfront payment under the BMS Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes our research and development expenses for each of the periods presented (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:36.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Increase (Decrease)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct research and development expenses by program:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Obexelimab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 94,563</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,446</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 69,117</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other programs (ZB002 &amp; ZB004)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,115</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,242</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,127)</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Partnered regional programs (ZB001 &amp; ZB005)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,737</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,738</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1)</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unallocated research and development expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Personnel expenses (including stock-based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,458</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,906</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,360</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,149</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 211</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 139,139</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60,033</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 79,106</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $139.1&#160;million for the year ended December 31, 2024, compared to $60.0&#160;million for the year ended December 31, 2023. The increase of $79.1&#160;million was primarily attributable to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a $69.1&#160;million increase in costs related to the development of obexelimab, our lead product candidate, driven by a $36.6&#160;million increase in manufacturing costs for clinical trial materials and also a $32.0 million increase clinical trial costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a $4.1&#160;million decrease in costs related to our other programs, including a $2.3&#160;million decrease related to ZB002 and a $1.8&#160;million decrease related to ZB004; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a $13.9&#160;million increase in personnel costs, including a $9.5&#160;million increase in salary and benefit related expense, primarily due to an increase in headcount, a $2.5&#160;million increase in stock-based compensation expense, and a $1.9&#160;million increase in external contractor expense and other personnel costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;">The following table summarizes our general and administrative expenses for each of the periods presented (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Increase</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel related expenses (including stock-based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,613</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,859</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,754</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Legal and professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,318</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,626</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,692</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Facilities and supplies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,375</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,825</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 550</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,443</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 804</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,639</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29,749</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,114</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,635</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $29.7 million for the year ended December 31, 2024, compared to $17.1&#160;million for the year ended December 31, 2023. The increase of $12.6&#160;million was primarily attributable to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a $8.8&#160;million increase in personnel costs, including a $4.9&#160;million increase in stock-based compensation expense, a $3.8&#160;million increase in salary and benefit related expense, primarily due to an increase in headcount, and a $0.1 million increase in recruiting expense, partially offset by a $0.1&#160;million decrease in external contractor expense; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a $1.7&#160;million increase in professional fees, including legal, audit and tax expenses, primarily attributable to operating as a public company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a $1.6 million increase in other expenses, including insurance and other variable costs related to operating as a public company. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Acquired In-Process Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There was no acquired IPR&amp;D expense recorded for the year ended December 31, 2024. Acquired IPR&amp;D for the year ended December 31, 2023 was comprised of a $10.0 million development milestone expense related to obexelimab. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Total Other Income (Expense), Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2024, total other income (expense), net increased from the comparable period in the prior year primarily due to interest earnings as a result of higher cash, cash equivalents and short-term investments due to proceeds from the Series C Preferred Stock and IPO. &#160;</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses since inception. We have not yet commercialized any product candidates, and we do not expect to generate revenue from sales of any product candidates or from other sources for several years, if at all. As of December 31, 2024, we had $350.8 million in cash, cash equivalents and short-term investments and we had an accumulated deficit of $387.4&#160;million. Through December 31, 2024, we have funded our operations primarily with gross proceeds of $358.0 million through the sale and issuance of our Preferred Stock, our convertible notes, as well as $55.0 million through our BMS Agreement and Tenacia Agreement, and most recently, from the sale of common stock in our IPO. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Future Funding Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that our available cash, cash equivalents and short-term investments, as of December 31, 2024, are sufficient to fund existing and planned cash requirements for at least the next 12 months, from the filing of this Form 10-K. Our primary uses of capital are, and we expect to continue to be, compensation and related expenses, third-party clinical research and development services, clinical costs, legal and other regulatory expenses and general overhead costs. We have based our estimates on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we currently expect. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, the process of testing drug candidates in clinical trials is costly, and the timing of progress in these trials is uncertain. We cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Our future funding requirements will depend on, and could increase significantly as a result of, many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, timing, progress results and costs of our ongoing obexelimab clinical studies and other research and development activities associated with the development of our other and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of establishing and maintaining arrangements with third-party manufacturers for the commercial supply of products that receive marketing approval, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of manufacturing for obexelimab and other product candidates, including commercial manufacturing at sufficient scale, if any product candidate is approved, including as a result of inflation, any supply chain issues or component shortages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sale of our products, should any product candidates receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cash requirements of any future acquisitions or discovery of product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of attracting, hiring and retaining skilled personnel to support our operations and continued growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of implementing operational, financial and management systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales of, or milestone payments related to or royalties on, current or future product candidates, if any; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with operating as a public company, including legal, accounting or other expenses in operating our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these or other variables with respect to the development of obexelimab or any other product candidate could significantly change the costs and timing associated with our operating plans. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have no products approved for commercial sale and have not generated any product revenues from product sales to date. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financing and additional funding from license, strategic alliances and collaboration arrangements. Except for any obligations of our collaborators to reimburse us for research and development expenses or make milestone or royalty payments under our agreements with them, we will not have any committed external source of liquidity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred losses and cumulative negative cash flows from operations since our inception. We anticipate that we will continue to incur significant losses for at least the next several years. We expect our research and development, general and administrative expenses will continue to increase. As a result, we will need additional capital to fund our operations, which we may raise through a combination of the sale of our equity, debt financings, or other sources, including potential collaborations. To the extent that we raise capital through the future sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we enter into debt financing arrangements, if available, they may involve restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, which could adversely impact our ability to conduct our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through license, strategic alliances or collaboration arrangements in the future, we may have to relinquish valuable rights to our technologies, future revenue streams or drug candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves. &#160;</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table provides information regarding our cash flows for each of the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (119,674)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (30,529)</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (30,552)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17)</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 412,958</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,116</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate changes on cash and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 157</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 78</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 262,889</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (10,352)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net Cash Used in Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2024 was $119.7&#160;million, and was primarily due to our net loss of $157.0&#160;million adjusted for non-cash items including stock-based compensation of $10.8 million, an investment accretion of $0.6 million and non-cash operating lease of $0.7 million, and an increase in assets and liabilities of $25.3 million. The significant items of the increase in operating assets and liabilities include an increase in accrued expenses and accounts payable of $33.8 million and prepaid expenses and other assets of $7.7 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2023 was $30.5 million, and was primarily due to our net loss of $37.1 million, adjusted for non-cash items including acquired in-process research and development expense related to a milestone payment of $10.0 million, stock-based compensation of $3.5 million and non-cash operating lease of $0.7 million, offset by a decrease in assets and liabilities of $8.0 million. The significant items of the decrease in operating assets and liabilities include a $4.0 million decrease in accrued expense and accounts payable and an increase of $3.3 million decrease in prepaid expenses and other assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net Cash Used in Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities for the year ended December 31, 2024 was $30.6&#160;million and was due to the purchase of $36.4 million of investments, partially offset by $6.0 million in proceeds from the maturities of investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities for the year ended December 31, 2023 was less than $0.1 million and consisted of purchases of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net Cash Provided by Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities for the year ended December 31, 2024 was $413.0&#160;million, resulting from $178.4 million in net proceeds received from the issuance and sale of shares of our Series&#160;C Preferred Stock, proceeds of $240.6 million from our IPO, net of underwriting discounts and commissions, and $0.3&#160;million of proceeds received from the exercise of stock options, partially offset by a $6.3 million payment of offering costs related to our IPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities for the year ended December 31, 2023 was $20.1 million, resulting from $20.0 million in proceeds received from the sale of the BMS Note and $0.1 million in proceeds received from the exercise of stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contractual obligations and commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have entered into lease arrangements for facilities, which are comprised of office space, through April 30, 2026. As of December 31, 2024, our total fixed lease payment obligations outstanding are $1.1 million of which $0.9 million is payable within 12 months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our lease obligations, please see <i style="font-style:italic;">Note 6, Leases</i>, to these consolidated financial statements.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">License and Option Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have entered into license agreements under which we may be obligated to make milestone and royalty payments, which are contingent upon future events, such as achieving certain development, regulatory, and commercial milestones or generating product sales. As of December 31, 2024 and 2023, we were unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our license and option agreements, please see <i style="font-style:italic;">Note 8, License and Option Agreements</i>, to these consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Purchase and Other Obligations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with CROs, CMOs, and other third-party vendors for clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including non-cancelable obligations of our service provided up to one year after the date of cancellation. &#160;As of December 31, 2024, our total clinical manufacturing contract payment obligations are $15.3 million of which the full obligation is payable within 12 months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Significant Judgments and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;), &#160;requires us to make judgments, assumptions and estimates that may affect the reported amounts of assets and liabilities, equity and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reported periods. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experiences. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements prospectively from the date of change in estimates. Other significant accounting policies are outlined in <i style="font-style:italic;">Note 2, Summary of Significant Accounting Policies</i>, to our consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have listed below our critical accounting estimates that we believe to have the greatest potential impact on our consolidated financial statements. Our assumptions, judgements and estimates relative to our critical accounting estimates have not differed materially from actual results. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accrued Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing contracts and vendor agreements, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. We make estimates of our accrued and prepaid clinical expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to CROs, and investigative sites in connection with clinical studies and to vendors related to product manufacturing and development of clinical supplies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We base our expenses related to clinical study and trial costs on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows and expense recognition. Payments under some of these contracts depend on factors out of our control, as such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual </p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in <i style="font-style:italic;">Note&#160;2, Summary of Significant Accounting Policies,</i> in our consolidated financial statements included elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We qualify as an &#8220;emerging growth company&#8221; as defined in the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure about our executive compensation arrangements, exemption from the requirements to hold nonbinding advisory votes on executive compensation and golden parachute payments and exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may take advantage of these exemptions until December 31, 2029 or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company earlier if we have more than $1.235&#160;billion in annual revenue, we have more than $700.0&#160;million in market value of our stock held by non-affiliates (and we have been a public company for at least twelve&#160;months and have filed one Annual Report on Form&#160;10-K) or we issue more than $1.0&#160;billion of nonconvertible debt securities over a three&#160;year period. For so long as we remain an emerging growth company, we are permitted, and intend, to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. We may choose to take advantage of some, but not all, of the available exemptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the JOBS Act provides that, an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i)&#160;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualify as an emerging growth company. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. Therefore, the reported results of operations contained in our financial statements may not be directly comparable to those of other public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates following the IPO is less than $100.0&#160;million during the most recently completed fiscal&#160;year. We may continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal&#160;year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. We may continue to be a smaller reporting company until the fiscal&#160;year following the determination that we no longer meet the requirements necessary to be considered a smaller reporting company.</p><a id="_26f868df_17fb_4fee_a132_016ceb50b19e"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under SEC rules and regulations, because we are considered to be a &#8220;smaller reporting company,&#8221; we are not required to provide the information required by this item in this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_bf4459b7_9d95_4d41_ab7b_5fdb23320cef"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 8. Financial Statements and Supplementary Data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ZENAS BIOPHARMA, INC.</b></p><a id="INDEXTOCONSOLIDATEDFINANCIALSTATEMENTS_9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consolidated Financial Statements for the Years Ended December 31, 2024 and 2023:</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:91.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:91.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.31;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:91.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:AuditorFirmId" id="Narr_1te48W9tpk-UbofLxJB7nA">42</ix:nonNumeric>)</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-left:10pt;text-indent:-10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:right;margin:0pt;">135</p></td></tr><tr><td style="vertical-align:top;width:91.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;margin:0pt;"><a href="#CondensedConsolidatedBalanceSheets_17182"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:right;margin:0pt;">136</p></td></tr><tr><td style="vertical-align:top;width:91.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;margin:0pt;"><a href="#CondensedConsolidatedStatementsofOperati"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:right;margin:0pt;">137</p></td></tr><tr><td style="vertical-align:top;width:91.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;margin:0pt;"><a href="#Equity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:right;margin:0pt;">138</p></td></tr><tr><td style="vertical-align:top;width:91.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;margin:0pt;"><a href="#Cashflow"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:right;margin:0pt;">139</p></td></tr><tr><td style="vertical-align:top;width:91.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#NotestoCondensedConsolidatedFinancialSta"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:right;margin:0pt;">140</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Shareholders and the Board of Directors of Zenas BioPharma, Inc. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have audited the accompanying consolidated balance sheets of Zenas BioPharma, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss,&#160;changes in convertible preferred stock and stockholders' equity (deficit) and cash flows for each of the two years in the period ended December 31, 2024, and the related notes<sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup>(collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:AuditorName" id="Narr_9zboc-xPdUOvYxKHWEaatw">Ernst &amp; Young LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="dei:AuditorLocation" id="Narr_c-mtfE4yBUeRwLrlx-ugcw">Boston, Massachusetts</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 11, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_7c03dda4_374d_422f_87eb_1060ae060a66"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PART&#160;I&#160;&#8212;FINANCIAL INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Zenas BioPharma,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="CondensedConsolidatedBalanceSheets_17182"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><a id="_60be9f63_66eb_46ec_acac_c5f2786d6957"></a><a id="Tc_7UrorK1dG0Ovey82qQ_GQA_1_2"></a><a id="Tc_ypp1bBKcZEi1fh79RDvjrQ_1_5"></a><a id="Tc_-6KD2DZh-UeNLNCdYLGijQ_2_2"></a><a id="Tc_entcDv5v80iwVndNR1RNbg_2_5"></a><a id="Tc_5bDaHNBPvEiaAmx1LmQ4OA_3_0"></a><a id="Tc_3EYE97a1J0SAAvlaCKjdOA_4_0"></a><a id="Tc_0IVr9H93xUO9J77pzCKbHQ_5_0"></a><a id="Tc_pVQ-oUTPDUm9sHtSIhj3Tg_5_2"></a><a id="Tc_o6-jLToY5EmJuLPrGOhOCw_5_5"></a><a id="Tc_JHF5c8r-hEqaUfEgyXgYsA_6_0"></a><a id="Tc_LC1OVOK2v028rbhQFEsEMQ_6_6"></a><a id="Tc_ThGJUGTmi0-BGe-rkY-cBA_7_0"></a><a id="Tc_g5fJOVOZkE-8Dsi3_ZLMSQ_7_6"></a><a id="Tc_jGYSZzCkjkGLIm_9J2hgeg_8_0"></a><a id="Tc_Ipy8V_DLWUisX-4J2PKKSw_9_0"></a><a id="Tc_2v9KhSGJVUO2GJfH6lZWpA_10_0"></a><a id="Tc_Hc6nNiaET0KLEyeeQEUn2A_11_0"></a><a id="Tc_LNvR-vwtukycZvg7ikcTCw_12_0"></a><a id="Tc_qxJU_sms-0GkwhzUM4p-kg_12_3"></a><a id="Tc_GVLEiDuoEEy6fHewEJrxSQ_13_0"></a><a id="Tc_P79aHOnjjEue1zBIW982iA_14_0"></a><a id="Tc_csgcomgaEU661qkAV1-6qw_14_2"></a><a id="Tc_bkuceG6_lUeuXknPOkRvFg_14_5"></a><a id="Tc_k7ua_PBrqkqWHjxO8E8IMQ_15_0"></a><a id="Tc_0ZzRH0EFU0SMfS_1-O-cFQ_16_0"></a><a id="Tc_X4A0Nf0x20e14r4SV7f_aQ_17_0"></a><a id="Tc_9FER45bvnE6e1rTfbuwbnw_17_2"></a><a id="Tc_fHfEtC7SmkmOsJcGt0n9Aw_17_5"></a><a id="Tc_u6noD6mB_0SBWZDzARD7BQ_18_0"></a><a id="Tc_ucSW7klUDUSbF2GQiW-XpA_19_0"></a><a id="Tc_9VTdqUjMrkyevX99FR9hoQ_20_0"></a><a id="Tc_3aU3gJC8Wki05xNjlOS66g_21_0"></a><a id="Tc_UYvUCuinS0qHZC7JyqUd8A_22_0"></a><a id="Tc_vGOGoQ8ghkqsezq9w0iOZA_22_3"></a><a id="Tc_pAIAFOnIm02WAdoHi0m5fg_23_0"></a><a id="Tc_GZ_rmWiJLE2wrqyFh5JRxQ_24_0"></a><a id="Tc_FKF6fi1bQUKx5_rCrZXV4w_25_0"></a><a id="Tc_5zIWo5mRTE2E5ag1k6VuZw_26_0"></a><a id="Tc_kCh8zStLF0SNJ1A0Hag3jw_26_3"></a><a id="Tc_qqBN0h_oKEifEqhujzYo3Q_27_0"></a><a id="Tc_81cN8kJuI0m3CKjtEbhhTA_27_3"></a><a id="Tc_qqWu13zhL0WYCWOAzqIZzg_28_0"></a><a id="Tc_TqCGqO9oTEmaEZQiwzZBCw_28_3"></a><a id="Tc_4CUjtIr-FEmiiQ0UGSd28A_29_0"></a><a id="Tc_RVsBTmae20aHIqPotY25lA_30_0"></a><a id="_dd562c1d_534d_4a5c_80b0_919f1b1585b1"></a><a id="_dd562c1d_534d_4a5c_80b0_919f1b1585b1_2"></a><a id="_dd562c1d_534d_4a5c_80b0_919f1b1585b1_3"></a><a id="_4360a8b5_f874_496a_b123_beb6d6a06674"></a><a id="_4360a8b5_f874_496a_b123_beb6d6a06674_2"></a><a id="_4360a8b5_f874_496a_b123_beb6d6a06674_3"></a><a id="Tc_LJ7kWZWNXk2my_nsvdDuuQ_31_0"></a><a id="Tc_qefm33Zsk06FlWCOkTkz0A_31_6"></a><a id="Tc_5PyeThOWIEiwGYJhMnOTpA_32_0"></a><a id="Tc_aW9kMIBCc0aUmkF3Rcj7cg_33_0"></a><a id="Tc_6yqtW1YhTkaAnclsEOp4zA_34_0"></a><a id="Tc_bSvjX5h630Wi02AuGJ6_JQ_35_0"></a><a id="Tc_hBjrAalRdUmoKmI4VQO19g_36_0"></a><a id="Tc_S-bXUjEGHU6fdOGjqVvqYw_36_2"></a><a id="Tc_-c64dA-kO0uRmDue_AbKyg_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_vBVqwNSOQUWUbUpWk3Ef7g_5_3">319,742</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_VdvEs3wjfUawGP2M0QlBHg_5_6">56,857</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_qcwof0gDuEyA9Ms0ZxcMWg_6_3">31,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_XKV2ElxFiEaiNQaN3z-gSw_7_3">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_zZYXS_n2A0qEbC7RjSHVmw_8_3">5,067</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_SQQX43zH1U-NAgaEaBsrng_8_6">2,947</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_eSGHx6FN3U6YqsW1TKGM0Q_9_3">355,923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_11WMlettf0WsUfYRh39SQw_9_6">59,804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_gc3G2n5VakqkbBlAXwFNqg_10_3">185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_kOTYOYnlOE-pVxcYlqKjDw_10_6">193</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_DTrlBeQoq0qcajsNiv5G_g_11_3">1,004</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_X7qZzBdbF0Or1j0bNiZ3qw_11_6">821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_UapzJqzPuEGj25pRIcL0JQ_12_6">86</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_uq3PVWsjbEiLPVEhBRj4Iw_13_3">12,856</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_yDK7EO2z0E-Q_OQJyezwXA_13_6">7,276</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total assets</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_WZsPiPYLlUqKwxEceucLaQ_14_3">369,968</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_7e0KiKZA4U2qr6xPjCTkbw_14_6">68,180</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable (includes $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UAmlIVGtOke4L0fxZoW0Qg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Narr_IwrPvAv0rkKTk6Fe_QkOeA">560</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4dqDswEkwU-V1_i6DzMeew" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Narr__JoqtazLuE2WgB6FaTo40Q">21</ix:nonFraction> owed to related parties, respectively)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_JU2X1e8kLEeqEJqYvMFFmg_17_3">17,136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_CS-oC3jFTUO4n93ToExClw_17_6">5,396</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses (includes $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UAmlIVGtOke4L0fxZoW0Qg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Narr_aSq5_M8wckeQJyywnkhWFQ">260</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4dqDswEkwU-V1_i6DzMeew" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Narr_BC3mb5FPBk6FTNfofFYB0A">404</ix:nonFraction> owed to related parties, respectively)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_iGU9i-HcZE26BoJKgs9Yag_18_3">39,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_vrNEbS_j-0uWpl7_zpkd1w_18_6">17,306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_S_uH6MibhEmcy7x8zvC7rw_19_3">785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_yL0VsMiYf0K2u1ArVRX7Uw_19_6">556</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc__hoBv-R850SIUnRXOi5VWA_20_3">57,292</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_XnSfIedC-0WImHXsntuY9A_20_6">23,258</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_0WsLt-H9C0aG3ghBHKww0Q_21_3">218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_KV9Ue00XUkyYqJqJGZ-uTg_21_6">257</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Convertible notes, at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" id="Tc_2HcMjgextEyse0umv7D3Bw_22_6">20,300</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_Nk1gjnBxY0m9P46XRL91hw_23_3">57,510</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_rgrFCpR_wE2JSVpE1D1RQQ_23_6">43,815</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;">Series Seed convertible preferred stock, par value </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_ZZdmbsT2GUmk3Mr7K_1wcw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_ywEHHvSO902MFN2_jPD2tQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_j1kzYdDl0EC6keKfHbjLWA">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> per share; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_ywEHHvSO902MFN2_jPD2tQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr__jblQQSogUmRKQ0BDst49w">0</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_qMV7iOHOyUKhNa9g6Iebwg">1,785,714</ix:nonFraction></span><span style="font-size:9pt;"> shares authorized, </span><span style="-sec-ix-hidden:Hidden_tse8iP5LeU69vjWcjdtpow;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_F93rW4YniU-isgi4W6XJYA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> as of </span><span style="-sec-ix-hidden:Hidden_rI0dKlRWL0ul7X3z9V1xFQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">December 31, 2024</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_M56D618pS0enhKGKHqPd0A;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">2023</span></span><span style="font-size:9pt;">, respectively.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_aJxcB-ypwEG30c-AL73Lew_26_6">956</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;">Series A convertible preferred stock, par value </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_p50s0gjNoECY3d5Tq4MNpw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_-xEDVh4-qkqlm3ytowN9Zw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_yWiGucHDfku-u1HjtilHbg">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> per share; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_-xEDVh4-qkqlm3ytowN9Zw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_1MNul9bKlku5YAapC3Y9cA">0</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_KFESHUwe3EqijbjFlZ9B_g">17,589,380</ix:nonFraction></span><span style="font-size:9pt;"> shares authorized, </span><span style="-sec-ix-hidden:Hidden_JnN4uMYIgkCjRU4tOzxuiw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_vdtRe09mgUqM8NRIjiuQ1g;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> as of </span><span style="-sec-ix-hidden:Hidden_i15PFzsJrE-iCOvEYrCCgQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">December 31, 2024</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_0P5EwUDT8EyCGvpmm1IS7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">2023</span></span><span style="font-size:9pt;">, respectively.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_c5KPS5YUkUimqpAUXMk-EQ_27_6">55,840</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;">Series B convertible preferred stock, par value </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_0G9xtNA6fUKNWPL4qvZI9g"><ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vZWP1gyCtEu9w9OaIMGbpg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_lIMuDiODNUOQ03WizrY9rw">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> per share; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vZWP1gyCtEu9w9OaIMGbpg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_GQM7M3soAUy8Kzxtekvhfg">0</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_tdSoP_aUo0uMZaVoHWN6ag">81,242,587</ix:nonFraction></span><span style="font-size:9pt;"> shares authorized, </span><span style="-sec-ix-hidden:Hidden_f4mwZhVtbEuTypHhSfyNFQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_l5gOCjZrikynZQNbg-mghw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> as of </span><span style="-sec-ix-hidden:Hidden_Ra8EPcJLvkyQ0y8ZKYex4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">December 31, 2024</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_3dAB6-rVS0a4E97pEhf7Sw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">2023</span></span><span style="font-size:9pt;">, respectively.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_Y-W1YOE2pkm4qh77Tz7qxQ_28_6">193,290</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity (deficit):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;">Preferred stock, par value </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Gs_oC417Z02bP-2x2JIQvQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_FaOJznPhHEiAoK7ouLeQ3w">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> per share; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_PPQ1Yu_WE0SGlhNntmpVkQ">25,000,000</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_VttpHrPuBUSgpDKjk2Zk4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">no</span></span><span style="font-size:9pt;"> shares authorized as of December 31, 2024 and 2023, respectively; </span><span style="font-size:9pt;">no</span><span style="font-size:9pt;"> shares issued and </span><span style="font-size:9pt;">outstanding</span><span style="font-size:9pt;"> as of December 31, 2024 and 2023. </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qnhQqOYVT0yoQAvJgJA5vQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_KM8jL8QJ50CvOax1NG6sbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;">Common stock, par value </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr__qvmwW56fEWgwEjxpn721Q"><ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_9zqjV3V3sEak39jsSKhZ6g">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> per share; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_2NTFJxLUs0KBSMX-aT6PdA"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_mmr9Zm1m50GT-F7lWddNog">175,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> shares authorized as of December 31, 2024 and 2023; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_kHn4YGdxOk-YiuPp-oFVrA">41,793,412</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_BrpUi2jxA0iArJpjpm8FBQ">1,576,854</ix:nonFraction></span><span style="font-size:9pt;"> shares </span><span style="-sec-ix-hidden:Hidden_E6IzMDPGE0WVp6F4hT3pfA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_8h-g-kbq5Uie_MXjyiAoRw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> as of December 31, 2024 and 2023, respectively.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_4Ia6xUfMb0GT_ljYaThksg_31_3">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_6eh9UAmm4U-Kf9WpgBhtbA_32_3">699,651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_OMVeGttDQkqMyYEHyLb8TQ_32_6">4,645</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_tVrmxxCBY02zdGuA5Jwf0w_33_3">194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_X2-rsaXTU0SDzXu1UwGlxw_33_6">37</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_7mpg5HMSm0yUA86AAv9sDg_34_3">387,391</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc__7NAlFCmF0Gafb4v7Mryyw_34_6">230,403</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total stockholders&#8217; equity (deficit)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_r69cTKmwN0uqlXMAQ20h-A_35_3">312,458</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_epMn9TrQa0Ow7q8OLE3rZw_35_6">225,721</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_yErOtmaeC0ypVic-rvTkdA_36_3">369,968</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Fa2D4kZvZUaSOp3oIIchVQ_36_6">68,180</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_50f822e3_3bc1_45ec_a1df_a46f6ad47728"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Zenas BioPharma,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="CondensedConsolidatedStatementsofOperati"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations and Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><a id="_88fa222b_554f_4f49_b9aa_147a0d212eb2"></a><a id="_202dcd4f_0a09_4863_b881_5f9e2d366d46"></a><a id="Tc_-bNMkxGX_0qwLAcqb2EW1w_2_3"></a><a id="Tc_TCn-a1X4FUK8QhyZYXR0lw_3_3"></a><a id="Tc_eJ3upswsaUaPPVLRvcHNXA_3_6"></a><a id="Tc_u6GpM1GDQEG1mKEikZ-QKA_4_0"></a><a id="Tc_yKxiWXx4PEmYP1Yjusy3DQ_5_0"></a><a id="Tc_YGr7s6f-yU-SId5KS7k3PA_5_2"></a><a id="Tc_YQ8O1xf3DU6KbsJ71tlyCw_5_5"></a><a id="Tc_AclRTDruuk2wTrQLcnUraw_6_0"></a><a id="Tc_ap4e5msWI0WqO2iwxpkgig_7_0"></a><a id="Tc_05NB0iySm06oAJraVbRESg_8_0"></a><a id="Tc_ZcFhbQx330OVrU9Po5iYMA_9_0"></a><a id="Tc_62ZXlx9cSUW7YiJqtHnyVw_10_0"></a><a id="Tc_nNMQXATeIk28cKvSPHHEIg_10_3"></a><a id="Tc_Jg3hjSh_c0qpB8AhNMu9CQ_11_0"></a><a id="Tc_YFGEv9dxf0aymVFdG1kvzg_12_0"></a><a id="Tc_QTLTXu8Dm0qqHEYQLk5vaA_13_0"></a><a id="Tc_AvhFp-qRkUyBfT7LsqxccA_14_0"></a><a id="Tc_qDj5ZTTJgU-A0OF-SHM6-Q_15_0"></a><a id="Tc_YHUjkpQPQEqZqKMLlsqgHw_16_0"></a><a id="Tc_JJYHhbRM80meOtg3NoSC8A_17_0"></a><a id="Tc_5ou8OG7IxE-9BC631IqaYw_18_0"></a><a id="Tc_i4mty1GjUUiZPN04VuiMlA_19_0"></a><a id="Tc_25m4V7xImkihYgRP33QfHA_19_2"></a><a id="Tc_PPg4-IppfUKIEHqEe7Uccg_19_5"></a><a id="Tc_ZRlBXHuHwEO1hVJFWcjYCg_20_0"></a><a id="Tc_Si6zuhskcE2vT_mH-3qrdA_20_2"></a><a id="Tc_RXs5N_cWrUSh7PE38NDvuQ_20_5"></a><a id="Tc_bH9Zq9Xl8UeHTETrP6GAaw_21_0"></a><a id="Tc_vpHGI7aBZkGWHNQkzp7_5Q_22_0"></a><a id="Tc_YfnmzhJ1Bkqkm1xXChQb6w_23_0"></a><a id="Tc__hEVT9d3ukK7i4aKSU9O2Q_23_2"></a><a id="Tc_-qXatMt560OPZ5mWtrJdpQ_23_5"></a><a id="Tc_d1p44BO3FUC5VZEfEF89gw_24_0"></a><a id="Tc_A0-Z9HybvUWM96Cg9bZ04A_25_0"></a><a id="Tc_CGvquFt0PUC2clZ4qs2QOw_25_6"></a><a id="Tc_Q4rmfLIfj0G3y1OiSb2yLA_26_0"></a><a id="Tc_3ZC6b8fr3Ey_5QdIA6kpBg_27_0"></a><a id="Tc_Vdk-LwxUWkqa7q1zVirM4A_27_2"></a><a id="Tc_iKD-8har-UOdERFWIjDwjA_27_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:33.31%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">License and collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_0QCKQDQX3EuLzud_995owg_5_3">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ry6Gpm9zC0KPeRlv_UZJSg_5_6">50,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_U9LihvG64EaQd9YXek6d2g_6_3">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_qwh-PKCiBUGmC3ig-YMI1Q_6_6">50,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development (includes $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xmuQWu9BX0O2k_q1aI5KuQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Narr_Vttsx7pR2UiXHlayamjZsA">3,524</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_98SvbTRA50yOezeZ029LuQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Narr_QxwyD6JPA0W1ZV8h6DFnuQ">3,041</ix:nonFraction> from related parties, respectively)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_6yzEtiGOP02ywnaWBuu_uQ_8_3">139,139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_61BoCZY5N0OWioLBFqmTbg_8_6">60,033</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative (includes $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xmuQWu9BX0O2k_q1aI5KuQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Narr_qcEo5eHh2UCyU-6kC9kLxw">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_98SvbTRA50yOezeZ029LuQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Narr_gZxHHmqUwEic0JH1a7ywqw">8</ix:nonFraction> from related parties, respectively)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_5EOQMeRL2ku4iWHv0CptMQ_9_3">29,749</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_EJCmd8DHSEO9wEc8TkF3kg_9_6">17,114</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquired in-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" scale="3" id="Tc_6XcGeKtxwkiBLERz6xljwg_10_6">10,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc__fj_ZU4o5kyGBId5J1fIkA_11_3">168,888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_T98nKwKuokOnNinWtuDkEQ_11_6">87,147</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_vz1jPy9avkOagrKZUiKnQQ_12_3">163,888</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_PaqH6omOokGGf1VjX457cQ_12_6">37,147</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income, net:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value adjustments to convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="zbio:FairValueAdjustmentOfConvertibleNotes" scale="3" id="Tc_iEUyQ7xnlEqHejoy610mFg_14_3">846</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="zbio:FairValueAdjustmentOfConvertibleNotes" scale="3" id="Tc_su_9mLFNxkaJBSADcaG6Jw_14_6">300</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_kpOOds1WSEaUskPA_g7Y2Q_15_3">8,175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_3rQZVD9YV0O-mOkTuuFiEA_15_6">624</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_-YSqJSuT8EGPt51CLMARgw_16_3">7,329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_YrG-icH3eEy9zS16I24eRg_16_6">324</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_MJEiC2RnuUO1kh_yM-gbyA_17_3">156,559</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_nEy2HRIa3UGYq0Xu63HtQA_17_6">36,823</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_e-OzMBdxUUyIfpQwTvgFlw_18_3">429</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_voHfLh5xdEq3RKONuW2CAQ_18_6">301</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_JcEGg9hPv0yzbOVVSkIXBg_19_3">156,988</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Nl77dDvRrU2pqWrBZW46NA_19_6">37,124</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share attributable to common stockholders - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_eG5afOEms0OWuYlduzt5OA_20_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_eG5afOEms0OWuYlduzt5OA_20_3_2">11.89</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_hdFu88UFwkCRS5IFRZuZzA_20_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_hdFu88UFwkCRS5IFRZuZzA_20_6_2">24.25</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common stock outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_d74cRoLRDki55VoEbPBaqA_21_3"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_d74cRoLRDki55VoEbPBaqA_21_3_2">13,198,960</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_2CElUignekqeyqrBBLUcvA_21_6"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_2CElUignekqeyqrBBLUcvA_21_6_2">1,531,178</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_r_bdIv4VT0KtrbOBQqozsA_23_3">156,988</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_VdeBvB3I5UCIukJiNaEigw_23_6">37,124</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Unrealized gain on marketable securities, net tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_E_oxkcQG9UChtdGnSTAxcg_25_3">31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_BB9KvbNB0EC0MuHqxHR30Q_26_3">126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_bgSx2G1a2Ui7ieWQ_1nOOg_26_6">78</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_RirwhnGXAkW34JRAZEryXw_27_3">156,831</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_IEgYXQmSWEagMUDGXcGxug_27_6">37,046</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9902e615_e4c5_41b9_bc9c_3cbe5308609b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Zenas BioPharma,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Equity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Changes in Convertible Preferred Stock and</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; Equity (Deficit)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9d22985b_50d5_4348_b953_b38df4dac2dc"></a><a id="Tc_0Cs2Q4-gT0eug1_mQgyitw_2_2"></a><a id="Tc_DwyMYEovP0KcMarVo_4QyA_3_2"></a><a id="Tc_cFsyJ5ez20O6WJ0ea7a0pg_3_7"></a><a id="Tc_tdPww81dlEqj9hLC8HjmLg_3_12"></a><a id="Tc_qMyq9WAsyk6ZjWU63w2ikQ_3_17"></a><a id="Tc_xU0ol3QiD0idH7ZQevn88w_3_21"></a><a id="Tc_BESMnfrVT0SHAK3tZLLMEg_3_26"></a><a id="Tc_L4mgPFvBBkaaW0D4YOf0Kg_3_29"></a><a id="Tc_qZs2G9Zbq0CePwmElciFPg_3_32"></a><a id="Tc_cgav5pdtWUeJTLeATIDw7g_3_35"></a><a id="Tc_m4Gjvf_bUUWPk_bC1-MRiA_4_2"></a><a id="Tc_prdIWWespkKrZNilmjW8rA_4_4"></a><a id="Tc_YIeaxlyQBkev9kTgiNLx8w_4_7"></a><a id="Tc_FBIf5-OttEGoBD3Xf16seA_4_9"></a><a id="Tc_JW-bF0H52EeYmm8GaMeNCw_4_12"></a><a id="Tc_culcwKtlC0CnuJeinV9tvg_4_14"></a><a id="Tc_MGXgwyAdMUar7-6wP8KQVg_4_17"></a><a id="Tc_1rxi3qO_oU2yfHZf-vOyWA_4_18"></a><a id="Tc_roZCZSmgOkOobcQTj-sYsg_4_21"></a><a id="Tc_Nf9O4xT5GkyjNWsFC8LGtQ_4_23"></a><a id="Tc_29Nb1C5TVkazUOkshgV8tg_4_26"></a><a id="Tc_P57xQ7xB4kyETI2-LNInEg_4_29"></a><a id="Tc_nFcqP1Mta0-qq95rJWPW8Q_4_32"></a><a id="Tc_BmQfNE3TPEC1Ipj8-Al8hg_4_35"></a><a id="Tc_GwoNs8NICECGeeEDMqnCuQ_5_0"></a><a id="Tc_M53B2CebG0SIawExXKUq7Q_5_4"></a><a id="Tc_0mIerkKW9EuFrWfZHw_pdQ_5_9"></a><a id="Tc_iqsUzcvGm0ukZU_Dk5X2Kw_5_14"></a><a id="Tc_l3MhdX5Da02J1WZdwN9LWg_5_17"></a><a id="Tc_4DoZit9r2Uqw4a1ZUGlRNg_5_18"></a><a id="Tc_oIKqXObnS02oA2BtVQh9Zg_5_19"></a><a id="Tc_Xw2T37fWokiyClZjO60b8Q_5_23"></a><a id="Tc_VpTnxL3GhU2-6qQUAMFazw_5_24"></a><a id="Tc_GMiUnRhK5kOfg9Im-ZalEw_5_26"></a><a id="Tc_s5gfv4A1wEOXTKYvojrNtA_5_29"></a><a id="Tc_snGAcXj9_EaTdtJD3FTY8g_5_32"></a><a id="Tc_qPfpr3HISk6rgvTkbXOTiQ_5_35"></a><a id="Tc_kAekFE5wgkGcYTyynCbACw_6_0"></a><a id="Tc_GU2pb3GsyE-YzKErdD_vuw_6_2"></a><a id="Tc_61hMjTE3b0yi3PlV0uyM5w_6_5"></a><a id="Tc_evvTdQOJAkCcWg4nHgupMw_6_7"></a><a id="Tc_UEgNBSqtukm0XkBwRs7J-g_6_10"></a><a id="Tc_WGEYaQtWiUWxQlV3nqv-Yw_6_17"></a><a id="Tc_YSVN_Bv4Q0yuTKF5rqnQLQ_6_19"></a><a id="Tc_51nrTgMlGUe6uDjMcHBZ_w_6_21"></a><a id="Tc_5xj65odpmEG3i4nkcoOnvQ_6_24"></a><a id="Tc_02OwlkvchUq8kx4BdYMovg_6_27"></a><a id="Tc_pEy5Z2jtmkqYBuM1VthUrw_6_30"></a><a id="Tc_16nySY-wB0ax9gcF9bmzTQ_6_33"></a><a id="Tc_iIuCpPIRgkucgLJTexBEuQ_6_36"></a><a id="Tc_6OjOvR8kZEmjXH587p0GEw_7_0"></a><a id="Tc_YMQpOdyuyEu-_n8ZrqJKTw_7_2"></a><a id="Tc_QfiD2qT_Nkapap6cHHHNOQ_7_5"></a><a id="Tc_VEX5MJQkv0-KqNzuB9NH-A_7_7"></a><a id="Tc_pJwYqXMSGU6MJgApA1KNRg_7_10"></a><a id="Tc_aVjRLOUFXku21NMNpBmpbQ_7_12"></a><a id="Tc_tvJsFUtoNEywYiAYUPt2aA_7_15"></a><a id="Tc_1H3qHUcveUyGr-7CVBpGCA_7_17"></a><a id="Tc_qfdxW0zgu0aUR_LAcMdgTQ_7_19"></a><a id="Tc_yzefe3r3jUSO80k8HoFp_w_7_24"></a><a id="Tc_nqn1ZU8dG0iFYE4whxqi-A_7_30"></a><a id="Tc_Tbh6kg24oEeKzfZPshhyxg_7_33"></a><a id="Tc_5tsxDGTaf0SLsnhrd0qc3g_8_0"></a><a id="Tc_0GwpCyMvx0-cBbR7mfXuww_8_2"></a><a id="Tc_TWMHwN-YRkehYgIzIdXfGQ_8_5"></a><a id="Tc_pXKnlLSc4kKeUGuYqr2KrQ_8_7"></a><a id="Tc_wk8LFM6gmkO_wQkoeUd8nQ_8_10"></a><a id="Tc_957imb6fCE-wyBTp0YhodQ_8_12"></a><a id="Tc_NzDwr-BiiUSJnDIoumFnWQ_8_15"></a><a id="Tc_6ovfV7mIKE6FNvHhbRQIWQ_8_17"></a><a id="Tc_lYA_qyTE5kaTLAEGJptZ5g_8_19"></a><a id="Tc_sok0f_TZn0Sd4KdCAiLFrA_8_21"></a><a id="Tc_qXRkL-7B7kiJy_WpRP07OQ_8_24"></a><a id="Tc__VkWFzq4WkOHXE9JeKDzWg_8_30"></a><a id="Tc_UvEnPBi6hEqpOtC8w1q2vw_8_33"></a><a id="Tc_UOkstaDsUk2RVOD6cAz7Iw_9_0"></a><a id="Tc_FBTr1Ur_1Eu7E-LX53MDwg_9_2"></a><a id="Tc_EuPiCZ3_ZEyDogKG1pegbw_9_5"></a><a id="Tc_4Em7cs7tDEefUiYT6B3wFA_9_7"></a><a id="Tc_796XCrLV4UuPrhXnvpbLJQ_9_10"></a><a id="Tc_Y6-b5_ZAkEeiTFJet8miCg_9_12"></a><a id="Tc_YsJbOabrQkuVxlypmVwmtA_9_15"></a><a id="Tc_DSYn-slgaE6S9GQPCagIBw_9_17"></a><a id="Tc_2i8pxQ9OXUWdEK2S_mEBSA_9_19"></a><a id="Tc_YiEXeXkkp0a5PGTJ90aMzw_9_21"></a><a id="Tc_VdTkMxRIMkOduNsThBDxVg_9_24"></a><a id="Tc_-rW3Lz0VJkao_vQbCJt-fQ_9_27"></a><a id="Tc_XVck5DtqCkafOHuNLzw5pA_9_33"></a><a id="Tc_gkKK7pS1_UW4xFkaQFBorQ_10_0"></a><a id="Tc_oUiBu0fS10-_QoZyU-t7DQ_10_2"></a><a id="Tc__jPZ7wcYkkmARm1tJvgasA_10_5"></a><a id="Tc_nEo8GcNa_EGhQ7rJ5iabGQ_10_7"></a><a id="Tc_7qzuYUf2rUyYXcTCbKqyag_10_10"></a><a id="Tc_mBKUz3Kf1Emfsg1Dfy-KMQ_10_12"></a><a id="Tc_GA1gKN4lEEiAlBs0Hq5ExQ_10_15"></a><a id="Tc_6VNKy2O0OkuWLJLY5FNODA_10_17"></a><a id="Tc_5g3n2mrsTk2LXO1FR3y9XA_10_19"></a><a id="Tc_hOvGeB-5G0GonRtztv6rLQ_10_21"></a><a id="Tc_GTGD4fwGF0qEJExwf_A9Nw_10_24"></a><a id="Tc_TGmsbhB6rUyTnLAVtJ-jlw_10_27"></a><a id="Tc_yfbo9W7L-U2Aht3FMARF5Q_10_30"></a><a id="Tc_Zr6PJNIT0kqVP4j61-fn4A_11_0"></a><a id="Tc_EnOk22Hvo0qFttPDhG1QTQ_11_4"></a><a id="Tc_m_sd3mod6k2vZDInPex26A_11_9"></a><a id="Tc_5budH4NH1E29tClaQE2PMg_11_14"></a><a id="Tc_lhxhXUPrM0q_BJEU7KY87A_11_17"></a><a id="Tc_PN6rxeufz0-Eo2uT71CmlQ_11_18"></a><a id="Tc_4jVUdUlq8EuUNR9MV6ZDZA_11_19"></a><a id="Tc_MFfLZFiTaUeaOaLVTItCjw_11_23"></a><a id="Tc_DKXXk1RsoE2j9KZSqKEbRQ_11_24"></a><a id="Tc_T2pP20-r6EegEvxuI2LdtA_11_26"></a><a id="Tc_l5ws_okjWkKYDspM8oryHQ_11_29"></a><a id="Tc_Bezr5f7Mf02OKP_jRrDReA_11_32"></a><a id="Tc_YgI4_20IbEqADEhKgml_NA_11_35"></a><a id="Tc_n6O6g5C560OmDM6MpR8q_A_12_0"></a><a id="Tc_thmh4_edAU6X8l-fhnyb1g_12_2"></a><a id="Tc_Br5Iue0W-0SrN5zLfFLBLw_12_5"></a><a id="Tc_ihv-ZXJMVEqdTe-zzITMEA_12_7"></a><a id="Tc_OyoQVHQqikKqLC8JZMFBrQ_12_10"></a><a id="Tc_z185kInKZUa1cRuOIcSLxQ_12_12"></a><a id="Tc_czsf18qS1EiRbjRn4zA4cQ_12_15"></a><a id="Tc_lBNyqHLQOkquaOQC9_gwag_12_17"></a><a id="Tc_LUpC4RR0SkyB-OYiupHaXg_12_19"></a><a id="Tc_SCI8zjb7JEq7aft0kCvMHQ_12_24"></a><a id="Tc_vtpij_NcukGuepp4cRzfHA_12_27"></a><a id="Tc_PgTvkoOPfkWrg8zSJCmsFQ_12_30"></a><a id="Tc_yF88uLG3gkq590N2juDQkA_12_33"></a><a id="Tc_BpaSvB51MUma0GwMMeWrdg_12_36"></a><a id="Tc_rPEvUDDhQUWsYHaGJVwaZQ_13_0"></a><a id="Tc_wFc1SHNR3E6CGZwzRtLJ7g_13_2"></a><a id="Tc_Ebe-efkxHk2q-9nfa6qENQ_13_5"></a><a id="Tc_J_ba8ioEn0yqPQSFw-WMjg_13_7"></a><a id="Tc_kkDKkg-y-kih6NxpxkPKog_13_10"></a><a id="Tc_oDEzf5-0-UCdyL4Y_buI4w_13_12"></a><a id="Tc_9Lq6ozk5Qki2daJJcQmsyQ_13_15"></a><a id="Tc_uSOhc9RYRkyjHVhcLE__pw_13_21"></a><a id="Tc_J8-yZhbDmEe52GCiqb9h0A_13_24"></a><a id="Tc_mOveK6rQekSEYuWNFIR7ig_13_27"></a><a id="Tc_8wejnrTkrEaLQrM1zuHM2w_13_30"></a><a id="Tc_0f3TEyO4HEeaUwIpuFB4jg_13_33"></a><a id="Tc_y6QgNQRIsEWGRPcZxffLcg_13_36"></a><a id="Tc_g0GC1Q_UdE-yCQltv1-RUw_14_0"></a><a id="Tc_87bgGqxdEkKwFi4ETRmoDw_14_30"></a><a id="Tc_vQpr4d-3HkOvthwGMd6IOA_14_33"></a><a id="Tc_UvE7JpXJ6ka3p99ejdpneg_15_0"></a><a id="Tc_eDoR1oDiNUysByCGy3rAOg_15_2"></a><a id="Tc_QthwCDNp4E2_C-eatX8MgQ_15_5"></a><a id="Tc_LkGXIf87E0K1jAt6OueS4w_15_7"></a><a id="Tc_ijgLJFwE_UG_kj6kBbhCyg_15_10"></a><a id="Tc_OyJrGnDQJkWrnZY5nY8MPA_15_12"></a><a id="Tc__AAIVC7bQUqJt-ctvnDByQ_15_15"></a><a id="Tc_RJUlzz8vkUiy6-g1ZtQQ6Q_15_17"></a><a id="Tc_ZvSEqgOxEUS1ASafJ3mLTg_15_19"></a><a id="Tc_qgkaOzKLNku-iD-LI8s_uA_15_30"></a><a id="Tc_xKOGyYc87UiDKA3qYLEbSA_15_33"></a><a id="Tc_50r9Ho2dckOcTt6sQPe18w_16_0"></a><a id="Tc_irfRpiJp90iVj_t7zycHjg_16_24"></a><a id="Tc_3HIIzpPmrUihIcRis5sBCg_16_30"></a><a id="Tc_9vy-TY1Dr0CR6c2Y7hPwNg_16_33"></a><a id="Tc_KT7dWwjXMk-nim5jn7QQrA_17_0"></a><a id="Tc_VqYd4KR3g02J0ERR0gis3g_17_2"></a><a id="Tc_I_ZmRKDW_US6EoKbonWJiQ_17_5"></a><a id="Tc_dVRL0mMuMEyT84X1mNuxCw_17_7"></a><a id="Tc_8Edx3-Prz0C5-NvbSsSzpQ_17_10"></a><a id="Tc_x87g2fTIbUSfdHcXR4hfNg_17_12"></a><a id="Tc_DhTouE0kX0qf84Gd7UHcAQ_17_15"></a><a id="Tc_q32FFJGNkESJLe0m_9rz9g_17_17"></a><a id="Tc_cDd_1JIghUCzhV4bELO2QA_17_19"></a><a id="Tc_6YQWMHqgpUiqRHAAYZWzuQ_17_21"></a><a id="Tc_X3yLROMtlECwSdnCwKLPvw_17_24"></a><a id="Tc_R6PUyvMmdkq0mDOcdrFHZg_17_30"></a><a id="Tc_hPq3JMj-vUyJ4jYZhyipvg_17_33"></a><a id="Tc_OqhVQdsBOEKX3p20Ed3FZA_18_0"></a><a id="Tc_QeqEMlv6_kK9CPyfLeT3bA_18_2"></a><a id="Tc_Tbuf4Nh-WEu0lMW3TUgoCg_18_5"></a><a id="Tc_4BN8jUGY3UulARZxh2kytg_18_7"></a><a id="Tc_rGkUz4HIN0C4p01fTnoT4A_18_10"></a><a id="Tc_5hjBwmBYdUCLtoX47_90zA_18_12"></a><a id="Tc_bYSUpKoGlUa80WtY4f9xzw_18_15"></a><a id="Tc_efXtUxfb0k6JsMgrpmNk8w_18_17"></a><a id="Tc_NiKHiUfx30O69lAqP9-cWg_18_19"></a><a id="Tc_ambE3qh61Ea7H6Ss9EZ2_w_18_21"></a><a id="Tc_uHv_anr_xEiS5XOQgJivWg_18_24"></a><a id="Tc_bbSIPswzz0SJ-uHQ6CP7jg_18_27"></a><a id="Tc_I08ILWCDyEKTQ_duq9zXxQ_18_33"></a><a id="Tc_vQvzparJO0-qLOrUTV2Mew_19_0"></a><a id="Tc_6xe8LTs6J0e7b-YfzzWTlQ_19_2"></a><a id="Tc_CBXI46l27UqAwTZ3IhyuIg_19_5"></a><a id="Tc_ry-Z8OCZjEeWwI2efAce9Q_19_7"></a><a id="Tc_nyV0u958ekuHFZpH6rsMyw_19_10"></a><a id="Tc_H2IC1DicG0K16JbS5lse5Q_19_12"></a><a id="Tc_2SDER9-j50uXur9xQ8piFg_19_15"></a><a id="Tc_gOf0aZDBg0aMRqkETC7yFg_19_17"></a><a id="Tc_TV_H6rmUi0KhrcV823ZEtg_19_19"></a><a id="Tc_4YJDvjC_uE6zpRusEC8mzw_19_21"></a><a id="Tc_JzanSP4WBUisAAZh1pBwDQ_19_24"></a><a id="Tc_ehmxIodznkSnfvhA4VMs3A_19_27"></a><a id="Tc_DqEfO05Yk02jrHFDCaVAjw_19_33"></a><a id="Tc_FTm2LrG6t0WRuiaGWpm-2A_20_0"></a><a id="Tc_QyGGRttp8Eee4YH8KkuGsA_20_2"></a><a id="Tc_YgXr5-Ivh0qR62Vpj35Rpg_20_5"></a><a id="Tc_aujYgD360U64-956eyp6yA_20_7"></a><a id="Tc_LIxmtoHIo0GDaTBsvKg73Q_20_10"></a><a id="Tc__SyxxwOaoUOpfU5dmH5Dtg_20_12"></a><a id="Tc_iWay98Opw06gLIMZ0VlH-Q_20_15"></a><a id="Tc_njC-V-rrjEmZ_y5ohu_ssQ_20_17"></a><a id="Tc_PyuWD8-MA06Ayi6w93i2Vw_20_19"></a><a id="Tc_sU_6xrvOi0ugJ_X-AbR2jA_20_21"></a><a id="Tc_9eVAethJFkqzdJqS_Q3CFg_20_24"></a><a id="Tc_KzDa7GOwCkmx1-pBJb9c4Q_20_27"></a><a id="Tc_isDQZHtGpEuPIMJ50zcFAA_20_30"></a><a id="Tc_EeOT4gZM3kOaOV-6UIPSYQ_21_0"></a><a id="Tc_KYUtfGVTs0W4F6iPD2IXyQ_21_2"></a><a id="Tc_QfWNdsEWdUWgOH_VYsbbrw_21_4"></a><a id="Tc_BH_wy2PMok63DCcnDNtNpA_21_5"></a><a id="Tc_3S7YMDqkckOC5TyDbR807A_21_7"></a><a id="Tc_0y0hszYeSUCmMNZQRL2PPQ_21_9"></a><a id="Tc_uO-n4F0OUkqHi2rb8QEy8w_21_10"></a><a id="Tc_Latb33VMbUWCzMUS0yqOAw_21_12"></a><a id="Tc_LkpE7WL3Qki76S5L7_PKYA_21_14"></a><a id="Tc_5QizwsbEjkOx_2CW_s3GFg_21_15"></a><a id="Tc_uFLek1zpZ0KjO1flHm0TwQ_21_17"></a><a id="Tc_eMe2qWnHhU-RmcWVhlczCw_21_18"></a><a id="Tc_o_6ZPgCZc06cT6r3QQD5zQ_21_19"></a><a id="Tc_a8uWaxFc7EKxf-CcxgCc0g_21_23"></a><a id="Tc_p8d7pVDqAUqDYtb139WlFQ_21_26"></a><a id="Tc_6vnJn_WlvUa7-xiCVVIQsw_21_29"></a><a id="Tc_JtplRq5ZHUSmgUl9AmgDDQ_21_32"></a><a id="Tc_8b-Vzcaxj0GuENcxAKIzgQ_21_35"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="23" style="vertical-align:bottom;white-space:nowrap;width:54.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="18" style="vertical-align:bottom;white-space:nowrap;width:43.02%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series Seed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C</b></p></td><td style="vertical-align:bottom;width:0.48%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b><b style="font-weight:bold;"><br/></b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional Paid-in</b></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated Other Comprehensive</b></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Stockholders' </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:4.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:4.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:4.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:5.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.56%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:5.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income (Loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:5.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:7.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWOR2Y6eb0qw6h_ECNiCyQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_Qz_yjSvFZkWQCm4Ha3BwLA_5_2">1,785,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWOR2Y6eb0qw6h_ECNiCyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_q1gUlxh1J0KeLgCOu8Werw_5_5">956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-zW7TSnNlEOWNVAWJEAmqg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_2FbEEOo7_UmnEAHagwSEBg_5_7">17,589,380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-zW7TSnNlEOWNVAWJEAmqg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_QMkOqJ_-tk2SLh68q9mL4g_5_10">55,840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zyuRWER_rEGXi84E3qArrg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_aWibbqrx9kaZmHGsgg-q8g_5_12">77,052,632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zyuRWER_rEGXi84E3qArrg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_HrsXXQeOM0aDKQt57JJqGw_5_15">183,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MtK5qqSc7EWFj3hxdd6E6w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_1W5GrBuPK0OuSeqYjJSl3g_5_21">1,549,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Uz8_I3wLr0SnQHkp_bKCXQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1yQpduisOU2fo0jUtQj2lA_5_27">1,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_nl_IrRmKGUmQBClrdDVOTA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_zH-_cB1k3EuQhjks1wVYVw_5_30">41</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uUos0deBaEyEN6bFnRun4w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc__MZ8eXjvEk6omNGlgMmnTA_5_33">193,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2022_7aoYVm8LsEqvEfiPlkF4lw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc__WAIGlWSbkyU7F8TzwYVXg_5_36">192,286</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series B convertible preferred stock as payment of Xencor milestone, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Gh9QtBp7z0aJp2U6HTSmvA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_0_fcEs6d-0a4bpLoKvJdOw">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Gh9QtBp7z0aJp2U6HTSmvA" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_UIokQpT1-EqecO6roJPd5Q_6_12">4,189,955</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Gh9QtBp7z0aJp2U6HTSmvA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_0XKjwtp6PU-G6TZIsIKEYw_6_15">10,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Exercises of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mWc24hPae06GpXVuJlDs0Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Ie-85q3xIUiGCGHyTZb3Hw_7_21">27,579</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QXQPHb61tUenoW1KiYC_bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_7jLxxYIs4EK-l78q57dhMw_7_27">116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_gkjSIYyiUUuDESwSqSdxzQ_7_36">116</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QXQPHb61tUenoW1KiYC_bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_BkqUE8EPvkCm8XiJRI98cA_8_27">3,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc__DrflBBFs0OpERRIZW9pHQ_8_36">3,495</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_03uBPrMelEOQgnXfrO0Rdg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_FfO0nsvm2ka8ntNB6lp5ew_9_30">78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_SY16GtSHvU-oOywGQP5YNQ_9_36">78</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I3LY6QQrkkmN4CYZS5IM0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_z_FdZp5GqEaY4noZT0ZcXA_10_33">37,124</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_nMZRwq4Cmk2Fz4lhFwIhew_10_36">37,124</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ocu-YDmfGkytPLv371WO_A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc__8EYxVshBUySAXqSmb_-iA_11_2">1,785,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ocu-YDmfGkytPLv371WO_A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_-s6v26if0U-0Yki3EoR9NA_11_5">956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xCsVy9CxU-Q-Ca38CHdgg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_nRr18LihSEWNBUgySrYEVg_11_7">17,589,380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xCsVy9CxU-Q-Ca38CHdgg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_H7LohFDz5E-EUyk5wB0Eow_11_10">55,840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mIxda3QBT0eGgkr2-TLdAg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_NUuSiF1fz0C7XmRx1dZy2w_11_12">81,242,587</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mIxda3QBT0eGgkr2-TLdAg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_RHc0cwDHc0ekKy_yv-NM7A_11_15">193,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0joMr_rkEkm7x1ZuVCT9ug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_bEfcX_YgEE2KzJPr4Scoiw_11_21">1,576,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tGb0cUxC9kK9Z8w9yezpew" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_OFEldAWgHkm9hsKIPN908g_11_27">4,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PBJ1X1nFxEWp13l1OkKMvw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_w3EehagmtUqoAW8Rx8UT7w_11_30">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vq8gJuFgxUeW6Sum5gLP_A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_rIvzxoZ2kkSCrmxDGfJ-xg_11_33">230,403</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_LCoRFQIcq0S31RZp2hLRxw_11_36">225,721</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Repurchase of unvested restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="Tc_joLmWxI6BEKZ3gkHt9IE6w_12_21">21,172</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series C convertible preferred stock, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-I220YjrTES2zT0dh6nXJQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_caA1lAxck0uardGssjA68w">619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-I220YjrTES2zT0dh6nXJQ" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_jn4vMLAackK1UPdxXJrZvQ_13_17">116,275,239</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-I220YjrTES2zT0dh6nXJQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_yc87UVIBu02gSH-cEFT0Ww_13_19">199,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of convertible preferred stock to common stock upon closing of initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2PJ0fHjSGkqSUHx6Zr4K0g" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversion" scale="0" id="Tc_dROJHeVcpkaTStgTCl9r2w_14_2">1,785,714</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2PJ0fHjSGkqSUHx6Zr4K0g" decimals="-3" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodValueConversion" scale="3" id="Tc_n1nWr6vWZkWrgWjGTrH1uQ_14_5">956</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_t-hVZE_DQ0aHW393n9Fzew" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversion" scale="0" id="Tc_2gA4JGjbe02F4NcpQQqG_A_14_7">17,589,380</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_t-hVZE_DQ0aHW393n9Fzew" decimals="-3" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodValueConversion" scale="3" id="Tc_H3FTPcpKZEmTVrhsOJs5QQ_14_10">55,840</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gw2rhLbrokS2ngyRmmip4Q" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversion" scale="0" id="Tc_hJlgcfcQc0G8FPryznLABA_14_12">81,242,587</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gw2rhLbrokS2ngyRmmip4Q" decimals="-3" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodValueConversion" scale="3" id="Tc_xPpsI3kXHU26l_AC6UjH7g_14_15">193,290</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-I220YjrTES2zT0dh6nXJQ" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversion" scale="0" id="Tc_iq-YuSVGlEem3paDfc6rBA_14_17">116,275,239</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-I220YjrTES2zT0dh6nXJQ" decimals="-3" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodValueConversion" scale="3" id="Tc_3ZYxrhJwnEG3Ils-M1wvbg_14_19">199,526</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_aJltESk7Gk6XbPGb83bLdA_14_21">24,978,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_t1qZaOq1DEW1L-vyT2N4Hg_14_24">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jWL8Je-UBU2gqCEY8KUEpg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_qmn0nHs8TUuXOHDp9bmv9Q_14_27">449,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_0LUlEb1pK0CENfmauKO6Pg_14_36">449,612</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock from initial public offering, net of underwriting discounts, commissions and other issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_NP2KrsPWx02XyTq6r379kQ_15_21">15,220,588</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_u-9qiB_eXEGeb1XsR52_Lg_15_24">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jWL8Je-UBU2gqCEY8KUEpg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_shvNzepcVE6wuhGF4yGCXA_15_27">234,300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_F4K8W5oI7Eqn9yB9TnA16Q_15_36">234,302</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Exercises of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Hp6HoDf_cEiyN4LnR24Rkw_16_21">38,427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jWL8Je-UBU2gqCEY8KUEpg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_4nZUl7fkwUGvgY3zieXjZA_16_27">275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_CDEyVYPcAEibVACitQL75w_16_36">275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jWL8Je-UBU2gqCEY8KUEpg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_nkb1J1ALlkWbnah-iSZaag_17_27">10,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_iyhfa3OqD0W5t3He2fetMQ_17_36">10,821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gain on investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Tjq4ptXuakWz2N7XO70BFQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_c9yI1IUFMk-8fzxCuHcFpg_18_30">31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_jTG2ITyKh0yhZZEkD045vQ_18_36">31</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Tjq4ptXuakWz2N7XO70BFQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_RPaWmk-qVU6CyOBzFG4DSw_19_30">126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_HQXn4z6Pf0iW953fO_P92g_19_36">126</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_LJ7TMbhoFUe0nr0lDe3Lmw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1WmqBMY7eka2Zkh9CQKEhg_20_33">156,988</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_s9CGpBM77Uai3P7kTXQglg_20_36">156,988</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-bottom:3px double #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wA5OCDooWEKaI_O_5zlfDg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_xfFrTJHSGUCZZgI2edOk9w_21_21">41,793,412</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wA5OCDooWEKaI_O_5zlfDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Q6qZjzLd_0m_-4jCv_C9JQ_21_24">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3nxvET59Gki8LFIKljY7FQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8Sl4MvSWtka3hO1OgFOOqw_21_27">699,651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_o_4zbocCK0S4kVmIQxpThw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_W-sfu-_jokS2in9tlcvA9g_21_30">194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_l5vJE3DbIEKeKPth4gy8Kg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_BlB21U5Piken9qWJY0G9Vw_21_33">387,391</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-Vfc9IPXJ0uouH7W-EwqOQ_21_36">312,458</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8a83434e_0dac_4f9b_88f5_2802b4df6b92"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Zenas BioPharma,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Cashflow"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><a id="_db8e42ef_ab0c_4e43_9b16_2617c03e14be"></a><a id="Tc_rRwJeReGz0OVFtIk9oH7oQ_1_3"></a><a id="Tc_d3M-zDbj2UeWpyPDaewkHw_2_3"></a><a id="Tc_aZUgBClP7kK4WjrqFlRk0w_3_3"></a><a id="Tc_QylcpFJQo0yRtfqmXL-eQg_3_6"></a><a id="Tc_j1jM_gandkqf6s-2g6o4Gw_4_0"></a><a id="Tc_CW2ggU-TgEa_lVV3xb_CXw_5_0"></a><a id="Tc_sNlSoOITIUaDQe0wJTSj4A_5_2"></a><a id="Tc_NUFisTnIaka2s_u7tUtTkg_5_5"></a><a id="Tc_0eVZl05s2U-OQfWPNjdA9w_6_0"></a><a id="Tc_xRgmHgobEkOt244qv6hZeg_7_0"></a><a id="Tc_InzXNAEApUuy-Kg0es8akw_7_3"></a><a id="Tc_O42DrOJ5s0Gmq8Tly45OBQ_8_0"></a><a id="Tc_mt354suWj0ejPb79zP27JQ_9_0"></a><a id="Tc_3pZN6kv48Eew5L4Dk-t2OQ_9_6"></a><a id="Tc_iiIYlCGCgUKwt9lCOG9weg_10_0"></a><a id="Tc__vWPLneQ5k29HS1ahX3K9A_11_0"></a><a id="Tc_Q07DM4CuBEi0DXUAr5ikgQ_12_0"></a><a id="Tc_refDBqdjcUeOEhjncuxgBA_13_0"></a><a id="Tc_Y2pEToE6LkeJkiXb5fH2nA_14_0"></a><a id="Tc_wG0fLCFbkEyOGInwtjHZeQ_15_0"></a><a id="Tc_Q6nJWsj4LUyIzMAa5HS3FQ_16_0"></a><a id="Tc_s3nCSwlPIUeuqmh_StmSaQ_17_0"></a><a id="Tc_ry2bxz18kkO3IbF8xcH6dg_18_0"></a><a id="Tc_r6lHurbo7k--x27Wb2jHkg_19_0"></a><a id="Tc_IEVsA98-TkOI0Q8kl1DEtQ_20_0"></a><a id="Tc_WTLb1zEOkkC5ZTmVdUoJgQ_21_0"></a><a id="Tc_Trl-4kiyxU-SIedaA_493w_21_6"></a><a id="Tc_eeNoZFRuOEKP-o1DVMVUmg_22_0"></a><a id="Tc_C2vcamV7JU2mnTRf9zoYJg_22_6"></a><a id="Tc_ZL6t6ogLXUqFgBsMmo14pw_23_0"></a><a id="Tc_bNtM3xUCTkKyY5qDotxE-g_24_0"></a><a id="Tc_dC3VRfLXfUiPoZDnQzcoZg_25_0"></a><a id="Tc_hrxSvf86WUmYD5O0TCqlEg_25_6"></a><a id="Tc_frWxXxzERkKDFFlaIJMb5A_26_0"></a><a id="Tc_KAPyQnjqgk2RtNFKtbCHIg_26_6"></a><a id="Tc_GCfif6qqw0aT1YgeNxhC5g_27_0"></a><a id="Tc_pBVRLRj-ckSN0q2zHbTq3g_27_6"></a><a id="Tc_RQ6IEQzpUEuocZb7wHgfhg_28_0"></a><a id="Tc_fo6db71Ky0uT7VP5YJXXPQ_28_3"></a><a id="Tc_rkCvj6WCDECmXx3yl6-wyA_29_0"></a><a id="Tc_Jvy1rHea9UWaecIS3Kcydg_30_0"></a><a id="Tc_aQQMMpXI-ECMVIO5vYiN6w_31_0"></a><a id="Tc_iviqjibVoEynyPnHraJ6Jg_32_0"></a><a id="Tc_Hp0oXUX5Fki24GtZfNUpqQ_33_0"></a><a id="Tc_CvLjH5N5kEOvS9V-NM8CNQ_34_0"></a><a id="Tc_wyWlVsdlF0uvf8v8kiX2yg_34_2"></a><a id="Tc_x7p9wIn320OG1fzPCFKvLw_34_5"></a><a id="Tc_SRJDPDdpHUCnlk5HLB6kGQ_36_0"></a><a id="Tc_Y9QNlSlByEycMDha-d4YAw_37_0"></a><a id="Tc_UvSdCQ3D1EOe8bakoUl_ww_37_2"></a><a id="Tc_999eNz2k8Eaxr6VSPP1L0Q_37_5"></a><a id="Tc_1T2INP1tckSzHdZPY2eRlw_37_6"></a><a id="Tc_4o7IbWPcIUOaBB2ov_ouCA_38_0"></a><a id="Tc_1-CsFBKZpke38msMFsP_Mw_38_2"></a><a id="Tc_Kaw5sqcSTU2tmhoZMf-q0w_38_5"></a><a id="Tc_I_MIgo_cmECiKnpYjDFNCg_38_6"></a><a id="Tc_3Zv_WUvlckG9ZleUnwuBTA_39_0"></a><a id="Tc_7FcDQHR2C0yQOYG7bwzEZA_39_2"></a><a id="Tc_qRGJy9GBW0ChcLUER_i71A_39_5"></a><a id="Tc_HipBnfS4ik28M2eMLc7ToQ_39_6"></a><a id="Tc_4Q51juYQoEOFnSiUI95QWw_40_0"></a><a id="Tc_Ak43KuOa6keSDZ16H7N_og_40_2"></a><a id="Tc_jnz3jbsPQ0qGAk6-B-U6gA_40_3"></a><a id="Tc_2Z47N7BSBEiF8gdenjoovg_40_5"></a><a id="Tc_hQYGYszoTUudZdTfcLNKDg_42_0"></a><a id="Tc_IveY3h5-VUiMOpGTiacX_A_43_0"></a><a id="Tc_WEVFnRJkZE-zG1yTu-7HxQ_43_2"></a><a id="Tc_Uu7dG9j_y0Gph7aGnO0KOQ_43_5"></a><a id="Tc_TzDgQp_olUK9L-OpBcpgJw_44_0"></a><a id="Tc_eucCz7mDR0K5-EziSI_yAw_45_0"></a><a id="Tc_xcnR4gjEa0Oob8e_27QRAw_45_2"></a><a id="Tc_v5RfcMHF102uMT1NimDjiA_45_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:30.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_QTRNc8ATP0mwEZ8Tb5ruNA_5_3">156,988</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ICwfKdlfTk6RyXA23wCZ1w_5_6">37,124</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Acquired in-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" scale="3" id="Tc_sVFIxWEGrUORsARErBAe2g_7_6">10,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_j-9BP9_nw0GIIyeLtlxTBA_8_3">137</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_55iKKJpSHE6XIuLet3tihw_8_6">113</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net amortization of premiums and accretion of discounts on short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" sign="-" scale="3" id="Tc_K1l7oBkwkkqb1HvtX3jvUA_9_3">602</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_1f7PAyL40E-8MoyXnVzr5w_10_3">10,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_3v9zvKRNvEavtkIqlLkp4g_10_6">3,495</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="zbio:FairValueAdjustmentOfConvertibleNotes" scale="3" id="Tc_uHQfaawNCUGhtcvtz6S_xA_11_3">846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="zbio:FairValueAdjustmentOfConvertibleNotes" scale="3" id="Tc_L8oJa6QKtUSIKY-36PvUrA_11_6">300</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Non-cash lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="zbio:NonCashLeaseExpense" scale="3" id="Tc_KkgomwI5z06eejl56EZbCQ_12_3">681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="zbio:NonCashLeaseExpense" scale="3" id="Tc_9kGIUfEtR0Wt5Q6scsG_NA_12_6">726</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_tO2pi65p2kyDcsOS3Ks43Q_14_3">7,701</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_v6WYCHJlYkSVx09kC2scqA_14_6">3,349</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_bYZ4reyzk0OLYZ9QK-ZqXA_15_3">11,740</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_osuO97Rv70OJcXJGblLzgA_15_6">418</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_NpEuiiCHEEOKOPd6vqdo1g_16_3">22,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_IjsVcjG_pU-ZKlbegogPMw_16_6">3,558</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_E_uN03Z1hUas5m6SzCTomQ_17_3">673</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_SVhx5m7FhUyVA5tbEwPWxw_17_6">714</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_Mh3eU6zy9kSin8gmGOUg9A_18_3">119,674</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc__i2xsz2iNkiONDmePqF7Mg_18_6">30,529</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_FCioojsVoEmk3RhYkgWWQA_20_3">131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_ylfzVllWNEyNLnRHGzwtNA_20_6">17</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="Tc_NJnBKiT7o0WiJTVDIDrurw_21_3">36,421</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from sale and maturities of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="Tc_CRKMJf_M8EGcHvC5ufjAbg_22_3">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_-63Kp00kvkGiJOs8_s2udw_23_3">30,552</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_qYm6x-JCekiXI28xXY4LKg_23_6">17</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of Series C convertible preferred stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Tc_6a3ODqmoSEKAetpCYRLALg_25_3">178,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from initial public offering, net of underwriting discount and commissions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Tc_R82itdqvokOI5Ec4uqLOAA_26_3">240,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Payment of initial public offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_rgGSPjjSYEe7F_t6Hh6FSQ_27_3">6,334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from sale of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="Tc_oHpnUh275EGHYEOzlBdEHA_28_6">20,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_O2Rh2YU9x0KSp4kMH0tMHg_29_3">275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_CdfZ3QgdnECyNRUlkVf44w_29_6">116</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc__tvfr-JpTkiMfbajZ5LMYQ_30_3">412,958</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_7TWhIMz0IUeh6QT04vYmxw_30_6">20,116</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_RRjGLRnCyUe9JrrBbLTPkg_31_3">157</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_Ahw2yWIyQ0CfB8Oh28mpnQ_31_6">78</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net increase (decrease) in cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_RUfTiuZLJkGEsLhKLR3Nhw_32_3">262,889</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_PRrUA5m82keGokO2YhrxXA_32_6">10,352</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_sgFwGmYFEkCPwshKzyGceQ_33_3">56,943</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2022_7aoYVm8LsEqvEfiPlkF4lw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Ew_Jt5ASoUCwrKQDonwVZQ_33_6">67,295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_I5ACHhXmzkqqghfCf9cXhA_34_3">319,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_MchD6-fdQ06zjh6tff3UNw_34_6">56,943</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of non-cash investing and financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of BMS Note recognized as Series C Convertible preferred stock upon conversion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesAssumed1" scale="3" id="Tc_ttMhd34TtkCMq3QbAcp1Uw_37_3">21,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of convertible preferred stock to common stock upon closing of initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="Tc_6BGCLJ1vy0W2YJm4pq79bA_38_3">449,612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets obtained under operating lease arrangements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_ZcCrCC-wK0K7DzZihlP6lw_39_3">1,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Deferred offering costs in accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="zbio:DeferredOfferingCostsIncludedInAccruedExpenses" scale="3" id="Tc_Hu8Kx8i87021BsAaTtUzRg_40_6">1,388</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reconciliation of cash, cash equivalents and restricted cash:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_8bzYxfeNBkWKbTmGP2fCfQ_43_3">319,742</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_1z1v5jbEc0mO0_CzjQAXMQ_43_6">56,857</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_LXq3MZsbFkuWlMbC0T4WKA_44_3">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_jJfoU4aU20GTRVVSirItYg_44_6">86</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_0FwKNTSdVkeIqFi5TIdSCQ_45_3">319,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_tTbXpN84ekaRxG89vzSY9Q_45_6">56,943</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Hlk184202230"></a><a id="_cceb3c93_cbdd_443d_b871_aa2ac2c6c621"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Zenas BioPharma,&#160;Inc.</b></p><a id="NotestoCondensedConsolidatedFinancialSta"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:NatureOfOperations" id="Tb_ZCJlJyQ7nUaUCNrflb0ejw" continuedAt="Tb_ZCJlJyQ7nUaUCNrflb0ejw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span>Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Organization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Zenas BioPharma,&#160;Inc. (&#8220;Zenas&#8221; or the &#8220;Company&#8221;) was incorporated in November&#160;2019 as Zenas BioPharma (Cayman) Limited, an exempted company incorporated in the Cayman Islands with limited liability, and commenced operations in 2020. On August&#160;2, 2023, the Company (then known as Zenas BioPharma (Cayman) Limited (&#8220;Zenas Cayman&#8221;)) de-registered from the Cayman Islands and registered by way of continuation in the State of Delaware (the &#8220;Redomicile&#8221;). Zenas is a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. The Company&#8217;s goal is to build an immunology and inflammation (&#8220;I&amp;I&#8221;) focused biopharmaceutical company. The Company has in-licensed and is developing several product candidates for the treatment of various auto-immune and rare diseases. The Company is headquartered in Waltham, Massachusetts and operates in <ix:nonFraction unitRef="Unit_Standard_segment_S86Rw8jTyUm70oUkTaBnEw" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_aehepwRTS0Ctf2DAsMoOGw">one</ix:nonFraction> segment, which is the business of acquiring and developing immune-based therapies for potential commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements include the accounts of its wholly owned subsidiaries which include Zenas BioPharma (HK) Limited (&#8220;Zenas HK&#8221;), Zenas BioPharma (USA) LLC (&#8220;Zenas US&#8221;), Shanghai Zenas Biotechnology Co. Limited (&#8220;Zenas China&#8221;), Zenas BioPharma Securities Corp., and Zenas BioPharma GmbH. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to clinical stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical studies and clinical trials, obtaining regulatory approval for product candidates, market acceptance of products, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary technology, compliance with government regulations, and the ability to raise additional capital to fund operations. The Company&#8217;s revenues to date have been generated from payments received under the Company&#8217;s license and collaboration agreement with Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and novation agreement with Tenacia Biotechnology (&#8220;Tenacia&#8221;) (see <i style="font-style:italic;">Note&#160;7, License and Collaboration Revenue</i>). The Company has not generated any revenue from product sales since inception, and its product candidates currently under development will require significant additional research and development efforts, including extensive clinical testing and regulatory approval prior to commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;16, 2024, the Company completed its initial public offering (&#8220;IPO&#8221;), in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rPANXOD_Fku39IGeijPdfw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_9k07kUcMj0GIo90w1fi4JA">15,220,588</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Zu6GA717E0C8cJ-Hhbeflg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ACUtTMupE0Gm8fpYR641vg">1,985,294</ix:nonFraction> shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_jvKsbpTO10eG_t6mtZmxgA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_P_Kwc_ouXUGwhihizDb5JA">17.00</ix:nonFraction> per share, for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rPANXOD_Fku39IGeijPdfw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_qei4da0Ua0mNLN-YjA9GPw">258.7</ix:nonFraction> million. The Company received $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rPANXOD_Fku39IGeijPdfw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_qvkdeZHQTkyPtoQ-BEjOLQ">234.3</ix:nonFraction> million in net proceeds after deducting underwriting discounts, commissions and other offering expenses. In connection with the IPO, all outstanding shares of convertible preferred stock converted into <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_jvKsbpTO10eG_t6mtZmxgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_UzG-nlI7U0KG7DUMgmOipg">24,978,715</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with, and prior to, the Company&#8217;s IPO, the Company effected a 1-for-<ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rPANXOD_Fku39IGeijPdfw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_yxBRp7BFmU-iCcqSs3IEoQ">8.6831</ix:nonFraction> reverse stock split of the Company&#8217;s issued and outstanding common stock and adjusted the conversion ratio of all the Company&#8217;s outstanding convertible preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split and the adjustment of the preferred stock conversion ratios.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has incurred operating losses and negative cash flows since its inception, including net losses of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_rPjw9xWwQU2V8xYi10LRtw">157.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_1NU2UlVe_kmvsksZvP8WDg">37.1</ix:nonFraction> million in the years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024 and 2023, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_FsQWBzNgbk-vi2FPb9qW6Q">387.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_aQb6OT79nUKPMkpRNHp3_Q">230.4</ix:nonFraction> million, respectively. Management expects operating losses and negative operating cash flows to continue for the foreseeable future.</p></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_ZCJlJyQ7nUaUCNrflb0ejw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company expects that its existing cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_n6rGkuwc906KSSh5KtKpzg">350.8</ix:nonFraction> million as of December&#160;31, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve&#160;months from the date this Form 10-K is filed. The Company will need additional financing to support its continuing operations and to pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of private or public equity financings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions and licensing agreements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company&#8217;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_2AowBK1XbU2nEygTq_RBDQ" continuedAt="Tb_2AowBK1XbU2nEygTq_RBDQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span>Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="zbio:BasisOfPresentationAndConsolidationPolicyTextBlock" id="Tb_EgoC-Y2Q_EGQTL1hi0r3Bw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the operations of the Company and its wholly-owned subsidiaries. All intercompany accounts, transactions, and balances have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been or omitted pursuant to such rules&#160;and regulations. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:UseOfEstimates" id="Tb_OHkvkMeI_kmtMwjPg5x11Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosures. The Company bases its estimates on historical experience, known trends and other market- specific factors or other relevant factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis using such factors and adjusts those estimates and assumptions as facts and circumstances dictate. Actual results may differ from those estimates or assumptions. Significant estimates in these consolidated financial statements include estimates made in connection with accrued research and development expenses, stock-based compensation and pre-initial public offering (&#8220;IPO&#8221;) valuations of common stock, and convertible debt.</span><b style="font-style:normal;font-weight:bold;"> </b></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_btLOyBxJJkuTXAlIAF-oKg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original or remaining maturity from the date of purchase of three&#160;months or less to be cash equivalents. Cash equivalents may include money market funds, corporate debt securities, U.S government agency notes and overnight deposits.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:InvestmentPolicyTextBlock" id="Tb_O2jzmaKyNkqOVWDv6L5i7w" continuedAt="Tb_O2jzmaKyNkqOVWDv6L5i7w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Short-Term Investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company classifies all investments with a remaining maturity when purchased of greater than three months as &#8220;available-for-sale&#8221;. Available-for-sale securities with a remaining maturity of greater than one year are classified as non-current assets. Available-for-sale securities are carried at fair value based upon market prices at period end, with the unrealized gains and losses included in accumulated other comprehensive loss as a component of stockholders&#8217; equity (deficit) until realized. The amortized cost of investments in this category is adjusted for amortization of premiums and accretions of discounts over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense). The Company reviews its portfolio of investments, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss. If the decline in fair value is due to credit-related factors, a loss is recognized in other income (expense).</p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_2AowBK1XbU2nEygTq_RBDQ_cont1" continuedAt="Tb_2AowBK1XbU2nEygTq_RBDQ_cont2"><ix:continuation id="Tb_O2jzmaKyNkqOVWDv6L5i7w_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_AxhqTPPDZUWqNHAowphNUg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Cash </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of cash held as collateral for a letter of credit the Company issued as a security deposit for its lease of office space in Waltham, MA, which terminated in January 2025. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:DeferredChargesPolicyTextBlock" id="Tb_VDlwzN8iuUmYulbZzawUzQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Deferred Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company capitalizes legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as other non-current assets until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in-capital generated as a result of the offering. If the Company terminates its plan for an equity financing, any costs deferred will be expensed immediately. Upon closing the IPO in September 2024, the related deferred offering costs were recorded against the IPO proceeds. <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DeferredCosts" scale="6" id="Narr_hPTw4Sbhj0OhBB_aU2MDyg">No</ix:nonFraction> deferred offering costs were recorded as of December 31, 2024. As of December 31, 2023, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredCosts" scale="6" id="Narr_yBWLsx_Bp0GO9yXDx3HKdg">1.4</ix:nonFraction> million in deferred offering costs which were included in other assets.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_c6Xo91C-P0-k3aVRft51fA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has <ix:nonFraction unitRef="Unit_Standard_segment_S86Rw8jTyUm70oUkTaBnEw" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_F_N2z5FiZUeUczhTlvokiw">one</ix:nonFraction> reportable segment focused on the research and development of precision immunology-based therapies. The Company&#8217;s chief operating decision-maker (the &#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of making operating decisions, assessing financial performance, and allocating resources. As of December 31, 2024 and 2023, the Company&#8217;s long-lived assets held outside of the U.S. were immaterial. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our segment reporting, see <i style="font-style:italic;">Note 17, Segment Information</i> to these consolidated financial statements. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_vSedSpjdc0WpNjVbkIiUtQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and short-term investments. The Company attempts to minimize the risks related to cash, cash equivalents and short- investments by investing in a broad range of financial instruments, as defined by the Company&#8217;s investment policy. The Company has established guidelines related to the quality of the institutions, financial instruments and allowable investments. The Company minimizes credit risk by choosing only highly rated financial institutions as counterparties. &#160;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="zbio:SignificantSuppliersPolicyTextBlock" id="Tb_rx58LPn9SU2DR-D6_bKUaA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant Suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs, including preclinical and clinical studies and testing. In particular, the Company relies on a single manufacturer and expects to continue to rely on a single or small number of manufacturers to supply it with its requirements for the drug product related to these programs. These programs could be adversely affected by a significant interruption in the supply of drug substance and drug product.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_F5wa97tnmk6fzG8h2OcLOw" continuedAt="Tb_F5wa97tnmk6fzG8h2OcLOw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Translation of Foreign Currency </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign subsidiaries into U.S. dollars are excluded from our determination of net loss and are recorded in accumulated other comprehensive income (loss), as a separate component of equity. For foreign subsidiaries where the functional currency of assets and liabilities differs from their local currency, non-monetary assets and liabilities are translated at the rate of the exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_2AowBK1XbU2nEygTq_RBDQ_cont2" continuedAt="Tb_2AowBK1XbU2nEygTq_RBDQ_cont3"><ix:continuation id="Tb_F5wa97tnmk6fzG8h2OcLOw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other (income) expense, net in our consolidated statements of income. Realized and unrealized foreign currency transaction losses were $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossAfterTax" sign="-" scale="6" id="Narr_EswHifWnVkScb1IwApNDUA">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossAfterTax" sign="-" scale="6" id="Narr_XOr8nwjwPkyJlSYdJPpwYg">0.1</ix:nonFraction> million for each of the&#160;years ended December&#160;31, 2024 and 2023, respectively. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_MAUyQarI90iwRE_TFGyJtA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 0pt 20pt;">Level&#160;1&#8212;<span style="font-style:normal;"> Quoted market prices in active markets for identical assets or liabilities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 0pt 20pt;">Level&#160;2&#8212;<span style="font-style:normal;"> Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 12pt 20.15pt;">Level&#160;3&#8212;<span style="font-style:normal;"> Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level&#160;3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The majority of our financial assets have been classified as Level 1. Our financial assets (which typically include cash equivalents and marketable equity securities) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market- based approaches and observable market inputs to determine value. These observation market inputs included reportable tables, benchmark yields, broker quotes, bids, offers, current spot rates and other industry and economic events. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_Ukn_Qij3YU6qKp8Au4aDCg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-Lived Assets </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amount of the assets to their undiscounted expected future cash flows. If this comparison indicates there is an impairment, the amount of the impairment is calculated as the difference between the carrying value and fair value. To date, no such impairments have been recognized. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_EooUtvYqK0qluvicTmF26Q" continuedAt="Tb_EooUtvYqK0qluvicTmF26Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Property and equipment are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (<span style="-sec-ix-hidden:Hidden_b_kdHKCFF0avLUjrQ41Fwg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_f7tghFWG2USaAbs-bXl6Jg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_TqkIXAAPDkm7I27C676iUA">seven years</ix:nonNumeric>). Assets under capital leases are amortized over the shorter of their useful </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_2AowBK1XbU2nEygTq_RBDQ_cont3" continuedAt="Tb_2AowBK1XbU2nEygTq_RBDQ_cont4"><ix:continuation id="Tb_EooUtvYqK0qluvicTmF26Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">lives or lease terms using the straight-line method. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="zbio:LicenseAndCollaborationRevenuePolicyTextBlock" id="Tb_GxS8WGy0k0aiOeipVDcGBg" continuedAt="Tb_GxS8WGy0k0aiOeipVDcGBg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License and Collaboration Revenue </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company enters into license and collaboration arrangements with third parties, under which the Company licenses or may license rights to certain of the Company&#8217;s product candidates and may perform research and development services in connection with such arrangements. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, clinical, regulatory and commercial sales milestone payments, and royalties on net sales of licensed products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">At contract inception, the Company analyzes its collaboration and license arrangements to assess whether such arrangements are within the scope of ASC Topic 808,&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Collaborative Arrangements</i><span style="letter-spacing:0.2pt;">&#160;(&#8220;ASC 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple&#160;units of account, the Company first determines which&#160;units of the collaboration are deemed to be within the scope of ASC 808 and which&#160;units of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of ASC Topic 606,&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Revenue from Contracts with Customers</i><span style="letter-spacing:0.2pt;">&#160;(&#8220;ASC&#160;606&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC 808: (i)&#160;the parties to the contract must actively participate in the joint operating activity and (ii)&#160;the joint operating activity must expose the parties to the possibility of significant risks and rewards, based on whether or not the activity is successful. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. Payments received from or made to a partner that are the result of a collaborative relationship with a partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction or increase to research and development expense, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">For the&#160;units of account within the scope of ASC 606, to determine the appropriate amount of revenue to be recognized for the arrangements, the Company performs the following five steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The promised goods or services in the Company&#8217;s arrangements typically consist of a license to the Company&#8217;s intellectual property and research and development services. The Company provides options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which </span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_2AowBK1XbU2nEygTq_RBDQ_cont4" continuedAt="Tb_2AowBK1XbU2nEygTq_RBDQ_cont5"><ix:continuation id="Tb_GxS8WGy0k0aiOeipVDcGBg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Due to the uncertainty of research and development and regulatory based milestones that are not within the control of the Company, payment becomes probable upon achievement. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and collaboration revenue in the period of adjustment. Any amounts due to the Company but not received as of period-end will be recorded to other current assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs including a reasonable margin. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services.</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_7TdVbv3X10Cm5upYXzsmhQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Research and development costs include (i)&#160;employee-related expenses, including salaries, benefits, and stock-based compensation expense; (ii)&#160;external research and development expenses incurred under arrangements with third parties, such as CRO agreements and consultants; (iii)&#160;costs associated with preclinical activities and (iv)&#160;lab supplies, lab expenses and an allocation of rent, depreciation, and infrastructure. Costs incurred in connection with research and development activities are expensed as incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data, such as patient enrollment or clinical site activations, provided by the Company&#8217;s clinical sites and vendors. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable. The Company monitors each of these factors and adjusts estimates accordingly. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="zbio:AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock" id="Tb_WACfHDOmnU6s4p1mM3g2gw" continuedAt="Tb_WACfHDOmnU6s4p1mM3g2gw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Asset Acquisitions and Acquired In-Process Research and Development Expense </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company accounts for acquisitions of assets or a group of assets that do not meet the definition of a business as asset acquisitions based on the cost to acquire the asset or group of assets, which include certain transaction costs. In an asset acquisition, the cost to acquire is allocated to the identifiable assets acquired and liabilities assumed based on their relative fair values as of the acquisition date. No goodwill is recorded in an asset acquisition. Assets that are </span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_2AowBK1XbU2nEygTq_RBDQ_cont5" continuedAt="Tb_2AowBK1XbU2nEygTq_RBDQ_cont6"><ix:continuation id="Tb_WACfHDOmnU6s4p1mM3g2gw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as in process research and development (&#8220;IPR&amp;D&#8221;). Acquired IPR&amp;D that has no alternative future use as of the acquisition date is recognized as acquired IPR&amp;D expense as of the acquisition date. The Company will recognize additional acquired IPR&amp;D expenses in the future if and when the Company becomes obligated to make contingent milestone payments under the terms of the agreements by which it acquired the IPR&amp;D assets. The Company classifies payments made for the acquisition of IPR&amp;D assets, whether capitalized or expensed, as investing activities on its statement of cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Contingent consideration in the form of milestone payments related to IPR&amp;D with no alternative future use are charged to expense when the related milestone is achieved and becomes payable. For the year ended December&#160;31, 2024, the Company did not recognize any acquired IPR&amp;D expense. For the year ended December 31, 2023, the Company recognized </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_ZeD0YqL9rEiNGm87-Fn0jw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" scale="6" id="Narr_NOl6uv2Pb0aElrkd8TmczQ">10.0</ix:nonFraction></span><span style="letter-spacing:0.2pt;">&#160;million of IPR&amp;D expense, in connection with the consideration due under the 2021 Xencor Agreement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our asset acquisitions and acquired in-process research and development, please see <i style="font-style:italic;">Note 8, License and Option Agreements,</i> to these consolidated financial statements.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_SYe1e2xBQUaQg9If6jM3Hg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss consists of net loss and other comprehensive loss. During the years ended December 31, 2024 and 2023, the Company&#8217;s only element of other comprehensive loss was foreign currency translation adjustments.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_UBhHr_vRY0y3WNfV_EZZVQ" continuedAt="Tb_UBhHr_vRY0y3WNfV_EZZVQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases </p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of use lease assets (&#8220;ROU assets&#8221;), current portion of lease obligations and long-term lease obligations on the Company&#8217;s consolidated balance sheet. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#8217;s consolidated balance sheet. Lease assets are tested for impairment in the same manner as</span><span style="font-family:'TimesNewRomanPSMT';"> </span><span style="font-size:10pt;">long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense, while expense for financing leases is recognized as depreciation expense (classified as an operating expense) and interest expense (classified as a non-operating expense) using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheet for leases with an original term of twelve months or less. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recognized based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. Certain adjustments to the ROU asset may be required for items such as incentives received from the lessor. The interest rate implicit in lease contracts is typically not readily determinable. Therefore, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasures the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company generally accounts for non-lease components together with lease components. The Company expenses variable payments included in a lease arrangement as such expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our leases, please see <i style="font-style:italic;">Note 6, Leases</i>, to these consolidated financial statements.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_2AowBK1XbU2nEygTq_RBDQ_cont6" continuedAt="Tb_2AowBK1XbU2nEygTq_RBDQ_cont7"><ix:continuation id="Tb_UBhHr_vRY0y3WNfV_EZZVQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_so4f_LFWaEOyOlKxWdAv6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740, <i style="font-style:italic;">Accounting for Income Taxes</i>, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a &#8220;more likely than not&#8221; threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_wglAYqEBDkac6RM5sBLcBA"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_3DmOugdSeEuqOKmlOOWrUw">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits included in the Company&#8217;s consolidated balance sheets as of December 31, 2024 and 2023. The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties related to uncertain tax positions in its consolidated statements of operations and comprehensive loss since inception.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_DARhzgwuyUeUONgF-0CCKA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The Company grants stock-based awards to employees, non-employee consultants and members of its board of directors (the &#8220;Board&#8221;). Stock-based compensation is recognized as expense for each stock-based award based on its estimated fair value on the date of grant. The Company&#8217;s share-based payments include stock options and grants of restricted common stock. The value of the award is recognized as expense on a straight-line basis over the requisite service period, and expense is adjusted for pre-vesting forfeitures in the period in which the forfeitures occur. Stock-based compensation expense is classified in the accompanying consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipients service payments are classified.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="letter-spacing:0.2pt;">The Company estimates the fair value of each restricted stock award (&#8220;RSA&#8217;s&#8221;) at its grant date based on the estimated fair value of the Company&#8217;s common stock on that date as determined by the Board. The Company estimates the fair value of stock option awards on the grant date using a Black-Scholes option pricing model. The Company estimates the expected option lives using the simplified method, volatility using historical stock prices of peer companies, the risk-free rates using the U.S Treasury yield curve in effect with a remaining term equal to the expected term and dividend yield based on the Company&#8217;s history of paying no dividends and the expectations of paying no cash dividends in the foreseeable future. Prior to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock on the date of grant was determined by the Board, taking into consideration its most recently available third-party valuations of common stock as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the grant date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;">For additional information on our share-based compensation, please see <i style="font-style:italic;">Note 11, Stock-Based Compensation</i>, to these consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="zbio:TemporaryEquityPolicyTextBlock" id="Tb_57Irw0Sc6EKxN-KFpZUwXg" continuedAt="Tb_57Irw0Sc6EKxN-KFpZUwXg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Convertible Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The Company classified its convertible preferred stock as temporary equity (between liabilities and stockholders&#8217; equity (deficit)) in the accompanying consolidated balance sheet because it could have become redeemable due to certain change in control clauses that were outside of the Company&#8217;s control. The convertible preferred stock was not redeemable, except in the event of a deemed liquidation event. As the occurrence of a deemed liquidation event was not currently probable at December 31, 2023, the carrying values of the convertible preferred stock were not being accreted to their redemption values. Upon the completion of the Company&#8217;s IPO on September 16, 2024, all outstanding shares of the Company&#8217;s convertible preferred stock converted into shares of the Company&#8217;s common stock. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our convertible preferred stock, please see <i style="font-style:italic;">Note 9, Convertible Preferred Stock</i>, to these consolidated financial statements.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_2AowBK1XbU2nEygTq_RBDQ_cont7" continuedAt="Tb_2AowBK1XbU2nEygTq_RBDQ_cont8"><ix:continuation id="Tb_57Irw0Sc6EKxN-KFpZUwXg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_WHg1lOivlEu9HTG2ruEFCw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two- class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#8217;s common shares and participating securities. The Company&#8217;s convertible preferred stock contained participation rights in any dividend paid by the Company and is deemed to be a participating security. Net loss attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Diluted net loss per share is computed using the more dilutive of (a)&#160;the two-class method or (b)&#160;the if- converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss per share gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders for the&#160;years ended December&#160;31, 2024 and 2023.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_pgqx-ABe70mcWg2fVdNI3Q" continuedAt="Tb_pgqx-ABe70mcWg2fVdNI3Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (&#8220;FASB&#8221;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated statements or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">In November&#160;2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280)&#8212;Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;)</i>, which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. This standard became effective for the Company for the annual reporting period ended December 31, 2024, using the retrospective method. The adoption of this standard resulted in additional disclosure of the significant expenses reviewed by the Company&#8217;s CODM. The adoption did not have a material impact on the consolidated financial position or results of operations. See <i style="font-style:italic;">Note 17, Segment Information</i>, for our updated segment presentation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740)&#8212;Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;)</i>, which requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company beginning in fiscal year 2025, with early adoption permitted. ASU 2023-09 may be applied retrospectively or prospectively to the financial statements. The Company is currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In November&#160;2024, the FASB issued 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;)</i>, which requires entities to disclose additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective annual periods beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_2AowBK1XbU2nEygTq_RBDQ_cont8"><ix:continuation id="Tb_pgqx-ABe70mcWg2fVdNI3Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">prospectively to the financial statements. The Company is currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation><a id="_5f704831_2d74_4687_be2a_3baa99f0ad40"></a><a id="Tc_8v6YlqkSVUeTGvqvZ0ieoA_2_3"></a><a id="Tc_BBfBMgvYuEOfzYbn-jzqZA_3_0"></a><a id="Tc_GAG-uDTbE0G9Us2D-eS_Mw_3_3"></a><a id="Tc_Ne8_4nCc_0CAxGMN5DbkDg_3_6"></a><a id="Tc_mlA4Lsa_102W4vYuhtzcAg_3_9"></a><a id="Tc_77d7J801_02Eoykps3d3iQ_3_12"></a><a id="Tc_RsUwS4mgEUqnEDRMx0RpEg_4_0"></a><a id="Tc_k9VNF4rz1k65PSZLeBhnRQ_5_0"></a><a id="Tc_7vutbrRJzEC0wWH_pS1lQQ_5_2"></a><a id="Tc_TUGqf9lbiUW6sGa2QoftAA_5_5"></a><a id="Tc_rM_7T4sYyEubw-hoGVgB8g_5_8"></a><a id="Tc_OPtbLJOl8EmMCCI3JIfX8w_5_9"></a><a id="Tc_oh5T_72HjUe8fm4GVarC6A_5_11"></a><a id="Tc_VC75NhVv3EeSDRF8WH-4Ug_5_12"></a><a id="Tc_LDDgnOGryU6e3kMg9OlViw_6_0"></a><a id="Tc_SI7rhE-3WE2sw2FOaJgLVg_6_9"></a><a id="Tc_i_r2QA0B-UeA4wC9c1SCmA_6_12"></a><a id="Tc_TwIH60ZRdkuy0cLbuHn5sA_7_0"></a><a id="Tc_jIUTI3_ITEKYXzb-L5mJYA_8_0"></a><a id="Tc_863u-PJJXUu-73ac864c7Q_8_6"></a><a id="Tc_LpmhWtY88Eydwk4TJDt94A_8_12"></a><a id="Tc_VUEq3gPebU6WiTHVoZNpDA_9_0"></a><a id="Tc_XoSmn3FiG0a1aoZ0ooJiGA_9_6"></a><a id="Tc_D4i9b7g3B0OhtdLoL1hFIQ_9_12"></a><a id="Tc_MaFmMTVlmEaScYbGAN-IIQ_10_0"></a><a id="Tc_A-iYP_ymOE6AYl0JnUwZHw_10_9"></a><a id="Tc_iJ5t9sYj3kqDpghRU6JRSg_10_12"></a><a id="Tc_7nhf-QaT-0Khp0JlH_7uMQ_11_0"></a><a id="Tc_AHW-WXsiHEGKrcTONF6MLg_11_2"></a><a id="Tc_ful_KrBSmki3qE1QENgRxA_11_5"></a><a id="Tc_zTybSG9m1EG6AFoEtFjHFQ_11_8"></a><a id="Tc_dTXXha4WXkiSKaIl3nkUqQ_11_11"></a><a id="Tc_IHjp5SzNbUid3LE8JLoV3w_11_12"></a><a id="_813f17d6_c3e6_448d_8949_1347a237532e"></a><a id="Tc__cVxAllnGE-N4dttnkAeYA_1_3"></a><a id="Tc_sQmTrIo1GkGFAIn75-WCuA_2_0"></a><a id="Tc__K7-YpQWM0moLHe1PjH5qw_2_3"></a><a id="Tc_EIDKJQspAEOVCeSfXxMmig_2_6"></a><a id="Tc_rm9tuBsfh06JhlO0-OfONw_2_9"></a><a id="Tc_miWDgEl0yESqpSr4VaNsNA_2_12"></a><a id="Tc_dl8x3uPN0EC8fcqAil7nqw_3_0"></a><a id="Tc_Km1v0qANHUKpWgpBgRwA-w_4_0"></a><a id="Tc_13lcGsWjtk6hylxIFUeEyg_4_2"></a><a id="Tc_vtzWZG-xP0a4uXPIBC1vIA_4_5"></a><a id="Tc_Sk9gVHtfyUya7mKEB0hBfw_4_6"></a><a id="Tc_4BSrv7KK4kSkZ4-k-kQXQg_4_8"></a><a id="Tc_H1IsBF9SjEGQ-zsQYIMjZQ_4_9"></a><a id="Tc_FJLq-VcFR0eymtrpPH1jsw_4_11"></a><a id="Tc_XKnbBpsNuEq5NSTiw4KsoA_5_0"></a><a id="Tc_C89bsQolMUqgqx-TFbgRAA_5_2"></a><a id="Tc_F8suZQq4gkaKnA1eTFuupw_5_5"></a><a id="Tc_CvYv30bnPEmqEgqLBbaSbQ_5_6"></a><a id="Tc_5Kz9HqT8V0-r4Ba-nfMUmw_5_8"></a><a id="Tc_hAAt4eAvFEWgOk-6pr5gEw_5_9"></a><a id="Tc_THX9giGWe0e7hdR8t3-MCw_5_11"></a><a id="Narr_IOB67YQKd0eprIes0kZAJQ"></a><a id="Narr_gLMShN1eXU-CIS9LtrnB4A"></a><a id="_25a3febc_c9b4_4991_8bfa_60cc5561e5fe"></a><a id="_25a3febc_c9b4_4991_8bfa_60cc5561e5fe_2"></a><a id="_25a3febc_c9b4_4991_8bfa_60cc5561e5fe_3"></a><a id="Narr_-mGGLcGm-0yojRCJa4r6Nw"></a><a id="Narr_M4xuyzvbp0e5FQqpPxu3zw"></a><a id="_4304caa1_a13c_4e75_9505_8ce74481590d"></a><a id="_4304caa1_a13c_4e75_9505_8ce74481590d_2"></a><a id="_4304caa1_a13c_4e75_9505_8ce74481590d_3"></a><a id="Narr_OaxrSawx-USIx8F4WYG1fQ"></a><a id="Narr_RA2vYGtetEiUvZ0K8Hgi0w"></a><a id="_8990f394_5486_4f26_9791_2a4d1af01e14"></a><a id="_8990f394_5486_4f26_9791_2a4d1af01e14_2"></a><a id="_8990f394_5486_4f26_9791_2a4d1af01e14_3"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_hOjRUWR00USUKCbpMzwvZw" continuedAt="Tb_hOjRUWR00USUKCbpMzwvZw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span>Fair Value Measurements</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_-Nl1URPON0SSYOHhhjxWZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following tables present information about the Company&#8217;s assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:bottom;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:28.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Carrying Value</b></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted Prices in Active Market </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other Observable Inputs</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other Observable Inputs</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Cash</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_iSqSAz9x4k2LDrxzSKy2MA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_c1urWglk00O5flXI5EuiuQ_5_3">19,070</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_45gRULzuSUK5_ORGEXpLOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_KUJv3JIPAUeb2znvY70LDQ_5_6">19,070</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Money market funds</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_cT92xtQ8cECq2AFu-XJeOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_5S8WorRezE65a5F5rtM88g_6_3">300,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_EbY1u8wvo0uxDj6anPPPCw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_at1n4verqEiyM8NmOAIdRQ_6_6">300,672</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investments:</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_T3DzdxiqpEyWSibLwwGToQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_Y9Isg9UhU0eAasIcO9r6vQ_8_3">3,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_82fSkNrj5kGcJKb3RNQoNg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_o18oPpYB3EKCUaafyCh29A_8_9">3,315</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Corporate debt securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_efoaGSp1_UmRJh64ycKRPQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_mSeF-T7V3ES67YCYKb0tqQ_9_3">8,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_LvhP6kTZU06gMvlc3p7_eQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_B9qhCzFkrESw5WwGDTQ6bA_9_9">8,601</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Government securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_fNDpCNYLYE233dylDwz8eQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_K_TvQomdqkWtpANDzoXEIg_10_3">19,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_wgLHoHG1-0qDKJPNdf5zYg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_Nohb4PU2iUq05GZyRuegAw_10_6">19,108</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">     Total assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_LWrKtXp_xEeU8LAphW72jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_S85etWOaZEyzEmtnqKYg1A_11_3">350,766</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_KwwFNWvkbkepTCv4eJzXUA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_upKMTjkKf0-TY9reO3exaQ_11_6">338,850</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_GlXgsGQE-0GNbt0DsdtK9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_t3OGjkqXfkiAUFrnIiux_Q_11_9">11,916</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:30.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:bottom;width:66.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2023</b></p></td></tr><tr><td style="vertical-align:middle;width:30.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Carrying Value</b></p></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted Prices in Active Market </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other Observable Inputs</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other Observable Inputs</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  BMS note</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9vmGc1uJ-UKFfbOjwwSZLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="Tc_UdH_0eXGT0GyUDe52jVNHQ_4_3">20,300</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_FVi09Cz6lESIybH__dVf2g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="Tc_mCgaoAf5yk6jwrBALbb7SQ_4_12">20,300</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:30.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">     Total liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9vmGc1uJ-UKFfbOjwwSZLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Tc_sqf5XRWSfEqOGT89DmOxRQ_5_3">20,300</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_FVi09Cz6lESIybH__dVf2g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Tc_z6Bv2cwOEEafklWVwM85Yg_5_12">20,300</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have been no material impairments of our assets measured and carried at fair value during the year ended December 31, 2024. The fair value of Level 1 instruments classified as money market funds and government securities are valued using quoted market prices in active markets. The fair value of Level 2 instruments classified as short-term investments was determined using other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and fair value is determined using models or other valuation methodologies. There were <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="0" format="ixt-sec:numwordsen" name="zbio:FairValueAssetsLevel2ToLevel1TransferAmount" scale="0" id="Narr_A8ayMaBB7Um0NdQ19alCJw"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="0" format="ixt-sec:numwordsen" name="zbio:FairValueAssetsLevel2ToLevel1TransferAmount" scale="0" id="Narr_hpXKGkAHD0WQJH2SLNxYWA"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="0" format="ixt-sec:numwordsen" name="zbio:FairValueAssetsLevel1ToLevel2TransferAmount" scale="0" id="Narr_7-6BLcq_5k2-tQbS9wRYnw"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="0" format="ixt-sec:numwordsen" name="zbio:FairValueAssetsLevel1ToLevel2TransferAmount" scale="0" id="Narr_Ur7sZsoHkEOFd_ou_63Bkg">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers between levels during the years ended December 31, 2024 and 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The short-term investments are classified as available-for-sales securities. As of December 31, 2024, the remaining contractual maturities of the available-for-sales securities were within one year, the balance in the Company&#8217;s accumulated other comprehensive income was comprised solely of activity related to the Company&#8217;s available-for-sale securities. There were <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" id="Narr_rnIG-SNuB0-WMI3YKguEOw">no</ix:nonFraction> realized gains or losses recognized on the sale or maturity of available-for-sale securities during the year ended December 31, 2024. As a result, the Company did not reclassify any amounts out of accumulated other comprehensive income for the same period. The Company has a limited number of available-for-sale securities in insignificant loss </p></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_fcc557f3_a32c_4e01_b239_1e796f974470"></a><a id="Tc_MoF_FNRX0kuf3AwF3lhIMw_1_2"></a><a id="Tc_SOgi6oEsFkeDHrpuTBusHA_2_2"></a><a id="Tc_sN3iVObE4kOoRg88SHrZvw_2_5"></a><a id="Tc_HhTj-eBP-k6yj0weWxaONw_2_8"></a><a id="Tc__G7ccyZWYEe6PyKWgmIEnQ_2_11"></a><a id="Tc_LLhpBygipU6U2MhpADgnvQ_3_0"></a><a id="Tc_H2sKkPsTzEGIDsddKHly9A_4_0"></a><a id="Tc_q9oT-Q0JO0GxlfBkMiH6Mg_4_1"></a><a id="Tc_SWuErZQEeUWYr1jsM7w50g_4_4"></a><a id="Tc_eMaM8dsmn02bs9q3SR3CSg_4_7"></a><a id="Tc_6TmIf9cdIE-Yw1wHu-tNKA_4_8"></a><a id="Tc_Vbug8Ih1u0qfPsAtX8d7qQ_4_10"></a><a id="Tc_gM3p0QHh3kO0cX7veVI7LA_5_0"></a><a id="Tc_ZpVYeZY6JE-gt2bcINY1wQ_5_8"></a><a id="Tc_NL06B8VMEEG8SIIFWAN9Kg_6_0"></a><a id="Tc_1IKuemQrqUG1WJvbCycJNQ_7_0"></a><a id="Tc_v2D9F52Ea02kOpGRECQdCw_7_1"></a><a id="Tc_sEUFCKboCEeypI0tWNJxug_7_4"></a><a id="Tc_tf34GN0SAUaSpVJYsanYpQ_7_7"></a><a id="Tc_7K43YaaBm0mH0rFMsLSVHg_7_10"></a><ix:continuation id="Tb_hOjRUWR00USUKCbpMzwvZw_cont1" continuedAt="Tb_hOjRUWR00USUKCbpMzwvZw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">positions as of December 31, 2024, which the Company does not intend to sell and has concluded will not be required to sell before recovery of the amortized cost for the investment maturity. </p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="Tb_QwPIkZkCh0moy3MEe7RxOQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the available-for-sale securities (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:bottom;width:56.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Unrealized Gains</b></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Unrealized Losses</b></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short-term investments:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ujsrnzhxWkaowceDO8G96A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_98hEPTBRAkmsMZHWbmSSTw_4_2">3,311</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ujsrnzhxWkaowceDO8G96A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_8gBEJOIPqECqXj9ISU6iyA_4_5">4</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ujsrnzhxWkaowceDO8G96A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_o_o5IchQe06vvbkBNaxN-g_4_11">3,315</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_tAB8gHGpxEa_vZYJC85hXw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc__iffzE7AYESwiKr5xVv7xQ_5_2">8,589</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_tAB8gHGpxEa_vZYJC85hXw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_7wJtEV7DeUSPKZtC1MBKvg_5_5">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_tAB8gHGpxEa_vZYJC85hXw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_2NnaBFnsKEGDRdZ3qgdqzg_5_11">8,601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_u4MSiO-PeECFV2npmPDRmQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_5q7LBLfDqE-7kyMwq6TBuA_6_2">19,093</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_u4MSiO-PeECFV2npmPDRmQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_SUECQZsbmU2Efbzj5LWeGg_6_5">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_u4MSiO-PeECFV2npmPDRmQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_6SgVYzJg90a4Ba_JIxxvWw_6_8">2</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_u4MSiO-PeECFV2npmPDRmQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_YoDFDNuR10qeLXW4v_Iwjg_6_11">19,108</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_-lgYIjdR60q9eCR0iUlmCg_7_2">30,993</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_ZV7QqcOwr0qBEtwaLfpqzQ_7_5">33</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_vqcEgGvi4ESI-YxaM6DlCw_7_8">2</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_z9sMLx0svEKmMgd_E_pxPA_7_11">31,024</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain short-term debt securities with original maturities of less than 90&#160;days are included in cash and cash equivalents on the consolidated balance sheets and are not included in the table above. The Company did not hold any investments as of December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Convertible Notes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2023, the Company entered into a $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_ExKbMgkUn0ititCiAzolAg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_aqoZINWZL0-O6GmCiEAmKg">20.0</ix:nonFraction> million convertible promissory note agreement with BMS (the &#8220;BMS Note&#8221;) in connection with its strategic license and collaboration agreement with BMS (the &#8220;BMS Agreement&#8221;) (see <i style="font-style:italic;">Note 7, License and Collaboration Revenue</i>). In the event that the Company issued and sold its convertible preferred stock to accredited investors with total gross proceeds equal to at least $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_8_1_2023_To_8_31_2023_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_P-ll4OVb3EWjFIKqvZMELA" decimals="-5" format="ixt:num-dot-decimal" name="zbio:MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes" scale="6" id="Narr_QiBKJX5ffk2sGrQzvv-1zg">70.0</ix:nonFraction> million (a &#8220;BMS Qualified Financing&#8221;), the outstanding principal and accrued interest of the BMS Note were automatically convertible into equity securities sold in the BMS Qualified Financing at the conversion price equal (i) to the outstanding principal and accrued interest under the BMS Note divided by (ii) the lowest cash price paid per equity security. The Company elected the fair value option to account for the BMS Note. Changes in fair value at every reporting date are recorded as a component of the other income (expense), net. The BMS Note was classified as a liability on the Company&#8217;s consolidated balance sheet as of December 31, 2023 and was initially recorded at fair value. The Company subsequently remeasured the fair value of the BMS Note at each applicable reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 3, 2024, the Company issued and sold Series C convertible preferred stock (&#8220;Series C Preferred Stock&#8221;), which was deemed to be a BMS Qualified Financing, as described above, and resulted in the outstanding BMS Note plus accrued interest being automatically converted into <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_5_3_2024_To_5_3_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_lcOoNTIEC06PQFCU3DRl5Q" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_cs18Q9pu4k60wcHzmN7c8g">12,284,686</ix:nonFraction> shares of Series C Preferred Stock (see<i style="font-style:italic;"> Note 9, Convertible Preferred Stock</i>). Immediately prior to settlement, the BMS Note was remeasured to fair value utilizing fair value of the shares of Series C Preferred Stock for which the BMS Note converted into. The BMS Note settling in shares of Series C Preferred Stock represents the redemption of stock-settled debt and was therefore accounted for as an extinguishment. Upon extinguishment, <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_5_3_2024_To_5_3_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_cwXLzP0nA0KjySFxWk-Usw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="Narr_pNXStqs0tEmNHzBCY1GEqw">no</ix:nonFraction> gain or loss was recognized. The Company recorded a $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember__ZDd67Q9eUCGYKadM0BTGw" decimals="-5" format="ixt:num-dot-decimal" name="zbio:FairValueAdjustmentOfConvertibleNotes" scale="6" id="Narr_wCDRYGo5e0OkbcXK1b5-mA">0.8</ix:nonFraction> million change in fair value of the BMS Note as component of other income (expense), net for the year ended December 31, 2024. </p></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_820153af_b3f3_49de_94f8_4c27adfca5d1"></a><a id="Tc_VdXQ6zb1tUm79jCuNOGmfw_1_3"></a><a id="Tc_6kkn08ZscUG8D34gRXw4cg_2_0"></a><a id="Tc_6l0uRKUd7U-A28iCFuxRxA_3_0"></a><a id="Tc_GEMDHlR390ipGPhPFUGlrg_3_2"></a><a id="Tc_pt6fqqM_4kKsRcBDA27yVQ_3_3"></a><a id="Tc_hP-8kGTD9Uy-LeuIs-ovhg_4_0"></a><a id="Tc_cXJUXvGMfU6MtSNSJx6EUA_6_0"></a><a id="Tc_h9gtc90AIEWhKmH3TaltWw_6_2"></a><a id="Tc_XEFUh9j3aUWGOBNn-sqFYQ_8_0"></a><a id="Tc_P16yiPxv002iFxWyZ0_aSg_9_0"></a><a id="Tc_so-S_piaHU6SnSVJ29ALSw_9_2"></a><a id="Tc_cUFytMR5VUWfd87umCXscg_9_3"></a><ix:continuation id="Tb_hOjRUWR00USUKCbpMzwvZw_cont2"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_FAIZ4nGClUqoj3Nt3JGawA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following tables presents changes to the Company&#8217;s liabilities with significant unobservable inputs (Level 3 liabilities) during the years ended December 31, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible notes</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible Note:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Balance as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of BMS Note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="Tc_HxXWtV__Vkyd2f7BPoXHyg_4_3">20,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_O9B88gheUkaquoX_9DV5hA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of BMS Note</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="Tc_pAbh0i3pDEmdgbLmeS4FLw_5_3">300</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Balance as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_LaZRhZfVnUWgIUrlOINM1w_6_3">20,300</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_jVXKwJzbK06otYl6OvTOJw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of BMS Note</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="Tc_I5RsYrfcvkyqApVB81q-Ng_7_3">846</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of Series C Preferred Stock in exchange for BMS Note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="Tc_Znelo1zuDUC4KOxFmKDQ3A_8_3">21,146</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Balance as of December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><a id="_7c615380_fec7_42a9_988c_54ceff68e4bf"></a><a id="Tc_X8XxWlo3IEeJ7OpVh_F9sg_1_2"></a><a id="Tc_Eb6si31zcEanvLb-_4R2kw_2_2"></a><a id="Tc_r5CRwnxDWky4ePVtHZhFrw_2_5"></a><a id="Tc_kfHFUVYb6kiOa9wkbqzC4Q_3_0"></a><a id="Tc_c7nqwPq4JEe6ef1Fs_inRQ_3_2"></a><a id="Tc_3JCZ167ugESP-01-cA9QRA_3_5"></a><a id="Tc_tJaQaI5gUkSO_B3WpQVGTw_4_0"></a><a id="Tc_A2fRKYPA80ObzvBNd8D_fQ_4_3"></a><a id="Tc_jmKxpqqxV0amq-jZkmAxEA_5_0"></a><a id="Tc_ZYH-HVUac0azcOUbXgvHwg_6_0"></a><a id="Tc_olF4zcF6REyolaCU-oex6A_6_2"></a><a id="Tc_KdgG2xgmF0CA4HURXZTCZQ_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:OtherAssetsDisclosureTextBlock" id="Tb_6Sg_GTgMuk-1bN8olDquMA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span>Other Assets</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" id="Tb__f7pUzQ3kEWb1QV-E15AZA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.63%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:54.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical trial deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="3" id="Tc_tRgKFDsUCUmHEyYS1MXucg_3_3">12,639</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="3" id="Tc_o_zxQxFT0kK70ATfe2lhcQ_3_6">5,788</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredCosts" scale="3" id="Tc_37V-WFy0O0yoY4zw-HHY6w_4_6">1,388</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:top;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="3" id="Tc_MWsm3NVPjk6dEeaMM1yimA_5_3">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="3" id="Tc_kaGUyF42rEu9zE1ZxHb-KA_5_6">100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_ylZQzGMVdEO_smswm8lslQ_6_3">12,856</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_45WEFWEzS0CugF7OxVc-ig_6_6">7,276</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c08670e4_6e19_4f71_9461_a9b86a7b54ef"></a><a id="Tc_0Eu9SpIBDk2IQVjGj7beDw_1_1"></a><a id="Tc_MSnABs9HeEitnmdJvbMOhg_2_1"></a><a id="Tc_kkIuA_E95E-13MYoyttHpA_2_4"></a><a id="Tc_uZdifmKs30KlB1J1VWZdrA_4_0"></a><a id="Tc_gYVCJF9npEqkcOJUoSF8KA_4_1"></a><a id="Tc_sCHNfHwIGkeBHMT7Xz__BA_4_4"></a><a id="Tc_rL0LQfIxzUKY3K5osFsARw_5_0"></a><a id="Tc_p5n76HjvjE-NTe1poltjhQ_6_0"></a><a id="Tc_iRwN8Bf4pUeBsofij2mTCw_7_0"></a><a id="Tc_-i9txbmkU0GfDK5yRILjSA_8_0"></a><a id="Tc_ApObdU1ZpUGU0ujuvvRNYg_9_0"></a><a id="Tc_4Axd8u-LFUSwb4uVVSRjsw_9_1"></a><a id="Tc_Ww_nJgKcjkywtArJ0Vhz7g_9_4"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Tb_VBDjlCeFjEq0jEmDf7EPaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></span>Accrued Expenses </p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_z0YvRLV91E-I78DQJCvFKQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:37.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.17%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">External research, development and manufacturing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="zbio:AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent" scale="3" id="Tc_HDSL_A9BOkea2fLsswONVg_4_2">29,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="zbio:AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent" scale="3" id="Tc_NcLDfra8mke7Gx_I4jgv0w_4_5">9,398</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_AknrHAw5oEyIRwAXmnznDw_5_2">8,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_kdTGs6tZUE2HVOjpbn1xfg_5_5">5,122</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional and consultant fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_v4gOBki7dkyL_gA_Xj_4zg_6_2">1,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_0NBVdfylDU2CtBJlJ89Gxg_6_5">2,379</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc_K2w6ieojb0mZCdqSIuB10Q_7_2">211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc__MtnqxOB-kut545Q_0fkLQ_7_5">301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_Ryiq3Ho9TUyYCAc4ScXRxQ_8_2">249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_vi_EK1b3-0eELN_SAIZBXw_8_5">106</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_NNYI3crLJ0ORCRuu9pId0A_9_2">39,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_MkF-bqmH-kixGackj8cMbw_9_5">17,306</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_8okKBxh4FEORV8W19p36Bg" continuedAt="Tb_8okKBxh4FEORV8W19p36Bg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">.</b></span>Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI';font-size:9pt;">T</span><span style="letter-spacing:0.2pt;">he Company has various leases for office space, which are accounted for as operating leases and generally have terms of less than </span><ix:nonNumeric contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_NqRrhXWjukms89aBos1YMQ"><span style="letter-spacing:0.2pt;">two years</span></ix:nonNumeric><span style="letter-spacing:0.2pt;"> in length, some of which have the option to renew. The Company recognizes monthly operating lease expense on a straight-line basis over the term of the lease as general and administrative expenses in the consolidated statements of operations and comprehensive loss. Variable lease expense relates primarily to office lease common area maintenance, insurance, and property taxes, is expensed as incurred, and is excluded from the </span></p></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4d8a8bc4_f9f8_4a8e_a355_b65d18bb131a"></a><a id="Tc_xZnGwIBOuUOP7QH8bomiLA_1_2"></a><a id="Tc_59XY2PDbi0CtY_K-UW47rg_2_3"></a><a id="Tc_S4LeIR0p8E-CH-KRbVYr5g_2_6"></a><a id="Tc_tAxBztzqC0mzHSXESkkkWQ_3_0"></a><a id="Tc_HuQoDQ0k2U-06OK1M0j9vA_3_2"></a><a id="Tc_IfKrCR4F-EqpPp8Y9thWwA_3_5"></a><a id="Tc_PoeobsBm8UqQ-1iQ0o4rzg_4_0"></a><a id="Tc_QWeE50CJl0aLdKGiiDJqJA_4_2"></a><a id="Tc_6apbFLJw-Ey6PRdmelicSw_4_5"></a><a id="Tc_LqvJNXp9dU2X8usjm3Rv7Q_5_0"></a><a id="Tc_D3XFfZd2Qki11mdrMkuPow_6_0"></a><a id="Tc_4yqOQbP21kGbA0eBG9sZNA_1_0"></a><a id="Tc_ggwr2DtTjk-rAR8aW7dAIw_1_2"></a><a id="Tc_5KTSCtsI8E-8pZ_hSYmYVg_2_0"></a><a id="Tc_lsLcUNPQt0eaPkQRnGPq-A_2_2"></a><a id="Tc_7VVWOg_of06HDbt1CCuPBA_3_0"></a><a id="Tc_F3hwPqe8wkGo8XdIrvC54w_4_0"></a><a id="Tc_Qm4bxePTukKwxKXouXYl_g_4_3"></a><a id="Tc_n8Jpv9nSxUqrWTYQ2n8uuA_5_0"></a><a id="Tc_Ngjytg0lREeFWyhHGxj9uA_6_0"></a><a id="Tc_Vhx4ReHxUkSEy1P-HwQtRw_7_0"></a><a id="Tc_je9mlJMkbkKyWXUd7uYpUw_7_2"></a><ix:continuation id="Tb_8okKBxh4FEORV8W19p36Bg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">calculation of the lease liabilities and right-of-use assets. For each of the years ended December 31, 2024 and 2023, the Company incurred variable lease expense of </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="6" id="Narr_xhdPI8HRt0KGuM6Pr8uYcg"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="6" id="Narr_XN6QuZDO6EygE_aePzKG8g">0.1</ix:nonFraction></ix:nonFraction></span><span style="letter-spacing:0.2pt;"> million, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:LeaseCostTableTextBlock" id="Tb_QRxe4FKkpUGksA5JGuqYEg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Supplemental balance sheet information related to operating lease assets and liabilities was as follows (in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_RJO5hxFg5kefDctb_QQwoQ_3_3">1,004</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_1DmQjY1iZEKP2U28RctyyA_3_6">821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_pizFkit59kyQ6tHRo2yr_A_4_3">1,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_99evoBAlRkGPoKLrOqKosw_4_6">813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_6ELP2yTDREC5T-Lxlq553w_5_3">1.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_AMOqqB7I6Ei8s5O9-qDoWQ_5_6">1.6</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate used to measure lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_66_dXZblfkWRphud2IPcVQ_6_3">10.99</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_twt-4mhQg0yET2bg7hxtMg_6_6">18.39</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">For each of the years ended December 31, 2024 and 2023, the total lease cost for operating leases (recorded in general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss) was </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="6" id="Narr_69mNCFfPNEGid32NySYYfA"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="6" id="Narr_JnLw-tMRKE6CZjJ8wfaGxg">0.9</ix:nonFraction></ix:nonFraction></span><span style="letter-spacing:0.2pt;"> million, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The minimum lease payments under the Company&#8217;s operating leases are expected to be as follows:</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="zbio:LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock" id="Tb_HoIA2BTTaUWYhfbmDYuzXg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fiscal Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_kKxRmYpewEOUNsch2Qqzxw_2_3">896</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_uO-QI7eziEypWvmp7XIcjQ_3_3">241</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_WMN-RoMUs06KnyziN85ngw_5_3">1,137</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_CWjpU0upgEO9G0FIMGKjyQ_6_3">134</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_44QzX6GIhUGcBnV-ceuamw_7_3">1,003</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">During the year ended December 31, 2024, the amount of right-of-use assets obtained under new operating lease arrangements was </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-5" format="ixt:num-dot-decimal" name="zbio:RightOfUseAssetObtainedUnderNewLeaseArrangement" scale="6" id="Narr_5bGg5AHe3EKrFNAwfB4vwQ">1.1</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> million. There were </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-5" format="ixt-sec:numwordsen" name="zbio:RightOfUseAssetObtainedUnderNewLeaseArrangement" scale="6" id="Narr_YVA90ZgD-k6Ov-pGAL7JvA">no</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> right-of-use assets obtained under new operating lease arrangements during the year ended December 31, 2023. Cash paid for lease liabilities was </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_Qcw_a4k81E6wBZLneCdkEA"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_unB3tkRz3kGtF-J9L9z25g">0.9</ix:nonFraction></ix:nonFraction></span><span style="letter-spacing:0.2pt;"> million for the years ended December 31, 2024 and 2023, respectively.</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_ewJybHwm1EmuDAVg78aj4w" continuedAt="Tb_ewJybHwm1EmuDAVg78aj4w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></span>License and Collaboration Revenue </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">License and Collaboration Agreement with Bristol-Myers Squibb</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August&#160;2023, the Company entered into a license and collaboration agreement with Bristol-Myers Squibb (the &#8220;BMS Agreement&#8221;), under which the Company granted BMS an exclusive license to (i)&#160;develop, manufacture (subject to the Company&#8217;s rights to be the exclusive manufacturer for BMS for a certain period of time), commercialize or otherwise exploit obexelimab and any biological product (irrespective of presentations, formulations or dosages) containing obexelimab but not any of the Company&#8217;s other proprietary active ingredient (the &#8220;BMS Product&#8221;) into Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia (collectively, the &#8220;BMS Territory&#8221;) and (ii)&#160;develop and manufacture obexelimab and the BMS Product outside the BMS Territory provided that obexelimab and the BMS Product are solely used in the BMS Territory. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the BMS Agreement, BMS paid the Company a one-time non-refundable upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_8_1_2023_To_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_68E-30ZXOka0SQILO84I2w" decimals="-5" format="ixt:num-dot-decimal" name="zbio:CollaborativeArrangementUpfrontPaymentReceived" scale="6" id="Narr_bvfHjRA01k2sgohT2fm5WQ">50.0</ix:nonFraction> million. The Company is entitled to receive further separate development and regulatory milestone payments from BMS up to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_yjecN0IOyEe3rAsWgnm7iQ" decimals="-5" format="ixt:num-dot-decimal" name="zbio:CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum" scale="6" id="Narr_d9NFml-LZU63Y9_qg1tELQ">79.5</ix:nonFraction> million. The Company is also entitled to receive one-time sales milestone payments up to $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_yjecN0IOyEe3rAsWgnm7iQ" decimals="-5" format="ixt:num-dot-decimal" name="zbio:CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum" scale="6" id="Narr_1DP9Y6JmrkiHyN0Z6RePKg">70.0</ix:nonFraction> million upon BMS achieving certain net sales milestones in a given year in the BMS Territory. The Company is also eligible to receive tiered high single-digit to low double-digit royalties on net sales in the BMS Territory, subject to specified reductions.</p></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0ab93f6b_933e_4f2c_a807_dbdff81cd152"></a><a id="_0ab93f6b_933e_4f2c_a807_dbdff81cd152_2"></a><a id="_0ab93f6b_933e_4f2c_a807_dbdff81cd152_3"></a><ix:continuation id="Tb_ewJybHwm1EmuDAVg78aj4w_cont1" continuedAt="Tb_ewJybHwm1EmuDAVg78aj4w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company will continue to perform and oversee the ongoing Phase 3 trial of obexelimab in the IgG4-RD indication and BMS will participate in the performance of the study. BMS also has the right to participate in other global clinical studies that the Company chooses to perform. Pursuant to such global studies, including the IgG4-RD study, the Company and BMS have defined roles with specified activities assigned to each party in their respective jurisdictions. These activities are overseen by a joint steering committee, which has equal representation of the parties. BMS will fund their pro rata share of the total global study costs up to a specified percentage of the patients enrolled in the study from the BMS Territory. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Should the percentage of patients from the BMS Territory fall below the specified percentage, BMS&#8217;s funding would proportionately decrease. BMS is responsible for the development and commercialization of obexelimab within the BMS Territory, including the performance of any local studies within its jurisdiction that it chooses to perform, while the Company retains responsibility for the development and commercialization for the remainder of the world. The Company is responsible for manufacturing the clinical supply and commercial supply of obexelimab, each at cost plus single-digit margin. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluated the terms of the BMS Agreement to determine whether it is a collaborative arrangement in the scope of ASC 808. The Company concluded that the BMS Agreement is a collaborative arrangement under ASC 808 as both parties are active participants in the global clinical trial and are exposed to significant risks and rewards of those activities. The Company determined that the BMS Agreement contained two material components: (i) the license granted to BMS to develop, manufacture and commercialize obexelimab within the BMS Territory, and related activities in the BMS Territory, including manufacturing and (ii) the global development of obexelimab, which at execution, solely relates to the ongoing Phase 3 trial for IgG4-RD. The Company used criteria specified in ASC 606 to determine whether the components of the BMS Agreement are performance obligations to a customer and concluded that BMS is the Company&#8217;s customer for the license and related activities in the BMS Territory under ASC 606. The global development activities under the agreement do not represent a transaction with a customer and reimbursement payments received by the Company for global development activities are accounted for as a reduction of the related research and development expenses. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_N0JzawarFE2rMLM5lKwjiw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="Narr__3y6VCFTYUCV-iV58lHC3Q">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_NYcJR8lqrkCLowTMNFUBTg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="Narr_DPP6eahpuUW0esq4W575hQ">4.1</ix:nonFraction> million as a reduction to research and development expenses during the years ended December 31, 2024 and 2023, respectively, with $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_CISJK2ppnkmIAMwch3Q_OA" decimals="-5" format="ixt:num-dot-decimal" name="zbio:CollaborativeArrangementReceivables" scale="6" id="Narr_posAD8mpTk-W0nGVMzJGyw">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_q9l-Yh0Dr0qScfAPmFwVvA" decimals="-5" format="ixt:num-dot-decimal" name="zbio:CollaborativeArrangementReceivables" scale="6" id="Narr_GySlWgGJLEeSwkBt12Ccww">1.3</ix:nonFraction> million of outstanding receivable, included in prepaid expenses and other current assets on the Company&#8217;s consolidated balance sheet as of December 31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluated the license and related activities under ASC 606 as these transactions are considered transactions with a customer, and identified four material promises at the outset of the BMS Agreement, which consists of (i) the exclusive license, (ii) the initial technology transfer, (iii) clinical manufacturing supply related to development in the BMS Territory and (iv) commercial manufacturing supply related to commercialization within the BMS Territory. The Company determined that the exclusive license and initial technology transfer were not distinct from each other, as the exclusive license has limited value without the corresponding technology transfer. As such, for the purposes of ASC 606, the Company determined that the two material promises, the exclusive license and the initial technology transfer, should be combined into one distinct performance obligation. The Company further evaluated the material promise associated with the clinical manufacturing supply and the commercial manufacturing supply, within the BMS Territory, concluding that because BMS is not obligated to purchase any minimum amount, the clinical manufacturing supply and commercial manufacturing supply represent a purchase option and not a performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company further concluded that the customer option is not priced at a significant and incremental discount at the execution of the arrangement and therefore does not represent a material right. Therefore, each of the clinical and commercial manufacturing activities were excluded as performance obligations at the outset of the arrangement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The transaction price of the BMS Agreement was determined to be $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_8_1_2023_To_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_68E-30ZXOka0SQILO84I2w" decimals="-5" format="ixt:num-dot-decimal" name="zbio:CollaborativeArrangementTransactionPrice" scale="6" id="Narr_8tPOxQldEkm8JW7NP0UeiQ">50.0</ix:nonFraction> million, which consisted of the upfront cash payment, and was allocated to the one combined performance obligation. The other potential consideration, which includes development, regulatory, and sales milestone payments that the Company is eligible to receive were excluded from the transaction price, as all milestones were not deemed probable of achievement and were therefore fully constrained. The Company issued the BMS Note in connection with the BMS Agreement, and the BMS Note was recorded at fair value separate from the transaction price of the BMS Agreement (see<i style="font-style:italic;"> Note 3, Fair Value Measurements</i>). The Company reevaluates the transaction price at the end of each reporting period as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company adjusts its estimate of the transaction price, and any addition to the </p></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_ewJybHwm1EmuDAVg78aj4w_cont2" continuedAt="Tb_ewJybHwm1EmuDAVg78aj4w_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">transaction price would be recognized as revenue when it becomes probable that inclusion would not lead to a significant revenue reversal. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluated the license under ASC 606 and concluded that the license is a functional intellectual property license. The Company determined that BMS benefited from the license along with the initial technology transfer at the time of the transfer, and therefore the related performance obligation is satisfied at a point in time. The Company satisfied the performance obligation through delivery of the license and initial technology transfer and therefore recognized the upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_NYcJR8lqrkCLowTMNFUBTg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_J3AzWjfi6EGV5EGy2X77PA">50.0</ix:nonFraction> million as revenue during year ended December 31, 2023. The Company did not recognize revenue under this arrangement in the year ended December 31, 2024, as no milestones were achieved or deemed probable of achievement, and as such, all remaining milestones remained fully constrained and excluded from the transaction price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Tenacia Biotechnology Co. Novation Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2024, the Company entered into a novation agreement with Tenacia Biotechnology (Hong Kong) Co., Limited (&#8220;Tenacia&#8221;), under which the Company transferred its rights and obligations under the agreements with Dianthus to Tenacia (the &#8220;Tenacia Agreement&#8221;). Pursuant to the Tenacia Agreement, the Company, transferred all the ZB005 inventory, analytical methods and manufacturing records generated, under the Dianthus Option Agreement and the License Agreement (collectively the &#8220;Dianthus Agreements&#8221;), see <i style="font-style:italic;">Note 8, License and Options Agreements, </i>for additional information, to Tenacia, for the exclusive right to research, develop, manufacture and commercialize products within greater China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Tenacia Agreement, Tenacia paid the Company a one-time non-refundable upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_TypeOfArrangementAxis_zbio_NovationAgreementMember_lnQAUx2mlkib0BNiLe_Jxg" decimals="-5" format="ixt:num-dot-decimal" name="zbio:CollaborativeArrangementUpfrontPaymentReceived" scale="6" id="Narr_8PbE3GyRC0m3UlH4AiaSZg">5.0</ix:nonFraction> million. The Company is entitled to receive further development, regulatory and sales milestones from Tenacia of up to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_10_31_2024_us-gaap_TypeOfArrangementAxis_zbio_NovationAgreementMember_8o3sYZV3iUWz0FuKhL7jow" decimals="-5" format="ixt:num-dot-decimal" name="zbio:CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum" scale="6" id="Narr_14rZmif32UihWFbqw35quw">86.0</ix:nonFraction> million if certain milestones are successfully achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluated the terms of the Tenacia Agreement and determined it is within the scope of <i style="font-style:italic;">ASC 606</i>. The Company identified the following promises in the Tenacia Agreement that were evaluated under the scope of <i style="font-style:italic;">ASC 606:</i> (i) transfer of the license, (ii) assignment of all rights, title and interests in ZB005 inventory, manufacturing records, analytical methods and draft IND component, (iii) services to be performed in accordance with manufacturing technology transfer and (iv) transfer, up to one year after the effective date, of any tangible embodiments of know-how that was not previously provided. The Company also evaluated whether certain options outlined in the Tenacia Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options conveyed a material right to Tenacia and, therefore, are not considered separate performance obligations within the Tenacia Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company assessed the above promises and determined that the license for ZB005, asset transfer and technology transfer are a combined distinct performance obligation within the scope of <i style="font-style:italic;">ASC 606</i>. &#160;The future technology know-how transfer services, for one year after the effective date, is a promise that is separately identifiable. The Company determined the likelihood of Tenacia requesting additional know-how transfer to be remote and any requests to require minimal resource allocation, as the Company has concluded all work on ZB005 within greater China. As such, the Company considered the continued know-how transfer to be immaterial in the context of the promises. Therefore, the license, asset transfer and technology transfer represent a single performance obligation within the scope of <i style="font-style:italic;">ASC 606</i> at contract inception. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company concluded that the transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_TypeOfArrangementAxis_zbio_NovationAgreementMember_lnQAUx2mlkib0BNiLe_Jxg" decimals="-5" format="ixt:num-dot-decimal" name="zbio:CollaborativeArrangementTransactionPrice" scale="6" id="Narr_jvRKRixNyUCI-v9142_uUQ">5.0</ix:nonFraction> million was allocated to the combined performance obligation, which was recognized upon delivery prior to December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company used the most likely amount method to estimate variable consideration and estimated that the most likely amount for each potential developmental and regulatory variable consideration milestone payment under the agreement is zero, as achievement of those milestones is uncertain and susceptible to factors outside the Company&#8217;s control. Accordingly, all such milestone payments were excluded from the transaction price. Management will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, will adjust the transaction price as necessary. Sales based milestones structured on the level of sales, were also excluded from the transaction price, as the license is deemed to be the predominant item to which the sales relate. The Company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </p></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_ewJybHwm1EmuDAVg78aj4w_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, no milestones were achieved or deemed probable of achievement. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="zbio:LicenseAndOptionAgreementsDisclosureTextBlock" id="Tb_0NRmQlpMIk21LAolTc8n8A" continuedAt="Tb_0NRmQlpMIk21LAolTc8n8A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></span>License and Option Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Xencor,&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2020 Xencor Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">In September&#160;2020, the Company entered into a license agreement (the &#8220;2020 Xencor Agreement&#8221;) with Xencor, Inc. (&#8220;Xencor&#8221;), to obtain (i)&#160;an exclusive, royalty-bearing, sublicensable worldwide license under certain patent rights controlled by Xencor and (ii)&#160;a non-exclusive payment bearing license under certain know-how controlled by Xencor to research, develop, manufacture, market and sell </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw" contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_WGP9j066HEmWArI6WB0Cow" decimals="INF" format="ixt-sec:numwordsen" name="zbio:NumberOfAntibodyProductCandidates" scale="0" id="Narr_s_yjbNGvs0Wi7DnzNPyr6w">three</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> antibody product candidates, including ZB002. The 2020 Xencor Agreement became effective in November&#160;2020, upon the Company&#8217;s issuance of </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_WGWYo6VeoEWAuqXTVFh8WQ" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_t2cIxBdarkKkS2pNpHc00Q">5,041,542</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> shares of its Series&#160;A Preferred Stock, which had a fair value of </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_WGWYo6VeoEWAuqXTVFh8WQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_2OTY3U5R9EuodorB9yvu5w">16.1</ix:nonFraction></span><span style="letter-spacing:0.2pt;">&#160;million to Xencor as initial consideration. The Company concluded that as no processes or other activities that would constitute a business were acquired, and the acquired assets did not have an alternative future use, the upfront consideration was expensed to acquired IPR&amp;D during the year ended December&#160;31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company is required to pay Xencor tiered royalties on annual net sales of successfully commercialized products utilizing the licensed assets. The royalty&#160;percentage rates vary by geographic areas as defined in the 2020 Xencor Agreement and range from the mid-single digits to the mid-teens.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company is also obligated to reimburse Xencor for third-party costs incurred by Xencor for certain patent filings, prosecution and maintenance as further specified in the 2020 Xencor Agreement. During the&#160;year ended December&#160;31, 2024 </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_86ES1U6DdEiWj8UWmZ87Nw" decimals="-5" format="ixt-sec:numwordsen" name="zbio:CollaborativeArrangementTransactionPrice" scale="6" id="Narr_J9dH18jP_0mQEWXNyeVaqw">no</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> costs were incurred related to the 2020 Xencor Agreement. During the year ended December 31, 2023, the Company incurred immaterial costs related to the 2020 Xencor Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2021 Xencor Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">In May&#160;2021, the Company entered into a license agreement (the &#8220;2021 Xencor Agreement&#8221;) with Xencor to obtain an (i)&#160;exclusive, royalty-bearing, sublicensable worldwide license under certain patent rights controlled by Xencor and (ii)&#160;a non-exclusive payment bearing license under certain know-how controlled by Xencor to research, develop, manufacture, market and sell obexelimab. The 2021 Xencor Agreement became effective in November&#160;2021, upon the execution of an amendment to the 2021 Xencor Agreement and the Company&#8217;s concurrent issuance of a warrant to Xencor (the &#8220;Xencor Warrant&#8221;) as initial consideration, which entitled Xencor to receive a number of the Company&#8217;s convertible preferred stock in the Company&#8217;s next &#8220;qualified financing&#8221;. The Company concluded that as no processes or other activities that would constitute a business were acquired, and the acquired assets did not have an alternative future use, the upfront consideration of </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_dyYvSl_2AEyLjKyAcaDc4w" decimals="-5" format="ixt:num-dot-decimal" name="zbio:CollaborativeArrangementTransactionPrice" scale="6" id="Narr_rxc_4yI86UWXUUMP5NBxug">20.7</ix:nonFraction></span><span style="letter-spacing:0.2pt;">&#160;million was expensed to acquired IPR&amp;D during the year ended December&#160;31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company is obligated to make specified development, regulatory and commercial milestone payments of up to </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_5_31_2021_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_r2kEzq5fF0emBdihAC_LuQ" decimals="-5" format="ixt:num-dot-decimal" name="zbio:LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable" scale="6" id="Narr_kppeWa-V2kG5vqMx9OUxqg">10.0</ix:nonFraction></span><span style="letter-spacing:0.2pt;">&#160;million at Xencor&#8217;s option either in cash or fully-paid newly issued shares. The Company is obligated to make regulatory milestone payments up to </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_5_31_2021_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_r2kEzq5fF0emBdihAC_LuQ" decimals="-5" format="ixt:num-dot-decimal" name="zbio:LicenseAndOptionAgreementsRegulatoryMilestonePayable" scale="6" id="Narr_K_CAPcJqU0S3F2mN16ZVwA">75.0</ix:nonFraction></span><span style="letter-spacing:0.2pt;">&#160;million. The Company is also obligated to make one-time sales milestone payments up to </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_5_31_2021_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_r2kEzq5fF0emBdihAC_LuQ" decimals="-5" format="ixt:num-dot-decimal" name="zbio:LicenseAndOptionAgreementsSalesMilestonePayable" scale="6" id="Narr_bNxz2Va90U2hJWANA-JTEg">385.0</ix:nonFraction></span><span style="letter-spacing:0.2pt;">&#160;million upon achieving milestone events of net sales in a given calendar year in the territory equal to certain threshold amounts. In addition, the Company is required to pay Xencor tiered royalties on annual net sales of successfully commercialized products utilizing obexelimab, with the royalty rates varying based on regions and ranging from the mid-single digits to the mid-teens.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">In April&#160;2023, the Company incurred a </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_4_30_2023_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_DlfSbRkRKkikwGFbk82kmQ" decimals="-5" format="ixt:num-dot-decimal" name="zbio:LicenseAndOptionAgreementsDevelopmentMilestonePayable" scale="6" id="Narr_MjX_ou3O-0uBWAqa08HvRw">10.0</ix:nonFraction></span><span style="letter-spacing:0.2pt;">&#160;million development milestone pursuant to the 2021 Xencor Agreement, which Xencor elected to receive in the form of the Company&#8217;s Series&#160;B Preferred Stock. </span>See <i style="font-style:italic;">Note&#160;9, Convertible Preferred Stock,</i> for details<span style="letter-spacing:0.2pt;">. The milestone was recorded as acquired IPR&amp;D expense in the Company&#8217;s consolidated statements of operations and comprehensive loss. The Company did not record any expenses related to reimbursable patent-related costs during the year ended December 31, 2024. The Company recorded an immaterial amount to general and administrative expenses in the consolidated statements of operations and comprehensive loss </span></p></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_0NRmQlpMIk21LAolTc8n8A_cont1" continuedAt="Tb_0NRmQlpMIk21LAolTc8n8A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">during each of the&#160;year ended December&#160;31, 2023, relating to reimbursable patent-related costs owed to Xencor. </span>During the year ended December 31, 2024 <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_JXqZc5v7Z0WJSg_JLf5b5g" decimals="-5" format="ixt-sec:numwordsen" name="zbio:LicenseAndOptionAgreementsDevelopmentMilestonePayable" scale="6" id="Narr__G72MG-mTEyHsXQPVcDSEA">no</ix:nonFraction> milestone expense was incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Dianthus Therapeutics&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">In September&#160;2020, the Company entered into an agreement (the &#8220;Dianthus Option Agreement&#8221;) with Dianthus Therapeutics Inc. (&#8220;Dianthus&#8221;), a therapeutic antibody company. Under the terms of the Dianthus Option Agreement, the Company obtained an exclusive option to negotiate and enter into exclusive license agreements with Dianthus for the rights to research, develop, manufacture, market and sell products related to either or both of </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw" contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_PgETU9rFK0q2wG2LI9cG2g" decimals="INF" format="ixt-sec:numwordsen" name="zbio:NumberOfAntibodyProductCandidates" scale="0" id="Narr_O5XFl0OjzEauUkZXJi5Qig">two</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> antibody product candidates based on Dianthus&#8217; proprietary technology in China, Hong Kong, Macau and Taiwan (the &#8220;Zenas Territories&#8221;). Dianthus retains all rights to develop and commercialize the product candidate subjects of the two options outside of the Zenas Territories. Upon execution of the Dianthus Option Agreement, the Company issued </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_bzLuOSUTJEyZzSgS11je2Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_IQbK9L7J60S2mN7F_rz5YA">18,063</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> shares of its common stock to Dianthus as initial consideration, which was recorded to acquired IPR&amp;D expense during the year ended December&#160;31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Under the Dianthus Option Agreement, Dianthus will notify the Company when it has identified each of </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw" contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_PgETU9rFK0q2wG2LI9cG2g" decimals="INF" format="ixt-sec:numwordsen" name="zbio:NumberOfAntibodyProductCandidates" scale="0" id="Narr_cUscKJ2a7k-nBouDW1-C8Q">two</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> antibody product candidates, and the Company will then have sixty (</span><ix:nonNumeric contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_PgETU9rFK0q2wG2LI9cG2g" format="ixt-sec:durday" name="zbio:ThresholdPeriodToNotifyIntentionForExercisingOption" id="Narr_KXi2Nt7eb0O5kAHfYqn6ug"><span style="letter-spacing:0.2pt;">60</span></ix:nonNumeric><span style="letter-spacing:0.2pt;">) days to notify Dianthus if the Company intends to exercise each of the options. In September&#160;2021, Dianthus notified the Company that it had identified the first lead antibody product candidate pursuant to the Dianthus Option Agreement, ZB005 (also known as DNTH103). In October&#160;2021, the Company notified Dianthus of its intention to exercise its option to ZB005 pursuant to the Dianthus Option Agreement. This notification resulted in a </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_10_31_2021_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_Bm0Xi9UVpUmszqhYv-4qFg" decimals="-5" format="ixt:num-dot-decimal" name="zbio:LicenseAndOptionAgreementsDevelopmentMilestonePayable" scale="6" id="Narr_iOFatTlHAki6SEpzYEHH8Q">1.0</ix:nonFraction></span><span style="letter-spacing:0.2pt;">&#160;million milestone obligation to Dianthus, which was expensed in 2021 upon exercise and subsequently paid during the year ended December&#160;31, 2022. The Company and Dianthus executed a license agreement for ZB005 in June&#160;2022 (the &#8220;Dianthus License Agreement&#8221;). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company is also required to reimburse Dianthus for a specified&#160;percentage of certain third-party costs which Dianthus incurs in its initial discovery and development activities related to each of the two options. To date, the Company has only exercised its option with respect to the ZB005 program, and as a result, it has only reimbursed Dianthus with respect to costs associated with the ZB005 program. During the&#160;years ended December&#160;31, 2024 and 2023, the Company incurred </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_ucAh8N2LEkm-jJRZJUsugg" decimals="-5" format="ixt:num-dot-decimal" name="zbio:LicenseAndOptionAgreementsReimbursableExpenses" scale="6" id="Narr_4JScSvBWNEKLTDz0iShycg">5.1</ix:nonFraction></span><span style="letter-spacing:0.2pt;">&#160;million and </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_3OZtyHKQXEeOnEHLhY6SNg" decimals="-5" format="ixt:num-dot-decimal" name="zbio:LicenseAndOptionAgreementsReimbursableExpenses" scale="6" id="Narr__7w3qhBZ5kuL5Wul7U7jqQ">3.0</ix:nonFraction></span><span style="letter-spacing:0.2pt;">&#160;million of reimbursable expenses, respectively, which are recorded within research and development expenses in the consolidated statements of operations and comprehensive loss. Of these amounts, </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_IxVPwAMKEkiMUjSqIZE_PQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="Narr_3mSMc8wPE0quXXgqC2mUfQ">0.5</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> million and an immaterial amount were recorded in accounts payable, and </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_IxVPwAMKEkiMUjSqIZE_PQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="Narr_FXI1KLQZBk26PD2z3TpcTQ">0.3</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> million and </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_yR58FFqVa0-kULPck87ZxA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="Narr_tCMnwwSzkUutrBeZbQpRTw">0.4</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> million were recorded in accrued expenses on the Company&#8217;s consolidated balance sheets as of December&#160;31, 2024 and 2023, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The binding key terms included in the Dianthus License Agreement, and that would be included in a future license agreement if the Company exercises its option with respect to a second research program, also include the Company&#8217;s obligation to make specified development milestone payments to Dianthus, one time only, regardless of the number of assets the Company in-licenses from Dianthus with respect to such research program. The milestone obligations for each research program would total up to </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_ZrowpMBVWkeOdGC2HRwpgg" decimals="-5" format="ixt:num-dot-decimal" name="zbio:LicenseAndOptionAgreementsMaximumMilestoneObligation" scale="6" id="Narr_ZmTR7biuf0yMNzuYRt_CMA">11.0</ix:nonFraction></span><span style="letter-spacing:0.2pt;">&#160;million, based on achievement of each of the specified milestone events. If the Company successfully commercializes a product(s) under a license agreement, the Company will be obligated to make tiered royalty payments, on a product-by-product basis, to Dianthus on annual net sales of such products. Royalties will be calculated as specified&#160;percentages of annual net sales, ranging from the mid-single digits to the low-double digits, with each specified tiered level of annual net sales having a specified&#160;percentage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2024, the Company entered into the Tenacia Agreement. Pursuant to the Tenacia Agreement, the Company transferred its rights, and obligations under the Dianthus Option Agreement and the Dianthus License Agreement to Tenacia. As a result, Zenas has no further obligations to Dianthus under the Dianthus Option Agreement and the Dianthus License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our Tenacia Agreement, please see <i style="font-style:italic;">Note 7, License and Collaboration Revenue</i>, to these consolidated financial statements. </p></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_0NRmQlpMIk21LAolTc8n8A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Viridian Therapeutics,&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">In October&#160;2020, the Company entered into a license agreement with Viridian Therapeutics, Inc. (&#8220;Viridian&#8221;), to obtain an exclusive, royalty-bearing, sublicensable license to research, develop, manufacture, market and sell certain antibody product candidates based on Viridian&#8217;s proprietary technology (the &#8220;Viridian Agreement&#8221;). The Company&#8217;s license rights are limited to non-oncology indications and to the Zenas Territories. Viridian retains its rights to develop and commercialize such product candidates outside of the Zenas Territories. Upon execution of the Viridian Agreement, the Company issued </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_KSqzhLiyzEyDgl5ybmBLIg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_YxIeg8-IgU-tzNXKNUk7Kw">38,707</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> shares of its common stock to Viridian as initial consideration which was recorded as acquired in-process research and development expense in its consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company is obligated to make development milestone payments to Viridian, totaling up to </span><span style="letter-spacing:0.2pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_10_31_2020_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_LluPYzM7VEa_H16QX3m4Sw" decimals="-5" format="ixt:num-dot-decimal" name="zbio:LicenseAndOptionAgreementsDevelopmentMilestonePayable" scale="6" id="Narr_pBC5cxmwrkWJ_8Mv568C3A">12.0</ix:nonFraction></span><span style="letter-spacing:0.2pt;">&#160;million, based on achievement of each of the specified milestone events. The Company is also required to pay Viridian tiered royalties on annual net sales of successfully commercialized products utilizing the licensed technology. The royalty&#160;percentage rates range from the mid-single digits to the low-double digits. During the year ended December&#160;31, 2024 and 2023, the Company did not incur or pay any milestones to Viridian. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2021, the Company and Viridian entered into two letter agreements to authorize initiation of certain manufacturing and development activities related to the licensed product candidate, ZB001 (also known as VRDN-001). In each of the letter agreements the Company requested, and Viridian agreed, to engage a third-party contract manufacturer (the &#8220;CMO&#8221;) to initiate certain work with respect to activities pursuant to one or more statements of work under existing agreements between Viridian and the two CMOs. In May&#160;2022, the Company entered into a manufacturing development and supply agreement with Viridian. The Company pays Viridian for all amounts the CMOs invoice to Viridian for the specified activities. The first letter agreement subsequently was amended three times to add further activities and costs to those detailed in the original letter agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">During the&#160;years ended December&#160;31, 2024 and 2023, the Company recognized an immaterial amount of expenses, respectively, which were recorded in research and development expenses in the consolidated statements of operations. </span>As of December 31, 2024, and 2023, immaterial amounts were recorded in accounts payable and accrued expenses. Viridian has agreed to reimburse the Company for certain services it performs on Viridian&#8217;s behalf, with reimbursements being recorded as a reduction in research and development expenses. During the year ended December 31, 2024, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_qV1cIVkt2kOoAoLtymHm9A" decimals="-5" format="ixt:num-dot-decimal" name="zbio:LicenseAndOptionAgreementsReimbursableExpenses" scale="6" id="Narr_YYPpICmnKkSdHdxQMk20pg">1.7</ix:nonFraction> million in reimbursable expenses. During the year ended December 31, 2023, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_4pkbHJxyX0aZXqN77xa8Kg" decimals="-5" format="ixt-sec:numwordsen" name="zbio:LicenseAndOptionAgreementsReimbursableExpenses" scale="6" id="Narr_M6dfSa0tpki5BmYjkkbkBQ">no</ix:nonFraction> reimbursable expenses. <span style="letter-spacing:0.2pt;">As of December&#160;31, 2024, Viridian had not notified the Company of any additional antibody product candidate.</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="zbio:TemporaryEquityDisclosureTextBlock" id="Tb_tcq5xYmURU2exhdPMq4vsg" continuedAt="Tb_tcq5xYmURU2exhdPMq4vsg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></span>Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September&#160;2020, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_O_WkNZwcXUq8f-ADKZOHMg" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_-qAUEL013UefH1-m8dCTZQ">1,785,714</ix:nonFraction> shares of Series&#160;Seed convertible preferred stock (&#8220;Series&#160;Seed Preferred Stock&#8221;) in a private financing transaction, at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_9_30_2020_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_np8ZhIOstUKtfTT_-Yj3vw" decimals="2" format="ixt:num-dot-decimal" name="zbio:TemporaryEquitySharesIssuedPricePerShare" scale="0" id="Narr_Lu0ibupTyEaobJN8Sxr32g">0.56</ix:nonFraction> per share, for total net cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_O_WkNZwcXUq8f-ADKZOHMg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_bCcAH0pI5UqeAPmmkE0a2A">1.0</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160;2020, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2020Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ybTmDoxkwUu0xUQqRigT7Q" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ysqZwhxZnk2qSnDrUn_KYQ">5,041,542</ix:nonFraction> shares of Series&#160;A convertible preferred stock (&#8220;Series&#160;A Preferred Stock&#8221;) to Xencor as initial consideration for the 2020 Xencor Agreement. Also in November&#160;2020, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VUl7HtcvHkydsDN2_JnMRg" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_V5YjctrxW0SMAdU2N6G00A">12,547,838</ix:nonFraction> shares of Series&#160;A Preferred Stock in a private financing transaction, at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_j5jOOcuea0CX4dm8xBjYxA" decimals="4" format="ixt:num-dot-decimal" name="zbio:TemporaryEquitySharesIssuedPricePerShare" scale="0" id="Narr_L2whQNSnVkiR24mku6jrBQ">3.1878</ix:nonFraction> per share, for total net cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VUl7HtcvHkydsDN2_JnMRg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_u1zZs_EXg0SfwjcPnOpi_g">39.9</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160;2022, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_TYxqnXTkYU-hgPL5w_6nXg" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_36dS4bDki0W2F8r1WbCZKA">25,139,732</ix:nonFraction> shares of Series&#160;B Preferred Stock in a private financing transaction, at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_11_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_P-kTuepM7kKaqc4rCr2AAQ" decimals="5" format="ixt:num-dot-decimal" name="zbio:TemporaryEquitySharesIssuedPricePerShare" scale="0" id="Narr_7ZB99ZQ5JkyontYWEgqDzQ">2.38666</ix:nonFraction> per share, for total net cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_TYxqnXTkYU-hgPL5w_6nXg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_WdDnWuHtW0WQe5LUn-QA7A">59.4</ix:nonFraction> million. Concurrent with the issuance and sale of the Series&#160;B Preferred Stock, which was deemed to be a qualified financing as defined in the &#160;convertible note agreement from notes issued to several investors in 2021, and resulted in the principal plus accrued interest being automatically converted into Series&#160;B Preferred Stock, the outstanding convertible notes from 2021 were exchanged for <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_DebtInstrumentAxis_zbio_ConvertiblePromissoryNotes2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_cwy_9SZUtkSEG0gNp7CNjw" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_zh4E_6twd0Kn5zL8vBPlGA">37,471,107</ix:nonFraction> shares of Series&#160;B Preferred Stock. At the same time, the Xencor Warrant, which was issued as initial consideration for the 2021 Xencor Agreement, was deemed exercised for <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_R9s5xpFO902Z05RAdLWrnQ" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="Narr_1cQecCbikEiJSa_bEqewsQ">14,441,793</ix:nonFraction> shares of Series&#160;B Preferred Stock.</p></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_58ef132c_41b8_4c4b_9535_7958031bdb38"></a><a id="_d512ba51_f430_44f7_8956_3370fdfeff68"></a><a id="Tc_NL4MfvEHEkSYuxKSAyrrxA_1_2"></a><a id="Tc_XRqDnmsoB0KmX5Mxxu_ZSg_2_4"></a><a id="Tc_kcS9q77SO0yXdVCvmNuuEg_2_12"></a><a id="Tc_75hYfce_7EiuZ_3q_sB45Q_3_2"></a><a id="Tc_GK9eCgYoskSW8zAFEPNOfg_3_4"></a><a id="Tc_gBrT9mzfG06RJ42noLtdoA_3_12"></a><a id="Tc_9u9xj99VZUit0fz7gslH4g_4_2"></a><a id="Tc_mcB7rl6k6kGPM5qMVb-HDA_4_4"></a><a id="Tc_muP-KwZhoECjXC2PaAheWw_4_6"></a><a id="Tc_8rfgNDjfZ0K8h92e5fhCdw_4_9"></a><a id="Tc_QLz-dV9kkUCWplQ49X1h2g_4_12"></a><a id="Tc_1SgvK-IcUEC_l8DAqLpH_Q_5_0"></a><a id="Tc_XpxmdkDzqU2ABm3z40Y4RA_5_6"></a><a id="Tc_r8WOB-GndUev0J0bw33NOw_5_9"></a><a id="Tc_pN8ohL_TOUa61N-ye0yHNQ_6_0"></a><a id="Tc_GAyq2zf_20eFMqt6iwQFag_7_0"></a><a id="Tc_mMoyiCrnk0WEECLpmt9BeQ_8_0"></a><a id="Tc_VqYSn5IiD0Ksq10BCsklUA_8_6"></a><a id="Tc_aoSskzSbNE6xizZkUz2hAA_8_9"></a><ix:continuation id="Tb_tcq5xYmURU2exhdPMq4vsg_cont1" continuedAt="Tb_tcq5xYmURU2exhdPMq4vsg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April&#160;2023, the Company incurred a $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_4_1_2023_To_4_30_2023_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_TKtQMBOy0kys1OFuL5HUrw" decimals="-5" format="ixt:num-dot-decimal" name="zbio:LicenseAndOptionAgreementDevelopmentMilestonePayment" scale="6" id="Narr_xfI0gyaFi06qd-BGi8VpMw">10.0</ix:nonFraction> million development milestone pursuant to the 2021 Xencor Agreement. Xencor elected to receive payment in the form of the Company&#8217;s Series&#160;B Preferred Stock and the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_4_1_2023_To_4_30_2023_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_TKtQMBOy0kys1OFuL5HUrw" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment" scale="0" id="Narr_79RI5DSzEEqP4apqMI8tuQ">4,189,955</ix:nonFraction> shares of Series&#160;B Preferred Stock as payment for the development milestone in June&#160;2023 (see <i style="font-style:italic;">Note 8, License and Option Agreement </i>to these consolidated financial statements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May&#160;2024, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_5_1_2024_To_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve5fM4bIxUmgiWyD_r9iHA" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_60BqChRhqkyaIyKU5SSSfQ">103,990,553</ix:nonFraction> shares of Series&#160;C convertible preferred stock (&#8220;Series&#160;C Preferred Stock&#8221;) in a private financing transaction, at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_T7YsONiFE0CzJJl1iFaCYg" decimals="5" format="ixt:num-dot-decimal" name="zbio:TemporaryEquitySharesIssuedPricePerShare" scale="0" id="Narr_OOYTx94oRketR6baBA5dRA">1.72131</ix:nonFraction> per share, for total net cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_5_1_2024_To_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve5fM4bIxUmgiWyD_r9iHA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_gUnYv4l7VkaFU5dy5x2ruw">178.4</ix:nonFraction> million. Concurrent with the issuance and sale of the Series&#160;C Preferred Stock, which was deemed to be a BMS Qualified Financing as defined above in <i style="font-style:italic;">Note&#160;3, Fair Value Measurements,</i> the principal plus accrued interest of the BMS Note&#160;was automatically converted into <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_5_1_2024_To_5_31_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_5MuMZ5_MaUWYN1Qu9wlrYw" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_XKY5jHFlp02vEo-0s8GpiQ">12,284,686</ix:nonFraction> shares of Series&#160;C Preferred Stock, thereby making the total Series&#160;C issuance equal to <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember__L6rvMfPYE6KDEiKRpOSYQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_5jdQQrLM5ke7hUTBig-zxg">116,275,239</ix:nonFraction> shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the issuance of the Series Seed, Series A, Series B, and Series C Preferred Stock, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2024, the Company completed its IPO, in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6aV-4PBKtEOUPe_8Z_Aj_Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_PBZDBOnwikKj7jypCEVK3Q">15,220,588</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_NlzJf7p5-kuuwrGA0pNVzQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_WuMBU-OfjEuHnyLlDQn99w">1,985,294</ix:nonFraction> shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vp9jOynptE6b6qFRS-0X-Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_rkfQPDRbY0KEjCDAALOLXA">17.00</ix:nonFraction> per share, for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6aV-4PBKtEOUPe_8Z_Aj_Q" decimals="-5" format="ixt:num-dot-decimal" name="zbio:ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses" scale="6" id="Narr_qZc48bdj402hv4wCrStuEQ">258.7</ix:nonFraction> million. The Company received approximately $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6aV-4PBKtEOUPe_8Z_Aj_Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_LjRWKPlizEeXaNotwQ_smQ">234.3</ix:nonFraction> million in net proceeds, after deducting underwriting discounts and commissions and other offering costs. In connection with the IPO, all outstanding shares of Preferred Stock converted into an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vp9jOynptE6b6qFRS-0X-Q" decimals="INF" format="ixt:num-dot-decimal" name="zbio:PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion" scale="0" id="Narr_tFZ3etTidUeAlfbY62GNyg">24,978,715</ix:nonFraction> shares of common stock and no convertible preferred stock was outstanding as of December 31, 2024.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:TemporaryEquityTableTextBlock" id="Tb_d6jNqs7c1kqVB-9vzX_3nw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stock consisted of the following as of December 31, 2023 (in thousands, except share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:70.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued and</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuable Upon</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Conversion</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series Seed Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_xvdd2uHQCkii4NJpMLXPIg_5_2">1,785,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_yN0lYIa1U06163xsdgJnYw_5_4"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_yN0lYIa1U06163xsdgJnYw_5_4_2">1,785,714</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_xXnobKdOmUeihVxrJQbE1g_5_7">956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_gBl_K_PGNkGXXrKbWzjpiA_5_10">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityCommonStockIssuableUponConversion" scale="0" id="Tc_i6uAvm9vcU-JJ2rhe-cMSQ_5_12">205,653</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_MhPBUrI2OU281SfNH8_c1w_6_2">17,589,380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_9xJR_8CMoEKyHFjubPL8-g_6_4"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_9xJR_8CMoEKyHFjubPL8-g_6_4_2">17,589,380</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_ULS4T_xa10yq9cGlV1fAIQ_6_7">55,840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_OfnVpvGw3UOxDm2_yuUX4Q_6_10">56,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityCommonStockIssuableUponConversion" scale="0" id="Tc_nexGoiRrBE6qK_09qmFaUg_6_12">2,025,699</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_qfDo1f7rsE6i8AafwCnVNQ_7_2">81,242,587</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_l_78w3jmP0-stiFfEV2tVw_7_4"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_l_78w3jmP0-stiFfEV2tVw_7_4_2">81,242,587</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_GK88NSVawkaVS7aTB4wyNQ_7_7">193,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_KRi0o7hTt02VHZiYi3VWFg_7_10">193,898</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityCommonStockIssuableUponConversion" scale="0" id="Tc_izEv1HzYaEip0E7cLcD2Hw_7_12">9,356,392</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_-23NNC6N_0W_PHlYZL5fzQ_8_2">100,617,681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_JiBms90yS0qvSQaybCuggg_8_4"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_JiBms90yS0qvSQaybCuggg_8_4_2">100,617,681</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_wcL6cjHgmk-A0p6JJeezKA_8_7">250,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_nU1uohxl_USrqSgkmQV-_g_8_10">250,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityCommonStockIssuableUponConversion" scale="0" id="Tc_WgzY2urlME2TYcro7I9HVA_8_12">11,587,744</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The holders of preferred stock had the following rights, preferences and privileges prior to conversion into common stock upon the closing of the IPO:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Voting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The holder of each share of Preferred Stock was entitled to </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_Vote_HZAN3AhGAkmyDfnWsC8kqg" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" format="ixt-sec:numwordsen" name="zbio:TemporaryEquityNumberOfVotesPerShare" scale="0" id="Narr_yDXoSUp_4UWBpJDOgVWTNA">one</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> vote for each share of common stock into which it would convert and to vote with the common stock on all matters.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Conversion</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Each share of convertible preferred stock was automatically converted into a share of common stock, upon affirmative vote of majority of the holders of each series or upon the closing of an initial public offering of the Company&#8217;s common stock which resulted in a specified minimum amount of gross cash proceeds. The conversion ratio was initially </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_xNqc_Cm5kkeTaAxYe54qmw">one</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> share of common stock for each share of convertible preferred stock and was adjustable in the event of a split or reverse split of the Company&#8217;s common stock, an issuance or declaration of dividends to holders of the Company&#8217;s common stock, a reorganization or merger transaction, or certain issuances of shares of common stock which were dilutive to holders of the Company&#8217;s preferred stock. Holders of preferred stock had the right to one vote for each share of the Company&#8217;s common stock which were dilutive to holders of the Company&#8217;s preferred stock. &#160;Holders of preferred stock had the right to </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_Vote_HZAN3AhGAkmyDfnWsC8kqg" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" format="ixt-sec:numwordsen" name="zbio:TemporaryEquityNumberOfVotesPerShare" scale="0" id="Narr_nIdONZNypUafDqy4o2giZw">one</ix:nonFraction></span><span style="letter-spacing:0.2pt;"> vote for each share of the Company&#8217;s common stock into which such holder&#8217;s shares of preferred stock could then convert.</span></p></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_tcq5xYmURU2exhdPMq4vsg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Holders of Series&#160;C Preferred Stock were entitled to receive dividends, only when, as and if declared by the Board, at the annual rate of </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_ftIqpFVSOkq5tizkN79ucQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_cHbaOYbEPEa11k33WRoCoA">6</ix:nonFraction>%</span><span style="letter-spacing:0.2pt;"> of the Series&#160;C Preferred Stock issue price, payable in preference to and satisfied before any dividend or distribution on any other class or series of the Company&#8217;s shares (except for certain exempted distributions). If any assets or funds remain after dividends had been distributed to holders of Series&#160;C Preferred Stock, holders of Series&#160;B Preferred Stock would have been entitled to receive dividends, only when, as and if declared by the Board, at the annual rate of </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_JZN4FpSog0SrROrSycy9eg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_AhIA-O1fR0iOUuDZ3ZBXvg">6</ix:nonFraction>%</span><span style="letter-spacing:0.2pt;"> of the Series&#160;B issue price, payable in preference to and satisfied before any dividend or distribution on any other class or series of the Company&#8217;s shares (except for certain exempted distributions). If any assets or funds remain after dividends had been distributed to holders of Series&#160;B Preferred Stock, holders of Series&#160;A Preferred Stock would had been entitled to receive dividends, only when, as and if declared by the Board, at the annual rate of </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_MfqeZTH_FECRP_tS5UQvHA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_I09f7k-wdE2q2K_F916piQ">6</ix:nonFraction>%</span><span style="letter-spacing:0.2pt;"> of the Series&#160;A issue price, payable in preference to and satisfied before any dividend or distribution on any other class or series of the Company&#8217;s shares (except for certain exempted distributions). If any assets or funds remain after dividends had been distributed to holders of Series A Preferred Stock, holders of Series Seed Preferred Stock would have been entitled to receive dividends, only when, as and if declared by the Board, at the annual rate of </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_b_-Mw3ef7kWZpywvWrh-sQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_ref4BmC_c0OyDf7_V7XMAg">6</ix:nonFraction>%</span><span style="letter-spacing:0.2pt;"> of the Series Seed issue price, payable in preference to and satisfied before any dividend or distribution on any other class or series of the Company&#8217;s shares (except for certain exempted distributions). The right to receive dividends on shares of all series of preferred stock was not cumulative, and no such right accrued to holders of such shares. There were </span><span style="letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" scale="6" id="Narr_Q9QbCQFkqECJyouOaQuPUA"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" scale="6" id="Narr_ALE9TZVjSUaLolo-RKExGw"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DividendsPreferredStock" scale="6" id="Narr_LDQnVsLTtU6CnYh0x63iPQ"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DividendsPreferredStock" scale="6" id="Narr_kj1zg5whWE-SnPC8zv5pGQ">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="letter-spacing:0.2pt;"> dividends declared or paid as of December 31, 2024 and 2023. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Liquidation Preference</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">In the event of a voluntary or involuntary liquidation, dissolution or winding up of the Company or a deemed liquidation event, holders of Series&#160;C Preferred Stock prior and in preference to any distribution to holders of Series&#160;B Preferred Stock, Series&#160;A Preferred Stock, Series Seed Preferred Stock and common shares, would have been entitled to be paid the issue price they originally paid to acquire their shares, plus any declared but unpaid dividends. After full payment to holders of Series&#160;C Preferred Stock, holders of Series&#160;B Preferred Stock prior and in preference to any distribution to holders of Series&#160;A Preferred Stock, Series Seed Preferred Stock and common shares, would have been entitled to be paid the issue price they originally paid to acquire their shares, plus any declared and unpaid dividends. After full payment to holders of Series&#160;B Preferred Stock and Series&#160;A Preferred Stock, holders of Series&#160;Seed Preferred Stock prior and in preference to any distribution to holders of common shares, would have been entitled to be paid the issue price they originally paid to acquire their shares, plus any declared and unpaid dividends. After full payment to holders of Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock, holders of Series Seed Preferred Stock prior and in preference to any distribution to holders of common shares, would have been entitled to be paid the issue price they originally paid to acquire their shares, plus any declared and unpaid dividends. Any remaining amounts after payment to holders of preferred stock, would have been paid to holders of common shares. A deemed liquidation event was defined as any consolidation, amalgamation, scheme of arrangement or merger of the Company (and any of its subsidiaries) or other reorganization resulting in loss of more than 50% voting power; the sale, transfer, lease or other disposition of all or substantially all of the Company&#8217;s assets; or the exclusive licensing of all or substantially all of the Company&#8217;s intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Redemption</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Preferred Stock did not have redemption rights, except for the contingent redemption upon the occurrence of a Liquidation Event.</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_g_QCfVMaxkatz7izfnz-jg" continuedAt="Tb_g_QCfVMaxkatz7izfnz-jg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span>Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August&#160;2023, all outstanding shares of ordinary stock of Zenas Cayman automatically converted into shares of common stock of the Company upon the Redomicile and incorporation of the Company in the State of Delaware as Zenas BioPharma,&#160;Inc. In May&#160;2024, the Company amended and restated its certificate of incorporation, whereby the Company increased the shares of common stock it was authorized to issue to <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_5_31_2024_R3mnM-yuCkeUi3lI4lcTJA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_gOuI0CMGEEKVeTmeu_Un4g">294,784,925</ix:nonFraction> shares. Upon consummation of the IPO, </p></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_Vkwj5HrhCEWvoy39FeSimw_1_2"></a><a id="Tc_J6wPE5hszkmsMhb_Ce7P2w_2_2"></a><a id="Tc_WcN6ft3_FEmIsCEo0k4gsg_2_4"></a><a id="Tc_U_IHa8pL70er1t0aQaBg2A_3_0"></a><a id="Tc_IfcT8qlGd065v_t9AOzHVg_3_2"></a><a id="Tc_3nqHDE7090CDIgou2BD46w_4_0"></a><a id="Tc_v3qqDMx92Um8LyqeT4sqVA_5_0"></a><a id="Tc_Qv2ltKiJ20qQPDgauA-hew_6_0"></a><ix:continuation id="Tb_g_QCfVMaxkatz7izfnz-jg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Company restated its certificate of incorporation, and as of December 31, 2024, the Company was authorized to issue <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_EIzsaUZokkyJxYnVevUClw">175,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_WlLTUpSOCE69nhRrFcIlOQ">0.0001</ix:nonFraction> par value common stock. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock were subject to and qualified by the rights, powers and preference of the holders of any preferred stock then issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The holders of the common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_HZAN3AhGAkmyDfnWsC8kqg" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" format="ixt-sec:numwordsen" name="zbio:CommonStockNumberOfVotesPerShare" scale="0" id="Narr_U5fyaDo1E0alKoBXsQE1Dg">one</ix:nonFraction> vote for each share of common stock held at all meetings of stockholders (and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The Company had reserved the following shares of common stock for the potential conversion of outstanding convertible preferred stock and exercise of stock options:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="zbio:ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock" id="Tb_MWJSxxCjE0y_xwF3wH01Ng" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:32.54%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of outstanding shares of convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock" scale="0" id="Tc_NQeNQopockmO5VHgPTCtJw_3_4">11,587,744</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_w4CSM3niZ02HoH5TiMGa5Q_4_2">8,706,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_fl5Z7zaoxEOhFraiPoBD7Q_4_4">2,382,933</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Remaining shares reserved for future issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" format="ixt:num-dot-decimal" name="zbio:RemainingCommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_fa36N3a_gUe4Wq0HfJsA0g_5_2">359,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" format="ixt:num-dot-decimal" name="zbio:RemainingCommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_GqMX0yMRLkuD6qBZlxcP2g_5_4">60,792</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_XyHJstQ-CkWKFLJx0NCaiQ_6_2">9,065,596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_VVMb2eJSx0m4RM5lJpwKsA_6_4">14,031,469</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_ltefzwWDWkOTvBbxbVFq4w" continuedAt="Tb_ltefzwWDWkOTvBbxbVFq4w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></span>Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><b style="font-style:normal;font-weight:bold;">2020 Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">On August 21,&#160;2020, the Company&#8217;s sole director and member approved the Zenas BioPharma (Cayman) Limited 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;). Upon effectiveness of the 2024 Plan (as defined below), the Company ceased granting additional awards under the 2020 Plan. The 2020 Plan allowed the Company to grant stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units, and other stock-based awards to employees, officers, directors and consultants of the Company and its subsidiaries. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Since inception of the 2020 Plan, the Company has granted RSAs and stock options which generally vest over </span><ix:nonNumeric contextRef="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_RshCuHFfukSw2KF3sIAoJg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_owzA9H2iMU-Hxidj4xgp2Q"><span style="font-style:normal;">four years</span></ix:nonNumeric><span style="font-style:normal;">, with </span><span style="font-style:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_n3k32el71EGZ_NhKc4uVgw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_e0OVPb9pI0ewimosRswGSw">25</ix:nonFraction>%</span><span style="font-style:normal;"> of the total shares granted vesting on the anniversary of the vesting commencement date and the remaining </span><span style="font-style:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_QSgjONif-0yTKlXy2bMn7g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_0pj6enAKNEmsVh0ni5-cJA">75</ix:nonFraction>%</span><span style="font-style:normal;"> vesting in equal monthly installments over the subsequent </span><span style="-sec-ix-hidden:Hidden_JhL2WXriOku-gXN73DMQHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-six</span></span><span style="font-style:normal;"> (36) months.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The 2020 Plan was subsequently amended by the Board and provided for the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_CULdaUsOIkCpMGAD6CrOEQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_Ipa7pJ8Rm02g1eg9_wLHYQ">2,560,401</ix:nonFraction> shares of common stock as of December 31, 2023, of which <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_CULdaUsOIkCpMGAD6CrOEQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_-0wmpsmnlUqMOj7n0pCUCA">60,792</ix:nonFraction> shares of common stock remained available for future grant under the 2020 Plan. &#160;Upon effectiveness of the 2024 Plan (as defined below), the remaining available shares for future grant were transferred to the 2024 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2024 Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 3, 2024, the Board adopted the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), which became effective immediately prior to the effectiveness of the registration statement for the Company&#8217;s IPO. The 2024 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, unrestricted stock, restricted stock units and other stock-based awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the effectiveness of the 2024 Plan, the number of shares of common stock initially reserved for issuance was <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_xOEKuB9Y7kOpDa77H2eCCg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_tPBTWuKehEOQnGQQs_NBCQ">4,775,477</ix:nonFraction> shares of common stock which is equal to <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_KToxdb6KqkaQTUoti9SqTg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_1G8tiVZHOEKGdR6lqQ75GQ">12</ix:nonFraction>% of the number of shares of common stock issued and outstanding immediately following the consummation of the Company&#8217;s IPO. The number of shares reserved and available for issuance under the 2024 Plan will automatically increase each January 1, beginning on January 1, 2025 through January 1, 2034, by the number of shares equal to the lesser of (a) <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_9_3_2024_To_9_3_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_bmG8cOK5ekOayAksSxcSeQ" decimals="2" format="ixt-sec:numwordsen" name="zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_2l2uZzVH70icqXozDMdvNw">five</ix:nonFraction> percent of the aggregate number of shares of common stock outstanding as of such date, and (b) a number of shares as may be determined by the Board on or prior to such date. </p></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_Ap11xOcOxU2TmosTDgucXQ_1_5"></a><a id="Tc_-nLVZHWX_kmsRQlcrH623w_2_2"></a><a id="Tc_-7z_a0k47kaTS-fwZDCGbw_2_5"></a><a id="Tc_O1xHO93d1kSlwH1sVIINzg_3_2"></a><a id="Tc_OATJIuwcJkeSLp5p1bLJQA_3_5"></a><a id="Tc_pEt0svJkSE6BK6rueoA9AQ_4_0"></a><a id="Tc_04FYuDnQeUO4OPTDFD4cMA_4_5"></a><a id="Tc_fWARt7DwO0qG_Vls7kzxnw_5_0"></a><a id="Tc_PSYyraUVc06u3awIrtzu2g_6_0"></a><a id="Tc_SS1fWzW3WE-CpH-LHuIVfw_7_0"></a><a id="Tc_vVkAnvZUc0Sp_87u4DClyw_7_3"></a><a id="Tc_44GNvCrc_UOtIYAbREckGA_7_5"></a><a id="Tc_vmonWRH3rUmdE5U8_BOo4g_7_6"></a><a id="Tc_EbMGP9rBF0WBgAKk6mziWw_1_3"></a><a id="Tc_Pi_o0uR6VUujfYzb2qd8gQ_2_3"></a><a id="Tc_rE4C30PapEaoTM9pey5I_g_2_6"></a><a id="Tc_90NiGkZny0OyqywBqmraLg_3_0"></a><a id="Tc_6EGgquXkC0KORWN0bwCvKA_3_4"></a><a id="Tc_Vx9_-_QbBEu78MPbvB_Hwg_3_7"></a><a id="Tc_Z26M4KzeYkaSpSlU0h90sA_4_0"></a><a id="Tc_X1ZZB-GyQke_odFjwlXLhg_5_0"></a><a id="Tc_xlKZV7mK90aGy1iekRZDrA_5_4"></a><a id="Tc_m8O2H_RbU0yjA0lXla50EA_5_7"></a><a id="Tc_gVOY2DG2kUurNIJcB35Rhw_6_0"></a><a id="Tc_-7GHk9o_8UC551UWB4LGWg_6_4"></a><a id="Tc_ycxChkZrVUKH-93JawK4qA_6_7"></a><a id="Tc_CywygsPghkOrAxcLPtvDVg_1_8"></a><a id="Tc_Yghau0twgketoyV1UDgk9g_1_11"></a><a id="Tc_xVAwdSWN4kmR3c6tfdjd1w_2_8"></a><a id="Tc_Aj4ZYncP30-v3PsKpB_Y9Q_2_11"></a><a id="Tc_-dgbdylA10W6Yi1VviGhcw_3_2"></a><a id="Tc_tReXTxOaaEilUbWHo_BnKg_3_5"></a><a id="Tc_Z71oQ5hOhEGguAEO-oZKzA_3_8"></a><a id="Tc_zPBOiKybWUywaBpFizt0NA_3_11"></a><a id="Tc_v5zL0XlyPkqr6gHyWofRWw_4_0"></a><a id="Tc_bV_bz3kqjUSKn5-7ONht4Q_4_5"></a><a id="Tc_AxpUIsEmUk6xJkOwerOUTg_4_11"></a><a id="Tc_hTHn9ZFYS0O6qUAB5d3f7A_5_0"></a><a id="Tc_dgs4jBRsvUak-Xl1Ju6FyQ_6_0"></a><a id="Tc_Hz8Y32pKfUy0DKIPkgBokQ_7_0"></a><a id="Tc_e81njE6UZ0mrdIbb2icpAg_8_0"></a><a id="Tc_LaF6YABtdEW9fxx_W7qtVg_8_5"></a><a id="Tc_FxItQu-JMUmFPYrxI3gShA_8_11"></a><a id="Tc_22Vjh14AukKl_0Vq7qn1mQ_9_0"></a><a id="Tc_Nwi6jS2ZaESWBN7k6KsoFg_9_5"></a><a id="Tc_xJZnsuW0E0WjiyYrUit66A_9_11"></a><a id="Tc_l-olzGb7706iDGQtDQQEYw_10_0"></a><a id="Tc_C3JvXnnU70GZPnIgMvJOug_10_5"></a><a id="Tc_4w3qNRBd7UGbC8aVB-MTSg_10_11"></a><ix:continuation id="Tb_ltefzwWDWkOTvBbxbVFq4w_cont1" continuedAt="Tb_ltefzwWDWkOTvBbxbVFq4w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_xOEKuB9Y7kOpDa77H2eCCg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_2FRYBIJoEkOGrEoPS1F77g">359,399</ix:nonFraction> shares available for issuance under the 2024 Plan. On January 1, 2025, the shares available for issuance under the 2024 Plan was increased to <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_1_1_2025_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hb-DK0AUdkWTw3-eUcEHIQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_14F75GrcIUSaTFLSjceJ7w">2,449,069</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Restricted Stock Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents a summary of the Company&#8217;s RSA activity and related information:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="Tb_3_vtFkGDhE-9np2qbF6x8g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average Grant-Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#ffffff;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:middle;width:2.8%;background:#ffffff;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#cceeff;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember__QbnTUUJpUmGv43XtvhTNg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_m96z4nO80U-Qh4UXguQkIQ_4_3">27,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember__QbnTUUJpUmGv43XtvhTNg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_NoQHX6L6Kk6gzX-GhmMklA_4_6">2.71</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W4Yt2rBhJE-FLWW_GHB-Pg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_XqnPQNJ04kK7j5Xa-ZO9xA_5_3">6,028</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W4Yt2rBhJE-FLWW_GHB-Pg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_3iopgq5D7E6Knw9DeBUCBA_5_6">0.01</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#cceeff;border-bottom:1.5pt solid #ffffff;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Repurchased</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W4Yt2rBhJE-FLWW_GHB-Pg" decimals="INF" format="ixt:num-dot-decimal" name="zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" scale="0" id="Tc_RuQQ2Dtw0UeZ0GaqF4OjCA_6_3">21,172</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W4Yt2rBhJE-FLWW_GHB-Pg" decimals="2" format="ixt:num-dot-decimal" name="zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_6cBOQZgp6k6QvOsHR6B2lg_6_6">3.48</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W4Yt2rBhJE-FLWW_GHB-Pg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_9BWVp6UgwkuFYzM7MgJzRQ">no</ix:nonFraction> RSAs granted during the year ended December&#160;31, 2024. As of December&#160;31, 2024, there was <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_2NdTZEI7VEekOwqqgqrnHA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_heZnsoDx8EenAUSzsmWTaw">no</ix:nonFraction> compensation cost related to unvested RSAs as all were fully vested. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has granted stock-based awards with either service or performance based vesting conditions. Compensation expense related to awards to employees and directors with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance based vesting conditions is recognized based on the grant date fair value once the achievement of the performance condition is probable. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The table below presents the weighted-average assumptions used in estimating the fair values of stock options granted during the years ended December 31, 2024 and 2023:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_NAGZMH_0akCLXtOVOfqJSA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:32.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:2.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:58.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_oPzQKvOZEkqe2HtnCK0T-A_3_3">3.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_HnzzC5bbHEaeLJ3lNWFZzg_3_6">4.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_5sKVsKvvm0OWozUsOhxxqg_4_3"> 6.07</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_sdHItF0jJ0a7SA9SzyQtWA_4_6"> 6.04</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_yTldksNqkUeN6rVZ_EDt_Q_5_3">94.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_F3VjtEXcVkyERE0f81qhjA_5_6">87.86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_RrCq7SAUHEq-L2gW7XIXJQ_6_3">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_xXJaPIDP20WJATT495w4mQ_6_6">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents a summary of the Company&#8217;s stock option activity and related information:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_ddRUotL4dU2NBOXFQmjdVQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted - Average Exercise Price</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Term (in years)</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value (in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding - December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cZRERuEIiEGchuqk65A2pQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_yXqUpxvx6Ui9I9PEKePsoQ_4_3">2,382,933</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cZRERuEIiEGchuqk65A2pQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_2XIbX97b60CP519FOsSTOA_4_6">8.51</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cZRERuEIiEGchuqk65A2pQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_jO9UAasP0UaInW5fI9uPLw_4_12">8,084</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_CWaOW4exoUa2MS_YpECSzw_5_3">6,736,822</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_3ZzcKLelo06X-eEuviEyPw_5_6">14.67</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_f-lrgySUj0udhZLSEesfdQ_6_3">38,427</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_mvBRWalCuUqguXbh8H-4OQ_6_6">7.11</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Tc_NlyNh-SQKEettvRiOU2cZw_6_12">231</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_AsJDyG00R0WloyrBowJ2JQ_7_3">375,131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_WMEp_cqPcEyFGNXvVImogw_7_6">10.29</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding - December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_mLNwOSuRhEiUA8gDPAnbsQ_8_3">8,706,197</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_iGOHVA0MwEat5IAuH3k18g_8_6">13.21</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_1Bah8xe0ikC3WeavUFa1WA_8_9"> 8.76</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_ydPqramq_06AbKzIVPVKiQ_8_12">2,104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_kkw6PSXoAUOEnPUPU8SPsQ_9_3">1,294,162</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_Lp2xOtc6iUu2zVjiIyan0g_9_6">7.64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_WRhtLI23G0ufHJ5hcj0Nxg_9_9"> 5.51</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_HZcsdfK7h0StcP9_4V0kmw_9_12">1,901</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and expected to vest as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_dFhagVAUz0m0zqNLMDpgDA_10_3">8,706,197</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_3B3dutwqQUKeuI3zO-82Ww_10_6">13.21</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc__BPvyLHXMkaJENSsDBnE_w_10_9"> 8.76</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="Tc_Rb1znHmbeEOlGsV2jHi0aA_10_12">2,104</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_89eed41b_2b00_434a_972f_3e8c6321366c"></a><a id="Tc_LX5vNq5D-0-ojzM9oZkOzw_1_2"></a><a id="Tc_Um7ZCeRL1UK8adbvwXiRzw_2_2"></a><a id="Tc_eVpZtTc_M0W__k6hm16cgQ_2_5"></a><a id="Tc_X3cHUI6w_ke9tVBuU02tWA_3_0"></a><a id="Tc_QFish_8JNkmN67E6S95_og_3_2"></a><a id="Tc_QTEXmk3sGESAdmifI6tnsg_3_5"></a><a id="Tc_ZUPyURSaU0W2ZSmNP7yi5A_4_0"></a><a id="Tc_dqMPW5SbU0uWP1VQE00vyQ_5_0"></a><a id="Tc_8JQdkyPvVES9WxDaR4X_DA_5_2"></a><a id="Tc_nnkQ84MhEEy7YEuFe-DGlQ_5_5"></a><ix:continuation id="Tb_ltefzwWDWkOTvBbxbVFq4w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of the stock options is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock for those stock options that had an exercise price lower than the fair value of the Company&#8217;s common stock as of the measurement date of December 31, 2024. There were <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_UJg6ogU5YUmjC_9Xz0B0NQ">38,427</ix:nonFraction> options exercised for the year ended December 31, 2024, resulting in total proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="Narr_I28EvywJtEKnjoC1Sueo0A">0.3</ix:nonFraction> million and <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_HOrvjeSBLESgV9L844izng">27,579</ix:nonFraction> options exercised for the year ended December 31, 2023, resulting in total proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_G0NmPLsouUWvcJv8UgGCEA">0.1</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of options granted during the years ended December 31, 2024 and 2023, was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_Ju_LSnlGoEW6SbVw0gldLA">11.38</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_9hyhJwBm8k-EUj9OuKjztA">8.11</ix:nonFraction> per share, respectively. The fair value is being expensed over the associated service period of the award on a straight-line basis based on the grant date fair value or once the achievement of the performance condition is probable. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, unrecognized compensation was $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_nXgeBa5Rj02DPLmvS641Sg">74.4</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_au8sAp8PMkejnIUYFb4dBw">3.6</ix:nonNumeric> years. The total fair value of options vested during the years ended December 31, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_CfHZjQ5TzEGGbzFHEpsufA">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_4WnKEAnmbEywksAF64jrvA">2.6</ix:nonFraction> million, respectively. </p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_IH5eIH-WZkW4F34CRbJdGg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company recognized stock-based compensation expense related to the issuance of equity awards to employees in the consolidated statement of operations as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:36.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fB6rJscJqE2qELeYONH6iw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_DlDrs7UkbU6JNlCpM2IUBg_3_3">4,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_jq1Qp6HsIE2fmcD8wUHsAQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_uOMLR-46U0-ukFMr6_Uwsw_3_6">1,600</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_AkdY1KqPtUenQWgty7TKCw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_mqcBBaBaskqwmea2YRt7eQ_4_3">6,755</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DSs7gyVtbUGlXl8c8Se1DQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_c81MJ8KDuECR07qmfCwinw_4_6">1,895</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Ca5yuPxqWkS3SJTxKOxeAA_5_3">10,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_0yoCPtd_VE6RIAdzAPFktw_5_6">3,495</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On September 3, 2024, the Board adopted the 2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective immediately prior to the effectiveness of the registration statement for the Company&#8217;s IPO. The Company initially reserved <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_9_3_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member__gcr5m9F8EmwZjNOy4gdqw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_El8oGOQQ-0m-IsvfuY3uLA">397,956</ix:nonFraction> shares for issuance under the ESPP. The number of shares of common stock available under the ESPP will &#160;automatically increase on January 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of each year, beginning on January 1, 2025 through January 2034, by the number of shares equal to the lesser of (a) <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_9_3_2024_To_9_3_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_mqyL0U5nuU2EVYmKwAc9sQ" decimals="2" format="ixt-sec:numwordsen" name="zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_RRseC5kwz0W-SRM6HWe6kw">one</ix:nonFraction> percent of the aggregate number of shares of common stock outstanding as of such date, and (b) a number of shares as may be determined by the Board on or prior to such date, up to a maximum of <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_9_3_2024_To_9_3_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_mqyL0U5nuU2EVYmKwAc9sQ" decimals="INF" format="ixt:num-dot-decimal" name="zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized" scale="0" id="Narr_QZY8823Mf0Cqlf5f0xu8nQ">1,000,000</ix:nonFraction> shares in the aggregate per year. On January 1, 2025, the shares of common stock reserved for issuance under the ESPP was increased to <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="As_Of_1_1_2025_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HT5QNFavaEuMvtiRET_mAQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_Z08mHw2gDEOyclK9b-XPhA">815,890</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_Uu3p6qpokUGtpEZwlhfejQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_9cqFPpMEFkSsj1aKE9_xLA">no</ix:nonFraction> shares of common stock have been issued and <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_Uu3p6qpokUGtpEZwlhfejQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_qUl5TrgBz0KqNDlv5NrrVw">no</ix:nonFraction> stock-based compensation has been recognized related to the ESPP. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7c4b0379_b069_4016_9bcc_6661f04c435f"></a><a id="_95ae61f3_73a1_4c1e_8ab6_bd0a7a0548da"></a><a id="Tc_vfjKs5Agjkmz5WdTpvoFAA_1_2"></a><a id="Tc_yP-0Ms9VwU667BOkAsuEJg_2_2"></a><a id="Tc_x34vgnLCGUqCqH53MjFL9Q_2_5"></a><a id="Tc_TOlSYXwY_EO2xVhGsD8HlQ_3_0"></a><a id="Tc_Z0sktT17vEOJUMeWowmaAA_4_0"></a><a id="Tc_OnQcOpeVBUSt4_t2gh_Irg_4_2"></a><a id="Tc_fUF2_MtwOECaBZ4zKOgEbw_4_5"></a><a id="Tc_zFB3ckjpGkq1rSEjWy5HXQ_5_0"></a><a id="Tc_xBksOETpJEqx-UhUXcr6wg_6_0"></a><a id="Tc_59M_iyp2YUmsFFRDAWJgXQ_7_0"></a><a id="Tc_8ydn1qnME0SUHoWsuzE88A_7_2"></a><a id="Tc_3Axp02XCqkO7e1DP2PRiag_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:EarningsPerShareTextBlock" id="Tb_-WBln9U_9kyBJcRFGGf37w" continuedAt="Tb_-WBln9U_9kyBJcRFGGf37w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></span>Net Loss Per Share</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_YReQafbUmUubnY_U0k_MqA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.61%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.47%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.61%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_7YkpwLngg0G1dXxy_OFsbQ_4_3">156,988</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_mDk-68NbIUGu23sp4oar4Q_4_6">37,124</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common stock outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_YyKYPnSTvkW_nKs6rzNDNA_6_3"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_YyKYPnSTvkW_nKs6rzNDNA_6_3_2">13,198,960</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_JLjzjEOrcEmy1Ysbo4VZYw_6_6"><ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_JLjzjEOrcEmy1Ysbo4VZYw_6_6_2">1,531,178</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share attributable to common stockholders - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_aCAHGqd5I0KocoSj9RC5ug_7_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_aCAHGqd5I0KocoSj9RC5ug_7_3_2">11.89</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_rEMjgGdTn0e2KSw4_pPWYQ_7_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_rEMjgGdTn0e2KSw4_pPWYQ_7_6_2">24.25</ix:nonFraction></ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company&#8217;s potentially dilutive securities, which include convertible preferred stock, restricted stock and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both </span></p></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_D027JQly3EqO5FaR0tFIpQ_1_2"></a><a id="Tc_UTmf4cS5RkaRhABK_uHpkA_2_2"></a><a id="Tc_z5gwPTS7fUS7A64TJue6jg_2_4"></a><a id="Tc_DKXIc_in_EyoqcMIzUn72A_3_0"></a><a id="Tc_Iqolzqka4EOxZalh_CaI0w_3_2"></a><a id="Tc_5KL2lDvjhU2t8pXYhAISLQ_4_0"></a><a id="Tc_nat48w2GK0W7Ilb0jz-wxA_4_2"></a><a id="Tc_lOa4SuPDLk2pRFfA9btKGQ_5_0"></a><ix:continuation id="Tb_-WBln9U_9kyBJcRFGGf37w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders as of December&#160;31, 2024 and 2023 because including them would have had an anti-dilutive effect:</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_2LpU3yrpDkeAtehul1smSg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:44.4%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock</p></td><td style="vertical-align:top;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_c8gM2cWCLkC5U2Dqd6witg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_eKvB9HXvH0GibQGlmm-5tA_3_4">11,587,744</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock</p></td><td style="vertical-align:top;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember__ml10lATXUGvzgwEsGWE_A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Wy9BI9AC5kaZyhabQunXzw_4_4">27,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock </p></td><td style="vertical-align:top;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_M12KVoNGq02-s4clKubiaw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_IWRffn8HpE-c2XzvBCpVIg_5_2">8,706,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_8iYMmA8-mkONHhlH8V6H4A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_cIi6xDV3P0ONJCwu8Ld78Q_5_4">2,382,933</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The BMS Note was also outstanding as of December 31, 2023, which could have obligated the Company to issue preferred shares or common shares upon the occurrence of various future events at prices and in amounts that are not determinable until the occurrence of those future events. Because necessary conditions for the conversion of the BMS Note had not been satisfied as of December 31, 2023, the Company has excluded the BMS Note from the table above and the calculation of diluted net loss per share. As of December 31, 2024 the BMS Note is no longer outstanding. </span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c3b879c3_a124_446f_808d_7b734452ee96"></a><a id="Tc_fe-2lHMX5E--CFWiSSKFiA_1_2"></a><a id="Tc_4W425Dilu0KFB3fCyUMYzQ_2_2"></a><a id="Tc_ydATgiiQu0iueb9vLqCvNQ_2_5"></a><a id="Tc_tAsRqOFPYEmoz9qPTDGY4g_3_0"></a><a id="Tc_QZ7vyRWLPU2t2EFBS40tJw_3_2"></a><a id="Tc_YGRhMoeQ40C_utTCwa-AoQ_3_5"></a><a id="Tc_ubyDI1Yi-0GnvwcPO2Mj9A_4_0"></a><a id="Tc_xiHe89MG5k-nhp9IYfHWag_5_0"></a><a id="Tc_DxDr05DzCUCfbU9xsjLESA_5_2"></a><a id="Tc_XTCIhWBfIkS8Xs8N_CCfLA_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_hzUJSHigsUqxhoSWI5ZeuQ" continuedAt="Tb_hzUJSHigsUqxhoSWI5ZeuQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></span>Income Taxes</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_KAixD94pEkeKtawjOv3wcQ" continuedAt="Tb_KAixD94pEkeKtawjOv3wcQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents the components of loss before the provision for (benefit from) income taxes during the years ended December 31, 2024 and 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_-_4J64pAFkGs9X3mWM1UYw_3_3">160,918</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_IHijaNPnyUayNtwMG_lKyg_3_6">10,845</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="Tc_iO45ILhKTUSdWfKqg83aIg_4_3">4,359</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_u0xJ8TbfMkKLjlAGxOMZ2g_4_6">25,978</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loss before taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_W4lBa0D7yUCQmfbrfp6kqw_5_3">156,559</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_6NfSMRBmrkiHFudjze8tIA_5_6">36,823</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_043e1f0d_3b19_4bcb_a1d5_554473230212"></a><a id="Tc_T-AFxqiGJU69foNW4gS3LQ_1_2"></a><a id="Tc_lxwaCLyI40Gl64ZJR3gupA_2_2"></a><a id="Tc_mbDp5QZ_AkOt1xgkHvdfAA_2_5"></a><a id="Tc_sv-PlFdxiEynLnThy_rNVA_3_0"></a><a id="Tc_MXrbknw2k02hnr0g8MOy2w_4_0"></a><a id="Tc_WUCR9ReAT0i79yNLWW0_YA_4_2"></a><a id="Tc_omWB-9hc9kO6vEh-2W8-Og_4_5"></a><a id="Tc_lv5q-mhejECN9-Nz9aoYLA_5_0"></a><a id="Tc_qtq6E6U0qEmAwyy2fuP0TA_6_0"></a><a id="Tc_mJtnQ_Deb0yM6tpe3ZALDA_6_3"></a><a id="Tc_yO1hMXcvVk66Z-GfOusSzw_6_6"></a><a id="Tc_HFOEi4psKECjFT2pKjtnqw_7_0"></a><a id="Tc_IdTgezFywUmWfAVJ8ZVfYQ_9_0"></a><a id="Tc_7pfsbVFxv0KSx2hwcfMlbg_10_0"></a><a id="Tc_IlLnnigDGEqANB6wLOh7iw_10_3"></a><a id="Tc_JtYCgixxpEiuySXiHttPOQ_10_6"></a><a id="Tc_TEEASDvej0WrH8H8MdIX0g_11_0"></a><a id="Tc_zQ6xdq__lEObflpkdhqrOw_11_3"></a><a id="Tc_gsbF5qluqkqmJM2gD9BdIg_11_6"></a><a id="Tc_OoKpF9l2iEGPMwLOi_t9pg_12_0"></a><a id="Tc_EdsnET3f0kmEnsY0YQK8nQ_12_2"></a><a id="Tc_jmwN-s1wykOEBQ7iWNE_Og_12_5"></a><a id="Tc_aKdgbiL2DkaPKtKn5xqxtQ_1_2"></a><a id="Tc_kbzjKfTX_ECJZ6z-nOeEwQ_2_2"></a><a id="Tc_Y2hGsamwvUumoPwi7qzjcw_2_4"></a><a id="Tc_TtO0iNKkRE-ynUEyVDphrw_3_0"></a><a id="Tc_0lgFIlaYFEik9qy78wF0yg_3_3"></a><a id="Tc_9QGEti-MbUOD-jWgu-u7Ug_3_5"></a><a id="Tc_e4u7M--ww0isy-MZ51aK3A_4_0"></a><a id="Tc_Naxt3dQZl06RDOK7XaZcZQ_5_0"></a><a id="Tc_HSijGQa01ku4f8wqWT631Q_6_0"></a><a id="Tc_nsobbwcN1kiWnJvKhvXvFQ_6_4"></a><a id="Tc_hyzinROw102xJre-jfOhHQ_7_0"></a><a id="Tc_eyUDKhy4bECoAzRfYBn6UA_8_0"></a><a id="Tc_SgbsUxp8aEaPoYJm8UKAZA_9_0"></a><a id="Tc_5tk5XRKuf0CQCKwDryDU6Q_9_4"></a><a id="Tc_vsmek1S3KEWtfFTVkYky-A_10_0"></a><a id="Tc_JZqZd2ZTukyE2mqnQ84hrg_10_3"></a><a id="Tc_IIjse1BBREKxyorcTSdh6w_10_5"></a><ix:continuation id="Tb_hzUJSHigsUqxhoSWI5ZeuQ_cont1" continuedAt="Tb_hzUJSHigsUqxhoSWI5ZeuQ_cont2"><ix:continuation id="Tb_KAixD94pEkeKtawjOv3wcQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_bGp4VPzrk0W2QeBODz6W1w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The components of the income tax provision for the years ended December 31, 2024 and 2023 are as follows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current income tax provision:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="Tc_7gQ8FV5j5UiB8s1IpE9D2w_4_3">123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="Tc_KJbs8pJreE-8G-u7QpxoPw_4_6">289</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_JqCM70dcj0qluoLlRsWjRg_5_3">306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_7JPmDod-3Uq3SdDF1AFO0g_5_6">12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_TffmLtZCxE-5zGcVNGCp9A_7_3">429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_j1hVb7GI3EqY_nYHxeqsQA_7_6">301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income tax provision:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal, state and foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_6zMnGza5HU6tq-vuTYLVkg_12_3">429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_M8KXKRsOyEmY8VTFsAl-og_12_6">301</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_pnmol-Oj3EimcKhYXb3uvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_o3HR_tNO1EuxQW36IB6IEw_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_iOGm3dhLLUqbkomiXkwjnw_3_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_Hdg8OdajK0W1-4vD_fPldg_4_2">6.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_e4HovmJm80SEKbmaIYM1uw_4_4">3.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_aFGYjo5gNk6v4AzYvn3wEg_5_2">32.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_eXxFVgxPTkqfxOj9vEYp0A_5_4">26.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">IP transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" sign="-" scale="-2" id="Tc_rdqJEleaUkaeBlbK7jzbeg_6_2">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" sign="-" scale="-2" id="Tc_YJcttf3wAEWYcDMjjN2YEg_7_2">4.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" sign="-" scale="-2" id="Tc_NKoFHWGU90abThsza8IzQw_7_4">8.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign tax rate differential</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Tc_qwrQcjmUaECjbmqnmbchxw_8_2">0.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" sign="-" scale="-2" id="Tc_IEOyQx-6d02YQAqHZ48UmQ_8_4">7.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_aYi4tf_TAUGnkTkPSSqv0Q_9_2">0.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_zm6rc6YSHUK6MgjCzGfRYg_10_2">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_c1ajiBByXE-HXADVYl0zig_10_4">0.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s change in effective tax rate for the year ended December 31, 2024 compared to the year ended December 31, 2023 decreased primarily due to a change in income earned in the U.S. </p></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_63b8ca82_6913_414d_8e33_c36979d18f80"></a><a id="Tc_SJ0eUlzvqkGG0pAaSang0Q_1_2"></a><a id="Tc_ZwXmHkK9D0Cj9gFRdZUUcA_2_2"></a><a id="Tc_mMCVx9XOd0WfwyEkWzAatg_2_5"></a><a id="Tc_tdqTLEHjo0GPahUXcIVrYg_3_0"></a><a id="Tc_vNs3zQ5hokuGW5_PkSyUPQ_4_0"></a><a id="Tc_8TRGOl-gCUmtjc_f4irlAA_4_2"></a><a id="Tc_rYBX5H9tKEmXY_fB1c9sRg_4_5"></a><a id="Tc_z89eLZDYP0CY0Oanc3ipgg_5_0"></a><a id="Tc_E4kDkuHDm0GhzklKBSbKOA_6_0"></a><a id="Tc_DtlyolIvEEm1JXt2PmhC2A_7_0"></a><a id="Tc_mjg6MxPuM0u6Qs5vj9bPTg_8_0"></a><a id="Tc_oQJZX3EwhEyrBgc_ElKt6g_9_0"></a><a id="Tc_SCYihbzmfEOv0zEDAAlByQ_10_0"></a><a id="Tc_8ALvfA1ahUGZWtLgxXyUIg_11_0"></a><a id="Tc_ZFscmJ19CUuGscZmyVNGOw_12_0"></a><a id="Tc_cMpKaJ2F8E6V9bMe5ofVTg_13_0"></a><a id="Tc_6Lv4UXDZDUuiLwYqs1QW-g_14_0"></a><a id="Tc_uvFYdI_ou0i77WAmWGqKKg_17_0"></a><a id="Tc_h8JhNZUXnE-ZGXMfya8NmA_18_0"></a><a id="Tc_1wkLK-CSvE6DoYJyKZW3mw_19_0"></a><a id="Tc_666Vv0_GY0-eYacibH19pQ_19_2"></a><a id="Tc_-DK3lj4Fc0Sahdvw2Sp_QA_19_3"></a><a id="Tc_Cx9XWTOfskiBMSKb__VKYg_19_5"></a><a id="Tc_-wtv6_Buc0aIH9wuqQ6F_A_19_6"></a><ix:continuation id="Tb_hzUJSHigsUqxhoSWI5ZeuQ_cont2" continuedAt="Tb_hzUJSHigsUqxhoSWI5ZeuQ_cont3"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_fc2JSzLDAEakt58HwSz2WQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the components of the Company&#8217;s deferred tax assets and liabilities (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_SNvxuePKvEKII9zoIlw3Yg_4_3">29,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_uY68AjrttEWUuu6zf5Kp6A_4_6">9,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_s_sgPQTZp0C_-cAq5PpjEw_5_3">39,716</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_5zDiINqpl0qva3ChtJUd1A_5_6">19,573</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_Wbweq6XMBUaBUImxrRiWwA_6_3">14,292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_qcD0CQI42UKB2IHcfxTukg_6_6">6,547</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_426ShqO69kukUtxUw5HS7Q_7_3">1,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_RKY1ARoOZ0Sfsy8qeosgcQ_7_6">1,424</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Milestone payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="zbio:DeferredTaxAssetsMilestonePayments" scale="3" id="Tc_cHaXFhlpQU2O7jjjj00Vaw_8_3">442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="zbio:DeferredTaxAssetsMilestonePayments" scale="3" id="Tc_wfHfmoiejUqRLGt5R4aOeQ_8_6">719</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_dmTXi3YZh0qy_6uN86RrJA_9_3">4,016</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_0fI-eyH_sUaIAVnKtveYgg_9_6">1,188</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_O_9cLi8tnUSNLi1EnLi-nw_10_3">901</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_N0Jfwgqqkkmb4fi9Ui035w_10_6">550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_3VEAzOa0f0qqK1PWInVxxw_11_3">90,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_SGhkRcfbTU6GoPURc97nRw_11_6">39,961</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="zbio:DeferredTaxLiabilitiesAmortizationAndOther" scale="3" id="Tc__XDEcIRn5E2g5JyeYM8JMw_13_3">563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="zbio:DeferredTaxLiabilitiesAmortizationAndOther" scale="3" id="Tc_DEMZEQVz50WQOP1Va-8rXQ_13_6">200</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="Tc_Asg6a9oOcU6bpSpIAV5FUg_14_3">563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="Tc_Y7bMFoc6X0aG1PHwlkT8VA_14_6">200</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax asset before valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="zbio:DeferredTaxAssetsNetBeforeValuationAllowance" scale="3" id="Tc_O-sIXv13qU-JGQ5Kiiv9ig_17_3">90,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="zbio:DeferredTaxAssetsNetBeforeValuationAllowance" scale="3" id="Tc_8NbjiHYnDk6gSzyFXQTXYg_17_6">39,761</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_TaELEu4RZEe56xJf_49J4Q_18_3">90,295</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_fmpTJELDNEeJsTmVdIlgmw_18_6">39,761</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ASC Topic 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded full valuation allowances against its domestic and foreign deferred tax assets as of December 31, 2024, because management has determined that it is more likely than not that these assets will not be realized. The valuation allowance increased by $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_59WCFKzOTU2riAsaeoAMPQ">50.5</ix:nonFraction> million from December 31, 2023 to December 31, 2024, primarily due to additional net operating losses related to the U.S. and non-U.S. entities as well as the capitalization of research and development expenses under Internal Revenue Code Section 174 (&#8220;Section 174&#8221;) at the U.S. entity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Beginning on or after January 1, 2022, Section 174 of the U.S. internal revenue code was amended as part of the Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;) to no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Rather, the research and development expenses must be capitalized and amortized over five years for research performed in the U.S. and fifteen years for research performed outside the U.S. As a result of this provision, the Company capitalized applicable costs resulting in a deferred tax asset of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_2-euo0XGO0qIb5EsNIp7SA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="Narr_7aSNxCBYNESAsYBkLch4bQ">39.7</ix:nonFraction> million as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="Narr_iN5xkEUgak6kRzvpXcS4YA">75.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_S8d5mvaW6kCmEbhIWUz3xQ">65.0</ix:nonFraction> million of U.S. federal and state net operating loss (&#8220;NOL&#8221;) carryforwards, respectively. As of December 31, 2023, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="Narr_OgP0Sy2q7kaM4FrtzB-a2g">2.3</ix:nonFraction> million of U.S. federal NOL carryforwards. The Company had <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_ruI9FORZa0i5EIvxHu6CEA">no</ix:nonFraction> state NOL carryforwards as of December 31, 2023. The Company utilized previous net operating loss carryforwards to offset the taxable income in prior years. The federal NOL carryforwards do not expire, but they may be limited in their usage to an annual deduction equal to <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="2" format="ixt:num-dot-decimal" name="zbio:PercentageOfAnnualDeductionEqualToTaxableIncomeFederal" scale="-2" id="Narr_O-sYR5rZsEC2DmIxwKhUVA">80</ix:nonFraction>% of annual taxable income. &#160;The state NOL carryforwards expire in <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_u2OmFVykgEeCNR0zO3JP-g" format="ixt-sec:durwordsen" name="zbio:OperatingLossCarryforwardsExpirationPeriod" id="Narr_MPm5GSJqbEenQeqxJMvdkg">20 years</ix:nonNumeric>, starting in 2042. The federal and state NOL carryforwards are fully offset by valuation allowances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_skdQla54vkylvNLfiCBCHQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_7IcAYjCflkKAWfDqCQNBlg">13.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_twRRvxhUHkGVSVijS4AHpA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr___9RmtQatUSZtc-ZKbhm1Q">1.2</ix:nonFraction> million in federal and state general business or research and development tax credit carryforwards. As of December 31, 2023, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_aeVZjo1Bqk-9JQbx0cC7vA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_hGuZPrR8kEWJ2WYjEwznsw">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_lvF2unTWUEenGdpAx5Ec3A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_8Uoa7negSkGpZ07-N7hvVA">0.8</ix:nonFraction> million in federal and state general business or research and development tax credit carryforwards. These carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The federal and state research credit carryforwards expire in <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_lwKQYiDgb0GvlfNmmVeNtA" format="ixt-sec:durwordsen" name="zbio:TaxCreditCarryforwardExpirationPeriod" id="Narr_HTvpWfEILky3iDKdCJcDFg">20 years</ix:nonNumeric> and <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_u2OmFVykgEeCNR0zO3JP-g" format="ixt-sec:durwordsen" name="zbio:TaxCreditCarryforwardExpirationPeriod" id="Narr_3WFmmBUvn0-SxX7QEOxKCw">15 years</ix:nonNumeric>, respectively, starting in 2036. The federal and state tax credit carryforwards are fully offset by valuation allowances. </p></ix:continuation></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_hzUJSHigsUqxhoSWI5ZeuQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2024 and 2023, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="Narr_J2LS_iojlU6EXgp4Ni4o3w">54.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="Narr_MwU2NCE9Hk-Tcu4X4PGZOA">53.7</ix:nonFraction> million of foreign NOL carryforwards, respectively. Foreign NOL carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="Narr__tcltZO41Ei4ukaFRm5jGQ">47.8</ix:nonFraction> million will carryforward indefinitely, with the remaining expiring between 2026 and 2028. The foreign NOL carryforwards are fully offset by valuation allowances. The Company files income tax returns in the U.S., as well as various state and foreign jurisdictions. The Company is not currently under any income tax examinations. All tax years generally remain open in each jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have been <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_LNY1-L2eSUCpBImSqTJXQQ">no</ix:nonFraction> unrecognized tax benefits since the Company&#8217;s inception. The Company&#8217;s policy is to record estimated interest and penalties related to the underpayment of income taxes as a component of its income tax provision. As of December 31, 2024 and 2023, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="6" id="Narr_5Z-rJmnluEGWmwycwY595A"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="6" id="Narr_pvx0uhSWdk2LqQGS6dHegQ">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions and since inception, <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ" decimals="-5" format="ixt-sec:numwordsen" name="zbio:UncertainTaxPositionsAmountRecognized" scale="6" id="Narr_n2lflRBZc0un6l5bi6vwoA"><ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-5" format="ixt-sec:numwordsen" name="zbio:UncertainTaxPositionsAmountRecognized" scale="6" id="Narr_Uq1urJTEa0a9ywAuLdVz_w">no</ix:nonFraction></ix:nonFraction> amounts have been recognized in the Company&#8217;s consolidated statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, utilization of the NOLs and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section 382, as well as similar state provisions. These ownership changes may limit the amount of NOLs and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. If a change in control as defined by Section 382 has occurred at any time since the Company&#8217;s formation, utilization of its NOLs or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could then be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOLs or research and development tax carryforwards before their utilization.&#160;</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_rpEYzsckakGNBlQQEgY0yQ" continuedAt="Tb_rpEYzsckakGNBlQQEgY0yQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></span>Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has entered into arrangements for leases of office space; see<i style="font-style:italic;"> Note&#160;6, Leases,</i> for details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">License and Option Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company entered into licenses agreement under which it is obligated to make fixed and contingent payments; see <i style="font-style:italic;">Note</i>&#160;<i style="font-style:italic;">8,</i> <i style="font-style:italic;">License and Option Agreements</i>, for details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Contracts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has entered into agreements with certain vendors for the provision of services that the Company is not contractually able to terminate for convenience and thereby avoid any and all future obligations to the vendors. Under such agreements, the Company is contractually obligated to make certain minimum payments to the vendors, with the exact amounts in the event of termination to be based on the timing of the termination and the exact terms of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and certain officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or services as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and had not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2024.</p></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">166</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_rpEYzsckakGNBlQQEgY0yQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Litigation and Other Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused. As of December 31, 2024, the Company was not subject to any material legal proceedings which would reasonably be expected to have a material adverse effect on the Company&#8217;s financial results.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_GBTzVkgMokquz7d61HdirA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15.</b></span>Employee Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Effective June&#160;2020, the Company adopted the Zenas BioPharma 401(k)&#160;Plan (the &#8220;401(k)&#160;Plan&#8221;) for its employees, which is designed to be qualified under Section&#160;401(k)&#160;of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k)&#160;Plan within statutory and 401(k)&#160;Plan limits. Since inception of the 401(k)&#160;Plan and through the year ended December&#160;31, 2024, the Company has made a one-time contribution of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_fYEpz0tGfEyUIf45CmcsvQ">0.1</ix:nonFraction> million to the 401(k)&#160;Plan.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Narr_yLvdz-Yn0UWtmvC-j1cLmw"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_SadPQiXqKUeNtT43S5E29Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16.</b></span>Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Xencor, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has obtained exclusive, worldwide licenses from Xencor to research, develop, manufacture, market and sell <ix:nonFraction unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-yJXARaZ-0OBYdCxepkloA" decimals="INF" format="ixt-sec:numwordsen" name="zbio:RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained" scale="0" id="Narr_TZlhAbKuuEuHD9w6oX9zRg">three</ix:nonFraction> antibody product candidates pursuant to <ix:nonFraction unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-yJXARaZ-0OBYdCxepkloA" decimals="INF" format="ixt-sec:numwordsen" name="zbio:RelatedPartyTransactionNumberOfLicenseAgreements" scale="0" id="Narr_pD87M9HcO0-KfKur0zf-NQ">two</ix:nonFraction> license agreements. The Company has concluded that Xencor is a related party, because as initial consideration for the 2020 Xencor Agreement, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_kl-ar1okCk6X0Cdxj6jlyA" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_kw93CLGJnkuJ5ap9I49TdA">5,041,542</ix:nonFraction> shares of its Series&#160;A Preferred Stock to Xencor during the&#160;year ended December&#160;31, 2020. In April&#160;2023, Xencor elected to receive payment for a development milestone in the form of the Company&#8217;s Series&#160;B Preferred Stock and the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jtEg9vA0hUWnfXmt4HMTXg" decimals="INF" format="ixt:num-dot-decimal" name="zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_pglSEePe40a_HOYzcb57dw">4,189,955</ix:nonFraction> shares of Series&#160;B Preferred Stock as payment for the development milestone in June&#160;2023. As of December 31, 2024, Xencor held <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SB8hnByb2k6XmWq5YFUxLw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee" scale="-2" id="Narr_P9YefiUaD0ykTpiFd-201g">7.4</ix:nonFraction>% of shares of the Company&#8217;s outstanding common stock. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember__kat8-A7DkaDtefaqsDstA" decimals="0" format="ixt-sec:numwordsen" name="zbio:RelatedPartyTransactionReimbursableCosts" scale="0" id="Narr_LpnP7dgl206ADPP3amCPFQ">no</ix:nonFraction>t incur any costs related to reimbursable patent-related costs as of December 31, 2024. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Viridian Therapeutics, Inc. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has obtained a license from Viridian to research, develop, manufacture, market and sell an antibody product candidate in China. The Company has concluded that Viridian is a related party because although Fairmount Funds Management LLC owns less than <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="As_Of_12_31_2024_dei_LegalEntityAxis_zbio_FairmountFundsManagementLlcMember_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QkW1FJbql0yPxwXvk72juA" decimals="2" format="ixt:num-dot-decimal" name="zbio:OwnershipPercentageByRelatedParty" scale="-2" id="Narr_tyc1k2sbiU-_Mygq-7HbTA">5</ix:nonFraction>% of shares of the Company&#8217;s outstanding common stock, they have a seat on the Board and are also a 10% or greater stockholder of Viridian and have <ix:nonFraction unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw" contextRef="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_zbio_FairmountFundsManagementLlcMember_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hnbEkcn98U2igS-6OHbaDg" decimals="INF" format="ixt-sec:numwordsen" name="zbio:NumberOfSeatsHeldInBoard" scale="0" id="Narr_7KKlh418Sk2yp_p-nDcU6w">two</ix:nonFraction> seats on Viridian&#8217;s board of directors. As initial consideration for this license, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_XJAUtiSe802lS1JD3MLPpQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_zQGir3nPbE64ZwsSM6328Q">38,707</ix:nonFraction> shares of its common stock to Viridian during the&#160;year ended December&#160;31, 2020. As of December 31, 2024, Viridian held less than <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_I6CRPAIoAkK_QxeW-_WiBQ" decimals="3" format="ixt:num-dot-decimal" name="zbio:OwnershipPercentageByRelatedParty" scale="-2" id="Narr_tunsFo4FLEWPNkOYbin9gw">0.1</ix:nonFraction>% of shares of the Company&#8217;s outstanding common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Dianthus Therapeutics, Inc</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company obtained an exclusive option to negotiate and enter into exclusive license agreements with Dianthus for the rights (in the Zenas Territories only) to either or both of <ix:nonFraction unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_DianthusTherapeuticsincMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CAe46DStS0ayGHbh_yaH1Q" decimals="INF" format="ixt-sec:numwordsen" name="zbio:RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained" scale="0" id="Narr_gRCVESNaZU-esk4KUeJvmg">two</ix:nonFraction> antibody product candidates. In June 2022, the Company and Dianthus entered into the Dianthus License Agreement. The Company has concluded that Dianthus is a related party because the Company&#8217;s Chair of the Board is a member of the board of directors of Dianthus. As initial consideration for this license, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_zbio_DianthusTherapeuticsincMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lvI7Gb31J0y7HORj3pCOSQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_xuOUk8hXlEOrsHO45u4jhg">18,063</ix:nonFraction> shares of its common stock to Dianthus during the&#160;year ended December&#160;31, 2020. In October 2024, the Dianthus Option Agreement and Dianthus License Agreement and all of their related rights and obligations were transferred to Tenacia. As of December 31, 2024, Dianthus held less than <ix:nonFraction unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_zbio_DianthusTherapeuticsincMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ZTb-Cr_H-k6rrUVG_vWbag" decimals="3" format="ixt:num-dot-decimal" name="zbio:OwnershipPercentageByRelatedParty" scale="-2" id="Narr_NlpiOlh3k0qkySGggLRkGw">0.1</ix:nonFraction>% of shares of the Company&#8217;s outstanding common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For additional information on our license arrangements, please see <i style="font-style:italic;">Note 8, License and Option Agreements</i>, to these consolidated financial statements. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_f8SYXBVIaUCnNAqKk702Wg" continuedAt="Tb_f8SYXBVIaUCnNAqKk702Wg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">17.</b></span><b style="font-weight:bold;">Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">The Company manages its operations on a consolidated basis as a single reportable segment focused on the research and development of precision immunology-based therapies. The accounting policies of the single reportable segment are </p></ix:nonNumeric></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">167</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_507ad295_525c_40f0_82a1_aaadd0c645ec"></a><a id="Tc_tmCnydSOKkWv7rfDFv4a8A_1_3"></a><a id="Tc_Jmfp2SEtEU2fhZCkMbD20w_2_3"></a><a id="Tc_mtm2PzHfF06dCNW8WPXL3w_2_6"></a><a id="Tc_Gy3tQ0FxuUGkPG7h7oj0yg_3_0"></a><a id="Tc_4DzcBuC1JkqGbXpWQrkTzA_3_2"></a><a id="Tc_a4dJs7AU8EKvMzSLQNkAlA_3_5"></a><a id="Tc_FG6EZS4nQECR85On0QXxYw_4_0"></a><a id="Tc_x33bQIz7XkCi04JrFmREJQ_5_0"></a><a id="Tc_BZD9P2N5xEemIB57IOU18w_6_0"></a><a id="Tc_W9_re0aNb0iXp-qBtppNjg_7_0"></a><a id="Tc_U-SxaVjPS0SxwoubWHGqow_8_0"></a><a id="Tc_NG7so_o33kuLcYlisPlQ4Q_9_0"></a><a id="Tc_C9TqmAwrIka3U2DKYSKT2g_10_0"></a><a id="Tc_VHu11fiVBEKZG_nCLH6Lyg_11_0"></a><a id="Tc_zYpp_AuSyEK4-47cok6fKA_12_0"></a><a id="Tc_us16_vLFcEK50EHU3dlAjA_13_0"></a><a id="Tc_M75RhSW3SE22GgVS2moq9g_13_2"></a><a id="Tc_HtZIw8KxjUSFuYoQ2ZYl4w_13_5"></a><ix:continuation id="Tb_f8SYXBVIaUCnNAqKk702Wg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">identical to those described in <i style="font-style:italic;">Note 2, Summary of Significant Accounting Policies</i>. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews consolidated net loss, total expense and direct expenses by program and compared to budget. The CODM allocates resources based on the Company&#8217;s available cash resources, forecasted expenditures on a consolidated basis, as well as an assessment of the probability of success of its research and development activities on a program basis. Segment asset information regularly provided to the CODM is consistent with that reported on the consolidated balance sheets with particular emphasis on the Company&#8217;s available liquidity, including its cash, cash equivalents and marketable securities balances. Revenue is primarily attributed to individual countries based on the location of the license, as of December 31, 2024 and 2023, revenue was attributed to our China and U.S. entity, respectively. </p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="Tb_oD2HwHDe7kOuJsCTq9zORg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">The following table presents certain financial data for the Company&#8217;s reportable segments for the years ended December 31, 2024 and 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_6qFo_iPi6UyCUadI_UkFIw_3_3">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_pAV7g9BFKE2QQiAhjUp8uA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_PLVgMvMY4kC6Sh_R8unlXA_3_6">50,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Less:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Direct research and development expenses:</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Obexelimab</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_ObexelimabMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_BA-_9VIA-E-YvYOM66DKZw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="3" id="Tc_nyasHqyPrk2i9Rw_0t0tDw_6_3">94,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_ObexelimabMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_Ue5uXg-mLkyi2JN6fkIuQA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="3" id="Tc_X2o0dpsva0OX3pkh9m3IfA_6_6">25,446</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Other programs (ZB002 &amp; ZB004)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_OtherProgramsZb002Zb004Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_7d3JG86c_Eaat0gaHhQcQw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="3" id="Tc_BPXQKThTUka9TGnXT0Tksw_7_3">2,115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_OtherProgramsZb002Zb004Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_VixgjipTjEKqNxHHsetS4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="3" id="Tc_kNysyGvBQ0e7NxYSN9NJVg_7_6">6,242</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Partnered regional programs (ZB001 &amp; ZB005)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_PartneredRegionalProgramsZb001Zb005Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_Rh91EjE7O02oJHALLAAHdA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="3" id="Tc_-XLdsBDsE0K36zjrE9B0lg_8_3">6,737</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_PartneredRegionalProgramsZb001Zb005Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_yj8rbVJ6iEu1uke5hj5FiQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="3" id="Tc_cHr8hXQ36UGfhrlrizp-kw_8_6">6,738</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Unallocated research and development</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_UnallocatedMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_ebJVNQcIrE6ToW4JVW_66A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="3" id="Tc_0cCp4WonH02bSuRSobkrqg_9_3">31,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_UnallocatedMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_FtxZwqa3A020C1JNgu1N7Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="3" id="Tc_PWi5oXowlEelChfl13tRfg_9_6">20,008</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  General and administrative</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" sign="-" scale="3" id="Tc_E-zzmlXDTUGdlGPAJcM6Cg_10_3">22,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_pAV7g9BFKE2QQiAhjUp8uA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" sign="-" scale="3" id="Tc_gn4_czOOekWubVcKj4fIMw_10_6">15,218</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Stock-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" sign="-" scale="3" id="Tc_Vk6Nj3TPBEeF5WSKN45J-A_11_3">10,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_pAV7g9BFKE2QQiAhjUp8uA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" sign="-" scale="3" id="Tc_h4XBVKIbCUGqL2s4QtJAMg_11_6">3,495</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Other segment items</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">4</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" sign="-" scale="3" id="Tc_-BZuuTCoG02iJnBVKn7nEw_12_3">6,901</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_pAV7g9BFKE2QQiAhjUp8uA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_zemnu5YyKUGkk4jEDFkDQw_12_6">9,977</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_q5fgKsmNCkKgx1ywF7YCzA_13_3">156,988</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_pAV7g9BFKE2QQiAhjUp8uA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6A66bBiuM0a-qf29RZBT1g_13_6">37,124</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> Direct research and development expenses primarily consist of direct costs incurred to specific programs research and development activities, including costs to conduct clinical trials and to manufacture clinical drug supply. </p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">2 </sup>Unallocated research and development expenses primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as personnel costs for employees involved in research and development activities, excluding stock-based compensation, as well as contract services not allocated to specific programs. </p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">3</sup>General and administrative expenses primarily consist of all other personnel costs, excluding stock-based compensation, professional fees, depreciation expense, as well as facilities expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">4 </sup>Other segment items consist of acquired in-process research and development, fair value adjustments to convertible notes, other income, net and income tax provision. Other income, net consists of interest income and realized and unrealized gains and losses on foreign currency transactions. </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" name="us-gaap:SubsequentEventsTextBlock" id="Tb_vJaGO4MqBUOv-qOfPgDD_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">18.</b></span>Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Zai License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 24, 2025, the Company entered into a license agreement (the &#8220;Zai License Agreement&#8221;) with Zai Lab (Hong Kong) Limited (&#8220;Zai&#8221;), under which the Company granted Zai an exclusive sublicense to develop and commercialize ZB001 and related programs in greater China. &#160;As partial consideration for the Zai License Agreement, the Company received an upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="Duration_1_24_2025_To_1_24_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_zbio_ZaiLicenseAgreementMember_OHpbECa01k2mu2U9YBMjnw" decimals="-5" format="ixt:num-dot-decimal" name="zbio:CollaborativeArrangementUpfrontPaymentReceived" scale="6" id="Narr_Tza8HzbBXEKBUSmPhE6txA">10.0</ix:nonFraction> million from Zai. In addition, the Company is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA" contextRef="As_Of_1_24_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_zbio_ZaiLicenseAgreementMember_E1agUD26v0u0FuWVhieCXw" decimals="-5" format="ixt:num-dot-decimal" name="zbio:CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone" scale="6" id="Narr_x3Ks5gUSeUWNFA6KmjdjEg">96.0</ix:nonFraction> million upon the achievement of certain future development and commercial milestones and royalty percentage rates from the low to mid-single digits, net of pass-through obligations due to Viridian.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">168</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4ba58af3_6f56_48e0_8308_4dedc5b96522"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a8afd7c6_caed_4181_90e8_9f573a2c7180"></a><a id="Item9AControlsandProcedures_496308"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of December 31, 2024. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2024, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management's Annual Report on Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of our independent registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_4869f8e2_601b_46d6_a1b2_c0d8982b59cb"></a><a id="Item9BOtherInformation_603035"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_vWXXcJXfZk-byM8YlaPwEQ">During our fiscal quarter ended December 31, 2024, no</ix:nonNumeric> &#8220;Rule 10b5-1 plans&#8221; or &#8220;non-Rule 10b5-1 <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_bmVqaJxLtUOKzNgAnmfwbw">trading</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g" format="ixt:fixed-false" name="zbio:Rule10b51ArrangementModifiedFlag" id="Narr_ccBwXx96UU-RA15QNKigSg">arrangements</ix:nonNumeric>&#8221;, as each term is defined in Item 408(a) of Regulation S-K, were <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_IatoIT6fNEmxXd6mF15APw">adopted</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_kj2N3t99JUehgYGcV8Hq1A">modified</ix:nonNumeric>, or <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g" format="ixt:fixed-false" name="zbio:NonRule10b51ArrangementModifiedFlag" id="Narr_ZU_pVNO-AUCgB_zyDEaptA">terminated</ix:nonNumeric> by officers or directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_a4c13090_b088_40a3_b37b_79766c70af83"></a><a id="Item9CForeignJurisdication"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item&#160;9C. Disclosure Regarding</b><b style="font-weight:bold;"> Foreign Jurisdiction that Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Not applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;background:#ffff00;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">169</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c2f61247_cfd9_43e1_9a17_ca38ecd29fce"></a><a id="PARTIII_517092"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART III</p><a id="_Hlk184052526"></a><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 10. Directors, Executive Officers, and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be included in our proxy statement with respect to our 2025 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days after the end of our 2024 fiscal year and is incorporated herein by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Insider Trading Policies and Procedures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have adopted an <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Narr_q71mi7a7akGlEWpwZYzq6Q">insider trading policy</ix:nonNumeric> that governs the purchase, sale, and other dispositions of our securities by our</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">directors, officers and employees, and other covered persons. The insider trading policy also applies to transactions by</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">the Company in its securities. We believe that the insider trading policy is reasonably designed to promote compliance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">with insider trading laws, rules and regulations and the listing standards of Nasdaq. A copy of our Insider Trading Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">is filed with this Annual Report on Form 10-K as Exhibit 19.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_490d8fb1_888e_4d51_a676_b2b2caafa9e8"></a><a id="Item11ExecutiveCompensation_760525"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 11. Executive Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be included in our proxy statement with respect to our 2025 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days after the end of our 2024 fiscal year and is incorporated herein by reference. </p><a id="_f084074a_24ca_4dc5_a411_16d8aa591449"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be included in our proxy statement with respect to our 2025 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days after the end of our 2024 fiscal year and is incorporated herein by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_90c3922e_124f_4c54_ab3d_0f432b2ae025"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 13. Certain Relationships and Related Transactions, and Director Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be included in our proxy statement with respect to our 2025 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days after the end of our 2024 fiscal year and is incorporated herein by reference.</p><a id="_ad4d7c1b_1eda_452c_bdcd_3f6482a48c40"></a><a id="Item14PrincipalAccountantFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 14. Principal Accountant Fees and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information required by this item will be included in our proxy statement with respect to our 2025 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days after the end of our 2024 fiscal year and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cd0829cc_523e_4af1_b6bb_831672e35ae3"></a><a id="PARTIV_161604"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART IV</p><a id="Item15Exhibits_681346"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15. Exhibits and Financial Statements.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For a list of the financial statements included herein, see the Index to the Consolidated Financial Statements on page </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">134</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this Annual Report on Form 10-K, incorporated into this item by reference. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial statement schedules have been omitted because they are either not required, not appliable or the information is included in the consolidated financial statements or the notes thereto.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">170</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_50211292_a790_4b47_b792_49874b57d2ab"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:85.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924100177/tm2332800d24_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Restated Certificate of Incorporation of Zenas BioPharma, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on September 16, 2024, File No. 001-42270)</span></a> </p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924100177/tm2332800d24_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of Zenas BioPharma, Inc. (incorporated by reference to Exhibit 3.2 to the Form 8-K filed on September 16, 2024, File No. 001-42270)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924097538/tm2332800d16_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen stock certificate evidencing shares of common stock (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924097538/tm2332800d16_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amended and Restated Shareholders Agreement, among the Registrant and certain of its stockholders, dated May 3, 2024 (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.3&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="zbio-20241231xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.1+</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement by and between Zenas BioPharma (Cayman) Limited and Xencor, Inc., dated September 23, 2020 (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to License Agreement by and between Zenas BioPharma, Inc. and Xencor, Inc., dated June 24, 2024 (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.3+</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement by and between Zenas BioPharma (Cayman) Limited and Xencor, Inc., dated May 27, 2021(incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 filed on August 22,2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.4+</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to License Agreement by and between Zenas BioPharma (Cayman) Limited and Xencor, Inc., dated May 27, 2021 (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.5+</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to License Agreement by and between Zenas BioPharma, Inc. and Xencor, Inc., dated May 27, 2021 (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.6+</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement by and between the Registrant and Bristol-Myers Squibb Company, dated as of August 30, 2023 (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.7#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.8#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.9#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">171</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.10#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Share Agreement under the Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.11#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Non-Qualified Stock Option Agreement (Non-Employee Directors) under the Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.12#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Non-Qualified Stock Option Agreement (Employees) under the Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.13#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement under the Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.14#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924097538/tm2332800d16_ex10-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Zenas BioPharma, Inc. Short-Term Incentive Plan (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.15#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924100244/tm2332800d22_ex4-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Zenas BioPharma, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 4.6 the Form S-8 filed on September 16, 2024, File No. 333-282151)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.16#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924097538/tm2332800d16_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of U.S. Non-Qualified Stock Option Agreement under the Zenas BioPharma, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.17#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924097538/tm2332800d16_ex10-17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Global Non-Qualified Stock Option Agreement under the Zenas BioPharma, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.17 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.18#&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="zbio-20241231xex10d18.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Zenas BioPharma, Inc. 2024 Employee Stock Purchase Plan (amended and restated).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.19#&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="zbio-20241231xex10d19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Zenas BioPharma, Inc. Non-Employee Director Compensation Policy (as amended)</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">.</span></a> </p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.20#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924097538/tm2332800d16_ex10-20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement between the Registrant and Leon O. Moulder, Jr., dated September 4, 2024 (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.21#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924097538/tm2332800d16_ex10-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement between the Registrant and Joseph Farmer, dated September 4, 2024 (incorporated by reference to Exhibit 10.21 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.22#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924097538/tm2332800d16_ex10-22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement between the Registrant and Jennifer Fox, dated September 4, 2024 (incorporated by reference to Exhibit 10.22 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.23#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924097538/tm2332800d16_ex10-23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement between the Registrant and Orlando Oliveira, dated September 4, 2024 (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.24#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between the Registrant and Tanya Fischer, dated September 22, 2023 (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">172</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:8.05pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.25#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800d12_ex10-24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Transition and Separation Agreement between the Registrant and Hua Mu, dated June 29, 2023 (incorporated by reference to Exhibit 10.24 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.26#</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924097538/tm2332800d16_ex10-26.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Transition and Separation Agreement between the Registrant and Tanya Fischer, dated August 29, 2024 (incorporated by reference to Exhibit 10.26 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.27</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924097538/tm2332800d16_ex10-27.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.27 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">19.1&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="zbio-20241231xex19d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Insider Trading Policy</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924097538/tm2332800d16_ex21-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713).</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">23.1&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="zbio-20241231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">31.1&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="zbio-20241231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">31.2&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="zbio-20241231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">32.1*</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="zbio-20241231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">32.2*</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="zbio-20241231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">97.1&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="zbio-20241231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Policy for Recoupment of Incentive Compensation (Clawback) Policy</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.INS&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document&#160;&#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.SCH&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.CAL&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.DEF&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.LAB&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.PRE&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">104&#8224;</p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page&#160;Interactive Data File (formatted in Inline XBRL and contained in Exhibit&#160;101)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Filed herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Indicates management contract or compensatory plan.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Portions of this exhibit (indicated by asterisks) have been redacted pursuant to Item 601 S-K because they are both not material and the registrant customarily and actually treats such information as private of confidential.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under </p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">173</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</p><a id="_d1a719db_9f13_479f_b1a0_2e341685fb04"></a><a id="Item16Form10KSummary_6829"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 16. Form 10-K Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">174</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_674f82bf_0b47_4084_bff4_bf20240dea5d"></a><a id="SIGNATURES_688965"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Date: March 11, 2025</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ZENAS BIOPHARMA,&#160;INC.</b></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:45.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Leon O. Moulder, Jr. </p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leon O. Moulder, Jr.</p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:12pt;"><td style="vertical-align:middle;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:45.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jennifer Fox</p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jennifer Fox</p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Business Officer and Chief Financial Officer</p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:30.37%;border-bottom:1px solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:10.5pt;font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:2.49%;border-bottom:1px solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;border-bottom:1px solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:10.5pt;font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:2.76%;border-bottom:1px solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:10.5pt;font-weight:bold;">Date</b></p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:30.37%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.49%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.76%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;">/s/ Leon O. Moulder, Jr.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Leon O. Moulder, Jr.</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Chief Executive Officer and Director</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:10.5pt;font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">March 11, 2025</span></p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;">/s/ Jennifer Fox</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Jennifer Fox</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Chief Business Officer and Chief</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Financial Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:10.5pt;font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">March 11, 2025</span></p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;">/s/ Patricia Allen</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Patricia Allen</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Director</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">March 11, 2025</span></p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;">/s/ James Boylan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">James Boylan</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Director</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">March 11, 2025</span></p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;">/s/ Patrick Enright</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Patrick Enright</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Director</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">March 11, 2025</span></p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;">/s/ Tomas Kiselak</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Tomas Kiselak</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Director</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">March 11, 2025</span></p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;">/s/ Hongbo Lu, Ph.D.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Hongbo Lu, Ph.D.</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Director</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">March 11, 2025</span></p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;">/s/ Jake Num</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Jake Nunn</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Director</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">March 11, 2025</span></p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">175</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;">/s/ John Orloff, M.D.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">John Orloff, M.D.</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Director</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">March 11, 2025</span></p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 0pt -2.25pt;"><span style="font-size:10.5pt;">/s/ Ting Xiao</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Ting Xiao</span></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">Director</span></p></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:10.5pt;">March 11, 2025</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">176</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>zbio-20241231xex4d3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/10/2025 09:10:54 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 4.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REGISTERED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following description of the securities of Zenas BioPharma, Inc. (&#8220;us&#8221;, &#8220;our&#8221;, &#8220;we&#8221; or the &#8220;Company&#8221;) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by a reference to, our second restated certificate of incorporation (the &#8220;Restated Charter&#8221;), amended and restated bylaws (&#8220;Restated Bylaws&#8221;) and applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). Copies of our Restated Charter and Restated Bylaws are incorporated by reference as Exhibit 3.1 and Exhibit 3.2, respectively, to the Annual Report on Form 10-K to which this Exhibit 4.3 is an exhibit.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">Our authorized capital stock consists of 175,000,000 shares of common stock, with a par value of $0.0001 per share, and 25,000,000 shares of preferred stock, with a par value of $0.0001 per share, all of which preferred stock are undesignated. Our common stock is registered under Section 12 of the Exchange Act and is listed on The Nasdaq Global Select Market under the symbol &#8220;ZBIO.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a majority of the votes cast by the stockholders entitled to vote on the election, except in the case of a contested election, in which case the election shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">Under the terms of our Restated Charter, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from seeking to acquire, a majority of our outstanding voting stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anti-takeover Effects of Our Restated Charter and Our Restated Bylaws and the DGCL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">Our Restated Charter and Restated Bylaws contain certain provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors but which may have the effect of delaying, deferring or preventing a future takeover or change in control of us unless such takeover or change in control is approved by our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These provisions include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classified board.</i> Our Restated Charter provides that our board of directors is divided into three classes of directors, with the classes as nearly equal in number as possible. As a result, approximately one-third of our board of directors will be elected each year. The classification of directors will have the effect of making it more difficult for stockholders to change the composition of our board of directors. Our Restated Charter also provides that, subject to any rights of holders of preferred stock to elect additional directors under specified circumstances, the number of directors will be fixed exclusively pursuant to a resolution adopted by our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Action by written consent; special meetings of stockholders.</i> Our Restated Charter provides that stockholder action can be taken only at an annual or special meeting of stockholders and cannot be taken by written consent in lieu of a meeting. Our Restated Charter and the Restated Bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called pursuant to a resolution adopted by a majority of our board of directors. Except as described above, stockholders will not be permitted to call a special meeting or to require our board of directors to call a special meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Removal of directors.</i> Our Restated Charter provides that our directors may be removed only for cause by the affirmative vote of at least a majority of the voting power of our outstanding shares of capital stock, voting together as a single class. This requirement of a supermajority vote to remove directors could enable a minority of our stockholders to prevent a change in the composition of our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Advance notice procedures.</i> Our Restated Bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice, in proper form, of the stockholder&#8217;s intention to bring that business before the meeting. Although the Restated Bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, the Restated Bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Supermajority approval requirements.</i> The DGCL generally provides that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws, unless either a corporation&#8217;s certificate of incorporation or bylaws requires a greater percentage. Our Restated Charter and Restated Bylaws provide that the affirmative vote of holders of at least 75% of the total votes eligible to be cast in the election of directors will be required to amend, alter, change or repeal specified provisions. This requirement of a supermajority vote to approve amendments to our Restated Charter and Restated Bylaws could enable a minority of our stockholders to exercise veto power over any such amendments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Authorized but unissued shares.</i> Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 2 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exclusive forum.</i> Our Restated Charter provides that, subject to limited exceptions, the Court of Chancery of the State of Delaware (or, if, and only if, the Court of Chancery of the State of Delaware dismisses a Covered Claim (as defined below) for lack of subject matter jurisdiction, any other state or federal court in the State of Delaware that does have subject matter jurisdiction) will, to the fullest extent permitted by applicable law, be the sole and exclusive forum for (i)&#160;any derivative claim brought in the right of the Company, (ii)&#160;any claim asserting a breach of a fiduciary duty to the Company or the Company&#8217;s stockholders owed by any current or former director, officer or other employee or stockholder of the Company, (iii)&#160;any claim against the Company arising pursuant to any provision of the DGCL, our Restated Charter or Restated Bylaws, (iv)&#160;any claim to interpret, apply, enforce or determine the validity of our Restated Charter or Restated Bylaws, (v)&#160;any claim against the Company governed by the internal affairs doctrine, and (vi)&#160;any other claim, not subject to exclusive federal jurisdiction and not asserting a cause of action arising under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), brought in any action asserting one or more of the claims specified in clauses (i) through (v)&#160;above (collectively, the &#8220;Covered Claims&#8221;). This provision will not apply to claims brought to enforce a duty or liability created by the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">Our Restated Charter provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. In addition, our Restated Charter provides that any person or entity purchasing or otherwise acquiring any interest in the shares of capital stock of the Company will be deemed to have notice of and consented to these choice-of-forum provisions and waived any argument relating to the inconvenience of the forums in connection with any Covered Claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">The choice of forum provisions contained in our Restated Charter may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. While the Delaware courts have determined that such choice of forum provisions are facially valid, it is possible that a court of law in another jurisdiction could rule that the choice of forum provisions contained in our Restated Charter are inapplicable or unenforceable if they are challenged in a proceeding or otherwise, which could cause us to incur additional costs associated with resolving such action in other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Section 203 of the DGCL</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">We are subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#8217;s voting stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: before the stockholder became interested, the corporation&#8217;s board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 3 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">stockholders&#8217; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s address is 150 Royall Street, Canton, Massachusetts 02021.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 4 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>3
<FILENAME>zbio-20241231xex10d18.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/10/2025 09:10:55 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.18</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="zbio-20241231xex10d18001.jpg" alt="Graphic" style="display:inline-block;height:42.24pt;width:116pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.95pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">ZENAS BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2024 EMPLOYEE STOCK PURCHASE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(AMENDED AND RESTATED ON FEBRUARY 27, 2025)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">Defined Terms</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Exhibit A, which is incorporated by reference, defines the terms used in this Plan and sets forth certain operational rules related to those terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">Purpose of Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purpose</u>. &#160;This Plan is intended to enable Eligible Employees to purchase shares of Stock in offerings under this Plan, and thereby acquire an interest in the Company. &#160;This Plan is intended to be exempt from the application and requirements of Section 409A of the Code, and is to be construed accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Qualified and Non-Qualified Offerings Permitted</u>. &#160;This Plan includes two components: a 423 Component and a Non-423 Component. &#160;The Company intends (but makes no undertaking or representation to maintain) the 423 Component to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423. &#160;The provisions of the 423 Component, accordingly, will be construed in a manner that is consistent with the requirements of Section 423. &#160;In addition, this Plan authorizes grants of Options under the Non-423 Component that do not meet the requirements of Section 423. &#160;Except as otherwise provided in this Plan or as the Administrator determines, the Non-423 Component will operate and be administered in the same manner as the 423 Component. &#160;Eligible Employees will be able to participate in either the 423 Component or the Non- 423 Component of this Plan, as the Administrator determines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">Options to Purchase Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to adjustment pursuant to Section 16 of this Plan, the maximum aggregate number of shares of Stock available for purchase pursuant to the exercise of Options granted under this Plan will be 397,956 shares (the &#8220;<b style="font-weight:bold;">Initial Share Pool</b>&#8221;). &#160;The Initial Share Pool will automatically increase on January 1<sup style="font-size:7.5pt;vertical-align:top;">st </sup>of each year beginning in 2025 and continuing through and including 2034 by the lesser of (i) one percent of the number of shares of Stock outstanding as of such date and (ii) the number of shares of Stock determined by the Board on or prior to such date for such year, up to a maximum of 1,000,000 shares in the aggregate per year (the Initial Share Pool, as it may be so increased, the &#8220;<b style="font-weight:bold;">Share Pool</b>&#8221;). &#160;The shares of Stock to be delivered upon exercise of Options under this Plan may be either shares of authorized but unissued Stock, treasury Stock, or previously issued Stock acquired by the Company. &#160;If any Option granted under this Plan expires or terminates for any reason without having been exercised in full or ceases for any reason to be exercisable in whole or in part, the unpurchased shares of Stock subject to such Option will not reduce the Share Pool and will again be available for purchase under this Plan. &#160;If, on an Exercise Date, the total number of shares of Stock that would otherwise be subject to Options granted under this Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">exceeds the number of shares then available in the Share Pool, the Administrator shall make a pro rata allocation of the shares remaining available for purchase under this Plan in as uniform a manner as is practicable and as it determines to be equitable. &#160;In such event, the Administrator shall notify each Participant of such reduction and of the effect on the Participant&#8217;s Options and may reduce the rate of a Participant&#8217;s payroll deductions, if necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">Eligibility</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. &#160;Options may be granted only to Eligible Employees of the Company or a Designated Subsidiary. &#160;Subject to the limitations contained in this Plan, each Employee (i) whose customary employment with the Company or a Designated Subsidiary, as applicable, is for more than five (5) months per calendar year, (ii) who customarily works twenty (20) hours or more per week, and (iii) who satisfies the requirements set forth in this Plan will be an Eligible Employee. &#160;Employees of a Designated Subsidiary may be Eligible Employees even if their customary employment is less than twenty (20) hours per week and/or five (5) months per calendar year, to the extent required by applicable law, or any lesser number of hours per week and/or number of months in any calendar year established by the Administrator (if required under applicable law) for purposes of any separate offering or Employees of a Designated Subsidiary under the Non-423 Component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Five Percent Shareholders</u><i style="font-style:italic;">. &#160;</i>No Employee may be granted an Option under this Plan if, immediately after the Option is granted, the Employee would own (or pursuant to Section 424(d) of the Code would be deemed to own) stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or of its Parent or Subsidiaries, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Requirements</u><i style="font-style:italic;">. &#160;</i>The Administrator may, for Offering Periods that have not yet commenced, establish additional or other eligibility requirements, or amend the eligibility requirements set forth in subsection (a) above, in each case, consistent with the requirements of Section 423 for the 423 Component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-423 Component Offerings</u>. &#160;Employees who are citizens or residents of a jurisdiction outside of the U.S. (without regard to whether they are also citizens of the U.S. &#160;or resident aliens (within the meaning of Section 7701(b)(1)(A) of the Code)) will not be eligible to participate in this Plan if (i) the grant of an Option under this Plan to the Employee is prohibited under the laws of such jurisdiction, or (ii) compliance with the laws of the foreign jurisdiction would cause this Plan to violate the requirements of Section 423. &#160;The Administrator may establish additional eligibility requirements, or fewer eligibility requirements, for Eligible Employees with respect to Options granted under the Non-423 Component even if such requirements are not consistent with Section 423.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-weight:bold;">Offering Periods</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Plan will generally be implemented by a series of separate offerings referred to as &#8220;<b style="font-weight:bold;">Offering Periods</b>&#8221;. &#160;Unless otherwise determined by the Administrator, the Offering Periods will be successive periods of approximately six (6) months. &#160;The last Business Day of each Offering Period will be an &#8220;<b style="font-weight:bold;">Exercise Date</b>&#8221;. &#160;The Administrator may change the Exercise Date, the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">commencement date, the ending date and the duration of each Offering Period; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that for Options made under the 423 Component to the extent permitted by Section 423. &#160;No Option may be exercised after 27 months from its grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;">Option Grant</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the requirements and limitations set forth in Sections 4 and 10 of this Plan and the Maximum Share Limit (as defined below), on the first day of an Offering Period, each Participant will automatically be granted an Option to purchase shares of Stock on the Exercise Date; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that no Participant will be granted an Option under this Plan that permits the Participant&#8217;s right to purchase shares of Stock under this Plan and under all other employee stock purchase plans of the Company and its Parent and Subsidiaries, if any, to accrue at a rate that exceeds U.S. $25,000 in Fair Market Value (or such other maximum as may be prescribed from time to time by the Code) for each calendar year during which any Option granted to such Participant is outstanding at any time, as determined in accordance with Section 423(b)(8) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-weight:bold;">Method of Participation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payroll Deduction and Participation Authorization</u>. &#160;To participate in an Offering Period, an Eligible Employee must execute and deliver to the Administrator a payroll deduction and participation authorization form in accordance with the procedures prescribed by, and in a form acceptable to, the Administrator and, in so doing, the Eligible Employee will thereby become a Participant as of the first day of such Offering Period. &#160;Such an Eligible Employee will remain a Participant with respect to subsequent Offering Periods until his or her participation in this Plan is terminated as provided herein. &#160;Such payroll deduction and participation authorization form must be delivered not later than ten (10) calendar days prior to the first day of an Offering Period, or such other time as specified by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continued Participation</u>. &#160;An Eligible Employee who remains a Participant with respect to subsequent Offering Periods is not required to submit additional enrollment documentation in order to continue participation in the Plan, unless requested by the Company for legal or administrative reasons and provided that participation in the Plan in any subsequent Offering Period will be governed by the terms and conditions of the Plan and the applicable agreement (if any) and other terms and conditions of participation in effect at such time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Changes to Payroll Deduction Authorization for Subsequent Offering Periods</u>. &#160;A Participant&#8217;s payroll deduction authorization will remain in effect for subsequent Offering Periods unless the Participant files a new authorization not later than ten (10) calendar days prior to the first day of the subsequent Offering Period (or such other time as specified by the Administrator) or the Participant&#8217;s Option is cancelled pursuant to Section 13 or Section 14 of this Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Changes to Payroll Deduction Authorization for Current Offering Period</u><i style="font-style:italic;">. &#160;</i>During an Offering Period, a Participant&#8217;s payroll deduction authorization may be prospectively decreased once during an Offering Period. &#160;Any request to decrease a Participant&#8217;s payroll deduction authorization must be communicated to the Administrator a minimum of ten (10) calendar days prior to the end of an Offering Period (or such other time as specified by the Administrator) in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">accordance with the procedures prescribed by, and in a form acceptable to, the Administrator and will be effective as soon as administratively practicable. &#160;A Participant may also terminate his or her payroll deduction authorization by canceling his or her Option in accordance with Section 13 of this Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payroll Deduction Percentage</u><i style="font-style:italic;">. &#160;</i>Each payroll deduction authorization will authorize payroll deductions as a whole percentage from one percent (1%) to fifteen percent (15%) of the employee&#8217;s Eligible Compensation per payroll period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payroll Deduction Account</u><i style="font-style:italic;">. &#160;</i>All payroll deductions made pursuant to this Section 7 will be credited to the Participant&#8217;s Account. &#160;Amounts credited to a Participant&#8217;s Account will not be required to be set aside in trust or otherwise segregated from the Company&#8217;s general assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-weight:bold;">Method of Payment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A Participant must pay for shares of Stock purchased under this Plan with accumulated payroll deductions credited to the Participant&#8217;s Account; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that the Administrator may allow Participants to make other contributions under the Plan via cash, check or other means instead of payroll deductions if payroll deductions are not permitted or feasible under applicable law and, for offerings under the 423 Component, the Administrator determines that such other contributions are permissible under Section 423.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-weight:bold;">Purchase Price</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Purchase Price of shares of Stock issued pursuant to the exercise of an Option on each Exercise Date will be eighty-five percent (85%) (or such other percentage specified by the Administrator to the extent permitted under Section 423) of the lesser of (a) the Fair Market Value of a share of Stock on the date on which the Option was granted pursuant to Section 6 of this Plan (<i style="font-style:italic;">i.e.</i>, the first day of the Offering Period) and (b) the Fair Market Value of a share of Stock on the date on which the Option is deemed exercised pursuant to Section 10 of this Plan (<i style="font-style:italic;">i.e.</i>, the Exercise Date).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-weight:bold;">Exercise of Options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase of Shares of Stock</u><i style="font-style:italic;">. &#160;</i>Subject to the limitations set forth in Section 6 of this Plan and this Section 10, with respect to each Offering Period, on the applicable Exercise Date, each Participant will be deemed to have exercised his or her Option and the accumulated payroll deductions in the Participant&#8217;s Account will be applied to purchase the greatest number of shares of Stock that can be purchased with such Account balance at the applicable Purchase Price; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that no more than twenty-five thousand (25,000) shares of Stock may be purchased by a Participant on any Exercise Date, or such other number as the Administrator may prescribe in accordance with Section 423 (the &#8220;<b style="font-weight:bold;">Maximum Share Limit</b>&#8221;). &#160;As soon as practicable thereafter, shares of Stock so purchased will be placed, in book-entry form, into a recordkeeping account in the name of the Participant. &#160;Unless the Administrator determines in its discretion that fractional shares may be purchased pursuant to the exercise of an Option under this Plan, the shares of Stock will be rounded down to the nearest whole share and any accumulated payroll deductions in a Participant&#8217;s Account that are not sufficient to purchase a whole share will be retained in the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Participant&#8217;s Account for the subsequent Offering Period, subject to earlier withdrawal by the Participant as provided in Section 13 of this Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Return of Account Balance</u><i style="font-style:italic;">. &#160;</i>Except as provided in Section 10(a) of this Plan with respect to fractional shares, any accumulated amount of payroll deductions in a Participant&#8217;s Account for an Offering Period that are not used for the purchase of shares of Stock, whether because of the Participant&#8217;s withdrawal from participation in an Offering Period or for any other reason, will be returned to the Participant (or his or her designated beneficiary or legal representative, as applicable), without interest, as soon as administratively practicable after such withdrawal or other event, as applicable. &#160;If the Participant&#8217;s accumulated payroll deductions on the Exercise Date of an Offering Period would otherwise enable the Participant to purchase shares of Stock in excess of the Maximum Share Limit or the maximum Fair Market Value set forth in Section 6 of this Plan, the excess of the amount of the accumulated payroll deductions over the aggregate Purchase Price of the shares of Stock actually purchased will be returned to the Participant, without interest (unless otherwise required by applicable law), as soon as administratively practicable after such Exercise Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-weight:bold;">Interest</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No interest will accrue or be payable on any amount held in the Account of any Participant, unless otherwise required by applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-weight:bold;">Tax Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Generally</u>. &#160;Payroll deductions will be made on an after-tax basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 409A of the Code</u>. &#160;Options granted under the 423 Component are intended to be exempt from the application of Section 409A of the Code under U.S. &#160;Treasury Regulation Section 1.409A-1(b)(5)(ii). &#160;Options granted under the Non-423 Component to U.S. &#160;taxpayers are intended to be exempt from the application of Section 409A of the Code under the short-term deferral exception and any ambiguities will be construed and interpreted in accordance with such intent. &#160;Subject to Section 12(c) of this Plan, Options granted to U.S. &#160;taxpayers under the Non- 423 Component will be subject to such terms and conditions that will permit such Options to satisfy the requirements of the short-term deferral exception available under Section 409A of the Code, including the requirement that the shares subject to an Option be delivered within the short- term deferral period. &#160;Notwithstanding the foregoing, the Company will have no liability to a Participant or any other party if an Option that is intended to be exempt from or compliant with Section 409A of the Code is not so exempt or compliant or for any action taken by the Administrator with respect thereto and in no event will the Company, any Designated Subsidiary or any affiliate be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by a Participant on account of non-compliance with Section 409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Guarantee of Tax Treatment</u>. &#160;Although the Company may endeavor to (i) qualify an Option for special tax treatment under the laws of the U.S. &#160;(e.g., under Section 423) or jurisdictions outside of the U.S., or (ii) avoid adverse tax treatment (e.g., under Section 409A of the Code), the Company makes no representation to that effect and expressly disavows any</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">covenant to maintain special or to avoid unfavorable tax treatment, notwithstanding anything to the contrary in this Plan, including Section 12(b) of this Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Withholding</u>. &#160;The Participant will make adequate provision to satisfy the Tax- Related Items withholding obligations, if any, of the Company and/or the applicable Designated Subsidiary which arise with respect to Participant&#8217;s participation in this Plan or upon the disposition of the shares of Stock. &#160;The Company shall not be required to issue any shares of Stock under this Plan until such obligations are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>The Administrator will have the right to make such provision as it deems necessary for, and may condition the exercise of an Option on, the satisfaction of its obligations to withhold federal, state, local income or other taxes incurred by reason of the purchase or disposition of shares of Stock under this Plan or otherwise in connection with the Plan. &#160;In the Administrator&#8217;s discretion and subject to applicable law, such tax obligations may be satisfied in whole or in part by delivery of shares of Stock to the Company, including shares of Stock purchased under this Plan, valued at Fair Market Value, but not in excess of the maximum withholding amount consistent with the award being subject to equity accounting treatment under the Accounting Rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>The Company and/or the Designated Subsidiary may, but will not be obligated to, (A) withhold from the Participant&#8217;s compensation or any other payments due the Participant the amount necessary to meet such withholding obligations, (B) withhold a sufficient whole number of shares of Stock issued following exercise having an aggregate value sufficient to pay the Tax- Related Items, (C) withhold from the proceeds of the sale of shares of Stock, either through a voluntary sale or a mandatory sale arranged by the Company or (D) withhold using any other method of withholding that the Company and/or the Designated Subsidiary deems appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>The Company and/or the Designated Subsidiary will have the right to take such other action as may be necessary in the opinion of the Company or a Designated Subsidiary to satisfy withholding and/or reporting obligations for such Tax-Related Items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-weight:bold;">Cancellation of Payroll Deduction Authorization and Withdrawal from Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A Participant who has been granted an Option under this Plan may cancel all (but not less than all) of such Option and terminate his or her participation in this Plan by notice delivered to the Administrator in accordance with the procedures prescribed by, and in a form acceptable to, the Administrator. &#160;To be effective with respect to an upcoming Exercise Date, such cancellation notice must be delivered not later than ten (10) calendar days prior to such Exercise Date (or such other time as specified by the Administrator). &#160;Upon such termination and cancellation, the balance in the Participant&#8217;s Account will be returned to the Participant, without interest (unless otherwise required by applicable law), as soon as administratively practicable thereafter. &#160;For the avoidance of doubt, a Participant who reduces his or her withholding rate for a future Offering Period to zero percent (0%) pursuant to Section 7 of this Plan will be deemed to have terminated his or her payroll deduction authorization and canceled his or her participation in this Plan as to such future Offering Period (but not, for the avoidance of doubt, the current Offering Period unless the Participant terminates participation in this Plan under this Section 13), unless the Participant delivers a new</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">payroll deduction authorization for a subsequent Offering Period in accordance with the rules of Section 7(b) of this Plan. &#160;A Participant will be deemed to have canceled his or her participation in this Plan under this Section 13 if the Participant does not have sufficient amounts in his or her pay to fulfill the elected payroll deduction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></font><b style="font-weight:bold;">Termination of Employment; Death of Participant</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon the termination of a Participant&#8217;s employment with the Company or a Designated Subsidiary, as applicable, for any reason (including the death of a Participant during an Offering Period prior to an Exercise Date) or in the event the Participant ceases to qualify as an Eligible Employee, the Participant will cease to be a Participant, any Option held by the Participant under this Plan will be canceled, the balance in the Participant&#8217;s Account will be returned to the Participant (or his or her estate or designated beneficiary in the event of the Participant&#8217;s death), without interest (unless otherwise required by applicable law), as soon as administratively practicable thereafter, and the Participant will have no further rights under this Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise determined by the Administrator, a Participant whose Employment transfers or whose Employment terminates with an immediate rehire by or between the Company or a Designated Subsidiary will be treated as having terminated Employment for purposes of participating in the Plan or an offering. &#160;The Administrator may establish additional or different rules to govern transfers of employment for purposes of participation in the Plan or an offering, consistent with the applicable requirements of Section 423 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15.</b></font><b style="font-weight:bold;">Equal Rights; Participant&#8217;s Rights Not Transferable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All Participants granted Options in an offering under the Section 423 Component of the Plan will have the same rights and privileges, consistent with the requirements set forth in Section 423. &#160;Any Option granted under this Plan will be exercisable during the Participant&#8217;s lifetime only by him or her and may not be sold, pledged, assigned, or transferred in any manner. &#160;In the event any Participant violates or attempts to violate the terms of this Section 15, as determined by the Administrator in its sole discretion, any Options granted to the Participant under this Plan may be terminated by the Company and, upon the return to the Participant of the balance of his or her Account, without interest (unless otherwise required by applicable law), all of the Participant&#8217;s rights under this Plan will terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16.</b></font><b style="font-weight:bold;">Change in Capitalization; Corporate Transaction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Capitalization</u>. &#160;In the event of a stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or other change in the Company&#8217;s capital structure that constitutes an equity restructuring within the meaning of the Accounting Rules, the Administrator shall make appropriate adjustments to the aggregate number and type of shares of stock available under this Plan, the number and type of shares of stock granted under any outstanding Option, the maximum number and type of shares of stock purchasable under any outstanding Option, and/or the Purchase Price under any outstanding Option, in any case, in a manner that complies with Section 423.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Transaction</u><i style="font-style:italic;">. &#160;</i>In the event of a sale of all or substantially all of the Stock or a sale of all or substantially all of the assets of the Company, or a merger or similar transaction</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in which the Company is not the surviving corporation or that results in the acquisition of the Company by another person, the Administrator may, in its discretion, (i) if the Company is merged with or acquired by another corporation, provide that each outstanding Option will be assumed or exchanged for a substitute Option granted by the acquiror or successor corporation or by a parent or subsidiary of the acquiror or successor corporation, (ii) cancel each outstanding Option and return the balances in Participants&#8217; Accounts to the Participants, and/or (iii) pursuant to Section 18 of this Plan, terminate the Offering Period on or before the date of the proposed sale, merger or similar transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">17.</b></font><b style="font-weight:bold;">Administration of Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Plan will be administered by the Administrator. &#160;The Administrator has discretionary authority, subject only to the express provisions of this Plan, to administer and interpret this Plan; to determine eligibility under this Plan; to prescribe forms, rules and procedures relating to this Plan; and to otherwise do all things necessary or desirable to carry out the purposes of this Plan, to the extent permitted under applicable law. &#160;The Administrator will determine which Subsidiary of the Company is a Designated Subsidiary, and if the Eligible Employees of a Designated Subsidiary will participate in the 423 Component (and, in such case, if the Eligible Employees of the Designated Subsidiary will participate in a separate offering from the Company and/or in a separate offering from other Designated Subsidiaries) or the Non-423 Component of this Plan. &#160;Determinations of the Administrator made with respect to this Plan are conclusive and bind all persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Administrator may specify the manner in which the Company and/or Employees are to provide notices and forms under this Plan, and may require that such notices and forms be submitted electronically.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">18.</b></font><b style="font-weight:bold;">Amendment and Termination of Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u><i style="font-style:italic;">. &#160;</i>The Administrator reserves the right at any time or times to amend this Plan to any extent and in any manner it may deem advisable; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that any amendment that would be treated as the adoption of a new plan for purposes of Section 423 will have no force or effect unless approved by the shareholders of the Company within twelve (12) months before or after its adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u><i style="font-style:italic;">. &#160;</i>The Administrator reserves the right at any time or times to suspend or terminate this Plan. &#160;In connection therewith, the Administrator may provide, in its sole discretion, either that outstanding Options will be exercisable on the Exercise Date for the applicable Offering Period or on such earlier date as the Administrator may specify (in which case such earlier date will be treated as the Exercise Date for the applicable Offering Period), or that the balance of each Participant&#8217;s Account will be returned to the Participant, without interest (unless otherwise required by applicable law).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">19.</b></font><b style="font-weight:bold;">Approvals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Shareholder approval of this Plan will be obtained prior to the date that is twelve (12) months after the date this Plan is approved by the Board. &#160;In the event that this Plan has not been approved by the shareholders of the Company prior to the one-year anniversary of the date that</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">this Plan is approved by the Board, all Options to purchase shares of Stock under this Plan will be cancelled and become null and void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding anything herein to the contrary, the obligation of the Company to issue and deliver shares of Stock under this Plan will be subject to the approval required of any governmental authority in connection with the authorization, issuance, sale or transfer of such shares of Stock and to any requirements of any national securities exchange applicable thereto, and to compliance by the Company with other applicable legal requirements in effect from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">20.</b></font><b style="font-weight:bold;">Participants&#8217; Rights as Shareholders and Employees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A Participant will have no rights or privileges as a shareholder of the Company and will not receive any dividends in respect of any shares of Stock covered by an Option granted hereunder until such Option has been exercised, full payment has been made for such shares, and the shares have been issued to the Participant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nothing contained in the provisions of this Plan will be construed as giving to any Employee the right to be retained in the employ of the Company or any Designated Subsidiary or as interfering with the right of the Company or any Designated Subsidiary to discharge, promote, demote or otherwise re-assign any Employee from one position to another within the Company or any Designated Subsidiary at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">21.</b></font><b style="font-weight:bold;">Restrictions on Transfer; Information Regarding Disqualifying Dispositions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictions on Transfer</u>. &#160;Shares of Stock purchased under this Plan may not be transferred, sold, pledged or alienated by a Participant, other than by will or by the laws of descent and distribution, for a period of three (3) months following the date on which such shares of Stock were purchased, or such other period as may be determined by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disposition of Stock</u>. &#160;By electing to participate in this Plan, each Participant agrees to provide such information about any transfer or disposition of Stock acquired under this Plan in order to assist the Company or any Designated Subsidiary in complying with applicable tax laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">22.</b></font><b style="font-weight:bold;">Miscellaneous</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Jury Trial</u>. &#160;By electing to participate in this Plan, each Participant waives (or will be deemed to have waived), to the maximum extent permitted under applicable law, any right to a trial by jury in any action, proceeding or counterclaim concerning any rights under this Plan or with respect to any Option, or under any amendment, waiver, consent, instrument, document or other agreement delivered or which in the future may be delivered in connection therewith, and agrees (or will be deemed to have agreed) that any such action, proceedings or counterclaim will be tried before a court and not before a jury. &#160;By electing to participate in this Plan, each Participant certifies that no officer, representative, or attorney of the Company has represented, expressly or otherwise, that the Company would not, in the event of any action, proceeding or counterclaim, seek to enforce the foregoing waivers. &#160;Notwithstanding anything to the contrary in this Plan, nothing herein is to be construed as limiting the ability of the Company and a Participant to agree to submit any dispute arising under the terms of this Plan or in respect</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of any Option to binding arbitration or as limiting the ability of the Company to require any individual to agree to submit such disputes to binding arbitration as a condition of receiving an Option hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation of Liability</u>. &#160;Notwithstanding anything to the contrary in this Plan, neither the Company, nor any of its subsidiaries, nor the Administrator, nor any person acting on behalf of the Company, any of its subsidiaries, or the Administrator, will be liable to any Participant, to any permitted transferee, to the estate or beneficiary of any Participant or any permitted transferee, or to any other person by reason of any acceleration of income, any additional tax, or any penalty, interest or other liability asserted by reason of the failure of this Plan or any Option to satisfy the requirements of Section 423, or otherwise asserted with respect to this Plan or any Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Unfunded Plan</u>. &#160;The Company&#8217;s obligations under this Plan are unfunded, and no Participant will have any right to specific assets of the Company in respect of any Option. &#160;Participants will be general unsecured creditors of the Company with respect to any amounts due or payable under this Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">23.</b></font><b style="font-weight:bold;">Establishment of Sub-Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing or any provision of this Plan to the contrary, consistent with the requirements of Section 423, the Administrator may, in its sole discretion, amend the terms of this Plan, or an offering and/or provide for separate offerings under this Plan in order to, among other things, reflect the impact of local law outside of the U.S. &#160;as applied to one or more Eligible Employees of a Designated Subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, the Administrator may adopt such rules, procedures and sub-plans relating to the operation and administration of this Plan as are necessary or appropriate under applicable laws to permit or facilitate participation in this Plan by Eligible Employees who are non-U.S. &#160;nationals or employed or providing services or located or otherwise subject to the laws of a jurisdiction outside the U.S. &#160;Without limiting the generality of, but consistent with, the foregoing, the Administrator specifically is authorized to adopt rules, procedures, and sub-plans, which, for purposes of the Non-423 Component, may be beyond the scope of Section 423, regarding, without limitation, eligibility to participate in this Plan, the definition of Eligible Compensation, the dates and duration of offerings or other periods during which Participants make contributions pursuant to the Plan, the method of determining the Purchase Price and the discount from Fair Market value at which shares of Stock may be purchased, handling and making of payroll deductions and Accounts as well as other methods for making contributions pursuant to the Plan, establishment of bank or trust accounts to hold payroll deductions, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures and handling of share issuances, any of which may vary according to applicable laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">24.</b></font><b style="font-weight:bold;">Governing Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Requirements of Corporate Law</u>. &#160;Options and shares of Stock will be granted, issued and administered consistent with the requirements of applicable Delaware law relating to the issuance of stock and the consideration to be received therefor, and with the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">applicable requirements of the stock exchanges or other trading systems on which the Stock is listed or entered for trading, in each case as determined by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Matters</u>. &#160;Except as otherwise provided by the express terms of a sub-plan described in Section 23 of this Plan or as provided in Section 24(a) of this Plan, the domestic substantive laws of the Commonwealth of Massachusetts govern the provisions of this Plan and of Options under this Plan and all claims or disputes arising out of or based upon this Plan or any Option or relating to the subject matter hereof or thereof without giving effect to any choice or conflict of laws provision or rule that would cause the application of the domestic substantive laws of any other jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction</u>. &#160;By electing to participate in this Plan, each Participant agrees or will be deemed to have agreed to (i) submit irrevocably and unconditionally to the jurisdiction of the federal and state courts located within the geographic boundaries of the U.S. &#160;District Court for the District of Massachusetts for the purpose of any suit, action or other proceeding arising out of or based upon this Plan or any Option; (ii) not commence any suit, action or other proceeding arising out of or based upon this Plan or any Option, except in the federal and state courts located within the geographic boundaries of the U.S. &#160;District Court for the District of Massachusetts; and (iii) waive, and not assert, by way of motion as a defense or otherwise, in any such suit, action or proceeding, any claim that he or she is not subject personally to the jurisdiction of the above- named courts that his or her property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Plan or any Option or the subject matter thereof may not be enforced in or by such court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">25.</b></font><b style="font-weight:bold;">Effective Date and Term</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Plan will become effective upon adoption of this Plan by the Board and no rights will be granted hereunder after the earliest to occur of (a) this Plan&#8217;s termination by the Company, (b) the issuance of all shares of Stock available for issuance under this Plan or (c) the day before the ten (10)-year anniversary of the date the Board approves this Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definition of Terms</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following terms, when used in the Plan, will have the meanings and be subject to the provisions set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;401(k) Plan&#8221;: </b>A retirement plan qualifying under Section 401(k) of the Code that is sponsored by the Company or one of its Subsidiaries for the benefit of its employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;423 Component&#8221;: </b>The part of this Plan, which excludes the Non-423 Component, pursuant to which Options that satisfy the requirements of Section 423.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Account&#8221;: </b>A notional payroll deduction account maintained in the Participant&#8217;s name on the books of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Accounting Rules&#8221;: </b>Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Administrator&#8221;: </b>The Compensation Committee, except that the Compensation Committee may delegate its authority under the Plan to a sub-committee comprised of one or more of its members, to members of the Board, or to officers or employees of the Company to the extent permitted by applicable law. &#160;In each case, references herein to the Administrator refer, as applicable, to such persons or groups so delegated to the extent of such delegation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Board&#8221;: </b>The board of directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Business Day&#8221;: </b>Any day on which the established national exchange or trading system (including the Nasdaq Global Stock Market) on which the Stock is traded is available and open for trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Code&#8221;: </b>The U.S. &#160;Internal Revenue Code of 1986, as from time to time amended and in effect, or any successor statute as from time to time in effect, including any applicable regulations and guidance thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Company&#8221;: </b>Zenas BioPharma, Inc., a Delaware corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Compensation Committee&#8221;: </b>The Compensation Committee of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Designated Subsidiary&#8221;: </b>A Subsidiary of the Company that has been designated by the Board or the Compensation Committee from time to time as eligible to participate in the Plan. &#160;A list of the Designated Subsidiaries was approved by the Board on or around the date the Plan was adopted by the Board and is set forth the prospectus as described in Rule 428(a) of the Securities Act. &#160;For the avoidance of doubt, any Subsidiary of the Company, whether or not a Subsidiary on the date the Plan was adopted by the Board, shall be eligible to be designated as a Designated Subsidiary hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Ex. A-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Eligible Compensation&#8221;: </b>Regular base salary, regular base wages, and overtime payments (excluding, for the avoidance of doubt, any long-term or equity-based incentive payments or awards, annual bonuses, commissions and sales incentives). &#160;Eligible Compensation will not be reduced by any income or employment tax withholdings or any contributions by the Employee to a 401(k) Plan or a plan under Section 125 of the Code, but will be reduced by any contributions made on the Employee&#8217;s behalf by the Company or any Subsidiary to any deferred compensation plan or welfare benefit program now or hereafter established. &#160;The Administrator shall have discretion to determine the application of this definition, including without limitation, to Participants on payrolls outside of the United States; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that such discretion shall be exercised in a uniform and nondiscriminatory basis for Participants in the 423 Component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Eligible Employee&#8221;: </b>Any Employee who meets the eligibility requirements set forth in Section 4 of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Employee&#8221;: </b>Any person providing services to the Company or a Designated Subsidiary in an employee-employer relationship. &#160;For the avoidance of doubt, independent contractors and consultants are not &#8220;Employees&#8221;. &#160;A Participant shall be deemed to have ceased to be an Employee either upon an actual termination of employment or, if applicable, upon the entity employing the Participant ceasing to be a Designated Subsidiary<font style="color:#3953a4;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Exercise Date&#8221;: </b>The date set forth in Section 5 of the Plan or otherwise designated by the Administrator with respect to a particular Offering Period on which a Participant will be deemed to have exercised the Option granted to him or her for such Offering Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Fair Market Value&#8221;:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>If the Stock is readily traded on an established national exchange or trading system (including the Nasdaq Global Stock Market), the closing price of a share of Stock as reported by the principal exchange on which such Stock is traded; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><i style="font-style:italic;">, </i><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><i style="font-style:italic;">, </i>that if such day is not a trading day, Fair Market Value will mean the reported closing price of a share of Stock for the immediately preceding day that is a trading day.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>If the Stock is not traded on an established national exchange or trading system, the average of the bid and ask prices for shares Stock where the bid and ask prices are quoted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>If the Stock cannot be valued pursuant to clauses (a) or (b), the value as determined in good faith by the Board in its sole discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Maximum Share Limit&#8221;: </b>The meaning set forth in Section 10 of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Non-423 Component&#8221;: </b>The part of this Plan, which excludes the 423 Component, pursuant to which Options that are not intended to satisfy the requirements for Section 423 may be granted to Eligible Employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Option&#8221;: </b>An option granted pursuant to the Plan entitling the holder to acquire shares of Stock upon payment of the Purchase Price per share of Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Ex. A-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Offering Period&#8221;: </b>An offering period established in accordance with Section 5 of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Parent&#8221;: </b>A &#8220;parent corporation&#8221; as defined in Section 424(e) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Participant&#8221;: </b>An Eligible Employee who elects to participate in an Offering Period under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Plan&#8221;: </b>The Zenas BioPharma, Inc. &#160;2024 Employee Stock Purchase Plan, as from time to time amended and in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Purchase Price&#8221;: </b>The price per share of Stock with respect to an Offering Period determined in accordance with Section 9 of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Section 423&#8221;: </b>Section 423 of the Code and the regulations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Stock&#8221;: </b>Common stock of the Company, par value U.S. &#160;$0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Subsidiary&#8221;: </b>A &#8220;subsidiary corporation&#8221; as defined in Section 424(f) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Tax-Related Items&#8221;: &#160;</b>Any U.S. &#160;federal, state, local and non-U.S. &#160;income tax, social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items arising in relation to a Participant&#8217;s participation in the Plan and legally applicable or deemed applicable to a Participant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;U.S.&#8221;: </b>The United States of America.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Ex. A-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>4
<FILENAME>zbio-20241231xex10d19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/10/2025 09:10:55 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.69pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><img src="zbio-20241231xex10d19001.jpg" alt="Graphic" style="display:inline-block;height:37.43pt;width:112.75pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.1pt 0pt;"><b style="font-size:12pt;font-variant:small-caps;font-weight:bold;">Zenas BioPharma, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 2.84pt 0pt;"><b style="font-size:12pt;font-variant:small-caps;font-weight:bold;">Non-Employee Director Compensation Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Beginning in the Company&#8217;s 2024 fiscal year (&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FY2024</u><font style="font-size:12pt;">&#8221;) and on the date of each annual stockholders&#8217; meeting thereafter, each member of the Zenas BioPharma, Inc. (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-size:12pt;">&#8221;) Board of Directors (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u><font style="font-size:12pt;">&#8221;) will be entitled to receive the compensation set forth in this Non- Employee Director Compensation Policy (this &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Policy</u><font style="font-size:12pt;">&#8221;). This Policy will be effective on September 12, 2024 (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-size:12pt;">&#8221;) and remain in effect until it is revised or rescinded by further action of the Board. A &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered Non-Employee Director</u><font style="font-size:12pt;">&#8221; is a member of the Board, other than any director who is employed by the Company or one of its subsidiaries or who is affiliated with an entity that owns shares of voting securities of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:56.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:43.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4pt 0pt 4pt 5.75pt;"><b style="font-size:12pt;font-weight:bold;">Type of Compensation</b></p></td><td style="vertical-align:top;width:56.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4pt 0pt 4pt 5.75pt;"><b style="font-size:12pt;font-weight:bold;">Amount and Form of Payment</b></p></td></tr><tr><td style="vertical-align:top;width:43.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 5.75pt 0pt 5.75pt;"><font style="font-size:12pt;">Annual cash retainer</font></p></td><td style="vertical-align:top;width:56.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 5.75pt;"><font style="font-size:12pt;">$40,000 (and an additional annual cash retainer of $30,000 for the lead independent director, if applicable)</font></p></td></tr><tr><td style="vertical-align:top;width:43.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 5.75pt 4pt 5.75pt;"><font style="font-size:12pt;">Additional annual cash retainer for members of the Audit Committee</font></p></td><td style="vertical-align:top;width:56.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 5.75pt;"><font style="font-size:12pt;">$10,000 ($20,000 for the chair of the Audit Committee)</font></p></td></tr><tr><td style="vertical-align:top;width:43.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.75pt 4pt 5.75pt;"><font style="font-size:12pt;">Additional annual cash retainer for members of the Compensation Committee</font></p></td><td style="vertical-align:top;width:56.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 5.75pt;"><font style="font-size:12pt;">$6,000 ($12,000 for the chair of the Compensation Committee)</font></p></td></tr><tr><td style="vertical-align:top;width:43.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.75pt 4pt 5.75pt;"><font style="font-size:12pt;">Additional annual cash retainer for members of the Nominating and Corporate Governance Committee</font></p></td><td style="vertical-align:top;width:56.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 5.75pt;"><font style="font-size:12pt;">$5,000 ($10,000 for the chair of the Nominating and Corporate Governance Committee)</font></p></td></tr><tr><td style="vertical-align:top;width:43.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.5pt;"><font style="font-size:12pt;">Equity Compensation</font></p></td><td style="vertical-align:top;width:56.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.75pt 4.84pt 5.75pt;"><font style="font-size:12pt;">Except for a newly elected or appointed member of the Board in the applicable fiscal year, as described below, each Covered Non-Employee Director will be granted a stock option to purchase 18,500 shares of the Company&#8217;s common stock (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Award</u><font style="font-size:12pt;">&#8221;). The Annual Award will vest on the earlier of: (i) the one-year anniversary of the date of grant or (ii) the date immediately prior to the annual meeting of stockholders of the Company, in each case, subject to the Covered Non-Employee Director&#8217;s continued service to the Board through the applicable vesting date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.75pt 2pt 5.75pt;"><font style="font-size:12pt;">Each Covered Non-Employee Director who is first elected or appointed to the Board following the Effective Date will, upon his or her initial election or appointment to the Board, be granted twice the number of shares subject to the Annual Award,</font></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:28.8pt;min-height:34.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">1</font><font style="font-size:12pt;">-</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:2pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:56.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:43.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:56.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.75pt 4pt 5.75pt;"><font style="font-size:12pt;">which will be a stock option to purchase 37,000 shares of the Company&#8217;s common stock (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Award</u><font style="font-size:12pt;">&#8221;). The Initial Award will vest in equal annual installments over a period of three years commencing from the date of grant, subject to the Covered Non-Employee Director&#8217;s continued service to the Board through the applicable vesting dates.</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">All cash fees will be payable in arrears on a quarterly basis or, to the extent earned, upon the earlier resignation or removal of the Covered Non-Employee Director and will be prorated for any calendar quarter of partial service, based on the number of calendar days the Covered Non- Employee Director was a member of the Board. For FY2024 the annual cash retainer shall be prorated based on the number of calendar days the Covered Non-Employee Director was a member of the Board for FY2024.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">The Board or the Compensation Committee will approve the grants of equity awards consistent with this Policy. The equity awards will be subject to the terms and conditions of the Company&#8217;s 2024 Equity Incentive Plan or successor equity plan and award agreement effectuating the grant of such equity award. Each stock option granted to a Covered Non-Employee Director will have</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">(i) a per share exercise price equal to the closing price of a share of the Company&#8217;s common stock on the date of grant (or if no closing price is reported on that date, the closing price on the immediately preceding date on which a closing price was reported), and (ii) a term of ten years from the date of grant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">The aggregate value of all compensation granted or paid by the Company to any individual for service as a Covered Non-Employee Director, including the equity award granted and cash retainers paid by the Company to such Covered Non-Employee Director, will not exceed (x) $750,000 annually in total value or (y) $1,000,000 annually for the lead independent director or for the Covered Non-Employee Director&#8217;s first year of service, in each case, calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">In addition, Covered Non-Employee Directors will be reimbursed by the Company for reasonable travel and other expenses incurred in connection with the Covered Non-Employee Director&#8217;s attendance at Board and committee meetings, in accordance with the Company&#8217;s policies as in effect from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">The Board may amend this Policy at any time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">First Revision Date: January 23, 2025 (changes effective as of January 1, 2025)</font></p></div><div style="clear:both;display:table;margin-bottom:28.8pt;min-height:34.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">2</font><font style="font-size:12pt;">-</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>5
<FILENAME>zbio-20241231xex19d1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/10/2025 09:10:55 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 19.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><img src="zbio-20241231xex19d1001.jpg" alt="Graphic" style="display:inline-block;height:42.24pt;width:115.94pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">INSIDER TRADING POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Purpose</u><font style="color:#231f20;">. This Insider Trading Policy (this &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Policy</u><font style="color:#231f20;">&#8221;) provides guidelines with respect to transactions in the securities of Zenas BioPharma, Inc. (the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="color:#231f20;">&#8221;) and the handling of confidential information about the Company and the companies with which the Company does business. The Company&#8217;s Board of Directors (the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Board</u><font style="color:#231f20;">&#8221;) has adopted this Policy to promote compliance with U.S. federal and state securities laws that prohibit certain persons who are aware of material nonpublic information about a company from: (i) trading in securities of that company; or (ii) providing such material nonpublic information to other persons who may trade on the basis of that information, commonly known as &#8220;tipping.&#8221; In addition, it is the policy of the Company to comply with all applicable securities laws when transacting in its own securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Persons Subject to this Policy</u><font style="color:#231f20;">. This Policy applies to all directors, officers and employees of the Company and its subsidiaries.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#231f20;">This Policy also applies to transactions by: (i) such directors&#8217;, officers&#8217; and employees&#8217; family members who reside with them; (ii) anyone else who lives in their household; (iii) any family members who do not live in their household but whose transactions in Company Securities (as defined below) are directed by them or are subject to their influence or control (such as parents or children who consult with them before they trade in Company Securities); and (iv) family trusts, family partnerships and similar entities controlled by them or any person described in clauses (i)-(iii) (collectively, &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Other Covered Persons</u><font style="color:#231f20;">&#8221;). Directors, officers and employees are responsible for transactions by Other Covered Persons and for informing them of this Policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#231f20;">The Company also may determine that other persons should be subject to this Policy, such as contractors or consultants who have access to material nonpublic information. Any such other persons will be notified by the Compliance Officer (as defined in Section 5 of this Policy).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Transactions Subject to this Policy</u><font style="color:#231f20;">. This Policy applies to transactions in the Company&#8217;s securities, including the Company&#8217;s common stock, options to purchase common stock, restricted stock units or any other type of security that the Company may issue (collectively, &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Securities</u><font style="color:#231f20;">&#8221;), other than transactions that are expressly excluded from this Policy as set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Individual Responsibility</u><font style="color:#231f20;">. Persons subject to this Policy have ethical and legal obligations to maintain the confidentiality of information about the Company and to not engage in transactions in Company Securities while in possession of material nonpublic information. Each individual is responsible for making sure that he or she complies with this Policy, and that any Other Covered Person whose transactions are subject to this Policy, as discussed above, also complies with this Policy. In all cases, the responsibility for determining whether an individual is in possession of material nonpublic information rests with that individual, and any action on the part of the Company, the Compliance Officer or any other employee or director pursuant to this Policy (or otherwise) does not in any way constitute legal advice or insulate an individual from liability under applicable securities laws. Persons subject to this Policy could be subject to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#231f20;">severe legal penalties and disciplinary action by the Company for any conduct prohibited by this Policy or applicable securities laws, as described below in more detail under the heading &#8220;Consequences of Violations.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Administration of this Policy</u><font style="color:#231f20;">. The head of the Company&#8217;s Legal Department or such other officer as is designated by the Chief Executive Officer will serve, in consultation with the Chief Executive Officer, as the Compliance Officer for the purposes of this Policy, and in such role, will be responsible for the administration of this Policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Statement of Policy</u><font style="color:#231f20;">. A director, officer or employee of the Company or its subsidiaries (or any other person designated as subject to this Policy) who is aware of material nonpublic information relating to the Company may not directly or indirectly through Other Covered Persons:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">engage in transactions in Company Securities, except as otherwise specified in this Policy under the headings &#8220;Transactions Not Subject to this Policy&#8221; and &#8220;Rule 10b5-1 Plans&#8221;;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recommend to anyone the purchase or sale of any securities when they are aware of material non-public information;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclose material nonpublic information to persons within the Company whose jobs do not require them to have that information, or anyone outside of the Company, unless any such disclosure is made in accordance with the Company&#8217;s policies regarding the external disclosure of Company information; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assist anyone engaged in the above activities in violation of this Policy.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#231f20;">In addition, this policy applies to material nonpublic information about a company with which the Company does business, including a customer or supplier of the Company. A director, officer or employee of the Company or its subsidiaries (or any other person designated as subject to this Policy) may not trade in that company&#8217;s securities until the information becomes public or is no longer material.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Definition of Material Nonpublic Information</u><font style="color:#231f20;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:32.4pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Material Information</u><font style="color:#231f20;">. Information is considered &#8220;material&#8221; if there is a substantial likelihood that a reasonable investor would consider the information important in making a decision to buy, hold or sell securities. Information expected to affect the Company&#8217;s stock price, whether positive or negative, should be considered material. No bright-line standard exists for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances and often is evaluated by enforcement authorities with the benefit of hindsight.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#231f20;">While defining all categories of material information is not possible, the following are some examples of information that ordinarily would be regarded as material:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:75.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#231f20;font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#231f20;">information regarding the progress or outcomes of the Company&#8217;s clinical trials, including regarding safety and efficacy;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timelines for development of new products or new indications;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant regulatory developments;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">projections of future earnings or losses, or other financial guidance;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes to previously announced financial guidance, or the decision to suspend financial guidance;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a pending or proposed merger, acquisition or tender offer;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a pending or proposed acquisition or disposition of a significant asset;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a pending or proposed significant joint venture or licensing arrangement;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a Company restructuring;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a change in dividend policy, the declaration of a stock split or an offering of additional securities;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">bank borrowings or other financing transactions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the establishment of a repurchase program for Company Securities;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a change in management;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pending or threatened significant litigation, or the resolution of such litigation;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impending bankruptcy or the existence of severe liquidity problems;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of a ban on trading in Company Securities or the securities of another company; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:75.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant cybersecurity breaches.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:37.35pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.2.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Nonpublic Information</u><font style="color:#231f20;">. Generally, information that has not been disclosed to the public is considered to be nonpublic information. In order to establish that the information has been disclosed to the public, it may be necessary to demonstrate that the information has been widely disseminated. Information generally would be considered widely disseminated if it has been disclosed through newswire services, a broadcast on widely available internet, radio or television programs, publication in a widely available newspaper, magazine or news website or public disclosure documents filed with or furnished to the Securities and Exchange Commission (the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">SEC</u><font style="color:#231f20;">&#8221;) that are available on the SEC&#8217;s website. By contrast, information would generally </font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">not</u><font style="color:#231f20;"> be considered widely disseminated if it is available only to the Company&#8217;s employees.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#231f20;">Once information is widely disseminated, the investing public should be afforded sufficient time to absorb the information. As a general rule, information is considered nonpublic until the end of the next full trading day after the information is released. For example, if the Company announces financial results after market close on Monday or before trading begins on a Tuesday, the first time a director, officer or employee can buy or sell Company Securities is generally the opening of the market on Wednesday (assuming he or she is not aware of other material nonpublic information at that time). If the Company announces financial results after trading begins on that Tuesday, however, the first time a director, officer or employee can buy or sell Company Securities is</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#231f20;">generally the opening of the market on Thursday (again assuming he or she is not aware of other material nonpublic information at that time). Depending on the particular circumstances, the Company may determine that a longer or shorter period should apply to the release of specific material nonpublic information.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Transactions Not Subject to this Policy</u><font style="color:#231f20;">. This Policy does not apply in the case of the following transactions, except as specifically noted:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:37.35pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.1.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Stock Option Exercises</u><font style="color:#231f20;">. This Policy does not apply to the exercise of a stock option acquired pursuant to a Company equity incentive plan or to a transaction in which a person has elected to have the Company withhold shares subject to an option award to satisfy tax withholding requirements. This Policy does apply, however, to any sale of shares as part of a broker-assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of or taxes associated with an option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:37.35pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.2.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock and Similar Awards</u><font style="color:#231f20;">. This Policy does not apply to the vesting of restricted stock, the settlement of restricted stock units or similar awards or to a transaction in which there is an election to have the Company withhold shares to satisfy tax withholding requirements upon the vesting of any restricted stock or the vesting or settlement of any restricted stock unit. This Policy does apply, however, to any market sale of shares received upon the settlement of any restricted stock unit or similar award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:37.35pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.3.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Employee Stock Purchase Plan</u><font style="color:#231f20;">. This Policy does not apply to periodic purchases under a Company employee stock purchase plan, if such plan exists, that are made as the result of an election made at the beginning of the purchase period. This Policy would apply, however, to an initial decision to participate in the plan or a decision to increase the level of contribution in a subsequent purchase period. The policy also applies to any sales of shares purchased under the plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:37.4pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.4.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">401(k) Plan</u><font style="color:#231f20;">. If the Company has a 401(k) plan that provides for the purchase of Company Securities, this Policy does not apply to purchases of Company Securities in such plan as a result of periodic contributions made pursuant to payroll deduction. The Policy does apply, however, to initial elections to participate in a Company stock fund and to increases or decreases in the level of participation, as well as to transfers in or out of a Company stock fund (including in connection with a plan loan).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:37.35pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.5.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Transactions in Mutual Funds</u><font style="color:#231f20;">. Transactions in mutual funds that are invested in Company Securities are not subject to this Policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:37.35pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.6.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Transactions with the Company</u><font style="color:#231f20;">. Any purchase of Company Securities from the Company or sales of Company Securities to the Company not already identified in this Section 8 are not subject to this Policy.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#231f20;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Special and Prohibited Transactions</u><font style="color:#231f20;">.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.1.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Prohibited Transactions</u><font style="color:#231f20;">. Persons covered by this Policy are prohibited from engaging in the following with respect to Company Securities: (i) short sales, (ii)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt 0pt 12pt 44.6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-4-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#231f20;">put options, call options or other derivative securities on an exchange or in any other organized market and (iii) hedging or monetization transactions, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.2.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Margin Accounts and Pledged Securities</u><font style="color:#231f20;">. Persons covered by this Policy are prohibited from holding Company Securities in a margin account or otherwise pledging Company Securities as collateral for a loan. An exception may be granted where an individual wishes to pledge Company Securities as collateral for a loan (not including margin debt) and clearly demonstrates the financial capacity to repay the loan without resort to the pledged securities. If an individual wishes to pledge Company Securities as collateral for a loan, he or she must submit a request for approval to the Compliance Officer at least two weeks prior to the proposed execution of documents evidencing the proposed pledge.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.3.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Standing and Limit Orders</u><font style="color:#231f20;">. Standing orders or limit orders, other than pursuant to Rule 10b5-1 Plans, are discouraged and must be approved by the Compliance Officer prior to placement of any such order.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Rule 10b5-1 Plans</u><font style="color:#231f20;">. Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</u><font style="color:#231f20;">&#8221;), provides a defense from insider trading liability under Rule 10b5 of the Exchange Act. If a person subject to this Policy enters into a plan that meets the requirements of Rule 10b5-1 (a &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Rule 10b5-1 Plan</u><font style="color:#231f20;">&#8221;), Company Securities may be purchased, sold or gifted pursuant to the 10b5-1 Plan without regard to certain insider trading restrictions. To comply with this Policy, a Rule 10b5-1 Plan must be approved by the Compliance Officer, and any amendment, suspension or termination of a Rule 10b5-1 Plan must be approved by the Compliance Officer in advance. Any Rule 10b5-1 Plan to be entered into or amended, suspended or terminated by the Compliance Officer must be approved by the Chief Financial Officer or Chief Executive Officer (or other designated officer).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Pre-Clearance Procedures and Trading Windows</u><font style="color:#231f20;">. To help prevent inadvertent violations of the federal securities laws and to avoid even the appearance of trading on the basis of inside information, persons subject to this Policy are required to comply with the following procedures, except that transactions pursuant to a Rule 10b5-1 Plan that complies with this Policy are not subject to the following procedures.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:37.35pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.1.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Pre-Clearance Procedures</u><font style="color:#231f20;">. Persons subject to this Policy may not engage in any transaction in Company Securities at any time (other than as specified in this Policy), even if not subject to a Blackout Period (as defined below), without first obtaining pre-clearance of the transaction from the Compliance Officer. A request for pre-clearance should be submitted to the Compliance Officer at least two trading days in advance of the proposed transaction. The Compliance Officer is under no obligation to approve a transaction submitted for pre-clearance, and may determine not to permit the transaction. If a person seeks pre-clearance and permission to engage in the transaction is denied, then he or she should refrain from initiating any transaction in Company Securities, and should not inform any other person of the restriction. Any request for pre-</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-5-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#231f20;">clearance by the Compliance Officer should be submitted to, and approved by, the Chief Financial Officer or Chief Executive Officer (or other designated officer).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#231f20;">When a request for pre-clearance is made, the requestor should carefully consider whether he or she may be aware of any material nonpublic information about the Company and should describe fully those circumstances to the Compliance Officer. The requestor also should indicate whether he or she has effected any non-exempt &#8220;oppositeway&#8221; transactions within the past six months, and should be prepared to report the proposed transaction on an appropriate Form 4 or Form 5, if applicable. The requestor should also be prepared to comply with Rule 144 under the Securities Act of 1933, as amended, and file a Form 144, if necessary, at the time of any sale. After receiving clearance to engage in a trade from the Compliance Officer, the requestor must complete the proposed trade within four trading days or make a new trading request.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.2.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Quarterly Trading Restrictions</u><font style="color:#231f20;">. Persons subject to this Policy may not engage in any transaction in Company Securities (other than as specified in this Policy) during a &#8220;Blackout Period&#8221; beginning on the day that is two weeks prior to the last day of each fiscal quarter and ending after the first full trading day following the date of the public release of the Company&#8217;s earnings results for that quarter. In other words, persons subject to this Policy may only conduct transactions in Company Securities during the period beginning on the day after the first full trading day following the public release of the Company&#8217;s earnings for a quarter and ending on the day that is two weeks prior to the last day of the next fiscal quarter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.3.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Event-Specific Trading Restrictions</u><font style="color:#231f20;">. In addition, from time to time, the Company may be involved in activities&#8212;such as proposed acquisitions&#8212;that are material and that are known only by a few people at the Company. For those individuals whose duties at the Company cause them to be aware of such activity, the Compliance Officer will notify them of an event-specific trading restriction, and those individuals will not be permitted to trade in Company Securities during such trading restriction. The existence of an event-specific trading restriction will not be widely announced and should not be communicated to anyone. Even if individuals are not notified of an event-specific trading restriction, they should not trade in Company Securities if they are aware of material nonpublic information.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Post-Termination Transactions</u><font style="color:#231f20;">. This Policy continues to apply to transactions in Company Securities even after termination of service to the Company. If an individual is in possession of material nonpublic information when his or her service terminates, that individual may not trade in Company Securities until that information has become public or is no longer material.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Unauthorized Disclosure</u><font style="color:#231f20;">. Maintaining the confidentiality of Company information is essential for competitive, security and other business reasons, as well as to comply with securities laws. Directors, officers and employees should treat all information they learn about the Company or its business plans in connection with their employment as confidential and proprietary to the Company. Inadvertent disclosure of confidential or inside information may expose the Company and individuals to significant risk of investigation and litigation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-6-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#231f20;">The timing and nature of the Company&#8217;s disclosure of material information to outsiders is subject to legal rules. Accordingly, it is important that responses to inquiries regarding the Company from the press, investment analysts or others in the financial community be made on the Company&#8217;s behalf only through authorized individuals, as expressly identified by the Compliance Officer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Consequences of Violations</u><font style="color:#231f20;">. The purchase or sale of securities while aware of material nonpublic information, or the disclosure of material nonpublic information to others who then trade in the Company&#8217;s Securities, is prohibited by U.S. federal and state laws. Insider trading violations are pursued vigorously by the SEC, U.S. Attorneys and state enforcement authorities as well as foreign regulatory authorities. Punishment for insider trading violations is severe and could include significant fines and imprisonment. While the regulatory authorities concentrate their efforts on the individuals who trade, or who tip inside information to others who trade, the federal securities laws also impose potential liability on companies and other &#8220;controlling persons&#8221; if they fail to take reasonable steps to prevent insider trading by company personnel.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#231f20;">In addition, an individual&#8217;s failure to comply with this Policy may subject the individual to Company-imposed sanctions, including dismissal for cause, whether or not the employee&#8217;s failure to comply results in a violation of law. In addition to the formal sanctions summarized above, a violation of law, or even an SEC investigation that does not result in prosecution, can tarnish a person&#8217;s reputation and irreparably damage a career.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:40.95pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.</font></font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Assistance</u><font style="color:#231f20;">. Any person who has a question about this Policy or its application to any proposed transaction may obtain additional guidance from the Compliance Officer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 5pt;"><i style="color:#231f20;font-style:italic;">Effective: September 12, 2024</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-7-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>zbio-20241231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/10/2025 09:11:05 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-282151) pertaining to the 2020 Equity Incentive Plan, the 2024 Equity Incentive Plan and the 2024 Employee Stock Purchase Plan of Zenas BioPharma, Inc. of our report dated March 11, 2025, with respect to the consolidated financial statements of Zenas BioPharma, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2024.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Ernst &amp; Young LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Boston, Massachusetts</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">March 11, 2025</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>zbio-20241231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/10/2025 09:11:06 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Leon O. Moulder, Jr., certify that: </p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K of </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Hlk87002707"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Zenas BioPharma, Inc</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: </font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.3pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.3pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313];</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.3pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.3pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><div style="margin-top:12pt;"></div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:&#160;&#160;March 11, 2025</p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:46.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Leon O. Moulder, Jr.</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leon O. Moulder, Jr. </p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>zbio-20241231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/10/2025 09:11:07 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Jennifer Fox, certify that: </p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K of Zenas BioPharma, Inc.; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: </font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:60pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:60pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313];</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:60pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:60pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:60pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:60pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><div style="margin-top:12pt;"></div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:3pt;"><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><div style="height:3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><div style="height:3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><div style="height:3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:&#160;March 11, 2025</p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:46.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jennifer Fox</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jennifer Fox</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Business Officer and Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>zbio-20241231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/10/2025 09:11:08 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 78pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk87004374"></a>Pursuant to 18 U.S.C. &#167; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Zenas BioPharma, Inc. (the &#8220;Company&#8221;) hereby certifies, to the best of my knowledge, that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.3pt;padding:0pt;">(i)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accompanying Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2024 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.3pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><div style="margin-top:12pt;"></div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:&#160;&#160;March 11, 2025</p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:46.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Leon O. Moulder, Jr. </p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leon O. Moulder, Jr. </p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>zbio-20241231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/10/2025 09:11:14 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 78pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to 18 U.S.C. &#167; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Zenas BioPharma, Inc. (the &#8220;Company&#8221;) hereby certifies, to the best of my knowledge, that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.3pt;padding:0pt;">(i)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accompanying Annual on Form 10-K of the Company for the fiscal year ended December 31, 2024 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.3pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><div style="margin-top:12pt;"></div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:&#160;&#160;March 11, 2025</p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:46.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jennifer Fox</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jennifer Fox</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Business Officer and Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>11
<FILENAME>zbio-20241231xex97d1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/10/2025 09:11:16 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 3.75pt 0pt;"><b style="font-weight:bold;">Exhibit 97.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><img src="zbio-20241231xex97d1001.jpg" alt="Graphic" style="display:inline-block;height:42.24pt;width:116pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">ZENAS BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Introduction</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">In accordance with Section 10D of the Securities Exchange Act of 1934, as amended (the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</u><font style="color:#231f20;">&#8221;), and the regulations thereunder, the Board of Directors (the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Board</u><font style="color:#231f20;">&#8221;) of Zenas BioPharma, Inc. (the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="color:#231f20;">&#8221;) has adopted this policy (the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Policy</u><font style="color:#231f20;">&#8221;) providing for the Company&#8217;s recoupment of certain incentive-based compensation received by Covered Executives (as defined below) in the event that the Company is required to prepare an accounting restatement due to its material noncompliance with any financial reporting requirement under the securities laws. This Policy is designed to comply with, and shall be construed and interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated under the Exchange Act and the related listing rules of the Nasdaq Stock Market.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Administration</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">Administration and enforcement of this Policy is delegated to the Compensation Committee of the Board (as constituted from time to time, and including any successor committee, the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Committee</u><font style="color:#231f20;">&#8221;). The Committee shall make all determinations under this Policy in its sole discretion. Determinations of the Committee under this Policy need not be uniform with respect to any or all Covered Executives and will be final and binding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">This Policy shall be effective as of the date the Company first lists shares of its common stock on the Nasdaq Stock Market (the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="color:#231f20;">&#8221;) and shall apply only to Covered Compensation (as defined below) that is received by Covered Executives on or after the Effective Date, except as otherwise agreed to by any Covered Executive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Covered Executives</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">This Policy covers each current or former officer of the Company subject to Section 16 of the Exchange Act (each, a &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Covered Executive</u><font style="color:#231f20;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Covered Compensation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">This Policy applies to any cash-based or equity-based incentive compensation, bonus, and/or award that is or was received by a Covered Executive and that is or was based, wholly or in part, upon the attainment of any financial reporting measure (&#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Covered Compensation</u><font style="color:#231f20;">&#8221;). For the avoidance of doubt, none of the following shall be deemed to be Covered Compensation: base salary, a bonus that is paid solely at the discretion of the Committee or Board and not paid from a bonus pool determined by satisfying a financial reporting measure performance goal, and cash or equity-based awards that are earned solely upon satisfaction of one or more subjective or strategic standards. This Policy shall apply to any Covered Compensation received by an employee who</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">served as a Covered Executive at any time during the performance period for that Covered Compensation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Financial Restatements; Recoupment</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">In the event that the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (such an accounting restatement, a &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Restatement</u><font style="color:#231f20;">&#8221;), the Committee shall review the Covered Compensation received by a Covered Executive during the period consisting of three fiscal years preceding the Required Financial Restatement Date (as defined below) as well as any transition period that results from a change in the Company&#8217;s fiscal year within or immediately following those three completed fiscal years. Regardless of whether the Company files the restated financial statements, the Committee shall, to the fullest extent permitted by governing law, seek recoupment of any Covered Compensation, whether in the form of cash or equity, received by a Covered Executive (computed without regard to any taxes paid), if and to the extent:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">a.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">the amount of the Covered Compensation was calculated based upon the achievement of certain financial results that were subsequently the subject of such Restatement; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">b.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">the amount of the Covered Compensation that would have been received by the Covered Executive had the financial results been properly reported would have been lower than the amount actually awarded (any such amount, &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Erroneously Awarded Compensation</u><font style="color:#231f20;">&#8221;).</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">To the extent Covered Compensation was based on the achievement of a financial reporting measure, but the amount of such Covered Compensation was not awarded or paid on a formulaic basis, the Committee shall determine the amount, if any, of such Covered Compensation that will be deemed to be Erroneously Awarded Compensation for purposes of this Policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 23pt;"><font style="color:#231f20;">For purposes of this Policy, the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Required Financial Restatement Date</u><font style="color:#231f20;">&#8221; is the earlier to occur</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">of:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">a.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">the date the Board, a committee of the Board, or any officer or officers authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Restatement; or</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">b.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">the date a court, regulator, or other legally authorized body directs the Company to prepare a Restatement.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">For the avoidance of doubt, a Covered Executive will be deemed to have received Covered Compensation in the Company&#8217;s fiscal period during which the financial reporting measure</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">specified in the award is attained, even if the Covered Executive remains subject to additional payment conditions with respect to such award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Method of Recoupment</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">The Committee will determine, in its sole discretion, the method for recouping Erroneously Awarded Compensation, which may include, without limitation:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.95pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#231f20;">a.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#231f20;">requiring reimbursement of cash incentive compensation previously paid;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#231f20;">b.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#231f20;">cancelling or rescinding some or all outstanding vested or unvested equity (and/or equity-based) awards;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.9pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#231f20;">c.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#231f20;">adjusting or withholding from unpaid compensation or other set-off to the extent permitted by applicable law; and/or</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#231f20;">d.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#231f20;">reducing or eliminating entitlements to future salary increases, cash-based or equity- based incentive compensation, bonuses, awards or severance.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Impracticability Exceptions</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">The Committee shall not seek recoupment of any Erroneously Awarded Compensation to the extent it determines that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">a.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of Erroneously Awarded Compensation to be recovered;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">b.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">recovery would violate home country law where that law was adopted prior to November 28, 2022; and/or</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">c.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#231f20;">recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to Company employees, to fail to meet the requirements of Sections 401(a)(13) and 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">No Indemnification</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">For the avoidance of doubt, the Company shall not indemnify any Covered Executive against the loss of any Erroneously Awarded Compensation or any Covered Compensation that is recouped pursuant to the terms of this Policy, or any claims relating to the Company&#8217;s enforcement of its rights under this Policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Severability</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">If any provision of this Policy or the application of any such provision to any Covered Executive shall be adjudicated to be invalid, illegal or unenforceable in any respect, such</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Amendments</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">The Committee may amend, modify or terminate this Policy in whole or in part at any time and may adopt such rules and procedures that it deems necessary or appropriate to implement this Policy or to comply with applicable laws and regulations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">No Impairment of Other Remedies</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 6.3pt 5pt;"><font style="color:#231f20;">The remedies under this Policy are in addition to, and not in lieu of, any legal and equitable claims the Company may have, the Company&#8217;s ability to enforce, without duplication, the recoupment provisions set forth in any separate Company policy or in any Company plan, program or agreement (each, a &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Separate Recoupment Policy</u><font style="color:#231f20;">&#8221; and collectively, the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Separate Recoupment Policies</u><font style="color:#231f20;">&#8221;), or any actions that may be imposed by law enforcement agencies, regulators or other authorities. Notwithstanding the foregoing, in the event that there is a conflict between the application of this Policy to a Covered Executive in the event of a Restatement and any additional recoupment provisions set forth in a Separate Recoupment Policy to which a Covered Executive is subject, the provisions of this Policy shall control. The Company may also adopt additional Separate Recoupment Policies in the future or amend existing requirements as required by law or regulation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="color:#211e1f;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><i style="color:#211e1f;font-style:italic;">Effective: September 12, 2024</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 13.85pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-4-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">ZENAS BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:50.65pt;margin:0pt 0pt 0pt 113.3pt;"><font style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">CLAWBACK POLICY ACKNOWLEDGMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:50.65pt;margin:0pt 0pt 0pt 113.3pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="color:#231f20;">Reference is made to the Zenas BioPharma, Inc. Policy for Recoupment of Incentive</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 5pt;"><font style="color:#231f20;">Compensation, effective as of [DATE] (the &#8220;</font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Clawback Policy</u><font style="color:#231f20;">&#8221;). By signing in the space indicated below, you acknowledge and agree that you have received and understand the Clawback Policy and that effective as of [DATE] the Clawback Policy applies and will continue to apply to you during and after your employment or other service in accordance with its terms.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXECUTIVE:</p></td></tr><tr><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: [NAME]</p></td></tr><tr><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5pt;">DATE: [DATE]</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-5-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>zbio-20241231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !" ,,# 2(  A$! Q$!_\0
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MQVL+:6XN/VAKV&"%#))(]W>!44#))/F<8Q7+_L ZC\2?''QUUN_NO&VM>*/
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M#""E=J_4^*/'G_!1?P/X\\%:[X=O/ 'B5[;5+*:S<211$?.A7/7L2#^%=/\
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M2>&VTN]N;6\D/EO?1;6*BY4<-)&RX#=P11\)?VB$_9>\)6OPR^*^AZWIVHZ
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34(.3\HQ111T >@^44444AH__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>zbio-20241231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %1 O\# 2(  A$! Q$!_\0
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MHHHKO.(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /LCX2_L=>"OB'\./ 5[<MXW37_%MK>L-4TV""?2-,EA+A&N<H&56PH5=
M^7((#+U'@>H?LW?$.P\&+XN&@B[\,R.B6^HVEW#*MR7F\F/RHP_F.6<@ !<X
M(. .:[#XB?'$2_L^_"SP?X6\5:C:W-E9:E;>(=-LY;BWB=99E,:2_=28%"_
M+  D'&:Z2Y_:$\-:!H?[.,]E<-K5QX*-Q+K.EB&1/*+21%=I=0C/M#E2I(!
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M'VT?\^\/_?-5:*+L+%K[:/\ GWA_[YH^VC_GWA_[YJK11=A8M?;1_P ^\/\
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M/MH_Y]X?^^:JT4786+7VT?\ /O#_ -\T?;1_S[P_]\U5HHNPL6OMH_Y]X?\
MOFC[:/\ GWA_[YJK11=A8M?;1_S[P_\ ?-'VT?\ /O#_ -\U5HHNPL6OMH_Y
M]X?^^:/MH_Y]X?\ OFJM%%V%BU]M'_/O#_WS1]M'_/O#_P!\U5HHNPL6OMH_
MY]X?^^:/MH_Y]X?^^:JT4786+7VT?\^\/_?-'VT?\^\/_?-5:*+L+%K[:/\
MGWA_[YH^VC_GWA_[YJK11=A8XJBBBOLCY,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JYHW_(4MO\
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M4IW;NUTZ?E_7H=3\0_B'J/@'P'#<M8VM]XQNK?;;:5;S,T#W CW2MO*AO(B
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M5VOGRWW4GP\TS6_@EK7AJ]\6Z7K%];S>#[31Y;C1K*XU@V=S!<3RB"00(\I
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M@/0?[/T8ZJ5W6Y5_MLT3W2J"&$:#Y7B\UN(P:GA([J5MN_9;OIN3'$2V:O\
MT^GR/I3QQXRLO /AY]9U"*XFM5N;:U*6RJS[I[B.!#AB!@-*I//0'&3P<GPM
M\4K/Q9XC?2[?2-4M8'BN)K+5+E(A;7Z02I%,T6V1I%"O(@'F(FX'*;@":^8O
MB-<_!6'P5HD?@YX1XWDUO3/MBVV?[;9AJ,'VC^V/^6OWR=_VGCSO+Q\X2O?]
M&\!?$#1O%.KZ]<>*?#VN7-^T<44<^B7%N;.W$B;HXV^V2+M""1MH0&20KN<!
M1MF5"G3IWEHW?=-=O7\2HU9SG:.RMMKW]#I- ^(\.N>*9=#?1=5TMVAGN+&[
MOTA6+4(H9(XY9(E61I JM+%S*B;@ZE=PYKKJ\[\.?##5--^(D_BC4]<L;Y_(
MDM4-EI(L[JYC+ QB]F64K<&,#"8CC"[F('S$5Z)7%44$UR?U]YTPYK>\%%%%
M9&AQ5%%%?9GR04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5S1O^0I;?[]4ZN:-_P A2V_WZRJ_!+T9
MI3^./J=31117R)]2%%%% !4&H:A:Z387-]?7,-G96T;33W-Q($CBC4$L[,>%
M4 $DG@ 5/7EO[1:B/P-I]Y=VSWGAZPUJPO=<@6,R V$<P:5W0<O'&0DCC!RD
M;<'I6E.'/-1[D3ERQ<B[I_[0/@;4)]/7^T[VRMM1=8[+4M2TB]LK"[9QF,0W
M<T*02;QRFUSOXV[LUT/C"+PYHWD>,=?D2S'AV"XE34'E=%@C=0)054X<$*OR
MD-R%P-P%<E\8_'T.G?#5M=LM-\*^,?"MU;-).NKZN8H+Q& ,,=NJ6UPMRTI^
M54XW$H%W%N/(OVL-3\4>*OAWX@CU3P+K:^&[#0EO&>VN+(V_]HO'N)F\RX25
MX[<,NW;$=TI+8!B0GMI4%4G&WNINVK7IY=SFJ57",KZM:[/_ ()]4W=U%8VL
MUS.VR&%&D=L$X4#).!["N&\)?'3P?XVO]*L],NM3CDU:(S:=)J6AWUA#?*$\
MS]Q+<0HDI\O+A48DJK,!@$B+4M<\::E8Z@;KPIIND^'I;"9WENM;+ZE#^X8[
M7MH[=H=V_P"4[;EACY@2?EKQ+X KXE\3/\,-!\=:KIEIIFCZ)8Z]X9L=-TZ2
M$ZLBV21;I+AYWR]N9COB1$R7B?)5B@FGAXNG*4WJNS]>U_TT'.LU.,8K?R]/
M0^L*R]*\3Z9K>J:UIUE<^=>:-<):7T7ELODRO#'.JY( ;,<L;94D?-CJ"!\G
M'7OB#JWA+5?'4FI:?I6MKJ\MI%<S^-M12*PN$N?)CL6T>*RDA<\+&8R'E?S"
MP<,59>DU[7[W2_B#X[T]M5D\-Z/K?CK3]-UC6;:78]K _A^U9424@&(RRI%"
M)1AE\T%2K;2+^IM73?\ PZ:OW[Z=?(GZRM';^G?_ "]#ZAK+\,>)M-\9:!9:
MUH]S]LTR]3S()_+9-ZY(SM8 CH>H%>&GP[I^B?M$:5X,L/&WB2[TV_\ #6I7
M-_X>N/$=Y/):MYMHD=PL[2F="PWA?WGR[7*;2S[O/_"7]N:5\(/@OX5\/321
MZ?XC:ZFOI+[Q/>::\\L0#16D5XJ32PA\._EPA"P@8!@&</,<*I1NI;V\M+2_
M'3T\QNNT[-?\/I_F?8U<!\1O"W@S4]<\/S^(&O=/UK49SI&GWNDW]Y87,[&.
M2X^SM-:NC&/;#(^UVV97^\1GQT>+O&'@KP#XZMI=>M;&PTS6=.T\ZA;ZO<:[
M-H$,\T8OF>[NK:,R^5'*) ',IBWG>0B*@O\ C7PWHG@OXL?!/3M,\6ZM?37N
MNRW1TG5]:GU-KA$TV\47:M</(\84OM(0JC>:,@E1BH8=PE?FMO:WDK_UO]VH
MI5E);=M_-V_K^D>JWWB?P;\#].T'PXEM>V<5RLWV#3](TJ\U&:780\TC+!'(
MY8M)N>1^69RQ)))IR?''P4?">O>(Y-8>VTW0%W:M'=65Q!=V(QD>=:O&)DR.
M0"GS Y&1S65XW_Y+W\+_ /KRUG_T"VKS7]I376M]:\;:AX6U*2TUO0/A]JJZ
MQ=Z=,4DM7D:&33U=UY20;;J1!D,%9CT895.C&JXIWO+5N_FUVZ]^['.I*FI-
M6LM/P]?Z1]*VEU%?6L-S V^&9%D1L$94C(.#[&I:^?;_ %35?#/QDO;R?5M1
MUR35;F]CT"+2]8:2R+P6!=]-N[$G9&RM$\JSQC>S?*[("$DXGP3JGCAM'^'O
MBZ36-/&H>(M0LQ)>R^-]1O8]1\U\W-JNE_83!"0@E $>PP&++R%4DWRL(VKI
M]OU_R_X WB$G9K^M/\_^"?7%%>#:7:VOQ$OOB+J?BOQCK7AV^\/:E<VBP:=K
MDVF0Z)9Q+N@N7B5UCD\R/%SON5D0AL8V+MKSGP7X@U:X\&?#CQ?K/C/6-7T.
M/3--M[NXTS6I(+ZTNI[UTCO;BU8E+J&?,<124,R!6\M&)8J+"W6^JMT[JZM_
M7I?0'7MT_I?U_F?7]94/B?39_$]SX>6=O[7M[2.^DMVB=1Y+LZ*RN1M;YD8$
M*21QD#(S\MZ_JWC;Q!+\2?$\VJ6NDMX>U>ZL[:Z?QQ?:<NDQ0/BV+Z;#9RP3
M&1=DN)O-,HF"@ ;4'KXDOI?CG\/+JZB@74KKP=JO]IBWWA%*SZ85VJX# !WD
M W -@G(R.%+#<F[Z/[TKC5?FV7;\78]:HHHKA.H**** "HC_ ,?*?[A_F*EJ
M(_\ 'RG^X?YB@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XJBBBOLSY(****
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M7@G^$>@J/3OASX3TCQ-=>(['PQHUEXANMWVC5K?3XH[N;<06WRA0[9(&<GG
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M4 %%%% !1110 4444 <51117V9\D%%%% !1110 4444 %%%% !1110 4444
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M:UW&+F>+#'S$CSN9<(_S $?*?0U4B^)?A";Q,?#D?BK1)/$(<Q'25U&$W>\
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MW_B-K5KN.5E,2>1%Y2>6 H(RO)R3STQTKIJX)M-Z>7Y'3&Z6H4445!04444
M%%%% !5_0?\ D,V?_7050J_H/_(9L_\ KH*RJ_!+T9I3^./J>DT445\B?4A1
M110 4444 %%%% !1110 4444 %>1>#_VC;'Q5:>&M2G\'>)?#^@>(Y8[?3-:
MU,6+6\TL@)B1E@NI98]^T@%XU&2 2"P!]=KXJ_9XTJ_L-/\ A+#X^\3ZG?\
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MM,&F60THQ6\LH$5T?*\\L1$P=XY8MN1A<H2\+#7CS\ZMMU_R\BO;VER\KO\
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M>44VVM->NU[=BXUE)JR>O^5SUD:Q8'5VTH7UL=46 71LO-7SA"6*B39G=M+
MC=C&011<:Q86FIVFG3WUM#J%XLCVUI),JRSK'M\PHA.6"[ER0.-PSU%> >*)
MO[(^/_BKQ^&81>&;31=)O6!X6QE:[>ZSC^%#<VUPW4XM1CT.#X]U6ZOOBQX?
M^(]F[FWCU'5?"VDRJ-ZA(M,NY&E"\CY[N"5.X988B>P&D<-S/?2U_G:]B'7M
MTZ_A>USZIK*M?%FAWWV#[-K.GW']H22Q6?E72-]I>/=YJQX/SE-C[@,XVG.,
M&O*KOXBZ^OP@^$6MQ:B#J?B"]T"*_G$,9^T)<B,S@+MVKN!8Y4#';%>2^ =
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MZE@6%F+(RJ _S,,+DD"NQ\-^*=+\76=U=:3=?:X+:]N=/E?RV3;/;S/#,F&
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M$;^4SR,F0WRI*@HGAG"#E?S^5[?U^81KJ4E&QZN?%.F#Q2OAPW7_ !.6LCJ
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M0?BMXCN]1UWQ+H=NLTOB.>XM_$<4VH6QG5;=I#%$I3>Y%ND8"AH\;'*GTO\
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M #-M' R<G Z9JQ7GG6>3T445]F?)!1110 4444 %%%?,7Q/T6SUGXZ>-Q/\
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M@^%O#T;6.MVL(AM=8TQ)&2"5R!OMUCD8F6 DJA8M&S*V1W4IUJD&E-WNNO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >3T445]F?)!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7M#.W5[0GH) :
MHU<T;_D*6W^_657X)>C-*?QQ]3T#^U(?]K\J/[4A_P!K\JR**^1/J37_ +4A
M_P!K\J/[4A_VORK(HH U_P"U(?\ :_*C^U(?]K\JR** -?\ M2'_ &ORH_M2
M'_:_*LBB@#7_ +4A_P!K\J/[4A_VORK(HH U_P"U(?\ :_*C^U(?]K\JR**
M-?\ M2'_ &ORH_M2'_:_*LBB@#7_ +4A_P!K\J/[4A_VORK(HH U_P"U(?\
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M:D/^U^59%% &O_:D/^U^5']J0_[7Y5D44 <51117V9\D%%%% !1110 4444
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M+ LN':1"T:%L*Q"Z?5I)KF:7^5[7^_S_  (]NFGRJ_\ PUSW^BOESQM]@O\
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M117V9\D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5<T;_D*6W^_5.KFC?\A2V_WZRJ_!+T9I3^./J=
M31117R)]2%%%% !1110 56U.Q&IZ;=V;.46XA>(L!DC<I&?UJS11L!XM\/\
MPEXQO/AE\.[K2]=E\)>(-&TE-)U'3]9TR6YLKKRT6)V:V\V%E<21;HY5<91R
M"'5E*TO'7P:6V^%?@SX=Z7)J=Q<_VHB_VW;1[&M$82M?3LRKMB$D$EU"H&.;
MA56N7^$FJ^'=9D:YUV\^)-]XC'B75(1-;2^))--Q'JEQ' N82;3RU18U(^X
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M$:VMG/;)OD9KF-)%DAP-P= 25*X3<=HGV>)M>UE\ET?W:7'ST+VO?[WV_P"
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MS"$$L>222>M1.591;F][=NMWT[VUZ[%05-R2BOSZ'H5%%%<!UA1110 4444
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MI/L8+9&3I/AFQ\.^&+?0=%4Z18VMM]FM?LV&:!0N PWA@S#KEPV3RV<G/"^
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M^$ND>"TU-H9+2[T^_N-0>+S&N;B"^BO)I&7*C=-)&Y)& #(2!QMK;\,^ /\
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MH^P3_P#/,_F*VZ* ,3[!/_SS/YBC[!/_ ,\S^8K;HH Q/L$__/,_F*/L$_\
MSS/YBMNB@#$^P3_\\S^8H^P3_P#/,_F*VZ* ,3[!/_SS/YBC[!/_ ,\S^8K;
MHH Q/L$__/,_F*/L$_\ SS/YBMNB@#$^P3_\\S^8H^P3_P#/,_F*VZ* ,3[!
M/_SS/YBC[!/_ ,\S^8K;HH Q/L$__/,_F*/L$_\ SS/YBMNB@#$^P3_\\S^8
MH^P3_P#/,_F*VZ* ,3[!/_SS/YBC[!/_ ,\S^8K;HH Q/L$__/,_F*/L$_\
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M7L3SO$K6L7EGSFPF\KN7"O'R=W%!?C#J4$C7=Y8Z;I]K<I +87^J>3:P@O=
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M: .RHKC-6^)5OI'B.?1I+"[DG2>RA26*WF>(_:) F7D6,I'MSG#,-W3C-6O
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M0H2"Y!8Y))))-1W'PT\/7-K';_9+B&-%V#[-?3PL4\N.(H61P64I#$"I)!V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>zbio-20241231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #_ -<# 2(  A$! Q$!_\0
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M"Q^WOKC6KMIR0PVWD2&2.*9-Y+17*;5(4%D;G'-?0"Z?9Q1^6EG:QQ[0OEI
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M3;2>5=DDL*.ZGL2H)KP+PS=^&9]?BU77= LM2U-(T3^U(%*RN$ "F6/.V0@
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MEOGR),.'SY@"YQUIVCW%H>R>8I&0ZXQNR&&,>OT]ZB6YADEEB2>)I8BHD19
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M[?$/4_#%OX?NK9!ID"6\02"&"*65(-WD+)*N'D$>]BNX\$YZ@4++\6MJ,O\
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-_C16KG"^YQ*G/L?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>zbio-20241231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %K D$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]"O\ AH'P
MA_SWN_\ P&:C_AH'PA_SWN__  &:OF(_>-'^>M79'-[21]._\- ^$/\ GO=_
M^ S4?\-!>$/^>]W_ . S5\Q?YZUH>&[*+4/$FDVDZ>9!<7<44B XW*S@$9^E
M%D'M)'T</V@/"!_Y;W?_ (#-2?\ #0/A#_GO=_\ @,U>2R>#]%US7C:Z=F*&
MT5EOWT]V:*-S/Y<6/-^8G'W@ 1G\ZKQ^ [;2M0TI;HW=^\^IM;'RH!]F5([@
M1,)6SD,W7 ]1ZTM"N:1[%_PT#X0_Y[W?_@,U'_#0/A#_ )[W?_@,U>/7'P_L
MM3O%32;JX\Z]:[6TMYXU4-+!*%9.#PI4DKW^7FA? >B&*:0:K?RH$O98Y(H$
M*LEJ0'/)'WLG'IQFBR%S2/8?^&@?"'_/>[_\!FH_X:!\(?\ />[_ / 9J\B_
MX5G8+]MEDU>6&U0PK S1@N/,@\T&11GU"X7KR>U,MO -BK6+)=SS7(;399XI
MH5,)2Z(&T8.3CWQD&BR#GD>P?\-!>$/^>]W_ . S4?\ #0/A#_GO=_\ @,U>
M+W'@>Q_LR6Y^VW$=XUI<WZQB%?(2.*X,14\[N1R,=,5?N/AEIL&J-9?VG<^9
M!;SW,ZN$!:-&54*8!QOW;L')4#D460<TSUG_ (:!\(?\][O_ ,!FH_X:!\(?
M\][O_P !FKQ#4O!-G::'JM[:7MS?RV,Q4XB\I!%N4*YW<MG)!V]".16CI'@N
MQB\,RWDZ3W5U<V$-W'(T(^SP[[I8]JMGE\9R#V-%D'/(]>_X:!\(?\][O_P&
M:C_AH'PA_P ][O\ \!FKSS3/"_AU-0L;.[T]IY;C6;^%RL0"E8!D1CYLJG3C
MDGG-<U+X(AOK)M7B>X@LIM.345\NV^1&>X\KR@!G.%^; .<\460^:1[1_P -
M ^$/^>]W_P" S4?\- ^$/^>]W_X#-7DH^%]B;^ZW:E<Q:;'%#)%.RJ7F$DC)
MY@4#(4;>5(#9X]ZX"YA$%S-$'$@CD9 X! ;!(S@],XIV0G.2W/IG_AH'PA_S
MWN__  &:C_AH'PA_SWN__ 9J^8O\]:/\]:+(7M)'U)8_'7PKJ-[;VL,UT9IY
M%B0&W8#<QP/U->@YKXK\.0K<^(M*A8NJR7<2$QL58 N!P1T/O7U2?AOIV?\
MC_UG_P &L_\ \52:L:0DY'5YHS7)_P#"M]._Y_\ 6?\ P:S_ /Q5'_"M]._Y
M_P#6?_!I/_\ %5)IJ=9FC-<G_P *WT[_ )_]9_\ !I/_ /%4?\*WT[_G_P!9
M_P#!I/\ _%4!J=9FC-<G_P *WT[_ )_]9_\ !I/_ /%4?\*WT[_G_P!9_P#!
MI/\ _%4!J=9FC-<G_P *WT[_ )_]9_\ !I/_ /%4?\*WT[_G_P!9_P#!I/\
M_%4!J=9FC-<G_P *WT[_ )_]9_\ !I/_ /%4?\*WT[_G_P!9_P#!I/\ _%4!
MJ=9FLGQ/XKTKP=I;ZAJ][#8VRD*&F<+O8]%&>IK)_P"%;Z=_S_ZS_P"#2?\
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M:?A$_P#,QZ=_W_%+E?8/K-#^=?>CJJ*Y7_A:7A'_ *&/3O\ O^*/^%I>$?\
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M_P"_2_X5;HH J?V38_\ /G;_ /?I?\*/[)L?^?.W_P"_2_X5;HH J?V38_\
M/G;_ /?I?\*/[)L?^?.W_P"_2_X5;HH J?V38_\ /G;_ /?I?\*/[)L?^?.W
M_P"_2_X5;HH J?V38_\ /G;_ /?I?\*/[)L?^?.W_P"_2_X5;HH J?V38_\
M/G;_ /?I?\*/[)L?^?.W_P"_2_X5;HH J?V38_\ /G;_ /?I?\*/[)L?^?.W
M_P"_2_X5;HH J?V38_\ /G;_ /?I?\*/[)L?^?.W_P"_2_X5;HH J?V38_\
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M(>_V_K[CTS^V+'_G]MO^_P O^-']L6/_ #^VW_?Y?\:\S_X91^$/_1/M$_\
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M_O[)_P#%4?\ "D/!/_0!B_[^R?\ Q5:>VB?'?ZO8K^:/X_Y'R%^%'X5]>_\
M"D/!/_0!B_[^R?\ Q5'_  I#P3_T 8O^_LG_ ,51[:(?ZO8K^:/X_P"1\A?A
M6_X5\3MX:@U<PR307=U#%'#-!C*;9E=N>V5!''K7T]_PI#P3_P! &+_O[)_\
M51_PI#P3_P! &+_O[)_\52=6++AD.+IRYHSC?Y]=.QX3=?$JPU'4S)="\-N;
MN_V-Y:EH+:XA$:*HR/NMDE<X]Z8WCS2!97]HCZ@+.338+*.(1".622*)D#F1
M7^49/*D,"#ZU[Q_PI#P1_P! &+_O[)_\51_PI#P1_P! &+_O[)_\54^T@=?]
MEX]MMRCKZ]K=CP'4_'>GWES?3I)?20W6F26<6F2QJL%DY6,;$(/*'8<G ZCC
M-5OB%XWL_%LEDUI$T44<[3^5)!L: $*/+#[V#+\O0!0/3K7T1_PI#P3_ - &
M+_O[)_\ %4G_  I#P1_T 8O^_LG_ ,50JD$3/*<=.,HRG&SWW_R_X!XA<?%N
M*YOY'F>]DL7OKN5X"BX:UD@V1Q8ST#Y;;T[]:)?&=OH-OX7^UQ+-J+QI-JSV
MLJ2MF.)H;9QVWA6\S:3U S@U[A_PI#P1_P! &+_O[)_\52#X'^" .- B'TD?
M_P"*I<\.QI_9F/=VYQO\]-O+RMZ-]SPEOB#IK0:A;R7&HSQRZ?':-<>2([F]
ME1' F>0/\ARP!4[P5'/-,N?B'975O>0++?VL3W-A<I#$@*3>3"D<L;C=P&*[
M@><X'%>\_P#"D/!'_0!B_P"_LG_Q5'_"D/!'_0!B_P"_LG_Q5'/ G^R\?:W-
M'\?/R\SYZ\0^-+#5_#%[8*UT9I+Z2YMHA$(XXD>9G(D(<B7@C&5!4]\5Q ^E
M?7O_  I#P3_T 8O^_LG_ ,51_P *0\$_] &+_OZ__P 55*K%'/5R3%UFI2E'
MMU_R/D+\*/PKZ]_X4AX)_P"@#%_W]D_^*H_X4AX)_P"@#%_W]D_^*JO;1,?]
M7L5_-'\?\CY"_"C\*^O?^%(>"?\ H Q?]_9/_BJ/^%(>"?\ H Q?]_9/_BJ/
M;1#_ %>Q7\T?Q_R/*OV7_P#D9=:X_P"71/\ T.OHX=*YWPW\/M \(7,UQH^G
M)933((Y&5V.Y<YQR371#I7-.2E*Z/K<NPT\)AU1F[M7V%HHHJ#TPHHHH _#5
M_P!J7XQ+(P'Q.\3X!/\ R_M2?\-2_&/_ **=XG_\#VKS"7_7/]3_ #IOXU^D
M>QI?RK[D?-\\NYZC_P -2_&/_HIWB?\ \#VH_P"&I?C'_P!%.\3_ /@>U>7?
MC0>>]'L:7\J^Y!SR[GJ _:G^,1)Q\3O$QQQQ?M2_\-2_&/\ Z*=XG_\  ]J[
M6Z\'Z%XUN/@M?7/B;PG8:##HMEIFK"\OXS+#.LDS,L]LCK)M/R*7RH&X98"M
MOQ%X7^%JW7B*?PS:^#KS76T;3IK?2]9U@PZ;!*S3+?-$R2[3,FR$A!(P&XE=
MV:XG4HK3V?X+O8Z_93>O,>8+^U%\97SM^)?BE@HR=M\QP/4^@I/^&I?C'_T4
M[Q/_ .![5W*ZA\/-.B\1Z7I,6FZ/'_PKV-VU"VU*4R:GJ<WV,RV[Y?:0I$O[
MD#KN)S@ =1>Q? Z379M,B\-^%XK!M=U/2%OHM5N-Z6*6/FV]V&,I7>UQ\BN1
MMQ\F.])SI+_EU^"#V4G]L\?3]J/XRR.$3XE^*7<\!5OG))]@*3_AJ7XQ?]%.
M\3_^![5[1\.]+^%W@JW^&&KC7/#H\3V.K:9-/JEI<B(RV\MM.;DSH96(,<GE
MH2RQX;.%VD5Y[^SQI'PPU+P]XJG\:P6VI:W'>Q+;6%W?1V8-B4D\V2&221%$
MH?8,_,P&,(<FCVE&TI>ST7DNX>RE=+G.:7]J3XR,0%^)GBAB> !?L230W[4G
MQC5BK?$SQ0K#@J;]@0?<5Z)H\?PILM#T1;6WT6UUBRTGP[K(UG[=)]K?46OU
M2\@<%]F%A&]D"C!^;(JYXBT#X8:KX4\>ZQJ&K>']1U[4-2U"_P!/G@N/+NXI
M!J2A83^]S(K0%W&(PA5OO%A0ZE%.SI>6R&J,FOC_ !/+O^&I?C'_ -%.\3_^
M![4?\-3?&+_HIWB?_P #VKW3P9X$^&OBCQEXW?3/ 6CZEH6FZ[%HF@P+J#LN
MM@I.QBAEEG13<,QA;<I.V,!0AR6K(LO"?P0-A\.8+JVT]O/N[!-<OI=42WDA
ME(D&H07$7F^:$5QM4A%5 J$,^ZI]M0O;V7X+U#V,]^8\B_X:E^,?_13O$_\
MX'M1_P -2_&/_HIWB?\ \#VKNM1?X1:[X,7=H&A>']0G\.1ZG-<Z9?3M<6]Z
MFHB$V\2/(PRUKF1D()8_,,=*WOB%I7P5T#6=4NM$T31+^TL=#U&YTZ)]7#V^
MHR))#]BW)%,T@DVM)N#%&D&044J35>TI7LZ6OH@]C/\ G_$\F_X:F^,6<?\
M"SO$^?\ L(-2_P##4OQC_P"BG>)__ ]J[OXDP_#ZW^'/Q!L_"-AX3:YCUNPO
M8)&O&:[@M)+)&D6S+/F0)<,Z;/F(!.<X!'SG^-=%*-*JK\B7R1A44J;MS7/4
M?^&I?C'_ -%.\3_^![4?\-2_&/\ Z*=XG_\  ]J\N_&C\:V]C2_E7W(RYY=S
MWGX5_M+_ !:U7XI>#;*\^(_B.ZL[G6K*&:"6^8I(C3H&5AW!!(/UK]HZ_ OX
M5W]MI7Q2\&WMY<1VMG;:U9333RMM2-%G0LS'L  237[/']JWX.@_\E*\-?\
M@QC_ ,:^;S:C[T/9Q[[(]+"3T?,RS^TW_P F]?$;_L WG_HIJ[;P?_R*6B?]
M>,'_ *+6O /V@?VE/A5XB^!_CO3--^(/A^]U"[T:ZA@MH;Y&>5VC(55 /))X
MQ7O_ (0&/"6B ]?L,'_HM:\6<)0I+F5M7^2.U-.6A6UKQG:Z+JBZ>UI?WET8
M1.4L[<RX3<5R<=.157_A8$7_ $!-=_\ !>U)%_R5&?\ [ Z?^CFKJZY2]3E?
M^%@1?] 37?\ P7M1_P + B_Z FN_^"]JZJB@+/N<K_PL"+_H":[_ ."]JY[X
M@?%O_A'O!VK7UKI>HVVH) T=DU_;&&%KE_EA5F/ RY4?C7I=>3?&1?[=\>_"
MSPRXW6]SK,FJW"]0R6<+2*#[>8\1_ 4T<^(E*%-M;NR^;=E^93^%,>E_#/PQ
M%:+H'B"ZUNZ N-7U5]-=IK^[(S)*[GDC<3@= , <"NT_X6/!_P! #Q#_ ."Q
MZ[ =*6D:PIJG%0AHD<=_PLB#_H >(?\ P6/1_P +(@_Z 'B'_P %CUV-%!=G
MW.-/Q'MP#_Q(/$/_ (+'H\._$.W\1>+K_1$TJ^M);2%93/<Q; P..".H^]QG
MK@UV5)MP20!D]Z L^X@4"EQ2T4%"8%)M%.HH S/$/AO2_%FCW6DZS80:IIMT
MA2:UND#QN/<'^?45YU\$;NY\.:KXJ^'M_=SWC>&[B.33)KJ0O+)IDZ[H S'E
MS&RR1;CSA%S7K%>3>+5_X1[]H3P'JD>$37-.OM#N?1O+"W,/X@K*!_O&FCAQ
M"4)0K+=-)^CT_-I_(]9HI%Z4M([@JIJO_(,O/^N+_P#H)JW535?^09>?]<7_
M /0336X'F'[)_P#R;E\/_P#L%I_,UZU7DO[)_P#R;E\/_P#L%I_,UZU6M?\
MBR]7^9G3^!!1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?C$_P"P;\=F=F'@209)_P"7^V_^.4W_ (8,^.__
M $(DG_@?;?\ QROV?HKWO[8K_P J_'_,X/J<.[/Q@_X8,^.__0B2?^!]M_\
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MY*C/_P!@=/\ T<U=72$@HHHH&%>4^- 1^T/\-BWW&TS5U7_>Q;G^5>K5Y/\
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M3_F1]5T5\J?\/,?@C_T$-;_\%$M'_#S'X(_]!#6__!1+1]2Q/_/M_<'MJ?\
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MRSA*G+EFK,TC)25TQ:***@H**** "BBB@ HHHH **** "BBB@ HHHH ****
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MGKT3P_\ LP3>%-&M-(T?XJ>.]/TNT3RK>UAN[79$G91FW)P*^?/^"@7PLO\
MP;^SZ^H7/C_Q5XEC_M:TC^PZQ<0/!DEOFPD2'(QQS7JX=0EBXS4MY>?<XZG,
MJ+5NA^:V/I1CZ48%&!7W!X@8^E&/I1@48% 'T#\+_@'HGQ,^"%GJ=N9[?QA)
MX@F5YS,?)_LJW^S"[.S&-T:W'F;L]%-=)K'[)^D>+?B-XAM/"\NH^'?#OE0?
MV++>>7<1R3-IHO6CD9I!(6VD'"*V X)X%?-EGXEUC3K-;2TU:^M;51,!!!<.
MB 2J%F  ./G555O[P !Z5HV?Q)\6Z>MPMOXHUF&*Y,7VB.._E03B-0B!L-R
M@"#T7CI7!*E7YFXS[G9&I2LE*)[+I/[-.G^*WT2=]6DT>VU&VT&RMTTO37NV
M-[?VS2B2<&3*1#9\S@\D_*HQBO./B'\,-.^'OASPO/-KLM]K^N6YNVL(;/\
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MG\T@,(_(;<0>AQC.#ZT6#VC['V!_PL'PU_T'=/\ _ A?\:/^%@^&O^@[I_\
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M[GX5^8O]]?SH\Q?[Z_G7[J?\,U_"C_HG/AC_ ,%</_Q-'_#-?PH_Z)SX8_\
M!7#_ /$T?VS3_D8?4Y=S\*_,7^^OYT>8O]Y?SK]U/^&:_A1_T3GPQ_X*X?\
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M]5^3.G[?R/2****P- HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM'LY=@_M;!?\_/S_ ,CVJBO%/^&H=('71-0'U9!_6C_AJ+1_^@+?_P#?<?\
MC1[.78/[6P7_ #\_/_(]KHKQ3_AJ'2/^@+?_ /?:?XT#]J'2".=$OQ_P./\
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M\*[8H4"(/0 8%>9?M.QX^#.KW2\26-Q97J'T:.[B;^AKU.O,/VF_^2$>+_\
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M@RD%6^8' QS6@?V<O'.HZI<6^A:9=:I%"MJ&FN)8K1VGGM5N$B5'ERSLC':
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M12W4;@ES*[8C(*X,>1N/%:_@W]FO1/B'K=M_:<DL.E-HFBP"]TZ6."2VN9[
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MG/\ _%T?\*TTG_GXU;_P9S__ !=8:'U?/7_D7W_\ ZRN27(^*DAQ_P P5?\
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M4M>S.Z<>>+CW/Y[O[*OO^?"Z_P"_#_X4?V5??\^%U_WX?_"OZ#_L\7_/)/\
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MVL5I",?P(H4$^YQ7@'PNU;7?&/BCX)MXDF:]\06?AB^UO4)64 CS_*BA9@
M&96?MV-?2U9GT>%DJ\Y5O1+TLF_G=V?H(:\K_9P&WP5K2GJOB35P1[_;):]4
M->5?L_#R++QY:<XMO&&J*!Z!Y!(/_1E(UJ:8BGZ2_0]6HHHH.PCN)'B@D>./
MS9%4E8P0-QQP,GIFN#NOBS#::UIUA-I=[;2SI,TMO+&//#*%VA%!^<')R5R!
MQG&:] KYY^*'B:2Q_:^^$E@H/V?^SM065NP,ZD(#[DP''TH.3$UO8Q4N[BOO
M:1[SH]_-J=BEQ-936#.3B"?&\#/!."<$^E7:**#K"N1^+TGD_"CQFYQ\NC7A
MY_ZXO775P'[0%Z-.^!_CN<]M%ND'U:)E'ZD4&%=\M&<GT3_(X']C6 VW@;Q9
M$<Y3Q+<#D8_Y=[>O?#VKQ3]EF'[-H_C^'_GEXNO(_P#OF&W']*]K/:MZ_P#$
M84%:E%>1X+\*?$NHZ9\1/&'A.\F%K;:S=7NI:#=*H8*T<OEW,14\;E8QR =P
MYKT'5=.\0ZS8G3]4T72-5C!XG%R\0)[,!M+(?H?QKRW56_LOQ#X!ULD(EOX[
MU"QDE/15N4GC"GV+[!]<5Y1\1OB]XQ\3?"+XC_VA*8O$OP^\9P7&;4>4?L:S
MYB!"XR!R">X S6-CRZN,CA?:1J7=KM>EE+_.WDCVGXU6,-A\,+F^74EUC5_!
MFH66M36C2K<-:JC RQG(W;6@:7&_DBJ_B3]G[4;G1-3T7P;JFC'P-KG^DC1=
M:MI)HM.F;YA/8O&ZM'R0X3HK<J1G%<;XQURST']I+P_XB6&.3P?\0/#4-GK2
MDX202/Y4,K#V,L2$]A)7L/[/&HW,'@V\\*:E(TNJ^$+Z30Y9'^]+"F&MI/\
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MIG^*:TG9& _X!.A_"F88C2=*7][\TU^=CUFBBBD=H5\K?%6?=\9M<\1'+_\
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MX:8O/^@#!_X$-_\ $T?\-,7G_0!M_P#P(;_XFBP<\3WZBO ?^&F+S_H V_\
MX$-_\31_PTQ>?] &W_\  AO_ (FBP<\3WZBO ?\ AIB\_P"@#;_^!#?_ !-'
M_#3%Y_T H/\ P(;_  HL'/$]^HKS7X7_ !8N/B%J=[:RZ='9BWA$H9)2V[+8
MQR*])%(M--70M%%% PHHHH Y;_A9WA/_ *&/3O\ P(6C_A9WA/\ Z&/3O_ A
M:^,2!N/%&!Z5U^Q7<^#_ -8:W\B_$^SO^%G>$_\ H8]._P# A:/^%G>$_P#H
M8]._\"%KXQP/2C ]*/8KN+_6&M_(OQ/L[_A9WA/_ *&/3O\ P(6C_A9WA/\
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M!BEHHI'KA7DMFP\5?M+W\V-]MX3T%+8'LMU>2;V_$10I_P!]UZP\BQJ68A5
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MR+W_ -NOH8<U#W.JG\(M%%%(T"BBB@#X)/WC17T,?V7--)S_ &_>?]^4I/\
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M2SO5UR[D:VF28(84PQ5@<'\J]GK&I-.W*?293ETZ$9K$P6MK;,Y'_A6.D_\
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M#_P:\575BVR]EM/L<#YQL>=EA5OP,F?PKK_"OAVV\)>&M)T2S7;:Z=:Q6D0
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M9TT_A"BBBL#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **\0/[4FF@D'0;S_ +_)1_PU+IG_
M $ ;S_OZE:>SEV/(_M;!?\_/P?\ D>WT5XA_PU+IG_0!O/\ OZE'_#4NF?\
M0!O/^_J4>SEV#^U\#_S\_!_Y'M]%>(?\-2:;_P! &\_[^I1_PU)IO_0!O/\
MOZE'LY=@_M? _P#/S\'_ )'M]%>(?\-2:;_T ;S_ +^I1_PU+IG_ $ ;S_OZ
ME'LY=@_M? _\_/P?^1[?17B'_#4NF?\ 0!O/^_J4?\-2Z9_T ;S_ +^I1[.7
M8/[7P7_/S\'_ )'M]%>(?\-2Z9_T ;S_ +^I1_PU)IG_ $ ;S_OZE'LY=@_M
M? _\_/P?^1[?17B'_#4NF?\ 0!O/^_J4?\-2Z9_T ;S_ +^I1[.78/[7P/\
MS\_!_P"1[?17B'_#4FF?] &\_P"_J4?\-2Z9_P! &\_[^I1[.78/[7P/_/S\
M'_D>WT5XA_PU+IG_ $ ;S_OZE'_#4NF?] &\_P"_J4>SEV#^U\#_ ,_/P?\
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MXFED!.(XH9D4,R8PI8%LXI?5\$M?9NWS_P P_?[<R/;#_P %:M''_-,]2_\
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ME9-IE_<6CN'>%RC,JLN3]& 8?0@56X]35O5=4N]:U&XO[V7S[N=MTDA &3@
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M*FZ_^*H_X9?T3_H<?'W_ (5-U_\ %5['11[>I_,'LX]CQS_AE_1/^AQ\??\
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M;2[TN>^MET^:]C%S>-9J'N_LR?\ +41J0Q((SGC)XKK=,L?COI7C/Q3XHB\
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MFG?]^!1_PJOPA_T+FG?]^!7544<S[A]6H?R+[D<K_P *K\(?]"YIW_?@4?\
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M5A^*_'7AWP+;07'B/7=.T*"=_+BDU&Y2!9&QG:I8C)QS0!N45Y]_PT+\,/\
MHH7AG_P:P?\ Q5'_  T)\,/^BA>&?_!K!_\ %4 >@T5Y]_PT)\,/^BA>&?\
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MS[/#_P \8O\ OV/\**EQ[BB@H_H%HHHH)"BBB@ HHHH **** "BBB@ HHHH
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MHI'H!7!_$GX;7WC36/#6LZ3XBD\.:MH,MP\$ZV:72.LT7ENK(Y';D$&N\HH
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8?\.I?#__ $4?7/\ P7VW^%%?=M% S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>zbio-20241231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $@ E<# 2(  A$! Q$!_\0
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M/TF5X\_]-J]K'056(:G)3C%)-;+[A4TTG%N]A:***YC4**** "BBB@ HHHH
M**** "BBB@ HHHH I:T2ND7Q!((@D(([?*:YSP]X&T"YT#39I=(M))9+:)W=
MHP2Q* DDUT6M_P#(&O\ _KWD_P#0347AC_D6M)_Z](?_ $ 4"ZE+_A /#G_0
M&L_^_0H_X0#PY_T!K/\ []"OFS]N?]JKQ?\ LV7?@^/PM9Z3=+JZW)G_ +3A
MDDV^7LV[=KKC[QZYKY8_X>D_%S_H$>%/_ .?_P"/5Z='+Z]>"J0M9^9RSKTZ
M<N5GZ=?\(!X<_P"@-9_]^A1_P@'AS_H#6?\ WZ%?F*?^"I7Q< _Y!/A3_P
MY_\ X]7Z/? KQSJ'Q*^#W@_Q3JJ01:CJ^FQ7EPEJI6)789(4$D@?4FL\1@ZN
M%BI5.I5.M"J[1-S_ (0#PY_T!K/_ +]"C_A /#G_ $!K/_OT*W]PSC(SUHS7
M!<Z+(P/^$ \.?] :S_[]"C_A /#G_0&L_P#OT*W\T@=6S@@X.#@]* LC!_X0
M#PY_T!K/_OT*/^$ \.?] :S_ ._0K?I"ZA@,C)Z#- 61@_\ " >'/^@-9_\
M?H4?\(!X<_Z UG_WZ%=!10%D<_\ \(!X<_Z UG_WZ%'_  @'AS_H#6?_ 'Z%
M=!10%D<=<^'-,T/Q-X?DT^QALY))9D=H5VEE\ES@_B!78#I6#KW_ ",7AO\
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M?S1OJEM<RV=['':/:^3,C8*&-W<@@%3G<0000<&M94Y1CS,A23=CKZ\4^/\
M_P 43XI\ ?$N,;(M$U(:3JSCI_9UZ5B9F]DF\A_P->UUSWQ!\&67Q#\#:]X9
MU #[)JUE+9R-CE=ZD!A[@D$>XHI24)IO;KZ=1R5UH= #FEKS3]G7QG>>,_A-
MI$FK'_BH=+,FCZNAZK>6S&&4G_>*!Q[.#7I=1.+A)Q?0:?,KA1114C"BBB@
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M0!FR>3D@]:T\4M:0I1IN\3AQ685\9%1JO1;>6_\ GZOJ8&O?\C%X;_Z[S?\
MHAZWATK!U[_D8O#?_7>;_P!$/6\.E;'F+<6BBB@84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!3U?2K77-,O-.O8EGL[R%[>>)AD/&
MZE64^Q!->5?LOZG=0?#^X\':G,9M8\$W\WAZX=S\TD46#;2GV>W:(Y]<U[#7
MBFH8^'7[4&GWH'EZ3\0-,-C,<_*-2LP7B)]WMVE7W\D5O3]Z,H?/[O\ @7,Y
M:-2/:Z*0'-+6!H%%%% !1110 4444 %%%% !1110!7U"W-W8W$ (4RQL@8]L
MC%8&FP>)=-TZUM!#I4@@B2(,9Y1NV@#.-GM73T4"L8'G>)O^?;2?^_\ +_\
M$4>=XF_Y]M)_[_R__$5OT4!8P/.\3?\ /MI/_?\ E_\ B*/.\3?\^VD_]_Y?
M_B*WZ* L8'G>)O\ GVTG_O\ R_\ Q%'G>)O^?;2?^_\ +_\ $5OT4!8P/.\3
M?\^VD_\ ?^7_ .(H\[Q-_P ^VD_]_P"7_P"(K?HH"Q@>=XF_Y]M)_P"_\O\
M\11YWB;_ )]M)_[_ ,O_ ,16_10%C \[Q-_S[:3_ -_Y?_B*/.\3?\^VD_\
M?^7_ .(K?HH"Q@>=XF_Y]M)_[_R__$4>=XF_Y]M)_P"_\O\ \16_10%CFAI^
MM7^LZ9<WRV$4%F\CD6\CL[%D*@<J!WS72#I2T4!8****!A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !2&EI#S0!YSKOQOTKPUJUU9:CI>LVRQ^:MM<-:#
M9?21LBO'"-VXG=*@#$!&).&XKJ/!OB^V\::4]Y;P3V<D%Q+9W5G=*!+;SQMM
M=&VD@X/(*D@@@@\UP>K_  ,OM?\ $/B/4]0\5O<#5 @M@VGQ^=IRQR)+!'%)
MNQY:21ABNWYR3N)XQVW@3P:?!FDW%O+?/J=]>7DU_>7CQB/S9I&RQ" D*H&
M!DX ')ZUO-4U'W7J9KFOJ=+1116!H%>5?M+^&KW6?A5>:IH\>_Q#X9N(O$6F
M =6GM6\PI_P.,21_\#KU6FN RD, 0>"#WJX2Y)*2Z$R7,K&7X2\2V7C/POI.
MOZ;()=/U.TBO(''=)%##\<&M:O%?V<&/A%_&?PSF^4^$M58Z>K=],NLSVV/4
M+NDB_P"V6*]JIU(J$VEM^G0(NZN%%%%9E!1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1XR?<#I7IM5&I5PZE3[VZ)B<8U+2['C)U+X\^'L?:-$\%>,85[V%]<:9.W_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUJ"A:*0$&EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2:L[,XQ:***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A&1BE
MI"0H)/ % 'G?Q:^!GA?XN^'9M.U.T^QWH?[1::O8@1W=I/VE1P,D^H.0>]>'
M^"OBS\2O@1XGA\$?$R+_ (2ZVD)&DZU9IMN+^%>3Y8/$LJCEH21)CE?,%>]?
M#[XY^ _BKJVL:9X2\3V.N7^D/LO8+5B6CY*[AD#<N01N7(R.M;/COP%H?Q*\
M-76@^(;"/4=-N,,48E6C<<K)&PY1U/*LI!!Z4Y4TGRS33[]5_FO)_*SU.^AC
MZE.'LY6G3?V9;>J>\7YQMV=UH2>%?%^B>/M&34]$U"#4[&3*%HCRI[HZGE6'
M0JP!'<5YSJ'A?5_@MJ%QK7@NQDU7PG.[3:GX3A^_;DG+7%B.@/4M#T;DK@\'
MR;6?#>K_  1\6P'Q!X@GTF*Z=;?2OB5#&#'.W2.TUR'A'8\*MSQNXRRMU]GT
M/XP3Z+J5MH7Q"L(_#.JSD)::I$Y?2M1/;RIC]QC_ ,\Y,'T+5R5H.+7M=.TE
MM_P/-/\ $]C"I6E/ ?O(/XZ4OBLO)6YK=)PM):MJ*.^\)^+=*\<:#:ZSHM['
M?Z?<#*2Q]B."K \JP/!4\@C!K7(W"O)_%_@34O!NL7GC7P%Y,5]+F;5] E?9
M::LH'+@](IP!Q(.&Z-GJ,WX1_M9>!/BU>7EI:W4FB7ENJLL.L-' 9U/>,[B&
M(/!'7H>])8A0DJ=9VD]NS]/\O^',9Y34Q%&6,R^+J4H_%UE"_227X22M):Z-
M.*TOBQ\*M2OM;MO'?@2:#2_B'IL7E*9R5M=8M@<FSN\=5/\ !)]Z-N1QD'E[
MF'3_ -HW1+7Q7X5N'\&?%?PI*]MMO$_TC3;CK+87J#_6V\GY$$.AR*]\BN([
MB(21.LJ'HR'(/XBO)_BO\+M6EUV'X@?#^2#3_']C$(I8)SLM==M1S]DN<=#U
M\N7JC'^Z2*]6G4O9-ZK9_H_+^MCYF<;=/7^NYI?"[XGVGQ4TS5-#U[2DT;Q;
MI>+77_#-X1+Y)8<.N1B6WD&2C@8(.#@@@<AJOPFU[X)+=ZY\)[U$T6,/<WG@
M35'9K"50"SFS<9:UD.#A1F,G^$=:@N(;']H?1K/QSX&NF\)?%#PX[V96_BVS
M6DPYFTW4(QRT+'\LAT/KWWPC^+=O\2K*^L[VR?0/%^CN+;6] N&S+9RD<,I_
MCB?[R2#AA[@@6[PO**TZKM_P.SZ?FE:5K_)GD_[*_P"W#H?[2NNZUHKZ1_PB
MVJ6FV6TMKF]21KN(D@A1A3O7 W* >"*^F@<UPOBCX&^ O&.D3:=J7A/2S;RS
M&YWVUNMO,DY_Y;)+&%=)/]L$'WKASH'Q2^#(W:%?2?%;PI'S_9&L3K%K5LGI
M#='"7 ']V4*QZ;S4S5*K*]+W?)_Y_P"81<H*T]?,]SHK@OAS\;O"GQ-FN+'3
M+R6RUVT'^F:!JL1M=1M3_MP/AL?[2Y4]B:[P'-<THR@[25F:IIZH6BBBI&%%
M%% &-XK\':'XZT6?1_$.DVFLZ7.,26E["LJ'WP1P1V(Y%>,ZS\.O&GP-T>_U
M/X=:W+XA\.6,$D\G@CQ([W(,:J6*6=US+&<#"QOO4GCBO?Z2M85)0TW78AQ3
MUZGQO^QS\;O!_P"TCI?B?PQK7PX\+>&9H)_M4>D06L9BOHWR'?RG0%G0@!V
M/WATZ5['/^RWX9T>1[CP3J_B#X=W)Y"^'M1=;4G_ &K67?"1[!176_$;X.>&
M_B;IEO;ZC:-97UG*;C3]7TUOL][83'_EK#*O*D]QR&Z,"*X+3_BIXC^"=Y!H
MWQ9=+[0'<0V'Q M(?+MG)X5+^,9^SR'IY@_=,>Z'BNN4_:2<J&G]V]_N[^AD
MH\JM/7S,;Q[\*/B5K6CG3?$%OX0^,.D1,'C34X'T;4XC_>BGBWHK^C*$/O7G
MT'QG^(/[/P"ZOH7BG4?#4/#:9XIA%S<6ZCJ+?5;??'*!V6X56Q_'7V7#<1W$
M*2Q.LL4BAT=""K*>001U%4];U[3?#VF3ZAJM[;Z=I\*[I;BZD6.-1[D\5FL2
MDK5(IK[O^ ODC1493DE3O=[=?^"SQ3PS\3/@S^V=X-OM'AN;'6'N+9XKC2M0
MB2/4;/<""RJP)4KU#ID CK7G_@/]EOPI^SKX-U#6?"7QEUCPV9)]UQJTD]M<
M64Y7(2.2W*E'9>1\I#G./:M?Q_X \.?M$RN_A#X=6$<K!EC\>ZA;MI_E$@C?
M;A LTY]SA#W)%>3:=^R_\7_V?+RQ\2>&[;PUXTAMY&>XTI[-[F6#TF@C9DRY
M YV$/Z9KGCBYU)JCA/AENY?"K?G?Y?Y?1QRC#8?#SQ.9UN6I%JU.*O.2>]];
M0MUYKM+7EV3]8A^)_P >=3\,7$FG>&+;6=,69$C\1V-G]COKBW(^::'3[F0
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M;4-!5=.U'3F4_P"JD1,JZ<@[7#(0?>NC_P"%B?$+X.'R_B!HY\9^&8^!XO\
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M2".?,4D_WNAK?A_:1USX<,(_$FK>$OB3HR YUCPGJMO;Z@BC^*6QDDVN<?\
M/)_HM>J^#_V=?AMX&\.66B:7X+T8V-HNU&N[*.XF;)R2\D@+,23U)K:_X5%X
M%_Z$OP[_ ."J#_XBMY5J3;YDY+SW^_<A0FEI9',^!_VH/A5\0M(74M'\=Z*8
M>CQ7EVEM-&W]UHY"K _A70?\+I^'V<?\)UX;_P#!M;__ !=8OCG]FGX7_$72
M?[.USP/HLT(.Z.2WM$MYHF_O))&%93]#7FLW[.OB'X;OYOA>T\+_ !%T=/\
MF"^+],MXKY5_NQ7T<?S'T\U#_O5"CAY[-KR?^?\ G8=ZBW1Z)X\_:?\ A?\
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MM>HY2>[;;;Z;MWV/%?\ AB[X)_\ 1/-,_P"^Y?\ XNC_ (8N^"?_ $3S3/\
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M]A=>&Y-4$LAD%Q?73O-%_LHP(P!Z?GFO,_%__!+OX9:R[2Z)?:CH<O4*VV=
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M+GP/=GPX=!U>V:[=9Y?&7EF]#8&%Q<!2$Q@C P<GOFNKUC]G[]E77-_VC1_
MD9;J;748K<_^0Y!2?LY?#C]FV?P7=/X#M= \2Z=]L=;B[UJ-;FY64 ?*3<+N
M5<8P  #G//)KU;_A6?PE_P"A4\%?^"ZT_P#B:RJU7&H[2FO7<<8WBKI'SZW[
M(7[,%O>?:M,UZPT6<=&L_$D3*/\ @,C.#^(JCXD_98^$NN:?/9)\6-%-O*I
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MX.M;9;5S+?V5PD-Y:J.=\8/SA@>P4YZ8-4OA'^RM^S+XY^%EJVAW">)K-Y)
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M@YR>[",G_P!"J(_5X=&WYK]+C?M'V^\\D^*'PI^$P\%ZGX@^-_Q>U+Q]<QJ
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M<<@D0,,X(R,C%.IJ]Z=7$;A1110 4444 %%%% !1110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>zbio-20241231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $A CT# 2(  A$! Q$!_\0
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MZ_I'MU%>.C]IS0=(;9XN\/>*O [#AI=9T:5[<'_KO!YD>/<L!7<^$?BEX/\
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MZD9QJ8>,X[-M_@O\R6G&HT^@ZJ5E_P ?VH?]=%_] 6KM4K+_ (_M0_ZZ+_Z
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M#7OA;QMHFMZ=K>NQZG);7'DQ0ZG;65G9VX:W2?E[>0N6+Q.5.0!&S\;:]*^
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M;0VZ1RV@#(657;S3@':=Y)&:]ZT&\U#4-'M+C5=.72=0D3,UBMPLXA.3QY@
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MYS/&3^:FE_MO6(A^]\/R-ZFWNHW_ )[:/[3I+XX37_<.;_%1:_$/J\GLT_\
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M3H**Y_9XFC^[/I<_^]%(G\B:7[5XD3K9:;+C^[<.O\UH_M%+XZ,U_P!NW_\
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MW08ON?V4-./I@1O&#^F:]$IU'S-OS9S4ERU)Q]'^GZ!11161UA1110 4444
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MAS-M8FW>/Y/_ ()UU%%%2=@4444 %%%% !1110 4444 %%%% !1110 4444
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M8F*P1ER K D\>PK74[E!YYYYIU%(U4;2;"BBB@L**** "BBB@ HHHH ****
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MAU6[@DB(^NY15^U\=>'+U<PZ[IT@/I<I_C6V4### ,/<51N= TR\!^T:=:7
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MS(HR*I_9[S_G[7_OR/\ &C[/>?\ /VO_ 'Y'^-'S"Y<R*,BJ?V>\_P"?M?\
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M-'S"Y<R*,BJ?V>\_Y^U_[\C_ !H^SWG_ #]K_P!^1_C1\PN7,BC(JG]GO/\
MG[7_ +\C_&C[/>?\_:_]^1_C1\PN/?3K.2\6[:WB:Z4868H-P'UJSD53^SWG
M_/VO_?D?XT?9[S_G[7_OR/\ &G\Q+39%S(HR*I_9[S_G[7_OR/\ &C[/>?\
M/VO_ 'Y'^-+YCN7,BC(JG]GO/^?M?^_(_P :/L]Y_P _:_\ ?D?XT_F%RYD4
M9%4_L]Y_S]K_ -^1_C1]GO/^?M?^_(_QI?,+ES(HR*I_9[S_ )^U_P"_(_QH
M^SWG_/VO_?D?XT?,+ES(IOFIDC>,@@$9Z'M38U9442/YC#JP&,_A7B]IX)O]
M<O;6Z>WG_M?2?&MS?7$DTS(IMV#B.15SMD A:%5R#C! P0:N,5*]V)NQ[/\
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M*#-Y?W6+>8IVL"?EXD!PU=%X1^ FH^%/&NC:O!>:;%:6$UTSI# V^6.26X<
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M0PR"",D9!]*\#3]G;6#.)Q>Z-9B4R*MG;V\IM]))\K]_9 L"LQ\HDDX&YL]
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MHM%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>zbio-20241231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "@ R8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=?G!(C1.R.I1U)#*PP0?0TVON/\ 4O+OYY_>O_D3YO\ UAQ?\L?N?^9^D/\
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M ,B'^L.+_EC]S_S/TA_X;&^%'_0Q3?\ @NN/_C='_#8WPH_Z&*;_ ,%UQ_\
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MZ&*;_P %UQ_\;H_X;&^%'_0Q3?\ @NN/_C=?F]11_J5EW\\_O7_R(?ZPXO\
MEC]S_P S](?^&QOA1_T,4W_@NN/_ (W1_P -C?"C_H8IO_!=<?\ QNOS>HH_
MU*R[^>?WK_Y$/]8<7_+'[G_F?I#_ ,-C?"C_ *&*;_P77'_QNC_AL;X4?]#%
M-_X+KC_XW7YO44?ZE9=_//[U_P#(A_K#B_Y8_<_\S](?^&QOA1_T,4W_ (+K
MC_XW1_PV-\*/^ABF_P#!=<?_ !NOS>HH_P!2LN_GG]Z_^1#_ %AQ?\L?N?\
MF?I#_P -C?"C_H8IO_!=<?\ QNC_ (;&^%'_ $,4W_@NN/\ XW7YO44?ZE9=
M_//[U_\ (A_K#B_Y8_<_\S]2?AY\>O!/Q3UB?2_#6JO?7L$!N9(VM98@(PRJ
M3EU ZNO'O7H5?!?[ W_)6M;_ .P'+_Z/@K[TK\TS[+Z668UX>BVXI)Z[Z^B1
M]?EF*GC,.JM1*]WL%%%%?/'JA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%>9>(?"^E^+?C$EKJ]HM];Q:")4C=F
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M\6>!]!TGQ)8^'QKC+XA,=M+]NM8@NG6@F65A'B9C<2#8 "QB&!SUXE\>^*O
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M )_/$'_A2:C_ /'Z_">+_P#D:2_PQ/TK(O\ <EZLZNBN4_X5II'_ #^>(/\
MPI-1_P#C]9/ANQ_L'XK:II=M>ZC-8?V+;7(@OM1N+L+(T\ZE@9G8C(11QZ5\
M4?0GH-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 8\U_.LKJ), ,0.!3?[1N/\ GI_XZ*BN/]?)_O'^=1T 6?[1N/\
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MP?\ H#U]&4 %<./^2VM_V+P_]*37<5PX_P"2VM_V+P_]*30!W%%%% !39/\
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MEE_\B']BX_\ Y]_BO\SXVHK[)_X=Z1_]#X__ (*!_P#'Z/\ AWI'_P!#X_\
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MV3N**** "BO@_P#;@\=>)/#'QAL[71_$.JZ3;/I$,K0V-[+"C.9906*JP&<
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M+/$-W?SAS'#_ &Q*FX*A=N6D &%4GKVI.G97;*CQ+3DU&-)MOS/UBHK\B_\
MA;GCK_H=/$/_ (-9_P#XNM(^.?B6/#8U_P#X2SQ#_9)NS8BX_MB7_7! ^W;Y
MF[[I!SC'O0X65VP7$M.6U)_>?K%17Y%_\+<\=?\ 0Z>(?_!K/_\ %UH:!X^^
M)'BC6K+2-,\6^(;G4+R588(?[8E3>YZ#+. /Q-/V38O]9J7_ #Z?WGZR45^1
MLOQ8\>0RO&_C/Q"KH2K#^U9^"/\ @=>U_L<_$#Q1XA^.FF6>J^)-7U.S:UN6
M-O>7\LL9(C.#M9B,BDX:7N=%#B"%:M&A[-IMVWV/T'HHHK(^L"BBB@ HHHH
M**** ,"X_P!?)_O'^=1U)<?Z^3_>/\ZCH **XOXC?$^+X>FSB3P]K7B:]N(I
M[HV>B1PM)%;0A?.G8S2Q+M4R1C:K%V+C:C8.*&E_&S2]8\4V6F6^CZP=)OYC
M:6?B5HH1I]Q="(RM;K^]\X,%5QN:(1[D9-^["D7O;?U_6WF]-P?NJ[_K_AMW
MV6NQZ'16%X@\867A_5=%TMXI[S4]7G,5M:6JJS[% ,LS9("Q1@@LQ/5E4!G=
M%; \)?%VR\6>)CI"Z)K&F17$,MSI>IWZ0BUU:&)U222W*2NX +H0)4C+*X9
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M >O5V^-7@)&*GQ?HX(."/M:?XT =K7#C_DMK?]B\/_2DT[_A=G@'_H;]'_\
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M^2VZG_V+UI_Z4W%=Q7E7B#QUH'@?XT7<NO:I!ID=QX?M5B:<D;R+FXR!CZT
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MFWX$&AZWJG@/7;:RN9[K_A*8+6VU@>'['18I$V%I(3%;SL)<$*P?RQMR06Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?]\H_P")?F?I-1117(?L@4444 %%%% !1110!@7'^OD_WC_.HZTI-+9Y&;S
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M/^TQXKXUU;]N7]HK0=1N-/U+QM?Z??6[;)K:YTJTCDC;T93#D&OT]KSGXO\
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MJ90K?$.Z SGY+&T4_F(J\!HH^J8?_GW'[D'MJO\ ,_O/H+_AOSX^?]%"N/\
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MN9-V^?G_ )/[GV/6_P#AOSX^?]%"N/\ P76?_P 9H_X;\^/G_10KC_P76?\
M\9KY]HK7ZIAO^?<?N1/MJO\ ,_O/H+_AOSX^?]%"N/\ P76?_P 9H_X;\^/G
M_10KC_P76?\ \9KY]K8/@_5QX.7Q4;3_ (D+7YTP7?F)_P ?(C$A39G=]P@Y
MQCMG-2\-A8ZRIQ7R0U5JO12?WL]J_P"&_/CY_P!%"N/_  76?_QFC_AOSX^?
M]%"N/_!=9_\ QFOGVBJ^J8;_ )]Q^Y"]M5_F?WGT%_PWY\?/^BA7'_@NL_\
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M:[HWC3Q3+KFF6V@RWD5N]K!$%E%Q;H&S'&I^Z[#!..:_0FORF_X)._\ )?\
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M'<V4Z'<<CDULZ=;93Z+[[.^]]WR^>CU.1R]]R25GT^:VVV7,M]VM-#UCQ;\
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M6?\ YXR?]\FOZ*Z*/]8/^G7X_P# #^SO[_X?\$_G4^RS_P#/&3_ODT?99_\
MGC)_WR:_HKHH_P!8/^G7X_\  #^SO[_X?\$_G4^RS_\ /&3_ +Y-'V6?_GC)
M_P!\FOZ*Z*/]8/\ IU^/_ #^SO[_ .'_  3^=3[+/_SQD_[Y-'V6?_GC)_WR
M:_HKHH_U@_Z=?C_P _L[^_\ A_P3^=3[+/\ \\9/^^31]EG_ .>,G_?)K^BN
MBC_6#_IU^/\ P _L[^_^'_!/YU/LL_\ SQD_[Y-'V6?_ )XR?]\FOZ*Z*/\
M6#_IU^/_   _L[^_^'_!/YU/LL__ #QD_P"^31]EG_YXR?\ ?)K^BNBC_6#_
M *=?C_P _L[^_P#A_P $_G4^RS_\\9/^^31]EG_YXR?]\FOZ*Z*/]8/^G7X_
M\ /[._O_ (?\$_G4^RS_ //&3_ODT?99_P#GC)_WR:_HKHH_U@_Z=?C_ , /
M[._O_A_P3^=3[+/_ ,\9/^^31]EG_P">,G_?)K^BNBC_ %@_Z=?C_P  /[._
MO_A_P3^=3[+/_P \9/\ ODT?99_^>,G_ 'R:_HKHH_U@_P"G7X_\ /[._O\
MX?\ !/YU/LL__/&3_ODT?99_^>,G_?)K^BNBC_6#_IU^/_ #^SO[_P"'_!/Y
MU/LL_P#SQD_[Y-'V6?\ YXR?]\FOZ*Z*/]8/^G7X_P# #^SO[_X?\$_G4^RS
M_P#/&3_ODT?99_\ GC)_WR:_HKHH_P!8/^G7X_\  #^SO[_X?\$_*C_@E#$\
M7Q_\2[T9,^&)\;AC_E[M:_5>BBOG\;BOKE;VMK?B>C0I>QAR7N%%%%<)T!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>zbio-20241231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $O E4# 2(  A$! Q$!_\0
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MY%9I&!) 5!_?!KUTG%<[X)\"V'@;3[J"UFNKZZO;EKR]U"_D$EQ=3, N]V
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M)@@#R!>P9@3CWK4VC/2CI0 M%%% !1110 4444 %%%% !1110 4444 %%%%
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M=2AZ./I75@Y%0U;<].G4A5CS0=T+1112-0HHHH **** "BBB@ HHHH ****
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M PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8_B._M_'6KQ>'[2Y271X4%UK%Q"X*&/JD&X?WR,M_LJ?[U3OXRTZ22YM=/\
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M*.,MM/ZUQ6J>,_BEX;TF^6>WM[U]/GM=/-]!I$]P\I^RK)+="-&!D1IOW0"
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MJ3MT.6M0=5W4W%^3_P _^'/(F\,>*_$LRR:OIXO\$,L>KW:QVB'U^S09W_\
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M^AKQOXE?$;Q1HOBN^6\N]&M?#)D4Z7)J&FR3:?<)L&X27<;[H)@VX$,H&W&
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ME18Y)@/F95SM!/MD_G5BBN@\EI/<****!A1110 4444 %%%% !1110 4444
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MW9!]#GV%>T-&KHR, R,,%2,@CTKYN^-7[#7@CXEO-J6@I_PAWB$GS!<6,?\
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M=]^A+O<J_%/X7:)\8O!UQX9\0BY.EW$D<KBTF,3DHVY?F';('%?.&K_\$U/
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M8+N,, ?53U4^XP:^1/'7[#_B3X<ZT_BGX)^)KO3;U/F_LJXN-CD?W$EZ.O\
MLR#\:^U^E'%;TJ\Z7PO3MT(E%2W/C#X=_MV:EX3UD>%_C1X=N= U6$A&U.&V
M*#_>DA]/]J/(]J^@XOVC? 5WXT\+^&K+7;;4+OQ%;R7%C/:R*\)VXVHS _*S
M?-M4\Y0CKBMOXG?##PK\3_#\UEXHT&'6X(T9HQL_?H<?\LG&"K?0CWK\QKW]
MESXL6.MS7FC^ -<L(([HS66)8WF@4-F/+AN6 "\CN*[J=.AB;OX7ZZ&4G.'F
M?K4#D4M>;? /Q?XK\6_#ZS?QMX?O?#WB>TQ;7D=U$$6Y8 8FCP2,,.2.QR/2
MO1V/2O,E%Q;BS=.ZN8/B]B]A' <^7-,HDQW498C\=N*P=4F@OC'N0/#$-P#C
M/..OY5R&E_$V/XC^+_$6C0V%]!/H=P8T=%#K\IVE\#N3GKG@XXYKHK=99)D,
MDR21+(HDB6(HS#(RIR>.OI7GN:F[QV9])2H.A'DGI);KM=)_?:W8[O0[0V>F
M6ZL,.5WOQ_$>3_/%:%)D#O5>]OH+"(RSRB-!Z]2?0#N:[59(^?;<Y-]61ZS=
MM9:=-,F/, VH#_>/ _4BN&5%B4(OW5X&!U]_QZTW7]=N]7UG3HEWV]DDCR>5
MGE\(<%_Q(X[?R=)*D$3RRR+##&I=Y'. B@9))] ,FN.4U-Z=#WJ%!X>"<MWJ
M.R*,BO&8_$7B3XD6Z:M!KE[X3\/7(\S3K+3(HUO)X#]R>>:16V%Q\PC11M4C
M<220+FE>+M<\"ZI80Z[J[^(O#=]<1V7V^[ACCO-.FD.V(R-& LL+N50MM#(S
M*3N!./2EEM>-/G=O3J<$<UP\JOLE]_0]:X^OL>]=;X9N6GTY8V)9H&,1)[@#
M*G\B*Y+D$@C!'8UO>$GQ<W2=BB/^.6']*\ZF[2.S%Q4J3?8Z:BBBNP\$****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"<"LW46-]*+),A&7,[@'
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MC/XAOEUL71L]A+_:EP%DR,!/;KTXQ7J8ISAR.U[@G=7%HHHK,84444 %%%%
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MGDG[/?[>NC^,1:Z%\0?(\/ZXV(X]54[;*Y;_ &L_ZIC[_+[CI7UK]H6XMQ+
MRRJR[D9#N#<<$'O7S_\ #C]A?X8> _*GOM.E\5Z@N#Y^LMOC!]H1A/S!KZ!M
M;2"PMH;:VACMK>)!''#$H5$4# 50.  .PK#$.C*7[E-?UT+AS)>\?*G[,J6R
MWWC>36GN+6Y-X%=$D>.5I"SDKP03]*]E"A)P]HHA@>1 8YY/,=OG'S,PZ'''
M?ZUY[X4^(%SXB^-'C^UCAM5BA AC\J!2YBB;#2$'[[9)Y.<#H.,5WYLK9(99
M8X@TDB8\U%!D8=N>/;T%>!"*4(J.J77T;1]MB)3GC*\ZT>64I)N-[I<T8R7;
MHT=](EYL9I;J*W0<DQIG'XL<?I64;1+QRUNDMXW3[1*V!CV8]O\ =&*3POJ
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M*]B1U'8Y':BMX2YXJ2/G\30GA:TJ,]XNWD_->3W7D>FT4459SA1110 4444
M%,E=8XV=F"*HR68X 'K3ZS+ISJ-V+-2RQQX>=@2#ZJO3!!P<\]/K03)V0EC&
M;ZX^WRI@8*VX(!*IW8$'^+ /TQ6GBD50@P.E.H"*L@HHHH*"BBB@ HHHH **
M*C:=%E$9=?,(R$W#<1]* )**BM[F*[A66&1)HF&5DC8,I^A%2T 9>N>&[#Q#
M"D=Y!O*9,<J,4D0G^ZPY'TZ&N;'PETL-DWNH$>F^,?J$S7<5#]JB,[0B1#,J
MAS&&&X D@$CK@X//M6L:LX*T96,Y4X3=Y*YYQXOU[3?A5]CLM'T*ZU#7=6WQ
M6OD1F1F8#C?(W8$@[<],G@ FH_V?-9EU3P;<P7VJSZGJUG>RP7BW+$O;L#A4
MY[87/U+>E>EQ2PW8\R-XY=C,FY"&VD'!&1T.1@BJ6E^'-,T.YOKBPL8;2>^E
M,US)$@5IGY^9CW/)_.K]I%TW%K7N;+E4>5(9XGL;_4= U"VTR]&FW\L)6&[*
M[A&WKCK[9'(SD<UY1\,/B+XW\0QZ+$-(M=9T43/9W>MK=#>"A(W%1U( ZA<-
MD-\N2![8.:R/"WA#2/!>G/8Z+9)86CRM,T2$D%VQEN2>3@4H5(Q@XN-WT&FD
MFFC77..>M+116! 4444 %,EB29"DB*Z'@JPR#3Z0G% &4?"VDE]WV&//ISC\
MJLW$EGH&F7-RR);VMM$TTA1<85023Q["KM(5# @\@]C57;W$DD?.7P;\2:]H
MLBZCIWAZ\U+PGXFU.1X9?,W3VH#,NY^V,*HR3C]V><D _10A0R"0HIEQMWXY
MQZ9I(;>.WC6.)%BC7HB*% _ 5(!@5K6JJK/F2L:2ES.XM%(3BEK @**** "D
MI:* $(XZ<UP'B3P]XC\=:O)8SS+HOA2$X=4(DNM0;OG^%(QZ');N .#Z!151
MERNZ-J55T9<T4K]+]/->?];GG'C/PCH'A_PC<2+9V_VD20;;N\_>R;A*F"7?
M)  &>.  <8Q5Z+1Y?B(C7>LI)'X>D_X]=(;*_:$[27'<YZB/H!C<">!9\4>%
M+CQ;XFT=+QE'A[3V-Y) &R;JY^[&KC^X@+,1W)7L#77*NT=<UHYVBNYURQ#C
M3C:5YZN_:_1>>E_+[SS72K=M4UVR\+ZLHO$T:*<R"90RW*%52!V'?]W(P/\
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M7S]XB^$VK>.?CQKM_LM-+TRU.CW,>LR6KF_5H6D=H[27(5%;&R3KPY&#D5]
MTF.: /DCPQK'CCP_#\.=#TW3M?T=[!+%;N(6\CVMQ!//(+@F+RBH,2XW%Y%(
M)7:O<Z_A&Z\=^)IM,T277?%)M)-7F74O$5O"8!=1?89G40K- K6H$RQADPP#
M$*KD$@?4&/<TFWZT ?+5CX@^(WA[PXC:U<>)]6_MG0=.N;VY\CR&TV^DG:.9
MD\J%FC14"EHU1B.HQDL.=%]X]AGBUZ9_%-MXM?P[!;:<;?3&,>HW<6H78ABN
M\Q8 ,31LV[R_E=F."!C[(V^YHQ[F@#Y-UK6?&_A:.'3="TO7M/OTUS4-3C>U
MAD:WO1+JSAHF01,'Q#F3+O&NQP1N/0UZ\\7ZGJ>H6UQJ_BV[L+/Q-8W=QK6E
MQS6\<5I]HE1H%@,(92B^67\LR(ZA7R.17UEMXZFC'N: /&_@SK&O3^-_%]CJ
M][J^MP))YT.JW$,EO9KF60"W2"2)"DB*%R49T8;6R"<5[+3=H]S3J "BBB@
MHHHH X7XZWEWIWP8\<7-A/-;7L6C73PRVSE)%<1-@JPY!ST(Y%>(RCQ!\(]0
MT36]<>^M=)$NHZA;Z/;7\^L/9PQZ8=P\Q\&4O(#($/RKV/)Q]3D C!Y%(4!Q
MQ0!\J0?'_P 6IH4]W=ZY8I9:=K#6TUQ EM)?7<'V>"5?(CW^3<;6E=66%BY
M4+E@<[3?$;XC:QJ&ZTUZSTZTO;K7888CH^][:.PD80G+,-S2  -N&,?=P>:^
MC/L5OMB7R(]L1!C78,(1T(]/PJ78/2@#YU\,?'S6_$GQ'\'Z>DB);ZBEO!J>
MF/#&ODRR:>;HRQ?,92@8HH=E"')4989JSXS^,GB71;KXCSVVH646H^'R8-.\
M*R6X,T\&R%CJ#,3O>,>9(V$ 4",@G.<>_BWC60R!%$A 4L%&2!T&?2@V\9F$
MNQ?- VA\#<!Z9]* /CKQ=XQ\2>)K(76H:E%>E=+NX[>\T6[659XAJ>E[6D\@
MF,2@,ZD*>GIDBO;OA%\0]4\2^-?%>BZOJEOJ-S9/YL2Z8D4EE%"99$0"9&+"
M3"@-%* X*DC*D8]6BMHH(Q''&D<8Z(J@ ?A1%;10,YCC6,NVYMB@;CZGU- $
MM%%% !1110 4444 )@>E+110!0N='M[S4;&]D5O/LF=HBIP/G7:V?7C^E7Z*
M*!MMI)] K/N="L+O6K/5I;2.34;.*2&WN6&6B20J9 OINV)G_=%:%% CC4^$
M'@^+4X=1BT"VANXO.PT)9%<2N[R*ZJ0KJ6ED;:P(!=L8S4<?P7\$QZ#<Z*?#
MEG-I=S!!;36TX:59(H'+PH2Q)*HS$J.W;BNVHH Y.7X5>$[CQ-+X@FT*VEU:
M60RO.^X@R&+RC)LSMWF/Y"V,E>"2*JV7P:\'Z;+HTMIHJV\FCQK#9-'<2J8X
MU<NL;?/\Z*Q)57RJ]@*[:B@#D_#7PL\*^#M8FU71M$M["_E1XC-$6)6-WWM&
M@)(1"XW;5 &><5GVOP.\$6,5REKX?BL_M"A&>VGEB=$$GF!(V5@8T#_,%0A0
M2>.:[RB@#C8/A!X.M9;=X?#UI"8((+9%C!5=D,HEBW*#ABD@W!B"P)//)S9E
M^&7A>?Q2WB.31+:366.YKA@2"VSR]Y3.TOL)3?C=MXSCBNIHH \ON/@+HBWG
MARWT](M-\-Z3J2ZP=*2-I3+=QC$!5W<^5&F<[$4#@ $#(.UJ7P9\':L;PW.A
MQE[N].HR/%-+$PN"I5I496!C9E)#;,;LG=G-=M10!S5A\.?#NF^)!KT&F(-5
M6/RX[B25Y/*!54/EJS%4)5%!*@$@<DUTM%% !1110 4444 %%%% "8S3)HEF
MA>-D5U<%2K $$>X-244 <#+X;;PY;)!% B6,0^1H$PJC))RH^[^''TKY\^(F
MKCX/?M$^%?B#<9CT*^1M,U68'Y8X9%5?,)]$98G)_NH]?7Y4,:X/XG?!_1_B
M1X<OM,N!]F:=?D<+N1''1MG3U!]02#G-<LZ<HM5*>K73\&OFKH^AP&-HIRH8
MK2$URMI;;-.W]UI.RWM8[J*19(PRL&4\A@<@CU%9WB;Q)IWA'P_J&MZM=)9Z
M9I\#W-S.YP$11DGW^G<U\KV6K_&?]F33(]&.EVGCGPG !'8RS22B2U3^&,2H
MK-L'0+(N0. Q  JLVB?%+]JK5+"'Q3:)X5\#VTRSO86JN(Y64Y#.T@#3L#]T
M;513@G) JOK%+9-M]K._^2];V\V..1XAOVDY15'_ )^<R<;>6O,WVC;FOHTC
ML_V4?#<_C#2_%WC[Q!9F.Z\5ZL]Y'#*,M%&N0B?\!4JGU0T5]!Z%HEGX?T:S
MTS3X1;V5K$(HHU[*/Y_6BG&G=7FDV]7ZO^M#S\7C)5:S=%N,%915_LQ22OYV
M2OYFA1116YYH4444 %4K^SDO'B3<%M]VZ0 D,<8*@$=L]?45=HH$U=68U1@<
MTZBB@84444 %%%% !1110 5CW_BJPT[Q/I6@3.XU'4X+BXMU"$J4A\OS,GL?
MWJ8'?GTK8KC?'GP^?Q?J6BZI9:W>>'M8T@S"VOK..*4^7*H62-DD5E(.U#TR
M"HJHV;]X3O;0['-&:\X_X5YXR_Z*GK'_ (*[#_XS1_PKSQE_T5/6/_!78?\
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M^"NP_P#C-'_"O/&7_14]8_\ !78?_&:7)'^9?C_D',^QZ/FC-><?\*\\9?\
M14]8_P#!78?_ !FC_A7GC+_HJ>L?^"NP_P#C-')'^9?C_D',^QZ/FC-><?\
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9%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>zbio-20241231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #' F # 2(  A$! Q$!_\0
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M;X5TU+#2K1+.U5F?8I)+,QRS,Q)+,3U)))J72!_HC?\ 767_ -#:@"]1110
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MWS%V2,F6"D@9VYQG(!&<'BM+2/\ CT;_ *ZR_P#H;4 7:*** "BBB@ HHHH
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M3Q&;E;'4)[.UB@LYK'P[/'+8RF(O,D]^!Y;%HWC(1B>JX"D'=[PO2@#-\/\
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MS<)-'G^)&(."/7!H$[I:%VBO-Q\&I<?\C_XU_P#!G'_\:I?^%-2_]#_XU_\
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M73)HD486%7="UP%QM$R,NX 9W XKZZNK5;VTE@=G5)5*%HW*, 1C(8<@^XH
MQ? ?C:T^('AV+6+&*2*W>62';(5/S(Y1B&4E67*G# D&M72/^/1O^NLO_H;5
M4\,>%=.\(::UEIL+11/,]Q(TDC222RNVYW=F)+,3W-6](_X]&_ZZR_\ H;4
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M7WKHZJ:5I=MHNG6MA90):V=K$L$,,8PL:*,*H]@!5NLSZ2G%Q@HOH@HHHH-
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M:6WDBN5 =)(W*.IP2IPRD94D'UJ[I'_'HW_767_T-J +M%%% !1110 4444
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M .2!SZURNO\ QG\%^'-#BU>Y\1V4UG/!]HM_L4GVE[E"0J^4L>2^YB%&.K$
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MOHK>-)Y Y<-(% 8[B 3DYY(%:%% !1110 4444 %%%% !1110 4444 %%%%
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MA@I4DJ%4 5[01FC% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"-1YO[G:%P,!SESS7O8Z4 +1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1163J/BO1](OEM+W4
M[6UN6 *PRR!6.3@<>YH UJ*2N8\:?$72? 7V7^U#./M.XQ^3'O\ NXSGGW%
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M],OM1NM8LHK&QA:YN9_/4K#$,Y=L'@<'GV- &U1638^*-*U.ZO[:UU&WEN+
M@7,8<;HLHK@D>FUU.>G/6I-/\1Z7JEM'/:ZC;3Q/$DX9)1_JV^ZV.P/8T :5
M%80\;:(=3DL/[2A^U1S);,O.T2NNY(]^-N\CG;G/3U%;@.10 M%%% !1110!
MR_Q'GUVW\*W,GAU9&U(/'S!&DDHCWC>8U?Y2VW. :U]":_DT2P;4TCCU,V\9
MNDC/R++M&\#VW9K0*@GFC&* (=UP/^6<?_?9_P *-]Q_SSC_ .^S_A4]% B#
M?<?\\X_^^S_A1ON/^><?_?9_PJ>B@"#?<?\ /./_ +[/^%&^X_YYQ_\ ?9_P
MK/M/%FBW\\$-MJ]E<33^>8HXKA&:00N$F( /.QB%;^Z2 <5'-XST2"#5IGU2
MV$>DRB"_8/G[-(55@KXZ'#H<?[0H&:F^X_YYQ_\ ?9_PHWW'_/./_OL_X56N
M=?T^RU:STR>]@AU"\61[>V=P'E$8!<J.^T,I/U%7P<@'.0>] B'?<?\ /./_
M +[/^%&^X_YYQ_\ ?9_PJ>B@"#?<?\\X_P#OL_X4;[C_ )YQ_P#?9_PJ>B@"
M#?<?\\X_^^S_ (4;[C_GG'_WV?\ "IZ* (-]Q_SSC_[[/^%&^X_YYQ_]]G_"
MLGQ#XZ\.^$[[3K/6M=T[2;O49/*LX+VZ2)[A\@80,06Y(''<@=2*N:/K^G:]
M:R76GWT%[;QSR6SR0N&598W*2(3V964J1ZB@"UON/^><?_?9_P *-]Q_SSC_
M .^S_A4C2*H)W*.O4^G6L;3?&FB:OJ]UI5EJMM=:C:M(D]O$^YHFCV!PWH1Y
MB9'^T* -7?<?\\X_^^S_ (4;[C_GG'_WV?\ "I&D51RP!SMY/?TJEHNO:=XB
MM)+G3;V"^@CFEMGD@<,%EC<I(A]U92".Q!H L[[C_GG'_P!]G_"C?<?\\X_^
M^S_A4]% $&^X_P"><?\ WV?\*-]Q_P \X_\ OL_X5/10!E:MI<VKQ1H9[BTV
M-NW6ER8RW'0G;R*X'Q'\#D\1ZY!J4FM7J/$$&)6$S?*V>'."/Z5ZG24Q.*>Y
MP7BSP%J.H>';ZWT[5=1^VR(!&)]0;9G(SGY?3-<YX:^"DEYHPM_%LLU]/%.S
MPB.^<JJL%SVZG'Z"NXUGXF>%= \1Q:!J7B"PL]<EMVNH].EF G>(!B65.IX1
MN!R=IQTK7TOQ%I6M1/)8ZA;72IMWB.4$QDH' 8=5.U@V#@X(HN+D5[GDOAKX
M/:_9^(K@:C?R?V$Z2Q+##?/OV'A5/'3'!IGBOX&7EL+8>$)&L0P;[2);YQNZ
M;<8'UKUS4?$.FZ5)9)<WD<37DPMX!DMOD(8@<=/NMR>.*M?VC9A&;[5#M1=S
M'S!A1G&3SP,C%%Q<B.*O_AS=ZCX6DTYM6OQ<2VHB;SKQGBW;0#E<<C/;-9O@
M'X07?A"QNX)]7G+32!Q_9\S0+C&.1@Y-=U8^*=)U+6[_ $>TU""XU.P2*2YM
M4?+Q+("T9(]& )%:U%Q\JW*%A:SV%I' &>X"9_>7$Q=VYSR<<U8WW'_/./\
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M6FGC3[!IX(T9!,N^-"Q#"82J\JMQO0$9P,?2E @HHHH **** "BBB@ HHHH
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I///9:?/<,L]S,\3;WC?$:>7LD"L@RPE.[IR44!<]VHHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>zbio-20241231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '[ AP# 2(  A$! Q$!_\0
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M>L1W?[0T0>.>^9(3%#=W(;<<IG>!]W^_R/?/-?0?BS51HOAZ]NL;G";(U/\
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M17L=% 'CA_:?T#1<KXO\.^*_ I7.Z;6M&E>V&.I^T0>;$![EA7=^$/BCX/\
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MN$,<T7U0\_CTJ&FCLIXFE4:47J_Z^?R-NBBBD=04444 %%%% !1110 4444
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M7I-J!;ZC]AABC:[C;:RV^!P/F7)/) SZU]/ZSH.G>(;0VVIV,%_;YSY=Q&'
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MIC9@5+-SQ@^R?!SQS>?$7P#9ZSJ-I!9:EY]S9W45J[/#YL$\D+M&6 .QC&6
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M%%%% !116?K^O6'A?1;[5]5NXK#3+&![FYNICA(HT!9F)]  : .,^-'Q)N?
M7A^TL]#MH]3\9Z]<?V;H.FN?EEN2"3+)W$,2AI)&[*N.K"M'X3?#>U^%W@Z#
M2([J34]0EE>]U359Q^^U"]D.Z:X?W9N@Z*H51PHKB_@QH5_XY\07?Q9\36DM
MI?ZK;_9?#^EW*X?2M*+!EW+_  SSD++)W \M/X#GV4 #I0 M%%% !1110 44
M44 )FO)/AS\>8?&GBCQE8W6G_P!G:;I0DNM)O5<N=3LHG>"><+CC;/%(H SE
M3&P^]7H'C>TUK4/"6L6GAVY@L=<N+22*RN[H$QP2LI"R,%Y.W.<#KBO&[?\
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M&:YGEOSI.H7$C:VC(5C%Q:,BPQRJ2KF92S$KC)#&O:* "BBB@ HHHH ****
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MZ,.E+6=H&I-K&C6-\\+V[W,*2M$ZD%"1D@@UHUF>M&2DDT%%%%!04UU#HRL
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M U%]'\%Z@T!Q</&+:#'7>Y"+C\ZJUTD<4IJ%2<WTBOU_R.$N5/B"RDU"3/\
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M//TKK*&TM$:4:51S]K5>O_ _SOW$Z4M%-DD6)2S$*H&23T J#O.!B\-Z1?\
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M[$G@=R37AO[.6E2?%.^LOB+J;B71M'CFTKPC:<X6'<5FU!@>DDPPJ?W8@/\
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M"VF2,&<?\3*[0\6T)ZIG^^W3'8&B6_\ $?BX^58VK^&].;AKV[ -TZ_[$?\
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MI->=7FGO:?"+0+%A^\N9K,./4O*K'^==+\496;PG)91_ZW49XK%<=?G< _\
MCN:SOBI>QZ+H^A 1--'%J4#"*,@,P0%MHSQV'6K70\O%--S;V4;?>_\ @'SQ
MK?[1/A_]I'XO^)?@]IM[+IWAG1/-N/%-W,2C7]M:N%DM(,<[9'95D;CY%8#[
M_'T-\-I/)UO7[2.V6TM7%M>QVR*%6#S(_P#5X' P%7BO!?#OA+P]K/Q/N]6L
M-"L=)OM:NY+C5=1@C"2W$&_S#YS#C"A?H3R<U]$?#?%]#K&M 'R]4OGE@8C&
MZ%0$0_0A2?QJFN5:F%#$_6JL7#9-_/37Y:JQV5%%%9'MA1110 4444 %%%%
M!1110 4444 %87C/Q&OA;P_=7NWS+CB.WB[R2MPBC\:W:X345_X2GXE6EB?F
ML=#B%W*.S3OQ&#]!DU26ISUYN,+1W>B_KRW+&AV)^'WA 2W%M<ZC?2OY]X;5
M/,DDE<_,<=P.GT%4[GXO6$;10P:3JTUY,WEPV\EJ8O,?^Z"W%=-X@\4Z5X5@
M$NI7L=ON!*1DY>3V51R:\[U35]4N;N+Q+<6;0W,C?8M TN;[V]^LT@['';TJ
MDKZLX:TW02ITI;=+7LN_KV[L9JNK-9ZY:7WB91J.O,P_L[P]:N&CMBQPK.3Q
MN/J?P]NH2/Q_>CSO-T;3,\BV*/*1[,W^%8.O>$HO"NAZ/))*;K5+C6+:2\OI
M.7E<L<\_W1V%>K4-KH*A2E*4E-M;/1ZZ]WU?X>1Y!K>J/=Z];6FM&+PSXM@4
M&RU2W?=;SJ3@(_<*2",-6[%\3I]&N%T[Q'H]W;ZEL+ V,?GQS*.KICG'MVI=
M1TBTU_XFZA8WT*W%K)HRJR,.G[W@CT/O6!+I>JVVHIH:W1?6]'_TS1;R8X^U
M6YX:%S^E/1G.W5I2<HOK;UMW7>VSTOL^AW.D>(+3QK!>VATR_AM&CV.U[;F)
M9 W! SWK.^'=Y-I<E_X6O9"]SI; V\C=9;9ON'\.A_"KWAOQ_I^NR+97!.F:
MRORR:==?+(&[[<_>'N*SOB"IT'5=&\41# M91:WF/XK>0XY_W6P?QJ?(['-<
ML:\97MOZ/?[M_D=T.E+2 @@$'(]:6H/3"BBB@ HHHH K:C80:G936EU"MQ;S
M*4DC<9# UQL-QJOP\_<7,=QK/AU/]5<Q#?<VB_W9%ZNH_O#GUKNZ0C)IIV,:
ME/F?-%VDNO\ GW10T?7M/UZW$^GWD5W'W,39(]B.H/UJ_D5SNJ_#_1-6N#<M
M:FTO#_R]6;F&7\UQG\:I?\(9JUL<6GB[4DC[+<1QS$?B5S3T(YZT=)1OZ/\
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M?B&^SNCLH8=/C/;./,?]2*[&J;M8Y*4544W+:3?X:?H>1^#_ (-319.MK#%
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M5[?6_!>B:G:DF";4+25<]1E^A]P>*]#KR+4=)N]%^%FCV5["8+D:I"?*)!*
MSD@<<=*]=I/1&N&E*4W*2LVH_J<58?/\6]7_ -G2X1^;FN7UKQ%=:MXLTG6X
M(HXM%T[4QIR3G_63L^5<C_8!XKI;)6/Q6UT [6?2X=I_X$U8-YX7OK?X+2V,
MUN\&H6A:Y\M2"V5E+9!'<C)JU:YQU%.4)*/1R?S3T1Z;+IUI<7,-Q+;0R7$/
M,<KQ@NGT/451\5:4FN^&]2L&&1/;N@^N./UQ7(Z1I/B36M)M9K7QGOTZ>)62
M86:&?![%LXR.F:[O3[-K*Q@MWGENFC0(TTQ!=_=O>H>AZ,)>VBTX637EK]S9
MC?#W5&UCP9I%U(<R& (_^\ORG^5='7$_"(_\4G(G\,5]<HOT$AQ7;42W96&D
MY48-]D%%%%2=(4444 %%%% !1110 5R/B,B;QWX3AQ]S[5,?PC"C_P!"KKJY
M&\'G_%+3EZBWTN:3Z;I%7^E5$YL1K%+S7YH/ X\S5_%LW][5"G_?,:"NM-<E
M\-CYNG:O<=?/U6Z?/J ^W^E==2>X8?\ A)]_U9Q5E%_Q7WBFV(R+JQMY<>O#
MH:N?#"4R^!-'SU2$Q'_@+%?Z5%(1;?%2$]!=:2R_4I*#_)J/ACF+P]<6Q&#:
MW]S#CTQ*3_6J>QS4M*UO\7YIG74445!Z04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7'?$G_1+?1-3''V'4X'9O1&)1O\ T*NQKF_B-9&_\#ZU
M$HRXMFD7_>3YA_*FMSGQ";I2MO;\M3I**I:+?#4M(L;L'(G@27/U4&KM(W34
ME=')?$3Y[?08NTNL6JD>P8G^E'PK/_%#V(_NO,/_ "*]1^.3YFL^$(/[VJ!\
M?[L;FG?"LX\'Q)_<N;A?_(SU?V3SHZXMOR:_]).OIDLJPQ/(YVHBEF)[ 4^N
M8^)&H2:=X*U5HCB::/[-%CJ6D(08_P"^JE:L[JD_9P<WT17^%\32>&6U&3_6
MZI<S7K9]&8[?_'0M=?5/1[!=+TJSLD "6\*1#'^R /Z5<H;NR:,.2G&+Z(**
M**1L%%%% !1110 4444 %%%% !1110 4444 17,0N()(CT=2OYC%<=\)KL#P
MJNF2';=Z7-):31'JN&)4X]""*[4C-<OKGP^T[6-2;48Y[O2]0<;9+BPF,9D'
M;<.AIJVS.6K&:G&I!7:NK>3M_D='<B-XF64@1NI5@QQD'J*IZ;::;H&G16MH
ML%G9Q#"HK *H^I-<[#\)M!=O,OOMFJS?\]+VZ=C^A J1?A+X35MW]DJWLTTA
M'Y%J>A-ZS?-R*_K_ /:F9J^IQ>/_ !/INEZ6PN=.TVY6\OKQ.8]RYV1 ]"2>
MN*]#JII^EVFE6J6UE;QVMNGW8XE"J/P%6Z3?8UI4W"\IN[?]6.#\722>$_%M
MEXG\IY=,> V5^8QDQ+NW))CT!X-==9:O8:K;+-:7<%S"XR&1P015MXUD4JP#
M*PP01D$5R]U\+?"MW,TKZ/"CL<MY+-&"?HI IW3W,^2I3DW3LT];/37\39T;
M3=/T:W-KIT<4$.]I/*B.0"QR3C/K4VK:E!I&G7-]<N(X+>-I&9C@# KF9?A'
MX8*?NK%[:0=)8+B17'X[JCC^%>G/+$;_ %#4]5MXV#):WMT7BR.F1W_&C3N3
M>O%<L8+[]/R1/\*K.6S\%6+3*4EN3)=,I'(\QRP_0BNOIJH$ "@ #@ =!3J3
M=W<Z*4/9P4%T04444C4**** "BBB@ HHHH *X;6+F^T+QS<:H-(O=1MIM/2V
MA:R0.0X<L0PSQVYKN:3:*:=C&I3]HE9V:U.?\ Z3<:+X4LK:[3R[L[I9ESG#
MNQ8C/MG%=#2 8HH;OJ7""IP4%T.,\9W0T/Q3X?UF:*9K*)9X+B6&)I-@905)
M YQD5)\.FDFCUNZ$,L-E=ZA)<6IF0HSH0N3M/(&0<9KKR :,4[Z6,%1M5]I?
M3>WRL+1114G4%%)D4M !1110 4444 %%%% !1110 4444 %%%% !1110 5!>
MP+=6DT#<K+&R'Z$8J>FMQSZ4":NK'&?#;7+5?"F@6$]S&E^T+Q1PLV&?RF*M
M@=\8%=H#D9KR[PUX)M?%_@G3Y7GFL;V"\N9[2]MCB2(F9OS!]/:O0=&MKVQL
MA%?WXU"9?^7@PB(D>X!QGW&*J5KG#A93<(J2TLK/Y=3 \6<^,?!N?N_:+C\_
M*./ZTGPN_P"1=N/3^T+K'T\UJPV\4+XKO/!VII ;=?[6N+<(7W9 1UW9QWQF
ME\&>)TT'P]X>@: R_P!K:E<0>9NVB,F1R#[] /QJK:6.6%6'MW4OH_U4$CTL
MG KA?&6J6FNWN@Z=:W$5R/[92.X6-L[#$I<J??@5T/B/2M1UFU%O8ZL^DJV1
M)+#"'D(]B3A?KBN0NO"MCX,N?!MK8AR@U1S)+*V7E=XGRS'UXI1L=6)E-KE2
M]W2[^:V_X)Z0!2T45!WA1110 4444 %%%% !1110 4444 (>U?*G@_5_&>N_
M%;5I=(N_%\\MEXRO+?49;^3.@KI4;,#%&K'_ %@&T+Y8W!NIQFOJRLO0O#&F
M>&H[Y--M%M5O;N6_N I)\R>0YD<Y)Y)_"@#PW6_CKJNM_#+PE=+816-QXO\
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M% '(?"J3/@?3H?XK<RV[>Q21A_2JGQ>?R= TV7C]WJMH_/\ OU8\$'^S=?\
M$^CM@>7>?;85_P"F<PSQ_P "#51^-S;/!<;YQMOK=O\ Q^M%\1Y4W;!2796^
M[3]"_P#$/]_<>&;3^*;54(^BHY-2_"N3?X"TH=XU>,CW5V']*B\0$7WQ"\+6
MXY6".YO&'_ 0BG_QXT?#8?9[/6;#/-GJMQ&!Z*S;Q^C4OLE1?^U.7JOPB_\
M,[&N.\>?Z1JOA.S'+2:HLN/]F-&8_P!*[&N-G/\ :OQ2M8UYBTFQ:5_:28[0
M/^^5/YTEN=.(UBH]VOSU_"YV-+114G4%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112
M'H: *NIZG;:/937M[/';6D"%Y99#A5 [FN CN->^*?[RWEN?#7A-ONRJ-E[?
MKZK_ ,\D/K]X^U.N+8?$GQQ<VUS^\\-:!(JO!_!=WN-WS>JQ@CC^\?:O1U&
M!C'M5?#ZGGV>*;UM!:?XK;_+\_3?C)K3PO\ ";0S>0Z?':1!UC+Q1^9/*[''
M+'YF/4\GL:MS:GXG,NM-;Z;:26\<*OIC&4AKAB,D."?E_2M/Q'X>LO$EG'!?
M6XN8X95N$C+E077.W)';FL2R\7ZCI5OI47B/3FAU'4+M[:-+ &6-!GY69NP-
M&X27LI<M^6'2R^6NENJMZ$O]NM>7NFZ+K.BL\]W9FXN'\H26L+#[R%CQ_D5F
MW?PNMK&0W_A*_E\-7S?/MMCOLYO]^$_+@^JX-2^)/%=GK^@^(+*RTV\UI[68
M6-U:09B<EC@E6[@>HKJ-#L8='T>SLX4DCA@B5$29]SJ .A/<CI3NTB5"G7ER
MR]Y+9]5TT:]'JF<SX>\>W*:M'H'B>T32-;?/D2(V;:] [Q.>_JAY%=O6/XG\
M+Z?XPTB6PU&+S8'^9'4X>)QT=&_A8'H17/\ @;Q!?VNI77A;7Y/-UBRC$L%Y
MC OK;.!+C^\.C#UY[TM'JC2$YT9JG5=T]G^C\^SZ^N_<44@YI:D[@HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .,UX_V-\0-!U(?+#?I)IDY'][
M[\9/X@C\:H_'%2WP^N6Z[)X6/M\XK5^)UH\O@^[N81_I%@Z7T9'8QL&/Z U4
M^)^W6/A;J\T7S)):+<(1Z AOY5HNC/*Q"M3KT^ZO]Z:_3\1-'D_M#XD7$IY%
MIH\$8/O(Y8_^@BI_#(^R>//%EKT64VUVH_WDVD_FM5?AX_VG7_$%QUS%8H#[
M"W!_]FJW;CROBO>8X\[2(V^I65A_[-284]5"?]Y_JCKF.T9S@=S7'_#@'48-
M6UU\[M5O7>,G_GBG[N,?DI/XUH^/]4;1_!VJW,?^N\@QQ8Z[W^5?U85?\.:4
MNAZ#I]@@P+:!(S[D 9/YYI=#KE[]9+^57^_1?J:5%%%2=04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !17/>-?$K^&=*22W@%U?W,JVUI;DX#R,
M>,^PZFL*T\::GX:O8[+Q?## DV?)U6US]G8XSL8=5/\ .J2;.:>(A"7++[^B
MOM=G<SW$5K$TDTJ0QKU=V"@?B:6&9)XUDC=9(V&0RD$'\:\CU72=9^)]E-K:
M*%L+>17TS2YQA+I5/S-)_O#(%6_AE>^7XMU'3].LKNPTH0"2YL+H<6=QG[J'
M/0C/Y4^70YEC&ZBCR^[+9]_/^M;:GJE+7DEYJ_B#5-*\1>)+379+.TL+B5+2
MT2%&CE2/ RQ//)S7=:?XRTDZ?:276JV$=Q)"CNGGJ,,5!(QGCFDXM&U/%0J.
MSTZZVU7WG0T5#;7<-Y"LT$J3Q-]V2-@RGZ$5-4G9N%%%% !1110 4444 %%%
M% !6+XO\1Q>$_#>H:K,"PMHBRH.KN>$4>Y8@?C6U7"?&9"G@>:]P&73[JWO7
MC8\.J2J2OY4TKM(YL3-TZ,YQW29I_#?P[+X:\(V5M=<ZA+NNKQ^[3R'>_P"1
M./PKJ*CAD$T:R+G:X##/H14E#=W<TI0C3A&$=DK"8S1@4M%(U&+$B;BJA2>3
M@8S7(>*;.3Q!K]KHSZM:Q:=/:R?;-,/_ !\3*>CH>V"!S]:[$UR_B2SN;;6]
M*U33M(M+VZW_ &>YO)WV/;V_)8J?SIK<YJZO"W2ZOOM\OZ[E*>1O 5Y9-<:K
M;V7A2&W2SCMID+2M,3A3O]_7Z_6JWQ5B_LNVTCQ1 -MQHMXCR,#C=;R$1RJ?
M;!!_X#6IXEU*+6/#@?1VTK5;J9@;**\D5H974\X]2!GI5?XEQO+\+=>%TJK-
M_9SLZKT#A<\?0BK6Z..M']U4C'9*Z\GNM?*R=CLE(*@@Y!Z&EJCH3M)H>G._
M+M;QD_7:*O5F>G%W284444%!1110 4444 %%%% !1110 4444 %%%% !1110
M!7U"U6^L;BV<92:-HR/8C']:XWPA:MXE^%,&GR/M>6SDLB[#."NZ,$C\*[*_
MNDL;&XN7X2&-I&/L!G^E<M\,)8[7PAI5J\J"\EA:Z:'<-ZAW+9(]/F%4MCCJ
M).LHOJG^:_X)6^'5FVDZSXCTZ63S9K=K4&3&-X\A5!QZ?*:M B;XL/M/^HT<
M!\?[4W'\C63I7B&WG^+EU!!'<0S7%EY5S#<1E"CQG*..Q5E8\CTI/"7B.WO/
MB)XFC,4\MZ\JP )$2D,,0P"S=!N8MQUJG?<XX3@HPII_;:_-_P"1L?$=1<0:
M#9MRESJUNKKZJ"6Q_P".BNN%<3\0]0M_LNG744L<DFF:K;23(K L@+;#D=OO
M5VPJ7LCNIM.K/Y?K^MQ:***DZ@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ,+Q?X6@\6:4UK*6AG0^9;7*'#0RC[K UC>&FB^(/A%['7K=9KBVF
M-K>1'C,L9^\,=,\'\379R2+"C.[!44%F8G  [FN*^%K&\L]:U905@U+4I9H,
M\;D&%#?C@U2V.*I&/MHK^9._FE_7XG2:SJ5OX:T*YO&18[>SA+!%&!@#A1^@
MKROP/<>(=<T.:+2+8VDFHRO/?ZW=CC<W\,2]6VC@'I73:K#-\1/%4NENKQ^'
M=*<?:\Y7[7/U$?\ NKU-=#XNU*X\-^&I9=,LS<70VP6T$:9568A5) Z*.M4M
M-#GJ+VTG4;:A&ZTW?>WY=][%-X_#G@GPM#H^HW=O%8B(QLERPW3 _>)'4Y)-
M<JNN_#F$;;31%O1ZV^F-(#^)6NH\,_#NQTI1>ZB!J^MR_-/>W0WG=W" \*!V
MQ6IJOBS1/#GR7VHVUFW_ #S+#=_WR.:5^PW"3BI348I;75[+UND>=?#WQ[I/
MA/2%TS4HKO3Y9+F6=5DMF$<4;O\ +SV X&>E>O(V]00<@\@CO7A?B7Q!#XBU
M[7O[*MKK5AJUA%96TBV[@1.'Y&2.%/WL^U>V:9;-9Z?;0,VYHHDC+>I  IS7
M4G U).].]XQT3^__ (<M4445F>L%%%% !1110 4444 -8X'I7FK%_BSXBVJ?
M^*.TFX^8]M2ND/3WB0_F1[5K?%S49[7PS;V4%S]A.JWL.G27F<>1'(3O;/8X
M! /J174:-I%IH>EVMA8Q+!9VT8CBC7H%'^>M4M%<X*B^L5?8OX8V;\^R].K[
M[=RXHQ[4ZBBI.\**** "HYH4GB>-T5XW!5E89# ]014E% '/)X#T&-=+5=,A
M2/3)&EM$&=L;MR3CO^-9/QEN-GP\U*W0XFO6BLXP.[22*N/R)KMCTKSN[G_X
M6!\0+6T@/F:)X<E\^ZF'W9KW!"1CUV EC[D"K6]WT//Q,8QI.E!6<]%]UOP7
MX(] MH%MK:*%?NQH$'T Q4M(.E+4'>E;0****!A1110 4444 %%%% !1110
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M@S1,.Y Y /\ 6NTT/7;/Q%ID-]8RB6"4?0J>ZL.Q'<5\^6?ASQ_+.)8K>_\
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M2.+"Z1E#M)_B[K\&+1114G:%%%% !1110 4444 %%%% !1110 4444 %%%%
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MX;%X=X'"/FNUS/IIK9=]>NWJ6Z***]4_*0HHHH **** "BBB@ HHHH ****
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M10 4444 %%%% !1110 4444 %5M1U"WTFPN;Z\F2WM+:)IIII#A4102S$^@
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>zbio-20241231xex10d18001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231xex10d18001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !5 .D# 2(  A$! Q$!_\0
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M?WOSKXT_:*^'7[4&O_%74;WX;^*O[.\(O#$+:V75(H-CA?GRC1D\GOFO-/\
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M0+73$;/E0KS)<SD<-($#$=EZ#G)/ZO\ AG0;'POX?T_1]-@6VT^P@2VMX5&
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M**:C'X+\*Z=X1\.0^)OB1J]DEQ=6MI'));6;MGY1&A+NW?;D8[FM+_@JH/\
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M4E",=D[GG8BK4PL4XT95&][6_5K\#U?P1X0T_P  >$](\.Z3$(=-TNUCM8%
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M_P"TS7O/[&__ ";-\/\ _L'#_P!"->"_\%5S_P 6B\+?]AC_ -IFO>?V-O\
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M^-OC+1M;_;L^#^BV$\4^HZ3YHO3&0?*+@E48COCG%=#XR'_&PWP5R>/#4_\
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MHH<GIY$12U,_P3\-M'\#_#S3?!5LLE_HMC:?8E6_(D:6/!R'X .<GM7A4W[
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%[J21_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>zbio-20241231xex10d19001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231xex10d19001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !+ .(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**3O0
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I/^$?TS'3[+%_Z **MPHL,21QJ$C10JJHP !T HKQ'5BWL>DHNVY__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>zbio-20241231xex19d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231xex19d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !5 .@# 2(  A$! Q$!_\0
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MI?B719)9=+U*+SK=YH6B<KDCE6Y'3O3L[<W05U>QT%(>E+2'H:0R/S%/>@2
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M 2 5/(R.3FOH+4-.MM2LY[6YA2YMID,<L,JAD=2,$,#P1CUK\L?!GAU/V?\
M_@HK:>']#)M],.L+;1P@G"VUU'N\L>H7?@9_NCTIP=''0G%04915U8F7/0DF
MW=-GZLO,J$9SS[5\=_M/_P#!0C1O@[K5UX8\(6$/B?Q/;G9<RSR%;.S?^XQ7
MEW_V1C'<U[+^U=\49OA#\"/$_B.T?9J,=O\ 9[1O2:0A$/X$Y_"ODO\ X)Q_
MLZ:7XHMKSXI>*;9=7N3=O#I:78WJ)!S+<$'JY8X!/3DUS8:E35.5>LKI:)=V
M;5)2<E3AN<SIW[2O[8?BZ$:OHWA6^DTQ_G06_A<>2PZ_+O\ G(]\UZE\#?\
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M!XUT;XB^$[:>-=8TF'2ULW@B=@I:)@,X!( )/&1D$5U6H@'_ (*4Z8#_ -"
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+HHH;;;;*^'1'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>zbio-20241231xex97d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 zbio-20241231xex97d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !5 .D# 2(  A$! Q$!_\0
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M#]MS_H=V_'7(/_C-=]/"1J14O:Q5_,YG6:=E%GZ*F0'^(4Y6'8YK\L?BY/\
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C=SZ?'-+<![UU>3=(Y9N0 ,9/'%=WM%%%#DY2<GN%N6R1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>26
<FILENAME>zbio-20241231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2025 9:11:27 PM-->
<!--Modified on: 3/10/2025 9:11:27 PM-->
<xsd:schema targetNamespace="http://zenasbio.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:zbio="http://zenasbio.com/20241231" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://zenasbio.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" id="StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>995200405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureOtherAssetsDetails" id="DisclosureOtherAssetsDetails">
        <link:definition>99940401 - Disclosure - Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>99940501 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails" id="DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails">
        <link:definition>99940603 - Disclosure - Leases - Maturities of Operating Lease Liabilities and Quantitative Disclosure (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetailsCalc2" id="DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetailsCalc2">
        <link:definition>40702 - Disclosure - Leases - Maturities of operating lease liabilities and quantitative disclosure (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureCommonStockReservedForIssuanceDetails" id="DisclosureCommonStockReservedForIssuanceDetails">
        <link:definition>99941002 - Disclosure - Common Stock - Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" id="DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails">
        <link:definition>99941301 - Disclosure - Income Taxes - Components of loss before the provision for (benefit from) income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails" id="DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails">
        <link:definition>99941302 - Disclosure - Income Taxes - Components of the income tax provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails">
        <link:definition>99941303 - Disclosure - Income Taxes - Reconciliation of the income tax expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>99941304 - Disclosure - Income Taxes - Components of the Company's deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureSegmentInformationDetailss" id="DisclosureSegmentInformationDetailss">
        <link:definition>41701 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical">
        <link:definition>995200205 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>995200300 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>995200305 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureNatureOfBusinessDetails" id="DisclosureNatureOfBusinessDetails">
        <link:definition>99940101 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>99940201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails" id="DisclosureFairValueMeasurementsValuationTechniquesDetails">
        <link:definition>99940301 - Disclosure - Fair Value Measurements - Valuation Techniques (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails" id="DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails">
        <link:definition>99940303 - Disclosure - Fair Value Measurements - Available-for-sale securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails" id="DisclosureFairValueMeasurementsConvertibleNotesDetails">
        <link:definition>99940304 - Disclosure - Fair Value Measurements - Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>99940601 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails" id="DisclosureLicenseAndCollaborationRevenueDetails">
        <link:definition>99940701 - Disclosure - License and Collaboration Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails" id="DisclosureLicenseAndOptionAgreementsDetails">
        <link:definition>99940801 - Disclosure - License and Option Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails" id="DisclosureConvertiblePreferredStockDetails">
        <link:definition>99940901 - Disclosure - Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails" id="DisclosureConvertiblePreferredStockScheduleDetails">
        <link:definition>99940902 - Disclosure - Convertible Preferred Stock - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails" id="DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails">
        <link:definition>99940903 - Disclosure - Convertible Preferred Stock - Rights and Privileges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationDetails" id="DisclosureStockBasedCompensationDetails">
        <link:definition>99941101 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails" id="DisclosureStockBasedCompensationRestrictedStockAwardsDetails">
        <link:definition>99941102 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails" id="DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails">
        <link:definition>99941103 - Disclosure - Stock-Based Compensation -Fair values of stock options granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails" id="DisclosureStockBasedCompensationStockOptionsDetails">
        <link:definition>99941104 - Disclosure - Stock-Based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>99941105 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails">
        <link:definition>99941202 - Disclosure - Net Loss Per Share - Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>99941305 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>99941601 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureSegmentInformationDetails" id="DisclosureSegmentInformationDetails">
        <link:definition>99941701 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99941801 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>995210101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995210201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995210301 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureOtherAssets" id="DisclosureOtherAssets">
        <link:definition>995210401 - Disclosure - Other Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>995210501 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995210601 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenue" id="DisclosureLicenseAndCollaborationRevenue">
        <link:definition>995210701 - Disclosure - License and Collaboration Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureLicenseAndOptionAgreements" id="DisclosureLicenseAndOptionAgreements">
        <link:definition>995210801 - Disclosure - License and Option Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStock" id="DisclosureConvertiblePreferredStock">
        <link:definition>995210901 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>995211001 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>995211101 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995211201 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995211301 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995211401 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureEmployeeBenefitPlans" id="DisclosureEmployeeBenefitPlans">
        <link:definition>995211501 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>995211601 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995211701 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211801 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>99930303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureOtherAssetsTables" id="DisclosureOtherAssetsTables">
        <link:definition>99930403 - Disclosure - Other Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>99930503 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>99930603 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStockTables" id="DisclosureConvertiblePreferredStockTables">
        <link:definition>99930903 - Disclosure - Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureCommonStockTables" id="DisclosureCommonStockTables">
        <link:definition>99931003 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>99931103 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>99931203 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>99931303 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>99931703 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsFairValueTransfersDetails" id="DisclosureFairValueMeasurementsFairValueTransfersDetails">
        <link:definition>99940302 - Disclosure - Fair Value Measurements - Fair Value Transfers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails" id="DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails">
        <link:definition>99940305 - Disclosure - Fair Value Measurement - Changes in Liabilities With Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeaseAssetsAndLiabilitiesDetails" id="DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeaseAssetsAndLiabilitiesDetails">
        <link:definition>99940602 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Operating Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureCommonStockDetails" id="DisclosureCommonStockDetails">
        <link:definition>99941001 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails" id="DisclosureNetLossPerShareBasicAndDilutedDetails">
        <link:definition>99941201 - Disclosure - Net Loss Per Share - Basic and diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureEmployeeBenefitPlansDetails" id="DisclosureEmployeeBenefitPlansDetails">
        <link:definition>99941501 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="zbio-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="zbio-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="zbio-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="zbio-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://zenasbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd" />
  <xsd:element name="SeriesSeedConvertiblePreferredStockMember" id="zbio_SeriesSeedConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FairValueAdjustmentOfConvertibleNotes" id="zbio_FairValueAdjustmentOfConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredOfferingCostsIncludedInAccruedExpenses" id="zbio_DeferredOfferingCostsIncludedInAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NonCashLeaseExpense" id="zbio_NonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborativeArrangementAbstract" id="zbio_CollaborativeArrangementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicenseAndOptionAgreementsAbstract" id="zbio_LicenseAndOptionAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicenseAndOptionAgreementsDisclosureTextBlock" id="zbio_LicenseAndOptionAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock" id="zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LicenseAgreementWithBristolMyersSquibbMember" id="zbio_LicenseAgreementWithBristolMyersSquibbMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborativeArrangementUpfrontPaymentReceived" id="zbio_CollaborativeArrangementUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum" id="zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborativeArrangementReceivables" id="zbio_CollaborativeArrangementReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="XencorAgreement2020Member" id="zbio_XencorAgreement2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="XencorAgreement2021Member" id="zbio_XencorAgreement2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DianthusOptionAgreementMember" id="zbio_DianthusOptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ViridianAgreementMember" id="zbio_ViridianAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicenseAndOptionAgreementsReimbursableExpenses" id="zbio_LicenseAndOptionAgreementsReimbursableExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfAntibodyProductCandidates" id="zbio_NumberOfAntibodyProductCandidates" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ThresholdPeriodToNotifyIntentionForExercisingOption" id="zbio_ThresholdPeriodToNotifyIntentionForExercisingOption" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LicenseAndOptionAgreementsDevelopmentMilestonePayable" id="zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" id="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodValueConversion" id="zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesConversion" id="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent" id="zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TwoThousandTwentyPlanMember" id="zbio_TwoThousandTwentyPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" id="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" id="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" id="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" id="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="XencorIncMember" id="zbio_XencorIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ViridianTherapeuticsIncMember" id="zbio_ViridianTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DianthusTherapeuticsincMember" id="zbio_DianthusTherapeuticsincMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FairmountFundsManagementLlcMember" id="zbio_FairmountFundsManagementLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained" id="zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RelatedPartyTransactionNumberOfLicenseAgreements" id="zbio_RelatedPartyTransactionNumberOfLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RelatedPartyTransactionReimbursableCosts" id="zbio_RelatedPartyTransactionReimbursableCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfSeatsHeldInBoard" id="zbio_NumberOfSeatsHeldInBoard" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FairValueAssetsLevel1ToLevel2TransferAmount" id="zbio_FairValueAssetsLevel1ToLevel2TransferAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FairValueAssetsLevel2ToLevel1TransferAmount" id="zbio_FairValueAssetsLevel2ToLevel1TransferAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FairValueLiabilitiesLevel1ToLevel2TransferAmount" id="zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BmsConvertiblePromissoryNotesMember" id="zbio_BmsConvertiblePromissoryNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes" id="zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" id="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock" id="zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonStockNumberOfVotesPerShare" id="zbio_CommonStockNumberOfVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="RemainingCommonStockCapitalSharesReservedForFutureIssuance" id="zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TemporaryEquityDisclosureTextBlock" id="zbio_TemporaryEquityDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ConvertiblePromissoryNotes2021Member" id="zbio_ConvertiblePromissoryNotes2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TemporaryEquitySharesIssuedPricePerShare" id="zbio_TemporaryEquitySharesIssuedPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" id="zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LicenseAndOptionAgreementDevelopmentMilestonePayment" id="zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment" id="zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses" id="zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion" id="zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TemporaryEquityNumberOfVotesPerShare" id="zbio_TemporaryEquityNumberOfVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TemporaryEquityCommonStockIssuableUponConversion" id="zbio_TemporaryEquityCommonStockIssuableUponConversion" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EquityIncentivePlan2024Member" id="zbio_EquityIncentivePlan2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EmployeeStockPurchasePlan2024Member" id="zbio_EmployeeStockPurchasePlan2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" id="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized" id="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NovationAgreementMember" id="zbio_NovationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone" id="zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock" id="zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract" id="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OwnershipPercentageByRelatedParty" id="zbio_OwnershipPercentageByRelatedParty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DeferredTaxAssetsMilestonePayments" id="zbio_DeferredTaxAssetsMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxLiabilitiesAmortizationAndOther" id="zbio_DeferredTaxLiabilitiesAmortizationAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PercentageOfAnnualDeductionEqualToTaxableIncomeFederal" id="zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TaxCreditCarryforwardExpirationPeriod" id="zbio_TaxCreditCarryforwardExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="UncertainTaxPositionsAmountRecognized" id="zbio_UncertainTaxPositionsAmountRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Rule10b51ArrangementModifiedFlag" id="zbio_Rule10b51ArrangementModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NonRule10b51ArrangementModifiedFlag" id="zbio_NonRule10b51ArrangementModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OperatingLossCarryforwardsExpirationPeriod" id="zbio_OperatingLossCarryforwardsExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsNetBeforeValuationAllowance" id="zbio_DeferredTaxAssetsNetBeforeValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BasisOfPresentationAndConsolidationPolicyTextBlock" id="zbio_BasisOfPresentationAndConsolidationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SignificantSuppliersPolicyTextBlock" id="zbio_SignificantSuppliersPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LicenseAndCollaborationRevenuePolicyTextBlock" id="zbio_LicenseAndCollaborationRevenuePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock" id="zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TemporaryEquityPolicyTextBlock" id="zbio_TemporaryEquityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InvestmentFairValueDisclosureAbstract" id="zbio_InvestmentFairValueDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ZaiLicenseAgreementMember" id="zbio_ZaiLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SingleReportableSegmentMember" id="zbio_SingleReportableSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ObexelimabMember" id="zbio_ObexelimabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnallocatedMember" id="zbio_UnallocatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RightOfUseAssetObtainedUnderNewLeaseArrangement" id="zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum" id="zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborativeArrangementTransactionPrice" id="zbio_CollaborativeArrangementTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable" id="zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAndOptionAgreementsRegulatoryMilestonePayable" id="zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAndOptionAgreementsSalesMilestonePayable" id="zbio_LicenseAndOptionAgreementsSalesMilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAndOptionAgreementsMaximumMilestoneObligation" id="zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherProgramsZb002Zb004Member" id="zbio_OtherProgramsZb002Zb004Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PartneredRegionalProgramsZb001Zb005Member" id="zbio_PartneredRegionalProgramsZb001Zb005Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>27
<FILENAME>zbio-20241231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2025 9:11:27 PM-->
<!--Modified on: 3/10/2025 9:11:27 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://zenasbio.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureOtherAssetsDetails" roleURI="http://zenasbio.com/role/DisclosureOtherAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://zenasbio.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails" roleURI="http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetailsCalc2" roleURI="http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureCommonStockReservedForIssuanceDetails" roleURI="http://zenasbio.com/role/DisclosureCommonStockReservedForIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails" roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails" roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureSegmentInformationDetailss" roleURI="http://zenasbio.com/role/DisclosureSegmentInformationDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://zenasbio.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638772378847210533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638772378847210533" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638772378847210533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638772378847210533" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638772378847210533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638772378847210533" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638772378847210533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638772378847210533" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638772378847210533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638772378847210533" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638772378847210533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638772378847210533" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638772378847210533" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638772378847210533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638772378847210533" xlink:to="us-gaap_ShortTermInvestments_638772378847210533" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638772378847220533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638772378847210533" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638772378847220533" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638772378847220533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638772378847210533" xlink:to="us-gaap_RestrictedCashCurrent_638772378847220533" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638772378847220533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638772378847220533" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638772378847220533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638772378847220533" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638772378847220533" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638772378847220533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638772378847220533" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638772378847220533" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638772378847220533" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638772378847220533" xlink:to="us-gaap_AdditionalPaidInCapital_638772378847220533" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638772378847230528" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638772378847220533" xlink:to="us-gaap_CommonStockValue_638772378847230528" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638772378847230528" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638772378847220533" xlink:to="us-gaap_PreferredStockValue_638772378847230528" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638772378847230528" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638772378847230528" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_638772378847230528" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638772378847230528" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_638772378847230528" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638772378847230528" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638772378847230528" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638772378847230528" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638772378847240519" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638772378847230528" xlink:to="us-gaap_LiabilitiesCurrent_638772378847240519" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638772378847240519" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638772378847240519" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638772378847240519" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638772378847240519" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638772378847240519" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638772378847240519" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638772378847240519" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638772378847240519" xlink:to="us-gaap_AccountsPayableCurrent_638772378847240519" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638772378847240519" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638772378847240519" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638772378847250535" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638772378847250535" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638772378847470545" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638772378847470545" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638772378847470545" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638772378847470545" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638772378847470545" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638772378847470545" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638772378847470545" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638772378847470545" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638772378847470545" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638772378847480542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638772378847470545" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638772378847480542" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638772378847480542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638772378847480542" xlink:to="us-gaap_OperatingIncomeLoss_638772378847480542" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638772378847480542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638772378847480542" xlink:to="us-gaap_OperatingExpenses_638772378847480542" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638772378847480542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638772378847480542" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638772378847480542" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638772378847480542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638772378847480542" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638772378847480542" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_638772378847480542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638772378847480542" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_638772378847480542" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638772378847480542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638772378847480542" xlink:to="us-gaap_Revenues_638772378847480542" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638772378847490542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Revenues_638772378847480542" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638772378847490542" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638772378847490542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638772378847480542" xlink:to="us-gaap_NonoperatingIncomeExpense_638772378847490542" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueAdjustmentOfConvertibleNotes" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes_638772378847490542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638772378847490542" xlink:to="zbio_FairValueAdjustmentOfConvertibleNotes_638772378847490542" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638772378847490542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638772378847490542" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638772378847490542" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638772378847500542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638772378847500542" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638772378847500542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638772378847500542" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638772378847500542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638772378847500542" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638772378847500542" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638772378847500542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638772378847500542" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638772378847500542" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638772378847500542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638772378847500542" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638772378847500542" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638772378847500542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638772378847500542" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638772378847500542" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638772378847500542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638772378847500542" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638772378847500542" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638772378847510541" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638772378847510541" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638772378847510541" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638772378847510541" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638772378847510541" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments_638772378847510541" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638772378847510541" xlink:to="us-gaap_PaymentsToAcquireInvestments_638772378847510541" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_638772378847510541" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638772378847510541" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_638772378847510541" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638772378847510541" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638772378847510541" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638772378847520543" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638772378847520543" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638772378847520543" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638772378847520543" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638772378847520543" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638772378847520543" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NonCashLeaseExpense" xlink:label="zbio_NonCashLeaseExpense_638772378847520543" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" xlink:to="zbio_NonCashLeaseExpense_638772378847520543" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueAdjustmentOfConvertibleNotes" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes_638772378847520543" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" xlink:to="zbio_FairValueAdjustmentOfConvertibleNotes_638772378847520543" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638772378847530583" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" xlink:to="us-gaap_ShareBasedCompensation_638772378847530583" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638772378847530583" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" xlink:to="us-gaap_Depreciation_638772378847530583" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_638772378847530583" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_638772378847530583" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638772378847530583" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" xlink:to="us-gaap_NetIncomeLoss_638772378847530583" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638772378847530583" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378847510541" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638772378847530583" order="11" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="995200405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638772378847540559" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638772378847540559" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638772378847540559" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashCurrent_638772378847540559" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638772378847540559" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent_638772378847540559" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/DisclosureOtherAssetsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Other Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_638772378847550559" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent_1" xlink:to="us-gaap_PrepaidExpenseNoncurrent_638772378847550559" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts_638772378847550559" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent_1" xlink:to="us-gaap_DeferredCosts_638772378847550559" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_638772378847550559" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent_1" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent_638772378847550559" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638772378847550559" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638772378847550559" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638772378847550559" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638772378847550559" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638772378847560562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638772378847560562" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent" xlink:label="zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent_638772378847560562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent_638772378847560562" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638772378847560562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638772378847560562" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails" xlink:type="extended" xlink:title="99940603 - Disclosure - Leases - Maturities of Operating Lease Liabilities and Quantitative Disclosure (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638772378847560562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638772378847560562" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638772378847560562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638772378847560562" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetailsCalc2" xlink:type="extended" xlink:title="40702 - Disclosure - Leases - Maturities of operating lease liabilities and quantitative disclosure (Details) (Calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638772378847570563" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638772378847570563" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638772378847570563" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_OperatingLeaseLiability_638772378847570563" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/DisclosureCommonStockReservedForIssuanceDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Common Stock - Reserved for Issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638772378847570563" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638772378847570563" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance_638772378847570563" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xlink:to="zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance_638772378847570563" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock" xlink:label="zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock_638772378847580560" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xlink:to="zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock_638772378847580560" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Income Taxes - Components of loss before the provision for (benefit from) income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638772378847580560" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638772378847580560" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638772378847580560" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638772378847580560" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails" xlink:type="extended" xlink:title="99941302 - Disclosure - Income Taxes - Components of the income tax provision (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638772378847580560" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638772378847580560" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638772378847590562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638772378847580560" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638772378847590562" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638772378847590562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638772378847580560" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638772378847590562" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="99941303 - Disclosure - Income Taxes - Reconciliation of the income tax expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638772378847590562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638772378847590562" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638772378847590562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638772378847590562" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638772378847590562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638772378847590562" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_638772378847590562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_638772378847590562" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638772378847600563" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638772378847600563" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638772378847600563" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638772378847600563" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638772378847600563" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638772378847600563" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99941304 - Disclosure - Income Taxes - Components of the Company's deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638772378847600563" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638772378847600563" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:label="zbio_DeferredTaxAssetsNetBeforeValuationAllowance_638772378847600563" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="zbio_DeferredTaxAssetsNetBeforeValuationAllowance_638772378847600563" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638772378847610550" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="zbio_DeferredTaxAssetsNetBeforeValuationAllowance_638772378847600563" xlink:to="us-gaap_DeferredTaxAssetsGross_638772378847610550" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638772378847610550" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638772378847610550" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638772378847610550" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638772378847610550" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638772378847610550" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638772378847610550" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638772378847610550" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638772378847610550" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638772378847610550" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638772378847610550" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638772378847610550" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638772378847610550" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DeferredTaxAssetsMilestonePayments" xlink:label="zbio_DeferredTaxAssetsMilestonePayments_638772378847610550" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638772378847610550" xlink:to="zbio_DeferredTaxAssetsMilestonePayments_638772378847610550" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638772378847620590" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638772378847610550" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638772378847620590" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638772378847620590" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638772378847610550" xlink:to="us-gaap_DeferredTaxAssetsOther_638772378847620590" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638772378847620590" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="zbio_DeferredTaxAssetsNetBeforeValuationAllowance_638772378847600563" xlink:to="us-gaap_DeferredTaxLiabilities_638772378847620590" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DeferredTaxLiabilitiesAmortizationAndOther" xlink:label="zbio_DeferredTaxLiabilitiesAmortizationAndOther_638772378847620590" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities_638772378847620590" xlink:to="zbio_DeferredTaxLiabilitiesAmortizationAndOther_638772378847620590" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://zenasbio.com/role/DisclosureSegmentInformationDetailss" xlink:type="extended" xlink:title="41701 - Disclosure - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638772378847620590" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="us-gaap_Revenues_638772378847620590" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638772378847630569" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638772378847630569" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638772378847630569" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638772378847630569" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638772378847630569" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638772378847630569" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638772378847630569" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638772378847630569" order="5" use="optional" weight="-1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>28
<FILENAME>zbio-20241231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2025 9:11:27 PM-->
<!--Modified on: 3/10/2025 9:11:27 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://zenasbio.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureNatureOfBusinessDetails" roleURI="http://zenasbio.com/role/DisclosureNatureOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureFairValueMeasurementsValuationTechniquesDetails" roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails" roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureFairValueMeasurementsConvertibleNotesDetails" roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLicenseAndCollaborationRevenueDetails" roleURI="http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLicenseAndOptionAgreementsDetails" roleURI="http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureConvertiblePreferredStockDetails" roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureConvertiblePreferredStockScheduleDetails" roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails" roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureStockBasedCompensationRestrictedStockAwardsDetails" roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails" roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" roleURI="http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureSegmentInformationDetails" roleURI="http://zenasbio.com/role/DisclosureSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://zenasbio.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple" />
  <link:roleRef roleURI="http://zenasbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="zbio-20241231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://zenasbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1" xlink:title="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1" xlink:title="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1 To us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:title="us-gaap_FairValueByMeasurementBasisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementBasisAxis_1 To us-gaap_PortionAtFairValueFairValueDisclosureMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_1" xlink:title="us-gaap_FairValueByAssetClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByAssetClassAxis_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByAssetClassAxis_1 To us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueAdjustmentOfConvertibleNotes" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes" xlink:title="zbio_FairValueAdjustmentOfConvertibleNotes" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="zbio_FairValueAdjustmentOfConvertibleNotes" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To zbio_FairValueAdjustmentOfConvertibleNotes" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_1" xlink:title="us-gaap_ResearchAndDevelopmentExpense_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_ResearchAndDevelopmentExpense_1" order="2" priority="0" />
  </link:definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="extended" xlink:title="995200205 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="995200305 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureNatureOfBusinessDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Nature of Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorAgreement2021Member" xlink:label="zbio_XencorAgreement2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="zbio_XencorAgreement2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Fair Value Measurements - Valuation Techniques (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_InvestmentFairValueDisclosureAbstract" xlink:label="zbio_InvestmentFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="zbio_InvestmentFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="zbio_InvestmentFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails" xlink:type="extended" xlink:title="99940303 - Disclosure - Fair Value Measurements - Available-for-sale securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails" xlink:type="extended" xlink:title="99940304 - Disclosure - Fair Value Measurements - Convertible Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_BmsConvertiblePromissoryNotesMember" xlink:label="zbio_BmsConvertiblePromissoryNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="zbio_BmsConvertiblePromissoryNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes" xlink:label="zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueAdjustmentOfConvertibleNotes" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="zbio_FairValueAdjustmentOfConvertibleNotes" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - License and Collaboration Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAgreementWithBristolMyersSquibbMember" xlink:label="zbio_LicenseAgreementWithBristolMyersSquibbMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="zbio_LicenseAgreementWithBristolMyersSquibbMember" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NovationAgreementMember" xlink:label="zbio_NovationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="zbio_NovationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementUpfrontPaymentReceived" xlink:label="zbio_CollaborativeArrangementUpfrontPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_CollaborativeArrangementUpfrontPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum" xlink:label="zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementReceivables" xlink:label="zbio_CollaborativeArrangementReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_CollaborativeArrangementReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum" xlink:label="zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementTransactionPrice" xlink:label="zbio_CollaborativeArrangementTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_CollaborativeArrangementTransactionPrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - License and Option Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorAgreement2020Member" xlink:label="zbio_XencorAgreement2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="zbio_XencorAgreement2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorAgreement2021Member" xlink:label="zbio_XencorAgreement2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="zbio_XencorAgreement2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DianthusOptionAgreementMember" xlink:label="zbio_DianthusOptionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="zbio_DianthusOptionAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ViridianAgreementMember" xlink:label="zbio_ViridianAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="zbio_ViridianAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsReimbursableExpenses" xlink:label="zbio_LicenseAndOptionAgreementsReimbursableExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_LicenseAndOptionAgreementsReimbursableExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NumberOfAntibodyProductCandidates" xlink:label="zbio_NumberOfAntibodyProductCandidates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_NumberOfAntibodyProductCandidates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ThresholdPeriodToNotifyIntentionForExercisingOption" xlink:label="zbio_ThresholdPeriodToNotifyIntentionForExercisingOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_ThresholdPeriodToNotifyIntentionForExercisingOption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable" xlink:label="zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementTransactionPrice" xlink:label="zbio_CollaborativeArrangementTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_CollaborativeArrangementTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable" xlink:label="zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable" xlink:label="zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsSalesMilestonePayable" xlink:label="zbio_LicenseAndOptionAgreementsSalesMilestonePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_LicenseAndOptionAgreementsSalesMilestonePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation" xlink:label="zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorAgreement2020Member" xlink:label="zbio_XencorAgreement2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="zbio_XencorAgreement2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorAgreement2021Member" xlink:label="zbio_XencorAgreement2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="zbio_XencorAgreement2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_BmsConvertiblePromissoryNotesMember" xlink:label="zbio_BmsConvertiblePromissoryNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="zbio_BmsConvertiblePromissoryNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ConvertiblePromissoryNotes2021Member" xlink:label="zbio_ConvertiblePromissoryNotes2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="zbio_ConvertiblePromissoryNotes2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquitySharesIssuedPricePerShare" xlink:label="zbio_TemporaryEquitySharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="zbio_TemporaryEquitySharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment" xlink:label="zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment" xlink:label="zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses" xlink:label="zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion" xlink:label="zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Convertible Preferred Stock - Schedule (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityCommonStockIssuableUponConversion" xlink:label="zbio_TemporaryEquityCommonStockIssuableUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="zbio_TemporaryEquityCommonStockIssuableUponConversion" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Convertible Preferred Stock - Rights and Privileges (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityNumberOfVotesPerShare" xlink:label="zbio_TemporaryEquityNumberOfVotesPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="zbio_TemporaryEquityNumberOfVotesPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DividendsPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Stock-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TwoThousandTwentyPlanMember" xlink:label="zbio_TwoThousandTwentyPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="zbio_TwoThousandTwentyPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_EquityIncentivePlan2024Member" xlink:label="zbio_EquityIncentivePlan2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="zbio_EquityIncentivePlan2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_EmployeeStockPurchasePlan2024Member" xlink:label="zbio_EmployeeStockPurchasePlan2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="zbio_EmployeeStockPurchasePlan2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - Stock-Based Compensation -Fair values of stock options granted (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="99941104 - Disclosure - Stock-Based Compensation - Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99941105 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Net Loss Per Share - Anti-dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="99941305 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal" xlink:label="zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_OperatingLossCarryforwardsExpirationPeriod" xlink:label="zbio_OperatingLossCarryforwardsExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="zbio_OperatingLossCarryforwardsExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TaxCreditCarryforwardExpirationPeriod" xlink:label="zbio_TaxCreditCarryforwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="zbio_TaxCreditCarryforwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_UncertainTaxPositionsAmountRecognized" xlink:label="zbio_UncertainTaxPositionsAmountRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="zbio_UncertainTaxPositionsAmountRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - Related Party Transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorIncMember" xlink:label="zbio_XencorIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="zbio_XencorIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ViridianTherapeuticsIncMember" xlink:label="zbio_ViridianTherapeuticsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="zbio_ViridianTherapeuticsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DianthusTherapeuticsincMember" xlink:label="zbio_DianthusTherapeuticsincMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="zbio_DianthusTherapeuticsincMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairmountFundsManagementLlcMember" xlink:label="zbio_FairmountFundsManagementLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="zbio_FairmountFundsManagementLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained" xlink:label="zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RelatedPartyTransactionNumberOfLicenseAgreements" xlink:label="zbio_RelatedPartyTransactionNumberOfLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="zbio_RelatedPartyTransactionNumberOfLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee" xlink:label="us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RelatedPartyTransactionReimbursableCosts" xlink:label="zbio_RelatedPartyTransactionReimbursableCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="zbio_RelatedPartyTransactionReimbursableCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_OwnershipPercentageByRelatedParty" xlink:label="zbio_OwnershipPercentageByRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="zbio_OwnershipPercentageByRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NumberOfSeatsHeldInBoard" xlink:label="zbio_NumberOfSeatsHeldInBoard" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="zbio_NumberOfSeatsHeldInBoard" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureSegmentInformationDetails" xlink:type="extended" xlink:title="99941701 - Disclosure - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SingleReportableSegmentMember" xlink:label="zbio_SingleReportableSegmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="zbio_SingleReportableSegmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ObexelimabMember" xlink:label="zbio_ObexelimabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="zbio_ObexelimabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_OtherProgramsZb002Zb004Member" xlink:label="zbio_OtherProgramsZb002Zb004Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="zbio_OtherProgramsZb002Zb004Member" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_PartneredRegionalProgramsZb001Zb005Member" xlink:label="zbio_PartneredRegionalProgramsZb001Zb005Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="zbio_PartneredRegionalProgramsZb001Zb005Member" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_UnallocatedMember" xlink:label="zbio_UnallocatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="zbio_UnallocatedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://zenasbio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941801 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ZaiLicenseAgreementMember" xlink:label="zbio_ZaiLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="zbio_ZaiLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementUpfrontPaymentReceived" xlink:label="zbio_CollaborativeArrangementUpfrontPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="zbio_CollaborativeArrangementUpfrontPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone" xlink:label="zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>29
<FILENAME>zbio-20241231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2025 9:11:27 PM-->
<!--Modified on: 3/10/2025 9:11:27 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_SeriesSeedConvertiblePreferredStockMember" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series seed convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Seed Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Seed convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable (includes $560 and $21 owed to related parties, respectively)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses (includes $260 and $404 owed to related parties, respectively)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes, at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 14)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity (deficit):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value $0.0001 per share; 25,000,000 and no shares authorized as of December 31, 2024 and 2023, respectively; no shares issued and outstanding as of December 31, 2024 and 2023.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value $0.0001 per share; 175,000,000 shares authorized as of December 31, 2024 and 2023; 41,793,412 and 1,576,854 shares issued and outstanding as of December 31, 2024 and 2023, respectively.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and collaboration revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development (includes $3,524 and $3,041 from related parties, respectively)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative (includes $0 and $8 from related parties, respectively)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Capitalized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired in-process research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired IPR&amp;D expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income, net:</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueAdjustmentOfConvertibleNotes" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_FairValueAdjustmentOfConvertibleNotes" xlink:to="zbio_FairValueAdjustmentOfConvertibleNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair value of convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustments to convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of BMS Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total income tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders - basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders - diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common stock outstanding - basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common stock outstanding - diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain on marketable securities, net tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain on investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of convertible preferred stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of preferred stock issued</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of conversion of securities from temporary equity to permanent equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Value, Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock to common stock upon closing of initial public offering</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares converted from temporary equity to permanent equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchased During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase of unvested restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercises of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercises of common stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock to common stock upon closing of initial public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net amortization of premiums and accretion of discounts on short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NonCashLeaseExpense" xlink:label="zbio_NonCashLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_NonCashLeaseExpense" xlink:to="zbio_NonCashLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_NonCashLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of non-cash lease expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_NonCashLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash lease expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_NonCashLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale, Maturity and Collection of Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale and maturities of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Series C convertible preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from initial public offering, net of underwriting discount and commissions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of initial public offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of non-cash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAssumed1" xlink:label="us-gaap_NotesAssumed1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAssumed1" xlink:to="us-gaap_NotesAssumed1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAssumed1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAssumed1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of BMS Note recognized as Series C Convertible preferred stock upon conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock to common stock upon closing of initial public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets obtained under operating lease arrangements</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:label="zbio_DeferredOfferingCostsIncludedInAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:to="zbio_DeferredOfferingCostsIncludedInAccruedExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_DeferredOfferingCostsIncludedInAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of deferred offering costs included in accrued expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_DeferredOfferingCostsIncludedInAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs Included In Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_DeferredOfferingCostsIncludedInAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs in accrued expenses</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract" xlink:label="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract" xlink:to="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation Of Cash Cash Equivalents And Restricted Cash And Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of cash, cash equivalents and restricted cash:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementAbstract" xlink:label="zbio_CollaborativeArrangementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_CollaborativeArrangementAbstract" xlink:to="zbio_CollaborativeArrangementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_CollaborativeArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/a.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_CollaborativeArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Revenue</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsAbstract" xlink:label="zbio_LicenseAndOptionAgreementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_LicenseAndOptionAgreementsAbstract" xlink:to="zbio_LicenseAndOptionAgreementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_LicenseAndOptionAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_LicenseAndOptionAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Option Agreements</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsDisclosureTextBlock" xlink:label="zbio_LicenseAndOptionAgreementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_LicenseAndOptionAgreementsDisclosureTextBlock" xlink:to="zbio_LicenseAndOptionAgreementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_LicenseAndOptionAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for license and option agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_LicenseAndOptionAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Option Agreements, Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_LicenseAndOptionAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Option Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityDisclosureTextBlock" xlink:label="zbio_TemporaryEquityDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TemporaryEquityDisclosureTextBlock" xlink:to="zbio_TemporaryEquityDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of terms, amounts, nature of changes, rights and privileges, conversions and other matters related to temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Benefits [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:label="zbio_BasisOfPresentationAndConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:to="zbio_BasisOfPresentationAndConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_BasisOfPresentationAndConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for basis of presentation and consolidation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_BasisOfPresentationAndConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Presentation And Consolidation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_BasisOfPresentationAndConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SignificantSuppliersPolicyTextBlock" xlink:label="zbio_SignificantSuppliersPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_SignificantSuppliersPolicyTextBlock" xlink:to="zbio_SignificantSuppliersPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_SignificantSuppliersPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for significant suppliers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_SignificantSuppliersPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Suppliers [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_SignificantSuppliersPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Suppliers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Translation of Foreign Currency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndCollaborationRevenuePolicyTextBlock" xlink:label="zbio_LicenseAndCollaborationRevenuePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_LicenseAndCollaborationRevenuePolicyTextBlock" xlink:to="zbio_LicenseAndCollaborationRevenuePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_LicenseAndCollaborationRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for license and collaboration revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_LicenseAndCollaborationRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Revenue [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_LicenseAndCollaborationRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock" xlink:label="zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock" xlink:to="zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for asset acquisitions and acquired in-process research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisitions And Acquired In Process Research And Development Expense [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisitions and Acquired In-Process Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityPolicyTextBlock" xlink:label="zbio_TemporaryEquityPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TemporaryEquityPolicyTextBlock" xlink:to="zbio_TemporaryEquityPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TemporaryEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TemporaryEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_TemporaryEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information about the Company's assets and liabilities that are regularly measured and carried at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in the company's liabilities with significant unobservable inputs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Other Assets, Noncurrent [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of balance sheet information related to operating lease assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock" xlink:label="zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock" xlink:to="zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of undiscounted cash flows of lessee's operating lease liability, Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position and quantitative information pursuant to operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Maturity And Quantitative Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of minimum lease payments under the Company's operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock" xlink:label="zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock" xlink:to="zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of common stock reserved for potential conversion of securities and shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Common Stock Reserved For Potential Conversion Of Securities And Future Issuance [Tables Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of common stock reserved for potential conversion and future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of RSA activity and related information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair values of stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity and related information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense as reflected in condensed consolidated statements of operations and comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of anti-dilutive securities excluded from the computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of loss before the provision for (benefit from) income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of the income tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of the income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of the Company's deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial data for reportable segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriter's option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of initial consideration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock into common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorAgreement2021Member" xlink:label="zbio_XencorAgreement2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_XencorAgreement2021Member" xlink:to="zbio_XencorAgreement2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_XencorAgreement2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2021 Xencor Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_XencorAgreement2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Xencor Agreement 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_XencorAgreement2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Xencor Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss), Foreign Currency Transaction, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized and unrealized foreign currency transaction losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Paper [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial paper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Government Corporations and Agencies Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion at Fair Value Measurement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reported Value Measurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate of Fair Value Measurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate of fair value measurement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_InvestmentFairValueDisclosureAbstract" xlink:label="zbio_InvestmentFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_InvestmentFairValueDisclosureAbstract" xlink:to="zbio_InvestmentFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_InvestmentFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_InvestmentFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt, Fair Value Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BMS note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueAssetsLevel1ToLevel2TransferAmount" xlink:label="zbio_FairValueAssetsLevel1ToLevel2TransferAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_FairValueAssetsLevel1ToLevel2TransferAmount" xlink:to="zbio_FairValueAssetsLevel1ToLevel2TransferAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_FairValueAssetsLevel1ToLevel2TransferAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_FairValueAssetsLevel1ToLevel2TransferAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 1 to Level 2 Transfer, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_FairValueAssetsLevel1ToLevel2TransferAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets - Transfer from level 1 to 2</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueAssetsLevel2ToLevel1TransferAmount" xlink:label="zbio_FairValueAssetsLevel2ToLevel1TransferAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_FairValueAssetsLevel2ToLevel1TransferAmount" xlink:to="zbio_FairValueAssetsLevel2ToLevel1TransferAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_FairValueAssetsLevel2ToLevel1TransferAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_FairValueAssetsLevel2ToLevel1TransferAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 2 to Level 1 Transfer, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_FairValueAssetsLevel2ToLevel1TransferAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets - Transfer from level 2 to 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets - Transfer into level 3</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount" xlink:label="zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount" xlink:to="zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities, Level 1 to Level 2 Transfer, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities - Transfer from level 1 to 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities - Transfer into level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Realized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized gain (loss) recognized on the sale or maturity of available-for-sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_BmsConvertiblePromissoryNotesMember" xlink:label="zbio_BmsConvertiblePromissoryNotesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_BmsConvertiblePromissoryNotesMember" xlink:to="zbio_BmsConvertiblePromissoryNotesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_BmsConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the BMS convertible promissory notes payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_BmsConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BMS Convertible Promissory Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_BmsConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BMS Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="zbio_BmsConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BMS Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face value of notes</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes" xlink:label="zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes" xlink:to="zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum cash inflow required from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock for automatic conversion of the convertible promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Proceeds from Issuance of Convertible Preferred Stock For Automatic Conversion Of Convertible Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum proceeds from issuance of convertible preferred stock for automatic conversion of convertible promissory notes</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of convertible preferred stock classified as temporary equity issued upon conversion of convertible notes during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued upon conversion of convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued on conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on extinguishment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in company's liabilities with significant unobservable inputs (Level 3 liabilities)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of BMS Note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of BMS Note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series C Preferred Stock in exchange for BMS Note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical trial deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Miscellaneous, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent" xlink:label="zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent" xlink:to="zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for external research, development and manufacturing expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued External Research, Development And Manufacturing Expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">External research, development and manufacturing expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional and consultant fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Income Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable lease expense</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement" xlink:label="zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement" xlink:to="zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in right-of-use asset obtained under new operating lease arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained under New Lease Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets obtained under new operating lease arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease cost for operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining term in years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate used to measure lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of the operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAgreementWithBristolMyersSquibbMember" xlink:label="zbio_LicenseAgreementWithBristolMyersSquibbMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_LicenseAgreementWithBristolMyersSquibbMember" xlink:to="zbio_LicenseAgreementWithBristolMyersSquibbMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_LicenseAgreementWithBristolMyersSquibbMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to license agreement with Bristol-Myers Squibb.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_LicenseAgreementWithBristolMyersSquibbMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement With Bristol Myers Squibb [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_LicenseAgreementWithBristolMyersSquibbMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BMS Agreement</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NovationAgreementMember" xlink:label="zbio_NovationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_NovationAgreementMember" xlink:to="zbio_NovationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_NovationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Novation Agreement with Tenacia.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_NovationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novation Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_NovationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novation Agreement</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementUpfrontPaymentReceived" xlink:label="zbio_CollaborativeArrangementUpfrontPaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_CollaborativeArrangementUpfrontPaymentReceived" xlink:to="zbio_CollaborativeArrangementUpfrontPaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_CollaborativeArrangementUpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash inflow from upfront payment received pursuant to the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_CollaborativeArrangementUpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Upfront Payment, Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_CollaborativeArrangementUpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront cash payment received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="zbio_CollaborativeArrangementUpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-refundable upfront fee</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum" xlink:label="zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum" xlink:to="zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of receivable from development, regulatory, and sales milestone payments if certain milestones are successfully achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Development, Regulatory and Sales Milestone Payments, Receivable, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of payments receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of reduction to research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementReceivables" xlink:label="zbio_CollaborativeArrangementReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_CollaborativeArrangementReceivables" xlink:to="zbio_CollaborativeArrangementReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_CollaborativeArrangementReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of receivable in the collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_CollaborativeArrangementReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_CollaborativeArrangementReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount receivable</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum" xlink:label="zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum" xlink:to="zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of receivable from sales milestone payments if certain milestones are successfully achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Sales Milestone Payments, Receivable, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestone payments receivable</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementTransactionPrice" xlink:label="zbio_CollaborativeArrangementTransactionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_CollaborativeArrangementTransactionPrice" xlink:to="zbio_CollaborativeArrangementTransactionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_CollaborativeArrangementTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of transaction price receivable under the collaborative agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_CollaborativeArrangementTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Transaction Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_CollaborativeArrangementTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement transaction price</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorAgreement2020Member" xlink:label="zbio_XencorAgreement2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_XencorAgreement2020Member" xlink:to="zbio_XencorAgreement2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_XencorAgreement2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2020 Xencor Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_XencorAgreement2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Xencor Agreement 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_XencorAgreement2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Xencor Agreement</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DianthusOptionAgreementMember" xlink:label="zbio_DianthusOptionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_DianthusOptionAgreementMember" xlink:to="zbio_DianthusOptionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_DianthusOptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Dianthus Option Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_DianthusOptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dianthus Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_DianthusOptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dianthus Option Agreement</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ViridianAgreementMember" xlink:label="zbio_ViridianAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ViridianAgreementMember" xlink:to="zbio_ViridianAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ViridianAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Viridian Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ViridianAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viridian Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ViridianAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viridian Agreement</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsReimbursableExpenses" xlink:label="zbio_LicenseAndOptionAgreementsReimbursableExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_LicenseAndOptionAgreementsReimbursableExpenses" xlink:to="zbio_LicenseAndOptionAgreementsReimbursableExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_LicenseAndOptionAgreementsReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of reimbursable expenses incurred pursuant to the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_LicenseAndOptionAgreementsReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Option Agreements, Reimbursable Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_LicenseAndOptionAgreementsReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursable costs</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NumberOfAntibodyProductCandidates" xlink:label="zbio_NumberOfAntibodyProductCandidates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_NumberOfAntibodyProductCandidates" xlink:to="zbio_NumberOfAntibodyProductCandidates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_NumberOfAntibodyProductCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denotes number of antibody product candidates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_NumberOfAntibodyProductCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Antibody Product Candidates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_NumberOfAntibodyProductCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of antibody product candidates</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ThresholdPeriodToNotifyIntentionForExercisingOption" xlink:label="zbio_ThresholdPeriodToNotifyIntentionForExercisingOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ThresholdPeriodToNotifyIntentionForExercisingOption" xlink:to="zbio_ThresholdPeriodToNotifyIntentionForExercisingOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ThresholdPeriodToNotifyIntentionForExercisingOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denotes threshold period to notify intention for exercising option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ThresholdPeriodToNotifyIntentionForExercisingOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Period To Notify Intention For Exercising Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ThresholdPeriodToNotifyIntentionForExercisingOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period to notify intention for exercising option</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable" xlink:label="zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable" xlink:to="zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of development milestone payable in connection with the agreement during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Option Agreements, Development Milestone Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestone expense payable</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable" xlink:label="zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable" xlink:to="zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of development, regulatory and commercial milestone payable in connection with the agreement during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Option Agreements, Development, Regulatory and Commercial Milestone Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable" xlink:label="zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable" xlink:to="zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of regulatory milestone payable in connection with the agreement during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Option Agreements, Regulatory Milestone Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory milestone payments</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsSalesMilestonePayable" xlink:label="zbio_LicenseAndOptionAgreementsSalesMilestonePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_LicenseAndOptionAgreementsSalesMilestonePayable" xlink:to="zbio_LicenseAndOptionAgreementsSalesMilestonePayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_LicenseAndOptionAgreementsSalesMilestonePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of sales milestone payable in connection with the agreement during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_LicenseAndOptionAgreementsSalesMilestonePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Option Agreements, Sales Milestone Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_LicenseAndOptionAgreementsSalesMilestonePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestone payments</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation" xlink:label="zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation" xlink:to="zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of total milestone obligations for each research program based on achievement of each of the specified milestone events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Option Agreements, Maximum Milestone Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ConvertiblePromissoryNotes2021Member" xlink:label="zbio_ConvertiblePromissoryNotes2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ConvertiblePromissoryNotes2021Member" xlink:to="zbio_ConvertiblePromissoryNotes2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ConvertiblePromissoryNotes2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to 2021 convertible promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ConvertiblePromissoryNotes2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Promissory Notes 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ConvertiblePromissoryNotes2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquitySharesIssuedPricePerShare" xlink:label="zbio_TemporaryEquitySharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TemporaryEquitySharesIssuedPricePerShare" xlink:to="zbio_TemporaryEquitySharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TemporaryEquitySharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount to be received per share that is classified as temporary equity by entity upon sale of convertible preferred stock. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TemporaryEquitySharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_TemporaryEquitySharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash proceeds from issuance</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of convertible preferred stock classified as temporary equity issued upon exercise of warrants during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued upon exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment" xlink:label="zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment" xlink:to="zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of development milestone payment incurred in connection with the agreement during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Option Agreement, Development Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestone expense</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment" xlink:label="zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment" xlink:to="zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of convertible preferred stock classified as temporary equity issued in connection with the development milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued During Period For Development Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued in pursuant to development milestone payment</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses" xlink:label="zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses" xlink:to="zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gross proceeds from initial public offering before deduction of underwriter discounts and offering expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Initial Public Offering, Before Deduction Of Underwriter Discounts And Offering Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from initial public offering</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion" xlink:label="zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion" xlink:to="zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate number of common shares issued upon conversion of convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Aggregate Number Of Shares Issued Upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares issued upon conversion of convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Liquidation Preference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation Value</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityCommonStockIssuableUponConversion" xlink:label="zbio_TemporaryEquityCommonStockIssuableUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TemporaryEquityCommonStockIssuableUponConversion" xlink:to="zbio_TemporaryEquityCommonStockIssuableUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TemporaryEquityCommonStockIssuableUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares issuable upon conversion of Convertible preferred stock classified as temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TemporaryEquityCommonStockIssuableUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Common Stock Issuable Upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_TemporaryEquityCommonStockIssuableUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Issuable Upon Conversion</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityNumberOfVotesPerShare" xlink:label="zbio_TemporaryEquityNumberOfVotesPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TemporaryEquityNumberOfVotesPerShare" xlink:to="zbio_TemporaryEquityNumberOfVotesPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TemporaryEquityNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes per share entitled to each holder of convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TemporaryEquityNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Number of Votes per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_TemporaryEquityNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, number of votes per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend rate, percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends declared</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Ordinary Dividends, Preferred Stock and Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends paid</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CommonStockNumberOfVotesPerShare" xlink:label="zbio_CommonStockNumberOfVotesPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_CommonStockNumberOfVotesPerShare" xlink:to="zbio_CommonStockNumberOfVotesPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes per share entitled to each holder of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Number Of Votes Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes per share</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock" xlink:label="zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock" xlink:to="zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares issuable upon conversion of Convertible preferred stock classified as temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Common Stock Issuable Upon Conversion of Preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of outstanding shares of convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance outstanding at end of year (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance outstanding at beginning of year (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining number of common stock reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Common Stock, Capital Shares, Reserved For Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock remain available for future grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TwoThousandTwentyPlanMember" xlink:label="zbio_TwoThousandTwentyPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TwoThousandTwentyPlanMember" xlink:to="zbio_TwoThousandTwentyPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TwoThousandTwentyPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2020 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TwoThousandTwentyPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Twenty Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_TwoThousandTwentyPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Plan</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_EquityIncentivePlan2024Member" xlink:label="zbio_EquityIncentivePlan2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_EquityIncentivePlan2024Member" xlink:to="zbio_EquityIncentivePlan2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_EquityIncentivePlan2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2024 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_EquityIncentivePlan2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_EquityIncentivePlan2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 Plan</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_EmployeeStockPurchasePlan2024Member" xlink:label="zbio_EmployeeStockPurchasePlan2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_EmployeeStockPurchasePlan2024Member" xlink:to="zbio_EmployeeStockPurchasePlan2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_EmployeeStockPurchasePlan2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2024 Employee Stock Purchase Plan .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_EmployeeStockPurchasePlan2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_EmployeeStockPurchasePlan2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting on the anniversary of the vesting commencement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting in equal monthly installments over the subsequent thirty-six (36) months</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage (%)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized to issue under plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of outstanding stock maximum</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum additional number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share-Based Payment Award, Additional shares authorized, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum additional number of outstanding capital stock percent</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of additional shares to be authorized for issuance under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Additional Shares To Be Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional shares To Be authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock in period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested as of ending (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested as of beginning (Shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (shares)</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of equity-based payment instruments, excluding stock (or unit) options, that repurchased during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Repurchased in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchased (shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Grant-Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested as of ending ($ per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested as of beginning ($ per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested ($ per share)</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan repurchased during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Repurchased in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchased ($ per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSAs granted (shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited or cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and exercisable at end of year (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and expected to vest end of year (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted - Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance outstanding at end of year (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance outstanding at beginning of year (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited or cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and exercisable at end of year (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and expected to vest at end of year (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Remaining Contractual Term (In years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance outstanding at end of year (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and exercisable at end of year (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and expected to vest at end of year (in years)</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and exercisable at end of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and expected to vest at end of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost related to unvested stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period over which unrecognized compensation cost is expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total fair value of options vested during the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (Loss) Income Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive securities excluded from computation of diluted net (loss) per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-U.S.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current income tax provision:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current income tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income taxes, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IP transfer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign tax rate differential</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Asset, In-Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DeferredTaxAssetsMilestonePayments" xlink:label="zbio_DeferredTaxAssetsMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_DeferredTaxAssetsMilestonePayments" xlink:to="zbio_DeferredTaxAssetsMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_DeferredTaxAssetsMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_DeferredTaxAssetsMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_DeferredTaxAssetsMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DeferredTaxLiabilitiesAmortizationAndOther" xlink:label="zbio_DeferredTaxLiabilitiesAmortizationAndOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_DeferredTaxLiabilitiesAmortizationAndOther" xlink:to="zbio_DeferredTaxLiabilitiesAmortizationAndOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_DeferredTaxLiabilitiesAmortizationAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from amortization and other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_DeferredTaxLiabilitiesAmortizationAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Amortization and Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="zbio_DeferredTaxLiabilitiesAmortizationAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:label="zbio_DeferredTaxAssetsNetBeforeValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:to="zbio_DeferredTaxAssetsNetBeforeValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_DeferredTaxAssetsNetBeforeValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax asset, net of deferred tax liability, before allocation of valuation allowances attributable to deductible differences and carryforwards, without jurisdictional netting.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_DeferredTaxAssetsNetBeforeValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net, Before Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="zbio_DeferredTaxAssetsNetBeforeValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax asset before valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards, Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards, State</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal" xlink:label="zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal" xlink:to="zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of annual deduction equal to annual taxable income on domestic  operating loss carryforwards .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Annual Deduction Equal To Taxable Income, Federal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of annual deduction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_OperatingLossCarryforwardsExpirationPeriod" xlink:label="zbio_OperatingLossCarryforwardsExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_OperatingLossCarryforwardsExpirationPeriod" xlink:to="zbio_OperatingLossCarryforwardsExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_OperatingLossCarryforwardsExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period of each operating loss carryforward included in operating loss carryforward.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_OperatingLossCarryforwardsExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_OperatingLossCarryforwardsExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforward expiration period</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TaxCreditCarryforwardExpirationPeriod" xlink:label="zbio_TaxCreditCarryforwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_TaxCreditCarryforwardExpirationPeriod" xlink:to="zbio_TaxCreditCarryforwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_TaxCreditCarryforwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period of the tax credit carryforward.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_TaxCreditCarryforwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_TaxCreditCarryforwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards, Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards, Foreign expiration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability for Uncertainty in Income Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest or penalties related to uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_UncertainTaxPositionsAmountRecognized" xlink:label="zbio_UncertainTaxPositionsAmountRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_UncertainTaxPositionsAmountRecognized" xlink:to="zbio_UncertainTaxPositionsAmountRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_UncertainTaxPositionsAmountRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount recognized for uncertain tax positions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_UncertainTaxPositionsAmountRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain Tax Positions, Amount Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_UncertainTaxPositionsAmountRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount recognized for uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Onetime contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorIncMember" xlink:label="zbio_XencorIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_XencorIncMember" xlink:to="zbio_XencorIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_XencorIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Xencor, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_XencorIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Xencor, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_XencorIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Xencor</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ViridianTherapeuticsIncMember" xlink:label="zbio_ViridianTherapeuticsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ViridianTherapeuticsIncMember" xlink:to="zbio_ViridianTherapeuticsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ViridianTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Viridian Therapeutics, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ViridianTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viridian Therapeutics, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ViridianTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viridian</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DianthusTherapeuticsincMember" xlink:label="zbio_DianthusTherapeuticsincMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_DianthusTherapeuticsincMember" xlink:to="zbio_DianthusTherapeuticsincMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_DianthusTherapeuticsincMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Dianthus Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_DianthusTherapeuticsincMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dianthus Therapeutics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_DianthusTherapeuticsincMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dianthus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairmountFundsManagementLlcMember" xlink:label="zbio_FairmountFundsManagementLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_FairmountFundsManagementLlcMember" xlink:to="zbio_FairmountFundsManagementLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_FairmountFundsManagementLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to Fairmount Funds Management LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_FairmountFundsManagementLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fairmount Funds Management LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_FairmountFundsManagementLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fairmount Funds Management LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained" xlink:label="zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained" xlink:to="zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of antibody product candidates for which license has been obtained.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Number of Antibody Product License Obtained</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of antibody product candidates</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RelatedPartyTransactionNumberOfLicenseAgreements" xlink:label="zbio_RelatedPartyTransactionNumberOfLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_RelatedPartyTransactionNumberOfLicenseAgreements" xlink:to="zbio_RelatedPartyTransactionNumberOfLicenseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_RelatedPartyTransactionNumberOfLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_RelatedPartyTransactionNumberOfLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Number of License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_RelatedPartyTransactionNumberOfLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of license agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee" xlink:label="us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee" xlink:to="us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity interest held (in percent)</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RelatedPartyTransactionReimbursableCosts" xlink:label="zbio_RelatedPartyTransactionReimbursableCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_RelatedPartyTransactionReimbursableCosts" xlink:to="zbio_RelatedPartyTransactionReimbursableCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_RelatedPartyTransactionReimbursableCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of reimbursable costs incurred with the related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_RelatedPartyTransactionReimbursableCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Reimbursable Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_RelatedPartyTransactionReimbursableCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursable costs</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_OwnershipPercentageByRelatedParty" xlink:label="zbio_OwnershipPercentageByRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_OwnershipPercentageByRelatedParty" xlink:to="zbio_OwnershipPercentageByRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_OwnershipPercentageByRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of ownership of the entity's common stock by a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_OwnershipPercentageByRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership Percentage by Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_OwnershipPercentageByRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership percentage by related party</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NumberOfSeatsHeldInBoard" xlink:label="zbio_NumberOfSeatsHeldInBoard" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_NumberOfSeatsHeldInBoard" xlink:to="zbio_NumberOfSeatsHeldInBoard_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_NumberOfSeatsHeldInBoard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of seats held in the board of related entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_NumberOfSeatsHeldInBoard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Seats Held in Board</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_NumberOfSeatsHeldInBoard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of seats held in board</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Domain]</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SingleReportableSegmentMember" xlink:label="zbio_SingleReportableSegmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_SingleReportableSegmentMember" xlink:to="zbio_SingleReportableSegmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to single reportable segmentfocused on the research and development of precision immunology-based therapies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single Reportable Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single Reportable Segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ObexelimabMember" xlink:label="zbio_ObexelimabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ObexelimabMember" xlink:to="zbio_ObexelimabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ObexelimabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Obexelimab.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ObexelimabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obexelimab [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ObexelimabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obexelimab</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_OtherProgramsZb002Zb004Member" xlink:label="zbio_OtherProgramsZb002Zb004Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_OtherProgramsZb002Zb004Member" xlink:to="zbio_OtherProgramsZb002Zb004Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_OtherProgramsZb002Zb004Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Other Programs (ZB002 &amp; ZB004).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_OtherProgramsZb002Zb004Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Programs (ZB002 &amp; ZB004) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_OtherProgramsZb002Zb004Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other programs (ZB002 &amp; ZB004)</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_PartneredRegionalProgramsZb001Zb005Member" xlink:label="zbio_PartneredRegionalProgramsZb001Zb005Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_PartneredRegionalProgramsZb001Zb005Member" xlink:to="zbio_PartneredRegionalProgramsZb001Zb005Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_PartneredRegionalProgramsZb001Zb005Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Partnered regional programs (ZB001 &amp; ZB005).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_PartneredRegionalProgramsZb001Zb005Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnered Regional Programs (ZB001 &amp; ZB005) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_PartneredRegionalProgramsZb001Zb005Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnered regional programs (ZB001 &amp; ZB005)</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_UnallocatedMember" xlink:label="zbio_UnallocatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_UnallocatedMember" xlink:to="zbio_UnallocatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_UnallocatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to unallocated products or services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_UnallocatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unallocated [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_UnallocatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unallocated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Other Segment Item, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other segment items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ZaiLicenseAgreementMember" xlink:label="zbio_ZaiLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_ZaiLicenseAgreementMember" xlink:to="zbio_ZaiLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_ZaiLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Zai License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_ZaiLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Zai License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_ZaiLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Zai license agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent event</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone" xlink:label="zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone" xlink:to="zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of payment receivable on achievement of certain regulatory and commercial milestones in the collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Regulatory And Commercial Milestones, Maximum Payment Receivable On Achievement of Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payment eligible to receive</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_Rule10b51ArrangementModifiedFlag" xlink:label="zbio_Rule10b51ArrangementModifiedFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_Rule10b51ArrangementModifiedFlag" xlink:to="zbio_Rule10b51ArrangementModifiedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_Rule10b51ArrangementModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_Rule10b51ArrangementModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arrangement Modified [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_Rule10b51ArrangementModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arrangement Modified</label>
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NonRule10b51ArrangementModifiedFlag" xlink:label="zbio_NonRule10b51ArrangementModifiedFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zbio_NonRule10b51ArrangementModifiedFlag" xlink:to="zbio_NonRule10b51ArrangementModifiedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="zbio_NonRule10b51ArrangementModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="zbio_NonRule10b51ArrangementModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Rule 10b5-1 Arrangement Modified [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="zbio_NonRule10b51ArrangementModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Rule 10b5-1 Arrangement Modified</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>30
<FILENAME>zbio-20241231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2025 9:11:27 PM-->
<!--Modified on: 3/10/2025 9:11:27 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://zenasbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://zenasbio.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureNatureOfBusiness" roleURI="http://zenasbio.com/role/DisclosureNatureOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureFairValueMeasurements" roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureOtherAssets" roleURI="http://zenasbio.com/role/DisclosureOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureAccruedExpenses" roleURI="http://zenasbio.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLeases" roleURI="http://zenasbio.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLicenseAndCollaborationRevenue" roleURI="http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLicenseAndOptionAgreements" roleURI="http://zenasbio.com/role/DisclosureLicenseAndOptionAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureConvertiblePreferredStock" roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureCommonStock" roleURI="http://zenasbio.com/role/DisclosureCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureStockBasedCompensation" roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureNetLossPerShare" roleURI="http://zenasbio.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureIncomeTaxes" roleURI="http://zenasbio.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://zenasbio.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureEmployeeBenefitPlans" roleURI="http://zenasbio.com/role/DisclosureEmployeeBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://zenasbio.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureSegmentInformation" roleURI="http://zenasbio.com/role/DisclosureSegmentInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureSubsequentEvents" roleURI="http://zenasbio.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureOtherAssetsTables" roleURI="http://zenasbio.com/role/DisclosureOtherAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureAccruedExpensesTables" roleURI="http://zenasbio.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLeasesTables" roleURI="http://zenasbio.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureConvertiblePreferredStockTables" roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureCommonStockTables" roleURI="http://zenasbio.com/role/DisclosureCommonStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureNetLossPerShareTables" roleURI="http://zenasbio.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureIncomeTaxesTables" roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureSegmentInformationTables" roleURI="http://zenasbio.com/role/DisclosureSegmentInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureNatureOfBusinessDetails" roleURI="http://zenasbio.com/role/DisclosureNatureOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureFairValueMeasurementsValuationTechniquesDetails" roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureFairValueMeasurementsFairValueTransfersDetails" roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsFairValueTransfersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails" roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureFairValueMeasurementsConvertibleNotesDetails" roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails" roleURI="http://zenasbio.com/role/DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureOtherAssetsDetails" roleURI="http://zenasbio.com/role/DisclosureOtherAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://zenasbio.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLeasesDetails" roleURI="http://zenasbio.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeaseAssetsAndLiabilitiesDetails" roleURI="http://zenasbio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeaseAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails" roleURI="http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLicenseAndCollaborationRevenueDetails" roleURI="http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureLicenseAndOptionAgreementsDetails" roleURI="http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureConvertiblePreferredStockDetails" roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureConvertiblePreferredStockScheduleDetails" roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails" roleURI="http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureCommonStockDetails" roleURI="http://zenasbio.com/role/DisclosureCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureCommonStockReservedForIssuanceDetails" roleURI="http://zenasbio.com/role/DisclosureCommonStockReservedForIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureStockBasedCompensationRestrictedStockAwardsDetails" roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails" roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureNetLossPerShareBasicAndDilutedDetails" roleURI="http://zenasbio.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" roleURI="http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails" roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails" roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://zenasbio.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureEmployeeBenefitPlansDetails" roleURI="http://zenasbio.com/role/DisclosureEmployeeBenefitPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureSegmentInformationDetails" roleURI="http://zenasbio.com/role/DisclosureSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="zbio-20241231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://zenasbio.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://zenasbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638772378848760667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638772378848760667" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638772378848760667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638772378848760667" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638772378848760667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638772378848760667" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638772378848760667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638772378848760667" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638772378848760667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638772378848760667" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638772378848760667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638772378848760667" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638772378848760667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638772378848760667" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638772378848770664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638772378848770664" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638772378848770664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638772378848770664" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638772378848770664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638772378848770664" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638772378848770664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638772378848770664" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638772378848770664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638772378848770664" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638772378848770664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638772378848770664" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638772378848770664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638772378848770664" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638772378848770664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638772378848770664" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638772378848780655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638772378848780655" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638772378848780655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638772378848780655" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638772378848780655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638772378848780655" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638772378848780655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638772378848780655" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638772378848780655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638772378848780655" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638772378848780655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638772378848780655" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638772378848780655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638772378848780655" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638772378848790654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638772378848790654" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638772378848790654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638772378848790654" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638772378848790654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638772378848790654" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638772378848790654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638772378848790654" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638772378848790654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638772378848790654" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638772378848790654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638772378848790654" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638772378848790654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638772378848790654" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638772378848800654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638772378848800654" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638772378848800654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638772378848800654" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638772378848800654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638772378848800654" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638772378848800654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638772378848800654" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638772378848800654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638772378848800654" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638772378848810657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638772378848810657" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_638772378848810657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_638772378848810657" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638772378848810657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638772378848810657" order="37" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638772378848810657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638772378848810657" order="38" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638772378848810657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638772378848810657" order="39" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638772378848820663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638772378848820663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638772378848820663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378848820663" xlink:to="us-gaap_StatementClassOfStockAxis_638772378848820663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638772378848820663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378848820663" xlink:to="us-gaap_ClassOfStockDomain_638772378848820663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember_638772378848820663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378848820663" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember_638772378848820663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638772378848820663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378848820663" xlink:to="us-gaap_SeriesAPreferredStockMember_638772378848820663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638772378848830666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378848820663" xlink:to="us-gaap_SeriesBPreferredStockMember_638772378848830666" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638772378848830666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378848820663" xlink:to="us-gaap_StatementLineItems_638772378848830666" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638772378848830666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848830666" xlink:to="us-gaap_AssetsAbstract_638772378848830666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638772378848830666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638772378848830666" xlink:to="us-gaap_AssetsCurrentAbstract_638772378848830666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638772378848830666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638772378848830666" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638772378848830666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638772378848830666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638772378848830666" xlink:to="us-gaap_ShortTermInvestments_638772378848830666" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638772378848830666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638772378848830666" xlink:to="us-gaap_RestrictedCashCurrent_638772378848830666" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638772378848830666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638772378848830666" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638772378848830666" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638772378848830666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638772378848830666" xlink:to="us-gaap_AssetsCurrent_638772378848830666" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638772378848840659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638772378848830666" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638772378848840659" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638772378848840659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638772378848830666" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638772378848840659" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638772378848840659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638772378848830666" xlink:to="us-gaap_RestrictedCashNoncurrent_638772378848840659" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638772378848840659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638772378848830666" xlink:to="us-gaap_OtherAssetsNoncurrent_638772378848840659" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638772378848840659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638772378848830666" xlink:to="us-gaap_Assets_638772378848840659" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638772378848840659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848830666" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638772378848840659" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638772378848840659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638772378848840659" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638772378848840659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638772378848850661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638772378848840659" xlink:to="us-gaap_AccountsPayableCurrent_638772378848850661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638772378848850661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638772378848840659" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638772378848850661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638772378848850661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638772378848840659" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638772378848850661" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638772378848850661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638772378848840659" xlink:to="us-gaap_LiabilitiesCurrent_638772378848850661" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638772378848850661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638772378848840659" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638772378848850661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_638772378848850661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638772378848840659" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_638772378848850661" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638772378848860661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638772378848840659" xlink:to="us-gaap_Liabilities_638772378848860661" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638772378848860661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638772378848840659" xlink:to="us-gaap_CommitmentsAndContingencies_638772378848860661" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_638772378848860661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638772378848840659" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_638772378848860661" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638772378848860661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_638772378848860661" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638772378848860661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638772378848860661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638772378848840659" xlink:to="us-gaap_StockholdersEquityAbstract_638772378848860661" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638772378848860661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638772378848860661" xlink:to="us-gaap_PreferredStockValue_638772378848860661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638772378848870661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638772378848860661" xlink:to="us-gaap_CommonStockValue_638772378848870661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638772378848870661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638772378848860661" xlink:to="us-gaap_AdditionalPaidInCapital_638772378848870661" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638772378848870661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638772378848860661" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638772378848870661" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638772378848870661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638772378848860661" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638772378848870661" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638772378848870661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638772378848860661" xlink:to="us-gaap_StockholdersEquity_638772378848870661" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638772378848880663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638772378848840659" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638772378848880663" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638772378848880663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_StatementTable_638772378848880663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638772378848880663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378848880663" xlink:to="us-gaap_StatementClassOfStockAxis_638772378848880663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638772378848880663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378848880663" xlink:to="us-gaap_ClassOfStockDomain_638772378848880663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember_638772378848880663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378848880663" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember_638772378848880663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638772378848880663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378848880663" xlink:to="us-gaap_SeriesAPreferredStockMember_638772378848880663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638772378848890675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378848880663" xlink:to="us-gaap_SeriesBPreferredStockMember_638772378848890675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638772378848890675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378848880663" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638772378848890675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638772378848890675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638772378848890675" xlink:to="us-gaap_RelatedPartyDomain_638772378848890675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638772378848890675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638772378848890675" xlink:to="us-gaap_RelatedPartyMember_638772378848890675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638772378848890675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378848880663" xlink:to="us-gaap_StatementLineItems_638772378848890675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638772378848890675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_AccountsPayableCurrent_638772378848890675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638772378848890675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638772378848890675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_638772378848960717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_638772378848960717" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_638772378848960717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_638772378848960717" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_638772378848960717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_TemporaryEquitySharesIssued_638772378848960717" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638772378848960717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638772378848960717" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638772378848960717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638772378848960717" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638772378848960717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_PreferredStockSharesAuthorized_638772378848960717" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638772378848960717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_PreferredStockSharesIssued_638772378848960717" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638772378848970673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_PreferredStockSharesOutstanding_638772378848970673" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638772378848970673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638772378848970673" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638772378848970673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_CommonStockSharesAuthorized_638772378848970673" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638772378848970673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_CommonStockSharesIssued_638772378848970673" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638772378848970673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378848890675" xlink:to="us-gaap_CommonStockSharesOutstanding_638772378848970673" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638772378848980679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenuesAbstract_638772378848980679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638772378848980679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638772378848980679" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638772378848980679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638772378848980679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638772378848980679" xlink:to="us-gaap_Revenues_638772378848980679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638772378848980679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638772378848980679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638772378848980679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638772378848980679" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638772378848980679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638772378848980679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638772378848980679" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638772378848980679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_638772378848980679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638772378848980679" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_638772378848980679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638772378848980679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638772378848980679" xlink:to="us-gaap_OperatingExpenses_638772378848980679" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638772378848980679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638772378848980679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638772378848990677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638772378848990677" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueAdjustmentOfConvertibleNotes" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes_638772378848990677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638772378848990677" xlink:to="zbio_FairValueAdjustmentOfConvertibleNotes_638772378848990677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638772378848990677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638772378848990677" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638772378848990677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638772378848990677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638772378848990677" xlink:to="us-gaap_NonoperatingIncomeExpense_638772378848990677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638772378848990677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638772378848990677" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638772378848990677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638772378848990677" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638772378848990677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_638772378848990677" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638772378848990677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638772378848990677" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638772378849000675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638772378849000675" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638772378849000675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638772378849000675" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638772378849000675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638772378849000675" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638772378849000675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638772378849000675" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638772378849000675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638772378849000675" xlink:to="us-gaap_NetIncomeLoss_638772378849000675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638772378849000675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638772378849000675" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638772378849000675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638772378849010676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638772378849000675" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638772378849010676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638772378849010676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638772378849000675" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638772378849010676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638772378849010676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638772378849000675" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638772378849010676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="extended" xlink:title="995200205 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638772378849010676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_StatementTable_638772378849010676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638772378849010676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378849010676" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638772378849010676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638772378849010676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638772378849010676" xlink:to="us-gaap_RelatedPartyDomain_638772378849010676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638772378849020680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638772378849010676" xlink:to="us-gaap_RelatedPartyMember_638772378849020680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638772378849020680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378849010676" xlink:to="us-gaap_StatementLineItems_638772378849020680" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638772378849020680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378849020680" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638772378849020680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638772378849020680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378849020680" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638772378849020680" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638772378849020680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638772378849020680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638772378849020680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378849020680" xlink:to="us-gaap_StatementEquityComponentsAxis_638772378849020680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638772378849020680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638772378849020680" xlink:to="us-gaap_PreferredStockMember_638772378849020680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638772378849030681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638772378849020680" xlink:to="us-gaap_CommonStockMember_638772378849030681" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638772378849030681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638772378849020680" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638772378849030681" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638772378849030681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638772378849020680" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638772378849030681" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638772378849030681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638772378849020680" xlink:to="us-gaap_RetainedEarningsMember_638772378849030681" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638772378849030681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638772378849020680" xlink:to="us-gaap_EquityComponentDomain_638772378849030681" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638772378849030681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378849020680" xlink:to="us-gaap_StatementClassOfStockAxis_638772378849030681" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember_638772378849030681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378849030681" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember_638772378849030681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638772378849030681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378849030681" xlink:to="us-gaap_SeriesAPreferredStockMember_638772378849030681" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638772378849030681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378849030681" xlink:to="us-gaap_SeriesBPreferredStockMember_638772378849030681" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_638772378849040675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378849030681" xlink:to="us-gaap_SeriesCPreferredStockMember_638772378849040675" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638772378849040675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378849030681" xlink:to="us-gaap_ClassOfStockDomain_638772378849040675" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638772378849040675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378849020680" xlink:to="us-gaap_StatementLineItems_638772378849040675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638772378849040675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378849040675" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638772378849040675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638772378849040675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638772378849040675" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638772378849040675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638772378849040675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638772378849040675" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638772378849040675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_638772378849040675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638772378849040675" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_638772378849040675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638772378849040675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638772378849040675" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638772378849040675" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion_638772378849050680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638772378849040675" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion_638772378849050680" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion_638772378849050680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638772378849040675" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion_638772378849050680" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638772378849050680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638772378849040675" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638772378849050680" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638772378849050680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638772378849040675" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638772378849050680" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378849040675" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638772378849050680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_StockholdersEquity_638772378849050680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638772378849060680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_SharesOutstanding_638772378849060680" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_638772378849060680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_638772378849060680" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638772378849060680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638772378849060680" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638772378849060680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638772378849060680" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638772378849060680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638772378849060680" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638772378849060680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638772378849060680" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638772378849070684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638772378849070684" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638772378849070684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638772378849070684" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638772378849070684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638772378849070684" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638772378849070684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_NetIncomeLoss_638772378849070684" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638772378849070684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638772378849070684" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638772378849070684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638772378849070684" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638772378849080683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_StockholdersEquity_638772378849080683" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638772378849080683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638772378849050680" xlink:to="us-gaap_SharesOutstanding_638772378849080683" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="995200305 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638772378849080683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1" xlink:to="us-gaap_StatementTable_638772378849080683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638772378849090687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378849080683" xlink:to="us-gaap_StatementEquityComponentsAxis_638772378849090687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638772378849090687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638772378849090687" xlink:to="us-gaap_EquityComponentDomain_638772378849090687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638772378849090687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638772378849090687" xlink:to="us-gaap_PreferredStockMember_638772378849090687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638772378849090687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378849080683" xlink:to="us-gaap_StatementClassOfStockAxis_638772378849090687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638772378849090687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378849090687" xlink:to="us-gaap_ClassOfStockDomain_638772378849090687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638772378849090687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849090687" xlink:to="us-gaap_SeriesBPreferredStockMember_638772378849090687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_638772378849090687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849090687" xlink:to="us-gaap_SeriesCPreferredStockMember_638772378849090687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638772378849090687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638772378849080683" xlink:to="us-gaap_StatementLineItems_638772378849090687" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638772378849090687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638772378849090687" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638772378849090687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638772378849100684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" xlink:to="us-gaap_NetIncomeLoss_638772378849100684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_638772378849100684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_638772378849100684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638772378849100684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" xlink:to="us-gaap_Depreciation_638772378849100684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638772378849100684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638772378849100684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638772378849100684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" xlink:to="us-gaap_ShareBasedCompensation_638772378849100684" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueAdjustmentOfConvertibleNotes" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes_638772378849100684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" xlink:to="zbio_FairValueAdjustmentOfConvertibleNotes_638772378849100684" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NonCashLeaseExpense" xlink:label="zbio_NonCashLeaseExpense_638772378849110687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" xlink:to="zbio_NonCashLeaseExpense_638772378849110687" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638772378849110687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638772378849110687" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638772378849110687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638772378849110687" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638772378849110687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638772378849110687" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638772378849110687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638772378849110687" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378849110687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638772378849100684" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638772378849110687" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638772378849120735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638772378849120735" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638772378849120735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638772378849120735" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638772378849120735" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments_638772378849120735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638772378849120735" xlink:to="us-gaap_PaymentsToAcquireInvestments_638772378849120735" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_638772378849120735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638772378849120735" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_638772378849120735" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638772378849120735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638772378849120735" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638772378849120735" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638772378849120735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638772378849120735" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638772378849120735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638772378849120735" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638772378849120735" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638772378849130689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638772378849120735" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638772378849130689" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638772378849130689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638772378849120735" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638772378849130689" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638772378849130689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638772378849120735" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638772378849130689" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638772378849130689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638772378849120735" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638772378849130689" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638772378849130689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638772378849120735" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638772378849130689" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638772378849130689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638772378849130689" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638772378849140682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638772378849140682" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638772378849140682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638772378849140682" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6387723788491406821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6387723788491406821" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638772378849140682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638772378849140682" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAssumed1" xlink:label="us-gaap_NotesAssumed1_638772378849140682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638772378849140682" xlink:to="us-gaap_NotesAssumed1_638772378849140682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_638772378849140682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638772378849140682" xlink:to="us-gaap_ConversionOfStockAmountConverted1_638772378849140682" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638772378849150686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638772378849140682" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638772378849150686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:label="zbio_DeferredOfferingCostsIncludedInAccruedExpenses_638772378849150686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638772378849140682" xlink:to="zbio_DeferredOfferingCostsIncludedInAccruedExpenses_638772378849150686" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="995200405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract" xlink:label="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract_638772378849150686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1" xlink:to="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract_638772378849150686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638772378849150686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract_638772378849150686" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638772378849150686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638772378849150686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract_638772378849150686" xlink:to="us-gaap_RestrictedCashCurrent_638772378849150686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638772378849160696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract_638772378849150686" xlink:to="us-gaap_RestrictedCashNoncurrent_638772378849160696" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638772378849160696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract_638772378849150686" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638772378849160696" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="995210101 - Disclosure - Nature of Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638772378849160696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638772378849160696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638772378849170745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638772378849170745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="995210301 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638772378849170745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638772378849170745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureOtherAssets" xlink:type="extended" xlink:title="995210401 - Disclosure - Other Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_638772378849170745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_638772378849170745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="995210501 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638772378849180713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638772378849180713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureLeases" xlink:type="extended" xlink:title="995210601 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638772378849180713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638772378849180713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenue" xlink:type="extended" xlink:title="995210701 - Disclosure - License and Collaboration Revenue" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementAbstract" xlink:label="zbio_CollaborativeArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638772378849180713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_CollaborativeArrangementAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638772378849180713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureLicenseAndOptionAgreements" xlink:type="extended" xlink:title="995210801 - Disclosure - License and Option Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsAbstract" xlink:label="zbio_LicenseAndOptionAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsDisclosureTextBlock" xlink:label="zbio_LicenseAndOptionAgreementsDisclosureTextBlock_638772378849190710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_LicenseAndOptionAgreementsAbstract" xlink:to="zbio_LicenseAndOptionAgreementsDisclosureTextBlock_638772378849190710" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureConvertiblePreferredStock" xlink:type="extended" xlink:title="995210901 - Disclosure - Convertible Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityDisclosureTextBlock" xlink:label="zbio_TemporaryEquityDisclosureTextBlock_638772378849190710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="zbio_TemporaryEquityDisclosureTextBlock_638772378849190710" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureCommonStock" xlink:type="extended" xlink:title="995211001 - Disclosure - Common Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638772378849190710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638772378849190710" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="995211101 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638772378849200712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638772378849200712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="995211201 - Disclosure - Net Loss Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638772378849200712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638772378849200712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995211301 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638772378849210709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638772378849210709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995211401 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638772378849210709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638772378849210709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureEmployeeBenefitPlans" xlink:type="extended" xlink:title="995211501 - Disclosure - Employee Benefit Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638772378849210709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638772378849210709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="995211601 - Disclosure - Related Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638772378849220708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638772378849220708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureSegmentInformation" xlink:type="extended" xlink:title="995211701 - Disclosure - Segment Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638772378849220708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638772378849220708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211801 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638772378849220708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638772378849220708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:label="zbio_BasisOfPresentationAndConsolidationPolicyTextBlock_638772378849230709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="zbio_BasisOfPresentationAndConsolidationPolicyTextBlock_638772378849230709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638772378849230709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_UseOfEstimates_638772378849230709" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638772378849230709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638772378849230709" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock_638772378849230709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_InvestmentPolicyTextBlock_638772378849230709" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638772378849230709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638772378849230709" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_638772378849230709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_638772378849230709" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638772378849230709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638772378849230709" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638772378849240712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638772378849240712" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SignificantSuppliersPolicyTextBlock" xlink:label="zbio_SignificantSuppliersPolicyTextBlock_638772378849240712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="zbio_SignificantSuppliersPolicyTextBlock_638772378849240712" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638772378849240712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638772378849240712" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638772378849240712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638772378849240712" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638772378849240712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638772378849240712" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638772378849240712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638772378849240712" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndCollaborationRevenuePolicyTextBlock" xlink:label="zbio_LicenseAndCollaborationRevenuePolicyTextBlock_638772378849240712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="zbio_LicenseAndCollaborationRevenuePolicyTextBlock_638772378849240712" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638772378849240712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638772378849240712" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock" xlink:label="zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock_638772378849250714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock_638772378849250714" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638772378849250714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638772378849250714" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638772378849250714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638772378849250714" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638772378849250714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638772378849250714" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638772378849250714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638772378849250714" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityPolicyTextBlock" xlink:label="zbio_TemporaryEquityPolicyTextBlock_638772378849260716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="zbio_TemporaryEquityPolicyTextBlock_638772378849260716" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638772378849260716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638772378849260716" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638772378849260716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638772378849260716" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638772378849260716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638772378849260716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_638772378849270716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_638772378849270716" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638772378849270716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638772378849270716" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureOtherAssetsTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Other Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_638772378849270716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_638772378849270716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638772378849270716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_1" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638772378849270716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="99930603 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638772378849280715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_LeaseCostTableTextBlock_638772378849280715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock" xlink:label="zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock_638772378849280715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock_638772378849280715" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureConvertiblePreferredStockTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Convertible Preferred Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock_638772378849280715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_1" xlink:to="us-gaap_TemporaryEquityTableTextBlock_638772378849280715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureCommonStockTables" xlink:type="extended" xlink:title="99931003 - Disclosure - Common Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock" xlink:label="zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock_638772378849290715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1" xlink:to="zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock_638772378849290715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99931103 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638772378849290715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638772378849290715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638772378849290715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638772378849290715" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638772378849290715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638772378849290715" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638772378849290715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638772378849290715" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="99931203 - Disclosure - Net Loss Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638772378849300716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638772378849300716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638772378849300716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638772378849300716" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="99931303 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638772378849310740" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638772378849310740" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638772378849310740" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638772378849310740" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638772378849310740" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638772378849310740" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638772378849310740" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638772378849310740" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureSegmentInformationTables" xlink:type="extended" xlink:title="99931703 - Disclosure - Segment Information (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638772378849310740" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638772378849310740" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureNatureOfBusinessDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Nature of Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849320720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849320720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638772378849320720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849320720" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638772378849320720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638772378849320720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638772378849320720" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638772378849320720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638772378849320720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638772378849320720" xlink:to="us-gaap_IPOMember_638772378849320720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638772378849320720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638772378849320720" xlink:to="us-gaap_OverAllotmentOptionMember_638772378849320720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849320720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849320720" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849320720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638772378849320720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849320720" xlink:to="us-gaap_NumberOfOperatingSegments_638772378849320720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638772378849320720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849320720" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638772378849320720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638772378849320720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849320720" xlink:to="us-gaap_SharesIssuedPricePerShare_638772378849320720" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638772378849330728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849320720" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638772378849330728" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638772378849330728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849320720" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638772378849330728" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638772378849330728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849320720" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638772378849330728" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638772378849330728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849320720" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638772378849330728" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638772378849330728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849320720" xlink:to="us-gaap_NetIncomeLoss_638772378849330728" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638772378849330728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849320720" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638772378849330728" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638772378849330728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849320720" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638772378849330728" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849340725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849340725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638772378849340725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849340725" xlink:to="us-gaap_TypeOfArrangementAxis_638772378849340725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849340725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638772378849340725" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849340725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorAgreement2021Member" xlink:label="zbio_XencorAgreement2021Member_638772378849340725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849340725" xlink:to="zbio_XencorAgreement2021Member_638772378849340725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638772378849340725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849340725" xlink:to="srt_RangeAxis_638772378849340725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638772378849340725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638772378849340725" xlink:to="srt_RangeMember_638772378849340725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638772378849340725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638772378849340725" xlink:to="srt_MinimumMember_638772378849340725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638772378849340725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638772378849340725" xlink:to="srt_MaximumMember_638772378849340725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849350721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849340725" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849350721" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts_638772378849350721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849350721" xlink:to="us-gaap_DeferredCosts_638772378849350721" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638772378849350721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849350721" xlink:to="us-gaap_NumberOfReportableSegments_638772378849350721" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_638772378849350721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849350721" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_638772378849350721" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638772378849350721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849350721" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638772378849350721" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_638772378849350721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849350721" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_638772378849350721" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638772378849350721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849350721" xlink:to="us-gaap_UnrecognizedTaxBenefits_638772378849350721" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Fair Value Measurements - Valuation Techniques (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638772378849360731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638772378849360731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638772378849360731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638772378849360731" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638772378849360731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638772378849360731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638772378849360731" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638772378849360731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638772378849360731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638772378849360731" xlink:to="us-gaap_FairValueInputsLevel1Member_638772378849360731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638772378849360731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638772378849360731" xlink:to="us-gaap_FairValueInputsLevel2Member_638772378849360731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638772378849360731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638772378849360731" xlink:to="us-gaap_FairValueInputsLevel3Member_638772378849360731" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638772378849360731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638772378849360731" xlink:to="us-gaap_FinancialInstrumentAxis_638772378849360731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638772378849360731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638772378849360731" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638772378849360731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638772378849370723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638772378849360731" xlink:to="us-gaap_CommercialPaperMember_638772378849370723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638772378849370723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638772378849360731" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638772378849370723" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_638772378849370723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638772378849360731" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_638772378849370723" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_638772378849370723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638772378849360731" xlink:to="us-gaap_FairValueByAssetClassAxis_638772378849370723" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638772378849370723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis_638772378849370723" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638772378849370723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember_638772378849370723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638772378849370723" xlink:to="us-gaap_CashMember_638772378849370723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638772378849370723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638772378849370723" xlink:to="us-gaap_MoneyMarketFundsMember_638772378849370723" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_638772378849370723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638772378849360731" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_638772378849370723" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_638772378849380723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_638772378849370723" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_638772378849380723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_638772378849380723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_638772378849380723" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_638772378849380723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638772378849380723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_638772378849380723" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638772378849380723" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638772378849380723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638772378849360731" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638772378849380723" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_638772378849380723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638772378849380723" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_638772378849380723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638772378849380723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638772378849380723" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638772378849380723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_InvestmentFairValueDisclosureAbstract" xlink:label="zbio_InvestmentFairValueDisclosureAbstract_638772378849380723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638772378849380723" xlink:to="zbio_InvestmentFairValueDisclosureAbstract_638772378849380723" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638772378849390725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_InvestmentFairValueDisclosureAbstract_638772378849380723" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638772378849390725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638772378849390725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638772378849380723" xlink:to="us-gaap_AssetsFairValueDisclosure_638772378849390725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_638772378849390725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638772378849380723" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_638772378849390725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_638772378849390725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_638772378849390725" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_638772378849390725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_638772378849390725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_638772378849390725" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_638772378849390725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureFairValueMeasurementsFairValueTransfersDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - Fair Value Measurements - Fair Value Transfers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueAssetsLevel1ToLevel2TransferAmount" xlink:label="zbio_FairValueAssetsLevel1ToLevel2TransferAmount_638772378849400738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="zbio_FairValueAssetsLevel1ToLevel2TransferAmount_638772378849400738" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueAssetsLevel2ToLevel1TransferAmount" xlink:label="zbio_FairValueAssetsLevel2ToLevel1TransferAmount_638772378849400738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="zbio_FairValueAssetsLevel2ToLevel1TransferAmount_638772378849400738" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_638772378849400738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_638772378849400738" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount" xlink:label="zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount_638772378849400738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount_638772378849400738" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_638772378849400738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_638772378849400738" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_638772378849400738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_638772378849400738" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails" xlink:type="extended" xlink:title="99940303 - Disclosure - Fair Value Measurements - Available-for-sale securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638772378849410744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_6" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638772378849410744" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638772378849410744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638772378849410744" xlink:to="us-gaap_FinancialInstrumentAxis_638772378849410744" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638772378849410744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638772378849410744" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638772378849410744" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638772378849410744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638772378849410744" xlink:to="us-gaap_CommercialPaperMember_638772378849410744" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638772378849410744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638772378849410744" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638772378849410744" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_638772378849410744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638772378849410744" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_638772378849410744" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638772378849420745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638772378849410744" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638772378849420745" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638772378849420745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638772378849420745" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638772378849420745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638772378849420745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638772378849420745" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638772378849420745" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638772378849420745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638772378849420745" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638772378849420745" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_638772378849420745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638772378849420745" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_638772378849420745" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails" xlink:type="extended" xlink:title="99940304 - Disclosure - Fair Value Measurements - Convertible Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638772378849420745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_DebtInstrumentTable_638772378849420745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638772378849420745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638772378849420745" xlink:to="us-gaap_DebtInstrumentAxis_638772378849420745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638772378849430750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638772378849420745" xlink:to="us-gaap_DebtInstrumentNameDomain_638772378849430750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_BmsConvertiblePromissoryNotesMember" xlink:label="zbio_BmsConvertiblePromissoryNotesMember_638772378849430750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638772378849430750" xlink:to="zbio_BmsConvertiblePromissoryNotesMember_638772378849430750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638772378849430750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638772378849420745" xlink:to="us-gaap_StatementClassOfStockAxis_638772378849430750" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638772378849430750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378849430750" xlink:to="us-gaap_ClassOfStockDomain_638772378849430750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_638772378849430750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849430750" xlink:to="us-gaap_SeriesCPreferredStockMember_638772378849430750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638772378849430750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638772378849420745" xlink:to="us-gaap_DebtInstrumentLineItems_638772378849430750" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638772378849430750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638772378849430750" xlink:to="us-gaap_DebtInstrumentFaceAmount_638772378849430750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes" xlink:label="zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes_638772378849430750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638772378849430750" xlink:to="zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes_638772378849430750" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638772378849430750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638772378849430750" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638772378849430750" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638772378849440747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638772378849430750" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638772378849440747" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairValueAdjustmentOfConvertibleNotes" xlink:label="zbio_FairValueAdjustmentOfConvertibleNotes_638772378849440747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638772378849430750" xlink:to="zbio_FairValueAdjustmentOfConvertibleNotes_638772378849440747" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails" xlink:type="extended" xlink:title="99940305 - Disclosure - Fair Value Measurement - Changes in Liabilities With Significant Unobservable Inputs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638772378849440747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_5" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638772378849440747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638772378849440747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638772378849440747" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638772378849440747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638772378849440747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638772378849440747" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638772378849440747" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638772378849450746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638772378849440747" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638772378849450746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638772378849450746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638772378849450746" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638772378849450746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638772378849450746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638772378849440747" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638772378849450746" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638772378849450746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638772378849440747" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638772378849450746" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureOtherAssetsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Other Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_638772378849450746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_2" xlink:to="us-gaap_PrepaidExpenseNoncurrent_638772378849450746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts_638772378849460758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_2" xlink:to="us-gaap_DeferredCosts_638772378849460758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_638772378849460758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_2" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent_638772378849460758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638772378849460758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_2" xlink:to="us-gaap_OtherAssetsNoncurrent_638772378849460758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_2" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent" xlink:label="zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent_638772378849460758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent_638772378849460758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638772378849460758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638772378849460758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638772378849460758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638772378849460758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638772378849460758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638772378849460758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638772378849460758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638772378849460758" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638772378849470748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638772378849470748" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638772378849470748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638772378849470748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638772378849470748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_VariableLeaseCost_638772378849470748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement" xlink:label="zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement_638772378849470748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement_638772378849470748" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638772378849470748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_OperatingLeasePayments_638772378849470748" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638772378849470748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_OperatingLeaseCost_638772378849470748" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeaseAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Operating Lease Assets and Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638772378849480751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_4" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638772378849480751" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638772378849480751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_4" xlink:to="us-gaap_OperatingLeaseLiability_638772378849480751" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638772378849480751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_4" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638772378849480751" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638772378849480751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_4" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638772378849480751" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails" xlink:type="extended" xlink:title="99940603 - Disclosure - Leases - Maturities of Operating Lease Liabilities and Quantitative Disclosure (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638772378849480751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_3" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638772378849480751" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638772378849490750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638772378849480751" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638772378849490750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638772378849490750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638772378849480751" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638772378849490750" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638772378849490750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638772378849480751" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638772378849490750" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638772378849490750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638772378849480751" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638772378849490750" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638772378849490750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638772378849480751" xlink:to="us-gaap_OperatingLeaseLiability_638772378849490750" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - License and Collaboration Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementAbstract" xlink:label="zbio_CollaborativeArrangementAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849490750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_CollaborativeArrangementAbstract_1" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849490750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638772378849490750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849490750" xlink:to="us-gaap_TypeOfArrangementAxis_638772378849490750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849490750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638772378849490750" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849490750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAgreementWithBristolMyersSquibbMember" xlink:label="zbio_LicenseAgreementWithBristolMyersSquibbMember_638772378849500762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849490750" xlink:to="zbio_LicenseAgreementWithBristolMyersSquibbMember_638772378849500762" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NovationAgreementMember" xlink:label="zbio_NovationAgreementMember_638772378849500762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849490750" xlink:to="zbio_NovationAgreementMember_638772378849500762" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849500762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849490750" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849500762" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementUpfrontPaymentReceived" xlink:label="zbio_CollaborativeArrangementUpfrontPaymentReceived_638772378849500762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849500762" xlink:to="zbio_CollaborativeArrangementUpfrontPaymentReceived_638772378849500762" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum" xlink:label="zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum_638772378849500762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849500762" xlink:to="zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum_638772378849500762" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638772378849500762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849500762" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638772378849500762" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638772378849500762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638772378849500762" xlink:to="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638772378849500762" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementReceivables" xlink:label="zbio_CollaborativeArrangementReceivables_638772378849500762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849500762" xlink:to="zbio_CollaborativeArrangementReceivables_638772378849500762" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638772378849500762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849500762" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638772378849500762" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum" xlink:label="zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum_638772378849510787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849500762" xlink:to="zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum_638772378849510787" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementTransactionPrice" xlink:label="zbio_CollaborativeArrangementTransactionPrice_638772378849510787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849500762" xlink:to="zbio_CollaborativeArrangementTransactionPrice_638772378849510787" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - License and Option Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsAbstract" xlink:label="zbio_LicenseAndOptionAgreementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849510787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_LicenseAndOptionAgreementsAbstract_1" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849510787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638772378849510787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849510787" xlink:to="us-gaap_TypeOfArrangementAxis_638772378849510787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849510787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638772378849510787" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849510787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorAgreement2020Member" xlink:label="zbio_XencorAgreement2020Member_638772378849510787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849510787" xlink:to="zbio_XencorAgreement2020Member_638772378849510787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorAgreement2021Member" xlink:label="zbio_XencorAgreement2021Member_638772378849520770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849510787" xlink:to="zbio_XencorAgreement2021Member_638772378849520770" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DianthusOptionAgreementMember" xlink:label="zbio_DianthusOptionAgreementMember_638772378849520770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849510787" xlink:to="zbio_DianthusOptionAgreementMember_638772378849520770" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ViridianAgreementMember" xlink:label="zbio_ViridianAgreementMember_638772378849520770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378849510787" xlink:to="zbio_ViridianAgreementMember_638772378849520770" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638772378849520770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849510787" xlink:to="us-gaap_StatementClassOfStockAxis_638772378849520770" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638772378849520770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378849520770" xlink:to="us-gaap_ClassOfStockDomain_638772378849520770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638772378849520770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849520770" xlink:to="us-gaap_SeriesAPreferredStockMember_638772378849520770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638772378849510787" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsReimbursableExpenses" xlink:label="zbio_LicenseAndOptionAgreementsReimbursableExpenses_638772378849520770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="zbio_LicenseAndOptionAgreementsReimbursableExpenses_638772378849520770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NumberOfAntibodyProductCandidates" xlink:label="zbio_NumberOfAntibodyProductCandidates_638772378849520770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="zbio_NumberOfAntibodyProductCandidates_638772378849520770" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ThresholdPeriodToNotifyIntentionForExercisingOption" xlink:label="zbio_ThresholdPeriodToNotifyIntentionForExercisingOption_638772378849530775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="zbio_ThresholdPeriodToNotifyIntentionForExercisingOption_638772378849530775" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638772378849530775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="us-gaap_AccountsPayableCurrent_638772378849530775" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638772378849530775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638772378849530775" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable" xlink:label="zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable_638772378849530775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable_638772378849530775" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638772378849530775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638772378849530775" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementTransactionPrice" xlink:label="zbio_CollaborativeArrangementTransactionPrice_638772378849530775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="zbio_CollaborativeArrangementTransactionPrice_638772378849530775" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable" xlink:label="zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable_638772378849530775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable_638772378849530775" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable" xlink:label="zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable_638772378849530775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable_638772378849530775" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsSalesMilestonePayable" xlink:label="zbio_LicenseAndOptionAgreementsSalesMilestonePayable_638772378849540767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="zbio_LicenseAndOptionAgreementsSalesMilestonePayable_638772378849540767" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation" xlink:label="zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation_638772378849540767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation_638772378849540767" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638772378849540767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638772378849540767" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638772378849540767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638772378849520770" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638772378849540767" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638772378849550777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_2" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638772378849550777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638772378849550777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638772378849550777" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638772378849550777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638772378849550777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638772378849550777" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638772378849550777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638772378849550777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638772378849550777" xlink:to="us-gaap_PrivatePlacementMember_638772378849550777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638772378849550777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638772378849550777" xlink:to="us-gaap_IPOMember_638772378849550777" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638772378849550777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638772378849550777" xlink:to="us-gaap_OverAllotmentOptionMember_638772378849550777" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638772378849550777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638772378849550777" xlink:to="us-gaap_StatementClassOfStockAxis_638772378849550777" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638772378849550777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378849550777" xlink:to="us-gaap_ClassOfStockDomain_638772378849550777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember_638772378849550777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849550777" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember_638772378849550777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638772378849550777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849550777" xlink:to="us-gaap_SeriesAPreferredStockMember_638772378849550777" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638772378849560829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849550777" xlink:to="us-gaap_SeriesBPreferredStockMember_638772378849560829" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_638772378849560829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849550777" xlink:to="us-gaap_SeriesCPreferredStockMember_638772378849560829" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638772378849560829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638772378849550777" xlink:to="us-gaap_RelatedPartyTransactionAxis_638772378849560829" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638772378849560829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638772378849560829" xlink:to="us-gaap_RelatedPartyTransactionDomain_638772378849560829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorAgreement2020Member" xlink:label="zbio_XencorAgreement2020Member_638772378849560829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638772378849560829" xlink:to="zbio_XencorAgreement2020Member_638772378849560829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorAgreement2021Member" xlink:label="zbio_XencorAgreement2021Member_638772378849560829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638772378849560829" xlink:to="zbio_XencorAgreement2021Member_638772378849560829" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638772378849560829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638772378849550777" xlink:to="us-gaap_DebtInstrumentAxis_638772378849560829" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638772378849560829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638772378849560829" xlink:to="us-gaap_DebtInstrumentNameDomain_638772378849560829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_BmsConvertiblePromissoryNotesMember" xlink:label="zbio_BmsConvertiblePromissoryNotesMember_638772378849570776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638772378849560829" xlink:to="zbio_BmsConvertiblePromissoryNotesMember_638772378849570776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ConvertiblePromissoryNotes2021Member" xlink:label="zbio_ConvertiblePromissoryNotes2021Member_638772378849570776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638772378849560829" xlink:to="zbio_ConvertiblePromissoryNotes2021Member_638772378849570776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638772378849570776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638772378849550777" xlink:to="us-gaap_TemporaryEquityLineItems_638772378849570776" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638772378849570776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638772378849570776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquitySharesIssuedPricePerShare" xlink:label="zbio_TemporaryEquitySharesIssuedPricePerShare_638772378849570776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="zbio_TemporaryEquitySharesIssuedPricePerShare_638772378849570776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_638772378849570776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_638772378849570776" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638772378849570776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638772378849570776" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_638772378849580772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_638772378849580772" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment" xlink:label="zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment_638772378849580772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment_638772378849580772" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment" xlink:label="zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment_638772378849580772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment_638772378849580772" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_638772378849580772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="us-gaap_TemporaryEquitySharesIssued_638772378849580772" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638772378849580772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638772378849580772" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638772378849580772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="us-gaap_SharesIssuedPricePerShare_638772378849580772" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses" xlink:label="zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses_638772378849590773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses_638772378849590773" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638772378849590773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638772378849590773" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion" xlink:label="zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion_638772378849590773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849570776" xlink:to="zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion_638772378849590773" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Convertible Preferred Stock - Schedule (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638772378849600772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_3" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638772378849600772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638772378849600772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638772378849600772" xlink:to="us-gaap_StatementClassOfStockAxis_638772378849600772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638772378849600772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378849600772" xlink:to="us-gaap_ClassOfStockDomain_638772378849600772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember_638772378849600772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849600772" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember_638772378849600772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638772378849600772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849600772" xlink:to="us-gaap_SeriesAPreferredStockMember_638772378849600772" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638772378849600772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849600772" xlink:to="us-gaap_SeriesBPreferredStockMember_638772378849600772" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638772378849610783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638772378849600772" xlink:to="us-gaap_TemporaryEquityLineItems_638772378849610783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_638772378849610783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849610783" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_638772378849610783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_638772378849610783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849610783" xlink:to="us-gaap_TemporaryEquitySharesIssued_638772378849610783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638772378849610783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849610783" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638772378849610783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638772378849610783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849610783" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638772378849610783" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_638772378849610783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849610783" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_638772378849610783" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityCommonStockIssuableUponConversion" xlink:label="zbio_TemporaryEquityCommonStockIssuableUponConversion_638772378849610783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849610783" xlink:to="zbio_TemporaryEquityCommonStockIssuableUponConversion_638772378849610783" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Convertible Preferred Stock - Rights and Privileges (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638772378849620775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_4" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638772378849620775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638772378849620775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638772378849620775" xlink:to="us-gaap_StatementClassOfStockAxis_638772378849620775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638772378849620775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378849620775" xlink:to="us-gaap_ClassOfStockDomain_638772378849620775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SeriesSeedConvertiblePreferredStockMember" xlink:label="zbio_SeriesSeedConvertiblePreferredStockMember_638772378849700790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849620775" xlink:to="zbio_SeriesSeedConvertiblePreferredStockMember_638772378849700790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638772378849700790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849620775" xlink:to="us-gaap_SeriesAPreferredStockMember_638772378849700790" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638772378849750783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849620775" xlink:to="us-gaap_SeriesBPreferredStockMember_638772378849750783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_638772378849750783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378849620775" xlink:to="us-gaap_SeriesCPreferredStockMember_638772378849750783" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638772378849750783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638772378849620775" xlink:to="us-gaap_TemporaryEquityLineItems_638772378849750783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityNumberOfVotesPerShare" xlink:label="zbio_TemporaryEquityNumberOfVotesPerShare_638772378849750783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849750783" xlink:to="zbio_TemporaryEquityNumberOfVotesPerShare_638772378849750783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_638772378849750783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849750783" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_638772378849750783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638772378849750783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849750783" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638772378849750783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock_638772378849750783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849750783" xlink:to="us-gaap_DividendsPreferredStock_638772378849750783" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_638772378849760784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638772378849750783" xlink:to="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_638772378849760784" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638772378849760784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_2" xlink:to="us-gaap_CommonStockSharesAuthorized_638772378849760784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638772378849760784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_2" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638772378849760784" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CommonStockNumberOfVotesPerShare" xlink:label="zbio_CommonStockNumberOfVotesPerShare_638772378849760784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_2" xlink:to="zbio_CommonStockNumberOfVotesPerShare_638772378849760784" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureCommonStockReservedForIssuanceDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Common Stock - Reserved for Issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_3" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock" xlink:label="zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock_638772378849770776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_3" xlink:to="zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock_638772378849770776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638772378849770776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_3" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638772378849770776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance_638772378849770776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_3" xlink:to="zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance_638772378849770776" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638772378849770776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_3" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638772378849770776" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Stock-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849770776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849770776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638772378849770776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849770776" xlink:to="us-gaap_PlanNameAxis_638772378849770776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638772378849770776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638772378849770776" xlink:to="us-gaap_PlanNameDomain_638772378849770776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TwoThousandTwentyPlanMember" xlink:label="zbio_TwoThousandTwentyPlanMember_638772378849780775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638772378849770776" xlink:to="zbio_TwoThousandTwentyPlanMember_638772378849780775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_EquityIncentivePlan2024Member" xlink:label="zbio_EquityIncentivePlan2024Member_638772378849780775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638772378849770776" xlink:to="zbio_EquityIncentivePlan2024Member_638772378849780775" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_EmployeeStockPurchasePlan2024Member" xlink:label="zbio_EmployeeStockPurchasePlan2024Member_638772378849780775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638772378849770776" xlink:to="zbio_EmployeeStockPurchasePlan2024Member_638772378849780775" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638772378849780775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849770776" xlink:to="us-gaap_VestingAxis_638772378849780775" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638772378849780775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638772378849780775" xlink:to="us-gaap_VestingDomain_638772378849780775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638772378849780775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638772378849780775" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638772378849780775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638772378849780775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638772378849780775" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638772378849780775" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638772378849780775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849770776" xlink:to="us-gaap_SubsequentEventTypeAxis_638772378849780775" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638772378849780775" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638772378849780775" xlink:to="us-gaap_SubsequentEventTypeDomain_638772378849780775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638772378849790789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638772378849780775" xlink:to="us-gaap_SubsequentEventMember_638772378849790789" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849790789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849770776" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849790789" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638772378849790789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849790789" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638772378849790789" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638772378849790789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849790789" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638772378849790789" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638772378849790789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849790789" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638772378849790789" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638772378849790789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849790789" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638772378849790789" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_638772378849790789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849790789" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_638772378849790789" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638772378849800779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849790789" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638772378849800779" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized_638772378849800779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849790789" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized_638772378849800779" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638772378849800779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849790789" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638772378849800779" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638772378849800779" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849790789" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638772378849800779" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849810809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849810809" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638772378849810809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849810809" xlink:to="us-gaap_AwardTypeAxis_638772378849810809" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638772378849810809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638772378849810809" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638772378849810809" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638772378849810809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638772378849810809" xlink:to="us-gaap_RestrictedStockMember_638772378849810809" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849810809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849810809" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849810809" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638772378849820801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849810809" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638772378849820801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638772378849820801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638772378849820801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638772378849820801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638772378849820801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638772378849820801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638772378849820801" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod_638772378849820801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638772378849820801" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod_638772378849820801" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6387723788498208011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638772378849820801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6387723788498208011" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638772378849820801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849810809" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638772378849820801" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638772378849830811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638772378849820801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638772378849830811" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638772378849830811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638772378849820801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638772378849830811" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_638772378849830811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638772378849820801" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_638772378849830811" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6387723788498308111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638772378849820801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6387723788498308111" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638772378849830811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849810809" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638772378849830811" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638772378849830811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849810809" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638772378849830811" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - Stock-Based Compensation -Fair values of stock options granted (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849840801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849840801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638772378849840801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849840801" xlink:to="us-gaap_AwardTypeAxis_638772378849840801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638772378849840801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638772378849840801" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638772378849840801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638772378849850802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638772378849840801" xlink:to="us-gaap_EmployeeStockOptionMember_638772378849850802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849850802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849840801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849850802" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638772378849850802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849850802" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638772378849850802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638772378849850802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849850802" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638772378849850802" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638772378849850802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849850802" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638772378849850802" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638772378849850802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849850802" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638772378849850802" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="99941104 - Disclosure - Stock-Based Compensation - Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849860817" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849860817" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638772378849860817" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849860817" xlink:to="us-gaap_AwardTypeAxis_638772378849860817" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638772378849860817" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638772378849860817" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638772378849860817" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638772378849860817" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638772378849860817" xlink:to="us-gaap_EmployeeStockOptionMember_638772378849860817" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849870801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638772378849860817" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849870801" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638772378849870801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849870801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638772378849870801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638772378849870801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849870801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638772378849870801" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638772378849870801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638772378849870801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638772378849870801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638772378849870801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638772378849870801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638772378849870801" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638772378849870801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638772378849870801" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638772378849870801" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638772378849870801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638772378849870801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638772378849870801" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638772378849880802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638772378849870801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638772378849880802" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638772378849880802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638772378849870801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638772378849880802" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638772378849880802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638772378849870801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638772378849880802" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638772378849880802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849870801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638772378849880802" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638772378849880802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638772378849880802" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638772378849880802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638772378849890813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638772378849880802" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638772378849890813" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638772378849890813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638772378849880802" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638772378849890813" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638772378849890813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638772378849880802" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638772378849890813" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638772378849890813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638772378849880802" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638772378849890813" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638772378849900807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638772378849880802" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638772378849900807" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638772378849900807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638772378849880802" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638772378849900807" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_638772378849900807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849870801" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_638772378849900807" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638772378849922370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_638772378849900807" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638772378849922370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638772378849922370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_638772378849900807" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638772378849922370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638772378849922370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_638772378849900807" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638772378849922370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638772378849922370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849870801" xlink:to="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638772378849922370" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638772378849922370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638772378849922370" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638772378849922370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638772378849930816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638772378849922370" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638772378849930816" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638772378849930816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638772378849922370" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638772378849930816" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638772378849930816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638772378849922370" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638772378849930816" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638772378849930816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638772378849922370" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638772378849930816" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638772378849930816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849870801" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638772378849930816" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638772378849930816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849870801" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638772378849930816" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638772378849940903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849870801" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638772378849940903" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638772378849940903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849870801" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638772378849940903" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638772378849940903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638772378849870801" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638772378849940903" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99941105 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638772378849950826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638772378849950826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638772378849950826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638772378849950826" xlink:to="us-gaap_IncomeStatementLocationAxis_638772378849950826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638772378849950826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638772378849950826" xlink:to="us-gaap_IncomeStatementLocationDomain_638772378849950826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638772378849950826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638772378849950826" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638772378849950826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638772378849950826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638772378849950826" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638772378849950826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638772378849950826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638772378849950826" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638772378849950826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638772378849950826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638772378849950826" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638772378849950826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Net Loss Per Share - Basic and diluted (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638772378849960887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638772378849960887" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638772378849960887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638772378849960887" xlink:to="us-gaap_NetIncomeLoss_638772378849960887" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638772378849960887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638772378849960887" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638772378849960887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638772378849960887" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638772378849960887" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638772378849960887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638772378849960887" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638772378849960887" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638772378849960887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638772378849960887" xlink:to="us-gaap_EarningsPerShareBasic_638772378849960887" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638772378849960887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638772378849960887" xlink:to="us-gaap_EarningsPerShareDiluted_638772378849960887" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Net Loss Per Share - Anti-dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638772378849970831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638772378849970831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638772378849970831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638772378849970831" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638772378849970831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638772378849970831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638772378849970831" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638772378849970831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638772378849970831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638772378849970831" xlink:to="us-gaap_ConvertiblePreferredStockMember_638772378849970831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638772378849970831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638772378849970831" xlink:to="us-gaap_RestrictedStockMember_638772378849970831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638772378849970831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638772378849970831" xlink:to="us-gaap_EmployeeStockOptionMember_638772378849970831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638772378849970831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638772378849970831" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638772378849970831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638772378849980812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638772378849970831" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638772378849980812" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Income Taxes - Components of loss before the provision for (benefit from) income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638772378849980812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638772378849980812" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638772378849980812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638772378849980812" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638772378849980812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638772378849980812" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails" xlink:type="extended" xlink:title="99941302 - Disclosure - Income Taxes - Components of the income tax provision (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_638772378849980812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_638772378849980812" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638772378849980812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_638772378849980812" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638772378849980812" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638772378849990840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_638772378849980812" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638772378849990840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638772378849990840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_638772378849980812" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638772378849990840" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638772378849990840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638772378849990840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="99941303 - Disclosure - Income Taxes - Reconciliation of the income tax expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638772378849990840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638772378849990840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638772378849990840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638772378849990840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638772378849990840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638772378849990840" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_638772378849990840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_638772378849990840" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638772378850000816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638772378850000816" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638772378850000816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638772378850000816" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638772378850000816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638772378850000816" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638772378850000816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638772378850000816" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99941304 - Disclosure - Income Taxes - Components of the Company's deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638772378850000816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638772378850000816" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638772378850000816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638772378850000816" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638772378850000816" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638772378850000816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638772378850000816" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638772378850000816" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638772378850010786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638772378850000816" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638772378850010786" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638772378850010786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638772378850000816" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638772378850010786" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DeferredTaxAssetsMilestonePayments" xlink:label="zbio_DeferredTaxAssetsMilestonePayments_638772378850010786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638772378850000816" xlink:to="zbio_DeferredTaxAssetsMilestonePayments_638772378850010786" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638772378850010786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638772378850000816" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638772378850010786" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638772378850010786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638772378850000816" xlink:to="us-gaap_DeferredTaxAssetsOther_638772378850010786" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638772378850010786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638772378850000816" xlink:to="us-gaap_DeferredTaxAssetsGross_638772378850010786" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638772378850010786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638772378850010786" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DeferredTaxLiabilitiesAmortizationAndOther" xlink:label="zbio_DeferredTaxLiabilitiesAmortizationAndOther_638772378850010786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638772378850010786" xlink:to="zbio_DeferredTaxLiabilitiesAmortizationAndOther_638772378850010786" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638772378850010786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638772378850010786" xlink:to="us-gaap_DeferredTaxLiabilities_638772378850010786" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:label="zbio_DeferredTaxAssetsNetBeforeValuationAllowance_638772378850020783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638772378850010786" xlink:to="zbio_DeferredTaxAssetsNetBeforeValuationAllowance_638772378850020783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638772378850020783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638772378850010786" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638772378850020783" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638772378850020783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638772378850010786" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638772378850020783" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="99941305 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable_638772378850020783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_TaxCreditCarryforwardTable_638772378850020783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638772378850020783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_638772378850020783" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638772378850020783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638772378850030802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638772378850020783" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638772378850030802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638772378850030802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638772378850030802" xlink:to="us-gaap_ResearchMember_638772378850030802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638772378850030802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_638772378850020783" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638772378850030802" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638772378850030802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638772378850030802" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638772378850030802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638772378850030802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638772378850030802" xlink:to="us-gaap_DomesticCountryMember_638772378850030802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638772378850030802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638772378850030802" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638772378850030802" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_638772378850020783" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638772378850030802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638772378850030802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638772378850030802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638772378850030802" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638772378850040880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638772378850040880" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638772378850040880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638772378850040880" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal" xlink:label="zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal_638772378850040880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal_638772378850040880" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638772378850040880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638772378850040880" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_OperatingLossCarryforwardsExpirationPeriod" xlink:label="zbio_OperatingLossCarryforwardsExpirationPeriod_638772378850040880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="zbio_OperatingLossCarryforwardsExpirationPeriod_638772378850040880" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TaxCreditCarryforwardExpirationPeriod" xlink:label="zbio_TaxCreditCarryforwardExpirationPeriod_638772378850040880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="zbio_TaxCreditCarryforwardExpirationPeriod_638772378850040880" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_638772378850040880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_638772378850040880" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_638772378850040880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_638772378850040880" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638772378850050799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="us-gaap_UnrecognizedTaxBenefits_638772378850050799" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_638772378850050799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_638772378850050799" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_UncertainTaxPositionsAmountRecognized" xlink:label="zbio_UncertainTaxPositionsAmountRecognized_638772378850050799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638772378850030802" xlink:to="zbio_UncertainTaxPositionsAmountRecognized_638772378850050799" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureEmployeeBenefitPlansDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - Employee Benefit Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_638772378850060791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_1" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_638772378850060791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - Related Party Transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638772378850060791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_1" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638772378850060791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638772378850060791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638772378850060791" xlink:to="srt_CounterpartyNameAxis_638772378850060791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638772378850060791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638772378850060791" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638772378850060791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_XencorIncMember" xlink:label="zbio_XencorIncMember_638772378850060791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638772378850060791" xlink:to="zbio_XencorIncMember_638772378850060791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ViridianTherapeuticsIncMember" xlink:label="zbio_ViridianTherapeuticsIncMember_638772378850070791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638772378850060791" xlink:to="zbio_ViridianTherapeuticsIncMember_638772378850070791" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_DianthusTherapeuticsincMember" xlink:label="zbio_DianthusTherapeuticsincMember_638772378850070791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638772378850060791" xlink:to="zbio_DianthusTherapeuticsincMember_638772378850070791" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638772378850070791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638772378850060791" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638772378850070791" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638772378850070791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638772378850070791" xlink:to="us-gaap_RelatedPartyDomain_638772378850070791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638772378850070791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638772378850070791" xlink:to="us-gaap_RelatedPartyMember_638772378850070791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638772378850070791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638772378850060791" xlink:to="us-gaap_StatementClassOfStockAxis_638772378850070791" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638772378850070791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638772378850070791" xlink:to="us-gaap_ClassOfStockDomain_638772378850070791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638772378850070791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378850070791" xlink:to="us-gaap_SeriesAPreferredStockMember_638772378850070791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638772378850070791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638772378850070791" xlink:to="us-gaap_SeriesBPreferredStockMember_638772378850070791" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638772378850080793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638772378850060791" xlink:to="dei_LegalEntityAxis_638772378850080793" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638772378850080793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638772378850080793" xlink:to="dei_EntityDomain_638772378850080793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_FairmountFundsManagementLlcMember" xlink:label="zbio_FairmountFundsManagementLlcMember_638772378850080793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638772378850080793" xlink:to="zbio_FairmountFundsManagementLlcMember_638772378850080793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638772378850080793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638772378850060791" xlink:to="srt_RangeAxis_638772378850080793" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638772378850080793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638772378850080793" xlink:to="srt_RangeMember_638772378850080793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638772378850080793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638772378850080793" xlink:to="srt_MaximumMember_638772378850080793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638772378850080793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638772378850060791" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638772378850080793" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained" xlink:label="zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained_638772378850080793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638772378850080793" xlink:to="zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained_638772378850080793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RelatedPartyTransactionNumberOfLicenseAgreements" xlink:label="zbio_RelatedPartyTransactionNumberOfLicenseAgreements_638772378850090801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638772378850080793" xlink:to="zbio_RelatedPartyTransactionNumberOfLicenseAgreements_638772378850090801" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638772378850090801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638772378850080793" xlink:to="zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638772378850090801" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee" xlink:label="us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee_638772378850090801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638772378850080793" xlink:to="us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee_638772378850090801" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_RelatedPartyTransactionReimbursableCosts" xlink:label="zbio_RelatedPartyTransactionReimbursableCosts_638772378850090801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638772378850080793" xlink:to="zbio_RelatedPartyTransactionReimbursableCosts_638772378850090801" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_OwnershipPercentageByRelatedParty" xlink:label="zbio_OwnershipPercentageByRelatedParty_638772378850090801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638772378850080793" xlink:to="zbio_OwnershipPercentageByRelatedParty_638772378850090801" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NumberOfSeatsHeldInBoard" xlink:label="zbio_NumberOfSeatsHeldInBoard_638772378850090801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638772378850080793" xlink:to="zbio_NumberOfSeatsHeldInBoard_638772378850090801" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638772378850090801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638772378850080793" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638772378850090801" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureSegmentInformationDetails" xlink:type="extended" xlink:title="99941701 - Disclosure - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638772378850100796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638772378850100796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638772378850100796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638772378850100796" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638772378850100796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638772378850100796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638772378850100796" xlink:to="us-gaap_SegmentDomain_638772378850100796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_SingleReportableSegmentMember" xlink:label="zbio_SingleReportableSegmentMember_638772378850100796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638772378850100796" xlink:to="zbio_SingleReportableSegmentMember_638772378850100796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638772378850100796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638772378850100796" xlink:to="srt_ProductOrServiceAxis_638772378850100796" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638772378850100796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638772378850100796" xlink:to="srt_ProductsAndServicesDomain_638772378850100796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ObexelimabMember" xlink:label="zbio_ObexelimabMember_638772378850110823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638772378850100796" xlink:to="zbio_ObexelimabMember_638772378850110823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_OtherProgramsZb002Zb004Member" xlink:label="zbio_OtherProgramsZb002Zb004Member_638772378850110823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638772378850100796" xlink:to="zbio_OtherProgramsZb002Zb004Member_638772378850110823" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_PartneredRegionalProgramsZb001Zb005Member" xlink:label="zbio_PartneredRegionalProgramsZb001Zb005Member_638772378850110823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638772378850100796" xlink:to="zbio_PartneredRegionalProgramsZb001Zb005Member_638772378850110823" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_UnallocatedMember" xlink:label="zbio_UnallocatedMember_638772378850110823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638772378850100796" xlink:to="zbio_UnallocatedMember_638772378850110823" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638772378850110823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638772378850100796" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638772378850110823" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638772378850110823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638772378850110823" xlink:to="us-gaap_Revenues_638772378850110823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638772378850110823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638772378850110823" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638772378850110823" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638772378850110823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638772378850110823" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638772378850110823" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638772378850110823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638772378850110823" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638772378850110823" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638772378850120808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638772378850110823" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638772378850120808" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638772378850120808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638772378850110823" xlink:to="us-gaap_NetIncomeLoss_638772378850120808" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://zenasbio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941801 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638772378850120808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_638772378850120808" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638772378850120808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638772378850120808" xlink:to="us-gaap_SubsequentEventTypeAxis_638772378850120808" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638772378850130826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638772378850120808" xlink:to="us-gaap_SubsequentEventTypeDomain_638772378850130826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638772378850130826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638772378850130826" xlink:to="us-gaap_SubsequentEventMember_638772378850130826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638772378850130826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638772378850120808" xlink:to="us-gaap_TypeOfArrangementAxis_638772378850130826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378850130826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638772378850130826" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378850130826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_ZaiLicenseAgreementMember" xlink:label="zbio_ZaiLicenseAgreementMember_638772378850130826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638772378850130826" xlink:to="zbio_ZaiLicenseAgreementMember_638772378850130826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638772378850130826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638772378850120808" xlink:to="us-gaap_SubsequentEventLineItems_638772378850130826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementUpfrontPaymentReceived" xlink:label="zbio_CollaborativeArrangementUpfrontPaymentReceived_638772378850130826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638772378850130826" xlink:to="zbio_CollaborativeArrangementUpfrontPaymentReceived_638772378850130826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone" xlink:label="zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone_638772378850130826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638772378850130826" xlink:to="zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone_638772378850130826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_Rule10b51ArrangementModifiedFlag" xlink:label="zbio_Rule10b51ArrangementModifiedFlag_638772378850140814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="zbio_Rule10b51ArrangementModifiedFlag_638772378850140814" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="zbio-20241231.xsd#zbio_NonRule10b51ArrangementModifiedFlag" xlink:label="zbio_NonRule10b51ArrangementModifiedFlag_638772378850140814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="zbio_NonRule10b51ArrangementModifiedFlag_638772378850140814" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended" xlink:title="995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793420896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Zenas BioPharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">93-2749244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">852 Winter Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">271-2954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZBIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,799,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001953926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Portions of the Registrant&#8217;s definitive proxy statement relating to the 2025 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant&#8217;s fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K. </p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793084688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 319,742<span></span>
</td>
<td class="nump">$ 56,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">31,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,067<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">355,923<span></span>
</td>
<td class="nump">59,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">12,856<span></span>
</td>
<td class="nump">7,276<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">369,968<span></span>
</td>
<td class="nump">68,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable (includes $560 and $21 owed to related parties, respectively)</a></td>
<td class="nump">17,136<span></span>
</td>
<td class="nump">5,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (includes $260 and $404 owed to related parties, respectively)</a></td>
<td class="nump">39,371<span></span>
</td>
<td class="nump">17,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">57,292<span></span>
</td>
<td class="nump">23,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">57,510<span></span>
</td>
<td class="nump">43,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract', window );"><strong>Convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.0001 per share; 25,000,000 and no shares authorized as of December 31, 2024 and 2023, respectively; no shares issued and outstanding as of December 31, 2024 and 2023.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001 per share; 175,000,000 shares authorized as of December 31, 2024 and 2023; 41,793,412 and 1,576,854 shares issued and outstanding as of December 31, 2024 and 2023, respectively.</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">699,651<span></span>
</td>
<td class="nump">4,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(387,391)<span></span>
</td>
<td class="num">(230,403)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">312,458<span></span>
</td>
<td class="num">(225,721)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">$ 369,968<span></span>
</td>
<td class="nump">68,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract', window );"><strong>Convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract', window );"><strong>Convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract', window );"><strong>Convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793933984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 17,136<span></span>
</td>
<td class="nump">$ 5,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 39,371<span></span>
</td>
<td class="nump">$ 17,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,617,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,617,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,617,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollar per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollar per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">41,793,412<span></span>
</td>
<td class="nump">1,576,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">41,793,412<span></span>
</td>
<td class="nump">1,576,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 560<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,785,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,785,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,785,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,589,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,589,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,589,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,242,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,242,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,242,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522792943440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (includes $3,524 and $3,041 from related parties, respectively)</a></td>
<td class="nump">139,139<span></span>
</td>
<td class="nump">60,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative (includes $0 and $8 from related parties, respectively)</a></td>
<td class="nump">29,749<span></span>
</td>
<td class="nump">17,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">168,888<span></span>
</td>
<td class="nump">87,147<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(163,888)<span></span>
</td>
<td class="num">(37,147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_FairValueAdjustmentOfConvertibleNotes', window );">Fair value adjustments to convertible notes</a></td>
<td class="num">(846)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">8,175<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">7,329<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(156,559)<span></span>
</td>
<td class="num">(36,823)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(429)<span></span>
</td>
<td class="num">(301)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss to common stockholders</a></td>
<td class="num">$ (156,988)<span></span>
</td>
<td class="num">$ (37,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders - basic (in dollars per share)</a></td>
<td class="num">$ (11.89)<span></span>
</td>
<td class="num">$ (24.25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - diluted (in dollars per share)</a></td>
<td class="num">$ (11.89)<span></span>
</td>
<td class="num">$ (24.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding - basic (in shares)</a></td>
<td class="nump">13,198,960<span></span>
</td>
<td class="nump">1,531,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding - diluted (in shares)</a></td>
<td class="nump">13,198,960<span></span>
</td>
<td class="nump">1,531,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss to common stockholders</a></td>
<td class="num">$ (156,988)<span></span>
</td>
<td class="num">$ (37,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities, net tax</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (156,831)<span></span>
</td>
<td class="num">$ (37,046)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized from cost for research and development asset acquired in transaction other than business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_FairValueAdjustmentOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_FairValueAdjustmentOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793271584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 139,139<span></span>
</td>
<td class="nump">$ 60,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">29,749<span></span>
</td>
<td class="nump">17,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,524<span></span>
</td>
<td class="nump">3,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793688688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series Seed convertible preferred stock</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A convertible preferred stock</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series B convertible preferred stock</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series C convertible preferred stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series Seed convertible preferred stock</div></th>
<th class="th"><div>Series A convertible preferred stock</div></th>
<th class="th"><div>Series B convertible preferred stock</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at beginning at Dec. 31, 2022</a></td>
<td class="nump">$ 956<span></span>
</td>
<td class="nump">$ 55,840<span></span>
</td>
<td class="nump">$ 183,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at beginning (in shares) at Dec. 31, 2022</a></td>
<td class="nump">1,785,714<span></span>
</td>
<td class="nump">17,589,380<span></span>
</td>
<td class="nump">77,052,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Changes in Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,189,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at end at Dec. 31, 2023</a></td>
<td class="nump">$ 956<span></span>
</td>
<td class="nump">$ 55,840<span></span>
</td>
<td class="nump">$ 193,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 956<span></span>
</td>
<td class="nump">$ 55,840<span></span>
</td>
<td class="nump">$ 193,290<span></span>
</td>
<td class="nump">$ 250,086<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the end (in shares) at Dec. 31, 2023</a></td>
<td class="nump">1,785,714<span></span>
</td>
<td class="nump">17,589,380<span></span>
</td>
<td class="nump">81,242,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,785,714<span></span>
</td>
<td class="nump">17,589,380<span></span>
</td>
<td class="nump">81,242,587<span></span>
</td>
<td class="nump">100,617,681<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (193,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (192,286)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,549,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,124)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,645<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="num">(230,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225,721)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,576,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Changes in Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,275,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion', window );">Conversion of convertible preferred stock to common stock upon closing of initial public offering</a></td>
<td class="num">$ (956)<span></span>
</td>
<td class="num">$ (55,840)<span></span>
</td>
<td class="num">$ (193,290)<span></span>
</td>
<td class="num">$ (199,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion', window );">Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)</a></td>
<td class="num">(1,785,714)<span></span>
</td>
<td class="num">(17,589,380)<span></span>
</td>
<td class="num">(81,242,587)<span></span>
</td>
<td class="num">(116,275,239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the end (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of unvested restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">234,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,220,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(156,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(156,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock upon closing of initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">449,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,978,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 699,651<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="num">$ (387,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,458<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,793,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares converted from temporary equity to permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of conversion of securities from temporary equity to permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788761648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - Convertible Preferred Stock - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Series C convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793665504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (156,988)<span></span>
</td>
<td class="num">$ (37,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Net amortization of premiums and accretion of discounts on short-term investments</a></td>
<td class="num">(602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10,821<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_FairValueAdjustmentOfConvertibleNotes', window );">Change in fair value of convertible notes</a></td>
<td class="nump">846<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">681<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(7,701)<span></span>
</td>
<td class="num">(3,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">11,740<span></span>
</td>
<td class="num">(418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">22,065<span></span>
</td>
<td class="num">(3,558)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(673)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(119,674)<span></span>
</td>
<td class="num">(30,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(36,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sale and maturities of short-term investments</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(30,552)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of Series C convertible preferred stock, net of issuance costs</a></td>
<td class="nump">178,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discount and commissions</a></td>
<td class="nump">240,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of initial public offering costs</a></td>
<td class="num">(6,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from sale of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">412,958<span></span>
</td>
<td class="nump">20,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">262,889<span></span>
</td>
<td class="num">(10,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">56,943<span></span>
</td>
<td class="nump">67,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">319,832<span></span>
</td>
<td class="nump">56,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAssumed1', window );">Fair value of BMS Note recognized as Series C Convertible preferred stock upon conversion</a></td>
<td class="nump">21,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock to common stock upon closing of initial public offering</a></td>
<td class="nump">449,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained under operating lease arrangements</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_DeferredOfferingCostsIncludedInAccruedExpenses', window );">Deferred offering costs in accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized from cost for research and development asset acquired in transaction other than business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_DeferredOfferingCostsIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred offering costs included in accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_DeferredOfferingCostsIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_FairValueAdjustmentOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_FairValueAdjustmentOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522789418000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 319,742<span></span>
</td>
<td class="nump">$ 56,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 319,832<span></span>
</td>
<td class="nump">$ 56,943<span></span>
</td>
<td class="nump">$ 67,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522896069568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span>Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Organization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Zenas BioPharma,&#160;Inc. (&#8220;Zenas&#8221; or the &#8220;Company&#8221;) was incorporated in November&#160;2019 as Zenas BioPharma (Cayman) Limited, an exempted company incorporated in the Cayman Islands with limited liability, and commenced operations in 2020. On August&#160;2, 2023, the Company (then known as Zenas BioPharma (Cayman) Limited (&#8220;Zenas Cayman&#8221;)) de-registered from the Cayman Islands and registered by way of continuation in the State of Delaware (the &#8220;Redomicile&#8221;). Zenas is a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. The Company&#8217;s goal is to build an immunology and inflammation (&#8220;I&amp;I&#8221;) focused biopharmaceutical company. The Company has in-licensed and is developing several product candidates for the treatment of various auto-immune and rare diseases. The Company is headquartered in Waltham, Massachusetts and operates in one segment, which is the business of acquiring and developing immune-based therapies for potential commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements include the accounts of its wholly owned subsidiaries which include Zenas BioPharma (HK) Limited (&#8220;Zenas HK&#8221;), Zenas BioPharma (USA) LLC (&#8220;Zenas US&#8221;), Shanghai Zenas Biotechnology Co. Limited (&#8220;Zenas China&#8221;), Zenas BioPharma Securities Corp., and Zenas BioPharma GmbH. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to clinical stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical studies and clinical trials, obtaining regulatory approval for product candidates, market acceptance of products, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary technology, compliance with government regulations, and the ability to raise additional capital to fund operations. The Company&#8217;s revenues to date have been generated from payments received under the Company&#8217;s license and collaboration agreement with Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and novation agreement with Tenacia Biotechnology (&#8220;Tenacia&#8221;) (see <i style="font-style:italic;">Note&#160;7, License and Collaboration Revenue</i>). The Company has not generated any revenue from product sales since inception, and its product candidates currently under development will require significant additional research and development efforts, including extensive clinical testing and regulatory approval prior to commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;16, 2024, the Company completed its initial public offering (&#8220;IPO&#8221;), in which the Company issued and sold 15,220,588 shares of its common stock, including 1,985,294 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $17.00 per share, for aggregate gross proceeds of $258.7 million. The Company received $234.3 million in net proceeds after deducting underwriting discounts, commissions and other offering expenses. In connection with the IPO, all outstanding shares of convertible preferred stock converted into 24,978,715 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with, and prior to, the Company&#8217;s IPO, the Company effected a 1-for-8.6831 reverse stock split of the Company&#8217;s issued and outstanding common stock and adjusted the conversion ratio of all the Company&#8217;s outstanding convertible preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split and the adjustment of the preferred stock conversion ratios.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has incurred operating losses and negative cash flows since its inception, including net losses of $157.0 million and $37.1 million in the years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024 and 2023, the Company had an accumulated deficit of $387.4 million and $230.4 million, respectively. Management expects operating losses and negative operating cash flows to continue for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company expects that its existing cash, cash equivalents and short-term investments of $350.8 million as of December&#160;31, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve&#160;months from the date this Form 10-K is filed. The Company will need additional financing to support its continuing operations and to pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of private or public equity financings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions and licensing agreements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company&#8217;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522795040128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span>Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the operations of the Company and its wholly-owned subsidiaries. All intercompany accounts, transactions, and balances have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been or omitted pursuant to such rules&#160;and regulations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosures. The Company bases its estimates on historical experience, known trends and other market- specific factors or other relevant factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis using such factors and adjusts those estimates and assumptions as facts and circumstances dictate. Actual results may differ from those estimates or assumptions. Significant estimates in these consolidated financial statements include estimates made in connection with accrued research and development expenses, stock-based compensation and pre-initial public offering (&#8220;IPO&#8221;) valuations of common stock, and convertible debt.</span><b style="font-style:normal;font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original or remaining maturity from the date of purchase of three&#160;months or less to be cash equivalents. Cash equivalents may include money market funds, corporate debt securities, U.S government agency notes and overnight deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Short-Term Investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company classifies all investments with a remaining maturity when purchased of greater than three months as &#8220;available-for-sale&#8221;. Available-for-sale securities with a remaining maturity of greater than one year are classified as non-current assets. Available-for-sale securities are carried at fair value based upon market prices at period end, with the unrealized gains and losses included in accumulated other comprehensive loss as a component of stockholders&#8217; equity (deficit) until realized. The amortized cost of investments in this category is adjusted for amortization of premiums and accretions of discounts over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense). The Company reviews its portfolio of investments, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss. If the decline in fair value is due to credit-related factors, a loss is recognized in other income (expense).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Cash </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of cash held as collateral for a letter of credit the Company issued as a security deposit for its lease of office space in Waltham, MA, which terminated in January 2025. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Deferred Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company capitalizes legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as other non-current assets until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in-capital generated as a result of the offering. If the Company terminates its plan for an equity financing, any costs deferred will be expensed immediately. Upon closing the IPO in September 2024, the related deferred offering costs were recorded against the IPO proceeds. No deferred offering costs were recorded as of December 31, 2024. As of December 31, 2023, the Company had $1.4 million in deferred offering costs which were included in other assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one reportable segment focused on the research and development of precision immunology-based therapies. The Company&#8217;s chief operating decision-maker (the &#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of making operating decisions, assessing financial performance, and allocating resources. As of December 31, 2024 and 2023, the Company&#8217;s long-lived assets held outside of the U.S. were immaterial. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our segment reporting, see <i style="font-style:italic;">Note 17, Segment Information</i> to these consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and short-term investments. The Company attempts to minimize the risks related to cash, cash equivalents and short- investments by investing in a broad range of financial instruments, as defined by the Company&#8217;s investment policy. The Company has established guidelines related to the quality of the institutions, financial instruments and allowable investments. The Company minimizes credit risk by choosing only highly rated financial institutions as counterparties. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant Suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs, including preclinical and clinical studies and testing. In particular, the Company relies on a single manufacturer and expects to continue to rely on a single or small number of manufacturers to supply it with its requirements for the drug product related to these programs. These programs could be adversely affected by a significant interruption in the supply of drug substance and drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Translation of Foreign Currency </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign subsidiaries into U.S. dollars are excluded from our determination of net loss and are recorded in accumulated other comprehensive income (loss), as a separate component of equity. For foreign subsidiaries where the functional currency of assets and liabilities differs from their local currency, non-monetary assets and liabilities are translated at the rate of the exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other (income) expense, net in our consolidated statements of income. Realized and unrealized foreign currency transaction losses were $0.2 million and $0.1 million for each of the&#160;years ended December&#160;31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 0pt 20pt;">Level&#160;1&#8212;<span style="font-style:normal;"> Quoted market prices in active markets for identical assets or liabilities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 0pt 20pt;">Level&#160;2&#8212;<span style="font-style:normal;"> Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 12pt 20.15pt;">Level&#160;3&#8212;<span style="font-style:normal;"> Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level&#160;3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The majority of our financial assets have been classified as Level 1. Our financial assets (which typically include cash equivalents and marketable equity securities) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market- based approaches and observable market inputs to determine value. These observation market inputs included reportable tables, benchmark yields, broker quotes, bids, offers, current spot rates and other industry and economic events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-Lived Assets </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amount of the assets to their undiscounted expected future cash flows. If this comparison indicates there is an impairment, the amount of the impairment is calculated as the difference between the carrying value and fair value. To date, no such impairments have been recognized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Property and equipment are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (<span style="-sec-ix-hidden:Hidden_b_kdHKCFF0avLUjrQ41Fwg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to seven years). Assets under capital leases are amortized over the shorter of their useful </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">lives or lease terms using the straight-line method. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License and Collaboration Revenue </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company enters into license and collaboration arrangements with third parties, under which the Company licenses or may license rights to certain of the Company&#8217;s product candidates and may perform research and development services in connection with such arrangements. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, clinical, regulatory and commercial sales milestone payments, and royalties on net sales of licensed products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">At contract inception, the Company analyzes its collaboration and license arrangements to assess whether such arrangements are within the scope of ASC Topic 808,&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Collaborative Arrangements</i><span style="letter-spacing:0.2pt;">&#160;(&#8220;ASC 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple&#160;units of account, the Company first determines which&#160;units of the collaboration are deemed to be within the scope of ASC 808 and which&#160;units of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of ASC Topic 606,&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Revenue from Contracts with Customers</i><span style="letter-spacing:0.2pt;">&#160;(&#8220;ASC&#160;606&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC 808: (i)&#160;the parties to the contract must actively participate in the joint operating activity and (ii)&#160;the joint operating activity must expose the parties to the possibility of significant risks and rewards, based on whether or not the activity is successful. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. Payments received from or made to a partner that are the result of a collaborative relationship with a partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction or increase to research and development expense, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">For the&#160;units of account within the scope of ASC 606, to determine the appropriate amount of revenue to be recognized for the arrangements, the Company performs the following five steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The promised goods or services in the Company&#8217;s arrangements typically consist of a license to the Company&#8217;s intellectual property and research and development services. The Company provides options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Due to the uncertainty of research and development and regulatory based milestones that are not within the control of the Company, payment becomes probable upon achievement. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and collaboration revenue in the period of adjustment. Any amounts due to the Company but not received as of period-end will be recorded to other current assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs including a reasonable margin. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Research and development costs include (i)&#160;employee-related expenses, including salaries, benefits, and stock-based compensation expense; (ii)&#160;external research and development expenses incurred under arrangements with third parties, such as CRO agreements and consultants; (iii)&#160;costs associated with preclinical activities and (iv)&#160;lab supplies, lab expenses and an allocation of rent, depreciation, and infrastructure. Costs incurred in connection with research and development activities are expensed as incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data, such as patient enrollment or clinical site activations, provided by the Company&#8217;s clinical sites and vendors. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable. The Company monitors each of these factors and adjusts estimates accordingly. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Asset Acquisitions and Acquired In-Process Research and Development Expense </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company accounts for acquisitions of assets or a group of assets that do not meet the definition of a business as asset acquisitions based on the cost to acquire the asset or group of assets, which include certain transaction costs. In an asset acquisition, the cost to acquire is allocated to the identifiable assets acquired and liabilities assumed based on their relative fair values as of the acquisition date. No goodwill is recorded in an asset acquisition. Assets that are </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as in process research and development (&#8220;IPR&amp;D&#8221;). Acquired IPR&amp;D that has no alternative future use as of the acquisition date is recognized as acquired IPR&amp;D expense as of the acquisition date. The Company will recognize additional acquired IPR&amp;D expenses in the future if and when the Company becomes obligated to make contingent milestone payments under the terms of the agreements by which it acquired the IPR&amp;D assets. The Company classifies payments made for the acquisition of IPR&amp;D assets, whether capitalized or expensed, as investing activities on its statement of cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Contingent consideration in the form of milestone payments related to IPR&amp;D with no alternative future use are charged to expense when the related milestone is achieved and becomes payable. For the year ended December&#160;31, 2024, the Company did not recognize any acquired IPR&amp;D expense. For the year ended December 31, 2023, the Company recognized </span><span style="letter-spacing:0.2pt;">$10.0</span><span style="letter-spacing:0.2pt;">&#160;million of IPR&amp;D expense, in connection with the consideration due under the 2021 Xencor Agreement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our asset acquisitions and acquired in-process research and development, please see <i style="font-style:italic;">Note 8, License and Option Agreements,</i> to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss consists of net loss and other comprehensive loss. During the years ended December 31, 2024 and 2023, the Company&#8217;s only element of other comprehensive loss was foreign currency translation adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases </p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of use lease assets (&#8220;ROU assets&#8221;), current portion of lease obligations and long-term lease obligations on the Company&#8217;s consolidated balance sheet. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#8217;s consolidated balance sheet. Lease assets are tested for impairment in the same manner as</span><span style="font-family:'TimesNewRomanPSMT';"> </span><span style="font-size:10pt;">long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense, while expense for financing leases is recognized as depreciation expense (classified as an operating expense) and interest expense (classified as a non-operating expense) using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheet for leases with an original term of twelve months or less. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recognized based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. Certain adjustments to the ROU asset may be required for items such as incentives received from the lessor. The interest rate implicit in lease contracts is typically not readily determinable. Therefore, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasures the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company generally accounts for non-lease components together with lease components. The Company expenses variable payments included in a lease arrangement as such expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our leases, please see <i style="font-style:italic;">Note 6, Leases</i>, to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740, <i style="font-style:italic;">Accounting for Income Taxes</i>, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a &#8220;more likely than not&#8221; threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are no unrecognized tax benefits included in the Company&#8217;s consolidated balance sheets as of December 31, 2024 and 2023. The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties related to uncertain tax positions in its consolidated statements of operations and comprehensive loss since inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The Company grants stock-based awards to employees, non-employee consultants and members of its board of directors (the &#8220;Board&#8221;). Stock-based compensation is recognized as expense for each stock-based award based on its estimated fair value on the date of grant. The Company&#8217;s share-based payments include stock options and grants of restricted common stock. The value of the award is recognized as expense on a straight-line basis over the requisite service period, and expense is adjusted for pre-vesting forfeitures in the period in which the forfeitures occur. Stock-based compensation expense is classified in the accompanying consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipients service payments are classified.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="letter-spacing:0.2pt;">The Company estimates the fair value of each restricted stock award (&#8220;RSA&#8217;s&#8221;) at its grant date based on the estimated fair value of the Company&#8217;s common stock on that date as determined by the Board. The Company estimates the fair value of stock option awards on the grant date using a Black-Scholes option pricing model. The Company estimates the expected option lives using the simplified method, volatility using historical stock prices of peer companies, the risk-free rates using the U.S Treasury yield curve in effect with a remaining term equal to the expected term and dividend yield based on the Company&#8217;s history of paying no dividends and the expectations of paying no cash dividends in the foreseeable future. Prior to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock on the date of grant was determined by the Board, taking into consideration its most recently available third-party valuations of common stock as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the grant date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;">For additional information on our share-based compensation, please see <i style="font-style:italic;">Note 11, Stock-Based Compensation</i>, to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Convertible Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The Company classified its convertible preferred stock as temporary equity (between liabilities and stockholders&#8217; equity (deficit)) in the accompanying consolidated balance sheet because it could have become redeemable due to certain change in control clauses that were outside of the Company&#8217;s control. The convertible preferred stock was not redeemable, except in the event of a deemed liquidation event. As the occurrence of a deemed liquidation event was not currently probable at December 31, 2023, the carrying values of the convertible preferred stock were not being accreted to their redemption values. Upon the completion of the Company&#8217;s IPO on September 16, 2024, all outstanding shares of the Company&#8217;s convertible preferred stock converted into shares of the Company&#8217;s common stock. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our convertible preferred stock, please see <i style="font-style:italic;">Note 9, Convertible Preferred Stock</i>, to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two- class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#8217;s common shares and participating securities. The Company&#8217;s convertible preferred stock contained participation rights in any dividend paid by the Company and is deemed to be a participating security. Net loss attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Diluted net loss per share is computed using the more dilutive of (a)&#160;the two-class method or (b)&#160;the if- converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss per share gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders for the&#160;years ended December&#160;31, 2024 and 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (&#8220;FASB&#8221;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated statements or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">In November&#160;2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280)&#8212;Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;)</i>, which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. This standard became effective for the Company for the annual reporting period ended December 31, 2024, using the retrospective method. The adoption of this standard resulted in additional disclosure of the significant expenses reviewed by the Company&#8217;s CODM. The adoption did not have a material impact on the consolidated financial position or results of operations. See <i style="font-style:italic;">Note 17, Segment Information</i>, for our updated segment presentation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740)&#8212;Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;)</i>, which requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company beginning in fiscal year 2025, with early adoption permitted. ASU 2023-09 may be applied retrospectively or prospectively to the financial statements. The Company is currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In November&#160;2024, the FASB issued 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;)</i>, which requires entities to disclose additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective annual periods beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">prospectively to the financial statements. The Company is currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522890585136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span>Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following tables present information about the Company&#8217;s assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:bottom;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:28.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Carrying Value</b></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted Prices in Active Market </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other Observable Inputs</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other Observable Inputs</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Cash</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Money market funds</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300,672</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investments:</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,315</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Corporate debt securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,601</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Government securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,108</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">     Total assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 350,766</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 338,850</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,916</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:30.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:bottom;width:66.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2023</b></p></td></tr><tr><td style="vertical-align:middle;width:30.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Carrying Value</b></p></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted Prices in Active Market </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other Observable Inputs</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other Observable Inputs</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  BMS note</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,300</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,300</p></td></tr><tr><td style="vertical-align:bottom;width:30.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">     Total liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,300</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,300</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have been no material impairments of our assets measured and carried at fair value during the year ended December 31, 2024. The fair value of Level 1 instruments classified as money market funds and government securities are valued using quoted market prices in active markets. The fair value of Level 2 instruments classified as short-term investments was determined using other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and fair value is determined using models or other valuation methodologies. There were no transfers between levels during the years ended December 31, 2024 and 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The short-term investments are classified as available-for-sales securities. As of December 31, 2024, the remaining contractual maturities of the available-for-sales securities were within one year, the balance in the Company&#8217;s accumulated other comprehensive income was comprised solely of activity related to the Company&#8217;s available-for-sale securities. There were no realized gains or losses recognized on the sale or maturity of available-for-sale securities during the year ended December 31, 2024. As a result, the Company did not reclassify any amounts out of accumulated other comprehensive income for the same period. The Company has a limited number of available-for-sale securities in insignificant loss </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">positions as of December 31, 2024, which the Company does not intend to sell and has concluded will not be required to sell before recovery of the amortized cost for the investment maturity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the available-for-sale securities (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:bottom;width:56.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Unrealized Gains</b></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Unrealized Losses</b></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short-term investments:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,311</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,315</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,601</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,108</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,993</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,024</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain short-term debt securities with original maturities of less than 90&#160;days are included in cash and cash equivalents on the consolidated balance sheets and are not included in the table above. The Company did not hold any investments as of December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Convertible Notes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2023, the Company entered into a $20.0 million convertible promissory note agreement with BMS (the &#8220;BMS Note&#8221;) in connection with its strategic license and collaboration agreement with BMS (the &#8220;BMS Agreement&#8221;) (see <i style="font-style:italic;">Note 7, License and Collaboration Revenue</i>). In the event that the Company issued and sold its convertible preferred stock to accredited investors with total gross proceeds equal to at least $70.0 million (a &#8220;BMS Qualified Financing&#8221;), the outstanding principal and accrued interest of the BMS Note were automatically convertible into equity securities sold in the BMS Qualified Financing at the conversion price equal (i) to the outstanding principal and accrued interest under the BMS Note divided by (ii) the lowest cash price paid per equity security. The Company elected the fair value option to account for the BMS Note. Changes in fair value at every reporting date are recorded as a component of the other income (expense), net. The BMS Note was classified as a liability on the Company&#8217;s consolidated balance sheet as of December 31, 2023 and was initially recorded at fair value. The Company subsequently remeasured the fair value of the BMS Note at each applicable reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 3, 2024, the Company issued and sold Series C convertible preferred stock (&#8220;Series C Preferred Stock&#8221;), which was deemed to be a BMS Qualified Financing, as described above, and resulted in the outstanding BMS Note plus accrued interest being automatically converted into 12,284,686 shares of Series C Preferred Stock (see<i style="font-style:italic;"> Note 9, Convertible Preferred Stock</i>). Immediately prior to settlement, the BMS Note was remeasured to fair value utilizing fair value of the shares of Series C Preferred Stock for which the BMS Note converted into. The BMS Note settling in shares of Series C Preferred Stock represents the redemption of stock-settled debt and was therefore accounted for as an extinguishment. Upon extinguishment, no gain or loss was recognized. The Company recorded a $0.8 million change in fair value of the BMS Note as component of other income (expense), net for the year ended December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following tables presents changes to the Company&#8217;s liabilities with significant unobservable inputs (Level 3 liabilities) during the years ended December 31, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible notes</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible Note:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Balance as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of BMS Note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_O9B88gheUkaquoX_9DV5hA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of BMS Note</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Balance as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,300</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_jVXKwJzbK06otYl6OvTOJw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of BMS Note</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 846</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of Series C Preferred Stock in exchange for BMS Note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,146)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Balance as of December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522787972432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Other Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span>Other Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.63%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:54.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical trial deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,788</p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,388</p></td></tr><tr><td style="vertical-align:top;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:top;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,276</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522795029536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></span>Accrued Expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:37.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.17%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">External research, development and manufacturing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,398</p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,122</p></td></tr><tr><td style="vertical-align:top;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional and consultant fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,379</p></td></tr><tr><td style="vertical-align:top;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 301</p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106</p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,306</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788576848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">.</b></span>Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI';font-size:9pt;">T</span><span style="letter-spacing:0.2pt;">he Company has various leases for office space, which are accounted for as operating leases and generally have terms of less than </span><span style="letter-spacing:0.2pt;">two years</span><span style="letter-spacing:0.2pt;"> in length, some of which have the option to renew. The Company recognizes monthly operating lease expense on a straight-line basis over the term of the lease as general and administrative expenses in the consolidated statements of operations and comprehensive loss. Variable lease expense relates primarily to office lease common area maintenance, insurance, and property taxes, is expensed as incurred, and is excluded from the </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">calculation of the lease liabilities and right-of-use assets. For each of the years ended December 31, 2024 and 2023, the Company incurred variable lease expense of </span><span style="letter-spacing:0.2pt;">$0.1</span><span style="letter-spacing:0.2pt;"> million, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Supplemental balance sheet information related to operating lease assets and liabilities was as follows (in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">821</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">813</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.6</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate used to measure lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10.99%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">18.39%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">For each of the years ended December 31, 2024 and 2023, the total lease cost for operating leases (recorded in general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss) was </span><span style="letter-spacing:0.2pt;">$0.9</span><span style="letter-spacing:0.2pt;"> million, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The minimum lease payments under the Company&#8217;s operating leases are expected to be as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fiscal Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 896</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,137</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (134)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,003</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">During the year ended December 31, 2024, the amount of right-of-use assets obtained under new operating lease arrangements was </span><span style="letter-spacing:0.2pt;">$1.1</span><span style="letter-spacing:0.2pt;"> million. There were </span><span style="letter-spacing:0.2pt;">no</span><span style="letter-spacing:0.2pt;"> right-of-use assets obtained under new operating lease arrangements during the year ended December 31, 2023. Cash paid for lease liabilities was </span><span style="letter-spacing:0.2pt;">$0.9</span><span style="letter-spacing:0.2pt;"> million for the years ended December 31, 2024 and 2023, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522795058960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementAbstract', window );"><strong>License and Collaboration Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Revenue</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></span>License and Collaboration Revenue </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">License and Collaboration Agreement with Bristol-Myers Squibb</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August&#160;2023, the Company entered into a license and collaboration agreement with Bristol-Myers Squibb (the &#8220;BMS Agreement&#8221;), under which the Company granted BMS an exclusive license to (i)&#160;develop, manufacture (subject to the Company&#8217;s rights to be the exclusive manufacturer for BMS for a certain period of time), commercialize or otherwise exploit obexelimab and any biological product (irrespective of presentations, formulations or dosages) containing obexelimab but not any of the Company&#8217;s other proprietary active ingredient (the &#8220;BMS Product&#8221;) into Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia (collectively, the &#8220;BMS Territory&#8221;) and (ii)&#160;develop and manufacture obexelimab and the BMS Product outside the BMS Territory provided that obexelimab and the BMS Product are solely used in the BMS Territory. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the BMS Agreement, BMS paid the Company a one-time non-refundable upfront cash payment of $50.0 million. The Company is entitled to receive further separate development and regulatory milestone payments from BMS up to approximately $79.5 million. The Company is also entitled to receive one-time sales milestone payments up to $70.0 million upon BMS achieving certain net sales milestones in a given year in the BMS Territory. The Company is also eligible to receive tiered high single-digit to low double-digit royalties on net sales in the BMS Territory, subject to specified reductions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company will continue to perform and oversee the ongoing Phase 3 trial of obexelimab in the IgG4-RD indication and BMS will participate in the performance of the study. BMS also has the right to participate in other global clinical studies that the Company chooses to perform. Pursuant to such global studies, including the IgG4-RD study, the Company and BMS have defined roles with specified activities assigned to each party in their respective jurisdictions. These activities are overseen by a joint steering committee, which has equal representation of the parties. BMS will fund their pro rata share of the total global study costs up to a specified percentage of the patients enrolled in the study from the BMS Territory. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Should the percentage of patients from the BMS Territory fall below the specified percentage, BMS&#8217;s funding would proportionately decrease. BMS is responsible for the development and commercialization of obexelimab within the BMS Territory, including the performance of any local studies within its jurisdiction that it chooses to perform, while the Company retains responsibility for the development and commercialization for the remainder of the world. The Company is responsible for manufacturing the clinical supply and commercial supply of obexelimab, each at cost plus single-digit margin. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluated the terms of the BMS Agreement to determine whether it is a collaborative arrangement in the scope of ASC 808. The Company concluded that the BMS Agreement is a collaborative arrangement under ASC 808 as both parties are active participants in the global clinical trial and are exposed to significant risks and rewards of those activities. The Company determined that the BMS Agreement contained two material components: (i) the license granted to BMS to develop, manufacture and commercialize obexelimab within the BMS Territory, and related activities in the BMS Territory, including manufacturing and (ii) the global development of obexelimab, which at execution, solely relates to the ongoing Phase 3 trial for IgG4-RD. The Company used criteria specified in ASC 606 to determine whether the components of the BMS Agreement are performance obligations to a customer and concluded that BMS is the Company&#8217;s customer for the license and related activities in the BMS Territory under ASC 606. The global development activities under the agreement do not represent a transaction with a customer and reimbursement payments received by the Company for global development activities are accounted for as a reduction of the related research and development expenses. The Company recorded $6.0 million and $4.1 million as a reduction to research and development expenses during the years ended December 31, 2024 and 2023, respectively, with $2.0 million and $1.3 million of outstanding receivable, included in prepaid expenses and other current assets on the Company&#8217;s consolidated balance sheet as of December 31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluated the license and related activities under ASC 606 as these transactions are considered transactions with a customer, and identified four material promises at the outset of the BMS Agreement, which consists of (i) the exclusive license, (ii) the initial technology transfer, (iii) clinical manufacturing supply related to development in the BMS Territory and (iv) commercial manufacturing supply related to commercialization within the BMS Territory. The Company determined that the exclusive license and initial technology transfer were not distinct from each other, as the exclusive license has limited value without the corresponding technology transfer. As such, for the purposes of ASC 606, the Company determined that the two material promises, the exclusive license and the initial technology transfer, should be combined into one distinct performance obligation. The Company further evaluated the material promise associated with the clinical manufacturing supply and the commercial manufacturing supply, within the BMS Territory, concluding that because BMS is not obligated to purchase any minimum amount, the clinical manufacturing supply and commercial manufacturing supply represent a purchase option and not a performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company further concluded that the customer option is not priced at a significant and incremental discount at the execution of the arrangement and therefore does not represent a material right. Therefore, each of the clinical and commercial manufacturing activities were excluded as performance obligations at the outset of the arrangement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The transaction price of the BMS Agreement was determined to be $50.0 million, which consisted of the upfront cash payment, and was allocated to the one combined performance obligation. The other potential consideration, which includes development, regulatory, and sales milestone payments that the Company is eligible to receive were excluded from the transaction price, as all milestones were not deemed probable of achievement and were therefore fully constrained. The Company issued the BMS Note in connection with the BMS Agreement, and the BMS Note was recorded at fair value separate from the transaction price of the BMS Agreement (see<i style="font-style:italic;"> Note 3, Fair Value Measurements</i>). The Company reevaluates the transaction price at the end of each reporting period as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company adjusts its estimate of the transaction price, and any addition to the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">transaction price would be recognized as revenue when it becomes probable that inclusion would not lead to a significant revenue reversal. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluated the license under ASC 606 and concluded that the license is a functional intellectual property license. The Company determined that BMS benefited from the license along with the initial technology transfer at the time of the transfer, and therefore the related performance obligation is satisfied at a point in time. The Company satisfied the performance obligation through delivery of the license and initial technology transfer and therefore recognized the upfront payment of $50.0 million as revenue during year ended December 31, 2023. The Company did not recognize revenue under this arrangement in the year ended December 31, 2024, as no milestones were achieved or deemed probable of achievement, and as such, all remaining milestones remained fully constrained and excluded from the transaction price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Tenacia Biotechnology Co. Novation Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2024, the Company entered into a novation agreement with Tenacia Biotechnology (Hong Kong) Co., Limited (&#8220;Tenacia&#8221;), under which the Company transferred its rights and obligations under the agreements with Dianthus to Tenacia (the &#8220;Tenacia Agreement&#8221;). Pursuant to the Tenacia Agreement, the Company, transferred all the ZB005 inventory, analytical methods and manufacturing records generated, under the Dianthus Option Agreement and the License Agreement (collectively the &#8220;Dianthus Agreements&#8221;), see <i style="font-style:italic;">Note 8, License and Options Agreements, </i>for additional information, to Tenacia, for the exclusive right to research, develop, manufacture and commercialize products within greater China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Tenacia Agreement, Tenacia paid the Company a one-time non-refundable upfront cash payment of $5.0 million. The Company is entitled to receive further development, regulatory and sales milestones from Tenacia of up to approximately $86.0 million if certain milestones are successfully achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluated the terms of the Tenacia Agreement and determined it is within the scope of <i style="font-style:italic;">ASC 606</i>. The Company identified the following promises in the Tenacia Agreement that were evaluated under the scope of <i style="font-style:italic;">ASC 606:</i> (i) transfer of the license, (ii) assignment of all rights, title and interests in ZB005 inventory, manufacturing records, analytical methods and draft IND component, (iii) services to be performed in accordance with manufacturing technology transfer and (iv) transfer, up to one year after the effective date, of any tangible embodiments of know-how that was not previously provided. The Company also evaluated whether certain options outlined in the Tenacia Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options conveyed a material right to Tenacia and, therefore, are not considered separate performance obligations within the Tenacia Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company assessed the above promises and determined that the license for ZB005, asset transfer and technology transfer are a combined distinct performance obligation within the scope of <i style="font-style:italic;">ASC 606</i>. &#160;The future technology know-how transfer services, for one year after the effective date, is a promise that is separately identifiable. The Company determined the likelihood of Tenacia requesting additional know-how transfer to be remote and any requests to require minimal resource allocation, as the Company has concluded all work on ZB005 within greater China. As such, the Company considered the continued know-how transfer to be immaterial in the context of the promises. Therefore, the license, asset transfer and technology transfer represent a single performance obligation within the scope of <i style="font-style:italic;">ASC 606</i> at contract inception. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company concluded that the transaction price of $5.0 million was allocated to the combined performance obligation, which was recognized upon delivery prior to December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company used the most likely amount method to estimate variable consideration and estimated that the most likely amount for each potential developmental and regulatory variable consideration milestone payment under the agreement is zero, as achievement of those milestones is uncertain and susceptible to factors outside the Company&#8217;s control. Accordingly, all such milestone payments were excluded from the transaction price. Management will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, will adjust the transaction price as necessary. Sales based milestones structured on the level of sales, were also excluded from the transaction price, as the license is deemed to be the predominant item to which the sales relate. The Company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, no milestones were achieved or deemed probable of achievement. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_CollaborativeArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/a.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_CollaborativeArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522787787232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Option Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndOptionAgreementsAbstract', window );"><strong>License and Option Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndOptionAgreementsDisclosureTextBlock', window );">License and Option Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></span>License and Option Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Xencor,&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2020 Xencor Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">In September&#160;2020, the Company entered into a license agreement (the &#8220;2020 Xencor Agreement&#8221;) with Xencor, Inc. (&#8220;Xencor&#8221;), to obtain (i)&#160;an exclusive, royalty-bearing, sublicensable worldwide license under certain patent rights controlled by Xencor and (ii)&#160;a non-exclusive payment bearing license under certain know-how controlled by Xencor to research, develop, manufacture, market and sell </span><span style="letter-spacing:0.2pt;">three</span><span style="letter-spacing:0.2pt;"> antibody product candidates, including ZB002. The 2020 Xencor Agreement became effective in November&#160;2020, upon the Company&#8217;s issuance of </span><span style="letter-spacing:0.2pt;">5,041,542</span><span style="letter-spacing:0.2pt;"> shares of its Series&#160;A Preferred Stock, which had a fair value of </span><span style="letter-spacing:0.2pt;">$16.1</span><span style="letter-spacing:0.2pt;">&#160;million to Xencor as initial consideration. The Company concluded that as no processes or other activities that would constitute a business were acquired, and the acquired assets did not have an alternative future use, the upfront consideration was expensed to acquired IPR&amp;D during the year ended December&#160;31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company is required to pay Xencor tiered royalties on annual net sales of successfully commercialized products utilizing the licensed assets. The royalty&#160;percentage rates vary by geographic areas as defined in the 2020 Xencor Agreement and range from the mid-single digits to the mid-teens.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company is also obligated to reimburse Xencor for third-party costs incurred by Xencor for certain patent filings, prosecution and maintenance as further specified in the 2020 Xencor Agreement. During the&#160;year ended December&#160;31, 2024 </span><span style="letter-spacing:0.2pt;">no</span><span style="letter-spacing:0.2pt;"> costs were incurred related to the 2020 Xencor Agreement. During the year ended December 31, 2023, the Company incurred immaterial costs related to the 2020 Xencor Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2021 Xencor Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">In May&#160;2021, the Company entered into a license agreement (the &#8220;2021 Xencor Agreement&#8221;) with Xencor to obtain an (i)&#160;exclusive, royalty-bearing, sublicensable worldwide license under certain patent rights controlled by Xencor and (ii)&#160;a non-exclusive payment bearing license under certain know-how controlled by Xencor to research, develop, manufacture, market and sell obexelimab. The 2021 Xencor Agreement became effective in November&#160;2021, upon the execution of an amendment to the 2021 Xencor Agreement and the Company&#8217;s concurrent issuance of a warrant to Xencor (the &#8220;Xencor Warrant&#8221;) as initial consideration, which entitled Xencor to receive a number of the Company&#8217;s convertible preferred stock in the Company&#8217;s next &#8220;qualified financing&#8221;. The Company concluded that as no processes or other activities that would constitute a business were acquired, and the acquired assets did not have an alternative future use, the upfront consideration of </span><span style="letter-spacing:0.2pt;">$20.7</span><span style="letter-spacing:0.2pt;">&#160;million was expensed to acquired IPR&amp;D during the year ended December&#160;31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company is obligated to make specified development, regulatory and commercial milestone payments of up to </span><span style="letter-spacing:0.2pt;">$10.0</span><span style="letter-spacing:0.2pt;">&#160;million at Xencor&#8217;s option either in cash or fully-paid newly issued shares. The Company is obligated to make regulatory milestone payments up to </span><span style="letter-spacing:0.2pt;">$75.0</span><span style="letter-spacing:0.2pt;">&#160;million. The Company is also obligated to make one-time sales milestone payments up to </span><span style="letter-spacing:0.2pt;">$385.0</span><span style="letter-spacing:0.2pt;">&#160;million upon achieving milestone events of net sales in a given calendar year in the territory equal to certain threshold amounts. In addition, the Company is required to pay Xencor tiered royalties on annual net sales of successfully commercialized products utilizing obexelimab, with the royalty rates varying based on regions and ranging from the mid-single digits to the mid-teens.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">In April&#160;2023, the Company incurred a </span><span style="letter-spacing:0.2pt;">$10.0</span><span style="letter-spacing:0.2pt;">&#160;million development milestone pursuant to the 2021 Xencor Agreement, which Xencor elected to receive in the form of the Company&#8217;s Series&#160;B Preferred Stock. </span>See <i style="font-style:italic;">Note&#160;9, Convertible Preferred Stock,</i> for details<span style="letter-spacing:0.2pt;">. The milestone was recorded as acquired IPR&amp;D expense in the Company&#8217;s consolidated statements of operations and comprehensive loss. The Company did not record any expenses related to reimbursable patent-related costs during the year ended December 31, 2024. The Company recorded an immaterial amount to general and administrative expenses in the consolidated statements of operations and comprehensive loss </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">during each of the&#160;year ended December&#160;31, 2023, relating to reimbursable patent-related costs owed to Xencor. </span>During the year ended December 31, 2024 no milestone expense was incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Dianthus Therapeutics&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">In September&#160;2020, the Company entered into an agreement (the &#8220;Dianthus Option Agreement&#8221;) with Dianthus Therapeutics Inc. (&#8220;Dianthus&#8221;), a therapeutic antibody company. Under the terms of the Dianthus Option Agreement, the Company obtained an exclusive option to negotiate and enter into exclusive license agreements with Dianthus for the rights to research, develop, manufacture, market and sell products related to either or both of </span><span style="letter-spacing:0.2pt;">two</span><span style="letter-spacing:0.2pt;"> antibody product candidates based on Dianthus&#8217; proprietary technology in China, Hong Kong, Macau and Taiwan (the &#8220;Zenas Territories&#8221;). Dianthus retains all rights to develop and commercialize the product candidate subjects of the two options outside of the Zenas Territories. Upon execution of the Dianthus Option Agreement, the Company issued </span><span style="letter-spacing:0.2pt;">18,063</span><span style="letter-spacing:0.2pt;"> shares of its common stock to Dianthus as initial consideration, which was recorded to acquired IPR&amp;D expense during the year ended December&#160;31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Under the Dianthus Option Agreement, Dianthus will notify the Company when it has identified each of </span><span style="letter-spacing:0.2pt;">two</span><span style="letter-spacing:0.2pt;"> antibody product candidates, and the Company will then have sixty (</span><span style="letter-spacing:0.2pt;">60</span><span style="letter-spacing:0.2pt;">) days to notify Dianthus if the Company intends to exercise each of the options. In September&#160;2021, Dianthus notified the Company that it had identified the first lead antibody product candidate pursuant to the Dianthus Option Agreement, ZB005 (also known as DNTH103). In October&#160;2021, the Company notified Dianthus of its intention to exercise its option to ZB005 pursuant to the Dianthus Option Agreement. This notification resulted in a </span><span style="letter-spacing:0.2pt;">$1.0</span><span style="letter-spacing:0.2pt;">&#160;million milestone obligation to Dianthus, which was expensed in 2021 upon exercise and subsequently paid during the year ended December&#160;31, 2022. The Company and Dianthus executed a license agreement for ZB005 in June&#160;2022 (the &#8220;Dianthus License Agreement&#8221;). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company is also required to reimburse Dianthus for a specified&#160;percentage of certain third-party costs which Dianthus incurs in its initial discovery and development activities related to each of the two options. To date, the Company has only exercised its option with respect to the ZB005 program, and as a result, it has only reimbursed Dianthus with respect to costs associated with the ZB005 program. During the&#160;years ended December&#160;31, 2024 and 2023, the Company incurred </span><span style="letter-spacing:0.2pt;">$5.1</span><span style="letter-spacing:0.2pt;">&#160;million and </span><span style="letter-spacing:0.2pt;">$3.0</span><span style="letter-spacing:0.2pt;">&#160;million of reimbursable expenses, respectively, which are recorded within research and development expenses in the consolidated statements of operations and comprehensive loss. Of these amounts, </span><span style="letter-spacing:0.2pt;">$0.5</span><span style="letter-spacing:0.2pt;"> million and an immaterial amount were recorded in accounts payable, and </span><span style="letter-spacing:0.2pt;">$0.3</span><span style="letter-spacing:0.2pt;"> million and </span><span style="letter-spacing:0.2pt;">$0.4</span><span style="letter-spacing:0.2pt;"> million were recorded in accrued expenses on the Company&#8217;s consolidated balance sheets as of December&#160;31, 2024 and 2023, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The binding key terms included in the Dianthus License Agreement, and that would be included in a future license agreement if the Company exercises its option with respect to a second research program, also include the Company&#8217;s obligation to make specified development milestone payments to Dianthus, one time only, regardless of the number of assets the Company in-licenses from Dianthus with respect to such research program. The milestone obligations for each research program would total up to </span><span style="letter-spacing:0.2pt;">$11.0</span><span style="letter-spacing:0.2pt;">&#160;million, based on achievement of each of the specified milestone events. If the Company successfully commercializes a product(s) under a license agreement, the Company will be obligated to make tiered royalty payments, on a product-by-product basis, to Dianthus on annual net sales of such products. Royalties will be calculated as specified&#160;percentages of annual net sales, ranging from the mid-single digits to the low-double digits, with each specified tiered level of annual net sales having a specified&#160;percentage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2024, the Company entered into the Tenacia Agreement. Pursuant to the Tenacia Agreement, the Company transferred its rights, and obligations under the Dianthus Option Agreement and the Dianthus License Agreement to Tenacia. As a result, Zenas has no further obligations to Dianthus under the Dianthus Option Agreement and the Dianthus License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our Tenacia Agreement, please see <i style="font-style:italic;">Note 7, License and Collaboration Revenue</i>, to these consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Viridian Therapeutics,&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">In October&#160;2020, the Company entered into a license agreement with Viridian Therapeutics, Inc. (&#8220;Viridian&#8221;), to obtain an exclusive, royalty-bearing, sublicensable license to research, develop, manufacture, market and sell certain antibody product candidates based on Viridian&#8217;s proprietary technology (the &#8220;Viridian Agreement&#8221;). The Company&#8217;s license rights are limited to non-oncology indications and to the Zenas Territories. Viridian retains its rights to develop and commercialize such product candidates outside of the Zenas Territories. Upon execution of the Viridian Agreement, the Company issued </span><span style="letter-spacing:0.2pt;">38,707</span><span style="letter-spacing:0.2pt;"> shares of its common stock to Viridian as initial consideration which was recorded as acquired in-process research and development expense in its consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company is obligated to make development milestone payments to Viridian, totaling up to </span><span style="letter-spacing:0.2pt;">$12.0</span><span style="letter-spacing:0.2pt;">&#160;million, based on achievement of each of the specified milestone events. The Company is also required to pay Viridian tiered royalties on annual net sales of successfully commercialized products utilizing the licensed technology. The royalty&#160;percentage rates range from the mid-single digits to the low-double digits. During the year ended December&#160;31, 2024 and 2023, the Company did not incur or pay any milestones to Viridian. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2021, the Company and Viridian entered into two letter agreements to authorize initiation of certain manufacturing and development activities related to the licensed product candidate, ZB001 (also known as VRDN-001). In each of the letter agreements the Company requested, and Viridian agreed, to engage a third-party contract manufacturer (the &#8220;CMO&#8221;) to initiate certain work with respect to activities pursuant to one or more statements of work under existing agreements between Viridian and the two CMOs. In May&#160;2022, the Company entered into a manufacturing development and supply agreement with Viridian. The Company pays Viridian for all amounts the CMOs invoice to Viridian for the specified activities. The first letter agreement subsequently was amended three times to add further activities and costs to those detailed in the original letter agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">During the&#160;years ended December&#160;31, 2024 and 2023, the Company recognized an immaterial amount of expenses, respectively, which were recorded in research and development expenses in the consolidated statements of operations. </span>As of December 31, 2024, and 2023, immaterial amounts were recorded in accounts payable and accrued expenses. Viridian has agreed to reimburse the Company for certain services it performs on Viridian&#8217;s behalf, with reimbursements being recorded as a reduction in research and development expenses. During the year ended December 31, 2024, the Company recorded $1.7 million in reimbursable expenses. During the year ended December 31, 2023, the Company had no reimbursable expenses. <span style="letter-spacing:0.2pt;">As of December&#160;31, 2024, Viridian had not notified the Company of any additional antibody product candidate.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_LicenseAndOptionAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_LicenseAndOptionAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_LicenseAndOptionAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for license and option agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_LicenseAndOptionAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788032768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityDisclosureTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></span>Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September&#160;2020, the Company issued and sold 1,785,714 shares of Series&#160;Seed convertible preferred stock (&#8220;Series&#160;Seed Preferred Stock&#8221;) in a private financing transaction, at a purchase price of $0.56 per share, for total net cash proceeds of $1.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160;2020, the Company issued 5,041,542 shares of Series&#160;A convertible preferred stock (&#8220;Series&#160;A Preferred Stock&#8221;) to Xencor as initial consideration for the 2020 Xencor Agreement. Also in November&#160;2020, the Company issued and sold 12,547,838 shares of Series&#160;A Preferred Stock in a private financing transaction, at a purchase price of $3.1878 per share, for total net cash proceeds of $39.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160;2022, the Company issued and sold 25,139,732 shares of Series&#160;B Preferred Stock in a private financing transaction, at a purchase price of $2.38666 per share, for total net cash proceeds of $59.4 million. Concurrent with the issuance and sale of the Series&#160;B Preferred Stock, which was deemed to be a qualified financing as defined in the &#160;convertible note agreement from notes issued to several investors in 2021, and resulted in the principal plus accrued interest being automatically converted into Series&#160;B Preferred Stock, the outstanding convertible notes from 2021 were exchanged for 37,471,107 shares of Series&#160;B Preferred Stock. At the same time, the Xencor Warrant, which was issued as initial consideration for the 2021 Xencor Agreement, was deemed exercised for 14,441,793 shares of Series&#160;B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April&#160;2023, the Company incurred a $10.0 million development milestone pursuant to the 2021 Xencor Agreement. Xencor elected to receive payment in the form of the Company&#8217;s Series&#160;B Preferred Stock and the Company issued 4,189,955 shares of Series&#160;B Preferred Stock as payment for the development milestone in June&#160;2023 (see <i style="font-style:italic;">Note 8, License and Option Agreement </i>to these consolidated financial statements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May&#160;2024, the Company issued and sold 103,990,553 shares of Series&#160;C convertible preferred stock (&#8220;Series&#160;C Preferred Stock&#8221;) in a private financing transaction, at a purchase price of $1.72131 per share, for total net cash proceeds of $178.4 million. Concurrent with the issuance and sale of the Series&#160;C Preferred Stock, which was deemed to be a BMS Qualified Financing as defined above in <i style="font-style:italic;">Note&#160;3, Fair Value Measurements,</i> the principal plus accrued interest of the BMS Note&#160;was automatically converted into 12,284,686 shares of Series&#160;C Preferred Stock, thereby making the total Series&#160;C issuance equal to 116,275,239 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the issuance of the Series Seed, Series A, Series B, and Series C Preferred Stock, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2024, the Company completed its IPO, in which the Company issued and sold 15,220,588 shares of its common stock, including 1,985,294 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $17.00 per share, for aggregate gross proceeds of $258.7 million. The Company received approximately $234.3 million in net proceeds, after deducting underwriting discounts and commissions and other offering costs. In connection with the IPO, all outstanding shares of Preferred Stock converted into an aggregate of 24,978,715 shares of common stock and no convertible preferred stock was outstanding as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stock consisted of the following as of December 31, 2023 (in thousands, except share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:70.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued and</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuable Upon</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Conversion</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series Seed Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,785,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,785,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 205,653</p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,589,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,589,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,025,699</p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,242,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,242,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 193,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 193,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,356,392</p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,617,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,617,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,587,744</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The holders of preferred stock had the following rights, preferences and privileges prior to conversion into common stock upon the closing of the IPO:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Voting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The holder of each share of Preferred Stock was entitled to </span><span style="letter-spacing:0.2pt;">one</span><span style="letter-spacing:0.2pt;"> vote for each share of common stock into which it would convert and to vote with the common stock on all matters.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Conversion</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Each share of convertible preferred stock was automatically converted into a share of common stock, upon affirmative vote of majority of the holders of each series or upon the closing of an initial public offering of the Company&#8217;s common stock which resulted in a specified minimum amount of gross cash proceeds. The conversion ratio was initially </span><span style="letter-spacing:0.2pt;">one</span><span style="letter-spacing:0.2pt;"> share of common stock for each share of convertible preferred stock and was adjustable in the event of a split or reverse split of the Company&#8217;s common stock, an issuance or declaration of dividends to holders of the Company&#8217;s common stock, a reorganization or merger transaction, or certain issuances of shares of common stock which were dilutive to holders of the Company&#8217;s preferred stock. Holders of preferred stock had the right to one vote for each share of the Company&#8217;s common stock which were dilutive to holders of the Company&#8217;s preferred stock. &#160;Holders of preferred stock had the right to </span><span style="letter-spacing:0.2pt;">one</span><span style="letter-spacing:0.2pt;"> vote for each share of the Company&#8217;s common stock into which such holder&#8217;s shares of preferred stock could then convert.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Holders of Series&#160;C Preferred Stock were entitled to receive dividends, only when, as and if declared by the Board, at the annual rate of </span><span style="letter-spacing:0.2pt;">6%</span><span style="letter-spacing:0.2pt;"> of the Series&#160;C Preferred Stock issue price, payable in preference to and satisfied before any dividend or distribution on any other class or series of the Company&#8217;s shares (except for certain exempted distributions). If any assets or funds remain after dividends had been distributed to holders of Series&#160;C Preferred Stock, holders of Series&#160;B Preferred Stock would have been entitled to receive dividends, only when, as and if declared by the Board, at the annual rate of </span><span style="letter-spacing:0.2pt;">6%</span><span style="letter-spacing:0.2pt;"> of the Series&#160;B issue price, payable in preference to and satisfied before any dividend or distribution on any other class or series of the Company&#8217;s shares (except for certain exempted distributions). If any assets or funds remain after dividends had been distributed to holders of Series&#160;B Preferred Stock, holders of Series&#160;A Preferred Stock would had been entitled to receive dividends, only when, as and if declared by the Board, at the annual rate of </span><span style="letter-spacing:0.2pt;">6%</span><span style="letter-spacing:0.2pt;"> of the Series&#160;A issue price, payable in preference to and satisfied before any dividend or distribution on any other class or series of the Company&#8217;s shares (except for certain exempted distributions). If any assets or funds remain after dividends had been distributed to holders of Series A Preferred Stock, holders of Series Seed Preferred Stock would have been entitled to receive dividends, only when, as and if declared by the Board, at the annual rate of </span><span style="letter-spacing:0.2pt;">6%</span><span style="letter-spacing:0.2pt;"> of the Series Seed issue price, payable in preference to and satisfied before any dividend or distribution on any other class or series of the Company&#8217;s shares (except for certain exempted distributions). The right to receive dividends on shares of all series of preferred stock was not cumulative, and no such right accrued to holders of such shares. There were </span><span style="letter-spacing:0.2pt;">no</span><span style="letter-spacing:0.2pt;"> dividends declared or paid as of December 31, 2024 and 2023. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Liquidation Preference</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">In the event of a voluntary or involuntary liquidation, dissolution or winding up of the Company or a deemed liquidation event, holders of Series&#160;C Preferred Stock prior and in preference to any distribution to holders of Series&#160;B Preferred Stock, Series&#160;A Preferred Stock, Series Seed Preferred Stock and common shares, would have been entitled to be paid the issue price they originally paid to acquire their shares, plus any declared but unpaid dividends. After full payment to holders of Series&#160;C Preferred Stock, holders of Series&#160;B Preferred Stock prior and in preference to any distribution to holders of Series&#160;A Preferred Stock, Series Seed Preferred Stock and common shares, would have been entitled to be paid the issue price they originally paid to acquire their shares, plus any declared and unpaid dividends. After full payment to holders of Series&#160;B Preferred Stock and Series&#160;A Preferred Stock, holders of Series&#160;Seed Preferred Stock prior and in preference to any distribution to holders of common shares, would have been entitled to be paid the issue price they originally paid to acquire their shares, plus any declared and unpaid dividends. After full payment to holders of Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock, holders of Series Seed Preferred Stock prior and in preference to any distribution to holders of common shares, would have been entitled to be paid the issue price they originally paid to acquire their shares, plus any declared and unpaid dividends. Any remaining amounts after payment to holders of preferred stock, would have been paid to holders of common shares. A deemed liquidation event was defined as any consolidation, amalgamation, scheme of arrangement or merger of the Company (and any of its subsidiaries) or other reorganization resulting in loss of more than 50% voting power; the sale, transfer, lease or other disposition of all or substantially all of the Company&#8217;s assets; or the exclusive licensing of all or substantially all of the Company&#8217;s intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Redemption</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Preferred Stock did not have redemption rights, except for the contingent redemption upon the occurrence of a Liquidation Event.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of terms, amounts, nature of changes, rights and privileges, conversions and other matters related to temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522794958768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span>Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August&#160;2023, all outstanding shares of ordinary stock of Zenas Cayman automatically converted into shares of common stock of the Company upon the Redomicile and incorporation of the Company in the State of Delaware as Zenas BioPharma,&#160;Inc. In May&#160;2024, the Company amended and restated its certificate of incorporation, whereby the Company increased the shares of common stock it was authorized to issue to 294,784,925 shares. Upon consummation of the IPO, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Company restated its certificate of incorporation, and as of December 31, 2024, the Company was authorized to issue 175,000,000 shares of $0.0001 par value common stock. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock were subject to and qualified by the rights, powers and preference of the holders of any preferred stock then issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders (and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The Company had reserved the following shares of common stock for the potential conversion of outstanding convertible preferred stock and exercise of stock options:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:32.54%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of outstanding shares of convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,587,744</p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,706,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,382,933</p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Remaining shares reserved for future issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 359,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,792</p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,065,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,031,469</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788023664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></span>Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><b style="font-style:normal;font-weight:bold;">2020 Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">On August 21,&#160;2020, the Company&#8217;s sole director and member approved the Zenas BioPharma (Cayman) Limited 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;). Upon effectiveness of the 2024 Plan (as defined below), the Company ceased granting additional awards under the 2020 Plan. The 2020 Plan allowed the Company to grant stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units, and other stock-based awards to employees, officers, directors and consultants of the Company and its subsidiaries. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Since inception of the 2020 Plan, the Company has granted RSAs and stock options which generally vest over </span><span style="font-style:normal;">four years</span><span style="font-style:normal;">, with </span><span style="font-style:normal;">25%</span><span style="font-style:normal;"> of the total shares granted vesting on the anniversary of the vesting commencement date and the remaining </span><span style="font-style:normal;">75%</span><span style="font-style:normal;"> vesting in equal monthly installments over the subsequent </span><span style="-sec-ix-hidden:Hidden_JhL2WXriOku-gXN73DMQHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-six</span></span><span style="font-style:normal;"> (36) months.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The 2020 Plan was subsequently amended by the Board and provided for the issuance of 2,560,401 shares of common stock as of December 31, 2023, of which 60,792 shares of common stock remained available for future grant under the 2020 Plan. &#160;Upon effectiveness of the 2024 Plan (as defined below), the remaining available shares for future grant were transferred to the 2024 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2024 Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 3, 2024, the Board adopted the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), which became effective immediately prior to the effectiveness of the registration statement for the Company&#8217;s IPO. The 2024 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, unrestricted stock, restricted stock units and other stock-based awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the effectiveness of the 2024 Plan, the number of shares of common stock initially reserved for issuance was 4,775,477 shares of common stock which is equal to 12% of the number of shares of common stock issued and outstanding immediately following the consummation of the Company&#8217;s IPO. The number of shares reserved and available for issuance under the 2024 Plan will automatically increase each January 1, beginning on January 1, 2025 through January 1, 2034, by the number of shares equal to the lesser of (a) five percent of the aggregate number of shares of common stock outstanding as of such date, and (b) a number of shares as may be determined by the Board on or prior to such date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, there were 359,399 shares available for issuance under the 2024 Plan. On January 1, 2025, the shares available for issuance under the 2024 Plan was increased to 2,449,069. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Restricted Stock Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents a summary of the Company&#8217;s RSA activity and related information:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average Grant-Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#ffffff;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:middle;width:2.8%;background:#ffffff;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#cceeff;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.71</p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,028)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.01</p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#cceeff;border-bottom:1.5pt solid #ffffff;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Repurchased</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,172)</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.48</p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">There were no RSAs granted during the year ended December&#160;31, 2024. As of December&#160;31, 2024, there was no compensation cost related to unvested RSAs as all were fully vested. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has granted stock-based awards with either service or performance based vesting conditions. Compensation expense related to awards to employees and directors with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance based vesting conditions is recognized based on the grant date fair value once the achievement of the performance condition is probable. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The table below presents the weighted-average assumptions used in estimating the fair values of stock options granted during the years ended December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:32.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:2.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents a summary of the Company&#8217;s stock option activity and related information:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted - Average Exercise Price</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Term (in years)</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value (in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding - December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,382,933</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.51</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,084</p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,736,822</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.67</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (38,427)</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.11</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 231</p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (375,131)</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.29</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding - December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,706,197</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.21</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.76</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,104</p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,294,162</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,901</p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and expected to vest as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,706,197</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.21</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.76</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,104</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of the stock options is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock for those stock options that had an exercise price lower than the fair value of the Company&#8217;s common stock as of the measurement date of December 31, 2024. There were 38,427 options exercised for the year ended December 31, 2024, resulting in total proceeds of $0.3 million and 27,579 options exercised for the year ended December 31, 2023, resulting in total proceeds of $0.1 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of options granted during the years ended December 31, 2024 and 2023, was $11.38 and $8.11 per share, respectively. The fair value is being expensed over the associated service period of the award on a straight-line basis based on the grant date fair value or once the achievement of the performance condition is probable. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, unrecognized compensation was $74.4 million, which is expected to be recognized over a weighted average period of 3.6 years. The total fair value of options vested during the years ended December 31, 2024 and 2023 was $4.6 million and $2.6 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company recognized stock-based compensation expense related to the issuance of equity awards to employees in the consolidated statement of operations as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:36.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,066</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,600</p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,895</p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,495</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On September 3, 2024, the Board adopted the 2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective immediately prior to the effectiveness of the registration statement for the Company&#8217;s IPO. The Company initially reserved 397,956 shares for issuance under the ESPP. The number of shares of common stock available under the ESPP will &#160;automatically increase on January 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of each year, beginning on January 1, 2025 through January 2034, by the number of shares equal to the lesser of (a) one percent of the aggregate number of shares of common stock outstanding as of such date, and (b) a number of shares as may be determined by the Board on or prior to such date, up to a maximum of 1,000,000 shares in the aggregate per year. On January 1, 2025, the shares of common stock reserved for issuance under the ESPP was increased to 815,890.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, no shares of common stock have been issued and no stock-based compensation has been recognized related to the ESPP. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522794976064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></span>Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.61%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.47%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.61%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (156,988)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (37,124)</p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common stock outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,198,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,531,178</p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share attributable to common stockholders - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11.89)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24.25)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company&#8217;s potentially dilutive securities, which include convertible preferred stock, restricted stock and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders as of December&#160;31, 2024 and 2023 because including them would have had an anti-dilutive effect:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:44.4%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock</p></td><td style="vertical-align:top;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,587,744</p></td></tr><tr><td style="vertical-align:top;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock</p></td><td style="vertical-align:top;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,200</p></td></tr><tr><td style="vertical-align:top;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock </p></td><td style="vertical-align:top;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,706,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,382,933</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The BMS Note was also outstanding as of December 31, 2023, which could have obligated the Company to issue preferred shares or common shares upon the occurrence of various future events at prices and in amounts that are not determinable until the occurrence of those future events. Because necessary conditions for the conversion of the BMS Note had not been satisfied as of December 31, 2023, the Company has excluded the BMS Note from the table above and the calculation of diluted net loss per share. As of December 31, 2024 the BMS Note is no longer outstanding. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522787474800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></span>Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents the components of loss before the provision for (benefit from) income taxes during the years ended December 31, 2024 and 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (160,918)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,845)</p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,978)</p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loss before taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (156,559)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (36,823)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The components of the income tax provision for the years ended December 31, 2024 and 2023 are as follows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current income tax provision:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 289</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 301</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income tax provision:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal, state and foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 301</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">IP transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign tax rate differential</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s change in effective tax rate for the year ended December 31, 2024 compared to the year ended December 31, 2023 decreased primarily due to a change in income earned in the U.S. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the components of the Company&#8217;s deferred tax assets and liabilities (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,960</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,716</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,573</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,547</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,424</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Milestone payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 719</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,188</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 550</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,961</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (200)</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (200)</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax asset before valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,761</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (90,295)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (39,761)</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ASC Topic 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded full valuation allowances against its domestic and foreign deferred tax assets as of December 31, 2024, because management has determined that it is more likely than not that these assets will not be realized. The valuation allowance increased by $50.5 million from December 31, 2023 to December 31, 2024, primarily due to additional net operating losses related to the U.S. and non-U.S. entities as well as the capitalization of research and development expenses under Internal Revenue Code Section 174 (&#8220;Section 174&#8221;) at the U.S. entity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Beginning on or after January 1, 2022, Section 174 of the U.S. internal revenue code was amended as part of the Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;) to no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Rather, the research and development expenses must be capitalized and amortized over five years for research performed in the U.S. and fifteen years for research performed outside the U.S. As a result of this provision, the Company capitalized applicable costs resulting in a deferred tax asset of $39.7 million as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had approximately $75.5 million and $65.0 million of U.S. federal and state net operating loss (&#8220;NOL&#8221;) carryforwards, respectively. As of December 31, 2023, the Company had approximately $2.3 million of U.S. federal NOL carryforwards. The Company had no state NOL carryforwards as of December 31, 2023. The Company utilized previous net operating loss carryforwards to offset the taxable income in prior years. The federal NOL carryforwards do not expire, but they may be limited in their usage to an annual deduction equal to 80% of annual taxable income. &#160;The state NOL carryforwards expire in 20 years, starting in 2042. The federal and state NOL carryforwards are fully offset by valuation allowances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had $13.3 million and $1.2 million in federal and state general business or research and development tax credit carryforwards. As of December 31, 2023, the Company had $5.9 million and $0.8 million in federal and state general business or research and development tax credit carryforwards. These carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The federal and state research credit carryforwards expire in 20 years and 15 years, respectively, starting in 2036. The federal and state tax credit carryforwards are fully offset by valuation allowances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2024 and 2023, the Company had $54.2 million and $53.7 million of foreign NOL carryforwards, respectively. Foreign NOL carryforwards of $47.8 million will carryforward indefinitely, with the remaining expiring between 2026 and 2028. The foreign NOL carryforwards are fully offset by valuation allowances. The Company files income tax returns in the U.S., as well as various state and foreign jurisdictions. The Company is not currently under any income tax examinations. All tax years generally remain open in each jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have been no unrecognized tax benefits since the Company&#8217;s inception. The Company&#8217;s policy is to record estimated interest and penalties related to the underpayment of income taxes as a component of its income tax provision. As of December 31, 2024 and 2023, the Company had no accrued interest or penalties related to uncertain tax positions and since inception, no amounts have been recognized in the Company&#8217;s consolidated statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, utilization of the NOLs and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section 382, as well as similar state provisions. These ownership changes may limit the amount of NOLs and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. If a change in control as defined by Section 382 has occurred at any time since the Company&#8217;s formation, utilization of its NOLs or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could then be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOLs or research and development tax carryforwards before their utilization.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522787973792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></span>Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has entered into arrangements for leases of office space; see<i style="font-style:italic;"> Note&#160;6, Leases,</i> for details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">License and Option Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company entered into licenses agreement under which it is obligated to make fixed and contingent payments; see <i style="font-style:italic;">Note</i>&#160;<i style="font-style:italic;">8,</i> <i style="font-style:italic;">License and Option Agreements</i>, for details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Contracts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has entered into agreements with certain vendors for the provision of services that the Company is not contractually able to terminate for convenience and thereby avoid any and all future obligations to the vendors. Under such agreements, the Company is contractually obligated to make certain minimum payments to the vendors, with the exact amounts in the event of termination to be based on the timing of the termination and the exact terms of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and certain officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or services as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and had not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Litigation and Other Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused. As of December 31, 2024, the Company was not subject to any material legal proceedings which would reasonably be expected to have a material adverse effect on the Company&#8217;s financial results.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522795069344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15.</b></span>Employee Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Effective June&#160;2020, the Company adopted the Zenas BioPharma 401(k)&#160;Plan (the &#8220;401(k)&#160;Plan&#8221;) for its employees, which is designed to be qualified under Section&#160;401(k)&#160;of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k)&#160;Plan within statutory and 401(k)&#160;Plan limits. Since inception of the 401(k)&#160;Plan and through the year ended December&#160;31, 2024, the Company has made a one-time contribution of $0.1 million to the 401(k)&#160;Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788562992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16.</b></span>Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Xencor, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has obtained exclusive, worldwide licenses from Xencor to research, develop, manufacture, market and sell three antibody product candidates pursuant to two license agreements. The Company has concluded that Xencor is a related party, because as initial consideration for the 2020 Xencor Agreement, the Company issued 5,041,542 shares of its Series&#160;A Preferred Stock to Xencor during the&#160;year ended December&#160;31, 2020. In April&#160;2023, Xencor elected to receive payment for a development milestone in the form of the Company&#8217;s Series&#160;B Preferred Stock and the Company issued 4,189,955 shares of Series&#160;B Preferred Stock as payment for the development milestone in June&#160;2023. As of December 31, 2024, Xencor held 7.4% of shares of the Company&#8217;s outstanding common stock. The Company did not incur any costs related to reimbursable patent-related costs as of December 31, 2024. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Viridian Therapeutics, Inc. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has obtained a license from Viridian to research, develop, manufacture, market and sell an antibody product candidate in China. The Company has concluded that Viridian is a related party because although Fairmount Funds Management LLC owns less than 5% of shares of the Company&#8217;s outstanding common stock, they have a seat on the Board and are also a 10% or greater stockholder of Viridian and have two seats on Viridian&#8217;s board of directors. As initial consideration for this license, the Company issued 38,707 shares of its common stock to Viridian during the&#160;year ended December&#160;31, 2020. As of December 31, 2024, Viridian held less than 0.1% of shares of the Company&#8217;s outstanding common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Dianthus Therapeutics, Inc</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company obtained an exclusive option to negotiate and enter into exclusive license agreements with Dianthus for the rights (in the Zenas Territories only) to either or both of two antibody product candidates. In June 2022, the Company and Dianthus entered into the Dianthus License Agreement. The Company has concluded that Dianthus is a related party because the Company&#8217;s Chair of the Board is a member of the board of directors of Dianthus. As initial consideration for this license, the Company issued 18,063 shares of its common stock to Dianthus during the&#160;year ended December&#160;31, 2020. In October 2024, the Dianthus Option Agreement and Dianthus License Agreement and all of their related rights and obligations were transferred to Tenacia. As of December 31, 2024, Dianthus held less than 0.1% of shares of the Company&#8217;s outstanding common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For additional information on our license arrangements, please see <i style="font-style:italic;">Note 8, License and Option Agreements</i>, to these consolidated financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788544560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">17.</b></span><b style="font-weight:bold;">Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">The Company manages its operations on a consolidated basis as a single reportable segment focused on the research and development of precision immunology-based therapies. The accounting policies of the single reportable segment are </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">identical to those described in <i style="font-style:italic;">Note 2, Summary of Significant Accounting Policies</i>. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews consolidated net loss, total expense and direct expenses by program and compared to budget. The CODM allocates resources based on the Company&#8217;s available cash resources, forecasted expenditures on a consolidated basis, as well as an assessment of the probability of success of its research and development activities on a program basis. Segment asset information regularly provided to the CODM is consistent with that reported on the consolidated balance sheets with particular emphasis on the Company&#8217;s available liquidity, including its cash, cash equivalents and marketable securities balances. Revenue is primarily attributed to individual countries based on the location of the license, as of December 31, 2024 and 2023, revenue was attributed to our China and U.S. entity, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">The following table presents certain financial data for the Company&#8217;s reportable segments for the years ended December 31, 2024 and 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Less:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Direct research and development expenses:</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Obexelimab</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,446</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Other programs (ZB002 &amp; ZB004)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,242</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Partnered regional programs (ZB001 &amp; ZB005)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,737</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,738</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Unallocated research and development</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,008</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  General and administrative</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,218</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Stock-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,495</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Other segment items</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">4</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,901)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,977</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (156,988)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,124)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> Direct research and development expenses primarily consist of direct costs incurred to specific programs research and development activities, including costs to conduct clinical trials and to manufacture clinical drug supply. </p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">2 </sup>Unallocated research and development expenses primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as personnel costs for employees involved in research and development activities, excluding stock-based compensation, as well as contract services not allocated to specific programs. </p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">3</sup>General and administrative expenses primarily consist of all other personnel costs, excluding stock-based compensation, professional fees, depreciation expense, as well as facilities expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">4 </sup>Other segment items consist of acquired in-process research and development, fair value adjustments to convertible notes, other income, net and income tax provision. Other income, net consists of interest income and realized and unrealized gains and losses on foreign currency transactions. </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522795118464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">18.</b></span>Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Zai License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 24, 2025, the Company entered into a license agreement (the &#8220;Zai License Agreement&#8221;) with Zai Lab (Hong Kong) Limited (&#8220;Zai&#8221;), under which the Company granted Zai an exclusive sublicense to develop and commercialize ZB001 and related programs in greater China. &#160;As partial consideration for the Zai License Agreement, the Company received an upfront fee of $10.0 million from Zai. In addition, the Company is eligible to receive up to $96.0 million upon the achievement of certain future development and commercial milestones and royalty percentage rates from the low to mid-single digits, net of pass-through obligations due to Viridian.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788565952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (156,988)<span></span>
</td>
<td class="num">$ (37,124)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793598272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_Rule10b51ArrangementModifiedFlag', window );">Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_NonRule10b51ArrangementModifiedFlag', window );">Non-Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_NonRule10b51ArrangementModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_NonRule10b51ArrangementModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_Rule10b51ArrangementModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_Rule10b51ArrangementModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522789945328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788669616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Risk Management and Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have developed and maintain an information security program designed to assess, identify, and manage risks from cybersecurity threats. As part of this program, we conduct periodic assessments of our assets to evaluate the effectiveness of applicable security controls. These assessments are informed by industry standard frameworks and include a review of our information security controls to assess cybersecurity maturity compared to our peers and other security awareness trainings. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We engage security technology vendors to assist with detecting potential threats to our information assets. In addition, we have implemented a cybersecurity third party risk management process to assess mission and business critical third parties for cyber risks and to assist the business in making risk-informed technology product and services decisions. Our practice is to perform due diligence, including the completion of security questionnaires and risk assessments, as appropriate, on third parties who maintain material data or information to help us evaluate and verify third party information security capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our process designed to detect and respond to cybersecurity incidents that may represent a threat to the confidentiality, integrity or availability of our information assets is based on industry standards and best practices of peer companies. Our technology, procedures and key vendors with security responsibilities are designed to help contain, eradicate and recover from cybersecurity incidents in a timely manner. Senior management is informed about incidents that may have a significant impact on the business. Incidents are reviewed once they are resolved, and policies and controls are updated to help mitigate gaps. We have not identified risks from known cybersecurity threats or past incidents that have materially affected or are reasonably likely to materially affect us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. &#8220;Risk Factors&#8221; in this Annual Report.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have developed and maintain an information security program designed to assess, identify, and manage risks from cybersecurity threats. As part of this program, we conduct periodic assessments of our assets to evaluate the effectiveness of applicable security controls. These assessments are informed by industry standard frameworks and include a review of our information security controls to assess cybersecurity maturity compared to our peers and other security awareness trainings. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We engage security technology vendors to assist with detecting potential threats to our information assets. In addition, we have implemented a cybersecurity third party risk management process to assess mission and business critical third parties for cyber risks and to assist the business in making risk-informed technology product and services decisions. Our practice is to perform due diligence, including the completion of security questionnaires and risk assessments, as appropriate, on third parties who maintain material data or information to help us evaluate and verify third party information security capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our process designed to detect and respond to cybersecurity incidents that may represent a threat to the confidentiality, integrity or availability of our information assets is based on industry standards and best practices of peer companies. Our technology, procedures and key vendors with security responsibilities are designed to help contain, eradicate and recover from cybersecurity incidents in a timely manner. Senior management is informed about incidents that may have a significant impact on the business. Incidents are reviewed once they are resolved, and policies and controls are updated to help mitigate gaps. We have not identified risks from known cybersecurity threats or past incidents that have materially affected or are reasonably likely to materially affect us. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">our Board of Directors, as a whole and through committees, has responsibility for the oversight of risk management, including risks from cybersecurity threats. Our Audit Committee has specific oversight of risk management, including risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Audit Committee<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Executive Director of IT reports to our Chief Human Resources Officer and provides periodic cybersecurity updates to the Audit Committee of our Board of Directors on at least an annual basis. Our incident response process contemplates that the executive team will notify the Audit Committee of our Board of Directors of any material cybersecurity incident.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Management is responsible for the day-to-day management of risks we face,Our Executive Director of IT is responsible for developing, implementing, and maintaining our cybersecurity risk management policies and procedures. The individual currently serving in the role of Executive Director of IT has over thirty years of experience in cybersecurity, information security, data protection, privacy, regulatory compliance and risk management within complex and international business verticals such as pharmaceutical/biotech, technology, semiconductor and telecom. The Executive Director of IT reports to our Chief Human Resources Officer and provides periodic cybersecurity updates to the Audit Committee of our Board of Directors on at least an annual basis. Our incident response process contemplates that the executive team will notify the Audit Committee of our Board of Directors of any material cybersecurity incident.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Executive Director of IT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Executive Director of IT has over thirty years of experience in cybersecurity, information security, data protection, privacy, regulatory compliance and risk management within complex and international business verticals such as pharmaceutical/biotech, technology, semiconductor and telecom.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The Executive Director of IT reports to our Chief Human Resources Officer and provides periodic cybersecurity updates to the Audit Committee of our Board of Directors on at least an annual basis. Our incident response process contemplates that the executive team will notify the Audit Committee of our Board of Directors of any material cybersecurity incident.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788869248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_BasisOfPresentationAndConsolidationPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the operations of the Company and its wholly-owned subsidiaries. All intercompany accounts, transactions, and balances have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been or omitted pursuant to such rules&#160;and regulations. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosures. The Company bases its estimates on historical experience, known trends and other market- specific factors or other relevant factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis using such factors and adjusts those estimates and assumptions as facts and circumstances dictate. Actual results may differ from those estimates or assumptions. Significant estimates in these consolidated financial statements include estimates made in connection with accrued research and development expenses, stock-based compensation and pre-initial public offering (&#8220;IPO&#8221;) valuations of common stock, and convertible debt.</span><b style="font-style:normal;font-weight:bold;"> </b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original or remaining maturity from the date of purchase of three&#160;months or less to be cash equivalents. Cash equivalents may include money market funds, corporate debt securities, U.S government agency notes and overnight deposits.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Short-Term Investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company classifies all investments with a remaining maturity when purchased of greater than three months as &#8220;available-for-sale&#8221;. Available-for-sale securities with a remaining maturity of greater than one year are classified as non-current assets. Available-for-sale securities are carried at fair value based upon market prices at period end, with the unrealized gains and losses included in accumulated other comprehensive loss as a component of stockholders&#8217; equity (deficit) until realized. The amortized cost of investments in this category is adjusted for amortization of premiums and accretions of discounts over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense). The Company reviews its portfolio of investments, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss. If the decline in fair value is due to credit-related factors, a loss is recognized in other income (expense).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Cash </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of cash held as collateral for a letter of credit the Company issued as a security deposit for its lease of office space in Waltham, MA, which terminated in January 2025. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Deferred Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company capitalizes legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as other non-current assets until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in-capital generated as a result of the offering. If the Company terminates its plan for an equity financing, any costs deferred will be expensed immediately. Upon closing the IPO in September 2024, the related deferred offering costs were recorded against the IPO proceeds. No deferred offering costs were recorded as of December 31, 2024. As of December 31, 2023, the Company had $1.4 million in deferred offering costs which were included in other assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one reportable segment focused on the research and development of precision immunology-based therapies. The Company&#8217;s chief operating decision-maker (the &#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of making operating decisions, assessing financial performance, and allocating resources. As of December 31, 2024 and 2023, the Company&#8217;s long-lived assets held outside of the U.S. were immaterial. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our segment reporting, see <i style="font-style:italic;">Note 17, Segment Information</i> to these consolidated financial statements. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and short-term investments. The Company attempts to minimize the risks related to cash, cash equivalents and short- investments by investing in a broad range of financial instruments, as defined by the Company&#8217;s investment policy. The Company has established guidelines related to the quality of the institutions, financial instruments and allowable investments. The Company minimizes credit risk by choosing only highly rated financial institutions as counterparties. &#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_SignificantSuppliersPolicyTextBlock', window );">Significant Suppliers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant Suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs, including preclinical and clinical studies and testing. In particular, the Company relies on a single manufacturer and expects to continue to rely on a single or small number of manufacturers to supply it with its requirements for the drug product related to these programs. These programs could be adversely affected by a significant interruption in the supply of drug substance and drug product.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation of Foreign Currency</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Translation of Foreign Currency </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign subsidiaries into U.S. dollars are excluded from our determination of net loss and are recorded in accumulated other comprehensive income (loss), as a separate component of equity. For foreign subsidiaries where the functional currency of assets and liabilities differs from their local currency, non-monetary assets and liabilities are translated at the rate of the exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other (income) expense, net in our consolidated statements of income. Realized and unrealized foreign currency transaction losses were $0.2 million and $0.1 million for each of the&#160;years ended December&#160;31, 2024 and 2023, respectively. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 0pt 20pt;">Level&#160;1&#8212;<span style="font-style:normal;"> Quoted market prices in active markets for identical assets or liabilities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 0pt 20pt;">Level&#160;2&#8212;<span style="font-style:normal;"> Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 12pt 20.15pt;">Level&#160;3&#8212;<span style="font-style:normal;"> Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level&#160;3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The majority of our financial assets have been classified as Level 1. Our financial assets (which typically include cash equivalents and marketable equity securities) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market- based approaches and observable market inputs to determine value. These observation market inputs included reportable tables, benchmark yields, broker quotes, bids, offers, current spot rates and other industry and economic events. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-Lived Assets </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amount of the assets to their undiscounted expected future cash flows. If this comparison indicates there is an impairment, the amount of the impairment is calculated as the difference between the carrying value and fair value. To date, no such impairments have been recognized. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Property and equipment are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (<span style="-sec-ix-hidden:Hidden_b_kdHKCFF0avLUjrQ41Fwg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to seven years). Assets under capital leases are amortized over the shorter of their useful </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">lives or lease terms using the straight-line method. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndCollaborationRevenuePolicyTextBlock', window );">License and Collaboration Revenue</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License and Collaboration Revenue </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company enters into license and collaboration arrangements with third parties, under which the Company licenses or may license rights to certain of the Company&#8217;s product candidates and may perform research and development services in connection with such arrangements. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, clinical, regulatory and commercial sales milestone payments, and royalties on net sales of licensed products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">At contract inception, the Company analyzes its collaboration and license arrangements to assess whether such arrangements are within the scope of ASC Topic 808,&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Collaborative Arrangements</i><span style="letter-spacing:0.2pt;">&#160;(&#8220;ASC 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple&#160;units of account, the Company first determines which&#160;units of the collaboration are deemed to be within the scope of ASC 808 and which&#160;units of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of ASC Topic 606,&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Revenue from Contracts with Customers</i><span style="letter-spacing:0.2pt;">&#160;(&#8220;ASC&#160;606&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC 808: (i)&#160;the parties to the contract must actively participate in the joint operating activity and (ii)&#160;the joint operating activity must expose the parties to the possibility of significant risks and rewards, based on whether or not the activity is successful. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. Payments received from or made to a partner that are the result of a collaborative relationship with a partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction or increase to research and development expense, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">For the&#160;units of account within the scope of ASC 606, to determine the appropriate amount of revenue to be recognized for the arrangements, the Company performs the following five steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The promised goods or services in the Company&#8217;s arrangements typically consist of a license to the Company&#8217;s intellectual property and research and development services. The Company provides options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Due to the uncertainty of research and development and regulatory based milestones that are not within the control of the Company, payment becomes probable upon achievement. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and collaboration revenue in the period of adjustment. Any amounts due to the Company but not received as of period-end will be recorded to other current assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs including a reasonable margin. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Research and development costs include (i)&#160;employee-related expenses, including salaries, benefits, and stock-based compensation expense; (ii)&#160;external research and development expenses incurred under arrangements with third parties, such as CRO agreements and consultants; (iii)&#160;costs associated with preclinical activities and (iv)&#160;lab supplies, lab expenses and an allocation of rent, depreciation, and infrastructure. Costs incurred in connection with research and development activities are expensed as incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data, such as patient enrollment or clinical site activations, provided by the Company&#8217;s clinical sites and vendors. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable. The Company monitors each of these factors and adjusts estimates accordingly. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock', window );">Asset Acquisitions and Acquired In-Process Research and Development Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Asset Acquisitions and Acquired In-Process Research and Development Expense </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">The Company accounts for acquisitions of assets or a group of assets that do not meet the definition of a business as asset acquisitions based on the cost to acquire the asset or group of assets, which include certain transaction costs. In an asset acquisition, the cost to acquire is allocated to the identifiable assets acquired and liabilities assumed based on their relative fair values as of the acquisition date. No goodwill is recorded in an asset acquisition. Assets that are </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as in process research and development (&#8220;IPR&amp;D&#8221;). Acquired IPR&amp;D that has no alternative future use as of the acquisition date is recognized as acquired IPR&amp;D expense as of the acquisition date. The Company will recognize additional acquired IPR&amp;D expenses in the future if and when the Company becomes obligated to make contingent milestone payments under the terms of the agreements by which it acquired the IPR&amp;D assets. The Company classifies payments made for the acquisition of IPR&amp;D assets, whether capitalized or expensed, as investing activities on its statement of cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Contingent consideration in the form of milestone payments related to IPR&amp;D with no alternative future use are charged to expense when the related milestone is achieved and becomes payable. For the year ended December&#160;31, 2024, the Company did not recognize any acquired IPR&amp;D expense. For the year ended December 31, 2023, the Company recognized </span><span style="letter-spacing:0.2pt;">$10.0</span><span style="letter-spacing:0.2pt;">&#160;million of IPR&amp;D expense, in connection with the consideration due under the 2021 Xencor Agreement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our asset acquisitions and acquired in-process research and development, please see <i style="font-style:italic;">Note 8, License and Option Agreements,</i> to these consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss consists of net loss and other comprehensive loss. During the years ended December 31, 2024 and 2023, the Company&#8217;s only element of other comprehensive loss was foreign currency translation adjustments.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases </p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of use lease assets (&#8220;ROU assets&#8221;), current portion of lease obligations and long-term lease obligations on the Company&#8217;s consolidated balance sheet. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#8217;s consolidated balance sheet. Lease assets are tested for impairment in the same manner as</span><span style="font-family:'TimesNewRomanPSMT';"> </span><span style="font-size:10pt;">long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense, while expense for financing leases is recognized as depreciation expense (classified as an operating expense) and interest expense (classified as a non-operating expense) using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheet for leases with an original term of twelve months or less. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recognized based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. Certain adjustments to the ROU asset may be required for items such as incentives received from the lessor. The interest rate implicit in lease contracts is typically not readily determinable. Therefore, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasures the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company generally accounts for non-lease components together with lease components. The Company expenses variable payments included in a lease arrangement as such expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our leases, please see <i style="font-style:italic;">Note 6, Leases</i>, to these consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740, <i style="font-style:italic;">Accounting for Income Taxes</i>, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a &#8220;more likely than not&#8221; threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are no unrecognized tax benefits included in the Company&#8217;s consolidated balance sheets as of December 31, 2024 and 2023. The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties related to uncertain tax positions in its consolidated statements of operations and comprehensive loss since inception.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The Company grants stock-based awards to employees, non-employee consultants and members of its board of directors (the &#8220;Board&#8221;). Stock-based compensation is recognized as expense for each stock-based award based on its estimated fair value on the date of grant. The Company&#8217;s share-based payments include stock options and grants of restricted common stock. The value of the award is recognized as expense on a straight-line basis over the requisite service period, and expense is adjusted for pre-vesting forfeitures in the period in which the forfeitures occur. Stock-based compensation expense is classified in the accompanying consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipients service payments are classified.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="letter-spacing:0.2pt;">The Company estimates the fair value of each restricted stock award (&#8220;RSA&#8217;s&#8221;) at its grant date based on the estimated fair value of the Company&#8217;s common stock on that date as determined by the Board. The Company estimates the fair value of stock option awards on the grant date using a Black-Scholes option pricing model. The Company estimates the expected option lives using the simplified method, volatility using historical stock prices of peer companies, the risk-free rates using the U.S Treasury yield curve in effect with a remaining term equal to the expected term and dividend yield based on the Company&#8217;s history of paying no dividends and the expectations of paying no cash dividends in the foreseeable future. Prior to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock on the date of grant was determined by the Board, taking into consideration its most recently available third-party valuations of common stock as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the grant date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;">For additional information on our share-based compensation, please see <i style="font-style:italic;">Note 11, Stock-Based Compensation</i>, to these consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Convertible Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The Company classified its convertible preferred stock as temporary equity (between liabilities and stockholders&#8217; equity (deficit)) in the accompanying consolidated balance sheet because it could have become redeemable due to certain change in control clauses that were outside of the Company&#8217;s control. The convertible preferred stock was not redeemable, except in the event of a deemed liquidation event. As the occurrence of a deemed liquidation event was not currently probable at December 31, 2023, the carrying values of the convertible preferred stock were not being accreted to their redemption values. Upon the completion of the Company&#8217;s IPO on September 16, 2024, all outstanding shares of the Company&#8217;s convertible preferred stock converted into shares of the Company&#8217;s common stock. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For additional information on our convertible preferred stock, please see <i style="font-style:italic;">Note 9, Convertible Preferred Stock</i>, to these consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two- class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#8217;s common shares and participating securities. The Company&#8217;s convertible preferred stock contained participation rights in any dividend paid by the Company and is deemed to be a participating security. Net loss attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Diluted net loss per share is computed using the more dilutive of (a)&#160;the two-class method or (b)&#160;the if- converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss per share gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders for the&#160;years ended December&#160;31, 2024 and 2023.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (&#8220;FASB&#8221;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated statements or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">In November&#160;2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280)&#8212;Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;)</i>, which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. This standard became effective for the Company for the annual reporting period ended December 31, 2024, using the retrospective method. The adoption of this standard resulted in additional disclosure of the significant expenses reviewed by the Company&#8217;s CODM. The adoption did not have a material impact on the consolidated financial position or results of operations. See <i style="font-style:italic;">Note 17, Segment Information</i>, for our updated segment presentation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740)&#8212;Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;)</i>, which requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company beginning in fiscal year 2025, with early adoption permitted. ASU 2023-09 may be applied retrospectively or prospectively to the financial statements. The Company is currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In November&#160;2024, the FASB issued 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;)</i>, which requires entities to disclose additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective annual periods beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">prospectively to the financial statements. The Company is currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for asset acquisitions and acquired in-process research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_BasisOfPresentationAndConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of presentation and consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_BasisOfPresentationAndConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_LicenseAndCollaborationRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for license and collaboration revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_LicenseAndCollaborationRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_SignificantSuppliersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for significant suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_SignificantSuppliersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522795014256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of information about the Company's assets and liabilities that are regularly measured and carried at fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following tables present information about the Company&#8217;s assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:bottom;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:28.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Carrying Value</b></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted Prices in Active Market </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other Observable Inputs</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other Observable Inputs</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Cash</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Money market funds</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300,672</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investments:</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,315</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Corporate debt securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,601</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Government securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,108</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">     Total assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 350,766</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 338,850</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,916</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:30.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:bottom;width:66.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2023</b></p></td></tr><tr><td style="vertical-align:middle;width:30.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Carrying Value</b></p></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted Prices in Active Market </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other Observable Inputs</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other Observable Inputs</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  BMS note</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,300</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,300</p></td></tr><tr><td style="vertical-align:bottom;width:30.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">     Total liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,300</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,300</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of available-for-sale securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the available-for-sale securities (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:bottom;width:56.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Unrealized Gains</b></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Unrealized Losses</b></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short-term investments:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,311</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,315</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,601</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,108</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,993</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,024</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of changes in the company's liabilities with significant unobservable inputs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following tables presents changes to the Company&#8217;s liabilities with significant unobservable inputs (Level 3 liabilities) during the years ended December 31, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible notes</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible Note:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Balance as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of BMS Note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_O9B88gheUkaquoX_9DV5hA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of BMS Note</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Balance as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,300</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_jVXKwJzbK06otYl6OvTOJw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of BMS Note</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 846</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of Series C Preferred Stock in exchange for BMS Note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,146)</p></td></tr><tr><td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Balance as of December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522794960128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Summary of other assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.63%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:54.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical trial deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,788</p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,388</p></td></tr><tr><td style="vertical-align:top;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:top;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,276</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788542896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:37.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.17%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">External research, development and manufacturing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,398</p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,122</p></td></tr><tr><td style="vertical-align:top;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional and consultant fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,379</p></td></tr><tr><td style="vertical-align:top;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 301</p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106</p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,306</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522794932256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of balance sheet information related to operating lease assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">Supplemental balance sheet information related to operating lease assets and liabilities was as follows (in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">821</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">813</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.6</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate used to measure lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10.99%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">18.39%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock', window );">Schedule of minimum lease payments under the Company's operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fiscal Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 896</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,137</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (134)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,003</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability, Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position and quantitative information pursuant to operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522890656896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of convertible preferred stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stock consisted of the following as of December 31, 2023 (in thousands, except share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:70.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued and</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuable Upon</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Conversion</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series Seed Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,785,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,785,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 205,653</p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,589,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,589,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,025,699</p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,242,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,242,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 193,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 193,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,356,392</p></td></tr><tr><td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,617,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,617,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,587,744</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522893002544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock', window );">Schedule of common stock reserved for potential conversion and future issuance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:32.54%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of outstanding shares of convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,587,744</p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,706,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,382,933</p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Remaining shares reserved for future issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 359,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,792</p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,065,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,031,469</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of common stock reserved for potential conversion of securities and shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522897483648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of RSA activity and related information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average Grant-Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#ffffff;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:middle;width:2.8%;background:#ffffff;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#cceeff;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.71</p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,028)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.01</p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#cceeff;border-bottom:1.5pt solid #ffffff;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Repurchased</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,172)</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.48</p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair values of stock options granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:32.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:2.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;">%</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity and related information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted - Average Exercise Price</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Term (in years)</b></p></td><td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value (in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding - December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,382,933</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.51</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,084</p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,736,822</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.67</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (38,427)</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.11</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 231</p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (375,131)</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.29</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding - December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,706,197</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.21</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.76</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,104</p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,294,162</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,901</p></td></tr><tr><td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and expected to vest as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,706,197</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.21</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.76</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,104</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense as reflected in condensed consolidated statements of operations and comprehensive loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company recognized stock-based compensation expense related to the issuance of equity awards to employees in the consolidated statement of operations as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:36.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,066</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,600</p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,895</p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,495</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522787667104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.61%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.47%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.61%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (156,988)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (37,124)</p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common stock outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,198,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,531,178</p></td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share attributable to common stockholders - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11.89)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24.25)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities excluded from the computation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:44.4%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock</p></td><td style="vertical-align:top;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,587,744</p></td></tr><tr><td style="vertical-align:top;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock</p></td><td style="vertical-align:top;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,200</p></td></tr><tr><td style="vertical-align:top;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock </p></td><td style="vertical-align:top;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,706,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,382,933</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522787604720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of loss before the provision for (benefit from) income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents the components of loss before the provision for (benefit from) income taxes during the years ended December 31, 2024 and 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (160,918)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,845)</p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,978)</p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loss before taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (156,559)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (36,823)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of the income tax provision</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The components of the income tax provision for the years ended December 31, 2024 and 2023 are as follows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current income tax provision:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 289</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 301</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income tax provision:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal, state and foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 301</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the income tax expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">IP transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign tax rate differential</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of the Company's deferred tax assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the components of the Company&#8217;s deferred tax assets and liabilities (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,960</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,716</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,573</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,547</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,424</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Milestone payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 719</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,188</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 550</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,961</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (200)</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (200)</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax asset before valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,761</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (90,295)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (39,761)</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522787760864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of financial data for reportable segments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">The following table presents certain financial data for the Company&#8217;s reportable segments for the years ended December 31, 2024 and 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Less:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Direct research and development expenses:</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Obexelimab</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,446</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Other programs (ZB002 &amp; ZB004)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,242</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Partnered regional programs (ZB001 &amp; ZB005)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,737</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,738</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Unallocated research and development</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,008</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  General and administrative</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,218</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Stock-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,495</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Other segment items</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">4</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,901)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,977</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (156,988)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,124)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> Direct research and development expenses primarily consist of direct costs incurred to specific programs research and development activities, including costs to conduct clinical trials and to manufacture clinical drug supply. </p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">2 </sup>Unallocated research and development expenses primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as personnel costs for employees involved in research and development activities, excluding stock-based compensation, as well as contract services not allocated to specific programs. </p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">3</sup>General and administrative expenses primarily consist of all other personnel costs, excluding stock-based compensation, professional fees, depreciation expense, as well as facilities expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">4 </sup>Other segment items consist of acquired in-process research and development, fair value adjustments to convertible notes, other income, net and income tax provision. Other income, net consists of interest income and realized and unrealized gains and losses on foreign currency transactions. </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793278208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 16, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(156,988)<span></span>
</td>
<td class="num">$ (37,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(387,391)<span></span>
</td>
<td class="num">$ (230,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="nump">15,220,588<span></span>
</td>
<td class="nump">15,220,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price | $ / shares</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate gross proceeds</a></td>
<td class="nump">$ 258,700<span></span>
</td>
<td class="nump">$ 234,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 234,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock into common stock | shares</a></td>
<td class="nump">24,978,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">8.6831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriter's option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="nump">1,985,294<span></span>
</td>
<td class="nump">1,985,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788506528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossAfterTax', window );">Realized and unrealized foreign currency transaction losses</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired', window );">Acquired IPR&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=zbio_XencorAgreement2021Member', window );">2021 Xencor Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired', window );">Acquired IPR&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-38<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized from cost for research and development asset acquired in transaction other than business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=zbio_XencorAgreement2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=zbio_XencorAgreement2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793989968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Valuation Techniques (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_InvestmentFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 350,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">BMS note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember', window );">Cash | Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">19,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">300,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_InvestmentFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_InvestmentFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">8,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government securities | Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_InvestmentFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">19,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Estimate of fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_InvestmentFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">338,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash | Estimate of fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">19,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds | Estimate of fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">300,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Government securities | Estimate of fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_InvestmentFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">19,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Estimate of fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_InvestmentFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">11,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper | Estimate of fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_InvestmentFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities | Estimate of fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_InvestmentFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">$ 8,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Estimate of fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">BMS note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_InvestmentFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_InvestmentFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793133136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Transfers (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_FairValueAssetsLevel1ToLevel2TransferAmount', window );">Assets - Transfer from level 1 to 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_FairValueAssetsLevel2ToLevel1TransferAmount', window );">Assets - Transfer from level 2 to 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Assets - Transfer into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount', window );">Liabilities - Transfer from level 1 to 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Liabilities - Transfer into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gain (loss) recognized on the sale or maturity of available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_FairValueAssetsLevel1ToLevel2TransferAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_FairValueAssetsLevel1ToLevel2TransferAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_FairValueAssetsLevel2ToLevel1TransferAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_FairValueAssetsLevel2ToLevel1TransferAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788720320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Available-for-sale securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 30,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">31,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">3,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">8,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">8,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">19,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">$ 19,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522789436272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Convertible Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 03, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_FairValueAdjustmentOfConvertibleNotes', window );">Change in fair value of BMS Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 846<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=zbio_BmsConvertiblePromissoryNotesMember', window );">BMS Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes', window );">Minimum proceeds from issuance of convertible preferred stock for automatic conversion of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on extinguishment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_FairValueAdjustmentOfConvertibleNotes', window );">Change in fair value of BMS Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=zbio_BmsConvertiblePromissoryNotesMember', window );">BMS Notes | Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued on conversion</a></td>
<td class="nump">12,284,686<span></span>
</td>
<td class="nump">12,284,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_FairValueAdjustmentOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_FairValueAdjustmentOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum cash inflow required from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock for automatic conversion of the convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of convertible preferred stock classified as temporary equity issued upon conversion of convertible notes during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=zbio_BmsConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=zbio_BmsConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793610640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Changes in Liabilities With Significant Unobservable Inputs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in company's liabilities with significant unobservable inputs (Level 3 liabilities)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 20,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of BMS Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of BMS Note</a></td>
<td class="nump">$ 846<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Fair Value Adjustment of Convertible Notes<span></span>
</td>
<td class="text">Fair Value Adjustment of Convertible Notes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Issuance of Series C Preferred Stock in exchange for BMS Note</a></td>
<td class="num">$ (21,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522787337776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Clinical trial deposits</a></td>
<td class="nump">$ 12,639<span></span>
</td>
<td class="nump">$ 5,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">$ 12,856<span></span>
</td>
<td class="nump">$ 7,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522894150656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent', window );">External research, development and manufacturing expenses</a></td>
<td class="nump">$ 29,338<span></span>
</td>
<td class="nump">$ 9,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">8,308<span></span>
</td>
<td class="nump">5,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional and consultant fees</a></td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">2,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 39,371<span></span>
</td>
<td class="nump">$ 17,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for external research, development and manufacturing expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522795117728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement', window );">Right-of-use assets obtained under new operating lease arrangements</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for lease liabilities</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total lease cost for operating leases</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained under new operating lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793408272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information Related to Operating Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 1,004<span></span>
</td>
<td class="nump">$ 821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 1,003<span></span>
</td>
<td class="nump">$ 813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term in years</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate used to measure lease liabilities</a></td>
<td class="nump">10.99%<span></span>
</td>
<td class="nump">18.39%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793406176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Lease Liabilities and Quantitative Disclosure (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of the operating lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,003<span></span>
</td>
<td class="nump">$ 813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522789814848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=zbio_LicenseAgreementWithBristolMyersSquibbMember', window );">BMS Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementUpfrontPaymentReceived', window );">Amount of upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum', window );">Maximum amount of payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Amount of reduction to research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Research and Development Expense<span></span>
</td>
<td class="text">Research and Development Expense<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementReceivables', window );">Amount receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum', window );">Sales milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementTransactionPrice', window );">Agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=zbio_NovationAgreementMember', window );">Novation Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementUpfrontPaymentReceived', window );">Amount of upfront cash payment received</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum', window );">Maximum amount of payments receivable</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementTransactionPrice', window );">Agreement transaction price</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable from development, regulatory, and sales milestone payments if certain milestones are successfully achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_CollaborativeArrangementReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable in the collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_CollaborativeArrangementReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable from sales milestone payments if certain milestones are successfully achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transaction price receivable under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_CollaborativeArrangementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from upfront payment received pursuant to the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_CollaborativeArrangementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=zbio_LicenseAgreementWithBristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=zbio_LicenseAgreementWithBristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=zbio_NovationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=zbio_NovationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522789271264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Option Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,136<span></span>
</td>
<td class="nump">$ 5,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,371<span></span>
</td>
<td class="nump">17,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=zbio_XencorAgreement2020Member', window );">2020 Xencor Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_NumberOfAntibodyProductCandidates', window );">Number of antibody product candidates | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementTransactionPrice', window );">Agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=zbio_XencorAgreement2020Member', window );">2020 Xencor Agreement | Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Fair value of initial consideration</a></td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of preferred stock issued | shares</a></td>
<td class="nump">5,041,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=zbio_XencorAgreement2021Member', window );">2021 Xencor Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable', window );">Development milestone expense payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementTransactionPrice', window );">Agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable', window );">Regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndOptionAgreementsSalesMilestonePayable', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=zbio_DianthusOptionAgreementMember', window );">Dianthus Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndOptionAgreementsReimbursableExpenses', window );">Reimbursable costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_NumberOfAntibodyProductCandidates', window );">Number of antibody product candidates | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_ThresholdPeriodToNotifyIntentionForExercisingOption', window );">Threshold period to notify intention for exercising option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable', window );">Development milestone expense payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation', window );">Milestone obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=zbio_ViridianAgreementMember', window );">Viridian Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndOptionAgreementsReimbursableExpenses', window );">Reimbursable costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable', window );">Development milestone expense payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transaction price receivable under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of development milestone payable in connection with the agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of development, regulatory and commercial milestone payable in connection with the agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of total milestone obligations for each research program based on achievement of each of the specified milestone events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of regulatory milestone payable in connection with the agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_LicenseAndOptionAgreementsReimbursableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reimbursable expenses incurred pursuant to the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_LicenseAndOptionAgreementsReimbursableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_LicenseAndOptionAgreementsSalesMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sales milestone payable in connection with the agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_LicenseAndOptionAgreementsSalesMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_NumberOfAntibodyProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Denotes number of antibody product candidates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_NumberOfAntibodyProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_ThresholdPeriodToNotifyIntentionForExercisingOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Denotes threshold period to notify intention for exercising option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_ThresholdPeriodToNotifyIntentionForExercisingOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=zbio_XencorAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=zbio_XencorAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=zbio_XencorAgreement2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=zbio_XencorAgreement2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=zbio_DianthusOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=zbio_DianthusOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=zbio_ViridianAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=zbio_ViridianAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522786189264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 16, 2024</div></th>
<th class="th"><div>May 03, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,617,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discount and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,785,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,589,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible preferred stock | 2020 Xencor Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,041,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,242,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible preferred stock | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,471,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible preferred stock | 2021 Xencor Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises', window );">Number of shares issued upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,441,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment', window );">Development milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment', window );">Number of shares issued in pursuant to development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,189,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,275,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible preferred stock | BMS Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,284,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,284,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private financing | Series Seed convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,785,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquitySharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net cash proceeds from issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private financing | Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,547,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquitySharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net cash proceeds from issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private financing | Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,139,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquitySharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net cash proceeds from issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private financing | Series C convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,990,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquitySharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.72131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net cash proceeds from issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="nump">15,220,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,220,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses', window );">Gross proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discount and commissions</a></td>
<td class="nump">$ 258,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion', window );">Number of common shares issued upon conversion of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,978,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriter's option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="nump">1,985,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,985,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of development milestone payment incurred in connection with the agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares issued upon conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross proceeds from initial public offering before deduction of underwriter discounts and offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of convertible preferred stock classified as temporary equity issued in connection with the development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquitySharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be received per share that is classified as temporary equity by entity upon sale of convertible preferred stock. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquitySharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of convertible preferred stock classified as temporary equity issued upon conversion of convertible notes during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of convertible preferred stock classified as temporary equity issued upon exercise of warrants during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=zbio_XencorAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=zbio_XencorAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=zbio_ConvertiblePromissoryNotes2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=zbio_ConvertiblePromissoryNotes2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=zbio_XencorAgreement2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=zbio_XencorAgreement2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=zbio_BmsConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=zbio_BmsConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522785973408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Schedule (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,617,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,617,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,617,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityCommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,587,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,785,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,785,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,785,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityCommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,589,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,589,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,589,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityCommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,025,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,242,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,242,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,242,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityCommonStockIssuableUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,356,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityCommonStockIssuableUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of Convertible preferred stock classified as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityCommonStockIssuableUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522792970784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Rights and Privileges (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Vote</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityNumberOfVotesPerShare', window );">Convertible preferred stock, number of votes per share | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends declared</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Dividends paid</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate, percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate, percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate, percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate, percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes per share entitled to each holder of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=zbio_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522794960416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="nump">294,784,925<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollar per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CommonStockNumberOfVotesPerShare', window );">Number of votes per share | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes per share entitled to each holder of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788450976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock', window );">Conversion of outstanding shares of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,587,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options to purchase common stock</a></td>
<td class="nump">8,706,197<span></span>
</td>
<td class="nump">2,382,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance', window );">Remaining shares reserved for future issuance</a></td>
<td class="nump">359,399<span></span>
</td>
<td class="nump">60,792<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">9,065,596<span></span>
</td>
<td class="nump">14,031,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining number of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of Convertible preferred stock classified as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522787533888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 03, 2024</div></th>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock remain available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,065,596<span></span>
</td>
<td class="nump">14,031,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,821<span></span>
</td>
<td class="nump">$ 3,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=zbio_TwoThousandTwentyPlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to issue under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,560,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock remain available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=zbio_TwoThousandTwentyPlanMember', window );">2020 Plan | Vesting on the anniversary of the vesting commencement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=zbio_TwoThousandTwentyPlanMember', window );">2020 Plan | Vesting in equal monthly installments over the subsequent thirty-six (36) months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=zbio_EquityIncentivePlan2024Member', window );">2024 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to issue under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,775,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding stock maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum', window );">Maximum additional number of outstanding capital stock percent</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock remain available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=zbio_EquityIncentivePlan2024Member', window );">2024 Plan | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock remain available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,449,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=zbio_EmployeeStockPurchasePlan2024Member', window );">2024 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to issue under plan</a></td>
<td class="nump">397,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum', window );">Maximum additional number of outstanding capital stock percent</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized', window );">Additional shares To Be authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Issuance of common stock in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=zbio_EmployeeStockPurchasePlan2024Member', window );">2024 ESPP | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to issue under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">815,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum additional number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of additional shares to be authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=zbio_TwoThousandTwentyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=zbio_TwoThousandTwentyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=zbio_EquityIncentivePlan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=zbio_EquityIncentivePlan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=zbio_EmployeeStockPurchasePlan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=zbio_EmployeeStockPurchasePlan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788540400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Awards (Details) - RSA<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested as of beginning (Shares)</a></td>
<td class="nump">27,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="num">(6,028)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod', window );">Repurchased (shares)</a></td>
<td class="num">(21,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested as of beginning ($ per share) | $ / shares</a></td>
<td class="nump">$ 2.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested ($ per share) | $ / shares</a></td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue', window );">Repurchased ($ per share) | $ / shares</a></td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSAs granted (shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Compensation cost | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that repurchased during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan repurchased during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522787791536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation -Fair values of stock options granted (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">4.13%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">94.31%<span></span>
</td>
<td class="nump">87.86%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522786972832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at beginning of year (in shares)</a></td>
<td class="nump">2,382,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at end of year (in shares)</a></td>
<td class="nump">8,706,197<span></span>
</td>
<td class="nump">2,382,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of common stock options</a></td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at beginning of year (in shares)</a></td>
<td class="nump">2,382,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">6,736,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(38,427)<span></span>
</td>
<td class="num">(27,579)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or cancelled (in shares)</a></td>
<td class="num">(375,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at end of year (in shares)</a></td>
<td class="nump">8,706,197<span></span>
</td>
<td class="nump">2,382,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options vested and exercisable at end of year (in shares)</a></td>
<td class="nump">1,294,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest end of year (in shares)</a></td>
<td class="nump">8,706,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted - Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at beginning of year (in dollars per share)</a></td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">14.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">7.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or cancelled (in dollars per share)</a></td>
<td class="nump">10.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at end of year (in dollars per share)</a></td>
<td class="nump">13.21<span></span>
</td>
<td class="nump">$ 8.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable at end of year (in dollars per share)</a></td>
<td class="nump">7.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at end of year (in dollars per share)</a></td>
<td class="nump">$ 13.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (In years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance outstanding at end of year (in years)</a></td>
<td class="text">8 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable at end of year (in years)</a></td>
<td class="text">5 years 6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest at end of year (in years)</a></td>
<td class="text">8 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at beginning of year</a></td>
<td class="nump">$ 8,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance outstanding at end of year</a></td>
<td class="nump">2,104<span></span>
</td>
<td class="nump">$ 8,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options vested and exercisable at end of year</a></td>
<td class="nump">1,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest at end of year</a></td>
<td class="nump">2,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of common stock options</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant (in dollars per share)</a></td>
<td class="nump">$ 11.38<span></span>
</td>
<td class="nump">$ 8.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested stock options</a></td>
<td class="nump">$ 74,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation cost is expected to be recognized</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of options vested during the period</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522789186784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10,821<span></span>
</td>
<td class="nump">$ 3,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,066<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,755<span></span>
</td>
<td class="nump">$ 1,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522787613424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and diluted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss to common stockholders</a></td>
<td class="num">$ (156,988)<span></span>
</td>
<td class="num">$ (37,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding - basic (in shares)</a></td>
<td class="nump">13,198,960<span></span>
</td>
<td class="nump">1,531,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding - diluted (in shares)</a></td>
<td class="nump">13,198,960<span></span>
</td>
<td class="nump">1,531,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders - basic (in dollars per share)</a></td>
<td class="num">$ (11.89)<span></span>
</td>
<td class="num">$ (24.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - diluted (in dollars per share)</a></td>
<td class="num">$ (11.89)<span></span>
</td>
<td class="num">$ (24.25)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793421056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,587,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net (loss) per share</a></td>
<td class="nump">8,706,197<span></span>
</td>
<td class="nump">2,382,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522890609232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of loss before the provision for (benefit from) income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (160,918)<span></span>
</td>
<td class="num">$ (10,845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non-U.S.</a></td>
<td class="nump">4,359<span></span>
</td>
<td class="num">(25,978)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (156,559)<span></span>
</td>
<td class="num">$ (36,823)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522794990672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of the income tax provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current income tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax provision</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="nump">$ 429<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793137216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the income tax expense (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(32.30%)<span></span>
</td>
<td class="num">(26.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets', window );">IP transfer</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(7.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788593712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Company's deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 29,605<span></span>
</td>
<td class="nump">$ 9,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">39,716<span></span>
</td>
<td class="nump">19,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">14,292<span></span>
</td>
<td class="nump">6,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accruals</a></td>
<td class="nump">1,886<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_DeferredTaxAssetsMilestonePayments', window );">Milestone payments</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">4,016<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">90,858<span></span>
</td>
<td class="nump">39,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_DeferredTaxLiabilitiesAmortizationAndOther', window );">Amortization and other</a></td>
<td class="num">(563)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_DeferredTaxAssetsNetBeforeValuationAllowance', window );">Net deferred tax asset before valuation allowance</a></td>
<td class="nump">90,295<span></span>
</td>
<td class="nump">39,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (90,295)<span></span>
</td>
<td class="num">$ (39,761)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_DeferredTaxAssetsMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_DeferredTaxAssetsMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_DeferredTaxAssetsNetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset, net of deferred tax liability, before allocation of valuation allowances attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_DeferredTaxAssetsNetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_DeferredTaxLiabilitiesAmortizationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from amortization and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_DeferredTaxLiabilitiesAmortizationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522890526496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 50,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized costs</a></td>
<td class="nump">39,716<span></span>
</td>
<td class="nump">$ 19,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net operating loss carryforwards, Federal</a></td>
<td class="nump">75,500<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforwards, State</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal', window );">Percentage of annual deduction</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Net operating loss carryforwards, Foreign</a></td>
<td class="nump">$ 54,200<span></span>
</td>
<td class="nump">53,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards, Foreign expiration</a></td>
<td class="nump">47,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_UncertainTaxPositionsAmountRecognized', window );">Amount recognized for uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 13,300<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TaxCreditCarryforwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_OperatingLossCarryforwardsExpirationPeriod', window );">NOL carryforward expiration period</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TaxCreditCarryforwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized costs</a></td>
<td class="nump">$ 39,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_OperatingLossCarryforwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration period of each operating loss carryforward included in operating loss carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_OperatingLossCarryforwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual deduction equal to annual taxable income on domestic  operating loss carryforwards .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TaxCreditCarryforwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration period of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TaxCreditCarryforwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_UncertainTaxPositionsAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_UncertainTaxPositionsAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522793294688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Onetime contribution</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522788082144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=zbio_XencorIncMember', window );">Xencor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_RelatedPartyTransactionReimbursableCosts', window );">Reimbursable costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=zbio_XencorIncMember', window );">Xencor | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained', window );">Number of antibody product candidates | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_RelatedPartyTransactionNumberOfLicenseAgreements', window );">Number of license agreements | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee', window );">Equity interest held (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=zbio_XencorIncMember', window );">Xencor | Related party | Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of preferred stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,041,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=zbio_XencorIncMember', window );">Xencor | Related party | Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of preferred stock issued | shares</a></td>
<td class="nump">4,189,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=zbio_ViridianTherapeuticsIncMember', window );">Viridian | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=zbio_ViridianTherapeuticsIncMember', window );">Viridian | Related party | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_OwnershipPercentageByRelatedParty', window );">Ownership percentage by related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=zbio_ViridianTherapeuticsIncMember', window );">Viridian | Related party | Fairmount Funds Management LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_NumberOfSeatsHeldInBoard', window );">Number of seats held in board | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=zbio_ViridianTherapeuticsIncMember', window );">Viridian | Related party | Fairmount Funds Management LLC | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_OwnershipPercentageByRelatedParty', window );">Ownership percentage by related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=zbio_DianthusTherapeuticsincMember', window );">Dianthus | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained', window );">Number of antibody product candidates | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=zbio_DianthusTherapeuticsincMember', window );">Dianthus | Related party | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_OwnershipPercentageByRelatedParty', window );">Ownership percentage by related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership of equity interest excluding interest in entity that is consolidated and equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_NumberOfSeatsHeldInBoard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of seats held in the board of related entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_NumberOfSeatsHeldInBoard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_OwnershipPercentageByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of the entity's common stock by a related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_OwnershipPercentageByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of antibody product candidates for which license has been obtained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_RelatedPartyTransactionNumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_RelatedPartyTransactionNumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_RelatedPartyTransactionReimbursableCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reimbursable costs incurred with the related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_RelatedPartyTransactionReimbursableCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=zbio_XencorIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=zbio_XencorIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=zbio_ViridianTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=zbio_ViridianTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=zbio_FairmountFundsManagementLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=zbio_FairmountFundsManagementLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=zbio_DianthusTherapeuticsincMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=zbio_DianthusTherapeuticsincMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522789496384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(139,139)<span></span>
</td>
<td class="num">(60,033)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(29,749)<span></span>
</td>
<td class="num">(17,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="num">(10,821)<span></span>
</td>
<td class="num">(3,495)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss to common stockholders</a></td>
<td class="num">(156,988)<span></span>
</td>
<td class="num">(37,124)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=zbio_SingleReportableSegmentMember', window );">Single Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">22,995<span></span>
</td>
<td class="nump">15,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">10,821<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="num">(6,901)<span></span>
</td>
<td class="nump">9,977<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss to common stockholders</a></td>
<td class="num">(156,988)<span></span>
</td>
<td class="num">(37,124)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=zbio_SingleReportableSegmentMember', window );">Single Reportable Segment | Obexelimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">94,563<span></span>
</td>
<td class="nump">25,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=zbio_SingleReportableSegmentMember', window );">Single Reportable Segment | Other programs (ZB002 &amp; ZB004)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">2,115<span></span>
</td>
<td class="nump">6,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=zbio_SingleReportableSegmentMember', window );">Single Reportable Segment | Partnered regional programs (ZB001 &amp; ZB005)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">6,737<span></span>
</td>
<td class="nump">6,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=zbio_SingleReportableSegmentMember', window );">Single Reportable Segment | Unallocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 31,658<span></span>
</td>
<td class="nump">$ 20,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=zbio_SingleReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=zbio_SingleReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=zbio_ObexelimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=zbio_ObexelimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=zbio_OtherProgramsZb002Zb004Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=zbio_OtherProgramsZb002Zb004Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=zbio_PartneredRegionalProgramsZb001Zb005Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=zbio_PartneredRegionalProgramsZb001Zb005Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=zbio_UnallocatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=zbio_UnallocatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46522789427568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent event - Zai license agreement<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 24, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementUpfrontPaymentReceived', window );">Non-refundable upfront fee</a></td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone', window );">Maximum payment eligible to receive</a></td>
<td class="nump">$ 96.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of payment receivable on achievement of certain regulatory and commercial milestones in the collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zbio_CollaborativeArrangementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from upfront payment received pursuant to the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zbio_CollaborativeArrangementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=zbio_ZaiLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=zbio_ZaiLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>109
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .PQ:UH'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #L,6M:@%SPF.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NFD9AZC+96BG(2$Q"<0M2KPMHDFCQ*C=V].&K1."!^ 8^\_G
MSY);'83N(S['/F DB^EN=)U/0H<U.Q$% 9#T"9U*Y93P4_/01Z=H>L8C!*4_
MU!&AKJH'<$C**%(P XNP$)ELC18ZHJ(^7O!&+_CP&;L,,QJP0X>>$O"2 Y/S
MQ' >NQ9N@!E&&%WZ+J!9B+GZ)S9W@%V28[)+:AB&<FAR;MJ!P]O3[B6O6UB?
M2'F-TZ]D!9T#KMEU\FNS>=QOF:RK>E543<'YGE>"KP2_?Y]=?_C=A%UO[,'^
M8^.KH&SAUUW(+U!+ P04    " #L,6M:F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M .PQ:UK"UQ=?TP<  &PI   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9IK;]LV%(;_"N$-Q0;$L439<=PF 1PGV8PUJ5>G+;IB'VB)CHA*I$=2<?SO
M=RC9EE-0M"!47Q+K<E[QX?7EY6(MY'<54ZK12YIP==F)M5Z][?54&-.4J%.Q
MHAR>+(5,B89+^=13*TE)E >E20][WEDO)8QWKB[R>S-Y=2$RG3!.9Q*I+$V)
MW%S31*PO.WYG=^,C>XJUN=&[NEB1)SJG^M-J)N&JMU>)6$JY8H(C29>7G;'_
M=M+')B!_XS.C:W7P&QF4A1#?S<4TNNQX)D4TH:$V$@3^/=,)31*C!.GX;RO:
MV7_3!![^WJG?Y?  LR"*3D3RA44ZONR<=U!$ER1+]$>Q_I-N@09&+Q2)RO^B
M=?'N(.B@,%-:I-M@2$'*>/&?O&PSXB#@W*L(P-L _$. WZ\("+8!00Y:I"S'
MNB&:7%U(L4;2O UJYD>>-WDTT#!NBG&N)3QE$*>O;D280:EH1'B$;KEF>H.F
MO*@>)IN[Z-/\!OWVZ^\7/0V?,T&]<"M]74CC"FD?HWO!=:Q -Z+1:X$>I'.?
M6+Q+[#5V*M[0\!0%_@G"'NY;$C1QA]_1Q2G"YWGXP)&<8)]W0:X7-,R[;^.%
MTA(JZK^VS"NT^W9MTWK?JA4)Z64'FJ>B\IEVKM[\XI]Y[VS@/TGL53;T]]G0
M=ZF7V?"X65$;J3O<][I_V9"<40V1!GND03VD&95,F,*-$#0O*]T1I5V5K:RS
MSOB&G&=[SK-ZG&/.,Y*@CW0EI+91NG6TS&QY,W%&-60;[MF&-:NE)##JY"VR
MFL^MM22)L@(ZPQH"GN\!SYV)VO8X=RRAZ"%+%U3:P-P:GN=W^Q@//1N<,[0A
MW&@/-ZH#]Y$^,=.'0C$^D-3:_MPZ_U!.%+IF8A83Z)=/H(,.3VVP3IF&L+Y7
MCL)>'5Q(G)!01?/QXP3--?0Y2$@T$1G7<@/_(VL>'%&_N;41NX.:(A\8#[\.
M\B-Y0=,(VBE;LK 8-ZLK\Q')4=#%P_X(]ZT=K3NX*2\N>7$=WG$4@;HZV?U
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M(LU_QI1 _V->@.=+(?3NPGQ@?\#RZG]02P,$%     @ [#%K6I!+C(<'!P
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M@+OW5J1X)?4[9L])SD%*EG*H=QW*TLZJMSS5C:#K\D7)$Q6"9N7EBN"8L")
M?KZD5+S?%.]>FG=ML_\ 4$L#!!0    ( .PQ:UIBZ5G%S@4  +T8   8
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M7-^)]1=H_1D8OE1P9?_)NK7U')*NE!9%"T8%!2N;D3ZU<=@"^/$!0- "@EU
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M-,?6"M(8X/E""+U9F NZ9IW\ 5!+ P04    " #L,6M:*Q=IG]0+  "BE
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MVER9Q,^5O7J^ [X_M8ZAF@'53*AF2<-IRR1-)KU/U6SHH Y4<Z&:!]5\J!9
MM1"E=4N^#9=)_'#9S\QWP"<G5SDT20;53*AF035;8J3<%AKI3?OI0 =UH9H'
MU7RH%D"U\.3*ZI9O&P^3^/&PSTE&HVW\O[)Z'Z/RV%P6;EQ?[JZ_UI59O-"I
MQ:": =5,J&9!-1NJ.=)P]BNI/_TO=$0/JOE0+8!J(?^U[9;MBZ] Y.?#7C%1
M"5^>7+_0*<6@F@G5+*AF0S5'8GQ-93_TZD*']*":#]4"J!:>>'&[%=QFPB1^
M)NRLJ4KXQN1:A::^H)H)U2RH9D,U!ZJYTC!A=2$J2[U_I=Z##NM#M0"JA6>\
M)-V:;<-B$G]ZL#_E7@K^,DW>!T!#9E#-A&J6-/RJQO['R])P#BI9UI=B_^-E
MZ(*Y4,V#:CY4"Z!:.+:V1CY>EMJTE\1/>_WI-UOPEV]RB4,#8E#-A&J6- R(
M$5E7-57L?UL'=%P'JKE0S8-J/E0+H%J(TKI[C38B)KUFYC+F31Q\<7*=0Y-B
M4,V$:I8T3(KUYTUB-%GJ^E(97,UF?;6@W'^G/&QT(6FJI(O]DVIHM@NJ!5 M
M9+PDDDAD9>R<NLUV2:@)R=@E!8UX034#JIE0S9*&$2]95'5)%@<GR="(%U1S
MH9H'U7RH%D"U$*4]U_P\WU!:&%$175_NHT<:1MECG.3"ECZ4_.*=6NXULOAQ
M<_RA2/=7,W$FW*=%D>[JAQL:K6E6-2C__I"FQ8\?YJ7_E&9?ZC&N_P]02P,$
M%     @ [#%K6L= N%>M @  #0@  !@   !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6RM5FUOVC 0_BM65FVMM#8A0+9U$*E J^U#)536[;-)+L2J8Z>V ^V_
MW]D)&>T@*E*_X+>[Y^YY+KICM)'J0>< ACP57.BQEQM37OJ^3G(HJ+Z0)0A\
MR:0JJ,&C6OFZ5$!3YU1P/PR"R"\H$UX\<G=S%8]D93@3,%=$5T5!U?,$N-R,
MO9ZWO;ACJ]S8"S\>E70%"S#WY5SAR6]14E: T$P*HB ;>U>]RVED[9W!;P8;
MO;,GELE2R@=[^)F.O< F!!P28Q$H+FN8 N<6"--X;#"]-J1UW-UOT6\<=^2R
MI!JFDO]AJ<G'WE>/I)#1BIL[N?D!#9^AQ4LDU^Z7;!K;P"-)I8TL&F?,H&"B
M7NE3H\..0R\ZX! V#N%KA\$!AW[CT'=$Z\P<K1DU-!XIN2'*6B.:W3AMG#>R
M8<)6<6$4OC+T,_%4"BTY2ZF!E"P,+E@BHXG,R#2G8@6:,$'0:@W*L"4',D>=
M02EG+I,'0D6SRR5/0>E/Y/JQ8N:9G,X@8PDS9^1T3A6BYF!80OD9.>\$/"?W
MBQDY/3DC)S;VKUQ6&H/HD6^0L$W;3QIRDYI<>(!<+R2W$N-J<BU22%\"^*A4
M*U>XE6L2=B+.(+D@_=YG$@;A8$]"T[>[]SO2Z;?5ZSN\P0&\!2B&%9J09$?/
MLM536SWWR=:):AO'I2YI F,/L32H-7CQQP^]*/B^C_([@;T08- *,.@6P'TQ
M3.N*B@10!FWV?B>=*,<2KL&&#LQVR74<C/SU'A;#EL7P+66<'EO&3M1C6;T3
MV L!HE: Z%W*&/VG?-3[UFI?\^B,="P/?Z>S%J!6;N!H3+ 2INX:[6T[TZY<
M*W]U/\%95X^F?S#UH+RE:L6$)APRA PNOB ]50^?^F!DZ?KW4AJ<!FZ;X[P&
M90WP/9/2; \V0/L/(/X+4$L#!!0    ( .PQ:UK%^/\AF0<  /4A   8
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M^>DM^@FE!?IM*TK%BD1=3C1@,)8F<7V_Z^I^9.!^F*#/HM!;A7XN$IX<&Y@
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M:4A:(4/]0F;5^-"E]Z[+6ECM9@ZF#T( E58O]@$=Y Q-7P%-IXL0]];+CY!
MM)5 U"^!["/QL=B,8?]6'TTBL=8,AB65PCTX%:J.M)B4ALH&]ZWU'6='HJ"W
M;_7C>JG?K3*BSSU2J1-_K&4-E[$33AG]UL]N&5$_8G3>Y>O)P0/TG,L[^UZ!
M0G;;43V);KYMWEWX8)_8=[Z_QA>KZ@V$UDSU0L1G)H':%"1Z R:#]Q% DM4[
M!M4'+7;V,?U::"UR>[GE#*K$#(#?-P*:3?W!W*!YTV/Y-U!+ P04    " #L
M,6M:YND0CKL"  !,"0  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*V6
M:V_:,!2&_XJ555,K=0WDQF40:055VX=)"-KMLYL<B%4GIK:![M_OV D1EQ31
MC2]);)_W/3Y/[#B#C9 O*@/0Y"WGA1HZF=;+ONNJ)(.<JCNQA )'YD+F5&-3
M+ERUE$!3*\JYZ[5:D9M35CCQP/9-9#P0*\U9 1-)U"K/J?QS#UQLAD[;V79,
MV2+3IL.-!TNZ@!GHI^5$8LNM75*60Z&8*(B$^=#YUNZ/(Q-O WXQV*B=9V(J
M>1;BQ31^I$.G928$'!)M'"C>UC "SHT13N.U\G3JE$:X^[QU?["U8RW/5,%(
M\-\LU=G0Z3HDA3E=<3T5F^]0U1,:OT1P9:]D4\9V>@Y)5DJ+O!+C#')6E'?Z
M5G'8$;2#=P1>)?#.%?B5P#]7$%2"P)(I2[$<QE33>"#%AD@3C6[FP<*T:BR?
M%>:US[3$488Z'8]$H01G*=60DIG&&[Y3K8B8DQ%5&7G =:'(]81*[,Y LX3R
M&_*%/,W&Y/KJAEP15I#'3*P4+5(U<#7.R3B[297_OLSOO9-_#,D=\=NWQ&MY
M08-\=+[<;Y"/SY=[^W(70=8TO9JF9_W\=_RFD(@B89Q1NZ@18H(0;^V5P.N*
MK2FW>!$6;AJE)4L,>#/>;X)7I@N:TYE/0E\M:0)#!_>\ KD&)_[\J1VUOC:A
MO*39^$)F>YC]&K-_RCVV*],@/.3:A+"T"JV5^0BN8[_=ZP3XNM>[<([#PJ@;
M=O:CQB?G]8]5!W75P<FJI_OKI:G6TB#:*:+7.JCS9(Z/+H(+F>WA"&L<X?_B
M.&GPT=T3'K'M1@>KXT+Y]G!$-8[H)(Y'H2G_P.>FB5?4M%6Z_N%6.0X+HU[@
M'\ XCHHZ7B^LH\HJW9VCR_QG_*1RP0I%.,Q1U[KKH($LS^ZRH<72GF;/0N/9
M:!\S_-T!:0)P?"Z$WC;, 5G_0,5_ 5!+ P04    " #L,6M:#IK^]&X*  "Q
M&0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RE66UOVS@2_BN$MRBZ
M@./X)6G<-@G0I+?7HIO=HMG> O>-EFB+&XE422JN[]??,T/JQ8F36^"^Q))(
M#F>>>>:%S/G6NCM?*!7$CZHT_F)4A%"_/3[V6:$JZ2>V5@8C:^LJ&?#J-L>^
M=DKFO*@JC^?3Z>OC2FHSNCSG;U_<Y;EM0JF-^N*$;ZI*NMV5*NWV8C0;M1^^
MZDT1Z,/QY7DM-^I6A6_U%X>WXTY*KBMEO+9&.+6^&+V?O;TZH?D\X5]:;?W@
M69 E*VOOZ.53?C&:DD*J5%D@"1(_]^I:E24)@AK?D\Q1MR4M'#ZWTG]AVV'+
M2GIU;<L_=1Z*B]%R)'*UEDT9OMKM1Y7L.25YF2T]_Q7;.'?V9B2RQ@=;I<70
MH-(F_LH?"8?!@N7TB07SM&#.>L>-6,L/,LC+<V>WPM%L2*,'-I570SEMR"FW
MP6%48UVX_$V&QBEAU^*J\1CS_OPX0"Z-'F=)QE64,7]"QFPN;JP)A1?_,+G*
M]P4<0Z%.JWFKU=7\68D?5#81B]E8S*?SDV?D+3HK%RQO\7]9&66<')9!T?'6
MUS)3%R/0WRMWKT:7+W^:O9Z^>T;#DT[#D^>D_TT-GY<QFXC?W48:_1_)C/^W
M,M*+*VV_%!($'HM/!K"^>OG3<CZ?ON-1?IZ]$]:)4"B1AJYM54NS2X,_BRW$
M:)-95ULG@\KQ(GZS]ZI:*0<7S=X(3'BPFWAU+7>5-#^+7W6EL6@LI!'JAZIJ
MDI#%+1Z))2WB0O')E]+D'@$1"E%&(?B5*UWJL"-Q+ 89(L, TI1CLTE5XLT4
M:!CQOMD@B,2<J;081_EI[U=X,>+.V*WY.P;L(Y>T;#'Z&:G@R*F-]D$YS%T[
M6QTRAI0>3%OM .Z.W)XA@K1IHN<2$+<!L-#@!U7*K00_7@V\]%7EMM*9+E6K
MQ"39H+&/R$ /G<E2^(#L*C:E7>%EI6W-YF6J"3S<>H*@U('L#%:LE#8;""F1
MY^'CI$^N[I'%:R >>O1=IF794@ZZ!B>-C]4"^5;HJFJ,+>UF=T39,R=!3M9:
M>8%)HL8LB&.G&:7RB?BC]Q#9-3M[Y\7&0E%819HUNLR)2KU@UD6;=2FK*JK1
M>NK32UG5^-L2>6V14@GVIU#8VUX4S/NC4F>H0BJ/^_@6!D+(X]%A>>ULWF1!
M9)BB<W@M6D>@!=3*P) !G'OIM&W@GB;8([9 14J0<W/M%2#R^TI@PP)>^-Y(
M%SD#I/Z492AD-18WTGN9%3 JA$BN& >* ;60[M6&-A^+;:&S@D&$\%5*,J23
MS+XWVK&_L7Y@7-3OL-ML@% =@=OGP&$/@M[>E@P-@D,;:6@)<3.H*A$@*YM<
ML7HRRVQ#'Z&>QL^VL&6),-D:K/;-RNM< TGE6ZO2VD<A_/'S4^'[\7/+BO'C
M9=]NWV/=K]</UGR[[=?<%M)L"JG[Q4%E12+DM9T\E34*V/[TSK<J:YP.9-DU
M\N(D9KF'L_Y9K3[2!O!;CE3(<Z[AG !$ORIO&Y=!P"U040P?/=3DF_W\1_2&
MNRVG7DQ3:[@6OS7(D.E:$N2(."IVT@'E 3VZ%."D]L25+&[_B+IPUE]HP%B.
M]G>1HPWT<0$=(QM*#$+,8L:#E!5C4D<N,VL?A:TV.=*[0S6(%( J8Y ["&-#
M5S."';.L4@52%=5[L!'6J*A5]S$X4-./A5V1CK0$&;LI9; .6->(]7O,XC!X
M%/9C-&?N#LTT* S,);D )$X3,3P$<,59MX9:$,UD-VAC.QXE"PVVX\)&B]&,
MYXJ%HG*IG4"T>VN,*J-K4W$D,&5 )LZ2EQ19(I!#2KW6@ 15N+0[1?HZA9J:
M)(9"N_RH1J9!L U:"4R#!2%UTM$>L 12@4C/^P1S%,=E>X,NP1DV-F$8I9%2
M#_0E)N%##D9C#F66Q&B,K1LSK/"'4XP#LJ917"7(%^ WZL]*H<9OE%&QQ>"Z
M7*,F<\X!$Q2*%#&2REPX(#4E_U3ORE*N;-1"R(U3G+NBJ5?@=[#ET<T.+A&W
MB,W5JF\U4A*XNNE2"$ML??M0V!^(>"3(!VFEE9)&.TFOO%)HR&#RV1AIH5?X
M>D_AKQ$@:HMNP<W8OLU>QRY[/S6D<$F) 4' N;YN5H #_E\KKA==F?WR>Y_2
MP+.8E,->)O!-*J H [F8G8ZQ<'RZ7 J/B%9=ID_) $AF=X.@%K/QFR76O#EI
MY]>-\XTTG%EHIW53EM1>HA1Y#CGZR&[=(J'")<FCH!&#@640D2$'[I$N2@=!
M$3B/[ 7E8SB_F)U-IE,*OKA@S-E ;N#$#3%OXZRG/&HSM#1LVXOYZ7)RAA-<
M63ZLD3T+7\P7)Y-%.RFV1*$7(]>P SF ,@FITUE'+V@>8LT<QT[.>^Z%N26@
MVMU;H7[41!!$T2=#==FDL&;B$6IP)P  G#C$(Q,;=D#O)BQ!4 >]*A7E4DBE
MKH0]UHYQEP*$0:LW9\OQV>QTL/Y0E W=?DBOF#& /S55=GQ0!JL])!WJ&400
M[<3L" XZ6DY>+Q<S3A0.;H\J>R2L\)1> ]X.P1BJRX,R_PMU*+9)"81X;4&1
MQTT6X#RTP;[4)X&=B/=HB1Q-*W?1.0QHA*6EH9!5;)N8C9B#$6US8B)JN!D<
ML:C!8D72OO^C-XNIBKI*HI*"9_O<BE=GX^4*^H46".HW%6E4 ]Y,PJ1Q["76
M);<#T.&0&[JZP&+:KIF^'&9:#[(_U+JCF7+]V1"FEHC+5.X-A2J=4#+I"[$N
M[1;=RJ&6J4]"%(U) B>!4V2!+EI)YHO%V60VC%_2?(?N"<T578W@()?%M-M>
M;O"R>#2%CVJ5<(2_?3SX/3U_OY7C,Q'<VE14915U:FL<#AF_%XOEV>1D7]/Y
M8MI_>KCYC31HP!A^RA89=>+/8MB/#M"DCBZ>:E5W&L(OJ*B($$C9=.>Q[[=V
M.QQO0FQ*?Z"LMH+'4;Q"<44+UE'3%^A;CY <*V!^KR)QHH\6I]/)LK?\"5"W
M& >;T:VN"305RPIW'7K/]C9WQG8@-2C\$16$+G <Z>92V' 8!CI$>PC<JA)(
M5?&FK+L?X$X%?9<7=,LH9M.CS]0WKW&LWS\,1R7IC#RL5RE<H1H4]DU= XE4
M2!EY&AE<C7!\V5@\(]%1JK;(^VBBH<@&OO^&=0C^ABJXKA1AMM<9R+Z=0KQL
M#!K*3')_%[N+V&&EQMC#2ZA(>BTHV/'0$XH 9N75$&-2,A3.-IN"[C!LM<*<
MONN$V^E&Q+6EF=!&^]BAP#WR*@P^T.18 %MWI?/1,+#W&KMTXY06=6>03DZ"
M"KOS58?,>FACL\A'Z;:?>Y"7*KDCHC6&(^!0VTNLX]TH8;M81]D;<?=>,&78
M>&E"*<Z(M;R'!2P6D< BJ(LITZ$,B#QLMEM$9-1^* ^]!-HTSO*R#W,-(^!5
M:P[6LKYT@'S1GGAE0F':[ST@7W<-T=/O,..Q[%G2T7DG*S3>B'IK6#6\)03K
M"'=#'!0YX+230U>VQX-K]$JY#?^S@"()-37>J'=?N_]'O(_7\/WT^,^,&^DV
M&J0HU1I+IY.STQ'.O_P/@O@2;,V7\BL;@JWXL>"[-IJ \;5%N4TOM$'W7YK+
M_P)02P,$%     @ [3%K6H (=SX\*   ((4  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&ULM3UK<]M&DG\%I=W:LJI(6I*]239^5,ER?.>K)/99]NY]
M!8DAB1@$F $@F?OKKY\S/0!(*7NW5;N.2&)F>GKZW3V-E_>-_]ING>NR;[NJ
M;E^=;;MN_^/3I^UJZW9YNVCVKH9?UHW?Y1U\])NG[=Z[O*!!N^KIU<7%=T]W
M>5F?O7Y)WWWTKU\V?5>5M?OHL[;?[7)_>..JYO[5V>69?O&IW&P[_.+IZY?[
M?.-N7?=E_]'#IZ=AEJ+<N;HMFSKS;OWJ[/KRQS?/\7EZX.^ENV_-WQGN9-DT
M7_'#^^+5V04"Y"JWZG"&'/YSYVY<5>%$ ,;O,N=96!('VK]U]G>T=]C+,F_=
M35/]HRRZ[:NS'\ZRPJWSONH^-??_Z60_?\7Y5DW5TK_9/3_[_-E9MNK;KMG)
M8(!@5];\W_R;X,$,^.'BR( K&7!%</-"!.7;O,M?O_3-?>;Q:9@-_Z"MTF@
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M$)U$@?#OID$R7I(([UO\FVA"H:)AQ6]@6R"$#9#$\2F10V$8_Y" "-A>(7V
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MZX*5 M&R 3;NB'GS.L41,(T007Z7EQ4R^AQ$Y[P%E A- ->,?C)[/P'(<&5
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M&4=I@+%^GP![QFH9L"9,@6=^*-$1 5*[BQ ^4PB_U'%N!4HYB?9HMW@ AE@
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M^6[_XJWI,AC(6W]30) /C\)Q%+%C\S0?KZ"2[=3Y6!:B0PJSVG3=\<E#S%W
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M.AG 8HAV+FKHY"N43[Q!.;XV-W2U;5W7<0?;HHP.!1B)P"TF3R17% "$6&+
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M!L O='D4NZ6O8>C%XON_GK'MH1_@('!*;([=-3OZ<^MR$*[X /R.;VW7#[@
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M1V6:#%@I^AT   LJQB@0I<J0M\9(:6G1O"[]8S'42TSH1/C-Y[?BV?FSL1!
M;7)Z;#KVF=_!Q#?1@33 1\P!H3'/&4%"5Y> EM(GB+:+L[X<<)=JN8$US@,9
M01H2J2181:1]=:%'V$A;!:.9$7:-E4S6.ZAEZ&+IAHT1U$BP*' [@H4R_CFW
M_/1@G +BF #QB!8[:6(@V U:=;]<]/K5'!X9)-^5N.-H3JUJ9NP\H79BV&,X
M[(-+94_)5<06TXOB8ALY7<<IG4(Y&]N?&]02TI)5,U2$-A0Y3\Z?3,<X9V-R
MP71R4*2,H&J./BG,*5P?_)($U+PG1N$>8'5J/$F/17S)Y]%[>B;+#NCH;3+A
MAHR*?X (#4-N97B42A45.F%T:9ST<,NMP(Z:5NGU''V()Y :V- V5E3,<PPF
M%8_+Y1.Y-#V'/ ^EA NI(8R^B88A2:6E:((T.4TD-5EQ)T$AF+'DE0=/LMZ:
MGGUP/;L8+HQY<B-\!Q]1#<!.#3>U L3H'4RQGL-<<6W$%/Q28FB1:"!D^SZX
MW)7K8G:5+E >8:KKI"_FWLPT,<74]+$.__&PE63C]I@CO>PQ?I/)G5,=-^B3
M,8F@-K6NV,3P%@>\W\U*3H_[:G6L$-T1YZ.0%KZ=IIW($)$^6DA6#+,TGHQ^
MVPE7CW2X$<,#8\+"]'8 8'1$:\VF\JA-9E;=)!)$_&+&SL-%Q.R]'4XQX")J
M3T>L.E6N&MJ+;+W "Q(.=^&V5*#&\!HZ@6BDH0+DY7<,"!Z1;Q_F#<5=1/=;
MGD-EX^ZJM[_,8O,?-H'8P(6,/Q6,BFCN?._+_0[';A&"8((VC0.H+9H4H1A3
M+#E\&)#=^F;,MYS[O&?BC>,1JD@@W/:VY:8R]#.(P?',-*7TJ*3'B"J.V./.
ML'!^0)AS>9HS-UY%T;H@V6FZ*HU]%/<@XQ3<%99@P2  Z'?.GU&;.AD_48T[
MXJPXTH*$6NG1$Z:<JU*BDL>B23$1U/)Q"M^4W ^08G"!7O=K(==4,XI[2GQW
M5@PU,+$S;=H.\,KQ?S+\1/^;*FD@''1M+2*D(B"2HW[4)Q &-<IZJJ#:<9T4
M*>5",Q51*V^?@YNL@L (':/<7JU/P< ["];"WQZ&CD U&?>H'3,@Y\3F^"?M
MD:F'NJA)Z,V4\(;-6Q(VU72[M@&C/$=Y#S[:'^[@N*HBH:GMHR\?1!23-Z;3
M$(J^1\VR\UA(A$6TZ:@&<=/O*Y?L,FE"'7<YQ!?9EM(+<G!UN+<YHKWHQ$)O
M[)2T9=@S+H,N+1NRU>* U&1KWB;,>6U+TSMO)X>8XWN'P%OT=<VS("W%R6"[
M8[/KU;""_J?QRS+<WZBL"9THR?GFFA\C5Z5N#S992&U#;4B[X,-J3\?4*:T7
MF3K:G.^)X*],\(.2KO=YZ29H;2*&DSS(Y]]]&EA_8D9#""TW"/: !FXPI]]O
M-%PX2'4F0W:OE:S"3BJ?5P,]^K0(D/OT7CM-UO[@DM_,$_JB;U@WQ"\JD>(3
MC=Y7$,1^MXUW'V\1R*YSU:@%E^SDAU0;:SH^2;X^UC;$TDL+];C)2^5SC'KY
MW#"=IZ2BPW_.+SL9XWD3284+',9*#7?NK;$&BMW*FGZY@@5JY)U-IU3W;8O&
M*F01E"/5H2.2/,S"?,*' =.CR=6.SW05:D3@F4C%X9$"8G\/=(3#-<-)8_;0
M),!&Q2=^1U'%.U7&?HV@R2_D>"LQD/47*;AV(8<)W /Z8 W52-0V<:--YIJW
M9@80N-T]BW[?B)_+SI"V7M,<A7>.G)OX^,X)\S3#TW2B^)"8%^*GT.J>AO/#
M\-C=)\XQJEB4+AT2\WB8%>*)Y4"8I]YI(,VJYXU'%#8_.XW7]D[!]T\(]VX=
M6:P8R4I>IA__<W-^_AA&1!C&6BCK;>=[/86.OW([IZ1A3#:TOEL"< CWJR+3
M,&GT<[OCT%A2XHL(61W(3W)%IGXBENYU@U-2\7A6C%YN\(SS9XK[&"M>^E..
M5?_@J>J!'F6J10E'&5%J<)T\4GV6[V7T(IUQ9G3X0+HO2^6<S^T('O?>>N]9
M,VQU4HWR.^]L8AGMMJE4AL_G(Y:T5'$N<)1S0]OHM%<8<]@KKC1X<G@7?C>S
M4P&F*@/AYM!YWC$.WD>;NQ;VDVU2'CS3#?(=S7'L?&/'%NH;'WBGJ@EV-)F;
M_9(RL0'FT9;.1VK]E:+*SX8!(?B\$J:BB$-#B(F'4F/4B_L*$>[)])^@26[S
MIY^IK<^2(DQ)668<8+C7R4\N:!&3ORMK?$^>-=KI7"(__R<8C]G#^=B[4@%J
MPB! \&BL&[TE,K$&[*Q!(_FF) 2E<Z:M+[E\WCPQ?MQWK)B)#X#N92Q]7,1C
MPAX(M3CE-CRGL<TQO=(I)B ^O*\46H-!<6I8.@\9F'--'5J,L M=4>O"&_52
MV[)?TV*UI)U/6?:V\'+)Z@N]179 )C0SBH!(\FDN(QZ]FEGEGD#?T?,13177
MK35%"&G!&%F$%HC?O;CG1+;3EH>6:7C9"U-]!>!IJ(2@55C33T,[X*'9M\(3
M+U@,#1^[.79]$;!H31!WGCR[Y'VU)QT,"$OS]C/==:A'CL(YL^:7RRC$XJ*?
M7R;9\HIO3N\'#/"2+@V-^"D>Y@- 284A77_(&[ZIO77Q_W6C,S'U4N59]AKL
M6MDEO^Q+Z03$\&_$IJOI?>(W_C7:X7;_,O('/L]U")D%'CV?/7U\XKNV^*4S
M+;]4.S==9];\[PKCH;)T WY?& !3^$(,TEO6K_\+4$L#!!0    ( .TQ:UK-
M[E;2[ T  )HQ   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;.5;:V_;
M.!;]*T2F&+2 XMA.TG:G#Z"/'<SL;J=%VYE9S#=:HFUN9=$EJ3B>7[_G\B7*
MEIVD+7:!7:!H8HFZO,]S#Z^5IQNE/YFE$)9=K^K&/#M96KO^X>S,E$NQXF:D
MUJ+!G;G2*V[Q42_.S%H+7KF'5O79=#Q^>+;BLCEY_M1=>Z>?/U6MK64CWFEF
MVM6*Z^U+4:O-LY/)2;SP7BZ6EBZ</7^ZY@OQ0=A?U^\T/ITE*95<B<9(U3 M
MYL].7DQ^>'E!Z]V"WZ38F.QW1I;,E/I$'WZNGIV,22%1B]*2!(X?5^*5J&L2
M!#4^!YDG:4MZ,/\]2O_1V0Y;9MR(5ZK^759V^>SD\0FKQ)RWM7VO-C^)8,\E
MR2M5;=S_;./7GH]/6-D:JU;A86BPDHW_R:^#'[(''A]Z8!H>F#J]_49.R]?<
M\N=/M=HP3:LAC7YQIKJGH9QL*"@?K,9=B>?L\W_($AX6C#<5>[MVCGJQT$+
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M#NZ49=7',R0[TEMG<G.DJ")W]^WN#/E&"?.";&;0]Y7@<>=;3FL*],4J':+
MOMUGG<UH\U'LN?L6M)WNOJA]S0OXG(8"EUCJ#Z;C(\=*_6!4;K\,72AC5&I_
MK@6'[=,$O%\J9>H'VJ#Y5/CLOU!+ P04    " #M,6M:7>J (<0$  #_"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R=5MMNW#80_15"*8(6$'8E
M[=V7!6RG1?(0Q(B3%N@;5YI=L:9(A:2LN%_?&5*2M:[71?-@KWB9,^<,9X:\
M:+6YMR6 8]\KJ>QE5#I7GTVG-B^AXG:B:U"XLM>FX@Z'YC"UM0%>>*-*3K,D
M64XK+E2TO?!SMV9[H1LGA8);PVQ35=P\7H/4[6641OW$9W$H'4U,MQ<U/\ =
MN*_UK<'1=$ I1 7*"JV8@?UE=)6>7<]IO]_PNX#6CKX9*=EI?4^##\5EE! A
MD) [0N#X\P W("4!(8UO'68TN"3#\7>/_IO7CEIVW,*-EG^(PI67T3IB!>QY
M(]UGW;Z'3L^"\'(MK?_/VK WG44L;ZS356>,#"JAPB__WL5A9+!.3AADG4'F
M>0='GN4[[OCVPNB6&=J-:/3AI7IK)"<4'<J=,[@JT,YM;W1587#NG,[O+Z8.
M$6E^FG?6U\$Z.V&=9NRC5JZT[%=50'$,,$4J Y^LYW.=O8KX#O()FZ4QRY)L
M_@K>;- W\WBS']07K.<O6U-%G-F:YW 98<I;, \0;=^^29?)^2O<Y@.W^6OH
M_\GM=>LTF; /BETU!\P2"M<L9EQ*AI5G'5>%4 =F2XZTF=XS;7 "JXY9\D8S
M?X+BEMWPQXIC<328:-R)'!$>6:[5 Q@'!1/*Z1%*'A@/&*X$ABIJKAY94^,*
M37R&0E<B%Q(8TD"(7)M:&^ZK\)F1""9WCCN@M7<@>8O>&%(+!*^%OD7_%8]1
M;>XE?^2//CWB(RB.K0)ST/M$NH2(SIUE.4H1>Y067!SQB5E;@H'=XS-6.38X
MB_8T>T*^<*Q%?ABY4AOQ-VW63%C; 'UDFWF\6L_C3;;H ";L*T4(8^L;X#@:
M'VX_'6OY'_Q)+K<A=CE4.S!#^1QCGB*;KA9QDB3T-Y+Z4S+!B935W+ '+G'?
M6/R$?4'D!^TPR6)6B =1@ JAE^);(XH@SU!+M+W*4LL"C'V6 F_?K+-T=6Z/
M@]OBH>!%L?L+FS=1)>1O#9<8!^3>'5> CUFM6\*E/5BE>S15.;S@E:(0-A@$
M"8YPBPJ!"/1'U1-$/F-]Q)(2%9033H: :N6# @PO2P8\+T- _Y4Z)4CTYGRY
M5MBYT9EWX%=[AS\3G=8(YR!<7I@X5"]20$.;>\-?0@XXRF//2&GGI>9-U4A.
MEUYW4EW @B[5^%RAL#PEQ8E4K[#@=C J"Y170#_H3H/O]X*NR<[?2P<P@N>U
M<%R^V$G.T:0%;$ A?^EP>'>@+[$:98DK3[JFHT'6E::\ B-ZE;[1B1WVJF>9
M$:+4%T_)?5.A"R TA;V6^)XY[K%'["@%:&.-?#!%4&MP9KNZ'[?I5VCXLX7O
M8')A8<@1IFN?#V>,RB>9G?_P[U'3Z">I>?@;!?6?XCR6?9K]V%V:/;E-TWBQ
M7L6K^9Q]"E+H_.K&Y"7FU'$D>YMUO$J6<;I9/?&,9^LLWLQF>.?0 W3$:S@L
M.H=]XQHSRJ3>?K;8Q+/-9A@ODWBUR=@73:G93V[B9+F(%YOE$_EYG&"XYLO!
M\J7'P'3T**O '/S3D]I<HUQXGPVSP^OV*CSJGK:'I_%';@X"0R1ACZ;)9+6(
M0BWW Z=K_\3;:8?WN/\L\84.AC;@^EYC%G8#<C"\^;?_ %!+ P04    " #M
M,6M:S;"' =8*  "!)   &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6S-
M6FMOVS@6_2N$)S-( $76P[;LY@$D;3K3Q<XV2-H.L-]HB;:)2J)+2G&]OW[O
M)2F9MN4\F@YVOR1ZD/?%>\\]I'R^$O*K6C!6D>]%7JJ+WJ*JEF_Z?94N6$&5
M+Y:LA#<S(0M:P:V<]]52,IKI247>CX)@U"\H+WN7Y_K9K;P\%W65\Y+=2J+J
MHJ!R?<URL;KHA;WFP1V?+RI\T+\\7](YNV?5Y^6MA+M^*R7C!2L5%R61;';1
MNPK?7 ]PO![PA;.5<JX)>C(5XBO>?,@N>@$:Q'*65BB!PK\']I;E.0H",[Y9
MF;U6)4YTKQOI[[7OX,N4*O96Y'_QK%I<],8]DK$9K?/J3JS^8-:?(<I+1:[T
M7[(R8Z-ACZ2UJD1A)X,%!2_-?_K=QL&9, X.3(CLA$C;;11I*]_1BEZ>2[$B
M$D>#-+S0KNK98!PO<5'N*PEO.<RK+N\KD7X]O0:_,O)6%+#6BF*XSOL52,<Q
M_=1*NC:2H@.2PHC\*<IJH<A-F;%L6T ?S&IMBQK;KJ-');YCJ4_BT"-1$ T>
MD1>WOL9:7OP3?#62!MV2L%+>J"5-V44/2D$Q^<!ZE[_]$HZ"LT?L'+1V#AZ3
M_B(['Y74;6<8^AC1@-SFM"0?2W)5SR'12&0B'7BD6C"MF);KWWX91V%RIH@2
M.2,9EU!-0A):9J1@Q93!Y7(IQ0.8BK/^S4JJR#47MPL*-4..W])U0<L3\D]>
M\ H&:<4WWVI>K<F',F4E%J6QY!@%H+XH.&OMT_?AV8E//B^AB-ELQG0=ETPI
M(F9:*::'%0'*H20A"AF9(N"<;#E#4J:#.I<4])9S0K.,8V1I3NB*RDR1&G)7
M-E*-"3[YY-X2FH-@ZV\CN!)&*%&X=D0L4:KR +94)7F*GILW5LVQ]?/N_DHU
M+G:,KDM>@12,M@!UTCP^G6HOK"A0S8IE+M:,P5 QF_&42;AJUDKIZ2F8 T %
M)K9A:VS'UZ &<'FJ>,:IY$SYY)[#ZA#\HWUQ8FW"L!W8!01>!P#L0I^TT*U8
MD-6"IPLRAY63$,$U>0!G"22.)#-12[)F%$SU /ZJ!8F&OS8**U'!ZBA()[91
M@7-Q_< N'$/+$E)"*N@JS;1F1"H*:"$I@S\5R6C%M&4X0C+L63@F 6W-> XY
M]JT&C05B&9C)2P4&Y#A?&7-Q,L8*QJ'0:L%EM3Y5_#LYCD<G9J+:39H55<XD
MD$M!8H9INM8"KP4LIK8-JXGC&^BX^A57JJ:X&.!:Y U'@3<(PB8B\ Q=A$#8
M_-*/ #E-<5KTC#$Q[ K _&02'9IOHH+9]4!Y3J=0]&C'K*YJR6R.=];(:\IS
MLQ0;K=:^/>4K!I<57*H9DQ++4&QK\1V% &[WD+\V%J:1>&Z\,\A.6\IZUK.0
M:;"%3)Z-ZY2EL*:;$! .F0?E5#%8[:7DN)K&U,XH23;G4/T:Z&$M8)I.V28)
M=N'XP^W'-L6LLS9Q5#M' P3*YZT[._!4"LSNJ@:86.^^L_D$Z,Y2;LR22'$.
MHYH'F;'[ZA"H/8II-IL.QJKUV:QE6>OUA9<'DAIRJ^(:=&P3-,75%A86Y\!+
MDJ$W2))#0LPJ<V7Q =8RC%J4>MH$T,5,@0,UAJ"7F88;)T=F AL+/D6)&K"!
M*+O@>S )]M2W?J+"[5)NO=XJ8YM#*YY#*X1\0,6I#ADDC\2V21@%__]!RQIA
M%G!E"AE;EA:&G><@;0ABI:CGB^WG,12?Q;L]B]NHXML<%MN\/:8G9(:9NV02
MD[@)!9W/H6(0SY\,O1MO X^J!D^P&9C6>CP](71?#HPMZ!K<!,RJF"P,;+EP
MC2LC-[7=BO7)52<,&^P!_-(@%@\G7CR9M.J>O4H^XMI.P$TEO%B43OUFA366
M1MY@,/&"T<0G=YO*U9247!G&@1GG)*M6I.DEMDC:[.\.)2W0 [,70Z#%\$N6
M4]3!2[/'A(1_H]$VB,_^]O]_Z6T;RT[WWORKS8?FR15T?]BHDM^Q$9V^P^1K
M7MV;P+^G7)(O-*\9^5PBI< *[.[(>_JBQ(.=='M[1"(_"<D7(V1W\/'("Z+Q
MR=[SP =J<,>6M4P7>D7W)@++#Y-H?V;L#\9/&3WH#&,8G3E6[S[YM$GX4AAN
MV+"XK)8-VB'[(X80[2E]NIK 6I"=.ELEN %VV606I'7=>&;8J4(6;ZR:U0T;
M99EO$_VCY:R?#E#<#AJN>2OCIJ,!]G(D;!)A2V<UUI\9OV&FI=E\0+MS=WF$
M?<=KYEK?0?5UZ6PXOE;?Z#VD"+L73!#SDO^':?B":@7.@25PBGM'G ECS'S;
M@0WMTM1YANG]H-.[9<)4*8'\ *-BU8//7&0M4J/MWJ9];G8 +D]'@/VQ.&C/
MGQ/F'>^?XR2*TSZD"\X>#".S;KD:6QVH FC8%"'1=&:#CIKL;C 2YZ\:X*$6
M52"0=6'SKE8:#PGZ@(AHJV1CFFEC6_NK U6E#I653B!$HK\?;+=T'QJD;=+(
M>,?5U].99+C]A+S ?:)TP78#6>. _-K>#OPPAML;2!O=LS"ER#%$48=A'_%&
M?I!T/=R@7"OJ04 *\AP[UNZ$R<"/0\>*<>*/1ZX9&4=6#K%><Y;O S(@MNO$
MSNWK6JV;(/]'/?>G]>RF(;<-NB6%+Q5YU^Y FR<?2N ^I>)I!R&PW;ZQ@YRV
MU.#F.]!4#J!U*Q$)WPJ0 H%':OMI)QT-3< 'U4+4"E8%'GYTN.KI<TB#%X\C
M;Q)OWAR1L3\,GW08AGG!>&"X3 =/&'E)//)@A[OW)ASXH_VZ>>I_$Y@.1A*/
MO4&4[-=GXH=/^]$& HKPO9 SID\9H?&FB,QYWJD0-GIA'.YK# ,_FKS8M<?7
M;)\SC;TD&'GA)'$6(XS]:-_9L9^,7$+HA0!.#3=IF!I4,S/!U>CP7.86>M%D
MX(6CR%&0^*/]@4,WG<!2;P(4L].(!G>%.=M[KB6OC(<+E9M=(6_+U[9R@Y#;
M+1.Z->QQT]I@(36-.>.S&30=S218M6+,'D0TE;W4E6WE-9*:0T67/'1C\M;6
MU)S4"+5K6+6@%1!.#.RN8CQ[QDFT_!&%M#U#*6#'5TOG7+1KK7R7OILZ;6UD
M;44WYTV/D7A]#E3GS1FK.=4%JI0REFF;C@(_)@7/<]VKD)HDWC"9_)BZ^#GJ
MPD:=86I[A.P )YR]GG%Y>LMR%(9^/-8/C\:(=4O<.F!KT=8OS;E7OC;F.28@
M0V>HT3+D[*5L_'7,7[Z6%Q_<SN'Q8<O/M[9S.E[)P!\T:^9L*%S@F;*M#0Z&
MA;8K2YJ5W80D]D=FS2Q;UWG2O=H6ZEZ\V,9V:)I;V7T4;1YT+7>SZW2\<3>=
MZ1,;I=WO!LR<:W?MGWC9GC>*G&<F=]KS9QT 9HZE];[9L%&U0UQ^'GE\=*_@
M[!&  U,)":"WP9"#N5AJ@S?M8> %H]%6YQH!M_[=;#_-P6A6 .DSI^X/^Z01
M.-!PV-$XQY,A^60^2SVU)([V -B4VTAC;S#92+^QZV$/(&[M <Z/?L9X3)K[
M->/F_O967_[O/V0T&=]Q6!]/$F\R'+G?A#H.-=&7 \?A>U_)V@/2[>F/GG^[
MI]P@YS",E>*0W@4@$,27E>[W !Q^*(_PT$F/=W!@I\R-VUT_.^@[/PLIF)SK
M'[\@(:C+ROQ"I'W:_K[FRORL9#/<_#CG3RKG0*=(SF8P-?"38<]\#6IN*K'4
M/S*9B@J"IR\7C$)L<0"\GPE1-3>HH/W5T>5_ 5!+ P04    " #M,6M:4KU1
M>]$$  !"#0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6RE5VU/XS@0
M_BM6]K3:E4+;I(46:"L!>ZL[Z>#0<GO[V4TFC85CYVRGA7]_,T[2-E"Z+'QI
M$]OSS./'\^),U]K<VQS L8="*CL+<N?*LW[?)CD4W/9T"0IG,FT*[O#5+/NV
M-,!3;U3(?CP8G/0++E0PG_JQ6S.?ZLI)H>#6,%L5!3>/ER#U>A9$03OP32QS
M1P/]^;3D2[@#][V\-?C6WZ"DH@!EA5;,0#8++J*SRQ&M]PO^%;"V.\^,=K+0
M^IY>_DQGP8 (@83$$0+'OQ5<@90$A#3^:S"#C4LRW'UNT;_ZO>->%MS"E98_
M1.KR63 )6 H9KZ3[IM=_0+.?8\)+M+3^EZWKM=%IP)+*.ETTQLB@$*K^YP^-
M#CL&D\$+!G%C$'O>M2//\@MW?#XU>LT,K48T>O!;]=9(3B@ZE#MG<%:@G9O?
MX+G_I:UEMV#87<X-3/L.<6FVGS08ES5&_ )&%+-KK5QNV>\JA;0+T$="&U9Q
MR^HR/HCX!9(>&T8ABP?QZ #><+/+H<<;OFN7-<9H/P9EQYDM>0*S ,/?@EE!
M,/_X(3H9G!]@.-HP'!U"?R7#@QC[&49QCUUR*Q+&5<I2(2L'*5/H3I*[$MU9
M<L>X<T8L*L<7$IC3+-%%@6F#$9C<YUJF8"Q;<\L2+I-*<D+!MTQ+S&O+/@G%
M7*XKBUYLR. A@=*UR.AXQT^A*^7LYS/V\<,D'@S/W_V/T0+% AU0Q+2#%#GT
M,V0W50&&.VU^W>--*]-KQ&F-?F.?HN.3\'0R^;P[-AR'43SZC&R5QD1^&Z$?
MOLI >L17N*<E=(@P++K6H=I"+=D1%:LGI_X4+1J&T>DD/#T9/)\*CU'-:#S9
M:O!KH7+(/RD4]2:G'7WB42\^WH[\DP.[TD7)U2,-1>-S9* =*">XE(\U)A9T
M9B&IC' ",.S6N4AR)E0BJY2T4:B2$\02$R(#8Y"$9QEB0[&XB<2U(YYH(V-)
M#0/A<E29+0 4Q3-!IBPSNL! ]\*7J(!O+3H[F%C6&T"682?")E7)%$%)-Z13
M)>!GG]OU2 )DK0V$?LGZZ=FKRD<]>F\/@.QL)PPJBZ3HB-JL90OM\CUG\\:*
M(.K-65[4A-LSVRI&TW65(#X-Q;?(^ HV*#6"=.J!KP.T45\+%I!PE*0)$2*$
M)(KF4/QQYQSK&MX6,,Z.-C%6G]W[*]9/*M75RP';@8KBG43%3)V,P_%HQ+ZC
MM27UGL7V2\;Q.,3;&_N[#GA2M:Q,DN,MIUM8VO63<#PXP9HQWB*$PTD<G@Z'
MG<2]O+YC-YBLOF%P:74G)O>?TK!-WV1[&'HAQ=*W&K<36DA36%MU-&HBWSQ)
MA:K4RMOJ!*N$ 87IAKY7W CL52RK7(6A!2LL*U3D$5$D:$;Q@@VM:54(@%,4
M@TH[O/(Y,%3 Z91P6L@]#K 5HH8=>&S#3? IW+FU> 6F"I6*6GO,\R8A* 9L
MDP]N5TP*36+@*Y+%G+&9J+OP?CEW-<,S[:;D!G63BG5F\85>U2W;LVG*QD_3
ML\<N7LB]CC,L%TJCJ5I2X=K&1(_MNT/U=^ZUV,.7_O9N*4"4JZ^XF]'-!\)%
M?2_>+J^_+JZY60J464*&IH/>^#A@IKZQUR].E_Z6C.41[]S^,<>/'#"T .<S
MC?R;%W*P^6R:_P]02P,$%     @ [3%K6F5MIPNA"P  :"4  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&ULO5IK<]NV$OTK&-7MV#.,+%'O/#SCN,TT
MG3XRB=O[&2(A"0T?*@E:5G_]/;O@ Y0H.4Y[[Q=;)('%[N+LV5V0KW=I]CG?
M*&7$8QPE^9O>QICMR^OK/-BH6.;]=*L2/%FE62P-+K/U=;[-E QY4AQ=^X/!
M]#J6.NG=O.9['[*;UVEA(IVH#YG(BSB6V?ZMBM+=F]ZP5]WXJ-<;0S>N;UYO
MY5I]4N;W[8<,5]>UE%#'*LEUFHA,K=[T;H<OWXYI/ _X0ZM=[OP69,DR33_3
MQ?OP36] "JE(!88D2/Q[4'<JBD@0U/BKE-FKEZ2)[N]*^CNV';8L9:[NTN@_
M.C2;-[UY3X1J)8O(?$QW/ZK2G@G)"](HY[]B9\<.1ST1%+E)XW(R-(AU8O_+
MQ](/SH3YX,0$OYS@L]YV(=;R>VGDS>LLW8F,1D,:_6!3>3:4TPEMRB>3X:G&
M/'/S/@G26(E[^:CRU]<&$NG^=5#.?FMG^R=F#WWQ2YJ832Y^2$(5M@5<0Y5:
M'[_2YZU_5N+W*NB+T= 3_L ?GY$WJNT;L;S15]IG9X^[9U-$O,RW,E!O>H!\
MKK('U;OY[IOA=/#JC&[C6K?Q.>E/ZG9V=K=NPU%?W&^46*41PDTG:V'D,E*"
M1R0F%P8/L>HV3?@R78DHS7.Q5(AOQ4^W6?J@.>9P2UPN5:)6VHA5EL970EN5
M#:DLPB+C%3!IKV26"T4@$-A"%2]55F^CD$E(/T;B4B<8GA8Y[N17+\5WW\S]
MP>C55_]O+57=Y"5YN=_[G_KU[0MQB7WS%L/Y5>O>P)N/)U?BUS1YT1H_]D:3
M17UUZ4^\Q0Q3?W;=Q6Z ITJWN&(G4V\R6;26&DV]N3]J;MT?[06YLG'QP58\
MP\\2RLF\1$'^K[O]F=MP5V09+.RT[%B9=RI4F8P<QPTAH[GRYPOQR4C3N'LT
MF-:_P4A@:W!QTA(\]%\=7=^G!LL$9Y1KL. OG-6&_\!1*X7EPN>YPA,YVTO;
MNWJ6<>&Y];Y0QMFI%RW77+2<<XND':1)H",M.0,? UP]HKC(;104!GH6><4H
MJQ(&9'IATFSOSLO('2;E@7>8*Y,]*SU[A>!8K12G^J,).G>"XM^+@D[TMZ+
MN1C5^#YMF#_L#\2WU3^+=9=X/9&@6H,W*Q]5'#WMC\6HWZQWMY')FN:*!QD5
M=A,D62^30(&/_#[8Z-+'M(:4WG\0)I-)#N TY#?H.[1U")>/2"TR"S:,SU ]
MH-#;QA129%  ]&F0V[B_$//^O(%VB>/:Z%!CWR@2-0P:]'UQ.>M/FT5_PU9G
M0H9_HB2*F2ZAE']UI,P/)W??&O$M_9_3?Y>%#S$4U(YKT%0+<KGX)!43HB5%
M7HG2,X-'<!K<A-(R1(1IU,8ZVB.Y,L*EHTMI$20E'-(LF'/6,U-^5]C45$%V
MRCQ7&$H;BN!=(H*-5O^[//)$_OC^6+7CM7^ED-@B' RY@(N:0&;9'KNUDUF8
MNQEDX4T'$^?&PEM,!^).;C4(3_^-E;)3F*ZSP,*;#9VTL_ FL]&7A4(]9^SY
M"[^^1+TPGHG;(,@*&3FCO/G<6<<;PRN_Z$BA,TBPR7)OHZ'.5.-&XFQ(F3(-
M/K]8,K@(!*!;RP--F3-P[?"&\WD9;-6]A</ID\G@,+4X>&EF>//)W/758CIL
M;Z,#J^?CZ#9.,Z/_+@D-KDY;"E].I@Y=7:(_O>I2VD7VN:G_=K7TU']"\K%W
MJYJSB\D/)<#__F)R=)LPBWWXXPLD7%H1Q\9?6B%7I[1L@NJ0F8_OW'ZZP[YL
M=2!FXP%"[J]"(^Y >5TV@@NQ4A'8)J4+?9G: A;$C"M/6,2GEB-WW)L3\\D'
MJ2.F1_6@0P7!GD#B1&40DW,C_5F!>PTH5R2IH1]&Y$2Z))IKF(QTJDBT2XV=
MQG.:O%10R?))7]RN#!"*<BC7(9.4K8=(%@EJM%D"RU@MUYQT"-R)6DNZ\%S>
M%AN9<WV544I9%9#3X34X<RUUDL-":!;"D-S W6XAV<G[G"6.DAJ44X$L4*_%
M,I%KQ<Q&>H0*QL6:LA)[["F/PHY<G?<79;0N&" 'EJERN1<7DT%_(F((X!X)
M'6I'<@5P.BPY3K0AR!EBP!+)42I1Y.M(FB:?<]KEW:GZ1BI=F$O@D)V"3;),
MO55:J3?]9'(IR^%<%"@4,O$^@5M)H8\8DQ2T]Z$2G\KSK.%L+"XIE/S!*^<>
MWQF^NA+6SZ+1;=\7;]5:)PE954*94?F33 J).M0ZQ_=:2Y1(9S&Z4B@K%0I(
MH1T,E;&M;? 398^I9MT#4W=%64G\E"YSY#=^Z ^&,W%)0TH+[N]^NJU5AX^3
M%(Y'W9.)+4'+0(+0<8P,RL4B,8&I&N/S_L2V%D0K9;U$,.=BS,9V@6E!FI.*
M&:.+VD'@[Z.DE&)#[NG]BE&5$GX#IX2@P=(F*F*B!YBRHI"V+7Q+;YA(QZL'
M11U'J<8.J>3\I!0>!GTT,V^)1#&PB,J=0#36O5N;1EH:;[>1#I@=K4NL"((+
M]))== _I%Z-%?U8'X0GJ8)VZ.:5-:JQ%ECXB.@T1Q\5LXH0XN>1B.D%?5-V!
M3#:Y:H5HA.V6CZ.X#I=??_NYQEJK2/3(Y*TM^*/]*:5'3RJ-QNJDAEB\O6C?
M;4%8&L!O;3@:>\*_H[:,PFB[H^@!'C3J]2YGM.4BY-+5BK:T#!*&0=EQ8/?!
MEP ?P[!L-TZ9@S3#=([@0#I'SBA8YAY)8T\Q$FF$<PUUG:'G1RYA"J8-!A5%
M3GRC*, U'LX'WW+"M /:"EJ-3KG,*D+K^0-K 1^H9!6P_<'8;]O4@*AC R"*
MTNV^\A?R4%?F?0;B+X8C!R^,\2$:X.H&5#Q6;(V6GUM_.C%1V,YS/-AT'X?(
M^V* 7TS0P+=41!O]?U'QGHN%XTW(B^6?B%1;&#[0^Q^2B<HIUX2,YJB =HC,
MX1@%COGL2#[2[LL"[6S&:?L4 FJ-N[3KP!9/'4XJH+E\<@B[T?34HJ>\\<_1
M5Y\1=VWQV$$=[_%DY% ['3B51>-16!P2Y[M3 SECC&<.=KC^<\? .<@T.M&&
M?;;3*(AM&J:7C.0]]CK]6"JSH_0(@Z:59?/J..24!E_N0Y=35]1SMPZ5%.J*
M)'=3MN?6?@\H+XEZC\]N_RPRG8>:">Y@%21JXL[R4!HJVDJ0'[G'IA+5MBSG
MWT917=7D5=1AJO47T3X'J)( L;MT\ZH#&L G&XGJ9$GN1/XI$FHNU@FG$9)>
MGC'"'IV43=CA$1(]V%K)78=JVQ35!9O((4NMBZ!^))8V':"VQ*6-8H4JDXOI
M@[*;W5$>>A"46N^CJ YM3KKXL6EM65T#?4UXP"F2#F=<7=.L6]4"GL@,>9^7
MY6X.>V4C7)=]C/65QX+CM*!3G&8+'.^7 #LZHX1 >#3D-1ED<76^5V;Z:D5R
M2:8V]"8=XBGY]\7OC*O6^SZ>6I7^H[E?%?'=;0@>#A?S*4.^K/Z]LO!HG?8C
M_JP6SZ;^JF!PB%[2!6RUI\1E+< %A5W31HMK0]G=I3M$1;[1V^HXM9F4VTZ
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MF@B+#H"D!15C$,3 "S$19DUKC-Y:PSKLY2D 5-&%SE$O&3AX04/8Q'*JOHC
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MB-YH1/0NDW1EBE+H#67"D5EXR!>[R<])7CG()&(QY2EJ45*N$HA0.EI:4S1
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M=@2^LQ);N5WSAT*:*N:(9"E=W_$X$OR'@Z]3D 7WNEM#LF4N<0]"$Y3TNX$
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M*9<E<WAAY'?!?3-+3A+@6+%.^J]F=8GK?(X"KS32Q2>L>MN<C,O.>:/6SJ1
M"=V_V<.Z#EL.)]E?'(JU0Q%U]X&BRK?,L_G4FA788$VT,(BI1F\2)W3X*#?>
MTJX@/S^_Z98.?W:H/;R[IZ>;IIZP83,MUXA%CRC^@L@+^&RT;QR\TQSY+B E
M/8.H8B-J4>PEOL5R!./\$(JLF.SAC8<DQY$W_I\D>\3D:42X&Z>N927.$CK\
M#NT])O,7S_+C[&R/P,D@<+*/_F\"]R/RDQ'<,0&?1$E7!N&\MH@J$+]H^,!T
M1U<.BDFLZ=$A^ ;APJB6Z4<@([3(06AO@(%<$]A . C6+YZ=%$5V]F2,N)>?
MO:3#ZYM>!EO"P:71-7RDQTMR4<)3C(,_F(W3(71T;BRL&E$V.\)JRW1P"D"F
M 1]*V3FZQ-1"EAN5))GC/367EDPXE$8IM*5@4OQ"N%MD61[7+4H64*TU1%6.
MDB4\TIJ%BT9H-H)S!RVSGER)0EV'-+'8.:CU15E/IKY;2HLEDD >Y'9M9>E>
M0(4(IH+G>3;*Z I+&9G6J  <P16U)LY%B+3+$@Y0BEHL9<QRC29LF#U_<[Q%
MZUIZ!%]6-H*J$;\:Q2S1>FK,4'6^L[@I5-S=+58@(34;C:XOEWEDTC]"2]MD
M3>T9J!BT&76'2-3-@PXE^"LG=$T:.6GU[A TQM@M<^Z5;ZSIZ@8,?:\Z5M,!
M[V(^M\(*+I@>Q9.5C9^\1^E69R.I=>S?CH1WVO=-;E@=?A'G?6?\8][_7SXS
M6PL*+[$BUVST^B@!V_?L?N)-&_ODTGCJNG'8T&\.;3"@_<H8OYF$ ,./<_X;
M4$L#!!0    ( .TQ:UI@*KQ#2P(  *4%   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;*U4:V^;,!3]*Q:KIE9:RS-IE@%2DZQ:I76*FG7[[,!-L HV
MLPVT_WZV(8Q6))JF?<&O>\X]Q_C>L&'\260 $CT7.161E4E9SFU;)!D46%RQ
M$J@ZV3%>8*F6?&^+D@-.#:C(;<]QIG:!";7BT.RM>1RR2N:$PIHC414%YB\+
MR%D36:YUV'@@^TSJ#3L.2[R'#<C'<LW5RNY94E( %811Q&$763?N?!GH>!/P
M@T C!G.DG6P9>]*+NS2R'"T(<DBD9L!JJ&$)>:Z)E(Q?':?5I]3 X?S ?FN\
M*R];+&#)\I\DE5EDS2R4P@Y7N7Q@S1?H_$PT7\)R8;ZH:6,G$PLEE9"LZ,!*
M04%H.^+G[AX& '=Z!.!U .\M(#@"\#N ;XRVRHRM%98X#CEK$-?1BDU/S-T8
MM')#J/Z+&\G5*5$X&:_Q"ZH%6@,W+X(F@%9$)#D3%0=TB1XW*W1^=H'.$*'H
M>\8J@6DJ0ENJW)K!3KH\BS:/=R2/ZZ%[1F4FT&>:0OJ:P%:B>^7>0?G".\FX
M@N0*^>X'Y#E>,")H^?=P_X0<O[](W_#Y_W*18_?5T@7C=+IXYZ+$"426JDX!
MO 8K?O_.G3J?QKS^)[)7SH/>>7"*/?ZF>LT=35@!Z/PK$^)BS&U+,3$4NK/4
M\:4[F7Z<S4*['AH9B?.O7?V#ZZ%$>_#B"^![TP@$2EA%9?N$^MV^U]R8$GNS
MOU ]J&T9?VC:!G:/^9Y0@7+8*4KGZEJ)XFU3:!>2E::NMDRJ*C733/51X#I
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M+%@S82KR,'N+$$8=G#+MN&@1!+,2,<7@01"\FW9DZ2KT^*R*B+2G-9)XTD@
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M1T[G\4QV7TWVGEXQDD@*EGIBA-(\<Z(JE%%"I:M())2*5,GW1S--FB3#C6'
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M";"Y=74+XA"VSD)3Z6-=52T"*,GR9E5430<$!!"#5_"Z!?GIQ*-(-(4Z!+.
M956=5+N\1>2QV-!TJ^TX.BR2"3[T-\^'_C;)ASX! @#T?FK:'$X]SB<G9QAG
M./UIB0 9& Q;^/$(.T'2Q#O(VX.!4^W^V>4(^UU:@N*!+R-T=NEGEZSD[IQ?
M#2&5-J"T[)EPVFW:)NEZ#5H%DY?;5S61Z8Y8#&X'WG?(;(H\7>8%D=<L<5]
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MY!W#4Z;LS0CWE\%_8/W>6+^UE%$,7JS=J@(!_:]):$WPNI>>U[V<Y%$? )!
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M5W.08PT8+?'?E&64Q,833A#**'3RCATI2@!@U@"VNMW8_!3<!7P#G<J#R)_
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MEX/Z#RZJV@AU>F9?4J7W6T7J)'D@;-9H/GZ:A>91FV0-V>&1$73?4A-SCHY
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M.'HW6Z YF;TO&WAIKS0B$ 22G,SKO_]A/L/%JWCMEK0-VO31@YXV+4DOI/P
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MU^,+\/NZ FR7/W !K!.D[;W^'U!+ P04    " #M,6M:9BVTRE0%  !#%0
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6SE&&MOVS;PKQ!NT"6 6TOR
M(\[+0.*L68"FS>JV^TQ+9XN(1*HDY23[];LC'46)'=79NFS8OMCBD??D/7EX
MK?2520$LN\DS:8Y:J;7%?J=CXA1R;MZJ B3NS)3.N<6EGG=,H8$G#BG/.E$0
M##HY%[(U.G2P2STZ5*7-A(1+S4R9YUS?GD"FKH]:8>L.\$G,4TN SNBPX'.8
M@/U27&I<=2HJB<A!&J$DTS [:AV'^R<#.N\.?!5P;6K?C#29*G5%B_/DJ!60
M0)!!;(D"Q[\%C"'+B!"*\6U)LU6Q),3Z]QWU=TYWU&7*#8Q5]IM(;'K4&K98
M C->9O:3NOX%EOKTB5ZL,N-^V?7R;-!B<6FLRI?(*$$NI/_G-TL[;((0+1$B
M)[=GY*0\Y9:/#K6Z9II.(S7Z<*HZ;!1.2+J4B=6X*Q#/CMYQH=E7GI7 +H";
M4@-:W!JV_9E/,S [AQV+7.AL)UY2//$4HR<HAA&[4-*FAOTL$T@>$NB@>)6,
MT9V,)U$CQ5.(W[)NV&91$/4:Z'4KG;N.7O=Y.J]3U1/JK2=$ ;-O"A[#40LC
MPH!>0&OT^E4X" X:Q.Q58O::J(\F&(!)F0%3,R:DCS_GR%,,+F938&.5%US>
M_F08-P;PUKA,6";X5&3""C!XB%O&-6#XS,N,Z^R6Y5[CQ)V-N=:"OBV;D5$6
M9)1U=FB6]#/*,E,9!KB0<V:=YS!G$6F;17_]:AB%NP<_5@&W(V0B8F[!<<M@
M 119-A72 6J'4P&:ZSB])3O3'H&]N!;B5(IOI1.DDIF5%L7[';E:A0G @L:X
M!$QK<5JGN^U8J=*@-&9GGY&J0??@?_=_;,BP&,.03T%7<5SMGX*)M2B<P>]@
MGY7E&1OCY=Z21_E8?4SXUU)9O(1++6*\(+3VL<OP[(+K*ZQFV^_=I8<[%<)$
MS*68H5>@5W[$"]7LXY2"EOR5G<NBI+SGL:(_A=7=J6E-_OQRMS[F)JT66RS<
M:P>[01/ 15YTT #!+ X8;MZ:LQ*]>(5K-PC:@]UH8_AC%D_!S^4"C'59^05-
MJ/(<="S0\PI>X#VO:-7NAOV-==KL]%CI0FG*4PE,+3,0E]JGOL>8P_8@"#?F
MOMGI,[4 +<G.39S1=\)@N"EXTSOV,;[,^_=>V.T'[=W!H [I#MO#_@-G#MM[
M8?U($\]_7^[K_L=RWOO[@OWW1^O)Q81)-$+M]J.@C0GG6;FM0O)6K[<</X1N
M0_O7K]J_?G/[Y\<D<B"^X"(CV[_!5NJ-X7@)]^&ZKEUKIKRF75L.9=C5^%:G
MD>,_WMH\W4Q4@9<K;5V/-E;&KFR?:64,^R)QC/6=W!F.KZN);^78>URO29"U
M@6*2(N,WU!-B=+Y $5LI6ENN\-RG_BW6JWVO^JLO4]\O0\-V?[BW6@,VK_&^
M(C57'.I2]KJK7'970-NU;/6H(/F01LV"]EZ-&!62VJ).8(L<J7FV'%11.]AX
M:(M3+N<^35-,Q=6T5D\W-)0P4\NWI53WN5:X7+LNQ)O%:)K(3"48SB_K9K'G
MBE>5@CKF#DOP=HDY<K@%K@T#>@]8$[PTKKFR^%?SREAAR&'<DVA4(\P#R >$
MK-(\X1F7,6:\M:4Z6A,[Y\:4#@7/4S7Z4*]&=_]8!@*L'6-G:?* VF38A$<%
MIUFDNA,O*]2SN0Q[@P=J3$#398^QL8 9:)JN)U;%5T02;KR[H#_IIREN1V$[
M[ UVOB-\0RY:%WR=VL,6IKFY>[Y#_U6EM/Z-JX)6+X3'_F'L_KA_7L0.:4XY
M/H,9H@9O=[%&:O]DYQ=6%>Z9;*JL5;G[3($GH.D [L\4ZKU<$(/JW73T!U!+
M P04    " #M,6M:+TQ:_8("   .!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6RE56U/VS 0_BN6F1!(%4F<OJVTD2ALVCX@$+#MLYM<&@O'SFR7
MLG^_L]-F84 U:5]BW_F>Q\_E<I?Y5IM'6P$X\EQ+91>T<JZ919'-*ZBY/=,-
M*#PIM:FY0].L(]L8X$4 U3)B<3R.:BX4S>;!=VNRN=XX*13<&F(W=<W-KR5(
MO5W0A.X==V)=.>^(LGG#UW /[EMS:]"*.I9"U*"LT(H8*!?T(IDMASX^!'P7
ML+6]/?&9K+1^],;78D%C+P@DY,XS<%R>X!*D]$0HX^>.DW97>F!_OV?_''+'
M7%;<PJ66/T3AJ@6=4E) R3?2W>GM%]CE,_)\N98V/,FVC65#2O*-=;K>@5%!
M+52[\N?=>^@!IO$[ +8#L*"[O2BHO.*.9W.CM\3X:&3SFY!J0*,XH7Q1[IW!
M4X$XE]VX"@RYL!:<)2</?"7!GLXCA]0^(,IW-,N6AKU#DS!RK96K+/FD"BA>
M$D2HJ1/&]L*6["#C%>1G)$T&A,5L>( O[1)- U_Z#XF^E5^+'KZ-]JTQLPW/
M84'QV[=@GH!FQT?).#X_H&W8:1L>8L_NVXX@NB0ZR.3ORCQ,=--#DUQCZU@'
MA>?% U)JB3THU)J<"(4>O;%<%?9T1HZ/IBQ.S_][Q:)!O4()OG![IR^@?Z3D
M$O6*G$OBC,!G 8VV I7N(S^0A W&Z<>>8S283*?(6X(Q(1/<^ QR;7O _IJP
MU[J208HL[=OY^XPED]?Q<4P>M$.-_7J\U#D=C7N.R8!-.ONM3R+J]6@-9ATF
MD2_21KFV73MO-^PNVA[_$]Y.RFMNUD)9(J%$:'PV&5%BVNG3&DXWH>-7VN'\
M"-L*!S88'X#GI=9N;_@+NE] ]AM02P,$%     @ [3%K6C240EG< @  R 8
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M"<#]4N #'";F@/&/(_L#4$L#!!0    ( .TQ:UKW.ES?(P4  /00   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;+U8;7.;.!#^*QJWUVEG,.;-@//B
MF:1->_W0:R9)T\\*K&U-0'(E82?WZV\E;$("L=.[:[\8)*35LZMG'VE]M!;R
M5BT -+DK"ZZ.!PNMEP>CD<H64%+EBB5P_#(3LJ0:FW(^4DL)-+>3RF(4>%X\
M*BGC@^F1[3N7TR-1Z8)Q.)=$565)Y?TI%&)]// 'VXX+-E]HTS&:'BWI'"Y!
M?UN>2VR-&BLY*X$K)CB1,#L>G/@'IXD9;P=<,UBKUCLQGMP(<6L:G_/C@6<
M00&9-A8H/E;P'HK"&$(8/S8V!\V29F+[?6O]H_4=?;FA"MZ+XCO+]>)XD Y(
M#C-:%?I"K/^$C3]C8R\3A;*_9+T9ZPU(5BDMRLUD1% R7C_IW28.+YD0;"8$
M%G>]D$7Y@6HZ/9)B3:09C=;,BW75SD9PC)M-N=02OS*<IZ>76F2WPU/T*R?O
M18E[K:@-U]LK>E. >G<TTKB,&3S*-B9/:Y/!,R;]@'P17"\4.>,YY(\-C!!?
M S+8@CP-=EK\ )E+0M\A@1=$.^R%C=.AM1?^I--]OM:6HGY+)F4.U))F<#S
MG% @5S"8OGGEQ][A#IQ1@S/:97UZB2F85P40,2,7ER<UA9F^)Y3GF!$%U>@
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M)2(RM>U$W=S!FKAA3?QBUK1I\J\T:O=2OTNC_C>-VPI8(VCSN81Y'\7V/2_
MW*L8GS<]G[F6#*]$68^ ;M1QBX,,&RD]NP.9,07D7+(,\,Q#*[A1%2W(U1,:
MU[)J.O1"5 IW$3N_5EII?#5(AB\162=, V<2/GQY35)W[.]U&(<Y7AK5VM^C
MJ[&3A+&3!D'GBQ^Y<3??]CVW@>E1\#!UHB#IYG7B^OO]: *!R8NWQQDPXXV0
M)*,\PRMH[X+)V/%#O[NB[[G!Y*==V[UGW3,F=1(O=OQ)TMH,/W2#KK.IF\3M
M ]3Q4=2^;DZ)[<F&V0]U<,T]\L4GG>\$D\CQXZ"U0.+&W8'C-IT0J3/!([D7
MQ%:OA>U^,9+_%H\=$ILT$IO\G,0.;^Q=(VM?TXU[7-GX8CE3U*YB\F8"[]Z\
M'LZ5*%ANA1@9H0%K*FV#@*6=I'7$3*B,80D+4W&M@!1"J3ZQW@WZ:@'V2DWY
M/0+*Q)RSO^VZ>_!O3PK<)8TFF%*5R12#$GY4]CQ94YDK,P#*92'N :7.JA0\
MX^)3#Q69B0*+4/5$W0Y^ST6D=0'!0H'BS=$&/8<55L9+"_B!0Y'CQ?$C>L=X
M<'\"CNX4=A[-L1ID2AOW5MV3!85R/.[)KG0R)E="HY&]6]):W4/);6=;Z$23
M<1_%1ZU*M 0YM_6V0OL5UW51VO0V)?U)7<D^#*__#_A"Y1Q/.E+ #*=Z;H*7
M3%G7V'5#BZ6M:V^$QBK9OBZ YB#- /P^$T)O&V:!YH^.Z3]02P,$%     @
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MKVQ3HKJ>>YH\&#TO/:*M&K3P#%H0PF?!=:[@%YYA]B. 1]1:?N&)WRJ\B/B
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M@?A^30@_W!0=-,>TTW\ 4$L#!!0    ( .TQ:UIM[_3LU0,  &$1   9
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M@S0#\'TBA-XUS 3U5Y7A?U!+ P04    " #M,6M:J6FJI+L%    +0  &0
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M=LX':$Z6A;QL:+&RM7 A-%96^YCBW0>D"<#Q1 B];9@)ZMM4^!=02P,$%
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M@2\^#J=OX3;:;3U[K6>OXJ,?]-QGJ&88]3.8UKI4!8M@;F'O*)!;L,+/G]S
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MDTV]L4=26-&2FUNY_0JUGPO+ETBNW95LJ]@A!B>E-C*OP:@@9Z*ZTZ<Z#WN
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M5'.@F@O5/*CF0[4 JH4H34Y96Q^A3Q&[6M :":AF034;JCE0S85J'E3SH5H
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M[WZY?U+P;7W3PB=>%'Q3/US3**&BFJ!\?\5Y\?ZDZN!P#]+E_P!02P,$%
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M[_20FH-J+JIYJ.:C6H!J(:I%J!93FAS&MI>AH\4,'6UFH)J#:BZJ>:CFHUJ
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MN4,**&G']5KLO\+@)S9\N>#*/LF^CTTBA^2=TJ(>P*B@9DW_I@_#/AP _%.
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M%S/T)_ONW4^T:&T#W B-[=0.*[SP0)H _%X*H9\FIJ>.5VCV%U!+ P04
M" #M,6M:Q:;?J5<'  #K0P  &0   'AL+W=O<FMS:&5E=',O<VAE970V,BYX
M;6R]G&MOVS88A?\*X75# JRQ[HZSQ$ 325@'= B:MOO,V(PM5!=7I)QDV(\?
M=8DER@IG%:<+D$22]3ZD='@]IG3YF.5?^88Q09Z2..57DXT0VXOIE"\W+*'\
M+-NR5'[RD.4)%7(W7T_Y-F=T504E\=0R#&^:T"B=+"ZK8[?YXC(K1!RE[#8G
MO$@2FC]?LSA[O)J8DY<#'Z/U1I0'IHO++5VS.R8^;V]SN3?=4U91PE(>92G)
MV</5Y)UY$=I>&5"=\25BC[RS3<I+N<^RK^7.^]75Q"ASQ&*V%"6"RG\[=L/B
MN"3)?'QKH)-]FF5@=_N%'E87+R_FGG)VD\5_12NQN9J<3\B*/= B%A^SQ]]9
M<T%NR5MF,:_^DL?F7&-"E@476=($RQPD45K_IT_-C>@$F,XK 5838!T;8#<!
M=C_ >R7 :0*<8U-PFP#WV "O":C$G-8WJ[K3/A5T<9EGCR0OSY:T<J.2JXJ6
M-SA*RY)U)W+Y:23CQ.).9,NO;Z^E-BMRDR6RP'):27[B,T&CF)^2M^3SG4].
MWIR2-R1*R:=-5G":KOCE5,@,E)CILDG,KQ.S7DG,M,B'+!4;3H)TQ58J8"IS
MOL^^]9+]:TM+O&/;,V+8OQ++L)R!#-WHP]\5ZS-BF56X,70]^G"?+<^(;;Z:
M>G!\N#T0'NK#_Z"IO/8ZW-7<2WM?%.R*9X\L"@,YNZY)SC"I; TO^)8NV=5$
M-G><Y3LV6?SRD^D9OPUIA(3Y2%B A(4@F**ML]?6T=$7?Q;)/<M)]D"669+(
MZLU+L6774'8^A.YD3:?W,2.RJR(/A2AR1M8Y3<60]MJ4QFJ/A/DUS*M@99>Z
M6\P-SW7GWN5TUY7U\#S3,6S3\>;JB2$H=XID[EXR5RM971WOJ^JX[+;,[*G<
M9D/2:(ECI4'"_!KF=F^Y<6Z9/6$.S[*=N=L3!90O111O+XJG%:7L)\AM3 <;
M16WHV+N/A/E(6("$A2"8(N9L+^8,UN'-D-HB83X2%B!A(0BF:'N^U_9<6U&_
M,"ZB=$VV+(^R%3EY9C3GIT/*:CECE=5GRB%5-H941.8B0,)"$$Q1<;Y7<7[D
ML(5OJ,036HA-ED=_RQHK,A)Q7C!2R+E$3K:O-,K:!,;*BX3Y2%@P/QC26*YG
M.$:OAPU!B2IJFD8[V33^MV&H/JFQRD)I/I06-+2NN)XQFUL]:5&)JMIVC 3S
MN*$1^8>\M+Y28;%AA*9IM&,YI_ESJ7UY:-><498#EBZ9_#.LLC;1T2HC:3Z4
M%D!I(8JF%@:K+0P6;&C5H% 2(VD^E!9 :2&*IDK<ND6FUK#HCK"6LO+2-2,G
M/P^.L/2@T0+7--/I-(?&F=6;)?K01 ,H+4315.5:+\C4FT%#+;7L?MFW@L8D
M*0W:^%D>X(+&<=DN<Y+)UKMJMGEQS^5Y\J#<C7+Q_)9'3^3$]D[KP*&Q[;4^
M.Z/UAUI&4%H I84HFEI,6O_)='%M.-1Y@M)\*"V TD(4396X=;-,O9UU_"Q9
M#QHML#Y;MO=Z:^)#<Q) :2&*ILK9^EFFUE(9TR5#_:R&UNN29P==,M2J@M)"
M%$U5KG6K3+TS5'Z!^*JOK(\=+1:2YD-I 906HFBJIJUW9<YQ_2?4IH+2?"@M
M@-)"%$U=?-#Z6=:Q?M9W^Y/Z%,8J#Z7YUJ'QY,QFKOSM?6\'339$T5116R/+
MTAM9MVWO*87-"B$G0NFJ[%=KMS*A3U%2)(-B0MTJ*,UO:+U.VK3Z4D)M*!1-
ME;*UH2RM![+X4$M%Z&H5E4VOG-^F^RK;579)MY&<[C8*-^.G086MH;MH](8Z
M-_I\C98.ZD)!:2&*IBK<NE"6WH5"?J.@3VIT[84N:VIHW:;8=N?V?-ZOOE"C
M"D53Q6V-*NL_C2KGQ:BZ:YTGMGNM<D*-)BC-A]("*"U$T5296Z/)PAE-%M1H
M@M)\*"V TD(4396X-9HLO:,#;::A5A24YD-I 906-C1EC8#CS(W.JD=5W=9W
MLO2^4]5.!W>WMX-R0:TF*,V'T@(H+4315$U;1\HZQS7*4(,*2O.AM !*"U$T
M5>+6H+)^^.HJZW#=D3V?S5VO/Q^".E)06@"EA2B:^@A'ZTC9>D<*/^-M$NS/
M>'L+RV[T^1K]% =T 164%J)HJL*M/67K[:EWK;)-M?V4D6O6J;R#*IH'%=4T
MJI^^CE#3"4H+H+0015-U;+TI6^]-O9?-*TV7[&!0+ ?$]?>Q@SI"%TM!:7Y#
MZY:Q7ND*H F&*)JJ8.=Y.;WW]#U/Z.B1H_7#/CI7TUR=?M@GXGZ$O62W]I)]
MA+U43EN.M)?TN-':0>TE*"V TD(4396YM9=LG+UD0^TE*,V'T@(H+4315(E;
M>\D^UE[Z[IF,/H71RD-=)2@M@-)"^]!5.C?=\[G1,Y6FG7<4)"Q?5V^3X++?
M+%)1/^^_/[I_8\6[ZCT-O>.^>1'4[YUH,?5K,#[0?!VEG,3L02++!4@3DM=O
MEJAW1+:MWH1PGPF1)=7FAE%9*LH3Y.</629>=LH$]N_W6/P+4$L#!!0    (
M .TQ:UILF<FL*P,  %L)   9    >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM
M;+56VV[;.!#]%4(;+!*@MBZ^-K4%V,FVVX<N@GB3/M/2V"(BD5J2LEM@/[Y#
M4I$51%8O0%\DWN:<,\,AAXNCD$\J ]#D2Y%SM?0RK<MKWU=)!@550U$"QYF=
MD 75V)5[7Y42:&J-BMR/@F#J%Y1Q+U[8L3L9+T2E<\;A3A)5%0657]>0B^/2
M"[WG@7NVS[09\.-%2?>P ?U0WDGL^0U*R@K@B@E.).R6WBJ\7H>1,; K'AD<
M5:M-C"M;(9Y,YV.Z] *C"')(M(&@^#O #>2Y04(=_]6@7L-I#-OM9_3WUGET
M9DL5W(C\,TMUMO3F'DEA1ZM<WXOCWU [-#%XB<B5_9)CO3;P2%(I+8K:&!44
MC+L__5('HF4P/F<0U08V$+XCLBIOJ:;Q0HHCD68UHIF&==5:HSC&S:YLM,19
MAG8ZWFB1/ W6Z%=*;D2!FZVH#=> W(/2DB4:9^PJLCI2F2IR>0N:LEQ=F36;
M%;D@/E$9E: (X^2!,ZW>X""V_\U$I2A/U<+7J-4P^DFM:^UT16=TA1'Y)+C.
M%/F+IY"^!/#1R<;3Z-G3==2+> O)D(S"-R0*HC%YV-R2RXNKMGCWZV$:-3$=
M6:;1&:9_JF(+DH@=V71 .JT.8=R-8([BM2II DL/SYH">0 O_O./<!J\Z]$W
M;O2-^]#C!W[ K<5MI<J(W,*><<[XGEPZO5==@AWDU$*:HWZ(HQD>_85_Z% R
M:91,>I4\.AV7ZCSOY!7O8!I$\V[>:<,[[>6]A[*226:SOH]\^IH\"L-9U,T^
M:]AGO?GQV5X5D Y6!Y!X]9$/DG(]P/,+Y#UEDCS2O((N/;/?D#7S1O7\%[/F
M@I28[C:,5^3_UI'J<L&1S-MY-)R%W0%]VTA[^T-I]%-"'"1>UR<EP3 XHR0,
M3O=I\..I]5.":N!V:$;#\9E,#UL7?-@KZ'0;X66MR-[DVG?2OD9LY_V9@QY&
M)QE1KXP7Q2412IMX=)([G$D/N=^J=P7(O:WJ"E$KKEWI:T:;E\/*U<O3<O?L
M^$0EYK$B.>S0-!C.D%>Z2NXZ6I2V>FZ%QEILFQF^?D":!3B_$T(_=PQ!\YZ*
MOP%02P,$%     @ [3%K6E\J &_+ @  \P<  !D   !X;"]W;W)K<VAE971S
M+W-H965T-C0N>&ULK55K;YLP%/TK%I.F5EK",R3K"%*3MMH^5*M:;?OLPB6Q
M8C"SG=>_W[4A+*EHE$G[ G[<<SCGVMR;;(5<J26 )KN25VKJ++6N;UQ794LH
MJ1J*&BK<*80LJ<:I7+BJED!S"RJY&WA>[):454Z:V+4GF29BK3FKX$D2M2Y+
M*O<SX&([=7SGL/#,%DMM%MPTJ>D"7D#_J)\DSMR.)6<E5(J)BD@HILZM?S,?
MFW@;\)/!5AV-B7'R*L3*3+[E4\<S@H!#I@T#Q=<&YL"Y(4(9OUM.I_ND 1Z/
M#^P/UCMZ>:4*YH+_8KE>3IV)0W(HZ)KK9[']"JV?D>'+!%?V2;9MK.>0;*VT
M*%LP*BA9U;SIKLW#$<"/WP$$+2"X%!"V@- :;9196W=4TS218DNDB48V,["Y
ML6ATPRISBB]:XBY#G$Y?M,A6@QDF(B=S4>+E4-3F=_! F20;RM>@B"B(,H%$
MU&93D86DE4;(U1UHRKBZ)@-R7]9<[ &(Y23?;6CB:E1ION5FK:)9HRAX1Y$?
MD$=1Z:4B]U4.^2F!B_8ZC\'!XRPXRW@'V9"$_B<2>$'4(VA^.3P\(R?L4AY:
MOO ?4]Z7JH8IZF<R?_B-JFD&4P=_805R T[Z\8,?>U_Z;/XGLA/346<Z.L>>
M/C.U&A02;P?#BX/\FDBJH<]S0^0WQV&JT";UAEXX2=S-L9O^L,@/N[@3H:-.
MZ.BLT/M=C14&CP95EN2*560/5*KK/J7GF>(&28(1R>E>]9W(901^U$-P8B[N
MS,67F=L(CG>.,[WO\Q7WI?9S%/IOCJ W;C*>Q/U',.Y4CB]3F;,-RZ'*R9X!
MS_N4-D1^=*S@C<BS(8T^]ZA^EB 7MJTHDHEUI9LRTZUVG>O6%NPWZS/L:$T#
M^DO3M,-'*A<,"R>' BF]X1B/7C8MIIEH4=LJ_2HTUGP[7&)7!FD"<+\00A\F
MY@-=GT__ %!+ P04    " #M,6M:<K[#=($&  "")0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6R]FEUSVC@4AO^*ANWLI#,-6!(8R";,)*2[VXON
M9IJFO1:V $]MBY4$)/OK5[*-A;&B&(JW%XUMI*/SGJ./Q[*NMXS_$$M*)7A.
MXE3<=)92KJYZ/1$L:4)$EZUHJGZ9,YX0J6[YHB=6G)(PJY3$/>1Y?B\A4=J9
M7&?/'OCDFJUE'*7T@0.Q3A+"7^YHS+8W'=C9/?@2+992/^A-KE=D01^I?%H]
M<'77*ZV$44)3$;$4<#J_Z=S"JRD>ZPI9B6\1W8J]:Z"ES!C[H6\^A3<=3WM$
M8QI(;8*H/QLZI7&L+2D__BF,=LHV=<7]ZYWUWS/Q2LR,"#IE\?<HE,N;SJ@#
M0CHGZUA^8=L_:2%HH.T%+!;9_V!;E/4Z(%@+R9*BLO(@B=+\+WDN K%7 ?5?
MJ8"*"NB@ GRM BXJX$QH[EDFZYY(,KGF; NX+JVLZ8LL-EEMI29*=1H?)5>_
M1JJ>G#Q*%ORXO%.!",&4):IW")+%]Q)D/X&_5_I6@(M[*DD4B_?JEZ?'>W#Q
M[CUX!WI + FG D0I>$HC*3ZHA^KZZY*M!4E#<=V3RDO=5B\H/+K+/4*O> 01
M^,Q2N13@8QK2L&J@I^25&M%.XQUR6KRG01=@^ $@#_4M#DV;5\<.=W 9<IS9
MPZ_8^VN=S"@'; X>L]C90I1;Z-LMZ*%])58DH#<=-78%Y1O:F?SZ"_2]WVSR
MSF2L(K9?BNV[K$_N2$S2@ (U@PBI.D24+@"18$8749KJ&Q6&%THXN%"])N]+
M[VT!R5OQLU;TU+29(#Q"8ZP2LMG7ZO3F1*V#4NO@%*TT#9NJ'-14CH:>#\?#
M Y7U<H?1J CP2P&^LV?>+A:<+HBDX%,J>:3FZ@!\(_&:VGSUS]E%SV2LHGI8
MJAXZT_;QF?(@$FH24UD*6)*HV4]D<Q_+YSZ;^MSD8#\#P\%!ENIE(/3M&1J5
MOH[<OB:KF+U06IF<;?XYS1R;G3,9JR@>EXK'/SU;CL\I]DS&*F*A9Y9C[W^9
M+XMFWIXPW?Z<JG<//Z!3[Q^<I%*QQUMR8$V./\3^"*%#.<[F3I6#C!S4:"YY
M6Q"J";K$HSXZG.EMY=1,,QS;YQ%H( 0ZE_V)@N YC73H&0>![G-QW,!M;'%[
M.( 8'OK=!G1 0QWP).PX8BF&=>*PK\66@L[%&!J<@&Z>V*'WA@J=)R4#T+Q_
MD5E,C]539P:(QGWHUT:0TZE3,V<0!#K7>KOHE7KI4S>298^/DNTW36,;" (-
M@\"A<YG[GKUO*HV7X'9#N7J#!KNY!#SP*+ B&'2"S;$+W[FL52-@R :ZT>:H
ME2]D<4RX "N%!EGV[<G/6QSM)[\[J$U5;> --'P#G41160$;RLH-P@I9]KM^
MK4NW@3+(H QRHTQU+6PFK3!9D3;LPL.4N5L^59F!%N2&%L?:V5 FM&30ZZ+Q
MH<XV: 89FD%NFFFXBC;4C"R:<1?5<HO<@[:JQ? .<O/.\8MI0UG8UF/]_J&J
M-G@(&1Y";AYJLJJ>'H)^+6/6Q+:Q-X,,3:%!HQ7V<K>^?J%ZFUOWZ2E+)2>!
M7),8?*4\ 1>?TBP(=J9 9R*D(BQM\!8RO(7<O-5PC#NBX;8_RJN",4CR75T,
M0O)B>XV?NBV=&@F#8,B]#W3\#.$(BKNI01$4OT%0VJ R9*@,N:GLQ(G#$1EW
M>\=TES:X#1EN0^Z-J:,V2]%9MZC.9:WZ^<* '6ZV1V6C<^O'#*^V$3KR1H<K
MI+O14T49IL-NIBMIU:J@OOV$:EL>1:$JTWEV;L&&P?#/,IC5X?JV$8)>+>3(
MG9BJRWO?M\Z(6E;OZ[M,<.S5XMT&4F&#5/C<2&65:MD]LB2J#73"!IVP>R/J
MI"\DA<W]SH7WAD,AK WXP09^L!M.2B8D!1,N],OX$>A;V*^@+^SBT:',>K%1
M%WKC_7^OC#J#+]C-%$\IIP%;I-&_J@,&^Y_R Z:Z(J<Q*;KF.BWZ[-LYK'_"
M&O;[]2RVP2C8, IV,T.Y=[;+HLI9Q-2P4[=@NXR"I9+L#$XD*F-W1H$I;HV+
MVR%<0,QP!S'^JQ#CMG1JZ S$8/?FTU<FU3O/G$0<;#2[Z '.JA-;N.9ZS9'+
M75RM 1G7.DK?K_>3>BGDUY;(WMYIEH3R17;(1ZA$K5.9'_HHGY8'B6ZSXS,'
MS^_@U30_#F3,Y*>3/A.NN$6 F,Z52:\[5"[Q_,!/?B/9*CLS,V-2LB2[7%(2
M4JX+J-_GC,G=C6Z@/'8U^0]02P,$%     @ [3%K6M_&JZ+P @  ,@L  !D
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MBG7 %1.<2*CGP?OX9A%;@%WQ-X.M.G@FQLJS$%_-X+Z:!Y%1!"V4VE!0_-G
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M8=FXGPAH[^#.:Z7LP? )IM]2\0=02P,$%     @ [3%K6KU_'KK3!0  $RX
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M6)DKF@D9]832=FT[L_EU-9_W8/UU>$'J^<D64T^7_D#EFN<*I6QED,'9U!R
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M<F]P<R]A<' N>&UL4$L! A0#%     @ [#%K6H!<\)CN    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ [#%K
M6IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #L,6M:PM<77],'  !L*0  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ [#%K
M6I!+C(<'!P  N"0  !@              ("!%A   'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( .PQ:UJ@6@<DTP0  '<;   8
M      " @5,7  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" #L,6M:8NE9Q<X%  "]&   &               @(%<'   >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ [#%K6H[9:R[! @  N <  !@
M             ("!8"(  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( .PQ:UHK%VF?U L  **4   8              " @5<E  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #L,6M:QT"X5ZT"   -
M"   &               @(%A,0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ [#%K6L7X_R&9!P  ]2$  !@              ("!1#0
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( .PQ:UKFZ1".
MNP(  $P)   8              " @1,\  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " #L,6M:#IK^]&X*  "Q&0  &0
M@($$/P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( .TQ
M:UJ "'<^/"@  ""%   9              " @:E)  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ [3%K6M))3=1Q"   <!T  !D
M         ("!''(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " #M,6M:#0 (^',"  #]!0  &0              @('$>@  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .TQ:UHFBDW'SP(  +<&
M   9              " @6Y]  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ [3%K6K%Q)9_V!   O0T  !D              ("!=(
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #M,6M:B97Z
ME$@.  !Q+0  &0              @(&AA0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( .TQ:UK-[E;2[ T  )HQ   9
M  " @2"4  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M[3%K6AV"?9-R"P  -BP  !D              ("!0Z(  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " #M,6M:7>J (<0$  #_"P  &0
M            @('LK0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( .TQ:UK-L(<!U@H  ($D   9              " @>>R  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ [3%K6E*]47O1!
M0@T  !D              ("!]+T  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " #M,6M:96VG"Z$+  !H)0  &0              @('\
MP@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( .TQ:UK,
MW;BKL@4   @.   9              " @=3.  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ [3%K6J72?*C= @  <@8  !D
M     ("!O=0  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .TQ:UI41=7880(  ,('   9              "
M@;KG  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ [3%K
M6CRE,S@1 @  W00  !D              ("!4NH  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " #M,6M:6AN!J^D(  "\*   &0
M        @(&:[   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( .TQ:UITX+7VXRD   ^2   9              " @;KU  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ [3%K6F8MM,I4!0  0Q4
M !D              ("!U!\! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " #M,6M:+TQ:_8("   .!@  &0              @(%?)0$
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( .TQ:UHTE$)9
MW (  ,@&   9              " @1@H 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ [3%K6GG45*XU P  S@@  !D
M ("!*RL! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #M
M,6M:IP9!Y2H#  "S"   &0              @(&7+@$ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .TQ:UI?TY-=N0(  $0&   9
M          " @?@Q 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#
M%     @ [3%K6O<Z7-\C!0  ]!   !D              ("!Z#0! 'AL+W=O
M<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #M,6M:,5&44F$#  !'
M"0  &0              @(%".@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;%!+ 0(4 Q0    ( .TQ:UITZS3?1 4  /P1   9              " @=H]
M 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ [3%K6JP/
M>_V# P  _0@  !D              ("!54,! 'AL+W=O<FMS:&5E=',O<VAE
M970T,BYX;6Q02P$"% ,4    " #M,6M:'69L@@,%  "R'0  &0
M    @($/1P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M .TQ:UIM[_3LU0,  &$1   9              " @4E, 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ [3%K6JEIJJ2[!0   "T  !D
M             ("!55 ! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " #M,6M:;WPY,>0"  !9"0  &0              @(%'5@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( .TQ:UK=25LQ4P,
M %0.   9              " @6)9 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ [3%K6@EA#A](!   D!D  !D              ("!
M[%P! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #M,6M:
M+"W?8I@#   ,"P  &0              @(%K80$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .TQ:UI)#/ZB:P(  +L&   9
M      " @3IE 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ [3%K6G,8LAC= @  1 @  !D              ("!W&<! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #M,6M:C&5U'MP"  !^"
M&0              @('P:@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( .TQ:UI^5[+PQ0(  *P'   9              " @0-N 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ [3%K6O?D6X2Y
M @  : @  !D              ("!_W ! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " #M,6M:]OV+R]P$  !X'@  &0
M@('O<P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( .TQ
M:UIK:U\B2PD  (]T   9              " @0)Y 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ [3%K6LAEN,NP#0  >\X  !D
M         ("!A((! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M    " #M,6M:W"LA :4$  "O'   &0              @(%KD $ >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( .TQ:UK0($>5K0,  %43
M   9              " @4>5 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL
M4$L! A0#%     @ [3%K6CH1]2>7 @  1 @  !D              ("!*YD!
M 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #M,6M:PW9L
M[* "  !.!P  &0              @('YFP$ >&PO=V]R:W-H965T<R]S:&5E
M=#8Q+GAM;%!+ 0(4 Q0    ( .TQ:UK%IM^I5P<  .M#   9
M  " @="> 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
M[3%K6FR9R:PK P  6PD  !D              ("!7J8! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " #M,6M:7RH ;\L"  #S!P  &0
M            @(' J0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( .TQ:UIROL-T@08  ((E   9              " @<*L 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ [3%K6M_&JZ+P @
M,@L  !D              ("!>K,! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    " #M,6M:$?4@S"<#   C"@  &0              @(&A
MM@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( .TQ:UJ&
MLOTA*0,  .8,   9              " @?^Y 0!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ [3%K6E7_^U6G @  "P<  !D
M     ("!7[T! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .TQ:UK%K0"2( (  *($   9              "
M@8_/ 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ [3%K
M6KU_'KK3!0  $RX  !D              ("!YM$! 'AL+W=O<FMS:&5E=',O
M<VAE970W-2YX;6Q02P$"% ,4    " #M,6M:'1/,*\D$  !O&   &0
M        @('PUP$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0
M   ( .TQ:UJ1)BW&,P(  ,($   9              " @?#< 0!X;"]W;W)K
M<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ [3%K6F6?X:5= P  MA8
M  T              ( !6M\! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #M
M,6M:EXJ[',     3 @  "P              @ 'BX@$ 7W)E;',O+G)E;'-0
M2P$"% ,4    " #M,6M:*KA*]=@%  "*,@  #P              @ '+XP$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ [3%K6GKM3FU6 @  CBT  !H
M             ( !T.D! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ [3%K6E6HN6<2 @  <RP  !,              ( !7NP! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     %4 50!*%P  H>X!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>184</ContextCount>
  <ElementCount>395</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200205 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200300 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995200305 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995200400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995200405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureOtherAssets</Role>
      <ShortName>Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - License and Collaboration Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenue</Role>
      <ShortName>License and Collaboration Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - License and Option Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureLicenseAndOptionAgreements</Role>
      <ShortName>License and Option Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995211301 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995211401 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995211501 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995211601 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995211701 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995211801 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureOtherAssetsTables</Role>
      <ShortName>Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureOtherAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureLeases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureConvertiblePreferredStockTables</Role>
      <ShortName>Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureConvertiblePreferredStock</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99931003 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureCommonStock</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99931103 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99931203 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99931303 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99931703 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureSegmentInformation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureNatureOfBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureNatureOfBusiness</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Fair Value Measurements - Valuation Techniques (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails</Role>
      <ShortName>Fair Value Measurements - Valuation Techniques (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940302 - Disclosure - Fair Value Measurements - Fair Value Transfers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureFairValueMeasurementsFairValueTransfersDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Transfers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940303 - Disclosure - Fair Value Measurements - Available-for-sale securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Available-for-sale securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940304 - Disclosure - Fair Value Measurements - Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails</Role>
      <ShortName>Fair Value Measurements - Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940305 - Disclosure - Fair Value Measurement - Changes in Liabilities With Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurement - Changes in Liabilities With Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureOtherAssetsDetails</Role>
      <ShortName>Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureOtherAssetsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureLeasesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99940602 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Operating Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeaseAssetsAndLiabilitiesDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information Related to Operating Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99940603 - Disclosure - Leases - Maturities of Operating Lease Liabilities and Quantitative Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails</Role>
      <ShortName>Leases - Maturities of Operating Lease Liabilities and Quantitative Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - License and Collaboration Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails</Role>
      <ShortName>License and Collaboration Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenue</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - License and Option Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails</Role>
      <ShortName>License and Option Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureLicenseAndOptionAgreements</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureConvertiblePreferredStockTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - Convertible Preferred Stock - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails</Role>
      <ShortName>Convertible Preferred Stock - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99940903 - Disclosure - Convertible Preferred Stock - Rights and Privileges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails</Role>
      <ShortName>Convertible Preferred Stock - Rights and Privileges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureCommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureCommonStockTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>99941002 - Disclosure - Common Stock - Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureCommonStockReservedForIssuanceDetails</Role>
      <ShortName>Common Stock - Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>99941102 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>99941103 - Disclosure - Stock-Based Compensation -Fair values of stock options granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation -Fair values of stock options granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>99941104 - Disclosure - Stock-Based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>99941105 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Net Loss Per Share - Basic and diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails</Role>
      <ShortName>Net Loss Per Share - Basic and diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>99941202 - Disclosure - Net Loss Per Share - Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>99941301 - Disclosure - Income Taxes - Components of loss before the provision for (benefit from) income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of loss before the provision for (benefit from) income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>99941302 - Disclosure - Income Taxes - Components of the income tax provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Components of the income tax provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>99941303 - Disclosure - Income Taxes - Reconciliation of the income tax expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the income tax expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>99941304 - Disclosure - Income Taxes - Components of the Company's deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of the Company's deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>99941305 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>99941501 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureEmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureEmployeeBenefitPlans</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>99941601 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>99941701 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureSegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="zbio-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>99941801 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zenasbio.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zenasbio.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>zbio-20241231.xsd</File>
    <File>zbio-20241231_cal.xml</File>
    <File>zbio-20241231_def.xml</File>
    <File>zbio-20241231_lab.xml</File>
    <File>zbio-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="zbio-20241231x10k.htm">zbio-20241231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>zbio-20241231x10k004.jpg</File>
    <File>zbio-20241231x10k007.jpg</File>
    <File>zbio-20241231x10k008.jpg</File>
    <File>zbio-20241231x10k010.jpg</File>
    <File>zbio-20241231x10k011.jpg</File>
    <File>zbio-20241231x10k012.jpg</File>
    <File>zbio-20241231x10k013.jpg</File>
    <File>zbio-20241231x10k014.jpg</File>
    <File>zbio-20241231x10k015.jpg</File>
    <File>zbio-20241231x10k016.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="621">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>116
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zbio-20241231x10k.htm": {
   "nsprefix": "zbio",
   "nsuri": "http://zenasbio.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "zbio-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "zbio-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "zbio-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "zbio-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zbio-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "zbio-20241231x10k.htm"
     ]
    }
   },
   "keyStandard": 330,
   "keyCustom": 65,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 35,
   "memberCustom": 22,
   "hidden": {
    "total": 40,
    "http://fasb.org/us-gaap/2024": 33,
    "http://zenasbio.com/20241231": 2,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 184,
   "entityCount": 1,
   "segmentCount": 61,
   "elementCount": 687,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 621,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://zenasbio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical",
     "longName": "995200205 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xmuQWu9BX0O2k_q1aI5KuQ",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
     "longName": "995200300 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "shortName": "Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWOR2Y6eb0qw6h_ECNiCyQ",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWOR2Y6eb0qw6h_ECNiCyQ",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "longName": "995200305 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Gh9QtBp7z0aJp2U6HTSmvA",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Gh9QtBp7z0aJp2U6HTSmvA",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical",
     "longName": "995200405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://zenasbio.com/role/DisclosureNatureOfBusiness",
     "longName": "995210101 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://zenasbio.com/role/DisclosureFairValueMeasurements",
     "longName": "995210301 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://zenasbio.com/role/DisclosureOtherAssets",
     "longName": "995210401 - Disclosure - Other Assets",
     "shortName": "Other Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://zenasbio.com/role/DisclosureAccruedExpenses",
     "longName": "995210501 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://zenasbio.com/role/DisclosureLeases",
     "longName": "995210601 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenue",
     "longName": "995210701 - Disclosure - License and Collaboration Revenue",
     "shortName": "License and Collaboration Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreements",
     "longName": "995210801 - Disclosure - License and Option Agreements",
     "shortName": "License and Option Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "zbio:LicenseAndOptionAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "zbio:LicenseAndOptionAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://zenasbio.com/role/DisclosureConvertiblePreferredStock",
     "longName": "995210901 - Disclosure - Convertible Preferred Stock",
     "shortName": "Convertible Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "zbio:TemporaryEquityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "zbio:TemporaryEquityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://zenasbio.com/role/DisclosureCommonStock",
     "longName": "995211001 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://zenasbio.com/role/DisclosureStockBasedCompensation",
     "longName": "995211101 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://zenasbio.com/role/DisclosureNetLossPerShare",
     "longName": "995211201 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://zenasbio.com/role/DisclosureIncomeTaxes",
     "longName": "995211301 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://zenasbio.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995211401 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://zenasbio.com/role/DisclosureEmployeeBenefitPlans",
     "longName": "995211501 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://zenasbio.com/role/DisclosureRelatedPartyTransactions",
     "longName": "995211601 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://zenasbio.com/role/DisclosureSegmentInformation",
     "longName": "995211701 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://zenasbio.com/role/DisclosureSubsequentEvents",
     "longName": "995211801 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "zbio:BasisOfPresentationAndConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "zbio:BasisOfPresentationAndConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://zenasbio.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "99930303 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://zenasbio.com/role/DisclosureOtherAssetsTables",
     "longName": "99930403 - Disclosure - Other Assets (Tables)",
     "shortName": "Other Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://zenasbio.com/role/DisclosureAccruedExpensesTables",
     "longName": "99930503 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://zenasbio.com/role/DisclosureLeasesTables",
     "longName": "99930603 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://zenasbio.com/role/DisclosureConvertiblePreferredStockTables",
     "longName": "99930903 - Disclosure - Convertible Preferred Stock (Tables)",
     "shortName": "Convertible Preferred Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://zenasbio.com/role/DisclosureCommonStockTables",
     "longName": "99931003 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "zbio:ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "zbio:ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://zenasbio.com/role/DisclosureStockBasedCompensationTables",
     "longName": "99931103 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://zenasbio.com/role/DisclosureNetLossPerShareTables",
     "longName": "99931203 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://zenasbio.com/role/DisclosureIncomeTaxesTables",
     "longName": "99931303 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://zenasbio.com/role/DisclosureSegmentInformationTables",
     "longName": "99931703 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails",
     "longName": "99940101 - Disclosure - Nature of Business (Details)",
     "shortName": "Nature of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_S86Rw8jTyUm70oUkTaBnEw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_S86Rw8jTyUm70oUkTaBnEw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:DeferredCosts",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:DeferredChargesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Unit_Standard_segment_S86Rw8jTyUm70oUkTaBnEw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails",
     "longName": "99940301 - Disclosure - Fair Value Measurements - Valuation Techniques (Details)",
     "shortName": "Fair Value Measurements - Valuation Techniques (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_LWrKtXp_xEeU8LAphW72jw",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_LWrKtXp_xEeU8LAphW72jw",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://zenasbio.com/role/DisclosureFairValueMeasurementsFairValueTransfersDetails",
     "longName": "99940302 - Disclosure - Fair Value Measurements - Fair Value Transfers (Details)",
     "shortName": "Fair Value Measurements - Fair Value Transfers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "zbio:FairValueAssetsLevel1ToLevel2TransferAmount",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "zbio:FairValueAssetsLevel1ToLevel2TransferAmount",
       "zbio:FairValueAssetsLevel2ToLevel1TransferAmount",
       "zbio:FairValueAssetsLevel2ToLevel1TransferAmount",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "zbio:FairValueAssetsLevel1ToLevel2TransferAmount",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "zbio:FairValueAssetsLevel1ToLevel2TransferAmount",
       "zbio:FairValueAssetsLevel2ToLevel1TransferAmount",
       "zbio:FairValueAssetsLevel2ToLevel1TransferAmount",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails",
     "longName": "99940303 - Disclosure - Fair Value Measurements - Available-for-sale securities (Details)",
     "shortName": "Fair Value Measurements - Available-for-sale securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails",
     "longName": "99940304 - Disclosure - Fair Value Measurements - Convertible Notes (Details)",
     "shortName": "Fair Value Measurements - Convertible Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "zbio:FairValueAdjustmentOfConvertibleNotes",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_ExKbMgkUn0ititCiAzolAg",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://zenasbio.com/role/DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails",
     "longName": "99940305 - Disclosure - Fair Value Measurement - Changes in Liabilities With Significant Unobservable Inputs (Details)",
     "shortName": "Fair Value Measurement - Changes in Liabilities With Significant Unobservable Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://zenasbio.com/role/DisclosureOtherAssetsDetails",
     "longName": "99940401 - Disclosure - Other Assets (Details)",
     "shortName": "Other Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:PrepaidExpenseNoncurrent",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:PrepaidExpenseNoncurrent",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://zenasbio.com/role/DisclosureAccruedExpensesDetails",
     "longName": "99940501 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "zbio:AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "zbio:AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://zenasbio.com/role/DisclosureLeasesDetails",
     "longName": "99940601 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://zenasbio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeaseAssetsAndLiabilitiesDetails",
     "longName": "99940602 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Operating Lease Assets and Liabilities (Details)",
     "shortName": "Leases - Supplemental Balance Sheet Information Related to Operating Lease Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails",
     "longName": "99940603 - Disclosure - Leases - Maturities of Operating Lease Liabilities and Quantitative Disclosure (Details)",
     "shortName": "Leases - Maturities of Operating Lease Liabilities and Quantitative Disclosure (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "zbio:LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "zbio:LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails",
     "longName": "99940701 - Disclosure - License and Collaboration Revenue (Details)",
     "shortName": "License and Collaboration Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_1_2023_To_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_68E-30ZXOka0SQILO84I2w",
      "name": "zbio:CollaborativeArrangementUpfrontPaymentReceived",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
     "longName": "99940801 - Disclosure - License and Option Agreements (Details)",
     "shortName": "License and Option Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_WGP9j066HEmWArI6WB0Cow",
      "name": "zbio:NumberOfAntibodyProductCandidates",
      "unitRef": "Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "zbio:LicenseAndOptionAgreementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
     "longName": "99940901 - Disclosure - Convertible Preferred Stock (Details)",
     "shortName": "Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA",
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_1_2020_To_11_30_2020_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2020Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ybTmDoxkwUu0xUQqRigT7Q",
      "name": "zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "zbio:TemporaryEquityDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails",
     "longName": "99940902 - Disclosure - Convertible Preferred Stock - Schedule (Details)",
     "shortName": "Convertible Preferred Stock - Schedule (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA",
      "name": "us-gaap:TemporaryEquityLiquidationPreference",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails",
     "longName": "99940903 - Disclosure - Convertible Preferred Stock - Rights and Privileges (Details)",
     "shortName": "Convertible Preferred Stock - Rights and Privileges (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "zbio:TemporaryEquityNumberOfVotesPerShare",
      "unitRef": "Unit_Standard_Vote_HZAN3AhGAkmyDfnWsC8kqg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "zbio:TemporaryEquityNumberOfVotesPerShare",
      "unitRef": "Unit_Standard_Vote_HZAN3AhGAkmyDfnWsC8kqg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://zenasbio.com/role/DisclosureCommonStockDetails",
     "longName": "99941001 - Disclosure - Common Stock (Details)",
     "shortName": "Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_31_2024_R3mnM-yuCkeUi3lI4lcTJA",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://zenasbio.com/role/DisclosureCommonStockReservedForIssuanceDetails",
     "longName": "99941002 - Disclosure - Common Stock - Reserved for Issuance (Details)",
     "shortName": "Common Stock - Reserved for Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA",
      "name": "zbio:TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "zbio:ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA",
      "name": "zbio:TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "zbio:ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails",
     "longName": "99941101 - Disclosure - Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "zbio:ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_RshCuHFfukSw2KF3sIAoJg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails",
     "longName": "99941102 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details)",
     "shortName": "Stock-Based Compensation - Restricted Stock Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember__QbnTUUJpUmGv43XtvhTNg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember__QbnTUUJpUmGv43XtvhTNg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails",
     "longName": "99941103 - Disclosure - Stock-Based Compensation -Fair values of stock options granted (Details)",
     "shortName": "Stock-Based Compensation -Fair values of stock options granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
     "longName": "99941104 - Disclosure - Stock-Based Compensation - Stock Options (Details)",
     "shortName": "Stock-Based Compensation - Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "zbio:ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
     "longName": "99941105 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fB6rJscJqE2qELeYONH6iw",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://zenasbio.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails",
     "longName": "99941201 - Disclosure - Net Loss Per Share - Basic and diluted (Details)",
     "shortName": "Net Loss Per Share - Basic and diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R68": {
     "role": "http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails",
     "longName": "99941202 - Disclosure - Net Loss Per Share - Anti-dilutive Securities (Details)",
     "shortName": "Net Loss Per Share - Anti-dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_c8gM2cWCLkC5U2Dqd6witg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_c8gM2cWCLkC5U2Dqd6witg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails",
     "longName": "99941301 - Disclosure - Income Taxes - Components of loss before the provision for (benefit from) income taxes (Details)",
     "shortName": "Income Taxes - Components of loss before the provision for (benefit from) income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails",
     "longName": "99941302 - Disclosure - Income Taxes - Components of the income tax provision (Details)",
     "shortName": "Income Taxes - Components of the income tax provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails",
     "longName": "99941303 - Disclosure - Income Taxes - Reconciliation of the income tax expense (Details)",
     "shortName": "Income Taxes - Reconciliation of the income tax expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "99941304 - Disclosure - Income Taxes - Components of the Company's deferred tax assets and liabilities (Details)",
     "shortName": "Income Taxes - Components of the Company's deferred tax assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_btgOtUF74023dciFSkKbYw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://zenasbio.com/role/DisclosureIncomeTaxesDetails",
     "longName": "99941305 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://zenasbio.com/role/DisclosureEmployeeBenefitPlansDetails",
     "longName": "99941501 - Disclosure - Employee Benefit Plans (Details)",
     "shortName": "Employee Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
     "longName": "99941601 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember__kat8-A7DkaDtefaqsDstA",
      "name": "zbio:RelatedPartyTransactionReimbursableCosts",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember__kat8-A7DkaDtefaqsDstA",
      "name": "zbio:RelatedPartyTransactionReimbursableCosts",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://zenasbio.com/role/DisclosureSegmentInformationDetails",
     "longName": "99941701 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://zenasbio.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99941801 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "Duration_1_24_2025_To_1_24_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_zbio_ZaiLicenseAgreementMember_OHpbECa01k2mu2U9YBMjnw",
      "name": "zbio:CollaborativeArrangementUpfrontPaymentReceived",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_24_2025_To_1_24_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_zbio_ZaiLicenseAgreementMember_OHpbECa01k2mu2U9YBMjnw",
      "name": "zbio:CollaborativeArrangementUpfrontPaymentReceived",
      "unitRef": "Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zbio-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable (includes $560 and $21 owed to related parties, respectively)",
        "verboseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r792"
     ]
    },
    "zbio_AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for external research, development and manufacturing expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued External Research, Development And Manufacturing Expenses, Current",
        "terseLabel": "External research, development and manufacturing expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r101"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureAccruedExpensesDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses (includes $260 and $404 owed to related parties, respectively)",
        "totalLabel": "Total accrued expenses",
        "verboseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional and consultant fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r67",
      "r141",
      "r591",
      "r632",
      "r633"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r18",
      "r470",
      "r473",
      "r531",
      "r628",
      "r629",
      "r943",
      "r944",
      "r945",
      "r953",
      "r954",
      "r955",
      "r956"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r792",
      "r1092"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r953",
      "r954",
      "r955",
      "r956",
      "r1032",
      "r1094"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r381"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Stock issuance costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r89"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r844",
      "r854",
      "r887"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r847",
      "r857",
      "r890"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r848",
      "r858",
      "r882",
      "r891",
      "r895",
      "r903"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "negatedLabel": "Stock-based compensation",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r416"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Net amortization of premiums and accretion of discounts on short-term investments",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r72",
      "r336",
      "r1044"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of diluted net (loss) per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net (Loss) Income Per Share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/DisclosureSubsequentEventsDetails",
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "zbio_AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for asset acquisitions and acquired in-process research and development expense.",
        "label": "Asset Acquisitions And Acquired In Process Research And Development Expense [Policy Text Block]",
        "terseLabel": "Asset Acquisitions and Acquired In-Process Research and Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r112",
      "r137",
      "r161",
      "r197",
      "r205",
      "r230",
      "r234",
      "r275",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r465",
      "r467",
      "r505",
      "r585",
      "r683",
      "r756",
      "r757",
      "r792",
      "r811",
      "r990",
      "r991",
      "r1049"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r142",
      "r161",
      "r275",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r465",
      "r467",
      "r505",
      "r792",
      "r990",
      "r991",
      "r1049"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r780"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r817",
      "r840"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r817",
      "r840"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r817",
      "r840"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r283",
      "r584"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Investments",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r283",
      "r481",
      "r578",
      "r780",
      "r783",
      "r965",
      "r1036",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r283"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "zbio_BasisOfPresentationAndConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "BasisOfPresentationAndConsolidationPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of presentation and consolidation.",
        "label": "Basis Of Presentation And Consolidation [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_BmsConvertiblePromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "BmsConvertiblePromissoryNotesMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the BMS convertible promissory notes payable.",
        "label": "BMS Convertible Promissory Notes [Member]",
        "terseLabel": "BMS Notes",
        "verboseLabel": "BMS Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying value",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r135",
      "r744"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Assets",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r97"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r77",
      "r158"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r77"
     ]
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Member]",
        "terseLabel": "Cash",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r138",
      "r139",
      "r140",
      "r161",
      "r186",
      "r187",
      "r189",
      "r191",
      "r199",
      "r200",
      "r275",
      "r312",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r339",
      "r340",
      "r344",
      "r347",
      "r355",
      "r505",
      "r640",
      "r641",
      "r642",
      "r643",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r671",
      "r692",
      "r714",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r926",
      "r948",
      "r957"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "zbio_CollaborativeArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "CollaborativeArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/a.",
        "label": "License and Collaboration Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable from development, regulatory, and sales milestone payments if certain milestones are successfully achieved.",
        "label": "Collaborative Arrangement, Development, Regulatory and Sales Milestone Payments, Receivable, Maximum",
        "terseLabel": "Maximum amount of payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Revenue",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r119",
      "r128"
     ]
    },
    "zbio_CollaborativeArrangementReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "CollaborativeArrangementReceivables",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable in the collaborative arrangement.",
        "label": "Collaborative Arrangement, Receivables",
        "terseLabel": "Amount receivable"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of payment receivable on achievement of certain regulatory and commercial milestones in the collaborative arrangement.",
        "label": "Collaborative Arrangement, Regulatory And Commercial Milestones, Maximum Payment Receivable On Achievement of Milestone",
        "terseLabel": "Maximum payment eligible to receive"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable from sales milestone payments if certain milestones are successfully achieved.",
        "label": "Collaborative Arrangement, Sales Milestone Payments, Receivable, Maximum",
        "terseLabel": "Sales milestone payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_CollaborativeArrangementTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "CollaborativeArrangementTransactionPrice",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of transaction price receivable under the collaborative agreement.",
        "label": "Collaborative Arrangement, Transaction Price",
        "terseLabel": "Agreement transaction price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "zbio_CollaborativeArrangementUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "CollaborativeArrangementUpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails",
      "http://zenasbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from upfront payment received pursuant to the agreement.",
        "label": "Collaborative Arrangement, Upfront Payment, Received",
        "terseLabel": "Amount of upfront cash payment received",
        "verboseLabel": "Non-refundable upfront fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails",
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Nature of Business",
        "verboseLabel": "Summary of Significant Accounting Policies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r311",
      "r805",
      "r806",
      "r807",
      "r808"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (Note 14)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r103",
      "r587",
      "r670"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r305",
      "r306",
      "r739",
      "r982",
      "r987"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://zenasbio.com/role/DisclosureCommonStockReservedForIssuanceDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of common stock remain available for future grant",
        "totalLabel": "Total",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r802",
      "r803",
      "r805",
      "r806",
      "r807",
      "r808",
      "r953",
      "r954",
      "r956",
      "r1032",
      "r1091",
      "r1094"
     ]
    },
    "zbio_CommonStockNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "CommonStockNumberOfVotesPerShare",
     "presentation": [
      "http://zenasbio.com/role/DisclosureCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes per share entitled to each holder of common stock.",
        "label": "Common Stock, Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://zenasbio.com/role/DisclosureCommonStockDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollar per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://zenasbio.com/role/DisclosureCommonStockDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r671"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r671",
      "r689",
      "r1094",
      "r1095"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.0001 per share; 175,000,000 shares authorized as of December 31, 2024 and 2023; 41,793,412 and 1,576,854 shares issued and outstanding as of December 31, 2024 and 2023, respectively.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r589",
      "r792"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r93"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r146",
      "r148",
      "r154",
      "r579",
      "r601",
      "r602"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r121"
     ]
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "BMS note",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible notes, at fair value",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r344",
      "r805",
      "r806",
      "r807",
      "r808"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preferred stock into common stock",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r60",
      "r87",
      "r350"
     ]
    },
    "zbio_ConvertiblePromissoryNotes2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ConvertiblePromissoryNotes2021Member",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to 2021 convertible promissory notes.",
        "label": "Convertible Promissory Notes 2021 [Member]",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r774",
      "r780",
      "r793",
      "r799",
      "r1087"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r324",
      "r342",
      "r538",
      "r559",
      "r583",
      "r745",
      "r747"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current income tax provision:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r951",
      "r1030"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current income tax provision",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r951"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r951",
      "r1030"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r914"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r914"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r916"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r916"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r918"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r916"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r909"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r910"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r910"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r908"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r908"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r908"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r911"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r824",
      "r913"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r824",
      "r913"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r914"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r917"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r915"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r912"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r52",
      "r53",
      "r100",
      "r102",
      "r168",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r790",
      "r949",
      "r983",
      "r984",
      "r985",
      "r1043",
      "r1045"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Face value of notes",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r514",
      "r515",
      "r766",
      "r767",
      "r790"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "verboseLabel": "Fair Value Measurements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r790",
      "r949",
      "r1043",
      "r1045"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r168",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r790",
      "r949",
      "r983",
      "r984",
      "r985",
      "r1043",
      "r1045"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r39",
      "r40",
      "r49",
      "r86",
      "r88",
      "r168",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r790",
      "r949",
      "r1043",
      "r1045"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsFairValueTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "terseLabel": "Realized gain (loss) recognized on the sale or maturity of available-for-sale",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of available-for-sale securities",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureOtherAssetsDetails",
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred offering costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r938"
     ]
    },
    "zbio_DeferredOfferingCostsIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "DeferredOfferingCostsIncludedInAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred offering costs included in accrued expenses.",
        "label": "Deferred Offering Costs Included In Accrued Expenses",
        "terseLabel": "Deferred offering costs in accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails",
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Capitalized research and development",
        "verboseLabel": "Capitalized costs",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "zbio_DeferredTaxAssetsMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "DeferredTaxAssetsMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from milestone payments.",
        "label": "Deferred Tax Assets, Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_DeferredTaxAssetsNetBeforeValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "DeferredTaxAssetsNetBeforeValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset, net of deferred tax liability, before allocation of valuation allowances attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net, Before Valuation Allowance",
        "totalLabel": "Net deferred tax asset before valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Net operating loss carryforwards, Federal",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Net operating loss carryforwards, Foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards, Foreign expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Net operating loss carryforwards, State",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Total deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "zbio_DeferredTaxLiabilitiesAmortizationAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "DeferredTaxLiabilitiesAmortizationAndOther",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from amortization and other.",
        "label": "Deferred Tax Liabilities, Amortization and Other",
        "negatedLabel": "Amortization and other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Onetime contribution",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r35"
     ]
    },
    "zbio_DianthusOptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "DianthusOptionAgreementMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Dianthus Option Agreement.",
        "label": "Dianthus Option Agreement [Member]",
        "terseLabel": "Dianthus Option Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_DianthusTherapeuticsincMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "DianthusTherapeuticsincMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Dianthus Therapeutics Inc.",
        "label": "Dianthus Therapeutics Inc [Member]",
        "terseLabel": "Dianthus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r383",
      "r411",
      "r412",
      "r414",
      "r776"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Preferred Stock",
        "terseLabel": "Dividends declared",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r89"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r816",
      "r817",
      "r840"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r816",
      "r817",
      "r840",
      "r883"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders - basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r184",
      "r186",
      "r189",
      "r190",
      "r191",
      "r196",
      "r460",
      "r463",
      "r478",
      "r479",
      "r580",
      "r603",
      "r748"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders - diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r186",
      "r189",
      "r190",
      "r191",
      "r196",
      "r460",
      "r463",
      "r478",
      "r479",
      "r580",
      "r603",
      "r748"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r193"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r192",
      "r194",
      "r195"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "verboseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r779"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r427",
      "r451",
      "r779"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r779",
      "r952",
      "r1023"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfAssets",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent",
        "terseLabel": "IP transfer",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign tax rate differential",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r431",
      "r779",
      "r952",
      "r1023"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other adjustments",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r952",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r779",
      "r952",
      "r1023"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research and development tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r952",
      "r1023",
      "r1025"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-Based Compensation Expense",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period over which unrecognized compensation cost is expected to be recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation cost",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested stock options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options to purchase common stock",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "zbio_EmployeeStockPurchasePlan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "EmployeeStockPurchasePlan2024Member",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2024 Employee Stock Purchase Plan .",
        "label": "Employee Stock Purchase Plan 2024 [Member]",
        "terseLabel": "2024 ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r130",
      "r150",
      "r151",
      "r152",
      "r169",
      "r170",
      "r171",
      "r173",
      "r178",
      "r180",
      "r182",
      "r198",
      "r276",
      "r277",
      "r298",
      "r356",
      "r449",
      "r450",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r516",
      "r518",
      "r531",
      "r599",
      "r628",
      "r629",
      "r630",
      "r649",
      "r714"
     ]
    },
    "zbio_EquityIncentivePlan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "EquityIncentivePlan2024Member",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2024 Equity Incentive Plan.",
        "label": "Equity Incentive Plan 2024 [Member]",
        "terseLabel": "2024 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage",
        "terseLabel": "Equity interest held (in percent)",
        "documentation": "Percentage of ownership of equity interest excluding interest in entity that is consolidated and equity method investee."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r844",
      "r854",
      "r887"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r841",
      "r851",
      "r884"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of fair value measurement",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r504",
      "r766",
      "r767"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "zbio_FairValueAdjustmentOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "FairValueAdjustmentOfConvertibleNotes",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of convertible notes.",
        "label": "Fair Value Adjustment of Convertible Notes",
        "negatedLabel": "Fair value adjustments to convertible notes",
        "terseLabel": "Change in fair value of BMS Note",
        "verboseLabel": "Change in fair value of convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r495",
      "r780"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r495",
      "r780"
     ]
    },
    "zbio_FairValueAssetsLevel1ToLevel2TransferAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "FairValueAssetsLevel1ToLevel2TransferAmount",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsFairValueTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfer, Amount",
        "terseLabel": "Assets - Transfer from level 1 to 2"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_FairValueAssetsLevel2ToLevel1TransferAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "FairValueAssetsLevel2ToLevel1TransferAmount",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsFairValueTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfer, Amount",
        "terseLabel": "Assets - Transfer from level 2 to 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r496",
      "r781"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r496",
      "r781"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r494",
      "r495",
      "r497",
      "r546",
      "r547",
      "r548",
      "r766",
      "r767",
      "r772",
      "r773",
      "r774",
      "r780",
      "r783"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r766",
      "r767"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r492",
      "r493",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r577",
      "r780",
      "r784"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r362",
      "r367",
      "r482",
      "r495",
      "r546",
      "r772",
      "r773",
      "r774",
      "r780"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r362",
      "r367",
      "r482",
      "r483",
      "r495",
      "r547",
      "r766",
      "r767",
      "r772",
      "r773",
      "r774",
      "r780"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r482",
      "r483",
      "r484",
      "r485",
      "r495",
      "r548",
      "r766",
      "r767",
      "r772",
      "r773",
      "r774",
      "r780",
      "r783"
     ]
    },
    "zbio_FairValueLiabilitiesLevel1ToLevel2TransferAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransferAmount",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsFairValueTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfer, Amount",
        "terseLabel": "Liabilities - Transfer from level 1 to 2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Changes in company's liabilities with significant unobservable inputs (Level 3 liabilities)",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of changes in the company's liabilities with significant unobservable inputs",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r491",
      "r496"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsFairValueTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "terseLabel": "Liabilities - Transfer into level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r496"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsFairValueTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Assets - Transfer into level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r496",
      "r781"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value of BMS Note",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r496"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Issuance of BMS Note",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r496"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Issuance of Series C Preferred Stock in exchange for BMS Note",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r496"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r496"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r494",
      "r495",
      "r497",
      "r546",
      "r547",
      "r548",
      "r766",
      "r767",
      "r772",
      "r773",
      "r774",
      "r780",
      "r783"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementChangesInLiabilitiesWithSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r496"
     ]
    },
    "zbio_FairmountFundsManagementLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "FairmountFundsManagementLlcMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to Fairmount Funds Management LLC.",
        "label": "Fairmount Funds Management LLC [Member]",
        "terseLabel": "Fairmount Funds Management LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r337",
      "r353",
      "r475",
      "r502",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r600",
      "r763",
      "r780",
      "r781",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r793",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r977",
      "r978",
      "r979",
      "r980",
      "r1033",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossAfterTax",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, after Tax",
        "negatedLabel": "Realized and unrealized foreign currency transaction losses",
        "documentation": "Amount, after tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1093",
      "r1096"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Translation of Foreign Currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r848",
      "r858",
      "r891"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r848",
      "r858",
      "r891"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r848",
      "r858",
      "r891"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r848",
      "r858",
      "r891"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r848",
      "r858",
      "r891"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "verboseLabel": "Gain (Loss) on extinguishment",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36",
      "r37"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "negatedLabel": "General and administrative",
        "terseLabel": "General and administrative (includes $0 and $8 from related parties, respectively)",
        "verboseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r694"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r82"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S.",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r426"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r107",
      "r111",
      "r581",
      "r597",
      "r750",
      "r756",
      "r959",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Non-U.S.",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r426"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r301",
      "r302",
      "r487",
      "r491",
      "r496",
      "r625",
      "r627",
      "r699",
      "r742",
      "r782",
      "r1060"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r487",
      "r491",
      "r496",
      "r625",
      "r627",
      "r699",
      "r742",
      "r782",
      "r1060"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r427",
      "r428",
      "r436",
      "r445",
      "r779",
      "r1027"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r427",
      "r428",
      "r436",
      "r445",
      "r779",
      "r1027"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r421",
      "r427",
      "r433",
      "r434",
      "r435",
      "r438",
      "r444",
      "r452",
      "r454",
      "r455",
      "r456",
      "r645",
      "r779"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax provision",
        "totalLabel": "Total income tax provision",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r126",
      "r181",
      "r182",
      "r197",
      "r213",
      "r234",
      "r425",
      "r427",
      "r453",
      "r605",
      "r779"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r423",
      "r424",
      "r438",
      "r439",
      "r443",
      "r447",
      "r639"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r946"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Changes in Stockholders' Equity (Deficit)",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Changes in Convertible Preferred Stock",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r848",
      "r858",
      "r882",
      "r891",
      "r895",
      "r903"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r907"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r907"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r907"
     ]
    },
    "zbio_InvestmentFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "InvestmentFairValueDisclosureAbstract",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Fair Value Disclosure [Abstract]",
        "terseLabel": "Investments:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Policy [Policy Text Block]",
        "verboseLabel": "Short-Term Investments",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r635",
      "r636",
      "r637",
      "r638",
      "r724",
      "r725"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of balance sheet information related to operating lease assets and liabilities",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "zbio_LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability, Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position and quantitative information pursuant to operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity And Quantitative Disclosure [Table Text Block]",
        "terseLabel": "Schedule of minimum lease payments under the Company's operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r161",
      "r275",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r466",
      "r467",
      "r468",
      "r505",
      "r669",
      "r749",
      "r811",
      "r990",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity (deficit)",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r104",
      "r593",
      "r792",
      "r950",
      "r981",
      "r1041"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r134",
      "r161",
      "r275",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r466",
      "r467",
      "r468",
      "r505",
      "r792",
      "r990",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r1034"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "zbio_LicenseAgreementWithBristolMyersSquibbMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "LicenseAgreementWithBristolMyersSquibbMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to license agreement with Bristol-Myers Squibb.",
        "label": "License Agreement With Bristol Myers Squibb [Member]",
        "terseLabel": "BMS Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_LicenseAndCollaborationRevenuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "LicenseAndCollaborationRevenuePolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for license and collaboration revenue.",
        "label": "License And Collaboration Revenue [Policy Text Block]",
        "terseLabel": "License and Collaboration Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_LicenseAndOptionAgreementDevelopmentMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "LicenseAndOptionAgreementDevelopmentMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development milestone payment incurred in connection with the agreement during the period.",
        "label": "License and Option Agreement, Development Milestone Payment",
        "terseLabel": "Development milestone expense"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_LicenseAndOptionAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "LicenseAndOptionAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "License and Option Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_LicenseAndOptionAgreementsDevelopmentMilestonePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "LicenseAndOptionAgreementsDevelopmentMilestonePayable",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development milestone payable in connection with the agreement during the period.",
        "label": "License and Option Agreements, Development Milestone Payable",
        "terseLabel": "Development milestone expense payable"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development, regulatory and commercial milestone payable in connection with the agreement during the period.",
        "label": "License and Option Agreements, Development, Regulatory and Commercial Milestone Payable",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_LicenseAndOptionAgreementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "LicenseAndOptionAgreementsDisclosureTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for license and option agreements.",
        "label": "License and Option Agreements, Disclosure [Text Block]",
        "terseLabel": "License and Option Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_LicenseAndOptionAgreementsMaximumMilestoneObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "LicenseAndOptionAgreementsMaximumMilestoneObligation",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of total milestone obligations for each research program based on achievement of each of the specified milestone events.",
        "label": "License and Option Agreements, Maximum Milestone Obligation",
        "terseLabel": "Milestone obligations"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_LicenseAndOptionAgreementsRegulatoryMilestonePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "LicenseAndOptionAgreementsRegulatoryMilestonePayable",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of regulatory milestone payable in connection with the agreement during the period.",
        "label": "License and Option Agreements, Regulatory Milestone Payable",
        "terseLabel": "Regulatory milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_LicenseAndOptionAgreementsReimbursableExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "LicenseAndOptionAgreementsReimbursableExpenses",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reimbursable expenses incurred pursuant to the agreement.",
        "label": "License and Option Agreements, Reimbursable Expenses",
        "terseLabel": "Reimbursable costs"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_LicenseAndOptionAgreementsSalesMilestonePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "LicenseAndOptionAgreementsSalesMilestonePayable",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sales milestone payable in connection with the agreement during the period.",
        "label": "License and Option Agreements, Sales Milestone Payable",
        "terseLabel": "Sales milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r378",
      "r417",
      "r485",
      "r575",
      "r624",
      "r626",
      "r634",
      "r661",
      "r662",
      "r722",
      "r726",
      "r729",
      "r730",
      "r731",
      "r740",
      "r741",
      "r762",
      "r770",
      "r775",
      "r783",
      "r784",
      "r788",
      "r789",
      "r795",
      "r992",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r378",
      "r417",
      "r485",
      "r575",
      "r624",
      "r626",
      "r634",
      "r661",
      "r662",
      "r722",
      "r726",
      "r729",
      "r730",
      "r731",
      "r740",
      "r741",
      "r762",
      "r770",
      "r775",
      "r783",
      "r784",
      "r788",
      "r795",
      "r992",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "zbio_MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum cash inflow required from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock for automatic conversion of the convertible promissory notes.",
        "label": "Minimum Proceeds from Issuance of Convertible Preferred Stock For Automatic Conversion Of Convertible Promissory Notes",
        "verboseLabel": "Minimum proceeds from issuance of convertible preferred stock for automatic conversion of convertible promissory notes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r127"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r79"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails",
      "http://zenasbio.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails",
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss to common stockholders",
        "verboseLabel": "Net loss to common stockholders",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r79",
      "r108",
      "r132",
      "r145",
      "r147",
      "r152",
      "r161",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r181",
      "r182",
      "r188",
      "r275",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r460",
      "r463",
      "r479",
      "r505",
      "r598",
      "r691",
      "r712",
      "r713",
      "r809",
      "r990"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "zbio_NonCashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "NonCashLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-cash lease expense.",
        "label": "Non-cash lease expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r848",
      "r858",
      "r882",
      "r891"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "zbio_NonRule10b51ArrangementModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "NonRule10b51ArrangementModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Non-Rule 10b5-1 Arrangement Modified [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income, net:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of RSA activity and related information",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_NotesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Assumed",
        "terseLabel": "Fair value of BMS Note recognized as Series C Convertible preferred stock upon conversion",
        "documentation": "The fair value of notes assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "zbio_NovationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "NovationAgreementMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Novation Agreement with Tenacia.",
        "label": "Novation Agreement [Member]",
        "terseLabel": "Novation Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_NumberOfAntibodyProductCandidates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "NumberOfAntibodyProductCandidates",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denotes number of antibody product candidates.",
        "label": "Number Of Antibody Product Candidates",
        "terseLabel": "Number of antibody product candidates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r960"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r960"
     ]
    },
    "zbio_NumberOfSeatsHeldInBoard": {
     "xbrltype": "integerItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "NumberOfSeatsHeldInBoard",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of seats held in the board of related entity.",
        "label": "Number of Seats Held in Board",
        "terseLabel": "Number of seats held in board"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_ObexelimabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ObexelimabMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Obexelimab.",
        "label": "Obexelimab [Member]",
        "terseLabel": "Obexelimab"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r750",
      "r959",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Total lease cost for operating leases",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r791"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Maturities of the operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesMaturitiesOfOperatingLeaseLiabilitiesAndQuantitativeDisclosureDetails",
      "http://zenasbio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeaseAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r525"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeaseAssetsAndLiabilitiesDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets, net",
        "verboseLabel": "Operating lease assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeaseAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate used to measure lease liabilities",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r791"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeaseAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining term in years",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r791"
     ]
    },
    "zbio_OperatingLossCarryforwardsExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "OperatingLossCarryforwardsExpirationPeriod",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration period of each operating loss carryforward included in operating loss carryforward.",
        "label": "Operating Loss Carryforwards, Expiration Period",
        "terseLabel": "NOL carryforward expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureOtherAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Disclosure [Text Block]",
        "terseLabel": "Other Assets",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "terseLabel": "Other",
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureOtherAssetsDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "totalLabel": "Total other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_OtherAssetsNoncurrentDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrentDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r9",
      "r96"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain on marketable securities, net tax",
        "verboseLabel": "Unrealized gain on investments",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r274"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "zbio_OtherProgramsZb002Zb004Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "OtherProgramsZb002Zb004Member",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Other Programs (ZB002 &amp; ZB004).",
        "label": "Other Programs (ZB002 &amp; ZB004) [Member]",
        "terseLabel": "Other programs (ZB002 &amp; ZB004)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r846",
      "r856",
      "r889"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r849",
      "r859",
      "r892"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r849",
      "r859",
      "r892"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriter's option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "zbio_OwnershipPercentageByRelatedParty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "OwnershipPercentageByRelatedParty",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of the entity's common stock by a related party.",
        "label": "Ownership Percentage by Related Party",
        "terseLabel": "Ownership percentage by related party"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_PartneredRegionalProgramsZb001Zb005Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "PartneredRegionalProgramsZb001Zb005Member",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Partnered regional programs (ZB001 &amp; ZB005).",
        "label": "Partnered Regional Programs (ZB001 &amp; ZB005) [Member]",
        "terseLabel": "Partnered regional programs (ZB001 &amp; ZB005)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock",
        "terseLabel": "Dividends paid",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of initial public offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchase of short-term investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureEmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r367",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r774"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "zbio_PercentageOfAnnualDeductionEqualToTaxableIncomeFederal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "PercentageOfAnnualDeductionEqualToTaxableIncomeFederal",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual deduction equal to annual taxable income on domestic  operating loss carryforwards .",
        "label": "Percentage Of Annual Deduction Equal To Taxable Income, Federal",
        "terseLabel": "Percentage of annual deduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "zbio_PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares issued upon conversion of convertible preferred stock.",
        "label": "Preferred Stock, Convertible, Aggregate Number Of Shares Issued Upon Conversion",
        "terseLabel": "Number of common shares issued upon conversion of convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Dividend rate, percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r723",
      "r727",
      "r728",
      "r732"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r802",
      "r805",
      "r806",
      "r807",
      "r808",
      "r1091",
      "r1094"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollar per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r339"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r671"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r339"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r671",
      "r689",
      "r1094",
      "r1095"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.0001 per share; 25,000,000 and no shares authorized as of December 31, 2024 and 2023, respectively; no shares issued and outstanding as of December 31, 2024 and 2023.",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r588",
      "r792"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Noncurrent",
        "verboseLabel": "Clinical trial deposits",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private financing",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from sale of convertible notes",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of underwriting discount and commissions",
        "verboseLabel": "Aggregate gross proceeds",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "zbio_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross proceeds from initial public offering before deduction of underwriter discounts and offering expenses.",
        "label": "Proceeds From Issuance Initial Public Offering, Before Deduction Of Underwriter Discounts And Offering Expenses",
        "terseLabel": "Gross proceeds from initial public offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Net cash proceeds from issuance",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of Series C convertible preferred stock, net of issuance costs",
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sale and maturities of short-term investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r576",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r743",
      "r771",
      "r794",
      "r795",
      "r796",
      "r798",
      "r800",
      "r988",
      "r989",
      "r994",
      "r1059",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1088",
      "r1089"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r576",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r743",
      "r771",
      "r794",
      "r795",
      "r796",
      "r798",
      "r800",
      "r988",
      "r989",
      "r994",
      "r1059",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r530",
      "r582",
      "r596",
      "r792"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r122",
      "r125",
      "r595"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r360",
      "r378",
      "r406",
      "r407",
      "r408",
      "r417",
      "r485",
      "r549",
      "r558",
      "r575",
      "r624",
      "r626",
      "r634",
      "r661",
      "r662",
      "r722",
      "r726",
      "r729",
      "r730",
      "r731",
      "r740",
      "r741",
      "r762",
      "r770",
      "r775",
      "r783",
      "r784",
      "r788",
      "r789",
      "r795",
      "r803",
      "r986",
      "r992",
      "r1037",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r360",
      "r378",
      "r406",
      "r407",
      "r408",
      "r417",
      "r485",
      "r549",
      "r558",
      "r575",
      "r624",
      "r626",
      "r634",
      "r661",
      "r662",
      "r722",
      "r726",
      "r729",
      "r730",
      "r731",
      "r740",
      "r741",
      "r762",
      "r770",
      "r775",
      "r783",
      "r784",
      "r788",
      "r789",
      "r795",
      "r803",
      "r986",
      "r992",
      "r1037",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "zbio_ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash And Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of financial data for reportable segments",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r841",
      "r851",
      "r884"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r369",
      "r535",
      "r536",
      "r586",
      "r594",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r688",
      "r690",
      "r721"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r535",
      "r536",
      "r537",
      "r538",
      "r586",
      "r594",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r688",
      "r690",
      "r721"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r536",
      "r1048"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transactions",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r695",
      "r696",
      "r699"
     ]
    },
    "zbio_RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained": {
     "xbrltype": "integerItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of antibody product candidates for which license has been obtained.",
        "label": "Related Party Transaction, Number of Antibody Product License Obtained",
        "terseLabel": "Number of antibody product candidates"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_RelatedPartyTransactionNumberOfLicenseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "RelatedPartyTransactionNumberOfLicenseAgreements",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of license agreements.",
        "label": "Related Party Transaction, Number of License Agreements",
        "terseLabel": "Number of license agreements"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_RelatedPartyTransactionReimbursableCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "RelatedPartyTransactionReimbursableCosts",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reimbursable costs incurred with the related party.",
        "label": "Related Party Transaction, Reimbursable Costs",
        "terseLabel": "Reimbursable costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r369",
      "r535",
      "r536",
      "r586",
      "r594",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r688",
      "r690",
      "r721",
      "r1048"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r534",
      "r536",
      "r539",
      "r646",
      "r647",
      "r648",
      "r697",
      "r698",
      "r699",
      "r718",
      "r720"
     ]
    },
    "zbio_RemainingCommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "RemainingCommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://zenasbio.com/role/DisclosureCommonStockReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining number of common stock reserved for future issuance.",
        "label": "Remaining Common Stock, Capital Shares, Reserved For Future Issuance",
        "terseLabel": "Remaining shares reserved for future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r324",
      "r342",
      "r538",
      "r559",
      "r583",
      "r746",
      "r747"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Capitalized Cost",
        "terseLabel": "Acquired in-process research and development",
        "verboseLabel": "Acquired IPR&amp;D expense",
        "documentation": "Amount of asset recognized from cost for research and development asset acquired in transaction other than business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development expenses",
        "terseLabel": "Research and development (includes $3,524 and $3,041 from related parties, respectively)",
        "verboseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r742",
      "r756",
      "r1057"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and development",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r842",
      "r852",
      "r885"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r843",
      "r853",
      "r886"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r860",
      "r893"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r947"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r938",
      "r947"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "RSA",
        "verboseLabel": "Unvested restricted stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r89",
      "r592",
      "r631",
      "r633",
      "r644",
      "r672",
      "r792"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r169",
      "r170",
      "r171",
      "r173",
      "r178",
      "r180",
      "r182",
      "r276",
      "r277",
      "r298",
      "r449",
      "r450",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r469",
      "r471",
      "r472",
      "r474",
      "r477",
      "r516",
      "r518",
      "r628",
      "r630",
      "r649",
      "r1094"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Amount of reduction to research and development expenses",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r1031"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "License and collaboration revenue",
        "verboseLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r197",
      "r206",
      "r207",
      "r228",
      "r234",
      "r238",
      "r240",
      "r241",
      "r357",
      "r358",
      "r576"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "terseLabel": "Revenue",
        "totalLabel": "Total revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r153",
      "r161",
      "r197",
      "r206",
      "r207",
      "r228",
      "r234",
      "r238",
      "r240",
      "r241",
      "r275",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r505",
      "r581",
      "r756",
      "r990"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained under operating lease arrangements",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r791"
     ]
    },
    "zbio_RightOfUseAssetObtainedUnderNewLeaseArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "RightOfUseAssetObtainedUnderNewLeaseArrangement",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained under new operating lease arrangement.",
        "label": "Right-of-Use Asset Obtained under New Lease Arrangement",
        "terseLabel": "Right-of-use assets obtained under new operating lease arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "zbio_Rule10b51ArrangementModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "Rule10b51ArrangementModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Rule 10b5-1 Arrangement Modified [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds",
        "verboseLabel": "Fair value of initial consideration",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive securities excluded from the computation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails",
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "zbio_ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of common stock reserved for potential conversion of securities and shares reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Potential Conversion Of Securities And Future Issuance [Tables Text Block]",
        "terseLabel": "Schedule of common stock reserved for potential conversion and future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of the income tax provision",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of components of the Company's deferred tax assets and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the income tax expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r779",
      "r1023"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense as reflected in condensed consolidated statements of operations and comprehensive loss",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of information about the Company's assets and liabilities that are regularly measured and carried at fair value",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of components of loss before the provision for (benefit from) income taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureOtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "terseLabel": "Summary of other assets",
        "documentation": "Tabular disclosure of noncurrent assets."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r695",
      "r696",
      "r699"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity and related information",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r92"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair values of stock options granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r197",
      "r202",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r241",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r303",
      "r304",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r753",
      "r756",
      "r757",
      "r764",
      "r797",
      "r1059",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r197",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r217",
      "r219",
      "r220",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r241",
      "r751",
      "r754",
      "r755",
      "r756",
      "r758",
      "r760",
      "r761"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r219",
      "r220",
      "r234",
      "r756"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r237",
      "r240",
      "r752",
      "r753",
      "r759"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Information",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A convertible preferred stock",
        "verboseLabel": "Series A preferred stock",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r940",
      "r993"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails",
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B convertible preferred stock",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r940",
      "r993"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C convertible preferred stock",
        "verboseLabel": "Series C Preferred Stock",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r940",
      "r993"
     ]
    },
    "zbio_SeriesSeedConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "SeriesSeedConvertiblePreferredStockMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series seed convertible preferred stock.",
        "label": "Series Seed Convertible Preferred Stock [Member]",
        "terseLabel": "Series Seed convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum additional number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement by Share-Based Payment Award, Additional shares authorized, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Maximum additional number of outstanding capital stock percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (years)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of RSAs granted (shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested as of ending (Shares)",
        "periodStartLabel": "Unvested as of beginning (Shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested as of ending ($ per share)",
        "periodStartLabel": "Unvested as of beginning ($ per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant-Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that repurchased during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Repurchased in Period",
        "negatedLabel": "Repurchased (shares)"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan repurchased during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Repurchased in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Repurchased ($ per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested ($ per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ]
    },
    "zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of additional shares to be authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Additional Shares To Be Authorized",
        "terseLabel": "Additional shares To Be authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized to issue under plan",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options vested and exercisable at end of year (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and exercisable at end of year (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or cancelled (in shares)",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or cancelled (in dollars per share)",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Balance outstanding at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://zenasbio.com/role/DisclosureCommonStockReservedForIssuanceDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance outstanding at end of year (in shares)",
        "periodStartLabel": "Balance outstanding at beginning of year (in shares)",
        "terseLabel": "Options to purchase common stock",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance outstanding at end of year (in dollars per share)",
        "periodStartLabel": "Balance outstanding at beginning of year (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted - Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (In years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest at end of year",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest end of year (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest at end of year (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding stock maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Issuance of common stock in period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails",
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting on the anniversary of the vesting commencement",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting in equal monthly installments over the subsequent thirty-six (36) months",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage (%)",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options vested and exercisable at end of year",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and exercisable at end of year (in years)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Balance outstanding at end of year (in years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest at end of year (in years)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of options vested during the period",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Public offering price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end (in shares)",
        "periodStartLabel": "Balance at beginning (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r941"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r159"
     ]
    },
    "zbio_SignificantSuppliersPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "SignificantSuppliersPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for significant suppliers.",
        "label": "Significant Suppliers [Policy Text Block]",
        "terseLabel": "Significant Suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_SingleReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "SingleReportableSegmentMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to single reportable segmentfocused on the research and development of precision immunology-based therapies.",
        "label": "Single Reportable Segment [Member]",
        "terseLabel": "Single Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r131",
      "r197",
      "r202",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r241",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r300",
      "r303",
      "r304",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r753",
      "r756",
      "r757",
      "r764",
      "r797",
      "r1059",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r138",
      "r139",
      "r140",
      "r161",
      "r186",
      "r187",
      "r189",
      "r191",
      "r199",
      "r200",
      "r275",
      "r312",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r339",
      "r340",
      "r344",
      "r347",
      "r355",
      "r505",
      "r640",
      "r641",
      "r642",
      "r643",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r671",
      "r692",
      "r714",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r926",
      "r948",
      "r957"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r64",
      "r65",
      "r130",
      "r150",
      "r151",
      "r152",
      "r169",
      "r170",
      "r171",
      "r173",
      "r178",
      "r180",
      "r182",
      "r198",
      "r276",
      "r277",
      "r298",
      "r356",
      "r449",
      "r450",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r516",
      "r518",
      "r531",
      "r599",
      "r628",
      "r629",
      "r630",
      "r649",
      "r714"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r198",
      "r518",
      "r576",
      "r635",
      "r660",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r671",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r690",
      "r693",
      "r694",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r714",
      "r804"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r198",
      "r242",
      "r518",
      "r576",
      "r635",
      "r660",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r671",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r690",
      "r693",
      "r694",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r714",
      "r804"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r845",
      "r855",
      "r888"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r39",
      "r61",
      "r64",
      "r89",
      "r331"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails",
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)",
        "verboseLabel": "Number of common stock issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r61",
      "r89",
      "r640",
      "r714",
      "r734"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercises of common stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r61",
      "r89",
      "r392"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r64",
      "r65",
      "r89"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r61",
      "r89",
      "r649",
      "r714",
      "r734",
      "r810"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercises of common stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r64",
      "r65",
      "r89"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of unvested restricted stock awards (in shares)",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r61",
      "r89",
      "r643",
      "r714",
      "r736"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance at end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total stockholders' equity (deficit)",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64",
      "r65",
      "r81",
      "r673",
      "r689",
      "r715",
      "r716",
      "r792",
      "r811",
      "r950",
      "r981",
      "r1041",
      "r1094"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Common Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r160",
      "r338",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r354",
      "r356",
      "r476",
      "r717",
      "r719",
      "r738"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent event",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r541"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails",
      "http://zenasbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r541"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r541"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails",
      "http://zenasbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r541"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails",
      "http://zenasbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r541"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r542"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "zbio_TaxCreditCarryforwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TaxCreditCarryforwardExpirationPeriod",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration period of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Income Taxes",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, by Class of Stock [Table]",
        "documentation": "Disclosure of information about equity instrument classified as temporary equity. Includes, but not is limited to, description of share, value, share authorized, issued, and outstanding, redemption price per share, and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r38"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balance at end",
        "periodStartLabel": "Balance at beginning",
        "terseLabel": "Convertible preferred stock",
        "verboseLabel": "Carrying Value",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r415",
      "r590"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests [Abstract]",
        "terseLabel": "Convertible preferred stock:"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_TemporaryEquityCommonStockIssuableUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TemporaryEquityCommonStockIssuableUponConversion",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of Convertible preferred stock classified as temporary equity.",
        "label": "Temporary Equity, Common Stock Issuable Upon Conversion",
        "terseLabel": "Common Stock Issuable Upon Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureCommonStockReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of Convertible preferred stock classified as temporary equity.",
        "label": "Temporary Equity, Common Stock Issuable Upon Conversion of Preferred stock",
        "terseLabel": "Conversion of outstanding shares of convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_TemporaryEquityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TemporaryEquityDisclosureTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of terms, amounts, nature of changes, rights and privileges, conversions and other matters related to temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity.",
        "label": "Temporary Equity Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Liquidation Preference",
        "verboseLabel": "Liquidation Value",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "zbio_TemporaryEquityNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TemporaryEquityNumberOfVotesPerShare",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockRightsAndPrivilegesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes per share entitled to each holder of convertible preferred stock.",
        "label": "Temporary Equity, Number of Votes per Share",
        "terseLabel": "Convertible preferred stock, number of votes per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r38"
     ]
    },
    "zbio_TemporaryEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TemporaryEquityPolicyTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for temporary equity.",
        "label": "Temporary Equity [Policy Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized",
        "verboseLabel": "Preferred Stock Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued",
        "verboseLabel": "Preferred Stock Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "zbio_TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of convertible preferred stock classified as temporary equity issued in connection with the development milestone payments.",
        "label": "Temporary Equity, Shares Issued During Period For Development Milestone Payment",
        "terseLabel": "Number of shares issued in pursuant to development milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_TemporaryEquitySharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TemporaryEquitySharesIssuedPricePerShare",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be received per share that is classified as temporary equity by entity upon sale of convertible preferred stock. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity.",
        "label": "Temporary Equity, Shares Issued, Price Per Share",
        "terseLabel": "Purchase price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockScheduleDetails",
      "http://zenasbio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at beginning (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "verboseLabel": "Preferred Stock Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversion",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares converted from temporary equity to permanent equity.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Conversion",
        "negatedLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of convertible preferred stock classified as temporary equity issued upon conversion of convertible notes during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Number of shares issued upon conversion of convertible notes",
        "verboseLabel": "Number of shares issued on conversion"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of convertible preferred stock (in shares)",
        "verboseLabel": "Number of preferred stock issued"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of convertible preferred stock classified as temporary equity issued upon exercise of warrants during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Warrant Exercises",
        "terseLabel": "Number of shares issued upon exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_TemporaryEquityStockIssuedDuringPeriodValueConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversion",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of conversion of securities from temporary equity to permanent equity.",
        "label": "Temporary Equity, Stock Issued During Period, Value, Conversion",
        "negatedLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of convertible preferred stock",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of convertible preferred stock",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r38"
     ]
    },
    "zbio_ThresholdPeriodToNotifyIntentionForExercisingOption": {
     "xbrltype": "durationItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ThresholdPeriodToNotifyIntentionForExercisingOption",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denotes threshold period to notify intention for exercising option.",
        "label": "Threshold Period To Notify Intention For Exercising Option",
        "terseLabel": "Threshold period to notify intention for exercising option"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://zenasbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r337",
      "r353",
      "r475",
      "r502",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r600",
      "r780",
      "r781",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r793",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r977",
      "r978",
      "r979",
      "r980",
      "r1033",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "zbio_TwoThousandTwentyPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "TwoThousandTwentyPlanMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2020 Plan.",
        "label": "Two Thousand Twenty Plan [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndCollaborationRevenueDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/DisclosureSubsequentEventsDetails",
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsAvailableForSaleSecuritiesDetails",
      "http://zenasbio.com/role/DisclosureFairValueMeasurementsValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "Government securities",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "zbio_UnallocatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "UnallocatedMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to unallocated products or services.",
        "label": "Unallocated [Member]",
        "terseLabel": "Unallocated"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_UncertainTaxPositionsAmountRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "UncertainTaxPositionsAmountRecognized",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertain tax positions.",
        "label": "Uncertain Tax Positions, Amount Recognized",
        "terseLabel": "Amount recognized for uncertain tax positions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails",
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r437",
      "r778"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r118",
      "r120",
      "r123",
      "r124"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r791"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://zenasbio.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021"
     ]
    },
    "zbio_ViridianAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ViridianAgreementMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Viridian Agreement.",
        "label": "Viridian Agreement [Member]",
        "terseLabel": "Viridian Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_ViridianTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ViridianTherapeuticsIncMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Viridian Therapeutics, Inc.",
        "label": "Viridian Therapeutics, Inc [Member]",
        "terseLabel": "Viridian"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common stock outstanding - diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r191"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://zenasbio.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails",
      "http://zenasbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common stock outstanding - basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r191"
     ]
    },
    "zbio_XencorAgreement2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "XencorAgreement2020Member",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2020 Xencor Agreement.",
        "label": "Xencor Agreement 2020 [Member]",
        "terseLabel": "2020 Xencor Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_XencorAgreement2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "XencorAgreement2021Member",
     "presentation": [
      "http://zenasbio.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://zenasbio.com/role/DisclosureLicenseAndOptionAgreementsDetails",
      "http://zenasbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2021 Xencor Agreement.",
        "label": "Xencor Agreement 2021 [Member]",
        "terseLabel": "2021 Xencor Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "zbio_XencorIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "XencorIncMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Xencor, Inc.",
        "label": "Xencor, Inc [Member]",
        "terseLabel": "Xencor"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "zbio_ZaiLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zenasbio.com/20241231",
     "localname": "ZaiLicenseAgreementMember",
     "presentation": [
      "http://zenasbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Zai License Agreement.",
        "label": "Zai License Agreement [Member]",
        "terseLabel": "Zai license agreement"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-38"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>117
<FILENAME>0001558370-25-002631-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-002631-xbrl.zip
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M["%K#=DM59%D?I1MV#\2&=3N!;;G8 >WU"_7@JO#4].BTJ:;%-;#WAKV? =
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MCLJHE%\6Z9%I=IY5 U)(L^%0_[1'K_WV6_[5@-C(;1BU/$C: ^?B!JB#:IO
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M#VXJ3F+H#;MDDTYM-9;=\K^5GK(-RL_03YE!U^PDWX^,J.0DO*6*$NDOC*X
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M*ME3\BOK6Q[+97NR.>=+BB(AB;L4H0"DQ\JOOP"I!TGAR1=:-JMV)Y:$1[\
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M7V/,5'CRS-\$NHE7:<)^9M9O&(590%41&;/+^I:GT].[@PE;W!NDTB.Z]>\
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M.<:KJG?V3N%//HX3IDE>15G37][1W!FX_SW"% 6_O$M(VKMRE5]B:=P+U48
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M%_Z.<AK2!:?&9,:I(SD(#/H!<%1:G @&"'6]?O=NU>"?:9ZB4Y(@Z;YNV!'
M R"FZ\T0(Q=NW]O09S86XLF'^Q<J</R GE&<(FM_[P^'[S=L9AAY<3 JS3':
M3 +?RSL\<&X>9KL>'C@W>_570X7A@7-7;B2E"$-[X'R[?V^?]?Y'F"S.24@3
M''U9,[WMD6EXTZG<^6W7'X!3J>DSZ'8(=\"Q._R<'7\[".3,D38%X)YHR@<I
M;L-#R<-#R1T=OKT[-"5;@ RCKRM&XSBY]];\TP/R$?N]^K)BK1$ ;!A="4PM
M>G1M_,K@*;SC^(#F/$(,DS4/Z_<B1+^$[)\$QV@#+LWAY;*[>4S>1A0:3P7
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M,>1*#+D20ZY$OY?.0Z[$D"O1J79RH*T.,3:=Q]ATXXT>I\F"&09_V7FDB[T
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M38R:U8IN=:Y^=[V;F$DF$T6F"_/5<KL!45%%6MD#8$WI#@2AN"<IR>'T0)-
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MI>B"7PR0)&12?L]&1(1L+JZ4-I&V%P SUE2,B\S2XN7:]9"0D,?_Z#DD:0M
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MQJ'L"0$0!?-?J/^X8R*MV;3$>:2?COL-C6^V9^5(VT;HOC1P![Z1160XZ$4
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MN$WN,9Q7&JGL#U0SZFUIGP\R,/*<.;8VNQ0 U;W=U]D/=^AJ:U[;_&OOA#>
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M$-,=U+5^HN(II#XGBCVZXQQY3.U0?R1!IR_>*6MO#0:\%E(R(H(3NKFJ)6O
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MNX?6W!3\UORMV!-8?W5B8:6; Z]9!YE$7- U@\F]^%W/@^V1F.!&JFELVGQ
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MC.^UV75F+;9>2:DXG&"&B_;TZCFE80*GDA_\1'4H-QOSA:#[+-^@$=HGY;P
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MEJP='Z_DL^45*>U</CY0732!.*24Q\; @,"*G\;T0A1)Z>P_'L< 85\:GKV
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M9:'?%(;-[2%*:Y!74(7BK/;$?"BXZ3;+ILTL=_[C+DTZ:_9/Q6L!N#B5A<\
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M:8QI(;59&RA1FAP<0QJ1PQ!;9&=X9?<5KA\C''9WM#=@'L!TI7ZS/D%X_XG
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M6^=PF/5LYPZ\1Z\8@B2/U8?E>AB"AP"^6@@)'@:*-%%$]%)#@K66UJPG05L
M.0;7=S]X#P'\P!@]^NLX0K\.?!O5(BKG=GZ1^"G]^=@;*KV\4.H^BZVH/756
MMJ?RJ6R5-Z)ZR6D[I&E5V45^JXE=7;7Y04 ?+-NH@= Z!RS8RWHK.@6<EZ>
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M3J%0[GZE"0EO-MN__KL+(+8 -E_Q^L]PO.&KK"Q].B$#@WSB*!G!K/QJ4P:
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ME^<3E::&RFC(X@*9YO%31&#KQ\A%@&UI_57/%D6QD$.2E?Y/@'D/G"GJG[4
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MM-_X_DHN>S2\#.C[_NIR\&OXOM?8CA \W/LK\L>P2;95H'$WM)+(7UX0#;R
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M"[J\'B-F*?Z:2=>QU48?QTLPL0N1 89;NTX=1V%/H[ #-2EUQ28[2UNM/E\
M?B^*?GX;^"2<0FQY. H8)3;'P+TQ9ISQWJ*IB+>!.[#W>G#?I8%[PEK"^NU)
M4;\GZ"_C0<:3BC2G+%X**,C MZ M4*4;YC14I4<I;=Z3XP#L<P#*4I"!5W$M
M4!6VR?L>E_(Z>!RN?0[7CO6FU!U?]QN_Z6(!R?N91X2-ZX>NG83V[&>C5_-U
M50:6MAN[)OA*.O)7:1F3 V81P^XOSXK?4V4LJ$#13N_(.& _2/=&4>\:DBRU
MES'#\^FB'G'6U8OC\!E> P;NF<Q;;(ZC99#%ICA$VFY(5'/!D'-@4\2OAR.\
MO0\>!TKM0.D/=P.OH#J]%*<H>3!?"DI_CF.LR\5(KEH,.SRHC@E%Q)<0FHO>
MCBJ4[_]=L!2DCIYUW"_,R"_OT.#>9G7J)7IB;2\.=P0H@+-2SF_R<D0 ^.':
MH!K@I\#_2%9"C&5(SB_RO\?IAIZ"Z#]!] +L8.&[?P(G/R%11DTOWR[J\&Q\
M/=;T)87H6!D.W72$7!U'"!/'9!)Z"&#Z(UR.MDGOMQ/',3,<S.G@N39C\,CQ
M9\@6[.W"W*W;2_ES!SL@>@4TNSD<&Y;_M/13?)K@AZ!!0M1ST82H5;]*/W_,
MD=HD=>;Y<#E2N5:GJ4>Z@?XVF^^O/T0VOGRI$K]5'.OGXZN387>K[0E0,4_V
M!IS."0D??31QHID2P8PQ_9IBP,BJRJBA&JWZHT"9?J(P&4@B9AI59AW5B"2J
M3&XZ,,35F1 O2$,(W>74=^[ !_""-18Z-7*8"4\Y:FI"#H9JR_1H*K;VV4Q_
M!3Z EH?DGCHKUW?QBAZY'X"'*UQU361+<\&U3R4J9R'_6I,*5_)75./@D'91
M']!JS_)4?N!4PY..<PIY^2JKQLD^>%%F8PNL>GF_W-')V!- "T\8(N RN5T;
MFQZN%R,LA _!3L:3_4,P](41_L0(?6-$/H)^2+XSLGQGY"1?4O^\Z]Z"^"G>
M%JJ:DRQ:\=]Z=UI%"DA,#:R%Z0<"&4_2;P&B]RH]!%T&'J)PF&J]1K+&[14'
MS\7XZFK8:"<L%94G"+EBFQ7SH( -#VU4HX)<Y=:0IU-"X O/X0FQY[V39(29
MS<DP*WB2LJ<:T694HY78#"-%6K/>)?%"0NR)EB0B;:C&("F<:$XU.B9F+6 4
M/-+)O@2+&--HK1PVUX10,6M6VU\66+-79=D#80Z_[$K%/I'.CW2H<#(D+7V@
M'&%)W\LSNWX.:J9^Y!)1W0_P"NP8]<$%88/SFA.N\QK\N2].^KW1[H.'<VQS
M.IQK$0;?*>GZ_M/V8J36!S3*\$EE'*7'H?LB\/D4R?A(<=!=CJ].A\U,SU(F
MRTVH,RQTOLEO"<K-IKH!AG]1AU]4C:D]<*_BRJ-G?,UC_Y.U DS?IKIJJO&P
M;TKPDK(&,9V9=8M?K,#(1>/V.>LM.7!F>KS4U-*#5S5:+9.CB=3:.T:] &2U
MN#C 03TM*LL:2@9^626='B'JO0=#>SOMWG<RB4 M;R@9Q.25=%PT)"%:KM1U
M?F^RFE>-;CH:VFPP]7=Q:X?.=!7$/NTX1TK;1=BOQE>3$P6G3$ETDLY>!H8Z
M.\XE[AQOUB<(L?B!C]^AS>;XY/0&S .(#-3@PPU1ZP\!O $^F+L1QBI73_BT
M]K3L79<T-R+MH7_NNC(*YB,/'^.^D]Z,HB5 X*1=&J$?C?[RGO1JA-GUOT9N
MTE)$6E+^6'<+XPZ-FI-=1HW^??)VSD#)^$%#S(_1J)FM09I0."%1GBWH+V%$
MO2=LT:)J\UN-ILHSE&S9S?)M:( .FK* NV _V&O2X"$RC26Z66X-#<"Y_T1@
M(Q1<WX(;8I0\!>BW?H3D\I(HPP#1@CVG=_+%0Z1J*VQDN6 P'5C[->:V/][:
M<@U,MM(%.]-DPV;:SA++66P'9I'U?MU^&T,\!!^ @Q]4DE>94]_!CS(]U,/T
M^4]JQ]?(U:0IG::;RMMS:4*;97P582DAP<6@4BW5R")-]W6TXD/"2 :Q467S
MB%VWB.'U^.ILV%QEW;.I 1YF6>HI#MM)7H1,E$J'QR(1('HQCOLW];AXHPEA
MA"V>!OIO/7T,O#G"+^U]V_7<]*Q_'X(&VZ/3FNU1\9,56R2@2\!$N1NDL]X]
M$.9S8.,[H&VO7M"<6E3/-#_?QJ@/FT)AFJ]"^Y9UFDS.*OT7.L+ +%N8!Z7"
M4I^;NUJ0C];D0;!.2'BSS&0>>&Z7.-KRHW^7RH<*3<,01"&.I;P-5?/#\NTV
MTY_ 5PZ"E&WQ,.R]( =B"/UU$+J)W99@U8*/%:T=!.]XY38KH1\/,NB'MT@L
M-PJS")8MZ%5N+(?R^1C]S]!9E3IA%Z?8;5/572?D\DEJO')6527IE=ZB%TK<
MN:@B5I2+A6],MKJF#X)ZC4 P*UL=#TRS: G@U/GO.(Q(X/D6M-MOZB!HQB6T
M84G<*F&I\L<0(E-5 X92B%M46;G-%')!P7^W_,UK::.#=^2N]8X&5J/ #Z?C
M,V&_E+0O_S,<.6EOR &L1?I#@GEZNQX=VGEL[ZEG\BPILZ/&0X6GKDZS267>
ME^92FG5J6I(]G4;]!?8.O+4@W,P#2/+E4?@BT()JK&E.@C*AVL)@.*T>_6<8
MV"#<[EZ+.2QXN573S$$1K D69IW!ER#9'I(4QEO-H9-@*T5<)^/+*X,YU@ *
MLX[/JQ#)?I8Z-F TX ? 5O?4MF%L>2'Y+\@;X0+<:]+\H9%2&D9*'<;_B?9_
MA(*3D],)H2'^21F ;ZX'P@CAF^4XW&,79RT32=-&]+9GY]K-7+?YI"F^DSJI
MA=593G#FE.:SF/"G3"1G[WB9=0A?WF+A$V/N;2DN?%"LHDMLUBEZ2?!?(3W5
M2'7A@^(%7>)>#LF'/@7-F83-CD(K&E"-/[+.0WE%5>I<H=Z,SHNU"F#D_IDM
MM%5+BF!MU;C04K5TV[H)#FV/.57S3ZF&HW[MT6_O+LZ7!F+W\A9&]G;\"41)
MN(1:MU[A^D603A!(IV9P0PX29CV=:^XF+N;J;!:3VF+0]@10X14IP2$'*1I?
MO PJUCH\]G#(+^N\<&"7H@;^0>=,_Z #\^ZYZ'N$5U[*L3*YT"NH-JYK<"Z/
M6T'1=$X&4"DJ(T4*M;QJ2A?4(2<)J)(:QX':3",UM8HHG8ZOQL.&#!)3)R<=
M:L35F129.T9=]H=<(2U47J.RLN(Y9-0^X\=VA9S&T9+8BHPEH+JP%LH7F?\%
MQ)1TP#3(."^+R9SU:<554[^ ]GA4;^@DGP6EOL41\^&&.==7EE5?[4)S/;^,
MVD_YA2@;_R>&;NBX-A:"28*:6H;1H8FTVF='J5PXO]9D[V%74HT6W>P-V>)V
MX,'<+R_*)]_[QYM9C!1F@AS19K3@#EOU9?Y( >'XN(?GRD'H08LA])("0B<Y
M#%4B&/TM74WFFP8M%1$^&U]=#1NKJ!N:-<3!\,<]=%0*]F5[LA6:.W3&U8.A
MPRN=9P!MK*@%R1_IQY9W!YR8[$'N_T#_>@L0%-AP378Z:;C.*@>A9BT9Q2+9
M.)CUM*?Z@H1ERC-J&,6;IO(J]5"&,L'0)]#[S[6;Q+Y!0\8-G*I)A;^V4820
M(;M2KV4HY*@$B8<77!7-HT1SL66]D5%C*1$PT]B)'\4;,HI4DF%(279]<"1[
M"J+7^/V_@1V]!;OAV)YSU>T>.@4%4,F.,,=F4/*[#X$=+'SW3P)4]KZ:0C1*
MZ2)0Y^/+ZVO]Z2,B:T8*0PZV,Y_O#9J:O_LV@)'EXL#+SVE8[S#-[D1A"6]U
M(VG32OB,1TJ_'ZV4*ME3OFQ'3)6)S571*%*T%#NC0[?'S!V]K+A?K;U@ [*4
M7\^>Y8L_L3@?3_:?6&3MCM*&1Z1E]1];[$4R>0&1"P&^RN)^?"'0PF]#V+9H
M4#@X#C%TWV.R>42*P2%9J+."4-WB"+E (V0RZ,0@J(U*^[2AU+U<HW<T+;P
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M6TJ(1,+A),^' ,.SH4@21D, L/$0$)(#2"<9$..C3ALC"ZT56B_5O+7-T!
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MF$,AAD6\Y$,'G'7%X7K$.?2-N1IO9&0\]+*/@U1'FI3FK<9 DN HU8_@\3I
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M[V:+?K%P"C[>NFS'BN%@+%NSUDE'BN QS-D1,UJ>1!X>\_D+0QNVYM=K5I8
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MX3X6<#L(E*Y'N7DGVTYPRTQ^IBL*4VS%YY>%M?3.99L]]NK,<)FQ.#LY3]9
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M6FI2ZC<6L!?J]Z3TI0FP*WE\)?(XK+]]+'D\MOE0QN@70I.8872Z^?ZLQX/
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MZ,!>K&4KT6&Y?@%WG0+$UC\P@/8$MF[E>5KH+#+)22GYF)@GE_!)AQ=/VY_
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M@/ U1>Q@9"FCE=:)<4TT*6?B7C9?DA;,/!X@B%VBE]:S<0Q_?]/X+]0@&B!
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M=/5_"MZY&W=J-LY:E$^1LN[D"RGKC+@627NDTGMS_'/7XGC< QY@4>3$2:5
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M$^1JIS(VU:(I,]W1.==\0$O9J'1V@FM##S!0(R,J%\. H>1-=-Z>\:\U&%%
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M^WLA_L\A_\_Q'E_T\].K_DGG[/)C<"[[>6J0T1XT0T*\DC&$ZPV>T'#5DHF
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MFKV^'N?!X9?H"401(BR2NH*O[-,7QG:*E/(VJV:#N/#VBU9!5TZ'CQD;JMA
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M<Q@#&O'*1[*ZI1&"*$"I)L&KT7*"B/@JN&,P.1TL9C?1R  O#&T77@/<;G3
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M>1$;BKP[\MJ)3B 588;%/1HMLV6$7*?[[O*"E1GB3?$XW5P'!N9 [BFHI45
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MZ6M:5FAB4PIKRFSH^;#",XE!+0.%& 6*S5DN(FZ#<YCFP0G-;]O 3HW@>ME
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M F*P3UDVQK60!SR'W -O<?Q-,H=QQX#YL-O(%"^[[DH2'I,Y83!A(3X6%T[
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M][K[S]V4@G:#2H["G,K6U;I_LH '<' HR8+C?O?P1UHX7&M:].-]_;?GB%A
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MC\B>61(3T6N#Q/2BT"9,^D@]1O_^_5_<4X++W[D'[$J9M]SL8KN3.:R5-\B
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M/AI_\_0QN4.T2CQA(!?0O)S^=02W2<V:LW4U_6!IN7E6U!%Z\N^/_G+X*)@
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MW9V -CGJ9#L22G.=T12GENX+\A<#)OW3G,HFJG,2V=1(3CXDFJEDSCF7LT6
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MK3F[W=)Q9%ON!.6:I(]=]R37J,>OXSCTG)>N3BO:CF*MJZ"=L_F^)&]55,)
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MA?:$N3(Z,MJ(X4D2&>'D1$CS#L:#=^&$]Z=A;^FYCE)BZ5WD95[OM/3ZK3*
M>A?LX":&WSKFF^#N)$+"*?1Q!V17H]%&48+%($#L=E(4:*IYJHV>TKIP224@
ME+U$8^34=%1,K893Z(OT9S)##D=OK'^6+<PP<8U;FDZ6&PRB$BKP5>>KNG#)
M=-8F"XQ9< )<#(QV++3FUC:N\]ZOZA3OBUJ^QD/\9/@0<UQGG7W(^93.VUKR
MO7;R1/ 9B'Z%&)@G:,[QFRY2/T&_VN/6AD32\\U@6 10,SY=PB*I*/F^]D!G
M+#UW8QHYN/A7=KW!-<+WADMPD53J$*\(92^2Z/* NIH@1I:LD9UB;P#,2/M<
M:0)4XTH<IPY !4]OS\F.EC4*?7&*A:,;G)>"%@&!M5BBP*$LJU/3RJ/+ZCI\
M@G2#P RD?U$6Z#6?"2&[C3R4(R?;2SY 7M=6LS]2H/VJN$*9P%C1]G@?[)JQ
M[!&,H&YB.3(_F^:+FHY3.E#\\M20O)[+ )W8(60^U7R<2502%0TBA<BJ,K)K
M_#!+&4 ,)_\GK',Z*34%(=:B!P)9V8I$2K$;6;C<$-KSU.GN2@FAZQC2ZUY,
M[G K=\,0J8*>3TXL)FG;;B3P##N;UC^Y?8Z1RX[\T4#G!6X]G)@ SJ1)B%0]
M[=]K6J/DA+O5A,\%YQCBC#D?PXUC?*K!>GH!9V^FMB96@2%@_>,+'Z*)P*MP
MA>W>Q&%-:#GFQ=JZCXBC$%*K&B2?3O,%)PQ=76N2(W25;OG'O)Z2Q3^:M3#]
M281R#X-">BANL!0(:7!V:"U#:S,#].$YLSJ[ELK:A#G'AG^'C/36 "[ 5@4X
MBH6W.I#8+P--6""*TKW" 2"&T@^]]!ZS]/1+4B(A;%-P4[%+5(XTZ^[K!C %
MI/X7.3Z:E:6DRSW* )1?-3XH>7LS;'7LNQ$*@?[!P6E$->>2E95.ID&;<E*7
M?PHV]95@L@VX)R="TNVNL%19<^FGOQ4#T2&%4_V__R1!NBKH OW;@^(_@S_+
M%V#37ES@<L^2%GRPWQTQ9)*"1Y;9MF&QT7JVC//[TYI!2'H\.>/.62.;=G^>
M] 5)Y%1R-V-/X.P&\$2 AS"T(:XG:M2FEW0&!:$04N3,4LV;8HB+9.>LA=VC
M;TA[+W( CSS&V:OEX%LT,4_N;7Y+),O.AI8LZ7@8W,>#8BBAJZ>3JG<G!/-,
M"_]Z@8D=RZ;3052CO&E&D7E'PQN&Z [HB3"Y.T5!U*ZM89(,E3K"J#"L"0[3
M+@D*=$AM= Q+4S0P8:3[!%H"-MQ8A>Y%62O60Y8'[SZ4_H1.5M;F8N8NDCKM
M1B-/5C?0&A<G4B0@^"W#]\D2_R4.?D:= ]#@>,#P'DL6$>--S,%QPG(C3682
MX%]8A+ /%2W4A;TS3*2CMPWQW%UR6 @*%,K*?L\M^XS)<O#Z2:KF@*LQ&+^[
M9*ZBO+L_=!'QSC:7@F>XOKX^M-RL $0/293&/:! PXX!8! C-)C$WL< P,]F
M29\HR$A >=*YY.[.RXN(<O?%\JQV/9?_V+2 .ABP"T<56^9MJ2V,25/E^3KA
MM,8E:<= 8")FT2EH1+V($  9*E<86[LP0%OHM^J!C!,[0: %21G.FYR]!68)
M4 'BI719[KPQD!HVS3X/G+*Y)YF?YB:4&CGCN[F4!&A7PH*G2()_F>N)GG'K
M,7L*5LBY0N OF2K_4_=%'N_ F@&XO(Q,%*&2T'(+N@[6\=3^KMWH/A=Q?3Q(
M&?<'5CL?5Z51JG8H"%21A&Z:<O.B_=2"GBZN&% BVHG'EZKY**2@!)>PZ^FI
M=,]KR?H@N2MF+W=^^D![50!-9RO+QVGC6@GYRTOQ#2._FV3KZ67>=&.C'&48
MA%VFTU6A"0Q]OM28K_E;\>Z%;AZ%BQYXS EJ!UQ\([;#B[8Q.5%BM4#T^:1V
M2.\#;*4'+.>XRQ(]>VN)'V<)M( T=<5A&*M63Y"#;+D5E0'M->I3D.5\F2_F
M(VGB^]S[)P*+9,ZB4'V#$%#T@Q5S)&LR2-D8ZV*B(#6>B%3!M.'A&'^(%Y0^
M)F)0KV(]:(4."IHUS8CC$:VV@^)Q7T^^"PKQ> ^%V$,A_L10B#LP1CWW:V#.
MM+O.M.( !;-:_L%S,A? PFU0F^@#.,J7L(UH<!+]M-B#I#!2M1A(:9-(WZ+X
MD+NNA-=,K9NMM?\56XX"@>=@4]'DW&9Q+H#+-QE7OBP\\#I]*2:@?"H+I202
MHBDU!I* ZUA!WQ;J<Z'0W?Q17X\M^"X.[L@1 (HQ?Y>%%-XKO5TDL<MD,,@N
M+@%=LZ2VW,/C6#-[ _?X.*UO-_+QI ?K(K_*0O&,42G<A@R!]\#QKP]T?_-G
ML,O%'NN\7=+=U01VEU$*()A@8:D!?"V8/5 7"$/5 $HM'R 7M5U.D%2C\2[H
M<)5"@J9-8E.**#$50R</^.5)V")"RC%Q-BF-2@B1MC*_R$)P.EM.BHL6(4D5
ME*3,4';K*@_15]) ,8_5Y[$?1U<Q[DJ,$".AJ@50B:&MCL6NG@YLBBM3AO9W
M",&ZP?R>"4,@1G9"QZ2"KWA_:6BT2%9P907\31*[6B&=E>2+$PM5&6C-M9>Z
MH[GW_VT[[/D2#PBYENCO6VM6_)5#\:%A^QSU,\<:?\@_PL(/V ^N@[ 85:A4
M"0E0F723,TWN./2^SMQS8IK)SPR32NX,Z4E=KQ"\LMH9FU^FPY#:51UHLT0]
MQP3=<EDAW'E-&=>R_R5A\TCC--TU\"G)TL6+6=NS;V:X&TN+8_NDED23:W-)
M[82B(GX%<F.;$(=&C+L!"T)XGKZ="^S7(AUV>GR[24@G/K^.XGEEU9*'HQ.M
M3XDSQ/2EZ)^'J/1G<ZV^->7)V)U&)GPPH\]=VHS[*W0X>A_*J2^J<*U4**N'
MZX6X#I\BQ^<@R47F7XXOQ="08R)?=WW9.(D4=Q:FS4PK%[5JLXKK4*R;[N9(
MOD5+JI,]%4@4#F.X,@*MHZB8IO@8QJ&9ZZ+B8,".=3 1FU6YE!R)3R.A1 R0
M)\R+-)*.R7Q$PPCY&M'70"<%M6$,'19'D:"?RU*11-!9D SP9*.%G'S=Z?BC
M/95T"$');E8'^U)T8OXQ6S(^9>#5H5EU.A,;DA^$U/7H(A9![\:!0<_.T\67
MJ_X:.60-)#9^[$:6E"TV32$/<+/AL\+KG^?+AD$6OV#N5DQ]YY'I8MTDLID$
M6<0 G@LR(?![\NZ5=$DLAGJ7^];E_M>\$MHN;#0KH#=@6$>^(=Q.6EOL2/[T
MWNDQ3Y-D6_!G//P)X6DB"R=?2(HE5IMJ:6E"4<2&4I'I[:6I7%9MG.T(7U%<
M$I-C1PBEV:TF'Q'=J*>;X_=!&W?T.6E9P HF>;Q^)07-1"S,<F2L$8U F<I-
M/-I6%XPXARFT]/6-7>X#!-Z O13K@#-JY"KN?G^:@0(U0*67&7<L!O:JN=NR
M[+=R==$]5C3.D@J76.2F'+I(V4:8JB'<HT1+":<[" A7Y;BK<8QQDO;[77CK
M_'-[7-!)D7+-(9"3V=IL.S:@5(M7D]PTI-*$1M??E_#D=Z&F2/RZ@<\DI(I#
MS+9Q[BSCM9G_62=&&R_.). @/ <^.CL.'AQ^Y&BVT!1?YG1T<)TUCJLDJ2VP
M/CE]/):QS<TZ-KTWZ=EB$14^.&5Y]5IQ5#H (6P%]92L?!G].UGQ4,9LXN52
M&M&%&0C$Q 3L2CI*3+KIYP2;G7B')_T3H,HC8B.3 /M-<F-,,L8^P?:US,;T
ME>RY+Y0N2J680G(OGV)O)(W1;5+@QBGBP[K' .YC>6O5KA>P=#V</)O:JQWT
M! &3$9"X#B2^XXW MFZ;MEZ,@A4< @6RLZD,77J5./@.GP12@8#--NW2H<Z,
M;C[@!WK)LR&053=;YA ">EM-<W:MMT^(B;<07]CD64P4K_NV3&CYV0P^SB /
MN;@%;&T[6F//GY\D6];8V3H_,!^FN_MKN7"*4EP?UZQ"53._?MRI.MAVWX8C
M&^ERYI6'7SH H;/)=ZP?3T*::3$?10<76 X;Y3?GF<"6QH<P64;&=V^VCB;E
M45/RM#_NB@8$-YK6.K5& 0\AM*;ZD:M:;(/$](DJZUXC_8_;)N^H0M)E\GT/
M0Q()Y<AREK0H5/YX[2H 5OA6% 3WGN4@E$>T"2V]1OLZY":I:2RO'6PLX<V'
M+>C;\2U1PQ[S_R"B_+N884C5/F>X*V?X9)\SW.<,]SG#3\H9<DQP0-5:VH*[
MS-*]1U<9.R<:&Q:\FA NI3@9UEK1VE4BG[$27W(OS;7V4HDN;U"EGELB:>81
MF[ P.IH6@H;.V*UECH1@T2R3!Z$UT%AJ=A>K45ZFO32U#J&'\B%KDP51?AE;
M$ DG,;<;FG*$4C(;RSQ4.URTB PP'&C9EO;;2+ MI<-3;00ZSSDT:I'+?*&F
M871G< GPQ=CI^O#R_.CL_?U#^:\?S/86,UH'/>)K4_N6(%@>8G :<(_NAC0V
M8:97A&CCSV1#6M%;Q.<6];1=-APM;>+;'!N71?#TGE]EG)#VN-]S=^W20*X8
MDU>K]6!7:.(WN<(>'^-V7KQK^.1-Z4%IOD,ZK>26'VMXTD#8)>C.9C$9[T+'
M8DQ%>RN&NAPO&0<RG*4D]8C<'(/^93;0N.=B.%A3E3;&37RN#M]1]"LXQN8X
MO9+L-.Q$#5S@/\CLB?R;N^F-+P[Q<SU>X&U-@[,#M.7N$[?K./HU-;V!U(9L
M_KM0]G1G OJ>-GM@$T,@.;#!:5#'2X-OJX*D7+?]VR!--6NC !))NW65&Q<?
MV=I++NIYR_$8OW>'O=0QW\=C$NSR;FNRM+9D:+Y:Y1(8_#KU(B&*;$ <^I&L
MG&4XUDQ :7#F=C7C,$%:5"B>0A+''#IH/B&:GFP\)T =5%>, U+"=BM93N7O
M#J11ZZ*Q)]'KEI6>M:A.$*RI9P<?\GPE#+MPV\&MS&=]@]=RV<R4HW& ]H1
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MN_2+Q$C76DP>(J4:^_-!T7VZ<4NZ\>D^W;A/-^[3C9^K5 U#$U.'%KPLYKT
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M=\C#^=]\D\M=)N*6!"&W8 KT,909L@<%_*>MJUOHI\Y3?0]P3@Y;X'6C^M9
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MK'<WUJ9=/3NU6[#%O%H-5H&4R:$BE' Z\ #$DR)$0MFR(_\*&:BCI0FY@LT
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MTM=&.[P'9<"5[BP7"><'%H2XW[ EAA\DM[>WI_\$-CG/JU-)>6)6MV+>Y"S
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MH-<R['![CU,N9Z!#@Q,_PT8=[2C>N\UA RD)-9!X60;^(' EABZ.8G9AHW2
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MA.Y7U?(%+L!CUZZJ6O+?R1$P.0*B=P2,[UND-) X]#=PY8V>PYZ)?!,'-XZ
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M@\=R$/W8U;!OZ,RQ2Q3FE*<,0K0!Y_9&LA',CR;OMOB<-RTYZII5LNCP828
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M1="X(;W???K8BG1WE)U4$310)6 $#5*E(4&#2G&-@-1!@X[-6]B]X,F1$>_
M>QZXM7>*7?=?VJ!11U2M["8('('_ZQ%ZL-K*O6\/EX,1R+#<YPG-)VQJ1V0Z
MN%M_)*)+*(?R#IBH,7%R, .G?VX#L;=[52,&P6>=@3]7M:B.@ ^_!_5 WK6A
M:^T)^\$J'E_A; <+X[W83]= Q7H^+!4"77;NXS?2D,\#H<,0DG-3B_8.RN$1
M>,?>\VFQ;89AH'>^0@F$.MQ)B8Q8'#*7NCQ8T S:UY.-)Z^4E IK^4@#ZLE2
M<HJJS@$#K-R).>,K2\GFY-L*J"B!?&;JS4()LUP(F0, &F><#MPYKR0)D,E&
M3/U^\\UQ9AG6-B">Q7'&G(<%?)SSHSS2ZW27EW-QWH.]/RQR>I<OA$1.[_+^
M_ '?W738/.T!B7-D9/9.1R<O(<'[0<_^T2[=.Y^<AWM]2(+<W?C"D?[0.Y[,
M==ZV#\S8'O#=FTW!&MC,$2J0I%\F[__V#NJ,OO_KU0S1/%<B^?'=%98>D?BD
M%'XI$(7<0Z<\IVM74BZVV]/DAQM1)MC)"E^ )&L:+G+R/V*^<-S[07Q3<><B
M;Q"^E:0Y@^X2M@V"%7&IP!KKM5)/5BOI+V=*8CV'7FFU>2D6+.'TVVZQ3>C0
MSA)LUHH9^JJ+$#RC:L!XB:9T3)4%$"52.9<%UH#)I^ 74ZNU0ZW6+J=6:^:]
M4ZNUK[356E".*?(;[O/0@*'05O):: 9$3=(4GR)\8\B0/1:YP2MG'#)BW<>'
M/29^2QWBW4= 6_D-E@X[,4++$KUI'>=3\-8.^S+D\7"'#.+1NH\/^[S<YP=1
MX]S'C\*:]-8\Y'SP.FE!:]5B&/3Y'G9#I12$=N"J&I$44,E-)8!2.Y$WEWH*
MSO,*O1/4[#5M&JDAK(5461;L;=BCRE 75WD!FWQAY:H7,#HMY326W>"Y\5)X
MA_+,_;SG?!!!<P<S%VNZPP:%M]BS000"LY[OA*1W='1L]V.9$$?T&=M)BS\&
MO=2?Y''GW?_4476<?BKXH'>N_UPDH:RHRK+!L*\[8A#CSGM\L!>]UVT.&SC?
MJ\P);K]U7T(G: 0>Y6;0->\.^KEJPK;CN-OI-PT\\G+Z.D?@45%*QQ^T.V&K
M =#G$IJH#MU+=Q0ZFH?K5-Q!84 (O*7#+":4P[B7+! _@\%4PKX1]HFC0-R>
MWXF%AY\6=TA7M#D@7Q5A2!A'8/3O</VPI82!9C3=!A FPSX1"#5RIUB,#=<3
M,S8/]?7E_C1M7A(BI[19MS.(86W2NIT!%)II\E+5S2QY^_$74G,]QQD@LC1^
MMYLOX(!_2$_7%!Q<^6:XZ,XW%&I)%#! PV8YS-C<YP<10-W'CRA5]#O,KO/A
M<@6?TLNB"Q:%U;!TVO$*Y&$C."!+Z;PA P,M:NCXAMW:K&N!GM]>&#!Y_MN<
MBIG9EUU0G->/$2,Z3@^HC&HP%Y;PD3=-]_ 8T;C,L"'!F2O8ARAP7L,*@8]-
M<Q2HY1=B2C-X6=@@G1@0N*#C4-&^<'-"@*N^=(N.4]IV,8<."V 0=2PY7J,L
MQO"'CB*@R_\$K_JF$:_5#V_NP:&N C4@E-]8?GP4Y1B#D7>KZMK7R_RSZ(5E
MM+S**C9!;OFVEO];J$7P8]BSXHG]AR]:A!<;PNG)Z;^Y74F)@CL"CO_;.MV\
ML2; WG*>Z)^^??7\Q:LWWSUI%_:\W(=VHPKW 'YY*"2Q)X;^\)_NB>3N#^3^
M$93X\=W51 FD1'_I^%=("!.,GPB"!.&4A(D:2 T+97,B"!#$BNE,%$&*[.G_
M_152@C.%)FH@-;KI@K#^V9N#^A42@AV)$S5(DICVF1-!@"![G&68R^2T+G>2
M/^<"-#:HWN!\W:1#KS7[Z78S0M_HC#2P4I^ ;?T$[?/)5S#Y"F+Q%9P?!$GX
MFGP%XU,B$E_!^(2(S%<P/D%B\A6,3XW(? 7C$\3R%?2"BGV%)'EONG-&HO>.
M3Y./XB87MQ,QD!C?5VF]B,-S,#XQ'D&%Q\79F_<?OV_PQ_,WCR?23$J930C1
MKO*LP0)(:?^*2-S2?N+=5^N5'IT0JM!UH@908Q_,Y=='B3UHC5\?(;#N>R(%
M\@HJ?I^(,4F02,.:HQ,#<VHG2H HG4X$\8EJD2\G5A&3538Z'1  9B+%I&?:
MT9,#2'!?'S6HQFR\5 ,&3)E!AH'JP\S^^G\*2"'@JJ"\O($^U==4%60C356U
MKHS; 9U2[;,1:1=:;)N2NBG]8$H_B%VG.MGIT?/56E\1D,*4(4X447X*J,:<
MJ$'4Z.\J]S52HA;0CJ*\CL.#%0%!(K''(J $HE=,M$CC2D@?FQ+(,"9NH;P6
M$"=$%,:)(,0^)\FJCD8&?2FB2?V,@")R.NM)!8TMK!X!+?:BZG^-Q" 0*4#M
M )@I@H''FY/T-Z+\PVET?A!=_P^Y.X@TG\F/SA%#_W\9Q$M\;D79@/.P%-<5
M8@Y594)-;K8)M/!)3$.\MMA.CL7)L3@8?/#\V57=C_H&)VPA;K!^;EE7:_ZC
M@S/^EZJ2MUJ-_@ 0OGDFW.(\E<#ZE[<?= (K=E^HJTTBST$\7.#%R/H547B&
M]_M64$A"4$<I>7+DS[>[6X=[-5W[Z=I''WR5FLC%R&(6](^)%M$%5\8F14Q^
MP;%I$8]?<&Q*(*SG=$<BM.['ID5D1:Y14,0H_!--8HN[C4V)M1#1A!/&I@5!
M8$_$8!%;MN SZ.)QEHY-DFI>@'6/_=DFDDPJJ4.)#M'GTZ25+X.N86E9BGJ6
MY$M,-BTF6*O)#W10\B1EMYZ+.A:/Z\6XM\EJ%-(HE_4"VA'OM'$ 3^Q<)(4\
MS=CG6,Z3&JV(Q2PQ?4/@<NJAHX8>HY$=8VN>\3BY1J;$/)JDC;&CT45U*Z+1
MP,=6K5;]_>>_0E(HACZ1(S+OQ<B$L+6$B2235'6+4.IJ,Y&"P\S1^/C&IL3$
M.N.+JXZM:$7CPQH]4M1V]:1S\@696(72LJJF/6EKD;;H2%E6A3333KIHA.OY
MR*F!T<C6L0DQT0'IL)+_C,>+,3(QZK2-QKLU,BEB<NB,3 KET)F"8E-0;.\A
MB0=L96P$NWA\.F.#E<WE\)OI7'#*0:GX:#RYL".3!'2OB11DMA62]<^C\6V,
M#I+;;*JRF5C'(7T0E/6I8&W2R0XG*F55 X6A.YDX4!K9UR.2,W2NP8.D4G1N
MA7R<8G>M0)!'+JI<I3<BR<NF6R[E7R/".AF[#'W9E9'TW8F &/&X[,>F1&P]
M>\?.(.JR:/2_L6D1%=#)V,2()YHS-B7BZ:<2 3&F8S&)U-VLLNEZ&'5_(H72
M+.9-"S;+)%.U_[&))\PY-BV6L71VC( 6JEYGH@?18S[)DTF>^*3X\=U5TFVJ
M$B$7I7!9YTT# (+5,DF3[_]Z-;EA)S?L03=LTVTVQ19<I__HY +;+1P=:(FS
MJ2OL>I.EY2)?@$L?F^7(,=!*1UX#]-:6(A-- RB5V#2'&N7 <-^M6]6'O+JV
MJQ8>S<MT(=D_ !/*]\HQ+8(48C.>]49>0R&/]W5^(T8OQ]P7!,%E3[=ONGW[
MG0;]ETR'+[H2&K76=$[RA4C$<BFRUKJ&)G*?9*L48#;D?.2>90V$1]HDK45R
MDXM; IB4>XQ32!"@)-E4K4 [1-Z_4BSS=@K93:<U.-0K-E4=3]7<J' #^V@$
MR+JQS"A* D75,C%6(K4 "EQ>QS*I*&D4">C)V>FK**G31E1/$.7Y:7+YT72B
MT4$^) ]1NLGC<5-&2:6(<JVCI$^=YO$D449)H29=BG8;3=.R*&G45H5D1O,<
MW%:QS"Q*0L63GQ E>02X'M-L.D,'K;2JS$1=-N,5!L^QE4ROU^P-I U'Y+ZR
M?C-YKT;W7EF-D50T8F^, ]RO@&H"'M-F5=TFZ48^M:DQ_L!".;$%#[AC%0.9
M)1$I?L_'3H!"XD:CY8U-CE( Z'-$58=3SF0DE,A+D*U%UTRGPTK^:;HBGL#"
MV.28+HNBQ"1@S:$ 7]QM1(Z4L0D2$QK=V+2()Q%_;$KD:ZF)3I)5<XUHT(/&
MID1$::1CDT)\SJ,*+X]-#ZC16*3U @O4TUHX'7L7(LL75&ZN^\21XX!3UI,.
M>J";?$CP?4"_G[0X-BW25++3Q[!!\%S.H2IWG1;0PUD4U09P%4_W.\$6^8TB
MH>6:.B=GXW=/Y)_=_UK/9X5(Z]=SJ7"\6>3-IDBWK_&EGM?K$MU>\M\K(N?%
MB]-+V$C+J?6-\U[G92>9* K?!T5O]MZPN9>C8'G?,DDY4?-J7E\\W;3)F?F?
M_.3SI]\]V?00Z=_LU<S3[--U777E IR+5?WZVS/\OS<6^11ET&]V+4[FM4@_
MG:1+^?G7:7&;;AM>ZXM7IY?&!ZBF!A1.SL\D6?\CL7XV&^AL\N<3BV[L@3LI
MQ+)]S</4[VJ<E/IEU>!I?5V+ CT6WJ99AP<W_"'VAI>K-N'2[,1W:;*JQ?*_
MOOGVMU_>]GD2AR_W;^@-EC?[K?RKW<_P2?IG:YO[SS^O'JEX(BEF>7J)BN:7
M+OEWJ$I_E$<]>P1/)/^97.#(QQZ]O8TS'E>];?"K/:]_L"NC'-;>3@$[X9UZ
M7SJ;L\OD+UTFK[CD+&S80BYXVX2-J;*LJ\.&W*Y$Z'K"'M=9<$&CJ#H_:$@>
M2*RF:S:B7(A%X,9LNC9P5P()?#>*K:IB$3BOP*,B_RJ%8 J=1H+&S;>!WY'Z
M:_AA21#!JJJ'=O,\\%ON\S^^NPIZ?I#&[N-0!9)B:GS0L&552UDP=,S<,58K
MX)!A:=>NJEHR--&$43J0$J$;\_[C]T/WWYO/\M#C9Z<O0P^E^_J\E'*D[:@=
M9MC H,=O5WFV"AH!(# :E$HJ]7,A'U,Z/;2% R5=2H4D];3Z)(=F<_*(KI%M
M8K\Y8J)4FE<GBD/ /^=;^0*IQJ<<74S659G+XP8?FU?2!CE-?M6#"1[+&DY3
MR]=2_LLO+3JR%$P7P&299F">S)(<0@R@-F!XLZN%8Z'L+$$N*\ND]IF6F4B@
M-;BQ=;2=@\V@<3TX1AHF;24U7_FQGD] L=G>=__E[0=\4;K9%'(6H)]9G[ON
MI DDYR?XS7*E\MA Y0M28 =$;&";7[CG>R/J])CC]SQ0*CP/E]3>$*G2B<!9
M#<H0?U:#U]4;,,S80^GTXFZ<W?O,<:S=&W0T;_?&!3!W;V17PD0;,:A,^D<!
M>4/8F+QI.O(EI MI5C=N&9ES244#)GC>K/#I;)6+&Z$O%?2A%6DI/[+L%'^0
MG&U3Y26\)ENEY;7 OK77E?Q."6QA\*CW"ME@(3!XN,Y\&T,RSKQI:PK%!PGT
M[)CIG04>?O<;19I]"OS @'1^Y2V?BFK#O@&8@> ;#%)+JD!]KFSSL@N<6*BN
M<:3!X'WEJ$_@K3#.M\TH%O=;S[FX!#DM+Z.\P* EH*4L9:>E@,A_I5*%2"C<
MGAP^36Y:8KJ>Y]==U2&#4<DMD@E #>J:7XA_ZTJ#T3ED$3WWCBNRK: QDG%)
MKG0:-.;]DBD6-&I8 ?"LPJ8-^X#<LZ#GRVK(X':?)Y_1(!O\HE6'KJ$JBT$I
MYPQ85PM)V,!!?\3*\R6HO('+AVO*9H#*MYVI2,!<F!;64F378B/2EB 1[AIF
M ,O$RH,<F.HSS_VBDR;#QLW%5DXX;(Q4MP;YP,Z0-'!!MX%?R+JZ1NX:. R\
MSNM- 9#%#SM!R)4)W)JPYUFBA T:--R?!>I0WO/RH(,,")T6E&DGU;Q-<]!T
MY8VK/PD(B5("\(V\-56-]Y">Z7M _K:IU@!MW97RX@FRUB5;AK]@MHZYS4=I
M%?2IX_20RW"E14W\P3ZPI_O=O;P[E]PG8Y/AH;[Q@-.7VM ^7/+[>7^UT1;5
M0WT#6>R#'<ZZ-SOC7MX-FM*#S?OAZ#VOJ[07#B_VB8-5 *[0?\6+BB \_YI3
M9TFE=$O%[0\/]1#MP#T;-J*1QFH.]3#ED/[E#>P&5;RG@9J!]_P"/#_Y'(,-
M82.E.2M''N4!^L(Y'N7H\_<HK4%G&?1%/@W4]ORI=?/_%8-6@C=HT!'D/8]M
M8HUNI6!/#K_CA;=9)CHQ1)(789OU(HR OA/W* *^"*.?^WA>9K5(FT'EUQVU
MD6=[F,K/=_3LINEJ<3J6N^OGM-P&N:P@!,7Q, )(RU+)<S"05X@4K.H9Q.+
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MQ02\+3<RW"6P>SHC*C=<N,XQ?D2^'S.1U:FQMK*A2 2/^Y3*X)6>' N'S\G
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M,F%7*O+6*GD+=AA#$EFPE0GZY53K;^T*0V.97&:%S,D</I7?OVJW 5^U4D#
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M6U3;K6!^#WKSUV4N$[AC5\%6)F (( Y"95.LJO*K]*RI;SEUJZ2*E>D+KS;
M9*;E>X0R;9DQU8>9$$->'H]IUC"5<.8GPAT*#6,;2JH[!8M-$')JP^@S@Y!Q
M"E<S_#+,B2'*TC,F^S:-X_0164BL62HI/_=\IAEEU)Z[,S\%*[[_]NW"BL/,
MP+BFY@1&@L.3YO+GR!%44T$(+NS0B>>U+W#AB$J1;;@Y%Y:$,X/TFYH5&YF'
MNTPLXG2&Y?-3\V)11ANE*_ERR2[Z:!=, !,3,;YN,*54VY1VR'3!3EHL_C/5
M]@8/K4QH,Q1IL!&'-*&D$&%"]55W/+W-\&>8(:-JZ;1-%&ACX%0" N4:G'!J
MA9F@Y%V3NHN)+@\Z23IY6M#2S(TH%:)MFK=3398SOISQ<]NFX4FWKX?*!VW2
MZ(,80W[X9([W2DY<:60J1<*D$6V"]=,P44#G6KNIFU[I35F)G+V DY?N1"(P
MWPS3RF RF-IV3(\ZM2VG;",8!Z0'_ )N0\Q<H?PW3* B3SO\#CY  LN+7#O+
M\47'&-9SG2[G9CDWP^_&T_>9+@6NSQK%<RAQ= T[>BOQ*)8%O;%=NI+)_,,B
MSI=M^;NPBU\M,9IY<&(^)O'$C)A?A.;E$J&9T?Z87X!F8H;,,#XS,4=F%)Z9
M6G;,+3PS\<Z84W1F:H5C/BC@$W,"@<.R8R:*D^G[GZ/DF(G#%CCQ;&H9&A;A
MK/H'3+TUL,C0H%0M+"&6Y$6YF9$"-C4[YF/-3LV)Y:!8OJ\EHKVX1W\W[M$S
M=8*?2O-86!&:5CTB*L1L\/0GYL>L]-'EBIT1.]0-NS!C3E9L!T+R<W;W3+PE
MSH 1?(;<.(^<\!DR9$[!@VDY,:.6/1-S8KT8)-K-52(F+R;Q+0P)Y]6;96I&
M+$:[.2/M3/M9<.79[=?+]M#;XW[!)9@+*^83)IB:$_/+>IN:(S/+>IN:'?-+
M>YN:(S/,>YN:)?/11J?FA(;C6MBQJ%^=G;$^R#R?4:;7U!Q9;!1]H<R"#3/8
M$'__YV*A+!:*S0FJ?6P4"->"%&MU3;EPLT$<M2 HTD!U:>H%N-1M$K Y'CX\
M%V8K!%\1Y^(1OEHLZ4I+NM(YW8I?/F]*]DUG$BQ"_N:']U79,<RO1!^BZLZB
M6ZO@*^"',J8QEDVY;,I%X5_\K;_/V/;4K)A1<'MJ5H11)(X+-XPG?F;9A%/S
M8TXYR%/S8DY)MU/S8EYIIE-S UM>E'-*3Y^:(>M%T]"<0)"_![DIERNEYLB#
M .MOAV;Q(D$63V-G>RR<,+=*F< ]"T.3&U(!N19AL@FSS5Q2R^YNOYJ:2P@]
M*_/@F&*7<VI\%FSD=BL(4Y*:)QL?\QN$\9N1WZSQD\5MMKC-&H?J;F*?@ [0
M+-R@DB'LE3Z7/*/)N3$3365R/NC0#@8Z%X;,*)%D>HSW6;!A\NTPE\#+Y(Q8
M!*8Q9V:5Y#XY/^:4XCXY,V:6X#XY/^:6WCXY0S!EINYA48"1'^W#9"<PARS$
MA)E$9 &8_& ,8\Y,JX\20?C)I"Y?;?6ON#WM$=C(!_.-#3O]3JD8?_T2?CU)
M0^J?3O2*/M&;QV0;K87.Q1.; *%0T[((8I'LBOU3L!%Q^(0-IK=!6 1A'-\&
M;Q/]8V2Q(@3.4LL.F81KS$-ZJO/[5C@5L)/(A]*3ZY<'C]3W^IB)!UR!,E>^
MF;HMO/RW6;CN-URS]W=CP\D"7ANU-MPZC7M=+J=7XU?1.@Q=/^*+MH<,TS#.
M$[2?%Q^/PMD#WGJ'NY]]^_E8'B2&KU@OR40.[XF<_>S;5$7*>\NQS/+2Q>(V
M2<A\ [68@0W+XYE!$F&]J]K2K%?)A/>6_"@B%)3,EU3MJ'AO"YV[L_W\-I0Q
M[PT@9:+P2*?UWR#$DCXI1V*I^@+5W$6W?SF IH4D6ZE<O)A("?\^[F5$W5N4
M SD,=IF H;(@EA]$+/=INJ$N2F6$Z9?7%$%GY8OM^3R5G_QW$85EWJM,]Y"<
M\=*?>L'CB&/OPX<11S?B;+07;.$&3/#2&N\5C5#%]0>'31KN1#;J!U37P^KW
MN46W:53V*M_7&?X$)-=U!M]@"[CT>#@!U7*=EX@M2-%B3!;U&L?7&3L2&96E
MF!M3:'S)\[3/AJ@ STZH *YK]AE3";#?H[Z01S2,#XV+]Y9'^7WJ4KHL O$Q
MQ*:Y*Q[5HTO?LIX/,R8!V$8J]LPC(QG#Y7;*7%.W,6 1Q"+<=%4LL/S6XB,H
M1H=PO0I(&U(6L/IOPU:.8( ,+*EB_V8C\R.8D*])\;+"W\\I_@U_WRO3Z_Z5
MPDEL1+?_T!JW-=A-).+8#D:KD:T1KJZS10)[1AB5[?Z%M@F?52;AJ[L.>^B_
M_]'\FG48?=AE:9EL,,L@S5Y_\8S^>=-@G^$,!=!WXF8-&NJ'FW +KW\=QH]@
MLNMO??7U[?,Z&<!,[3F9J@@_^9]!X\^U\Z+EX/AXT^";#L7?Q&);O-9DYF<9
M3<K\,,TEGOS7F<!PV(.P%JWA.*$%'V-M+./\>;T2?PV#?2:V_^L/7_SR_IN^
ME *WY^D793-L@V_@M[#RU87W9?BWQC+W[W_]]<3%&^!8(^5#<;'^89O]':ZJ
M7\)6C_Z$3P3_%=P3Y9\M?EL+5Z=>5,N&/SHQ_&A'QNU&08L,$W4*-,*H!RRP
M_-WN'R]N?OIV%?SP\XIZ</[\S^]N@[=HK*F.N*M =_D$\EV*EIUR69'70-(8
M*6%!E(DJO4/'E^[DV6]$JM\U34GC6A,?L9FN*LCSN/;OAMWZ;3(T8UD$,5JP
M+ HJ0>1-RN7":3].MAZ'0-OA//Y6?D3>QYNL,9?>TB9["R<*-P?>^"Y5I$V9
MB!T=.-['F:H4UBI1_V33.)KV/?SE".H=>6T3T=CDF$YX9NR[CG[4/3QT"N4!
M*%07ZHJS>*B.L#3B..1-G>/(XL'YESV[_<HZ;+QEN4@.\#;<>Z<.UW[>&-\L
M(MC-J>(RBVPC(IFSE\;M!N]\$6QD%HG3^+$V"Y/'Z,<LG8;"1:*S[?5\D*2*
MU*+.G$*ZN!H.3KAE/XBB??/=!K"'@AQC"11G28*HS"A'%N_5;5G IP1-O\'Y
M>;[L6,*[+#RXMH!%Y?8<=U_C<>)>#C2X7]K&F6L_6 2>;O>7)XUG'J'[!%D$
M6/7*(GB2(F:N4)@P)U7O9J?Q;%'JX^"W)_YR:D^XY+!%^,YQHS#]#M;H&Y=X
M^ MW12V",()3#Y_MY+5%)Q["N/0(6UEQ&^>%:B^+KQ9GT57*!H_,><#M[P'K
M13 YKF0QC\8M>>QE9;*KBGCVN7FT106FH4Q^*V6^#VCQ*;"/)F2.^B/%U[I*
M8+'/TG*W#ZA<8IUF)-=602PCD>1T[Q@+*TN?PKAX"L(LPSP.O')RS#2(PES0
M'U1X#FPXE3B 5D2P%B)1X;QP\Q F1;@3::DLM)*FA7T\@39/X]9E1G=<,]5
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M-.&+V-V8AB?]K1P.WD?# 4Z9]1..I.*O[ O8G,.&NX*)R^NSBSNP.()RR9@
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MUCO'W<<_/W9O!7>;+ANJS26>+,RU*"K=X)A,+[[-7$\)^)(K >W6 ,P7^$C
M#A >?P59Z_&(R0O<S\98/$;30=!@4S#=D"*H[0N3)A"@OAX4^S07 :'@UD#F
MVF624X8$9@Q@&D+=+Y6>\C/ N6;-D#HVEETSJ+#8V[ 95"2:C%@J3O'2\::^
M0^_[B"6*OOG*@\:FTS7BKAQO[$8'@Q$_($ZC#[Y.IT%%M!@#'6UTI9UY>^8&
M;7^N:VYX#3EH([YZ!C_%PE*S/+3 +IP_KRF#ARK3)A /S,853M7'SM_UT>6M
ME&)O!;.O)4,8\SI2.'4'ZW$/W<%*W^:]P*!BC[DJZ.]RAVXL[K*>/J9Y<:.;
MM,/;MC([^)1A6JZ\HMPX&Z79?A]WGS0;1Y?UN$<W5:;U:WOBL.MWX>S[;?D'
M>1Y5N0W,>YS]6R[[?)\F*98;+JD5;9X[]AW/I^J1\F9Q+4$XL4@TLJ!#S#$^
MH-;>:72$/U 'X.IP"\VT@M.1[)]D_B'_Z[KUVB;EJ8L1/G?]MY\P6P*$$(>\
M-L37*) &OOD]7))#W_KW,I<);)VA[\9BEJ'O?G\4F0$RFBVZQGMFC']M&,HA
MVH@C(O.Q:-#;E0FGQ]Z*P#/[83!#\%H.\:;DH^5=,X^"UW/% S&?=SE>E@VS
M#:73P\G3<WI7$'W#O(GI/-!550;2K"1IY&"MJ""E\1:\5P\BBR2<R'_KFI8L
M"./8"=]C._5[D[HF3(L*-BFEDE'#>\IZU\ZL=I^^^ON#/(S%;0"41"*3!Y%C
M,ACB>L(]BMYM!/8DUE .&UC?:5;P*J2X>(M;F< 5[G:LV^5T.4PP<@9'[6)"
MUN-<C,9&KC*+SDM$V36(/B+J^4 1U:83H5,MZWR/C]9OK0UO*>%X.,-+%RU^
M7P:ZBV]V%U;G4?@+TVMN/8_E9LY-8#=Z=?OR+YR51T#2HO#$7&7>/)TNQ2CN
M>#1[$3Y(YTW5>1%W1=S%;A:)W_&WN>R;ZGGI-O9H&M6^ @AC,/!4NP9^%#=
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M+?)#I-*8'-FK>2Z-7T3Y.%!.%Q+>2L:631[I@P[?V BL<F7AU:(CQ?I!&GC
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MN];<OC1^-?K*NPZVU<@S!!W$$].$N!K8K;N<Y[F-U62!A5>AYN"5C*O9NE=
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MXANT?KXA"VJQYA9K3F4+RGN12HU5')48\=9IBB4"E*O:4Y5>]/8O\-\&*XS
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M>(BW*KPNN+K>CT7C[4KH?+,_Y.0L>E.&VN))&FTDF1!@Z<>ZP)=!S6=E^N:
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M)N+$^@C,X>9]!K4P8VU%?\N#$_V"X2%OB@CS1G%;\F:[/,$"YLM40^)Y0]J
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M7H#Y0MYTDNX:H:"OO:$H=UM7"./D3<$9I/UUJ8)"W0[3_#EI7:D1D/7FR(V
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MFO<@OA_:=J!X)P<8$6WH"AY8UY5I(WLI6(F,4&H[?HRRJRA/V$D0YJ4I*:^
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MS2Q4";<"Z::J[B"'D)LO$NX1NC;31'\0CXCT+VZ.">_Y\&;75TX44'(YH"+
M_9H<=Y:W%KY+](Z;QL/=*WY87O?3\[),UNP,*[_7R:'@)HJ%-,5S\FA$PJ3
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MIF/;NE597IQ.5K'YZ&\>V&FKUHV\QTFA>CE7^;D@>D#S21 !G1DO=P-TG][
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M)@(G$/""8@/P[[V:^_DK=8-8;O[?=<;M#':SD6GJ>N75R,X(3XYXLI'8F\L
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MKDG+\4'K<NP"ZOPY[<+LFM'8!N7;Y%*7=@8=G)ATMFBPCCK'A[:5PKB&"E]
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M30R]HI:Y;4 =6R18&0:ZE4YNM;EY#M+"6J7873U+-J5)E7.KE:MLXZ+SB^(
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M3@#EWJN^P8V2%@LUT]2566%R]^GB2^?PKF6AEBY/K7?2S!AX63]$%.YX[R>
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MG2B6\G2O8;4,$5C2 4EH:><X)P< QEVJIG6&P 2'FP2C^<.C&5_E0EFIV)\
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MJTPM[1/D)$J^^<>'=W_2H6^0%%%TZCT,PC)_X!T+3W!P(F]QO]$GZ9'^6F=
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M_B%3^]J!3=7F!]:]SIL67WR9K58P*!:O%\OL(5LVB!>.DY-BR(OA7,QTA."
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M A?@>4G"%Q/.?/H[@$Z1K,GMG>SYF+3B4#+SL=P!<:&/?6$@4 =/.IG7KEA
M1I$?;)0>E(;;NV?XOFVD;.6J" B(K\'TN9>C=T,?!P9J]!LR38)ZEJ@!\"1-
MUGF]0_5@LNX-.<UT T1C6(_IO%(+A:=_NK>WM\1D(\"-PC\=1I'CWGVZE^ZB
M2Y,-856-2'3X44>KG*[OO)QR<6*)B,?T#8(UBX1M']/]W_[^=D)I5L;BM8_I
M'16@"459+'WO*"E3#"OT]CY&.K!MB?7!EI!)&^;X=Z2TT5R:+B,G>K9=[YCS
MFW;%Y>D>S7\-@O6%G&KPGW2=)7.%-ST93-M*[0QOF N\;KSEH$@%5&/()XKH
M8!A Q!8INMG;EFGKCD<H11P$_>PPA=\1A&I7@KEBLGZU&K$D.B3B62OS3$/.
M5S8#$)G/EN76?QT3PC0<JS:,:0&O$F7@KKPZV"Y_VPF%K@S">=^F.A]URF_(
M#Y=GH!/H-$!<'-_=XM+"[5MN._UTYH2,LHYJMMTJ<=&WH)QJ1&58$^$I.Z7,
M!$68Y/EZ'9$@Z#?YHX%/MI)5@$A+6:0U448GEWT^TM]%37Q=7U:?$IDTWUL'
M-EP=E/+(RC-ENZO*ZL_Z/)$EY+I&V^P)HFY4R'9AJ \6H&Z A#2,RJDIA'?R
MBF<ZVS#=M7*,6#J0C!':(O."T.<@MHF-$/X*GHU61 EGQ$4+3G1O")U![27]
M%59,[(*-32\;?CDI'JY#>")\S4JE.QNF*[=(1-H4-O#G*"]N&D1=E@4Y,%-4
M)':@%&"D8GF3M'G%;IX]G#WMYW"5(2D &/^1PU+ZR RCH%E$I.%$$# XY*!C
M[!H^$GXJJ!N?>MM;9>%<V!IVZ6TZ[GP/8].Q-U 8FQ"NKG!C2<'E(C+*PAD(
M9QSG2 ]?JTQV56I)DXY_?C^1RO!/,TT>.2PL5\R=Z+#TGL=P:YS^W6L:L]UZ
MC8Y_JX'78QAV@N</2O8\ :,R1$P]/#6&)>E.)EE[#315CJB)<),</<+];]!L
MYAS/4]"$.5KFZ=:_:6"CMWFZ4"'].5;4(^BT-CK18B<W@;$NH4/M4K#>V#"Y
MQA+ #=BHQZUU[3^P%&0V']LJU9:W;>GI!SJA.<-IQL4?MJB8-Y4Z-WHEE\7L
M4SW'5T6$^X[/_0VSY]A@^5THIF7/1R'@WH77<V1Y>CB;N+BR3*+W&SAYNM)Y
M:;6#U]W#1>3ST\=8(J&L[B C'SO2&E4.]J?GV.ME,E/YOK-,,YU12'[,'8)?
M8 UNV^H!/5SZG-()1Z,8RX] /_MZ[CA8A[^G^]J5CE1#8;D16X_:,ENMT!#Q
M\Q!S5=Q3SN326B==4:'^8^=*V/K)RR994GLEW:4< /Z_27ZAX"LR->ZJS'P1
M$K&8_D@0",BIR7SX@#60/!K">G%I?3D&9:1C: _64X/7AGD,\0ZO8"26="L$
M"XA,KPG@8B.HC'J8)69WR)J) 2EPW\E:Z,,CQI9#?HME6BT)$&2I=@@*21&&
M+CN5:O^'\IK>%H?D2EUQC+KBY96ZHNOW2EWQ/Y2Z0J3/&QH>6."*HG2M3[:-
M(UK^Y;X2Q8D^F?.HYPD38H9$72^A=AX#WA/>2$*8CI;%2-:*0L"R!6!U:__Y
M2 :($S\C#] X^%%D:!V?6- UH9O5?UXKPL(AA*@F0KB894EA-Y.[1C%V)\Y@
M4AYK#174>DB\"@F3.3!@&V6[)R'@.C:?N$KOLZ4PL JQ__[OUK 2LJ)<*3G?
M3[#T+'>FWZ0#'Y>]&>L7.6DB'WY])WM>SAD(YJ_H>00RV\AF$9LS'NQSV;;Z
MSX:--OD-;F5[\.[YG; %7_@4E)(+R0XIW0DSNIE686TJG'QA$3#!>RY9'>;4
MJMD/GWX4OMB'3UQ>T*D0(UQ8[@GP4O*L^ R&DZQ1?:AWBBL5./6#6!H)62L4
M\+P^.KAPK"83M&)5F>!YO+*%6ZP0#@&;6-8 5 M^&_O.H35;K=Q#GU1"K]4H
M4% Q_*08131N;PWR&@@Q+GE)\2:4QF/>2NA.C1(5H1LM1E0$;=C8?\]5QR>Z
MA$,(=R1?P^Y_$)564I#6>@>+.[$[6 ZE;-.!.])@JGC5ZK\)V*+F:C. @]1L
MXFK'W_!Z15$SLQ$*LYMT/T%1./.*/1(BV?-1-D#0AKN)0_:M<@^_+TI6/0K:
M1:25]!LA#X&L!<_D'C2 +UJQ)S\DDRI8^Z3'B"4FN$*7F+ -#\EX,GG<'TVV
M^,SCZX3T7A'8T6$3,OZU(8^G;*_2SZIRHWWH/&C@M-ZG65'O$K/!O)@?M*,C
MH7,@VZ3C#CL=ZRAJ-\5?EU+HP0-DM]',W[K/R R+SNM R_!/C"7G7QM2,F$^
M^2)HH/%B96W88]Q/6=SQ'M%>AJ#PK6 _K< LI$N)OS*$N9Y!.%3*V(M)A=),
M6K6H%)\I_96XA'O)M\+T7B?/0KAW3-Q%UBH&D;N7Z3P!$*70<]F"7U@P]R$H
MZ/FA0XXG#&@0M-@"MUBB=TV8W1$<#1#^E5(Q[L67LG/_<L2Q[[795IG:I6S:
ME=_N<U'NGZU+3I<-YA-!N"FS0_S'><",8/+T62/DL=^,IT ];=8\RVC@II%^
M=.DZ2?=AE,'=VX>Z E34"G6K*,*/(6>3+,;(WO-!S"E;K;(%*%FR2)@L-J<*
M6 "VGN&U\"8)GY<%8^6A995'B<93>!.DX=YE5A/KG3 .+5Q:QWB7[=_(L]*/
MLH()\5#FK$K0TR8CKXA7@U<$ZW$-? DK3&N)4$&$J8F!@J@6ZP(+-&1SBI#E
M0D^:J#*C]SSM4AX$U5>\9%..=<U[C7Z3;3$^"3%0A_.:]<M[#2H^IR3TG3RN
MX-7)3FVV9956A]#01T!AM=V9P@I#QZV3AG6-?FHA"HP3;D7D0S=Q9G=;;6V,
M[N-M9-4C!HN$[*;)NM>+.5W_W=>8;HQ]-#S4F-ZC(4].6)[I!F@BP6#&]$W8
M:)/UGK58Y1-.@6Z/R7J/A)\:TW57FS3=&$8;FG#YLT(7 2HLEHA5)/TBK3$U
M.9'*TUU?>XIK\<RT %6+NZ2#,60%:EP$)BPLZO:,J)WWE61-VRTD:B6<5[3F
M&+:+X/0(G&K"*KTX_T\X^XE7RU&BF)8];' AS#>H4JQ)%(XA>WP,M5L\2O.)
M(.\1^ZM'U69WLA"!'$S\B9G(Q$Q?O.$4@L(+WRC"2W@B&/XHXL 3/KJL7>8"
MK,W(M#'<J&#3&$S9#DJ^$_XZ=JDH*EGNBZ3U"F@$.IW<8-MG-65JQZD[-CH:
MIP*, _&;KN\.HFY*&,*';-H5@C]NZ@D10TG23-;[?L*5F12C>%)@S/F4\+[3
M[L8I\673IEBL)Y0US808L!898#II9BMB;J8;X^W2X@3EAYDDT#\8YY>Y67F"
M*IER$=@MD<$BH7XQQCJ0ZN#!VI9L;4AH)#:5\%MD!)XXZ30,_(,P,B!['K.X
M9)-@(Y!!!B2?9!+HZ%F.OFAAU"5I"M,0-3VSR3S?>7V3O,UW:R(T-!S:I#7F
MN8414IMM7AZ4HOK9M$90BX10L3%>A5D46.U&>N0L4C>,Q<!_(1=#YOTGZS^-
M=2^/Z#L2^_[;*>^O$:_=[H](37/$$ @_ P(XQ2R?Z3[M\B&K$=]IL@$FW/?1
MC!XC^MZMLVJZ-T<NT2P6IWY$__MUI-XYHF]"6YGLDRXPCV"ZKSK=LDPI;1R7
M?2^5(7'2$PC@N?6F=,!-6:'QH1_) -0P6]X%2:Z0TF \=>T2]TW<@=L,<<Q3
MR4L$S'-0I!#73S_1@E$GF'R>Z,]M,2J"*_K]:NB]X)Y&APS\[8\&M/N\#7BK
MY6QTHOEC%.5A"?VE<Y1W"X9E$'I:>OV*%-_M^.JA:P/U(?2DX5.X '.=ZS]O
M,E@1[ 1!"\K[HBT3P!%US06'&G#;CZO SZK6R&0>^J))4YAV^45K^PL;9@L,
M2$3"J'<1J3!AB8QPG*88.U*W3Z9]PQB#.&A"NU76A/?/OQ1:Q&&!U!KT8%7<
M\Y#;O5JT%;*:B=LMLFK1;!Y41-EK[PLE2[7(X;0OV^H>^MN.$,N0SKW4:4#T
M9F@IX>5!XIXV1,?$9O=(HG>9EI>:'44A0!)EH#-O]T;XH5Z')TDS? D;_:[3
M;IX:MD]:;.%/WHF]22NFA:LF+O_]Q\</GWX1+I:PNEI:83L"<Q!4$K@^N7'\
MC_([[/5ZF>GM(JRVM7X$62L>+JCG:4GNX0Q@+8='8D",Y4C;1$>:\$Z[G3^S
MESD<=5WD19H6W*F$G J+N_'Y5MMZ/MP*.AI6D!*75M0ZO4?46%V\NT'0(K/:
MB;>"J$B \908(R<Y]O+XGZ ,8G:%+V[<@Z+5&)B>4I\)YQ6T.I4GW;WGJ#PW
MR2];6S!$*B@]F_?$EET7#-$OVU)(7WV:&5X'JP_53?6 <$VTS$Y?+B\$<4FA
MFK17&@\5-6;2ATW4D1!H!Z&;/,*D#6@DI )%\(L+R4VE/"Y#U*8,E'J/Q^0^
MK9:<^Z^'M\-HD[?^D5HK3EKT:;=E\^9P1H?F':&9A?/.CA>J"$FJATFZA1OJ
MN&/_T7E/.>OC64(RYIW>TW'.!"LHSHWJ_M% X!L_,-GTB?H"GP!%RH\-2""E
MT?.1]&EWV"+X:WX@JY@P(A&P%F$@""S:RBLKGT@7=W&F86740YHWQN6P<H @
M3,+YJD$6*B/J2*OT.B/3WG)000OL$-X<^B28ZB6"ZFI5$^3GO%P>3)KZP&63
ME(3^K=WTFJG.R-9V$JV_(IA0=S>:=2,1K;[@7>2B6+?78XI73@W=+_0-B*^-
M%9F$/:X])"NP5.%ZR*B"+^F8</250!GXND+>D+LEQ%-G+SNZH-L;,$_W\)9X
M[U@#PI .P=K@9R!DTEIS\WG7;:%=%PM,^[>7?DND^!,"T8$54&+*C+W&6Z#F
M&2;$Z&^,5?Q@H*<:X#A]S!*P=Z-!Y,)%L<X%L#=6E$-C;]>45H0@U;M)$5 (
MV"K9!N,LJG*H%N%=5*6)'FI59*5S-W]-//;?!CTB-JZ$V\U\"KW.M3KB@;$J
M!6R^0AD[K'6M,%+G><\LLGX86<-T4[(QM3 1S)YP83/8DO )A2F0K%41/+^
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M&,"(_]RFZAXZ!)\6OB?=I8@+6J<KI3V<"DE!TL7Y:B!^&;8 *=<9X0@-D?'
M$Y67IPQC@@V%14/WK<)#\$Y6=S'U2F1+EG#U(V1.YZXFV%.X"U1:+=:S! ;
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M^ZV[ K^:F0"3^J@P]KBC,*I&3<*<OY;'[-TO__O]#\]NOTM@LDNUR1:SUB!
M$#IX%N[<#?PKZ2#(J/QT66X0QG6AO0,FK/DHW!KH%ABG+)L:NLT("1(9(!)3
M%VR'U*B0!64%ULU&+5N3.(E&0!M,SA9SF7(.5M^39]9"YI1L5T?4;(_^,]E
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MP0$? GK5NCN!\!#( F#R/<"Y9Y,$5WYM'2-S=$8&#X_]HEU5"T*/X6)=,^%
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MKCX?X^"M+H.1,=]E5135/7Z&Y!S%(7IW/OG>T95?I)M&O-+_N'D"S[:.F*#
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MCL/E _"0:I)_Z< X6HOD#<R^Q7XPER]OFN2_NE(D5Q=7SY.%R/)&K>1W^99
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M;Y9=P?P,'2L>R2KUZJ?NE<E5@>#OU,QA#<_ E5-:M\YY\KH_^PC=T.XC3F3
M0 L3./@HSL3"%'A=J5RW[0.)!A E>=/Z]5\GG/PWD"A[YAH,(M6WJH?&\4/L
M 7>$M#C, +[?V'1M &;PGH2YUQ1TA$U7B'7ZT:]UCI,8\-"QUX8YO,=#6&XL
M.$0XCY)%;$U/'SLKK@27X:#,G2>_":P<+2OL&(MW52NUE/RC*/)558%*6J88
MR4:]$U0NB8IB:KG#!2VC6'@@4U2%I(*\[(BZP%B>>@Q16!:@=JO@'J@J,A>'
M_H -9-5YAN^X&@'HWSG%R',9I"*E#LGF=94NSI-WH/3"Z^"#35'=XU\ZJ=F
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M %D$WN31:T?NTF18-.F\ZG@4WIC:F%LZY]^/C')0#15LL%)D["*J$!O+_DY
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MQ.C&'_)T5Y,YEX(]#]%7@A%B1;GHLI9*HGOP!+B9'F0H3Q]%A4F!'2*J=:Z
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MKJB //8GF19W2B%7AXM45H@[?S7HD\R&B^\EVT-S,=2&W  0N#H7)MV20E'
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M<V'FR,)[3/L<]H%8EW"+T@M6%7QPE=9K3&BR*YP&- *ETM=6S1JJ^&55GKF
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M>:$BYMH'%-S;,_&**GN7X-GFQ1K3G ?<P-R("][C($S I)_3T99Y 'B,R=>
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M@$!H/G<F(=A\]J?RI;\7KWOZBL('V&U_@^ NF=^HQ= 5!5N>K!#'VFX0U/<
MD.Q"R.D>/]:DO4/3\$$V"$"/0@GFH_FB'N*O,7%K5?_V3"S@F49W0QD  H?>
M.STP:-^ Q>R+TO=)N>WRA6P;>_,8+UQ7GZ?+S"7O2AD][I$.[F@>/^NCM^ME
M8!$]?MRW?&,C'M_"[B2PKQ3K$YYV7R,H5M[;C0Z\+#K8G;=UNM9PLEN/"'5Q
MQ+^J+@46"J5V%]$YVN86VG&@LJJD)].^_PCU,8)!FBC2=%B$[B!L]#Q2<4#9
MX%?!W@YC 65@%U2F;I4R.L!S@2";Q 1@WUS<PAL1._.6Q,.B[FX14!J/I^S
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MX1J6CLM)U%YP$F<]>0,*+LIQ=\U=WG 7D;F&("G0M97ZNVZXAF_BS6JW970
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M9K>9" J)#37QG55/ R;M8N:.KA.@-5KA3/+E:4'*%->K^Z"#HO&L:C5Z6#F
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M1<H'&,:4H"T:+]7D$QV@!%;>J>O2;)/<=T?!K4':;N4-6GD8&(9+T+6W9[:
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MADB:BDB^*<6&4AX!6 I.@DAW$<&5)+/FI=>;,GX3(L*GNF1;'[B1P 894,H
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MD3+R-)61EX=WTMJUFA9-.WZ(S=&?:W;AK-J*KSVQ3.7\/S_[_.WK%[OT5K?
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M3"X*,*6B%@KU&LN]I2!$191@>#'#%SI?1B6$\)O!R%Z%.5;;P;5@VB9N28K
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M@PHS1JL 7-/?/I]>GCP[.Q:T-E%;W$?$0;]$;P>UVD%% /Y;\O ,6>M.)2P
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M[7'O/F[F:O=MT.17J7 5:5]5 8"/1K36ZH;O75&-QX5J93P#59TJQE'(6(.
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M:[1K-M00!_ALD7B1*K*GD=H8S5THO&:)%*ZP[][:1*%TC$-A3<I[>[=QTP@
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MV$)'8PI6/\$;Y7W(H:&K0:\TFW\*8T-Y#RBUJU9I)IK;.\CGL/K#3>EJ#7U
M!K R2I2C*1=6T!=D!;VLH-_A"OHM& A3PX5%;$N0CGW=YM7<\_(E1)D1B(T(
M^#1U""/DJ,H)D*(X4(0@R(-U!' V4WY+&U%/=D0&X;$1OQ/1' DP V=T:H)J
M\43(Q 0K%A. /Z;'QV":>K/H24\C?A)\)P^[BFS:20 :0&=_4Y>I4=N'B534
M7<$>D-E1[8XC%ER&AA;#)QDV&G2Z<ST/P5 &^4-]OH1"T78LVC3($D^"PF?
M2W1N!O@-[)/L#"D=PCH97,]),#\[P7R=):;Y:M[O6X$"B JEN$%$[(.QA>DE
M%$6;[<P/)2,2W%&CCCO!0@N9@#ZA"33?]G2#)O8B0\XN4H>B <"W13Z;$&MY
M8/U@@@ >$RER#$ YMN2E5/D<GA,S><7F\,1VW(T /4CF!U&Y*3(X'5 VPCY
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M.^,JAJY0G%NXYAF&R^K"-K";M30<+*NB^B @O;<U$U3RB4(QMVLQT0\DQ0^
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M4O,Y+-KS8!D"9JI__"CT(WP?-MXD[*C:P4ZO[N#-@N'-AZ&O<51XV .8FKG
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MG1HT0%+24Y,&PMJ53%D!]>>-P(JG",F %.T*N-]T@A:QD;&PA.%P(>![&_4
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MDHU5<( %N>'PQ(\71D YWG 4!#NXLA4F08@#3M#(LLD0JB$-\8'FC4SY)/@
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M$[7Y<Q=,R=@3^++0]Q<X@679LL]_!)(-)!LLR[7LS GLMM=8I)H.((9\5"E
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M99Y85H/$PYCA;'IEJ*:+?;L:Y]1+%"7#>EKN*&L6[M3!\Z"]9U1_C0\OGWL
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MN]^[5O%G-QSAKPPP2_[,\K-:7\ N(%R 69Z:Y=7KY\ NY[$+]A7%@%WR9Q<
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M6)-=$:J2@VG=KS>YR3:!J.3. 'P'PS>W'?2)UP'R%IWOS?V_90L?;PG<^)4
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M8B<Q[(UV5/J5<];/2=',&U1<V"V%"UQ[Y30(KJ.Z)O#YG%G\P^N] 8OGS.(
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MZU#,4'[@([XA3@"U&-0J/#?#_ )7K2!80*U"$"R@[A;P"P"B[TO0 \%RXVX
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M@CNZKP[&_2PC^TVFMS*?Q[HFUC4QB.3CS)5=@K-&81YB?R/V-^(LH2]I36Q
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M)R7, 5T<16!*!;9!:FS%63D!&LJ[(/H@XVCY8$+0#QDQP<>"@2;&\K!0Z%*
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MF?6'/!(&_L5)6'_4)RL!+J<@DA0IXDS)@66-K^]V7R'X5UN;-C/V@4\_0Q4
M+81&M2&U,+%7$'M:$AUJ4=+]-N$,WO:[U#]\E6J6AFG!/K&)$5W3UF-=P7B$
M(3-M,.-?!+_\;<P44%@E;O]0,&<"XWRL"2^" B5YO$0%[Y.A8R"TI.P6+XCW
MD,;/M*JHAB;)4.""4W2=\0-X1X+7.;^\B<A+M0@0IOO=@JGA18[DNGSK<R?O
M68]@02+MP3Q2#!L*$C$BM2$14DEH$N^&5= H!.*W'BL/IICQL[7&7Y'3R?B=
MJC=W(C?6XSY!'8Y,0@(3!J>UX2!Y?9!FD'79MDV+:8- P5 X"*BEH^$QP ;F
MIU)J,I<2BTDQDA6/5DW 9AA):W!*O5P"CDQA%&A47@=T?S#^-XM#WT75J+6E
M%OW=^"KGDQ7T8<"^@;^'\LDA^G&5%53&%I(\1P\2;8#@41?;4+.CZDRM[4#Y
MQ!26>)(A SS\%-MBF!@@?N77AC,6FF4:+$K2LDR?&3$9WC-L6P2W X,A!,\Z
M*T"W"'UAVSJT*5BB*&>ELZ7Q2;6OV?<,+#,K2Z-4!P$&OVU5L88UNYQAQY-T
MU2$VVFP&B">!7T1?9M/]!R^3H*]!,>!H]%JC*H=+CTSAM/[G8+O>58F7GR$M
MLV^X>6:Q9"TK7/@"\#T)E+NKH21Q@+\N&E1,,I,,*9"3OQ3VB<$5OP:N*,;@
MBAA<\4>!*XJO E>4-G]C:QCI,X+1+/[<51XW!<AL,S_JGQU>*_7FJJF?/EX/
MJXOB3J94L:$DZ%C>-GOJU>6@(T&:O.:P@[W3#([-5CR@NU\\H)1/)Y\Y :L^
M(SBT+8^<'8?,W/3(-$?()LB3$UD7F.GDHV0D1.3*JX,<M$VDQ .Y,<^=6@-5
M"O]PO? JO *G-):55EGR (^9^X ;7JHZR+,3=9RCI49;M AMW%BSIN3HHO.R
M7GN^7Q0$WN^ 3RB"CB9M;X#1 !]IN]:PS*;*C5VY<B8Q%!8'@:%XI81T9<DG
M11!B^.:KAP60.RIRL@0_$J-S(9!J+)*",$*B>$][J3C:2##L>RDJ3.YP3!Z-
M)8&G#:2(1F<3$Y$Y#PWMJ<$9^6F79=Z#J)GWV(K0D60^SZ>9J1OEUN.[P:Z+
MHR40<M,BPD616W6P0O]%M;0!NTWBL>BH.>11Z014&+4G5//)P3^YV4"4#.M/
M!0F^E4#'Z0]38@2(#SG+!OX>70M?G+@SS:#);XNV6*N#FNM/R]?#P[-)QIH>
MC:Z?GDJ7UK$[JVY!2&#54\.=;:AZVC/\):*:<9^GDT8"')9CO7K[4-\_F"IJ
ML7U>L/?/U/WJCW_?=\SY_L 9-YW>(=7XV=Q0U0X[T]/![394R!N..7<P:[KC
M88?4W8?FZ4QO-J^MWO+'OX89 >E8^P6="&G_H_;CGPKI[)??$ AH_>8;RX!R
M]\NPL?H6FAV,\GIQ)7B;>L0!AAA.N2Z.9$A\XK7FY-]ZD*:HW*F  N"?@B2Z
MJ"]M4B*:P8MF27,B'VTCZ0I"U$U;OX?EZ592JM4G7+76I)3L-ALW9JQNLBH/
MJNW)TWCIKGJDU[P8'Z;2M=II=1>MR@XFGN_CP2B/\M,LS->F"HTM2$D/)- K
M6% '8\H\)]].8NA*_"@GL_,S!202=R1LV(%)&_"S;B$#\2<(.S_/]N'//J"Y
MLREW/W1S)=]S8:)CJ->^?2;3I VE#!T1MQ]R^C0<?[3FL"?T8..MKX?9V*>]
M^#M, I])QGKG4$%B1"^SF6FPI]E7O(L"#-QBIS<.]/E+0@RQ8P:UEQ;,&>Q$
MNBSGS&*!61Z+ITHB)=#$].<1T1R,KF[):94?X[1_&Q=.^JQT.2@8*U65S;/@
MT/EEU19Q%1SH,IM<N.N<:W)>,EU+2$07F:J I?5[:6YOQ/;GV;]^DAMX#\PU
M$_9,.-CV>^SDLE!X1(C>SF4;G W?0T5TJF(6A?PB](+. NY^)E4;6*>"GXL^
M_'UA20@R5FQ2">11<UH U"-K\?$M Y0E5N@XWDFI\]SQ3>SK"MW<'97:UMX]
MFT?]A!5?MGW9LY[YBZQ,LW0?@1=9N.'8U7<RL3 A&H7^-7MNHM$>6XSG +N.
MA%6<"E$05!GH.Z(FT.QI:F11[<P<1/]CO;U.HFNAV;]*K#1"G04JOXN M\AR
MW_VK2;REIKI%T7V>6N$0("(!P)H:.GM#WF9@V=>7E@UFQ?D,X N&Z37@7<?R
MCPBHC/PL9C7X+_BX>F(3PHI2N(R^I$65E[6I;DJCU4Q&[(V7[<:U4P,OC#9L
MRR1X3+SLA!FJ[F,S?E:XY((R;Y+_C(0R*2"4624\I@Y>FD[JCL1((=V>B'1_
MG](,@R4,QR@R[^5AP+^EGC#+;S8WZ>@($%OX7"&\$NF:M+R#LMML['CZ[U77
M1_(A+A]2K[U0RE!O8Y.Q]S9W3.]*'M!ERVJMZ@AEW61X%TH-:YGNJ,7ZZ>-%
MZO1P?M=;WD24/H]^;G?QCC73P.LR$+&6):)-N)Y?QE*732GF%7I#FGM#\M2#
M(Q9<@)=_BBCE.@P&7X$0$K7@N?+SW@%$M*HY?_WUO/461$ -B*I@*J7#D0P\
M;(O.,^TH(<AB(NA_A?_K0ZX%=1X=M6N+9,LE1)M,UP%ENEEMXXL>J]_&25IZ
MGKKH31)JK%$_60P6P\XL2,8I9W6-3LR06[D+1F;,"U2I'%M!MK_@?9;#*O65
M3PA#1[@A%4I5+ NGG+,,>(6+MPR/</9L1ET#]"S$)T! ^H*AP,RQ5O<2/1':
M#?) ;3A(0<5VZ'2Q#F>*(C\,F6SI(D'\"TG;0 7;6]9KXQCXWU@,Q7RV(=G5
MVOD4F2WC?NW95$DFMBBX& 'QT0B(4HR B!$0?Q0"HO0J!$1Y\S>V&I:?@8"H
M*Q8XQ':+6!TX?C9R:!V/,WI36^AUMW+</<I:;OVPMMQ%6_B"FF>0>P<5,A,X
MIMTGMZ(^%UU=+]5M3KACAR%&:@>X#O._,4" $0/Q*'?*V=2084J!4AG4Q#1<
MM%HDQYH;%Y+A,O1SYGB!G,2!IN.WGNF*'WQYFP^#H9Z$%*@A?)]*;/*YQOWR
M>;[5%+20+L)#4!S'T@:NPT(19N %[B'@,*D:<MGME3]09VFFF(_BA;0XF0:F
MDQ N1S(G+=A$M!T>Y_/!&!&3*] BHA?/V(!LR'BU!]R\JC9GB0 VH68WNC[1
M(?]GC%&'E<R1VC1Y,AD#[1@K/RB&7)E! E-1("I0OT*)[N)*6J"7+$MXK%+_
M^73 "H>(S=G\FIP2)^6;W.RF06&9=WYQ"F\AQ9+P'3I1A@R6 S5<L;NBZ-:F
M)1!$<^)*Q2>EA[!C,.^#BYB!$Q+R ;R"NU)S/O""[U;NS$1)KGSM8?OQ?\5_
M6*)KVSU6E6] H/)JO8J@&*$-L4B+(A4U!F4DZR*LS3*0'M!&*<F[C$H_\VMK
M^#M>LQBSX)IJ$#(H@<.X$N"Z@8>W#4EX45Z?:083P>V)-O<@!%QMO?A0"<D"
M3J0G"\/-LS[&&PM^/0!DBE0#>&<*)-6(J><?A(C10M&QT#A^6Z9M#T0#0A>G
M:],0R]>[$!1)MP>AM>+ 0+Y7O#RLE^\6;<2#2GS#X)GO:&*3(&%G2+W*"IP!
M)FU9Y;[@U$MNZ],+C1GO"EE!R8LV,U_2%KM>69<+:8+A<!)4HK0-"<A*?XD0
MRV<FL1N:,( +O&K&Q*G--&$4$T20[<D'5[T_1_.O1\]WI!8)':H/O6Y9IF&Z
M/&',WD[A,A\_/*:J^Z24GJG7X^SH:GC1R$703$0_M[O7+FUVK2CAT8.S\FEW
M+X>HXK09*V5$_YND4K04T%YF/0<ZR@P1%%-NTQ]ZH5-I> +SR2Z!/=S$8;6S
M[P$F@!L \_UL\;!-=3:\/3"'FG_5D5"&])24\A!Y90+:!3^#GJ4>]@Q(F67-
M+I&01K-5UT;J0-H0M[,'1 <".#_;%S_@%0?A=]%\E*)S-M-34%-*W"<K/A$\
M$#-03>6'M*/1/!9VB.HH@ ]]#(B[&(K+TB/HPEQ(.LZ_7H'U$0.O=GJH\%+I
MTG-Y%AW"2I^U/;3_3Y:CD2VG_T*?,OM/8P80>N(E2K-G44.+UP_\N?%VC-0+
ML7'DU V>64V/*)>Z2:I4@<(44TV"53D&U ;S+GZ\+MBL"]Z]GUSSU:\:@;XA
MFJ#:C)>6,<!%0P]Q+U$%!+\W!M$WF713&@WW0FTSF!V^/@X.2 %S7R<1/=X+
MM*G9DDA@9C/KH# Y!H1N"<2U8/#<OV7+%-@M&XZ*Y>&P48HW>>G9D080:<Z<
M]%QK>3BI-=N7;[@,G9&U+LK6CT<4RKJ]7HYV$U=34O*'+.+XJ=D!AT:6<B?0
M+U:,C:<,^Y=5TEH*S1.U+2RRT,B2;*S24FL>G*_U0+!%;E8C6S(EO!P%T^(]
M7\,)[E&)>AF6@TJV$+Z&+R1,P)"[A2HS=\[U&'^0IY;SDG&?I,.^"$$@5;5!
M<_(Y55MY3M4&LO=^>IEPF[2L__@SVK6R5;LJ'&2WXBRK&+\#8/&CQL"S4C:
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M(YK;\EP1H;PJJZHK1RI2N1CLU/4,'>S7RI&GREC/-U:N'(F@3AY(C=$3L;:
ME'L5T0-21N2QA'^2">(QS-$%!FD1[)W"ROD*)")P!KU1U44M8,<^4I$XR$*%
MU1".V5#P-8/%$5JNKA$:.HL$T1*-C: /<\36,D<T1/-M$^!%2A1F CP)X0A6
M^>HN$5\@T-F*1@&"1-;L&S'V'G2V3GNLB* #9OOD'TY0YR*S^8NM($.D6/8X
M=I&@ST:WOW#B+H+,X;U>?+;G.AX69'E1_.=D)>]%N_D==6>&HZ9CPS)A0M'4
M88\^^/<_' T)+8<%3$>1E;^F5\(&/Q,TV$$QYH.DWR$S0N__RX@K9J,:FTVD
M[JRDUK^68R.";2L:P?6_*-O? )4#K,'D%1O@',-7C-N<\U?,+U_INV@@'7IA
M8HQ_0JO%R X5_\M0$P7DWG]V&UG7SDWP-Z)J)-!$1WVY\14Z^[#M@O@F*^.Y
M-+OH-V-OQ>C. ,;N,12#"&*[U1I0W'WI!/\!5,F/B-;9WW %]=](V,"=?_;@
MO8>XG6O+0MM<._IX$RT,%K^#$<O&8HE19,!$PNP@RM.AP3 <20U"?"(5'Z42
MT6B"_D4 P9A.DYI<&!3J[4=ZJH\BZ54A(D[*M14<-OM7=AIC(2[GU<*4SY64
MN=[-Z&HI/0@?7JG6(\)#8YB/3AMR>YQ,=DK*\W*%KHSM7UF:=%^"?*89G,8W
M+_2*[Z^91AVN3.Y?.2@F6';SW'_*\_'FIM(?S\IYJ86N#(7V+ZU6)_/,9BS,
M>_%>N#:9IW-C:=D:1 8'FR^%U<JTJ7:W^6(YIW)<I21N4NE!]/#*14KN!EOT
M?8,NKL519EH32O':&/)/#L#4U_/*<RO/]_I/2NA%K256,1JNC.Y?R=>86I)3
M9Q(='JJI1:33CF0[<&5B_\IX=U8>I5BNG \^K4*KDA[4ZA58YP&8'H;Z.%F>
MA'1Z,6JJ:>TQR246.$_F8$OC6F1.MTJ3R+1!LX^))?]03E33@]CAYI_G#T_\
M\U/\/A\<:^$A6ZX_A580#3YX?;U*QS/)AUH^7TQVRN5"/UU/5<:#^.$S0^6*
MSL]:RJ)7#/7OE\/LAKVOMP:)PRN7X5RJ$ OG&3H\;<R+[7RVQ657Z,H#T*OY
M7B%;&<K9/+^9EVFM7[]?ZV-TY0'HM5$D6JS3G72/Z<P?[I]41GJ:P]L/0)^H
M1"-/#).9T;,2K11J:K7S4()G6@!%IRQH;()D.#CPC</!I/'2[O7;--WK]"K9
MX;RV72V?5P.X-$1T/'0'SZ6UUZX.7^-0?-VQ9\H<U? #N1@ Q*?DT)ADM"!0
MF020O5B=5M'!CZV@"=;!)5;400];">AKN'((1L1"%Q1^=_F01ZH.C[5 I#)L
M+"-B!EXH4 I96=4LC6IGWEC:H6%M.12@B^C5;U&7\4G416_,B#([_6421FO5
M+$^?I]D)/9,WD5J>3[37C=8OBD?*]!P]7%-T_C8HQ_Y*613E%5:<R5PX?89N
M0,]3C]AQ=F7T-[;29!VQ$Z?^^?M%Q\L=BUQ%Z;OD+9OZ^QW+WS$S->XCS$,(
M<UI\-QX(^-U;S)^'!2343HXV]Y'P"4BXL:#RD>#+(Z]@P9=''D""+X\\@ 1C
M3KR/A=MBX8Y.^$CPY9&/A)!_-'M\)-BK'JKOF"C_FFSP]I[?.O0J%K]+>:JF
M_J,-K\VX FFB'@D%R!_@A7_OX*NOPAX'T/BDGIJ>XI?K ,'-L/\^/).V F%9
M6=7.'#SP)BO[YD6%3MA] I%\#EM\)8A\.[8I*I ;UY.LM$-(9%1]]O'9YTKC
MQ<!]\XW9IXJ3==_#/Z\Y57X>M?C\<\3=\'WX!VI=W.9E7LSN]UK-_,DY1Z[E
M*7_?*$Q.VSA>@\?GF3U'B^_]!EXV_>W'@\'[;.)SA<\5/E?<ABL,^^7'PP';
M*C\>##Y7.*R2;P*'+QYS))UQL_)LQBLLM)R9,W->^0I!Q4NTVGJUD]KG#+WQ
M4M^LZ*[)E2 Q$M!$V>JUXVS*:A%-$VC&;)'UHBK2=K+N3QEYQ?*Y1K*8BG^D
M]>I^4=!>R9 9R($X#F[ Y=+7*I6<Y)O=3#L]G:FUYU)_..MTNJM!% HO(X%(
M*'2-7JR?[N&^Q3 Y7PKX4L +4F#700+[V'<N=@A097 Q9)=9NXB&Y#B3OV^4
MFXM\=O'XDBIW>G%A X7!L5__1GVQX(N%5\T[;XF%2W:1_>0(DT^HUR+4V\L<
M__S:.[]V9Y?S),OJBL+;6K7M3BIY(,?*[*3%T_'E<CC-U)EU/8@;:(2(%AN[
MR/R6KQ(A,PU792XKT%*30V"T5=)_/W^-RPP;>[,=N/&;^_J_JH Q2-3)Z(:@
MT=*9Y+A4G*_SS&#Y_'2?3<8FCZO;FLL#833:YA/IIWQG)524V/IAF5A#MQID
M+B<#L63J/7JQ9T,G7T(#\>'BBZ'O)(;>;:\G5O=:_B&1XWN=9N59RX9JF<H2
M6M0C>ST4]@63+YBN#9<SW0(> \SU/04>V[#/(=[E$$^*5/_HOIBK(ER7F$Q!
M4BOY8J[-/4<68VZQQ7-D0F!!Q.E3 ;=O$5 ONLU!^0K^R"_D@+A=6OL7EB6]
MSHXT3;D"/4K3$I<>\^A.7CV0,'JTUA$:P2:?SQ8>PM)\ULRU9ZW;^BABBT0U
M4QWE%OE@8KJIK1;Q;D9/#^+@HPBE G0J<CU;X)L?W]Z001X'@B^$OKD0>K>'
MHM/+9UO/ZG#6"^='P^U+K-KGB]#!&SP4"5\J^5+I^KX'#TNE RA1OWVQ= &Q
M!*7$I\12O#-^>-K>CU,T$\TP@_OR>KWLKY!82O[Z]]!O^L=/(/'%TL4=/AX6
M2[ZR=&6?T).<*^3J>CM$+_CJ8S^Z')17+Z 6@4\(66PA.OD#\U>ZLL:(7]35
M_(FIUQZ;=>Y!:3+4Q@VM5TA$Z7"$8X5"9UH9/MTXCR0HCI_*+UP[3B]2?+9-
M"SUQEH7)/U!V00=2[_/1G)=@[;'@@F<T$5]$^"+BDT3$NSTHSP^)UH)MK!1Z
MD<EK*Z8ZFB^V,%LLAN2&+S-\F7'%' U/RXP;^$X\(S1>\V\L%VQ^7%P*T7RG
M''Q:,[5X3L1##J_LW_"%QH\1&D=/"4\+C6^H:+S=^[!-J;7JFE:7^<JL-N8&
M^<%\W4S#$%(HG@D%<*_LT]Z'_\%S&/\]& I^@S&3[^'I&RPSB_@+J7J4NNM4
MMU>E0ZT$;4+)B&8%B1'-X:/P@SRB1%Z%D9EHIRF:M#3GF(U*,0J>"$^&H**G
MLXPZP>-1\1\P"'6)D(_'RY/!]XA6L9\1SY<?,B(CL3Q:$\^C2^ ^>""9N+I[
M*-Q'YFXR0WG).^?,FU/M)[+(X7GVMOY[>[->K9[L%.*,R-VM,'&RD6!6EK D
MA-W69<W6C_0&*RU+5%H?H\LPP *.V;BX>R3&CR93#/5_KB+'DH88BU@.6) Q
M>[[9[5"0!YF9:@-=4Y%G@JK*R@;#T'#$YM>586T\[4DT(FLM*Z2WLI@>.T1A
M[$VBT+F8 CJDTC-T%NUD7IS(O#JC* -F(3^7Z_WG*AULQ(NSK)!/SRICI ^A
M\^! W%$(NR* D;71P]S:%5 \XH:QPO,XK0US;J;6H7X#BD#@A.E_X#-L'W\,
M_?,'\Z<L23Q!$+Y'0$R"UH^X<2RPE"BPO*3RA(%AENW0\&^?\ZJT>8GUOM\J
MSZ/SS4&W^.^_@H9(D$44!NNC$@&J:GMSUO'F-K_D)>@Q*OS[YXXJ$VD WVD@
MCC0'32+@Z#R''Z*".(#=.0'(CW@%J%;59'8* YH9ED6?!0U3,@@.63$$H0;>
M8&J,NP0CR"/E@E-!HJ$OX3X-B40&<<:E"=\:Y9P<&*3?E2_,!\V@*$8;#\-(
MOO]2*%<6R^=:OII^!Q_ &__6!$F8Z;.F :(">F49X0$$>V/D6(L!_ [ 'BD/
M:1TI:&BO++E(19O>N\&Q>%>F:@F9ROUC;#2:AM6BTMHNE\'0%C%5XB13_6;L
MA-M"*!5& J( (_HCC4T2)B)/UC45T ACI.<*.IF$.4.&@ /UZ$0((F&(J,$8
M[6VR'K5"7U.,N5%&%#<.@L3"$TY);6,_B GQ2M:C7%9(&:3/6K"#I:&SE%#H
M;^$/4.D;5X_4:%YQ;H 3E@(<P\,->B8\%/THRBNX&A_QY*5S!IW"<W2O<R\;
MYU'-BTCTP%QT&,P-W8.7T#V8DN>8;P@S@OBT1J&;J[BCLDCS&"/((*#8[D0P
MX/%$=86?@PL<[1 4"ZQ$P+1U!5:.=  &@6DVER40&@:&9/2/ EJ&/..IW_QZ
M#N('X5OB-;+H'0IAT+O(J"K! 'Z<*#!$RS/5&F.+N(PC\8]Z0LTY,G\^@C$"
M[T+LI F84G9;T&R[=L)4U8<J CK:&;YAAF22KKC >(\N 7(,BU2U^1P)8JQ;
M[6"($"G(W,WTHX9$U9@-%<%PB09.2O@.>AU:2?:DF/]M,+MUL26**"R+=MR.
MS$T$%, "!V<9!T0Y1- ZQH4!"E^JLHHPA&6!>AK JT/\I(O:3G^U<Z&%A;FH
MJX=<..0Q?[L)#5/?.O/,42>($]0!RXX6L?%B]D S3*E_'PTO)O)SZ\BQ$QM$
MB.&(CAWK[TN<.N8ST.HTK"=D@:D:(XP"1Y"=X"GK/#",IXAL0ZYWR_DL'6^V
M"ME>)-<68XY@>KE>./_PZO(SB.$KFSP67/A-94QC"" (#4W,"AT,QR/'U,[B
MM4XHVG9"L6HHV4K-]>@T3J_8TG963[#),=1'!L+):"">C!^>4P1OP+3'2!;K
M5J=5*T)BJ0!E-RGV'F-J53-$ZP)""Z(T)-!!^LI(AFN:B!$5V#O3$,W;)8UL
M%S2ZAN3B%@CX4/J<L2V0_(0)':]TDO^>@,8+A3=BZ_;55R YAR[!YB&\ _V
M: !S$;H+"XP@V3I'#&13+L.!@5V>YC&%+H#EPH$@48B/T!)T09T Q.ZH'CIN
M]KX,7-K7<WV>95>/U6V3EM)TY673*:S[TV!/79W0%!'H6& XF("(8+QO,.$)
M-63.1D/*.Z#3&,%"796\>?VQHRU46LO/ZJ5M)OL4*N87JU__2O(AZXS!QX&P
M(H+:3BB5E<<2.*V=!^?N<+V>"A\:A"R\N"0;?00S@^<<%T^T4GPO6WRJ,%R-
MSG2+IS!S4@S"+ <\RB'-P?E,\&%;PW$%?)7-M9^*<HRG&],A^U@)#6/!6?K7
MO_3=80;1SJC%VMR>,G>@HJA.K>V$QF8IC!N>03JH!&C=5["B=Q3Q(:)% ;($
M26<,SZ)M<J5M/B>+[#L%_.N3?SA!G8O,YB]V0AF:B^5@QEE%Z+,Q(S2<N(O$
MT%?."9ZVYSH>%F1Y4?SG]-R02\X /3K_(QPU/?66'A:*T8>3/>'?_W",,;4\
M\$%6%F7EK^EFM\'/! WVN(_Y()F2RHS0^_\RXHK9J,9F$ZF[B)F:^-?RU$>P
M@D@CN/X79?L;H'* M1FS#MH 9SCX25&<<9OYG4)FNAI?OC*MU4"Z)L\)QC]A
M0&MDAXK_9:B) J+E/[N-K.LD&WSV2\#NHF.:C?'5KW^[6,E'?)0%285./\L?
MS?QK0[,[ ]A+"X,(8KO5&E#<?>D$_P%4R8^(UMG?< 7UWU08W_EG#]Y[B-O%
M:BRTS;6CCS?1PF Y-4B&Z5 LPHP&P\@H,HBF.'Z0BHZ2@R@;3C#<B&5B7.@7
M 01CQB@>N,=6?#L,:;U9(O62U>N-XFRT0O(\LG]E?#J5Z.2SRO:*R5PD.FX_
MKJ+L>! >T =7BK3>KO2X1"^8#B>%;$%?M]=I=%X?7%G,UW(EL1U)T<*\V)PT
M"[VBJ(SA9-^_<J[%1XM%;1"=5M0VF\FEPXG-0PM=>;#.23.8G!:[N51O$ZSR
M>ED-RLL)M"P[>#O[>-][7!9KHUZ\IG7JG?MU/-^#<KZ#*R>IL<:FZ'0YWY]4
M9J5(EQ$UG,=^L,['?*$W2;U$F%Z_V,C4I:"Z*#RU!LG#9S9#\8W07"]I.BP@
MC6/S3 ^8SGB0.KQ2E8.=P5Q@2KUX1^H\W(=3Z6IGA:X\>#O;*VRT6COVT.N/
MN&1"GV4?51:>:4)I[U @]PT'D\9+N]=OTW2OTZMDA_/:=K5\7@W@4GB'(_CT
M)A6@VXR)3QUMO: KP<@VWRDU9[W4>%]=LH[EJN%OP$G%1.]N2&TP/,!(P2E_
M/4D>(K&R!#8O2W,=K0,MB$5WX85TT<HR(E)N?YE[*Z3+SU&IF!5["_DE4M<B
M]T5FA3099,TR<[0(I);PUSAW7G< @)HVDD517H%6C\])<,$:2CMKN((,]]:^
MYT7<@8KX<57T4F2VLXP$#JX=D) J@:"D4K^K_)(7J8C]SC\4A\T_2ZE0CVD5
MV#S _IO?V-*7=15]H_[YBV4JB5J9)R4)3&/'^ESE_YI_V&$%B<C&:0FBE"6R
MVGF,'0K#PP-)4\RWVD:7__I 'D$B<I>(^-/274*^MOO>4'3_YIGUQQ-?$B?;
M8?MXN0U>(G?AE(\7[^$E'+H+GRS0]1'S(<1\O#CHU:/F9G!)O@$N5Q7J'X9
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M_?2^NK3N6!6Y;N+Y6>)%.;35<[ULM-)8%V:57"N2AM8A2 $/!4(N$OK/E];
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M9/_E.U"\ZT#QUIZ_L'?EO5Q^CGOE\[E<6VG!Z&S2&M.;?#<\'"<F:ZT&0WY
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M/)K%^LCTC]%W](%&[3#H+20*H"AK@B:20E2%O(X:Z0KF>96?,[AKDL$\&)-
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M$/;0L:SQ/ XF@7=#T-"G@.&K ?#R"QWM5N'M#@H3'1C:O'JW0R.8C\;*D+D
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M8A:K&\X"4UK:W4,&>2@\ A0B69E7#VQ9BPAQ),*HMQGA1#C[/ T+J2?Q9SM
ML$#!? >[1Q+BF)? 5>3;-O%Y"#5P:+?N,5;</1]0?F(70SA1T\\Q.T,I[.X
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M1DB&^'/&1!$A+5^.!:7=/"02@,B@%G-5Z)(EOP$U<>^5=BT5/2NP,^T#6&P
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MELA_:#X*8ZS#ZB#/6BNQM\X!]VV8V(VN;(3K$F=V9S>BL+J\/.!>[%ER<SQ
M)8K9S.ORE(1[Q:D#EATM8N/%[(%FF%+_/AI>3.3GUC$78\A&3.C#/C6AAVMX
M\UF14=7&J*.A4Q13E'4%$I>\FFXB51[G%^$K#++Z($WVG^3X R_G^VE]\=A]
M*$R2_=8IFCSIJ^SRL[FL,,HFO]"1@H:76<:506386Q.[6CH8ANA8P#^Y$ZH6
M9LOK# +YM#+MA.?U>8FE:7!<!NAH*!"+AC]$K 2+0"&05$:@2X@K35E IO#R
M=ZT&(5QGJT5Z&WE=SW_]E8GKC;FZX"0S=I"UNT#-%)Z&9'.*N_K#PXWN4Z07
M:Z?RNLS)2B:U6>HQ:$01_]@@.T(\I@,=G7GF^:I:V=L.I^W)]G D!1?)4? .
M\NK.Z6BKN[6%IG'JK*#I$'ZCANCD1A:?9?+AT!NWJ[(SOS%[8IA)Q+CG)P,>
M,K0]B72@,Z*6NFJ$MZP,,X?[&3S^1N\-4NU@OJ'<;/]?9C;_)_?*+#@".\-T
MI:^@XGY0K;S9J,W+J<!["6E&1);4^3,[58TT3W>T16<D"<HW=MW1P?-L3UYR
M)%QRNXQ+74,@VYIH-S1'D^P(^1OJ+<&_K0&I@BLJES "!NF18UX>*\P<"6%P
MQ4/T0K6:TQHA47=- D=/0%[M'.(S@0L:@5;<K])JM0<_:#R/^[A[#*7?C_QP
MM,+1;,+JI&=BD20!"PH7).V$20M>I$;J^&3>F1=PX9Z],T+ DL9(ZT2TJ)I=
M$TB2-21?25@Y9-3=^!%[I\2CY'1'[>;5$HI]391%/33)]!T=^8Z?Z\EXOA/J
MQ7-<7NB_)'O]V7,R43^5QGG*COE0>/L^Q95"R9?F@)ZU\OW'^H9_8!:K#\\_
M)=2&3U"+Y&PM?,ZBD9.%/$[G@_4.6^8)6<)9+_6<%/C\F9'G^Z]"7])_56,V
MENT;^ICGZA  ;IXKFV^*L;FG?-_4KI.OY<0XA.AY3HR0S8GA:.\#:CAZ#&>V
MI=:.OL?4ZEV2+\S>=W9W"(.4=9"PFLU"L9.'\56?7+2;<'?$B#%-8ZN^P0Y6
M4N: L(;]5,>&_N%,6(4DELPMPUL%"\\\C?=OD2 3SU@PM/XW&LU!O@*PC;'J
M;V1@><710#2)D$.3"+U/DP@9F@2W>5IVQ$$XG=]47RJ;-,ODV.AM&A$I:W80
MW923\5[_L=>K-6/US%H?PYEQE[B<9^"RQG+HAY_]GV*M. R5&3.UC[LX5;UE
M[YYVF.QF56_=D+5):5?L,JRLA*?Y[2(V*M#\+,,)DW1V4-7?/<_N1(#]2'57
MU@*WO<0+=!%7=I_.YWR?"3Z$I\78<E%;IQJ]]0*Q>\BM7/_=[(Z.D%W0CTRY
M)9%G7L#G#60/0KDF&++@30GB>D^)7XE61RWBJCZH*3RDRM/#,GUB>P^Q[2CL
M+**J#++I)GN_Z-&=2"$\JX?BSP^K]*]_$V[IUN\E*O=AB(?T<.[@3)\FWD83
M!V6D1\EA6%]OPP],BNZ%)_?]=#T=O._FD8R))"])#\2(V$W;W"':2&"61\[A
MEN:X35@PX,LQ=U.SFAN3N5K0L=BPI2!&K$YDI!"3_'4DE)!I:M8&[;DT/MO)
M[)BP8C8&,O-_=PYEN)0D6:/7(HE)6I,:CF+XT7<5W]S9D9XK@FA9R<=\9<SM
M!5?4"+:>U>7HN.#*B:/.L#UM5Z;"=%4L#*?)\'1V7<WI+/%5>WD<R'JD$:3U
M3#^]8.AD:=E>75I%LC=9MYU1>RTR7-T?IO_!^)Z'#B?.+@N&4,.S(8]X(.S!
M_\Q^\/_.)++.6:U0R%-2 4B5MMP:^_D$N")OA'-PD5@5U7- 1L[\'7B<+5)5
M-S/2L#*/>5$<0P]4,T< 2UYHU&8V;29VS%SA)^AAN+&ZK.Z/_;*UH5)(]:<U
MBL'FOS9#/-@[2+Q_0?-GXNP^;?CN2L7<9QHA&-K<YT:%%7HOZ:%CS#OCH 85
M^DQA]XNUS%V9Y[MA0MD%K#\&^MQ"D9A?*.(7BGR_0I'3&?QOR/>_W+#EZZAK
MALRVC1 X+S:.)^< 1$'@GW,XR"MRC)"SWCJ7SXNW1BD/C,DZK@#>/RZ>V=@R
M\4SW[SOCP7UU%!O&3M6+GXJG7T[_&Q03X5HQ..OF-R7UL=5\8!%0TJ[!=;O1
M:>@=*V:7KW'15@-?R4:Z9"V(U:H/FDXP<Q[9OJQZS<H0KU1C2$>"V4<;(3H#
MVJYP<Q9FF)?L2C,8W'G'N'J7V\Z2!=Y1/:O"WM$AZ^B2G/LCD76BM.XBVH9K
M&&U9XL>R!@."2#,!@ :!A<N HV/]+JUQT48KH[>'NBTOBTV+-_S6Z-EX O%5
M4NP_L5C#A-:>J#3D<G.<[_922J%"+\*K8KA:3K'%\/AS"S8:L<>"2#=>MGE&
M[TV?'^^%6$L8__I76WTLQ>E$N<;.06;G"V0UXB;>R%K6(#/3UL\&F4^X 4^
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M$<W*1B_@_=ZYLB1N+/;@[#(9>XF,J?6F.#:$M *%EC-K@ ]C2-Z J;[BAUH
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ME]G:=#KA$!%CC[?M!P'!S4KIBL?GNA\[M+[=:/:&ETBMP2QE:(S46Z9DGF<
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M/ELIW L<>;';-:B45305[,^)'GQ?3_! < A$__>V$!.GO*_WSO? )TLJW5>
M,#M ]7I!CLAK5@[-&KE"#ZX7;;/V$/S%<]=A-BGN;;A; *%0WE\WP <P]/9;
MY :QKJP!MR<#/"] ]Q?;ADZT'.PY/!O#!38=?:I(BBK[#JRD&[ R/7! PE_R
M>S;<XRLO5::*#BP4!X_F/6!:T6O@_E,Q[KUH49.2,?#R97&U>7,BOG-1H$]
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M /,>1,V&F07@3?; OJ%I?N8A]#FX&@DN:^CV<+3[.0ZV0#^^.'CBC:##OZK
M]GE__4O\^W*BGX)HM;[H;W[^J.#WIGE&JI9(>5(55^S$;"ZEIOS" .&78! _
MGNW<G +L&ZP/JP.F8G9WW2[0B"+-G_1UMMQ?5)Q??P: !$<P0;W;!!(K#H?
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M0EH).(H7ATT8S*6@K5+?16U__?GW^=3ST$'ZNH2YCCW#;N4AW)=)PW=,VFN
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M!#)-%,W%P'[&;0@E@:?H>(H\TB_H$=AEY:;W#.Q'/N@ E"6/E9K[%% @_&^
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M3FR GQ843T \L,, &^(X^)0TS]5F92XW:9IC5"QQ*6$)O3Q-/VEL]DW&2%Q
MH%I9<^V%/ZGP1H?#E^+;'JC'*VQ[9RH@C- QYU6R90S3:Z0TKV35!5DQC+9S
M@A^GCB7 *WH,"<%'[*%#>.[X"83\*]B ESO;;ITYB![]9OF:<-KE30^.?>K)
M?<AX6B)Z"$ZGA!Y"I00"02DAU9,D@:(H=( 0$H&3@QW@<B%%BC+X&R[0N(@*
MA(3* B/V**'71T1:1$B"Z8O[4.>+P;ADDNQP/)FNR4Z_-5OH.98]!C*_JB60
MLIEJ.SQ%T>GJA#5M[F%X#&1^B1.+H?:8R?/SS+Q XN5Q[C%U%&2^556;ST_.
ML\!5L65[E#>S3$&M'P.9[R+FQ&JA](*K/O!EN:,[4Y$]"@A?U>I2=2:WTWS3
M(@0+&XZ$HC$$*P^><\#G,*%L.54N(Z:[Q+I4'7(]>)1\\)SK7!J7)N-9?C)'
MC28W[JS(PM-1D/EE>F)6N=;L@9LO$_R(?Y(,RAD*U.%*,E46E-4,>^:G9B[7
MR+*=AR&X)GT$N'[5U]"Y5N:0)E_0.Z:]YAB&!2L/W@AGES,$>\K,)U5:1K,U
MK-90Q"%8&0*NORA($B<:,/M@@NW=W6@.08X2G;2JI7@A-5FE'Z1&+I\?X+0/
MU0G,O=QGK1?6N5CZZ(4@D5Y0]A?'O@3C5!3-S>'TX/MZ1D\!08H6A@?"J6,M
M0F?()A^9N^&GB5$LZ34<N1:F(ENQ1]TT8X!#,9=%UP;/VI,0X(HH$JPR5F O
M>]^=$7(H-<\-N2X.>OR4MWO:L\ C$Z$\9R\D!SLVWGT^KZW)>\*8!DBH0A)N
M<$]CHF492L_VT*: .Q-V1D> #;)ANA'J[F"%H\!5\9B\E&0@:/Z5P8U#]YGJ
MMF9]=7 K)DFA$9;"J[[/+3!A(K[<(5_0)!.!6]TC7Z@D'8%;W2%C(D-VGWR)
M#-F=\H5,1OIRU^!6GLO\;5%F/F/FORU1W@YN=;)TG4D2Q\%DO@^@2NP<@%??
M1N\.ZPN_K2;>"VA1!&\52<I;P\74<:BX;R4IGX2W.K2X]] \\M([NUEST=*-
MWQ?3D7L@P?41"-QH,2*#EV6Z,S";.R!,I":1FNSG,+ZMEGQL&[VE"%2"8](W
M'(Z>S1K\,)GW5/_63947[R?U=\!;O^>[-#WVUU?O.@<*[ &(P'H1$/2 ]P;7
M.-(M2C]/9LZC-APB>;3_M%P)U9S9\Z&"4)**IYC#.;]_?S^5WP7#.0@4(HMP
M1HO@;?:W?LW[,@@7;R=_LT&89B<)BJGTBGS>QG!S1NBB0=0]C!Z<CJ/8X53<
MOW]2QB K:_I4T:*<010,13F#*&<0J4F4,XAR!O 6'7_.?2*8<W^R%ST1Z^T7
M9G_WB"(*(.Z$1%\@'?%A+*LS-BZ_GI! WA5^!,:!]6S#;N-Y"#O#[=C8[RP&
M4<GSJO1<TYJMQ:0C:"63,M:5;(45*)BF^+;4\=MJ#HCT+OK 1C,4CZ,I)IZB
MCF'I7P1#\'XM<93;^3(TN_]$T2U,]?M31=<UU0^/X_68JQH2-UVASV9/)]K=
M9P>8(NH:IOI&U'F'J3Y-']=4QTD<C:/T8=;]C-C8=YEUJWRL-?.2P<2=4>B.
M<@TWM\K7.K>\PU<_Z\E%5EDH?=D]M_"M+F.F\'9KE9IRF&$N-*F2Z92?G',[
MR-B[K.[1QO/#4XRMD14S;"$_[Y-%I*1+>G.<:F1(&X(IO!HO?$V"^/O/QTCB
M[CM U5.O[SGG._J-;.O/M:VG4K<W?_,[-*WO=V@O;%H-KCP>YOLM#9&Q4M,A
MA%FM\PRQ;U[U[[\F0=Y@6D^3!)I6C$ABQT#77SE%OR$,^[X]O#62U[L>5I4M
M"Q@1:'=<^Y#$W#6M(W#@,QUBJ'CXWV[L  '(35FR#<529#/ *%<T2;7[\$!#
M<RT=M$@S0Q[(AB'WO6@D#I%.0; B6<$G;D#BGWW,((/!Y;;0AO+2O60_-C#T
MJ8N@!Q'W0*3CJHT^>!&PQ@SAH<<<W5;[$*L7Q$?@<6Q)]B"A#[[GHF6#I]8-
MV8-L=?8/;+9 P$&@Y2,TALYN;!^B=8.&$P-2,8KM;(M[ AONJ0UU#DNJ+!IP
MKQC]$X PN1*_A[Z&NSL2^-WO7L;H) XAMW=[BT/7W;E80I)5=1^%>R<8/F]W
M\LEV'(P(MI#-_H%2V&'/,?SW?W8:K#?;9,)/ROE[88A^ 6G<;7$H)[S^;7$
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MDH596,@F2.N7'N$R'6,2!@/&23]#&QM*4RN7)-3,:H)"#.#5:YF[#[^IGY\
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MI_67NV[[RNP.W)>4*G(7H#IFJ4/V+0[99-@A6^CU=7."$.-#G[G196.?'+%
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M2+8'O3M6EB_N2PE^T#&?JIO1B9U#)_:@Z#37?@##)*?+MEUIU7":XWR# A
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ML$3@"-N+-Y&*-RK>CHO/?'OQEOH713LJWK82;ZE]B;?5IAA)=BR W'(F^ /
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MW*QL')Q<7%R,+#R\W)R\[)Q<G/].0D%U_@TU#1T-#1TG$P,3Y_^SSEH MHO
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MRL7!Z )WK$&57)'1IU%Q18.)UN: CC?!HL<"C/BJKPD=V#L?,W%C\"+J[=1
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M^KTE:K3HGRGTO.T9@GWDU0&"[(X=R>YKXN;Z(TCNQ=- <=A)!C8 98=]\LJ
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MY/-/.[[/@^Z$'*_F08[SLL"OFT];_[R9ZEDN7AL7L2I3ECGU[.K:[E)9Z/B
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M([$3S;G4*T_M&#1#0YAK*-,?MV3GY:@<]_?RWDO\ELVM(*4Z%>%DT'$1=2D
M[6909JC"3EU0:*)+*YQK@ QNF:W!R9T^GGQ6J+AK8"''Y>7!/#Y6,E9.8&5Q
MQ5"WDV=NY[G55-VJ_8U1_ET)[(F21!1$$H))B1%PMUQD=_=YVI7_9-IT^MZ[
MO3NA-7SJ<?;L2;65?1DT36E:!O;6W=#\ZT/+GM3L(C4:%W;/VSORKEZ.X0$H
MU<=+),N?+@+!Z"A<J\_TW#$U?=KLLW%6[L'K@(>XJIPW5VMFJ?_7K"U4PQSD
M[W&O"UM>:>[!X?"V\$]?R5W^Q<\@_VQ_@PCIU7]9W_UG($(D>Q;GZ%O'$>@
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MVR/NG<M;6R4!5AGA+:,,"\(1M[0BUP+!LZA[;H&/]TK<.T^L(#GI'(]:W B
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M:8)N4S.=._-$')>.><M*VX\!5>@U_NVAVKRK6(%V/T#UBSV:C,\9_R8 Z0B
ME(\$P!L"0-+H']4% -U_57C^DY$Q7>G,N7R^_VP)V#]*P4(TB)I#'@2S BIE
MP]4)@ ^C^9>^3!EV$;:)D_F#W,9@_'#,# &@J-90<!P^5CMAQQ.JHWLAS&V&
M^_-O5SHU 4;_H=,#QNZ_G:7LE(?:'58U/;LN\;>SHK\Y;NTR$OT7'R*JZ;?F
MCNOA(3O'QD)HU[9^93?N?2$!4"M! !2( :3_:P?_?W:((!5&0[M7H ^&FHR
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MU*?W[>\@>.VEY.FE'[U)RV@V"Y6H[;3FXA$^5U'3&Z_^4T>*J6E-P;-MY9&
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M4U[-O@/$,L)CK]VA6.W-;JDC"_/JG"JMM_@)#H_X.:4\7B12K@X/:9BOV*H
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MJ8B%HF3;5:TP0E&N]9HHZ0/!:U5J9$1MCO%"D<BK8JEFVFUZ0D8Y%X_2B3N
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MS3B-;#[AUK+JJ(EIS9 -C^NS':[,T-EG-^KM15)Y<O0^/+I1@1QH#:JAW*6
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MU1]8S2(_00G)2$W-=OG;55V_MK[F'V&7_ -%=H,)D^I,J2H 4<H'3,YNW?*
M.\!'G]U^JB#X/BLZS2FA''SD<Y,MZ7,V)X]9N@.P7-4?W5S;Q.>VQ&8:@R6"
M[@#+(:F\!K&@.;?=4[EP12QK%9:RNYML19@&:>K,Z!!5!9$.D2PNDI@N*2:I
MH" NH<[E251V^!3&Q2807R0UJ+*1@\Y%(8S0]L7^*,T1ZRO%C#/4!NI"JGT/
M)I(>!)=\K"S@T_>MHHQ0)!Z1/VZX.Y5QB 8B](V>"*;\[$;7#$[<<IG= 9P<
M;JEDFZMA-WFW<M=#](*2J[Z'(FMN8T,Y?_;3TMW0<5;HID*W<C_97MH H[T6
MN^KL\NY*D& 0R _\F].@"N1.U/O$:M#]L7[1O:(RIU,97KYI.N#0Y9:4!EG^
M&B//3]D1A1>:S$J]];M2I;TI?A7@EZ@!O74O+T_2J3<5I,/WGNF^0+J/EA2C
MNWL"@LMKAI8/Z2S\/+J!GQ> BKY%-TVF0HPB3&,@GASZF"]&VISJ:0&1<V&#
MBYG*4M%E"W/7=&O"=O>KX)+^I+5HEIVSL:Y+O,SH_'JT:SAWCD3[1^2;K%M>
M,+WH ,GFYQ+)-"9;&Z9:X_>$AQ*DE6@FX_8)B.**9@BMQ9P?KE7'C];6B25U
MX2!&RT'[YC"F_*>O$E5!.B.X=3&F^"L:5US4,]P5NUAA.&+,/9#1K73SQO18
M-BFRI?#Z=3TF%X:BER BH7#CG(0*G+@)75#:$OX>DE'K\_ODRL_84V6JHO[N
MZR*6(G_)48&P0>U4T_C[U"'Q9?%T8?4,+./ 7RB7F_F+^;O2><;#LO)TD(9<
MTA :?O&IO&SH2XA%R#\VXS^4_=/[-?RG%:2IQXJ]T#DG.Z;&$?Q_ZG7_5_"H
M_XPV_PX@[_&/@SM#WCJQ'F\*WQQ;IRL'Y"%I9#F&+S_*UH^$?&\DNSC.O+TH
MO"+2O0/D28<<9IU4/+G]73[[8.KQ0J[S3419R-A7^/D(ZQ_SJ.N+H3L !%&L
MIWH6H?U+/I]T[QBX)ZAT"UG_QRF@MUU3"INCP*N-=KY8A08^'\53 E^'K#O
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M5U.W6G+S76:R-(D,?.1*9R2M>)*9-K)8GUPX77F4>E(RJ-W_:CS3B'D&"F9
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M6V[= ?XDT0[%Y<@::F;+>M@2<H&&08D:^?J (=( >VKLB'Q]I?GV3(:[A>4
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M%>9,U3A8"YEF/$5BH"$*T1L%!X(4XRS =&=ZN23$%I#<T;);] +N48-GJC#
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M 7*8\>)_FZJN5)?P/_^:^[_!2/XM_A]02P,$%     @ [3%K6@;^EW+M2
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MF=&-)7['Q93@K>&#B,CS$L#5LW[KN'UNS7/TF>UH0,!5Y-^HI9!MJ(J'-V,
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MQ=T,*H&1W0LCSNPA[UL_AF802XIQ"VLG>-RUOQ<O8RC]M3IOP/O;JHF'W8!
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M2GGZK$^WP8$]TK7G5N>W/7JT( I,=3Q(D& ^B+4'*ZC%I;D;SR7#>EV6A<I
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MP&GX7@2=JC(8$*_QH(T"3D,HS5[U@_#&MHF%@"MKG7=!Y@F#'3A]UW:G5H]
M1&I,XWW.4;MSM$ZF2&0D>8U,<X*G8]K$3((!*NKV*<LD'W7X"O'I=7S9@.M/
M&X'[6&ANH& N_+:A]*8$TCM$%L\NE?HU(-LB'/@U.I\RQ.L%T"NFWR]<]3A'
M1EF=OA$=2X*=QBWMPO0UTU&T#!-[E)BNB9M#),E*$/AF5YS>([A/H!._(V[E
MID]][P6PX.U2@2U,\@)H>#\KT0"T3*@K=8T^W I;<:O[WANS2>5]5M*;YH=_
MEJ2_Y^6]YR5S5&ZT(,4[(UI,>QQ8J)MJ'GE!BDV.C(1:9L$,#K9:I$$-WHL"
M=!2+N\J#4,^'7@"4O!J\+3FN)#B<W')SV[P:S=1NMYT[^RIX$]?P2;$M=RJ#
M\\&LK_8@OQA.QX-VZ@[5QF"KX@6#@US&-D5<W"4(J,!RU#/ A(ARF,1(^% #
MIHUV%GX=T#S7+N>,'F(N;!F.Y.U1W4\K$MW/F.XGKNP<(#2DL;>IW73#4PZ<
M<UZB31JI&YD@S"U$]LH\2DFR0V37%C%47XHY'6QF"XMF!GV[%_RNF!)VH9KN
M;(*'/X+4 \#"NB8:-'C4.H.L9,.M]#-%_#E'=I8P<B+W,3^@4\T.MA=-.4XP
M2X@XTM'@;-0Y67T*T?YD9>YN:=P^!&S2.%%BEMRZ/-(TM^,NH''E)1]ZLTR2
M&),[2Q5ZGPP2_\($2)Q!0!\9-T6Z, QLPA D[/FPR[N&@U+VCUSM3CC-U/V%
MKZ@V6N:RC]!:W6Y*?4X/N8:*!(<'EM^HJ6LESGV;RXS+6"=O::C(R,_4[1QW
M.55LE'K]B3]!:'Z!YEI4FW]&D%X?<[[&1A]S$X)VJT5S9QJ,$B>%(T&163IG
M:=K1;85R@GN@OCS-P#P>RYTS_U#9L4>EUN9H"\/^D!(FM.5"1 XB[1Z<.E"W
M=AHEH! _C/^H.LR%X4G'&%!0]9%@V)E;CIBD+415!RO) 9UONJNOAB!@?FH;
M-<9L7.6L:F_]0$N[")U#>G7+5+V#6>]+DE$5'3++,&0GZ%LAYSAYI%DBSAOA
M[++[(*2:7YWX?DMZ]N&?R7)+[7@E\(8P/_(FZ&<<E2PUL^9[&CDLRJ\%!H&W
M-4YW^]MPCF@_>3^?20S^2%]?C73W:>6)^Y?$-![!<ND;12\ ]G\]H.M<:#NJ
M=]2K]@70G7A@3"7QK;G=]R=H_=^O*>-(E2H2WM'93D[?TK.$KP$L/^X!GGN9
M:)-7^K##1,76XM_<EL_IYVZ\ #3!O$$K) CT@*7*,'I02$BV+?,"QJNSV*7-
MM!= J/_&E]T'IAO_SKQ-_::C,UR-TX&N\..J!.L$^O:/-&$81:DTRUNL2=54
M'ZFN69I/E;T"/XV>@6VX_[ED?(?]];1"1DOBED  XD?^L?+V^RW9S%#RZNHW
M,XWF]J:FJ55;[A_&#=%NUMJ3*V<1PU\S%K)-YN@$ EV1O%&E]%,B124\:_)3
MY&,2%WE'MQ)(UB<7[H,D1^+<=EK)\P@?%9IAF=>^/(JY^_+;43N>#17\WMNI
MR/)VRJNKQ "GA=W<PLP22)6/U(RVBB)$X#.F&>JUPVO>-KF!AA6K#+L%:E&Y
M\60,IU<>@V@2I682NV-=I^^>I>YW2/U'YU\ :XJ/8]2O/:CUSZYC-U;QV(O/
M^*._U5,W# .3;0@@5@^\D.QCO#[6[%-B5G>B&HD^-O[1(6&5H)IV1UYQVC:8
MZ0R47+YAV+*I(1/R(Y Q$W718+#.H?T<$U+:P.:\H1U*X\'K63P-R3T[V6Z$
MX@-Y%/:V$VE=7!92\1N_('?C?I^V$;Z)/]Z:9O3VUNJ<86QJ#5=_(/K5;LUV
MMD5J-7CW"0# 4G;@R7[CKSKX IC,\%_C> R].N1X?(I_1NT::\'MS=':&=PY
MZ5MA;(&5Y!0K@E49FG+/"3L5A5[?30 \U4:2_-1!?ZV;7@#HMI??^<JJV[^9
MA_7)-L^N\;OA\KH[ZJ]VQ'5_#K8_(=)5H6&QBG%.+@ ;XS\*E>ZEWUN,-:;K
M.:VP-=1&Q*<UZ7?^X?00B7X[N2Q(1T*4^VZP=H^E&&AAJZ'H2V3V-/4"D +'
M-S3H'HQUB1]WU,<Q^5MM_J_#_GAUR/("2/\O?-/OPOO],;K"#AN4]#;[&Y]I
MTHT"C!#?E[=2$!!-74LK8(%GD'Q[_6].KK_:H@X9;R"B33:K7:<G4:Y@7W'R
M-@U68=?2.JC25#P[WO&#$ZX$;YR3YTYY32!?G8/+M4IAY#.?A-K _SZHL%H/
M=ZC\T]_)&8&.0W318S&)95ZMB8RU'$ML649O]/G7PQ?:#R4K4<;J _Z39;Z3
MCU'W [B[QE["HUD!<P0MOT7B+\I/N#22<X9JBT?68V+T<[9,GFP:DFJ3DUMK
M6V#*]$L>:W$V0D"VL)N_S&U"2X[P)'Y;+G2 *T/1+V"2V?/?'VFV[ #&7)N"
MR=IX/^]I18>-][\G#Q36E$E ?0* M0NU-N9W2+\RAOA0.A6.NKMW5RI&Q;^$
M==/L!'"0IYP;X3D56DDH!(\#7V&VR-EEE)\3DF!>6'55R=I+?YOB? $$JM+*
MI3:M^ZEZQ2N # &?DW9;RFN73(''N,Y["C>D679_NN-@ 2F@H'YDGMA"5W1X
M9_*I<KNHRKH^YF,PEPJ[Z0M Z=VV/<SJK.9[IC'3L&FN(-%^'I*H5-V%VE31
M>^F^(]68%P#>>O<CI_^;>S^J 6\LXSIO%97,Q<=.J\E='7]PV'6TQ[.*_]1C
MO(G+D%[ZY_KZ]@Y\X]4<[L51-P':5WE8A"F&41_OOJ--VFY=YJ?3%DW_G"F$
MX;M:'Q\=NLGK*9*DZ4H=B0"T:$P:_RA[H"8FL5S>B<BTY2''.!4%L/+G;@H-
MN+BMD/VI=H'PZUXU']60B*S(D:.[:$FTJH8#\(/T=R0\'+ATR%^KZB/53@A;
MMI*LG7;,QF:_;8>G@U#M^<:DMJU)4W7E@;O?6!>0O)#&9;1F*U=_E[O--N15
M!Z_VM*(@QLJJ.3(K2-^2?GWOE"?"?4P:(W#C='NHI$F%^0>RXOXO&?\E>.=4
MR_LQ$&/;X/&Q@LBPO,7_^RODJAR!7KR/C?J_9E+-+=4MSS-J+\+>H&:]<I!$
M:KXLK[OU[L7U,E'ZJL)*S*"=JHEGIY9J$L(%J$=ZU!DBV4U'*!I[&3M.C1+.
MM5&W%S"&-K#10RLH]54)5O7'T1JX>V^1E@W:T-"QRJ4]625)[6Z+$?\C7 BC
M]W@30+JYM2^O$P.YRFZ!'D4-@[<N I4<MNQ_LYJ>71?"<_(U5K==BD@R;F7*
MC+<K^\.[C8,;0<Y.*Y/7[/3H[W_B7.\MJT:M^^PSHW.5)P <8ST[UO3YZCLI
MR3]/(RDX4U=PBUZ^=_\ @&I>>!=)MUNI_P"V8YH1N>"&VEB9VCR/G.YQP,D$
M?>.,@=:FN? 'AUY9FC\0+#;QR%0^Z)R%#<;QN&79?N[?E^4YQ7&/"'R"HSG.
M:J21*#T%=+H5'_R]?W(Y5B:,=Z*^]EG7+*VT[5I[>SN3=VB[6CF. 6!4'!P2
M,C.#CN#5 C-(XV'VI0016DJ;22;N9TZZ<WI9#X!^_3\>GTHI;<?OT_'^5%<<
MHV9ZT9Z'GDMROG.-N1N.<_6J\LRJ1LR..:AFGS.P XW$?K4,\A$A7.,"OP\_
M4BQ*S( ['@]*9+,753C'OGK44TRD(.H[BHWS*HP"$'4T")AN7:Y&1UJ":X,N
M> I!J.2X9&**3M]ZKR2ER%( /K0!.9=\62>^,=J))5CBY7DU%\B6S%CU/%5X
MYPI;S 6R.* )M^_YQE<"HVN % VC..<]Z@,I R1^%-!&2S<>WI2 E>3*\+C/
MI34F=1@8SV-,9UQA2:89%3:H.X>M*X$AE#;MXRW3(J[H6N/X9UW3M5@.YK64
M.P]4Z,/Q4FLR65<X'!IDAPH]^U5"<J<E..ZU(E&,XN,MF?9T4L=U!'-"V^&5
M0Z,.ZD9!JUI3Z=#?J^JVMS>V01PT-I.(9"Y4A"'((P&P2,<@$5YM\"O$AU[P
M/':2MFZTQS;,">?+ZQG\N/PKTS3+ZWTJ^6YNM.MM5A5'0VMXSB(EE*ACM(.5
M)##GJ!G(K]JP]=8K#QK1^TK_ / _0_+*U)T*SIRZ,Q]A &X@M@9(XR:WK-M"
MOAIMM=7<-K;"/%V$ML7$<H5R93+CYE)"@+G^(#;E<G(*%% )W$#&3U-=-I_B
MK3+"#3O/MI;I[5(L(\2!(73.2ISEP^02#@?*.];5N9KW4_D94[7U?WE;3KOP
M:\]I<W5K-%&J()K:/S)&W; &V[OE;G>26(Y"[1C(JC;CP>K)'<K?% #F>,MN
M7##:NWOE2VX]>..U:%[XDT&^MDEN-&$U\L*PB1N$)6$*I ! QO!)!ZYSUXJO
M+KOAB.6,P: IC!4GS?G.!SCEL$YP"<?,.M8J,NTOO->9)6]W3R,^RD\+G^T8
M+S?%8M=1O T<327!08!7>1\J9W'J'_WL\5YQX0\Q62*Y:'#!T$DAE#;ARI("
M[ N2H/S;N&XK4?6O#4#%Y-&D\_<"%N+<-D'C?RX^7' 3&,X.:K3ZWX7\Y9?[
M$>;YERDPY W#>2V_YR5SM&!M/K32E?:7WA=6M[OW%=V\$9GA\J9(_,)BE/FD
MN,)MW'JJ ALX^?DX)XKG/% \-?9!'HT4ZW"R@F65W(D4[]PP>@&$QW()SS52
M;RV=]GRKN.T,<D#)QG\*IRQC /8]#V/TKNIT.62?/+[SCK5G*+CR1^[\C+=,
MU#C8:O3*I7.0*K2)G/'XUVM7/*MRZH+8YF7\?Y44VV^6X4'W_E17-*&IVPK:
M'D-Q.!.^WIN/\Z);D !CAF/Z4V33;V6=P(#RQ_B7U^M,;2;T,083D#^\O^-?
M@1^U!YP5<G[QI)[C 7!8 ]:1=-O,C,!/_ E_QICZ9>DX,+8!_O+_ (T@&O/N
M8*HR!5=B2^T]:G^PW:OE;=AC_:7_ !IKZ?>'#_9R2?\ :7_&E<"(AF;:6V@=
M30\@*J">1P*'L[T'_4-SU^9?\:0Z9=[@1 W_ 'TO^-(5Q@D89SAATQ3'?<!C
MGUJVNEWA4M]G)QVW+_C4(T>_1N83@_[2_P"- RJSC(* J1US2HP8GN/2K)TN
M[&1]G/\ WTO^-*-.NHE!^RDD_P"TO^-!**QV'^')].]2,=J@-U':I!H]Y(Q;
MR",_[2\?K3I]+NT5?]'8GUW+_C0,[/X%^)O[$\=Q6LCE;74T^S,">!)UC/YY
M'_ J^I=)U6?0=16\MH[>29$>,+=VZ3QX="C91@1D!C@]C@CD5\20V.H6[)+#
M"R31,)(WWKPP.0>OJ*^Q/#FH/XB\/:=J?DF,W4"R,A(^5B/F'YYK]"X;Q*J4
M9X:?37Y/?\?S/B\\H<E2->/73YK^OP) @C4*,X P,G)KJK?6)[?1=#L6\-FX
M"ES932H9!<NY_?%4*D'.%''3:*YY[:0_P?J*NVFIW%F;3_1EECMX9[<H7*^9
M',6WC(.5/S'!'ZU]?4M-+K;_ "/F8MP9MP:]8W.KRVU]H#0RP1%#:K ))#MC
M""(KM^5?NDMPW Y]>;U3Q-9:E:7D,.B6ENES"8P41=T38^4JV,X0]#P2,9K5
MM/&%SIUC;VEIIL$=O 7V*\A9B&.?F;@EATW<9  QP*P]=N[C6[T74D BD$4<
M1 ;.[8NW<?<^@&*RITUS7:T]?Z_X!I*=X[_@:E[\05U+5I;N_P!)M[A"[&)6
M 9X5(.T MG<0Q)QPO/08%4(O%FE0QH'\/6TK[4#[E4(X5B2H7'R@@CGDDCGB
ML9[24Y^3]14#V4G]S]16_L*-K+\R'6J;MW^2-Q?&MBT,*W6AP2F/<3LCA"N6
MV[@04X#;><=.V,FHY?'>FS_/<>'H;B3 W;MF)!C&T_+\J@X8%<$E1G()K :R
ME/&S]1_C59[&;/$9_,?XU7U>C_3?^8_;U4M/R7^1JQ^,K5+N\FETF)8[F.$.
MD,46%DC#CS54KM!^<';C!*C.:Y'7;B+4-4NKNWMDLX9G+K G1 >W]>..>.*T
MI=.F/_+,\^X_QJE)IT_:/@]LC_&NJE"E3ES1>OJ<=>=6I'EDM/0RHH\SKZ\_
MRHJ_'IEP)@?*.!G^(?XT5JYPON<2IS['_]E02P,$%     @ [3%K6HMRU*#!
MG@  K;4  !@   !Z8FEO+3(P,C0Q,C,Q>#$P:S Q,"YJ<&?LO'=4%%VS/MI(
ME"A*!AD5$"4J03(C(I)$!"4+@Y)!0')F)(D$&8* $B6)9)$H:<A(DISCD#-#
M'F"8^;7O]YUS]#WG=]*]:]U_;D.O1=&]:U?5KOW44TT/^%'\+'!!Y8'R X#@
M'  0@%\ ?@*0!PC/G?OU#1Y$X#<Q&3$Q$1$Q.2DI"1DE.24E!3D%!17UQ0M4
MU+34%!07&"[07J*CIZ>GI&%D8J!CNDA'3_=+"0$A.(:(^#PQ\7DZ*@HJNO_Q
M@:\':,D(;,[)$1)< \[1$A#2$N"; 0AH)S'!7P?PSX/@'&@C"2G9>7(*\(:R
M"\ Y D+"<T2$OZP&K_J UP$B6N*+5V_+D5S2>$YZS8%.R"\JC8SC7G$#O68?
MFE/XA:/_>7(&1B9F%J[KW#=N\HB(WA$3EY"4OZ_P0%%)6>7)4RUM'5T]?1-3
M,W,+2RMK)V<75S=W#\^ P* WP6]#0J-CWL?&Q7_XF)">D9GU.?M+3NZWDM*R
M\HK*[U6-3<TMK6T_VCOZ!P:'AD=&Q\91<_,+BTO+*ZMK.[M[^P>'1YCCDU]^
M$0"$!/]R_(=^T8)^G2,B(B0B_>47P3FW7S?0$A%?O4UR44Z#]+G#I6M"?F1T
M]Z+2BAO.<PAKHNE?./:1,W"*H+AV?KGVEV?_/<?\_U>>_:MC_^;7.$!)2  N
M'B$M  7.R/' &S]T,/:H&@_4FV?@6$@;(7O3VWB (*'N!=2]#^<Y-,8VW:\X
M@$3WRE[  RE'< SE(+Q)SET>YS6%!V:%=;I@RP66[G8=_/+-"6J9JTMR#FYT
MFE?$)_-G:5.S&.0V.7W8H)8T9)!C>S<\\+I;&0]0$:)HCK?_DHQ4N0/V#9V,
M[E2YOGC3IV<_H^YJF>$$C6>0GOF0Y#-+P(Q=J_$E+.\OH[II]V[JM">GK'CW
M$\3\:<3L_4;MG_)BSV@TUE7O?<_T8L2*T 1"EVMG<(2BD-]L'9H?@=!LE$FU
MJ%U?F_]9:U-66I$B^KB_X8;V(QKRI]&U."-+&,'*FYN9+ 78+Q</=1="B7C:
MK>\ZM4.\N-F3S,.N.BD=0C"6$#)XCQ<22V(-17WROHH'9+;P )HY[P<2I3<J
M.&$6HQ/'^O16/F6?_WQ70#>) O,!1=!Z^^;#<C15:%D8U^3>LS<#9BDWTYZ<
M5TTGZ0N(07B;LO %I"A^_3V2&G]&1M!AU@NRT6[G.^%P>5[_V4S^"_K=B^*%
ME KJ4M_9PIU;8)48L\\-N:+QA\D]'XEKCH3S HDS'FC=^T#*>F37T/Y8@DZ/
M5*1'[_^^P#7RFFBUY,_!N=/C1I,SG2:WG[RMR:2U>USHYCC63FI_3X(^(]-=
MH%60LM-#4MW%Q>DYU:2C",<&>KM*]S#/(K[5D<9$(=+IQ\'V_S4\/2(]%!@7
M40I6J5J9[+AY/6101_.YV->F#V1?YCK/1WMT.VEBKK&N7Q^:\WK+]WD@1@,F
M,+'PP O!VP%8B,,2@65I#5-9*_:^/P*C^-M*>]S P%[8;U58Z]RV*FZAC'K4
MD;5T4:E]B9CPZH/IIZ_'YJ<K*3[<9Q2^SZ;$$14I3D32P"$N(QSJ>L\I>O+$
MXO=@('YSXC@,>Y"!/4C_8=2O.!@'O>S-^V5Z8KQ)M"_!@X&39.KU9!OA@>B*
M1%$H5H)\$A.F$A26V^YV\1(KO3&%7\-EFEH?35_6U3$\@#BSP ,D)7A@YVE"
M<2;G@HM'AF@['FBL&$ NXP%P91KR\0!6"X(NV-\^Q@/#<+05% _0:UKE#)N'
MCW#C ?*91W@@]2\M,;^TP'\;FOEK*,'_YW=^\U:?J^5M&#=88ZG=N'.GX]Z;
MCXW;)GT//!- 3X/LL^$].#   >"NQ^3N;H>E NK-!2H#RE^'"_-]FRY4S?CN
M&G$POLA\GLCSJA8AL]+[48(K749RXM$05CO,P<O]Q"AIWMG55?VT[4EO3<"@
M*[VSMPP:?2];]<T]SYK DDMKRA(Y6%K46RPC2H9#[LV<ZI?]==/R2YU'J9:M
MZMD#97:/R7ESVCM1-ILT1U7$V+>D4.,:)TX^&;H4G;T"*(U[D&AIG%A(@6#!
MQ,O#;SX+LG6S)\,-S(6PYL>%B7/\EYX$+T3KX5KN0!?3;W$Y[5][;1/_U$5$
MDS!!GX+\1OKK_Z>G+#,(L6T%5Z&W,T1S&@792U<6+),-V3)RB/4>D<E^.OQL
M'MY+U#O]S$!I5]Y)1$B<9YLM2,]O[3QI@J>U3@AK:T4\!6ME;.3#>N$(>=J4
MNC/K<LON*R+[B M3*Q4P*[]HU2"="^VRS^J[CY))7K$M[&UK6GE>+\JQ$A.+
ML^&U.KRO(!SRZH+R"*%TP-#KPVY3\S*16D<IJNNX1@,YQWA->4GDA\<MG*:Q
MTCZH/;90DG>)/>288/GA+;ZEE*U1H8?^.Y2) A>Y./T"DHR=90AZ5'+,4,F.
ME@]W$\.8?)N/BI6%;^UITE.>>^T423:1DIP[CWWP<;DF<C1-3$?'[;Y']J)P
MTR+M $;QRE$ZY"W"*O].L6UV&_770_-A@R*1;\6[0_3-IL8FEN(+EY0\F:.L
MV*_Z??Z@;P3Y&MX%B6*:NY>?N0L-B4_5Y/TT.-%2M=D:*;!IT?\\;B71YJWF
M(ZXH1]W+79-?4#J$S/6Y)G,B4>.PB2:SPZ=5":J1MLL\)G'W)ZZV:ZI4&-;0
M1@N'VJ8V6Q6("I93,(W5]5DX?.VXVUUC1N_I;.RT>7>H^N/ JA%GO)*8L'R.
M:E;[%?CMY 0)Y@A"$^EH]Y^2IX.2<:D%*[?D[;TK7%\IZ:4'+4DQ^8M=^#3_
MA?F(O2P[&]-[OB ]1=C6CM_X:[2[;OR[B[,/33764VYC^K%WATLW[0[';9@K
MOAU7]U^Y3_O&I^/2C6QN/H.(VNYS_2,2/17/@FD./U:\L:!:NB,O-BW1\V3R
M*,OPWIHX W%ULO&3V! SX]?+$A1)U'>A03K=S)^57]FPO*X6,WE<S6CFFNCW
M"O<<IC;V4R8W38(S)MJ#,^%A7P)@)&,Y/QPC8OZ!I8X.#T3E*>"!HE'X_HN1
M<:T=^R!6'$\!(P[Y' _T#M?U?[%0$,BFV4$VGP3[UUUP[X3UFRFYR(BI5%:5
M1_5*YK\-S.%QY^#(<D@0?.W+NU8E&K3N;7ICY,Y.UU/W%[VSWP(0M=L&,Z4S
MV,219OM38!J^\KEPH@$/[-ZT3#V8)\6%Z4\++60YQYW%K%2_'UHTZ<8#*#UO
M;3R0_G,&HSH._X4ZWS %>$ A&8F.+\4#<WDC*SF'_1MUBSCY!2.XEW0 CCZ^
MQ?Z$;Q,/!-9F@_"IB.45#)W9UYO  ^>]U'$\M;ZA,J75@M_AD8Z"T-H4.1#8
M.N<JSAA<020V&L #H1E_UV"$5& ?-XR?1/Z08$R=[KD" IG9C@$N3 J.$K3"
M RT:_TY%$2P=82O0N05;8 OKV;:(Z$3/S"7=+HWVMC)3( Z192R=I4:VP*YC
M]3!NIW)8'4PJZK)J([M09>V;8;)D>X95D=;R)U<=I ]W(O.9F1_UU<P&O;P$
M2ZOH]<G]Z2Z,$&46\C*EA<EXBP^*R@BW2FHE%7'RTL0;#W<RO8C(O>CB*WZ<
M<8\5\?XF,R6OBGO.0+R0ZI8BOR$WT[K%\HH/C5UAY*>H@!]T),:WSF]9Z\N%
MZB](W>>F7ZJ3V=GZR#65E8+(M1R/*_D\DS%I]<WH]<K=YV6-)*82'$O/7SM4
MGZOE:H6?#*&;\4")D#<;)L\K7W$N9+GBO:KD)8I[ZT2%#QOUY([1?E7&T:1T
M0U4EP?2:62+?.9R/AH=E!]#(MU=W'@18Y,K117(UFC;=:FJNCS5]Z:9-Q.:I
M7>CSSB/^-8X%#"A7MLS!8869&X_(KD';ETY(?&U8$ \U(=#D5F<#Q]&799^1
MB((%AU4-)[)1'9&LLG6^DO\7GY'<.&41WK") A?(%EP8N7=PL%8-P-^!%;4
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MDR86;'G2D^?@6!KKO?/P$2@( 9+V\[!,+Q981]V"]XQT=4H&'J!2W4'@0MW
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MSA2-!D7Y[^$!]10*A,#639+,M.?0VJ[07D:'MXWT]C6ZC]<T'OV,C_MA'9X
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M1I, KU5=/&9?8L0H@7R])B;_USMTRV"/:8RQP054P7%$@IA?CQU(FV#[EP=
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M!60[!#I_?2Z..6X"]^8\2(;HX9C<ZHSX:,502Y9HRW'<QR_MS!_YMC(J;^<
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MLUL7# 7+I?H;]V4V:8G*_<'.-3^9B$@TZ0(8CJ%%DIF924^R8A3YQTZ3CLR
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M>!^UYVT< VY[LL5Y3/Q/<D"7Y&%?U^  9W/@%?6*#&OL1 MX:&@(G>B<UVB
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MMR%MGO$%2&<^3B]=H[XYF_*<>PV8=JT:>&K64#2$$9J5O6,T\:PI[T=4XL!
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MCTKM1*F./M#D'7O=;;^\^HZ5\R;S3U1ABH[EC;9K2#=DY82QK)5+4['(4(9
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MBGYP6[>2@ I.3T\PRQ%T^BUSR(U[?G4H96S!UWGSC49]*ZWND#?66&G24F!
MDQ1*$WT,*@9)CB=J'0Z%.@R.J? ]EC=5 KWZA /445X%&TIOVS<6GWJ>H[F7
MF8<N>M"ZQ=T;8YBR>^C7GQ4R)[\T@59A!N-?\V*H?^;%\ ,N?U )S!=NB2!B
M1#FABE7.839U]P/.7\9?)MD1R00^\,3.<MI:E5@_<1S@A54XY 9'@&2B-P[
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M3L8>5C.]$R4M=OC<[V:"FKH6!H52 AWU  ^2U*>7<8 <O%(&Q>C*UU<4(G&
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M\V=46C"QZM@0[0.\@0P:PC,%M1Q=>Y0SSPR1=+NA21FS(^26Q,3QU?QCX>N
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MS(76K2S%\OA9K?LM1;6S!"5WM] R^/"^SP8H'UG>A$:AN4C1O/6W2=&P>SA
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M&0PRIW_&H^??8$/<[&D<VKU>1U Z?ZYB/%L@[NH]#8LO:\D.I@#H-CENJ<C
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M2QS@CXV@O%*7A=BP?(5M_KRDD<L.-OY*L9@,U)-9*0O1\B5-HIWMB3/M<IC
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M;L:TYN$28=FJHD?V1%3L"8C,;Z/5ZO8H%WPPVC]PZ8!P,WG3R,%8_*K576@
M(JB7LCR.P2+=M=;:TR5Q>TIFO B&S\X@YTY%XP$S\P[?9='T%6I/-)%.7U\K
MI/PQ67R>)624X(%?J2']#6Q>.1A!?[3P4X2FE7&>%FD.EL[YZ% L%K]>,]%X
MWT<Z;+]WLB_NYZ/'LZ]4+#V?1LSH$F6"H[#T:.7&X1"VA=^;]D8P_QM/*[#3
MNC7S/:L:R\O2-]X.?'=]T_6^@-.+)WM<291:I%!G:V-G8U4KS8EG+/$3>&E/
M 8BYH:R- Y#@D=.!VV8JP1>W S*P5,\ONSG]7$+2+PH<B-UVV;MNKB.!:F>X
MB)UR6:CC,$SN^2+,97S$)M41J>9IF)H2EZ.] FG# :)RKB--EWZKM^KX!'^=
MZ[+?*1;IU:1:#+0\H^#R+TA_F+5&8'/WT[5I.=XNBM#4U*<<S;!U[33OK'7U
M<>"?PI%3\ _A "[MF?V%./JE"15BI)B3=/S'P7"JH]*-*-?;#2J\R4 I9X;9
MLC7!0G*1N9>D $CV2DQO)5(<CAU:\FB&Y8P:C'>L2LQH?MG>H>^8X]-'*:4/
MK6NOE82QR3Q\9NQ9[DE&#S1J\?ER$0+$ZQP8W7UQV=/.[*]LP.=&496;.,#Q
MHQ,Q-,L?0AJ]O4",9;]=N.+XJ7QD[Z'"0^.9%Y,LH[&N\HU%'W(;]!0U:M2?
MVSBE"^\QL2(75>B1I$O8.KB8Y605M!*$S&%L-(Z<V>+*TGU80^/*'U]PM_?0
M;4ZKYUW#75*BJLB?M4>>*A\OT!T!9S42*GA5C*IR_"OVRZ)_YV%\L/YA&X24
MCL6'CE#BE*7$%HQZNU&]$=?P7HG/@,1@\#T?O$^?$;=PVE.*T;9[KO>RB.,$
M%3JXDA,'UVV!D.ZX+.\D,C@I\+V99M][-K+;>']2TDE?)"E3GB@RN"Q9\SME
M]..]GH@=[>TINK(MV,XZ\#1Q7;V9$RED'Y</B<Q\MS=8S(@W$]K_E1I"#D*X
M?>B2$)6Q[J$2T#=XL=1D;G9NNYCW^$S;X<:5GQH()MM7KEE7@+SD:UYF#!!2
M+)U?>(?,C$Q6(5-'9(.-G=2OG7AQ6#7D4?*RDRW1LESN!SK)VW<*0E\L9XS#
MM4'V>T<XP!T,=J[[%"]RQ,[#7>C1_Y!AO(UI8DH&+IDYF[*#EUT8.9%K06N%
M2-F6 +$]S25+%E3KRQD__8/'Z@R9I2M=3L$O3W^$8'B=6,^H7LI\ 7UB_7ZO
MF*7LPV*3S9)]=.Z.@FIZ6MG6/-NDV//:JO&SZBPELU#Q65>BZ#XA65%MB8C9
M;:>EE\X+#0&ST,#S<R)+![#?!2N68QQOX8:EQL!PETL6J:.5B_&F+L^I"+PX
M(8;E:C;&?,9R(@E;6$(BY\E-O]QXO%D?,\\#!\U>S;?+B+9\DQ5KNQ?_\M5>
M;R:\?K,@8W&[0^<! KSN-5CE[+GF"7R& ]A!9]6Z3G,0,C7Y,WZ/=]H&"J8+
M9G4\_%*B"54&/@G&!:PWI_RONIK+)N:3T\\)%(O0J+U94W#6G[ML;7[TZ8_W
M1KS-B,\K8[]T^QU[H(_0EE$<7Q*4=9BE;'^13(8WRN, 9/:-F=:I[4-$(]Q7
M2$RYA;]I+EY1(]L5>M;,43E94^^:G:B2[^+K:L.30LMFY1W3CV3JN5<3.733
M@92K+EC6H&Y$-'-YO-VS4O^^YI-I=?V2.\'WN"KS$64UI.]L&J=Y@ Y"_/&^
M*5>YN ;BR@G>;GQ='),6C;(3^*6GE>?;@"K%!F2><=+DN2BRQNK8=\]FT3?4
M-Z4M=)^7L= ?PK/*W\EQRP\\X&MC?TXA<G_=OB9&48 O_DSRVO)UI4Y]DCN2
MG1HBX:&F-5C)\2K^@ABG91/;"&OQ!VY)G^+MC@R?\@.>G2_'PIB<,]_(OOS=
M1S7FJ]\XPNR:]($=L<[4PWQ_BKF# ^'F9WQJM9 XCP,LG=%<\[M_UN8A-#_@
M%J9=6!57+$Y-)R"1 !Q'[PR!G#=/%B+)..I$(E.^WNUAB[:-]Q>G\GEE<T3I
M\?JU6%]"HZ=\STHVPB&:)KI,F-XF74B(0FZW-#]'5T(G%OWH)\ $HGO/0'5E
M+X UJ^]-HZ[*_CVI!&LU@9LZ81J'*FJSG<958GY!4XZ]>DZUOP-V#V9]GX6W
MG%'(?'3E7?L!LNK\$7N3)]G1QDZX;.GI">&G'F;FXH"-,$A;)G6NA__M'90Y
M4N1U''8K+YF0_P5M-EQAA5Y_H8NEH^25<\K=!=NW+:P]KJP-#Y]"TW?5+&62
M[SA7%RW'ZYI6I<\?>@A+]+"5Q;)\$F$+,;,AC!/H) 8&K,H_&[-,@>DV3-;5
MN<,[#Y?EF*N"10GYIG\D=Z/R90G/;GW_:((('2U:+GJP2/4X^/8VQHI(V[3Q
M0[)^3\U9'M=L]]3=YY+AHYF%>!G[?]J[SJBFNBY]P0)(4RG2)$H30>"5*C4H
M4B(OHD@O!J6#@/10(TA1I A2I(;> ]*1%J170Z_2 DB'4 V0,O']IGSS??-K
MUOR96?/CK'7*6OON>\\]S][/.OOLXU3\,6#XGO0 $>DS0P(*M_'@,I]T[>L.
M.E/5)8E7(+24)1QSXOUY4)D7?):E1,_#Y:%=EH$0?VXTD0JZ">4YFF_S/;M]
M9)C36/T]Y6J?K%Y<+,.6HUE*.!X%Y_3F&GV[J%\%KFSL<;SAT*E*>R<BCV<H
MB9G[C_:"3B:P--4S7:KHHTR75;Z:(8TO_LD"4<-29PHP<WU1)64O:9<)*3.\
M24'?L?8]HQ_5%<$&=951ZAZTU2KE[*^ISBG>.\S=I>^C@8>0 .U38GK2=/PG
MN\1?K%&+<]<$^XOZ/AV:L_E3LYA$/],_,M/9-1YU$MNU.MA9=1S64&:_![R6
M P!0B&Y/L3H=LO_$DT%1B\LG6=RV)P^2NYCR;ML/DH,6=@P7[C:;.;] =3[U
MTND\D15%?M0:#PG T<J0@08J 'L8@QE@FM@>A*]UE-7=-:U&YJ(KNUG4+Z5&
MBNAOD( B63&<,9$,2AEDI%ZX,X]7!6&K\6(DX#ZYK\6(;'8W7=2$Z1F+5\KP
MFR2  HZ/Z8&W3F!1A/-0<M/Z;^8PI&P1?DJ-(E(._#:&)N%WU0+[H"<31$H2
M<,(;^P_C>HP,FS4!O+AH?^_\[H/IO'AFM6=,&7,";M&?&=H-O,/OJ@ZF"57$
MF2Z7I!WJ$PQUAE0AXW]19K%H:NQJEW.8\>*)R)&&F)_B:]R2F] /9?!N@2F\
MI7C<(-<[?YLIZ\<&B%;JNOICK=/:L)4/SRO.E:6\PNA0G767HK!"NY+TUC/M
M/JR(8J.:,\TSV$ZFLZX''2J3^;O0\Q7[C[MV_J?@#NA/6X-^$.N.8<#D/+VS
MWH%S[G1NR8:\XF+=0\++LOS*\)-GF%?18N$! C#D'U1A'KOT/!#"T+F<6&*B
MNB1OHKAG/NCV+1+P9@Z:>61U$_.1Z]. ,%V$CJ);#UZ7!&!C X:4:$8N4WUH
M.S7;J;V'IH1XSJ@@_-C?G1J4>+ L(R[T[!F$$V_"9IMAU?3/SGB^-?@G=+-5
MY _E220?U;_"M)X-Q4-_.N)KH#X0//I&,^&S@I0'<I,CMZ8!,\MC9GRL]6"#
M7@Q:5Q.8[^?LPO'QXFNPD U>G/B>!*A$1Z.PA?7D62N>7$,V-6G_E/-/]>4F
M SD=*@L^N+2TBQ=R0OW.WYIXJ'W*Y>=/GCNM"1+ \KQ+E7LN_X"J,MJBZY\&
MU?\+X=DSHT3S8Y<MV.H_#?Y$XP2IOCG*M( JSS82FF_N/<X7.ZXN>:Y67JKM
M=9'&R:^6S]+B[73S<5DB:B&;FW7<[\697)K\_6%GC^*#$F/(L0DUAYUTY(EC
M$4W+46DCO]T9S$U3,UMH,+HR/E%EGXEW/'FC0G2<(BR;;H*LXR5:C!>!"<T$
M7RCZ*_3E"90)M98.(Y/L"\_@>U+'Q'%0?_-!^TJBQ9O][-ZTXOBS1O=3G<^#
M;RX5 LMT[E+S\-8@7!H)>'C0/H\32ODK;33SM?;=TUOIOT_%Z,[CM;A_B\ N
M)UJ<^\9-78\+PVBX^[*7+#3$LR=H#F,4Z"RMKD1Y'Y:..T_!.SW'3RM-V[*-
M9R=_V+.6Y:,+U$2=^,N?\O>V([JJ&1;<@N17PT=P\ 5T)(A>] ARZ!PVO<Z1
MEO2E(?Q )<%P^8-/'5O+C3#5&V]GJ&[$F)S&D8 JUK+BR,>[+=.CM2C;T=((
M!#;ZWD5-7+#!PS=-HW2,BPKA/],@![ZQD4V/WZEQ-9]ZR:Z#K1B93&%!$Y#A
MH^NT!G%K"3ZS_=C'<V81!CP2ER#!(@GB@F890>(_ "UKU3-QW,RVW"M&YUQC
M>Y\T0F>:\PNE3 [3QIJ===<.7_5K"?W#3%6BU#WW2G]V'BQMQWW\BO,H-+70
M>*M2;^0G+W;JD<.I$)):2BL98!QBKKO M2I0@92,CCH-*%M$/AYIJ=]&3H19
MUG_2WC]DEQ:L\_2.&2UDB/R::$>\JFI9I+]YCP1 L?!SZAQF",R+62+:P%@[
ML/$^<GZ#U57342#*O?#P),&7_L$TT6CI(#C#QKZ*SX*]^U64D.;NE"]TR+%Z
M$VFA/RB9XBCS,-HT_*=OZ)5YY0-"ZAUOY5Z54&B2^@U&S,4&84?H<<C(SD)R
M6XM/7A)+2;)[@J=G (=E;26K&.\,'Z1J6WGDD2'7CDA/0;4)*MIXZ*OF;NC$
MA+X,A^9:67[?8B''_%;GP@^ 8M6UMR.^IWLW^?EP-5&00 RT)VOM.AS0#;YB
MGJ(2<IA";3,ZBXF2=4H 5_37(+U6^OLIL]F>IMR(/W]9@Y<EY 7VEO&X K@$
M%M2["QFK0EY=X-\:EQ%0,PPN;Q_I?'3!G9YGB?[3!%N9>CH). [Z.E9%,':F
M<&!RT/?<GTY[K$6IG[["5^.@?U"Y7[Z?&A'"M9":7)AWJVN =W&+F[86RUI)
M^$#_:;T;VK8OB9E:-7G+BG<_T)5V29_B#<_5*4V,\_$X(V._ZW S>N^>HLW"
M3'3D\YLX> YTIGS$V4GD9N/HVQLQO*^L@NV[;@W2Z:643:5T)KMS]#16C#B*
M'G[=129J)Q_?=8.-VW/O;O60 )&']BI7J;_#>C#UL^)=2\WQ2V!F7)88X""^
M$2  L1B[ZDBI'VJ^4\%UXYS3=>8([DE9=I9\>!%QB"/9 >J E2YS<2O2\I9M
M@M/7(JPG7-[M$/O/X.[\>A3EB*=OM4:+2N*R*S9'F>T41S9</IS=W=2W:;]=
MY#!W;5A4TI%=:N9=[NBYVKC=J^T@^[0(HFM,0WK2.:G8=.J]Z-8R>EOH%?>^
MM3O;SGS2KV<G'_WYI:J<]8_>J#>7]W;.T_=Z7VP ;R&BQ&%OVWV:NMJ0^L?0
MR^N%.1OZ$TK78Y"KM:H1-Z:BV/T^3_ZA:" %CG8D*OH]PF[)B7Y=N&ZM>6^E
M-K6Z-FPYW,@JE)%'QOK<IY5%#8"!HM,MYK%CKJQJ:<:8O SS[HA;AX(ZQNQ9
MQW1@\WA9SJA38W6P9,8%C8F=+$&*I^I63X#5*(<[/ SA30T^[J5G_XHZS?^&
M.B!L1O,M^)#"G@SQTN_M)@>D;E[\)VA@]Y+ SE +GVUP_).<HQOFR7#NO ;T
M/\">Y#^!6O[V"WS?+H.1IU(!"0AZ N]YLC=!",PD\Y:C4R<Y@U4#/!/O(NJ#
MWY4]WDXO;AYL)S+3!)W3P:6S(>U\J;OU5;Q.B^52JL%:P3KT6E*/)I, PKG[
M^$OO:.SOM.TKU^^K,C^A$B:C<5DKZ&_W#"X\_??6_*\% SU5 XD=-W_CL'VQ
MKUQE>"$4-7SP:SY\/E#][^IF>LQN2HM']J#NYF57%+8(?Y,$//A)?H^ "Z#_
MU/+0?=I_%C96 .<YB^DE :W%V# ";;(7 <<,_X\ZR]A3=8D=D'XF_L..NO#?
M:_./JG&AZ_Y/:.9VV>\N-K=D;X A\ 5S^1=WCV#*$H;[H$CWUH1PK=JO);=;
M$=^8FRC#!7-L?[M<?U_472Z9/MC3R%SZR&S%&T3]C64%46DY;.0GE]+F5NX0
M3;OAY<-I>;#2<?L/$K L$-5D%*KJ#7XS<<:XA&IONL7Y<O3%2'5WHJ*FVO@^
ME[^YL0T+U+-:]E?]V1@9R$;&&>U/*M#J)""X<H&QLZ'#%%)B[S,V>JM027L'
M SX1K3Z,&*;.\E)D@93=)" D24 M\;N/@BO]0*'Q+/HFN-TFP>!W/+8[[QU=
M1:2JUE$$2O6T<@C/5$S^P/<7MFEU%P@UK7.KT<=+^L1J30P\?*(%Q="HB:%\
M/>V)D&KUK<^<!+.VX!U2"2E.6A,M<,JOCAWN!2_19V^=B7VZ<%NLAQC56CKW
M^:5V[ILC55, "4@/>)V@W6:II:ZS8@S5/2[VXBS3K\(_3ER8".'\!J)5$,N"
M#'0@@Z&V%F-Y+YIU DK['2KS"C8?YWB,!.5?H-Z*_WW$[=]W(&Y3]PR(, .?
ME:K,3X>'E&G>;JHQ(O^G.@:8JYY0D)??_TAY_K2H]MAF6S%#,SI1#UL]6PC>
M5G%C?GL8LSFVV:N@J[6[?7-!&!9JW*<Z)L;/6R%ATOF5! 2"AI.ZPG$O24 3
M"(V/UJF+_AZR]%VFT)2@Z@W:(A3G?3J36]=!A\A)(6>K6\"MX_N]D8BS)7"D
M[SG/LB3KQKHA(J6?=YA6=VWEN-1G9-I%3]X0NW<DP"4GD7B2R8;)W\HK\HQ
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M@>F.GACV:U5A1YM,/;'D[6$&P=1-C)MM:LYV[AK;S#"_E[]7463D]^L&PA%
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M_@^/*>^R*(H\W*_I?6)#\XJO#<[G)34<:>V>3-E5BG^2JBK'H::R,@0]H50
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M(OX053/Q]R4N[Q"K%;L/I/\1-RH34P6<J0V:X;VX9.#'8LH;B^%=M;O^MO3
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M"-FDDB4_\5Y@QB# L&.%)QE?<PFGR1+V&\+W>%QBE"(*/S<I5;Y>*)3I]VG
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M<KO1Y>S7D+V.@]DF*!,87-(M$@T5<)YC3-V,<T^+Z]D' MVFW_)J0[O;5ZY
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MW"L7^5_G5Q*?4@!7)&0#&G!AO%P;_LCE171$W1,P-I;HU(3U.WDQ G,LOU=
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MFHZ"GI29E'WV5MV:8ZXB% 'D/]CFEBFYC%F(RZ&*@>EAN-R$P<?3,_^>N/B
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M.#6!027"E(-R7$,8AR)3AR-]R\L3YQVNK\CH<5W.NS+*<WWCQZU]/)6QZ[0
M^V(FYW'(.%$XWS\<@TA<PEN_^;,3&ZQJ9JWWSCBAVK>\S%)7,%M:#SR_ 0T!
M3NO8X%^W@J^ZSE_%I^1>5QX'B13-S&S1Y>+SRY(-2CTI %#V1N56$PLI,X37
MG[<MS>I6^F(CU^2TY"BT_O;>K5<9R7]U&:6%CFY5H3%&_N?(B&:F /X#&JM3
M70V:7JXTG!!.;MQW<7GIK4Y+*E1GA]T?YGPZ1/3+^1@(,D]W<9-S(XTGWB]A
MP=C2_O/.5!=1Q(Z7 FBI_%=Y+)J429]#.(E:P_#RRD&JC?+[S!LKU17Z 3D>
M^T))D0Y@33NHXL[V$C!J?PUO-])Z'LMOWE  'Z7B#GO]4:GP>O9#3V+72+\F
M^>A^HD"00L._I:Z9T8%Q;P)%$.!SV(FD %A TCZEKNJRP^Y()!:4(+.G6O^.
M*X-:=_E%.SG\QP\B/^$A3 :'CBKQJ6?A=?XY/??]*)9\K.HRDL'N/Q<N=I&N
MA7UQ@1WFC;T)CJXKS<298Q(&0]WO%[K)5YC&+ODQ=4WN(3M_TPDJF]-R=W>Z
M1H<UB<!NH['?4S#GD0FG%L%'RSVA-J\=?LH(-5,6V36O9O Z5582#][VB8J+
M/'4(VL]';NE4P&90HV<Q,&<\K/W"<C93<A"3U0(%$%>JN 3>]<.F8Q(^ZQ?Y
MCSQNK$TG:46ER,S;//)^>['SL7K)O1.4;"4IZ8@"B-7(PZ<&G4N]O'F5M,^(
M9]&/FK,TQ!H$_EY#UQCD-!:T+)1GMTE=</Z1[YQ%_0>)9%LY39/NVPNVG.6P
M/Y*/2Q3@K2*!!\FT?15;^OD(('R:J@-];;;KNW]<"YKNC0(81RAU':^+^KF]
ME?9;)/5*U\E4S&$I?(DYG*"(-V^I2ZS%"7;TXN[_??*S-ZC0]=_:\+X^?VOG
MY\]NK&?/%;VE%6$_G""*2EVD /ZD8_:)[!H40+LY>!DU58S);C=DFG7^7!W^
MYD/YQZ@#<8FGXR^?>7&_C*>AQ14G!#Y\.!'[=V%_ 2?<:J ZA9;57W3,742:
M8\!1>R'\79?4F8)>N>#N15YRY8IZBNQ^-A/NE+&NG%,-HETT8,%D1U0L7,9[
M=<C-<3Y&]%17W7\\E/QO"=GY9R79N92[8F5Z9M#;?R/9D<1F].2)\4NM9 7M
M"ZFAEP0BS,#Q(&/H(IIY;ILSJ5_N[BLCIKJ]9$O^,<$$;9V^@9Y<(>: PG_[
MUH&@>6HK9N63AM3M57Z^YAJPWH!EM])XDU0E4%A>&)T@TERL6E$#8BW@])7<
MM7"9J.I7.#OC?.((_:T8K?@WU_IR2M4M[:>Y(J.'[%5HZDHF0=JV!=8&X[S0
MDV?UM0;WK^Q6^=@C<AF.+B[R706K**(*B=L)SPL[K*2KOV<G[8T.>HL.KZ%L
M!XDA9X1\'[R G;BZU,:]4Y7J2*+YU4/.JG*7 T4B@^Q-!&$MG<P1'2_G1=.(
M[36_DEB^H?@>@IIP7($%N?4'AAP= 3.I/R3F'A0=&\!DH3CB$?$1!5!Q9Y2L
M+G U>/@U_%30B +X;;EF=GX5$MJ>PV_\I!X[UN5?N4U?$DNRTF(\&S?+)%C
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MH.T.E[BFEMPSDA 1JMM1V9.M.(=?T#D@=/0[!:-1#2?;'@E-:MB(,##K1I8
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M7\0"LC&/@;\\6CJX@$PP)=JO90^/BD2#&R'K\""6<R7^GMM@,/S>2Z+LN<X
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MD^#@87^#3T!$0$!$24I,2OD_'IC? ,5='%9<*3R<QP N!0X>!0ZF"V#&KI,
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M=>SJ]:9=1PH71YX*OU&UD#<@%NCSZEN0V_"-V8RR)-)02IXWSNPTB84D62#
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MD'"QR1YP)_\G-*S@FA?2.?C/QV-^XR%VC6^#?JKW@Q=^"JGU*[=@@-6<.<8
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M:2.5M+HZ#CY9R[AF0)GQN'TAP^ARK2!<NM[K.BR?W>W9XB"?EO)C.N9!@;'
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MIL:W#JROS_5Z6B?]DDZGN)HQ-W,GAMZUWS$V3U&9=,JKFU2TS3^ELX#N^BB
MCC*G$N9[I>S\Q..++O0UQA;,][-W)[7U\\7S#OZEB>#_)[N??F]#4O6C&,13
M#]X=$DW56!1@=,063&F3Q^,G$=,:F;BH%QN)DI-.HFJ)28^4K@_LX54R/JJ\
MS =?W'<+\&&$[83Y2Y"'U=361*=^-(RJIQ%V.QU8;(X^TMA\*J'K6-ROV3A^
MH>K4MG6ZOP6S-3+LM'0D;6EV(*'@4MJ0_51R!Z"2HM3)4#9^S9EOC;1!R_S
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M#T'X@G-9V\=3GD5VP'0?.]MG$];][D]U26RKZ[M'%I0;C1EW[KY<N)EB=>P
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M@!9VP6(7:CA::LR6XC,NSHZ4YRU15@\S\1>#=1*1"K,-#_J%<[<.)3]POC8
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M.)G-VLYAM/A6$K6:+V^$B:T3 11*$7//Q#<?]D;S=M-4C=^/8S_#Q(J5/?S
MKR6.VF_LAAUL3N*I(J1""G,A;&%\W*BYC::0MVV'V<0Z\;0VU4)K\LG(9THH
MU[ND@U1#;$C8L^9:9#82;XL]WG9/IU;,5W?*Y1O\&:0H[A),']6R_+%M9F^W
M6^LU#K[DH[5 *L.,-N3Y,)'^*%ZP9<Q01^Q634O@\TI/>5>_QU_,PZ<LOU_V
M"C>\!EV134B1,9L1]]!4=?/3]Y8C\#>Z86'Z4)FU[54TZF02'/;M@& ?!@E(
M"LI:\(:J'2Q78IC8E\]R<UQ<Y+\[",\'S22N^&RI#6>_A33/D]GG%YFT!#*B
M8"\W\SJE.8SZ5ZM"*T<?G?@_?*+Q,^2&;IL/Q=O(*>UQ6>M<I\A/ICC#9S\1
M6Z*BXMM0H]KF,0>^!D]0K^4[Q>7IAGN)%C8AY]OTNN=;/]T8;?18H*7!\;_X
M6>S4J%1B8H;J^[2>5!Q8;ZSJVD,_D\'X('!8G?6))GT_X%[<G2LOL&<\9XG(
M,W6K2NN'NDU@4,[MZMUW['J=]MVW?:4VJU-!B>M>?"OE"4.V#-_C#;8]W@S<
M^*KV7I]?2,73"J!1YP;L(MP(EVNKN-@Q3445;4YNSKDJ#OC59_L:IJW;[#&>
MYM_4=)%6'O5$8)O#XQM4>B5KU4YJX S!N1-R?J:SE"^%ZQE&[?W71"XQ [7:
MB-(NFD7O$XF[S$M2[*[',?LU>U-933NG)G$[G@=KHRD/\N0A.&N"YJYJR$1Q
M0I"$L*K"6%4A[*F6C+;-R(:._!U,(@WC;^%&4BRG\$)"BGR@8Q+;AMO($Y&X
M_ ?O'9+D='>JR);/=<49KWARR4W5V4P^=^#0B%'/<%AJ4%IH83=2?QEOR#XW
M*3]P(9W.Q(;BJ:-@OR.Y(P"^RQ__@'=<NC:!Z2PU%6FRAM*!VI<0'M6[?JY,
MG6@2'M7I.=GJ]:.#E8-**4?I))8^CBO_/I]A0?_Y4C>^U:=TZ'0F7:!L+8_)
M+3W8C_OG]>:DO5;AIB23?B'T$-/PEU7*OFA.UJ*/4VJS'_)E&6B9UY86CP+G
MDR'QK&YO?0RO.YARL9:9%SN)VPM_CSWJ\=EJK8U:5FAZ7MHW+FN8,0L3-:T8
M=;QY-=Y+*S+*^NRKODC)W':$"V_:TPJ')SYM[WXPV??VF]>^"NW>%X'9P@Y\
MC7406HT$X<B0X8[\TX@:A/ZH8ZI!LT%%A<U>TJW,IJ4!^82S]RV_BZ%P+'D"
M$5!M@W@9KLYM*668P (6@\J<W(1_ZY9$\+Z;A&C9'.\O7&O4+E*5N]2C%'G>
MMX((7!Y5(P+I0W3P!?5\(H YP?.'$8'?MJ+HSC/!&T3@K5G1QEJ)'H$Y-YH(
M@-.XB4![K"X16#J,76@ ;8%"4;D)#M[Y Z_.PAS><C>/.8JT?Q\=S'F?^"O\
M@VY/CH_N ?_7864F0/=?[V11$OA-P?Q8X"[Y>RW","D+2$O'K>67@)&]! S!
MC1,P^H^+6:<J2P0O^%)FH:["57BE(W@UCR!]ZS]N?QM[<CY]FR/JF!2U(D/!
M?]X7I-3'R"=GSK0Y>,IT";72&;"X*J@]&>S+L6"[WT\G(*?3A7H=!YN(:?IQ
MI)&1QL'QH"3ICA<+/8_]T/V9\/FEC,(GL57Q*T^+M:568@SF3!%EPW";:?B0
M#MY5]RS+F0C(@3'#+YJ0D9705XX&GCM=G2HV X$I2*67,NKR3R6GN1[TB-?(
MWQ\17E73W]GE7-!\9R_$7P\1WB\+>Q0.R&B+>>MA70@&2IVZ)@.^:R3._PE6
MB2.8S;9\0\Q(130[_L$5G1NVR O,K\;8'GE? ,\6VBY2RVN)C3[1C/.6J0YY
ME4AV_4<XLS2-V',:+X\N_DO"R .LL'[NKJVP*+*:"'CH6?]-AE'_(:FN,LS5
MU/P9X::FD<:M<NEN18,;#ZXX*O!4A/N992:Z+?J*]4TL+D*_1K=)3:;_-N\V
MNQ/ZU>K7[Y>W>+$#(D8.KT[5^+P+X:TMRXC<W%UL1 _^@ CT*(-04J#]42+
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M3$6RD,5\R4Z2YI8MG$.\R:)+TMBJ.:J(\R;!PM9ZT2"4/F_:]&)XL6-+TW[
M>4..I.M<ORWG&BXK[SJ<P4T\FZ0H=PI;-@D<'I/0LC57 Y:/LJ^L%LX,E4=F
M;^]*R)FY,%?E?"N4[P+Z[UF^*U.Y*-1Y:/6$;8:Y5)8/X][?E793^N%:4G<B
M<Z?8]+I7ZLE#83<;<S=UWIK;@K5 /1V?6K]@D$+?I7-(G4V=S?VMMC53C-MT
MM5<VPR^C#3!J(S]^K\UQQ&2Z )YTVTCQ(B6ERW;WVVQ\>_RH/N32W$;\$99E
MJT9*RXUY)BX<J2E=>DWJ<Y%^ MF;5LOS;;*+S5F8GH7N*,\"% 2O@*Z*F$U@
MBR=0I=JAI"H5;WVL_/:"M34Z3NS7\4>S/&:G3M#51MH%&5^NI1>8]. #&XDX
MZES-?+M/"C6M@=RMIJV?7OW$UYWV;PCJZ[[-GDA''OM9"^6K#_2)531AMXIV
MYU27'>0]Y7DKD6X1YE.Z(U.ZPY/B6+%'90\MXWR&O]2(??^VK&*('GS0)1DA
MWN1:58S\6.G[X&#J_C:A+;NI[4TN)%X+NQ=G=:61,V_EP9!C5C>7_"B>)]/8
MCDMYHDHD0\!DO9I=0VAT@U$ZX5&84$%?X5T/*V7]UZ_U*<)EG,+?F-AXY68L
M@JE@"6U[ZXLWH<+:@S(A(K+(O<7G7(/JB_&JL;_I>8,4-)8!5^',8JN^I9KC
MV2F9*M^JFA_=,&U/;V5ATP:LQHD$=,K$>&<FR-9!HKFFH(V/T$*NZ7N/+\E6
MN9A7[V=B\^ ;6L07\.5(9$=27'"0[#W.G(8OG ?KHD*_'*">](NB-P)&,V:;
M6Z0HW=WP+)@+IUTL>Y-V:1<QH@$E'U1L@JHXB\H&W[W[E33BN61P/N%W=/0O
M!OWG@O3I7_'F 7H8E>*LC=EKX[)\G($;MF4;QLL3:?'(&A'FS" RYK&8>]\C
M2S*BM6EH6)FSIHP*1>9DX&W'T_+?LK.715=V\Z0*X9EE-&$+R6%-&C?C.<)N
MO]*<Y*Z_^\G\TVS#;;;-.#EPR'.L!%]J24'N=(39J4:,A4/^M.P$MN.'E6&$
MX5"(5RTK#_D*:ON=VI2!#QR3W@&FQ5.DB::=S.F-O*[S'YS<<BI^]J)?J)WO
M6;RM15@0;TIMJXI<F7$+NJ*12U;/<R%@L8G:1].:K*Y^.#*'=HK[XRT7GHX&
MKY()@VF5.XIKM@([0UH2D$(\N^A&V*.T>G#=6\1F\P<O^;IOF_(WG*[#%Q_E
M:W(4"WBK1]>B,G+>0%)B'KTDZW8QU7KC)XM#+CB1X>7K,)_K(TH*L[K>QJMA
M6;#?*K1'/U[1%!KIN6@5>[U&K<%=TCG@J1:FHHW=_BIM,2Y9 _T#%;@\'A%7
M79.O"!4>JSZBIO#GLSXFN"TY:K.]);M?E#U6;5"=+D?8S_S,Q[PK4^-!!*@+
MRX^/RJ9U7W178#3;TCA#"5HF7:BKB5SI#%JPHZ3/=\)LIK^J?JJ@#NU6:^4'
M=E^X,5=D;-8[A52&:1FJC@F[.8CLW!5NV@[?%&>\OO9]0Z-4_NN89]*+)F6F
M)_>Z6NS QRP^PD3@U2_P 24B2W 5C(HB*,]1P7^YTYZ1;8Y/+1F^BPY-9UF;
M#_"7GTA?4N L_KMZ;[1EP1U&20@Z(VWGYT;Q4(Z.--%A65-,DFVEJ<'HLU Y
M@*>I**,]O=*:$J1[' H<G @R=B7A"1QE%?5!(S*5\2>HD2?[K'U"(T4FR,M3
M'T7R;+M5/#GG,1YAD(YFKHE##I.;3>D:X9J\4EQ6C6]%R"5[']NS!@[-4%@Z
M\'FV5A&:P#]H0D-OD8+O_W"O]88<"]>GGX5-I)_H.9MV>1I^E'7["@,M*4_7
M8PLN)'+V!&\;W$R);@Q+#G\?50QX%3.ODG*LEF8N^,_)/"(PIXHGY9Z!9^A]
M0M  F$!*315 ;(2Y]#T3(?#6)4I"1%(S%.%[5M5HDH4;6IR)(X3D*Q48E41?
M4;%1%[BF>9=GCV<?<:ZD%G\+#R=MIGZ%&U[IW?V"A0V@"YM7-7D)C X,(X/M
M"XQ'NAHA(0OF%RB:;:(_;GA89R",<+X93.BCH$I?>$<\X09&/SBX*NS4E/%I
M]3ZO&I7*1'1]^A>&10/]TS9(N",BV>?!DA,]3&8;](N=4)#IF^64>I;LR=>2
M6"/C8?\JQ7))3@RJ0RK]Z78:10M@P4]2;XXAW"(D-[HU0T0N?R_7"?_QW-_H
M_6H9[R&3NF2.8PU<"CZ^.S6QH,JL+6'Q5#-;SU2HSM>QJ+HZ<LB$LSN.LZ43
M FPF!8<<%-][I'7O2640TF34]9<K7GSTAI9C+\,-K6KAD7#_S=+]H"X/OYLC
MLC=]U)<@5#V9,^JY:Q/W%D=H+_^:DHM19=TK::G4^I6X]U#><IJ/1D$G4>%X
MJ=-/'$,;3EV'K-K6,9%<^,"OVQBSU#<3,>41&SYOS?GF-C)-&G,S*T,ITQ07
MK%\__.IRF>VH61]VC64G,+QZ./+7M6>U-1RBX!Y$/WQ<3O6*U?V^;8B#:<G6
MS&B-JFO5RJ2IA&53_:;1:"6<#L^+7DX/Q,MAM?0>CX+TXU?5:Y*@$ZG^=\6D
MKSYD>O-=O[PS1OON@(_ \ )Z=UOH1+_,PLF"M!=VOO@=IV:MF^YS>2\!Z7;;
ML:@D7;?!.YDI4L8HR5W4,?^M_[V4?+-6"\[\ +.Q[2KK\5=CCHOCG+,J3>J3
MKX6.9[O:9N*GW[H,:GM-N&0OLPGN#N":Y!<-[KJT:_F(B!(!,@/WP[FA@DW4
MAW(8;0>$)@N-#*Q,?<OI..Y8(BIZ -O]/2;*_C3&6%"MZ,G-<:TR9J=D][>M
MR%P?VW<XQG8N45^J]B1+2:S9S4J]:TD^'I(G-KYB<\Y[J8\]7\MX2)?VI_C\
MN'@<JX Y"L$+6DODABS*F:A6)H;UGP\\*%7EL6"S4@%2 #%? 6^=$#_1TGKO
M9"?F3?<CFBF4315;W&2U@.6GR<$N_:',]S\-*J(DSIQP>4YQQ<?/:RUN=U^6
M].8;U50N1!CL;M0XZ4TWWB;EXS2XF*4VPG5DI8DOV*QAQ(UC/_/Y>EO6&&J&
M96NT.*D2NA^QO5SP**'W?JM%LA\%.U?--QBM:75Y7=HF@>&+L$/5^X53SJNW
M&5_97K]K,MC^@JX(U,_Q5M%1 9$B@M<JLF/?Q<Y,%/JZ%(4P0+;92DQWI$HD
M:[YH;T5D4<J^]-)OTNQ)NSDAX:UE0 0ZC:NP!;;OG;Q=?(5B.P*BR_JOFJG+
M<AV:-A8?S^F8UONB& _K?8K?;AZOQ<U6U]MMJB*.$/P)W^#?M7<)#6#"!^@T
MW!QT?)]3D- DTG*@B[C@8<M:P?!#6YV?-^DH_5<P09M2@P@@-!%G3'8.-L_O
MZ&$3 Q^4E.M@P.KYF:'+X)>7_ZA2_NP/3M\G+H.V0:LO$CIT IM9<7(+[Q?F
M+JZG3[+?KXU?,_'--&KQ%$R(KE'[,5W&S]:Z';KI"$;VSZV !^M$@])N8,"A
MLG=$&TT70+B'$@'.0M8:A-&P)YUVOU7YDUFI]DLXG'13V*_NS+10(290/B?D
M4V9$(")]W==G>ZP3US,/NNJC5#I:>4;>Q:X=D%/4K:7=_VS8:HSQJ8+\\VL]
M'HX&0GMKE_:!BW,-(E%IZ902R<5OF<9\]!EQ3V4*JL!;Q=+=)C)9WN*.Y:6-
M)O[]-,<Y<;I/U(H,C[)%:*5.G^$:.KA8RWYF8EBBLM$I1RTV 9JC\YA+/P?&
M%_0GG25&O@>^K-'ED:[^[; AJ<X?Q['W%H:5N]?E/&>,0VT:XX*INZ9,U]0+
M>OD^US]VCVF4NMEFN9<5V#ZE(:*K:!UK_<6#J>@XB[5.+FX.OH&2[[5+'=68
MMCPVA"? !TSYQ]<.9! L?C^P[+L?&Z7R)R$FYT<L@NC=%JEL#U,-)GE2<VDM
MX')#B0Z"+%:>K!I&!G??T5EGH0W;!TPZS'@KZ\9DU2_D9:QA*XQLC.W9G6MB
M4+?9+IT^ZK9FN1+&?D,L^_GY,$J+VC=T/JJX&JBMF[>OY_QDL>L95W^GQXTY
MM7J5)#:4Z82:UB1J@]M<1(U[%U3+^L!MKN=,7Y[?9"UD,?V\\0_4R3H#[L;B
MK 5"U6G5TWP7CJ+L6Z_6OS!]L]?P**)[>_J:G8"3.^JX.A9/4IM<U=T5;9J\
M1PDS4$0'/JV>ZWT6GJUL9+?2I(X_:,7W7J=T^D<>%QOF\(1TV_,NM?.9T]LS
M@_.I%V![41_GJ.6OXQ2(@#6,4;T*6;D-48A2'+L9JUU92V;A[9\1 YW2.^=0
M[ZB*:EL]NEUS=";57>RA,(JW-\>%+#9IMLO31#V.=+B][79<R0'=W-X['N[U
M92HE'#Y16F[=%RCU!$&/K3*7N7&!.;#@UF::!J2/ZB*"RD>T+N98Q&U&SZ0F
MR- 5UI7R=*.:\;ZF^94VZU,%3S/6&/47WPU>O-!7F]RNB:NN.&/)'5+RL[[T
MP,T+3Q!$I&>VQ.=50B$TCF[@B["W@_V&A.\8VN!./=N33 7^"'XUXZL,CSH]
MHZ5E/_:QF4!C2B*9D3&CS>30^@!8Y'Z7V8/:YO$JJ>JD"5-F)^%M\>.O<:\C
M;8I%=AT7#1EN@#[=8*9@E@F12:<^'+@\U\H^3@3\JP8,>U 2R9I\8=,0]7RA
M+G.#.U-FW]EV/C6K?K%,AE;TU'KZ&7O2XU87(:PXCRZ48^S2',5F0D![4M"W
MFEFVLCK#$9$;>PHU7WR+0SY=@L28OVE3CW .0FD-%L)M9XZW9E.KO6W=FK\=
M/Q2X^T':IGG5P8\(; S.;L\W475C#?=F8 U=J->5_CQ,DEY<0:Y3/C&78G0D
M%U=4G<-%D,IDR0(]MB\0''C.J!YIU5!Q[X&'=[-@22=L53+NE;/;]I^4&=LX
M=CG8P@5\IAF^IGZ51#XG\(+#A!O!\SFC55-4<EI5J?+"&K_7]RH-U;3YGD4X
M,G6S[@=Y M<X9Z#]6\UW<;-3BO+\&!8\3S.HOKFT.IZJ.W[/])Y&>=+\U_J&
ML,%GYN<2+W&9_=R(N*5O*\AOZXUH,*M6)\C.>)F=T AWN93TGIA6X4SR3$ST
M)N?1U$LX6B7T(;:8>J [T<5":NIEF8E;G+"C11Q+KP$J,)[OJ2%5C)&N"IUS
M0@N9F^]#VX.Z1MT\6LKBLYU"6RNNX)HGH1NK0Z_%3(]/.<FG^]Z49I5O&T0W
MOSUNN2(O8)=.)ZN8<]Q\?=A'T1I:9/HKMWC!-9Z#6N-Z7M>=3SR:M^Y[/O<I
MEUZ^;[]Z;:7F5 >7K'Z6B6P=L:W7JDYRNR^^YGK:WR0]>[+'=N[U#G_RLTCS
MKPWT[,][6_H$$/$R(IHH+;WX1M09OIY@EKQ>R&2U-;_,R4 $^$\@O6<]E6WH
MCL<CS:"U-/KAK)KA@Z:;FBS^@B9ORKY-Z5R;>GCN;FVWX@/9,MFC!5G%4S#4
M\"[.GYJVR^MUNL.BIDDAM94;F#9LU=O6L615U]$'UVF?>6(E;Y,D>=VD'Y("
MOIWOHX.+@\]K/<0>Z:&78Z HD0J1S^(#8LO6H]G5!K?V-!Q;O.N8(^G-;W6]
M&;R@/5B&@2ZR^*\@);2,0;2F.,%VZ,OZ\<.FJO;9%T*?6H]<ND!)B[SO+6U+
M'Q=M[EUAGAZ]?:H3L;-#L-T]@HY"GLZG\L:!9>!3C0V^&[.!Z:R$OGJGC]M5
MW@W4CVVY;C6-%QT^FWBI^07DUA0ZJ<J$@+I0[+(JW?N6C5G((5RO!?NB719^
MM%#Y7$T2'CBQ2XAPD9CI^NT >U2NMAP&SYDQU8R=NW>'GY<LQ0#1,6!BC,1S
MYMFE<9='/1Y#Q)7XM7[4+S9W%[[RU"K2ZGF?X*<W+R0!5N;AB4B,@QP6+B@Z
M[-MM-WBWNL !-[6/?QAZ*_\6QND?ZIPUQAPC!O6*&EXB,,I'!"X?GV*SB$"T
M1_L<EC. ""AXG8B]$X!;_B("0W$M9R<0=(GD[ 2'4T3D]:#[[]'H[\I41$"4
M?Z0!M="#CY\@ F4P^+KZ5YJL%\/<R*VLJEI/!O$Z_S76CY2N3[._/:#T_TZ&
M'=*N@ABC4="3UXB\6;,9N=PL^@_=S<;'EPUM]P9_["-79GJ7R$-_94:\^_NC
MI_^I+AA<101BI@J(P*\F6R*0(\4\;4@+)0)\-7HD-%ZC1$##\19Y;6;H+?+]
M(2R>-';R%1%XJ08^L!_?-_6]?>H'[[4O)0*EO* 32;OCDOHE=!8&CSP[011
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M-3OKO'*2[OG3$"6O;(L''D6/9"#IKI0X)8RGN?("@KL["XH.IP8];MXCJ*.
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MNN^&5%JAUF(K[0]J\ L16M<C+__F1C(4<. :%K Q!/[? L&:^B=02P,$%
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M:6WKZQ\8'!H>&1V;G9M?@"S^7H)N;FWO[.[M'QP>P2_^7%Y=WR!N[_[AA01
M0?IW^[_R(OC+"QD5%045XQ]>2,A>_W0@0$5[Q8=.**.!\=F%B.%U"";QVZ0?
M=;TO&/DU821FKC-8I$P"F\SP?ZC]&[-_C5CH_Q>S_R#VOWE! =@H2'\7#X4
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M6UB5OI<?DF*> ]M/"*D(OYV;570D/*T3^,,+9;)Y!@2C 8-5 QW@2M"5%IW
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M%I1[$I:P[0]P\ )X<'L*>[IF8IJ7*D44ZBK5<;\H;VE+FFN+5O6RGEQ=+N8
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M_6!RX/LUAF2BX0; 1VMF?3:2J4-.?UUKS^VR8U_]JVY,5^W[.N7A(EF6_H+
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M&[;K=*PT\0XT+Y0IC<ED&&<Z99D2H/5"$^'VV;>5B%_@.JTX;$Y/E'%=Y.]
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M])(VUD1.$W];Q0<*TX(/Z- ;\-U[S=$("MP="&,$^EPA5' #-Z[SGV-[B<\
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MH4;G>>7F)5&6=7/7-U&&7!=;25A%88HQ1%.O>(-@#;]^N0[Z[@C, FUW[OI
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MNG#Q-[:TU<]6$;_X4QHFM<&?]#/1, PES6THKDL)$EL@4A9KR#QZ8_I]@&\
M28*0;X6#=SBRVKI0C V,#]-.OOY#^C+^:%^=@.(-U"8QS6BY_O?W*3\X5C _
MZ%X_\4XI@HT=J0R^GJ5FA C"(J9?6XY_$QYA2CY6%/B2[Z;ER_&FR.D?3RVE
M@(8C2,/[TP5S4:!<P:]2P5WS^ZW9J'WDEBB8!V^D0OU;'C&65TP0'KG&L<60
M5;G6I+]"MLRD$7=8$_>9CS)('$?H/^TX!$*O%)<OEKX3DB1M<VR+*#"I!2=Z
MC79[KWSDN46[K1E71P$>Z,%=(&=\_:W4(P1%GUG@=[$SPX6?$X<\;9B(+JYK
MZL><Q.G>><_#>!0?]=UO^G-]"J+NT_NZFBZ^US0<;IK,>%91:> ^#CM9*9<J
M7M3>O1UZ[!,81"@^=:WLCSI*H=CQ+IL(LPLXV3KR@\[D<9*$_&KI??5&4U;!
M<01RSH$;(%(G_F< WK*_9'VV8KFY*LUM?I2;T]G<S\2N%:\^JQF4<PY")'8)
M5.Y@\!GPVAJV=U:+[(4V?T:+DS2LR?E6+N'U]ET MM*E>1"H/B\.Y+!)-27.
MNX8O<,![C&3M&BM/"K2H!"TJ^;$=#7Y##VP%*F_EA?J30LNEPC-U8QIS:8SU
M&A,M<K9S3?L.$HL^5NWSC+S#$CGZ;F* 4/EVG8,E-G*QZROLP*6J>!HW.J5?
M.\_%=7;FPGE>TN!*,ZXQ6CW=0H&S19>RDTUY>4&#\) I']NF"_>" L>&X@3Y
MWW>>T+#1BI\<I3,(F'4:2%KMX(@,7^9A!0[282-1EQW?GU!6=U399W86WGW[
M:^:0KO1=B3TE2;A0-X]<2JQ,F)YZ)Z\0@;\]A0]W[/-*RR69>\??05(-_SSW
MRR!?!/F.C8*U1?QA:=2PR,_.3T@.L\\E_-8<TY\Y@/F\@*6J8D/I(;>E>JV4
M>',M06A8^K$<@)481ZJKXS&R!/7NE^ >G#49LJZ7Y0?PR8L&*24']:$MR?C9
M$ORV%P#W8M-GX(C2ABKTD(9N2Z'82^([AL_M)(_GH11FW#7.S,B#C7;WO#=_
M<]VQ([3AIOG^EE#/H3#_CUQJZ:Y,;LT-/_MW"YS-?WH-4^M/4G8A7FEWI^,9
M*\-HVXIS>V5(ND$[OY#@FS-2CY/YPBIL S6>M$-XE#F<]2#Z&G-S&Q3MW5@8
M,,.N2HB,3G_0$NK.6\GJ!5+*]P^#@7/GE:W!@@&U_-:!X-MS/CETIYO1&DC]
MC4*>+6UXOWS_,Z"1+$3Z42W2MF8P;RUL10MTL?KV]S/@*UV<&2F*OR+4<UG_
M0I&T:%Z$SD2XILDURDBR%A.F;9[@)E OR5'[#/B1_'?EO2IH^[RB1,J==#0/
MX;F@ZF4DA"#1W];+)S$M;BH6.3DPQ 8@-+/N]6>75B3"2D.YWSE53]\80O0Q
MKTB''$$H@=3 <*D56LQIVR_'FQ:QY$AVE(*5S[E0QYEGP$\CQ[)1NW_3E.HY
M<[2+'USTF@3]N!1YPPBS0;VIOI#[3]+Q97F.T, *S?GY#YJ/+*S0]<S+*K];
M03A=F0.1@5#XV?6$G+7]/W(\SQ2F_^$N0QM$;YL<M0.N@;-<]#E"C/ITECP6
MSQ[A^ZC(!Q5D@S$N9^'2,+? ]$,C;JDSY(H^E45FIL"B[XITEU+H-!UZ(0M3
M/BFS*EV?N&VK^D@E=J;E4WE672WD,S> *MB?V-0UCB&W$Z,?:@+J$?7DI&F?
MPD=HSK_+]B!>K0/MS Q+I<K^V[T3CXI #5!_-&2X2_:Q=JQ4C>_T4U1O_&<E
M<WS=*U5,\328!)7T4YBXT'8. SY+GZ'-W-F-*N\M'TNZ Q?ERN266F/=>$05
M>STZ^B:3$XV:JGL@_U/:J?^;$F4('9$9OHM2F,NK30?84:MX\N:&8@41M2.U
MZ_F7R\2HQRU:GB&)_<"_&R_-M,;ZB;C!A?^^@4-\!9 #W0I?;S"2]1F +;D2
M?5<4UKOM?H[#%P72289;YXT'SK6*1(!L\J)\NWKI,!R-@EK:89)%W[C:U0L_
MPOJDE@OJ7Z]XO&'VC&T/U3B-Z;Y/JD=--%5-[WD&1'32P28J5$N.5V+;,[M"
M/1YSOL LFS-WU/_49SI&,O=\1G;TOIK_@T;KKF4,ZI%SOB[8@R=OAQ58L;J3
M]I@CO!2&KJHK_BW:CW@$7U?OIOW*[<^#X"SKGZ@W^E-'6M#4I67*"MJ#/"!H
MAW4@+_2!TK&3=\%?M;2G%"@88'0^>2$?+BI[G?FCYTM%BK0@8UJ"TM">ZM"+
M*CC5;1:\ '+?27V4MYI+79>E 0NK*#0Y-HIM-KC!55;V2+ H.,4[>Z.Y]P1Y
M&2=DNWH-6C7?VFC,,AXHLS:P*'HJG FTKI8R.OX,SX!&#XTY4/73OEH4CTS;
M7W<N_C[N%I=$'R@3KSEA<:03!P.Y*FG:3G52/C4(T!' Y0*4S G,@;E8O^?]
MU<M-3(X3Y18I%>:+&T(^XEE-N*SS$,&"FM<4_ZE3NC/;WX[FQ.F]YM XQT:H
M:K7J]FJ #R2R\DM'W)H)>0_A/EZQS]L@.>SJ9&TX!;1@2$8F#81K)YIIMXR<
M>LEP_ZTL>8(#C(67A0RHQ#G(_E("?LIKI_@,H6$T!-?F;ERH+-;X?\"I&DMQ
M7"U=$2G\IC@U.H0:U%'Q)L<\&D'T"R$]4S3K+UNX<D+ID6/1%O,><T%=5W('
MH_/3/UHB!5$/%YV#EVSE159?K\[?=]55<PF*T*TI^HH^ ^KI$8YG@2FNQK,U
MHN:X<TT?F4DYIV(D:9#KF>DA-XG;H%A:FI9I 0,%N?GM1C:IC20Z]=N"X=N:
M7Y"G G]T[QUU7+C#F&GC/!="UH5Y(.:VCJ/7:\>!#_6RWG]5YRJ%L9K#!>+=
M1XB#4(<B%LW8IC\O;L52%%!)!8;378X,XC1-Q_LB!CN>TB7?&9RXF]DA 4OO
MZ.,.)VPBK7Q^:2S'<U&E ;@9FZN//0XMG9%D)[]3LK?W \&HB<IF3E#" 20'
MS*7O1 C6%'[A+P'Q4S$VD_=\*=MB@<$2CQ;S?C=NB'&V@R9>Z8J9[#5D8JZU
M)1ARR_V9&E/29(XMF6;>)@+A!?GCJ?BKD^=<&MHO!-@1WZG9,PE+APE*12"Y
M8:]C\4.O7QUZ8_![:)Q<YA1!Q9)S6[9VXASSFPRM,_"2F1+?13%%6K*-\_*6
ML,9UIAZTE+4-?0E@9B<(\6$M3#L!SX("JOZ>7XO)V!8;5^")F%X,P6C5KP;L
MM*P);LQN'W"Q8NI'&3^<S.=)BV6>Z2G<WZ[M;NK)5ZZ#TW+X1^+?XY<2WL6C
MWC TV\A&?N1>-\/ - <-50F9+SG?!-BJ17JO+C/%LZ;FFF-],X<QQFV.S"HE
M?+H<8^C#<S#==0^*PE!DG<;+W$F9W\@A] W%#/_AMGXLQA 3!?N)D(6H1[X^
MJOA0;097[UMB')^K;!@N,![9DG+SV4\T_NQZA34CM\#HRI3 96_&M22.6VX@
M4WU\ >'&WS21M[E];+:*NU++E&ED9)1[,8;;HL/9P,OW5NR[\'51VE*LI+>+
M6@F:NXEX^2/SW;6$8WQ-[86I2YBS48"(E:7A+RLBUF94=A #1](N,58/3:P+
M4!'F[I$3Q8@4^?S$,5E\QEA/1LJN>BOJP);?1HCV7W]"_Y_&QV\<0II6 6QU
M*B$VX^<HW6I9']!>#HG[H>JY7.B-OOA+R$&3*&?L\O,@/_A"=:ZR<^05&8/B
MKM/EL,Z+H4W:8( ?SA>WN[RW]CIL  _4(M&HMY3_N]\;D;H+S;@Z=6F=W+'N
MS#RI!9 ^>)X2GKYCBWB%V4?[?H'+TP7E1+YGZ56M]^Q!R)15\\W;'Y0\I[P2
M@"-SEUE]66I9$[']XE-;4=?2*J9 TW] BU8,C[H38X9YAUD%2YWHF/!9/:T'
MWR^!$6__@:<)D+%/2&,#OFK<#HN!)6Q^CI0<^:)>@,Z\YN=,I_1H2PKC[E:/
MIY6"89[U[3P# ,#T?NZ 7W]Q;VKG^HD&$R/V9&AQ2IE"OKH%.,X9C)LQO&HX
M&ZU^H*Z.I70R=0Y(_@7T5H%6)SH6V2V^7C'+<OC^IJ$A0I[:\9#$U4@GN(@3
MF-Y9>2YB3HV0K(>-Z_5"?)R*FUBM:P% X6'Z)W2G0U^)KO#K+%/1)>]$Y^]D
M/B.2^S7S0F9V32G=*%F?+_L\../XSC*;W@J7;GXP--N=UT]%</U[#N2;3M.O
MIE02(5TKZ2C6P]WJSAW" [X_2X3=Q,RV<A8&\J,X>$+_GS5G]"C*#Y*DAW$'
M(_\M2-_'HSP*<#PVPY%@(),J^P86K7*L7I\,D2IJ<QC]R-[H9<#O/P.#+ZVB
M^F8#Q1$VT,7D2JD( <<SC%&)CX-C*ATPV@C<5;L[;]X=_8[5H-G!TEKRNM^\
ME3O[-9VU48J,AIJ)\Z+O>_0HT'PI,=TA;*"OH @H_*/8F)-8GV],IDNX9Q[1
MYK%HBOL*RV\;6R!]4R[6?%*>O6D_:@(A?6+/]3+HJYA=)]/A!I6H^*N_QR(-
MN>>+^_KI:IW*C-[O^-Z&R'UDZUE^\[F9.+_C2@]:'%UCO/:AS/ZU$'3-."#.
MNJ51$2W!5E+;VBWCP$5IQ^498*L>]I >6=TNRQW"?[W$]2G?&*Z;GY!AX>A#
MM4>/89==)CREMO42I1^N?1NTP-^U+-,G12RN_"6S)!(<S4:[I%QGSK1I9M*Y
M:@P<$GYGBB*^A?'5U?2??+"C0_=G<F*?&LJ\J0GW=%SE SK=CO&B?ZS@P-"1
M8JC'JT6-4T,WET+W?T_5'9$V-V2UE9A#I?[JE0L5EG^*MW;2:83!6]8?_3?5
MMI"[TPNR 57S?M'2I7/^MC/M7B%)XABLUP9G.[F:3,DH"<HO?[LF\$C'+7?2
M [EUE^;ZW(#AG]H6"QO)HHLZYM7%I/6_)<BI*:7>U\=E7Y?K;^)VT@)[29)V
M>C=H%BPST*+9ZD/OR@Y[@G;]HJ"?'TE,_OK++X+')+0FCR=/.\YB[MS7F2?S
M?)YRO^[T*R!5:DLE#&70F7VZ!?J-D:.;I ?0F\9T/XR,H@&70J!M+S2/T)&8
M*=+*UO=+1[88.XD73@CZR'UMDJQ6LO'[.MLNAV= ;4G/NJTK"-UH100I]K8H
M)+['F*[H6^L4XE7>]I=\\N6I:OLX7Q_]:'JZX-](SY&F[X&L<+(=)9G?QL"&
M(TKGFE='2]AE_ \,<"^QCS9-:8)NLZ;MCRTV7(I:5':5=(3^G^&UT+R^$BU8
M(QBBJB0VA6YT[,UPH11$PZ'5W/7RT^\HAM X04ZVU+@7Y\)5:0P-7EF/P[O1
MATYFSX >0:=3@Y'M?]RLM3B'%1KI%(X,B2NY+J]X9$#X0'^Q]N61&^F:MU$W
MI?-8^P6WZVX&@ZC\;6'N$+I>1R=C76N#&_575&FU#"3S9YS$PA9).C*U73Z"
MP'M%0!!'X.IM!HPL',D,?%1IFJT6=W)UA1A7B7V:#5PB31'T:@T((=YHR4AY
M!E 7  [>]27P.II7ZX%>=95_]"B8WAT*_Z<]U+%^6"Q4@N'ICY<KX^I/M^6#
MH?!GP*,&7(7N+"^,Z+BV9 /8<$\E>1_V44KIQNG5[3(TL*G4^%.K8 MZ,-"!
MCF3-@;B/7-E/D=Z^R<</,?*BG/1++#E&-VOF37RH.8E'5S22.+C?5Z"XR+YD
MTO7E_!E^VW"1#$>I"%[A^S<IB? ?; ^C(%+AKM3@Y=4O4RF0?_ 9 BSX .+^
M1Y6Q:ZJP'@??,D=?)W&?J,.X$23>?:V;P0(5JASRBPU2Q,KV# 9JO6^MXOS]
MB^+.@YX!=8&IM_V)A:5ZG_2U%PRL*6'/@!@I+ 0?K*_[(2_\VB\69TRS.8T_
M6>?'RMN#)FR&C!=G/82A'/.>(A6A*N*%+66K^\HQLS.YBH\2R(U6J1C9ZE 8
MYC 4V?PW3D)7;94C[1G@*'7\\Q'1N5,4X'@;VMQ$W#W&7G<N)],L1/W2;VGJ
M&4 @]1D41HMZ6=(Y5P0S^]4L&5BWNH.Y0A2"Z*GYY>1$_Z<Q;&6%_*P*\H'Z
M6_]O31(\= UA $'OGWY1WO1S;?.EC]OCZ>W^98^\176;P U5^W-.9]4M_4^)
M.ZF%[W9KT%Y=U]C@$'^[C7KS?5?:*E>=9_6 CN_]H>L0J,KG(E22W@0>O2,?
M?V85MF 9@F5U^4MKGRT+_PWF1:/B[@'JKQW2S2P.ZS!#JPC^)!;Q>0WKSZNY
M$AWHP)=1&E%Q99[73G1.$2D',36B,WLIA5FQY^G\5LRK!?(!#&9?OZ0=<WA0
M)U/:TD53!Z:F.!'#QHP+FV+GSH@;,21^WCX#/"R3>Q^"8$S<++\ 76 0EZ-D
MV2NK,+H-/$F+H:48BR4U .-B!UK*PM3/Y#1:-4+/.U#/#6*257^ZL,[1.-VN
MTY!"4 Y[<$]B:FZVY8+4[@(BA7-BI.(6P33_CHN36'N&4B$#1;(;["L4P8F_
MF,XFN\YN^0FU13L[4$**<L>-W$9-YY*P5(+C+;<M1\%LW[QGV8KZ,*SFA4-%
M%=!HV(=EY:&7[50 ]S5YTN@^$S:36D>+2?!,2AD%1KG_QX@303W)5TUBX #?
M?:RMD #XKSCK-+\DJ5#&3U)"J@. W:5\>-ZV=UB[>5EU"<CJG6C=((-H7)8G
M9\X8_6$LDTK1O!=^ME>%&3$\X-\^1WTJN@X0_^#I&=^P,<6Q9JH>]WT_H?X/
M3=@W"8Y#YLR!N5G)NRU_!*^B''BM8[/_<-?B4LSJ1__B9DC*4_GA,P K%G,G
M32#TAP)J684D"4P W)Z,&_*^C[^KK1E)_,N)JH/OA_M<[L)5HKVBR8,1-*5T
MY(/)^6$A&FTX/WC-?^O_96+P7X86SP"GS?$[ 8K.[A!R6%9R#XHZHIY1!/W[
MR2$^VL@RKDV;1JM0;"+.'KUVBR)=_WA)ISSFW(F1P7XB"0-[$  50#!__()]
M^+_64/S7\7+IP#GQ72#^OSU<8S[X-U9 U_,AXZONT/XPQ[7"M<"]]J,^\)P;
M .J1J1)7HL:ZCJYB,?XAU<SP@06TA>>X.)9_P)Y@:OD,D$E^>:]CLUQP8^!1
M5"S#JTZL2!4>.\];E_V#D#XJP.>_&S4$6:;]?SH<UP2 7(I7[^]XL2S7REI:
M;7ZRQ_<G2%%B)#L/U\JZ2KV49.K;,CRC%U3WXS\V*?WV78/:LV>_M8I1.]IP
M]LSE-QY#<ZRU1A_:"[X)XY 4G<R99(_UZ!1-6>G^5851\I<^F#\D[!4'].<%
MQ%19%LY=JG_7-:H9.4:BV75I*;P(>FFO9PGC&BA\<83*KK['=8/WP8** I#
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M.564&XC&S%_AX&ZLW?5!\'EL+N.*OC AMW/<[[_4_,!"HPZ>CKI'[<LC\Z>
M5"E)B*G-%SQ:EWS56%LE]Y\[+ K#OCTQ:X,^ _K=[5; X$@WC\<,-)97=U;N
M=X8!(KT)PO??NWNFS!@YRSX*^=TZ# E0>["/+DK$17WHKHGI<MY<Y4<PSA5#
M67]PZP WSNF=+W;Z0-;]?3%>5S\]Z'HEK5;:'TAL(S)+\"?O)_EW)AA/3>4U
MP;,>CUDGRSO@^L;(XDP?8P>Y*-YQ=0L 2Q>S4R"IPV8367]\'*W0#+$53?[]
MBFC3:!,Q!BX>6NX9VM> :"Y@]<H5Q'N(</6X3QUJ&\Z?O-V%P2#[&ESA[,(
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M%4T3)^@^4$\"KM%V0:)]]3"GVGFNS/VWG-TZ,<VTEB]XU1D3[\(U.&P5VW_
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M2ODOT5YJ=:Z>UQ"#]&Y%@GL/C3SY;T4Y1-7EM=BW5!NEU&/!Y#E5I[LCE^3
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M^1H8/O&QA_.$404Q!2F<! =/@1TIZW\TV%B):(>L[U;[#$7?G EMZ_\];0C
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M%*XMT]19_P=Z:K2W=G=73/>V^(<BPW<-QM?T_3))^BYJ"O0:,UUVRE5"FG]
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M:/A?J^.Q8^98(K^$[ECKZZ,K_4$C.L=7E 5\XX4[M8M\39!]P1PCLVOW"J>
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M'/#8<MK&[(%F,;3BP&+X<+S!"M!VZ^^Q8Z&8HH/YX/'&#[L5ZN\EJ0VZWOL
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MZ^.[5>4IA/ ,'9<8.FS!K:6W#87T20X9V[YZO/[H8ALG^!C.@(ZA_9JS!$?
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M)&-A!GN,9THZ.)0[-Q+%F9=> 3LJZR&S$N"\%_BWW#QL^PJ($'-[!4C##X=
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M0&SN&H)DE5Z&8N7:NKH:;//;DFJ*VGECW4\>]VA&7\R"*CJUX%5=T1>1WC-
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MQ[Q\+1VYE2(_0Z4\F+J,-3@<89"O+:&>*,"GRGL_SAQUV$%PT,.;.#"A\IT
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MT")7G"Q)>I4965KH*J?[]T (NHKSF$O1\1UGCKFMXRZ*P)[GD3_F.E&MV>7
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MPN3V1*) Z;E V#N3<RG^1^5=\A2R5T!GW&&>FWAVRZ&:M/7ZJ6O?SA\>+YT
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M1%RVYAMJJW%:T\@ZDD$D3?/5R3>54*LX8\P3UB]^+2\UZR$/5Y^4:7SS!?3
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M"=H*ISG]WLV9$B!N>ZM+8P$3$//_OPD 4$L#!!0    ( .TQ:UK*MOT[VY<
M  6@   8    >F)I;RTR,#(T,3(S,7@Q,&LP,38N:G!GK+MU7%O?MR9\L$*!
M0M'B*4[1HL6#%"]>W$HI[E#<H4"+%BA0H+@7E^#NT.)6K+A;@@8(R<OWSKTS
MO[DSG_O..Y]WYSQ_)'N?9*V3O=:SGGWV0?U!K0%/E>65Y $T= ! >W@!J"5
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M#<4*5Y:B+E>UF1O)*&!H!OIKF'99>V!+!?2%!2('^(_\'F65"#P!LU\IWZ
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M+5R9U^2,>S#E[:Z:TG/Z9N9WS8KQRY>+_*6ZR6F*YMU## W@=?Y(9(AA)Q(
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M53SFX?RU^_+@3V;([D+6J5KC+&O4U(Z]1ZQYEF)RL"V9^6<G"1ENZ:[*P]Y
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MNVW..1WMN4,-@[]FN#XWUWWS4$I-1MR"*K2.W&?#D$R2S/#*U>V=CZ20I/4
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M+#'M!JVJ7^0Q*0WM.!=+ES%N'F+*B+>U)IP8?I4D4#UY^BOQI,W%S\@=W8%
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M<ZBAE%2+4-9R6B7B'D&7JSMY*]P#;>+8'P4UP8P*O11*VT-Y$I$Y8IB5!S(
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MIY[P$5#@_!KQ"'B*I>'+QSOVK.^V;_'0[6]6.Y1"4&DL5ZH9)K4? R4> 3W
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M*G E:VK71<G++<\#_]+4=F@!*L4P1H8"!L-.K,,H^=]7I\FE K91[Y#R\$=
MURGV2!DX_-:F=/Q("LTE 6@:A<':/^[+3WAF$?D(L#^V$VJ(Z5[!JZFI'QM8
MZ"FC/0*VFD1^[Y!0\N XED+X0\B0RK/V6)VHT8F"%-"DBE-EG@6^(L;U<C#7
MW)-]8^8#P0=4A\O[J%3:)'@LU)7VTF1I-DJ?F(^!Y%O</:]2UYR@SC?M?IE,
M)^T&*=]4N_O5R3_WYUU9<)6RK^0#DSTKA-6-M0PX[$DL4LPQ*N4Z?)/OV[1[
MLQKLN]OPY1JR9._M0^T+0F5MUF(&SUZB2 UOM*[(.YB1N["CX)]F6"U#Y^CW
M)\H@$<?C?:TZ?>E)NRWM3K#RS%N'/2_4)[+>KP?YUDM74(=H33W'HE^;MC"[
ML=..=9/]$0L4IBZ4^XA[&5^\+H9?U5FXX;5HOEOD5*HVDH"OCR.D";X3XOX2
M>/8'] KWDG5UJ%T)A#W7642W]?$%O83R]'T("FT17O:):0>-T=QH_04ZRI5:
M%XKL-P5;,*EN@UVO.T9W]S"Z8Q8[.E<86X+[>]SXJ B:$H/T?QHH?0.U?,?T
MT74\D/)ALW>FG%(=?E5:)9L=_^FS9F*D_XN#%Q7]UFW*<_NKI@U5T0LB&]*I
M<J\&9*E: 0(5,)RY7:59EX[O=Q1Z!R/D-<-TB>I;@GK)?SX'#/P_K5UG-!Q<
MMQXF>$,00?3RAN@E>A]$@E$RT7L)$29Z[SU11P^"!"]!Q.B])PP3$74P#"9&
M=!EFU%$B-]^O>]>ZWW??[]YU?SS_SI^S]CEG/_LYS]J;2Y?K5<J13T?R;$23
MNLIJ.O> 2T!Y\L 7=-"ZUT\%NX#=\.+EATP695%>__S(Z(8])I^R5U_M;*U/
M4F>5C&#Q7/74&BB4SRJWV?$'P9SU%T>J"I\Z8)5!\YD:(49YKFLX'_\>'6*B
M/<$%F2S64BNE"BXGT4TO7VJ]W\GO,SL>)ST86[NCT_C6262M46.H+>:>(2 \
MC7F519WK4HLGR:LR8S"/:D#>_FX;80E=^_Y>=^[F 3F$T]Y^,@5-S6;5Y(,(
M/R1<S;)GSK5"ZV3M5"Z !LVS]?6K;=W9AOJ/] 7F^3HS''77"I*$% (F[%O(
MCJ"V/U5F[LU_\OA=F3 9+.OQ&D=UU+\]RL D(JRK$@(OWA&"2R*K:M_L^GHR
M$YM2V)9SOU;@\[3=R/<R'V3DNO#!5B<N)4I8W$&"*=C92Z5@W##!]OQX%IL6
MR0^;%JOG]JR06OG^?$61]6[SEY6XQJ-[%?74D]%NPL.YSA5O!:#'9WNR[H;*
M'$5I8^$4^*[1DWR?^#T1NWR,\F)Q4<.?))4+PU&B\]#)W+TM2>ZTZD^^_LZA
M-X+OXN<$R!Y.A9CSNEQK.O-:<8S?U9@(6QX7=M_\3:A2[<4).K K?H?>%^S(
M^*.WT9#6@CK) J\G^JGA#X0];][OT,G_JO+:"ZNQ4>NFWDJS6\(D.(EZ2#6X
M7;V\31O.VB&S..*]<5WBF0 #^4=[ 8-D_1O5?-D JGXC!WE)/#38TWLU3UFB
MI$Z_<F'QN3R5=O<;S6 FM+L'WZ'K2S)'*YLPROOT1NGA#C="OJW2[@];$,8;
MG7&[GM+?M.*-NF];R(#O@/E1I?-CK+17U9I47)^/2NGM_RL/^0TR^"<R_A@J
M8XA>G*'>M+"XL?YKY_#*1:]:7DKGEC;&"Z2;8/K'PD,(1@&AG%"RPE"Z%72
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MCE9'%P67ZP7I<X!=!0T86YJQ8+8D2MU%.M/B^\-*Y+$\)D;V3R[D22A3XND
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M9>ZV<(Q^_M(=0T9G29P,W(Z?[LF;^ BB(Z5^;Y;(D_2.$/1>L1PO/E%H-WJ
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M,B$GXK $$[3OQ?&Q0">4\6J2FZ[+12" </4^93%C6<;ZEA2*I+-NGU'\BNP
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M'*:%Y^WUS)6))6":*J8)&II@=@#>*:/<U "2'1D5QJ*%MY,-88:G3WSKHR-
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MIUJH&V%8>+*"@[7%0?1Q$ _7QD&\9!)(F^N[C@X0+:)_]'"$:&[<*Q!%R+R
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M-PL6#<4#$N@T%TI[=4PII_\XY\@E F1&I_A,3S 2*&EIU*<IF[!Y1:RH1DF
M^$%D_^%LYQ^I\0[3]IG#R)QV1%8=@D?(2<KKA8.G5;!)%SC%?6B&G^X.,4!U
MD]%J"?F1I!\I-G_A+$L*;&,E@J! ?.%O$@*7JH1[[AP>[29SV$[GVO@UZ#02
M2S.ZM6; ]T?U;;P@^281:$\]?$51HCLP22J*2OB.=<]X>Q.0$1 F#C?I2,3%
M6"F342R!K0&&80TC##H*SH@2T=OJ%><B1+C_3:F4:=1!,8'1)EC&1MNQEEE&
M5/6#.T3@9[<9X>[$1K]Z (=^\[AO4:ZUM?_Z]M_Z[7%/2.BGY?TBY_[H5(^H
MI;2,UZ_54^G)9;'/-J)F&$HC2HI5D_=-<]MBJ 9?U&F31[/\<A[,M1AB86R5
MJFZD3(.A@WNZMX0S#+*PHHHR+RQ@7VN;(;MUANSI-D.VS9!M,V379,BNEXB,
M0_18MD<;YJPN[BB%D'RJB,2JZK#+!_R.M;[WQU_H$VQ;@D6T,PL+!C4\BVQU
M.E*-OL3WN.)R4SJ\]KSIL)6PU8_60A+Z:4;RHSL)?[31_C'6KJ!^<$+#P_69
M6,8;@PFVA R#KD$<?^=ZIA#,CY^QWX#X,Y5U#7/3FRRC;]&U3-D],??S"*Y[
ML%Q.@I*9[EN$TN+*&P%R;[&KRR%F]#!P]N#?K>W8,PB/UF]Y'DNE2@4!F$(?
M?8L'U])&BN^5J1FI8S5Q$D%28UC%(O^I&LNWYB*LEH[,JU&9XCS T@)!:3N:
MY(&<C?Y10DY8F]7O)]SQ?+!L\%@D38&=H5^QS;HG6/9:&@8P]P5*9%BJ']>
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MX3K/]L&TSI?PSWD[+W_\_U!+ P04    " #M,6M:-MVJJVX+  !@1P  &0
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MW:T""V=LA$Q'A;&K[S?%%,QRJS.*F)T!)Z;\*Z?TPI2X1?C"\0!:A<&M0''
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MIYW;VMVBZ_H:18LG#R]:G,:X>]?R19\6V]6W&CD5I.,BS>O,D8:U)UGBAD7
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MILR5Y=!(%@E=;44?&R5B'_8 K0.TW@FT3D1QAL!2D3/;K)EST-D896 ,<#?
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MN:$+N4VJ8A?-6_;1EK(>, J/ G%U+=RS[9 (K+4%!%%U@#V^+\ +X#)K>;=
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M#8L2S.K+\,*N]6=79V/8Q<B(IX!?I,("KPV@%HC#;56[S],1ZL,T!+Z'HHA
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M%_:955W^_E-TJVH#KMQXCUNC,0S4;.[5'J1FR 4W=@CP"[#1<G&MAJ!6EQE
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M/)AW3;[-S]S/03OVUZ3_ U!+ P04    " #M,6M:HJ=J2],%  !R'P  &
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MR-AHZHQ^-V*?[$SG&^CJN909GCX=GS[^\GQ:.FBH+SU,=NH3_T%5C]_I.%S
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M_\WX^Z%@NRYM]EM8^U!^S?0A_QCJ_P-02P,$%     @ [3%K6B5\[\A4%
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MW!(4Y@5^Q-):(7)UY5PE-"ND7:7-\-4A*$-F@64J!#Y;7N4&4486#]6_R8)
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M@?LO)R#)<RKRCZT%^Q&X'%?L&G](D22V/OH^MZ496]YWBOG4(VR@EGQF.Y)
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M,C,Q7V-A;"YX;6Q02P$"% ,4    " #M,6M:.MJR0, W   '^0, %0
M        @ %=*0  >F)I;RTR,#(T,3(S,5]D968N>&UL4$L! A0#%     @
M[3%K6A50L I9CP  U&() !4              ( !4&$  'IB:6\M,C R-#$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( .TQ:UI<..TQL5\   I2!P 5
M      "  =SP  !Z8FEO+3(P,C0Q,C,Q7W!R92YX;6Q02P$"% ,4    " #M
M,6M:SO533Y!<!@!BGSX %0              @ ' 4 $ >F)I;RTR,#(T,3(S
M,7@Q,&LN:'1M4$L! A0#%     @ [3%K6AWD,:')&0  <1H  !@
M     ( !@ZT' 'IB:6\M,C R-#$R,S%X,3!K,# T+FIP9U!+ 0(4 Q0    (
M .TQ:UJ C-L?<98  .NJ   8              "  8+'!P!Z8FEO+3(P,C0Q
M,C,Q>#$P:S P-RYJ<&=02P$"% ,4    " #M,6M:!OZ7<NU(  "'20  &
M            @ $I7@@ >F)I;RTR,#(T,3(S,7@Q,&LP,#@N:G!G4$L! A0#
M%     @ [3%K6HMRU*#!G@  K;4  !@              ( !3*<( 'IB:6\M
M,C R-#$R,S%X,3!K,#$P+FIP9U!+ 0(4 Q0    ( .TQ:UKCI]<(07\  %>'
M   8              "  4-&"0!Z8FEO+3(P,C0Q,C,Q>#$P:S Q,2YJ<&=0
M2P$"% ,4    " #M,6M:KADQ!9%6   \7@  &               @ &ZQ0D
M>F)I;RTR,#(T,3(S,7@Q,&LP,3(N:G!G4$L! A0#%     @ [3%K6CQ91"?M
M2P  BEP  !@              ( !@1P* 'IB:6\M,C R-#$R,S%X,3!K,#$S
M+FIP9U!+ 0(4 Q0    ( .TQ:UJ+W2)9,HP  ."2   8              "
M :1H"@!Z8FEO+3(P,C0Q,C,Q>#$P:S Q-"YJ<&=02P$"% ,4    " #M,6M:
M$: Z269"  "'1P  &               @ $,]0H >F)I;RTR,#(T,3(S,7@Q
M,&LP,34N:G!G4$L! A0#%     @ [3%K6LJV_3O;EP  !:   !@
M     ( !J#<+ 'IB:6\M,C R-#$R,S%X,3!K,#$V+FIP9U!+ 0(4 Q0    (
M .TQ:UH'LDQ4.S8  ))K 0 9              "  ;G/"P!Z8FEO+3(P,C0Q
M,C,Q>&5X,3!D,3@N:'1M4$L! A0#%     @ [3%K6C;=JJMN"P  8$<  !D
M             ( !*P8, 'IB:6\M,C R-#$R,S%X97@Q,&0Q.2YH=&U02P$"
M% ,4    " #M,6M:>F2OF-0@  #+VP  &               @ '0$0P >F)I
M;RTR,#(T,3(S,7AE>#$Y9#$N:'1M4$L! A0#%     @ [3%K6G1,@]DG P
M,@H  !@              ( !VC(, 'IB:6\M,C R-#$R,S%X97@R,V0Q+FAT
M;5!+ 0(4 Q0    ( .TQ:UK'1-F44@D  & \   8              "  3<V
M# !Z8FEO+3(P,C0Q,C,Q>&5X,S%D,2YH=&U02P$"% ,4    " #M,6M:XNH7
MK2\)  #..@  &               @ &_/PP >F)I;RTR,#(T,3(S,7AE>#,Q
M9#(N:'1M4$L! A0#%     @ [3%K6J*G:DO3!0  <A\  !@
M ( !)$D, 'IB:6\M,C R-#$R,S%X97@S,F0Q+FAT;5!+ 0(4 Q0    ( .TQ
M:UK'MW3>Q04  $\?   8              "  2U/# !Z8FEO+3(P,C0Q,C,Q
M>&5X,S)D,BYH=&U02P$"% ,4    " #M,6M:+*'O70<5  "-50  %P
M        @ $H50P >F)I;RTR,#(T,3(S,7AE>#1D,RYH=&U02P$"% ,4
M" #M,6M:)7SOR%04  !9QP  &               @ %D:@P >F)I;RTR,#(T
E,3(S,7AE>#DW9#$N:'1M4$L%!@     : !H !P<  .Y^#     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>zbio-20241231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:zbio="http://zenasbio.com/20241231">
    <link:schemaRef xlink:href="zbio-20241231.xsd" xlink:type="simple"/>
    <context id="Duration_11_1_2022_To_11_30_2022_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_R9s5xpFO902Z05RAdLWrnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jtEg9vA0hUWnfXmt4HMTXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:XencorIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2020Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ybTmDoxkwUu0xUQqRigT7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zbio:XencorAgreement2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_kl-ar1okCk6X0Cdxj6jlyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:XencorIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_3_2024_To_5_3_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_lcOoNTIEC06PQFCU3DRl5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:BmsConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-03</startDate>
            <endDate>2024-05-03</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2024_To_5_31_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_5MuMZ5_MaUWYN1Qu9wlrYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:BmsConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_30_2022_us-gaap_DebtInstrumentAxis_zbio_ConvertiblePromissoryNotes2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_cwy_9SZUtkSEG0gNp7CNjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:ConvertiblePromissoryNotes2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2PJ0fHjSGkqSUHx6Zr4K0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gw2rhLbrokS2ngyRmmip4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_t-hVZE_DQ0aHW393n9Fzew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_T7YsONiFE0CzJJl1iFaCYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_P-kTuepM7kKaqc4rCr2AAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_j5jOOcuea0CX4dm8xBjYxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_np8ZhIOstUKtfTT_-Yj3vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_lwKQYiDgb0GvlfNmmVeNtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_3_2024_To_9_3_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_bmG8cOK5ekOayAksSxcSeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EquityIncentivePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="Duration_9_3_2024_To_9_3_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_mqyL0U5nuU2EVYmKwAc9sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember__kat8-A7DkaDtefaqsDstA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:XencorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-yJXARaZ-0OBYdCxepkloA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:XencorIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_DianthusTherapeuticsincMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CAe46DStS0ayGHbh_yaH1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:DianthusTherapeuticsincMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_dei_LegalEntityAxis_zbio_FairmountFundsManagementLlcMember_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QkW1FJbql0yPxwXvk72juA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:ViridianTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">zbio:FairmountFundsManagementLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_I6CRPAIoAkK_QxeW-_WiBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:ViridianTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_zbio_DianthusTherapeuticsincMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ZTb-Cr_H-k6rrUVG_vWbag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:DianthusTherapeuticsincMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_u2OmFVykgEeCNR0zO3JP-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_zbio_FairmountFundsManagementLlcMember_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hnbEkcn98U2igS-6OHbaDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:ViridianTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">zbio:FairmountFundsManagementLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_WGP9j066HEmWArI6WB0Cow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_PgETU9rFK0q2wG2LI9cG2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2023_To_8_31_2023_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_P-ll4OVb3EWjFIKqvZMELA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:BmsConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_qV1cIVkt2kOoAoLtymHm9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:ViridianAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_ucAh8N2LEkm-jJRZJUsugg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_4pkbHJxyX0aZXqN77xa8Kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:ViridianAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_3OZtyHKQXEeOnEHLhY6SNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_ZrowpMBVWkeOdGC2HRwpgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2021_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_r2kEzq5fF0emBdihAC_LuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_JXqZc5v7Z0WJSg_JLf5b5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2023_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_DlfSbRkRKkikwGFbk82kmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2021_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_Bm0Xi9UVpUmszqhYv-4qFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2020_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_LluPYzM7VEa_H16QX3m4Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:ViridianAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_4_30_2023_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_TKtQMBOy0kys1OFuL5HUrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember__ZDd67Q9eUCGYKadM0BTGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:BmsConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_24_2025_To_1_24_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_zbio_ZaiLicenseAgreementMember_OHpbECa01k2mu2U9YBMjnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:ZaiLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-24</startDate>
            <endDate>2025-01-24</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_us-gaap_TypeOfArrangementAxis_zbio_NovationAgreementMember_lnQAUx2mlkib0BNiLe_Jxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:NovationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_86ES1U6DdEiWj8UWmZ87Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2023_To_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_68E-30ZXOka0SQILO84I2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:LicenseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_dyYvSl_2AEyLjKyAcaDc4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_24_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_zbio_ZaiLicenseAgreementMember_E1agUD26v0u0FuWVhieCXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:ZaiLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-24</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_CISJK2ppnkmIAMwch3Q_OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:LicenseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_q9l-Yh0Dr0qScfAPmFwVvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:LicenseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2024_us-gaap_TypeOfArrangementAxis_zbio_NovationAgreementMember_8o3sYZV3iUWz0FuKhL7jow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:NovationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_yjecN0IOyEe3rAsWgnm7iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:LicenseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember__L6rvMfPYE6KDEiKRpOSYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_ywEHHvSO902MFN2_jPD2tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vZWP1gyCtEu9w9OaIMGbpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_-xEDVh4-qkqlm3ytowN9Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ocu-YDmfGkytPLv371WO_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mIxda3QBT0eGgkr2-TLdAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xCsVy9CxU-Q-Ca38CHdgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWOR2Y6eb0qw6h_ECNiCyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zyuRWER_rEGXi84E3qArrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-zW7TSnNlEOWNVAWJEAmqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_twRRvxhUHkGVSVijS4AHpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_skdQla54vkylvNLfiCBCHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_lvF2unTWUEenGdpAx5Ec3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_aeVZjo1Bqk-9JQbx0cC7vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mWc24hPae06GpXVuJlDs0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Zu6GA717E0C8cJ-Hhbeflg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-16</startDate>
            <endDate>2024-09-16</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_NlzJf7p5-kuuwrGA0pNVzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_XJAUtiSe802lS1JD3MLPpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:ViridianTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_zbio_DianthusTherapeuticsincMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lvI7Gb31J0y7HORj3pCOSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:DianthusTherapeuticsincMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_KSqzhLiyzEyDgl5ybmBLIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:ViridianAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_bzLuOSUTJEyZzSgS11je2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_l5vJE3DbIEKeKPth4gy8Kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3nxvET59Gki8LFIKljY7FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_o_4zbocCK0S4kVmIQxpThw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vq8gJuFgxUeW6Sum5gLP_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tGb0cUxC9kK9Z8w9yezpew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PBJ1X1nFxEWp13l1OkKMvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uUos0deBaEyEN6bFnRun4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Uz8_I3wLr0SnQHkp_bKCXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_nl_IrRmKGUmQBClrdDVOTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wA5OCDooWEKaI_O_5zlfDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0joMr_rkEkm7x1ZuVCT9ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MtK5qqSc7EWFj3hxdd6E6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vp9jOynptE6b6qFRS-0X-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_KToxdb6KqkaQTUoti9SqTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EquityIncentivePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cZRERuEIiEGchuqk65A2pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2025_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HT5QNFavaEuMvtiRET_mAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="As_Of_9_3_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member__gcr5m9F8EmwZjNOy4gdqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-03</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember__QbnTUUJpUmGv43XtvhTNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W4Yt2rBhJE-FLWW_GHB-Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_n3k32el71EGZ_NhKc4uVgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_QSgjONif-0yTKlXy2bMn7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_RshCuHFfukSw2KF3sIAoJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_WGWYo6VeoEWAuqXTVFh8WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_UnallocatedMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_ebJVNQcIrE6ToW4JVW_66A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:UnallocatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_PartneredRegionalProgramsZb001Zb005Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_Rh91EjE7O02oJHALLAAHdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:PartneredRegionalProgramsZb001Zb005Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_OtherProgramsZb002Zb004Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_7d3JG86c_Eaat0gaHhQcQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:OtherProgramsZb002Zb004Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_ObexelimabMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_BA-_9VIA-E-YvYOM66DKZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:ObexelimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_UnallocatedMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_FtxZwqa3A020C1JNgu1N7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:UnallocatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_PartneredRegionalProgramsZb001Zb005Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_yj8rbVJ6iEu1uke5hj5FiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:PartneredRegionalProgramsZb001Zb005Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_OtherProgramsZb002Zb004Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_VixgjipTjEKqNxHHsetS4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:OtherProgramsZb002Zb004Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_ObexelimabMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_Ue5uXg-mLkyi2JN6fkIuQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">zbio:ObexelimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_ZeD0YqL9rEiNGm87-Fn0jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:XencorAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_QdIMiSdGW0WnhcGmUQtR9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_f7tghFWG2USaAbs-bXl6Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_5_1_2024_To_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve5fM4bIxUmgiWyD_r9iHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_TYxqnXTkYU-hgPL5w_6nXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VUl7HtcvHkydsDN2_JnMRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_O_WkNZwcXUq8f-ADKZOHMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rPANXOD_Fku39IGeijPdfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-16</startDate>
            <endDate>2024-09-16</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6aV-4PBKtEOUPe_8Z_Aj_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_b_-Mw3ef7kWZpywvWrh-sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">zbio:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_ftIqpFVSOkq5tizkN79ucQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_JZN4FpSog0SrROrSycy9eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_MfqeZTH_FECRP_tS5UQvHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Tjq4ptXuakWz2N7XO70BFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_03uBPrMelEOQgnXfrO0Rdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_LJ7TMbhoFUe0nr0lDe3Lmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I3LY6QQrkkmN4CYZS5IM0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xmuQWu9BX0O2k_q1aI5KuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_98SvbTRA50yOezeZ029LuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_3_2024_To_5_3_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_cwXLzP0nA0KjySFxWk-Usw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:BmsConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-03</startDate>
            <endDate>2024-05-03</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SB8hnByb2k6XmWq5YFUxLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">zbio:XencorIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_2NdTZEI7VEekOwqqgqrnHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_2-euo0XGO0qIb5EsNIp7SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_ExKbMgkUn0ititCiAzolAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">zbio:BmsConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="As_Of_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_jvKsbpTO10eG_t6mtZmxgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-16</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_FVi09Cz6lESIybH__dVf2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9vmGc1uJ-UKFfbOjwwSZLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2024_R3mnM-yuCkeUi3lI4lcTJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2025_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hb-DK0AUdkWTw3-eUcEHIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EquityIncentivePlan2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_xOEKuB9Y7kOpDa77H2eCCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EquityIncentivePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_CULdaUsOIkCpMGAD6CrOEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_N0JzawarFE2rMLM5lKwjiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:LicenseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_NYcJR8lqrkCLowTMNFUBTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:LicenseAgreementWithBristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_7aoYVm8LsEqvEfiPlkF4lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_EbY1u8wvo0uxDj6anPPPCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_45gRULzuSUK5_ORGEXpLOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_cT92xtQ8cECq2AFu-XJeOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_iSqSAz9x4k2LDrxzSKy2MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_LvhP6kTZU06gMvlc3p7_eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_82fSkNrj5kGcJKb3RNQoNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_wgLHoHG1-0qDKJPNdf5zYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_fNDpCNYLYE233dylDwz8eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_efoaGSp1_UmRJh64ycKRPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_T3DzdxiqpEyWSibLwwGToQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_u4MSiO-PeECFV2npmPDRmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_tAB8gHGpxEa_vZYJC85hXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ujsrnzhxWkaowceDO8G96A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_GlXgsGQE-0GNbt0DsdtK9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_KwwFNWvkbkepTCv4eJzXUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_LWrKtXp_xEeU8LAphW72jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_M12KVoNGq02-s4clKubiaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember__ml10lATXUGvzgwEsGWE_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_8iYMmA8-mkONHhlH8V6H4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_c8gM2cWCLkC5U2Dqd6witg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_Uu3p6qpokUGtpEZwlhfejQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zbio:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fB6rJscJqE2qELeYONH6iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_AkdY1KqPtUenQWgty7TKCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_pAV7g9BFKE2QQiAhjUp8uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">zbio:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_jq1Qp6HsIE2fmcD8wUHsAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DSs7gyVtbUGlXl8c8Se1DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-I220YjrTES2zT0dh6nXJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Gh9QtBp7z0aJp2U6HTSmvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jWL8Je-UBU2gqCEY8KUEpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QXQPHb61tUenoW1KiYC_bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_yR58FFqVa0-kULPck87ZxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_IxVPwAMKEkiMUjSqIZE_PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">zbio:DianthusOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UAmlIVGtOke4L0fxZoW0Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4dqDswEkwU-V1_i6DzMeew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2025_53upKo0a90ad249nOUw4cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001953926</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_segment_S86Rw8jTyUm70oUkTaBnEw">
        <measure>zbio:segment</measure>
    </unit>
    <unit id="Unit_Standard_Vote_HZAN3AhGAkmyDfnWsC8kqg">
        <measure>zbio:Vote</measure>
    </unit>
    <unit id="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw">
        <measure>zbio:item</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_cchFbnGap0WnIciwC6uxpg_2_1">0001953926</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_vfGvexh720S7hVqr07MGtg_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_4hrYWDZfAUikKwSQfiiehA_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_DW30foDI10KMyOOkaBg4Vg_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_hIP6fBUXSUagePgzwDLPgA_6_1">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      id="Hidden_RszIZHKCe0GMwqFl0OU5UA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      id="Hidden_u6rv2-q7MkCwQ_XM0Co-uQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Hidden_H6svqTBFo02ndFqe1K9qSw"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Hidden_wjmjNqhE-0KUgjj9Uzc5Cw"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Hidden_RvIdhgb7eUKUzcaW1bgoAg"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Hidden_vM7VdH5LuUSIBHOTQRq6nQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="0"
      id="Hidden_sW4Bekr-zkyy8cLJvx_IHg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="0"
      id="Hidden_ROUB4IaZ3Eu4s5Lk4YZGGQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <zbio:FairValueLiabilitiesLevel1ToLevel2TransferAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="0"
      id="Hidden_bSbgkoQjBUSLdj7WXI6fFQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:FairValueLiabilitiesLevel1ToLevel2TransferAmount>
    <zbio:FairValueLiabilitiesLevel1ToLevel2TransferAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="0"
      id="Hidden_B8tiQTeac0KDjUIoilEa5w"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:FairValueLiabilitiesLevel1ToLevel2TransferAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="0"
      id="Hidden_-Wi87NuziUOMzVc46Eo1mw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="0"
      id="Hidden_o1GGffggSEu4tW6nelxegg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_NYcJR8lqrkCLowTMNFUBTg"
      id="Hidden_-H1KgnAtXU2ARs6PtzO9-g">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_N0JzawarFE2rMLM5lKwjiw"
      id="Hidden_0gQq9Ba02Ey1cgd67d3AOg">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_ywEHHvSO902MFN2_jPD2tQ"
      decimals="INF"
      id="Hidden_tse8iP5LeU69vjWcjdtpow"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA"
      decimals="INF"
      id="Hidden_F93rW4YniU-isgi4W6XJYA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1785714</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_ywEHHvSO902MFN2_jPD2tQ"
      decimals="INF"
      id="Hidden_rI0dKlRWL0ul7X3z9V1xFQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA"
      decimals="INF"
      id="Hidden_M56D618pS0enhKGKHqPd0A"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1785714</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_-xEDVh4-qkqlm3ytowN9Zw"
      decimals="INF"
      id="Hidden_JnN4uMYIgkCjRU4tOzxuiw"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ"
      decimals="INF"
      id="Hidden_vdtRe09mgUqM8NRIjiuQ1g"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">17589380</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_-xEDVh4-qkqlm3ytowN9Zw"
      decimals="INF"
      id="Hidden_i15PFzsJrE-iCOvEYrCCgQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ"
      decimals="INF"
      id="Hidden_0P5EwUDT8EyCGvpmm1IS7w"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">17589380</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vZWP1gyCtEu9w9OaIMGbpg"
      decimals="INF"
      id="Hidden_f4mwZhVtbEuTypHhSfyNFQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw"
      decimals="INF"
      id="Hidden_l5gOCjZrikynZQNbg-mghw"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">81242587</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vZWP1gyCtEu9w9OaIMGbpg"
      decimals="INF"
      id="Hidden_Ra8EPcJLvkyQ0y8ZKYex4A"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw"
      decimals="INF"
      id="Hidden_3dAB6-rVS0a4E97pEhf7Sw"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">81242587</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Hidden_VttpHrPuBUSgpDKjk2Zk4w"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      id="Hidden_qnhQqOYVT0yoQAvJgJA5vQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      id="Hidden_KM8jL8QJ50CvOax1NG6sbA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Hidden_E6IzMDPGE0WVp6F4hT3pfA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1576854</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Hidden_8h-g-kbq5Uie_MXjyiAoRw"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">41793412</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_QdIMiSdGW0WnhcGmUQtR9A"
      id="Hidden_b_kdHKCFF0avLUjrQ41Fwg">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      id="Hidden_O9B88gheUkaquoX_9DV5hA">http://zenasbio.com/20241231#FairValueAdjustmentOfConvertibleNotes</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Hidden_jVXKwJzbK06otYl6OvTOJw">http://zenasbio.com/20241231#FairValueAdjustmentOfConvertibleNotes</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_QSgjONif-0yTKlXy2bMn7g"
      id="Hidden_JhL2WXriOku-gXN73DMQHw">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_Nrd3JLEcFU2G_8VYhavuuA">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_Vjt2vE2jwEyAv69mY9dYIg">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr__oBZTN1IR0axWiBc-XgHtQ">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_QkwRpIgcf0-5LmDwf4uWhQ">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_a5HD7RE8OkWiCs0XMaNNdw">001-42270</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_EKATh28O_0yhrWz1dM8t1g">Zenas BioPharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_TLagL9frb06i7bGNKrYYrQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_7nJrxHxnEUepBg9JpbiEBA_1_1">93-2749244</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_rF4qa9y8TkSogbAEfAsMKQ">852 Winter Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_krHNQYCVL0SVOzWVJ3w_AA">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_-q7jOwQKWE-HvQcDdcxRaA">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_AalBGt5g_U-xcjuwIIEf2Q">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_xElLVPNiJkO_H-qtlwsf1Q">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_k8zCES-5602U00FB-PY19w">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_uXETooDQpkqYXcCqcqsS_w">271-2954</dei:LocalPhoneNumber>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_XpXaZXtx_kCUXxekSH93kw">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_eOUddGmnX0ikaBmw1-a4cw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_jzUZGrHlWU28xoSqTirvbg">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_5BrWiKaguU6ojOBe8HhmWA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_BuPISTz0HU-BJhIPhNGrQg_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_jXEyElTVt0GB2fHLRd55GA_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_GCRelm4nwkGHDYX3NnCPuQ_2_5">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_KHiDKeVy8kqPMEWub1aoiQ">false</dei:EntityExTransitionPeriod>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_i2zCtsLUn0Sq5gcLhIhUNw">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_LXKFNkYSg0qMnMN4k6umLg">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_62uYISbbBEGdwndZPNssfg_2_0">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_YI8LN3zGO0e3BUK948LQzA_2_1">ZBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tc_agk-AzerAEuFTTYxNNbtFA_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityPublicFloat
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="0"
      id="Narr_-1cDrho7wkCfY2U0372N4A"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_28_2025_53upKo0a90ad249nOUw4cw"
      decimals="INF"
      id="Narr_qxPRazrFt0moOEliKUFaNg"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">41799336</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_i9o69y1ZXUuUPkjApqp4Mw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"&gt;Portions of the Registrant&#x2019;s definitive proxy statement relating to the 2025 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant&#x2019;s fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K. &lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_zTSnOFfj6U62HOkA5X0Yww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Risk Management and Strategy&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;We have developed and maintain an information security program designed to assess, identify, and manage risks from cybersecurity threats. As part of this program, we conduct periodic assessments of our assets to evaluate the effectiveness of applicable security controls. These assessments are informed by industry standard frameworks and include a review of our information security controls to assess cybersecurity maturity compared to our peers and other security awareness trainings. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;We engage security technology vendors to assist with detecting potential threats to our information assets. In addition, we have implemented a cybersecurity third party risk management process to assess mission and business critical third parties for cyber risks and to assist the business in making risk-informed technology product and services decisions. Our practice is to perform due diligence, including the completion of security questionnaires and risk assessments, as appropriate, on third parties who maintain material data or information to help us evaluate and verify third party information security capabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Our process designed to detect and respond to cybersecurity incidents that may represent a threat to the confidentiality, integrity or availability of our information assets is based on industry standards and best practices of peer companies. Our technology, procedures and key vendors with security responsibilities are designed to help contain, eradicate and recover from cybersecurity incidents in a timely manner. Senior management is informed about incidents that may have a significant impact on the business. Incidents are reviewed once they are resolved, and policies and controls are updated to help mitigate gaps. We have not identified risks from known cybersecurity threats or past incidents that have materially affected or are reasonably likely to materially affect us. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. &#x201c;Risk Factors&#x201d; in this Annual Report.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_OEVzFKLZE0ODyVtMuLboAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;We have developed and maintain an information security program designed to assess, identify, and manage risks from cybersecurity threats. As part of this program, we conduct periodic assessments of our assets to evaluate the effectiveness of applicable security controls. These assessments are informed by industry standard frameworks and include a review of our information security controls to assess cybersecurity maturity compared to our peers and other security awareness trainings. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;We engage security technology vendors to assist with detecting potential threats to our information assets. In addition, we have implemented a cybersecurity third party risk management process to assess mission and business critical third parties for cyber risks and to assist the business in making risk-informed technology product and services decisions. Our practice is to perform due diligence, including the completion of security questionnaires and risk assessments, as appropriate, on third parties who maintain material data or information to help us evaluate and verify third party information security capabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Our process designed to detect and respond to cybersecurity incidents that may represent a threat to the confidentiality, integrity or availability of our information assets is based on industry standards and best practices of peer companies. Our technology, procedures and key vendors with security responsibilities are designed to help contain, eradicate and recover from cybersecurity incidents in a timely manner. Senior management is informed about incidents that may have a significant impact on the business. Incidents are reviewed once they are resolved, and policies and controls are updated to help mitigate gaps. We have not identified risks from known cybersecurity threats or past incidents that have materially affected or are reasonably likely to materially affect us. &lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_cmxbDdG_TkaTWkuwItk_hQ">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_ybInzAZTH0GBovZCHNUS6w">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr__8n9Tsrkik6thFJ11MdlmQ">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_XTyF7TnL3kmE1d7tW2lUyw">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Group_wdpc2szlsEe1OevoojKA4g">Management is responsible for the day-to-day management of risks we face,Our Executive Director of IT is responsible for developing, implementing, and maintaining our cybersecurity risk management policies and procedures. The individual currently serving in the role of Executive Director of IT has over thirty years of experience in cybersecurity, information security, data protection, privacy, regulatory compliance and risk management within complex and international business verticals such as pharmaceutical/biotech, technology, semiconductor and telecom. The Executive Director of IT reports to our Chief Human Resources Officer and provides periodic cybersecurity updates to the Audit Committee of our Board of Directors on at least an annual basis. Our incident response process contemplates that the executive team will notify the Audit Committee of our Board of Directors of any material cybersecurity incident.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_DpA8_ywOlkykdYdOiGTucQ">our Board of Directors, as a whole and through committees, has responsibility for the oversight of risk management, including risks from cybersecurity threats. Our Audit Committee has specific oversight of risk management, including risks from cybersecurity threats.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_D0vhjqInyUK6xib90-rC-w">Audit Committee</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_9XvnJFjj3EWwgSUwtHk2PA">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_gff0Gm28E0-EC5Bd_w4yRQ">Executive Director of IT</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_oHgOnUWFb0SnQt6kmRfT3w">Executive Director of IT has over thirty years of experience in cybersecurity, information security, data protection, privacy, regulatory compliance and risk management within complex and international business verticals such as pharmaceutical/biotech, technology, semiconductor and telecom.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_T5hec2wB1kWrWg68gjeQHw">The Executive Director of IT reports to our Chief Human Resources Officer and provides periodic cybersecurity updates to the Audit Committee of our Board of Directors on at least an annual basis. Our incident response process contemplates that the executive team will notify the Audit Committee of our Board of Directors of any material cybersecurity incident.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_XL72sE8BikiGQnUGzFy6Ew">The Executive Director of IT reports to our Chief Human Resources Officer and provides periodic cybersecurity updates to the Audit Committee of our Board of Directors on at least an annual basis. Our incident response process contemplates that the executive team will notify the Audit Committee of our Board of Directors of any material cybersecurity incident.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_XP5VTjwuk0y-4l87yr1snA">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_1te48W9tpk-UbofLxJB7nA">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_9zboc-xPdUOvYxKHWEaatw">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_c-mtfE4yBUeRwLrlx-ugcw">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_vBVqwNSOQUWUbUpWk3Ef7g_5_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">319742000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_VdvEs3wjfUawGP2M0QlBHg_5_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">56857000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_qcwof0gDuEyA9Ms0ZxcMWg_6_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">31024000</us-gaap:ShortTermInvestments>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_XKV2ElxFiEaiNQaN3z-gSw_7_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">90000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_zZYXS_n2A0qEbC7RjSHVmw_8_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">5067000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_SQQX43zH1U-NAgaEaBsrng_8_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">2947000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_eSGHx6FN3U6YqsW1TKGM0Q_9_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">355923000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_11WMlettf0WsUfYRh39SQw_9_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">59804000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_gc3G2n5VakqkbBlAXwFNqg_10_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">185000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_kOTYOYnlOE-pVxcYlqKjDw_10_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">193000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_DTrlBeQoq0qcajsNiv5G_g_11_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1004000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_X7qZzBdbF0Or1j0bNiZ3qw_11_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">821000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_UapzJqzPuEGj25pRIcL0JQ_12_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">86000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_uq3PVWsjbEiLPVEhBRj4Iw_13_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">12856000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_yDK7EO2z0E-Q_OQJyezwXA_13_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">7276000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_WZsPiPYLlUqKwxEceucLaQ_14_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">369968000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_7e0KiKZA4U2qr6xPjCTkbw_14_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">68180000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UAmlIVGtOke4L0fxZoW0Qg"
      decimals="-3"
      id="Narr_IwrPvAv0rkKTk6Fe_QkOeA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">560000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4dqDswEkwU-V1_i6DzMeew"
      decimals="-3"
      id="Narr__JoqtazLuE2WgB6FaTo40Q"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">21000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_JU2X1e8kLEeqEJqYvMFFmg_17_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">17136000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_CS-oC3jFTUO4n93ToExClw_17_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">5396000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UAmlIVGtOke4L0fxZoW0Qg"
      decimals="-3"
      id="Narr_aSq5_M8wckeQJyywnkhWFQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">260000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4dqDswEkwU-V1_i6DzMeew"
      decimals="-3"
      id="Narr_BC3mb5FPBk6FTNfofFYB0A"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">404000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_iGU9i-HcZE26BoJKgs9Yag_18_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">39371000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_vrNEbS_j-0uWpl7_zpkd1w_18_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">17306000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_S_uH6MibhEmcy7x8zvC7rw_19_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">785000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_yL0VsMiYf0K2u1ArVRX7Uw_19_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">556000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc__hoBv-R850SIUnRXOi5VWA_20_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">57292000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_XnSfIedC-0WImHXsntuY9A_20_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">23258000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_0WsLt-H9C0aG3ghBHKww0Q_21_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">218000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_KV9Ue00XUkyYqJqJGZ-uTg_21_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">257000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_2HcMjgextEyse0umv7D3Bw_22_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">20300000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_Nk1gjnBxY0m9P46XRL91hw_23_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">57510000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_rgrFCpR_wE2JSVpE1D1RQQ_23_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">43815000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA"
      decimals="INF"
      id="Narr_ZZdmbsT2GUmk3Mr7K_1wcw"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_ywEHHvSO902MFN2_jPD2tQ"
      decimals="INF"
      id="Narr_j1kzYdDl0EC6keKfHbjLWA"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_ywEHHvSO902MFN2_jPD2tQ"
      decimals="INF"
      id="Narr__jblQQSogUmRKQ0BDst49w"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA"
      decimals="INF"
      id="Narr_qMV7iOHOyUKhNa9g6Iebwg"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1785714</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA"
      decimals="-3"
      id="Tc_aJxcB-ypwEG30c-AL73Lew_26_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">956000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ"
      decimals="INF"
      id="Narr_p50s0gjNoECY3d5Tq4MNpw"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_-xEDVh4-qkqlm3ytowN9Zw"
      decimals="INF"
      id="Narr_yWiGucHDfku-u1HjtilHbg"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_-xEDVh4-qkqlm3ytowN9Zw"
      decimals="INF"
      id="Narr_1MNul9bKlku5YAapC3Y9cA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ"
      decimals="INF"
      id="Narr_KFESHUwe3EqijbjFlZ9B_g"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">17589380</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ"
      decimals="-3"
      id="Tc_c5KPS5YUkUimqpAUXMk-EQ_27_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">55840000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw"
      decimals="INF"
      id="Narr_0G9xtNA6fUKNWPL4qvZI9g"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vZWP1gyCtEu9w9OaIMGbpg"
      decimals="INF"
      id="Narr_lIMuDiODNUOQ03WizrY9rw"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vZWP1gyCtEu9w9OaIMGbpg"
      decimals="INF"
      id="Narr_GQM7M3soAUy8Kzxtekvhfg"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw"
      decimals="INF"
      id="Narr_tdSoP_aUo0uMZaVoHWN6ag"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">81242587</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw"
      decimals="-3"
      id="Tc_Y-W1YOE2pkm4qh77Tz7qxQ_28_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">193290000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Narr_Gs_oC417Z02bP-2x2JIQvQ"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Narr_FaOJznPhHEiAoK7ouLeQ3w"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Narr_PPQ1Yu_WE0SGlhNntmpVkQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Narr__qvmwW56fEWgwEjxpn721Q"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Narr_9zqjV3V3sEak39jsSKhZ6g"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Narr_2NTFJxLUs0KBSMX-aT6PdA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">175000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Narr_mmr9Zm1m50GT-F7lWddNog"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">175000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Narr_kHn4YGdxOk-YiuPp-oFVrA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">41793412</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Narr_BrpUi2jxA0iArJpjpm8FBQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1576854</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_4Ia6xUfMb0GT_ljYaThksg_31_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_6eh9UAmm4U-Kf9WpgBhtbA_32_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">699651000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_OMVeGttDQkqMyYEHyLb8TQ_32_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">4645000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_tVrmxxCBY02zdGuA5Jwf0w_33_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">194000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_X2-rsaXTU0SDzXu1UwGlxw_33_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">37000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_7mpg5HMSm0yUA86AAv9sDg_34_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-387391000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc__7NAlFCmF0Gafb4v7Mryyw_34_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-230403000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_r69cTKmwN0uqlXMAQ20h-A_35_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">312458000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_epMn9TrQa0Ow7q8OLE3rZw_35_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-225721000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_yErOtmaeC0ypVic-rvTkdA_36_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">369968000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_Fa2D4kZvZUaSOp3oIIchVQ_36_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">68180000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_0QCKQDQX3EuLzud_995owg_5_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_ry6Gpm9zC0KPeRlv_UZJSg_5_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_U9LihvG64EaQd9YXek6d2g_6_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_qwh-PKCiBUGmC3ig-YMI1Q_6_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">50000000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xmuQWu9BX0O2k_q1aI5KuQ"
      decimals="-3"
      id="Narr_Vttsx7pR2UiXHlayamjZsA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">3524000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_98SvbTRA50yOezeZ029LuQ"
      decimals="-3"
      id="Narr_QxwyD6JPA0W1ZV8h6DFnuQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">3041000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_6yzEtiGOP02ywnaWBuu_uQ_8_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">139139000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_61BoCZY5N0OWioLBFqmTbg_8_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">60033000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xmuQWu9BX0O2k_q1aI5KuQ"
      decimals="-3"
      id="Narr_qcEo5eHh2UCyU-6kC9kLxw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_98SvbTRA50yOezeZ029LuQ"
      decimals="-3"
      id="Narr_gZxHHmqUwEic0JH1a7ywqw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">8000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_5EOQMeRL2ku4iWHv0CptMQ_9_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">29749000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_EJCmd8DHSEO9wEc8TkF3kg_9_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">17114000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_6XcGeKtxwkiBLERz6xljwg_10_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">10000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc__fj_ZU4o5kyGBId5J1fIkA_11_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">168888000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_T98nKwKuokOnNinWtuDkEQ_11_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">87147000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_vz1jPy9avkOagrKZUiKnQQ_12_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-163888000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_PaqH6omOokGGf1VjX457cQ_12_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-37147000</us-gaap:OperatingIncomeLoss>
    <zbio:FairValueAdjustmentOfConvertibleNotes
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_iEUyQ7xnlEqHejoy610mFg_14_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">846000</zbio:FairValueAdjustmentOfConvertibleNotes>
    <zbio:FairValueAdjustmentOfConvertibleNotes
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_su_9mLFNxkaJBSADcaG6Jw_14_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">300000</zbio:FairValueAdjustmentOfConvertibleNotes>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_kpOOds1WSEaUskPA_g7Y2Q_15_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">8175000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_3rQZVD9YV0O-mOkTuuFiEA_15_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">624000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_-YSqJSuT8EGPt51CLMARgw_16_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">7329000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_YrG-icH3eEy9zS16I24eRg_16_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">324000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_MJEiC2RnuUO1kh_yM-gbyA_17_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-156559000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_nEy2HRIa3UGYq0Xu63HtQA_17_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-36823000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_e-OzMBdxUUyIfpQwTvgFlw_18_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">429000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_voHfLh5xdEq3RKONuW2CAQ_18_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">301000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_JcEGg9hPv0yzbOVVSkIXBg_19_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-156988000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_Nl77dDvRrU2pqWrBZW46NA_19_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-37124000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="2"
      id="Tc_eG5afOEms0OWuYlduzt5OA_20_3"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">-11.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="2"
      id="Tc_eG5afOEms0OWuYlduzt5OA_20_3_2"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">-11.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="2"
      id="Tc_hdFu88UFwkCRS5IFRZuZzA_20_6"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">-24.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="2"
      id="Tc_hdFu88UFwkCRS5IFRZuZzA_20_6_2"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">-24.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="0"
      id="Tc_d74cRoLRDki55VoEbPBaqA_21_3"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">13198960</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="0"
      id="Tc_d74cRoLRDki55VoEbPBaqA_21_3_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">13198960</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="0"
      id="Tc_2CElUignekqeyqrBBLUcvA_21_6"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1531178</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="0"
      id="Tc_2CElUignekqeyqrBBLUcvA_21_6_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1531178</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_r_bdIv4VT0KtrbOBQqozsA_23_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-156988000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_VdeBvB3I5UCIukJiNaEigw_23_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-37124000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_E_oxkcQG9UChtdGnSTAxcg_25_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">31000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_BB9KvbNB0EC0MuHqxHR30Q_26_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">126000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_bgSx2G1a2Ui7ieWQ_1nOOg_26_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">78000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_RirwhnGXAkW34JRAZEryXw_27_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-156831000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_IEgYXQmSWEagMUDGXcGxug_27_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-37046000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWOR2Y6eb0qw6h_ECNiCyQ"
      decimals="INF"
      id="Tc_Qz_yjSvFZkWQCm4Ha3BwLA_5_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1785714</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWOR2Y6eb0qw6h_ECNiCyQ"
      decimals="-3"
      id="Tc_q1gUlxh1J0KeLgCOu8Werw_5_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">956000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-zW7TSnNlEOWNVAWJEAmqg"
      decimals="INF"
      id="Tc_2FbEEOo7_UmnEAHagwSEBg_5_7"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">17589380</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-zW7TSnNlEOWNVAWJEAmqg"
      decimals="-3"
      id="Tc_QMkOqJ_-tk2SLh68q9mL4g_5_10"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">55840000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zyuRWER_rEGXi84E3qArrg"
      decimals="INF"
      id="Tc_aWibbqrx9kaZmHGsgg-q8g_5_12"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">77052632</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zyuRWER_rEGXi84E3qArrg"
      decimals="-3"
      id="Tc_HrsXXQeOM0aDKQt57JJqGw_5_15"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">183290000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MtK5qqSc7EWFj3hxdd6E6w"
      decimals="INF"
      id="Tc_1W5GrBuPK0OuSeqYjJSl3g_5_21"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1549275</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Uz8_I3wLr0SnQHkp_bKCXQ"
      decimals="-3"
      id="Tc_1yQpduisOU2fo0jUtQj2lA_5_27"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1034000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_nl_IrRmKGUmQBClrdDVOTA"
      decimals="-3"
      id="Tc_zH-_cB1k3EuQhjks1wVYVw_5_30"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uUos0deBaEyEN6bFnRun4w"
      decimals="-3"
      id="Tc__MZ8eXjvEk6omNGlgMmnTA_5_33"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-193279000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_7aoYVm8LsEqvEfiPlkF4lw"
      decimals="-3"
      id="Tc__WAIGlWSbkyU7F8TzwYVXg_5_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-192286000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Gh9QtBp7z0aJp2U6HTSmvA"
      decimals="-3"
      id="Narr_0_fcEs6d-0a4bpLoKvJdOw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Gh9QtBp7z0aJp2U6HTSmvA"
      decimals="INF"
      id="Tc_UIokQpT1-EqecO6roJPd5Q_6_12"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">4189955</zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Gh9QtBp7z0aJp2U6HTSmvA"
      decimals="-3"
      id="Tc_0XKjwtp6PU-G6TZIsIKEYw_6_15"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">10000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mWc24hPae06GpXVuJlDs0Q"
      decimals="INF"
      id="Tc_Ie-85q3xIUiGCGHyTZb3Hw_7_21"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">27579</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QXQPHb61tUenoW1KiYC_bA"
      decimals="-3"
      id="Tc_7jLxxYIs4EK-l78q57dhMw_7_27"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">116000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_gkjSIYyiUUuDESwSqSdxzQ_7_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">116000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QXQPHb61tUenoW1KiYC_bA"
      decimals="-3"
      id="Tc_BkqUE8EPvkCm8XiJRI98cA_8_27"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">3495000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc__DrflBBFs0OpERRIZW9pHQ_8_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">3495000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_03uBPrMelEOQgnXfrO0Rdg"
      decimals="-3"
      id="Tc_FfO0nsvm2ka8ntNB6lp5ew_9_30"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">78000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_SY16GtSHvU-oOywGQP5YNQ_9_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">78000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I3LY6QQrkkmN4CYZS5IM0g"
      decimals="-3"
      id="Tc_z_FdZp5GqEaY4noZT0ZcXA_10_33"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-37124000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_nMZRwq4Cmk2Fz4lhFwIhew_10_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-37124000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ocu-YDmfGkytPLv371WO_A"
      decimals="INF"
      id="Tc__8EYxVshBUySAXqSmb_-iA_11_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1785714</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ocu-YDmfGkytPLv371WO_A"
      decimals="-3"
      id="Tc_-s6v26if0U-0Yki3EoR9NA_11_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">956000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xCsVy9CxU-Q-Ca38CHdgg"
      decimals="INF"
      id="Tc_nRr18LihSEWNBUgySrYEVg_11_7"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">17589380</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xCsVy9CxU-Q-Ca38CHdgg"
      decimals="-3"
      id="Tc_H7LohFDz5E-EUyk5wB0Eow_11_10"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">55840000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mIxda3QBT0eGgkr2-TLdAg"
      decimals="INF"
      id="Tc_NUuSiF1fz0C7XmRx1dZy2w_11_12"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">81242587</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mIxda3QBT0eGgkr2-TLdAg"
      decimals="-3"
      id="Tc_RHc0cwDHc0ekKy_yv-NM7A_11_15"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">193290000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0joMr_rkEkm7x1ZuVCT9ug"
      decimals="INF"
      id="Tc_bEfcX_YgEE2KzJPr4Scoiw_11_21"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1576854</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tGb0cUxC9kK9Z8w9yezpew"
      decimals="-3"
      id="Tc_OFEldAWgHkm9hsKIPN908g_11_27"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">4645000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PBJ1X1nFxEWp13l1OkKMvw"
      decimals="-3"
      id="Tc_w3EehagmtUqoAW8Rx8UT7w_11_30"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vq8gJuFgxUeW6Sum5gLP_A"
      decimals="-3"
      id="Tc_rIvzxoZ2kkSCrmxDGfJ-xg_11_33"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-230403000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_LCoRFQIcq0S31RZp2hLRxw_11_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-225721000</us-gaap:StockholdersEquity>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q"
      decimals="INF"
      id="Tc_joLmWxI6BEKZ3gkHt9IE6w_12_21"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">21172</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-I220YjrTES2zT0dh6nXJQ"
      decimals="-3"
      id="Narr_caA1lAxck0uardGssjA68w"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">619000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-I220YjrTES2zT0dh6nXJQ"
      decimals="INF"
      id="Tc_jn4vMLAackK1UPdxXJrZvQ_13_17"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">116275239</zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-I220YjrTES2zT0dh6nXJQ"
      decimals="-3"
      id="Tc_yc87UVIBu02gSH-cEFT0Ww_13_19"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">199526000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversion
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2PJ0fHjSGkqSUHx6Zr4K0g"
      decimals="INF"
      id="Tc_dROJHeVcpkaTStgTCl9r2w_14_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1785714</zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversion>
    <zbio:TemporaryEquityStockIssuedDuringPeriodValueConversion
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2PJ0fHjSGkqSUHx6Zr4K0g"
      decimals="-3"
      id="Tc_n1nWr6vWZkWrgWjGTrH1uQ_14_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">956000</zbio:TemporaryEquityStockIssuedDuringPeriodValueConversion>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversion
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_t-hVZE_DQ0aHW393n9Fzew"
      decimals="INF"
      id="Tc_2gA4JGjbe02F4NcpQQqG_A_14_7"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">17589380</zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversion>
    <zbio:TemporaryEquityStockIssuedDuringPeriodValueConversion
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_t-hVZE_DQ0aHW393n9Fzew"
      decimals="-3"
      id="Tc_H3FTPcpKZEmTVrhsOJs5QQ_14_10"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">55840000</zbio:TemporaryEquityStockIssuedDuringPeriodValueConversion>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversion
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gw2rhLbrokS2ngyRmmip4Q"
      decimals="INF"
      id="Tc_hJlgcfcQc0G8FPryznLABA_14_12"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">81242587</zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversion>
    <zbio:TemporaryEquityStockIssuedDuringPeriodValueConversion
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gw2rhLbrokS2ngyRmmip4Q"
      decimals="-3"
      id="Tc_xPpsI3kXHU26l_AC6UjH7g_14_15"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">193290000</zbio:TemporaryEquityStockIssuedDuringPeriodValueConversion>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversion
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-I220YjrTES2zT0dh6nXJQ"
      decimals="INF"
      id="Tc_iq-YuSVGlEem3paDfc6rBA_14_17"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">116275239</zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversion>
    <zbio:TemporaryEquityStockIssuedDuringPeriodValueConversion
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-I220YjrTES2zT0dh6nXJQ"
      decimals="-3"
      id="Tc_3ZYxrhJwnEG3Ils-M1wvbg_14_19"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">199526000</zbio:TemporaryEquityStockIssuedDuringPeriodValueConversion>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q"
      decimals="INF"
      id="Tc_aJltESk7Gk6XbPGb83bLdA_14_21"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">24978715</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q"
      decimals="-3"
      id="Tc_t1qZaOq1DEW1L-vyT2N4Hg_14_24"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jWL8Je-UBU2gqCEY8KUEpg"
      decimals="-3"
      id="Tc_qmn0nHs8TUuXOHDp9bmv9Q_14_27"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">449610000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_0LUlEb1pK0CENfmauKO6Pg_14_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">449612000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q"
      decimals="INF"
      id="Tc_NP2KrsPWx02XyTq6r379kQ_15_21"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">15220588</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q"
      decimals="-3"
      id="Tc_u-9qiB_eXEGeb1XsR52_Lg_15_24"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jWL8Je-UBU2gqCEY8KUEpg"
      decimals="-3"
      id="Tc_shvNzepcVE6wuhGF4yGCXA_15_27"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">234300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_F4K8W5oI7Eqn9yB9TnA16Q_15_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">234302000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lnVt86olAE-9ByIgQXvN3Q"
      decimals="INF"
      id="Tc_Hp6HoDf_cEiyN4LnR24Rkw_16_21"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">38427</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jWL8Je-UBU2gqCEY8KUEpg"
      decimals="-3"
      id="Tc_4nZUl7fkwUGvgY3zieXjZA_16_27"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">275000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_CDEyVYPcAEibVACitQL75w_16_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">275000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jWL8Je-UBU2gqCEY8KUEpg"
      decimals="-3"
      id="Tc_nkb1J1ALlkWbnah-iSZaag_17_27"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">10821000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_iyhfa3OqD0W5t3He2fetMQ_17_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">10821000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Tjq4ptXuakWz2N7XO70BFQ"
      decimals="-3"
      id="Tc_c9yI1IUFMk-8fzxCuHcFpg_18_30"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">31000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_jTG2ITyKh0yhZZEkD045vQ_18_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">31000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Tjq4ptXuakWz2N7XO70BFQ"
      decimals="-3"
      id="Tc_RPaWmk-qVU6CyOBzFG4DSw_19_30"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">126000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_HQXn4z6Pf0iW953fO_P92g_19_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">126000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_LJ7TMbhoFUe0nr0lDe3Lmw"
      decimals="-3"
      id="Tc_1WmqBMY7eka2Zkh9CQKEhg_20_33"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-156988000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_s9CGpBM77Uai3P7kTXQglg_20_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-156988000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wA5OCDooWEKaI_O_5zlfDg"
      decimals="INF"
      id="Tc_xfFrTJHSGUCZZgI2edOk9w_21_21"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">41793412</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wA5OCDooWEKaI_O_5zlfDg"
      decimals="-3"
      id="Tc_Q6qZjzLd_0m_-4jCv_C9JQ_21_24"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3nxvET59Gki8LFIKljY7FQ"
      decimals="-3"
      id="Tc_8Sl4MvSWtka3hO1OgFOOqw_21_27"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">699651000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_o_4zbocCK0S4kVmIQxpThw"
      decimals="-3"
      id="Tc_W-sfu-_jokS2in9tlcvA9g_21_30"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">194000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_l5vJE3DbIEKeKPth4gy8Kg"
      decimals="-3"
      id="Tc_BlB21U5Piken9qWJY0G9Vw_21_33"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-387391000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_-Vfc9IPXJ0uouH7W-EwqOQ_21_36"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">312458000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_QTRNc8ATP0mwEZ8Tb5ruNA_5_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-156988000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_ICwfKdlfTk6RyXA23wCZ1w_5_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-37124000</us-gaap:NetIncomeLoss>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_sVFIxWEGrUORsARErBAe2g_7_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">10000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_j-9BP9_nw0GIIyeLtlxTBA_8_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">137000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_55iKKJpSHE6XIuLet3tihw_8_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">113000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_K1l7oBkwkkqb1HvtX3jvUA_9_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-602000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_1f7PAyL40E-8MoyXnVzr5w_10_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">10821000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_3v9zvKRNvEavtkIqlLkp4g_10_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">3495000</us-gaap:ShareBasedCompensation>
    <zbio:FairValueAdjustmentOfConvertibleNotes
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_uHQfaawNCUGhtcvtz6S_xA_11_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">846000</zbio:FairValueAdjustmentOfConvertibleNotes>
    <zbio:FairValueAdjustmentOfConvertibleNotes
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_L8oJa6QKtUSIKY-36PvUrA_11_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">300000</zbio:FairValueAdjustmentOfConvertibleNotes>
    <zbio:NonCashLeaseExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_KkgomwI5z06eejl56EZbCQ_12_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">681000</zbio:NonCashLeaseExpense>
    <zbio:NonCashLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_9kGIUfEtR0Wt5Q6scsG_NA_12_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">726000</zbio:NonCashLeaseExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_tO2pi65p2kyDcsOS3Ks43Q_14_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">7701000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_v6WYCHJlYkSVx09kC2scqA_14_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">3349000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_bYZ4reyzk0OLYZ9QK-ZqXA_15_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">11740000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_osuO97Rv70OJcXJGblLzgA_15_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-418000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_NpEuiiCHEEOKOPd6vqdo1g_16_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">22065000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_IjsVcjG_pU-ZKlbegogPMw_16_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-3558000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_E_uN03Z1hUas5m6SzCTomQ_17_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-673000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_SVhx5m7FhUyVA5tbEwPWxw_17_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-714000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_Mh3eU6zy9kSin8gmGOUg9A_18_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-119674000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc__i2xsz2iNkiONDmePqF7Mg_18_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-30529000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_FCioojsVoEmk3RhYkgWWQA_20_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">131000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_ylfzVllWNEyNLnRHGzwtNA_20_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">17000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_NJnBKiT7o0WiJTVDIDrurw_21_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">36421000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_CRKMJf_M8EGcHvC5ufjAbg_22_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">6000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_-63Kp00kvkGiJOs8_s2udw_23_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-30552000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_qYm6x-JCekiXI28xXY4LKg_23_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-17000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_6a3ODqmoSEKAetpCYRLALg_25_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">178381000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_R82itdqvokOI5Ec4uqLOAA_26_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">240636000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_rgGSPjjSYEe7F_t6Hh6FSQ_27_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">6334000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_oHpnUh275EGHYEOzlBdEHA_28_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">20000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_O2Rh2YU9x0KSp4kMH0tMHg_29_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">275000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_CdfZ3QgdnECyNRUlkVf44w_29_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">116000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc__tvfr-JpTkiMfbajZ5LMYQ_30_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">412958000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_7TWhIMz0IUeh6QT04vYmxw_30_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">20116000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_RRjGLRnCyUe9JrrBbLTPkg_31_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">157000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_Ahw2yWIyQ0CfB8Oh28mpnQ_31_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">78000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_RUfTiuZLJkGEsLhKLR3Nhw_32_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">262889000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_PRrUA5m82keGokO2YhrxXA_32_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-10352000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_sgFwGmYFEkCPwshKzyGceQ_33_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">56943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_7aoYVm8LsEqvEfiPlkF4lw"
      decimals="-3"
      id="Tc_Ew_Jt5ASoUCwrKQDonwVZQ_33_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">67295000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_I5ACHhXmzkqqghfCf9cXhA_34_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">319832000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_MchD6-fdQ06zjh6tff3UNw_34_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">56943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NotesAssumed1
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_ttMhd34TtkCMq3QbAcp1Uw_37_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">21146000</us-gaap:NotesAssumed1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_6BGCLJ1vy0W2YJm4pq79bA_38_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">449612000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_ZcCrCC-wK0K7DzZihlP6lw_39_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <zbio:DeferredOfferingCostsIncludedInAccruedExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_Hu8Kx8i87021BsAaTtUzRg_40_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1388000</zbio:DeferredOfferingCostsIncludedInAccruedExpenses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_8bzYxfeNBkWKbTmGP2fCfQ_43_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">319742000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_1z1v5jbEc0mO0_CzjQAXMQ_43_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">56857000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_LXq3MZsbFkuWlMbC0T4WKA_44_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">90000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_jJfoU4aU20GTRVVSirItYg_44_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">86000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_0FwKNTSdVkeIqFi5TIdSCQ_45_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">319832000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_tTbXpN84ekaRxG89vzSY9Q_45_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">56943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_ZCJlJyQ7nUaUCNrflb0ejw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;1.&lt;/b&gt;&lt;/span&gt;Nature of Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Zenas BioPharma,&#160;Inc. (&#x201c;Zenas&#x201d; or the &#x201c;Company&#x201d;) was incorporated in November&#160;2019 as Zenas BioPharma (Cayman) Limited, an exempted company incorporated in the Cayman Islands with limited liability, and commenced operations in 2020. On August&#160;2, 2023, the Company (then known as Zenas BioPharma (Cayman) Limited (&#x201c;Zenas Cayman&#x201d;)) de-registered from the Cayman Islands and registered by way of continuation in the State of Delaware (the &#x201c;Redomicile&#x201d;). Zenas is a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. The Company&#x2019;s goal is to build an immunology and inflammation (&#x201c;I&amp;amp;I&#x201d;) focused biopharmaceutical company. The Company has in-licensed and is developing several product candidates for the treatment of various auto-immune and rare diseases. The Company is headquartered in Waltham, Massachusetts and operates in one segment, which is the business of acquiring and developing immune-based therapies for potential commercialization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s consolidated financial statements include the accounts of its wholly owned subsidiaries which include Zenas BioPharma (HK) Limited (&#x201c;Zenas HK&#x201d;), Zenas BioPharma (USA) LLC (&#x201c;Zenas US&#x201d;), Shanghai Zenas Biotechnology Co. Limited (&#x201c;Zenas China&#x201d;), Zenas BioPharma Securities Corp., and Zenas BioPharma GmbH. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to clinical stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical studies and clinical trials, obtaining regulatory approval for product candidates, market acceptance of products, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary technology, compliance with government regulations, and the ability to raise additional capital to fund operations. The Company&#x2019;s revenues to date have been generated from payments received under the Company&#x2019;s license and collaboration agreement with Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;) and novation agreement with Tenacia Biotechnology (&#x201c;Tenacia&#x201d;) (see &lt;i style="font-style:italic;"&gt;Note&#160;7, License and Collaboration Revenue&lt;/i&gt;). The Company has not generated any revenue from product sales since inception, and its product candidates currently under development will require significant additional research and development efforts, including extensive clinical testing and regulatory approval prior to commercialization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;16, 2024, the Company completed its initial public offering (&#x201c;IPO&#x201d;), in which the Company issued and sold 15,220,588 shares of its common stock, including 1,985,294 shares pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $17.00 per share, for aggregate gross proceeds of $258.7 million. The Company received $234.3 million in net proceeds after deducting underwriting discounts, commissions and other offering expenses. In connection with the IPO, all outstanding shares of convertible preferred stock converted into 24,978,715 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In connection with, and prior to, the Company&#x2019;s IPO, the Company effected a 1-for-8.6831 reverse stock split of the Company&#x2019;s issued and outstanding common stock and adjusted the conversion ratio of all the Company&#x2019;s outstanding convertible preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split and the adjustment of the preferred stock conversion ratios.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred operating losses and negative cash flows since its inception, including net losses of $157.0 million and $37.1 million in the years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024 and 2023, the Company had an accumulated deficit of $387.4 million and $230.4 million, respectively. Management expects operating losses and negative operating cash flows to continue for the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company expects that its existing cash, cash equivalents and short-term investments of $350.8 million as of December&#160;31, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve&#160;months from the date this Form 10-K is filed. The Company will need additional financing to support its continuing operations and to pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of private or public equity financings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions and licensing agreements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company&#x2019;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="INF"
      id="Narr_aehepwRTS0Ctf2DAsMoOGw"
      unitRef="Unit_Standard_segment_S86Rw8jTyUm70oUkTaBnEw">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rPANXOD_Fku39IGeijPdfw"
      decimals="INF"
      id="Narr_9k07kUcMj0GIo90w1fi4JA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">15220588</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Zu6GA717E0C8cJ-Hhbeflg"
      decimals="INF"
      id="Narr_ACUtTMupE0Gm8fpYR641vg"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1985294</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_jvKsbpTO10eG_t6mtZmxgA"
      decimals="2"
      id="Narr_P_Kwc_ouXUGwhihizDb5JA"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">17</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rPANXOD_Fku39IGeijPdfw"
      decimals="-5"
      id="Narr_qei4da0Ua0mNLN-YjA9GPw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">258700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rPANXOD_Fku39IGeijPdfw"
      decimals="-5"
      id="Narr_qvkdeZHQTkyPtoQ-BEjOLQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">234300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_jvKsbpTO10eG_t6mtZmxgA"
      decimals="INF"
      id="Narr_UzG-nlI7U0KG7DUMgmOipg"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">24978715</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_9_16_2024_To_9_16_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rPANXOD_Fku39IGeijPdfw"
      decimals="4"
      id="Narr_yxBRp7BFmU-iCcqSs3IEoQ"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">8.6831</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-5"
      id="Narr_rPjw9xWwQU2V8xYi10LRtw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-157000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-5"
      id="Narr_1NU2UlVe_kmvsksZvP8WDg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-37100000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-5"
      id="Narr_FsQWBzNgbk-vi2FPb9qW6Q"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-387400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-5"
      id="Narr_aQb6OT79nUKPMkpRNHp3_Q"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-230400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-5"
      id="Narr_n6rGkuwc906KSSh5KtKpzg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">350800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_2AowBK1XbU2nEygTq_RBDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;2.&lt;/b&gt;&lt;/span&gt;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation and Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements include the operations of the Company and its wholly-owned subsidiaries. All intercompany accounts, transactions, and balances have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been or omitted pursuant to such rules&#160;and regulations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosures. The Company bases its estimates on historical experience, known trends and other market- specific factors or other relevant factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis using such factors and adjusts those estimates and assumptions as facts and circumstances dictate. Actual results may differ from those estimates or assumptions. Significant estimates in these consolidated financial statements include estimates made in connection with accrued research and development expenses, stock-based compensation and pre-initial public offering (&#x201c;IPO&#x201d;) valuations of common stock, and convertible debt.&lt;/span&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash, Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with original or remaining maturity from the date of purchase of three&#160;months or less to be cash equivalents. Cash equivalents may include money market funds, corporate debt securities, U.S government agency notes and overnight deposits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-Term Investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies all investments with a remaining maturity when purchased of greater than three months as &#x201c;available-for-sale&#x201d;. Available-for-sale securities with a remaining maturity of greater than one year are classified as non-current assets. Available-for-sale securities are carried at fair value based upon market prices at period end, with the unrealized gains and losses included in accumulated other comprehensive loss as a component of stockholders&#x2019; equity (deficit) until realized. The amortized cost of investments in this category is adjusted for amortization of premiums and accretions of discounts over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense). The Company reviews its portfolio of investments, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss. If the decline in fair value is due to credit-related factors, a loss is recognized in other income (expense).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Cash &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash consists of cash held as collateral for a letter of credit the Company issued as a security deposit for its lease of office space in Waltham, MA, which terminated in January 2025. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as other non-current assets until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders&#x2019; equity (deficit) as a reduction of additional paid-in-capital generated as a result of the offering. If the Company terminates its plan for an equity financing, any costs deferred will be expensed immediately. Upon closing the IPO in September 2024, the related deferred offering costs were recorded against the IPO proceeds. No deferred offering costs were recorded as of December 31, 2024. As of December 31, 2023, the Company had $1.4 million in deferred offering costs which were included in other assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one reportable segment focused on the research and development of precision immunology-based therapies. The Company&#x2019;s chief operating decision-maker (the &#x201c;CODM&#x201d;), its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of making operating decisions, assessing financial performance, and allocating resources. As of December 31, 2024 and 2023, the Company&#x2019;s long-lived assets held outside of the U.S. were immaterial. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For additional information on our segment reporting, see &lt;i style="font-style:italic;"&gt;Note 17, Segment Information&lt;/i&gt; to these consolidated financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and short-term investments. The Company attempts to minimize the risks related to cash, cash equivalents and short- investments by investing in a broad range of financial instruments, as defined by the Company&#x2019;s investment policy. The Company has established guidelines related to the quality of the institutions, financial instruments and allowable investments. The Company minimizes credit risk by choosing only highly rated financial institutions as counterparties. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Significant Suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs, including preclinical and clinical studies and testing. In particular, the Company relies on a single manufacturer and expects to continue to rely on a single or small number of manufacturers to supply it with its requirements for the drug product related to these programs. These programs could be adversely affected by a significant interruption in the supply of drug substance and drug product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Translation of Foreign Currency &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign subsidiaries into U.S. dollars are excluded from our determination of net loss and are recorded in accumulated other comprehensive income (loss), as a separate component of equity. For foreign subsidiaries where the functional currency of assets and liabilities differs from their local currency, non-monetary assets and liabilities are translated at the rate of the exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other (income) expense, net in our consolidated statements of income. Realized and unrealized foreign currency transaction losses were $0.2 million and $0.1 million for each of the&#160;years ended December&#160;31, 2024 and 2023, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value Measurements &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 0pt 20pt;"&gt;Level&#160;1&#x2014;&lt;span style="font-style:normal;"&gt; Quoted market prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 0pt 20pt;"&gt;Level&#160;2&#x2014;&lt;span style="font-style:normal;"&gt; Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 12pt 20.15pt;"&gt;Level&#160;3&#x2014;&lt;span style="font-style:normal;"&gt; Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level&#160;3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The majority of our financial assets have been classified as Level 1. Our financial assets (which typically include cash equivalents and marketable equity securities) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market- based approaches and observable market inputs to determine value. These observation market inputs included reportable tables, benchmark yields, broker quotes, bids, offers, current spot rates and other industry and economic events. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amount of the assets to their undiscounted expected future cash flows. If this comparison indicates there is an impairment, the amount of the impairment is calculated as the difference between the carrying value and fair value. To date, no such impairments have been recognized. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Property and equipment are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (&lt;span style="-sec-ix-hidden:Hidden_b_kdHKCFF0avLUjrQ41Fwg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to seven years). Assets under capital leases are amortized over the shorter of their useful &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;lives or lease terms using the straight-line method. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;License and Collaboration Revenue &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company enters into license and collaboration arrangements with third parties, under which the Company licenses or may license rights to certain of the Company&#x2019;s product candidates and may perform research and development services in connection with such arrangements. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, clinical, regulatory and commercial sales milestone payments, and royalties on net sales of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;At contract inception, the Company analyzes its collaboration and license arrangements to assess whether such arrangements are within the scope of ASC Topic 808,&#160;&lt;/span&gt;&lt;i style="font-style:italic;letter-spacing:0.2pt;"&gt;Collaborative Arrangements&lt;/i&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;(&#x201c;ASC 808&#x201d;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple&#160;units of account, the Company first determines which&#160;units of the collaboration are deemed to be within the scope of ASC 808 and which&#160;units of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of ASC Topic 606,&#160;&lt;/span&gt;&lt;i style="font-style:italic;letter-spacing:0.2pt;"&gt;Revenue from Contracts with Customers&lt;/i&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;(&#x201c;ASC&#160;606&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC 808: (i)&#160;the parties to the contract must actively participate in the joint operating activity and (ii)&#160;the joint operating activity must expose the parties to the possibility of significant risks and rewards, based on whether or not the activity is successful. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. Payments received from or made to a partner that are the result of a collaborative relationship with a partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction or increase to research and development expense, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;For the&#160;units of account within the scope of ASC 606, to determine the appropriate amount of revenue to be recognized for the arrangements, the Company performs the following five steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The promised goods or services in the Company&#x2019;s arrangements typically consist of a license to the Company&#x2019;s intellectual property and research and development services. The Company provides options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Due to the uncertainty of research and development and regulatory based milestones that are not within the control of the Company, payment becomes probable upon achievement. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and collaboration revenue in the period of adjustment. Any amounts due to the Company but not received as of period-end will be recorded to other current assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#x2019;s collaboration arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs including a reasonable margin. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Expenses &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Research and development costs include (i)&#160;employee-related expenses, including salaries, benefits, and stock-based compensation expense; (ii)&#160;external research and development expenses incurred under arrangements with third parties, such as CRO agreements and consultants; (iii)&#160;costs associated with preclinical activities and (iv)&#160;lab supplies, lab expenses and an allocation of rent, depreciation, and infrastructure. Costs incurred in connection with research and development activities are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data, such as patient enrollment or clinical site activations, provided by the Company&#x2019;s clinical sites and vendors. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable. The Company monitors each of these factors and adjusts estimates accordingly. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Asset Acquisitions and Acquired In-Process Research and Development Expense &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company accounts for acquisitions of assets or a group of assets that do not meet the definition of a business as asset acquisitions based on the cost to acquire the asset or group of assets, which include certain transaction costs. In an asset acquisition, the cost to acquire is allocated to the identifiable assets acquired and liabilities assumed based on their relative fair values as of the acquisition date. No goodwill is recorded in an asset acquisition. Assets that are &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as in process research and development (&#x201c;IPR&amp;amp;D&#x201d;). Acquired IPR&amp;amp;D that has no alternative future use as of the acquisition date is recognized as acquired IPR&amp;amp;D expense as of the acquisition date. The Company will recognize additional acquired IPR&amp;amp;D expenses in the future if and when the Company becomes obligated to make contingent milestone payments under the terms of the agreements by which it acquired the IPR&amp;amp;D assets. The Company classifies payments made for the acquisition of IPR&amp;amp;D assets, whether capitalized or expensed, as investing activities on its statement of cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Contingent consideration in the form of milestone payments related to IPR&amp;amp;D with no alternative future use are charged to expense when the related milestone is achieved and becomes payable. For the year ended December&#160;31, 2024, the Company did not recognize any acquired IPR&amp;amp;D expense. For the year ended December 31, 2023, the Company recognized &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$10.0&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million of IPR&amp;amp;D expense, in connection with the consideration due under the 2021 Xencor Agreement. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For additional information on our asset acquisitions and acquired in-process research and development, please see &lt;i style="font-style:italic;"&gt;Note 8, License and Option Agreements,&lt;/i&gt; to these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss consists of net loss and other comprehensive loss. During the years ended December 31, 2024 and 2023, the Company&#x2019;s only element of other comprehensive loss was foreign currency translation adjustments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of use lease assets (&#x201c;ROU assets&#x201d;), current portion of lease obligations and long-term lease obligations on the Company&#x2019;s consolidated balance sheet. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#x2019;s consolidated balance sheet. Lease assets are tested for impairment in the same manner as&lt;/span&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense, while expense for financing leases is recognized as depreciation expense (classified as an operating expense) and interest expense (classified as a non-operating expense) using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheet for leases with an original term of twelve months or less. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recognized based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. Certain adjustments to the ROU asset may be required for items such as incentives received from the lessor. The interest rate implicit in lease contracts is typically not readily determinable. Therefore, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasures the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company generally accounts for non-lease components together with lease components. The Company expenses variable payments included in a lease arrangement as such expenses are incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For additional information on our leases, please see &lt;i style="font-style:italic;"&gt;Note 6, Leases&lt;/i&gt;, to these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes in accordance with ASC Topic 740, &lt;i style="font-style:italic;"&gt;Accounting for Income Taxes&lt;/i&gt;, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a &#x201c;more likely than not&#x201d; threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are no unrecognized tax benefits included in the Company&#x2019;s consolidated balance sheets as of December 31, 2024 and 2023. The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties related to uncertain tax positions in its consolidated statements of operations and comprehensive loss since inception.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company grants stock-based awards to employees, non-employee consultants and members of its board of directors (the &#x201c;Board&#x201d;). Stock-based compensation is recognized as expense for each stock-based award based on its estimated fair value on the date of grant. The Company&#x2019;s share-based payments include stock options and grants of restricted common stock. The value of the award is recognized as expense on a straight-line basis over the requisite service period, and expense is adjusted for pre-vesting forfeitures in the period in which the forfeitures occur. Stock-based compensation expense is classified in the accompanying consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipients service payments are classified.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company estimates the fair value of each restricted stock award (&#x201c;RSA&#x2019;s&#x201d;) at its grant date based on the estimated fair value of the Company&#x2019;s common stock on that date as determined by the Board. The Company estimates the fair value of stock option awards on the grant date using a Black-Scholes option pricing model. The Company estimates the expected option lives using the simplified method, volatility using historical stock prices of peer companies, the risk-free rates using the U.S Treasury yield curve in effect with a remaining term equal to the expected term and dividend yield based on the Company&#x2019;s history of paying no dividends and the expectations of paying no cash dividends in the foreseeable future. Prior to the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock on the date of grant was determined by the Board, taking into consideration its most recently available third-party valuations of common stock as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the grant date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;"&gt;For additional information on our share-based compensation, please see &lt;i style="font-style:italic;"&gt;Note 11, Stock-Based Compensation&lt;/i&gt;, to these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Convertible Preferred Stock &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company classified its convertible preferred stock as temporary equity (between liabilities and stockholders&#x2019; equity (deficit)) in the accompanying consolidated balance sheet because it could have become redeemable due to certain change in control clauses that were outside of the Company&#x2019;s control. The convertible preferred stock was not redeemable, except in the event of a deemed liquidation event. As the occurrence of a deemed liquidation event was not currently probable at December 31, 2023, the carrying values of the convertible preferred stock were not being accreted to their redemption values. Upon the completion of the Company&#x2019;s IPO on September 16, 2024, all outstanding shares of the Company&#x2019;s convertible preferred stock converted into shares of the Company&#x2019;s common stock. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For additional information on our convertible preferred stock, please see &lt;i style="font-style:italic;"&gt;Note 9, Convertible Preferred Stock&lt;/i&gt;, to these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two- class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#x2019;s common shares and participating securities. The Company&#x2019;s convertible preferred stock contained participation rights in any dividend paid by the Company and is deemed to be a participating security. Net loss attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Diluted net loss per share is computed using the more dilutive of (a)&#160;the two-class method or (b)&#160;the if- converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss per share gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders for the&#160;years ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (&#x201c;FASB&#x201d;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated statements or disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"&gt;In November&#160;2023, the FASB issued ASU 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280)&#x2014;Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;)&lt;/i&gt;, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses on an interim and annual basis. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. This standard became effective for the Company for the annual reporting period ended December 31, 2024, using the retrospective method. The adoption of this standard resulted in additional disclosure of the significant expenses reviewed by the Company&#x2019;s CODM. The adoption did not have a material impact on the consolidated financial position or results of operations. See &lt;i style="font-style:italic;"&gt;Note 17, Segment Information&lt;/i&gt;, for our updated segment presentation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740)&#x2014;Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;)&lt;/i&gt;, which requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company beginning in fiscal year 2025, with early adoption permitted. ASU 2023-09 may be applied retrospectively or prospectively to the financial statements. The Company is currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In November&#160;2024, the FASB issued 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;)&lt;/i&gt;, which requires entities to disclose additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective annual periods beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;prospectively to the financial statements. The Company is currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <zbio:BasisOfPresentationAndConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_EgoC-Y2Q_EGQTL1hi0r3Bw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation and Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements include the operations of the Company and its wholly-owned subsidiaries. All intercompany accounts, transactions, and balances have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been or omitted pursuant to such rules&#160;and regulations. &lt;/p&gt;</zbio:BasisOfPresentationAndConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_OHkvkMeI_kmtMwjPg5x11Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosures. The Company bases its estimates on historical experience, known trends and other market- specific factors or other relevant factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis using such factors and adjusts those estimates and assumptions as facts and circumstances dictate. Actual results may differ from those estimates or assumptions. Significant estimates in these consolidated financial statements include estimates made in connection with accrued research and development expenses, stock-based compensation and pre-initial public offering (&#x201c;IPO&#x201d;) valuations of common stock, and convertible debt.&lt;/span&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_btLOyBxJJkuTXAlIAF-oKg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash, Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with original or remaining maturity from the date of purchase of three&#160;months or less to be cash equivalents. Cash equivalents may include money market funds, corporate debt securities, U.S government agency notes and overnight deposits.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_O2jzmaKyNkqOVWDv6L5i7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-Term Investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies all investments with a remaining maturity when purchased of greater than three months as &#x201c;available-for-sale&#x201d;. Available-for-sale securities with a remaining maturity of greater than one year are classified as non-current assets. Available-for-sale securities are carried at fair value based upon market prices at period end, with the unrealized gains and losses included in accumulated other comprehensive loss as a component of stockholders&#x2019; equity (deficit) until realized. The amortized cost of investments in this category is adjusted for amortization of premiums and accretions of discounts over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense). The Company reviews its portfolio of investments, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss. If the decline in fair value is due to credit-related factors, a loss is recognized in other income (expense).&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_AxhqTPPDZUWqNHAowphNUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Cash &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash consists of cash held as collateral for a letter of credit the Company issued as a security deposit for its lease of office space in Waltham, MA, which terminated in January 2025. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_VDlwzN8iuUmYulbZzawUzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as other non-current assets until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders&#x2019; equity (deficit) as a reduction of additional paid-in-capital generated as a result of the offering. If the Company terminates its plan for an equity financing, any costs deferred will be expensed immediately. Upon closing the IPO in September 2024, the related deferred offering costs were recorded against the IPO proceeds. No deferred offering costs were recorded as of December 31, 2024. As of December 31, 2023, the Company had $1.4 million in deferred offering costs which were included in other assets.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredCosts
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-5"
      id="Narr_hPTw4Sbhj0OhBB_aU2MDyg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-5"
      id="Narr_yBWLsx_Bp0GO9yXDx3HKdg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1400000</us-gaap:DeferredCosts>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_c6Xo91C-P0-k3aVRft51fA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one reportable segment focused on the research and development of precision immunology-based therapies. The Company&#x2019;s chief operating decision-maker (the &#x201c;CODM&#x201d;), its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of making operating decisions, assessing financial performance, and allocating resources. As of December 31, 2024 and 2023, the Company&#x2019;s long-lived assets held outside of the U.S. were immaterial. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For additional information on our segment reporting, see &lt;i style="font-style:italic;"&gt;Note 17, Segment Information&lt;/i&gt; to these consolidated financial statements. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="INF"
      id="Narr_F_N2z5FiZUeUczhTlvokiw"
      unitRef="Unit_Standard_segment_S86Rw8jTyUm70oUkTaBnEw">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_vSedSpjdc0WpNjVbkIiUtQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and short-term investments. The Company attempts to minimize the risks related to cash, cash equivalents and short- investments by investing in a broad range of financial instruments, as defined by the Company&#x2019;s investment policy. The Company has established guidelines related to the quality of the institutions, financial instruments and allowable investments. The Company minimizes credit risk by choosing only highly rated financial institutions as counterparties. &#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <zbio:SignificantSuppliersPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_rx58LPn9SU2DR-D6_bKUaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Significant Suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs, including preclinical and clinical studies and testing. In particular, the Company relies on a single manufacturer and expects to continue to rely on a single or small number of manufacturers to supply it with its requirements for the drug product related to these programs. These programs could be adversely affected by a significant interruption in the supply of drug substance and drug product.&lt;/p&gt;</zbio:SignificantSuppliersPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_F5wa97tnmk6fzG8h2OcLOw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Translation of Foreign Currency &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign subsidiaries into U.S. dollars are excluded from our determination of net loss and are recorded in accumulated other comprehensive income (loss), as a separate component of equity. For foreign subsidiaries where the functional currency of assets and liabilities differs from their local currency, non-monetary assets and liabilities are translated at the rate of the exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other (income) expense, net in our consolidated statements of income. Realized and unrealized foreign currency transaction losses were $0.2 million and $0.1 million for each of the&#160;years ended December&#160;31, 2024 and 2023, respectively. &lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-5"
      id="Narr_EswHifWnVkScb1IwApNDUA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-200000</us-gaap:ForeignCurrencyTransactionGainLossAfterTax>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-5"
      id="Narr_XOr8nwjwPkyJlSYdJPpwYg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-100000</us-gaap:ForeignCurrencyTransactionGainLossAfterTax>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_MAUyQarI90iwRE_TFGyJtA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value Measurements &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 0pt 20pt;"&gt;Level&#160;1&#x2014;&lt;span style="font-style:normal;"&gt; Quoted market prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 0pt 20pt;"&gt;Level&#160;2&#x2014;&lt;span style="font-style:normal;"&gt; Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:11pt;text-align:justify;margin:8pt 0pt 12pt 20.15pt;"&gt;Level&#160;3&#x2014;&lt;span style="font-style:normal;"&gt; Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level&#160;3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The majority of our financial assets have been classified as Level 1. Our financial assets (which typically include cash equivalents and marketable equity securities) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market- based approaches and observable market inputs to determine value. These observation market inputs included reportable tables, benchmark yields, broker quotes, bids, offers, current spot rates and other industry and economic events. &lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_Ukn_Qij3YU6qKp8Au4aDCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amount of the assets to their undiscounted expected future cash flows. If this comparison indicates there is an impairment, the amount of the impairment is calculated as the difference between the carrying value and fair value. To date, no such impairments have been recognized. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_EooUtvYqK0qluvicTmF26Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Property and equipment are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (&lt;span style="-sec-ix-hidden:Hidden_b_kdHKCFF0avLUjrQ41Fwg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to seven years). Assets under capital leases are amortized over the shorter of their useful &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;lives or lease terms using the straight-line method. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_f7tghFWG2USaAbs-bXl6Jg"
      id="Narr_TqkIXAAPDkm7I27C676iUA">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <zbio:LicenseAndCollaborationRevenuePolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_GxS8WGy0k0aiOeipVDcGBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;License and Collaboration Revenue &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company enters into license and collaboration arrangements with third parties, under which the Company licenses or may license rights to certain of the Company&#x2019;s product candidates and may perform research and development services in connection with such arrangements. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, clinical, regulatory and commercial sales milestone payments, and royalties on net sales of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;At contract inception, the Company analyzes its collaboration and license arrangements to assess whether such arrangements are within the scope of ASC Topic 808,&#160;&lt;/span&gt;&lt;i style="font-style:italic;letter-spacing:0.2pt;"&gt;Collaborative Arrangements&lt;/i&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;(&#x201c;ASC 808&#x201d;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple&#160;units of account, the Company first determines which&#160;units of the collaboration are deemed to be within the scope of ASC 808 and which&#160;units of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of ASC Topic 606,&#160;&lt;/span&gt;&lt;i style="font-style:italic;letter-spacing:0.2pt;"&gt;Revenue from Contracts with Customers&lt;/i&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;(&#x201c;ASC&#160;606&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC 808: (i)&#160;the parties to the contract must actively participate in the joint operating activity and (ii)&#160;the joint operating activity must expose the parties to the possibility of significant risks and rewards, based on whether or not the activity is successful. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. Payments received from or made to a partner that are the result of a collaborative relationship with a partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction or increase to research and development expense, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;For the&#160;units of account within the scope of ASC 606, to determine the appropriate amount of revenue to be recognized for the arrangements, the Company performs the following five steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The promised goods or services in the Company&#x2019;s arrangements typically consist of a license to the Company&#x2019;s intellectual property and research and development services. The Company provides options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Due to the uncertainty of research and development and regulatory based milestones that are not within the control of the Company, payment becomes probable upon achievement. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and collaboration revenue in the period of adjustment. Any amounts due to the Company but not received as of period-end will be recorded to other current assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#x2019;s collaboration arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs including a reasonable margin. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services.&lt;/span&gt;&lt;/p&gt;</zbio:LicenseAndCollaborationRevenuePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_7TdVbv3X10Cm5upYXzsmhQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Expenses &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Research and development costs include (i)&#160;employee-related expenses, including salaries, benefits, and stock-based compensation expense; (ii)&#160;external research and development expenses incurred under arrangements with third parties, such as CRO agreements and consultants; (iii)&#160;costs associated with preclinical activities and (iv)&#160;lab supplies, lab expenses and an allocation of rent, depreciation, and infrastructure. Costs incurred in connection with research and development activities are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data, such as patient enrollment or clinical site activations, provided by the Company&#x2019;s clinical sites and vendors. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable. The Company monitors each of these factors and adjusts estimates accordingly. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <zbio:AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_WACfHDOmnU6s4p1mM3g2gw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Asset Acquisitions and Acquired In-Process Research and Development Expense &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company accounts for acquisitions of assets or a group of assets that do not meet the definition of a business as asset acquisitions based on the cost to acquire the asset or group of assets, which include certain transaction costs. In an asset acquisition, the cost to acquire is allocated to the identifiable assets acquired and liabilities assumed based on their relative fair values as of the acquisition date. No goodwill is recorded in an asset acquisition. Assets that are &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as in process research and development (&#x201c;IPR&amp;amp;D&#x201d;). Acquired IPR&amp;amp;D that has no alternative future use as of the acquisition date is recognized as acquired IPR&amp;amp;D expense as of the acquisition date. The Company will recognize additional acquired IPR&amp;amp;D expenses in the future if and when the Company becomes obligated to make contingent milestone payments under the terms of the agreements by which it acquired the IPR&amp;amp;D assets. The Company classifies payments made for the acquisition of IPR&amp;amp;D assets, whether capitalized or expensed, as investing activities on its statement of cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Contingent consideration in the form of milestone payments related to IPR&amp;amp;D with no alternative future use are charged to expense when the related milestone is achieved and becomes payable. For the year ended December&#160;31, 2024, the Company did not recognize any acquired IPR&amp;amp;D expense. For the year ended December 31, 2023, the Company recognized &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$10.0&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million of IPR&amp;amp;D expense, in connection with the consideration due under the 2021 Xencor Agreement. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For additional information on our asset acquisitions and acquired in-process research and development, please see &lt;i style="font-style:italic;"&gt;Note 8, License and Option Agreements,&lt;/i&gt; to these consolidated financial statements.&lt;/p&gt;</zbio:AssetAcquisitionsAndAcquiredInProcessResearchAndDevelopmentExpensePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_ZeD0YqL9rEiNGm87-Fn0jw"
      decimals="-5"
      id="Narr_NOl6uv2Pb0aElrkd8TmczQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">10000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_SYe1e2xBQUaQg9If6jM3Hg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss consists of net loss and other comprehensive loss. During the years ended December 31, 2024 and 2023, the Company&#x2019;s only element of other comprehensive loss was foreign currency translation adjustments.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_UBhHr_vRY0y3WNfV_EZZVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of use lease assets (&#x201c;ROU assets&#x201d;), current portion of lease obligations and long-term lease obligations on the Company&#x2019;s consolidated balance sheet. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#x2019;s consolidated balance sheet. Lease assets are tested for impairment in the same manner as&lt;/span&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense, while expense for financing leases is recognized as depreciation expense (classified as an operating expense) and interest expense (classified as a non-operating expense) using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheet for leases with an original term of twelve months or less. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recognized based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. Certain adjustments to the ROU asset may be required for items such as incentives received from the lessor. The interest rate implicit in lease contracts is typically not readily determinable. Therefore, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasures the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company generally accounts for non-lease components together with lease components. The Company expenses variable payments included in a lease arrangement as such expenses are incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For additional information on our leases, please see &lt;i style="font-style:italic;"&gt;Note 6, Leases&lt;/i&gt;, to these consolidated financial statements.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_so4f_LFWaEOyOlKxWdAv6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes in accordance with ASC Topic 740, &lt;i style="font-style:italic;"&gt;Accounting for Income Taxes&lt;/i&gt;, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a &#x201c;more likely than not&#x201d; threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are no unrecognized tax benefits included in the Company&#x2019;s consolidated balance sheets as of December 31, 2024 and 2023. The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties related to uncertain tax positions in its consolidated statements of operations and comprehensive loss since inception.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-5"
      id="Narr_wglAYqEBDkac6RM5sBLcBA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-5"
      id="Narr_3DmOugdSeEuqOKmlOOWrUw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_DARhzgwuyUeUONgF-0CCKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company grants stock-based awards to employees, non-employee consultants and members of its board of directors (the &#x201c;Board&#x201d;). Stock-based compensation is recognized as expense for each stock-based award based on its estimated fair value on the date of grant. The Company&#x2019;s share-based payments include stock options and grants of restricted common stock. The value of the award is recognized as expense on a straight-line basis over the requisite service period, and expense is adjusted for pre-vesting forfeitures in the period in which the forfeitures occur. Stock-based compensation expense is classified in the accompanying consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipients service payments are classified.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company estimates the fair value of each restricted stock award (&#x201c;RSA&#x2019;s&#x201d;) at its grant date based on the estimated fair value of the Company&#x2019;s common stock on that date as determined by the Board. The Company estimates the fair value of stock option awards on the grant date using a Black-Scholes option pricing model. The Company estimates the expected option lives using the simplified method, volatility using historical stock prices of peer companies, the risk-free rates using the U.S Treasury yield curve in effect with a remaining term equal to the expected term and dividend yield based on the Company&#x2019;s history of paying no dividends and the expectations of paying no cash dividends in the foreseeable future. Prior to the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock on the date of grant was determined by the Board, taking into consideration its most recently available third-party valuations of common stock as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the grant date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;"&gt;For additional information on our share-based compensation, please see &lt;i style="font-style:italic;"&gt;Note 11, Stock-Based Compensation&lt;/i&gt;, to these consolidated financial statements.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <zbio:TemporaryEquityPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_57Irw0Sc6EKxN-KFpZUwXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Convertible Preferred Stock &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company classified its convertible preferred stock as temporary equity (between liabilities and stockholders&#x2019; equity (deficit)) in the accompanying consolidated balance sheet because it could have become redeemable due to certain change in control clauses that were outside of the Company&#x2019;s control. The convertible preferred stock was not redeemable, except in the event of a deemed liquidation event. As the occurrence of a deemed liquidation event was not currently probable at December 31, 2023, the carrying values of the convertible preferred stock were not being accreted to their redemption values. Upon the completion of the Company&#x2019;s IPO on September 16, 2024, all outstanding shares of the Company&#x2019;s convertible preferred stock converted into shares of the Company&#x2019;s common stock. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For additional information on our convertible preferred stock, please see &lt;i style="font-style:italic;"&gt;Note 9, Convertible Preferred Stock&lt;/i&gt;, to these consolidated financial statements.&lt;/p&gt;</zbio:TemporaryEquityPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_WHg1lOivlEu9HTG2ruEFCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two- class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#x2019;s common shares and participating securities. The Company&#x2019;s convertible preferred stock contained participation rights in any dividend paid by the Company and is deemed to be a participating security. Net loss attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Diluted net loss per share is computed using the more dilutive of (a)&#160;the two-class method or (b)&#160;the if- converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss per share gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders for the&#160;years ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_pgqx-ABe70mcWg2fVdNI3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (&#x201c;FASB&#x201d;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated statements or disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"&gt;In November&#160;2023, the FASB issued ASU 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280)&#x2014;Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;)&lt;/i&gt;, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses on an interim and annual basis. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. This standard became effective for the Company for the annual reporting period ended December 31, 2024, using the retrospective method. The adoption of this standard resulted in additional disclosure of the significant expenses reviewed by the Company&#x2019;s CODM. The adoption did not have a material impact on the consolidated financial position or results of operations. See &lt;i style="font-style:italic;"&gt;Note 17, Segment Information&lt;/i&gt;, for our updated segment presentation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740)&#x2014;Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;)&lt;/i&gt;, which requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company beginning in fiscal year 2025, with early adoption permitted. ASU 2023-09 may be applied retrospectively or prospectively to the financial statements. The Company is currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In November&#160;2024, the FASB issued 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;)&lt;/i&gt;, which requires entities to disclose additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective annual periods beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;prospectively to the financial statements. The Company is currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_hOjRUWR00USUKCbpMzwvZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;3.&lt;/b&gt;&lt;/span&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following tables present information about the Company&#x2019;s assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:28.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted Prices in Active Market &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant Other Observable Inputs&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant Other Observable Inputs&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets: &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,070&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,070&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 350,766&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 338,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:30.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;width:66.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:30.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted Prices in Active Market &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant Other Observable Inputs&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant Other Observable Inputs&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  BMS note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;There have been no material impairments of our assets measured and carried at fair value during the year ended December 31, 2024. The fair value of Level 1 instruments classified as money market funds and government securities are valued using quoted market prices in active markets. The fair value of Level 2 instruments classified as short-term investments was determined using other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and fair value is determined using models or other valuation methodologies. There were no transfers between levels during the years ended December 31, 2024 and 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The short-term investments are classified as available-for-sales securities. As of December 31, 2024, the remaining contractual maturities of the available-for-sales securities were within one year, the balance in the Company&#x2019;s accumulated other comprehensive income was comprised solely of activity related to the Company&#x2019;s available-for-sale securities. There were no realized gains or losses recognized on the sale or maturity of available-for-sale securities during the year ended December 31, 2024. As a result, the Company did not reclassify any amounts out of accumulated other comprehensive income for the same period. The Company has a limited number of available-for-sale securities in insignificant loss &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;positions as of December 31, 2024, which the Company does not intend to sell and has concluded will not be required to sell before recovery of the amortized cost for the investment maturity. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the available-for-sale securities (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;width:56.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross Unrealized Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross Unrealized Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-term investments:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,315&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,589&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,093&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,108&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Certain short-term debt securities with original maturities of less than 90&#160;days are included in cash and cash equivalents on the consolidated balance sheets and are not included in the table above. The Company did not hold any investments as of December&#160;31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Convertible Notes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2023, the Company entered into a $20.0 million convertible promissory note agreement with BMS (the &#x201c;BMS Note&#x201d;) in connection with its strategic license and collaboration agreement with BMS (the &#x201c;BMS Agreement&#x201d;) (see &lt;i style="font-style:italic;"&gt;Note 7, License and Collaboration Revenue&lt;/i&gt;). In the event that the Company issued and sold its convertible preferred stock to accredited investors with total gross proceeds equal to at least $70.0 million (a &#x201c;BMS Qualified Financing&#x201d;), the outstanding principal and accrued interest of the BMS Note were automatically convertible into equity securities sold in the BMS Qualified Financing at the conversion price equal (i) to the outstanding principal and accrued interest under the BMS Note divided by (ii) the lowest cash price paid per equity security. The Company elected the fair value option to account for the BMS Note. Changes in fair value at every reporting date are recorded as a component of the other income (expense), net. The BMS Note was classified as a liability on the Company&#x2019;s consolidated balance sheet as of December 31, 2023 and was initially recorded at fair value. The Company subsequently remeasured the fair value of the BMS Note at each applicable reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 3, 2024, the Company issued and sold Series C convertible preferred stock (&#x201c;Series C Preferred Stock&#x201d;), which was deemed to be a BMS Qualified Financing, as described above, and resulted in the outstanding BMS Note plus accrued interest being automatically converted into 12,284,686 shares of Series C Preferred Stock (see&lt;i style="font-style:italic;"&gt; Note 9, Convertible Preferred Stock&lt;/i&gt;). Immediately prior to settlement, the BMS Note was remeasured to fair value utilizing fair value of the shares of Series C Preferred Stock for which the BMS Note converted into. The BMS Note settling in shares of Series C Preferred Stock represents the redemption of stock-settled debt and was therefore accounted for as an extinguishment. Upon extinguishment, no gain or loss was recognized. The Company recorded a $0.8 million change in fair value of the BMS Note as component of other income (expense), net for the year ended December 31, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following tables presents changes to the Company&#x2019;s liabilities with significant unobservable inputs (Level 3 liabilities) during the years ended December 31, 2024 and 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Convertible notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Convertible Note:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Issuance of BMS Note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_O9B88gheUkaquoX_9DV5hA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value of BMS Note&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_jVXKwJzbK06otYl6OvTOJw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value of BMS Note&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Issuance of Series C Preferred Stock in exchange for BMS Note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,146)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_-Nl1URPON0SSYOHhhjxWZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following tables present information about the Company&#x2019;s assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:28.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted Prices in Active Market &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant Other Observable Inputs&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant Other Observable Inputs&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets: &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,070&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,070&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:28.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 350,766&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 338,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:30.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;width:66.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:30.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted Prices in Active Market &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant Other Observable Inputs&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant Other Observable Inputs&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  BMS note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_iSqSAz9x4k2LDrxzSKy2MA"
      decimals="-3"
      id="Tc_c1urWglk00O5flXI5EuiuQ_5_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">19070000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_45gRULzuSUK5_ORGEXpLOQ"
      decimals="-3"
      id="Tc_KUJv3JIPAUeb2znvY70LDQ_5_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">19070000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_cT92xtQ8cECq2AFu-XJeOQ"
      decimals="-3"
      id="Tc_5S8WorRezE65a5F5rtM88g_6_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">300672000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_EbY1u8wvo0uxDj6anPPPCw"
      decimals="-3"
      id="Tc_at1n4verqEiyM8NmOAIdRQ_6_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">300672000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_T3DzdxiqpEyWSibLwwGToQ"
      decimals="-3"
      id="Tc_Y9Isg9UhU0eAasIcO9r6vQ_8_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">3315000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_82fSkNrj5kGcJKb3RNQoNg"
      decimals="-3"
      id="Tc_o18oPpYB3EKCUaafyCh29A_8_9"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">3315000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_efoaGSp1_UmRJh64ycKRPQ"
      decimals="-3"
      id="Tc_mSeF-T7V3ES67YCYKb0tqQ_9_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">8601000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_LvhP6kTZU06gMvlc3p7_eQ"
      decimals="-3"
      id="Tc_B9qhCzFkrESw5WwGDTQ6bA_9_9"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">8601000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_fNDpCNYLYE233dylDwz8eQ"
      decimals="-3"
      id="Tc_K_TvQomdqkWtpANDzoXEIg_10_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">19108000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_wgLHoHG1-0qDKJPNdf5zYg"
      decimals="-3"
      id="Tc_Nohb4PU2iUq05GZyRuegAw_10_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">19108000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_LWrKtXp_xEeU8LAphW72jw"
      decimals="-3"
      id="Tc_S85etWOaZEyzEmtnqKYg1A_11_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">350766000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_KwwFNWvkbkepTCv4eJzXUA"
      decimals="-3"
      id="Tc_upKMTjkKf0-TY9reO3exaQ_11_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">338850000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_GlXgsGQE-0GNbt0DsdtK9g"
      decimals="-3"
      id="Tc_t3OGjkqXfkiAUFrnIiux_Q_11_9"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">11916000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9vmGc1uJ-UKFfbOjwwSZLA"
      decimals="-3"
      id="Tc_UdH_0eXGT0GyUDe52jVNHQ_4_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">20300000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_FVi09Cz6lESIybH__dVf2g"
      decimals="-3"
      id="Tc_mCgaoAf5yk6jwrBALbb7SQ_4_12"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">20300000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9vmGc1uJ-UKFfbOjwwSZLA"
      decimals="-3"
      id="Tc_sqf5XRWSfEqOGT89DmOxRQ_5_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">20300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_FVi09Cz6lESIybH__dVf2g"
      decimals="-3"
      id="Tc_z6Bv2cwOEEafklWVwM85Yg_5_12"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">20300000</us-gaap:LiabilitiesFairValueDisclosure>
    <zbio:FairValueAssetsLevel2ToLevel1TransferAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="0"
      id="Narr_A8ayMaBB7Um0NdQ19alCJw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:FairValueAssetsLevel2ToLevel1TransferAmount>
    <zbio:FairValueAssetsLevel2ToLevel1TransferAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="0"
      id="Narr_hpXKGkAHD0WQJH2SLNxYWA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:FairValueAssetsLevel2ToLevel1TransferAmount>
    <zbio:FairValueAssetsLevel1ToLevel2TransferAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="0"
      id="Narr_7-6BLcq_5k2-tQbS9wRYnw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:FairValueAssetsLevel1ToLevel2TransferAmount>
    <zbio:FairValueAssetsLevel1ToLevel2TransferAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="0"
      id="Narr_Ur7sZsoHkEOFd_ou_63Bkg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:FairValueAssetsLevel1ToLevel2TransferAmount>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="0"
      id="Narr_rnIG-SNuB0-WMI3YKguEOw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_QwPIkZkCh0moy3MEe7RxOQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the available-for-sale securities (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;width:56.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross Unrealized Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross Unrealized Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-term investments:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,315&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,589&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,093&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,108&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ujsrnzhxWkaowceDO8G96A"
      decimals="-3"
      id="Tc_98hEPTBRAkmsMZHWbmSSTw_4_2"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">3311000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ujsrnzhxWkaowceDO8G96A"
      decimals="-3"
      id="Tc_8gBEJOIPqECqXj9ISU6iyA_4_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ujsrnzhxWkaowceDO8G96A"
      decimals="-3"
      id="Tc_o_o5IchQe06vvbkBNaxN-g_4_11"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">3315000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_tAB8gHGpxEa_vZYJC85hXw"
      decimals="-3"
      id="Tc__iffzE7AYESwiKr5xVv7xQ_5_2"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">8589000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_tAB8gHGpxEa_vZYJC85hXw"
      decimals="-3"
      id="Tc_7wJtEV7DeUSPKZtC1MBKvg_5_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_tAB8gHGpxEa_vZYJC85hXw"
      decimals="-3"
      id="Tc_2NnaBFnsKEGDRdZ3qgdqzg_5_11"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">8601000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_u4MSiO-PeECFV2npmPDRmQ"
      decimals="-3"
      id="Tc_5q7LBLfDqE-7kyMwq6TBuA_6_2"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">19093000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_u4MSiO-PeECFV2npmPDRmQ"
      decimals="-3"
      id="Tc_SUECQZsbmU2Efbzj5LWeGg_6_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_u4MSiO-PeECFV2npmPDRmQ"
      decimals="-3"
      id="Tc_6SgVYzJg90a4Ba_JIxxvWw_6_8"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_u4MSiO-PeECFV2npmPDRmQ"
      decimals="-3"
      id="Tc_YoDFDNuR10qeLXW4v_Iwjg_6_11"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">19108000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_-lgYIjdR60q9eCR0iUlmCg_7_2"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">30993000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_ZV7QqcOwr0qBEtwaLfpqzQ_7_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">33000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_vqcEgGvi4ESI-YxaM6DlCw_7_8"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_z9sMLx0svEKmMgd_E_pxPA_7_11"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">31024000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_ExKbMgkUn0ititCiAzolAg"
      decimals="-5"
      id="Narr_aqoZINWZL0-O6GmCiEAmKg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">20000000</us-gaap:DebtInstrumentFaceAmount>
    <zbio:MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes
      contextRef="Duration_8_1_2023_To_8_31_2023_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_P-ll4OVb3EWjFIKqvZMELA"
      decimals="-5"
      id="Narr_QiBKJX5ffk2sGrQzvv-1zg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">70000000</zbio:MinimumProceedsFromIssuanceOfConvertiblePreferredStockForAutomaticConversionOfConvertiblePromissoryNotes>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_5_3_2024_To_5_3_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_lcOoNTIEC06PQFCU3DRl5Q"
      decimals="INF"
      id="Narr_cs18Q9pu4k60wcHzmN7c8g"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">12284686</zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_5_3_2024_To_5_3_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_cwXLzP0nA0KjySFxWk-Usw"
      decimals="-5"
      id="Narr_pNXStqs0tEmNHzBCY1GEqw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <zbio:FairValueAdjustmentOfConvertibleNotes
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember__ZDd67Q9eUCGYKadM0BTGw"
      decimals="-5"
      id="Narr_wCDRYGo5e0OkbcXK1b5-mA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">800000</zbio:FairValueAdjustmentOfConvertibleNotes>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_FAIZ4nGClUqoj3Nt3JGawA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following tables presents changes to the Company&#x2019;s liabilities with significant unobservable inputs (Level 3 liabilities) during the years ended December 31, 2024 and 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Convertible notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Convertible Note:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Issuance of BMS Note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_O9B88gheUkaquoX_9DV5hA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value of BMS Note&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_jVXKwJzbK06otYl6OvTOJw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value of BMS Note&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Issuance of Series C Preferred Stock in exchange for BMS Note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,146)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_HxXWtV__Vkyd2f7BPoXHyg_4_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">20000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_pAbh0i3pDEmdgbLmeS4FLw_5_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_LaZRhZfVnUWgIUrlOINM1w_6_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">20300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_I5RsYrfcvkyqApVB81q-Ng_7_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">846000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_Znelo1zuDUC4KOxFmKDQ3A_8_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">21146000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:OtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_6Sg_GTgMuk-1bN8olDquMA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.&lt;/b&gt;&lt;/span&gt;Other Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Other assets consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.63%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:54.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.63%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Clinical trial deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,639&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,788&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred offering costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,388&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,856&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,276&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb__f7pUzQ3kEWb1QV-E15AZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Other assets consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.63%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:54.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.63%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Clinical trial deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,639&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,788&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred offering costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,388&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,856&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,276&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_tRgKFDsUCUmHEyYS1MXucg_3_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">12639000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_o_zxQxFT0kK70ATfe2lhcQ_3_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">5788000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:DeferredCosts
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_37V-WFy0O0yoY4zw-HHY6w_4_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1388000</us-gaap:DeferredCosts>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_MWsm3NVPjk6dEeaMM1yimA_5_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">217000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_kaGUyF42rEu9zE1ZxHb-KA_5_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">100000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_ylZQzGMVdEO_smswm8lslQ_6_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">12856000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_45WEFWEzS0CugF7OxVc-ig_6_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">7276000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_VBDjlCeFjEq0jEmDf7EPaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;5.&lt;/b&gt;&lt;/span&gt;Accrued Expenses &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:37.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.17%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;External research, development and manufacturing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional and consultant fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income taxes payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_z0YvRLV91E-I78DQJCvFKQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:37.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.17%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;External research, development and manufacturing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional and consultant fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income taxes payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <zbio:AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_HDSL_A9BOkea2fLsswONVg_4_2"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">29338000</zbio:AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent>
    <zbio:AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_NcLDfra8mke7Gx_I4jgv0w_4_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">9398000</zbio:AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_AknrHAw5oEyIRwAXmnznDw_5_2"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">8308000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_kdTGs6tZUE2HVOjpbn1xfg_5_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">5122000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_v4gOBki7dkyL_gA_Xj_4zg_6_2"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1265000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_0NBVdfylDU2CtBJlJ89Gxg_6_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">2379000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_K2w6ieojb0mZCdqSIuB10Q_7_2"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">211000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc__MtnqxOB-kut545Q_0fkLQ_7_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">301000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_Ryiq3Ho9TUyYCAc4ScXRxQ_8_2"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">249000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_vi_EK1b3-0eELN_SAIZBXw_8_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">106000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_NNYI3crLJ0ORCRuu9pId0A_9_2"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">39371000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_MkF-bqmH-kixGackj8cMbw_9_5"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">17306000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_8okKBxh4FEORV8W19p36Bg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;6&lt;/span&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;.&lt;/b&gt;&lt;/span&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'Segoe UI';font-size:9pt;"&gt;T&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;he Company has various leases for office space, which are accounted for as operating leases and generally have terms of less than &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;two years&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; in length, some of which have the option to renew. The Company recognizes monthly operating lease expense on a straight-line basis over the term of the lease as general and administrative expenses in the consolidated statements of operations and comprehensive loss. Variable lease expense relates primarily to office lease common area maintenance, insurance, and property taxes, is expensed as incurred, and is excluded from the &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;calculation of the lease liabilities and right-of-use assets. For each of the years ended December 31, 2024 and 2023, the Company incurred variable lease expense of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$0.1&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Supplemental balance sheet information related to operating lease assets and liabilities was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,004&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;821&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate used to measure lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10.99%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;18.39%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;For each of the years ended December 31, 2024 and 2023, the total lease cost for operating leases (recorded in general and administrative expenses in the Company&#x2019;s consolidated statements of operations and comprehensive loss) was &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$0.9&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The minimum lease payments under the Company&#x2019;s operating leases are expected to be as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 896&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,137&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (134)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;During the year ended December 31, 2024, the amount of right-of-use assets obtained under new operating lease arrangements was &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$1.1&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; million. There were &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;no&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; right-of-use assets obtained under new operating lease arrangements during the year ended December 31, 2023. Cash paid for lease liabilities was &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$0.9&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; million for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      id="Narr_NqRrhXWjukms89aBos1YMQ">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-5"
      id="Narr_xhdPI8HRt0KGuM6Pr8uYcg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">100000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-5"
      id="Narr_XN6QuZDO6EygE_aePzKG8g"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">100000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_QRxe4FKkpUGksA5JGuqYEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Supplemental balance sheet information related to operating lease assets and liabilities was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,004&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;821&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate used to measure lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10.99%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;18.39%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_RJO5hxFg5kefDctb_QQwoQ_3_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1004000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_1DmQjY1iZEKP2U28RctyyA_3_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">821000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_pizFkit59kyQ6tHRo2yr_A_4_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1003000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_99evoBAlRkGPoKLrOqKosw_4_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">813000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      id="Tc_6ELP2yTDREC5T-Lxlq553w_5_3">P1Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      id="Tc_AMOqqB7I6Ei8s5O9-qDoWQ_5_6">P1Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="4"
      id="Tc_66_dXZblfkWRphud2IPcVQ_6_3"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.1099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="4"
      id="Tc_twt-4mhQg0yET2bg7hxtMg_6_6"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.1839</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-5"
      id="Narr_69mNCFfPNEGid32NySYYfA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">900000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-5"
      id="Narr_JnLw-tMRKE6CZjJ8wfaGxg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">900000</us-gaap:OperatingLeaseCost>
    <zbio:LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_HoIA2BTTaUWYhfbmDYuzXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 896&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,137&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (134)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</zbio:LesseeOperatingLeaseLiabilityToBePaidMaturityAndQuantitativeDisclosureTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_kKxRmYpewEOUNsch2Qqzxw_2_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">896000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_uO-QI7eziEypWvmp7XIcjQ_3_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">241000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_WMN-RoMUs06KnyziN85ngw_5_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1137000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_CWjpU0upgEO9G0FIMGKjyQ_6_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">134000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_44QzX6GIhUGcBnV-ceuamw_7_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1003000</us-gaap:OperatingLeaseLiability>
    <zbio:RightOfUseAssetObtainedUnderNewLeaseArrangement
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-5"
      id="Narr_5bGg5AHe3EKrFNAwfB4vwQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1100000</zbio:RightOfUseAssetObtainedUnderNewLeaseArrangement>
    <zbio:RightOfUseAssetObtainedUnderNewLeaseArrangement
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-5"
      id="Narr_YVA90ZgD-k6Ov-pGAL7JvA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:RightOfUseAssetObtainedUnderNewLeaseArrangement>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-5"
      id="Narr_Qcw_a4k81E6wBZLneCdkEA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-5"
      id="Narr_unB3tkRz3kGtF-J9L9z25g"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">900000</us-gaap:OperatingLeasePayments>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_ewJybHwm1EmuDAVg78aj4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;7.&lt;/b&gt;&lt;/span&gt;License and Collaboration Revenue &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;License and Collaboration Agreement with Bristol-Myers Squibb&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2023, the Company entered into a license and collaboration agreement with Bristol-Myers Squibb (the &#x201c;BMS Agreement&#x201d;), under which the Company granted BMS an exclusive license to (i)&#160;develop, manufacture (subject to the Company&#x2019;s rights to be the exclusive manufacturer for BMS for a certain period of time), commercialize or otherwise exploit obexelimab and any biological product (irrespective of presentations, formulations or dosages) containing obexelimab but not any of the Company&#x2019;s other proprietary active ingredient (the &#x201c;BMS Product&#x201d;) into Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia (collectively, the &#x201c;BMS Territory&#x201d;) and (ii)&#160;develop and manufacture obexelimab and the BMS Product outside the BMS Territory provided that obexelimab and the BMS Product are solely used in the BMS Territory. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the BMS Agreement, BMS paid the Company a one-time non-refundable upfront cash payment of $50.0 million. The Company is entitled to receive further separate development and regulatory milestone payments from BMS up to approximately $79.5 million. The Company is also entitled to receive one-time sales milestone payments up to $70.0 million upon BMS achieving certain net sales milestones in a given year in the BMS Territory. The Company is also eligible to receive tiered high single-digit to low double-digit royalties on net sales in the BMS Territory, subject to specified reductions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company will continue to perform and oversee the ongoing Phase 3 trial of obexelimab in the IgG4-RD indication and BMS will participate in the performance of the study. BMS also has the right to participate in other global clinical studies that the Company chooses to perform. Pursuant to such global studies, including the IgG4-RD study, the Company and BMS have defined roles with specified activities assigned to each party in their respective jurisdictions. These activities are overseen by a joint steering committee, which has equal representation of the parties. BMS will fund their pro rata share of the total global study costs up to a specified percentage of the patients enrolled in the study from the BMS Territory. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Should the percentage of patients from the BMS Territory fall below the specified percentage, BMS&#x2019;s funding would proportionately decrease. BMS is responsible for the development and commercialization of obexelimab within the BMS Territory, including the performance of any local studies within its jurisdiction that it chooses to perform, while the Company retains responsibility for the development and commercialization for the remainder of the world. The Company is responsible for manufacturing the clinical supply and commercial supply of obexelimab, each at cost plus single-digit margin. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluated the terms of the BMS Agreement to determine whether it is a collaborative arrangement in the scope of ASC 808. The Company concluded that the BMS Agreement is a collaborative arrangement under ASC 808 as both parties are active participants in the global clinical trial and are exposed to significant risks and rewards of those activities. The Company determined that the BMS Agreement contained two material components: (i) the license granted to BMS to develop, manufacture and commercialize obexelimab within the BMS Territory, and related activities in the BMS Territory, including manufacturing and (ii) the global development of obexelimab, which at execution, solely relates to the ongoing Phase 3 trial for IgG4-RD. The Company used criteria specified in ASC 606 to determine whether the components of the BMS Agreement are performance obligations to a customer and concluded that BMS is the Company&#x2019;s customer for the license and related activities in the BMS Territory under ASC 606. The global development activities under the agreement do not represent a transaction with a customer and reimbursement payments received by the Company for global development activities are accounted for as a reduction of the related research and development expenses. The Company recorded $6.0 million and $4.1 million as a reduction to research and development expenses during the years ended December 31, 2024 and 2023, respectively, with $2.0 million and $1.3 million of outstanding receivable, included in prepaid expenses and other current assets on the Company&#x2019;s consolidated balance sheet as of December 31, 2024 and 2023, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluated the license and related activities under ASC 606 as these transactions are considered transactions with a customer, and identified four material promises at the outset of the BMS Agreement, which consists of (i) the exclusive license, (ii) the initial technology transfer, (iii) clinical manufacturing supply related to development in the BMS Territory and (iv) commercial manufacturing supply related to commercialization within the BMS Territory. The Company determined that the exclusive license and initial technology transfer were not distinct from each other, as the exclusive license has limited value without the corresponding technology transfer. As such, for the purposes of ASC 606, the Company determined that the two material promises, the exclusive license and the initial technology transfer, should be combined into one distinct performance obligation. The Company further evaluated the material promise associated with the clinical manufacturing supply and the commercial manufacturing supply, within the BMS Territory, concluding that because BMS is not obligated to purchase any minimum amount, the clinical manufacturing supply and commercial manufacturing supply represent a purchase option and not a performance obligation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company further concluded that the customer option is not priced at a significant and incremental discount at the execution of the arrangement and therefore does not represent a material right. Therefore, each of the clinical and commercial manufacturing activities were excluded as performance obligations at the outset of the arrangement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The transaction price of the BMS Agreement was determined to be $50.0 million, which consisted of the upfront cash payment, and was allocated to the one combined performance obligation. The other potential consideration, which includes development, regulatory, and sales milestone payments that the Company is eligible to receive were excluded from the transaction price, as all milestones were not deemed probable of achievement and were therefore fully constrained. The Company issued the BMS Note in connection with the BMS Agreement, and the BMS Note was recorded at fair value separate from the transaction price of the BMS Agreement (see&lt;i style="font-style:italic;"&gt; Note 3, Fair Value Measurements&lt;/i&gt;). The Company reevaluates the transaction price at the end of each reporting period as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company adjusts its estimate of the transaction price, and any addition to the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;transaction price would be recognized as revenue when it becomes probable that inclusion would not lead to a significant revenue reversal. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluated the license under ASC 606 and concluded that the license is a functional intellectual property license. The Company determined that BMS benefited from the license along with the initial technology transfer at the time of the transfer, and therefore the related performance obligation is satisfied at a point in time. The Company satisfied the performance obligation through delivery of the license and initial technology transfer and therefore recognized the upfront payment of $50.0 million as revenue during year ended December 31, 2023. The Company did not recognize revenue under this arrangement in the year ended December 31, 2024, as no milestones were achieved or deemed probable of achievement, and as such, all remaining milestones remained fully constrained and excluded from the transaction price. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Tenacia Biotechnology Co. Novation Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In October 2024, the Company entered into a novation agreement with Tenacia Biotechnology (Hong Kong) Co., Limited (&#x201c;Tenacia&#x201d;), under which the Company transferred its rights and obligations under the agreements with Dianthus to Tenacia (the &#x201c;Tenacia Agreement&#x201d;). Pursuant to the Tenacia Agreement, the Company, transferred all the ZB005 inventory, analytical methods and manufacturing records generated, under the Dianthus Option Agreement and the License Agreement (collectively the &#x201c;Dianthus Agreements&#x201d;), see &lt;i style="font-style:italic;"&gt;Note 8, License and Options Agreements, &lt;/i&gt;for additional information, to Tenacia, for the exclusive right to research, develop, manufacture and commercialize products within greater China.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Tenacia Agreement, Tenacia paid the Company a one-time non-refundable upfront cash payment of $5.0 million. The Company is entitled to receive further development, regulatory and sales milestones from Tenacia of up to approximately $86.0 million if certain milestones are successfully achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluated the terms of the Tenacia Agreement and determined it is within the scope of &lt;i style="font-style:italic;"&gt;ASC 606&lt;/i&gt;. The Company identified the following promises in the Tenacia Agreement that were evaluated under the scope of &lt;i style="font-style:italic;"&gt;ASC 606:&lt;/i&gt; (i) transfer of the license, (ii) assignment of all rights, title and interests in ZB005 inventory, manufacturing records, analytical methods and draft IND component, (iii) services to be performed in accordance with manufacturing technology transfer and (iv) transfer, up to one year after the effective date, of any tangible embodiments of know-how that was not previously provided. The Company also evaluated whether certain options outlined in the Tenacia Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options conveyed a material right to Tenacia and, therefore, are not considered separate performance obligations within the Tenacia Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company assessed the above promises and determined that the license for ZB005, asset transfer and technology transfer are a combined distinct performance obligation within the scope of &lt;i style="font-style:italic;"&gt;ASC 606&lt;/i&gt;. &#160;The future technology know-how transfer services, for one year after the effective date, is a promise that is separately identifiable. The Company determined the likelihood of Tenacia requesting additional know-how transfer to be remote and any requests to require minimal resource allocation, as the Company has concluded all work on ZB005 within greater China. As such, the Company considered the continued know-how transfer to be immaterial in the context of the promises. Therefore, the license, asset transfer and technology transfer represent a single performance obligation within the scope of &lt;i style="font-style:italic;"&gt;ASC 606&lt;/i&gt; at contract inception. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the transaction price of $5.0 million was allocated to the combined performance obligation, which was recognized upon delivery prior to December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company used the most likely amount method to estimate variable consideration and estimated that the most likely amount for each potential developmental and regulatory variable consideration milestone payment under the agreement is zero, as achievement of those milestones is uncertain and susceptible to factors outside the Company&#x2019;s control. Accordingly, all such milestone payments were excluded from the transaction price. Management will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, will adjust the transaction price as necessary. Sales based milestones structured on the level of sales, were also excluded from the transaction price, as the license is deemed to be the predominant item to which the sales relate. The Company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, no milestones were achieved or deemed probable of achievement. &lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <zbio:CollaborativeArrangementUpfrontPaymentReceived
      contextRef="Duration_8_1_2023_To_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_68E-30ZXOka0SQILO84I2w"
      decimals="-5"
      id="Narr_bvfHjRA01k2sgohT2fm5WQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">50000000</zbio:CollaborativeArrangementUpfrontPaymentReceived>
    <zbio:CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum
      contextRef="As_Of_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_yjecN0IOyEe3rAsWgnm7iQ"
      decimals="-5"
      id="Narr_d9NFml-LZU63Y9_qg1tELQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">79500000</zbio:CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum>
    <zbio:CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum
      contextRef="As_Of_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_yjecN0IOyEe3rAsWgnm7iQ"
      decimals="-5"
      id="Narr_1DP9Y6JmrkiHyN0Z6RePKg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">70000000</zbio:CollaborativeArrangementSalesMilestonePaymentsReceivableMaximum>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_N0JzawarFE2rMLM5lKwjiw"
      decimals="-5"
      id="Narr__3y6VCFTYUCV-iV58lHC3Q"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">6000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_NYcJR8lqrkCLowTMNFUBTg"
      decimals="-5"
      id="Narr_DPP6eahpuUW0esq4W575hQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">4100000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <zbio:CollaborativeArrangementReceivables
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_CISJK2ppnkmIAMwch3Q_OA"
      decimals="-5"
      id="Narr_posAD8mpTk-W0nGVMzJGyw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">2000000</zbio:CollaborativeArrangementReceivables>
    <zbio:CollaborativeArrangementReceivables
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_q9l-Yh0Dr0qScfAPmFwVvA"
      decimals="-5"
      id="Narr_GySlWgGJLEeSwkBt12Ccww"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1300000</zbio:CollaborativeArrangementReceivables>
    <zbio:CollaborativeArrangementTransactionPrice
      contextRef="Duration_8_1_2023_To_8_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_68E-30ZXOka0SQILO84I2w"
      decimals="-5"
      id="Narr_8tPOxQldEkm8JW7NP0UeiQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">50000000</zbio:CollaborativeArrangementTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_LicenseAgreementWithBristolMyersSquibbMember_NYcJR8lqrkCLowTMNFUBTg"
      decimals="-5"
      id="Narr_J3AzWjfi6EGV5EGy2X77PA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <zbio:CollaborativeArrangementUpfrontPaymentReceived
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_TypeOfArrangementAxis_zbio_NovationAgreementMember_lnQAUx2mlkib0BNiLe_Jxg"
      decimals="-5"
      id="Narr_8PbE3GyRC0m3UlH4AiaSZg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">5000000</zbio:CollaborativeArrangementUpfrontPaymentReceived>
    <zbio:CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum
      contextRef="As_Of_10_31_2024_us-gaap_TypeOfArrangementAxis_zbio_NovationAgreementMember_8o3sYZV3iUWz0FuKhL7jow"
      decimals="-5"
      id="Narr_14rZmif32UihWFbqw35quw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">86000000</zbio:CollaborativeArrangementDevelopmentRegulatoryAndSalesMilestonePaymentsReceivableMaximum>
    <zbio:CollaborativeArrangementTransactionPrice
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_TypeOfArrangementAxis_zbio_NovationAgreementMember_lnQAUx2mlkib0BNiLe_Jxg"
      decimals="-5"
      id="Narr_jvRKRixNyUCI-v9142_uUQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">5000000</zbio:CollaborativeArrangementTransactionPrice>
    <zbio:LicenseAndOptionAgreementsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_0NRmQlpMIk21LAolTc8n8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;8.&lt;/b&gt;&lt;/span&gt;License and Option Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Xencor,&#160;Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;2020 Xencor Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;In September&#160;2020, the Company entered into a license agreement (the &#x201c;2020 Xencor Agreement&#x201d;) with Xencor, Inc. (&#x201c;Xencor&#x201d;), to obtain (i)&#160;an exclusive, royalty-bearing, sublicensable worldwide license under certain patent rights controlled by Xencor and (ii)&#160;a non-exclusive payment bearing license under certain know-how controlled by Xencor to research, develop, manufacture, market and sell &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;three&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; antibody product candidates, including ZB002. The 2020 Xencor Agreement became effective in November&#160;2020, upon the Company&#x2019;s issuance of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;5,041,542&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; shares of its Series&#160;A Preferred Stock, which had a fair value of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$16.1&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million to Xencor as initial consideration. The Company concluded that as no processes or other activities that would constitute a business were acquired, and the acquired assets did not have an alternative future use, the upfront consideration was expensed to acquired IPR&amp;amp;D during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company is required to pay Xencor tiered royalties on annual net sales of successfully commercialized products utilizing the licensed assets. The royalty&#160;percentage rates vary by geographic areas as defined in the 2020 Xencor Agreement and range from the mid-single digits to the mid-teens.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company is also obligated to reimburse Xencor for third-party costs incurred by Xencor for certain patent filings, prosecution and maintenance as further specified in the 2020 Xencor Agreement. During the&#160;year ended December&#160;31, 2024 &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;no&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; costs were incurred related to the 2020 Xencor Agreement. During the year ended December 31, 2023, the Company incurred immaterial costs related to the 2020 Xencor Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;2021 Xencor Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;In May&#160;2021, the Company entered into a license agreement (the &#x201c;2021 Xencor Agreement&#x201d;) with Xencor to obtain an (i)&#160;exclusive, royalty-bearing, sublicensable worldwide license under certain patent rights controlled by Xencor and (ii)&#160;a non-exclusive payment bearing license under certain know-how controlled by Xencor to research, develop, manufacture, market and sell obexelimab. The 2021 Xencor Agreement became effective in November&#160;2021, upon the execution of an amendment to the 2021 Xencor Agreement and the Company&#x2019;s concurrent issuance of a warrant to Xencor (the &#x201c;Xencor Warrant&#x201d;) as initial consideration, which entitled Xencor to receive a number of the Company&#x2019;s convertible preferred stock in the Company&#x2019;s next &#x201c;qualified financing&#x201d;. The Company concluded that as no processes or other activities that would constitute a business were acquired, and the acquired assets did not have an alternative future use, the upfront consideration of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$20.7&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million was expensed to acquired IPR&amp;amp;D during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company is obligated to make specified development, regulatory and commercial milestone payments of up to &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$10.0&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million at Xencor&#x2019;s option either in cash or fully-paid newly issued shares. The Company is obligated to make regulatory milestone payments up to &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$75.0&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million. The Company is also obligated to make one-time sales milestone payments up to &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$385.0&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million upon achieving milestone events of net sales in a given calendar year in the territory equal to certain threshold amounts. In addition, the Company is required to pay Xencor tiered royalties on annual net sales of successfully commercialized products utilizing obexelimab, with the royalty rates varying based on regions and ranging from the mid-single digits to the mid-teens.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;In April&#160;2023, the Company incurred a &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$10.0&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million development milestone pursuant to the 2021 Xencor Agreement, which Xencor elected to receive in the form of the Company&#x2019;s Series&#160;B Preferred Stock. &lt;/span&gt;See &lt;i style="font-style:italic;"&gt;Note&#160;9, Convertible Preferred Stock,&lt;/i&gt; for details&lt;span style="letter-spacing:0.2pt;"&gt;. The milestone was recorded as acquired IPR&amp;amp;D expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss. The Company did not record any expenses related to reimbursable patent-related costs during the year ended December 31, 2024. The Company recorded an immaterial amount to general and administrative expenses in the consolidated statements of operations and comprehensive loss &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;during each of the&#160;year ended December&#160;31, 2023, relating to reimbursable patent-related costs owed to Xencor. &lt;/span&gt;During the year ended December 31, 2024 no milestone expense was incurred. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Dianthus Therapeutics&#160;Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;In September&#160;2020, the Company entered into an agreement (the &#x201c;Dianthus Option Agreement&#x201d;) with Dianthus Therapeutics Inc. (&#x201c;Dianthus&#x201d;), a therapeutic antibody company. Under the terms of the Dianthus Option Agreement, the Company obtained an exclusive option to negotiate and enter into exclusive license agreements with Dianthus for the rights to research, develop, manufacture, market and sell products related to either or both of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;two&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; antibody product candidates based on Dianthus&#x2019; proprietary technology in China, Hong Kong, Macau and Taiwan (the &#x201c;Zenas Territories&#x201d;). Dianthus retains all rights to develop and commercialize the product candidate subjects of the two options outside of the Zenas Territories. Upon execution of the Dianthus Option Agreement, the Company issued &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;18,063&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; shares of its common stock to Dianthus as initial consideration, which was recorded to acquired IPR&amp;amp;D expense during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Under the Dianthus Option Agreement, Dianthus will notify the Company when it has identified each of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;two&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; antibody product candidates, and the Company will then have sixty (&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;60&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;) days to notify Dianthus if the Company intends to exercise each of the options. In September&#160;2021, Dianthus notified the Company that it had identified the first lead antibody product candidate pursuant to the Dianthus Option Agreement, ZB005 (also known as DNTH103). In October&#160;2021, the Company notified Dianthus of its intention to exercise its option to ZB005 pursuant to the Dianthus Option Agreement. This notification resulted in a &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$1.0&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million milestone obligation to Dianthus, which was expensed in 2021 upon exercise and subsequently paid during the year ended December&#160;31, 2022. The Company and Dianthus executed a license agreement for ZB005 in June&#160;2022 (the &#x201c;Dianthus License Agreement&#x201d;). &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company is also required to reimburse Dianthus for a specified&#160;percentage of certain third-party costs which Dianthus incurs in its initial discovery and development activities related to each of the two options. To date, the Company has only exercised its option with respect to the ZB005 program, and as a result, it has only reimbursed Dianthus with respect to costs associated with the ZB005 program. During the&#160;years ended December&#160;31, 2024 and 2023, the Company incurred &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$5.1&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million and &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$3.0&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million of reimbursable expenses, respectively, which are recorded within research and development expenses in the consolidated statements of operations and comprehensive loss. Of these amounts, &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$0.5&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; million and an immaterial amount were recorded in accounts payable, and &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$0.3&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; million and &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$0.4&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; million were recorded in accrued expenses on the Company&#x2019;s consolidated balance sheets as of December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The binding key terms included in the Dianthus License Agreement, and that would be included in a future license agreement if the Company exercises its option with respect to a second research program, also include the Company&#x2019;s obligation to make specified development milestone payments to Dianthus, one time only, regardless of the number of assets the Company in-licenses from Dianthus with respect to such research program. The milestone obligations for each research program would total up to &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$11.0&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million, based on achievement of each of the specified milestone events. If the Company successfully commercializes a product(s) under a license agreement, the Company will be obligated to make tiered royalty payments, on a product-by-product basis, to Dianthus on annual net sales of such products. Royalties will be calculated as specified&#160;percentages of annual net sales, ranging from the mid-single digits to the low-double digits, with each specified tiered level of annual net sales having a specified&#160;percentage.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In October 2024, the Company entered into the Tenacia Agreement. Pursuant to the Tenacia Agreement, the Company transferred its rights, and obligations under the Dianthus Option Agreement and the Dianthus License Agreement to Tenacia. As a result, Zenas has no further obligations to Dianthus under the Dianthus Option Agreement and the Dianthus License Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For additional information on our Tenacia Agreement, please see &lt;i style="font-style:italic;"&gt;Note 7, License and Collaboration Revenue&lt;/i&gt;, to these consolidated financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Viridian Therapeutics,&#160;Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;In October&#160;2020, the Company entered into a license agreement with Viridian Therapeutics, Inc. (&#x201c;Viridian&#x201d;), to obtain an exclusive, royalty-bearing, sublicensable license to research, develop, manufacture, market and sell certain antibody product candidates based on Viridian&#x2019;s proprietary technology (the &#x201c;Viridian Agreement&#x201d;). The Company&#x2019;s license rights are limited to non-oncology indications and to the Zenas Territories. Viridian retains its rights to develop and commercialize such product candidates outside of the Zenas Territories. Upon execution of the Viridian Agreement, the Company issued &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;38,707&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; shares of its common stock to Viridian as initial consideration which was recorded as acquired in-process research and development expense in its consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company is obligated to make development milestone payments to Viridian, totaling up to &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;$12.0&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#160;million, based on achievement of each of the specified milestone events. The Company is also required to pay Viridian tiered royalties on annual net sales of successfully commercialized products utilizing the licensed technology. The royalty&#160;percentage rates range from the mid-single digits to the low-double digits. During the year ended December&#160;31, 2024 and 2023, the Company did not incur or pay any milestones to Viridian. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;During the year ended December&#160;31, 2021, the Company and Viridian entered into two letter agreements to authorize initiation of certain manufacturing and development activities related to the licensed product candidate, ZB001 (also known as VRDN-001). In each of the letter agreements the Company requested, and Viridian agreed, to engage a third-party contract manufacturer (the &#x201c;CMO&#x201d;) to initiate certain work with respect to activities pursuant to one or more statements of work under existing agreements between Viridian and the two CMOs. In May&#160;2022, the Company entered into a manufacturing development and supply agreement with Viridian. The Company pays Viridian for all amounts the CMOs invoice to Viridian for the specified activities. The first letter agreement subsequently was amended three times to add further activities and costs to those detailed in the original letter agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;During the&#160;years ended December&#160;31, 2024 and 2023, the Company recognized an immaterial amount of expenses, respectively, which were recorded in research and development expenses in the consolidated statements of operations. &lt;/span&gt;As of December 31, 2024, and 2023, immaterial amounts were recorded in accounts payable and accrued expenses. Viridian has agreed to reimburse the Company for certain services it performs on Viridian&#x2019;s behalf, with reimbursements being recorded as a reduction in research and development expenses. During the year ended December 31, 2024, the Company recorded $1.7 million in reimbursable expenses. During the year ended December 31, 2023, the Company had no reimbursable expenses. &lt;span style="letter-spacing:0.2pt;"&gt;As of December&#160;31, 2024, Viridian had not notified the Company of any additional antibody product candidate.&lt;/span&gt;&lt;/p&gt;</zbio:LicenseAndOptionAgreementsDisclosureTextBlock>
    <zbio:NumberOfAntibodyProductCandidates
      contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_WGP9j066HEmWArI6WB0Cow"
      decimals="INF"
      id="Narr_s_yjbNGvs0Wi7DnzNPyr6w"
      unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw">3</zbio:NumberOfAntibodyProductCandidates>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_WGWYo6VeoEWAuqXTVFh8WQ"
      decimals="INF"
      id="Narr_t2cIxBdarkKkS2pNpHc00Q"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">5041542</zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_WGWYo6VeoEWAuqXTVFh8WQ"
      decimals="-5"
      id="Narr_2OTY3U5R9EuodorB9yvu5w"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">16100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <zbio:CollaborativeArrangementTransactionPrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2020Member_86ES1U6DdEiWj8UWmZ87Nw"
      decimals="-5"
      id="Narr_J9dH18jP_0mQEWXNyeVaqw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:CollaborativeArrangementTransactionPrice>
    <zbio:CollaborativeArrangementTransactionPrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_dyYvSl_2AEyLjKyAcaDc4w"
      decimals="-5"
      id="Narr_rxc_4yI86UWXUUMP5NBxug"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">20700000</zbio:CollaborativeArrangementTransactionPrice>
    <zbio:LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable
      contextRef="As_Of_5_31_2021_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_r2kEzq5fF0emBdihAC_LuQ"
      decimals="-5"
      id="Narr_kppeWa-V2kG5vqMx9OUxqg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">10000000</zbio:LicenseAndOptionAgreementsDevelopmentRegulatoryAndCommercialMilestonePayable>
    <zbio:LicenseAndOptionAgreementsRegulatoryMilestonePayable
      contextRef="As_Of_5_31_2021_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_r2kEzq5fF0emBdihAC_LuQ"
      decimals="-5"
      id="Narr_K_CAPcJqU0S3F2mN16ZVwA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">75000000</zbio:LicenseAndOptionAgreementsRegulatoryMilestonePayable>
    <zbio:LicenseAndOptionAgreementsSalesMilestonePayable
      contextRef="As_Of_5_31_2021_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_r2kEzq5fF0emBdihAC_LuQ"
      decimals="-5"
      id="Narr_bNxz2Va90U2hJWANA-JTEg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">385000000</zbio:LicenseAndOptionAgreementsSalesMilestonePayable>
    <zbio:LicenseAndOptionAgreementsDevelopmentMilestonePayable
      contextRef="As_Of_4_30_2023_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_DlfSbRkRKkikwGFbk82kmQ"
      decimals="-5"
      id="Narr_MjX_ou3O-0uBWAqa08HvRw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">10000000</zbio:LicenseAndOptionAgreementsDevelopmentMilestonePayable>
    <zbio:LicenseAndOptionAgreementsDevelopmentMilestonePayable
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_XencorAgreement2021Member_JXqZc5v7Z0WJSg_JLf5b5g"
      decimals="-5"
      id="Narr__G72MG-mTEyHsXQPVcDSEA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:LicenseAndOptionAgreementsDevelopmentMilestonePayable>
    <zbio:NumberOfAntibodyProductCandidates
      contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_PgETU9rFK0q2wG2LI9cG2g"
      decimals="INF"
      id="Narr_O5XFl0OjzEauUkZXJi5Qig"
      unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw">2</zbio:NumberOfAntibodyProductCandidates>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_bzLuOSUTJEyZzSgS11je2Q"
      decimals="INF"
      id="Narr_IQbK9L7J60S2mN7F_rz5YA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">18063</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <zbio:NumberOfAntibodyProductCandidates
      contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_PgETU9rFK0q2wG2LI9cG2g"
      decimals="INF"
      id="Narr_cUscKJ2a7k-nBouDW1-C8Q"
      unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw">2</zbio:NumberOfAntibodyProductCandidates>
    <zbio:ThresholdPeriodToNotifyIntentionForExercisingOption
      contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_PgETU9rFK0q2wG2LI9cG2g"
      id="Narr_KXi2Nt7eb0O5kAHfYqn6ug">P60D</zbio:ThresholdPeriodToNotifyIntentionForExercisingOption>
    <zbio:LicenseAndOptionAgreementsDevelopmentMilestonePayable
      contextRef="As_Of_10_31_2021_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_Bm0Xi9UVpUmszqhYv-4qFg"
      decimals="-5"
      id="Narr_iOFatTlHAki6SEpzYEHH8Q"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1000000</zbio:LicenseAndOptionAgreementsDevelopmentMilestonePayable>
    <zbio:LicenseAndOptionAgreementsReimbursableExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_ucAh8N2LEkm-jJRZJUsugg"
      decimals="-5"
      id="Narr_4JScSvBWNEKLTDz0iShycg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">5100000</zbio:LicenseAndOptionAgreementsReimbursableExpenses>
    <zbio:LicenseAndOptionAgreementsReimbursableExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_3OZtyHKQXEeOnEHLhY6SNg"
      decimals="-5"
      id="Narr__7w3qhBZ5kuL5Wul7U7jqQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">3000000</zbio:LicenseAndOptionAgreementsReimbursableExpenses>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_IxVPwAMKEkiMUjSqIZE_PQ"
      decimals="-5"
      id="Narr_3mSMc8wPE0quXXgqC2mUfQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_IxVPwAMKEkiMUjSqIZE_PQ"
      decimals="-5"
      id="Narr_FXI1KLQZBk26PD2z3TpcTQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">300000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_yR58FFqVa0-kULPck87ZxA"
      decimals="-5"
      id="Narr_tCMnwwSzkUutrBeZbQpRTw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">400000</us-gaap:AccruedLiabilitiesCurrent>
    <zbio:LicenseAndOptionAgreementsMaximumMilestoneObligation
      contextRef="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_zbio_DianthusOptionAgreementMember_ZrowpMBVWkeOdGC2HRwpgg"
      decimals="-5"
      id="Narr_ZmTR7biuf0yMNzuYRt_CMA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">11000000</zbio:LicenseAndOptionAgreementsMaximumMilestoneObligation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_KSqzhLiyzEyDgl5ybmBLIg"
      decimals="INF"
      id="Narr_YxIeg8-IgU-tzNXKNUk7Kw"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">38707</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <zbio:LicenseAndOptionAgreementsDevelopmentMilestonePayable
      contextRef="As_Of_10_31_2020_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_LluPYzM7VEa_H16QX3m4Sw"
      decimals="-5"
      id="Narr_pBC5cxmwrkWJ_8Mv568C3A"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">12000000</zbio:LicenseAndOptionAgreementsDevelopmentMilestonePayable>
    <zbio:LicenseAndOptionAgreementsReimbursableExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_qV1cIVkt2kOoAoLtymHm9A"
      decimals="-5"
      id="Narr_YYPpICmnKkSdHdxQMk20pg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1700000</zbio:LicenseAndOptionAgreementsReimbursableExpenses>
    <zbio:LicenseAndOptionAgreementsReimbursableExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_zbio_ViridianAgreementMember_4pkbHJxyX0aZXqN77xa8Kg"
      decimals="-5"
      id="Narr_M6dfSa0tpki5BmYjkkbkBQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:LicenseAndOptionAgreementsReimbursableExpenses>
    <zbio:TemporaryEquityDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_tcq5xYmURU2exhdPMq4vsg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;9.&lt;/b&gt;&lt;/span&gt;Convertible Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In September&#160;2020, the Company issued and sold 1,785,714 shares of Series&#160;Seed convertible preferred stock (&#x201c;Series&#160;Seed Preferred Stock&#x201d;) in a private financing transaction, at a purchase price of $0.56 per share, for total net cash proceeds of $1.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In November&#160;2020, the Company issued 5,041,542 shares of Series&#160;A convertible preferred stock (&#x201c;Series&#160;A Preferred Stock&#x201d;) to Xencor as initial consideration for the 2020 Xencor Agreement. Also in November&#160;2020, the Company issued and sold 12,547,838 shares of Series&#160;A Preferred Stock in a private financing transaction, at a purchase price of $3.1878 per share, for total net cash proceeds of $39.9 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In November&#160;2022, the Company issued and sold 25,139,732 shares of Series&#160;B Preferred Stock in a private financing transaction, at a purchase price of $2.38666 per share, for total net cash proceeds of $59.4 million. Concurrent with the issuance and sale of the Series&#160;B Preferred Stock, which was deemed to be a qualified financing as defined in the &#160;convertible note agreement from notes issued to several investors in 2021, and resulted in the principal plus accrued interest being automatically converted into Series&#160;B Preferred Stock, the outstanding convertible notes from 2021 were exchanged for 37,471,107 shares of Series&#160;B Preferred Stock. At the same time, the Xencor Warrant, which was issued as initial consideration for the 2021 Xencor Agreement, was deemed exercised for 14,441,793 shares of Series&#160;B Preferred Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;2023, the Company incurred a $10.0 million development milestone pursuant to the 2021 Xencor Agreement. Xencor elected to receive payment in the form of the Company&#x2019;s Series&#160;B Preferred Stock and the Company issued 4,189,955 shares of Series&#160;B Preferred Stock as payment for the development milestone in June&#160;2023 (see &lt;i style="font-style:italic;"&gt;Note 8, License and Option Agreement &lt;/i&gt;to these consolidated financial statements).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In May&#160;2024, the Company issued and sold 103,990,553 shares of Series&#160;C convertible preferred stock (&#x201c;Series&#160;C Preferred Stock&#x201d;) in a private financing transaction, at a purchase price of $1.72131 per share, for total net cash proceeds of $178.4 million. Concurrent with the issuance and sale of the Series&#160;C Preferred Stock, which was deemed to be a BMS Qualified Financing as defined above in &lt;i style="font-style:italic;"&gt;Note&#160;3, Fair Value Measurements,&lt;/i&gt; the principal plus accrued interest of the BMS Note&#160;was automatically converted into 12,284,686 shares of Series&#160;C Preferred Stock, thereby making the total Series&#160;C issuance equal to 116,275,239 shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Upon the issuance of the Series Seed, Series A, Series B, and Series C Preferred Stock, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In September 2024, the Company completed its IPO, in which the Company issued and sold 15,220,588 shares of its common stock, including 1,985,294 shares pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $17.00 per share, for aggregate gross proceeds of $258.7 million. The Company received approximately $234.3 million in net proceeds, after deducting underwriting discounts and commissions and other offering costs. In connection with the IPO, all outstanding shares of Preferred Stock converted into an aggregate of 24,978,715 shares of common stock and no convertible preferred stock was outstanding as of December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock consisted of the following as of December 31, 2023 (in thousands, except share amounts):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;width:70.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuable Upon&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liquidation Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Conversion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series Seed Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,785,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,785,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 956&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 205,653&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,589,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,589,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 56,071&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,025,699&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,242,587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,242,587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 193,290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 193,898&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,356,392&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,617,681&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,617,681&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,587,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The holders of preferred stock had the following rights, preferences and privileges prior to conversion into common stock upon the closing of the IPO:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;i style="font-style:italic;letter-spacing:0.2pt;"&gt;Voting&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The holder of each share of Preferred Stock was entitled to &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;one&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; vote for each share of common stock into which it would convert and to vote with the common stock on all matters.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;i style="font-style:italic;letter-spacing:0.2pt;"&gt;Conversion&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Each share of convertible preferred stock was automatically converted into a share of common stock, upon affirmative vote of majority of the holders of each series or upon the closing of an initial public offering of the Company&#x2019;s common stock which resulted in a specified minimum amount of gross cash proceeds. The conversion ratio was initially &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;one&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; share of common stock for each share of convertible preferred stock and was adjustable in the event of a split or reverse split of the Company&#x2019;s common stock, an issuance or declaration of dividends to holders of the Company&#x2019;s common stock, a reorganization or merger transaction, or certain issuances of shares of common stock which were dilutive to holders of the Company&#x2019;s preferred stock. Holders of preferred stock had the right to one vote for each share of the Company&#x2019;s common stock which were dilutive to holders of the Company&#x2019;s preferred stock. &#160;Holders of preferred stock had the right to &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;one&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; vote for each share of the Company&#x2019;s common stock into which such holder&#x2019;s shares of preferred stock could then convert.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;i style="font-style:italic;letter-spacing:0.2pt;"&gt;Dividends&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Holders of Series&#160;C Preferred Stock were entitled to receive dividends, only when, as and if declared by the Board, at the annual rate of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;6%&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; of the Series&#160;C Preferred Stock issue price, payable in preference to and satisfied before any dividend or distribution on any other class or series of the Company&#x2019;s shares (except for certain exempted distributions). If any assets or funds remain after dividends had been distributed to holders of Series&#160;C Preferred Stock, holders of Series&#160;B Preferred Stock would have been entitled to receive dividends, only when, as and if declared by the Board, at the annual rate of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;6%&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; of the Series&#160;B issue price, payable in preference to and satisfied before any dividend or distribution on any other class or series of the Company&#x2019;s shares (except for certain exempted distributions). If any assets or funds remain after dividends had been distributed to holders of Series&#160;B Preferred Stock, holders of Series&#160;A Preferred Stock would had been entitled to receive dividends, only when, as and if declared by the Board, at the annual rate of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;6%&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; of the Series&#160;A issue price, payable in preference to and satisfied before any dividend or distribution on any other class or series of the Company&#x2019;s shares (except for certain exempted distributions). If any assets or funds remain after dividends had been distributed to holders of Series A Preferred Stock, holders of Series Seed Preferred Stock would have been entitled to receive dividends, only when, as and if declared by the Board, at the annual rate of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;6%&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; of the Series Seed issue price, payable in preference to and satisfied before any dividend or distribution on any other class or series of the Company&#x2019;s shares (except for certain exempted distributions). The right to receive dividends on shares of all series of preferred stock was not cumulative, and no such right accrued to holders of such shares. There were &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;no&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt; dividends declared or paid as of December 31, 2024 and 2023. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;i style="font-style:italic;letter-spacing:0.2pt;"&gt;Liquidation Preference&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;In the event of a voluntary or involuntary liquidation, dissolution or winding up of the Company or a deemed liquidation event, holders of Series&#160;C Preferred Stock prior and in preference to any distribution to holders of Series&#160;B Preferred Stock, Series&#160;A Preferred Stock, Series Seed Preferred Stock and common shares, would have been entitled to be paid the issue price they originally paid to acquire their shares, plus any declared but unpaid dividends. After full payment to holders of Series&#160;C Preferred Stock, holders of Series&#160;B Preferred Stock prior and in preference to any distribution to holders of Series&#160;A Preferred Stock, Series Seed Preferred Stock and common shares, would have been entitled to be paid the issue price they originally paid to acquire their shares, plus any declared and unpaid dividends. After full payment to holders of Series&#160;B Preferred Stock and Series&#160;A Preferred Stock, holders of Series&#160;Seed Preferred Stock prior and in preference to any distribution to holders of common shares, would have been entitled to be paid the issue price they originally paid to acquire their shares, plus any declared and unpaid dividends. After full payment to holders of Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock, holders of Series Seed Preferred Stock prior and in preference to any distribution to holders of common shares, would have been entitled to be paid the issue price they originally paid to acquire their shares, plus any declared and unpaid dividends. Any remaining amounts after payment to holders of preferred stock, would have been paid to holders of common shares. A deemed liquidation event was defined as any consolidation, amalgamation, scheme of arrangement or merger of the Company (and any of its subsidiaries) or other reorganization resulting in loss of more than 50% voting power; the sale, transfer, lease or other disposition of all or substantially all of the Company&#x2019;s assets; or the exclusive licensing of all or substantially all of the Company&#x2019;s intellectual property.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;i style="font-style:italic;letter-spacing:0.2pt;"&gt;Redemption&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Preferred Stock did not have redemption rights, except for the contingent redemption upon the occurrence of a Liquidation Event.&lt;/span&gt;&lt;/p&gt;</zbio:TemporaryEquityDisclosureTextBlock>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_O_WkNZwcXUq8f-ADKZOHMg"
      decimals="INF"
      id="Narr_-qAUEL013UefH1-m8dCTZQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1785714</zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <zbio:TemporaryEquitySharesIssuedPricePerShare
      contextRef="As_Of_9_30_2020_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_np8ZhIOstUKtfTT_-Yj3vw"
      decimals="2"
      id="Narr_Lu0ibupTyEaobJN8Sxr32g"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.56</zbio:TemporaryEquitySharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_O_WkNZwcXUq8f-ADKZOHMg"
      decimals="-5"
      id="Narr_bCcAH0pI5UqeAPmmkE0a2A"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2020Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ybTmDoxkwUu0xUQqRigT7Q"
      decimals="INF"
      id="Narr_ysqZwhxZnk2qSnDrUn_KYQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">5041542</zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VUl7HtcvHkydsDN2_JnMRg"
      decimals="INF"
      id="Narr_V5YjctrxW0SMAdU2N6G00A"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">12547838</zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <zbio:TemporaryEquitySharesIssuedPricePerShare
      contextRef="As_Of_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_j5jOOcuea0CX4dm8xBjYxA"
      decimals="4"
      id="Narr_L2whQNSnVkiR24mku6jrBQ"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">3.1878</zbio:TemporaryEquitySharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VUl7HtcvHkydsDN2_JnMRg"
      decimals="-5"
      id="Narr_u1zZs_EXg0SfwjcPnOpi_g"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">39900000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_TYxqnXTkYU-hgPL5w_6nXg"
      decimals="INF"
      id="Narr_36dS4bDki0W2F8r1WbCZKA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">25139732</zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <zbio:TemporaryEquitySharesIssuedPricePerShare
      contextRef="As_Of_11_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_P-kTuepM7kKaqc4rCr2AAQ"
      decimals="5"
      id="Narr_7ZB99ZQ5JkyontYWEgqDzQ"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">2.38666</zbio:TemporaryEquitySharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_TYxqnXTkYU-hgPL5w_6nXg"
      decimals="-5"
      id="Narr_WdDnWuHtW0WQe5LUn-QA7A"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">59400000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_DebtInstrumentAxis_zbio_ConvertiblePromissoryNotes2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_cwy_9SZUtkSEG0gNp7CNjw"
      decimals="INF"
      id="Narr_zh4E_6twd0Kn5zL8vBPlGA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">37471107</zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_R9s5xpFO902Z05RAdLWrnQ"
      decimals="INF"
      id="Narr_1cQecCbikEiJSa_bEqewsQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">14441793</zbio:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <zbio:LicenseAndOptionAgreementDevelopmentMilestonePayment
      contextRef="Duration_4_1_2023_To_4_30_2023_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_TKtQMBOy0kys1OFuL5HUrw"
      decimals="-5"
      id="Narr_xfI0gyaFi06qd-BGi8VpMw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">10000000</zbio:LicenseAndOptionAgreementDevelopmentMilestonePayment>
    <zbio:TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment
      contextRef="Duration_4_1_2023_To_4_30_2023_us-gaap_RelatedPartyTransactionAxis_zbio_XencorAgreement2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_TKtQMBOy0kys1OFuL5HUrw"
      decimals="INF"
      id="Narr_79RI5DSzEEqP4apqMI8tuQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">4189955</zbio:TemporaryEquitySharesIssuedDuringPeriodForDevelopmentMilestonePayment>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_1_2024_To_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve5fM4bIxUmgiWyD_r9iHA"
      decimals="INF"
      id="Narr_60BqChRhqkyaIyKU5SSSfQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">103990553</zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <zbio:TemporaryEquitySharesIssuedPricePerShare
      contextRef="As_Of_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_T7YsONiFE0CzJJl1iFaCYg"
      decimals="5"
      id="Narr_OOYTx94oRketR6baBA5dRA"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">1.72131</zbio:TemporaryEquitySharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_5_1_2024_To_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve5fM4bIxUmgiWyD_r9iHA"
      decimals="-5"
      id="Narr_gUnYv4l7VkaFU5dy5x2ruw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">178400000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_5_1_2024_To_5_31_2024_us-gaap_DebtInstrumentAxis_zbio_BmsConvertiblePromissoryNotesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_5MuMZ5_MaUWYN1Qu9wlrYw"
      decimals="INF"
      id="Narr_XKY5jHFlp02vEo-0s8GpiQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">12284686</zbio:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_5_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember__L6rvMfPYE6KDEiKRpOSYQ"
      decimals="INF"
      id="Narr_5jdQQrLM5ke7hUTBig-zxg"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">116275239</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6aV-4PBKtEOUPe_8Z_Aj_Q"
      decimals="INF"
      id="Narr_PBZDBOnwikKj7jypCEVK3Q"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">15220588</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_NlzJf7p5-kuuwrGA0pNVzQ"
      decimals="INF"
      id="Narr_WuMBU-OfjEuHnyLlDQn99w"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1985294</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vp9jOynptE6b6qFRS-0X-Q"
      decimals="2"
      id="Narr_rkfQPDRbY0KEjCDAALOLXA"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">17</us-gaap:SharesIssuedPricePerShare>
    <zbio:ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6aV-4PBKtEOUPe_8Z_Aj_Q"
      decimals="-5"
      id="Narr_qZc48bdj402hv4wCrStuEQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">258700000</zbio:ProceedsFromIssuanceInitialPublicOfferingBeforeDeductionOfUnderwriterDiscountsAndOfferingExpenses>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6aV-4PBKtEOUPe_8Z_Aj_Q"
      decimals="-5"
      id="Narr_LjRWKPlizEeXaNotwQ_smQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">234300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <zbio:PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion
      contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vp9jOynptE6b6qFRS-0X-Q"
      decimals="INF"
      id="Narr_tFZ3etTidUeAlfbY62GNyg"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">24978715</zbio:PreferredStockConvertibleAggregateNumberOfSharesIssuedUponConversion>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_d6jNqs7c1kqVB-9vzX_3nw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock consisted of the following as of December 31, 2023 (in thousands, except share amounts):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;width:70.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuable Upon&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liquidation Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Conversion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series Seed Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,785,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,785,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 956&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 205,653&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,589,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,589,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 56,071&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,025,699&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,242,587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,242,587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 193,290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 193,898&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,356,392&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,617,681&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,617,681&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,587,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA"
      decimals="INF"
      id="Tc_xvdd2uHQCkii4NJpMLXPIg_5_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1785714</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA"
      decimals="INF"
      id="Tc_yN0lYIa1U06163xsdgJnYw_5_4"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1785714</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA"
      decimals="INF"
      id="Tc_yN0lYIa1U06163xsdgJnYw_5_4_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1785714</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA"
      decimals="-3"
      id="Tc_xXnobKdOmUeihVxrJQbE1g_5_7"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">956000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA"
      decimals="-3"
      id="Tc_gBl_K_PGNkGXXrKbWzjpiA_5_10"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1000000</us-gaap:TemporaryEquityLiquidationPreference>
    <zbio:TemporaryEquityCommonStockIssuableUponConversion
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_YJk-vvacZU6Ls8zA8jZmXA"
      decimals="INF"
      id="Tc_i6uAvm9vcU-JJ2rhe-cMSQ_5_12"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">205653</zbio:TemporaryEquityCommonStockIssuableUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ"
      decimals="INF"
      id="Tc_MhPBUrI2OU281SfNH8_c1w_6_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">17589380</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ"
      decimals="INF"
      id="Tc_9xJR_8CMoEKyHFjubPL8-g_6_4"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">17589380</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ"
      decimals="INF"
      id="Tc_9xJR_8CMoEKyHFjubPL8-g_6_4_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">17589380</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ"
      decimals="-3"
      id="Tc_ULS4T_xa10yq9cGlV1fAIQ_6_7"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">55840000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ"
      decimals="-3"
      id="Tc_OfnVpvGw3UOxDm2_yuUX4Q_6_10"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">56071000</us-gaap:TemporaryEquityLiquidationPreference>
    <zbio:TemporaryEquityCommonStockIssuableUponConversion
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_uY9rLZ6NnEqwKuT__GZuaQ"
      decimals="INF"
      id="Tc_nexGoiRrBE6qK_09qmFaUg_6_12"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">2025699</zbio:TemporaryEquityCommonStockIssuableUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw"
      decimals="INF"
      id="Tc_qfDo1f7rsE6i8AafwCnVNQ_7_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">81242587</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw"
      decimals="INF"
      id="Tc_l_78w3jmP0-stiFfEV2tVw_7_4"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">81242587</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw"
      decimals="INF"
      id="Tc_l_78w3jmP0-stiFfEV2tVw_7_4_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">81242587</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw"
      decimals="-3"
      id="Tc_GK88NSVawkaVS7aTB4wyNQ_7_7"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">193290000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw"
      decimals="-3"
      id="Tc_KRi0o7hTt02VHZiYi3VWFg_7_10"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">193898000</us-gaap:TemporaryEquityLiquidationPreference>
    <zbio:TemporaryEquityCommonStockIssuableUponConversion
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B-cw94r790enbLKTdPuAOw"
      decimals="INF"
      id="Tc_izEv1HzYaEip0E7cLcD2Hw_7_12"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">9356392</zbio:TemporaryEquityCommonStockIssuableUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Tc_-23NNC6N_0W_PHlYZL5fzQ_8_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">100617681</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Tc_JiBms90yS0qvSQaybCuggg_8_4"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">100617681</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Tc_JiBms90yS0qvSQaybCuggg_8_4_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">100617681</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_wcL6cjHgmk-A0p6JJeezKA_8_7"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">250086000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_nU1uohxl_USrqSgkmQV-_g_8_10"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">250969000</us-gaap:TemporaryEquityLiquidationPreference>
    <zbio:TemporaryEquityCommonStockIssuableUponConversion
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Tc_WgzY2urlME2TYcro7I9HVA_8_12"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">11587744</zbio:TemporaryEquityCommonStockIssuableUponConversion>
    <zbio:TemporaryEquityNumberOfVotesPerShare
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Narr_yDXoSUp_4UWBpJDOgVWTNA"
      unitRef="Unit_Standard_Vote_HZAN3AhGAkmyDfnWsC8kqg">1</zbio:TemporaryEquityNumberOfVotesPerShare>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="0"
      id="Narr_xNqc_Cm5kkeTaAxYe54qmw"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <zbio:TemporaryEquityNumberOfVotesPerShare
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Narr_nIdONZNypUafDqy4o2giZw"
      unitRef="Unit_Standard_Vote_HZAN3AhGAkmyDfnWsC8kqg">1</zbio:TemporaryEquityNumberOfVotesPerShare>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_ftIqpFVSOkq5tizkN79ucQ"
      decimals="2"
      id="Narr_cHbaOYbEPEa11k33WRoCoA"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_JZN4FpSog0SrROrSycy9eg"
      decimals="2"
      id="Narr_AhIA-O1fR0iOUuDZ3ZBXvg"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_MfqeZTH_FECRP_tS5UQvHA"
      decimals="2"
      id="Narr_I09f7k-wdE2q2K_F916piQ"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_zbio_SeriesSeedConvertiblePreferredStockMember_b_-Mw3ef7kWZpywvWrh-sQ"
      decimals="2"
      id="Narr_ref4BmC_c0OyDf7_V7XMAg"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-5"
      id="Narr_Q9QbCQFkqECJyouOaQuPUA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-5"
      id="Narr_ALE9TZVjSUaLolo-RKExGw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-5"
      id="Narr_LDQnVsLTtU6CnYh0x63iPQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-5"
      id="Narr_kj1zg5whWE-SnPC8zv5pGQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:DividendsPreferredStock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_g_QCfVMaxkatz7izfnz-jg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;10.&lt;/b&gt;&lt;/span&gt;Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In August&#160;2023, all outstanding shares of ordinary stock of Zenas Cayman automatically converted into shares of common stock of the Company upon the Redomicile and incorporation of the Company in the State of Delaware as Zenas BioPharma,&#160;Inc. In May&#160;2024, the Company amended and restated its certificate of incorporation, whereby the Company increased the shares of common stock it was authorized to issue to 294,784,925 shares. Upon consummation of the IPO, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the Company restated its certificate of incorporation, and as of December 31, 2024, the Company was authorized to issue 175,000,000 shares of $0.0001 par value common stock. The voting, dividend and liquidation rights of the holders of the Company&#x2019;s common stock were subject to and qualified by the rights, powers and preference of the holders of any preferred stock then issued and outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders (and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of convertible preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"&gt;The Company had reserved the following shares of common stock for the potential conversion of outstanding convertible preferred stock and exercise of stock options:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:32.54%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Conversion of outstanding shares of convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,587,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,706,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,382,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Remaining shares reserved for future issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 359,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60,792&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,065,596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,031,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_5_31_2024_R3mnM-yuCkeUi3lI4lcTJA"
      decimals="INF"
      id="Narr_gOuI0CMGEEKVeTmeu_Un4g"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">294784925</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Narr_EIzsaUZokkyJxYnVevUClw"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">175000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="4"
      id="Narr_WlLTUpSOCE69nhRrFcIlOQ"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <zbio:CommonStockNumberOfVotesPerShare
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Narr_U5fyaDo1E0alKoBXsQE1Dg"
      unitRef="Unit_Standard_Vote_HZAN3AhGAkmyDfnWsC8kqg">1</zbio:CommonStockNumberOfVotesPerShare>
    <zbio:ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_MWJSxxCjE0y_xwF3wH01Ng">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:32.54%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Conversion of outstanding shares of convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,587,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,706,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,382,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Remaining shares reserved for future issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 359,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60,792&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,065,596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,031,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</zbio:ScheduleOfCommonStockReservedForPotentialConversionOfSecuritiesAndFutureIssuanceTablesTextBlock>
    <zbio:TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Tc_NQeNQopockmO5VHgPTCtJw_3_4"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">11587744</zbio:TemporaryEquityCommonStockIssuableUponConversionOfPreferredStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Tc_w4CSM3niZ02HoH5TiMGa5Q_4_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">8706197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Tc_fl5Z7zaoxEOhFraiPoBD7Q_4_4"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">2382933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <zbio:RemainingCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Tc_fa36N3a_gUe4Wq0HfJsA0g_5_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">359399</zbio:RemainingCommonStockCapitalSharesReservedForFutureIssuance>
    <zbio:RemainingCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Tc_GqMX0yMRLkuD6qBZlxcP2g_5_4"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">60792</zbio:RemainingCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="INF"
      id="Tc_XyHJstQ-CkWKFLJx0NCaiQ_6_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">9065596</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="INF"
      id="Tc_VVMb2eJSx0m4RM5lJpwKsA_6_4"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">14031469</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_ltefzwWDWkOTvBbxbVFq4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;11.&lt;/b&gt;&lt;/span&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;2020 Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;On August 21,&#160;2020, the Company&#x2019;s sole director and member approved the Zenas BioPharma (Cayman) Limited 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;). Upon effectiveness of the 2024 Plan (as defined below), the Company ceased granting additional awards under the 2020 Plan. The 2020 Plan allowed the Company to grant stock options, restricted stock awards (&#x201c;RSAs&#x201d;), restricted stock units, and other stock-based awards to employees, officers, directors and consultants of the Company and its subsidiaries. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Since inception of the 2020 Plan, the Company has granted RSAs and stock options which generally vest over &lt;/span&gt;&lt;span style="font-style:normal;"&gt;four years&lt;/span&gt;&lt;span style="font-style:normal;"&gt;, with &lt;/span&gt;&lt;span style="font-style:normal;"&gt;25%&lt;/span&gt;&lt;span style="font-style:normal;"&gt; of the total shares granted vesting on the anniversary of the vesting commencement date and the remaining &lt;/span&gt;&lt;span style="font-style:normal;"&gt;75%&lt;/span&gt;&lt;span style="font-style:normal;"&gt; vesting in equal monthly installments over the subsequent &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_JhL2WXriOku-gXN73DMQHw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;thirty-six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:normal;"&gt; (36) months.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The 2020 Plan was subsequently amended by the Board and provided for the issuance of 2,560,401 shares of common stock as of December 31, 2023, of which 60,792 shares of common stock remained available for future grant under the 2020 Plan. &#160;Upon effectiveness of the 2024 Plan (as defined below), the remaining available shares for future grant were transferred to the 2024 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024 Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September 3, 2024, the Board adopted the 2024 Equity Incentive Plan (the &#x201c;2024 Plan&#x201d;), which became effective immediately prior to the effectiveness of the registration statement for the Company&#x2019;s IPO. The 2024 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, unrestricted stock, restricted stock units and other stock-based awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Upon the effectiveness of the 2024 Plan, the number of shares of common stock initially reserved for issuance was 4,775,477 shares of common stock which is equal to 12% of the number of shares of common stock issued and outstanding immediately following the consummation of the Company&#x2019;s IPO. The number of shares reserved and available for issuance under the 2024 Plan will automatically increase each January 1, beginning on January 1, 2025 through January 1, 2034, by the number of shares equal to the lesser of (a) five percent of the aggregate number of shares of common stock outstanding as of such date, and (b) a number of shares as may be determined by the Board on or prior to such date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, there were 359,399 shares available for issuance under the 2024 Plan. On January 1, 2025, the shares available for issuance under the 2024 Plan was increased to 2,449,069. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents a summary of the Company&#x2019;s RSA activity and related information:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.78%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.04%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average Grant-Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#ffffff;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;background:#ffffff;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#cceeff;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.71&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,028)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.01&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#cceeff;border-bottom:1.5pt solid #ffffff;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Repurchased&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,172)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;There were no RSAs granted during the year ended December&#160;31, 2024. As of December&#160;31, 2024, there was no compensation cost related to unvested RSAs as all were fully vested. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has granted stock-based awards with either service or performance based vesting conditions. Compensation expense related to awards to employees and directors with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance based vesting conditions is recognized based on the grant date fair value once the achievement of the performance condition is probable. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The table below presents the weighted-average assumptions used in estimating the fair values of stock options granted during the years ended December 31, 2024 and 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:32.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.74%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="8" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents a summary of the Company&#x2019;s stock option activity and related information:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted - Average Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual Term (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding - December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,382,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,736,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (38,427)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (375,131)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding - December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,706,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and exercisable as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,294,162&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,901&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and expected to vest as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,706,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of the stock options is calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s common stock for those stock options that had an exercise price lower than the fair value of the Company&#x2019;s common stock as of the measurement date of December 31, 2024. There were 38,427 options exercised for the year ended December 31, 2024, resulting in total proceeds of $0.3 million and 27,579 options exercised for the year ended December 31, 2023, resulting in total proceeds of $0.1 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant date fair value of options granted during the years ended December 31, 2024 and 2023, was $11.38 and $8.11 per share, respectively. The fair value is being expensed over the associated service period of the award on a straight-line basis based on the grant date fair value or once the achievement of the performance condition is probable. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2024, unrecognized compensation was $74.4 million, which is expected to be recognized over a weighted average period of 3.6 years. The total fair value of options vested during the years ended December 31, 2024 and 2023 was $4.6 million and $2.6 million, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company recognized stock-based compensation expense related to the issuance of equity awards to employees in the consolidated statement of operations as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.89%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:36.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.89%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,066&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,755&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,495&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On September 3, 2024, the Board adopted the 2024 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective immediately prior to the effectiveness of the registration statement for the Company&#x2019;s IPO. The Company initially reserved 397,956 shares for issuance under the ESPP. The number of shares of common stock available under the ESPP will &#160;automatically increase on January 1&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;st&lt;/sup&gt; of each year, beginning on January 1, 2025 through January 2034, by the number of shares equal to the lesser of (a) one percent of the aggregate number of shares of common stock outstanding as of such date, and (b) a number of shares as may be determined by the Board on or prior to such date, up to a maximum of 1,000,000 shares in the aggregate per year. On January 1, 2025, the shares of common stock reserved for issuance under the ESPP was increased to 815,890.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2024, no shares of common stock have been issued and no stock-based compensation has been recognized related to the ESPP. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_RshCuHFfukSw2KF3sIAoJg"
      id="Narr_owzA9H2iMU-Hxidj4xgp2Q">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_n3k32el71EGZ_NhKc4uVgw"
      decimals="2"
      id="Narr_e0OVPb9pI0ewimosRswGSw"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_8_21_2020_To_8_21_2020_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_QSgjONif-0yTKlXy2bMn7g"
      decimals="2"
      id="Narr_0pj6enAKNEmsVh0ni5-cJA"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_CULdaUsOIkCpMGAD6CrOEQ"
      decimals="INF"
      id="Narr_Ipa7pJ8Rm02g1eg9_wLHYQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">2560401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_zbio_TwoThousandTwentyPlanMember_CULdaUsOIkCpMGAD6CrOEQ"
      decimals="INF"
      id="Narr_-0wmpsmnlUqMOj7n0pCUCA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">60792</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_xOEKuB9Y7kOpDa77H2eCCg"
      decimals="INF"
      id="Narr_tPBTWuKehEOQnGQQs_NBCQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">4775477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_KToxdb6KqkaQTUoti9SqTg"
      decimals="2"
      id="Narr_1G8tiVZHOEKGdR6lqQ75GQ"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum
      contextRef="Duration_9_3_2024_To_9_3_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_bmG8cOK5ekOayAksSxcSeQ"
      decimals="2"
      id="Narr_2l2uZzVH70icqXozDMdvNw"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.05</zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_xOEKuB9Y7kOpDa77H2eCCg"
      decimals="INF"
      id="Narr_2FRYBIJoEkOGrEoPS1F77g"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">359399</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_1_2025_us-gaap_PlanNameAxis_zbio_EquityIncentivePlan2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hb-DK0AUdkWTw3-eUcEHIQ"
      decimals="INF"
      id="Narr_14F75GrcIUSaTFLSjceJ7w"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">2449069</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_3_vtFkGDhE-9np2qbF6x8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.78%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.04%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average Grant-Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#ffffff;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;background:#ffffff;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:18.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#cceeff;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.71&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,028)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.01&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#cceeff;border-bottom:1.5pt solid #ffffff;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Repurchased&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,172)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;border-left:1px solid #ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember__QbnTUUJpUmGv43XtvhTNg"
      decimals="INF"
      id="Tc_m96z4nO80U-Qh4UXguQkIQ_4_3"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">27200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember__QbnTUUJpUmGv43XtvhTNg"
      decimals="2"
      id="Tc_NoQHX6L6Kk6gzX-GhmMklA_4_6"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">2.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W4Yt2rBhJE-FLWW_GHB-Pg"
      decimals="INF"
      id="Tc_XqnPQNJ04kK7j5Xa-ZO9xA_5_3"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">6028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W4Yt2rBhJE-FLWW_GHB-Pg"
      decimals="2"
      id="Tc_3iopgq5D7E6Knw9DeBUCBA_5_6"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W4Yt2rBhJE-FLWW_GHB-Pg"
      decimals="INF"
      id="Tc_RuQQ2Dtw0UeZ0GaqF4OjCA_6_3"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">21172</zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod>
    <zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W4Yt2rBhJE-FLWW_GHB-Pg"
      decimals="2"
      id="Tc_6cBOQZgp6k6QvOsHR6B2lg_6_6"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">3.48</zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W4Yt2rBhJE-FLWW_GHB-Pg"
      decimals="INF"
      id="Narr_9BWVp6UgwkuFYzM7MgJzRQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_2NdTZEI7VEekOwqqgqrnHA"
      decimals="-3"
      id="Narr_heZnsoDx8EenAUSzsmWTaw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_NAGZMH_0akCLXtOVOfqJSA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:32.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.74%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="8" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="4"
      id="Tc_oPzQKvOZEkqe2HtnCK0T-A_3_3"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw"
      decimals="4"
      id="Tc_HnzzC5bbHEaeLJ3lNWFZzg_3_6"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.0413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      id="Tc_5sKVsKvvm0OWozUsOhxxqg_4_3">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw"
      id="Tc_sdHItF0jJ0a7SA9SzyQtWA_4_6">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="4"
      id="Tc_yTldksNqkUeN6rVZ_EDt_Q_5_3"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.9431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw"
      decimals="4"
      id="Tc_F3VjtEXcVkyERE0f81qhjA_5_6"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.8786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="4"
      id="Tc_RrCq7SAUHEq-L2gW7XIXJQ_6_3"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw"
      decimals="4"
      id="Tc_xXJaPIDP20WJATT495w4mQ_6_6"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_ddRUotL4dU2NBOXFQmjdVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted - Average Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.37%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual Term (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding - December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,382,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,736,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (38,427)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (375,131)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding - December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,706,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and exercisable as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,294,162&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,901&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and expected to vest as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,706,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cZRERuEIiEGchuqk65A2pQ"
      decimals="INF"
      id="Tc_yXqUpxvx6Ui9I9PEKePsoQ_4_3"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">2382933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cZRERuEIiEGchuqk65A2pQ"
      decimals="2"
      id="Tc_2XIbX97b60CP519FOsSTOA_4_6"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">8.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cZRERuEIiEGchuqk65A2pQ"
      decimals="-3"
      id="Tc_jO9UAasP0UaInW5fI9uPLw_4_12"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">8084000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="INF"
      id="Tc_CWaOW4exoUa2MS_YpECSzw_5_3"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">6736822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="2"
      id="Tc_3ZzcKLelo06X-eEuviEyPw_5_6"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">14.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="INF"
      id="Tc_f-lrgySUj0udhZLSEesfdQ_6_3"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">38427</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="2"
      id="Tc_mvBRWalCuUqguXbh8H-4OQ_6_6"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">7.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="-3"
      id="Tc_NlyNh-SQKEettvRiOU2cZw_6_12"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">231000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="INF"
      id="Tc_AsJDyG00R0WloyrBowJ2JQ_7_3"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">375131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="2"
      id="Tc_WMEp_cqPcEyFGNXvVImogw_7_6"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">10.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw"
      decimals="INF"
      id="Tc_mLNwOSuRhEiUA8gDPAnbsQ_8_3"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">8706197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw"
      decimals="2"
      id="Tc_iGOHVA0MwEat5IAuH3k18g_8_6"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">13.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      id="Tc_1Bah8xe0ikC3WeavUFa1WA_8_9">P8Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw"
      decimals="-3"
      id="Tc_ydPqramq_06AbKzIVPVKiQ_8_12"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">2104000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw"
      decimals="INF"
      id="Tc_kkw6PSXoAUOEnPUPU8SPsQ_9_3"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1294162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw"
      decimals="2"
      id="Tc_Lp2xOtc6iUu2zVjiIyan0g_9_6"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">7.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      id="Tc_WRhtLI23G0ufHJ5hcj0Nxg_9_9">P5Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw"
      decimals="-3"
      id="Tc_HZcsdfK7h0StcP9_4V0kmw_9_12"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1901000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw"
      decimals="INF"
      id="Tc_dFhagVAUz0m0zqNLMDpgDA_10_3"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">8706197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw"
      decimals="2"
      id="Tc_3B3dutwqQUKeuI3zO-82Ww_10_6"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">13.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      id="Tc__BPvyLHXMkaJENSsDBnE_w_10_9">P8Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw"
      decimals="-3"
      id="Tc_Rb1znHmbeEOlGsV2jHi0aA_10_12"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">2104000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="INF"
      id="Narr_UJg6ogU5YUmjC_9Xz0B0NQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">38427</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="-5"
      id="Narr_I28EvywJtEKnjoC1Sueo0A"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw"
      decimals="INF"
      id="Narr_HOrvjeSBLESgV9L844izng"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">27579</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw"
      decimals="-5"
      id="Narr_G0NmPLsouUWvcJv8UgGCEA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="2"
      id="Narr_Ju_LSnlGoEW6SbVw0gldLA"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">11.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw"
      decimals="2"
      id="Narr_9hyhJwBm8k-EUj9OuKjztA"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">8.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_t4ILb8ZdSUiG25km5bvFAw"
      decimals="-5"
      id="Narr_nXgeBa5Rj02DPLmvS641Sg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">74400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      id="Narr_au8sAp8PMkejnIUYFb4dBw">P3Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AsHTqBIwNUqxm47-As0nxg"
      decimals="-5"
      id="Narr_CfHZjQ5TzEGGbzFHEpsufA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">4600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ya3cfZu1dkOTUEs6gTteHw"
      decimals="-5"
      id="Narr_4WnKEAnmbEywksAF64jrvA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">2600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_IH5eIH-WZkW4F34CRbJdGg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company recognized stock-based compensation expense related to the issuance of equity awards to employees in the consolidated statement of operations as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.89%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:36.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.89%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,066&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,755&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,495&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fB6rJscJqE2qELeYONH6iw"
      decimals="-3"
      id="Tc_DlDrs7UkbU6JNlCpM2IUBg_3_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">4066000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_jq1Qp6HsIE2fmcD8wUHsAQ"
      decimals="-3"
      id="Tc_uOMLR-46U0-ukFMr6_Uwsw_3_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_AkdY1KqPtUenQWgty7TKCw"
      decimals="-3"
      id="Tc_mqcBBaBaskqwmea2YRt7eQ_4_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">6755000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DSs7gyVtbUGlXl8c8Se1DQ"
      decimals="-3"
      id="Tc_c81MJ8KDuECR07qmfCwinw_4_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1895000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_Ca5yuPxqWkS3SJTxKOxeAA_5_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">10821000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_0yoCPtd_VE6RIAdzAPFktw_5_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">3495000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_3_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member__gcr5m9F8EmwZjNOy4gdqw"
      decimals="INF"
      id="Narr_El8oGOQQ-0m-IsvfuY3uLA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">397956</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum
      contextRef="Duration_9_3_2024_To_9_3_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_mqyL0U5nuU2EVYmKwAc9sQ"
      decimals="2"
      id="Narr_RRseC5kwz0W-SRM6HWe6kw"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.01</zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum>
    <zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized
      contextRef="Duration_9_3_2024_To_9_3_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_mqyL0U5nuU2EVYmKwAc9sQ"
      decimals="INF"
      id="Narr_QZY8823Mf0Cqlf5f0xu8nQ"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1000000</zbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesToBeAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_1_1_2025_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HT5QNFavaEuMvtiRET_mAQ"
      decimals="INF"
      id="Narr_Z08mHw2gDEOyclK9b-XPhA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">815890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_Uu3p6qpokUGtpEZwlhfejQ"
      decimals="INF"
      id="Narr_9cqFPpMEFkSsj1aKE9_xLA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_zbio_EmployeeStockPurchasePlan2024Member_Uu3p6qpokUGtpEZwlhfejQ"
      decimals="-5"
      id="Narr_qUl5TrgBz0KqNDlv5NrrVw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_-WBln9U_9kyBJcRFGGf37w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;12.&lt;/b&gt;&lt;/span&gt;Net Loss Per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.61%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.47%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.61%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (156,988)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (37,124)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average common stock outstanding - basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,198,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,531,178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share attributable to common stockholders - basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11.89)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24.25)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The Company&#x2019;s potentially dilutive securities, which include convertible preferred stock, restricted stock and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders as of December&#160;31, 2024 and 2023 because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.03%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:44.4%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.03%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,587,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,706,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,382,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;The BMS Note was also outstanding as of December 31, 2023, which could have obligated the Company to issue preferred shares or common shares upon the occurrence of various future events at prices and in amounts that are not determinable until the occurrence of those future events. Because necessary conditions for the conversion of the BMS Note had not been satisfied as of December 31, 2023, the Company has excluded the BMS Note from the table above and the calculation of diluted net loss per share. As of December 31, 2024 the BMS Note is no longer outstanding. &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_YReQafbUmUubnY_U0k_MqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.61%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.47%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.61%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.58%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (156,988)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (37,124)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average common stock outstanding - basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,198,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,531,178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share attributable to common stockholders - basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11.89)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24.25)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_7YkpwLngg0G1dXxy_OFsbQ_4_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-156988000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_mDk-68NbIUGu23sp4oar4Q_4_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-37124000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="0"
      id="Tc_YyKYPnSTvkW_nKs6rzNDNA_6_3"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">13198960</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="0"
      id="Tc_YyKYPnSTvkW_nKs6rzNDNA_6_3_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">13198960</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="0"
      id="Tc_JLjzjEOrcEmy1Ysbo4VZYw_6_6"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1531178</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="0"
      id="Tc_JLjzjEOrcEmy1Ysbo4VZYw_6_6_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">1531178</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="2"
      id="Tc_aCAHGqd5I0KocoSj9RC5ug_7_3"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">-11.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="2"
      id="Tc_aCAHGqd5I0KocoSj9RC5ug_7_3_2"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">-11.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="2"
      id="Tc_rEMjgGdTn0e2KSw4_pPWYQ_7_6"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">-24.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="2"
      id="Tc_rEMjgGdTn0e2KSw4_pPWYQ_7_6_2"
      unitRef="Unit_Divide_USD_shares_8s93VTy9mE2rsvncNCWMXw">-24.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_2LpU3yrpDkeAtehul1smSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.03%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:44.4%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.03%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,587,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,706,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,382,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_c8gM2cWCLkC5U2Dqd6witg"
      decimals="INF"
      id="Tc_eKvB9HXvH0GibQGlmm-5tA_3_4"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">11587744</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember__ml10lATXUGvzgwEsGWE_A"
      decimals="INF"
      id="Tc_Wy9BI9AC5kaZyhabQunXzw_4_4"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">27200</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_M12KVoNGq02-s4clKubiaw"
      decimals="INF"
      id="Tc_IWRffn8HpE-c2XzvBCpVIg_5_2"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">8706197</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_8iYMmA8-mkONHhlH8V6H4A"
      decimals="INF"
      id="Tc_cIi6xDV3P0ONJCwu8Ld78Q_5_4"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">2382933</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_hzUJSHigsUqxhoSWI5ZeuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;13.&lt;/b&gt;&lt;/span&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table presents the components of loss before the provision for (benefit from) income taxes during the years ended December 31, 2024 and 2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (160,918)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,845)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,978)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Loss before taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (156,559)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (36,823)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The components of the income tax provision for the years ended December 31, 2024 and 2023 are as follows (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current income tax provision:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 289&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 306&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total current income tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred income tax provision:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal, state and foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred income tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total income tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (26.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;IP transfer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign tax rate differential&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s change in effective tax rate for the year ended December 31, 2024 compared to the year ended December 31, 2023 decreased primarily due to a change in income earned in the U.S. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the components of the Company&#x2019;s deferred tax assets and liabilities (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,716&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,573&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,424&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Milestone payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 442&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,188&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 901&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,961&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (200)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (200)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net deferred tax asset before valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,761&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (90,295)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (39,761)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;ASC Topic 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded full valuation allowances against its domestic and foreign deferred tax assets as of December 31, 2024, because management has determined that it is more likely than not that these assets will not be realized. The valuation allowance increased by $50.5 million from December 31, 2023 to December 31, 2024, primarily due to additional net operating losses related to the U.S. and non-U.S. entities as well as the capitalization of research and development expenses under Internal Revenue Code Section 174 (&#x201c;Section 174&#x201d;) at the U.S. entity. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Beginning on or after January 1, 2022, Section 174 of the U.S. internal revenue code was amended as part of the Tax Cuts and Jobs Act of 2017 (the &#x201c;TCJA&#x201d;) to no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Rather, the research and development expenses must be capitalized and amortized over five years for research performed in the U.S. and fifteen years for research performed outside the U.S. As a result of this provision, the Company capitalized applicable costs resulting in a deferred tax asset of $39.7 million as of December 31, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the Company had approximately $75.5 million and $65.0 million of U.S. federal and state net operating loss (&#x201c;NOL&#x201d;) carryforwards, respectively. As of December 31, 2023, the Company had approximately $2.3 million of U.S. federal NOL carryforwards. The Company had no state NOL carryforwards as of December 31, 2023. The Company utilized previous net operating loss carryforwards to offset the taxable income in prior years. The federal NOL carryforwards do not expire, but they may be limited in their usage to an annual deduction equal to 80% of annual taxable income. &#160;The state NOL carryforwards expire in 20 years, starting in 2042. The federal and state NOL carryforwards are fully offset by valuation allowances. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the Company had $13.3 million and $1.2 million in federal and state general business or research and development tax credit carryforwards. As of December 31, 2023, the Company had $5.9 million and $0.8 million in federal and state general business or research and development tax credit carryforwards. These carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The federal and state research credit carryforwards expire in 20 years and 15 years, respectively, starting in 2036. The federal and state tax credit carryforwards are fully offset by valuation allowances. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2024 and 2023, the Company had $54.2 million and $53.7 million of foreign NOL carryforwards, respectively. Foreign NOL carryforwards of $47.8 million will carryforward indefinitely, with the remaining expiring between 2026 and 2028. The foreign NOL carryforwards are fully offset by valuation allowances. The Company files income tax returns in the U.S., as well as various state and foreign jurisdictions. The Company is not currently under any income tax examinations. All tax years generally remain open in each jurisdiction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;There have been no unrecognized tax benefits since the Company&#x2019;s inception. The Company&#x2019;s policy is to record estimated interest and penalties related to the underpayment of income taxes as a component of its income tax provision. As of December 31, 2024 and 2023, the Company had no accrued interest or penalties related to uncertain tax positions and since inception, no amounts have been recognized in the Company&#x2019;s consolidated statements of operations and comprehensive loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, utilization of the NOLs and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section 382, as well as similar state provisions. These ownership changes may limit the amount of NOLs and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. If a change in control as defined by Section 382 has occurred at any time since the Company&#x2019;s formation, utilization of its NOLs or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could then be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOLs or research and development tax carryforwards before their utilization.&#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_KAixD94pEkeKtawjOv3wcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table presents the components of loss before the provision for (benefit from) income taxes during the years ended December 31, 2024 and 2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (160,918)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,845)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,978)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Loss before taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (156,559)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (36,823)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_-_4J64pAFkGs9X3mWM1UYw_3_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-160918000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_IHijaNPnyUayNtwMG_lKyg_3_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-10845000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_iO45ILhKTUSdWfKqg83aIg_4_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">4359000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_u0xJ8TbfMkKLjlAGxOMZ2g_4_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-25978000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_W4lBa0D7yUCQmfbrfp6kqw_5_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-156559000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_6NfSMRBmrkiHFudjze8tIA_5_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-36823000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_bGp4VPzrk0W2QeBODz6W1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The components of the income tax provision for the years ended December 31, 2024 and 2023 are as follows (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current income tax provision:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 289&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 306&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total current income tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred income tax provision:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal, state and foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred income tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total income tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_7gQ8FV5j5UiB8s1IpE9D2w_4_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">123000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_KJbs8pJreE-8G-u7QpxoPw_4_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">289000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_JqCM70dcj0qluoLlRsWjRg_5_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">306000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_7JPmDod-3Uq3SdDF1AFO0g_5_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">12000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_TffmLtZCxE-5zGcVNGCp9A_7_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">429000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_j1hVb7GI3EqY_nYHxeqsQA_7_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">301000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-3"
      id="Tc_6zMnGza5HU6tq-vuTYLVkg_12_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">429000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-3"
      id="Tc_M8KXKRsOyEmY8VTFsAl-og_12_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">301000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_pnmol-Oj3EimcKhYXb3uvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (26.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;IP transfer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign tax rate differential&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="3"
      id="Tc_o3HR_tNO1EuxQW36IB6IEw_3_2"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="3"
      id="Tc_iOGm3dhLLUqbkomiXkwjnw_3_4"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="3"
      id="Tc_Hdg8OdajK0W1-4vD_fPldg_4_2"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.064</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="3"
      id="Tc_e4HovmJm80SEKbmaIYM1uw_4_4"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="3"
      id="Tc_aFGYjo5gNk6v4AzYvn3wEg_5_2"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">-0.323</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="3"
      id="Tc_eXxFVgxPTkqfxOj9vEYp0A_5_4"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">-0.264</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="3"
      id="Tc_rdqJEleaUkaeBlbK7jzbeg_6_2"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="3"
      id="Tc_YJcttf3wAEWYcDMjjN2YEg_7_2"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">-0.049</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="3"
      id="Tc_NKoFHWGU90abThsza8IzQw_7_4"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">-0.088</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="3"
      id="Tc_qwrQcjmUaECjbmqnmbchxw_8_2"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="3"
      id="Tc_IEOyQx-6d02YQAqHZ48UmQ_8_4"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">-0.076</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="3"
      id="Tc_aYi4tf_TAUGnkTkPSSqv0Q_9_2"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="3"
      id="Tc_zm6rc6YSHUK6MgjCzGfRYg_10_2"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="3"
      id="Tc_c1ajiBByXE-HXADVYl0zig_10_4"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">-0.008</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_fc2JSzLDAEakt58HwSz2WQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the components of the Company&#x2019;s deferred tax assets and liabilities (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,716&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,573&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,424&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Milestone payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 442&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,188&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 901&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,961&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (200)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (200)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net deferred tax asset before valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,761&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (90,295)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (39,761)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_SNvxuePKvEKII9zoIlw3Yg_4_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">29605000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_uY68AjrttEWUuu6zf5Kp6A_4_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">9960000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_s_sgPQTZp0C_-cAq5PpjEw_5_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">39716000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_5zDiINqpl0qva3ChtJUd1A_5_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">19573000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_Wbweq6XMBUaBUImxrRiWwA_6_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">14292000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_qcD0CQI42UKB2IHcfxTukg_6_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">6547000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_426ShqO69kukUtxUw5HS7Q_7_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1886000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_RKY1ARoOZ0Sfsy8qeosgcQ_7_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1424000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <zbio:DeferredTaxAssetsMilestonePayments
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_cHaXFhlpQU2O7jjjj00Vaw_8_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">442000</zbio:DeferredTaxAssetsMilestonePayments>
    <zbio:DeferredTaxAssetsMilestonePayments
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_wfHfmoiejUqRLGt5R4aOeQ_8_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">719000</zbio:DeferredTaxAssetsMilestonePayments>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_dmTXi3YZh0qy_6uN86RrJA_9_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">4016000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_0fI-eyH_sUaIAVnKtveYgg_9_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1188000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_O_9cLi8tnUSNLi1EnLi-nw_10_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">901000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_N0Jfwgqqkkmb4fi9Ui035w_10_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">550000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_3VEAzOa0f0qqK1PWInVxxw_11_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">90858000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_SGhkRcfbTU6GoPURc97nRw_11_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">39961000</us-gaap:DeferredTaxAssetsGross>
    <zbio:DeferredTaxLiabilitiesAmortizationAndOther
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc__XDEcIRn5E2g5JyeYM8JMw_13_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">563000</zbio:DeferredTaxLiabilitiesAmortizationAndOther>
    <zbio:DeferredTaxLiabilitiesAmortizationAndOther
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_DEMZEQVz50WQOP1Va-8rXQ_13_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">200000</zbio:DeferredTaxLiabilitiesAmortizationAndOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_Asg6a9oOcU6bpSpIAV5FUg_14_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">563000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_Y7bMFoc6X0aG1PHwlkT8VA_14_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">200000</us-gaap:DeferredTaxLiabilities>
    <zbio:DeferredTaxAssetsNetBeforeValuationAllowance
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_O-sIXv13qU-JGQ5Kiiv9ig_17_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">90295000</zbio:DeferredTaxAssetsNetBeforeValuationAllowance>
    <zbio:DeferredTaxAssetsNetBeforeValuationAllowance
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_8NbjiHYnDk6gSzyFXQTXYg_17_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">39761000</zbio:DeferredTaxAssetsNetBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-3"
      id="Tc_TaELEu4RZEe56xJf_49J4Q_18_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">90295000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-3"
      id="Tc_fmpTJELDNEeJsTmVdIlgmw_18_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">39761000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-5"
      id="Narr_59WCFKzOTU2riAsaeoAMPQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">50500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_2-euo0XGO0qIb5EsNIp7SA"
      decimals="-5"
      id="Narr_7aSNxCBYNESAsYBkLch4bQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">39700000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-5"
      id="Narr_iN5xkEUgak6kRzvpXcS4YA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">75500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-5"
      id="Narr_S8d5mvaW6kCmEbhIWUz3xQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">65000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-5"
      id="Narr_OgP0Sy2q7kaM4FrtzB-a2g"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">2300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-5"
      id="Narr_ruI9FORZa0i5EIvxHu6CEA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <zbio:PercentageOfAnnualDeductionEqualToTaxableIncomeFederal
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="2"
      id="Narr_O-sYR5rZsEC2DmIxwKhUVA"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.80</zbio:PercentageOfAnnualDeductionEqualToTaxableIncomeFederal>
    <zbio:OperatingLossCarryforwardsExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_u2OmFVykgEeCNR0zO3JP-g"
      id="Narr_MPm5GSJqbEenQeqxJMvdkg">P20Y</zbio:OperatingLossCarryforwardsExpirationPeriod>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_skdQla54vkylvNLfiCBCHQ"
      decimals="-5"
      id="Narr_7IcAYjCflkKAWfDqCQNBlg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">13300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_twRRvxhUHkGVSVijS4AHpA"
      decimals="-5"
      id="Narr___9RmtQatUSZtc-ZKbhm1Q"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">1200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_aeVZjo1Bqk-9JQbx0cC7vA"
      decimals="-5"
      id="Narr_hGuZPrR8kEWJ2WYjEwznsw"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">5900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_lvF2unTWUEenGdpAx5Ec3A"
      decimals="-5"
      id="Narr_8Uoa7negSkGpZ07-N7hvVA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">800000</us-gaap:TaxCreditCarryforwardAmount>
    <zbio:TaxCreditCarryforwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_lwKQYiDgb0GvlfNmmVeNtA"
      id="Narr_HTvpWfEILky3iDKdCJcDFg">P20Y</zbio:TaxCreditCarryforwardExpirationPeriod>
    <zbio:TaxCreditCarryforwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_u2OmFVykgEeCNR0zO3JP-g"
      id="Narr_3WFmmBUvn0-SxX7QEOxKCw">P15Y</zbio:TaxCreditCarryforwardExpirationPeriod>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-5"
      id="Narr_J2LS_iojlU6EXgp4Ni4o3w"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">54200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-5"
      id="Narr_MwU2NCE9Hk-Tcu4X4PGZOA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">53700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-5"
      id="Narr__tcltZO41Ei4ukaFRm5jGQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">47800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-5"
      id="Narr_LNY1-L2eSUCpBImSqTJXQQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="As_Of_12_31_2023_k8WdFLh1rkGfWzz7QrHumA"
      decimals="-5"
      id="Narr_5Z-rJmnluEGWmwycwY595A"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="As_Of_12_31_2024_btgOtUF74023dciFSkKbYw"
      decimals="-5"
      id="Narr_pvx0uhSWdk2LqQGS6dHegQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <zbio:UncertainTaxPositionsAmountRecognized
      contextRef="Duration_1_1_2023_To_12_31_2023_yUjRajGql0-RhI5E_6bJkQ"
      decimals="-5"
      id="Narr_n2lflRBZc0un6l5bi6vwoA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:UncertainTaxPositionsAmountRecognized>
    <zbio:UncertainTaxPositionsAmountRecognized
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-5"
      id="Narr_Uq1urJTEa0a9ywAuLdVz_w"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:UncertainTaxPositionsAmountRecognized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_rpEYzsckakGNBlQQEgY0yQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;14.&lt;/b&gt;&lt;/span&gt;Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Operating Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into arrangements for leases of office space; see&lt;i style="font-style:italic;"&gt; Note&#160;6, Leases,&lt;/i&gt; for details.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;License and Option Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into licenses agreement under which it is obligated to make fixed and contingent payments; see &lt;i style="font-style:italic;"&gt;Note&lt;/i&gt;&#160;&lt;i style="font-style:italic;"&gt;8,&lt;/i&gt; &lt;i style="font-style:italic;"&gt;License and Option Agreements&lt;/i&gt;, for details.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Other Contracts&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into agreements with certain vendors for the provision of services that the Company is not contractually able to terminate for convenience and thereby avoid any and all future obligations to the vendors. Under such agreements, the Company is contractually obligated to make certain minimum payments to the vendors, with the exact amounts in the event of termination to be based on the timing of the termination and the exact terms of the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Indemnification Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and certain officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or services as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and had not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Litigation and Other Proceedings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused. As of December 31, 2024, the Company was not subject to any material legal proceedings which would reasonably be expected to have a material adverse effect on the Company&#x2019;s financial results.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_GBTzVkgMokquz7d61HdirA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;15.&lt;/b&gt;&lt;/span&gt;Employee Benefit Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Effective June&#160;2020, the Company adopted the Zenas BioPharma 401(k)&#160;Plan (the &#x201c;401(k)&#160;Plan&#x201d;) for its employees, which is designed to be qualified under Section&#160;401(k)&#160;of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k)&#160;Plan within statutory and 401(k)&#160;Plan limits. Since inception of the 401(k)&#160;Plan and through the year ended December&#160;31, 2024, the Company has made a one-time contribution of $0.1 million to the 401(k)&#160;Plan.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      decimals="-5"
      id="Narr_fYEpz0tGfEyUIf45CmcsvQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_SadPQiXqKUeNtT43S5E29Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;16.&lt;/b&gt;&lt;/span&gt;Related Party Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Xencor, Inc.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has obtained exclusive, worldwide licenses from Xencor to research, develop, manufacture, market and sell three antibody product candidates pursuant to two license agreements. The Company has concluded that Xencor is a related party, because as initial consideration for the 2020 Xencor Agreement, the Company issued 5,041,542 shares of its Series&#160;A Preferred Stock to Xencor during the&#160;year ended December&#160;31, 2020. In April&#160;2023, Xencor elected to receive payment for a development milestone in the form of the Company&#x2019;s Series&#160;B Preferred Stock and the Company issued 4,189,955 shares of Series&#160;B Preferred Stock as payment for the development milestone in June&#160;2023. As of December 31, 2024, Xencor held 7.4% of shares of the Company&#x2019;s outstanding common stock. The Company did not incur any costs related to reimbursable patent-related costs as of December 31, 2024. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Viridian Therapeutics, Inc. &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has obtained a license from Viridian to research, develop, manufacture, market and sell an antibody product candidate in China. The Company has concluded that Viridian is a related party because although Fairmount Funds Management LLC owns less than 5% of shares of the Company&#x2019;s outstanding common stock, they have a seat on the Board and are also a 10% or greater stockholder of Viridian and have two seats on Viridian&#x2019;s board of directors. As initial consideration for this license, the Company issued 38,707 shares of its common stock to Viridian during the&#160;year ended December&#160;31, 2020. As of December 31, 2024, Viridian held less than 0.1% of shares of the Company&#x2019;s outstanding common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dianthus Therapeutics, Inc&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company obtained an exclusive option to negotiate and enter into exclusive license agreements with Dianthus for the rights (in the Zenas Territories only) to either or both of two antibody product candidates. In June 2022, the Company and Dianthus entered into the Dianthus License Agreement. The Company has concluded that Dianthus is a related party because the Company&#x2019;s Chair of the Board is a member of the board of directors of Dianthus. As initial consideration for this license, the Company issued 18,063 shares of its common stock to Dianthus during the&#160;year ended December&#160;31, 2020. In October 2024, the Dianthus Option Agreement and Dianthus License Agreement and all of their related rights and obligations were transferred to Tenacia. As of December 31, 2024, Dianthus held less than 0.1% of shares of the Company&#x2019;s outstanding common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For additional information on our license arrangements, please see &lt;i style="font-style:italic;"&gt;Note 8, License and Option Agreements&lt;/i&gt;, to these consolidated financial statements. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <zbio:RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-yJXARaZ-0OBYdCxepkloA"
      decimals="INF"
      id="Narr_TZlhAbKuuEuHD9w6oX9zRg"
      unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw">3</zbio:RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained>
    <zbio:RelatedPartyTransactionNumberOfLicenseAgreements
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-yJXARaZ-0OBYdCxepkloA"
      decimals="INF"
      id="Narr_pD87M9HcO0-KfKur0zf-NQ"
      unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw">2</zbio:RelatedPartyTransactionNumberOfLicenseAgreements>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_kl-ar1okCk6X0Cdxj6jlyA"
      decimals="INF"
      id="Narr_kw93CLGJnkuJ5ap9I49TdA"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">5041542</zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jtEg9vA0hUWnfXmt4HMTXg"
      decimals="INF"
      id="Narr_pglSEePe40a_HOYzcb57dw"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">4189955</zbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SB8hnByb2k6XmWq5YFUxLw"
      decimals="3"
      id="Narr_P9YefiUaD0ykTpiFd-201g"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.074</us-gaap:EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee>
    <zbio:RelatedPartyTransactionReimbursableCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_XencorIncMember__kat8-A7DkaDtefaqsDstA"
      decimals="0"
      id="Narr_LpnP7dgl206ADPP3amCPFQ"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">0</zbio:RelatedPartyTransactionReimbursableCosts>
    <zbio:OwnershipPercentageByRelatedParty
      contextRef="As_Of_12_31_2024_dei_LegalEntityAxis_zbio_FairmountFundsManagementLlcMember_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QkW1FJbql0yPxwXvk72juA"
      decimals="2"
      id="Narr_tyc1k2sbiU-_Mygq-7HbTA"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.05</zbio:OwnershipPercentageByRelatedParty>
    <zbio:NumberOfSeatsHeldInBoard
      contextRef="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_zbio_FairmountFundsManagementLlcMember_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hnbEkcn98U2igS-6OHbaDg"
      decimals="INF"
      id="Narr_7KKlh418Sk2yp_p-nDcU6w"
      unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw">2</zbio:NumberOfSeatsHeldInBoard>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_XJAUtiSe802lS1JD3MLPpQ"
      decimals="INF"
      id="Narr_zQGir3nPbE64ZwsSM6328Q"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">38707</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <zbio:OwnershipPercentageByRelatedParty
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_zbio_ViridianTherapeuticsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_I6CRPAIoAkK_QxeW-_WiBQ"
      decimals="3"
      id="Narr_tunsFo4FLEWPNkOYbin9gw"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.001</zbio:OwnershipPercentageByRelatedParty>
    <zbio:RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_zbio_DianthusTherapeuticsincMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CAe46DStS0ayGHbh_yaH1Q"
      decimals="INF"
      id="Narr_gRCVESNaZU-esk4KUeJvmg"
      unitRef="Unit_Standard_item_Q-7wjKC9wkyhRmVoo-dRJw">2</zbio:RelatedPartyTransactionNumberOfAntibodyProductLicenseObtained>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_zbio_DianthusTherapeuticsincMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lvI7Gb31J0y7HORj3pCOSQ"
      decimals="INF"
      id="Narr_xuOUk8hXlEOrsHO45u4jhg"
      unitRef="Unit_Standard_shares_ccfq5gqmV0aaHWJ42qhoZQ">18063</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <zbio:OwnershipPercentageByRelatedParty
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_zbio_DianthusTherapeuticsincMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ZTb-Cr_H-k6rrUVG_vWbag"
      decimals="3"
      id="Narr_NlpiOlh3k0qkySGggLRkGw"
      unitRef="Unit_Standard_pure_WXdAm_-ZxUmjtkDvlsw8jg">0.001</zbio:OwnershipPercentageByRelatedParty>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_f8SYXBVIaUCnNAqKk702Wg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;17.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Segment Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"&gt;The Company manages its operations on a consolidated basis as a single reportable segment focused on the research and development of precision immunology-based therapies. The accounting policies of the single reportable segment are &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;identical to those described in &lt;i style="font-style:italic;"&gt;Note 2, Summary of Significant Accounting Policies&lt;/i&gt;. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews consolidated net loss, total expense and direct expenses by program and compared to budget. The CODM allocates resources based on the Company&#x2019;s available cash resources, forecasted expenditures on a consolidated basis, as well as an assessment of the probability of success of its research and development activities on a program basis. Segment asset information regularly provided to the CODM is consistent with that reported on the consolidated balance sheets with particular emphasis on the Company&#x2019;s available liquidity, including its cash, cash equivalents and marketable securities balances. Revenue is primarily attributed to individual countries based on the location of the license, as of December 31, 2024 and 2023, revenue was attributed to our China and U.S. entity, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"&gt;The following table presents certain financial data for the Company&#x2019;s reportable segments for the years ended December 31, 2024 and 2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Direct research and development expenses:&lt;/span&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Obexelimab&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 94,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,446&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Other programs (ZB002 &amp;amp; ZB004)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Partnered regional programs (ZB001 &amp;amp; ZB005)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,737&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,738&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Unallocated research and development&lt;/span&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;2&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,008&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  General and administrative&lt;/span&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;3&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,495&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Other segment items&lt;/span&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;4&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,901)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,977&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Segment Net Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (156,988)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,124)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt; Direct research and development expenses primarily consist of direct costs incurred to specific programs research and development activities, including costs to conduct clinical trials and to manufacture clinical drug supply. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"&gt;2 &lt;/sup&gt;Unallocated research and development expenses primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as personnel costs for employees involved in research and development activities, excluding stock-based compensation, as well as contract services not allocated to specific programs. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"&gt;3&lt;/sup&gt;General and administrative expenses primarily consist of all other personnel costs, excluding stock-based compensation, professional fees, depreciation expense, as well as facilities expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"&gt;4 &lt;/sup&gt;Other segment items consist of acquired in-process research and development, fair value adjustments to convertible notes, other income, net and income tax provision. Other income, net consists of interest income and realized and unrealized gains and losses on foreign currency transactions. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_oD2HwHDe7kOuJsCTq9zORg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"&gt;The following table presents certain financial data for the Company&#x2019;s reportable segments for the years ended December 31, 2024 and 2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Direct research and development expenses:&lt;/span&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Obexelimab&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 94,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,446&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Other programs (ZB002 &amp;amp; ZB004)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Partnered regional programs (ZB001 &amp;amp; ZB005)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,737&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,738&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Unallocated research and development&lt;/span&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;2&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,008&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  General and administrative&lt;/span&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;3&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,495&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Other segment items&lt;/span&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;4&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,901)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,977&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Segment Net Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (156,988)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,124)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt; Direct research and development expenses primarily consist of direct costs incurred to specific programs research and development activities, including costs to conduct clinical trials and to manufacture clinical drug supply. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"&gt;2 &lt;/sup&gt;Unallocated research and development expenses primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as personnel costs for employees involved in research and development activities, excluding stock-based compensation, as well as contract services not allocated to specific programs. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"&gt;3&lt;/sup&gt;General and administrative expenses primarily consist of all other personnel costs, excluding stock-based compensation, professional fees, depreciation expense, as well as facilities expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"&gt;4 &lt;/sup&gt;Other segment items consist of acquired in-process research and development, fair value adjustments to convertible notes, other income, net and income tax provision. Other income, net consists of interest income and realized and unrealized gains and losses on foreign currency transactions. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g"
      decimals="-3"
      id="Tc_6qFo_iPi6UyCUadI_UkFIw_3_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_pAV7g9BFKE2QQiAhjUp8uA"
      decimals="-3"
      id="Tc_PLVgMvMY4kC6Sh_R8unlXA_3_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">50000000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_ObexelimabMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_BA-_9VIA-E-YvYOM66DKZw"
      decimals="-3"
      id="Tc_nyasHqyPrk2i9Rw_0t0tDw_6_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-94563000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_ObexelimabMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_Ue5uXg-mLkyi2JN6fkIuQA"
      decimals="-3"
      id="Tc_X2o0dpsva0OX3pkh9m3IfA_6_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-25446000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_OtherProgramsZb002Zb004Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_7d3JG86c_Eaat0gaHhQcQw"
      decimals="-3"
      id="Tc_BPXQKThTUka9TGnXT0Tksw_7_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-2115000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_OtherProgramsZb002Zb004Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_VixgjipTjEKqNxHHsetS4g"
      decimals="-3"
      id="Tc_kNysyGvBQ0e7NxYSN9NJVg_7_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-6242000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_PartneredRegionalProgramsZb001Zb005Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_Rh91EjE7O02oJHALLAAHdA"
      decimals="-3"
      id="Tc_-XLdsBDsE0K36zjrE9B0lg_8_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-6737000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_PartneredRegionalProgramsZb001Zb005Member_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_yj8rbVJ6iEu1uke5hj5FiQ"
      decimals="-3"
      id="Tc_cHr8hXQ36UGfhrlrizp-kw_8_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-6738000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_zbio_UnallocatedMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_ebJVNQcIrE6ToW4JVW_66A"
      decimals="-3"
      id="Tc_0cCp4WonH02bSuRSobkrqg_9_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-31658000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_zbio_UnallocatedMember_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_FtxZwqa3A020C1JNgu1N7Q"
      decimals="-3"
      id="Tc_PWi5oXowlEelChfl13tRfg_9_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-20008000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g"
      decimals="-3"
      id="Tc_E-zzmlXDTUGdlGPAJcM6Cg_10_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-22995000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_pAV7g9BFKE2QQiAhjUp8uA"
      decimals="-3"
      id="Tc_gn4_czOOekWubVcKj4fIMw_10_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-15218000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g"
      decimals="-3"
      id="Tc_Vk6Nj3TPBEeF5WSKN45J-A_11_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-10821000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_pAV7g9BFKE2QQiAhjUp8uA"
      decimals="-3"
      id="Tc_h4XBVKIbCUGqL2s4QtJAMg_11_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-3495000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g"
      decimals="-3"
      id="Tc_-BZuuTCoG02iJnBVKn7nEw_12_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-6901000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_pAV7g9BFKE2QQiAhjUp8uA"
      decimals="-3"
      id="Tc_zemnu5YyKUGkk4jEDFkDQw_12_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">9977000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_IRZ52GpdHE2hLCeQ5y_A7g"
      decimals="-3"
      id="Tc_q5fgKsmNCkKgx1ywF7YCzA_13_3"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-156988000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_zbio_SingleReportableSegmentMember_pAV7g9BFKE2QQiAhjUp8uA"
      decimals="-3"
      id="Tc_6A66bBiuM0a-qf29RZBT1g_13_6"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">-37124000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Tb_vJaGO4MqBUOv-qOfPgDD_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;18.&lt;/b&gt;&lt;/span&gt;Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Zai License Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On January 24, 2025, the Company entered into a license agreement (the &#x201c;Zai License Agreement&#x201d;) with Zai Lab (Hong Kong) Limited (&#x201c;Zai&#x201d;), under which the Company granted Zai an exclusive sublicense to develop and commercialize ZB001 and related programs in greater China. &#160;As partial consideration for the Zai License Agreement, the Company received an upfront fee of $10.0 million from Zai. In addition, the Company is eligible to receive up to $96.0 million upon the achievement of certain future development and commercial milestones and royalty percentage rates from the low to mid-single digits, net of pass-through obligations due to Viridian.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <zbio:CollaborativeArrangementUpfrontPaymentReceived
      contextRef="Duration_1_24_2025_To_1_24_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_zbio_ZaiLicenseAgreementMember_OHpbECa01k2mu2U9YBMjnw"
      decimals="-5"
      id="Narr_Tza8HzbBXEKBUSmPhE6txA"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">10000000</zbio:CollaborativeArrangementUpfrontPaymentReceived>
    <zbio:CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone
      contextRef="As_Of_1_24_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_zbio_ZaiLicenseAgreementMember_E1agUD26v0u0FuWVhieCXw"
      decimals="-5"
      id="Narr_x3Ks5gUSeUWNFA6KmjdjEg"
      unitRef="Unit_Standard_USD_wdROCaDSE0qp-UgQ8kIjMA">96000000</zbio:CollaborativeArrangementRegulatoryAndCommercialMilestonesMaximumPaymentReceivableOnAchievementOfMilestone>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g"
      id="Narr_vWXXcJXfZk-byM8YlaPwEQ">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g"
      id="Narr_bmVqaJxLtUOKzNgAnmfwbw">false</ecd:NonRule10b51ArrAdoptedFlag>
    <zbio:Rule10b51ArrangementModifiedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g"
      id="Narr_ccBwXx96UU-RA15QNKigSg">false</zbio:Rule10b51ArrangementModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g"
      id="Narr_IatoIT6fNEmxXd6mF15APw">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g"
      id="Narr_kj2N3t99JUehgYGcV8Hq1A">false</ecd:NonRule10b51ArrTrmntdFlag>
    <zbio:NonRule10b51ArrangementModifiedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_X7BU_iF5LUWhsnq202pS3g"
      id="Narr_ZU_pVNO-AUCgB_zyDEaptA">false</zbio:NonRule10b51ArrangementModifiedFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_TP5lYStxq0K-3zESHPmU9g"
      id="Narr_q71mi7a7akGlEWpwZYzq6Q">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
